PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chang, BH; Smith, L; Huang, J; Thayer, M				Chang, B. H.; Smith, L.; Huang, J.; Thayer, M.			Chromosomes with delayed replication timing lead to checkpoint activation, delayed recruitment of Aurora B and chromosome instability	ONCOGENE			English	Article						replication checkpoint; chromosome passenger complex; genomic instability; spindle assembly checkpoint; endoreduplication; chromosome instability	DNA-DAMAGE; ARREST; TRANSLOCATIONS; ADAPTATION; SURVIVIN; CELLS; G2	Certain chromosome rearrangements display a significant delay in chromosome replication timing (DRT) that is associated with a subsequent delay in mitotic chromosome condensation (DMC). DRT/DMC chromosomes are common in tumor cells in vitro and in vivo and occur frequently in cells exposed to ionizing radiation. A hallmark for these chromosomes is the delayed phosphorylation of serine 10 of histone H3 during mitosis. The chromosome passenger complex, consisting of multiple proteins including Aurora B kinase and INCENP is thought to be responsible for H3 phosphorylation, chromosome condensation and the subsequent segregation of chromosomes. In this report, we show that chromosomes with DRT/DMC contain phosphorylated Chk1, consistent with activation of the S-M phase checkpoint. Furthermore, we show that INCENP is recruited to the DRT/DMC chromosomes during all phases of mitosis. In contrast, Aurora B kinase is absent on DRT/DMC chromosomes when these chromosomes lack serine 10 phosphorylation of H3. We also show that mitotic arrest deficient 2 (Mad2), a member of the spindle assembly checkpoint, is present on DRT/DMC chromosomes at a time when the normally condensed chromosomes show no Mad2 staining, indicating that DRT/DMC activates the spindle assembly checkpoint. Finally, cells with DRT/DMC chromosomes have centrosome amplication, abnormal spindle assembly, endoreduplication and significant chromosome instability.	Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Hematol & Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Thayer, M (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	thayerm@ohsu.edu		Chang, Bill/0000-0003-3783-1820; Smith, Leslie/0000-0001-6452-6624	NCI NIH HHS [CA 97021, R01 CA097021, R01 CA104693, CA 104693] Funding Source: Medline; NIGMS NIH HHS [F32 GM071176, F32 GM071176-01A1, F32-GM071176-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097021, R01CA104693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Breger KS, 2005, HUM MOL GENET, V14, P2813, DOI 10.1093/hmg/ddi314; Breger KS, 2004, CANCER RES, V64, P8231, DOI 10.1158/0008-5472.CAN-04-0879; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Liu QH, 2000, GENE DEV, V14, P1448; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Mills AD, 2000, NAT CELL BIOL, V2, P244, DOI 10.1038/35008670; Rajagopalan H, 2004, CANCER CHEMOTH PHARM, V54, pS65, DOI 10.1007/s00280-004-0889-8; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Smith A, 1998, PHARM SCI TECHNOL TO, V1, P47, DOI 10.1016/S1461-5347(98)00021-2; Smith L, 2001, P NATL ACAD SCI USA, V98, P13300, DOI 10.1073/pnas.241355098; Trask B, 1990, Methods Cell Biol, V33, P383; Yu KR, 2000, NAT CELL BIOL, V2, P609, DOI 10.1038/35023555	23	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1852	1861		10.1038/sj.onc.1209995	http://dx.doi.org/10.1038/sj.onc.1209995			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001311	Green Accepted			2022-12-25	WOS:000245117700003
J	Tsuchiya, A; Tashiro, E; Yoshida, M; Imoto, M				Tsuchiya, A.; Tashiro, E.; Yoshida, M.; Imoto, M.			Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1 in leptomycin B-inhibited cyclin D1 expression	ONCOGENE			English	Article						leptomycin B; cyclin D1; PP2A; c-jun	ANTI-FUNGAL ANTIBIOTICS; C-JUN; EXPORT SIGNALS; CELL-CYCLE; SERINE/THREONINE PHOSPHATASES; NUCLEOCYTOPLASMIC TRANSPORT; AP-1 ACTIVITY; OKADAIC ACID; HIV-1 REV; IN-VIVO	Leptomycin B (LMB) is a Streptomyces metabolite that causes the specific inhibition of the nuclear export of proteins containing a nuclear export signal (NES). LMB was reported to inhibit cell cycle progression in fission yeast and mammalian cells, however, the mechanism underlying LMB-induced cell cycle arrest is still obscure. In this study, we found that in serum-starved NIH3T3 cells, LMB inhibited serum-induced cyclin D1 expression at the level of transcription. However, this inhibition was reversed by inhibitors of protein phosphatase 2A (PP2A). Furthermore, we found that PP2A accumulated in the nucleus upon treatment with LMB. The finding prompted us to identify the functional NES in PP2A catalytic subunit a. These results indicated that LMB inhibited the chromosomal region maintenance 1(CRM1)-dependent nuclear export of PP2A, resulting in sustained dephosphorylation in the nucleus. Although phosphorylation of c-Jun at Ser-63 is required for activator protein 1 (AP-1)-dependent expression of cyclin D1, it decreased in LMB-treated cells compared to untreated cells. Moreover, the inhibitors of PP2A restored the levels of c-Jun phosphorylated at Ser-63. We propose that inhibition of cyclin D1 expression by LMB is mediated by the LMB-induced nuclear accumulation of PP2A, leading to sustained dephosphorylation of c-Jun at Ser-63, which leads to inactivation of the transcription of the AP-1-responsive cyclin D1 gene.	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; RIKEN, Chem Genet Lab, Wako, Saitama 35101, Japan	Keio University; RIKEN	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, 3-14-1 Hiyohi, Yokohama, Kanagawa 2238522, Japan.	imoto@bio.keio.ac.jp	Tashiro, Etsu/C-4903-2014; Imoto, Masaya/F-7957-2014; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Tashiro, Etsu/0000-0003-4533-623X				Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Haasen D, 1999, PLANT J, V20, P695, DOI 10.1046/j.1365-313X.1999.00644.x; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lecane PS, 2003, PROSTATE, V54, P258, DOI 10.1002/pros.10197; Lubert EJ, 2003, BIOCHEM BIOPH RES CO, V303, P908, DOI 10.1016/S0006-291X(03)00434-0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Ramirez CJ, 2005, J CELL BIOCHEM, V96, P170, DOI 10.1002/jcb.20520; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shiozawa T, 2004, ONCOGENE, V23, P8603, DOI 10.1038/sj.onc.1207849; Sigoillot FD, 2005, J BIOL CHEM, V280, P25611, DOI 10.1074/jbc.M504581200; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Uchida S, 2004, BIOCHEM BIOPH RES CO, V316, P226, DOI 10.1016/j.bbrc.2004.02.039; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zhang MJ, 1998, BIOCHEM BIOPH RES CO, V243, P113, DOI 10.1006/bbrc.1997.8070	57	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2007	26	11					1522	1532		10.1038/sj.onc.1209962	http://dx.doi.org/10.1038/sj.onc.1209962			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964287				2022-12-25	WOS:000244782500002
J	Kim, KE; Song, H; Kim, TS; Yoon, D; Kim, CW; Bang, SI; Hur, DY; Park, H; Cho, DH				Kim, K-E; Song, H.; Kim, T. S.; Yoon, D.; Kim, C-w; Bang, S. I.; Hur, D. Y.; Park, H.; Cho, D-H			Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines	ONCOGENE			English	Article						ERK1/2; F-actin; IL-18; migration; tensin; VEGF	GAMMA-INDUCING FACTOR; IL-18; EXPRESSION; METASTASIS; PROTEIN; PROLIFERATION; ANGIOGENESIS; IMMUNITY; TENSIN; ACTS	Cell migration and angiogenesis are key steps in tumor metastasis. However, the mechanism of migration regulated by vascular endothelial growth factor ( VEGF), a potent regulator of angiogenesis, is not completely understood. This study examined the relationship between VEGF and migration, along with the mechanism involved in the VEGF-regulated migration of human gastric cancer cells. The level of cell migration was increased by recombinant human (rh) VEGF-165 in the VEGF receptor-2-expressing SNU-601 cells. Interleukin (IL)-18 is associated with the malignant progression of tumors. Accordingly, this study examined the effect of IL-18 on the migration of cancer cells in order to identify the factors involved in VEGF-enhanced migration. Inhibiting IL-18 markedly reduced the level of VEGF-enhanced migration, and IL-18 increased cell migration directly through filamentous-actin polymerization and tensin downregulation. It was confirmed that rhVEGF-165 increased IL-18 production significantly. An antioxidant and an extracellular signal-regulated kinase (ERK) 1/2-specific inhibitor blocked rhVEGF-165-enhanced IL-18 production. Accordingly, rhVEGF-165 increased the generation of region of interest (ROI) and activated the ERK1/2 pathway. These results suggest that rhVEGF-165 enhances IL-18 production via the generation of ROI and ERK1/2 phosphorylation, which results in the increased migration of gastric cancer cells.	Catholic Univ Korea, Dept Dermatol, St Marys Hosp, Coll Med, Seoul, South Korea; Sookmyung Womens Univ, Dept Life Sci, Seoul 140742, South Korea; Inje Univ, Coll Med, Dept Anat, Pusan, South Korea; Korea Univ, Sch Life Sci & Technol, Seoul 136701, South Korea; Konkuk Univ, Grad Sch, Div Biosci & Biotechnol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; Seoul Natl Univ, Coll Med, Tumor Immun Med Res Ctr, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Dept Plast Surg, Samsung Med Ctr, Seoul, South Korea	Catholic University of Korea; Catholic University Korea Hospital; Seoul St. Mary's Hospital; Sookmyung Women's University; Inje University; Korea University; Konkuk University; Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Park, H (corresponding author), Catholic Univ Korea, Dept Dermatol, St Marys Hosp, Coll Med, Seoul, South Korea.	hjpark@catholic.ac.kr; cdhkor@sookmyung.ac.kr	Kim, Chul-Woo/F-7008-2011					Cao RH, 1999, FASEB J, V13, P2195, DOI 10.1096/fasebj.13.15.2195; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carrascal MT, 2003, CANCER RES, V63, P491; Chen JH, 2004, CELL COMMUN ADHES, V11, P1, DOI 10.1080/15419060490471739; Cho D, 2000, CANCER RES, V60, P2703; Cho DH, 2002, BIOCHEM BIOPH RES CO, V298, P289, DOI 10.1016/S0006-291X(02)02433-6; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Gossart S, 1996, J IMMUNOL, V156, P1540; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Ishida Y, 2004, FEBS LETT, V569, P156, DOI 10.1016/j.febslet.2004.05.039; Ju DW, 2001, CANCER RES, V61, P3735; Lissoni P, 2000, J BIOL REG HOMEOS AG, V14, P275; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Majima T, 2006, INT J CANCER, V118, P388, DOI 10.1002/ijc.21334; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Stoll S, 1997, J IMMUNOL, V159, P298; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734; Zhang B, 2004, LEUKEMIA RES, V28, P91, DOI 10.1016/S0145-2126(03)00121-8; Zhang H, 2002, WORLD J GASTROENTERO, V8, P994, DOI 10.3748/wjg.v8.i6.994	25	64	68	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1468	1476		10.1038/sj.onc.1209926	http://dx.doi.org/10.1038/sj.onc.1209926			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	17001321				2022-12-25	WOS:000244558800011
J	Rojas, P; Cadenas, MB; Lin, PC; Benavides, F; Conti, CJ; Rodriguez-Puebla, ML				Rojas, P.; Cadenas, M. B.; Lin, P. -C; Benavides, F.; Conti, C. J.; Rodriguez-Puebla, M. L.			Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis	ONCOGENE			English	Article						cyclin D3; cyclin D2; skin; DMBA; keratinocytes; papillomas	DEPENDENT KINASE-ACTIVITY; SQUAMOUS-CELL CARCINOMA; TUMOR-DEVELOPMENT; IN-VIVO; TRANSGENIC MICE; EXPRESSION; PROLIFERATION; D1; DIFFERENTIATION; PROGRESSION	D-type cyclins are components of the cell-cycle engine that link cell signaling pathways and passage throughout G1 phase. We previously described the effects of overexpression cyclin D1, D2 or D3 in mouse epidermis and tumor development. We now asked whether cyclin D2 and/or cyclin D3 play a relevant role in ras-dependent tumorigenesis. Here, we described the effect of cyclin D3 and cyclin D2 overexpression in mouse skin tumor development. Notably, overexpression of cyclin D3 results in reduced tumor development and malignant progression to squamous cell carcinomas (SCC). Biochemical analysis of keratinocytes shows that overexpression of cyclin D3 results in strong reduction of cyclin D2 and its associated kinase activity. Furthermore, we found that reinstatement of cyclin D2 level in the cyclin D3/cyclin D2 bigenic mice results in a complete reversion of the inhibitory action of cyclin D3. Supporting these results, ablation of cyclin D2 results in reduced tumorigenesis and malignant progression. On the other hand, overexpression of cyclin D2 results in an increased number of papillomas and malignant progression. We conclude that cyclin D3 and cyclin D2 play opposite roles in mouse skin tumor development and that the suppressive activity of cyclin D3 is associated with cyclin D2 downregulation.	N Carolina State Univ, Coll Vet Med, Ctr Comparat Med & Translat Res Mol Biomed Sci, CVM, Raleigh, NC 27606 USA; MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Div, Smithville, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of North Carolina; North Carolina State University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rodriguez-Puebla, ML (corresponding author), N Carolina State Univ, Coll Vet Med, Ctr Comparat Med & Translat Res Mol Biomed Sci, CVM, 4700 Hillsborough St, Raleigh, NC 27606 USA.	marcelo_rodriguez-puebla@ncsu.edu	Lin, Pei-Chun/A-3200-2013	Benavides, Fernando/0000-0003-1275-4320	NATIONAL CANCER INSTITUTE [R01CA116328] Funding Source: NIH RePORTER; NCI NIH HHS [CA116328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; de Marval PLM, 2004, ONCOGENE, V23, P1863, DOI 10.1038/sj.onc.1207309; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Filipits M, 2002, CLIN CANCER RES, V8, P729; Fujii M, 2001, CANCER LETT, V172, P187, DOI 10.1016/S0304-3835(01)00651-6; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; HOULDSWORTH J, 1997, CELL GROWTH DIFFER, V8, P292; Ito Y, 2001, ANTICANCER RES, V21, P1043; KIESS M, 1995, ONCOGENE, V10, P159; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Mariappan I, 2005, MOL BIOL CELL, V16, P1948, DOI 10.1091/mbc.E04-02-0154; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Pruneri G, 2005, CLIN CANCER RES, V11, P242; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1999, GENE DEV, V10, P1491; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J	33	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1723	1730		10.1038/sj.onc.1209970	http://dx.doi.org/10.1038/sj.onc.1209970			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983339				2022-12-25	WOS:000244955600006
J	Hawtin, SR; Simms, J; Conner, M; Lawson, Z; Parslow, RA; Trim, J; Sheppard, A; Wheatley, M				Hawtin, Stuart R.; Simms, John; Conner, Matthew; Lawson, Zoe; Parslow, Rosemary A.; Trim, Julie; Sheppard, Andrew; Wheatley, Mark			Charged extracellular residues, conserved throughout a G-protein-coupled receptor family, are required for ligand binding, receptor activation, and cell-surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-1A VASOPRESSIN RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTORS; SITE-DIRECTED MUTAGENESIS; HIGH-AFFINITY; N-TERMINUS; AGONIST BINDING; ANGIOTENSIN-II; IDENTIFICATION; PEPTIDE; ANTAGONIST	For G-protein-coupled receptors (GPCRs) in general, the roles of extracellular residues are not well defined compared with residues in transmembrane helices (TMs). Nevertheless, extracellular residues are important for various functions in both peptide-GPCRs and amine-GPCRs. In this study, the V-1a vasopressin receptor was used to systematically investigate the role of extracellular charged residues that are highly conserved throughout a subfamily of peptide-GPCRs, using a combination of mutagenesis and molecular modeling. Of the 13 conserved charged residues identified in the extracellular loops (ECLs), Arg(116) (ECL1), Arg(125) ( top of TMIII), and Asp(204) (ECL2) are important for agonist binding and/or receptor activation. Molecular modeling revealed that Arg(125) ( and Lys(125)) stabilizes TMIII by interacting with lipid head groups. Charge reversal (Asp(125)) caused re-ordering of the lipids, altered helical packing, and increased solvent penetration of the TM bundle. Interestingly, a negative charge is excluded at this locus in peptide-GPCRs, whereas a positive charge is excluded in amine-GPCRs. This contrasting conserved charge may reflect differences in GPCR binding modes between peptides and amines, with amines needing to access a binding site crevice within the receptor TM bundle, whereas the binding site of peptide-GPCRs includes more extracellular domains. A conserved negative charge at residue 204 ( ECL2), juxtaposed to the highly conserved disulfide bond, was essential for agonist binding and signaling. Asp(204) ( and Glu(204)) establishes TMIII contacts required for maintaining the beta-hairpin fold of ECL2, which if broken (Ala(204) or Arg(204)) resulted in ECL2 unfolding and receptor dysfunction. This study provides mechanistic insight into the roles of conserved extracellular residues.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Ferring Res Ltd, Southampton SO16 7NP, Hants, England	University of Birmingham	Wheatley, M (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	m.wheatley@bham.ac.uk		Simms, John/0000-0002-4675-0902; Wheatley, Mark/0000-0001-6261-5682	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arthus MF, 2000, J AM SOC NEPHROL, V11, P1044, DOI 10.1681/ASN.V1161044; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BIRNBAUMER M, 1994, MOL ENDOCRINOL, V8, P886, DOI 10.1210/me.8.7.886; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Conner AC, 2005, MOL PHARMACOL, V67, P20, DOI 10.1124/mol.67.1.20; Cotte N, 1998, J BIOL CHEM, V273, P29462, DOI 10.1074/jbc.273.45.29462; Ding XQ, 2002, MOL PHARMACOL, V61, P1041, DOI 10.1124/mol.61.5.1041; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Fromme BJ, 2001, MOL PHARMACOL, V60, P1280, DOI 10.1124/mol.60.6.1280; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Gnagey AL, 1999, MOL PHARMACOL, V56, P1245, DOI 10.1124/mol.56.6.1245; Hausmann H, 1996, P NATL ACAD SCI USA, V93, P6907, DOI 10.1073/pnas.93.14.6907; Hawtin SR, 2005, MOL ENDOCRINOL, V19, P2871, DOI 10.1210/me.2005-0148; Hawtin SR, 2003, EUR J BIOCHEM, V270, P4681, DOI 10.1046/j.1432-1033.2003.03865.x; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; Hawtin SR, 2001, BIOCHEM J, V354, P465, DOI 10.1042/0264-6021:3540465; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Hawtin SR, 2000, BIOCHEMISTRY-US, V39, P13524, DOI 10.1021/bi0013400; Hibert M, 1999, J RECEPT SIGNAL TR R, V19, P589, DOI 10.3109/10799899909036674; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; Howl J, 1997, FASEB J, V11, P582, DOI 10.1096/fasebj.11.7.9212082; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; Katancik JA, 2000, CYTOKINE, V12, P1480, DOI 10.1006/cyto.2000.0742; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Marie J, 2001, J BIOL CHEM, V276, P41100, DOI 10.1074/jbc.M104875200; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; Ott TR, 2002, MOL ENDOCRINOL, V16, P1079, DOI 10.1210/me.16.5.1079; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Strandberg E, 2003, FEBS LETT, V544, P69, DOI 10.1016/S0014-5793(03)00475-7; Tan FI, 2000, BIOL REPROD, V62, P8, DOI 10.1095/biolreprod62.1.8; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wesley VJ, 2002, BIOCHEMISTRY-US, V41, P5086, DOI 10.1021/bi015990v; Zhao MM, 1996, MOL PHARMACOL, V50, P1118	52	41	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38478	38488		10.1074/jbc.M607639200	http://dx.doi.org/10.1074/jbc.M607639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	16990262	hybrid, Green Accepted			2022-12-25	WOS:000242709500042
J	Bredemeyer, AJ; Carrigan, PE; Fehniger, TA; Smith, DF; Ley, TJ				Bredemeyer, Andrew J.; Carrigan, Patricia E.; Fehniger, Todd A.; Smith, David F.; Ley, Timothy J.			Hop cleavage and function in granzyme B-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CYTOCHROME-C RELEASE; STRESS-INDUCIBLE PROTEIN-1; CASPASE ACTIVATION; CELL-DEATH; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; MEDIATED APOPTOSIS; DNA FRAGMENTATION; IN-VIVO	Granzyme B (GzmB) is a cytotoxic protease found in the granules of natural killer cells and cytotoxic T lymphocytes. GzmB cleaves multiple intracellular protein substrates, leading to caspase activation, DNA fragmentation, cytoskeletal instability, and rapid induction of target cell apoptosis. However, no known individual substrate is required for GzmB to induce apoptosis. GzmB is therefore thought to initiate multiple cell death pathways simultaneously to ensure the death of target cells. We previously identified Hop (Hsp70/Hsp90-organizing protein) as a GzmB substrate in a proteomic survey (Bredemeyer, A. J., Lewis, R. M., Malone, J. P., Davis, A. E., Gross, J., Townsend, R. R., and Ley, T. J. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 11785 11790). Hop is a co-chaperone for Hsp70 and Hsp90, which have been implicated in the negative regulation of apoptosis. We therefore hypothesized that Hop may have an anti-apoptotic function that is abolished upon cleavage, lowering the threshold for GzmB-induced apoptosis. Here, we show that Hop was cleaved directly by GzmB in vitro and in cells undergoing GzmB induced apoptosis. Expression of the two cleavage fragments of Hop did not induce cell death. Although cleavage of Hop by GzmB destroyed Hop function in vitro, both cells overexpressing GzmB-resistant Hop and cells with a 90-95% reduction in Hop levels exhibited unaltered susceptibility to GzmB-induced death. We conclude that Hop per se does not set the threshold for susceptibility to GzmB-induced apoptosis. Although it is possible that Hop may be cleaved by GzmB as an "innocent bystander" during the induction of apoptosis, it may also act to facilitate apoptosis in concert with other GzmB substrates.	Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Washington University (WUSTL); Mayo Clinic; Mayo Clinic Phoenix	Ley, TJ (corresponding author), Washington Univ, Sch Med, Dept Med, Div Oncol, Campus Box 8007,660 S Euclid Ave, St Louis, MO 63110 USA.	tley@im.wustl.edu		Fehniger, Todd/0000-0002-8705-2887	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044923, R01DK049786] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK49786, R01-DK44923] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Adrain C, 2005, J BIOL CHEM, V280, P4663, DOI 10.1074/jbc.M410915200; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Andrade F, 2003, ACTA HAEMATOL-BASEL, V111, P28, DOI 10.1159/000074484; Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Beresford PJ, 1998, J IMMUNOL, V161, P161; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Carrigan PE, 2004, J BIOL CHEM, V279, P16185, DOI 10.1074/jbc.M314130200; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; CRIPE TP, 1995, J VIROL, V69, P7807, DOI 10.1128/JVI.69.12.7807-7813.1995; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Goping IS, 2006, J CELL SCI, V119, P858, DOI 10.1242/jcs.02791; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Grossman WJ, 2004, BLOOD, V104, P2840, DOI 10.1182/blood-2004-03-0859; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; JINDAL S, 1992, J VIROL, V66, P5357, DOI 10.1128/JVI.66.9.5357-5362.1992; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; Kelly JM, 2004, J BIOL CHEM, V279, P22236, DOI 10.1074/jbc.M401670200; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lane AA, 2005, MOL CELL BIOL, V25, P23, DOI 10.1128/MCB.25.1.23-33.2005; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Loeb CRK, 2006, J BIOL CHEM, V281, P28326, DOI 10.1074/jbc.M604544200; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; MACEJAK DG, 1992, J VIROL, V66, P1520, DOI 10.1128/JVI.66.3.1520-1527.1992; McClellan AJ, 2005, CELL, V121, P739, DOI 10.1016/j.cell.2005.03.024; Nelson GM, 2003, CELL STRESS CHAPERON, V8, P125, DOI 10.1379/1466-1268(2003)008<0125:COTCDR>2.0.CO;2; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pham CTN, 1998, J BIOL CHEM, V273, P1629, DOI 10.1074/jbc.273.3.1629; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Revell PA, 2005, J IMMUNOL, V174, P2124, DOI 10.4049/jimmunol.174.4.2124; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SULLIVAN WP, 1985, BIOCHEMISTRY-US, V24, P4214, DOI 10.1021/bi00336a060; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Waterhouse NJ, 2006, IMMUNOL CELL BIOL, V84, P72, DOI 10.1111/j.1440-1711.2005.01416.x; Waterhouse NJ, 2006, CELL DEATH DIFFER, V13, P607, DOI 10.1038/sj.cdd.4401772; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598; Zhang D, 2001, J BIOL CHEM, V276, P3683, DOI 10.1074/jbc.M005390200	72	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37130	37141		10.1074/jbc.M607969200	http://dx.doi.org/10.1074/jbc.M607969200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17005566	hybrid			2022-12-25	WOS:000242220800074
J	Lee, HR; Johnson, KA				Lee, Harold R.; Johnson, Kenneth A.			Fidelity of the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; ACTIVE-SITE; REPLICATION; NUCLEOSIDE; DYSFUNCTION; MUTATION; GAMMA; CARDIOMYOPATHY; SUBSTITUTION; MECHANISM	We have quantified the fidelity of polymerization of DNA by human mitochondrial DNA polymerase using synthetic DNA oligonucleotides and recombinant holoenzyme and examining each of the possible 16-base pair combinations. Although the kinetics of incorporation for all correct nucleotides are similar, with an average K-d of 0.8 mu M and an average k(pol) of 37 s(-1), the kinetics of misincorporation vary widely. The ground state binding Kd of incorrect bases ranges from a low of 25 mu M for a dATP: A mispair to a high of 360 mu M for a dCTP: T mispair. Similarly, the rates of incorporation of incorrect bases vary from 0.0031 s(-1) for a dCTP: C mispair to 1.16 s(-1) for a dGTP: T mispair. Due to the variability in the kinetic parameters for misincorporation, the estimates of fidelity range from 1 error in 3563 nucleotides for dGTP: T to 1 error in 2.3 x 10(6) nucleotides for dCTP: C. Interestingly, the discrimination against a dGTP: T mismatch is 16.5 times lower than that of a dTTP: G mismatch due to a tighter K-d for ground state binding and a faster rate of incorporation of the dGTP: T mismatch relative to the dTTP: G mismatch. We calculate an average fidelity of 1 error in 440,000 nucleotides.	Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, 2500 Speedway,A4800, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu			NIGMS NIH HHS [R01 GM044613] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003; Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8; Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Hanes JW, 2006, J BIOL CHEM, V281, P36241, DOI 10.1074/jbc.M607965200; He L, 2003, LEUKEMIA, V17, P2487, DOI 10.1038/sj.leu.2403146; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim TW, 2006, J BIOL CHEM, V281, P2289, DOI 10.1074/jbc.M510744200; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288; Lewis W, 2003, ANTIVIR RES, V58, P189, DOI 10.1016/S0166-3542(03)00069-X; Lewis W, 2001, LAB INVEST, V81, P1527, DOI 10.1038/labinvest.3780366; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Minnick DT, 2002, P NATL ACAD SCI USA, V99, P1194, DOI 10.1073/pnas.032457899; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pesole G, 1999, J MOL EVOL, V48, P427, DOI 10.1007/PL00006487; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PLESS RC, 1983, BIOCHEMISTRY-US, V22, P4905, DOI 10.1021/bi00290a006; Santorelli FM, 1996, NEUROLOGY, V47, P1320, DOI 10.1212/WNL.47.5.1320; Santorelli FM, 1996, AM J HUM GENET, V58, P933; Squires KE, 2001, ANTIVIR THER, V6, P1; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	43	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36236	36240		10.1074/jbc.M607964200	http://dx.doi.org/10.1074/jbc.M607964200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005554	hybrid			2022-12-25	WOS:000242100500075
J	Opitz, B; Vinzing, M; van Laak, V; Schmeck, B; Heine, G; Gunther, S; Preissner, R; Slevogt, H; N'Guessan, PD; Eitel, J; Goldmann, T; Flieger, A; Suttorp, N; Hippenstiel, S				Opitz, Bastian; Vinzing, Maya; van Laak, Vincent; Schmeck, Bernd; Heine, Guido; Guenther, Stefan; Preissner, Robert; Slevogt, Hortense; N'Guessan, Philippe Dje; Eitel, Julia; Goldmann, Torsten; Flieger, Antje; Suttorp, Norbert; Hippenstiel, Stefan			Legionella pneumophila induces IFN beta in lung epithelial cells via IPS-1 and IRF3, which also control bacterial replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; INNATE IMMUNE-RESPONSES; NF-KAPPA-B; LISTERIA-MONOCYTOGENES; ADAPTER PROTEIN; RIG-I; RNA HELICASE; P38 MAPK; INFECTION; INTERFERON	Legionella pneumophila, a Gram-negative facultative intracellular bacterium, causes severe pneumonia ( Legionnaires' disease). Type I interferons (IFNs) were so far associated with antiviral immunity, but recent studies also indicated a role of these cytokines in immune responses against ( intracellular) bacteria. Here we show that wild-type L. pneumophila and flagellin-deficient Legionella, but not L. pneumophila lacking a functional type IV secretion system Dot/Icm, or heat-inactivated Legionella induced IFN beta expression in human lung epithelial cells. We found that factor (IRF)-3 and NF-kappa B-p65 translocated into the nucleus and bound to the IFN beta gene enhancer after L. pneumophila infection of lung epithelial cells. RNA interference demonstrated that in addition to IRF3, the caspase recruitment domain (CARD)-containing adapter molecule IPS-1 (interferon-beta promoter stimulator 1) is crucial for L. pneumophila-induced IFN beta expression, whereas other CARD-possessing molecules, such as RIG-I ( retinoic acid-inducible protein I), MDA5 ( melanoma differentiation-associated gene 5), Nod27(nucleotide-binding oligomerization domain protein 27), and ASC (apoptosis-associated speck-like protein containing a CARD) seemed not to be involved. Finally, bacterial multiplication assays in small interfering RNA-treated cells indicated that IPS-1, IRF3, and IFN beta were essential for the control of intracellular replication of L. pneumophila in lung epithelial cells. In conclusion, we demonstrated a critical role of IPS-1, IRF3, and IFN beta in Legionella infection of lung epithelium.	Charite Univ Med Berlin, Dept Internal Med Infect Dis & Resp Med, D-13353 Berlin, Germany; Charite Univ Med Berlin, Allergy Ctr Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany; Inst Biochem Charite, D-10117 Berlin, Germany; Res Ctr Borstel, D-23845 Borstel, Germany; Robert Koch Inst, Res Grp NG5 Pathogenesis Legionella Infect, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Forschungszentrum Borstel; Robert Koch Institute	Opitz, B (corresponding author), Charite Univ Med Berlin, Dept Internal Med Infect Dis & Resp Med, Augustenburguer Pl 1, D-13353 Berlin, Germany.	bastian.opitz@charite.de	Goldmann, Torsten/E-5906-2010; Günther, Stefan/AAY-8944-2020; Heine, Guido/G-1656-2018	Goldmann, Torsten/0000-0002-1621-560X; Heine, Guido/0000-0003-1467-9862; Opitz, Bastian/0000-0003-1276-836X; Flieger, Antje/0000-0003-3819-2979; Hippenstiel, Stefan/0000-0002-5146-1064; Suttorp, Norbert/0000-0002-3958-1151; preissner, robert/0000-0002-2407-1087				Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Auerbuch V, 2004, J EXP MED, V200, P527, DOI 10.1084/jem.20040976; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Beutler B, 2005, IMMUNOGENETICS, V57, P385, DOI 10.1007/s00251-005-0011-3; Carrero JA, 2004, J EXP MED, V200, P535, DOI 10.1084/jem.20040769; Conti BJ, 2005, J BIOL CHEM, V280, P18375, DOI 10.1074/jbc.M413169200; Decker T, 2005, NAT REV IMMUNOL, V5, P675, DOI 10.1038/nri1684; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kumar H, 2006, J EXP MED, V203, P1795, DOI 10.1084/jem.20060792; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; McCaffrey RL, 2004, P NATL ACAD SCI USA, V101, P11386, DOI 10.1073/pnas.0403215101; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Neild AL, 2004, CELL MICROBIOL, V6, P1011, DOI 10.1111/j.1462-5822.2004.00450.x; O'Connell RM, 2005, J IMMUNOL, V174, P1602, DOI 10.4049/jimmunol.174.3.1602; O'Connell RM, 2004, J EXP MED, V200, P437, DOI 10.1084/jem.20040712; O'Riordan M, 2002, P NATL ACAD SCI USA, V99, P13861, DOI 10.1073/pnas.202476699; Opitz B, 2006, J IMMUNOL, V176, P484, DOI 10.4049/jimmunol.176.1.484; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Ren T, 2006, PLOS PATHOG, V2, P175, DOI 10.1371/journal.ppat.0020018; Schiavoni G, 2004, J IMMUNOL, V173, P1266, DOI 10.4049/jimmunol.173.2.1266; Schmeck B, 2004, J BIOL CHEM, V279, P53241, DOI 10.1074/jbc.M313702200; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Soulat D, 2006, FEBS LETT, V580, P2341, DOI 10.1016/j.febslet.2006.03.057; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Stockinger S, 2004, J IMMUNOL, V173, P7416, DOI 10.4049/jimmunol.173.12.7416; Stockinger S, 2002, J IMMUNOL, V169, P6522, DOI 10.4049/jimmunol.169.11.6522; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Swanson MS, 2000, ANNU REV MICROBIOL, V54, P567, DOI 10.1146/annurev.micro.54.1.567; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305	39	102	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36173	36179		10.1074/jbc.M604638200	http://dx.doi.org/10.1074/jbc.M604638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16984921	hybrid			2022-12-25	WOS:000242100500067
J	Song, R; Koo, BK; Yoon, KJ; Yoon, MJ; Yoo, KW; Kim, HT; Oh, HJ; Kim, YY; Han, JK; Kim, CH; Kong, YY				Song, Ran; Koo, Bon-Kyoung; Yoon, Ki-Jun; Yoon, Mi-Jeong; Yoo, Kyeong-Won; Kim, Hyun-Taek; Oh, Hyeon-Jeong; Kim, Yoon-Young; Han, Jin-Kwan; Kim, Cheol-Hee; Kong, Young-Yun			Neuralized-2 regulates a Notch ligand in cooperation with mind bomb-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; CELL FATE; NEUROGENIC GENES; DROSOPHILA; DELTA; ACTIVATION; ENDOCYTOSIS; EXPRESSION; PROTEINS; HOMOLOG	Mutations in Drosophila neuralized (Dneur) result in a variety of developmental defects that closely resemble those of Notch mutants and other Notch pathway mutants. However, mice with disrupted neur1 do not show any aberrant cell fate specifications in neurogenesis and somitogenesis. Thus, we speculated that other vertebrate neur homolog(s) might compensate for loss of the neur gene. Here, we report the paralog of mouse Neur1, named Neuralized-2 (Neur2), which is a ubiquitin-protein isopeptide ligase (E3) that interacts with and ubiquitinates Delta. Both murine Neur1 and Neur2 have similar degrees of homology to DNeur, and neur2 is expressed in patterns similar to those of neur1 in embryos, suggesting potential functional redundancy. Interestingly, two distinct classes of E3 ligases, Mind bomb-1 (Mib1) and Neur2, have cooperative but distinct roles in Delta endocytosis to Hrs-positive vesicles, i.e. Mib1 functions in the initial step of Delta endocytosis, and Neur2 is required for targeting endocytosed Delta to Hrs-positive vesicles. Thus, our study provides a new insight into how distinct E3 ligases work together in the endocytic pathways for Notch signaling.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea	Pohang University of Science & Technology (POSTECH); Chungnam National University	Kong, YY (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea.	ykong@postech.ac.kr	Yoon, Ki-Jun/S-8170-2018; Koo, Bon-Kyoung/V-5219-2017	Koo, Bon-Kyoung/0000-0002-4134-8033; Kim, Cheol-Hee/0000-0002-3019-0699; Yoon, Ki-Jun/0000-0003-2985-2541				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Chen WB, 2004, DEV BIOL, V267, P361, DOI 10.1016/j.ydbio.2003.11.010; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Deblandre GA, 2001, DEV CELL, V1, P795, DOI 10.1016/S1534-5807(01)00091-0; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Emery G, 2005, CELL, V122, P763, DOI 10.1016/j.cell.2005.08.017; Hagedorn EJ, 2006, J CELL BIOL, V173, P443, DOI 10.1083/jcb.200602054; Hamada Y, 1999, DEVELOPMENT, V126, P3415; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Itoh M, 2001, MECH DEVELOP, V102, P263, DOI 10.1016/S0925-4773(01)00308-2; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Kim CH, 1997, NEUROSCI LETT, V239, P113, DOI 10.1016/S0304-3940(97)00908-7; Klueg KM, 1999, J CELL SCI, V112, P3289; Koo BK, 2005, DEVELOPMENT, V132, P3459, DOI 10.1242/dev.01922; Koo BK, 2005, J BIOL CHEM, V280, P22335, DOI 10.1074/jbc.M501631200; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Lai EC, 2005, DEVELOPMENT, V132, P2319, DOI 10.1242/dev.01825; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lai EC, 2001, P NATL ACAD SCI USA, V98, P5637, DOI 10.1073/pnas.101135498; Lai EC, 2001, DEV BIOL, V231, P217, DOI 10.1006/dbio.2000.0124; Le Borgne R, 2005, PLOS BIOL, V3, P688, DOI 10.1371/journal.pbio.0030096; Le Borgne R, 2003, DEV CELL, V5, P139, DOI 10.1016/S1534-5807(03)00187-4; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; OKA C, 1995, DEVELOPMENT, V121, P3291; Overstreet E, 2004, DEVELOPMENT, V131, P5355, DOI 10.1242/dev.01434; Parks AL, 2000, DEVELOPMENT, V127, P1373; Pavlopoulos E, 2001, DEV CELL, V1, P807, DOI 10.1016/S1534-5807(01)00093-4; Pavlopoulos E, 2002, BBA-GENE STRUCT EXPR, V1574, P375, DOI 10.1016/S0167-4781(01)00330-X; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Pitsouli C, 2005, DEVELOPMENT, V132, P4041, DOI 10.1242/dev.01979; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Ruan YL, 2001, P NATL ACAD SCI USA, V98, P9907, DOI 10.1073/pnas.171321098; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; THISSE C, 1993, DEVELOPMENT, V119, P1203; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Vollrath B, 2001, MOL CELL BIOL, V21, P7481, DOI 10.1128/MCB.21.21.7481-7494.2001; Wang WD, 2005, DEVELOPMENT, V132, P2883, DOI 10.1242/dev.01860; Wang WD, 2004, DEVELOPMENT, V131, P5367, DOI 10.1242/dev.01413; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yeh E, 2001, CURR BIOL, V11, P1675, DOI 10.1016/S0960-9822(01)00527-9; Yeh E, 2000, EMBO J, V19, P4827, DOI 10.1093/emboj/19.17.4827; Zhong WM, 2000, P NATL ACAD SCI USA, V97, P6844, DOI 10.1073/pnas.97.12.6844	49	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36391	36400		10.1074/jbc.M606601200	http://dx.doi.org/10.1074/jbc.M606601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003037	hybrid			2022-12-25	WOS:000242100500090
J	Wong, KA; Lodish, HF				Wong, Kelly A.; Lodish, Harvey F.			A revised model for AMP-activated protein kinase structure - The alpha-subunit binds to both the beta- and gamma-subunits although there is no direct binding between the beta- and gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATIONS; UPSTREAM KINASE; CASCADE; DOMAIN; OXIDATION; GLYCOGEN; COMPLEX; STRESS; SNF1; LKB1	The 5'-AMP-activated protein kinase ( AMPK) is a master sensor for cellular metabolic energy state. It is activated by a high AMP/ATP ratio and leads to metabolic changes that conserve energy and utilize alternative cellular fuel sources. The kinase is composed of a heterotrimeric protein complex containing a catalytic alpha-subunit, an AMP-binding gamma-subunit, and a scaffolding beta-subunit thought to bind directly both the alpha- and gamma-subunits. Here, we use coimmunoprecipitation of proteins in transiently transfected cells to show that the alpha 2-subunit binds directly not only to the beta-subunit, confirming previous work, but also to the gamma 1-subunit. Deletion analysis of the alpha 2-subunit reveals that the C-terminal 386 - 552 residues are sufficient to bind to the beta-subunit. The gamma 1-subunit binds directly to the alpha 2-subunit at two interaction sites, one within the catalytic domain consisting of alpha 2 amino acids 1 - 312 and a second within residues 386-552. Binding of the alpha 2 and the gamma 1-subunits was not affected by 400 mu M AMP or ATP. Furthermore, we show that the beta-subunit C terminus is essential for binding to the alpha 2-subunit but, in contrast to previous work, the beta-subunit does not bind directly to the gamma 1-subunit. Taken together, this study presents a new model for AMPK heterotrimer structure where through its C terminus the beta-subunit binds to the alpha-subunit that, in turn, binds to the gamma-subunit. There is no direct interaction between the alpha- and gamma-subunits.	Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.	lodish@wi.mit.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK47618, DK069021] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; ISELI TJ, 2005, J BIOL CHEM; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Nayak V, 2006, STRUCTURE, V14, P477, DOI 10.1016/j.str.2005.12.008; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005	25	32	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36434	36442		10.1074/jbc.M607410200	http://dx.doi.org/10.1074/jbc.M607410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012231	hybrid			2022-12-25	WOS:000242100500094
J	Aberg, E; Perander, M; Johansen, B; Julien, C; Meloche, S; Keyse, SM; Seternes, OM				Aberg, Espen; Perander, Maria; Johansen, Bjarne; Julien, Catherine; Meloche, Sylvain; Keyse, Stephen M.; Seternes, Ole-Morten			Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; NUCLEAR EXPORT; MESSENGER-RNA; LEPTOMYCIN B; BINDING; ERK3; PATHWAY; FAMILY; GENE; PROGRESSION	MAPK-activated protein kinase 5 (MK5) was recently identified as a physiological substrate of the atypical MAPK ERK3. Complex formation between ERK3 and MK5 results in phosphorylation and activation of MK5, concomitant stabilization of ERK3, and the nuclear exclusion of both proteins. However, ablation of ERK3 in HeLa cells using small interfering RNA or in fibroblasts derived from ERK3 null mice reduces the activity of endogenous MK5 by only 50%, suggesting additional mechanisms of MK5 regulation. Here we identify the ERK3-related kinase ERK4 as a bona fide interaction partner of MK5. Binding of ERK4 to MK5 is accompanied by phosphorylation and activation of MK5. Furthermore, complex formation also results in the relocalization of MK5 from nucleus to cytoplasm. However unlike ERK3, ERK4 is a stable protein, and its half-life is not modified by the presence or absence of MK5. Finally, although knock-down of ERK4 protein in HeLa cells reduces endogenous MK5 activity by similar to 50%, a combination of small interfering RNAs targeting both ERK4 and ERK3 causes a further reduction in the MK5 activity by more than 80%. We conclude that MK5 activation is dependent on both ERK3 and ERK4 in these cells and that these atypical MAPKs are both physiological regulators of MK5 activity.	Univ Tromso, Med Biol Inst, Dept Pharmacol, N-9037 Tromso, Norway; Univ Montreal, Inst Rech Immunovirol & Cancerol, Montreal, PQ H3C 3J7, Canada; Ninewells Hosp & Med Sch, Canc Res UK Stress Response Lab, Dundee DD1 9SY, Scotland	UiT The Arctic University of Tromso; Universite de Montreal; University of Dundee	Seternes, OM (corresponding author), Univ Tromso, Med Biol Inst, Dept Pharmacol, N-9037 Tromso, Norway.	olems@fagmed.uit.no	Keyse, Stephen M./B-9575-2009; Seternes, Ole Morten/M-9520-2019	Keyse, Stephen M./0000-0002-5150-8221; Seternes, Ole Morten/0000-0001-8537-3612; Perander, Maria/0000-0002-1177-2407				BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Goldberg JM, 2006, PLOS GENET, V2, P291, DOI 10.1371/journal.pgen.0020038; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Julien C, 2003, J BIOL CHEM, V278, P42615, DOI 10.1074/jbc.M302724200; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Ni H, 1998, BIOCHEM BIOPH RES CO, V243, P492, DOI 10.1006/bbrc.1998.8135; Schumacher S, 2004, EMBO J, V23, P4770, DOI 10.1038/sj.emboj.7600467; Seternes OM, 2004, EMBO J, V23, P4780, DOI 10.1038/sj.emboj.7600489; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Shi Y, 2003, MOL CELL BIOL, V23, P7732, DOI 10.1128/MCB.23.21.7732-7741.2003; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Turgeon B, 2002, GENOMICS, V80, P673, DOI 10.1006/geno.2002.7013; Turgeon B, 2000, BIOCHEM J, V346, P169, DOI 10.1042/0264-6021:3460169; Voncken JW, 2005, J BIOL CHEM, V280, P5178, DOI 10.1074/jbc.M407155200; Watanabe N, 2005, DEVELOPMENT, V132, P3175, DOI 10.1242/dev.01895; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199	32	53	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35499	35510		10.1074/jbc.M606225200	http://dx.doi.org/10.1074/jbc.M606225200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16971392	hybrid			2022-12-25	WOS:000241933700083
J	Kubarenko, A; Sergiev, P; Wintermeyer, W; Dontsova, O; Rodnina, MV				Kubarenko, Andrew; Sergiev, Petr; Wintermeyer, Wolfgang; Dontsova, Olga; Rodnina, Marina V.			Involvement of Helix 34 of 16 S rRNA in decoding and translocation on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR G; AMINOACYL-TRANSFER-RNA; ESCHERICHIA-COLI RIBOSOMES; DIRECTED CROSS-LINKING; MESSENGER-RNA; FACTOR TU; TRANSLATIONAL FIDELITY; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; BACTERIAL RIBOSOME	Helix 34 of 16 S rRNA is located in the head of the 30 S ribosomal subunit close to the decoding center and has been invoked in a number of ribosome functions. In the present work, we have studied the effects of mutations in helix 34 both in vivo and in vitro. Several nucleotides in helix 34 that are either highly conserved or form important tertiary contacts in 16 S rRNA (U961, C1109, A1191, and A1201) were mutated, and the mutant ribosomes were expressed in the Escherichia coli MC250 Delta 7 strain that lacks all seven chromosomal rRNA operons. Mutations at positions A1191 and U961 reduced the efficiency of subunit association and resulted in structural rearrangements in helix 27 (position 908) and helix 31 (position 974) of 16 S rRNA. All mutants exhibited increased levels of frameshifting and nonsense readthrough. The effects on frameshifting were specific in that-1 frameshifting was enhanced with mutant A1191G and-1 frameshifting with the other mutants. Mutations of A1191 moderately (similar to 2-fold) inhibited tRNA translocation. No significant effects were found on efficiency and rate of initiation, misreading of sense codons, or binding of tRNA to the E site. The data indicate that helix 34 is involved in controlling the maintenance of the reading frame and in tRNA translocation.	Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia; Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany; Univ Witten Herdecke, Inst Mol Biol, D-58448 Witten, Germany	Lomonosov Moscow State University; Witten Herdecke University; Witten Herdecke University	Dontsova, O (corresponding author), Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia.	dontsova@genebee.msu.su; rodnina@uni-wh.de	Dontsova, Olga/T-6072-2019; Sergiev, Petr V/D-7493-2012; Rodnina, Marina V./AAD-4667-2019	Sergiev, Petr V/0000-0001-8866-1863; Rodnina, Marina V./0000-0003-0105-3879				Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; BILGIN N, 1990, EMBO J, V9, P735, DOI 10.1002/j.1460-2075.1990.tb08167.x; BRINK MF, 1994, NUCLEIC ACIDS RES, V22, P325, DOI 10.1093/nar/22.3.325; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X; Harger JW, 2002, TRENDS BIOCHEM SCI, V27, P448, DOI 10.1016/S0968-0004(02)02149-7; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HOGAN JJ, 1978, BIOCHEMISTRY-US, V17, P587, DOI 10.1021/bi00597a005; JOHANSON U, 1995, NUCLEIC ACIDS RES, V23, P464, DOI 10.1093/nar/23.3.464; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1988, J MOL BIOL, V203, P699, DOI 10.1016/0022-2836(88)90203-3; Marquez V, 2004, CELL, V118, P45, DOI 10.1016/j.cell.2004.06.012; Matassova NB, 2001, RNA, V7, P1879; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; MOINE H, 1994, J MOL BIOL, V243, P402, DOI 10.1006/jmbi.1994.1668; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; OConnor M, 1997, NUCLEIC ACIDS RES, V25, P1185, DOI 10.1093/nar/25.6.1185; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Pape T, 2000, NAT STRUCT BIOL, V7, P104; Peske F, 2004, J MOL BIOL, V343, P1183, DOI 10.1016/j.jmb.2004.08.097; PRESCOTT C, 1991, NUCLEIC ACIDS RES, V19, P5281, DOI 10.1093/nar/19.19.5281; PRESCOTT CD, 1992, NUCLEIC ACIDS RES, V20, P1567, DOI 10.1093/nar/20.7.1567; RODNINA MV, 1994, ANAL BIOCHEM, V219, P380, DOI 10.1006/abio.1994.1282; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 2000, BIOL CHEM, V381, P377, DOI 10.1515/BC.2000.050; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; Rodriguez-Correa D, 2004, RNA, V10, P28, DOI 10.1261/rna.5172104; Savelsbergh A, 2003, MOL CELL, V11, P1517, DOI 10.1016/S1097-2765(03)00230-2; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Sergiev PV, 2000, J MOL BIOL, V299, P379, DOI 10.1006/jmbi.2000.3739; Sergiev PV, 1997, RNA, V3, P464; Sergiev PV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P963; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; STERN S, 1988, METHOD ENZYMOL, V164, P481; Tama F, 2003, P NATL ACAD SCI USA, V100, P9319, DOI 10.1073/pnas.1632476100; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; VanLoock MS, 2000, J MOL BIOL, V304, P507, DOI 10.1006/jmbi.2000.4213; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Yassin A, 2005, P NATL ACAD SCI USA, V102, P16620, DOI 10.1073/pnas.0508444102; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	53	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35235	35244		10.1074/jbc.M608060200	http://dx.doi.org/10.1074/jbc.M608060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990269	hybrid, Green Published			2022-12-25	WOS:000241933700057
J	Mirza, O; Skov, LK; Sprogoe, D; van den Broek, LAM; Beldman, G; Kastrup, JS; Gajhede, M				Mirza, Osman; Skov, Lars K.; Sprogoe, Desiree; van den Broek, Lambertus A. M.; Beldman, Gerrit; Kastrup, Jette S.; Gajhede, Michael			Structural rearrangements of sucrose phosphorylase from Bifidobacterium adolescentis during sucrose conversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMYLASE FAMILY; CRYSTAL-STRUCTURE; NEISSERIA-POLYSACCHAREA; AMYLOSUCRASE; MECHANISM; GLUCOSE; COMPLEX; ENZYME	The reaction mechanism of sucrose phosphorylase from Bifidobacterium adolescentis (BiSP) was studied by site-directed mutagenesis and x-ray crystallography. An inactive mutant of BiSP (E232Q) was co-crystallized with sucrose. The structure revealed a substrate-binding mode comparable with that seen in other related sucrose-acting enzymes. Wild-type BiSP was also crystallized in the presence of sucrose. In the dimeric structure, a covalent glucosyl intermediate was formed in one molecule of the BiSP dimer, and after hydrolysis of the glucosyl intermediate, a beta-D-glucose product complex was formed in the other molecule. Although the overall structure of the BiSP-glucosyl intermediate complex is similar to that of the BiSP(E232Q)-sucrose complex, the glucose complex discloses major differences in loop conformations. Two loops ( residues 336-344 and 132-137) in the proximity of the active site move up to 16 and 4 A, respectively. On the basis of these findings, we have suggested a reaction cycle that takes into account the large movements in the active-site entrance loops.	Danish Univ Pharmaceut Sci, Dept Med Chem, Biostruct Res Unit, DK-2100 Copenhagen, Denmark; Univ Wageningen & Res Ctr, Food Chem Lab, NL-6700 EV Wageningen, Netherlands	University of Copenhagen; Wageningen University & Research	Gajhede, M (corresponding author), Danish Univ Pharmaceut Sci, Dept Med Chem, Biostruct Res Unit, Universitetsparken 2, DK-2100 Copenhagen, Denmark.	mig@dfuni.dk	van den Broek, Lambertus/K-4930-2012; van den Broek, Lambertus/O-1253-2019; Beldman, Gerrit/A-1901-2009	van den Broek, Lambertus/0000-0002-4374-5753; van den Broek, Lambertus/0000-0002-4374-5753; Kastrup, Jette Sandholm/0000-0003-2654-1510; Mirza, Osman Asghar/0000-0001-9435-0690; Gajhede, Michael/0000-0001-9864-2287				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DOUDOROFF M, 1947, J BIOL CHEM, V168, P725; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hondoh H, 2003, J MOL BIOL, V326, P177, DOI 10.1016/S0022-2836(02)01402-X; Jensen MH, 2004, BIOCHEMISTRY-US, V43, P3104, DOI 10.1021/bi0357762; Kim JS, 1999, J BIOL CHEM, V274, P26279, DOI 10.1074/jbc.274.37.26279; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOIT CCP4 ESFEACMB N, V26; Mirza O, 2001, BIOCHEMISTRY-US, V40, P9032, DOI 10.1021/bi010706l; Park KH, 2000, BBA-PROTEIN STRUCT M, V1478, P165, DOI 10.1016/S0167-4838(00)00041-8; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; SILVERSTEIN R, 1967, J BIOL CHEM, V242, P1338; Sprogoe D, 2004, BIOCHEMISTRY-US, V43, P1156, DOI 10.1021/bi0356395; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; van den Broek LAM, 2004, APPL MICROBIOL BIOT, V65, P219, DOI 10.1007/s00253-003-1534-x; VOET JG, 1970, J BIOL CHEM, V245, P1020	21	60	65	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35576	35584		10.1074/jbc.M605611200	http://dx.doi.org/10.1074/jbc.M605611200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990265	hybrid			2022-12-25	WOS:000241933700090
J	Zraly, CB; Middleton, FA; Dingwall, AK				Zraly, Claudia B.; Middleton, Frank A.; Dingwall, Andrew K.			Hormone-response genes are direct in vivo regulatory targets of brahma (SWI/SNF) complex function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; IMMUNE-RESPONSE; RHABDOID TUMORS; DROSOPHILA SNR1; TRANSCRIPTION; EXPRESSION; BRM; ACTIVATION	Metazoan SWI/SNF chromatin remodeling complexes exhibit ATP-dependent activation and repression of target genes. The Drosophila Brahma (SWI/SNF) complex subunits BRM and SNR1 are highly conserved with direct counterparts in yeast (SWI2/SNF2 and SNF5) and mammals (BRG1/hBRM and INI1/hSNF5). BRM encodes the catalytic ATPase required for chromatin remodeling and SNR1 is a regulatory subunit. Importantly, SNR1 mediates ATP-independent repression functions of the complex in cooperation with histone deacetylases and direct contacts with gene-specific repressors. SNR1 and INI1, as components of their respective SWI/SNF complexes, are important for developmental growth control and patterning, with direct function as a tumor suppressor. To identify direct regulatory targets of the Brm complex, we performed oligonucleotide-based transcriptome microarray analyses using RNA isolated from mutant fly strains harboring dominant-negative alleles of snr1 and brm. Steady-state RNA isolated from early pupae was examined, as this developmental stage critically requires Brm complex function. We found the hormone-responsive Ecdys-one-induced genes (Eig) were strongly misregulated and that the Brm complex is directly associated with the promoter regions of these genes in vivo. Our results reveal that the Brm complex assists in coordinating hormone-dependent transcription regulation of the Eig genes.	Loyola Univ Chicago, Stritch Sch Med, Cardinal Bernardin Canc Ctr, Inst Oncol, Maywood, IL 60153 USA; Loyola Univ Chicago, Dept Pathol, Maywood, IL 60153 USA; SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA	Loyola University Chicago; Loyola University Chicago; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Dingwall, AK (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Cardinal Bernardin Canc Ctr, Inst Oncol, 2160 S 1st Ave, Maywood, IL 60153 USA.	adingwall@lumc.edu		Middleton, Frank/0000-0002-3107-7188				Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Armstrong JA, 2002, EMBO J, V21, P5245, DOI 10.1093/emboj/cdf517; Badenhorst P, 2005, GENE DEV, V19, P2540, DOI 10.1101/gad.1342605; Beckstead RB, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-r99; Beltran S, 2003, P NATL ACAD SCI USA, V100, P3293, DOI 10.1073/pnas.0538075100; Bennicelli Jeannette L., 1999, Current Opinion in Oncology, V11, P267, DOI 10.1097/00001622-199907000-00006; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 2002, CLIN CANCER RES, V8, P3461; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brumby AM, 2002, EMBO J, V21, P3377, DOI 10.1093/emboj/cdf334; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cho YS, 2005, GENOMICS, V86, P606, DOI 10.1016/j.ygeno.2005.07.007; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Elfring LK, 1998, GENETICS, V148, P251; Geng FQ, 2001, MOL CELL BIOL, V21, P4311, DOI 10.1128/MCB.21.13.4311-4320.2001; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; King-Jones K, 2005, NAT REV GENET, V6, P311, DOI 10.1038/nrg1581; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Korayem AM, 2004, INSECT BIOCHEM MOLEC, V34, P1297, DOI 10.1016/j.ibmb.2004.09.001; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Marenda DR, 2004, DEV BIOL, V267, P279, DOI 10.1016/j.ydbio.2003.10.040; Marenda DR, 2003, MOL CELL BIOL, V23, P289, DOI 10.1128/MCB.23.1.289-305.2003; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Medjkane S, 2004, CANCER RES, V64, P3406, DOI 10.1158/0008-5472.CAN-03-3004; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Papoulas O, 2001, P NATL ACAD SCI USA, V98, P5728, DOI 10.1073/pnas.091533398; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; RESTIFO LL, 1986, DEV BIOL, V115, P507, DOI 10.1016/0012-1606(86)90271-X; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Smith CL, 2003, NAT STRUCT BIOL, V10, P141, DOI 10.1038/nsb888; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tsikitis M, 2005, P NATL ACAD SCI USA, V102, P12129, DOI 10.1073/pnas.0505300102; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Wright LG, 1996, J MOL BIOL, V255, P387, DOI 10.1006/jmbi.1996.0032; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000; Wu DY, 2002, J BIOL CHEM, V277, P27706, DOI 10.1074/jbc.M200955200; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zraly CB, 2004, GENETICS, V168, P199, DOI 10.1534/genetics.104.029439; Zraly CB, 2003, DEV BIOL, V253, P291, DOI 10.1016/S0012-1606(02)00011-8	66	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35305	35315		10.1074/jbc.M607806200	http://dx.doi.org/10.1074/jbc.M607806200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990270	hybrid			2022-12-25	WOS:000241933700065
J	Cui, HJ; Ma, J; Ding, J; Li, T; Alam, G; Ding, HF				Cui, Hongjuan; Ma, Jun; Ding, Jane; Li, Tai; Alam, Goleeta; Ding, Han-Fei			Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREST STEM-CELLS; NEURO-BLASTOMA CELLS; MYC TRANSGENIC MICE; NERVOUS-SYSTEM; EXPRESSION; GROWTH; LINES; GENE; VARIANTS; INVITRO	Human neuroblastoma I-type cells have been proposed as a population of malignant neural crest stem cells, based on their high tumorigenic potential, expression of stem cell markers, and ability to differentiate into cells of neural crest lineages, including neuroblastic (N-type) and Schwann/glial (S-type) cells. Here, we demonstrate at single cell levels that a subpopulation of I-type cells possess clonogenic self-renewal capacity that requires the Polycomb group family transcription repressor Bmi-1. We further show that Bmi-1 expression levels exert an instructive influence on lineage commitment by I-type cells. Spontaneous and induced differentiation of I-type cells into S-type cells is accompanied by a marked reduction in the level of Bmi-1 expression, and enforced down-regulation of BMI-1 facilitates spontaneous differentiation of I-type cells into S-type cells. By contrast, N-type neuroblastoma cell lines and differentiated N-type cells express higher levels of Bmi-1 relative to I-type cells, and overexpression of BMI-1 promotes the differentiation of I-type cells along the neuronal lineage. Thus, Bmi-1 acts in a concentration-dependent manner in the control of the delicate balance between the self-renewal and differentiation of neuroblastoma I-type cells. These observations suggest that graded activation of a master regulator within individual tumors could trigger divergent developmental programs responsible for both tumor growth and heterogeneity.	Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA		Ding, HF (corresponding author), 3035 Arlington Ave, Toledo, OH 43614 USA.	hding@meduohio.edu		Ding, Han-Fei/0000-0001-5702-3439	NATIONAL CANCER INSTITUTE [R01CA106550] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106550] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; Bixby S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; BRONNERFRASER M, 1987, DEV BIOL, V123, P321, DOI 10.1016/0012-1606(87)90390-3; BUICK RN, 1981, BRIT J CANCER, V44, P349, DOI 10.1038/bjc.1981.191; Castleberry RP, 1997, EUR J CANCER, V33, P1430, DOI 10.1016/S0959-8049(97)00308-0; CICCARONE V, 1989, CANCER RES, V49, P219; Cui HJ, 2002, MOL CANCER THER, V1, P679; DECLERCK YA, 1987, CANCER RES, V47, P6505; Dyer MA, 2004, J CLIN PATHOL, V57, P561, DOI 10.1136/jcp.2003.009910; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEPPNER GH, 1984, CANCER RES, V44, P2259; Hoehner JC, 1998, LAB INVEST, V78, P29; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Lupo G, 2006, NAT REV NEUROSCI, V7, P103, DOI 10.1038/nrn1843; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mora J, 2001, CANCER RES, V61, P6892; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; PARYSEK LM, 1988, NEURON, V1, P395, DOI 10.1016/0896-6273(88)90189-4; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; RETTIG WJ, 1987, CANCER RES, V47, P1383; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1985, CANCER RES, V45, P1628; Ross RA, 2003, CANCER LETT, V197, P35, DOI 10.1016/S0304-3835(03)00079-X; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SIDELL N, 1982, J NATL CANCER I, V68, P589; Stamataki D, 2005, GENE DEV, V19, P626, DOI 10.1101/gad.325905; SUGIMOTO T, 1988, CANCER RES, V48, P2531; THOMSON SP, 1982, CANCER RES, V42, P4606; TSOKOS M, 1987, AM J PATHOL, V128, P484; TUCKER GC, 1988, CELL TISSUE RES, V251, P457, DOI 10.1007/BF00215855; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Zencak D, 2005, J NEUROSCI, V25, P5774, DOI 10.1523/JNEUROSCI.3452-04.2005	51	69	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34696	34704		10.1074/jbc.M604009200	http://dx.doi.org/10.1074/jbc.M604009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16982619	hybrid			2022-12-25	WOS:000241767600088
J	Dolmer, K; Gettins, PGW				Dolmer, Klavs; Gettins, Peter G. W.			Three complement-like repeats compose the complete alpha(2)-macroglobulin binding site in the second ligand binding cluster of the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; LDL-RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; ALPHA-MACROGLOBULINS; IN-VIVO; RECOGNITION; CALCIUM; DOMAIN; LRP	Given the importance of the low density lipoprotein receptor-related protein ( LRP) as an essential endocytosis and signaling receptor for many protein ligands, and of alpha(2)-macroglobulin (alpha M-2)-proteinase complexes as one such set of ligands, an understanding of the specificity of their interaction with LRP is an important goal. A starting point is the known role of the 138-residue receptor binding domain (RBD) in binding to LRP. Previous studies have localized high affinity alpha M-2 binding to the eight complement repeat (CR)-containing cluster 2 of LRP. In the present study we have identified the minimum CR domains that constitute the full binding site for RBD and, hence, for alpha M-2 on LRP. We report on the ability of the triple construct of CR3-4-5 to bind RBD with an affinity (K-d = 130 nM) the same as for isolated RBD to intact LRP. This K-d is 30-fold smaller than for RBD to CR5-6-7, demonstrating the specificity of the interaction with CR3-4-5. Binding requires previously identified critical lysine residues but is almost pH-independent within the range of pH values encountered between extracellular and internal compartments, consistent with an earlier proposed model of intracellular ligand displacement by intramolecular YWTD domains. The present findings suggest a model to explain the ability of LRP to bind a wide range of structurally unrelated ligands in which a nonspecific ligand interaction with the acidic region present in most CR domains is augmented by interactions with other CR surface residues that are unique to a particular CR cluster.	UIC, Dept Biochem & Mol Genet, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago	Gettins, PGW (corresponding author), UIC, Dept Biochem & Mol Genet, Coll Med, 900 S Ashland Ave,MC 669, Chicago, IL 60607 USA.	pgettins@uic.edu	Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X	NIGMS NIH HHS [GM54414] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen OM, 2000, BIOCHEMISTRY-US, V39, P10627, DOI 10.1021/bi000498h; Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; Arandjelovic S, 2005, ARCH BIOCHEM BIOPHYS, V438, P29, DOI 10.1016/j.abb.2005.03.019; Beglova N, 2001, BIOCHEMISTRY-US, V40, P2808, DOI 10.1021/bi0027276; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; Dolmer K, 1998, BIOCHEMISTRY-US, V37, P17016, DOI 10.1021/bi982022s; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; Fisher C, 2006, MOL CELL, V22, P277, DOI 10.1016/j.molcel.2006.02.021; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Huang W, 2000, J BIOL CHEM, V275, P1089, DOI 10.1074/jbc.275.2.1089; HUANG W, 1998, PROTEIN SCI, V7, P2602; Jeong KJ, 2005, NAT BIOTECHNOL, V23, P1493, DOI 10.1038/nbt1205-1493; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LEWIS SD, 1985, J BIOL CHEM, V260, P192; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Oganesyan Natalia, 2005, Journal of Structural and Functional Genomics, V6, P177, DOI 10.1007/s10969-005-2827-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rodenburg KW, 1998, BIOCHEM J, V329, P55; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Silverman J, 2005, NAT BIOTECHNOL, V23, P1556, DOI 10.1038/nbt1166; Simonovic M, 2001, BIOCHEMISTRY-US, V40, P15127, DOI 10.1021/bi015688m; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1985, P NATL ACAD SCI USA, V82, P9, DOI 10.1073/pnas.82.1.9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1982, BIOCHEM J, V203, P405, DOI 10.1042/bj2030405; Verdaguer N, 2004, NAT STRUCT MOL BIOL, V11, P429, DOI 10.1038/nsmb753; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	45	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34189	34196		10.1074/jbc.M604389200	http://dx.doi.org/10.1074/jbc.M604389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16982616	hybrid			2022-12-25	WOS:000241767600039
J	Dougherty, MJ; Boyd, JM; Downs, DM				Dougherty, Michael J.; Boyd, Jeffrey M.; Downs, Diana M.			Inhibition of fructose-1,6-bisphosphatase by aminoimidazole carboxamide ribotide prevents growth of Salmonella enterica purH mutants on glycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE; ESCHERICHIA-COLI; FRUCTOSE-BISPHOSPHATASE; THIAMINE SYNTHESIS; AMP; PURIFICATION; CONSTRUCTION; MUTAGENESIS; SITE	The enzyme fructose-1,6-bisphosphatase (FBP) is key regulatory point in gluconeogenesis. Mutants of Salmonella enterica lacking purH accumulate 5-amino-4-imidazole carboxamide ribotide (AICAR) and are unable to utilize glycerol as sole carbon and energy sources. The work described here demonstrates this lack of growth is due to inhibition of FBP by AICAR. Mutant alleles of fbp that restore growth on glycerol encode proteins resistant to inhibition by AICAR and the allosteric regulator AMP. This is the first report of biochemical characterization of substitutions causing AMP resistance in a bacterial FBP. Inhibition of FBP activity by AICAR occurs at physiologically relevant concentrations and may represent a form of regulation of gluconeogenic flux in Salmonella enterica.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Downs, DM (corresponding author), 420 Henry Mall, Madison, WI 53706 USA.	downs@bact.wisc.edu		Boyd, Jeffrey/0000-0001-7721-3926	NIGMS NIH HHS [GM47296, T32 GM08349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296, T32GM008349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen S, 2002, J BACTERIOL, V184, P6130, DOI 10.1128/JB.184.22.6130-6137.2002; BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Beck BJ, 1998, J BACTERIOL, V180, P885, DOI 10.1128/JB.180.4.885-891.1998; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOCHNER BR, 1982, CELL, V29, P929, DOI 10.1016/0092-8674(82)90455-X; CAETANOANOLLES G, 1993, PCR METH APPL, V3, P85; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN M, 1994, J BIOL CHEM, V269, P5554; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; DAVIES RW, 1980, ADV BACTERIAL GENETI; DOWNS DM, 1994, J BACTERIOL, V176, P4858, DOI 10.1128/jb.176.16.4858-4864.1994; DOWNS DM, 1987, PURINE METABOLISM CR; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; GIDHJAIN M, 1994, J BIOL CHEM, V269, P27732; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; Hines JK, 2006, J BIOL CHEM, V281, P18386, DOI 10.1074/jbc.M602553200; Iancu CV, 2005, J BIOL CHEM, V280, P19737, DOI 10.1074/jbc.M501011200; Iversen LF, 1997, PROTEIN SCI, V6, P971, DOI 10.1002/pro.5560060503; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley-Loughnane N, 2002, BBA-PROTEIN STRUCT M, V1594, P6, DOI 10.1016/S0167-4838(01)00261-8; Kelley-Loughnane N, 2001, BBA-PROTEIN STRUCT M, V1548, P66, DOI 10.1016/S0167-4838(01)00218-7; KLECKNER N, 1977, J MOL BIOL, V116, P125, DOI 10.1016/0022-2836(77)90123-1; LIANG JY, 1993, P NATL ACAD SCI USA, V90, P2132, DOI 10.1073/pnas.90.6.2132; MARCUS F, 1984, BIOCHEM BIOPH RES CO, V119, P1103, DOI 10.1016/0006-291X(84)90888-X; McKinney J, 2002, J BACTERIOL, V184, P6056, DOI 10.1128/JB.184.21.6056-6059.2002; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; Petersen L, 1996, GENETICS, V143, P37; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PONTREMO.S, 1965, J BIOL CHEM, V240, P3459; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Rebora K, 2005, GENETICS, V170, P61, DOI 10.1534/genetics.104.039396; ROBERTS GP, 1978, ISOLATION CHARACTERI; ROHLMAN CE, 1990, J BACTERIOL, V172, P7200, DOI 10.1128/jb.172.12.7200-7210.1990; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; SEDIVY JM, 1986, P NATL ACAD SCI USA, V83, P1656, DOI 10.1073/pnas.83.6.1656; Shyur LF, 1996, J BIOL CHEM, V271, P3005, DOI 10.1074/jbc.271.6.3005; Soberon M, 1997, MOL GEN GENET, V254, P665, DOI 10.1007/s004380050464; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vincent MF, 1996, DIABETOLOGIA, V39, P1148, DOI 10.1007/BF02658500; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Webb E, 1998, J BIOL CHEM, V273, P8946, DOI 10.1074/jbc.273.15.8946; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133; ZHANG R, 1995, J BIOL CHEM, V270, P54, DOI 10.1074/jbc.270.1.54	54	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33892	33899		10.1074/jbc.M604429200	http://dx.doi.org/10.1074/jbc.M604429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16987812	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000241767600010
J	Achur, RN; Agbor-Enoh, ST; Gowda, DC				Achur, Rajeshwara N.; Agbor-Enoh, Sean T.; Gowda, D. Channe			Rat spongiotrophoblast-specific protein is predominantly a unique low sulfated chondroitin sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; PLASMODIUM-FALCIPARUM; HUMAN PLACENTA; ADHERENCE; ADHESION; MALARIA; BERGHEI	We have previously demonstrated that the human placenta contains a uniquely low sulfated extracellular aggrecan family chondroitin sulfate proteoglycan (CSPG). This CSPG is a major receptor for the adherence of Plasmodium falciparum-infected red blood cells (IRBCs) in placentas, causing pregnancy-specific malaria. However, it is not known whether such low sulfated CSPGs occur in placentas of other animals and, if so, whether IRBCs bind to those CSPGs. In this study, we show that rat placenta contains a uniquely low sulfated extracellular CSPG bearing chondroitin sulfate (CS) chains, which comprise only similar to 2% 4-sulfated and the remainder nonsulfated disaccharides. Surprisingly, the core protein of the rat placental CSPG, unlike that of the human placental CSPG, is a spongiotrophoblast-specific protein (SSP), which is expressed in a pregnancy stage-dependent manner. The majority of rat placental SSP is present in the CSPG form, and only similar to 10% occurs without CS chain substitution. Of the total SSP-CSPG in rat placenta, similar to 57% is modified with a single CS chain, and similar to 43% carries two CS chains. These data together with the previous finding on human placental CSPG suggest that the expression of low sulfated CSPG is a common feature of animal placentas. Our data also show that the unique species-specific difference in the biology of the rat and human placentas is reflected in the occurrence of completely different CSPG core protein types. Furthermore, the rat SSP-CSPG binds P. falciparum IRBCs in aCS chain-dependent manner. Since IRBCs have been reported to accumulate in the placentas of malaria parasite-infected rodents, our results have important implications for exploiting pregnant rats as a model for studying chondroitin 4-sulfate-based therapeutics for human placental malaria.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Georgetown University	Gowda, DC (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA USA.	gowda@psu.edu		Gowda, Channe/0000-0002-6860-5108; Agbor-Enoh, Sean/0000-0002-9380-9161; Achur, Rajeshwara/0000-0001-9867-8917	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045086, R01AI045086] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45086] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achur RN, 2004, BBA-PROTEINS PROTEOM, V1701, P109, DOI 10.1016/j.bbapap.2004.06.007; Achur RN, 2003, J BIOL CHEM, V278, P11705, DOI 10.1074/jbc.M211015200; Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; Bowen JM, 2002, PLACENTA, V23, P239, DOI 10.1053/plac.2001.0781; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Chai WG, 2002, J BIOL CHEM, V277, P22438, DOI 10.1074/jbc.M111401200; Desowitz R. S., 2001, Malaria in pregnancy: deadly parasite, susceptible host, P127, DOI 10.4324/9780203302255_chapter_5; DISCHE Z, 1947, J BIOL CHEM, V167, P189; Fried M, 2000, EXP PARASITOL, V95, P75, DOI 10.1006/expr.2000.4510; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Iwatsuki K, 2000, BIOL REPROD, V62, P1352, DOI 10.1095/biolreprod62.5.1352; Keelan JA, 2003, PLACENTA, V24, pS33, DOI 10.1053/plac.2002.0948; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; MITCHELL MD, 1993, PLACENTA, V14, P249, DOI 10.1016/S0143-4004(05)80426-6; Muthusamy A, 2004, AM J PATHOL, V164, P2013, DOI 10.1016/S0002-9440(10)63761-3; NIEFELD JJ, 1994, EXPERIENTIA, V70, P217; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; ODUOLA AMJ, 1986, EXP PARASITOL, V62, P181, DOI 10.1016/0014-4894(86)90022-6; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; POOLE AR, 1986, BIOCHEM J, V236, P1; Poovassery J, 2006, INFECT IMMUN, V74, P2839, DOI 10.1128/IAI.74.5.2839-2848.2006; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAITO H, 1968, J BIOL CHEM, V243, P1536; Saito S, 2000, J REPROD IMMUNOL, V47, P87, DOI 10.1016/S0165-0378(00)00060-7; Soares MJ, 1998, BIOL REPROD, V58, P273, DOI 10.1095/biolreprod58.2.273; Soloveva V, 2004, PLACENTA, V25, P29, DOI 10.1016/S0143-4004(03)00215-7; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; TEGOSHI T, 1992, AM J TROP MED HYG, V47, P643, DOI 10.4269/ajtmh.1992.47.643; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	34	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32327	32334		10.1074/jbc.M605841200	http://dx.doi.org/10.1074/jbc.M605841200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954212	hybrid			2022-12-25	WOS:000241414500030
J	Davoust, N; Vuaillat, C; Cavillon, G; Domenget, C; Hatterer, E; Bernard, A; Dumontel, C; Jurdic, P; Malcus, C; Confavreux, C; Belin, MF; Nataf, S				Davoust, N.; Vuaillat, C.; Cavillon, G.; Domenget, C.; Hatterer, E.; Bernard, A.; Dumontel, C.; Jurdic, P.; Malcus, C.; Confavreux, C.; Belin, M. F.; Nataf, S.			Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia	FASEB JOURNAL			English	Article						glial cell; bone marrow; stem cells; cell transfer	CENTRAL-NERVOUS-SYSTEM; CELLS; RECRUITMENT; EXPRESSION	Recent evidence indicates that microglial cells may not derive from blood circulating mature monocytes as they express features of myeloid progenitors. Here, we observed that a subpopulation of microglial cells expressed CD34 and B220 antigens during brain development. We thus hypothesized that microglia, or a subset of microglial cells, originate from blood circulating CD34(+)/B220(+) myeloid progenitors, which could target the brain under developmental or neuroinflammatory conditions. Using experimental allergic encephalomyelitis (EAE) as a model of chronic neuroinflammation, we found that a discrete population of CD34(+)/B220(+) cells expands in both blood and brain of diseased animals. In EAE mice, intravenous transfer experiments showed that macrophage-colony stimulating factor (M-CSF)-expanded CD34(+) myeloid progenitors target the inflamed central nervous system (CNS) while keeping their immature phenotype. Based on these results, we then assessed whether CD34(+)/B220(+) cells display in vitro differentiation potential toward microglia. For this purpose, CD34(+)/B220(+) cells were sorted from M-CSF-stimulated bone marrow (BM) cultures and exposed to a glial cell conditioned medium. Under these experimental conditions, CD34(+)/B220(+) cells were able to differentiate into microglial-like cells showing the morphological and phenotypic features of native microglia. Overall, our data suggest that under developmental or neuroinflammatory conditions, a subpopulation of microglial cells derive from CNS-invading CD34(+)/B220(+) myeloid progenitors.	Fac Med Laennec, INSERM U433, IFR Neurosci Lyon, F-69372 Lyon, France; ENS, CNR 5161, Labs Biol Mol Cellule, Lyon, France; Hop Neurol, Immunol Lab, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); CHU Lyon	Nataf, S (corresponding author), Fac Med Laennec, INSERM U433, IFR Neurosci Lyon, 07 Rue Guillaume Paradin, F-69372 Lyon, France.	nataf@lyon.inserm.fr	Davoust, Nathalie/S-5676-2017					Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; ALLIOT F, 1991, P NATL ACAD SCI USA, V88, P1541, DOI 10.1073/pnas.88.4.1541; Asheuer M, 2004, P NATL ACAD SCI USA, V101, P3557, DOI 10.1073/pnas.0306431101; Camelo S, 2000, J NEUROVIROL, V6, P507, DOI 10.3109/13550280009091951; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Davoust N, 1999, J IMMUNOL, V163, P6551; del Hoyo GM, 2002, NATURE, V415, P1043, DOI 10.1038/4151043a; Flugel A, 2001, J NEUROSCI RES, V66, P74, DOI 10.1002/jnr.1198; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GIULIAN D, 1995, J NEUROSCI, V15, P7712; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Lesniak MS, 2005, NEUROL RES, V27, P820, DOI 10.1179/016164105X49454; Lima FRS, 2001, J NEUROSCI, V21, P2028, DOI 10.1523/JNEUROSCI.21-06-02028.2001; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; MILES JM, 1988, J NEUROPATH EXP NEUR, V47, P579, DOI 10.1097/00005072-198811000-00001; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ohsawa K, 2000, J CELL SCI, V113, P3073; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; Peterson JW, 2002, J NEUROPATH EXP NEUR, V61, P539, DOI 10.1093/jnen/61.6.539; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Rakic S, 2003, GLIA, V41, P117, DOI 10.1002/glia.10140; Santambrogio L, 2001, P NATL ACAD SCI USA, V98, P6295, DOI 10.1073/pnas.111152498; Tabatabai G, 2005, BRAIN, V128, P2200, DOI 10.1093/brain/awh563; Udani V, 2005, NEUROL RES, V27, P801, DOI 10.1179/016164105X49319; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	33	45	48	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2081	2092		10.1096/fj.05-5593com	http://dx.doi.org/10.1096/fj.05-5593com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012260				2022-12-25	WOS:000241156900016
J	Yamagata, M; Rook, SL; Sassa, Y; Ma, RC; Geraldes, P; Goddard, L; Clermont, A; Gao, B; Salti, H; Gundel, R; White, M; Feener, EP; Aiello, LP; King, GL				Yamagata, Michiko; Rook, Susan L.; Sassa, Yukio; Ma, Ronald C.; Geraldes, Pedro; Goddard, Lucy; Clermont, Allen; Gao, Benbo; Salti, Haytham; Gundel, Robert; White, Mark; Feener, Edward P.; Aiello, Lloyd Paul; King, George L.			Bactericidal/permeability-increasing protein's signaling pathways and its retinal trophic and anti-angiogenic effects	FASEB JOURNAL			English	Article						ERK; Akt; diabetic retinopathy; age-related macular degeneration; glypican 4	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; IN-VIVO; BPI; NEOVASCULARIZATION; RETINOPATHY; EXPRESSION; APOPTOSIS; FRAGMENT; CELLS	Bactericidal/permeability-increasing protein (BPI) was originally identified as a lipopolysaccharide (LPS) binding protein with Gram-negative bactericidal activity in the leukocytes. In this study, we characterized the previously unknown effects of BPI in the eye and the molecular mechanisms involved in its action. BPI mRNA was detected in bovine retina; retinal pigment epithelium; and primary cultures of bovine retinal pigment epithelial cells (RPE), pericytes (RPC), and endothelial cells (REC); while BPI protein was measured in human vitreous and plasma. BPI, but not control protein thaumatin, activated extracellular regulated kinase (ERK) and AKT, and increased DNA synthesis in RPE and RPC but not in REC. A human recombinant 21 kDa modified amino-terminal fragment of BPI (rBPI(21)) reduced H2O2-induced apoptosis in RPE and inhibited vascular endothelial growth factor (VEGF)-stimulated ERK phosphorylation in REC when preincubated with VEGF. Intraperitoneal (i.p.)-injected rBPI21 reduced ischemia-induced retinal neovascularization and diabetes-induced retinal permeability. Since BPI has unusual dual properties of promoting RPC and RPE growth while suppressing VEGF-induced REC growth and vascular permeability, the mechanistic understanding of BPI's action may provide novel therapeutic opportunities for diabetic retinopathy and age-related macular degeneration.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; XOMA US LLC, Dept Preclin Res & Cellular, Berkeley, CA USA; XOMA US LLC, Dept Analyt Dev, Berkeley, CA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	King, GL (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	george.king@joslin.harvard.edu	Ma, Ronald/C-2788-2009; Sassa, Yukio/H-6339-2012	Ma, Ronald/0000-0002-1227-803X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x; Canny G, 2002, P NATL ACAD SCI USA, V99, P3902, DOI 10.1073/pnas.052533799; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Harkin DW, 2001, ANN SURG, V234, P233, DOI 10.1097/00000658-200108000-00014; KING GL, 1987, DIABETES, V36, P1460, DOI 10.2337/diabetes.36.12.1460; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; Levine KB, 2002, BIOCHEMISTRY-US, V41, P12629, DOI 10.1021/bi0258997; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Rauniyar RK, 2002, INVEST OPHTH VIS SCI, V43, P503; SHAFER WM, 1984, INFECT IMMUN, V45, P29, DOI 10.1128/IAI.45.1.29-35.1984; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Takahashi M, 2004, EXP DERMATOL, V13, P55, DOI 10.1111/j.0906-6705.2004.00116.x; van der Schaft DWJ, 2000, BLOOD, V96, P176, DOI 10.1182/blood.V96.1.176.013k32_176_181; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WEISS J, 1978, J BIOL CHEM, V253, P2664	32	19	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2058	2067		10.1096/05-5662com	http://dx.doi.org/10.1096/05-5662com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012258				2022-12-25	WOS:000241156900014
J	Szabo, R; Molinolo, A; List, K; Bugge, TH				Szabo, R.; Molinolo, A.; List, K.; Bugge, T. H.			Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development	ONCOGENE			English	Article						placenta development; labyrinth formation; membrane proteolysis; trophoblast differentiation; basement membrane; protease inhibition	SERINE-PROTEASE INHIBITOR; BARRIER FUNCTION; EXPRESSION; HEPSIN; GENE; IDENTIFICATION; DEFICIENT; LETHALITY; HAI-1	Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a Kunitz-type transmembrane serine protease inhibitor that forms inhibitor complexes with several trypsin-like serine proteases and is required for mouse placental development and embryo survival. Here we show that the essential function of HAI-1 in placentation and all other embryonic processes is to restrict the activity of the type II transmembrane serine protease, matriptase. Enzymatic gene trapping of matriptase combined with HAI-1 immunohistochemistry revealed that matriptase is co-expressed with HAI-1 in both extraembryonic and embryonic tissues. As early as embryonic day 8.5, matriptase and HAI-1 were expressed in a population of chorionic trophoblasts. Ablation of HAI-1 disrupted the epithelial integrity of this cell population, causing disorganized laminin deposition and altered expression of E-cadherin and beta-catenin. This led to a complete loss of undifferentiated chorionic trophoblasts after embryonic day 9.5 and prevented the formation of the placental labyrinth. Genetic ablation of matriptase activity in HAI-1-deficient embryos, however, restored the integrity of chorionic trophoblasts and enabled placental labyrinth formation and development to term. Furthermore, matriptase/HAI-1 double-deficient mice were phenotypically indistinguishable from matriptase single-deficient litter-mates. Oncogene	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ascenzi P, 2003, CURR PROTEIN PEPT SC, V4, P231, DOI 10.2174/1389203033487180; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Gailani D, 1997, BLOOD COAGUL FIBRIN, V8, P134, DOI 10.1097/00001721-199703000-00008; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Hooper JD, 2003, BIOCHEM J, V373, P689, DOI 10.1042/BJ20030390; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Itoh H, 2004, GASTROENTEROLOGY, V127, P1423, DOI 10.1053/j.gastro.2004.08.027; Kaufmann MH, 1999, ANATOMICAL BASIS MOU; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Oberst MD, 2003, J HISTOCHEM CYTOCHEM, V51, P1017, DOI 10.1177/002215540305100805; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohmuraya M, 2005, GASTROENTEROLOGY, V129, P696, DOI 10.1053/j.gastro.2005.05.057; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Szabo R, 2005, BIOCHEM J, V390, P231, DOI 10.1042/BJ20050299; Tanaka H, 2005, MOL CELL BIOL, V25, P5687, DOI 10.1128/MCB.25.13.5687-5698.2005; Velasco G, 2002, J BIOL CHEM, V277, P37637, DOI 10.1074/jbc.M203007200; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; Zeeuwen PLJM, 2002, HUM MOL GENET, V11, P2867, DOI 10.1093/hmg/11.23.2867	26	107	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1546	1556		10.1038/sj.onc.1209966	http://dx.doi.org/10.1038/sj.onc.1209966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983341				2022-12-25	WOS:000244782500004
J	Martowicz, ML; Grass, JA; Bresnick, EH				Martowicz, Melissa L.; Grass, Jeffrey A.; Bresnick, Emery H.			GATA-1-mediated transcriptional repression yields persistent transcription factor IIB-chromatin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HEMATOPOIETIC STEM-CELLS; CORE PROMOTER ELEMENT; MOUSE GATA-2 GENE; MESSENGER-RNA; ERYTHROID-DIFFERENTIATION; IN-VIVO; C-KIT; EXPRESSION; REGION	The hematopoietic GATA factors GATA-1 and GATA-2, which have distinct and overlapping roles to regulate blood cell development, are reciprocally expressed during erythropoiesis. GATA-1 directly represses Gata2 transcription, and reduced GATA-2 synthesis promotes red blood cell development. Gata2 repression involves "GATA switches" in which GATA-1 displaces GATA-2 from Gata2 regulatory regions. We show that extragenic GATA switch sites occupied by GATA-2 associate with as much RNA polymerase II (Pol II) and basal transcription factors as present at the active Gata2 promoters. Pol II bound to GATA switch sites in the active locus was phosphorylated on serine 5 of the carboxyl-terminal domain, indicative of elongation competence. GATA-1-mediated displacement of GATA-2 from GATA switch sites reduced Pol II recruitment to all sites except the far upstream -77-kb region. Surprisingly, TFIIB occupancy persisted at most sites upon repression. These results indicate that GATA-2-bound extragenic regulatory elements recruit Pol II, GATA-1 binding expels Pol II, and despite the persistent TFIIB-chromatin complexes, Pol II recruitment is blocked.	Univ Wisconsin, Sch Med, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Mol & Cellular Pharmacol Program, 1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@wisc.edu			NIDDK NIH HHS [DK55700, DK68634] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068634, R56DK068634, R01DK055700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartunek P, 2003, ONCOGENE, V22, P1927, DOI 10.1038/sj.onc.1206281; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Deng WS, 2005, GENE DEV, V19, P2418, DOI 10.1101/gad.342405; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Grass JA, 2006, MOL CELL BIOL, V26, P7056, DOI 10.1128/MCB.01033-06; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Haussecker D, 2005, MOL CELL BIOL, V25, P9724, DOI 10.1128/MCB.25.21.9724-9733.2005; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Im Hogune, 2004, Methods Mol Biol, V284, P129; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LEONARD M, 1993, BLOOD, V82, P1071; Letting DL, 2004, P NATL ACAD SCI USA, V101, P476, DOI 10.1073/pnas.0306315101; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; Ling JH, 2004, J BIOL CHEM, V279, P51704, DOI 10.1074/jbc.M404039200; Ling KW, 2004, J EXP MED, V200, P871, DOI 10.1084/jem.20031556; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Martowicz ML, 2005, J BIOL CHEM, V280, P1724, DOI 10.1074/jbc.M406038200; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Minegishi N, 1999, BLOOD, V93, P4196, DOI 10.1182/blood.V93.12.4196.412k23_4196_4207; Munugalavadla V, 2005, MOL CELL BIOL, V25, P6747, DOI 10.1128/MCB.25.15.6747-6759.2005; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Rodrigues NP, 2005, BLOOD, V106, P477, DOI 10.1182/blood-2004-08-2989; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; ZON LI, 1991, J BIOL CHEM, V266, P22948	61	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37345	37352		10.1074/jbc.M605774200	http://dx.doi.org/10.1074/jbc.M605774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16963445	hybrid			2022-12-25	WOS:000242477100011
J	Kikuchi, H; Ozaki, T; Furuya, K; Hanamoto, T; Nakanishi, M; Yamamoto, H; Yoshida, K; Todo, S; Nakagawara, A				Kikuchi, H.; Ozaki, T.; Furuya, K.; Hanamoto, T.; Nakanishi, M.; Yamamoto, H.; Yoshida, K.; Todo, S.; Nakagawara, A.			NF-kappa B regulates the stability and activity of p73 by inducing its proteolytic degradation through a ubiquitin-dependent proteasome pathway	ONCOGENE			English	Article						apoptosis; NF-B; p53; p73; ubiquitination	KINASE C-ABL; DNA-DAMAGE; TYROSINE KINASE; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; CELL-SURVIVAL; P53; ACTIVATION; DEATH; INHIBITION	Nuclear factor kappa B (NF-kappa B), which exists as heterodimeric complexes composed of p50 and p65, has been shown to play an important role in cell survival processes. In the present study, we found for the first time that NF-kappa B has an ability to induce the ubiquitin-dependent proteasomal degradation of proapoptotic p73 alpha. The activation of NF-kappa B in tumor necrosis factor a (TNF-alpha)-stimulated H1299 cells resulted in a significant reduction in the amounts of the endogenous p73 alpha. Consistent with these results, TNF-alpha-mediated down-regulation of p73 alpha was observed in wild-type (WT) mouse embryonic fibroblasts (MEFs) but not in p65-deficient MEFs. Ectopic expression of NF-kappa B decreased a half-life of p73a by increasing its ubiquitination levels, and thereby inhibiting the transcriptional activity as well as proapoptotic function of p73a, whereas NF-kappa B had undetectable effects on p53. Immunoprecipitation experiments demonstrated that, under our experimental conditions, NF-kappa B does not bind to p73a in mammalian cultured cells. In contrast to WT p65, the COOH-terminal deletion mutant of p65 (p65 Delta C) failed to reduce the expression levels of p73a, suggesting that NF-kappa B-mediated proteolytic degradation of p73a requires the transcriptional activity of NF-kappa B. Taken together, our present results imply that NF-kappa B-mediated degradation of proapoptotic p73 is a novel inhibitory mechanism of p73 that regulates cell survival and death.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Dept Gen Surg, Sch Med, Kita Ku, Sapporo, Hokkaido, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gong JG, 1999, NATURE, V399, P806; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kim JS, 2004, BIOCHEM PHARMACOL, V67, P1459, DOI 10.1016/j.bcp.2003.12.013; Kramer S, 2005, ONCOGENE, V24, P938, DOI 10.1038/sj.onc.1208257; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; VAN AD, 1996, SCIENCE, V274, P787; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	45	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7608	7617		10.1038/sj.onc.1209748	http://dx.doi.org/10.1038/sj.onc.1209748			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16953234				2022-12-25	WOS:000242655500006
J	Riekhof, WR; Voelker, DR				Riekhof, Wayne R.; Voelker, Dennis R.			Uptake and utilization of lyso-phosphatidylethanolamine by Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLTRANSFERASE ACTIVITY; PHOSPHATIDYLSERINE DECARBOXYLASE-2; LYSOPHOSPHOLIPID ACYLTRANSFERASE; PHOSPHOLIPID TRANSLOCATION; PLASMA-MEMBRANE; GOLGI-COMPLEX; NULL ALLELE; IN-VIVO; YEAST; GENE	Phosphatidylethanolamine (PtdEtn) is synthesized by multiple pathways located in different subcellular compartments in yeast. Strains defective in the synthesis of PtdEtn via phosphatidylserine (PtdSer) synthase/decarboxylase are auxotrophic for ethanolamine, which must be transported into the cell and converted to phospholipid by the cytidinediphosphate-ethanolaminedependent Kennedy pathway. We now demonstrate that yeast strains with psd1 Delta psd2 Delta mutations, devoid of PtdSer decarboxylases, import and acylate exogenous 1-acyl-2hydroxyl-sn-glycero-3- phosphoethanolamine (lyso-PtdEtn). Lyso-PtdEtn supports growth and replaces the mitochondrial pool of PtdEtn much more efficiently than and independently of PtdEtn derived from the Kennedy pathway. Deletion of both the PtdSer decarboxylase and Kennedy pathways yields a strain that is a stringent lyso-PtdEtn auxotroph. Evidence for the specific uptake of lyso-PtdEtn by yeast comes from analysis of strains harboring deletions of the aminophospholipid translocating P-type ATPases (APLTs). Elimination of the APLTs, Dnf1p and Dnf2p, or their noncatalytic ss-subunit, Lem3p, blocked the import of radiolabeled lyso-PtdEtn and resulted in growth inhibition of lyso-PtdEtn auxotrophs. In cell extracts, lyso-PtdEtn is rapidly converted to PtdEtn by an acyl-CoA-dependent acyltransferase. These results now provide 1) an assay for APLT function based on an auxotrophic phenotype, 2) direct demonstration of APLT action on a physiologically relevant substrate, and 3) a genetic screen aimed at finding additional components that mediate the internalization, trafficking, and acylation of exogenous lyso-phospholipids.	Natl Jewish Med & Res Ctr, Dept Med, Program Cell Biol, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Program Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM076798, R01GM081461, R37GM032453, R01GM032453] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM032453, R01 GM081461, 1F32-GM076798, 2R37-GM32453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Boumann HA, 2004, FEBS LETT, V569, P173, DOI 10.1016/j.febslet.2004.05.043; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Chambers K, 2004, BIOCHEM BIOPH RES CO, V313, P681, DOI 10.1016/j.bbrc.2003.12.016; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; DOWHAN W, 1992, METHOD ENZYMOL, V209, P287; Drecktrah D, 2003, MOL BIOL CELL, V14, P3459, DOI 10.1091/mbc.E02-11-0711; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P128, DOI 10.1016/0005-2760(65)90101-3; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P139, DOI 10.1016/0005-2760(65)90102-5; FIELD FJ, 1991, LIPIDS, V26, P1; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Kato U, 2002, J BIOL CHEM, V277, P37855, DOI 10.1074/jbc.M205564200; Kitamura H, 2002, J BIOL CHEM, V277, P33720, DOI 10.1074/jbc.M205672200; KODAKI T, 1987, J BIOL CHEM, V262, P15428; PATTONVOGT J, 2006, IN PRESS BIOCH BIOPH; PLUCKTHUN A, 1985, J BIOL CHEM, V260, P1099; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Richard MG, 1998, LIPIDS, V33, P1229, DOI 10.1007/s11745-998-0328-1; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schumacher MM, 2002, J BIOL CHEM, V277, P51033, DOI 10.1074/jbc.M205301200; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; Testet E, 2005, BIOCHEM J, V387, P617, DOI 10.1042/BJ20041491; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; Voelker DR, 2005, TRENDS BIOCHEM SCI, V30, P396, DOI 10.1016/j.tibs.2005.05.008; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200	34	79	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36588	36596		10.1074/jbc.M608851200	http://dx.doi.org/10.1074/jbc.M608851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17015438	hybrid			2022-12-25	WOS:000242220800015
J	Fischer, RS; Yarmola, EG; Weber, KL; Speicher, KD; Speicher, DW; Bubb, MR; Fowler, VM				Fischer, Robert S.; Yarmola, Elena G.; Weber, Kari L.; Speicher, Kaye D.; Speicher, David W.; Bubb, Michael R.; Fowler, Velia M.			Tropomodulin 3 binds to actin monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HALF; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; CAPPING PROTEIN; POINTED ENDS; TROPOMYOSIN BINDING; FILAMENT TURNOVER; SKELETAL-MUSCLE; ADP-ACTIN; DYNAMICS	Regulation of the actin cytoskeleton by filament capping proteins is critical to myriad dynamic cellular functions. The ability of these proteins to bind both filaments as well as monomers is often central to their cellular functions. The ubiquitous pointed end capping protein Tmod3 ( tropomodulin 3) acts as a negative regulator of cell migration, yet mechanisms behind its cellular functions are not understood. Analysis of Tmod3 effects on kinetics of actin polymerization and steady state monomer levels revealed that Tmod3, unlike previously characterized tropomodulins, sequesters actin monomers with an affinity similar to its affinity for capping pointed ends. Furthermore, Tmod3 is found bound to actin in high speed supernatant cytosolic extracts, suggesting that Tmod3 can bind to monomers in the context of other cytosolic monomer binding proteins. The Tmod3-actin complex can be efficiently cross-linked with 1-ethyl-3-(dimethylaminopropyl)carbodiimide/N-hydroxylsulfosuccinimide in a 1: 1 complex. Subsequent tryptic digestion and liquid chromatography/tandem mass spectrometry revealed two binding interfaces on actin, one distinct from other actin monomer binding proteins, and two potential binding sites in Tmod3, which are independent of the previously characterized leucine-rich repeat structure involved in pointed end capping. These data suggest that the Tmod3 isoform may regulate actin dynamics differently in cells than the previously described tropomodulin isoforms.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Wistar Inst Anat & Biol, Syst Biol Div, Philadelphia, PA 19104 USA	Scripps Research Institute; State University System of Florida; University of Florida; The Wistar Institute	Fischer, RS (corresponding author), Scripps Res Inst, Dept Cell Biol, CB163, La Jolla, CA 92037 USA.	bfischer@scripps.edu		Fowler, Velia/0000-0002-3161-8802; Fischer, Robert/0000-0003-0650-2696	NATIONAL EYE INSTITUTE [R03EY014972] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794, R01HL083464, P01HL079063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K25AR048918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER; NEI NIH HHS [EY014972] Funding Source: Medline; NHLBI NIH HHS [HL083464, HL38794, P01 HL079063] Funding Source: Medline; NIAMS NIH HHS [5K25AR048918] Funding Source: Medline; NIGMS NIH HHS [GM34225] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguda AH, 2005, EMBO REP, V6, P220, DOI 10.1038/sj.embor.7400363; Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Blondin L, 2002, EUR J BIOCHEM, V269, P4194, DOI 10.1046/j.1432-1033.2002.03101.x; Bubb MR, 2002, J BIOL CHEM, V277, P20999, DOI 10.1074/jbc.M201371200; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Chu X, 2003, AM J PHYSIOL-HEART C, V284, pH1827, DOI 10.1152/ajpheart.00947.2002; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Dominguez R, 2004, TRENDS BIOCHEM SCI, V29, P572, DOI 10.1016/j.tibs.2004.09.004; Fischer RS, 2003, TRENDS CELL BIOL, V13, P593, DOI 10.1016/j.tcb.2003.09.007; Fischer RS, 2003, J CELL BIOL, V161, P371, DOI 10.1083/jcb.200209057; Fowler VM, 2003, J BIOL CHEM, V278, P40000, DOI 10.1074/jbc.M306895200; Fritz-Six KL, 2003, J CELL BIOL, V163, P1033, DOI 10.1083/jcb.200308164; Fujisawa T, 2001, FEBS LETT, V498, P67, DOI 10.1016/S0014-5793(01)02498-X; Greenfield NJ, 2005, BIOPHYS J, V88, P372, DOI 10.1529/biophysj.104.051128; Greenfield NJ, 2002, BIOPHYS J, V82, P2580, DOI 10.1016/S0006-3495(02)75600-2; Harris ES, 2006, METHOD ENZYMOL, V406, P190, DOI 10.1016/S0076-6879(06)06015-0; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Irobi E, 2004, EMBO J, V23, P3599, DOI 10.1038/sj.emboj.7600372; Kostyukova A, 2000, EUR J BIOCHEM, V267, P6470, DOI 10.1046/j.1432-1327.2000.01738.x; Kostyukova AS, 2005, BIOCHEMISTRY-US, V44, P4905, DOI 10.1021/bi047468p; Kostyukova AS, 2004, J BIOL CHEM, V279, P5066, DOI 10.1074/jbc.M311186200; Krieger I, 2002, BIOPHYS J, V83, P2716, DOI 10.1016/S0006-3495(02)75281-8; Krieger I, 2001, ACTA CRYSTALLOGR D, V57, P743, DOI 10.1107/S0907444901003924; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; LAL AA, 1984, J BIOL CHEM, V259, P8794; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; Lu SY, 2004, PROTEINS, V56, P384, DOI 10.1002/prot.10597; Mattila PK, 2004, MOL BIOL CELL, V15, P5158, DOI 10.1091/mbc.E04-06-0444; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; Paavilainen VO, 2004, TRENDS CELL BIOL, V14, P386, DOI 10.1016/j.tcb.2004.05.002; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; Speicher MR, 2000, LAB INVEST, V80, P1031, DOI 10.1038/labinvest.3780108; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; Wear MA, 2004, TRENDS BIOCHEM SCI, V29, P418, DOI 10.1016/j.tibs.2004.06.003; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Yarmola EG, 2004, J BIOL CHEM, V279, P33519, DOI 10.1074/jbc.M404392200; Yarmola EG, 2001, J BIOL CHEM, V276, P45555, DOI 10.1074/jbc.M105723200; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001	49	39	39	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36454	36465		10.1074/jbc.M606315200	http://dx.doi.org/10.1074/jbc.M606315200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012745	hybrid			2022-12-25	WOS:000242100500096
J	Kuznetsova, E; Proudfoot, M; Gonzales, CF; Brown, G; Omelchenko, MV; Borozan, I; Carmel, L; Wolf, YI; Mori, H; Savchenko, AV; Arrowsmith, CH; Koonin, EV; Edwards, AM; Yakunin, AF				Kuznetsova, Ekaterina; Proudfoot, Michael; Gonzales, Claudio F.; Brown, Greg; Omelchenko, Marina V.; Borozan, Ivan; Carmel, Liran; Wolf, Yuri I.; Mori, Hirotada; Savchenko, Alexei V.; Arrowsmith, Cheryl H.; Koonin, Eugene V.; Edwards, Aled M.; Yakunin, Alexander F.			Genome-wide analysis of substrate specificities of the Escherichia coli haloacid dehalogenase-like phosphatase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL ENZYMATIC SCREENS; CATALYTIC PROMISCUITY; CRYSTAL-STRUCTURE; NONENZYMATIC GLYCOSYLATION; L-2-HALOACID DEHALOGENASE; PHOSPHOSERINE PHOSPHATASE; BETA-PHOSPHOGLUCOMUTASE; ALKALINE-PHOSPHATASE; ACID DEHALOGENASE; MOLECULAR-CLONING	Haloacid dehalogenase (HAD)-like hydrolases are a vast superfamily of largely uncharacterized enzymes, with a few members shown to possess phosphatase, beta-phosphoglucomutase, phosphonatase, and dehalogenase activities. Using a representative set of 80 phosphorylated substrates, we characterized the substrate specificities of 23 soluble HADs encoded in the Escherichia coli genome. We identified small molecule phosphatase activity in 21 HADs and beta-phosphoglucomutase activity in one protein. The E. coli HAD phosphatases show high catalytic efficiency and affinity to a wide range of phosphorylated metabolites that are intermediates of various metabolic reactions. Rather than following the classical "one enzyme-one substrate" model, most of the E. coli HADs show remarkably broad and overlapping substrate spectra. At least 12 reactions catalyzed by HADs currently have no EC numbers assigned in Enzyme Nomenclature. Surprisingly, most HADs hydrolyzed small phosphodonors ( acetyl phosphate, carbamoyl phosphate, and phosphoramidate), which also serve as substrates for autophosphorylation of the receiver domains of the two-component signal transduction systems. The physiological relevance of the phosphatase activity with the preferred substrate was validated in vivo for one of the HADs, YniC. Many of the secondary activities of HADs might have no immediate physiological function but could comprise a reservoir for evolution of novel phosphatases.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L6, Canada; Ontario Canc Inst, Ontario Ctr Struct Proteom, Toronto, ON M5G 2C4, Canada; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Nara Institute of Science & Technology; University of Toronto; Structural Genomics Consortium	Edwards, AM (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St,Rm 024, Toronto, ON M5G 1L6, Canada.	aled.edwards@utoronto.ca; a.iakounine@utoronto.ca	Yakunin, Alexander/J-1519-2014; Carmel, Liran/A-9681-2008; Mori, Hirotada/B-4934-2011	Wolf, Yuri/0000-0002-0247-8708; Edwards, Aled/0000-0002-4782-6016; Arrowsmith, Cheryl/0000-0002-4971-3250; Borozan, Ivan/0000-0002-3145-3550; Yakunin, Alexander/0000-0003-0813-6490	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62414-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi J., 1992, COMPUTER SCI MONOGRA, V27, P1; Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; AMEYAMA M, 1981, J BACTERIOL, V145, P814, DOI 10.1128/JB.145.2.814-823.1981; Anantharaman V, 2003, CURR OPIN CHEM BIOL, V7, P12, DOI 10.1016/S1367-5931(02)00018-2; Aravind L, 2002, CURR OPIN STRUC BIOL, V12, P392, DOI 10.1016/S0959-440X(02)00334-2; BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; Bartlett GJ, 2003, J MOL BIOL, V331, P829, DOI 10.1016/S0022-2836(03)00734-4; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BHATTACHARYA M, 1995, ANAL BIOCHEM, V232, P98, DOI 10.1006/abio.1995.9954; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; Bornscheuer UT, 2004, ANGEW CHEM INT EDIT, V43, P6032, DOI 10.1002/anie.200460416; Buchholz A, 2002, BIOMOL ENG, V19, P5, DOI 10.1016/S1389-0344(02)00003-5; Buchholz A, 2001, ANAL BIOCHEM, V295, P129, DOI 10.1006/abio.2001.5183; BUSCHMEIER B, 1985, FEMS MICROBIOL LETT, V29, P231, DOI 10.1111/j.1574-6968.1985.tb00868.x; Charbit A, 1996, J BIOL CHEM, V271, P9997, DOI 10.1074/jbc.271.17.9997; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Chou TF, 2005, J BIOL CHEM, V280, P15356, DOI 10.1074/jbc.M500434200; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DESILVA AO, 1979, J BIOL CHEM, V254, P237; DIETZ GW, 1971, J BIOL CHEM, V246, P2881; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FONDA ML, 1992, J BIOL CHEM, V267, P15978; Fortpied J, 2006, J BIOL CHEM, V281, P18378, DOI 10.1074/jbc.M513208200; FROMAN BE, 1989, MOL GEN GENET, V217, P126, DOI 10.1007/BF00330951; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; IWASAKI I, 1956, B CHEM SOC JPN, V29, P860, DOI 10.1246/bcsj.29.860; James LC, 2001, PROTEIN SCI, V10, P2600, DOI 10.1110/ps.ps.14601; Jang YM, 2003, J BIOL CHEM, V278, P50040, DOI 10.1074/jbc.M309619200; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Kandror O, 2002, P NATL ACAD SCI USA, V99, P9727, DOI 10.1073/pnas.142314099; Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108; Kim YC, 2004, J BIOL CHEM, V279, P517, DOI 10.1074/jbc.M306054200; Kneidinger B, 2002, J BACTERIOL, V184, P363, DOI 10.1128/JB.184.2.363-369.2002; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; Kuznetsova E, 2005, FEMS MICROBIOL REV, V29, P263, DOI 10.1016/j.femsre.2004.12.006; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; LINN ECC, 1996, ESCHERICHIA COLI SAL, P307; LIPMANN F, 1950, BIOCHIM BIOPHYS ACTA, V4, P301, DOI 10.1016/0006-3002(50)90036-9; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUMENG L, 1975, J BIOL CHEM, V250, P8126; Lynch M, 2000, GENETICS, V154, P459; Macchiarulo A, 2004, NAT BIOTECHNOL, V22, P1039, DOI 10.1038/nbt999; Massingham T, 2001, BIOESSAYS, V23, P873, DOI 10.1002/bies.1128; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; Mironova R, 2005, MOL MICROBIOL, V55, P1801, DOI 10.1111/j.1365-2958.2005.04504.x; Mironova R, 2001, MOL MICROBIOL, V39, P1061, DOI 10.1046/j.1365-2958.2001.02304.x; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Nobeli I, 2003, J MOL BIOL, V334, P697, DOI 10.1016/j.jmb.2003.10.008; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Pellicer MT, 2003, J BACTERIOL, V185, P5815, DOI 10.1128/JB.185.19.5815-5821.2003; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRADEL E, 1988, J BACTERIOL, V170, P4916, DOI 10.1128/jb.170.10.4916-4923.1988; Proudfoot M, 2004, J BIOL CHEM, V279, P54687, DOI 10.1074/jbc.M411023200; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; RIMMELE M, 1994, J BACTERIOL, V176, P5654, DOI 10.1128/JB.176.18.5654-5664.1994; Roberts A, 2005, PROTEINS, V58, P790, DOI 10.1002/prot.20267; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Roodveldt C, 2005, BIOCHEMISTRY-US, V44, P12728, DOI 10.1021/bi051021e; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Silversmith RE, 1997, BIOCHEMISTRY-US, V36, P14965, DOI 10.1021/bi9715573; STROM AR, 1993, MOL MICROBIOL, V8, P205, DOI 10.1111/j.1365-2958.1993.tb01564.x; THOMPSON J, 1987, FEMS MICROBIOL LETT, V46, P221, DOI 10.1111/j.1574-6968.1987.tb02462.x; Tremblay LW, 2006, BIOCHEMISTRY-US, V45, P1183, DOI 10.1021/bi051842j; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wu J, 2003, J BIOL CHEM, V278, P18117, DOI 10.1074/jbc.M301983200; Zhang GF, 2005, BIOCHEMISTRY-US, V44, P9404, DOI 10.1021/bi050558p; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X	80	206	246	4	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36149	36161		10.1074/jbc.M605449200	http://dx.doi.org/10.1074/jbc.M605449200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990279	hybrid			2022-12-25	WOS:000242100500065
J	Mbonye, UR; Wada, M; Rieke, CJ; Tang, HY; DeWitt, DL; Smith, WL				Mbonye, Uri R.; Wada, Masayuki; Rieke, Caroline J.; Tang, Hui-Yuan; DeWitt, David L.; Smith, William L.			The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE H SYNTHASES-1; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS; SIGNALING PATHWAYS; GENE-EXPRESSION; ER DEGRADATION; UP-REGULATION; PROTEASOME; INHIBITION; GLYCANS	Cyclooxygenase ( COX) isoforms catalyze the committed step in prostaglandin biosynthesis. The primary structures of COX-1 and COX-2 are very similar except that COX-2 has a 19-amino acid (19-AA) segment of unknown function located just inside its C terminus. Here we provide evidence that the major role of the 19-AA cassette is to mediate entry of COX-2 into the ER-associated degradation system that transports ER proteins to the cytoplasm. COX-1 is constitutively expressed in many cells, whereas COX-2 is usually expressed inducibly and transiently. In murine NIH/3T3 fibroblasts, we find that COX-2 protein is degraded with a half-life (t(1/2)) of about 2 h, whereas COX-1 is reasonably stable (t(1/2) > 12 h); COX-2 degradation is retarded by 26 S proteasome inhibitors. Similarly, COX-1 expressed heterologously in HEK293 cells is quite stable (t(1/2) > 24 h), whereas COX-2 expressed heterologously is degraded with a t(1/2) of similar to 5 h, and its degradation is slowed by proteasome inhibitors. A deletion mutant of COX-2 was prepared lacking 18 residues of the 19-AA cassette. This mutant retains native COX-2 activity but, unlike native COX-2, is stable in HEK293 cells. Conversely, inserting the COX-2 19-AA cassette near the C terminus of COX-1 yields a mutant ins594-612 COX-1 that is unstable (t(1/2) similar to 3 h). Mutation of Asn-594,an N-glycosylation site at the beginning of the 19-AA cassette, stabilizes both COX-2 and ins594-612 COX-1; nonetheless, COX mutants that are glycosylated at Asn-594 but lack the remainder of the 19-amino acid cassette (i.e. del597-612 COX-2 and ins594-596 COX-1) are stable. Thus, although glycosylation of Asn-594 is necessary for COX-2 degradation, at least part of the remainder of the 19-AA insert is also required. Finally, kifunensine, a mannosidase inhibitor that can block entry of ER proteins into the	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	University of Michigan System; University of Michigan; Michigan State University	Smith, WL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 5416 Med Sci Bldg 1,1301 E Catherine St, Ann Arbor, MI 48109 USA.	smithww@umich.edu	Mbonye, Uri/AAG-8861-2020	Mbonye, Uri/0000-0002-7694-0803	NIGMS NIH HHS [GM68848] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068848] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1996, AM J PHYSIOL-LUNG C, V271, pL126, DOI 10.1152/ajplung.1996.271.1.L126; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Figueiredo-Pereira ME, 2002, J BIOL CHEM, V277, P25283, DOI 10.1074/jbc.M109145200; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Harris RC, 2001, AM J PHYSIOL-RENAL, V281, pF1, DOI 10.1152/ajprenal.2001.281.1.F1; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERSCHMAN HR, 1993, J LIPID MEDIATOR, V6, P89; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Kitzmuller C, 2003, BIOCHEM J, V376, P687, DOI 10.1042/BJ20030887; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; MIRAFZALI Z, 2006, J BIOL CHEM; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Murray BP, 2001, ARCH BIOCHEM BIOPHYS, V393, P106, DOI 10.1006/abbi.2001.2482; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Ristimaki A, 1997, CANCER RES, V57, P1276; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SMITH WL, 1987, HDB EICOSANOIDS PROS, P175; Song I, 1996, ARCH BIOCHEM BIOPHYS, V334, P67, DOI 10.1006/abbi.1996.0430; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Spear ED, 2005, J CELL BIOL, V169, P73, DOI 10.1083/jcb.200411136; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Spiro RG, 2004, CELL MOL LIFE SCI, V61, P1025, DOI 10.1007/s00018-004-4037-8; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsuda H, 2006, THROMB RES, V117, P323, DOI 10.1016/j.thromres.2005.02.017; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; Wada M, 2004, J BIOCHEM, V135, P455, DOI 10.1093/jb/mvh059; Wang DZ, 2005, GASTROENTEROLOGY, V128, P1445, DOI 10.1053/j.gastro.2004.09.080; Webster JM, 2003, J BIOL CHEM, V278, P38238, DOI 10.1074/jbc.M305600200; Xiao GS, 1998, J BIOL CHEM, V273, P6801, DOI 10.1074/jbc.273.12.6801; Yoshida Y, 2003, J BIOCHEM, V134, P183, DOI 10.1093/jb/mvg128; YUAN C, 2006, P NATL ACAD SCI US	61	84	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35770	35778		10.1074/jbc.M608281200	http://dx.doi.org/10.1074/jbc.M608281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17001073	hybrid			2022-12-25	WOS:000242100500023
J	Misra, S; Toole, BP; Ghatak, S				Misra, Suniti; Toole, Bryan P.; Ghatak, Shibnath			Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD44 CLEAVAGE; TUMOR-CELLS; CANCER-THERAPY; MIGRATION; GROWTH; EXPRESSION; ERBB2; INFLAMMATION; INVASION; TARGETS	Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on tumor progression in animal models. Increased HA production stimulates ERBB2 activation, leading to increased cell survival activities and several malignant cell properties. On the other hand, inhibition of constitutive HA-tumor cell interactions in malignant cells inhibits these properties. We have now investigated the role of HA in activation of several additional receptor tyrosine kinases (RTKs), i.e. IGF1R-beta, PDGFR-beta, EGFR and c-MET, in colon, prostate, and breast carcinoma cells. In each case we show that antagonists of endogenous HA interactions inhibit their tyrosine phosphorylation, i.e. activation. On the other hand, we show that these RTKs are activated in phenotypically normal or relatively benign tumor cells by experimentally increasing HA production. We also investigated the role of HA in constitutive versus ligand-induced activation of RTKs. In HCA7 colon and C4-2 prostate carcinoma cells, ERBB2 is constitutively activated in a ligand-independent manner, whereas IGF1R-beta and PDGFR-beta require ligand interaction for activation. We show that both constitutive activation of ERBB2 and ligand-mediated activation of IGF1R-beta and PDGFR-beta are reversed by co-treatment of the cells with a HA antagonist. We conclude that HA serves a general function in RTK activation.	Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina	Misra, S (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, 171 Ashley Ave, Charleston, SC 29425 USA.	misra@musc.edu; ghatak@musc.edu			NATIONAL CANCER INSTITUTE [R01CA073839, R01CA082867] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017698, P20RR016434] Funding Source: NIH RePORTER; NCI NIH HHS [CA082867, CA073839] Funding Source: Medline; NCRR NIH HHS [P20 RR017698, P20 RR016434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Enegd B, 2002, NEUROSURGERY, V50, P1311, DOI 10.1097/00006123-200206000-00023; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Gordon LB, 2003, HUM GENET, V113, P178, DOI 10.1007/s00439-003-0958-9; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li LL, 2006, J BIOL CHEM, V281, P26512, DOI 10.1074/jbc.M605607200; Lokeshwar VB, 2005, CANCER RES, V65, P7782, DOI 10.1158/0008-5472.CAN-05-1022; Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863; Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200; Mummert ME, 2005, IMMUNOL RES, V31, P189, DOI 10.1385/IR:31:3:189; Murai T, 2004, J BIOL CHEM, V279, P4541, DOI 10.1074/jbc.M307356200; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; Naor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Simpson MA, 2006, AM J PATHOL, V169, P247, DOI 10.2353/ajpath.2006.060032; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Sugahara KN, 2006, J BIOL CHEM, V281, P5861, DOI 10.1074/jbc.M506740200; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Yasuda M, 2002, HISTOL HISTOPATHOL, V17, P945, DOI 10.14670/HH-17.945	32	147	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34936	34941		10.1074/jbc.C600138200	http://dx.doi.org/10.1074/jbc.C600138200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16959784	hybrid			2022-12-25	WOS:000241933700026
J	Playford, MP; Lyons, PD; Sastry, SK; Schaller, MD				Playford, Martin P.; Lyons, Patrick D.; Sastry, Sarita K.; Schaller, Michael D.			Identification of a filamin docking site on PTP-PEST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE P50(CSK); CLEAVAGE FURROW; TARGETS FILAMIN; CELL-DIVISION; SH3 DOMAIN; ASSOCIATION; ACTIN; CYTOKINESIS; SUBSTRATE	PTP-PEST is a cytoplasmic protein-tyrosine phosphatase (PTP) implicated in the regulation of biological processes such as cell motility, cytokinesis, focal adhesion disassembly, and lymphocyte activation. Using a proteomics approach, filamin-A was identified as a novel interacting protein that bound to GST-PTP-PEST. This interaction was confirmed in vitro and in cells by coimmunoprecipitation. The site of filamin interaction on PTP-PEST was mapped to the fourth proline-rich region (Pro4). PTP-PEST has previously been implicated in the regulation of cytokinesis. In further support of this finding, expression of PTP-PEST in HeLa cells resulted in the formation of multinucleated cells. A PTP-PEST mutant lacking Pro4 and unable to bind filamin-A failed to induce the multinucleated phenotype. Further, depletion of filamin-A in HeLa cells was found to reduce the PTP-PEST-dependent multinucleation phenotype. Hence, we conclude that the interaction of PTP-PEST with filamin-A may function in the control of cytokinesis in mammalian cells.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Medical Branch Galveston	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090,534 Taylor Hall, Chapel Hill, NC 27599 USA.	crispy4@med.unc.edu	Sastry, Sarita/A-1291-2013; , UNC Flow Cytometry Core/AGU-9839-2022; , Proteomics Core UNC/AFQ-7201-2022		NATIONAL CANCER INSTITUTE [R01CA090901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NCI NIH HHS [CA90901] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cole PA, 2003, CURR OPIN CHEM BIOL, V7, P580, DOI 10.1016/j.cbpa.2003.08.009; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 2002, J BIOL CHEM, V277, P2973, DOI 10.1074/jbc.M106428200; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fujikawa K, 2002, P NATL ACAD SCI USA, V99, P4313, DOI 10.1073/pnas.052715699; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HABIB T, 1994, J BIOL CHEM, V269, P25243; Haskell MD, 2001, J CELL SCI, V114, P1699; Kim YW, 1996, ONCOGENE, V13, P2275; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Medley QG, 2003, J BIOL CHEM, V278, P13265, DOI 10.1074/jbc.M300277200; Moasser MM, 1999, CANCER RES, V59, P6145; Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530; Ng MM, 2005, DEV CELL, V9, P781, DOI 10.1016/j.devcel.2005.11.002; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; NUNNALLY MH, 1980, J CELL BIOL, V87, P219, DOI 10.1083/jcb.87.1.219; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sastry SK, 2006, J BIOL CHEM, V281, P11627, DOI 10.1074/jbc.M600897200; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Sharma CP, 2004, CELL BIOL INT, V28, P935, DOI 10.1016/j.cellbi.2004.09.006; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	47	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34104	34112		10.1074/jbc.M606277200	http://dx.doi.org/10.1074/jbc.M606277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973606	hybrid, Green Published			2022-12-25	WOS:000241767600031
J	Hein, P; Rochais, F; Hoffmann, C; Dorsch, S; Nikolaev, VO; Engelhardt, S; Berlot, CH; Lohse, MJ; Bunemann, M				Hein, Peter; Rochais, Francesca; Hoffmann, Carsten; Dorsch, Sandra; Nikolaev, Viacheslav O.; Engelhardt, Stefan; Berlot, Catherine H.; Lohse, Martin J.; Buenemann, Moritz			G(S) activation is time-limiting in initiating receptor-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; LIVING CELLS; BETA(2)-ADRENERGIC RECEPTOR; SUBUNITS; DISSOCIATION; DYNAMICS; MYOCYTES; CHANNELS; BINDING; CAMP	To analyze individual steps of G(S)-linked signaling in intact cells, we used fluorescence resonance energy transfer (FRET)based assays for receptor-G protein interaction, G protein activation, and cAMP effector activation. To do so, we developed a FRET-based sensor to directly monitor G(S) activation in living cells. This was done by coexpressing a G alpha s mutant, in which a yellow fluorescent protein was inserted, together with cyan fluorescent protein-tagged G beta gamma subunits and appropriate receptors in HEK293 cells. Together with assays for receptor activation and receptor-G protein interaction, it is possible to characterize large parts of the G(S) signaling cascade. When A(2A)-adenosine or beta(1)-adrenergic receptors are coexpressed with G(S) in HEK293T cells, the receptor-G(S) interaction was on the same time scale as A(2A) receptor activation with a time constant of < 50 ms. G(S) activation was markedly slower and around 450 ms with similar kinetics following activation of A(2A)-or beta(1)-receptors. Taken together, our kinetic measurements demonstrate that the rate of G(S) activation limits initiation of G(S)-coupled receptor signaling.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Wurzburg, Rudolf Virchow Ctr, DFG, Res Ctr Expt Biomed, Wurzburg, Germany; Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA	University of Wurzburg; German Research Foundation (DFG); University of Wurzburg	Bunemann, M (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	m-buenemann@toxi.uni-wuerzburg.de	Rochais, Francesca/ABF-4675-2021; Hein, Peter/A-7477-2008; Rochais, Francesca/A-5326-2017; Nikolaev, Vyacheslav/AAT-7746-2020; Engelhardt, Stefan/AAA-9329-2019; Lohse, Martin J/A-7160-2012	Rochais, Francesca/0000-0001-9355-8916; Hein, Peter/0000-0002-5899-3979; Rochais, Francesca/0000-0001-9355-8916; Engelhardt, Stefan/0000-0001-5378-8661; Lohse, Martin J/0000-0002-0599-3510				Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Bunemann M, 2001, J BIOL CHEM, V276, P47512, DOI 10.1074/jbc.M108652200; Bunemann M, 1997, J PHYSIOL-LONDON, V501, P549, DOI 10.1111/j.1469-7793.1997.549bm.x; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gibson SK, 2006, P NATL ACAD SCI USA, V103, P212, DOI 10.1073/pnas.0509763102; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Hynes TR, 2004, J BIOL CHEM, V279, P44101, DOI 10.1074/jbc.M405151200; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; Mervine SM, 2006, MOL PHARMACOL, V70, P194, DOI 10.1124/mol.106.022616; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	31	110	110	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33345	33351		10.1074/jbc.M606713200	http://dx.doi.org/10.1074/jbc.M606713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963443	hybrid			2022-12-25	WOS:000241621400044
J	Inoue, K; Mikuni-Takagaki, Y; Oikawa, K; Itoh, T; Inada, M; Noguchi, T; Park, JS; Onodera, T; Krane, SM; Noda, M; Itohara, S				Inoue, Keiichi; Mikuni-Takagaki, Yuko; Oikawa, Kaoru; Itoh, Takeshi; Inada, Masaki; Noguchi, Takanori; Park, Jin-Sung; Onodera, Takashi; Krane, Stephen M.; Noda, Masaki; Itohara, Shigeyoshi			A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-2; MULTICENTRIC OSTEOLYSIS; COLLAGENASE CLEAVAGE; IN-VIVO; MINERALIZATION; OSTEOBLASTS; SCLEROSTIN; ARTHRITIS; CARTILAGE; DENSITY	Extracellular matrix production and degradation by bone cells are critical steps in bone metabolism. Mutations of the gene encoding MMP-2, an extracellular matrix-degrading enzyme, are associated with a human genetic disorder characterized by subcutaneous nodules, arthropathy, and focal osteolysis. It is not known how the loss of MMP-2 function results in the pathology. Here, we show that Mmp2(-/-) mice exhibited opposing bone phenotypes caused by an impaired osteocytic canalicular network. Mmp2(-/-) mice showed decreased bone mineral density in the limb and trunk bones but increased bone volume in the calvariae. In the long bones, there was moderate disruption of the osteocytic networks and reduced bone density throughout life, whereas osteoblast and osteoclast function was normal. In contrast, aged but not young Mmp2(-/-) mice had calvarial sclerosis with osteocyte death. Severe disruption of the osteocytic networks preceded osteocyte loss in Mmp2(-/-) calvariae. Successful transplantation of wild-type periosteum restored the osteocytic canalicular networks in the Mmp2(-/-) calvariae, suggesting local roles of MMP-2 in determining bone phenotypes. Our results indicate that MMP-2 plays a crucial role in forming and maintaining the osteocytic canalicular network, and we propose that osteocytic network formation is a determinant of bone remodeling and mineralization.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1010062, Japan; RIKEN, Brain Sci Inst, Lab Behav Genet, Wako, Saitama 3510198, Japan; Tokyo Med & Dent Univ, Ctr Excellence Program Mol Destruct & Reconstruct, Chiyoda Ku, Tokyo 1010062, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Mol Immunol, Bunkyo Ku, Tokyo 1138657, Japan; Kanagawa Dent Coll, Dept Funct Biol, Div Biochem & Mol Biol, Kanagawa 2388580, Japan; Shionogi & Co Ltd, Discovery Res Labs, Osaka 5610825, Japan; Massachusetts Gen Hosp, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA	Tokyo Medical & Dental University (TMDU); RIKEN; Tokyo Medical & Dental University (TMDU); University of Tokyo; Kanagawa Dental College; Shionogi & Company Limited; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Itohara, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, 2-3-10 Kanda Surugadai, Tokyo 1010062, Japan.	sitohara@brain.riken.jp	inada, masaki/D-1581-2013; Park, Jin-Sung/F-9867-2011; Itohara, Shigeyoshi/I-8769-2012	inada, masaki/0000-0002-5066-8506; Itohara, Shigeyoshi/0000-0002-2410-9989; Inoue, Keiichi/0000-0002-7101-486X				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Al Aqeel A, 2000, AM J MED GENET, V93, P11, DOI 10.1002/1096-8628(20000703)93:1<11::AID-AJMG3>3.0.CO;2-3; Al-Mayouf SM, 2000, AM J MED GENET, V93, P5, DOI 10.1002/1096-8628(20000703)93:1<5::AID-AJMG2>3.0.CO;2-Y; Al-Otaibi L, 2002, PEDIATR RADIOL, V32, P523, DOI 10.1007/s00247-001-0649-4; Andersen TL, 2004, BONE, V35, P1107, DOI 10.1016/j.bone.2004.06.019; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; BILEZIKIAN J, 2002, PRINCIPLES BONE BIOL, P3; Breckon JJW, 1999, J BONE MINER RES, V14, P1880, DOI 10.1359/jbmr.1999.14.11.1880; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; Collins JM, 2005, J BIOMECH, V38, P485, DOI 10.1016/j.jbiomech.2004.04.018; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; Follet H, 2004, BONE, V34, P783, DOI 10.1016/j.bone.2003.12.012; Hatori K, 2004, ANAT REC PART A, V277A, P262, DOI 10.1002/ar.a.20007; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200; Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643; Judex S, 2005, J CELL BIOCHEM, V94, P982, DOI 10.1002/jcb.20363; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KUSUZAKI K, 1995, ACTA ORTHOP SCAND, V66, P166, DOI 10.3109/17453679508995514; Kusuzaki K, 2000, BONE, V27, P655, DOI 10.1016/S8756-3282(00)00383-5; Ling YF, 2005, J BONE MINER RES, V20, P2169, DOI 10.1359/JBMR.050815; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Marenzana M, 2005, BONE, V37, P545, DOI 10.1016/j.bone.2005.04.036; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Martin RB, 2000, BONE, V26, P71, DOI 10.1016/S8756-3282(99)00242-2; Metz LN, 2003, BONE, V33, P753, DOI 10.1016/S8756-3282(03)00245-X; Meunier PJ, 1997, BONE, V21, P373, DOI 10.1016/S8756-3282(97)00170-1; Mikuni-Takagaki Y, 1999, J BONE MINER METAB, V17, P57, DOI 10.1007/s007740050065; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakamura H, 2004, BONE, V34, P48, DOI 10.1016/j.bone.2003.09.001; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Sasano Y, 2002, J HISTOCHEM CYTOCHEM, V50, P325, DOI 10.1177/002215540205000304; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023; Suzuki Y, 1998, J DENT RES, V77, P1799, DOI 10.1177/00220345980770100701; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Vu TH, 2001, NAT GENET, V28, P202, DOI 10.1038/90023; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Ye L, 2005, J BIOL CHEM, V280, P6197, DOI 10.1074/jbc.M412911200; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zhu SL, 1997, BIOCHEM J, V323, P637, DOI 10.1042/bj3230637	50	144	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33814	33824		10.1074/jbc.M607290200	http://dx.doi.org/10.1074/jbc.M607290200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959767	hybrid			2022-12-25	WOS:000241621400087
J	Toczylowski, T; Yan, H				Toczylowski, Thomas; Yan, Hong			Mechanistic analysis of a DNA end processing pathway mediated by the Xenopus Werner syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI; EGG EXTRACTS; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; TELOMERE MAINTENANCE; EXONUCLEASE ACTIVITY; NUCLEASE ACTIVITY; HUMAN-CELLS; REPAIR	The first step of homology-dependent repair of DNA double-strand breaks is the strand-specific processing of DNA ends to generate 3' single-strand tails. Despite its importance, the molecular mechanism underlying end processing is poorly understood in eukaryotic cells. We have taken a biochemical approach to investigate DNA end processing in nucleoplasmic extracts derived from the unfertilized eggs of Xenopus laevis. We found that double-strand DNA ends are specifically degraded in the 5' -> 3' direction in this system. The reaction consists of two steps: an ATP-dependent unwinding of double-strand ends and an ATP-independent 5' -> 3' degradation of single-strand tails. We also found that the Xenopus Werner syndrome protein, a member of the RecQ helicase family, plays an important role in DNA end processing. Mechanistically, Xenopus Werner syndrome protein (xWRN) is required for the unwinding of DNA ends but not for the degradation of single-strand tails. The xWRN-mediated end processing is remarkably similar to the end processing that has been proposed for the Escherichia coli RecQ helicase and RecJ single-strand nuclease, suggesting that this mechanism might be conserved in prokaryotes and eukaryotes.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Yan, H (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Hong_Yan@fccc.edu			NIGMS NIH HHS [R01 GM57962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amundsen SK, 2003, CELL, V112, P741, DOI 10.1016/S0092-8674(03)00197-1; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Budd ME, 2000, MUTAT RES-DNA REPAIR, V459, P173, DOI 10.1016/S0921-8777(99)00072-5; Carroll D, 1996, PROG NUCLEIC ACID RE, V54, P101, DOI 10.1016/S0079-6603(08)60361-X; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Ivancic-Bace I, 2003, GENETICS, V163, P485; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Krogh BO, 2005, GENETICS, V171, P1561, DOI 10.1534/genetics.105.049478; Labhart P, 1999, MOL CELL BIOL, V19, P2585; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; MARYON E, 1989, MOL CELL BIOL, V9, P4862, DOI 10.1128/MCB.9.11.4862; Moreau S, 1999, MOL CELL BIOL, V19, P556; Moreau S, 2001, GENETICS, V159, P1423; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; SCHELLENBERG GD, 1998, GENETIC BASIS HUMAN, P347; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; Tran PT, 2004, DNA REPAIR, V3, P1549, DOI 10.1016/j.dnarep.2004.05.015; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Yan H, 2005, J CELL BIOL, V171, P217, DOI 10.1083/jcb.200502077; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; YAN H, 1995, SCIENCE, V269, P1883, DOI 10.1126/science.7569932	43	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33198	33205		10.1074/jbc.M605044200	http://dx.doi.org/10.1074/jbc.M605044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959775	hybrid			2022-12-25	WOS:000241621400028
J	Deshpande, AM; Akunowicz, JD; Reveles, XT; Patel, BB; Saria, EA; Gorlick, RG; Naylor, SL; Leach, RJ; Hansen, MF				Deshpande, A. M.; Akunowicz, J. D.; Reveles, X. T.; Patel, B. B.; Saria, E. A.; Gorlick, R. G.; Naylor, S. L.; Leach, R. J.; Hansen, M. F.			PHC3, a component of the hPRC-H complex, associates with E2F6 during G(0) and is lost in osteosarcoma tumors	ONCOGENE			English	Article						tumor suppressor gene; osteosarcoma; polycomb gene; polyhomeotic-like; cell cycle regulation	POLYCOMB-GROUP PROTEINS; DROSOPHILA-MELANOGASTER; GENES; CHROMATIN; IDENTIFICATION; REPRESSION; HOMOLOGS; BMI1; EED; CONSTITUENTS	Polyhomeotic-like 3 (PHC3) is a ubiquitously expressed member of the polycomb gene family and part of the human polycomb complex hPRC-H. We found that in normal cells PHC3 associated with both hPRC-H complex components and with the transcription factor E2F6. In differentiating and confluent cells, PHC3 and E2F6 showed nuclear colocalization in a punctate pattern that resembled the binding of polycomb bodies to heterochromatin. This punctate pattern was not seen in proliferating cells suggesting that PHC3 may be part of an E2F6-polycomb complex that has been shown to occupy and silence target promoters in G(0). Previous loss of heterozygosity (LoH) analyses had shown that the region containing PHC3 underwent frequent LoH in primary human osteosarcoma tumors. When we examined normal bone and human osteosarcoma tumors, we found loss of PHC3 expression in 36 of 56 osteosarcoma tumors. Sequence analysis revealed that PHC3 was mutated in nine of 15 primary osteosarcoma tumors. These findings suggest that loss of PHC3 may favor tumorigenesis by potentially disrupting the ability of cells to remain in G(0).	Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA	University of Connecticut; University of Texas System; University of Texas Health San Antonio; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore	Hansen, MF (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.	mhansen@nso2.uchc.edu		GORLICK, RICHARD/0000-0001-8995-2929; Leach, Robin/0000-0002-3201-5579	NCI NIH HHS [R01 CA074802-03, CA074802, R01 CA074802-04] Funding Source: Medline; NIAMS NIH HHS [R01 AR049940-03, R01 AR049940-05, R01 AR049940-04, R01 AR049940-01A1, R01 AR049940, R01 AR049940-02, AR049940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ali JY, 2004, MOL CELL BIOL, V24, P7737, DOI 10.1128/MCB.24.17.7737-7747.2004; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEATRICK J, 1991, GENE, V105, P185, DOI 10.1016/0378-1119(91)90150-A; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Harlow E., 1988, ANTIBODIES LAB MANUA; Isono K, 2005, MOL CELL BIOL, V25, P6694, DOI 10.1128/MCB.25.15.6694-6706.2005; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; King IFG, 2002, MOL CELL BIOL, V22, P7919, DOI 10.1128/MCB.22.22.7919-7928.2002; Kruzelock RP, 1997, CANCER RES, V57, P106; Lavigne M, 2004, MOL CELL, V13, P415, DOI 10.1016/S1097-2765(04)00006-1; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pasini D, 2004, CELL CYCLE, V3, P396; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Raaphorst FM, 2005, HUM MOL GENET, V14, pR93, DOI 10.1093/hmg/ddi111; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tonkin E, 2002, HUM GENET, V111, P435, DOI 10.1007/s00439-002-0814-3; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005	38	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1714	1722		10.1038/sj.onc.1209988	http://dx.doi.org/10.1038/sj.onc.1209988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001316	Green Accepted			2022-12-25	WOS:000244955600005
J	Pochampalli, MR; el Bejjani, RM; Schroeder, JA				Pochampalli, M. R.; el Bejjani, R. M.; Schroeder, J. A.			MUC1 is a novel regulator of erbB1 receptor trafficking	ONCOGENE			English	Article						erbB1; MUC1; phosphorylation; ubiquitination; breast cancer	GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; C-SRC; TYROSINE KINASES; MAMMARY-GLAND; CANCER; CELLS; OVEREXPRESSION; SUPPRESSION; C-CBL/SLI-1	ErbB receptors are key regulators of cell survival and growth in normal and transformed tissues. The oncogenic glycoprotein MUC1 is a binding partner and substrate for erbB1 and MUC1 expression can potentiate erbB-dependent signal transduction. After receptor activation, erbB1 is typically downregulated via an endocytic pathway that results in receptor degradation or recycling. We report here that MUC1 expression inhibits the degradation of ligand-activated erbB1. Through the use of both RNAi-mediated knock down and overexpression constructs of MUC1, we show that MUC1 expression inhibits erbB1 degradation after ligand treatment in breast epithelial cells. This MUC1-mediated protection against erbB1 degradation can increase total cellular pools of erbB1 over time. Biotinylation of surface proteins demonstrates that cell-surface associated erbB1 receptor is protected by MUC1 against ligand-induced degradation, although this is accompanied by an increase in erbB1 internalization. The MUC1-mediated protection against degradation occurs with a decrease in EGF-stimulated ubiquitination of erbB1, and an increase in erbB1 recycling. These data indicate that MUC1 expression is a potent regulator of erbB1 receptor stability upon activation and may promote transformation through the inhibition of erbB1 degradation.	Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Univ Arizona, Bio5 Inst, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Schroeder, JA (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA.	jschroeder@azcc.arizona.edu		El Bejjani, Rachid/0000-0003-2328-0773; schroeder, joyce/0000-0003-1277-5172	NATIONAL CANCER INSTITUTE [R01CA102113] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102113-02, R01 CA102113] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kuwada SK, 1998, AM J PHYSIOL-CELL PH, V275, pC1419, DOI 10.1152/ajpcell.1998.275.6.C1419; LAN MS, 1990, J BIOL CHEM, V265, P15294; Lee FT, 2005, CLIN CANCER RES, V11, p7080S, DOI 10.1158/1078-0432.CCR-1004-0019; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li XJ, 2005, CANCER BIOL THER, V4, P968, DOI 10.4161/cbt.4.9.1913; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yan Q, 2005, EXP CELL RES, V304, P265, DOI 10.1016/j.yexcr.2004.11.003; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	37	86	90	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1693	1701		10.1038/sj.onc.1209976	http://dx.doi.org/10.1038/sj.onc.1209976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983337				2022-12-25	WOS:000244955600003
J	Estabrook, RA; Reich, N				Estabrook, R. August; Reich, Norbert			Observing an induced-fit mechanism during sequence-specific DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; ESCHERICHIA-COLI; KINETIC MECHANISM; ECORV ENDONUCLEASE; CRYSTAL-STRUCTURE; SITE RECOGNITION; BINARY COMPLEX; TRANSFER-RNA; TARGET BASE; METHYLTRANSFERASE	The characterization of conformational changes that drive induced-fit mechanisms and their quantitative importance to enzyme specificity are essential for a full understanding of enzyme function. Here, we report on M. HhaI, a sequence-specific DNA cytosine C-5 methyltransferase that reorganizes a flexible loop (residues 80-100) upon binding cognate DNA as part of an induced-fit mechanism. To directly observe this similar to 26 angstrom conformational rearrangement and provide a basis for understanding its importance to specificity, we replaced loop residues Lys-91 and Glu-94 with tryptophans. The double mutants W41F/K91W and W41F/E94W are relatively unperturbed in kinetic and thermodynamic properties. W41F/E94W shows DNA sequence-dependent changes in fluorescence: significant changes in equilibrium and transient state fluorescence that occur when the enzyme binds cognate DNA are absent with nonspecific DNA. These real-time, solution-based results provide direct evidence that binding to cognate DNA induces loop reorganization into the closed conformer, resulting in the correct assembly of the active site. We propose that M. HhaI scans nonspecific DNA in the loop-open conformer and rearranges to the closed form once the cognate site is recognized. The fluorescence data exclude mechanisms in which loop motion precedes base flipping, and we show loop rearrangements are directly coupled to base flipping, because the sequential removal of single hydrogen bonds within the target guanosine: cytosine base pair results in corresponding changes in loop motion.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Reich, N (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Rm 1142D, Santa Barbara, CA 93106 USA.	reich@chem.ucsb.edu						Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; Arora K, 2005, BIOCHEMISTRY-US, V44, P13328, DOI 10.1021/bi0507682; Blumenthal RM, 2001, NAT STRUCT BIOL, V8, P101, DOI 10.1038/84072; Bovee ML, 2003, BIOCHEMISTRY-US, V42, P15102, DOI 10.1021/bi0355701; Chen BN, 2002, COMB CHEM HIGH T SCR, V5, P409; CHENG X, 1993, COLD SPRING HARB SYM, V58, P331, DOI 10.1101/SQB.1993.058.01.039; Daujotyte D, 2004, STRUCTURE, V12, P1047, DOI 10.1016/j.str.2004.04.007; de la Sierra IML, 2000, BIOCHEMISTRY-US, V39, P15870, DOI 10.1021/bi0015360; ERIE DA, 1994, SCIENCE, V266, P1562, DOI 10.1126/science.7985026; Estabrook RA, 2004, J BIOL CHEM, V279, P31419, DOI 10.1074/jbc.M402950200; Fromme JC, 2004, CURR OPIN STRUC BIOL, V14, P43, DOI 10.1016/j.sbi.2004.01.003; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gowher H, 2000, J MOL BIOL, V303, P93, DOI 10.1006/jmbi.2000.4127; Gueron M, 1995, METHOD ENZYMOL, V261, P383; Halford SE, 2004, NUCLEIC ACIDS RES, V32, P3040, DOI 10.1093/nar/gkh624; Halford SE, 2002, EUR BIOPHYS J BIOPHY, V31, P257, DOI 10.1007/s00249-002-0224-4; Hiller DA, 2003, BIOCHEMISTRY-US, V42, P14375, DOI 10.1021/bi035520w; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Hopkins BB, 2004, J BIOL CHEM, V279, P37049, DOI 10.1074/jbc.M404573200; Horton JR, 2005, CELL, V121, P349, DOI 10.1016/j.cell.2005.02.021; Huang N, 2003, P NATL ACAD SCI USA, V100, P68, DOI 10.1073/pnas.0135427100; HUNTER WN, 1986, J BIOMOL STRUCT DYN, V4, P173, DOI 10.1080/07391102.1986.10506338; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOSHLAND DE, 1958, FED PROC, V17, P1145; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Kurpiewski MR, 2004, STRUCTURE, V12, P1775, DOI 10.1016/j.str.2004.07.016; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Martin AM, 1999, BIOCHEMISTRY-US, V38, P8430, DOI 10.1021/bi9905359; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; MOE JG, 1992, BIOCHEMISTRY-US, V31, P8421, DOI 10.1021/bi00151a005; Neely RK, 2005, NUCLEIC ACIDS RES, V33, P6953, DOI 10.1093/nar/gki995; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; Powell RM, 2002, J BIOL CHEM, V277, P7776, DOI 10.1074/jbc.M110147200; Purohit V, 2003, BIOCHEMISTRY-US, V42, P10200, DOI 10.1021/bi0341206; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Sapienza PJ, 2005, J MOL BIOL, V348, P307, DOI 10.1016/j.jmb.2005.02.051; Schonbrunn E, 2000, BIOCHEMISTRY-US, V39, P2164, DOI 10.1021/bi991091j; Stivers JT, 2004, PROG NUCLEIC ACID RE, V77, P37, DOI 10.1016/S0079-6603(04)77002-6; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Svedruzic ZM, 2004, BIOCHEMISTRY-US, V43, P11460, DOI 10.1021/bi0496743; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3962, DOI 10.1093/nar/28.20.3962; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; Turner B, 2005, RNA, V11, P1192, DOI 10.1261/rna.2680605; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; von Hippel PH, 2004, SCIENCE, V305, P350, DOI 10.1126/science.1101270; Wang PF, 2005, IUBMB LIFE, V57, P355, DOI 10.1080/15216540500091999; Wang PY, 2000, J AM CHEM SOC, V122, P12422, DOI 10.1021/ja001989s; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang R, 2005, BIOPHYS J, V89, P95, DOI 10.1529/biophysj.105.061556; Youngblood B, 2006, J MOL BIOL, V362, P334, DOI 10.1016/j.jmb.2006.07.031; Zhang XD, 2006, P NATL ACAD SCI USA, V103, P6148, DOI 10.1073/pnas.0601587103	58	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37205	37214		10.1074/jbc.M607538200	http://dx.doi.org/10.1074/jbc.M607538200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17005571	hybrid			2022-12-25	WOS:000242220800081
J	Deng, WB; Neve, RL; Rosenberg, PA; Volpe, JJ; Jensen, FE				Deng, Wenbin; Neve, Rachael L.; Rosenberg, Paul A.; Volpe, Joseph J.; Jensen, Frances E.			alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subunit composition and cAMP-response element-binding protein regulate oligodendrocyte excitotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE-MATTER INJURY; GLUTAMATE RECEPTORS; NMDA RECEPTORS; MEDIATE EXCITOTOXICITY; KAINATE RECEPTORS; NERVOUS-SYSTEM; AMPA RECEPTORS; EXPRESSION; TOXICITY; CHANNELS	Developing oligodendrocytes (OLs) are highly vulnerable to glutamate excitotoxicity. Although OL excitotoxicity is mainly mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate ( AMPA) receptors (AMPARs) and is Ca2+-dependent, the molecular basis for AMPAR-mediated Ca2+ influx in OLs remains largely unclear. Ca2+ permeability of AMPARs is inversely correlated with the abundance of the AMPAR subunit glutamate receptor 2 (GluR2). Here we report that GluR2-containing and GluR2-lacking AMPARs are co-expressed in individual OLs and that a subset of AMPARs on each OL are Ca2+ permeable and mediate OL excitotoxicity. Virus-mediated overexpression of GluR2 reduces OL excitotoxicity, whereas expression of its unedited form GluR2(Q) enhances the excitotoxicity. These findings indicate that GluR2 critically controls OL excitotoxicity. During OL excitotoxicity, the transcriptional factor cAMP-response element-binding protein (CREB) is transiently phosphorylated and subsequently down-regulated. Virus-mediated expression of a constitutively active form of CREB, both in cultured OLs in vitro and in developing cerebral white matter in vivo, up-regulates GluR2, inhibits Ca2+ permeability, and protects OLs from excitotoxicity. Overall, these data suggest that targeting GluR2-lacking AMPARs or CREB may be a useful strategy for treating nervous system disorders associated with OL excitotoxicity.	Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Program Neurosci, Boston, MA 02115 USA; McLean Hosp, Dept Psychiat, Boston, MA 02478 USA; McLean Hosp, Program Neurosci, Boston, MA 02478 USA; Harvard Univ, Sch Med, Boston, MA 02478 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; McLean Hospital; Harvard University; McLean Hospital; Harvard University; Harvard Medical School	Jensen, FE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.	frances.jensen@tch.harvard.edu		Rosenberg, Paul/0000-0002-5185-1118	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038475, R01NS031718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000222] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG00222] Funding Source: Medline; NICHD NIH HHS [P30 HD18655] Funding Source: Medline; NINDS NIH HHS [P01 NS38475, R01 NS31718] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberdi E, 2002, NEUROBIOL DIS, V9, P234, DOI 10.1006/nbdi.2001.0457; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Deng WB, 2004, P NATL ACAD SCI USA, V101, P7751, DOI 10.1073/pnas.0307850101; Deng WB, 2003, P NATL ACAD SCI USA, V100, P6801, DOI 10.1073/pnas.1136624100; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fern R, 2000, J NEUROSCI, V20, P34, DOI 10.1523/JNEUROSCI.20-01-00034.2000; Follett PL, 2000, J NEUROSCI, V20, P9235; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Liu YQ, 2002, PEDIATR RES, V51, P25, DOI 10.1203/00006450-200201000-00007; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; Pende M, 1997, J NEUROSCI, V17, P1291; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; Rubio ME, 1997, NEURON, V18, P939, DOI 10.1016/S0896-6273(00)80333-5; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Sanchez RM, 2001, J NEUROSCI, V21, P8154, DOI 10.1523/JNEUROSCI.21-20-08154.2001; Sanchez-Gomez MV, 1999, NEUROBIOL DIS, V6, P475, DOI 10.1006/nbdi.1999.0264; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Volpe JJ, 2001, NEUROLOGY NEWBORN, V4th, P217; Washburn MS, 1997, J NEUROSCI, V17, P9393; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Yoshioka A, 1996, J NEUROSCI RES, V46, P427; YOSHIOKA A, 1995, J NEUROCHEM, V64, P2442	36	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36004	36011		10.1074/jbc.M606459200	http://dx.doi.org/10.1074/jbc.M606459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990276	hybrid			2022-12-25	WOS:000242100500048
J	Duym, WW; Fiala, KA; Bhatt, N; Suo, Z				Duym, Wade W.; Fiala, Kevin A.; Bhatt, Nikunj; Suo, Zucai			Kinetic effect of a downstream strand and its 5'-terminal moieties on single nucleotide gap-filling synthesis catalyzed by human DNA polymerase lambda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; PURIFIED PROTEINS; ABASIC SITE; POL LAMBDA; BETA; FIDELITY; RECONSTITUTION; IDENTIFICATION; CORRECT; ENZYME	During short-patch base excision repair, the excision of a 5'-terminal 2-deoxyribose-5-phosphate moiety of the downstream strand by the 5'-2-deoxyribose-5-phosphate lyase activity of either DNA polymerase beta or lambda is believed to occur after each respective enzyme catalyzes gap-filling DNA synthesis. Yet the effects of this 5'-terminal 2-deoxyribose-5-phosphate moiety on the polymerase activities of these two enzymes have never been quantitatively determined. Moreover, x-ray crystal structures of truncated polymerase lambda have revealed that the downstream strand and its 5'-phosphate group of gapped DNA interact intensely with the dRPase domain, but the kinetic effect of these interactions is unclear. Here, we utilized pre-steadystate kinetic methods to systematically investigate the effect of a downstream strand and its 5'-moieties on the polymerase activity of the full-length human polymerase lambda. The downstream strand and its 5'-phosphate were both found to increase nucleotide incorporation efficiency (k(p)/K-d) by 15- and 11-fold, respectively, with the increase procured by the effect on the nucleotide incorporation rate constant k(p) rather than the ground state nucleotide binding affinity K-d. With 4 single nucleotide-gapped DNA substrates containing a 1,2-dideoxyribose-5-phosphate moiety, a 2-deoxyribose-5-phosphate mimic, we measured the incorporation efficiencies of 16 possible nucleotides. Our results demonstrate that although this 5'-terminal 2-deoxyribose-5-phosphate mimic does not affect the fidelity of polymerase lambda, it moderately decreased the polymerase efficiency by 3.4-fold. Moreover, this decrease in polymerase efficiency is due to a drop of similar magnitude in k(p) rather han K-d. The implication of the downstream strand and its 5'-moieties on the kinetics of gap-filling synthesis is discussed.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Biophys Program, Columbus, OH 43210 USA; Ohio State Univ, Mol & Cellular Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Suo, Z (corresponding author), 740 Biol Sci,484 W 12th Ave, Columbus, OH 43210 USA.	suo.2@osu.edu						Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Batra VK, 2006, STRUCTURE, V14, P757, DOI 10.1016/j.str.2006.01.011; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; BRAITHWAITE EK, 2005, J BIOL CHEM; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; DeRose EF, 2003, BIOCHEMISTRY-US, V42, P9564, DOI 10.1021/bi034298s; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P6751, DOI 10.1021/bi049975c; Fiala KA, 2006, J BIOL CHEM, V281, P19038, DOI 10.1074/jbc.M601178200; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Garcia-Diaz M, 2005, NAT STRUCT MOL BIOL, V12, P97, DOI 10.1038/nsmb876; Garcia-Diaz M, 2006, CELL, V124, P331, DOI [10.1016/j.cell.2005.10.039, 10.1016/j.cel.2005.10.039]; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kraynov VS, 1997, BIOCHEM J, V323, P103, DOI 10.1042/bj3230103; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lawley P D, 1966, Prog Nucleic Acid Res Mol Biol, V5, P89, DOI 10.1016/S0079-6603(08)60232-9; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu J, 2001, BIOCHEMISTRY-US, V40, P9014, DOI 10.1021/bi010646j; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; LUTZ WK, 1990, MUTAT RES, V238, P287, DOI 10.1016/0165-1110(90)90020-C; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Uchiyama Y, 2004, EUR J BIOCHEM, V271, P2799, DOI 10.1111/j.1432-1033.2004.04214.x; Wang KY, 1997, BIOCHEMISTRY-US, V36, P11629, DOI 10.1021/bi971464l; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	53	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35649	35655		10.1074/jbc.M607479200	http://dx.doi.org/10.1074/jbc.M607479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005572	hybrid			2022-12-25	WOS:000242100500009
J	Herz, C; Aumailley, M; Schulte, C; Schlortzer-Schrehardt, U; Bruckner-Tuderman, L; Has, C				Herz, Corinna; Aumailley, Monique; Schulte, Carsten; Schloertzer-Schrehardt, Ursula; Bruckner-Tuderman, Leena; Has, Cristina			Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; KINDLER-SYNDROME; COLLAGEN XVII; BASEMENT-MEMBRANE; ADHESION; BETA-1-INTEGRIN; MUTATIONS; GENE; CYTOSKELETON; INTEGRATORS	A novel family of focal adhesion proteins, the kindlins, is involved in attachment of the actin cytoskeleton to the plasma membrane and in integrin-mediated cellular processes. Deficiency of kindlin-1, as a result of loss-of-function mutations in the KIND1 gene, causes Kindler syndrome, an autosomal recessive genodermatosis characterized by skin blistering, progressive skin atrophy, photosensitivity and, occasionally, carcinogenesis. Here we characterized authentic and recombinantly expressed kindlin-1 and show that it is localized in basal epidermal keratinocytes in a polar fashion, close to the cell surface facing the basement membrane, in the areas between the hemidesmosomes. We identified two forms of kindlin-1 in keratinocytes, with apparent molecular masses of 78 and 74 kDa,corresponding to phosphorylated and desphosphorylated forms of the protein. In kindlin-1-deficient skin, basal keratinocytes show multiple abnormalities: cell polarity is lost, proliferation is strongly reduced, and several cells undergo apoptosis. In vitro, deficiency of kindlin-1 in keratinocytes leads to strongly reduced cell proliferation, decreased adhesion, undirected motility, and intense protrusion activity of the plasma membrane. Taken together, these results show that kindlin-1 plays a role in keratinocyte adhesion, polarization, proliferation, and migration. It is involved in organization and anchorage of the actin cytoskeleton to integrin-associated signaling platforms.	Univ Freiburg, Med Ctr, Dept Dermatol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Biol, D-79104 Freiburg, Germany; Univ Cologne, Ctr Biochim, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Univ Erlangen Nurnberg, Dept Ophthalmol, D-91054 Erlangen, Germany	University of Freiburg; University of Freiburg; University of Cologne; University of Cologne; University of Erlangen Nuremberg	Has, C (corresponding author), Univ Freiburg, Med Ctr, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	crishas@haut.ukl.uni-freiburg.de	Schulte, Carsten/R-2370-2016; Has, Cristina/V-2132-2019; Has, Cristina/B-3310-2017; Has, Cristina/AGF-7185-2022	Schulte, Carsten/0000-0002-7554-5342; Has, Cristina/0000-0001-6066-507X; Has, Cristina/0000-0001-6066-507X; Has, Cristina/0000-0001-6066-507X; Herz, Corinna/0000-0003-3837-0544				Balla T, 2005, J CELL SCI, V118, P2093, DOI 10.1242/jcs.02387; Bibby AC, 2005, INT J BIOL SCI, V1, P67; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Brakebusch C, 2005, CANCER METAST REV, V24, P403, DOI 10.1007/s10555-005-5132-5; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Canton DA, 2006, CELL SIGNAL, V18, P267, DOI 10.1016/j.cellsig.2005.07.008; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; Gkretsi V, 2005, J CELL SCI, V118, P697, DOI 10.1242/jcs.01638; Has C, 2004, J INVEST DERMATOL, V122, P84, DOI 10.1046/j.0022-202X.2003.22138.x; Has C, 2006, J INVEST DERMATOL, V126, P1776, DOI 10.1038/sj.jid.5700339; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jobard F, 2003, HUM MOL GENET, V12, P925, DOI 10.1093/hmg/ddg097; Kloeker S, 2004, J BIOL CHEM, V279, P6824, DOI 10.1074/jbc.M307978200; Lanschuetzer C M, 2004, Hum Genet, V115, P175; Raghavan S, 2003, DEV CELL, V5, P415, DOI 10.1016/S1534-5807(03)00261-2; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Siegel DH, 2003, AM J HUM GENET, V73, P174, DOI 10.1086/376609; Tasanen K, 2004, AM J PATHOL, V164, P2027, DOI 10.1016/S0002-9440(10)63762-5; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; White SJ, 2005, J DERMATOL SCI, V38, P169, DOI 10.1016/j.jdermsci.2004.12.026	25	107	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36082	36090		10.1074/jbc.M606259200	http://dx.doi.org/10.1074/jbc.M606259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012746	hybrid, Green Published			2022-12-25	WOS:000242100500057
J	Nicolas, E; Lee, MG; Hakimi, MA; Cam, HP; Grewal, SIS; Shiekhattar, R				Nicolas, Estelle; Lee, Min Gyu; Hakimi, Mohamed-Ali; Cam, Hugh P.; Grewal, Shiv I. S.; Shiekhattar, Ramin			Fission yeast homologs of human histone H3 lysine 4 demethylase regulate a common set of genes with diverse functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METHYLATION; ANDROGEN-RECEPTOR; SWIRM DOMAIN; COMPLEX; COMPONENT; FAMILY; LSD1; COREST; TRANSCRIPTION; REPRESSION	Schizosaccharomyces pombe contains two proteins, SWIRM1 and SWIRM2, with close homology to human histone H3 lysine 4 demethylase. Both proteins contain the amino oxidase catalytic domain and a recently described DNA interaction SWIRM domain. Here we describe the biochemical isolation and the functional characterization of SWIRM1 and SWIRM2. Our results indicate that while SWIRM2 is an essential gene, cells lacking SWIRM1 are viable. We found that SWIRM1 and SWIRM2 are stably associated in a multiprotein complex, but intriguingly, unlike their human counterpart, S. pombe SWIRM complex contains neither a histone deacetylase nor any detectable demethylase activity. Genome-wide chromatin immunoprecipitation unexpectedly showed the absence of both SWIRM proteins from heterochromatic domains. Instead, consistent with biochemical analyses, SWIRM1 and SWIRM2 co-localize to a common set of target gene promoters whose functions are implicated in diverse processes including mitochondrial metabolism and transcriptional regulation. Importantly, we show that SWIRM1 is not only required for optimum transcription of its target genes but also display a global role in regulation of antisense transcription.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); The Wistar Institute	Grewal, SIS (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov; shiekhattar@wistar.org	Nicolas, Estelle/C-4425-2008; HAKIMI, Mohamed-Ali/F-9806-2014; HAKIMI, Mohamed-ali/Q-6475-2019; HAKIMI, Mohamed-ali/GYJ-0879-2022	Nicolas, Estelle/0000-0003-0412-8477; HAKIMI, Mohamed-Ali/0000-0002-2547-8233; HAKIMI, Mohamed-ali/0000-0002-2547-8233; 	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM61204] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061204] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Da GP, 2006, P NATL ACAD SCI USA, V103, P2057, DOI 10.1073/pnas.0510949103; Eimer S, 2002, EMBO J, V21, P5787, DOI 10.1093/emboj/cdf561; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Iwase S, 2004, BIOCHEM BIOPH RES CO, V322, P601, DOI 10.1016/j.bbrc.2004.07.163; Iyer L. M, 2002, GENOME BIOL, V3; Jarriault S, 2002, GENE DEV, V16, P2713, DOI 10.1101/gad.1022402; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Nakayama J, 2003, EMBO J, V22, P2776, DOI 10.1093/emboj/cdg248; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tochio N, 2006, STRUCTURE, V14, P457, DOI 10.1016/j.str.2005.12.004; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454	33	21	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35983	35988		10.1074/jbc.M606349200	http://dx.doi.org/10.1074/jbc.M606349200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990277	hybrid			2022-12-25	WOS:000242100500045
J	Sottocornola, B; Visconti, S; Orsi, S; Gazzarrini, S; Giacometti, S; Olivari, C; Camoni, L; Aducci, P; Marra, M; Abenavoli, A; Thiel, G; Moroni, A				Sottocornola, Barbara; Visconti, Sabina; Orsi, Sara; Gazzarrini, Sabrina; Giacometti, Sonia; Olivari, Claudio; Camoni, Lorenzo; Aducci, Patrizia; Marra, Mauro; Abenavoli, Alessandra; Thiel, Gerhard; Moroni, Anna			The potassium channel KAT1 is activated by plant and animal 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEINS; K+ CHANNEL; FUNCTIONAL EXPRESSION; ARABIDOPSIS; VOLTAGE; MODULATION; MUTATIONS; CELLS	14-3-3 proteins modulate the plant inward rectifier K+ channel KAT1 heterologously expressed in Xenopus oocytes. Injection of recombinant plant 14-3-3 proteins into oocytes shifted the activation curve of KAT1 by + 11 mV and increased the tau on. KAT1 was also modulated by 14-3-3 proteins of Xenopus oocytes. Titration of the endogenous 14-3-3 proteins by injection of the peptide Raf 621p resulted in a strong decrease in KAT1 current (similar to 70% at -150 mV). The mutation K56E performed on plant protein 14-3-3 in a highly conserved recognition site prevented channel activation. Because the maximal conductance of KAT1 was unaffected by 14-3-3, we can exclude that they act by increasing the number of channels, thus ruling out any effect of these proteins on channel trafficking and/or insertion into the oocyte membrane. 14-3-3 proteins also increased KAT1 current in inside-out patches, suggesting a direct interaction with the channel. Direct interaction was confirmed by overlay experiments with radioactive 14-3-3 on oocyte membranes expressing KAT1.	Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Milan, Ist Biofis, CNR, I-20133 Milan, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Tech Univ Darmstadt, Inst Bot, D-64287 Darmstadt, Germany; Unita Univ Milan, Ist Nazl Fis Mat, I-20133 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Milan; University of Rome Tor Vergata; Technical University of Darmstadt; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Milan	Moroni, A (corresponding author), Univ Milan, Dipartimento Biol, Via Celoria 26, I-20133 Milan, Italy.	anna.moroni@unimi.it	moroni, anna/H-2097-2014; Camoni, Lorenzo/C-2584-2012; Olivari, Claudio/D-7768-2017	moroni, anna/0000-0002-1860-406X; Olivari, Claudio/0000-0002-7209-1496; Thiel, Gerhard/0000-0002-2335-1351; gazzarrini, sabrina/0000-0003-3062-7536				Aducci P, 2002, IUBMB LIFE, V53, P49, DOI 10.1080/15216540210813; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Baizabal-Aguirre VM, 1999, J MEMBRANE BIOL, V167, P119, DOI 10.1007/s002329900476; Booij PP, 1999, PLANT J, V20, P673, DOI 10.1046/j.1365-313X.1999.00643.x; Bruggemann L, 1999, P NATL ACAD SCI USA, V96, P3298, DOI 10.1073/pnas.96.6.3298; Bruggemann L, 1999, PLANTA, V207, P370, DOI 10.1007/s004250050494; Chan HC, 2000, BIOCHEM BIOPH RES CO, V270, P581, DOI 10.1006/bbrc.2000.2454; Cherel I, 2004, J EXP BOT, V55, P337, DOI 10.1093/jxb/erh028; De Jong JC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017904.77985.03; DiFrancesco D, 1999, J PHYSIOL-LONDON, V515, P367, DOI 10.1111/j.1469-7793.1999.367ac.x; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacRobbie EAC, 1998, PHILOS T ROY SOC B, V353, P1475, DOI 10.1098/rstb.1998.0303; Marra M, 2000, PLANT BIOLOGY, V2, P11, DOI 10.1055/s-2000-9458; MARRE MT, 1989, PLANT SCI, V62, P21, DOI 10.1016/0168-9452(89)90184-2; Moroni A, 1998, J MEMBRANE BIOL, V163, P25, DOI 10.1007/s002329900367; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Pilot G, 2001, J BIOL CHEM, V276, P3215, DOI 10.1074/jbc.M007303200; Saalbach G, 1997, FEBS LETT, V413, P294, DOI 10.1016/S0014-5793(97)00865-X; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; Szyroki A, 2001, P NATL ACAD SCI USA, V98, P2917, DOI 10.1073/pnas.051616698; Tang HX, 1996, PLANT CELL, V8, P1545, DOI 10.1105/tpc.8.9.1545; Tang XD, 1999, BIOPHYS J, V76, P3089, DOI 10.1016/S0006-3495(99)77461-8; Thiel G, 1997, TRENDS PLANT SCI, V2, P339, DOI 10.1016/S1360-1385(97)84621-3; THIEL G, 1992, J MEMBRANE BIOL, V126, P1; van den Wijngaard PWJ, 2005, PLANT J, V41, P43, DOI 10.1111/j.1365-313X.2004.02273.x; van den Wijngaard PWJ, 2001, FEBS LETT, V488, P100, DOI 10.1016/S0014-5793(00)02394-2; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; Visconti S, 2003, J BIOL CHEM, V278, P8172, DOI 10.1074/jbc.M211039200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zei PC, 1998, J GEN PHYSIOL, V112, P679, DOI 10.1085/jgp.112.6.679; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4; [No title captured]	40	53	60	5	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35735	35741		10.1074/jbc.M603361200	http://dx.doi.org/10.1074/jbc.M603361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990282	Green Published, hybrid			2022-12-25	WOS:000242100500018
J	Zhang, YW; Rudnick, G				Zhang, Yuan-Wei; Rudnick, Gary			The cytoplasmic substrate permeation pathway of serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; DEPENDENT NEUROTRANSMITTER TRANSPORTERS; CRYSTAL-STRUCTURE; PLATELET 5-HYDROXYTRYPTAMINE; TRANSLOCATION PATHWAY; TRANSMEMBRANE DOMAIN; BACTERIAL HOMOLOG; ESCHERICHIA-COLI; COCAINE BINDING; MECHANISM	Serotonin transporter (SERT) catalyzes reuptake of the neurotransmitter serotonin (5-HT) and is a target for antidepressant drugs and psychostimulants. It is a member of a large family of neurotransmitter and amino acid transporters. A recent study using site-directed cysteine modification identified a helical region of the transporter with high accessibility to the cytoplasm. Subsequently, the high resolution structure of LeuT,a prokaryotic homologue, showed that the residues corresponding to this helical region are part of the fifth transmembrane domain. The accessibility of these positions is now shown to depend on conformational changes corresponding to interconversion of SERT between two forms that face the extracellular medium and the cytoplasm, respectively. Binding of the extracellular inhibitor cocaine decreased accessibility at these positions, whereas 5-HT, the transported substrate, increased it. The effect of 5-HT required the simultaneous presence of Na+ and Cl-, which are transported into the cell together (symported) with 5-HT. In light of the LeuT structure, these results begin to define the pathway through which 5-HT diffuses between its binding site and the cytoplasm. They also confirm a prediction of the alternating access model for transport, namely, that all symported substrates must bind together before translocation.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,POB 208066, New Haven, CT 06520 USA.	gary.rudnick@yale.edu		ZHANG, YUAN-WEI/0000-0002-4276-9251	NIDA NIH HHS [DA008213, DA012408, DA007259] Funding Source: Medline; NIGMS NIH HHS [GM075347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007259, P01DA012408, R01DA008213] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Androutsellis-Theotokis A, 2003, J BIOL CHEM, V278, P12703, DOI 10.1074/jbc.M206563200; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; Keller PC, 2004, BIOCHEMISTRY-US, V43, P8510, DOI 10.1021/bi035971g; Mitchell SM, 2004, J BIOL CHEM, V279, P24089, DOI 10.1074/jbc.M311173200; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; NELSON PJ, 1979, J BIOL CHEM, V254, P84; Ni YG, 2001, J BIOL CHEM, V276, P30942, DOI 10.1074/jbc.M104653200; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Quick M, 2006, J BIOL CHEM, V281, P26444, DOI 10.1074/jbc.M602438200; RUDNICK G, 1991, MOL PHARMACOL, V40, P421; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Rudnick G., 2002, TRANSMEMBRANE TRANSP, P125; Rudnick Gary, 2002, P25; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Stahl SM, 1998, J AFFECT DISORDERS, V51, P215, DOI 10.1016/S0165-0327(98)00221-3; STEIN WD, 1986, TRANSPORT DIFFUSION, P397; STEIN WD, 1986, TRANSPORT DIFFUSION, P306; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; TANFORD C, 1983, P NATL ACAD SCI-BIOL, V80, P3701, DOI 10.1073/pnas.80.12.3701; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WALL SC, 1993, MOL PHARMACOL, V43, P264; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zhang YW, 2005, J BIOL CHEM, V280, P30807, DOI 10.1074/jbc.M504087200	40	102	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36213	36220		10.1074/jbc.M605468200	http://dx.doi.org/10.1074/jbc.M605468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008313	hybrid			2022-12-25	WOS:000242100500072
J	Eren, E; Kennedy, DC; Maroney, MJ; Arguello, JM				Eren, Elif; Kennedy, David C.; Maroney, Michael J.; Arguello, Jose M.			A novel regulatory metal binding domain is present in the C terminus of Arabidopsis Zn2+-ATPase HMA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSONS-DISEASE PROTEIN; FULGIDUS CU+-ATPASE; COPPER-TRANSPORTING ATPASE; CIRCULAR-DICHROISM SPECTRA; MENKES-DISEASE; PLASMA-MEMBRANE; SECONDARY STRUCTURE; CATALYTIC ACTIVITY; ESCHERICHIA-COLI	HMA2 is a Zn2+-ATPase from Arabidopsis thaliana. It contributes to the maintenance of metal homeostasis in cells by driving Zn2+ efflux. Distinct from P-1B-type ATPases, plant Zn2+-ATPases have long C-terminal sequences rich in Cys and His. Removal of the 244 amino acid C terminus of HMA2 leads to a 43% reduction in enzyme turnover without significant effect on the Zn2+ K-1/2 for enzyme activation. Characterization of the isolated HMA2 C terminus showed that this fragment binds three Zn2+ with high affinity (K-d = 16 +/- 3 nM). Circular dichroism spectral analysis indicated the presence of 8% alpha-helix, 45% beta-sheet, and 48% random coil in the C-terminal peptide with noticeable structural changes upon metal binding ( 8% alpha-helix, 39% beta-sheet, and 52% random coil). Zn K-edge XAS of Zn-CMBD in the presence of one equivalent of Zn2+ shows that the average zinc complex formed is composed of three His and one Cys residues. Upon the addition of two extra Zn2+ ions per C-MBD, these appear coordinated primarily by His residues thus, suggesting that the three Zn2+ binding domains might not be identical. Modification of His residues with diethyl pyrocarbonate completely inhibited Zn2+ binding to the C terminus, pointing out the importance of His residues in Zn2+ coordination. In contrast, alkylation of Cys with iodoacetic acid did not prevent Zn2+ binding to the HMA2C terminus. Zn K-edge XAS of the Cys-alkylated protein was consistent with (N/O())4 coordination of the zinc site, with three of those ligands fitting for His residues. In summary, plant Zn2+-ATPases contain novel metal binding domains in their cytoplasmic C terminus. Structurally distinct from the well characterized N-terminal metal binding domains present in most P-1B-type ATPases, they also appear to regulate enzyme turnover rate.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	Worcester Polytechnic Institute; University of Massachusetts System; University of Massachusetts Amherst	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, 100 Inst Rd, Worcester, MA 01609 USA.	arguello@wpi.edu	; Arguello, Jose/D-1997-2012	Maroney, Michael/0000-0002-5598-3038; Eren, Elif/0000-0002-7942-4943; Arguello, Jose/0000-0003-3940-6297; Kennedy, David/0000-0002-5110-1886	NIGMS NIH HHS [R01-GM061696] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Axelsen KB, 2001, PLANT PHYSIOL, V126, P696, DOI 10.1104/pp.126.2.696; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Baekgaard L, 2005, J BIOENERG BIOMEMBR, V37, P369, DOI 10.1007/s10863-005-9473-0; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; Clark-Baldwin K, 1998, J AM CHEM SOC, V120, P8401, DOI 10.1021/ja980580o; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Eren E, 2004, PLANT PHYSIOL, V136, P3712, DOI 10.1104/pp.104.046292; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; Gravot A, 2004, FEBS LETT, V561, P22, DOI 10.1016/S0014-5793(04)00072-9; Guo JQ, 1997, BIOCHEMISTRY-US, V36, P730, DOI 10.1021/bi9617769; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Harrison MD, 1999, BBA-MOL BASIS DIS, V1453, P254, DOI 10.1016/S0925-4439(98)00110-0; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Hussain D, 2004, PLANT CELL, V16, P1327, DOI 10.1105/tpc.020487; Jensen PY, 1999, BBA-PROTEIN STRUCT M, V1434, P103, DOI 10.1016/S0167-4838(99)00161-2; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14231, DOI 10.1073/pnas.94.26.14231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Liu JB, 2006, BIOCHEMISTRY-US, V45, P763, DOI 10.1021/bi051836n; Liu JB, 2005, BIOCHEMISTRY-US, V44, P5159, DOI 10.1021/bi0476275; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mana-Capelli S, 2003, J BIOL CHEM, V278, P40534, DOI 10.1074/jbc.M306907200; Mandal AK, 2004, J BIOL CHEM, V279, P54802, DOI 10.1074/jbc.M410854200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mills RF, 2005, FEBS LETT, V579, P783, DOI 10.1016/j.febslet.2004.12.040; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; Padden KM, 2001, CHEM MATER, V13, P4305, DOI 10.1021/cm010502r; Pennella MA, 2006, J MOL BIOL, V356, P1124, DOI 10.1016/j.jmb.2005.12.019; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rimessi A, 2005, J BIOL CHEM, V280, P37195, DOI 10.1074/jbc.M504921200; Sazinsky MH, 2006, BIOCHEMISTRY-US, V45, P9949, DOI 10.1021/bi0610045; Sazinsky MH, 2006, J BIOL CHEM, V281, P11161, DOI 10.1074/jbc.M510708200; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; Verret F, 2004, FEBS LETT, V576, P306, DOI 10.1016/j.febslet.2004.09.023; Verret F, 2005, FEBS LETT, V579, P1515, DOI 10.1016/j.febslet.2005.01.065; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Walkup GK, 1997, J AM CHEM SOC, V119, P3443, DOI 10.1021/ja9642121; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Williams LE, 2005, TRENDS PLANT SCI, V10, P491, DOI 10.1016/j.tplants.2005.08.008	64	51	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33881	33891		10.1074/jbc.M605218200	http://dx.doi.org/10.1074/jbc.M605218200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973620	hybrid			2022-12-25	WOS:000241767600009
J	Matsumura, Y; Ban, N; Ueda, K; Inagaki, N				Matsumura, Yoshihiro; Ban, Nobuhiro; Ueda, Kazumitsu; Inagaki, Nobuya			Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CONGENITAL ALVEOLAR PROTEINOSIS; INTERSTITIAL LUNG-DISEASE; PULMONARY SURFACTANT; II CELLS; STARGARDT-DISEASE; SP-C; MEMBRANE-PROTEIN; MESSENGER-RNAS; GENE-MUTATIONS	The ATP-binding cassette transporter ABCA3 is expressed predominantly at the limiting membrane of the lamellar bodies in lung alveolar type II cells. Recent study has shown that mutation of the ABCA3 gene causes fatal surfactant deficiency in newborns. In this study, we investigated in HEK293 cells the intracellular localization and N-glycosylation of the ABCA3 mutants so far identified in fatal surfactant deficiency patients. Green fluorescent protein-tagged L101P, L982P, L1553P, Q1591P, and Ins1518fs/ter1519 mutant proteins remained localized in the endoplasmic reticulum, and processing of oligosaccharide was impaired, whereas wild-type and N568D, G1221S, and L1580P mutant ABCA3 proteins trafficked to the LAMP3-positive intracellular vesicle, accompanied by processing of oligosaccharide from high mannose type to complex type. Vanadate-induced nucleotide trapping and ATP-binding analyses showed that ATP hydrolysis activity was dramatically decreased in the N568D, G1221S, and L1580P mutants, accompanied by a moderate decrease in ATP binding in N568D and L1580P mutants but not in the G1221S mutant, compared with the wild-type ABCA3 protein. In addition, mutational analyses of the Gly-1221 residue in the 11th transmembrane segment and the Leu-1580 residue in the cytoplasmic tail, and homology modeling of nucleotide binding domain 2 demonstrate the significance of these residues for ATP hydrolysis and suggest a mechanism for impaired ATP hydrolysis in G1221S and L1580P mutants. Thus, surfactant deficiency because of ABCA3 gene mutation may be classified into two categories as follows: abnormal intracellular localization (type I) and normal intracellular localization with decreased ATP binding and/or ATP hydrolysis of the ABCA3 protein (type II). These distinct pathophysiologies may reflect both the severity and effective therapy for surfactant deficiency.	Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Sakyo Ku, Kyoto 6068507, Japan; Japan Sci & Technol Program, CREST, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Agr, Lab Cellular Biochem, Div Appl Life Sci, Kyoto 6068502, Japan; Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Akita University	Inagaki, N (corresponding author), Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.	inagaki@metab.kuhp.kyoto-u.ac.jp		Matsumura, Yoshihiro/0000-0002-3108-0440; Inagaki, Nobuya/0000-0001-8261-2593; Ueda, Kazumitsu/0000-0003-2980-6078				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; BATENBURG JJ, 1989, BIOCHIM BIOPHYS ACTA, V1006, P329, DOI 10.1016/0005-2760(89)90020-9; Beers MF, 2005, ANNU REV PHYSIOL, V67, P663, DOI 10.1146/annurev.physiol.67.040403.101937; Beneke S, 2001, BBA-MOL CELL BIOL L, V1534, P56, DOI 10.1016/S1388-1981(01)00178-0; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; CHANDER A, 1990, AM J PHYSIOL, V258, P241; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Cheong N, 2006, J BIOL CHEM, V281, P9791, DOI 10.1074/jbc.M507515200; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DEMELLO DE, 1994, J PEDIATR-US, V125, P43, DOI 10.1016/S0022-3476(94)70119-9; des Georges Marie, 2004, J Cyst Fibros, V3, P265, DOI 10.1016/j.jcf.2004.04.008; DOBBS LG, 1994, AM J RESP CRIT CARE, V150, pS31, DOI 10.1164/ajrccm/150.5_Pt_2.S31; Dork T, 1997, HUM GENET, V100, P365, DOI 10.1007/s004390050518; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Fumagalli A, 2001, HUM GENET, V109, P326, DOI 10.1007/s004390100583; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; Hawgood S, 1998, BBA-MOL BASIS DIS, V1408, P150, DOI 10.1016/S0925-4439(98)00064-7; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; HOROWITZ AD, 1993, BIOCHEMISTRY-US, V32, P9513, DOI 10.1021/bi00088a001; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; LILEY HG, 1989, J CLIN INVEST, V83, P1191, DOI 10.1172/JCI114000; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Mason RJ, 1998, BBA-MOL BASIS DIS, V1408, P226, DOI 10.1016/S0925-4439(98)00070-2; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Nagata K, 2004, BIOCHEM BIOPH RES CO, V324, P262, DOI 10.1016/j.bbrc.2004.09.043; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; Prevelige P., 1989, PREDICTION PROTEIN S, P391; Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090; Rooney SA, 2001, COMP BIOCHEM PHYS A, V129, P233, DOI 10.1016/S1095-6433(01)00320-8; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Situ D, 2004, J BIOL CHEM, V279, P38871, DOI 10.1074/jbc.M403832200; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Thomas AQ, 2002, AM J RESP CRIT CARE, V165, P1322, DOI 10.1164/rccm.200112-123OC; Vankeerberghen A, 1998, HUM MOL GENET, V7, P1761, DOI 10.1093/hmg/7.11.1761; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; Wang WJ, 2002, J BIOL CHEM, V277, P19929, DOI 10.1074/jbc.M201537200; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; Yoshida I, 2004, BIOCHEM BIOPH RES CO, V323, P547, DOI 10.1016/j.bbrc.2004.08.133; Zhang DW, 2003, BIOCHEMISTRY-US, V42, P9989, DOI 10.1021/bi034462b; ZIMMERMANN LJ, 1993, AM J PHYSIOL, V264, pL575, DOI 10.1152/ajplung.1993.264.6.L575	51	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34503	34514		10.1074/jbc.M600071200	http://dx.doi.org/10.1074/jbc.M600071200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16959783	hybrid			2022-12-25	WOS:000241767600071
J	Rocha-Viegas, L; Vicent, GP; Baranao, JL; Beato, M; Pecci, A				Rocha-Viegas, Luciana; Vicent, Guillermo P.; Baranao, Jose L.; Beato, Miguel; Pecci, Adali			Glucocorticoids repress bcl-X expression in lymphoid cells by recruiting STAT5B to the P4 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; SIGNAL TRANSDUCER; PREVENT APOPTOSIS; T-LYMPHOCYTES; IN-VIVO; RECEPTOR; PROTEIN; ACTIVATION; GENE; DEXAMETHASONE	The bcl-X gene plays a critical role in apoptosis. Six different isoforms generated by tissue-specific promoter usage and alternative splicing were described. Some of them exert opposite effects on cell death. In mammary epithelial cells glucocorticoids induce bcl-X expression and increase the ratio bcl-XL (antiapoptotic)/bcl-XS (apoptotic) by activating P4 promoter, which contains two hormone response elements. Here we show that, on mouse thymocytes and T lymphocyte derivative S49 cells, glucocorticoids inhibited transcription from P4 and decreased the ratio bcl-X-L/bcl-X-S favoring apoptosis. Upon hormonal treatment, glucocorticoid receptor (GR), steroid receptor coactivator-1, and RNA polymerase II were transiently recruited to P4 promoter, whereas STAT5B was also recruited but remained bound. Concomitant with the release of GR, silencing mediator for retinoic acid receptor and thyroid hormone receptor and histone deacetylase 3 were recruited, histone H3 was deacetylated, and RNA polymerase II left the promoter. Inhibition of STAT5 activity reverted glucocorticoid repression to activation of transcription and was accompanied by stable recruitment of GR and RNA polymerase II toP4.	Univ Buenos Aires, IFIBYNE, Consejo Nacl Invest Cient & Tecn,Ciudad Univ, Fac Ciencias Exactas & Nat,Dept Fisiol Biol Mol &, Buenos Aires, DF, Argentina; Univ Buenos Aires, IFIBYNE, Consejo Nacl Invest Cient & Tecn,Ciudad Univ, Fac Ciencias Exactas & Nat,Dept Quim Biol, Buenos Aires, DF, Argentina; Univ Pompeu Fabra, Ctr Regulac Genom, Barcelona 08003, Spain	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG)	Pecci, A (corresponding author), Univ Buenos Aires, IFIBYNE, Consejo Nacl Invest Cient & Tecn,Ciudad Univ, Fac Ciencias Exactas & Nat,Dept Fisiol Biol Mol &, Intendente Guiraldes 2160,Pab 2,2do Piso,C1428EGA, Buenos Aires, DF, Argentina.	apecci@qb.fcen.uba.ar	Vicent, Guillermo P./K-5432-2015; Beato, Miguel/B-5564-2015	Vicent, Guillermo P./0000-0002-0554-2226; Beato, Miguel/0000-0002-2878-2222; Rocha-Viegas, Luciana/0000-0001-7857-0212				Amsterdam A, 2002, BIOCHEM PHARMACOL, V64, P843, DOI 10.1016/S0006-2952(02)01147-4; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Berg MN, 2002, ENDOCRINOLOGY, V143, P222, DOI 10.1210/en.143.1.222; Biola A, 2001, MOL ENDOCRINOL, V15, P1062, DOI 10.1210/me.15.7.1062; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bottenstein J, 1979, Methods Enzymol, V58, P94; Broome HE, 2002, LEUKEMIA RES, V26, P311, DOI 10.1016/S0145-2126(01)00118-7; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; *CCAC, 1980, GUID CAR US EXP AN; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Debierre-Grockiego F, 2003, BRIT J HAEMATOL, V123, P933, DOI 10.1046/j.1365-2141.2003.04700.x; Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; FANG W, 1994, J IMMUNOL, V153, P4388; Floyd ZE, 2003, DIABETES, V52, P308, DOI 10.2337/diabetes.52.2.308; Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200; GEHRING U, 1982, MOL CELL ENDOCRINOL, V28, P605, DOI 10.1016/0303-7207(82)90149-6; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Guenther MG, 2000, GENE DEV, V14, P1048; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hillier SG, 1998, J REPROD IMMUNOL, V39, P21, DOI 10.1016/S0165-0378(98)00011-4; Hoijman E, 2004, ENDOCRINOLOGY, V145, P418, DOI 10.1210/en.2003-0764; HYMAN R, 1973, J NATL CANCER I, V50, P415, DOI 10.1093/jnci/50.2.415; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; Nakajima H, 2001, EMBO J, V20, P6836, DOI 10.1093/emboj/20.23.6836; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Schmitt E, 2004, ONCOGENE, V23, P3915, DOI 10.1038/sj.onc.1207554; Schorr K, 2000, CANCER RES, V60, P5950; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Strutt H, 1999, METH MOL B, V119, P455; Tronche F, 2004, GENE DEV, V18, P492, DOI 10.1101/gad.284704; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Vicent GP, 2002, EXP CELL RES, V276, P142, DOI 10.1006/excr.2002.5532; Viegas LR, 2004, J BIOL CHEM, V279, P9831, DOI 10.1074/jbc.M312402200; Xue LY, 2003, ONCOGENE, V22, P9197, DOI 10.1038/sj.onc.1207019; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	54	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33959	33970		10.1074/jbc.M602408200	http://dx.doi.org/10.1074/jbc.M602408200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16959781	hybrid, Green Published			2022-12-25	WOS:000241767600017
J	Sopory, S; Nelsen, SM; Degnin, C; Wong, C; Christian, JL				Sopory, Shailaja; Nelsen, Sylvia M.; Degnin, Catherine; Wong, Crispin; Christian, Jan L.			Regulation of bone morphogenetic protein-4 activity by sequence elements within the prodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPEMANN ORGANIZER; SIGNALING RANGE; PRO-DOMAINS; VG1 PROTEIN; XENOPUS; INDUCTION; MESODERM; GROWTH; MATURE; DISRUPTION	Bone morphogenetic protein-4 (BMP-4) is synthesized as a large precursor protein, which undergoes proprotein convertase-mediated proteolytic maturation along the secretory pathway to release the active ligand. Pro-BMP-4 is initially cleaved at a consensus furin motif adjacent to the mature ligand domain (the S1 site), and this allows for subsequent cleavage at an upstream motif (the S2 site). This sequential cleavage liberates a small, evolutionarily conserved, prodomain fragment (the linker peptide) of unknown fate and function. Here we show that the linker domain is essential for proper folding, exit from the endoplasmic reticulum, and thus cleavage of the BMP-4 precursor when overexpressed in Xenopus oocytes and embryos but not in cultured mammalian cells. Mature BMP-4 synthesized from a precursor in which the S1 site is non-cleavable, such that the linker domain remains covalently attached to the ligand, has little or no activity in vivo. Finally, analysis of folding, cleavage, and bioactivity of chimeric precursors containing the BMP-7 prodomain and BMP-4 mature domain, or vice versa, with or without the BMP-4 linker domain revealed that the linker domain is only functional in the context of the BMP-4 prodomain, and that differential cleavage around this domain can regulate the activity of a heterologous	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA	Oregon Health & Science University	Christian, JL (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	christia@ohsu.edu	Nelsen, Sylvia/AAD-6878-2022	Nelsen, Sylvia/0000-0002-3770-4728	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037976] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042598] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD037976, R01 HD042598] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Cui YZ, 2001, GENE DEV, V15, P2797; Degnin C, 2004, MOL BIOL CELL, V15, P5012, DOI 10.1091/mbc.E04-08-0673; Eimon PM, 2002, DEVELOPMENT, V129, P3089; Goldman DC, 2006, DEVELOPMENT, V133, P1933, DOI 10.1242/dev.02368; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Gregory KE, 2005, J BIOL CHEM, V280, P27970, DOI 10.1074/jbc.M504270200; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JONES WK, 1994, GROWTH FACTORS, V11, P215, DOI 10.3109/08977199409046919; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; Le Good JA, 2005, CURR BIOL, V15, P31, DOI 10.1016/j.cub.2004.12.062; Liao WX, 2003, J BIOL CHEM, V278, P3713, DOI 10.1074/jbc.M210598200; LOPEZ AR, 1992, MOL CELL BIOL, V12, P1674, DOI 10.1128/MCB.12.4.1674; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moon R. T., 1989, TECHNIQUE, V1, P76; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Suzuki A, 1997, DEV BIOL, V189, P112, DOI 10.1006/dbio.1997.8652; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Todorovic V, 2005, INT J BIOCHEM CELL B, V37, P38, DOI 10.1016/j.biocel.2004.03.011; Zacchigna L, 2006, CELL, V124, P929, DOI 10.1016/j.cell.2005.12.035	28	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34021	34031		10.1074/jbc.M605330200	http://dx.doi.org/10.1074/jbc.M605330200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966322	hybrid			2022-12-25	WOS:000241767600022
J	Castello, A; Alvarez, E; Carrasco, L				Castello, Alfredo; Alvarez, Enrique; Carrasco, Luis			Differential cleavage of eIF4GI and eIF4GII in mammalian cells - Effects on translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4G; POLY(A) BINDING-PROTEIN; POLY(A)-BINDING PROTEIN; POLIOVIRUS INFECTION; HOST TRANSLATION; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; P220 CLEAVAGE; 3C PROTEASE	Two isoforms of the translation initiation factor eIF4G, eIF4GI and eIF4GII, have been described in eukaryotic cells. The exact function of each isoform during the initiation of protein synthesis is still under investigation. We have developed an efficient and reliable method of expressing poliovirus 2Apro, which differentially proteolyzes eIF4GI and eIF4GII in a time-and dose-dependent manner. This system is based on the electroporation of an in vitro transcribed mRNA that contains the encephalomyocarditis virus internal ribosome entry site followed by the sequence of poliovirus 2Apro. In contrast to HeLa cells, expression of this protease in BHK-21 cells induces delayed hydrolysis kinetics of eIF4GI with respect to eIF4GII. Moreover, under these conditions the polyadenylate binding protein is not cleaved. Interestingly, translation of de novo synthesized luciferase mRNA is highly dependent on eIF4GI integrity, whereas ongoing translation is inhibited at the same time as eIF4GII cleavage. Moreover, reinitiation of a preexisting mRNA translation after polysome run-off is dependent on the integrity of eIF4GII. Notably, de novo translation of heat shock protein 70 mRNA depends little on eIF4GI integrity but is more susceptible to eIF4GII hydrolysis. Finally, translation of an mRNA containing encephalomyocarditis virus internal ribosome entry site when the two isoforms of eIF4G are differentially hydrolyzed has been examined.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Carrasco, L (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, E-28049 Madrid, Spain.	lcarrasco@cbm.uam.es	Carrasco, Luis/H-3001-2017; Castello, Alfredo/U-6317-2018; Carrasco, Luis/E-2435-2012; Palomares, Alfredo Castello/K-8062-2019	Carrasco, Luis/0000-0003-3833-8835; Castello, Alfredo/0000-0002-1499-4662; Palomares, Alfredo Castello/0000-0002-1499-4662; Alvarez Vazquez, Enrique/0000-0002-4889-175X				Alvarez E, 2006, BIOCHEM J, V396, P219, DOI 10.1042/BJ20060108; Alvarez E, 2003, J VIROL, V77, P12392, DOI 10.1128/JVI.77.23.12392-12400.2003; Barco A, 2000, J VIROL, V74, P2383, DOI 10.1128/JVI.74.5.2383-2392.2000; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BONNEAU AM, 1987, J VIROL, V61, P986, DOI 10.1128/JVI.61.4.986-991.1987; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Castello A, 2006, J MOL BIOL, V355, P942, DOI 10.1016/j.jmb.2005.11.024; Chin SY, 2004, GENE DEV, V18, P745, DOI 10.1101/gad.1170204; Fortes P, 2000, MOL CELL, V6, P191, DOI 10.1016/S1097-2765(00)00020-4; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gradi A, 2004, J VIROL, V78, P3271, DOI 10.1128/JVI.78.7.3271-3278.2004; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; HELLEN CUT, 1992, J VIROL, V66, P3330, DOI 10.1128/JVI.66.6.3330-3338.1992; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; IRURZUN A, 1995, J VIROL, V69, P7453, DOI 10.1128/JVI.69.12.7453-7460.1995; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Keiper BD, 1997, NUCLEIC ACIDS RES, V25, P395, DOI 10.1093/nar/25.2.395; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; Kuyumcu-Martinez NM, 2004, MOL CELL BIOL, V24, P1779, DOI 10.1128/MCB.24.4.1779-1790.2004; Kuyumcu-Martinez NM, 2002, J VIROL, V76, P2062, DOI 10.1128/JVI.76.5.2062-2074.2002; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lejeune F, 2004, NAT STRUCT MOL BIOL, V11, P992, DOI 10.1038/nsmb824; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAEDA Y, 1990, J MOL BIOL, V215, P321, DOI 10.1016/S0022-2836(05)80350-X; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Michel YM, 2001, MOL CELL BIOL, V21, P4097, DOI 10.1128/MCB.21.13.4097-4109.2001; Novoa I, 1999, MOL CELL BIOL, V19, P2445; PEREZ L, 1992, VIROLOGY, V189, P178, DOI 10.1016/0042-6822(92)90693-J; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rubtsova MP, 2003, J BIOL CHEM, V278, P22350, DOI 10.1074/jbc.M303213200; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; Svitkin YV, 2001, RNA, V7, P1743; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; Ventoso I, 1998, J BIOL CHEM, V273, P27960, DOI 10.1074/jbc.273.43.27960; Yueh A, 2000, GENE DEV, V14, P414	44	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33206	33216		10.1074/jbc.M604340200	http://dx.doi.org/10.1074/jbc.M604340200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959778	hybrid, Green Submitted			2022-12-25	WOS:000241621400029
J	Mulet, JM; Martin, DE; Loewith, R; Hall, MN				Mulet, Jose M.; Martin, Dietmar E.; Loewith, Robbie; Hall, Michael N.			Mutual antagonism of target of rapamycin and calcineurin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-GROWTH; NUCLEAR-LOCALIZATION; YEAST; PATHWAY; TOR2; ORGANIZATION	Growth and stress are generally incompatible states. Stressed cells adapt to an insult by restraining growth, and conversely, growing cells keep stress responses at bay. This is evident in many physiological settings, including for example, the effect of stress on the immune or nervous system, but the underlying signaling mechanisms mediating such mutual antagonism are poorly understood. In eukaryotes, a central activator of cell growth is the protein kinase target of rapamycin (TOR) and its namesake signaling network. Calcineurin is a conserved, Ca2+/calmodulin-dependent protein phosphatase and target of the immunosuppressant FK506 (tacrolimus) that is activated in yeast during stress to promote cell survival. Here we show yeast mutants defective for TOR complex 2 (TORC2) or the essential homologous TORC2 effectors, SLM1 and SLM2, exhibited constitutive activation of calcineurin-dependent transcription and actin depolarization. Conversely, cells defective in calcineurin exhibited SLM1 hyperphosphorylation and enhanced interaction between TORC2 and SLM1. Furthermore, a mutant SLM1 protein (SLM1(Delta C14)) lacking a sequence related to the consensus calcineurin docking site (PxIxIT) was insensitive to calcineurin, and SLM1(Delta C14) slm2 mutant cells were hypersensitive to oxidative stress. Thus, TORC2-SLM signaling negatively regulates calcineurin, and calcineurin negatively regulates TORC2-SLM. These findings provide a molecular basis for the mutual antagonism of growth and stress.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Hall, MN (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	M.Hall@unibas.ch	Loewith, Robbie J/S-6289-2016; Mulet, Jose Miguel/B-9063-2016	Loewith, Robbie J/0000-0002-2482-603X; Mulet, Jose Miguel/0000-0002-9087-3838; Hall, Michael N/0000-0002-2998-0757				Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Halpain S, 1998, J NEUROSCI, V18, P9835; Heath VL, 2004, EUKARYOT CELL, V3, P695, DOI 10.1128/EC.3.3.695-704.2004; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Martin DE, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-148; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shitamukai A, 2004, J BIOL CHEM, V279, P3651, DOI 10.1074/jbc.M306098200; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yokoyama H, 2006, EMBO REP, V7, P519, DOI 10.1038/sj.embor.7400647; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200	34	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33000	33007		10.1074/jbc.M604244200	http://dx.doi.org/10.1074/jbc.M604244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959779	hybrid, Green Accepted			2022-12-25	WOS:000241621400008
J	Peltoniemi, MJ; Karala, AR; Jurvansuu, JK; Kinnula, VL; Ruddock, LW				Peltoniemi, Mirva J.; Karala, Anna-Riikka; Jurvansuu, Jaana K.; Kinnula, Vuokko L.; Ruddock, Lloyd W.			Insights into deglutathionylation reactions - Different intermediates in the glutaredoxin and protein disulfide isomerase catalyzed reactions are defined by the gamma-linkage present in glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; NMR SOLUTION STRUCTURE; MIXED DISULFIDE; DEPENDENT SYNTHESIS; OXIDATIVE STRESS; PH-DEPENDENCE; REDOX STATE; THIOLTRANSFERASE; THIOREDOXIN; IDENTIFICATION	Glutaredoxins are small proteins with a conserved active site (-CXX(C/S)-) and thioredoxin fold. These thiol disulfide oxidoreductases catalyze disulfide reductions, preferring GSH-mixed disulfides as substrates. We have developed a new real-time fluorescence-based method for measuring the deglutathionylation activity of glutaredoxins using a glutathionylated peptide as a substrate. Mass spectrometric analysis showed that the only intermediate in the reaction is the glutaredoxin-GSH mixed disulfide. This specificity was solely dependent on the unusual gamma-linkage present in glutathione. The deglutathionylation activity of both wild-type Escherichia coli glutaredoxin and the C14S mutant was competitively inhibited by oxidized glutathione, with K-i values similar to the Km values for the glutathionylated peptide substrate, implying that glutaredoxin primarily recognizes the substrate via the glutathione moiety. In addition, wildtype glutaredoxin showed a sigmoidal dependence on GSH concentrations, the activity being significantly decreased at low GSH concentrations. Thus, under oxidative stress conditions, where the ratio of GSH/GSSG is decreased, the activity of glutaredoxin is dramatically reduced, and it will only have significant deglutathionylation activity once the oxidative stress has been removed. Different members of the protein disulfide isomerases (PDI) family showed lower activity levels when compared with glutaredoxins; however, their deglutathionylation activities were comparable with their oxidase activities. Furthermore, in contrast to the glutaredoxin-GSH mixed disulfide intermediate, the only intermediate in the PDI-catalyzed reaction was PDI peptide mixed disulfide.	Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Helsinki, Dept Med, Div Pulm Dis, FIN-00029 Helsinki, Finland; Helsinki Univ Hosp, FIN-00029 Helsinki, Finland; Biomed Helsinki, FIN-00029 Helsinki, Finland	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Ruddock, LW (corresponding author), Univ Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	lloyd.ruddock@oulu.fi		Ruddock, Lloyd/0000-0002-6247-686X; Saaranen, Mirva/0000-0003-3399-9415				Alanen HI, 2006, ANTIOXID REDOX SIGN, V8, P283, DOI 10.1089/ars.2006.8.283; Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P1, DOI 10.1016/0304-4165(75)90205-6; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Collinson EJ, 2003, J BIOL CHEM, V278, P22492, DOI 10.1074/jbc.M301387200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Foloppe N, 2004, STRUCTURE, V12, P289, DOI 10.1016/j.str.2004.01.009; Foloppe N, 2001, J MOL BIOL, V310, P449, DOI 10.1006/jmbi.2001.4767; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Gvakharia BO, 1996, J BIOL CHEM, V271, P15307, DOI 10.1074/jbc.271.26.15307; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jao SC, 2006, BIOCHEMISTRY-US, V45, P4785, DOI 10.1021/bi0516327; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Neves-Petersen MT, 2002, PROTEIN SCI, V11, P588, DOI 10.1110/ps.06002; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Nordstrand K, 2000, J MOL BIOL, V303, P423, DOI 10.1006/jmbi.2000.4145; RABENSTEIN DL, 1995, BBA-PROTEIN STRUCT M, V1249, P29, DOI 10.1016/0167-4838(95)00067-5; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Ruddock LW, 1996, BIOCHEM J, V315, P1001, DOI 10.1042/bj3151001; RUOPPOLO M, 1995, BIOCHEMISTRY-US, V34, P9380, DOI 10.1021/bi00029a014; Ruoppolo M, 1996, BIOCHEMISTRY-US, V35, P13636, DOI 10.1021/bi960755b; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Starke DW, 2003, J BIOL CHEM, V278, P14607, DOI 10.1074/jbc.M210434200; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; Takashima Y, 1999, IMMUNOL LETT, V68, P397, DOI 10.1016/S0165-2478(99)00087-5; XIA TH, 1992, PROTEIN SCI, V1, P310; Xiao RY, 2005, J BIOL CHEM, V280, P21099, DOI 10.1074/jbc.M411476200; YANG YF, 1991, J BIOL CHEM, V266, P12759; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	46	79	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33107	33114		10.1074/jbc.M605602200	http://dx.doi.org/10.1074/jbc.M605602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956877	hybrid			2022-12-25	WOS:000241621400019
J	Giacco, F; Perruolo, G; D'Agostino, E; Fratellanza, G; Perna, E; Misso, S; Saldalamacchia, G; Oriente, F; Fiory, F; Miele, C; Formisano, S; Beguinot, F; Formisano, P				Giacco, Ferdinando; Perruolo, Giuseppe; D'Agostino, Elio; Fratellanza, Giorgio; Perna, Enzo; Misso, Saverio; Saldalamacchia, Gennaro; Oriente, Francesco; Fiory, Francesca; Miele, Claudia; Formisano, Salvatore; Beguinot, Francesco; Formisano, Pietro			Thrombin-activated platelets induce proliferation of human skin fibroblasts by stimulating autocrine production of insulin-like growth factor-1	FASEB JOURNAL			English	Article						tyrosine kinase; growth factor receptors; Akt/PKB; ERK; diabetic foot	DIABETIC FOOT ULCERS; RICH PLASMA; IGF-I; RECEPTOR; PHOSPHORYLATION; ENHANCEMENT; COMPONENTS; THERAPY; EGF; AKT	Platelet components have found successful clinical utilization to initiate or to accelerate tissue-repair mechanisms. However, the molecular pathways by which platelet factors contribute to tissue regeneration have not been fully elucidated. We have studied the effect of thrombin-activated platelets (TAPs) on cell growth in vivo and in cultured cell systems. Application of TAPs to ulcerative skin lesions of diabetic patients induced local activation of ERK1/2 and Akt/PKB. Moreover, when applied to cultured human skin fibroblasts, TAPs promoted cell growth and DNA synthesis and activated platelet-derived growth factor ( PDGF) and insulin-like growth factor (IGF)-1 receptor tyrosine kinases. PDGF was released by TAPs and rapidly achieved a plateau. At variance, the release of IGF-1 was mainly provided by the TAPs-stimulated fibroblasts and progressively increased up to 48 h. The PDGF-R blocker Ag1296 reduced the activation of Akt/PKB and, at a lesser extent, of ERK1/2. Conversely, inhibition of IGF-1 signaling by Ag1024 and expression of a dominant-negative IGF-1R mutant selectively reduced the stimulation of ERK1/ 2 by TAPs and fibroblast-released factors, with minor changes of Akt/PKB activity. Thus, platelet factors promote fibroblast growth by acutely activating Akt/PKB and ERK1/2. Sustained activation of ERK1/ 2, however, requires autocrine production of IGF-1 by TAPs-stimulated fibroblasts.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Med Clin & Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	giuseppe, perruolo/AAW-3869-2021; Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	Perruolo, Giuseppe/0000-0003-0479-8729; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		Anitua E, 2004, THROMB HAEMOSTASIS, V91, P4, DOI 10.1160/TH03-07-0440; BENNETT JS, 1992, DM-DIS MON, V38, P579; Bennett SP, 2003, BRIT J SURG, V90, P133, DOI 10.1002/bjs.4019; Bhanot Sumeet, 2002, Facial Plast Surg, V18, P27, DOI 10.1055/s-2002-19824; Borzini P, 2005, TRANSFUSION, V45, P1759, DOI 10.1111/j.1537-2995.2005.00600.x; Chaudhary LR, 2001, J CELL BIOCHEM, V81, P304, DOI 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.3.CO;2-L; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184; Doucet C, 2005, J CELL PHYSIOL, V205, P228, DOI 10.1002/jcp.20391; Eldor R, 2004, DIABETIC MED, V21, P1161, DOI 10.1111/j.1464-5491.2004.01358.x; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KNIGHTON DR, 1986, ANN SURG, V204, P322, DOI 10.1097/00000658-198609000-00011; KOVALENKO M, 1994, CANCER RES, V54, P6106; Loots MAM, 2002, EUR J CELL BIOL, V81, P153, DOI 10.1078/0171-9335-00228; Margolis DJ, 2001, DIABETES CARE, V24, P483, DOI 10.2337/diacare.24.3.483; Marx RE, 2004, J ORAL MAXIL SURG, V62, P489, DOI 10.1016/j.joms.2003.12.003; Marx RE, 1998, ORAL SURG ORAL MED O, V85, P638, DOI 10.1016/S1079-2104(98)90029-4; Miller MC, 2005, BIODRUGS, V19, P363, DOI 10.2165/00063030-200519060-00004; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; O'Neill EM, 2001, VOX SANG, V81, P172, DOI 10.1046/j.1423-0410.2001.00099.x; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; PIERCE GF, 1995, ANNU REV MED, V46, P467; PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403; Saldalamacchia G, 2004, NUTR METAB CARDIOVAS, V14, P395, DOI 10.1016/S0939-4753(04)80029-2; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sly W S, 1979, Methods Enzymol, V58, P444; Snyder EL, 2001, TRANSFUSION, V41, P1186, DOI 10.1046/j.1537-2995.2001.41101186.x; STEED DL, 1992, DIABETES CARE, V15, P1598, DOI 10.2337/diacare.15.11.1598; Stefani C M, 2000, Implant Dent, V9, P126, DOI 10.1097/00008505-200009020-00004; Strawn LM, 1996, CANCER RES, V56, P3540; Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Wagner F W Jr, 1984, Compr Ther, V10, P29; Weibrich G, 2002, J CRANIO MAXILL SURG, V30, P97, DOI 10.1054/jcms.2002.0285; Zimmermann R, 2001, TRANSFUSION, V41, P1217, DOI 10.1046/j.1537-2995.2001.41101217.x	37	29	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13								10.1096/fj.06-6104fje	http://dx.doi.org/10.1096/fj.06-6104fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015410				2022-12-25	WOS:000241702600034
J	Xu, DS; Buehner, A; Xu, JP; Lambert, T; Nekl, C; Nielsen, MK; Zhou, Y				Xu, Dongsheng; Buehner, Angela; Xu, Jianping; Lambert, Travis; Nekl, Casey; Nielsen, Merlyn K.; Zhou, You			A polymorphic glucocorticoid receptor in a mouse population may explain inherited altered stress response and increased anxiety-type behaviors	FASEB JOURNAL			English	Article						corticosterone response; polyglutamine track; mouse model; open field assessment; elevated plus maze	HEAT-LOSS; POLYGLUTAMINE DISEASE; DIVERGENT SELECTION; TRANSGENIC MICE; 15 GENERATIONS; DNA-BINDING; GENE; CHAPERONES; PROTEIN; HSP70	A polymorphic glucocorticoid receptor (GRQn) with an expanded CAG track and two silent mutations, when compared with the sequence of other isoform (GRwt), is found in two outbred mouse lines that were produced by selection for high (SH) or low (SL) stress response from high or low heat loss lines of mice, respectively. The GRQn allele, which is also found in 5 of 16 commonly used inbred mouse lines, had a much higher frequency in SL mice; the GRwt/wt was found only in the SH line. Both GRQn/Qn and GRwt/Qn mice had a much weaker corticosterone response to stress than the GRwt/wt mice. Assessment of open field activity revealed that GRQn/Qn and GRwt/Qn mice exhibited significantly lower velocity and locomotor activity, less time in the center, and much longer duration in corner zones than the GRwt/wt mice. The increased anxiety-type behaviors of the GRQn/Qn and GRwt/Qn mice were confirmed by the "elevated plus maze" test in which GRQn/Qn and GRwt/Qn mice spent significantly less time in the "open arm" and longer duration in the "closed arm," than GRwt/wt mice. These results suggest this GR polymorphism plays a role in complex mechanisms leading to lower corticosterone response to stress, and may also be associated with decreased locomotive and increased anxiety-type behaviors in mice.	Univ Nebraska, Beadle Ctr, Dept Vet & Biomed Sci, Lincoln, NE 68588 USA; Univ Nebraska, Dept Anim Sci, Lincoln, NE 68588 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Zhou, Y (corresponding author), Univ Nebraska, Beadle Ctr, Dept Vet & Biomed Sci, Rm E117,1901 Vine St, Lincoln, NE 68588 USA.	yzhou2@unl.edu						BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blalock EM, 2003, J NEUROSCI, V23, P3807; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 1999, J NEUROSCI, V19, P10338; Dallman MF, 2004, ENDOCRINOLOGY, V145, P2633, DOI 10.1210/en.2004-0037; Diamond MI, 2000, P NATL ACAD SCI USA, V97, P657, DOI 10.1073/pnas.97.2.657; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Heeley RP, 2002, ENDOCR RES, V28, P217, DOI 10.1081/ERC-120015060; Heeley RP, 1998, MAMM GENOME, V9, P198, DOI 10.1007/s003359900725; Holmes A, 2000, PHYSIOL BEHAV, V71, P509, DOI 10.1016/S0031-9384(00)00373-5; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Karolyi IJ, 1999, P NATL ACAD SCI USA, V96, P11595, DOI 10.1073/pnas.96.20.11595; Kgwatalala PM, 2004, J ANIM SCI, V82, P2876; Kitchener P, 2004, EUR J NEUROSCI, V19, P1837, DOI 10.1111/j.1460-9568.2004.03267.x; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; MONTKOWSKI A, 1995, J NEUROENDOCRINOL, V7, P841, DOI 10.1111/j.1365-2826.1995.tb00724.x; Mousel MR, 2001, J ANIM SCI, V79, P861; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nielsen MK, 1997, J ANIM SCI, V75, P1469; Nielsen MK, 1997, J ANIM SCI, V75, P1461; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROYCE JR, 1971, J COMP PHYSIOL PSYCH, V76, P353, DOI 10.1037/h0031387; Southwick C. H., 1968, Communications in Behavioral Biology, VA1, P49; Steckler T, 2001, BEHAV NEUROSCI, V115, P207, DOI 10.1037//0735-7044.115.1.207; STORER JB, 1966, J GERONTOL, V21, P404, DOI 10.1093/geronj/21.3.404; Toyoshima I, 2002, J NEUROSCI RES, V68, P442, DOI 10.1002/jnr.10233; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Veenema AH, 2003, J NEUROENDOCRINOL, V15, P256, DOI 10.1046/j.1365-2826.2003.00986.x; Wei Q, 2004, P NATL ACAD SCI USA, V101, P11851, DOI 10.1073/pnas.0402208101; Wesolowski SR, 2003, PHYSIOL GENOMICS, V13, P129, DOI 10.1152/physiolgenomics.00184.2002; Wust S, 2004, J CLIN ENDOCR METAB, V89, P565, DOI 10.1210/jc.2003-031148; Yalcin B, 2004, NAT GENET, V36, P1197, DOI 10.1038/ng1450; Yudt MR, 2002, MOL ENDOCRINOL, V16, P1719, DOI 10.1210/me.2002-0106; Zhou Y, 1998, BRAIN RES, V788, P151, DOI 10.1016/S0006-8993(97)01533-3	35	20	20	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2414	+		10.1096/fj.06-5926fje	http://dx.doi.org/10.1096/fj.06-5926fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012242				2022-12-25	WOS:000241702600038
J	Giroux, V; Iovanna, J; Dagorn, JC				Giroux, Valentin; Iovanna, Juan; Dagorn, Jean-Charles			Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance	FASEB JOURNAL			English	Article						apoptosis; pancreatic; adenocarcinoma; chemotherapy	FACTOR-KAPPA-B; PROTEIN-KINASE; INHIBITION; EXPRESSION; APOPTOSIS; ADENOCARCINOMA; REGULATOR; CARCINOMA; THERAPY; SUBUNIT	Except for gemcitabine, chemotherapeutic agents are ineffective with pancreatic adenocarcinoma because this cancer is resistant to apoptosis induction. Involvement of specific kinases in such resistance is likely. We developed a systematic strategy to screen the human kinome and select kinases whose inhibition in pancreatic cancer cells can increase 1) spontaneous apoptosis or 2) gemcitabine-induced apoptosis. The pancreatic adenocarcinoma cell line MiaPaCa-2 was transfected with 645 pairs of siRNAs directed to all human kinases. The same experiment was conducted in cells treated with 150 mu M gemcitabine. Apoptosis was measured after 2 days and the results were normalized for cell viability. A panel of 56 kinases whose inhibition increased spontaneous apoptosis by at least 50% was established. Ten of them gave similar results on Panc1 and BxPC3 pancreatic adenocarcinoma cell lines. A panel of 83 kinases whose inhibition increased gemcitabine-induced apoptosis by 50% or more was also established. Twelve kinases appeared in both panels. A cumulative increase in apoptosis was observed when inhibiting simultaneously several kinases. Such a systematic approach allowed characterization of all kinases involved in pancreatic cancer cell survival and resistance to gemcitabine. Inhibitors of these kinases, used alone or in combination, might improve the treatment of pancreatic adenocarcinoma.	INSERM Unite 624, Ctr Rech, F-13288 Marseille 9, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Dagorn, JC (corresponding author), INSERM Unite 624, Ctr Rech, Parc Sci & Technol Luminy,Case 915, F-13288 Marseille 9, France.	dagorn@marseille.inserm.fr	Iovanna, Juan/M-9805-2017	Iovanna, Juan/0000-0003-1822-2237				Bondar VM, 2002, MOL CANCER THER, V1, P989; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Clark DE, 2005, CANCER RES, V65, P3108; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Demols A, 2006, BRIT J CANCER, V94, P481, DOI 10.1038/sj.bjc.6602966; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Friberg Gregory, 2005, Curr Oncol Rep, V7, P186, DOI 10.1007/s11912-005-0072-3; Giroux V, 2006, CLIN CANCER RES, V12, P235, DOI 10.1158/1078-0432.CCR-05-1700; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Katoh M, 2005, ONCOL REP, V14, P1583; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Metaye T, 2002, J CLIN ENDOCR METAB, V87, P3279, DOI 10.1210/jc.87.7.3279; Morgan-Lappe S, 2006, ONCOGENE, V25, P1340, DOI 10.1038/sj.onc.1209169; Ng SSW, 2000, CANCER RES, V60, P5451; Richards DA, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.06.024; Semba S, 2002, CLIN CANCER RES, V8, P3824; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Siu LL, 2006, CLIN CANCER RES, V12, P144, DOI 10.1158/1078-0432.CCR-05-1571; Sun CL, 2001, ONCOL REP, V8, P89; Taylor JM, 1999, J CELL SCI, V112, P231; Yokoi K, 2005, CANCER RES, V65, P10371, DOI 10.1158/0008-5472.CAN-05-1698; Zhang YX, 2006, CANCER RES, V66, P1025, DOI 10.1158/0008-5472.CAN-05-2968	31	76	80	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1982	1991		10.1096/fj.06-6239com	http://dx.doi.org/10.1096/fj.06-6239com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012250				2022-12-25	WOS:000241156900006
J	Nahirney, PC; Forbes, JG; Morris, HD; Chock, SC; Wang, K				Nahirney, Patrick C.; Forbes, Jeffrey G.; Morris, H. Douglas; Chock, Susanne C.; Wang, Kuan			What the buzz was all about: superfast song muscles rattle the tymbals of male periodical cicadas	FASEB JOURNAL			English	Article						multimodal imaging; Z-band lattice; myofilament length regulation; sarcomere proportion; supercontraction	FISH PORICHTHYS-NOTATUS; SKELETAL-MUSCLE; SOUND-PRODUCTION; MOTOR SYSTEM; Z-BAND; FILAMENTS; PROTEIN; FIBERS; ORGANIZATION; ARCHITECTURE	Male cicadas produce mating calls by oscillating a pair of superfast tymbal muscles in their anterior abdominal cavity that pull on and buckle stiff-ribbed cuticular tymbal membranes located beneath the folded wings. The functional anatomy and rattling of the tymbal organ in 17 yr periodical cicada, Magicicada cassini (Brood X), were revealed by high-resolution microcomputed tomography, magnetic resonance imaging, electron microscopy, and laser vibrometry to understand the mechanism of sound production in these insects. Each 50 Hz muscle contraction yielded five to six stages of rib buckling in the tymbal, and a small release of muscle tension resulted in a rapid recovery due to the spring-loaded nature of the stiff ribs in the resilin-rich tymbal. The tymbal muscle sarcomeres have thick and thin filaments that are 30% shorter than those in flight muscles, with Z-bands that were thicker and configured into novel perforated hexagonal lattices. Caffeine-treated fibers supercontracted by allowing thick filaments to traverse the Z-band through its open lattice. This superfast sonic muscle illustrates design features, especially the matching hexagonal symmetry of the myofilaments and the perforated Z-band that contribute to high-speed contractions, long endurance, and potentially supercontraction needed for producing enduring mating songs and choruses.	NIAMSD, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA; NINDS, NIH, Magnet Resonance Imaging Res Facil, NIH, Bethesda, MD 20892 USA; Dept Hlth & Human Serv, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Wang, K (corresponding author), NIAMSD, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bldg 50,Rm 1140, Bethesda, MD 20892 USA.	wangk@exchange.nih.gov		Morris, H. Douglas/0000-0002-7942-3748	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		APPELT D, 1991, J MUSCLE RES CELL M, V12, P543, DOI 10.1007/BF01738442; BASS AH, 1989, J COMP NEUROL, V286, P141, DOI 10.1002/cne.902860202; BASS AH, 1989, J COMP NEUROL, V286, P154, DOI 10.1002/cne.902860203; Conley KE, 2002, J EXP BIOL, V205, P2175; Conley KE, 1996, NATURE, V383, P71, DOI 10.1038/383071a0; EISENBERG BR, 1976, J ULTRA MOL STRUCT R, V54, P76, DOI 10.1016/S0022-5320(76)80010-X; EPSTEIN HF, 1985, J CELL BIOL, V100, P904, DOI 10.1083/jcb.100.3.904; FRANZINI.C, 1973, J CELL BIOL, V58, P630, DOI 10.1083/jcb.58.3.630; Gronenberg W, 1997, CELL TISSUE RES, V289, P347, DOI 10.1007/s004410050882; HEATH JE, 1968, AM MIDL NAT, V80, P440, DOI 10.2307/2423537; Hoyle G., 1983, MUSCLES THEIR NEURAL; Jasanoff A, 2002, J MAGN RESON, V158, P79, DOI 10.1016/S1090-7807(02)00063-0; Josephson RK, 2000, J EXP BIOL, V203, P2713; Knupp C, 2002, J MOL BIOL, V322, P731, DOI 10.1016/S0022-2836(02)00819-7; Kovacic-Milivojevic B, 2001, MOL BIOL CELL, V12, P2290, DOI 10.1091/mbc.12.8.2290; Kulke M, 2001, J CELL BIOL, V154, P1045, DOI 10.1083/jcb.200104016; Lewis MK, 2003, J STRUCT BIOL, V143, P56, DOI 10.1016/S1047-8477(03)00121-7; Lindstedt SL, 1998, COMP BIOCHEM PHYS B, V120, P35, DOI 10.1016/S0305-0491(98)00021-2; LLOYD M, 1966, EVOLUTION, V20, P466, DOI 10.1111/j.1558-5646.1966.tb03381.x; Mardahl-Dumesnil M, 2001, J CELL BIOL, V155, P1043, DOI 10.1083/jcb.200108026; Michaelis T, 2005, NEUROIMAGE, V24, P596, DOI 10.1016/j.neuroimage.2004.08.048; PRINGLE JWS, 1953, NATURE, V172, P248, DOI 10.1038/172248b0; Qiu F, 2005, J CELL SCI, V118, P1527, DOI 10.1242/jcs.02281; REID KH, 1971, SCIENCE, V172, P949, DOI 10.1126/science.172.3986.949; Rome LC, 1996, P NATL ACAD SCI USA, V93, P8095, DOI 10.1073/pnas.93.15.8095; Schaeffer PJ, 1996, J EXP BIOL, V199, P351; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SZENTGYORGYI AG, 1971, J MOL BIOL, V56, P239, DOI 10.1016/0022-2836(71)90462-1; van der Ven PFM, 2000, J CELL SCI, V113, P1405; VIGOREAUX JO, 1994, J MUSCLE RES CELL M, V15, P237; Wang K, 1996, J BIOL CHEM, V271, P4304; Wang K, 1996, ADV BIOPHYS, V33, P123; Wecker S, 2002, MAGN RESON IMAGING, V20, P105, DOI 10.1016/S0730-725X(01)00445-3; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039; WEISFOGH T, 1960, J EXP BIOL, V37, P889; WILLIAMS KS, 1995, ANNU REV ENTOMOL, V40, P269, DOI 10.1146/annurev.en.40.010195.001413; Wirkner CS, 2004, MICROSC RES TECHNIQ, V64, P250, DOI 10.1002/jemt.20076; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0; YOUNG D, 1983, J COMP PHYSIOL, V152, P197, DOI 10.1007/BF00611184; YOUNG D, 1972, J COMP PHYSIOL, V79, P343, DOI 10.1007/BF00696251; YOUNG D, 1983, J COMP PHYSIOL, V152, P183, DOI 10.1007/BF00611183	41	12	14	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2017	2026		10.1096/fj.06-5991com	http://dx.doi.org/10.1096/fj.06-5991com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012254				2022-12-25	WOS:000241156900010
J	Duckwitz, W; Hausmann, R; Aschrafi, A; Schmalzing, G				Duckwitz, Wiebke; Hausmann, Ralf; Aschrafi, Armaz; Schmalzing, Guenther			P2X(5) subunit assembly requires scaffolding by the second transmembrane domain and a conserved aspartate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTIFICIAL TRANSMEMBRANE SEGMENTS; BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; XENOPUS-LAEVIS OOCYTES; RECEPTOR SUBUNIT; HYDROPHOBIC MISMATCH; P2X(1) RECEPTOR; GXXXG MOTIF; HELIX; RESIDUES	Functional homomeric and heteromeric ATP-gated P2X receptor channels have been shown to display a characteristic trimeric architecture. Of the seven different isoforms (designated P2X(1)-P2X(7)), P2X(5) occurs in humans primarily as a nonfunctional variant lacking the C-terminal end of the ectodomain and the outer half of the second transmembrane domain. We show that this truncated variant, which results from the splice-skipping of exon 10, is prone to subunit aggregation because the residual transmembrane domain 2 is too short to insert into the membrane. Alleviation of the negative hydrophobic mismatch by the addition of a stretch of moderately hydrophobic residues enabled formation of a second membrane-spanning domain and strictly parallel homotrimerization. Systematic mutagenesis identified only one transmembrane domain 2 residue, Asp(355), which supported homotrimerization in a side chain-specific manner. Our results indicate that transmembrane domain 2 formation contributes 2-fold to hP2X(5) homotrimerization by tethering the end of the ectodomain to the membrane, thereby topologically restricting conformational mobility, and by intramembrane positioning of Asp355. While transmembrane domain 2 appears to favor assembly by enabling productive subunit interactions in the ectodomain, Asp355 seems to assist by simultaneously driving intramembrane helix interactions. Overall, these results indicate a complex interplay between topology, helix-helix interactions, and oligomerization to achieve a correctly folded structure.	Rhein Westfal TH Aachen, Dept Mol Pharmacol, D-52074 Aachen, Germany	RWTH Aachen University	Schmalzing, G (corresponding author), Rhein Westfal TH Aachen, Dept Mol Pharmacol, Wendlingweg 2, D-52074 Aachen, Germany.	gschmalzing@ukaachen.de	Aschrafi, Armaz/E-2202-2012	Aschrafi, Armaz/0000-0003-4089-0960				Aschrafi A, 2004, J MOL BIOL, V342, P333, DOI 10.1016/j.jmb.2004.06.092; Barrera NP, 2005, J BIOL CHEM, V280, P10759, DOI 10.1074/jbc.M412265200; Bechinger B, 2001, BIOPHYS J, V81, P2251, DOI 10.1016/S0006-3495(01)75872-9; Beitz E, 2000, BIOINFORMATICS, V16, P1050, DOI 10.1093/bioinformatics/16.11.1050; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Buttner C, 2001, J BIOL CHEM, V276, P42978, DOI 10.1074/jbc.M102121200; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Choma C, 2000, NAT STRUCT BIOL, V7, P161; CORNEA RL, 1994, BIOCHEMISTRY-US, V33, P2912, DOI 10.1021/bi00176a022; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; de Planque MRR, 2003, MOL MEMBR BIOL, V20, P271, DOI 10.1080/09687680310001605352; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; Engelman DM, 2003, FEBS LETT, V555, P122, DOI 10.1016/S0014-5793(03)01106-2; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Jiang LH, 2003, J NEUROSCI, V23, P8903; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jones DT, 1998, FEBS LETT, V423, P281, DOI 10.1016/S0014-5793(98)00095-7; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Le KT, 1997, FEBS LETT, V418, P195, DOI 10.1016/S0014-5793(97)01380-X; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEWIS BA, 1983, J MOL BIOL, V166, P203, DOI 10.1016/S0022-2836(83)80006-0; Lewis RNAH, 2001, BIOCHEMISTRY-US, V40, P12103, DOI 10.1021/bi010555m; Li ZY, 2004, J NEUROSCI, V24, P7378, DOI 10.1523/JNEUROSCI.1423-04.2004; Liu W, 2004, J MOL BIOL, V337, P713, DOI 10.1016/j.jmb.2004.02.001; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 2003, MOL PHARMACOL, V63, P243, DOI 10.1124/mol.63.1.243; Nicke A, 1999, J RECEPT SIGNAL TR R, V19, P493, DOI 10.3109/10799899909036667; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Percot A, 1999, BIOPOLYMERS, V50, P647, DOI 10.1002/(SICI)1097-0282(199911)50:6<647::AID-BIP9>3.0.CO;2-T; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; Rettinger J, 2003, J GEN PHYSIOL, V121, P451, DOI 10.1085/jgp.200208730; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; RYBA NJP, 1992, BIOCHEMISTRY-US, V31, P7511, DOI 10.1021/bi00148a011; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Silberberg SD, 2005, J GEN PHYSIOL, V125, P347, DOI 10.1085/jgp.200409221; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; Torres GE, 1999, J BIOL CHEM, V274, P22359, DOI 10.1074/jbc.274.32.22359; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WHITE MM, 1990, MOL PHARMACOL, V37, P720; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	61	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39561	39572		10.1074/jbc.M606113200	http://dx.doi.org/10.1074/jbc.M606113200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17001079	hybrid, Green Published			2022-12-25	WOS:000242898700064
J	Kirby, TW; Harvey, S; DeRose, EF; Chalov, S; Chikova, AK; Perrino, FW; Schaaper, RM; London, RE; Pedersen, LC				Kirby, Thomas W.; Harvey, Scott; DeRose, Eugene F.; Chalov, Sergey; Chikova, Anna K.; Perrino, Fred W.; Schaaper, Roel M.; London, Robert E.; Pedersen, Lars C.			Structure of the Escherichia coli DNA polymerase III epsilon-HOT proofreading complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORSION ANGLE DYNAMICS; THETA-SUBUNIT; PROTEIN; PROGRAM; DOMAIN; CRYSTALLOGRAPHY; REPLICATION; EXONUCLEASE; MUTANTS; SYSTEM	The epsilon subunit of Escherichia coli DNA polymerase III possesses 3'-exonucleolytic proofreading activity. Within the Pol III core, epsilon is tightly bound between the alpha subunit ( DNA polymerase) and theta subunit. Here, we present the crystal structure of epsilon in complex with HOT, the bacteriophage P1-encoded homolog of theta, at 2.1 angstrom resolution. The epsilon-HOT interface is defined by two areas of contact: an interaction of the previously unstructured N terminus of HOT with an edge of the epsilon central beta-sheet as well as interactions between HOT and the catalytically important helix alpha 1-loop-helix alpha 2 motif of epsilon. This structure provides insight into how HOT and, by implication, theta may stabilize the epsilon subunit, thus promoting efficient proofreading during chromosomal replication.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Wake Forest Univ, Dept Biochem, Winston Salem, NC 27157 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Wake Forest University	London, RE (corresponding author), NIEHS, Struct Biol Lab, NIH, MR 01,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	london@niehs.nih.gov	London, Robert E/F-7990-2019; Pedersen, Lars/C-6173-2019; Schaaper, Roel M/E-6680-2019	London, Robert E/0000-0001-9108-8463; Pedersen, Lars/0000-0002-4488-4077; Schaaper, Roel M/0000-0003-1344-3196; Kirby, Thomas/0000-0002-8791-2488	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065088, Z01ES050111, ZIAES050111, Z01ES065088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069962, GM 069962] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chikova AK, 2005, J BACTERIOL, V187, P5528, DOI 10.1128/JB.187.16.5528-5536.2005; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DeRose EF, 2004, STRUCTURE, V12, P2221, DOI 10.1016/j.str.2004.09.019; DeRose EF, 2002, BIOCHEMISTRY-US, V41, P94, DOI 10.1021/bi0114170; DONNELL M, 2006, J BIOL CHEM, V281, P10653; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; FOSTER PL, 1992, J BACTERIOL, V174, P7509, DOI 10.1128/JB.174.23.7509-7516.1992; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hamdan S, 2000, J STRUCT BIOL, V131, P164, DOI 10.1006/jsbi.2000.4291; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keniry MA, 2006, J BACTERIOL, V188, P4464, DOI 10.1128/JB.01992-05; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCY ED, 1989, J BACTERIOL, V171, P5572, DOI 10.1128/jb.171.10.5572-5580.1989; Lehtinen DA, 2004, BIOCHEM J, V384, P337, DOI 10.1042/BJ20040660; Liu W, 2004, J MOL BIOL, V337, P713, DOI 10.1016/j.jmb.2004.02.001; Lobocka MB, 2004, J BACTERIOL, V186, P7032, DOI 10.1128/JB.186.21.7032-7068.2004; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McHenry CS, 2003, MOL MICROBIOL, V49, P1157, DOI 10.1046/j.1365-2958.2003.03645.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minor W, 2002, ACTA PHYS POL A, V101, P613, DOI 10.12693/APhysPolA.101.613; Mueller GA, 2005, J BACTERIOL, V187, P7081, DOI 10.1128/JB.187.20.7081-7089.2005; Perrino FW, 1999, BIOCHEMISTRY-US, V38, P16001, DOI 10.1021/bi991429+; Perrino FW, 2005, J BIOL CHEM, V280, P15212, DOI 10.1074/jbc.M500108200; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Stano NM, 2006, NAT STRUCT MOL BIOL, V13, P458, DOI 10.1038/nsmb1078; Taft-Benz SA, 1999, J BACTERIOL, V181, P2963, DOI 10.1128/JB.181.9.2963-2965.1999; Taft-Benz SA, 2004, J BACTERIOL, V186, P2774, DOI 10.1128/JB.186.9.2774-2780.2004; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wieczorek A, 2006, J BIOL CHEM, V281, P12561, DOI 10.1074/jbc.M513844200	33	28	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38466	38471		10.1074/jbc.M606917200	http://dx.doi.org/10.1074/jbc.M606917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	16973612	Green Accepted, hybrid			2022-12-25	WOS:000242709500040
J	Zhang, YL; Hernandez-Ono, A; Siri, P; Weisberg, S; Conlon, D; Graham, MJ; Crooke, RM; Huang, LS; Ginsberg, HN				Zhang, Yuan-Li; Hernandez-Ono, Antonio; Siri, Patty; Weisberg, Stuart; Conlon, Donna; Graham, Mark J.; Crooke, Rosanne M.; Huang, Li-Shin; Ginsberg, Henry N.			Aberrant hepatic expression of PPAR gamma 2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; STEROL REGULATORY ELEMENT; BROWN ADIPOSE-TISSUE; APOLIPOPROTEIN-B-LIPOPROTEINS; FATTY-ACID SYNTHESIS; LIVER X-RECEPTORS; PPAR-GAMMA; GENE-EXPRESSION; APO-B; TRANSGENIC MOUSE	Insulin-resistant apoB/BATless mice have hypertriglyceridemia because of increased assembly and secretion of very low density apolipoprotein B ( apoB) and triglycerides compared with mice expressing only apoB (Siri, P., Candela, N., Ko, C., Zhang, Y., Eusufzai, S., Ginsberg, H. N., and Huang, L. S. ( 2001) J. Biol. Chem. 276, 46064-46072). Despite increased very low density lipoprotein secretion, apoB/BATless mice have fatty livers. We found that hepatic mRNA levels of key lipogenic enzymes, acetyl-CoA carboxylase, fatty-acid synthase, and stearoyl-CoA desaturase-1 were increased in apoB/BATless mice compared with levels in apoB mice, suggesting increased lipogenesis in apoB/BATless mice. This was confirmed by determining incorporation of tritiated water into fatty acids. Neither the hepatic mRNA of the lipogenic transcription factor, SREBP-1c ( sterol-response element-binding protein 1c), nor the nuclear levels of the mature form of SREBP-1 protein were elevated in apoB/BATless mice. By contrast, hepatic levels of peroxisomal proliferator-activated receptor 2 ( PPAR gamma 2) mRNA and protein were specifically increased in apoB/BATless mice, as were hepatic mRNA levels of two targets of PPAR gamma, CD36 and aP2. Treatment of apoB/BATless mice for 4 weeks with intraperitoneal injections of a PPAR gamma antisense oligonucleotide resulted in dramatic reductions of both PPAR gamma 1 and PPAR gamma 2 mRNA, PPAR gamma 2 protein, and mRNA levels of fatty-acid synthase and acetyl-CoA carboxylase. These changes were associated with decreased hepatic de novo lipogenesis and hepatic triglyceride concentrations. We conclude that hepatic steatosis in apoB/BATless mice is associated with elevated rates of hepatic lipogenesis that are linked directly to increased hepatic expression of PPAR gamma 2. The mechanism whereby hepatic Ppar gamma 2 gene expression is increased and how PPAR gamma 2 stimulates lipogenesis is under investigation.	Columbia Univ, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; ISIS Pharmaceut, Carlsbad, CA 92672 USA	Columbia University; Isis Pharmaceuticals Inc	Ginsberg, HN (corresponding author), Columbia Univ, Dept Med, Coll Phys & Surg, PH 10-350,630 W 168th St, New York, NY 10032 USA.	hng1@columbia.edu		Conlon, Donna/0000-0002-9471-3081; Weisberg, Stuart/0000-0002-8698-5976	NHLBI NIH HHS [HL55368, HL73030, HL62583] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073030, R01HL062583] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adiels M, 2005, ARTERIOSCL THROM VAS, V25, P1697, DOI 10.1161/01.ATV.0000172689.53992.25; Bellentani S, 2000, ANN INTERN MED, V132, P112, DOI 10.7326/0003-4819-132-2-200001180-00004; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; CABEZAS MC, 1993, J CLIN INVEST, V92, P160, DOI 10.1172/JCI116544; Chan DC, 2004, CLIN SCI, V107, P233, DOI 10.1042/CS20040109; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Costet P, 2000, J BIOL CHEM, V275, P28240; Diraison F, 1998, AM J PHYSIOL-ENDOC M, V274, pE321, DOI 10.1152/ajpendo.1998.274.2.E321; Edvardsson U, 2006, BIOCHEM BIOPH RES CO, V340, P111, DOI 10.1016/j.bbrc.2005.12.008; Elam MB, 2001, J LIPID RES, V42, P2039; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Hellerstein MK, 1999, EUR J CLIN NUTR, V53, pS53, DOI 10.1038/sj.ejcn.1600744; Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; KISSEBAH AH, 1974, CLIN SCI MOL MED, V47, P259, DOI 10.1042/cs0470259; KISSEBAH AH, 1982, DIABETES, V31, P217, DOI 10.2337/diabetes.31.3.217; Ko C, 2003, J LIPID RES, V44, P1946, DOI 10.1194/jlr.M300172-JLR200; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Lee CH, 2006, P NATL ACAD SCI USA, V103, P3444, DOI 10.1073/pnas.0511253103; Lewis G F, 1999, Curr Opin Lipidol, V10, P475, DOI 10.1097/00041433-199910000-00013; Lou DQ, 2005, HEPATOLOGY, V41, P1056, DOI 10.1002/hep.20663; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Mensenkamp AR, 2004, J HEPATOL, V40, P599, DOI 10.1016/j.jhep.2003.12.011; Miyazaki M, 2001, J LIPID RES, V42, P1018; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Myerson M, 2005, J LIPID RES, V46, P2735, DOI 10.1194/jlr.M500335-JLR200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; SALMON DMW, 1973, BIOCHEM J, V136, P551, DOI 10.1042/bj1360551; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Siri P, 2001, J BIOL CHEM, V276, P46064, DOI 10.1074/jbc.M108909200; Siri PW, 2003, METABOLISM, V52, P659, DOI 10.1016/S0026-0495(03)00061-1; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Tanoli T, 2004, J LIPID RES, V45, P941, DOI 10.1194/jlr.M300508-JLR200; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; Uno K, 2006, SCIENCE, V312, P1656, DOI 10.1126/science.1126010; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Voyiaziakis E, 1999, J LIPID RES, V40, P2004; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; WETTERAU JR, 1992, SCIENCE, V258, P999; Yki-Jarvinen H, 2005, ANN MED, V37, P347, DOI 10.1080/07853890510037383; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200	62	125	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37603	37615		10.1074/jbc.M604709200	http://dx.doi.org/10.1074/jbc.M604709200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16971390	hybrid			2022-12-25	WOS:000242477100037
J	Weigel, PH; Kyossev, Z; Torres, LC				Weigel, Paul H.; Kyossev, Zhetcho; Torres, Lindsey C.			Phospholipid dependence and liposome reconstitution of purified hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							10-N-NONYL ACRIDINE-ORANGE; STREPTOCOCCUS-PYOGENES; MOLECULAR-CLONING; BACILLUS-SUBTILIS; CARDIOLIPIN; BIOSYNTHESIS; EQUISIMILIS; DOMAINS; GENE; DYE	Previous radiation inactivation and enzyme characterization studies demonstrated that the Streptococcus equisimilis hyaluronan synthase (seHAS) is phospholipid-dependent and that cardiolipin (CL) is the best phospholipid for enzyme activation. Here we investigated the ability of seHAS, purified in the absence of added lipid, to be activated by synthetic phosphatidic acid (PA), phosphatidylserine, or CL lipids containing fatty acyl chains of different length or different numbers of double bonds. The most effective lipid was tetraoleoyl CL (TO-CL), whereas tetramyristoyl CL (TMCL) was ineffective. None of the phosphatidylserine species tested gave significant activation. PAs containing C10 to C18 saturated acyl chains were not effective activators, and neither were oleoyl lyso PA, dilinoleoyl PA, or PA containing one oleoyl chain and either a palmitoyl or stearoyl chain. In contrast, dioleoyl PA stimulated seHAS similar to 10-fold, to similar to 20% of the activity observed with TO-CL. The tested acidic lipids such as PA and CL activated the enzyme most efficiently if they contained only oleic acid. Mixing experiments showed that the enzyme interacts preferentially with TO-CL in the presence of TM-CL. Similarly, seHAS incorporated into phosphotidylcholine-based liposomes showed increasing activity with increasing TO-CL, but not TM-CL, content. Inactivation of membrane-bound seHAS by solubilization with Nonidet P-40 was prevented by TO-CL, but not TM-CL. The pH dependence of seHAS in the presence of synthetic or naturally occurring CLs showed the same pattern of lipid preference between pH6 and 10.5. Unexpectedly, HAS showed lipid-independent activity at pH 11.5. The results suggest that Class I HAS enzymes are lipid-dependent and that assembly of active seHAS-lipid complexes has high specificity for the phospholipid head group and the nature of the fatty acyl chains.	Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bodevin-Authelet S, 2005, J BIOL CHEM, V280, P8813, DOI 10.1074/jbc.M412803200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANDRA NC, 1991, ARCH BIOCHEM BIOPHYS, V290, P345, DOI 10.1016/0003-9861(91)90550-3; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; Fernandez MIG, 2004, ANAL BIOCHEM, V328, P174, DOI 10.1016/j.ab.2004.01.020; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Kawai F, 2004, J BACTERIOL, V186, P1475, DOI 10.1128/JB.186.5.1475-1483.2004; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; Kumari K, 2006, J BIOL CHEM, V281, P11755, DOI 10.1074/jbc.M600727200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Megli FM, 2000, BIOCHEMISTRY-US, V39, P5534, DOI 10.1021/bi992779z; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; Palsdottir H, 2004, BBA-BIOMEMBRANES, V1666, P2, DOI 10.1016/j.bbamem.2004.06.012; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Pummill PE, 2001, J BIOL CHEM, V276, P39832, DOI 10.1074/jbc.M105489200; Rigaud JL, 2003, METHOD ENZYMOL, V372, P65; Tlapak-Simmons VL, 2005, J BIOL CHEM, V280, P13012, DOI 10.1074/jbc.M409788200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 2004, BIOCHEMISTRY-US, V43, P9234, DOI 10.1021/bi049468v; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; VANDENBRINKVAND.E, 2003, J BACTERIOL, V185, P3773, DOI DOI 10.1128/JB.185.13.3773-3779.2003; Ward PN, 2001, INFECT IMMUN, V69, P392, DOI 10.1128/IAI.69.1.392-399.2001; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; WEIGEL PH, 2004, GLYCOFORUM HYALURONA; Widner B, 2005, APPL ENVIRON MICROB, V71, P3747, DOI 10.1128/AEM.71.7.3747-3752.2005; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Zazueta C, 2003, J MEMBRANE BIOL, V191, P113, DOI 10.1007/s00232-002-1047-z; Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200	37	16	18	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36542	36551		10.1074/jbc.M606529200	http://dx.doi.org/10.1074/jbc.M606529200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16984914	hybrid			2022-12-25	WOS:000242220800010
J	Yu, YM; Liang, YH; Brostromer, E; Quan, JM; Panjikar, S; Dong, YH; Su, XD				Yu, Yamei; Liang, Yu-He; Brostromer, Erik; Quan, Jun-Min; Panjikar, Santosh; Dong, Yu-Hui; Su, Xiao-Dong			A catalytic mechanism revealed by the crystal structures of the imidazolonepropionase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE AMMONIA-LYASE; COLI CYTOSINE DEAMINASE; UROCANIC ACID; DEGRADATION; CRYSTALLIZATION; DICTIONARY; METABOLISM; ENZYMES; CLONING; HUT	Imidazolonepropionase (EC 3.5.2.7) catalyzes the third step in the universal histidine degradation pathway, hydrolyzing the carbon-nitrogen bonds in 4-imidazolone-5-propionic acid to yield N-formimino-L-glutamic acid. Here we report the crystal structures of the Bacillus subtilis imidazolonepropionase and its complex at 2.0-A resolution with substrate analog imidazole-4-acetic acid sodium (I4AA). The structure of the native enzyme contains two domains, a TIM (triose-phosphate isomerase) barrel domain with two insertions and a small beta-sandwich domain. The TIM barrel domain is quite similar to the members of the alpha/beta barrel metallo-dependent hydrolase superfamily, especially to Escherichia coli cytosine deaminase. A metal ion was found in the central cavity of the TIM barrel and was tightly coordinated to residues His-80, His-82, His-249, Asp-324, and a water molecule. X-ray fluorescence scan analysis confirmed that the bound metal ion was a zinc ion. An acetate ion, 6 A away from the zinc ion, was also found in the potential active site. In the complex structure with I4AA, a substrate analog, I4AA replaced the acetate ion and contacted with Arg-89, Try-102, Tyr-152, His-185, and Glu-252, further defining and confirming the active site. The detailed structural studies allowed us to propose a zinc-activated nucleophilic attack mechanism for the hydrolysis reaction catalyzed by the enzyme.	Peking Univ, Coll Life Sci, Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China; Peking Univ, Shenzhen Grad Sch, Lab Chem Genom, Shenzhen 513055, Peoples R China; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Chinese Acad Sci, Inst High Energy Phys, Beijing Synchrotron Radiat Facil, Beijing 100049, Peoples R China	Peking University; Peking University; University Town of Shenzhen; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Chinese Academy of Sciences; Institute of High Energy Physics, CAS	Su, XD (corresponding author), Peking Univ, Coll Life Sci, Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China.	su-xd@pku.edu.cn	Panjikar, Santosh/D-2709-2012; , LiangYH/B-6704-2012	Panjikar, Santosh/0000-0001-7429-3879; Dong, Yuhui/0000-0002-4422-4685				Bond CS, 2003, BIOINFORMATICS, V19, P311, DOI 10.1093/bioinformatics/19.2.311; BROWN DD, 1960, J BIOL CHEM, V235, P2058; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHASIN LA, 1968, J BIOL CHEM, V243, P5165; COWTAN K, 1994, NEWSLETTER PROTEIN C, V31, P34; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hao Q, 2004, J APPL CRYSTALLOGR, V37, P498, DOI 10.1107/S0021889804008696; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Ireton GC, 2002, J MOL BIOL, V315, P687, DOI 10.1006/jmbi.2001.5277; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kessler D, 2004, J MOL BIOL, V342, P183, DOI 10.1016/j.jmb.2004.07.028; KIMHI Y, 1970, J BIOL CHEM, V245, P3545; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lopez R, 2003, NUCLEIC ACIDS RES, V31, P3795, DOI 10.1093/nar/gkg573; Morris RJ, 2004, J SYNCHROTRON RADIAT, V11, P56, DOI 10.1107/S090904950302394X; ODA M, 1988, J BACTERIOL, V170, P3199, DOI 10.1128/jb.170.7.3199-3205.1988; Okabe N, 1999, ACTA CRYSTALLOGR C, V55, P1142, DOI 10.1107/S0108270199004023; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panjikar S, 2005, ACTA CRYSTALLOGR D, V61, P449, DOI 10.1107/S0907444905001307; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Porter DJT, 2000, BBA-PROTEIN STRUCT M, V1476, P239, DOI 10.1016/S0167-4838(99)00246-0; RAO DR, 1960, BIOCHIM BIOPHYS ACTA, V43, P404; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schwede TF, 1999, BIOCHEMISTRY-US, V38, P5355, DOI 10.1021/bi982929q; Schwede TF, 1999, PROTEIN ENG, V12, P151, DOI 10.1093/protein/12.2.151; Sheldrick G.M, 2001, International Tables for Macromolecular Crystallography, P333; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; SMITH GR, 1971, J BIOL CHEM, V246, P3320; SNYDER SH, 1961, J BIOL CHEM, V236, P2996; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YOSHIDA K, 1995, MICROBIOL-UK, V141, P337, DOI 10.1099/13500872-141-2-337; Yu YM, 2006, BBA-PROTEINS PROTEOM, V1764, P153, DOI 10.1016/j.bbapap.2005.08.012	37	15	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36929	36936		10.1074/jbc.M607703200	http://dx.doi.org/10.1074/jbc.M607703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16990261	Green Published, hybrid			2022-12-25	WOS:000242220800052
J	Hatanaka, T; Hatanaka, Y; Setou, M				Hatanaka, Takahiro; Hatanaka, Yasue; Setou, Mitsutoshi			Regulation of amino acid transporter ATA2 by ubiquitin ligase Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE EXPRESSION PATTERN; EPITHELIAL SODIUM-CHANNEL; COUPLED ACTIVE-TRANSPORT; SKELETAL-MUSCLE CELLS; SYSTEM-A; GLUCOSE-TRANSPORTER; FUNCTIONAL-CHARACTERISTICS; GLUTAMINE TRANSPORTER; DEGRADATION; PROTEIN	We report here that ubiquitin ligase Nedd4-2 regulates amino acid transporter ATA2 activity on the cell surface. We first found that a proteasome inhibitor MG132 increased the uptake of alpha-(methylamino) isobutyric acid, a model substrate for amino acid transport system A, in 3T3-L1 adipocytes as well as the preadipocytes. Transient expression of Nedd4-2 in Xenopus oocytes and Chinese hamster ovary cells down-regulated the ATA2 transport activity induced by injected cRNA and transfected cDNA, respectively. Neither the Nedd4-2 mutant with defective catalytic domain nor c-Cbl affected the ATA2 activity significantly. RNA-mediated interference of Nedd4-2 increased the ATA2 activity in the cells, and this was associated with decreased polyubiquitination of ATA2 on the cell surface membrane. Immunofluorescent analysis of Nedd4-2 in the adipocytes stably transfected with the enhanced green fluorescent protein (EGFP)-tagged ATA2 showed the co-localization of Nedd4-2 and EGFP-ATA2 in the plasma membrane but not in the perinuclear ATA2 storage site, supporting the idea that the primary site for the ubiquitination of ATA2 is the plasma membrane. These data suggest that ATA2 on the plasma membrane is subject to polyubiquitination by Nedd4-2 with consequent endocytotic sequestration and proteasomal degradation and that this process is an important determinant of the density of ATA2 functioning on the cell surface.	Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 4448787, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Setou, M (corresponding author), Mitsubishi Kagaku Inst Life Sci, 11 Minamiooya, Machida, Tokyo 1948511, Japan.	setou@nips.ac.jp						Boehmer C, 2003, J NEUROCHEM, V86, P1181, DOI 10.1046/j.1471-4159.2003.01937.x; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dunn R, 2004, J CELL BIOL, V165, P135, DOI 10.1083/jcb.200309026; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; Flores-Morales A, 2006, MOL ENDOCRINOL, V20, P241, DOI 10.1210/me.2005-0170; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; Hatanaka T, 2004, J PHARMACOL EXP THER, V308, P1138, DOI 10.1124/jpet.103.057109; Hatanaka T, 2002, BIOCHEM BIOPH RES CO, V291, P291, DOI 10.1006/bbrc.2002.6441; Hatanaka T, 2001, BBA-BIOMEMBRANES, V1510, P10, DOI 10.1016/S0005-2736(00)00390-4; Hatanaka T, 2000, BBA-BIOMEMBRANES, V1467, P1, DOI 10.1016/S0005-2736(00)00252-2; Hatanaka T, 2001, J CLIN INVEST, V107, P1035, DOI 10.1172/JCI12060; HAUSSINGER D, 1992, MAMMALIAN AMINO ACID TRANSPORT, P113; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hyde R, 2002, J BIOL CHEM, V277, P13628, DOI 10.1074/jbc.M108609200; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; KILBERG MS, 1986, FED PROC, V45, P2438; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Malik B, 2005, AM J PHYSIOL-RENAL, V289, pF107, DOI 10.1152/ajprenal.00179.2002; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Nakanishi T, 2001, J PHYSIOL-LONDON, V532, P297, DOI 10.1111/j.1469-7793.2001.0297f.x; Palmada M, 2004, AM J PHYSIOL-GASTR L, V287, pG143, DOI 10.1152/ajpgi.00121.2003; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Ritchie JWA, 2001, CELL PHYSIOL BIOCHEM, V11, P259, DOI 10.1159/000047812; Rotmann A, 2004, J BIOL CHEM, V279, P54185, DOI 10.1074/jbc.M409556200; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; Sugawara M, 2000, BBA-BIOMEMBRANES, V1509, P7, DOI 10.1016/S0005-2736(00)00349-7; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Wang HP, 2000, BIOCHEM BIOPH RES CO, V273, P1175, DOI 10.1006/bbrc.2000.3061; Xia XF, 2004, J BIOL CHEM, V279, P44931, DOI 10.1074/jbc.M400969200; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	43	41	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35922	35930		10.1074/jbc.M606577200	http://dx.doi.org/10.1074/jbc.M606577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003038	hybrid			2022-12-25	WOS:000242100500039
J	Hagen, T; Cross, DAE; Culbert, AA; West, A; Frame, S; Morrice, N; Reith, AD				Hagen, Thilo; Cross, Darren A. E.; Culbert, Ainsley A.; West, Andrew; Frame, Sheelagh; Morrice, Nick; Reith, Alastair D.			FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITORS; WNT SIGNALING PATHWAY; BETA-CATENIN; CORTICAL ROTATION; CYCLIN D1; PHOSPHORYLATION; GSK-3; AXIN; ACTIVATION; INSULIN	FRAT1, like its Xenopus homolog glycogen synthase kinase-3 (GSK-3)-binding protein, is known to inhibit GSK-3-mediated phosphorylation of beta-catenin. It is currently unknown how FRAT-GSK-3-binding protein activity toward GSK-3 is regulated. FRAT1 has recently been shown to be a phosphoprotein in vivo; however, the responsible kinase(s) have not been determined. In this study, we identified Ser(188) as a phosphorylated residue in FRAT1. The identity of the kinase that catalyzes Ser188 phosphorylation and the significance of this phosphorylation to FRAT1 function were investigated. Protein kinase A (PKA) was found to phosphorylate Ser188 in vitro as well as in intact cells. Importantly, activation of endogenous cAMP-coupled beta-adrenergic receptors with norepinephrine stimulated the phosphorylation of FRAT1 at Ser188. GSK-3 was also able to phosphorylate FRAT1 at Ser188 and other residues in vitro or when overexpressed in intact cells. In contrast, endogenous GSK-3 did not lead to significant FRAT1 phosphorylation in cells, suggesting that GSK-3 is not a major FRAT1 kinase in vivo. Phosphorylation of Ser188 by PKA inhibited the ability of FRAT1 to activate beta-catenin-dependent transcription. In conclusion, PKA phosphorylates FRAT1 in vitro as well as in intact cells and may play a role in regulating the inhibitory activity of FRAT1 toward GSK-3.	GlaxoSmithKline Inc, Discovery Res Biol, Harlow CM19 5AD, Essex, England; GlaxoSmithKline Inc, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AD, Essex, England; GlaxoSmithKline Inc, Computat Analyt & Struct Sci, Harlow CM19 5AD, Essex, England; Med Res Ctr, Stevenage SG1 2NY, Herts, England; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Nottingham, Wolfson Digest Dis Ctr, Nottingham NG7 2UH, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Dundee; University of Nottingham	Hagen, T (corresponding author), GlaxoSmithKline Inc, Discovery Res Biol, Harlow CM19 5AD, Essex, England.	Thilo.Hagen@nottingham.ac.uk						Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dominguez I, 2000, DEVELOPMENT, V127, P861; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; Hay E, 2005, J BIOL CHEM, V280, P13616, DOI 10.1074/jbc.M411999200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Martin CP, 2002, BBA-MOL BASIS DIS, V1586, P113; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Saitoh T, 2001, BIOCHEM BIOPH RES CO, V281, P815, DOI 10.1006/bbrc.2001.4421; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stoothoff WH, 2005, J BIOL CHEM, V280, P270, DOI 10.1074/jbc.M410061200; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; van Amerongen R, 2004, J BIOL CHEM, V279, P26967, DOI 10.1074/jbc.M400439200; Weaver C, 2003, DEVELOPMENT, V130, P5425, DOI 10.1242/dev.00737; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35021	35029		10.1074/jbc.M607003200	http://dx.doi.org/10.1074/jbc.M607003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982607	hybrid			2022-12-25	WOS:000241933700035
J	Kant, S; Schumacher, S; Singh, MK; Kispert, A; Kotlyarov, A; Gaestel, M				Kant, Shashi; Schumacher, Stefanie; Singh, Manvendra Kumar; Kispert, Andreas; Kotlyarov, Alexey; Gaestel, Matthias			Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; REGULATED KINASE-3; PROTEASOME; FAMILY; DEGRADATION; MK5/PRAK; HOMOLOG; DEFINES	The extracellular-regulated kinase (ERK) 4 (MAPK4) and ERK3 (MAPK6) are structurally related atypical MAPKs displaying major differences only in the C-terminal extension. ERK3 is known as an unstable mostly cytoplasmic protein that binds, translocates, and activates the MAPK-activated protein kinase (MK) 5. Here we have investigated the stability and expression of ERK4 and have analyzed its ability to bind, translocate, and activate MK5. We show that, in contrast to ERK3, ERK4 is a stable protein that binds to endogenous MK5. Interaction of ERK4 with MK5 leads to translocation of MK5 to the cytoplasm and to its activation by phosphorylation. In transfected HEK293 cells, where overexpressed catalytically dead ERK3 is able to activate MK5, catalytic activity of ERK4 is necessary for activation of MK5, indicating that ERK4 directly phosphorylates MK5. Interestingly, ERK4 dimerizes and/or oligomerizes with ERK3, suggesting that overexpressed inactive ERK3 recruits active endogenous ERK4 to MK5 for its activation. Hence, ERK3 and ERK4 cooperate in activation of MK5.	Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Gaestel, M (corresponding author), Hannover Med Sch, Inst Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gaestel.matthias@mh-hannover.de	Kant, Shashi/B-1585-2016; Gaestel, Matthias/A-6560-2013; Singh, Manvendra K./AHE-0676-2022	Kant, Shashi/0000-0001-8772-6813; Gaestel, Matthias/0000-0002-4944-4652; Singh, Manvendra K./0000-0002-2884-0074				Abe MK, 2002, J BIOL CHEM, V277, P16733, DOI 10.1074/jbc.M112483200; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Garcia JI, 1996, MAMM GENOME, V7, P810, DOI 10.1007/s003359900242; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Julien C, 2003, J BIOL CHEM, V278, P42615, DOI 10.1074/jbc.M302724200; LI L, 1994, ONCOGENE, V9, P647; Mikalsen T, 2005, INT J BIOCHEM CELL B, V37, P2513, DOI 10.1016/j.biocel.2005.06.007; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Ni H, 1998, BIOCHEM BIOPH RES CO, V243, P492, DOI 10.1006/bbrc.1998.8135; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Schumacher S, 2004, EMBO J, V23, P4770, DOI 10.1038/sj.emboj.7600467; Seternes OM, 2004, EMBO J, V23, P4780, DOI 10.1038/sj.emboj.7600489; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Shi Y, 2003, MOL CELL BIOL, V23, P7732, DOI 10.1128/MCB.23.21.7732-7741.2003; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	21	67	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35511	35519		10.1074/jbc.M606693200	http://dx.doi.org/10.1074/jbc.M606693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973613	hybrid			2022-12-25	WOS:000241933700084
J	Sanchez-Heras, E; Howell, FV; Williams, G; Doherty, P				Sanchez-Heras, Elena; Howell, Fiona V.; Williams, Gareth; Doherty, Patrick			The fibroblast growth factor receptor acid box is essential for interactions with N-cadherin and all of the major isoforms of neural cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NEURITE OUTGROWTH; FGF-RECEPTOR; AXONAL GROWTH; VASE EXON; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; HEPARIN COMPLEX; CAM; NCAM; ACTIVATION	Interactions between the neural cell adhesion molecules NCAM and N-cadherin with the fibroblast growth factor receptor (FGFR) are important for a number of developmental events and have also been implicated in tumor progression. The factors regulating these interactions are not known. We have used co-immunoprecipitation and co-clustering paradigms to show that both adhesion molecules can interact with the 3Ig IIIC isoform of the FGFR1 in a number of cell types. Interestingly, whereas the interaction can be seen over most of the cell surface, it is not seen at points of cell-cell contact where the adhesion molecules accumulate at stable junctions. We also demonstrate for the first time that all of the major isoforms of NCAM can interact with the FGFR. Using deletion mutagenesis we have found that the adhesion molecule/FGFR interaction can withstand the removal of most of any one of the FGFR immunoglobulin-like domains (D1 - D3). In contrast, the FGFR interaction with N-cadherin and NCAM (but not FGF) is absolutely dependant on the presence of the acid box motif that can be found in the linker region between D1 and D2. As this motif can be spliced out of all four FGFRs, it suggests that this is one mechanism that can regulate the interaction of the receptor with different ligand classes.	Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 1UL, England	University of London; King's College London	Doherty, P (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, Wolfson Wing Hodgkin Bldg, London SE1 1UL, England.	patrick.doherty@kcl.ac.uk	Williams, Gareth/B-3202-2010; Doherty, Patrick/A-8752-2008	Williams, Gareth/0000-0001-9205-4943; Doherty, Patrick/0000-0002-0407-5689	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTON CH, 1988, DEVELOPMENT, V104, P165; Bottcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003-0040; BOURNE SP, 1991, J NEURO-ONCOL, V10, P111, DOI 10.1007/BF00146871; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Christensen C, 2006, FEBS LETT, V580, P3386, DOI 10.1016/j.febslet.2006.05.008; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; Erez N, 2004, EXP CELL RES, V294, P366, DOI 10.1016/j.yexcr.2003.11.033; Forni JJ, 2004, MOL CELL NEUROSCI, V26, P282, DOI 10.1016/j.mcn.2004.02.003; Garcia-Alonso L, 2000, NEURON, V28, P741, DOI 10.1016/S0896-6273(00)00150-1; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Harmer NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kiselyov VV, 2003, STRUCTURE, V11, P691, DOI 10.1016/S0969-2126(03)00096-0; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LIU L, 1993, J NEUROSCI RES, V35, P327, DOI 10.1002/jnr.490350313; Meiri KF, 1998, J NEUROSCI, V18, P10429; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Ordonez NG, 2003, HUM PATHOL, V34, P749, DOI 10.1016/S0046-8177(03)00285-5; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Peluso JJ, 2000, BIOL SIGNAL RECEPT, V9, P115; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Popovici C, 2005, BIOESSAYS, V27, P849, DOI 10.1002/bies.20261; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Ronn LCB, 2000, J NEUROCHEM, V75, P665, DOI 10.1046/j.1471-4159.2000.0750665.x; SAFFELL JL, 1994, J CELL BIOL, V125, P427, DOI 10.1083/jcb.125.2.427; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shimizu A, 2001, J BIOL CHEM, V276, P11031, DOI 10.1074/jbc.M003535200; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WALSH FS, 1992, J NEUROCHEM, V59, P1959, DOI 10.1111/j.1471-4159.1992.tb11033.x; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200	49	94	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35208	35216		10.1074/jbc.M608655200	http://dx.doi.org/10.1074/jbc.M608655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17005551	hybrid			2022-12-25	WOS:000241933700054
J	Usatyuk, PV; Parinandi, NL; Natarajan, V				Usatyuk, Peter V.; Parinandi, Narasimham L.; Natarajan, Viswanathan			Redox regulation of 4-hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCT; PHOSPHOLIPASE-D ACTIVATION; SIGNAL-TRANSDUCTION; N-ACETYLCYSTEINE; ACTIN; KINASE; CELLS; PERMEABILITY; GLUTATHIONE; PHOSPHATASE	4-Hydroxy-2-nonenal (4-HNE), one of the major biologically active aldehydes formed during inflammation and oxidative stress, has been implicated in a number of cardiovascular and pulmonary disorders. 4-HNE has been shown to increase vascular endothelial permeability; however, the underlying mechanisms are unclear. Hence, in the current study, we tested our hypothesis that 4-HNE-induced changes in cellular thiol redox status may contribute to modulation of cell signaling pathways that lead to endothelial barrier dysfunction. Exposure of bovine lung microvascular endothelial cells (BLMVECs) to 4-HNE induced reactive oxygen species generation, depleted intracellular glutathione, and altered cell-cell adhesion as measured by transendothelial electrical resistance. Pretreatment of BLMVECs with thiol protectants, N-acetylcysteine and mercaptopropionyl glycine, attenuated 4-HNE-induced decrease in transendothelial electrical resistance, reactive oxygen species generation, Michael protein adduct formation, protein tyrosine phosphorylation, activation of ERK, JNK, and p38 MAPK, and actin cytoskeletal rearrangement. Treatment of BLMVECs with 4-HNE resulted in the redistribution of FAK, paxillin, VE-cadherin, beta-catenin, and ZO-1, and intercellular gap formation. Western blot analyses confirmed the formation of 4-HNE-derived Michael adducts with the focal adhesion and adherens junction proteins. Also, 4-HNE decreased tyrosine phosphorylation of FAK without affecting total cellular FAK contents, suggesting the modification of integrins, which are natural FAK receptors. 4-HNE caused a decrease in the surface integrin in a time-dependent manner without altering total alpha 5 and beta 3 integrins. These results, for the first time, revealed that 4-HNE in redox-dependent fashion affected endothelial cell permeability by modulating cell-cell adhesion through focal adhesion, adherens, and tight junction proteins as well as integrin signal transduction that may lead dramatic alteration in endothelial cell barrier dysfunction during heart infarction, brain stroke, and lung diseases.	Univ Chicago, Div Biol Sci, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Div Pulm Crit Care & Sleep Med, Columbus, OH 43210 USA	University of Chicago; University System of Ohio; Ohio State University	Natarajan, V (corresponding author), Univ Chicago, Dept Med, Ctr Integrat Sci Bldg,Rm 408B,929 E 57th St, Chicago, IL 60637 USA.	vnataraj@medicine.bsd.uchicago.edu			NHLBI NIH HHS [R01 HL 69909, P01 HL 58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064, R01HL069909] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; Aldini G, 2005, J MASS SPECTROM, V40, P946, DOI 10.1002/jms.872; Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; Bianchi M, 2005, MOL CELL BIOCHEM, V272, P85, DOI 10.1007/s11010-005-7639-z; Bogatcheva NV, 2003, J INVEST MED, V51, P341, DOI 10.1136/jim-51-06-30; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Compton CN, 1998, J TRAUMA, V44, P783, DOI 10.1097/00005373-199805000-00007; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; Dianzani Mario Umberto, 2003, Molecular Aspects of Medicine, V24, P263; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; English D, 1999, J CELL BIOCHEM, V75, P105, DOI 10.1002/(SICI)1097-4644(19991001)75:1<105::AID-JCB11>3.3.CO;2-U; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GADONI E, 1993, CYTOTECHNOLOGY, V11, P62; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hamilton RF, 1998, AM J PHYSIOL-LUNG C, V274, pL8, DOI 10.1152/ajplung.1998.274.1.L8; Herbst U, 1999, J CELL PHYSIOL, V181, P295, DOI 10.1002/(SICI)1097-4652(199911)181:2<295::AID-JCP11>3.0.CO;2-I; Hernandez-Hernandez A, 1999, FREE RADICAL BIO MED, V26, P1218, DOI 10.1016/S0891-5849(98)00306-2; Hirase T, 1997, J CELL SCI, V110, P1603; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KIRUKOVA AA, 2004, J CELL PHYSL, V201, P55; Landar A, 2006, AM J PHYSIOL-HEART C, V290, pH1777, DOI 10.1152/ajpheart.01087.2005; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Mertsch K, 2001, NEUROSCI LETT, V314, P135, DOI 10.1016/S0304-3940(01)02299-6; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Minekura H, 2001, BIOCHEM BIOPH RES CO, V282, P557, DOI 10.1006/bbrc.2001.4586; Natarajan V, 1997, AM J RESP CELL MOL, V17, P251, DOI 10.1165/ajrcmb.17.2.2623; NATARAJAN V, 1995, J LAB CLIN MED, V125, P26; Natarajan V, 2005, ADV MOL CEL, V35, P105, DOI 10.1016/S1569-2558(05)35004-1; NATARAJAN V, 1993, FREE RADICAL BIO MED, V15, P365, DOI 10.1016/0891-5849(93)90036-T; Neely MD, 2005, BRAIN RES, V1037, P90, DOI 10.1016/j.brainres.2004.12.027; Ozeki M, 2005, J CHROMATOGR B, V827, P119, DOI 10.1016/j.jchromb.2005.02.025; Parinandi NL, 1999, ANTIOXID REDOX SIGN, V1, P193, DOI 10.1089/ars.1999.1.2-193; Parola M, 1999, ANTIOXID REDOX SIGN, V1, P255, DOI 10.1089/ars.1999.1.3-255; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Sharma R, 2004, ANTIOXID REDOX SIGN, V6, P289, DOI 10.1089/152308604322899350; Sochman J, 2002, J AM COLL CARDIOL, V39, P1422, DOI 10.1016/S0735-1097(02)01797-7; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; Stupack DG, 2004, CURR TOP DEV BIOL, V64, P207, DOI 10.1016/S0070-2153(04)64009-9; SU G, 2006, P AM THOR SOC NEW YO, V3, pA478; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200; Usatyuk PV, 2003, ANTIOXID REDOX SIGN, V5, P723, DOI 10.1089/152308603770380025; VANWINKLE WB, 1994, CELL MOTIL CYTOSKEL, V28, P119, DOI 10.1002/cm.970280204; Waschke J, 2005, AM J PHYSIOL-HEART C, V288, pH1296, DOI 10.1152/ajpheart.00687.2004; Wu MH, 2005, J PHYSIOL-LONDON, V569, P359, DOI 10.1113/jphysiol.2005.096537; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zhao XY, 2001, AM J PHYSIOL-LUNG C, V281, pL879, DOI 10.1152/ajplung.2001.281.4.L879	62	138	141	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35554	35566		10.1074/jbc.M607305200	http://dx.doi.org/10.1074/jbc.M607305200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982627	hybrid			2022-12-25	WOS:000241933700088
J	Hamilton, RF; Thakur, SA; Mayfair, JK; Holian, A				Hamilton, Raymond F., Jr.; Thakur, Sheetal A.; Mayfair, Jolene K.; Holian, Andrij			MARCO mediates silica uptake and toxicity in alveolar macrophages from C57BL/6 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; A SCAVENGER RECEPTORS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; LUNG DEFENSE; MURINE LUNG; CELL-LINE; SR-AI/II; PARTICLES; BINDING	Scavenger receptors (SR), on the surface of the macrophage, appear to be responsible for silica uptake and cell death signaling in the macrophage. The purpose of this study was to isolate which SRs (macrophage receptor with collagenous structure (MARCO), CD204, or CD36) were involved using a variety of SR single and double null mice. The findings indicated that MARCO was the critical SR involved in silica uptake and cytotoxicity in the primary alveolar macrophages (AM) from C57BL/6 mice, as there was no particle uptake or cell death in the absence of this SR. The level of MARCO expression on AM changed significantly with the absence of other SR, and silica uptake was proportional to cell surface MARCO expression. In addition, silica uptake and cytotoxicity were completely blocked by an anti-mouse MARCO antibody. Transfection of Chinese hamster ovary cells with human MARCO supported these conclusions, as silica particles bound to and initiated apoptosis in the MARCO-transfected cells. Strain differences with regard to SR distribution were also examined. There was a differential expression of these SR on AM from each strain, with MARCO dominant for C57BL/6, CD36 dominant on BALB/c, and all three SR expressed on 129/SvJ mice. Similar to the results with C57BL/6 AM, MARCO was involved with silica-induced cell death in the 129/SvJ strain. In contrast, BALB/c AM used an unidentified mechanism for silica uptake because the SR antibodies failed to block particle internalization. Taken together, these results indicate MARCO is the primary AM receptor interacting with silica, depending on mouse strain and level of constitutive expression.	Univ Montana, Dept Biomed & Pharmaceut Sci, Ctr Environm Hlth Sci, Missoula, MT 59812 USA	University of Montana System; University of Montana	Holian, A (corresponding author), 32 Campus Dr, Missoula, MT 59812 USA.	andrij.holian@umontana.edu		Holian, Andrij/0000-0003-0072-4538	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004804] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR-017670] Funding Source: Medline; NIEHS NIH HHS [ES-04804] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731; Arredouani MS, 2006, AM J RESP CELL MOL, V35, P474, DOI 10.1165/rcmb.2006-0128OC; Arredouani MS, 2004, CELL MOL BIOL, V50, P657; Arredouani MS, 2005, J IMMUNOL, V175, P6058, DOI 10.4049/jimmunol.175.9.6058; Calvo D, 1998, J LIPID RES, V39, P777; Chao SL, 2001, TOXICOL APPL PHARM, V174, P10, DOI 10.1006/taap.2001.9190; Coller SP, 2001, J LEUKOCYTE BIOL, V70, P142; Cooper GS, 2002, INT IMMUNOPHARMACOL, V2, P303, DOI 10.1016/S1567-5769(01)00181-3; CROWELL RE, 1992, EXP LUNG RES, V18, P435, DOI 10.3109/01902149209064338; Daugherty A, 2000, J LIPID RES, V41, P1568; Fubini B, 2003, FREE RADICAL BIO MED, V34, P1507, DOI 10.1016/S0891-5849(03)00149-7; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Hamilton Raymond F. Jr., 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P75; Hamilton RF, 2000, TOXICOL APPL PHARM, V162, P100, DOI 10.1006/taap.1999.8799; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; Hsu HY, 1998, J BIOL CHEM, V273, P1240, DOI 10.1074/jbc.273.2.1240; Hsu HY, 2001, J BIOL CHEM, V276, P28719, DOI 10.1074/jbc.M011117200; Jiang Y, 2006, J BIOL CHEM, V281, P9058, DOI 10.1074/jbc.M507874200; Jozefowski S, 2005, J IMMUNOL, V175, P8032, DOI 10.4049/jimmunol.175.12.8032; KOBZIK L, 1995, J IMMUNOL, V155, P367; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Migliaccio CT, 2005, TOXICOL APPL PHARM, V205, P168, DOI 10.1016/j.taap.2004.11.005; Murphy JE, 2005, ATHEROSCLEROSIS, V182, P1, DOI 10.1016/j.atherosclerosis.2005.03.036; Nakamura K, 2001, BBA-GENE STRUCT EXPR, V1522, P53, DOI 10.1016/S0167-4781(01)00284-6; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; Palecanda Aiyappa, 2001, Current Molecular Medicine (Hilversum), V1, P589, DOI 10.2174/1566524013363384; Peretz A, 2006, ISR MED ASSOC J, V8, P114; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; STRINGER B, 1995, CYTOMETRY, V20, P23, DOI 10.1002/cyto.990200106; Su SH, 2001, J IMMUNOL, V167, P5084, DOI 10.4049/jimmunol.167.9.5084; Whitman SC, 2000, J LIPID RES, V41, P807; Zeng YC, 2003, J BIOL CHEM, V278, P45931, DOI 10.1074/jbc.M307722200	33	111	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34218	34226		10.1074/jbc.M605229200	http://dx.doi.org/10.1074/jbc.M605229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16984918	hybrid			2022-12-25	WOS:000241767600042
J	Lamalice, L; Houle, F; Huot, J				Lamalice, Laurent; Houle, Francois; Huot, Jacques			Phosphorylation of Tyr(1214) within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ACTIN-BASED MOTILITY; PROTEIN-KINASE; SRC KINASE; AUTOPHOSPHORYLATION SITE; ADAPTER PROTEIN; DNA-SYNTHESIS; KDR; FAMILY; BINDING	VEGFR-2 is the major receptor that regulates the different functions of VEGF in adults. We have previously reported that following VEGF treatment of endothelial cells, VEGFR-2 is phosphorylated on Tyr1214 upstream of the Cdc42-SAPK2/p38MAPKAP K2 pathway. However, little is known of the earliest molecular events that compose the SAPK2/p38 pathway following VEGFR-2 activation. In this study, we address this question using HA-tagged constructs of either wild-type VEGFR-2 or Y1214F VEGFR-2 mutant in immunoprecipitation assays. We show that the Src family kinase member Fyn, but not c-Src itself, is recruited to VEGFR-2 and is activated in a p similar to Tyr(1214)-dependent manner. We also report that the SH2 domain-containing adapter molecule Nck, but not Grb2, is recruited to VEGFR-2 in a p similar to Tyr1214-dependent manner and that it associates with Fyn. Moreover, PAK-2 is phosphorylated in a Fyn-dependent manner. Using chemical and genetic inhibitors, we show that Fyn activity is required for SAPK2/p38 but not for FAK activation in response to VEGF. In contrast, c-Src permits activation of FAK, but not that of SAPK2/p38. In addition, Fyn is required for stress fiber formation and endothelial cell migration. We propose a model in which Fyn forms a molecular complex with Nck and PAK-2 and suggest that this complex assembles in a p similar to Tyr(1214)-dependent manner within VEGFR-2 following VEGF treatment. In turn, this triggers the activation of the SAPK2/p38 MAP kinase module, and promotes stress fiber formation and endothelial cell migration.	Univ Laval, Hotel Dieu, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Huot, J (corresponding author), Univ Laval, Hotel Dieu, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Cai J, 2006, MICROVASC RES, V71, P20, DOI 10.1016/j.mvr.2005.10.004; Chou MT, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-32; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ellis C, 1996, ONCOGENE, V12, P1727; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HOLMQVIST K, 2004, J BIOL CHEM, V16, P16; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Lamy S, 2002, CANCER RES, V62, P381; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Li H, 2004, J AM SOC NEPHROL, V15, P3006, DOI 10.1097/01.ASN.0000146689.88078.80; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; Lin HM, 1998, J BIOL CHEM, V273, P19914, DOI 10.1074/jbc.273.31.19914; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; MEYER RD, 2002, J BIOL CHEM, V22, P22; Mitola S, 2006, CIRC RES, V98, P45, DOI 10.1161/01.RES.0000199355.32422.7b; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; ROUSSEAU S, 2006, IN PRESS CELL SIGNAL; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Samayawardhena LA, 2006, CELL SIGNAL, V18, P1447, DOI 10.1016/j.cellsig.2005.11.005; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stoletov KV, 2004, EXP CELL RES, V295, P258, DOI 10.1016/j.yexcr.2004.01.008; STOLETOV KV, 2001, J BIOL CHEM, V8, P8; Summy JM, 2003, J CELL SCI, V116, P2585, DOI 10.1242/jcs.00466; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059	44	114	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34009	34020		10.1074/jbc.M603928200	http://dx.doi.org/10.1074/jbc.M603928200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966330	hybrid			2022-12-25	WOS:000241767600021
J	Li, YP; Hernandez-Martinez, S; Fernandez, F; Mayoral, JG; Topalis, P; Priestap, H; Perez, M; Navare, A; Noriega, FG				Li, Yiping; Hernandez-Martinez, Salvador; Fernandez, Facundo; Mayoral, Jaime G.; Topalis, Pantelis; Priestap, Horacio; Perez, Mario; Navare, Arti; Noriega, Fernando G.			Biochemical, molecular, and functional characterization of PISCF-allatostatin, a regulator of juvenile hormone biosynthesis in the mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORPORA ALLATA; III BIOSYNTHESIS; IDENTIFICATION; NEUROPEPTIDES; PEPTIDE; PATHWAY; ASSAY; CDNA; ACID; RNA	Aedes aegypti PISCF-allatostatin or allatostatin-C (Ae-AS-C) was isolated using a combination of high performance liquid chromatography and enzyme-linked immunosorbent assay (ELISA). The matrix-assisted laser desorption/ionization time-of-flight (TOF) mass spectrum of positive ELISA fractions revealed a molecular mass of 1919.0 Da, in agreement with the sequence qIRYRQCYFNPISCF, with bridged cysteines. This sequence was confirmed by matrix-assisted laser desorption/ionization tandem TOF/TOF mass spectrometry analysis. The corresponding Ae-AS-C cDNA was amplified by PCR, and the sequence of the peptide was confirmed. An in vitro radiochemical assay was used to study the inhibitory effect of synthetic Ae-AS-C on juvenile hormone biosynthesis by the isolated corpora allata(CA) of adult female A. aegypti. The inhibitory action of synthetic Ae-AS-C was dose-dependent; with a maximum at 10(-9) M. Ae-AS-C showed no inhibitory activity in the presence of farnesoic acid, an immediate precursor of juvenile hormone, indicating that the Ae-AS-C target is located before the formation of farnesoic acid in the pathway. The sensitivity of the CA to inhibition by Ae-AS-C in the in vitro assay varied during the adult life; the CA was most sensitive during periods of low synthetic activity. In addition, the levels of Ae-AS-C in the brain were studied using ELISA and reached a maximum at 3 days after eclosion. These studies suggest that Ae-AS-C is an important regulator of CA activity in A. aegypti.	Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA; INSP, Ctr Invest Sobre Enfermedades Infeddiosas, Cuernavaca 62100, Morelos, Mexico; Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece	State University System of Florida; Florida International University; University System of Georgia; Georgia Institute of Technology	Noriega, FG (corresponding author), Florida Int Univ, Dept Biol Sci, 11200 SW 8th St, Miami, FL 33199 USA.	noriegaf@fiu.edu	Fernandez, Facundo Martin/B-7015-2008; G. Mayoral, Jaime/J-5392-2018	Fernandez, Facundo Martin/0000-0002-0302-2534; G. Mayoral, Jaime/0000-0002-8813-6804; Hernandez-Martinez, Salvador/0000-0003-1276-9397	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045545] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI045545, R01 AI045545-08, AI 45545] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUDLEY N, 2002, PEPTIDES, V23, P717; Belles X, 2005, ANNU REV ENTOMOL, V50, P181, DOI 10.1146/annurev.ento.50.071803.130356; Bendena WG, 1999, ANN NY ACAD SCI, V897, P311, DOI 10.1111/j.1749-6632.1999.tb07902.x; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; ENGELMAN F, 1970, PHYSL INSECT REPROD; FEYEREISEN R, 1987, J BIOL CHEM, V262, P2676; FEYEREISEN R, 1981, ANAL BIOCHEM, V111, P372, DOI 10.1016/0003-2697(81)90575-3; FEYEREISEN R, 1985, METHOD ENZYMOL, V111, P530; Gilbert LI, 2000, INSECT BIOCHEM MOLEC, V30, P617, DOI 10.1016/S0965-1748(00)00034-5; Goodman W.G., 2005, COMPREHENSIVE MOL IN, P55; Hernandez-Martinez S, 2005, CELL TISSUE RES, V321, P105, DOI 10.1007/s00441-005-1133-5; Knudson DL, 2002, INSECT BIOCHEM MOLEC, V32, P1193, DOI 10.1016/S0965-1748(02)00082-6; KRAMER SJ, 1991, P NATL ACAD SCI USA, V88, P9458, DOI 10.1073/pnas.88.21.9458; Kreienkamp HJ, 2002, J BIOL CHEM, V277, P39937, DOI 10.1074/jbc.M206931200; Li YP, 2004, REGUL PEPTIDES, V118, P175, DOI 10.1016/j.regpep.2003.12.004; Li YP, 2003, INSECT BIOCHEM MOLEC, V33, P1307, DOI 10.1016/j.ibmb.2003.07.003; Li YP, 2003, J EXP BIOL, V206, P1825, DOI 10.1242/jeb.00371; Matthews HJ, 2006, J INSECT PHYSIOL, V52, P128, DOI 10.1016/j.jinsphys.2005.07.006; Noriega F.G., 1993, Insect Molecular Biology, V2, P21, DOI 10.1111/j.1365-2583.1993.tb00121.x; Noriega FG, 2006, INSECT BIOCHEM MOLEC, V36, P366, DOI 10.1016/j.ibmb.2006.01.013; Noriega FG, 1999, INSECT BIOCHEM MOLEC, V29, P243, DOI 10.1016/S0965-1748(98)00132-5; PRATT GE, 1990, MOL CELL ENDOCRINOL, V70, P185, DOI 10.1016/0303-7207(90)90158-5; Riehle MA, 2002, SCIENCE, V298, P172, DOI 10.1126/science.1076827; SHAPIRO AB, 1986, J INSECT PHYSIOL, V32, P867, DOI 10.1016/0022-1910(86)90102-2; Stay B, 2000, INSECT BIOCHEM MOLEC, V30, P653, DOI 10.1016/S0965-1748(00)00036-9; Sutherland TD, 1996, MOL CELL ENDOCRINOL, V120, P115, DOI 10.1016/0303-7207(96)03825-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Veenstra JA, 1999, PEPTIDES, V20, P1145, DOI 10.1016/S0196-9781(99)00117-5; Veenstra JA, 1997, PEPTIDES, V18, P937, DOI 10.1016/S0196-9781(97)00032-6	29	41	42	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34048	34055		10.1074/jbc.M606341200	http://dx.doi.org/10.1074/jbc.M606341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968697	Green Accepted, hybrid			2022-12-25	WOS:000241767600025
J	Panda, SP; Gao, YT; Roman, LJ; Martasek, P; Salerno, JC; Masters, BSS				Panda, Satya Prakash; Gao, Ying Tong; Roman, Linda J.; Martasek, Pavel; Salerno, John C.; Masters, Bettie Sue S.			The role of a conserved serine residue within hydrogen bonding distance of FAD in redox properties and the modulation of catalysis by Ca2+/calmodulin of constitutive nitric-oxide synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P450 OXIDOREDUCTASE; AUTOINHIBITORY CONTROL ELEMENT; ELECTRON FLOW-THROUGH; MOLECULAR-CLONING; BINDING DOMAIN; FERREDOXIN-NADP(+) REDUCTASE; P-450 OXIDOREDUCTASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; FMN	The crystal structure of the neuronal nitric-oxide synthase (nNOS) NADPH/FAD binding domain indicated that Ser-1176 is within hydrogen bonding distance of Asp-1393 and the O4 atom of FAD and is also near the N5 atom of FAD (3.7 angstrom). This serine residue is conserved in most of the ferredoxin-NADP(+) reductase family of proteins and is important in electron transfer. In the present study, the homologous serines of both nNOS(Ser-1176) and endothelial nitric-oxide synthase (eNOS) (Ser-942) were mutated to threonine and alanine. Both substitutions yielded proteins that exhibited decreased rates of electron transfer through the flavin domains, in the presence and absence of Ca2+/CaM, as measured by reduction of potassium ferricyanide and cytochrome c. Rapid kinetics measurements of flavin reduction of all the mutants also showed a decrease in the rate of flavin reduction, in the absence and presence of Ca2+/CaM, as compared with the wild type proteins. The serine to alanine substitution caused both nNOS and eNOS to synthesize NO more slowly; however, the threonine mutants gave equal or slightly higher rates of NO production compared with the wild type enzymes. The midpoint redox potential measurements of all the redox centers revealed that wild type and threonine mutants of both nNOS and eNOS are very similar. However, the redox potentials of the FMN/FMNH center dot couple for alanine substitutions of both nNOS and eNOS are > 100mV higher than those of wild type proteins and are positive. These data presented here suggest that hydrogen bonding of the hydroxyl group of serine or threonine with the isoalloxazine ring of FAD and with the amino acids in its immediate milieu, particularly nNOS Asp-1393, affects the redox potentials of various flavin states, influencing the rate of electron transfer.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Kennesaw State Coll, Coll Sci & Math, Dept Biol & Phys Sci, Kennesaw, GA 30144 USA; Charles Univ Prague, Sch Med 1, Dept Pediat, Prague 221, Czech Republic	University of Texas System; University of Texas Health San Antonio; University System of Georgia; Kennesaw State University; Charles University Prague	Masters, BSS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	masters@uthscsa.edu	salerno, john c/A-2595-2014; Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER LM, 1980, MICROSOMES DRUG OXID, P285; Aliverti A, 1999, METH MOL B, V131, P9; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Dunford AJ, 2004, EUR J BIOCHEM, V271, P2548, DOI 10.1111/j.1432-1033.2004.04185.x; Dutton P L, 1978, Methods Enzymol, V54, P411; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Faro M, 2002, EUR J BIOCHEM, V269, P2656, DOI 10.1046/j.1432-1033.2002.02925.x; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Flinspach M, 2004, BIOCHEMISTRY-US, V43, P5181, DOI 10.1021/bi0361867; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Gao YT, 2004, J BIOL CHEM, V279, P18759, DOI 10.1074/jbc.M308936200; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Ghosh DK, 2006, J BIOL CHEM, V281, P14173, DOI 10.1074/jbc.M509937200; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; Jachymova M, 2005, P NATL ACAD SCI USA, V102, P15833, DOI 10.1073/pnas.0506522102; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; Kimura S, 2003, J BIOL CHEM, V278, P3580, DOI 10.1074/jbc.M209838200; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; KURZBAN GP, 1990, J BIOL CHEM, V265, P12272; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Li HY, 2002, BIOCHEMISTRY-US, V41, P13868, DOI 10.1021/bi020417c; Makino K, 1999, GENES GENET SYST, V74, P227, DOI 10.1266/ggs.74.227; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Martasek P, 1999, METHOD ENZYMOL, V301, P70; Massey V, 2000, BIOCHEM SOC T, V28, P283, DOI 10.1042/0300-5127:0280283; Masters B, 1967, METHOD ENZYMOL, V10, P565; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; OHGIYA S, 1994, BBA-BIOENERGETICS, V1186, P137, DOI 10.1016/0005-2728(94)90146-5; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PIETRINI G, 1988, P NATL ACAD SCI USA, V85, P7246, DOI 10.1073/pnas.85.19.7246; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rieske JS, 1967, METHOD ENZYMOL, V10, P488, DOI DOI 10.1016/0076-6879(67)10081-5; Roman LJ, 2006, J BIOL CHEM, V281, P23111, DOI 10.1074/jbc.M603671200; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Roman LJ, 2003, J BIOL CHEM, V278, P25700, DOI 10.1074/jbc.M212309200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SEM DS, 1992, BIOCHEMISTRY-US, V31, P3391, DOI 10.1021/bi00128a013; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shen AL, 1996, BIOCHEMISTRY-US, V35, P9451, DOI 10.1021/bi960587n; Shen AL, 2000, J BIOL CHEM, V275, P41087, DOI 10.1074/jbc.M008380200; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; VAUCHERET H, 1989, MOL GEN GENET, V216, P10, DOI 10.1007/BF00332224; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016	65	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34246	34257		10.1074/jbc.M601041200	http://dx.doi.org/10.1074/jbc.M601041200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966328	Green Published, hybrid			2022-12-25	WOS:000241767600045
J	Watson, IR; Blanch, A; Lin, DCC; Ohh, M; Irwin, MS				Watson, Ian R.; Blanch, Alvaro; Lin, Dan C. C.; Ohh, Michael; Irwin, Meredith S.			Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; UBIQUITIN LIGASE; OVARIAN-CANCER; P73; P53; MDM2; DELTA-NP73; EXPRESSION	Mutations in p73 are rare in cancer. Emerging evidence suggests that the relative expression of various p73 isoforms may contribute to tumorigenesis. Alternative promoters and N-terminal splicing result in the transcription and processing of either full-length (TA) or N-terminally truncated (Delta N) p73 isoforms. TAp73 possesses pro-apoptotic functions, while Delta Np73 has anti-apoptotic properties via functional inhibition of TAp73 and p53. Here, we report that TAp73, but not Delta Np73, is covalently modified by NEDD8 under physiologic conditions in an Mdm2-dependent manner. Co-expression of NEDP1, a cysteine protease that specifically cleaves NEDD8 conjugates, was shown to deneddylate TAp73. In addition, blockage of the endogenous NEDD8 pathway increased TAp73-mediated transactivation of p53- and p73-responsive promoter-driven reporter activity, and in conjunction, neddylated TAp73 species were found preferentially in the cytoplasm. These results suggest that Mdm2 attenuates TAp73 transactivation function, at least in part, by promoting NEDD8-dependent TAp73 cytoplasmic localization and provide the first evidence of a covalent post-translational modification exclusively targeting the TA isoforms of p73.	Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Paediat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Irwin, MS (corresponding author), Hosp Sick Children, Canc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca		Watson, Ian/0000-0002-6025-3080				Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; CONSTANZO A, 2002, MOL CELL, V9, P175; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gong JG, 1999, NATURE, V399, P806; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Gu JJ, 2001, CANCER RES, V61, P6703; Guan M, 2005, J CLIN PATHOL, V58, P1175, DOI 10.1136/jcp.2005.026955; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HIRSCHBERG J, 1982, J CELL PHYSIOL, V113, P159, DOI 10.1002/jcp.1041130125; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Irwin MS, 2004, CELL DEATH DIFFER, V11, pS17, DOI 10.1038/sj.cdd.4401452; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	54	87	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34096	34103		10.1074/jbc.M603654200	http://dx.doi.org/10.1074/jbc.M603654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980297	hybrid			2022-12-25	WOS:000241767600030
J	Evans, CG; Wisen, S; Gestwicki, JE				Evans, Christopher G.; Wisen, Susanne; Gestwicki, Jason E.			Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; ALPHA-SYNUCLEIN AGGREGATION; ALZHEIMERS-DISEASE; MOLECULAR CHAPERONES; SECRETED OLIGOMERS; FIBRIL FORMATION; LIGANDS ADDLS; HSP70; PEPTIDE; MODULATORS	Alzheimer disease is a neurological disorder that is characterized by the presence of fibrils and oligomers composed of the amyloid beta(A beta) peptide. In models of Alzheimer disease, overexpression of molecular chaperones, specifically heat shock protein 70 (Hsp70), suppresses phenotypes related to A beta aggregation. These observations led to the hypothesis that chaperones might interact with A beta and block self-association. However, although biochemical evidence to support this model has been collected in other neurodegenerative systems, the interaction between chaperones and A beta has not been similarly explored. Here, we examine the effects of Hsp70/40 and Hsp90 on A beta aggregation in vitro. We found that recombinant Hsp70/40 and Hsp90 block A beta self-assembly and that these chaperones are effective at substoichiometric concentrations (similar to 1: 50). The antiaggregation activity of Hsp70 can be inhibited by a nonhydrolyzable nucleotide analog and encouraged by pharmacological stimulation of its ATPase activity. Finally, we were interested in discerning what type of amyloid structures can be acted upon by these chaperones. To address this question, we added Hsp70/ 40 and Hsp90 to pre-formed oligomers and fibrils. Based on thioflavin T reactivity, the combination of Hsp70/40 and Hsp90 caused structural changes in oligomers but had little effect on fibrils. These results suggest that if these chaperones are present in the same cellular compartment in which A beta is produced, Hsp70/40 and Hsp90 may suppress the early stages of self-assembly. Thus, these results are consistent with a model in which pharmacological activation of chaperones might have a favorable therapeutic effect on Alzheimer disease.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gestwicki, JE (corresponding author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.	gestwick@umich.edu			NIA NIH HHS [P50 AG08671] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguzzi A, 2004, J CLIN INVEST, V114, P153, DOI [10.1172/JCI22438, 10.1172/JCI200422438]; Aisen PS, 2005, CNS DRUGS, V19, P989, DOI 10.2165/00023210-200519120-00002; BAKTHISARAN R, 2005, BIOCHEM J, V392, P573; Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Bohrmann B, 2000, J STRUCT BIOL, V130, P232, DOI 10.1006/jsbi.2000.4241; Brendza RP, 2005, J CLIN INVEST, V115, P428, DOI 10.1172/JCI200523269; Brodsky JL, 1999, BIOCHEM PHARMACOL, V57, P877, DOI 10.1016/S0006-2952(98)00376-1; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; BURDICK D, 1992, J BIOL CHEM, V267, P546; Catalano SM, 2006, CURR TOP MED CHEM, V6, P597, DOI 10.2174/156802606776743066; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; De los Rios P, 2006, P NATL ACAD SCI USA, V103, P6166, DOI 10.1073/pnas.0510496103; Dedmon MM, 2005, J BIOL CHEM, V280, P14733, DOI 10.1074/jbc.m413024200; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dul JL, 2001, J CELL BIOL, V152, P705, DOI 10.1083/jcb.152.4.705; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Fewell SW, 2004, J BIOL CHEM, V279, P51131, DOI 10.1074/jbc.M404857200; Fewell SW, 2001, J BIOL CHEM, V276, P910, DOI 10.1074/jbc.M008535200; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; Findeis Mark A., 2002, Current Topics in Medicinal Chemistry, V2, P417, DOI 10.2174/1568026024607508; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Gestwicki JE, 2004, SCIENCE, V306, P865, DOI 10.1126/science.1101262; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Grant Susan M., 2000, Journal of Alzheimer's Disease, V2, P207; Hama E, 2001, J BIOCHEM-TOKYO, V130, P721, DOI 10.1093/oxfordjournals.jbchem.a003040; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; John V, 2006, CURR TOP MED CHEM, V6, P569, DOI 10.2174/156802606776743084; Kappe CO, 2003, METHOD ENZYMOL, V369, P197; Katsuno M, 2005, P NATL ACAD SCI USA, V102, P16801, DOI 10.1073/pnas.0506249102; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Lee S, 2005, PROTEIN SCI, V14, P593, DOI 10.1110/ps.041020705; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LeVine H, 1999, METHOD ENZYMOL, V309, P467; Lowe TL, 2001, BIOCHEMISTRY-US, V40, P7882, DOI 10.1021/bi002734u; Magrane J, 2005, J NEUROSCI, V25, P10960, DOI 10.1523/JNEUROSCI.1723-05.2005; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MATSUMOTO A, 1994, EUR J BIOCHEM, V225, P1055, DOI 10.1111/j.1432-1033.1994.1055b.x; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Morelli L, 2002, NEUROCHEM RES, V27, P1387, DOI 10.1023/A:1021679817756; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nadler SG, 1998, BIOCHEM BIOPH RES CO, V253, P176, DOI 10.1006/bbrc.1998.9775; Pangalos MN, 2005, BIOCHEM SOC T, V33, P553, DOI 10.1042/BST0330553; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; POLLARD TD, 1981, J CELL BIOL, V88, P654, DOI 10.1083/jcb.88.3.654; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rieger TR, 2006, BIOPHYS J, V90, P886, DOI 10.1529/biophysj.105.066662; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Schmidt B, 2006, CURR TOP MED CHEM, V6, P377, DOI 10.2174/156802606776287027; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Sengupta P, 2003, BIOCHEMISTRY-US, V42, P10506, DOI 10.1021/bi0341410; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; TABATON M, 1991, P NATL ACAD SCI USA, V88, P2098, DOI 10.1073/pnas.88.6.2098; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754; UMEZAWA H, 1981, J ANTIBIOT, V34, P1622, DOI 10.7164/antibiotics.34.1622; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Vetrivel KS, 2006, NEUROLOGY, V66, pS69, DOI 10.1212/01.wnl.0000192107.17175.39; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2004, PROTEIN PEPTIDE LETT, V11, P213, DOI 10.2174/0929866043407174; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Wegele H, 2006, J MOL BIOL, V356, P802, DOI 10.1016/j.jmb.2005.12.008; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389; Yan SD, 1997, NATURE, V389, P689	89	301	323	1	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33182	33191		10.1074/jbc.M606192200	http://dx.doi.org/10.1074/jbc.M606192200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16973602	hybrid			2022-12-25	WOS:000241621400026
J	Ho, MR; Lou, YC; Lin, WC; Lyu, PC; Huang, WN; Chen, C				Ho, Meng-Ru; Lou, Yuan-Chao; Lin, Wen-Chang; Lyu, Ping-Chiang; Huang, Wei-Ning; Chen, Chinpan			Human pancreatitis-associated protein forms fibrillar aggregates with a native-like conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-LIKE FIBRILS; PROBING SOLVENT ACCESSIBILITY; SOLUTION NMR-SPECTROSCOPY; URE2P PRION FILAMENTS; IN-VITRO; SECONDARY STRUCTURE; MESSENGER-RNA; RESONANCE ASSIGNMENTS; CIRCULAR-DICHROISM; ALZHEIMERS-DISEASE	Human pancreatitis-associated protein was identified in pathognomonic lesions of Alzheimer disease, a disease characterized by the presence of filamentous protein aggregates. Here, we showed that at physiological pH, human pancreatitis-associated protein forms non-Congo Red-binding, proteinase K-resistant fibrillar aggregates with diameters from 6 up to as large as 68 nm. Interestingly, circular dichroism and Fourier transform infrared spectra showed that, unlike typical amyloid fibrils, which have a cross-beta-sheet structure, these aggregates have a very similar secondary structure to that of the native protein, which is composed of two alpha-helices and eight beta-strands, as determined by NMR techniques. Surface structure analysis showed that the positively charged and negatively charged residues were clustered on opposite sides, and strong electrostatic interactions between molecules were therefore very likely, which was confirmed by cross-linking experiments. In addition, several hydrophobic residues were found to constitute a continuous hydrophobic surface. These results and protein aggregation prediction using the TANGO algorithm led us to synthesize peptide Thr(84) to Ser(116), which, very interestingly, was found to form amyloid-like fibrils with a cross-beta structure. Thus, our data suggested that human pancreatitis-associated protein fibrillization is initiated by protein aggregation primarily because of electrostatic interactions, and the loop from residues 84 to 116 may play an important role in the formation of fibrillar aggregates with a native-like conformation.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Tsing Hua Univ, Coll Life Sci, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan; Yuanpei Inst Sci & Technol, Dept Biotechnol, Hsinchu 300, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University	Chen, C (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	bmchinp@ibms.sinica.edu.tw	Ho, Meng-Ru/F-9844-2019; Chen, Chinpan/O-4202-2018; Lin, Wen-chang/B-3100-2011; Lin, Wen-chang/ABH-7976-2020	Ho, Meng-Ru/0000-0001-7344-695X; Lin, Wen-chang/0000-0003-0194-1745; Lin, Wen-chang/0000-0003-0194-1745				Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; BERNARD JP, 1992, GASTROENTEROLOGY, V103, P1277, DOI 10.1016/0016-5085(92)91516-7; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; de la Paz ML, 2004, P NATL ACAD SCI USA, V101, P87, DOI 10.1073/pnas.2634884100; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DELELLIS RA, 1968, J HISTOCHEM CYTOCHEM, V16, P663, DOI 10.1177/16.10.663-a; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dos Reis S, 2002, J BIOL CHEM, V277, P5703, DOI 10.1074/jbc.M110183200; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Duplan L, 2001, NEUROBIOL AGING, V22, P79, DOI 10.1016/S0197-4580(00)00182-2; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Eneqvist T, 2002, BIOCHEMISTRY-US, V41, P13143, DOI 10.1021/bi025800w; Eneqvist T, 2000, MOL CELL, V6, P1207, DOI 10.1016/S1097-2765(00)00117-9; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; Fowler SB, 2005, P NATL ACAD SCI USA, V102, P10105, DOI 10.1073/pnas.0501215102; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Graf R, 2001, J BIOL CHEM, V276, P21028, DOI 10.1074/jbc.M010717200; Gregoire C, 2001, EMBO J, V20, P3313, DOI 10.1093/emboj/20.13.3313; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Ho MR, 2004, J BIOMOL NMR, V30, P381, DOI 10.1007/s10858-004-3499-1; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LASSERRE C, 1992, CANCER RES, V52, P5089; Laurine E, 2003, J BIOL CHEM, V278, P51770, DOI 10.1074/jbc.M306767200; Lin TH, 1998, J BIOMOL NMR, V11, P363, DOI 10.1023/A:1008226515482; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; Makin OS, 2005, P NATL ACAD SCI USA, V102, P315, DOI 10.1073/pnas.0406847102; Motoo Y, 1998, INT J PANCREATOL, V23, P11; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Olofsson A, 2004, J BIOL CHEM, V279, P5699, DOI 10.1074/jbc.M310605200; ORELLE B, 1992, J CLIN INVEST, V90, P2284, DOI 10.1172/JCI116115; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Rosty C, 2002, CANCER RES, V62, P1868; SAFAR J, 1993, BIOPOLYMERS, V33, P1461, DOI 10.1002/bip.360330915; Sambashivan S, 2005, NATURE, V437, P266, DOI 10.1038/nature03916; Scheibel T, 2003, P NATL ACAD SCI USA, V100, P4527, DOI 10.1073/pnas.0431081100; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Staniforth RA, 2001, EMBO J, V20, P4774, DOI 10.1093/emboj/20.17.4774; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TACHIBANA K, 1988, MOL ENDOCRINOL, V2, P973, DOI 10.1210/mend-2-10-973; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Thirumalai D, 2003, CURR OPIN STRUC BIOL, V13, P146, DOI 10.1016/S0959-440X(03)00032-0; Thompson MJ, 2006, P NATL ACAD SCI USA, V103, P4074, DOI 10.1073/pnas.0511295103; Vasseur S, 2004, J BIOL CHEM, V279, P7199, DOI 10.1074/jbc.M309152200; VUILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303, DOI 10.1021/bi00090a005; Wang LM, 2002, P NATL ACAD SCI USA, V99, P15947, DOI 10.1073/pnas.252508399; Waterhouse SH, 2004, AUST J CHEM, V57, P519, DOI 10.1071/CH04070; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099	66	19	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33566	33576		10.1074/jbc.M604513200	http://dx.doi.org/10.1074/jbc.M604513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963458	hybrid			2022-12-25	WOS:000241621400066
J	Kim, S; Kim, H; Chang, B; Ahn, N; Hwang, S; Di Paolo, G; Chang, S				Kim, Sunyun; Kim, Hyunmyung; Chang, Belle; Ahn, Namhui; Hwang, Suha; Di Paolo, Gilbert; Chang, Sunghoe			Regulation of transferrin recycling kinetics by PtdIns[4,5]P-2 availability	FASEB JOURNAL			English	Article						endocytosis; membrane recycling	PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANE; ACTIN; VESICLES; BINDING; ENDOSOMES; MOLECULES; DOMAIN; LIPIDS	Phosphatidylinositol 4,5-bisphosphate (PtdIns[4,5]P-2) is a phosphoinositide involved in a variety of cellular functions, including signal transduction, organelle trafficking, and actin dynamics. Although the role of PtdIns[4,5]P-2 in endocytosis is well established, the precise trafficking steps relying on normal PtdIns[4,5]P-2 balance in the endosomal pathway have not yet been elucidated. Here we show that decrease in intracellular PtdIns[4,5]P-2 levels achieved by the overexpression of the 5-phosphatase domain of synaptojanin 1 or by siRNA knock-down of PIP5Ks expression lead to severe defects in the internalization of transferrin as well as in the recycling of internalized transferrin back to the cell surface in COS-7 cells. These defects suggest that PtdIns[4,5]P-2 participates in multiple trafficking and/or sorting events during endocytosis. Coexpression of the PtdIns[4,5]P-2 synthesizing enzyme, PIP5KI gamma, was able to rescue these endocytic defects. Furthermore, decreased levels of PtdIns[4,5]P-2 caused delays in rapid and slow membrane recycling pathways as well as a severe backup of endocytosed membrane. Taken together, our results demonstrate that PtdIns[4,5]P-2 availability regulates multiple steps in the endocytic cycle in non-neuronal cells.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea; Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Pathol, New York, NY USA	Gwangju Institute of Science & Technology (GIST); Columbia University	Chang, S (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju, South Korea.	sunghoe@gist.ac.kr	Chang, Sunghoe/J-2784-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD047733] Funding Source: NIH RePORTER; NICHD NIH HHS [HD047733-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Chang S, 2001, NAT NEUROSCI, V4, P787, DOI 10.1038/90489; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Gruenberg J, 2003, CURR OPIN CELL BIOL, V15, P382, DOI 10.1016/S0955-0674(03)00078-4; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kim WT, 2002, P NATL ACAD SCI USA, V99, P17143, DOI 10.1073/pnas.222657399; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sechi AS, 2000, J CELL SCI, V113, P3685; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2; Verstreken P, 2003, NEURON, V40, P733, DOI 10.1016/S0896-6273(03)00644-5; Wang Z, 2004, J HYDROMETEOROL, V5, P3, DOI 10.1175/1525-7541(2004)005<0003:UMBAAD>2.0.CO;2; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	33	24	24	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2399	+		10.1096/fj.05-4621fje	http://dx.doi.org/10.1096/fj.05-4621fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012244				2022-12-25	WOS:000241702600033
J	Pineda, AO; Chen, ZW; Bah, A; Garvey, LC; Mathews, FS; Di Cera, E				Pineda, Agustin O.; Chen, Zhi-Wei; Bah, Alaji; Garvey, Laura C.; Mathews, F. Scott; Di Cera, Enrico			Crystal structure of thrombin in a self-inhibited conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW FORM; SERINE PROTEASES; MOLECULAR-BASIS; PROTEIN-C; BINDING; CRYSTALLOGRAPHY; SPECIFICITY; TRANSITION; ALLOSTERY; COMPLEX	The activating effect of Na+ on thrombin is allosteric and depends on the conformational transition from a low activity Na+-free (slow) form to a high activity Na+-bound (fast) form. The structures of these active forms have been solved. Recent structures of thrombin obtained in the absence of Na+ have also documented inactive conformations that presumably exist in equilibrium with the active slow form. The validity of these inactive slow form structures, however, is called into question by the presence of packing interactions involving the Na+ site and the active site regions. Here, we report a 1.87 angstrom resolution structure of thrombin in the absence of inhibitors and salts with a single molecule in the asymmetric unit and devoid of significant packing interactions in regions involved in the allosteric slow -> fast transition. The structure shows an unprecedented self-inhibited conformation where Trp-215 and Arg-221a relocate > 10 angstrom to occlude the active site and the primary specificity pocket, and the guanidinium group of Arg-187 penetrates the protein core to fill the empty Na+-binding site. The extreme mobility of Trp-215 was investigated further with the W215P mutation. Remarkably, the mutation significantly compromises cleavage of the anticoagulant protein C but has no effect on the hydrolysis of fibrinogen and PAR1. These findings demonstrate that thrombin may assume an inactive conformation in the absence of Na+ and that its procoagulant and anticoagulant activities are closely linked to the mobility of residue 215.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu			NHLBI NIH HHS [HL 58141, HL 49413, HL 73813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058141, R29HL049413, R01HL049413, R01HL073813] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODE W, 1992, PROTEIN SCI, V1, P426; BOTTS J, 1953, T FARADAY SOC, V49, P696, DOI 10.1039/tf9534900696; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; Davie EW, 2006, SEMIN THROMB HEMOST, V32, P3, DOI 10.1055/s-2006-939550; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Johnson DJD, 2005, BIOCHEM J, V392, P21, DOI 10.1042/BJ20051217; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page MJ, 2006, PHYSIOL REV, V86, P1049, DOI 10.1152/physrev.00008.2006; Page MJ, 2005, J THROMB HAEMOST, V3, P2401, DOI 10.1111/j.1538-7836.2005.01456.x; Papaconstantinou ME, 2005, J BIOL CHEM, V280, P29393, DOI 10.1074/jbc.C500248200; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Xu H, 2005, J BIOL CHEM, V280, P7956, DOI 10.1074/jbc.M412869200	30	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32922	32928		10.1074/jbc.M605530200	http://dx.doi.org/10.1074/jbc.M605530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954215	hybrid			2022-12-25	WOS:000241414500090
J	Soria, RB; Spitzner, M; Schreiber, R; Kunzelmann, K				Soria, Rene Barro; Spitzner, Melanie; Schreiber, Rainer; Kunzelmann, Karl			Bestrophin-1 Enables Ca2+-activated Cl- Conductance in Epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CHLORIDE CHANNELS; CYSTIC-FIBROSIS; MACULAR DYSTROPHY; PRIMARY CULTURES; PROTEIN-KINASE; HT(29) CELLS; CALCIUM; MOUSE; TRANSPORT; CURRENTS	Epithelial cells express calcium-activated Cl- channels of unknown molecular identity. These Cl- channels play a central role in diseases such as secretory diarrhea, polycystic kidney disease, and cystic fibrosis. The family of bestrophins has been suggested to form calcium-activated Cl- channels. Here, we demonstrate molecular and functional expression of bestrophin-1 (BEST1) in mouse and human airways, colon, and kidney. Endogenous calcium-activated whole cell Cl- currents coincide with endogenous expression of the Vmd2 gene product BEST1 in murine and human epithelial cells, whereas calcium-activated Cl- currents are absent in epithelial tissues lacking BEST1 expression. Blocking expression of BEST1 with short interfering RNA or applying an anti-BEST1 antibody to a patch pipette suppressed ATP-induced whole cell Cl- currents. Calcium-dependent Cl- currents were activated by ATP in HEK293 cells expressing BEST1. Thus, BEST1 may form the Ca2+-activated Cl- current, or it may be a component of a Cl- channel complex in epithelial tissues.	[Soria, Rene Barro; Spitzner, Melanie; Schreiber, Rainer; Kunzelmann, Karl] Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany	University of Regensburg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu		Spitzner, Melanie/0000-0002-3673-0625	Deutsche Forschungsgemeinschaft [KU 756/9-1, SFB699]; Else Kroner-Fresenius-Stiftung [P36/05/A44/05]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else Kroner-Fresenius-Stiftung	This work was supported by Deutsche Forschungsgemeinschaft Grants KU 756/9-1 and SFB699 and Else Kroner-Fresenius-Stiftung P36/05/A44/05.	Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; Barriere H, 2003, AM J PHYSIOL-RENAL, V284, pF796, DOI 10.1152/ajprenal.00237.2002; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; Bidet M, 1996, AM J PHYSIOL-RENAL, V271, pF940, DOI 10.1152/ajprenal.1996.271.4.F940; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Dong YJ, 1997, P NATL ACAD SCI USA, V94, P3960, DOI 10.1073/pnas.94.8.3960; Duta V, 2004, FEBS LETT, V577, P551, DOI 10.1016/j.febslet.2004.10.068; Eggermont Jan, 2004, Proc Am Thorac Soc, V1, P22, DOI 10.1513/pats.2306010; EVANS MG, 1986, J PHYSIOL-LONDON, V378, P437, DOI 10.1113/jphysiol.1986.sp016229; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Greger R, 1996, PFLUG ARCH EUR J PHY, V432, P579, DOI 10.1007/s004240050173; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Grubb BR, 2006, AM J PHYSIOL-LUNG C, V290, pL270, DOI 10.1152/ajplung.00249.2005; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Ho MWY, 2001, J BIOL CHEM, V276, P18673, DOI 10.1074/jbc.M101128200; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KUBITZ R, 1992, PFLUG ARCH EUR J PHY, V421, P447, DOI 10.1007/BF00370255; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; Kunzelmann K, 2002, PFLUG ARCH EUR J PHY, V444, P220, DOI 10.1007/s00424-002-0796-y; KUNZELMANN K, 1992, PFLUG ARCH EUR J PHY, V421, P238, DOI 10.1007/BF00374833; Kunzelmann K., 1997, PFLUGERS ARCH, V434, P178, DOI DOI 10.1007/S004240050498; Kunzelmann Karl, 2003, Am J Respir Med, V2, P299; Kuruma A, 2000, J GEN PHYSIOL, V115, P59, DOI 10.1085/jgp.115.1.59; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; Lo CWY, 2006, FASEB J, V20, pA1301; Loewen ME, 2005, PHYSIOL REV, V85, P1061, DOI 10.1152/physrev.00016.2004; LU L, 1993, J MEMBRANE BIOL, V135, P181; Mall M, 2000, AM J PHYSIOL-GASTR L, V278, pG617, DOI 10.1152/ajpgi.2000.278.4.G617; Mall M, 2003, PEDIATR RES, V53, P608, DOI 10.1203/01.PDR.0000057204.51420.DC; Mall M, 1998, AM J PHYSIOL-GASTR L, V275, pG1274, DOI 10.1152/ajpgi.1998.275.6.G1274; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Marmorstein LY, 2006, J GEN PHYSIOL, V127, P577, DOI 10.1085/jgp.200509473; Nilius B, 2005, PFLUG ARCH EUR J PHY, V451, P1, DOI 10.1007/s00424-005-1462-y; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Qu ZQ, 2004, J GEN PHYSIOL, V123, P327, DOI 10.1085/jgp.200409031; Qu ZQ, 2003, AM J PHYSIOL-RENAL, V285, pF326, DOI 10.1152/ajprenal.00034.2003; SCHLATTER E, 1990, PFLUG ARCH EUR J PHY, V417, P317, DOI 10.1007/BF00370998; Stanton JB, 2006, BBA-BIOMEMBRANES, V1758, P241, DOI 10.1016/j.bbamem.2006.01.024; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Tarran R, 2006, ANNU REV PHYSIOL, V68, P543, DOI 10.1146/annurev.physiol.68.072304.112754; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; Tsunenari T, 2006, J GEN PHYSIOL, V127, P749, DOI 10.1085/jgp.200609527; Wei L, 1999, PFLUG ARCH EUR J PHY, V438, P635, DOI 10.1007/s004240051087; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	51	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	2009	284	43					29405	29412		10.1074/jbc.M605716200	http://dx.doi.org/10.1074/jbc.M605716200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	507ZW	17003041	Green Published, hybrid			2022-12-25	WOS:000270896800022
J	Cai, C; Chen, SY; Zheng, Z; Omwancha, J; Lin, MF; Balk, SP; Shemshedini, L				Cai, C.; Chen, S-Y; Zheng, Z.; Omwancha, J.; Lin, M-F; Balk, S. P.; Shemshedini, L.			Androgen regulation of soluble guanylyl cyclase alpha 1 mediates prostate cancer cell proliferation	ONCOGENE			English	Article						androgen receptor; soluble guanylyl cyclase; prostate cancer; proliferation	NITRIC-OXIDE; ACID-PHOSPHATASE; GENE-EXPRESSION; RECEPTOR; LNCAP; PROGRESSION; ANTIGEN; INHIBITION; BIOLOGY; DEATH	The growth and progression of prostate cancer are dependent on androgens and androgen receptor (AR), which act by modulating gene expression. Utilizing a gene microarray approach, we have identified the alpha 1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regulated gene. A heterodimeric cytoplasmic protein composed of one alpha and one beta subunit, sGC mediates the widespread cellular effects of nitric oxide (NO). We report here that, in prostate cancer cells, androgens stimulate the expression of sGC alpha 1. A cloned human sGC alpha 1 promoter is activated by androgen in an AR-dependent manner, suggesting that sGC alpha 1 may be a direct AR target gene. Disruption of sGC alpha 1 expression severely compromises the growth of both androgen-dependent and androgen-independent AR-positive prostate cancer cells. Overexpression of sGC alpha 1 alone is sufficient for stimulating prostate cancer cell proliferation. Interestingly, the major growth effect of sGC alpha 1 is independent of NO and cyclic guanosine monophosphate, a major mediator of the sGC enzyme. These data strongly suggest that sGC alpha 1 acts in prostate cancer via a novel pathway that does not depend on sGC beta 1. Tissue studies show that sGC alpha 1 expression is significantly elevated in advanced prostate cancer. Thus, sGC alpha 1 may be an important mediator of the procarcinogenic effects of androgens.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Nebraska, Coll Med, Ctr Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University System of Ohio; University of Toledo; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Nebraska System	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	lshemsh@utnet.utoledo.edu	Cai, Changmeng/AAE-6835-2020; CHEN, Shaoyong/ABF-3357-2021	Cai, Changmeng/0000-0002-8701-2586				Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; CHEN SY, 2006, IN PRESS ONCOGE 0529; Chen ZJ, 2002, CANCER LETT, V177, P181, DOI 10.1016/S0304-3835(01)00788-1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; ISAACS JT, 1994, VITAM HORM, V49, P433; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jenster G, 1999, SEMIN ONCOL, V26, P407; Jia L, 2003, MOL CANCER RES, V1, P385; Jiang J, 2004, CHINESE MED J-PEKING, V117, P684; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Koksal IT, 2002, PATHOLOGY, V34, P233, DOI 10.1080/00313020220131282; Krumenacker J, 2004, BRAIN RES BULL, V62, P505, DOI 10.1016/S0361-9230(03)00102-3; KRUMENACKER JS, 2001, P NATL ACAD SCI USA, V23, P170; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Meehan KL, 2003, FRONT BIOSCI-LANDMRK, V8, pD780, DOI 10.2741/1063; Mimeault M, 2005, PROSTATE, V62, P187, DOI 10.1002/pros.20138; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Postovit LM, 2002, J BIOL CHEM, V277, P35730, DOI 10.1074/jbc.M204529200; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sinnaeve P, 2001, CIRC RES, V88, P103, DOI 10.1161/01.RES.88.1.103; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; YOUNG CYF, 1994, ONCOL RES, V6, P203; YUAN SX, 1993, CANCER RES, V53, P1304	37	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1606	1615		10.1038/sj.onc.1209956	http://dx.doi.org/10.1038/sj.onc.1209956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964290				2022-12-25	WOS:000244782500010
J	Duvezin-Caubet, S; Jagasia, R; Wagener, J; Hofmann, S; Trifunovic, A; Hansson, A; Chomyn, A; Bauer, MF; Attardi, G; Larsson, NG; Neupert, W; Reichert, AS				Duvezin-Caubet, Stephane; Jagasia, Ravi; Wagener, Johannes; Hofmann, Sabine; Trifunovic, Aleksandra; Hansson, Anna; Chomyn, Anne; Bauer, Matthias F.; Attardi, Giuseppe; Larsson, Nils-Goeran; Neupert, Walter; Reichert, Andreas S.			Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; DOMINANT OPTIC ATROPHY; CYTOCHROME-C; HUMAN-CELLS; FUSION; APOPTOSIS; MEMBRANE; DNA; FISSION; GTPASE	Many muscular and neurological disorders are associated with mitochondrial dysfunction and are often accompanied by changes in mitochondrial morphology. Mutations in the gene encoding OPA1, a protein required for fusion of mitochondria, are associated with hereditary autosomal dominant optic atrophy type I. Here we show that mitochondrial fragmentation correlates with processing of large isoforms of OPA1 in cybrid cells from a patient with myoclonus epilepsy and ragged-red fibers syndrome and in mouse embryonic fibroblasts harboring an error-prone mitochondrial mtDNA polymerase gamma. Furthermore, processed OPA1 was observed in heart tissue derived from heart-specific TFAM knock-out mice suffering from mitochondrial cardiomyopathy and in skeletal muscles from patients suffering from mitochondrial myopathies such as myopathy encephalopathy lactic acidosis and stroke-like episodes. Dissipation of the mitochondrial membrane potential leads to fast induction of proteolytic processing of OPA1 and concomitant fragmentation of mitochondria. Recovery of mitochondrial fusion depended on protein synthesis and was accompanied by resynthesis of large isoforms of OPA1. Fragmentation of mitochondria was prevented by overexpressing OPA1. Taken together, our data indicate that proteolytic processing of OPA1 has a key role in inducing fragmentation of energetically compromised mitochondria. We present the hypothesis that this pathway regulates mitochondrial morphology and serves as an early response to prevent fusion of dysfunctional mitochondria with the functional mitochondrial network.	Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; GSF, Inst Dev Genet, Natl Res Ctr Environm & Hlth, D-85764 Munich, Germany; Karolinska Inst, Dept Lab Med, Div Metrol Dis, Novum, S-14186 Huddinge, Sweden; CALTECH, Div Biol, Pasadena, CA 91125 USA; Acad Hosp, Diabet Res Inst, D-80804 Munich, Germany; Acad Hosp, Inst Clin Chem Mol Diagnost & Mitochondrial Genet, D-80804 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Karolinska Institutet; California Institute of Technology	Reichert, AS (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	Andreas.Reichert@med.uni-muenchen.de	Wagener, Johannes/K-5904-2012; Reichert, Andreas/A-4090-2012; Wagener, Johannes/AAN-1359-2021	Wagener, Johannes/0000-0002-5952-9422; Larsson, Nils-Goran/0000-0001-5100-996X; Reichert, Andreas/0000-0001-9340-3113; Duvezin-Caubet, Stephane/0000-0002-0243-2697				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Arnoult D, 2005, J BIOL CHEM, V280, P35742, DOI 10.1074/jbc.M505970200; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100; Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Lyamzaev KG, 2004, BIOCHEM SOC T, V32, P1070, DOI 10.1042/BST0321070; Malka F, 2005, EMBO REP, V6, P853, DOI 10.1038/sj.embor.7400488; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027; Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976; Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Sesaki H, 2003, BIOCHEM BIOPH RES CO, V308, P276, DOI 10.1016/S0006-291X(03)01348-2; Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788; Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277; Skulachev VP, 2004, MOL CELL BIOCHEM, V256, P341, DOI 10.1023/B:MCBI.0000009880.94044.49; Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	48	332	334	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37972	37979		10.1074/jbc.M606059200	http://dx.doi.org/10.1074/jbc.M606059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17003040	hybrid, Green Accepted			2022-12-25	WOS:000242477100076
J	Scotton, P; Bleckmann, D; Stebler, M; Sciandra, F; Brancaccio, A; Meier, T; Stetefeld, J; Ruegg, MA				Scotton, Patrick; Bleckmann, Dorothee; Stebler, Michael; Sciandra, Francesca; Brancaccio, Andrea; Meier, Thomas; Stetefeld, Jorg; Ruegg, Markus A.			Activation of muscle-specific receptor tyrosine kinase and binding to dystroglycan are regulated by alternative mRNA splicing of agrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; FIBERS IN-VIVO; ALPHA-DYSTROGLYCAN; NEUROMUSCULAR-JUNCTION; CRYSTAL-STRUCTURE; POSTSYNAPTIC DIFFERENTIATION; EXTRACELLULAR-MATRIX; MUSCULAR-DYSTROPHY; INNERVATED MUSCLE; LAMININ-BINDING	Agrin induces the aggregation of postsynaptic proteins at the neuromuscular junction (NMJ). This activity requires the receptor-tyrosine kinase MuSK. Agrin isoforms differ in short amino acid stretches at two sites, called A and B, that are localized in the two most C-terminal laminin G (LG) domains. Importantly, agrin isoforms greatly differ in their activities of inducing MuSK phosphorylation and of binding to alpha-dystroglycan. By using site- directed mutagenesis, we characterized the amino acids important for these activities of agrin. We find that the conserved tripeptide asparagine-glutamate-isoleucine in the eight-amino acid long insert at the B-site is necessary and sufficient for full MuSK phosphorylation activity. However, even if all eight amino acids were replaced by alanines, this agrin mutant still has significantly higher MuSK phosphorylation activity than the splice version lacking any insert. We also show that binding to alpha-dystroglycan requires at least two LG domains and that amino acid inserts at the A and the B splice sites negatively affect binding.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Santhera Pharmaceut Switzerland Ltd, CH-4410 Liestal, Switzerland; Univ Cattolica Sacro Cuore, Ist Biochim & Biochim Clin, CNR, Ist Chim Riconoscimento Mol, I-00168 Rome, Italy	University of Basel; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Stetefeld, J (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	joerg.stetefeld@unibas.ch; markus-a.ruegg@unibas.ch	Sciandra, Francesca/AAY-4650-2020; Ruegg, Markus/X-7256-2019; Brancaccio, Andrea/C-5876-2009; Stetefeld, Joerg/H-7630-2017	Sciandra, Francesca/0000-0002-2123-1516; Ruegg, Markus/0000-0002-4974-9384; Brancaccio, Andrea/0000-0003-4690-8826; Stetefeld, Joerg/0000-0003-1478-3248	Telethon [GGP06225] Funding Source: Medline	Telethon(Fondazione Telethon)		Bentzinger CF, 2005, FASEB J, V19, P934, DOI 10.1096/fj.04-3376com; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; Bezakova G, 2001, J CELL BIOL, V153, P1441, DOI 10.1083/jcb.153.7.1441; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgess RW, 2000, J CELL BIOL, V151, P41, DOI 10.1083/jcb.151.1.41; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; Cohen I, 1997, MOL CELL NEUROSCI, V9, P237, DOI 10.1006/mcne.1997.0623; Cornish T, 1999, J CELL SCI, V112, P1213; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; Denzer AJ, 1998, EMBO J, V17, P335, DOI 10.1093/emboj/17.2.335; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Hoover CL, 2003, J CELL BIOL, V161, P923, DOI 10.1083/jcb.200301013; Hopf C, 1996, J BIOL CHEM, V271, P5231; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jones G, 1997, P NATL ACAD SCI USA, V94, P2654, DOI 10.1073/pnas.94.6.2654; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Mascarenhas JB, 2003, EMBO J, V22, P529, DOI 10.1093/emboj/cdg041; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Meier T, 1997, J NEUROSCI, V17, P6534; Meier T, 1998, EUR J NEUROSCI, V10, P3141, DOI 10.1046/j.1460-9568.1998.00320.x; Moll J, 2001, NATURE, V413, P302, DOI 10.1038/35095054; Neumann FR, 2001, MOL CELL NEUROSCI, V17, P208, DOI 10.1006/mcne.2000.0932; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; Qiao CP, 2005, P NATL ACAD SCI USA, V102, P11999, DOI 10.1073/pnas.0502137102; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sasaki T, 2002, J BIOL CHEM, V277, P44164, DOI 10.1074/jbc.M207340200; Stetefeld J, 2005, TRENDS BIOCHEM SCI, V30, P515, DOI 10.1016/j.tibs.2005.07.001; Stetefeld J, 2004, STRUCTURE, V12, P503, DOI 10.1016/j.str.2004.02.001; STONE DM, 1995, J NEUROSCI, V15, P6767; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; Tseng CN, 2003, J BIOL CHEM, V278, P17236, DOI 10.1074/jbc.M300282200; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1	60	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36835	36845		10.1074/jbc.M607887200	http://dx.doi.org/10.1074/jbc.M607887200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17012237	Green Published, hybrid			2022-12-25	WOS:000242220800042
J	Su, XF; Li, QN; Shrestha, K; Cormet-Boyaka, E; Chen, L; Smith, PR; Sorscher, EJ; Benos, DJ; Matalon, S; Ji, HL				Su, Xuefeng; Li, Qingnan; Shrestha, Kedar; Cormet-Boyaka, Estelle; Chen, Lan; Smith, Peter R.; Sorscher, Eric J.; Benos, Dale J.; Matalon, Sadis; Ji, Hong-Long			Interregulation of proton-gated Na+ channel 3 and cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; SENSING ION CHANNELS; XENOPUS OOCYTES; MOLECULAR-CLONING; AIRWAY EPITHELIA; OBSTRUCTIVE AZOOSPERMIA; FUNCTIONAL INTERACTIONS; FLUID TRANSPORT; CATION CHANNELS; CL-CONDUCTANCE	Proton-gated Na+ channels (ASIC) are new members of the epithelial sodium channel/degenerin gene family. ASIC3 mRNA has been detected in the homogenate of pulmonary tissues. However, whether ASIC3 is expressed in the apical membranes of lung epithelial cells and whether it regulates cystic fibrosis transmembrane conductance regulator (CFTR) function are not known at the present time. Using reverse transcription-PCR, we found that the ASIC3 mRNA was expressed in the human airway mucosal gland (Calu-3) and human airway epithelial (16HBE14o) cells. Indirect immunofluorescence microscopy revealed that ASIC3 was co-segregated with CFTR in the apical membranes of Calu-3 cells. Proton-gated, amiloride-sensitive short circuit Na+ currents were recorded across Calu-3 monolayers mounted in an Ussing chamber. In whole-cell patch clamp studies, activation of CFTR channels with cAMP reduced proton-gated Na+ current in Calu-3 cells from -154 +/- 28 to -33 +/- 16 pA (n = 5, p < 0.05) at -100 mV. On the other hand, cAMP-activated CFTR activity was significantly inhibited following constitutive activation of putative ASIC3 at pH 6.0. Immunoassays showed that both ASIC3 and CFTR proteins were expressed and co-immunoprecipitated mutually in Calu-3 cells. Similar results were obtained in human embryonic kidney 293T cells following transient co-transfection of ASIC3 and CFTR. Our results indicate that putative CFTR and ASIC3 channels functionally interact with each other, possibly via an intermolecular association. Because acidic luminal fluid in the cystic fibrosis airway and lung tends to stimulate ASIC3 channel expression and activity, the interaction of ASIC3 and CFTR may contribute to defective salt and fluid transepithelial transport in the cystic fibrotic pulmonary system.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35205 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35205 USA; Univ Alabama, Dept Physiol, Birmingham, AL 35205 USA; Univ Alabama, Dept Biophys, Birmingham, AL 35205 USA; Univ Alabama, Dept Med, Birmingham, AL 35205 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ji, HL (corresponding author), Univ Alabama, Dept Anesthesiol, 901 19th St S,232 BMR2, Birmingham, AL 35205 USA.	hlji@uab.edu	Cormet-Boyaka, Estelle/H-5624-2011; JI, HONGLONG/N-7822-2014	JI, HONGLONG/0000-0002-3228-7144; Sorscher, Eric J./0000-0001-9341-3354	NHLBI NIH HHS [HL31197, HL51173] Funding Source: Medline; NIDDK NIH HHS [DK054781, DK56596, DK53090, DK37206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031197, R01HL031197, R01HL051173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK053090, P30DK054781, R56DK037206, R01DK056596, R01DK037206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; Bertog M, 2000, AM J PHYSIOL-CELL PH, V278, pC885, DOI 10.1152/ajpcell.2000.278.5.C885; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248, DOI 10.1152/ajplung.2000.278.6.L1248; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Boucherot A, 2001, BBA-BIOMEMBRANES, V1515, P64, DOI 10.1016/S0005-2736(01)00396-0; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; DeCoursey TE, 2000, AM J PHYSIOL-CELL PH, V278, pC1, DOI 10.1152/ajpcell.2000.278.1.C1; Donaldson Scott H, 2002, Methods Mol Med, V70, P343; Ecke D, 1996, PFLUG ARCH EUR J PHY, V431, P984, DOI 10.1007/s004240050095; Freedman SD, 1998, EUR J CELL BIOL, V75, P153, DOI 10.1016/S0171-9335(98)80057-5; Freedman SD, 2001, GASTROENTEROLOGY, V121, P950, DOI 10.1053/gast.2001.27992; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Gitterman DP, 2005, J PHYSIOL-LONDON, V562, P759, DOI 10.1113/jphysiol.2004.075069; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hardiman KA, 2004, AM J RESP CELL MOL, V30, P720, DOI 10.1165/rcmb.2003-0325OC; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Inglis SK, 2002, J PHYSIOL-LONDON, V538, P527, DOI 10.1113/jphysiol.2001.012806; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Ji HL, 2006, J BIOL CHEM, V281, P8233, DOI 10.1074/jbc.M512293200; Ji HL, 2004, J BIOL CHEM, V279, P26939, DOI 10.1074/jbc.M401143200; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; Joo N S, 2001, JOP, V2, P280; Joo NS, 2006, J BIOL CHEM, V281, P7392, DOI 10.1074/jbc.M512766200; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; Konstas AA, 2003, PFLUG ARCH EUR J PHY, V445, P513, DOI 10.1007/s00424-002-0957-z; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Krouse ME, 2004, AM J PHYSIOL-LUNG C, V287, pL1274, DOI 10.1152/ajplung.00036.2004; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 2003, PFLUG ARCH EUR J PHY, V445, P504, DOI 10.1007/s00424-002-0958-y; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Leung GPH, 2001, BIOL REPROD, V64, P1509, DOI 10.1093/biolreprod/64.5.1509; Mall M, 1999, AM J PHYSIOL-GASTR L, V277, pG709, DOI 10.1152/ajpgi.1999.277.3.G709; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Mamet J, 2002, J NEUROSCI, V22, P10662; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Ojoo JC, 2005, THORAX, V60, P22, DOI 10.1136/thx.2003.017327; Peracchia C, 2004, BBA-BIOMEMBRANES, V1662, P61, DOI 10.1016/j.bbamem.2003.10.020; Reddy MM, 1998, AM J PHYSIOL-CELL PH, V275, pC1040, DOI 10.1152/ajpcell.1998.275.4.C1040; ROBINSON PJ, 1990, DIGEST DIS SCI, V35, P1299, DOI 10.1007/BF01536423; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Sherry AM, 1997, AM J PHYSIOL-CELL PH, V273, pC384, DOI 10.1152/ajpcell.1997.273.2.C384; SNGH M, 1997, AM J PHYSIOL, V272, pL690; Song YL, 2006, AM J PHYSIOL-CELL PH, V290, pC741, DOI 10.1152/ajpcell.00379.2005; Stroffekova K, 1998, AM J PHYSIOL-CELL PH, V275, pC1113, DOI 10.1152/ajpcell.1998.275.4.C1113; Suaud L, 2002, J BIOL CHEM, V277, P8928, DOI 10.1074/jbc.M111482200; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; von Eckardstein S, 2000, FERTIL STERIL, V73, P1226, DOI 10.1016/S0015-0282(00)00516-1; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wong CH, 1999, RESP MED, V93, P58, DOI 10.1016/S0954-6111(99)90078-1; WONG PYD, 1990, REPROD FERT DEVELOP, V2, P115, DOI 10.1071/RD9900115; Yan WS, 2004, J BIOL CHEM, V279, P23183, DOI 10.1074/jbc.M402373200; Zhang YL, 1996, AM J PHYSIOL-CELL PH, V270, pC1326, DOI 10.1152/ajpcell.1996.270.5.C1326	63	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36960	36968		10.1074/jbc.M608002200	http://dx.doi.org/10.1074/jbc.M608002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17012229	hybrid			2022-12-25	WOS:000242220800056
J	Ohtsuki, M; Taketomi, Y; Arata, S; Masuda, S; Ishikawa, Y; Ishii, T; Takanezawa, Y; Aoki, J; Arai, H; Yamamoto, K; Kudo, I; Murakami, M				Ohtsuki, Mitsuhiro; Taketomi, Yoshitaka; Arata, Satoru; Masuda, Seiko; Ishikawa, Yukio; Ishii, Toshiharu; Takanezawa, Yasukazu; Aoki, Junken; Arai, Hiroyuki; Yamamoto, Kei; Kudo, Ichiro; Murakami, Makoto			Transgenic expression of group V, but not group X, secreted phospholipase A(2) in mice leads to neonatal lethality because of lung dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; SURFACTANT PROTEIN-A; FATAL RESPIRATORY-DISTRESS; GROUP-IIA; A(2) ENZYMES; GROUP-XII; TARGETED DISRUPTION; GROUP-I; BACTERICIDAL PROPERTIES; PULMONARY INFLAMMATION	In an effort to elucidate the functions of secreted phospholipase A(2) (sPLA(2)) enzymes in vivo, we generated transgenic (Tg) mice for group V sPLA(2) (sPLA(2)-V) and group X sPLA(2) ( sPLA(2)X), which act potently on phosphatidylcholine in vitro. We found that sPLA(2)-V Tg mice died in the neonatal period because of respiratory failure. The lungs of sPLA(2)-V Tg mice exhibited atelectasis with thickened alveolar walls and narrow air spaces, accompanied by infiltration of macrophages and only modest changes in eicosanoid levels. This severe pulmonary defect in sPLA(2)-V Tg mice was attributable to marked reduction of the lung surfactant phospholipids, phosphatidylcholine and phosphatidylglycerol. Given that the expression of sPLA(2)-V is greatly elevated in human lungs with severe inflammation, our present results raise the intriguing possibility that this isozyme may contribute to ongoing surfactant hydrolysis often observed in the lungs of patients with respiratory distress syndrome. In contrast, sPLA(2)-X Tg neonates displayed minimal abnormality of the respiratory tract with normal alveolar architecture and surfactant composition. This unexpected result was likely because sPLA(2)-X protein existed as an inactive zymogen in most tissues. The active form of sPLA(2)-X was detected in tissues with inflammatory granulation in sPLA(2)-X Tg mice. These results suggest that sPLA(2)-X mostly remains inactive under physiological conditions and that its proteolytic activation occurs during inflammation or other as yet unidentified circumstances in vivo.	Showa Univ, Dept Hlth Chem, Sch Pharmaceut Sci, Shinagawa Ku, Tokyo 1428555, Japan; Tokyo Metropolitan Inst Med Sci, Biomembrane Signaling Project, Bunkyo Ku, Tokyo 1138613, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Soc Promot Sci, Tokyo 1028472, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Japan Society for the Promotion of Science	Murakami, M (corresponding author), Showa Univ, Dept Hlth Chem, Sch Pharmaceut Sci, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	mako@rinshoken.or.jp		Takanezawa, Yasukazu/0000-0002-9220-5825; Aoki, Junken/0000-0001-9435-1896				Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Balestrieri B, 2006, J BIOL CHEM, V281, P6691, DOI 10.1074/jbc.M508314200; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; BENNETT CF, 1990, BIOCHIM BIOPHYS ACTA, V1047, P271, DOI 10.1016/0005-2760(90)90526-4; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chabot S, 2003, J IMMUNOL, V171, P995, DOI 10.4049/jimmunol.171.2.995; Chang R, 1998, BBA-BIOMEMBRANES, V1371, P254, DOI 10.1016/S0005-2736(98)00031-5; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cheong N, 2006, J BIOL CHEM, V281, P9791, DOI 10.1074/jbc.M507515200; Chiba H, 2004, J BIOL CHEM, V279, P12890, DOI 10.1074/jbc.M305801200; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Conkright JJ, 2002, AM J RESP CELL MOL, V26, P85, DOI 10.1165/ajrcmb.26.1.4686; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Fisher AB, 2005, J LIPID RES, V46, P1248, DOI 10.1194/jlr.M400499-JLR200; Fox N, 1996, EUR J PHARMACOL, V308, P195, DOI 10.1016/0014-2999(96)00257-9; Furue S, 2001, CRIT CARE MED, V29, P719, DOI 10.1097/00003246-200104000-00004; GAFFNEY E, 1994, LAB METHODS HISTOTEC, P151; Gong MN, 2004, CHEST, V125, P203, DOI 10.1378/chest.125.1.203; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; Gronroos JO, 2001, J IMMUNOL, V166, P4029, DOI 10.4049/jimmunol.166.6.4029; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Han RNN, 2004, CIRC RES, V94, P1115, DOI 10.1161/01.RES.0000125624.85852.1E; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hiraoka M, 2006, MOL CELL BIOL, V26, P6139, DOI 10.1128/MCB.00627-06; Hite RD, 1998, AM J PHYSIOL-LUNG C, V275, pL740, DOI 10.1152/ajplung.1998.275.4.L740; HITE RD, 2005, AM J PHYSIOL, V288, P6618; HOLM BA, 1991, J APPL PHYSIOL, V71, P317, DOI 10.1152/jappl.1991.71.1.317; Huggins KW, 2002, AM J PHYSIOL-ENDOC M, V283, pE994, DOI 10.1152/ajpendo.00110.2002; Hurt-Camejo E, 2001, CIRC RES, V89, P298, DOI 10.1161/hh1601.095598; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kido T, 2005, DEV GROWTH DIFFER, V47, P15, DOI 10.1111/j.1440-169x.2004.00775.x; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koizumi H, 2003, J BIOL CHEM, V278, P12489, DOI 10.1074/jbc.M211836200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kuwaki T, 1996, AM J PHYSIOL-REG I, V270, pR1279, DOI 10.1152/ajpregu.1996.270.6.R1279; Labonte ED, 2006, DIABETES, V55, P935, DOI 10.2337/diabetes.55.04.06.db05-1286; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mancuso DJ, 2003, J BIOL CHEM, V278, P22231, DOI 10.1074/jbc.C300033200; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Masuda S, 2005, BBA-MOL CELL BIOL L, V1736, P200, DOI 10.1016/j.bbalip.2005.08.014; Masuda S, 2005, J BIOL CHEM, V280, P23203, DOI 10.1074/jbc.M500985200; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Masuda S, 2004, BBA-MOL CELL BIOL L, V1686, P61, DOI 10.1016/j.bbalip.2004.08.017; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Munoz-Sanjuan I, 2005, MOL CELL BIOL, V25, P3608, DOI 10.1128/MCB.25.9.3608-3619.2005; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Nag K, 1999, AM J PHYSIOL-LUNG C, V277, pL1179, DOI 10.1152/ajplung.1999.277.6.L1179; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; NAKANO T, 1994, BIOCHEM BIOPH RES CO, V198, P10, DOI 10.1006/bbrc.1994.1002; Ni Z, 2006, J BIOL CHEM, V281, P16245, DOI 10.1074/jbc.M513874200; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Pal P, 2006, HUM GENET, V120, P187, DOI 10.1007/s00439-006-0204-3; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Riffo MS, 1996, J EXP ZOOL, V275, P459, DOI 10.1002/(SICI)1097-010X(19960815)275:6&lt;459::AID-JEZ8&gt;3.0.CO;2-N; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; Rosengren B, 2006, ARTERIOSCL THROM VAS, V26, P1579, DOI 10.1161/01.ATV.0000221231.56617.67; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; Seeds MC, 2000, AM J RESP CELL MOL, V23, P37, DOI 10.1165/ajrcmb.23.1.4034; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Taube C, 2006, J IMMUNOL, V176, P3157, DOI 10.4049/jimmunol.176.5.3157; Touqui L, 1999, MOL MED TODAY, V5, P244, DOI 10.1016/S1357-4310(99)01470-7; TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Wan HJ, 2004, P NATL ACAD SCI USA, V101, P14449, DOI 10.1073/pnas.0404424101; Wang Z, 2003, AM J PHYSIOL-LUNG C, V285, pL550, DOI 10.1152/ajplung.00346.2002; Webb NR, 2003, ARTERIOSCL THROM VAS, V23, P263, DOI 10.1161/01.ATV.0000051701.90972.E5; Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399; Wijewickrama GT, 2006, J BIOL CHEM, V281, P10935, DOI 10.1074/jbc.M512657200; WU Y, 2002, AM J PHYSIOL, V282, P6743; Wu YZ, 2003, AM J RESP CRIT CARE, V168, P692, DOI 10.1164/rccm.200304-467OC	96	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36420	36433		10.1074/jbc.M607975200	http://dx.doi.org/10.1074/jbc.M607975200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008322	hybrid			2022-12-25	WOS:000242100500093
J	Pieck, JC; Hennecke, U; Pierik, AJ; Friedel, MG; Carell, T				Pieck, J. Carsten; Hennecke, Ulrich; Pierik, Antonio J.; Friedel, Marcus G.; Carell, Thomas			Characterization of a new thermophilic spore photoproduct lyase from geobacillus stearothermophilus (SplG) with defined lesion containing DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; IRON-SULFUR CLUSTERS; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; BIOTIN SYNTHASE; REPAIR ENZYME; ACID; PHOTOCHEMISTRY; RESISTANCE	The Geobacillus stearothermophilus splG gene encodes a thermophilic spore photoproduct lyase (SplG) that belongs to the family of radical S-adenosylmethionine ( AdoMet) enzymes. The aerobically purified apo-SplG forms a homodimer, which contains one [4Fe-4S] cluster per monomer unit after reconstitution to the holoform. Formation of the [4Fe-4S] cluster was proven by quantification of the amount of iron and sulfur per homodimer and by UV and EPR spectroscopy. The UV spectrum features a characteristic absorbance at 420 nm typical for [4Fe-4S] clusters, and the EPR data were found to be identical to those of other proteins containing an[4Fe-4S](+) center. Probing of the activity of the holo-SplG with oligonucleotides containing one spore photoproduct lesion at a defined site proved that the enzyme is able to turn over substrate. In addition to repair, we observed cleavage of AdoMet to generate 5'-deoxyadenosine. In the presence of aza-AdoMet the SplG is completely inhibited, which provides direct support for the repair mechanism.	Univ Munich, Dept Chem & Biochem, D-81377 Munich, Germany; Univ Marburg, Dept Microbiol, D-35032 Marburg, Germany	University of Munich; Philipps University Marburg	Carell, T (corresponding author), Univ Munich, Dept Chem & Biochem, Butenandtstr 5-13, D-81377 Munich, Germany.	thomas.carell@cup.uni-muenchen.de	Pierik, Antonio J/G-1108-2010; Hennecke, Ulrich/A-7723-2010; Carell, Thomas/G-4799-2012	Pierik, Antonio J/0000-0002-1509-6370; Hennecke, Ulrich/0000-0002-4904-6793; Carell, Thomas/0000-0001-7898-2831				Becker A, 1999, NAT STRUCT BIOL, V6, P969; BEINERT H, 1982, BIOCHIM BIOPHYS ACTA, V683, P245, DOI 10.1016/0304-4173(82)90003-9; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Devine DA, 2001, J APPL MICROBIOL, V91, P786, DOI 10.1046/j.1365-2672.2001.01438.x; DONNELLAN JE, 1968, BIOPHYS J, V8, P17, DOI 10.1016/S0006-3495(68)86471-9; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Douki T, 2005, PHOTOCH PHOTOBIO SCI, V4, P591, DOI 10.1039/b503771a; Douki T, 2005, PHOTOCHEM PHOTOBIOL, V81, P163, DOI 10.1562/2004-08-18-RA-278.1; Douki T, 2003, PHOTOCH PHOTOBIO SCI, V2, P433, DOI 10.1039/b300173c; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Fajardo-Cavazos P, 2005, CURR MICROBIOL, V51, P331, DOI 10.1007/s00284-005-0052-8; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; Friedel MG, 2006, CHEM COMMUN, P445, DOI 10.1039/b514103f; GERHARDT P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P43; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; Imai T, 2001, J BIOCHEM, V130, P649, DOI 10.1093/oxfordjournals.jbchem.a003030; JACKSON RFW, 1998, J CHEM SOC P1, V12, P1903; Jakimowicz P, 2005, J BIOL CHEM, V280, P8309, DOI 10.1074/jbc.M412622200; Jarrett JT, 2005, ARCH BIOCHEM BIOPHYS, V433, P312, DOI 10.1016/j.abb.2004.10.003; KING TE, 1967, METHOD ENZYMOL, V10, P634; Mehl RA, 1999, ORG LETT, V1, P1065, DOI 10.1021/ol9908676; MUNAKATA N, 1974, MOL GEN GENET, V130, P239, DOI 10.1007/BF00268802; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; NICHOLSON WL, 1990, J BACTERIOL, V172, P6900, DOI 10.1128/jb.172.12.6900-6906.1990; NICHOLSON WL, 1991, P NATL ACAD SCI USA, V88, P8288, DOI 10.1073/pnas.88.19.8288; NICHOLSON WL, 1995, J CELL BIOCHEM, P275; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; Penna TCV, 2002, APPL BIOCHEM BIOTECH, V98, P525, DOI 10.1385/ABAB:98-100:1-9:525; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; Rebeil R, 1998, J BACTERIOL, V180, P4879, DOI 10.1128/JB.180.18.4879-4885.1998; Sambrook J., 2001, MOL CLONING LAB MANU, P1, DOI DOI 10.1002/HUMU.1186.ABS; Setlow P., 1988, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V5, P253; Setlow P, 2001, ENVIRON MOL MUTAGEN, V38, P97, DOI 10.1002/em.1058; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Thompson MJ, 1999, J ORG CHEM, V64, P7467, DOI 10.1021/jo9907742; Ugulava NB, 2000, BIOCHEMISTRY-US, V39, P5206, DOI 10.1021/bi9926227; Voegtli WC, 2001, P NATL ACAD SCI USA, V98, P10073, DOI 10.1073/pnas.181336398; Vreeland RH, 2000, NATURE, V407, P897, DOI 10.1038/35038060; Yang MM, 2004, J ORG CHEM, V69, P3993, DOI 10.1021/jo040119g	46	33	34	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36317	36326		10.1074/jbc.M607053200	http://dx.doi.org/10.1074/jbc.M607053200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16968710	hybrid			2022-12-25	WOS:000242100500083
J	Shin, EY; Lee, CS; Cho, TG; Kim, YG; Song, S; Juhnn, YS; Park, SC; Manser, E; Kim, EG				Shin, Eun-Young; Lee, Chan-Soo; Cho, Tae Goo; Kim, Young Gyu; Song, Sukgil; Juhnn, Yong-Sung; Park, Sang Chul; Manser, Ed; Kim, Eung-Gook			beta Pak-interacting exchange factor-mediated Rac1 activation requires smgGDS guanine nucleotide exchange factor in basic fibroblast growth factor-induced neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; ACTIN CYTOSKELETON; DEPENDENT PATHWAY; PC12 CELLS; PROTEIN; PIX; FAMILY; MEMBRANE; BINDING; KINASE	Neuritogenesis requires active actin cytoskeleton rearrangement in which Rho GTPases play a pivotal role. In a previous study ( Shin, E. Y., Woo, K. N., Lee, C. S., Koo, S. H., Kim, Y. G., Kim, W. J., Bae, C. D., Chang, S. I., and Kim, E. G. ( 2004) J. Biol. Chem. 279, 1994-2004), we demonstrated that beta Pak-interacting exchange factor (beta PIX) guanine nucleotide exchange factor (GEF) mediates basic fibroblast growth factor (bFGF)-stimulated Rac1 activation through phosphorylation of Ser-525 and Thr-526 at the GIT-binding domain (GBD). However, the mechanism by which this phosphorylation event regulates the Rac1-GEF activity remained elusive. We show here that beta PIX binds to Rac1 via the GBD and also activates the GTPase via an associated GEF, smgGDS, in a phosphorylation-dependent manner. Notably, the Rac1-GEF activity of beta PIX persisted for an extended period of time following bFGF stimulation, unlike other Rho GEFs containing the Dbl homology domain. We demonstrate that C-PIX, containing proline-rich, GBD, and leucine zipper domains can interact with Rac1 via the GBD in vitro and in vivo and also mediated bFGF-stimulated Rac1 activation, as determined by a modified GEF assay and fluorescence resonance energy transfer analysis. However, nonphosphorylatable C-PIX ( S525A/T526A)failed to generate Rac1-GTP. Finally, beta PIX is shown to form a trimeric complex with smgGDS and Rac1; down-regulation of smgGDS expression by short interfering RNA causing significant inhibition of beta PIX-mediated Rac1 activation and neurite outgrowth. These results provide evidence for a new and unexpected mechanism whereby beta PIX can regulate Rac1 activity.	Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Coll Med, Dept Neurosurg, Cheongju 361763, South Korea; Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110799, South Korea; GlaxoSmithKline Inc, Inst Mol & Cell Biol Grp, Inst Mol & Cell Biol, Singapore 138973, Singapore	Chungbuk National University; Chungbuk National University; Chungbuk National University; Seoul National University (SNU); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline	Kim, EG (corresponding author), Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju 361763, South Korea.	egkim@chungbuk.ac.kr	Juhnn, Yong-Sung/J-2790-2012; Manser, Edward/ABD-2301-2020					Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Aoki K, 2004, J BIOL CHEM, V279, P713, DOI 10.1074/jbc.M306382200; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Baird D, 2005, CURR BIOL, V15, P1, DOI 10.1016/j.cub.2004.12.040; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Chahdi A, 2005, J BIOL CHEM, V280, P578, DOI 10.1074/jbc.M411130200; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Fleming IN, 2004, BIOCHEM J, V382, P857, DOI 10.1042/BJ20040916; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heo J, 2005, BIOCHEMISTRY-US, V44, P6573, DOI 10.1021/bi047443q; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Koh CG, 2001, J CELL SCI, V114, P4239; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Santy LC, 2005, CURR BIOL, V15, P1749, DOI 10.1016/j.cub.2005.08.052; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Takakura A, 2000, MOL BIOL CELL, V11, P1875, DOI 10.1091/mbc.11.5.1875; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vikis HG, 2002, ONCOGENE, V21, P2425, DOI 10.1038/sj.onc.1205306; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	41	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35954	35964		10.1074/jbc.M602399200	http://dx.doi.org/10.1074/jbc.M602399200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16954223	hybrid			2022-12-25	WOS:000242100500042
J	Sidorova, NY; Muradymov, S; Rau, DC				Sidorova, Nina Y.; Muradymov, Shakir; Rau, Donald C.			Differences in hydration coupled to specific and nonspecific competitive binding and to specific DNA binding of the restriction endonuclease BamHI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL HYDRATION; OSMOTIC-STRESS; WATER RELEASE; MACROMOLECULAR HYDRATION; PROTEIN STABILITY; RECOGNITION SITE; ECORI; COMPLEXES; REPRESSOR; EXCLUSION	Using the osmotic stress technique together with a self-cleavage assay we measure directly differences in sequestered water between specific and nonspecific DNA-BamHI complexes as well as the numbers of water molecules released coupled to specific complex formation. The difference between specific and nonspecific binding free energy of the BamHI scales linearly with solute osmolal concentration for seven neutral solutes used to set water activity. The observed osmotic dependence indicates that the nonspecific DNA-BamHI complex sequesters some 120-150 more water molecules than the specific complex. The weak sensitivity of the difference in number of waters to the solute identity suggests that these waters are sterically inaccessible to solutes. This result is in close agreement with differences in the structures determined by x-ray crystallography. We demonstrate additionally that when the same solutes that were used in competition experiments are used to probe changes accompanying the binding of free BamHI to its specific DNA sequence, the measured number of water molecules released in the binding process is strikingly solute-dependent ( with up to 10-fold difference between solutes). This result is expected for reactions resulting in a large change in a surface exposed	NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Sidorova, NY (corresponding author), Bldg 9,Rm 1E-108, Bethesda, MD 20892 USA.	sidorova@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008747, ZIAHD008811] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008811, Z01HD008747] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Auton M, 2005, P NATL ACAD SCI USA, V102, P15065, DOI 10.1073/pnas.0507053102; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; Chik J, 2005, J PHYS CHEM B, V109, P9111, DOI 10.1021/jp046999k; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; Davis-Searles PR, 2001, ANNU REV BIOPH BIOM, V30, P271, DOI 10.1146/annurev.biophys.30.1.271; Davis-Searles PR, 1998, BIOCHEMISTRY-US, V37, P17048, DOI 10.1021/bi981364v; Engler LE, 2001, J MOL BIOL, V307, P619, DOI 10.1006/jmbi.2000.4428; Fried MG, 2002, J BIOL CHEM, V277, P50676, DOI 10.1074/jbc.M208540200; GARNER MM, 1995, EMBO J, V14, P1257, DOI 10.1002/j.1460-2075.1995.tb07109.x; HONG J, 2005, BIOCHEM, P16896; Hultgren A, 2004, BIOCHEMISTRY-US, V43, P8272, DOI 10.1021/bi049559s; Khrapunov S, 2004, BIOPHYS J, V86, P371, DOI 10.1016/S0006-3495(04)74113-2; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; Kontur WS, 2006, BIOCHEMISTRY-US, V45, P2161, DOI 10.1021/bi051835v; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; Levy Y, 2006, ANNU REV BIOPH BIOM, V35, P389, DOI 10.1146/annurev.biophys.35.040405.102134; Li LK, 1997, BIOCHEMISTRY-US, V36, P7003, DOI 10.1021/bi962966m; Lundback T, 1998, J MOL BIOL, V276, P775, DOI 10.1006/jmbi.1997.1558; Lynch TW, 2000, J BIOL CHEM, V275, P30561, DOI 10.1074/jbc.M000266200; MAURICIO L, 2004, J BIOL CHEM, V279, P47968; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; Minton AP, 1998, METHOD ENZYMOL, V295, P127; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Poon J, 1997, BIOPHYS J, V73, P3257, DOI 10.1016/S0006-3495(97)78350-4; Rau DC, 2006, J MOL BIOL, V361, P352, DOI 10.1016/j.jmb.2006.06.036; Robinson CR, 1996, PROTEIN SCI, V5, P2119, DOI 10.1002/pro.5560051019; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P2186, DOI 10.1073/pnas.95.5.2186; Sidorova NY, 2005, NUCLEIC ACIDS RES, V33, P5145, DOI 10.1093/nar/gki808; Sidorova NY, 2004, BIOPHYS J, V87, P2564, DOI 10.1529/biophysj.104.042390; Sidorova NY, 1996, P NATL ACAD SCI USA, V93, P12272, DOI 10.1073/pnas.93.22.12272; Sidorova NY, 2001, J MOL BIOL, V310, P801, DOI 10.1006/jmbi.2001.4781; Stanley C, 2006, BIOPHYS J, V91, P912, DOI 10.1529/biophysj.106.086579; Swaminathan CP, 2002, J BIOL CHEM, V277, P4042, DOI 10.1074/jbc.M109237200; Timasheff SN, 2002, BIOCHEMISTRY-US, V41, P13473, DOI 10.1021/bi020316e; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; Vossen KM, 1997, BIOCHEMISTRY-US, V36, P11640, DOI 10.1021/bi971193e; Wenner JR, 1999, ANAL BIOCHEM, V268, P201, DOI 10.1006/abio.1998.3079; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0	43	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35656	35666		10.1074/jbc.M608018200	http://dx.doi.org/10.1074/jbc.M608018200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008319	hybrid			2022-12-25	WOS:000242100500010
J	Zhang, Z; Tavis, JE				Zhang, Zhian; Tavis, John E.			The duck hepatitis B virus reverse transcriptase functions as a full-length monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GENE-PRODUCT; DNA-POLYMERASE ACTIVITIES; CIS-ACTING SEQUENCES; PLUS-STRAND DNA; VIRAL-DNA; TYROSINE RESIDUE; POL GENE; RNA; REPLICATION; PARTICLES	Hepadnaviral reverse transcription occurs within cytoplasmic capsid particles and is catalyzed by a virally encoded reverse transcriptase, but the primary structure and multimeric state of the polymerase during reverse transcription are poorly understood. We measured these parameters for the duck hepatitis B virus polymerase employing active enzyme translated in vitro and derived from intracellular core particles and mature virions. In vitro-translated polymerase immunoprecipitated as a monomer, and polymerase molecules with complementary defects in the enzymatic active site and tyrosine 96, which primes DNA synthesis, could not complement or inhibit each other in priming assays. Western analysis using antibodies recognizing epitopes throughout the polymerase combined with nuclease digestion of permeabilized virion-derived capsid particles revealed that only full-length polymerase molecules were in virions and that they were all covalently attached to large DNA molecules. Because DNA synthesis is primed by the polymerase itself and only one copy of the viral DNA is in each capsid, the polymerase must function as an uncleaved monomer. Therefore, a single polymerase monomer is encapsidated, primes DNA synthesis, synthesizes both DNA strands, and participates in the three-strand transfers of DNA synthesis, with all steps after DNA priming performed while the polymerase is covalently coupled to the product DNA. Because the N-terminal domain of the polymerase is displaced from the active site on the same molecule by the viral DNA during reverse transcription, P must be structurally dynamic during DNA synthesis. Therefore, non-nucleoside compounds that interfere with this change may be novel antiviral agents.	St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Ctr Liver, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Tavis, JE (corresponding author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	tavisje@slu.edu			NIAID NIH HHS [AI38447] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038447, R01AI038447] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; BARTENSCHLAGER R, 1992, NUCLEIC ACIDS RES, V20, P195, DOI 10.1093/nar/20.2.195; BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; BAVAND M, 1989, J VIROL, V63, P1019, DOI 10.1128/JVI.63.2.1019-1021.1989; BAVAND MR, 1988, J VIROL, V62, P626, DOI 10.1128/JVI.62.2.626-628.1988; Beck J, 2001, J VIROL, V75, P7410, DOI 10.1128/JVI.75.16.7410-7419.2001; BENZAIR AB, 1982, J VIROL, V44, P720, DOI 10.1128/JVI.44.2.720-724.1982; BOSCH V, 1988, VIROLOGY, V166, P475, DOI 10.1016/0042-6822(88)90518-1; Cao F, 2005, J VIROL, V79, P10164, DOI 10.1128/JVI.79.16.10164-10170.2005; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHANG LJ, 1989, NATURE, V337, P364, DOI 10.1038/337364a0; CONDREAY LD, 1990, J VIROL, V64, P3249, DOI 10.1128/JVI.64.7.3249-3258.1990; Dryden KA, 2006, MOL CELL, V22, P843, DOI 10.1016/j.molcel.2006.04.025; GANEM D, 2001, FIELDS VIROLOGY, P2923; Gerelsaikhan T, 1996, J VIROL, V70, P4269, DOI 10.1128/JVI.70.7.4269-4274.1996; GOFF SP, 2001, FIELDS VIROLOGY, P1871; Havert MB, 1997, J VIROL, V71, P5336, DOI 10.1128/JVI.71.7.5336-5344.1997; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; Hollinger F.B., 2001, FIELDS VIROLOGY, P2971; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; Hottiger M, 1996, BIOL CHEM H-S, V377, P97; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2000, J VIROL, V74, P11447, DOI 10.1128/JVI.74.24.11447-11455.2000; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lanford RE, 1997, J VIROL, V71, P2996, DOI 10.1128/JVI.71.4.2996-3004.1997; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1993, REVERSE TRANSCRIPTAS, P163; Linial ML, 1999, J VIROL, V73, P1747, DOI 10.1128/JVI.73.3.1747-1755.1999; Liu N, 2004, J VIROL, V78, P642, DOI 10.1128/JVI.78.2.642-649.2004; MACK DH, 1988, J VIROL, V62, P4786, DOI 10.1128/JVI.62.12.4786-4790.1988; MORALEDA G, 1993, ANTIVIR RES, V20, P235, DOI 10.1016/0166-3542(93)90023-C; Oberhaus SM, 1996, VIROLOGY, V226, P132, DOI 10.1006/viro.1996.0636; OBERHAUS SM, 1993, J VIROL, V67, P6558, DOI 10.1128/JVI.67.11.6558-6566.1993; Park SG, 2001, J VIROL, V75, P6962, DOI 10.1128/JVI.75.15.6962-6968.2001; Perlman D, 2003, J VIROL, V77, P2287, DOI 10.1128/JVI.77.3.2287-2294.2003; Peters K, 2005, J VIROL, V79, P7005, DOI 10.1128/JVI.79.11.7005-7013.2005; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; RADZIWILL G, 1988, VIROLOGY, V163, P123, DOI 10.1016/0042-6822(88)90239-5; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; Shaw T, 2006, J HEPATOL, V44, P593, DOI 10.1016/j.jhep.2006.01.001; SHIN HJ, 1995, J BIOL CHEM, V270, P11047, DOI 10.1074/jbc.270.19.11047; SPRENGEL R, 1985, J MED VIROL, V15, P323, DOI 10.1002/jmv.1890150402; STAPRANS S, 1991, J VIROL, V65, P1255, DOI 10.1128/JVI.65.3.1255-1262.1991; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; Tavis JE, 1998, J VIROL, V72, P5789, DOI 10.1128/JVI.72.7.5789-5796.1998; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; WEBER M, 1994, J VIROL, V68, P2994, DOI 10.1128/JVI.68.5.2994-2999.1994; Wei Y, 1996, J VIROL, V70, P6455, DOI 10.1128/JVI.70.9.6455-6458.1996; WILSON W, 1988, CELL, V55, P1159, DOI 10.1016/0092-8674(88)90260-7; Yao EM, 2000, J VIROL, V74, P8648, DOI 10.1128/JVI.74.18.8648-8657.2000; Yu SF, 1996, SCIENCE, V271, P1579, DOI 10.1126/science.271.5255.1579; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	59	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35794	35801		10.1074/jbc.M608031200	http://dx.doi.org/10.1074/jbc.M608031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005569	hybrid			2022-12-25	WOS:000242100500026
J	Byun, HJ; Hong, IK; Kim, E; Jin, YJ; Jeoung, DI; Hahn, JH; Kim, YM; Park, SH; Lee, H				Byun, Hee-Jung; Hong, In-Kee; Kim, Eunsook; Jin, Young-June; Jeoung, Doo-Il; Hahn, Jang-Hee; Kim, Young-Myoung; Park, Seong Hoe; Lee, Hansoo			A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REED-STERNBERG PHENOTYPE; KAPPA-B ACTIVATION; PROTEIN-KINASE-B; GENE-EXPRESSION; TUMOR-CELLS; IN-VIVO; MONOCLONAL-ANTIBODY; CARCINOMA-CELLS; DOWN-REGULATION; IV COLLAGENASE	The CD99 gene encodes two distinct transmembrane proteins by alternative splicing of its transcript. To examine the effects of two CD99 isoforms on the invasive phenotypes of breast cancer cells, MDA-MB-231 and MCF-7 human breast cancer cell lines were stably transfected with CD99 cDNAs encoding the major wild-type form (type I) or a minor splice variant (type II). As a result, expression of CD99 type II, but not type I, markedly elevated the motility, binding to fibronectin, MMP-9 expression, and invasiveness of MDA-MB-231 and MCF-7 breast cancer cells. In MDA-MB-435 breast cancer cells expressing both CD99 type I and type II, invasion-related cellular activities were inhibited by the transfection of small interfering RNA (siRNA) targeted to CD99 type II. Meanwhile, CD99 type II-induced MMP-9 expression in MDA-MB-231 cells was shown to be mediated by the binding of AP-1 factors to the MMP-9 gene promoter. Gel shift assay revealed that ligation of CD99 type II with antibody resulted in the binding of JunD to the AP-1 site of the MMP-9 promoter region. Initiation of CD99 type II signaling by antibody ligation increased expression of JunD and FosB AP-1 factors, along with phosphorylation of Src, Akt, p38 MAPK, ERK, and JNK. Knockdown of JunD and FosB by siRNA transfection abolished the positive effects of CD99 type II on the motility and MMP-9 expression of MDA-MB-231 cells. Increased expression of JunD and FosB as well as elevated cell motility and MMP-9 expression by CD99 type II ligation were also abrogated by inhibitors, dominant-negative forms, and siRNAs for Akt1, ERK1/2, and JNK1 but not for p38 MAPK. These results suggest that expression of a splice variant of CD99 contributes to the invasive ability of human breast cancer cells by up-regulating AP-1-mediated gene expression through the Akt-dependent ERK and JNK signaling pathways.	Kangwon Natl Univ, Coll Nat Sci, Vasc Syst Res Ctr, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Coll Nat Sci, Div Life Sci, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Coll Med, Dept Anat, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Coll Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea	Kangwon National University; Kangwon National University; Kangwon National University; Kangwon National University; Seoul National University (SNU)	Lee, H (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Vasc Syst Res Ctr, Chunchon 200701, Kangwon Do, South Korea.	hslee@kangwon.ac.kr	Park, Seong Hoe/C-7353-2011					Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; ALBINI A, 1987, CANCER RES, V47, P3239; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Annabi B, 2004, J BIOL CHEM, V279, P21888, DOI 10.1074/jbc.M313694200; AUBRIT F, 1989, EUR J IMMUNOL, V19, P1431, DOI 10.1002/eji.1830190813; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BARSKY SH, 1983, LANCET, V1, P296; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bieche I, 2004, CLIN CANCER RES, V10, P6789, DOI 10.1158/1078-0432.CCR-04-0306; Bishnupuri KS, 2006, GASTROENTEROLOGY, V130, P137, DOI 10.1053/j.gastro.2005.10.001; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; Brown RE, 2003, ANN CLIN LAB SCI, V33, P131; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Choi FY, 1998, J IMMUNOL, V161, P749; CONNOLLY JM, 1993, CANCER LETT, V75, P137, DOI 10.1016/0304-3835(93)90198-I; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; DAVIES B, 1993, BRIT J CANCER, V67, P1126, DOI 10.1038/bjc.1993.207; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Dworzak MN, 2004, LEUKEMIA, V18, P703, DOI 10.1038/sj.leu.2403303; ELBAHASSI M, 2004, CLIN EXP METASTAS, V21, P293; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; GELIN C, 1991, EUR J IMMUNOL, V21, P715, DOI 10.1002/eji.1830210326; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P1561; Hah N, 2003, BIOCHEM BIOPH RES CO, V305, P428, DOI 10.1016/S0006-291X(03)00788-5; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hahn MJ, 2000, FEBS LETT, V470, P350, DOI 10.1016/S0014-5793(00)01330-2; HAMILTON G, 1988, CANCER RES, V48, P6127; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HOFMANN M, 1993, CANCER RES, V53, P1516; JAMAL HH, 1994, ONCOGENE, V9, P417; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Jung KC, 2002, J KOREAN MED SCI, V17, P483, DOI 10.3346/jkms.2002.17.4.483; Kasinrerk W, 2000, IMMUNOL LETT, V71, P33, DOI 10.1016/S0165-2478(99)00165-0; Kim HY, 2004, MOL CELLS, V18, P24; Kim SH, 1998, BLOOD, V92, P4287, DOI 10.1182/blood.V92.11.4287.423k41_4287_4295; Kim SH, 2000, BLOOD, V95, P294; Kim YI, 2003, BIOCHEM BIOPH RES CO, V307, P281, DOI 10.1016/S0006-291X(03)01195-1; KOVAR H, 1990, ONCOGENE, V5, P1067; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lee HJ, 2002, EXP MOL MED, V34, P177, DOI 10.1038/emm.2002.26; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; Lim SH, 1998, CANCER LETT, V133, P143, DOI 10.1016/S0304-3835(98)00219-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU XH, 1995, CANCER LETT, V92, P21, DOI 10.1016/0304-3835(95)03752-I; Maitra A, 2003, CLIN CANCER RES, V9, P5988; MAYER B, 1993, LANCET, V342, P1019, DOI 10.1016/0140-6736(93)92879-X; Milanezi F, 2001, HISTOPATHOLOGY, V39, P578, DOI 10.1046/j.1365-2559.2001.01309.x; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Na HJ, 2004, J IMMUNOL, V173, P1276, DOI 10.4049/jimmunol.173.2.1276; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Pelosi G, 2000, VIRCHOWS ARCH, V437, P270, DOI 10.1007/s004280000240; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PIROZZI G, 1994, CELL ADHES COMMUN, V2, P549, DOI 10.3109/15419069409014218; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; RAMANI P, 1993, HISTOPATHOLOGY, V23, P557, DOI 10.1111/j.1365-2559.1993.tb01243.x; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; SATO H, 1993, ONCOGENE, V8, P395; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Shen Q, 2003, J MAMMARY GLAND BIOL, V8, P45, DOI 10.1023/A:1025783221557; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THOMAS L, 1993, J INVEST DERMATOL, V100, P115, DOI 10.1111/1523-1747.ep12462776; Waclavicek M, 1998, J IMMUNOL, V161, P4671; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wingett D, 1999, CELL IMMUNOL, V193, P17, DOI 10.1006/cimm.1999.1470; Yoon SS, 2004, MOL CELLS, V18, P186; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; ZORN AM, 1992, DEV BIOL, V149, P197, DOI 10.1016/0012-1606(92)90276-M	88	85	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34833	34847		10.1074/jbc.M605483200	http://dx.doi.org/10.1074/jbc.M605483200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984917	hybrid			2022-12-25	WOS:000241933700016
J	Forneris, F; Binda, C; Dall'Aglio, A; Fraaije, MW; Battaglioli, E; Mattevi, A				Forneris, Federico; Binda, Claudia; Dall'Aglio, Annachiara; Fraaije, Marco W.; Battaglioli, Elena; Mattevi, Andrea			A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METHYLATION; CHROMATIN; H3K4ME3; OXIDASE	Human lysine-specific demethylase (LSD1) is a chromatin-modifying enzyme that specifically removes methyl groups from mono- and dimethylated Lys(4) of histone H3 (H3-K4). We used a combination of in vivo and in vitro experiments to characterize the substrate specificity and recognition by LSD1. Biochemical assays on histone peptides show that essentially all epigenetic modifications on the 21 N-terminal amino acids of histone H3 cause a significant reduction in enzymatic activity. Replacement of Lys(4) with Arg greatly enhances binding affinity, and a histone peptide incorporating this mutation has a strong inhibitory power. Conversely, a peptide bearing a trimethylated Lys(4) is only a weak inhibitor of the enzyme. Rapid kinetics measurements evidence that the enzyme is efficiently reoxidized by molecular oxygen with a second-order rate constant of 9.6 x 10(3) M-1 s(-1), and that the presence of the reaction product does not greatly influence the rate of flavin reoxidation. In vivo experiments provide a correlation between the in vitro inhibitory properties of the tested peptides and their ability of affecting endogenous LSD1 activity. Our results show that epigenetic modifications on histone H3 need to be removed before Lys4 demethylation can efficiently occur. The complex formed by LSD1 with histone deacetylases 1/2 may function as a "double-blade razor" that first eliminates the acetyl groups from acetylated Lys residues and then removes the methyl group from Lys4. We suggest that after H3-K4 demethylation, LSD1 recruits the forthcoming chromatin remodelers leading to the introduction of gene repression marks.	Univ Pavia, Dipartimento Gen & Microbiol, I-27100 Pavia, Italy; Univ Milan, Dipartimento Biol & Genet Sci Med, I-20133 Milan, Italy; Univ Groningen, Biochem Lab, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Pavia; University of Milan; University of Groningen	Mattevi, A (corresponding author), Univ Pavia, Dipartimento Gen & Microbiol, Via Ferrata 1, I-27100 Pavia, Italy.	mattevi@ipvgen.unipv.it	Forneris, Federico/AAL-5361-2020; Forneris, Federico/B-1145-2011; Mattevi, Andrea/R-4469-2019; Fraaije, Marco/E-8421-2014; mattevi, andrea/K-5464-2012; battaglioli, elena/H-9350-2017	Forneris, Federico/0000-0002-7818-1804; Forneris, Federico/0000-0002-7818-1804; Mattevi, Andrea/0000-0002-9523-7128; mattevi, andrea/0000-0002-9523-7128; Binda, Claudia/0000-0003-2038-9845; Fraaije, Marco/0000-0001-6346-5014; Battaglioli, Elena/0000-0001-9168-7212				Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; Biel M, 2005, ANGEW CHEM INT EDIT, V44, P3186, DOI 10.1002/anie.200461346; Chin HG, 2005, BIOCHEMISTRY-US, V44, P12998, DOI 10.1021/bi0509907; Culhane JC, 2006, J AM CHEM SOC, V128, P4536, DOI 10.1021/ja0602748; Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015; Forneris F, 2005, J BIOL CHEM, V280, P41360, DOI 10.1074/jbc.M509549200; Forneris F, 2006, ENZYMES, V24, P229, DOI 10.1016/S1874-6047(06)80010-7; Heinrichs A, 2006, NAT REV MOL CELL BIO, V7, P466, DOI 10.1038/nrm1967; Holbert MA, 2005, CURR OPIN STRUC BIOL, V15, P673, DOI 10.1016/j.sbi.2005.10.006; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Mattevi A, 2006, TRENDS BIOCHEM SCI, V31, P276, DOI 10.1016/j.tibs.2006.03.003; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Stavropoulos P, 2006, NAT STRUCT MOL BIOL, V13, P626, DOI 10.1038/nsmb1113; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Wysocka J, 2006, FRONT BIOSCI-LANDMRK, V11, P344, DOI 10.2741/1802; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012	25	100	108	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35289	35295		10.1074/jbc.M607411200	http://dx.doi.org/10.1074/jbc.M607411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987819	hybrid, Green Published			2022-12-25	WOS:000241933700063
J	Verzijl, D; Pardo, L; van Dijk, M; Gruijthuijsen, YK; Jongejan, A; Timmerman, H; Nicholas, J; Schwarz, M; Murphy, PM; Leurs, R; Smit, MJ				Verzijl, Dennis; Pardo, Leonardo; van Dijk, Marie; Gruijthuijsen, Yvonne K.; Jongejan, Aldo; Timmerman, Henk; Nicholas, John; Schwarz, Mario; Murphy, Philip M.; Leurs, Rob; Smit, Martine J.			Helix 8 of the viral chemokine receptor ORF74 directs chemokine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; KAPOSIS-SARCOMA; CONSTITUTIVE ACTIVITY; INVERSE AGONISTS; CARBOXYL-TERMINUS; CHARGED RESIDUES; ACTIVATION; RHODOPSIN; LIGAND; IDENTIFICATION	The constitutively active G-protein-coupled receptor and viral oncogene ORF74, encoded by Kaposi sarcoma-associated herpesvirus (human herpesvirus 8), binds a broad range of chemokines, including CXCL1 (agonist), CXCL8 ( neutral ligand), and CXCL10 (inverse agonist). Although chemokines interact with the extracellular N terminus and loops of the receptor, we demonstrate that helix 8 (Hx8) in the intracellular carboxyl tail (C-tail) of ORF74 directs chemokine binding. Partial deletion of the C-tail resulted in a phenotype with reduced constitutive activity but intact regulation by ligands. Complete deletion of the C-tail, including Hx8, resulted in an inactive phenotype that lacks CXCL8 binding sites and has an increased number of binding sites for CXCL10. Similar effects were obtained with the single R7.61(322)W or Q7.62(323)P mutations in Hx8. We propose that the conserved charged or polar side chain at position 7.61 has a specific role in stabilizing the end of transmembrane domain 7 (TM7). Disruption of Hx8 by deletion or mutation distorts an H-bonding network, involving highly conserved amino acids within TM2, TM7, and Hx8, that is crucial for positioning of the TM domains, coupling to G alpha q, and CXCL8 binding. Thus, Hx8 appears to exert a key role in receptor stabilization through the conserved residue R7.61, directing the ligand binding profile of ORF74 and likely also that of other class A G-protein-coupled receptors.	Vrije Univ Amsterdam, Div Med Chem, Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands; Univ Autonoma Barcelona, Fac Med, Unidad Bioestadist, Lab Med Computac, E-08193 Barcelona, Spain; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Med Microbiol, NL-6202 AZ Maastricht, Netherlands; Johns Hopkins Univ, Mol Virol Labs, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; NIAID, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Autonomous University of Barcelona; University of Barcelona; Maastricht University; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Smit, MJ (corresponding author), Vrije Univ Amsterdam, Div Med Chem, Leiden Amsterdam Ctr Drug Res, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	MJ.Smit@few.vu.nl	Leurs, Rob/ABB-4299-2021; Leurs, Rob/AAC-8508-2022; van Dijk, Marie/L-1901-2014	Leurs, Rob/0000-0003-1354-2848; Smit, Martine/0000-0003-2713-0238; van Dijk, Marie/0000-0003-1461-3441; Pardo, Leonardo/0000-0003-1778-7420; Verzijl, Dennis/0000-0002-7716-9838	NATIONAL CANCER INSTITUTE [R55CA076445, R01CA076445, P01CA113239, R21CA119887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000615] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA119887, P01 CA113239, CA119887, CA76445, CA113239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Deupi X, 2004, BIOPHYS J, V86, P105, DOI 10.1016/S0006-3495(04)74088-6; Fan GH, 2002, J BIOL CHEM, V277, P6590, DOI 10.1074/jbc.M110588200; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Jensen KK, 2005, J IMMUNOL, V174, P3686, DOI 10.4049/jimmunol.174.6.3686; Johnson MS, 2006, CELL SIGNAL, V18, P1793, DOI 10.1016/j.cellsig.2006.02.002; Jongejan A, 2005, NAT CHEM BIOL, V1, P98, DOI 10.1038/nchembio714; Kang DS, 2002, MOL PHARMACOL, V62, P281, DOI 10.1124/mol.62.2.281; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Liu CQ, 2004, J VIROL, V78, P2460, DOI 10.1128/JVI.78.5.2460-2471.2004; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Murphy PM, 2000, PHARMACOL REV, V52, P145; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Rosenkilde MM, 2004, J BIOL CHEM, V279, P32524, DOI 10.1074/jbc.M313392200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Santos N. M. D., 2006, J BIOL CHEM, V281, P12896; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Swift S, 2006, J BIOL CHEM, V281, P4109, DOI 10.1074/jbc.M509525200; Verzijl D, 2004, J VIROL, V78, P3343, DOI 10.1128/JVI.78.7.3343-3351.2004; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200	44	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35327	35335		10.1074/jbc.M606877200	http://dx.doi.org/10.1074/jbc.M606877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16997914	hybrid, Green Submitted			2022-12-25	WOS:000241933700067
J	Yi, L; Fang, J; Isik, N; Chim, J; Jin, T				Yi, Ling; Fang, Jun; Isik, Nilgun; Chim, Jimmy; Jin, Tian			HIV gp120-induced interaction between CD4 and CCR5 requires cholesterol-rich microenvironments revealed by live cell fluorescence resonance energy transfer imaging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTORS; T-CELLS; GP120; ENTRY; GLYCOPROTEIN; MICRODOMAINS; CORECEPTORS; INHIBITION; DYNAMICS	Binding of the human immunodeficiency virus (HIV) envelope gp120 glycoprotein to CD4 and CCR5 receptors on the plasma membrane initiates the viral entry process. Although plasma membrane cholesterol plays an important role in HIV entry, its modulating effect on the viral entry process is unclear. Using fluorescence resonance energy transfer imaging, we have provided evidence here that CD4 and CCR5 localize in different microenvironments on the surface of resting cells. Binding of the third variable region V3-containing gp120 core to CD4 and CCR5 induced association between these receptors, which could be directly monitored by fluorescence resonance energy transfer on the plasma membrane of live cells. Depletion of cholesterol from the plasma membrane abolished the gp120 core-induced associations between CD4 and CCR5, and reloading cholesterol restored the associations in live cells. Our studies suggest that, during the first step of the HIV entry process, gp120 binding alters the microenvironments of unbound CD4 and CCR5, with plasma membrane cholesterol required for the formation of the HIV entry complex.	NIAID, Lab Immunogenet, Twinbrook Facil 2, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jin, T (corresponding author), NIAID, Lab Immunogenet, Twinbrook Facil 2, NIH, Rockville, MD 20852 USA.	tjin@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000928, Z01AI000928] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Edidin M, 2003, NAT REV MOL CELL BIO, V4, P414, DOI 10.1038/nrm1102; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jiao XM, 2005, MOL CELL BIOL, V25, P5752, DOI 10.1128/MCB.25.13.5752-5762.2005; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880; Kramer JM, 2006, J IMMUNOL, V176, P711, DOI 10.4049/jimmunol.176.2.711; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lehner T, 2002, TRENDS IMMUNOL, V23, P347, DOI 10.1016/S1471-4906(02)02252-4; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Lusso P, 2002, VACCINE, V20, P1964, DOI 10.1016/S0264-410X(02)00079-8; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; OZEL M, 1988, ARCH VIROL, V100, P255, DOI 10.1007/BF01487688; Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557; Percherancier Y, 2003, J BIOL CHEM, V278, P3153, DOI 10.1074/jbc.M207371200; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Steffens CM, 2004, J VIROL, V78, P9573, DOI 10.1128/JVI.78.17.9573-9578.2004; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Trkola A, 2001, J VIROL, V75, P579, DOI 10.1128/JVI.75.2.579-588.2001; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; Xu XH, 2005, MOL BIOL CELL, V16, P676, DOI 10.1091/mbc.E04-07-0544; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zal T, 2002, IMMUNITY, V16, P521, DOI 10.1016/S1074-7613(02)00301-1; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	40	32	34	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35446	35453		10.1074/jbc.M607302200	http://dx.doi.org/10.1074/jbc.M607302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16963439	hybrid			2022-12-25	WOS:000241933700078
J	Dupre, DJ; Robitaille, M; Ethier, N; Villeneuve, LR; Mamarbachi, AM; Hebert, TE				Dupre, Denis J.; Robitaille, Melanie; Ethier, Nathalie; Villeneuve, Louis R.; Mamarbachi, Aida M.; Hebert, Terence E.			Seven transmembrane receptor core signaling complexes are assembled prior to plasma membrane trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; G-BETA-GAMMA; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; RECTIFYING POTASSIUM CHANNELS; CELL-SURFACE EXPRESSION; FORM STABLE COMPLEXES; GTP REGULATORY UNIT; YEAST G-PROTEIN; ENDOPLASMIC-RETICULUM; ADENYLATE-CYCLASE	Much is known about beta(2)-adrenergic receptor trafficking and internalization following prolonged agonist stimulation. However, less is known about outward trafficking of the beta(2)-adrenergic receptor to the plasma membrane or the role that trafficking might play in the assembly of receptor signaling complexes, important for targeting, specificity, and rapidity of subsequent signaling events. Here, by using a combination of bioluminescence resonance energy transfer, bimolecular fluorescence complementation, and confocal microscopy, we evaluated the steps in the formation of the core receptor-G protein heterotrimer complex. By using dominant negative Rab and Sar GTPase constructs, we demonstrate that receptor dimers and receptor-G beta gamma complexes initially associate in the endoplasmic reticulum, whereas G alpha subunits are added to the complex during endoplasmic reticulum-Golgi transit. We also observed that G protein heterotrimers adopt different trafficking itineraries when expressed alone or with stoichiometric co-expression with receptor. Furthermore, deliberate mistargeting of specific components of these complexes leads to diversion of other members from their normal subcellular localization, confirming the role of these early interactions in targeting and formation of specific signaling complexes.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada	McGill University; Universite de Montreal; Universite de Montreal	Hebert, TE (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.	terence.hebert@mcgill.ca	Robitaille, Melanie/ABA-5861-2020; Dupre, Denis J/AAI-2631-2021	Robitaille, Melanie/0000-0001-9354-5162; Dupre, Denis J/0000-0001-6401-6157				Altan-Bonnet N, 2004, CURR OPIN CELL BIOL, V16, P364, DOI 10.1016/j.ceb.2004.06.011; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; ARAD H, 1984, P NATL ACAD SCI-BIOL, V81, P6579, DOI 10.1073/pnas.81.21.6579; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Berthele A, 2001, NEUROREPORT, V12, P3269, DOI 10.1097/00001756-200110290-00025; Boivin B, 2006, CARDIOVASC RES, V71, P69, DOI 10.1016/j.cardiores.2006.03.015; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Clark JA, 2000, BRAIN RES, V860, P41, DOI 10.1016/S0006-8993(00)01958-2; DAVID M, 2006, IN PRESS CELL SIGNAL; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dunigan CD, 2002, BIOCHEMISTRY-US, V41, P8019, DOI 10.1021/bi025538r; Dupre DJ, 2006, CELL SIGNAL, V18, P1549, DOI 10.1016/j.cellsig.2006.03.009; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Filipeanu CM, 2004, J BIOL CHEM, V279, P41077, DOI 10.1074/jbc.M405988200; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Klein S, 2000, P NATL ACAD SCI USA, V97, P3219, DOI 10.1073/pnas.050015797; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Le-Niculescu H, 2005, J BIOL CHEM, V280, P22012, DOI 10.1074/jbc.M501833200; LEVITZKI A, 1981, CRC CR REV BIOCH MOL, V10, P81, DOI 10.3109/10409238109114550; LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758; LEVITZKI A, 1984, J RECEPTOR RES, V4, P399, DOI 10.3109/10799898409042564; LEVITZKI A, 1986, PHYSIOL REV, V66, P819, DOI 10.1152/physrev.1986.66.3.819; LEVITZKI A, 1988, TRENDS BIOCHEM SCI, V13, P298, DOI 10.1016/0968-0004(88)90122-3; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; MARBACH I, 1990, J BIOL CHEM, V265, P9999; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Pellegrino S, 1997, J BIOL CHEM, V272, P25360, DOI 10.1074/jbc.272.40.25360; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Rebois RV, 1997, CELL SIGNAL, V9, P141, DOI 10.1016/S0898-6568(96)00133-7; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rodman JS, 2000, J CELL SCI, V113, P183; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takida S, 2004, FEBS LETT, V567, P209, DOI 10.1016/j.febslet.2004.04.062; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOLKOVSKY AM, 1981, J CYCLIC NUCL PROT, V7, P139; TOLKOVSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P213, DOI 10.1073/pnas.79.2.213; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Xiao RP, 1999, CIRC RES, V84, P43	66	127	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34561	34573		10.1074/jbc.M605012200	http://dx.doi.org/10.1074/jbc.M605012200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16959776	hybrid			2022-12-25	WOS:000241767600076
J	Kunz, RC; Horng, YC; Ragsdale, SW				Kunz, Ryan C.; Horng, Yih-Chern; Ragsdale, Stephen W.			Spectroscopic and kinetic studies of the reaction of bromopropanesulfonate with methyl-coenzyme M reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOAUTOTROPHICUM STRAIN MARBURG; BIOLOGICAL METHANE FORMATION; F430 PENTAMETHYL ESTER; X-RAY-ABSORPTION; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOGENIC BACTERIA; TITANIUM(III) CITRATE; LIGAND-EXCHANGE; F-430 COFACTOR; ACTIVE-SITE	Methyl-coenzyme M reductase (MCR) catalyzes the final step of methanogenesis in which coenzyme B and methyl-coenzyme M are converted to methane and the heterodisulfide, CoMS-SCoB. MCR also appears to initiate anaerobic methane oxidation (reverse methanogenesis). At the active site of MCR is coenzyme F-430, a nickel tetrapyrrole. This paper describes the reaction of the active MCRred1 state with the potent inhibitor, 3-bromopropanesulfonate (BPS; I-50 = 50 nM) by UV-visible and EPR spectroscopy and by steady-state and rapid kinetics. BPS was shown to be an alternative substrate of MCR in an ionic reaction that is coenzyme B-independent and leads to debromination of BPS and formation of a distinct state ("MCRPS") with an EPR signal that was assigned to a Ni(III)-propylsulfonate species (Hinderberger, D., Piskorski, R. P., Goenrich, M., Thauer, . K., Schweiger, A., Harmer, J., and Jaun, B. (2006) Angew. Chem. Int. Ed. Engl. 45, 3602-3607). A similar EPR signal was generated by reacting MCRred1 with several halogenated sulfonate and carboxylate substrates. In rapid chemical quench experiments, the propylsulfonate ligand was identified by NMR spectroscopy and high performance liquid chromatography as propanesulfonic acid after protonolysis of the MCRPS complex. Propanesulfonate formation was also observed in steady-state reactions in the presence of Ti(III) citrate. Reaction of the alkyl-nickel intermediate with thiols regenerates the active MCRred1 state and eliminates the propylsulfonate group, presumably as the thioether. MCRPS is catalytically competent in both the generation of propanesulfonate and reformation of MCRred1. These results provide evidence for the intermediacy of an alkyl-nickel species in the final step in anaerobic methane oxidation and in the initial step of methanogenesis.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	sragsdale1@unl.edu	Horng, Yih-Chern/I-6682-2018	Horng, Yih-Chern/0000-0001-9558-3189	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR17675] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBRACHT SPJ, 1988, BIOCHIM BIOPHYS ACTA, V955, P86, DOI 10.1016/0167-4838(88)90182-3; Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Becker DF, 1998, BIOCHEMISTRY-US, V37, P2639, DOI 10.1021/bi972145x; BERKESSEL A, 1991, BIOORG CHEM, V19, P101, DOI 10.1016/0045-2068(91)90047-S; BOBIK TA, 1988, P NATL ACAD SCI USA, V85, P60, DOI 10.1073/pnas.85.1.60; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER MC, 1993, J BIOL CHEM, V268, P18491; Craft JL, 2004, J AM CHEM SOC, V126, P4068, DOI 10.1021/ja038082p; Craft JL, 2004, J BIOL INORG CHEM, V9, P77, DOI 10.1007/s00775-003-0499-7; DIEKERT G, 1980, FEBS LETT, V119, P118, DOI 10.1016/0014-5793(80)81011-8; DIEKERT G, 1980, ARCH MICROBIOL, V124, P103, DOI 10.1007/BF00407036; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; Duin EC, 2003, J BIOL INORG CHEM, V8, P141, DOI 10.1007/s00775-002-0399-2; ELLERMANN J, 1989, EUR J BIOCHEM, V184, P63, DOI 10.1111/j.1432-1033.1989.tb14990.x; ELLERMANN J, 1988, EUR J BIOCHEM, V172, P669, DOI 10.1111/j.1432-1033.1988.tb13941.x; ELLERMANN J, 1987, FEBS LETT, V220, P358, DOI 10.1016/0014-5793(87)80846-3; Ermler U, 1997, SCIENCE, V278, P1457, DOI 10.1126/science.278.5342.1457; Goenrich M, 2005, J BIOL INORG CHEM, V10, P333, DOI 10.1007/s00775-005-0636-6; Goenrich M, 2004, J BIOL INORG CHEM, V9, P691, DOI 10.1007/s00775-004-0552-1; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; Goubeaud M, 1997, EUR J BIOCHEM, V243, P110, DOI 10.1111/j.1432-1033.1997.00110.x; Grabarse W, 2001, J MOL BIOL, V309, P315, DOI 10.1006/jmbi.2001.4647; Grabarse WG, 2000, J MOL BIOL, V303, P329, DOI 10.1006/jmbi.2000.4136; GUNSALUS RP, 1978, BIOCHEMISTRY-US, V17, P2374, DOI 10.1021/bi00605a019; Harmer J, 2005, J AM CHEM SOC, V127, P17744, DOI 10.1021/ja053794w; Hinderberger D, 2006, ANGEW CHEM INT EDIT, V45, P3602, DOI 10.1002/anie.200600366; HOLLIGER C, 1993, J AM CHEM SOC, V115, P5651, DOI 10.1021/ja00066a034; Horng YC, 2001, BIOCHEMISTRY-US, V40, P12875, DOI 10.1021/bi011196y; JAUN B, 1990, HELV CHIM ACTA, V73, P2209, DOI 10.1002/hlca.19900730818; LAHIRI GK, 1993, INORG CHEM, V32, P4409, DOI 10.1021/ic00072a041; LIN SK, 1992, HELV CHIM ACTA, V75, P1478, DOI 10.1002/hlca.19920750504; LIN SK, 1991, HELV CHIM ACTA, V74, P1725, DOI 10.1002/hlca.19910740814; Mahlert F, 2002, J BIOL INORG CHEM, V7, P500, DOI 10.1007/s00775-001-0325-z; NOLL KM, 1987, J BIOL CHEM, V262, P513; Pelmenschikov V, 2003, J BIOL INORG CHEM, V8, P653, DOI 10.1007/s00775-003-0461-8; Pelmenschikov V, 2002, J AM CHEM SOC, V124, P4039, DOI 10.1021/ja011664r; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSPERT S, 1992, EUR J BIOCHEM, V210, P101, DOI 10.1111/j.1432-1033.1992.tb17396.x; ROSPERT S, 1990, EUR J BIOCHEM, V194, P871, DOI 10.1111/j.1432-1033.1990.tb19481.x; ROSPERT S, 1991, FEBS LETT, V291, P371, DOI 10.1016/0014-5793(91)81323-Z; SCHONHEIT P, 1980, ARCH MICROBIOL, V127, P59, DOI 10.1007/BF00414356; Signor L, 2000, CHEM-EUR J, V6, P3508, DOI 10.1002/1521-3765(20001002)6:19<3508::AID-CHEM3508>3.3.CO;2-N; Singh K, 2003, J AM CHEM SOC, V125, P2436, DOI 10.1021/ja028525+; Tang Q, 2002, J AM CHEM SOC, V124, P13242, DOI 10.1021/ja020314h; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; WHITMAN WB, 1980, BIOCHEM BIOPH RES CO, V92, P1196, DOI 10.1016/0006-291X(80)90413-1; Wondimagegn T, 2001, J AM CHEM SOC, V123, P1543, DOI 10.1021/ja001870j; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	49	30	31	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34663	34676		10.1074/jbc.M606715200	http://dx.doi.org/10.1074/jbc.M606715200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966321	hybrid			2022-12-25	WOS:000241767600085
J	Chang, DJ; Lupardus, PJ; Cimprich, KA				Chang, Debbie J.; Lupardus, Patrick J.; Cimprich, Karlene A.			Monoubiquitination of proliferating cell nuclear antigen induced by stalled replication requires uncoupling of DNA polymerase and mini-chromosome maintenance helicase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SINGLE-STRANDED-DNA; TRANSLESION SYNTHESIS; DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; FREE SYSTEM; ATR; PCNA; ACTIVATION; INITIATION	Proliferating cell nuclear antigen ( PCNA) is a homotrimeric, ring-shaped protein complex that functions as a processivity factor for DNA polymerases. Following genotoxic stress, PCNA is modified at a conserved site by either a single ubiquitin moiety or a polyubiquitin chain. These modifications are required to coordinate DNA damage tolerance processes with ongoing replication. The molecular mechanisms responsible for inducing PCNA ubiquitination are not well understood. Using Xenopus egg extracts, we show that ultraviolet radiation and aphidicolin treatment induce the mono- and diubiquitination of PCNA. PCNA ubiquitination is replication-dependent and coincides with activation of the ataxia telangiectasia mutated and Rad3-related (ATR)-dependent DNA damage checkpoint pathway. However, loss of ATR signaling by depletion of the ATR-interacting protein ( ATRIP) or Rad1, a component of the 911 checkpoint clamp, does not impair PCNA ubiquitination. Primed single-stranded DNA generated by uncoupling of mini-chromosome maintenance helicase and DNA polymerase activities has been shown previously to be necessary for ATR activation. Here we show that PCNA ubiquitination also requires uncoupling of helicase and polymerase activities. We further demonstrate that replicating single-stranded DNA, which mimics the structure produced upon uncoupling, is sufficient to induce PCNA monoubiquitination. Our results suggest that PCNA ubiquitination and ATR activation are two independent events that occur in response to a common single-stranded DNA intermediate generated by functional uncoupling of mini-chromosome maintenance (MCM) helicase and DNA polymerase activities.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Cimprich, KA (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, 318 Campus Dr, Stanford, CA 94305 USA.	cimprich@stanford.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062193] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES016486] Funding Source: Medline; NIGMS NIH HHS [GM 62193] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias EE, 2004, FRONT BIOSCI-LANDMRK, V9, P3029, DOI 10.2741/1457; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Bi XH, 2006, MOL CELL BIOL, V26, P3527, DOI 10.1128/MCB.26.9.3527-3540.2006; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Chiu RK, 2006, PLOS GENET, V2, P1070, DOI 10.1371/journal.pgen.0020116; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 2005, GENE DEV, V19, P1007, DOI 10.1101/gad.1316905; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Frampton J, 2006, MOL BIOL CELL, V17, P2976, DOI 10.1091/mbc.e05-11-1008; Friedberg EC, 2005, NAT REV MOL CELL BIO, V6, P943, DOI 10.1038/nrm1781; Garg P, 2005, P NATL ACAD SCI USA, V102, P18361, DOI 10.1073/pnas.0505949102; Haracska L, 2006, P NATL ACAD SCI USA, V103, P6477, DOI 10.1073/pnas.0510924103; Hirano Y, 2006, CURR BIOL, V16, P586, DOI 10.1016/j.cub.2006.01.063; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Kai M, 2003, MUTAT RES-FUND MOL M, V532, P59, DOI 10.1016/j.mrfmmm.2003.08.010; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Leach CA, 2005, J CELL BIOL, V171, P947, DOI 10.1083/jcb.200508100; Lehmann AR, 2005, FEBS LETT, V579, P873, DOI 10.1016/j.febslet.2004.11.029; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2006, MOL BIOL CELL, V17, P1559, DOI 10.1091/mbc.E05-09-0865; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Machida YJ, 2005, CELL, V123, P13, DOI 10.1016/j.cell.2005.09.019; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Mattock H, 2001, EXP CELL RES, V265, P242, DOI 10.1006/excr.2001.5181; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Paulovich AG, 1998, GENETICS, V150, P75; Sabbioneda S, 2005, J BIOL CHEM, V280, P38657, DOI 10.1074/jbc.M507638200; Sarkaria JN, 1999, CANCER RES, V59, P4375; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32081	32088		10.1074/jbc.M606799200	http://dx.doi.org/10.1074/jbc.M606799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16959771	hybrid			2022-12-25	WOS:000241414500005
J	Cottet, S; Michaut, L; Boisset, G; Schlecht, U; Gehring, W; Schorderet, DF				Cottet, Sandra; Michaut, Lydia; Boisset, Gaeelle; Schlecht, Ulrich; Gehring, Walter; Schorderet, Daniel F.			Biological characterization of gene response in Rpe65(-/-) mouse model of Leber's congenital amaurosis during progression of the disease	FASEB JOURNAL			English	Article						microarray; LCA; apoptosis	ALPHA-B-CRYSTALLIN; RETINAL-PIGMENT EPITHELIUM; HEAT-SHOCK-PROTEIN; A-CRYSTALLIN; PROTECTIVE ACTIVITY; BINDING-PROTEIN; DOWN-REGULATION; VISUAL-PIGMENT; MESSENGER-RNA; VITAMIN-A	RPE65 is the retinal isomerase essential for conversion of all-trans-retinyl ester to 11-cis-retinol in the visual cycle. Leber's congenital amaurosis (LCA), an autosomal recessive form of RP resulting in blindness, is commonly caused by mutations in the Rpe65 gene. Whereas the molecular mechanisms by which these mutations contribute to retinal disease remain largely unresolved, affected patients show marked RPE damage and photoreceptor degeneration. We evaluated gene expression in Rpe65(-/-) mouse model of LCA before and at the onset of photoreceptor cell death in 2, 4, and 6 month old animals. Microarray analysis demonstrates altered expression of genes involved in phototransduction, apoptosis regulation, cytoskeleton organization, and extracellular matrix (ECM) constituents. Cone-specific phototransduction genes are strongly decreased, reflecting early loss of cones. In addition, remaining rods show modified expression of genes encoding components of the cytoskeleton and ECM. This may affect rod physiology and interaction with the adjacent RPE and lead to loss of survival signals, as reflected by the alteration of apoptosis-related genes Together, these results suggest that RPE65 defect triggers an overall remodeling of the neurosensitive retina that may, in turn, disrupt photoreceptor homeostasis and induce apoptosis signaling cascade toward retinal cell death.	Inst Res Ophthalmol, Sion, Switzerland; Univ Basel, Biozentrum, Basel, Switzerland; Univ Lausanne, Lausanne, Switzerland; Ecole Polytech Fed Lausanne, Lausanne, Switzerland	University of Basel; University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Cottet, S (corresponding author), Av Grand Champsec 64, CH-1950 Sion 4, Switzerland.	sandra.cottet@iro.vsnet.ch						Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200; Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599; Aguirre G D, 1998, Mol Vis, V4, P23; ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168; Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cavusoglu N, 2003, MOL CELL PROTEOMICS, V2, P494, DOI 10.1074/mcp.M300029-MCP200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; D'Alessio G, 2002, EUR J BIOCHEM, V269, P3122, DOI 10.1046/j.1432-1033.2002.03004.x; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DERETIC D, 1994, J BIOL CHEM, V269, P16853; Dirks RPH, 1998, EXP EYE RES, V66, P267, DOI 10.1006/exer.1997.0439; DOW KE, 1994, EXP NEUROL, V128, P233, DOI 10.1006/exnr.1994.1132; Dufour EM, 2003, NEUROBIOL DIS, V14, P166, DOI 10.1016/S0969-9961(03)00102-5; Eckmiller MS, 2004, PROG RETIN EYE RES, V23, P495, DOI 10.1016/j.preteyeres.2004.04.005; Eckmiller MS, 1998, ACTA ANAT, V162, P133; El Matri L, 2006, GRAEF ARCH CLIN EXP, V244, P1104, DOI 10.1007/s00417-005-0096-2; Felbor U, 1998, CYTOGENET CELL GENET, V81, P12, DOI 10.1159/000015001; FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750; FUKUCHI T, 1994, EXP EYE RES, V58, P231, DOI 10.1006/exer.1994.1012; Galvin JA, 2005, OPHTHALMOLOGY, V112, P349, DOI 10.1016/j.ophtha.2004.08.023; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hasson T, 1999, CURR BIOL, V9, pR838, DOI 10.1016/S0960-9822(00)80040-8; HEAD MW, 1995, EXP EYE RES, V61, P423, DOI 10.1016/S0014-4835(05)80137-X; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Johnson EC, 1996, EXP EYE RES, V62, P663, DOI 10.1006/exer.1996.0077; Jones SE, 1999, INVEST OPHTH VIS SCI, V40, P3017; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e; Kelsell RE, 1998, AM J HUM GENET, V63, P274, DOI 10.1086/301905; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kusaka S, 1998, JPN J OPHTHALMOL, V42, P218, DOI 10.1016/S0021-5155(97)00136-6; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LIEM ATA, 1994, OPHTHALMOLOGY, V101, P1945; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Magabo KS, 2000, INVEST OPHTH VIS SCI, V41, P3056; Manes G, 1998, FEBS LETT, V423, P133, DOI 10.1016/S0014-5793(98)00081-7; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Narfstrom K., 1999, Veterinary Ophthalmology, V2, P75; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Porto FBO, 2002, J GENE MED, V4, P390, DOI 10.1002/jgm.278; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Selles-Navarro I, 2001, EXP NEUROL, V167, P282, DOI 10.1006/exnr.2000.7573; Sinha D, 1998, Mol Vis, V4, P8; Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Williams DS, 2002, VISION RES, V42, P455, DOI 10.1016/S0042-6989(01)00228-0; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; WRIGSTAD A, 1992, EXP EYE RES, V55, P805, DOI 10.1016/0014-4835(92)90007-F; Xi JH, 2003, MOL VIS, V9, P410; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Yoshimura N, 2003, INVEST OPHTH VIS SCI, V44, P2211, DOI 10.1167/iovs.02-0704; Znoiko SL, 2005, INVEST OPHTH VIS SCI, V46, P1473, DOI 10.1167/iovs.04-0653; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	84	38	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2036	2049		10.1096/fj.06-6211com	http://dx.doi.org/10.1096/fj.06-6211com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012256				2022-12-25	WOS:000241156900012
J	Zhang, XC; Shan, PY; Jiang, G; Zhang, SSM; Otterbein, LE; Fu, XY; Lee, PJ				Zhang, Xuchen; Shan, Peiying; Jiang, Ge; Zhang, Samuel S-M.; Otterbein, Leo E.; Fu, Xin-Yuan; Lee, Patty J.			Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury	FASEB JOURNAL			English	Article						signal transduction; oxygen	INDUCED CELL-DEATH; HEME OXYGENASE-1; SIGNAL TRANSDUCER; THERAPY PROTECTS; HYPEROXIA; KINASE; TRANSCRIPTION; ACTIVATION; ISCHEMIA; PATHWAY	Administering high levels of inspired oxygen, or hyperoxia, is commonly used as a life-sustaining measure in critically ill patients. Unfortunately, the oxidant stress generated by prolonged hyperoxia can lead to respiratory failure, multiorgan failure, and death. Although the endothelial cell is known to be a target for hyperoxia-induced injury, its precise role is unclear. Heme oxygenase-1 (HO-1) and "signal transducer and activator of transcription 3" (STAT3) have been found to confer protection against endothelial cell injury. We sought to elucidate the specific roles of HO-1 and STAT3 in hyperoxic lung and endothelial cell injury. Mice or murine lung endothelial cells (MLEC) administered HO-1 siRNA exhibited marked injury and death compared with nonspecific siRNA. Overexpression of either HO-1 or STAT3 confers protection. However, HO-1 and its reaction product carbon monoxide (CO) lose their protective effects in the presence of STAT3 siRNA in MLEC or in endothelial-specific, STAT3-deficient mice. STAT3 overexpression is able to partially rescue HO-1-deficient MLEC from hyperoxia-induced cell death. Our results demonstrate 1) the importance of the endothelium in lethal hyperoxic injury, 2) HO-1 and CO require endothelial STAT3 for their protective effects, and 3) STAT3 confers endothelial cell protection via both HO-1-dependent and independent mechanisms.	Yale Univ, Sch Med, Sect Pulm & Crit Care Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Surg, Sch Med, Boston, MA 02215 USA; Indiana Univ, Dept Microbiol & Immunol, Indianapolis, IN 46204 USA	Yale University; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Indiana University System; Indiana University-Purdue University Indianapolis	Lee, PJ (corresponding author), Yale Univ, Sch Med, Sect Pulm & Crit Care Med, POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	zhang, xu/GYE-3558-2022	Zhang, Xuchen/0000-0002-1484-4672	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071595] Funding Source: Medline; NIAID NIH HHS [R01 AI034522] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON IYR, 1970, ARCH PATHOL, V90, P463; Ahmad A, 2006, FREE RADICAL BIO MED, V40, P1108, DOI 10.1016/j.freeradbiomed.2005.10.045; Alam J, 2002, ANTIOXID REDOX SIGN, V4, P559, DOI 10.1089/15230860260220049; Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Deramaudt TB, 1999, P SOC EXP BIOL MED, V222, P185, DOI 10.1046/j.1525-1373.1999.d01-130.x; FISHER AB, 1980, AM REV RESPIR DIS, V122, P61, DOI 10.1164/arrd.1980.122.5P2.61; Fondevila C, 2004, HEPATOLOGY, V40, P1333, DOI 10.1002/hep.20480; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Hammerman C, 2002, J PEDIATR GASTR NUTR, V35, P344, DOI 10.1097/00005176-200209000-00020; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; Jin Y, 2005, AM J RESP CELL MOL, V33, P297, DOI 10.1165/rcmb.2005-0144OC; Kaizu T, 2005, SURGERY, V138, P229, DOI 10.1016/j.surg.2005.06.015; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kuhlencordt PJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1195, DOI 10.1152/ajpcell.00546.2002; Kunisada K, 2000, P NATL ACAD SCI USA, V97, P315, DOI 10.1073/pnas.97.1.315; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; Lee PJ, 2005, HEME OXYGENASE: THE ELEGANT ORCHESTRATION OF ITS PRODUCTS IN MEDICINE, P211; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Lu YB, 2001, J EXP MED, V193, P545, DOI 10.1084/jem.193.4.545; Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Neto JS, 2006, AM J PHYSIOL-RENAL, V290, pF324, DOI 10.1152/ajprenal.00026.2005; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Podewski EK, 2003, CIRCULATION, V107, P798, DOI 10.1161/01.CIR.0000057545.82749.FF; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Stephanou A, 1999, GENE EXPRESSION, V7, P311; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Tsan MF, 2001, INT J MOL MED, V7, P13; VanKlaveren RJ, 1997, AM J PHYSIOL-LUNG C, V273, pL548, DOI 10.1152/ajplung.1997.273.3.L548; Yamashita K, 2004, FASEB J, V18, P765, DOI 10.1096/fj.03-0839fje; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhou ZH, 2005, AM J PATHOL, V166, P27, DOI 10.1016/S0002-9440(10)62229-8	47	84	85	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2156	+		10.1096/fj.06-5668fje	http://dx.doi.org/10.1096/fj.06-5668fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16971418				2022-12-25	WOS:000241156900049
J	Mitchell, DC; Stafford, LJ; Li, D; Bar-Eli, M; Liu, M				Mitchell, D. C.; Stafford, L. J.; Li, D.; Bar-Eli, M.; Liu, M.			Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130	ONCOGENE			English	Article						KiSS1; GPR54; Sp1; CRSP3; cancer metastasis	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; COFACTOR COMPLEX CRSP; HUMAN GASTRIC-CANCER; COUPLED RECEPTOR; SUPPRESSOR GENE; FACTOR SP1; ACTIVATOR PROTEIN-2-ALPHA; FACTOR FAMILY; I-RECEPTOR	Loss of the metastasis suppressor gene, KiSS-1 has been strongly correlated to the progression of metastases in numerous types of cancers. The mechanism through which KiSS-1 is lost during metastasis, however, is still not completely known. Previous studies have shown that genetic material on human chromosome 6q16.3-q23 is essential for KiSS-1 expression in normal tissues. Additionally, microcell-mediated transfer of this chromosome in cancerous tissue results in rescued expression of KiSS-1 and reduced metastatic phenotype. Here, we show that loss of Sp1-coactivator protein DRIP-130, which is encoded by human chromosome 6q16.3-q23, results in reduced KiSS-1 promoter activation in highly malignant melanoma cells. Co-expression of Sp1 and DRIP-130 not only rescues KiSS-1 expression, but also induces an inhibition of the invasive and migratory behavior in highly metastatic melanoma cells, similar to the overexpression of KiSS-1 metastasis suppressor gene in those cells. Furthermore, we demonstrate that KiSS-1 expression is regulated by Sp1 elements within the first 100-bp region of the KiSS-1 promoter and that targeted deletion of a single GC-rich region spanning -93 to -58 interrupts Sp1- and DRIP-130-modulated transcriptional control of KiSS-1 expression. Our results thus suggest that DRIP-130 is a key regulator in KiSS-1 transactivation in normal tissue, and that the loss of DRIP-130 expression, as a result of the gross loss of human chromosome 6q16.3-q23, provokes increased tumor metastasis.	Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Mol & Cellular Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center	Liu, M (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu			NCI NIH HHS [1R01CA106479] Funding Source: Medline; NHLBI NIH HHS [5R01HL064792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Goldberg SF, 2003, CANCER RES, V63, P432; Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Jiang Y, 2005, CLIN EXP METASTAS, V22, P369, DOI 10.1007/s10585-005-8186-4; Jiang YX, 2004, CLIN EXP METASTAS, V21, P755, DOI 10.1007/s10585-005-1198-2; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Masui T, 2004, BIOCHEM BIOPH RES CO, V315, P85, DOI 10.1016/j.bbrc.2004.01.021; Miele ME, 2000, INT J CANCER, V86, P524, DOI 10.1002/(SICI)1097-0215(20000515)86:4<524::AID-IJC13>3.0.CO;2-W; Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Sanchez-Carbayo M, 2003, AM J PATHOL, V162, P609, DOI 10.1016/S0002-9440(10)63854-0; Shi Q, 2001, CANCER RES, V61, P4143; Shirasaki F, 2001, CANCER RES, V61, P7422; Stafford LJ, 2002, CANCER RES, V62, P5399; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taatjes DJ, 2004, MOL CELL, V14, P675, DOI 10.1016/j.molcel.2004.05.014; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	36	45	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1739	1747		10.1038/sj.onc.1209963	http://dx.doi.org/10.1038/sj.onc.1209963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964286				2022-12-25	WOS:000244955600008
J	Sumathipala, R; Xu, CS; Seago, J; Mould, AP; Humphries, MJ; Craig, SE; Patel, Y; Wijelath, ES; Sobel, M; Rahman, S				Sumathipala, Rushika; Xu, Cunshuan; Seago, Julian; Mould, A. Paul; Humphries, Martin J.; Craig, Sue E.; Patel, Yatin; Wijelath, Errol S.; Sobel, Michael; Rahman, Salman			The "linker" region (amino acids 38-47) of the disintegrin elegantin is a novel inhibitory domain of integrin alpha(5)beta(1)-dependent cell adhesion on fibronectin - Evidence for the negative regulation of fibronectin synergy site biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; SNAKE-VENOM PROTEINS; RGD SEQUENCE MOTIFS; HETERODIMERIC DISINTEGRIN; LIGAND RECOGNITION; 10TH-FIII DOMAINS; BINDING-SITES; FIBRINOGEN; COMPLEX; ALPHA(IIB)BETA(3)	Disintegrins are a family of potent inhibitors of cell-cell and cell-matrix adhesion. In this study we have identified a region of the disintegrin elegantin, termed the "linker domain" (amino acids 38-47), with inhibitory activity toward alpha(5)beta(1)-mediated cell adhesion on fibronectin (Fn). Using a chimeric structure-function approach in which sequences of the functionally distinct disintegrin kistrin were introduced into the elegantin template at targeted sites, a loss of inhibitory function toward alpha(5)beta(1)-mediated adhesion on Fn was observed when the elegantin linker domain was substituted. Subsequent analysis comparing the inhibitory efficacies of the panel of elegantin-kistrin chimeras toward CHO alpha(5) cell adhesion on recombinant Fn III6-10 fragments showed that the loss of inhibitory activity associated with the disruption of the elegantin linker domain was dependent upon the presence of a functional Fn III9 synergy site within the Fn III6-10 substrate. This suggested that the elegantin linker domain inhibits primarily the activity of the Fn synergy domain in promoting alpha(5)beta(1) integrin-mediated cell adhesion. Construction of a cyclic peptide corresponding to the entire region of the elegantin linker domain showed that this domain has intrinsic alpha(5)beta(1) inhibitory activity comparable with the activity of the RGDS peptide. These data demonstrate a novel biological function for a disintegrin domain that antagonizes integrin-mediated cell adhesion.	Kings Coll London, Sch Med, St Thomas Hosp, Div Cardiovasc Med,Lab Thrombosis & Vasc Remodell, London SE1 7EH, England; Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Washington, Sch Med, Div Vasc Surg, Seattle, WA 98108 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Manchester; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Rahman, S (corresponding author), Kings Coll London, Sch Med, St Thomas Hosp, Div Cardiovasc Med,Lab Thrombosis & Vasc Remodell, London SE1 7EH, England.	salman.rahman@kcl.ac.uk	Rahman, Salman/ABG-5006-2021	Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228				Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Altroff H, 2004, J BIOL CHEM, V279, P55995, DOI 10.1074/jbc.M406976200; Altroff H, 2003, J BIOL CHEM, V278, P491, DOI 10.1074/jbc.M209992200; AOTA S, 1994, J BIOL CHEM, V269, P24756; Benoit DSW, 2005, BIOMATERIALS, V26, P5209, DOI 10.1016/j.biomaterials.2005.01.045; Calvete JJ, 2005, CURR PHARM DESIGN, V11, P829, DOI 10.2174/1381612053381783; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Davidson LA, 2002, DEV BIOL, V242, P109, DOI 10.1006/dbio.2002.0537; HUANG TF, 1987, J BIOL CHEM, V262, P16157; Kisiel DG, 2004, FEBS LETT, V577, P478, DOI 10.1016/j.febslet.2004.10.050; LU XJ, 1993, BIOCHEM J, V296, P21, DOI 10.1042/bj2960021; Lu XJ, 1996, J BIOL CHEM, V271, P289, DOI 10.1074/jbc.271.1.289; Marcinkiewicz C, 1999, BIOCHEMISTRY-US, V38, P13302, DOI 10.1021/bi9906930; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Moursi AM, 1996, J CELL SCI, V109, P1369; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; RAHMAN S, 1995, BIOCHEM J, V312, P223, DOI 10.1042/bj3120223; Rahman S, 1998, BIOCHEM J, V335, P247, DOI 10.1042/bj3350247; Rahman S, 2000, BIOCHEM J, V345, P701, DOI 10.1042/0264-6021:3450701; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Sanz L, 2005, J BIOL CHEM, V280, P40714, DOI 10.1074/jbc.M509738200; Scaloni A, 1996, BIOCHEM J, V319, P775, DOI 10.1042/bj3190775; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; SUTCLIFFE MJ, 1994, NAT STRUCT BIOL, V1, P802, DOI 10.1038/nsb1194-802; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Tselepis VH, 1997, J BIOL CHEM, V272, P21341, DOI 10.1074/jbc.272.34.21341; Wierzbicka-Patynowski I, 1999, J BIOL CHEM, V274, P37809, DOI 10.1074/jbc.274.53.37809; WILLIAMS J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P81, DOI 10.1016/0167-4838(90)90229-9; WRIGHT PS, 1993, BIOCHEM J, V293, P263, DOI 10.1042/bj2930263; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	37	3	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37686	37696		10.1074/jbc.M603943200	http://dx.doi.org/10.1074/jbc.M603943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16982624	hybrid			2022-12-25	WOS:000242477100046
J	Meng, QJ; Lux, A; Holloschi, A; Li, J; Hughes, JMX; Foerg, T; McCarthy, JEG; Heagerty, AM; Kioschis, P; Hafner, M; Garland, JM				Meng, QingJun; Lux, Andreas; Holloschi, Andreas; Li, Jian; Hughes, John M. X.; Foerg, Tassilo; McCarthy, John E. G.; Heagerty, Anthony M.; Kioschis, Petra; Hafner, Mathias; Garland, John M.			Identification of Tctex2 beta, a novel dynein light chain family member that interacts with different transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CELLULAR-RESPONSES; PROTEIN-STRUCTURE; ENDOGLIN; EXPRESSION; MOTOR; TCTEX-1; COMPLEX; BINDING; PROLIFERATION	Endoglin is a membrane-inserted protein that is preferentially synthesized in angiogenic vascular endothelial and smooth muscle cells. Endoglin associates with members of the transforming growth factor-beta(TGF-beta) receptor family and has been identified as the gene involved in hereditary hemorrhagic telangiectasia. Although endoglin is known to affect cell responses to TGF-beta, its mode of action is largely unknown. We performed yeast two-hybrid screening of a human placental cDNA library and isolated a new endoglin-binding partner, a novel 221-amino acid member of the Tctex1/2 family of cytoplasmic dynein light chains named Tctex2 beta, as the founder of a new Tctex1/2 subfamily. The interaction was localized exclusively to the cytoplasmic domain of endoglin. Reverse transcription-PCR showed expression of Tctex2 beta in a wide range of tissues, including vascular endothelial and smooth muscle cells, placenta, and testis, as well as in several tumor cell lines. High expression levels were found in human umbilical vein endothelial cells and the large cell lung cancer cell line. Forced expression of Tctex2 beta had a profound inhibitory effect on TGF-beta signaling. Additional Tctex2 beta-interacting receptors were identified to be the TGF-beta type II receptor and most likely betaglycan, but not ALK5, ALK1, or the bone morphogenetic protein type II receptor. Upon fluorescence tagging, co-localization of Tctex2 beta and endoglin, as well as Tctex2 beta, endoglin, and the TGF-beta type II receptor, was observed by different microscopy techniques. Our findings link endoglin for the first time to microtubule-based minus end-directed transport machinery, suggesting that some endoglin functions might be regulated and directed by its interaction with the cytoplasmic dynein light chain Tctex2 beta.	Univ Manchester, Manchester Royal Infirm, Dept Med, Cardiovasc Clin Acad Grp, Manchester M13 9WL, Lancs, England; Univ Hosp, D-68163 Mannheim, Germany; Univ Appl Sci, Inst Mol Cell Biol, D-68163 Mannheim, Germany; Manchester Interdisciplinary Bioctr, Manchester M60 1QD, Lancs, England	University of Manchester; Ruprecht Karls University Heidelberg; University of Manchester	Meng, QJ (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Cardiovasc Clin Acad Grp, Oxford Rd, Manchester M13 9WL, Lancs, England.	qjmeng@manchester.ac.uk; a.lux@hs-mannheim.de		Meng, Qing Jun/0000-0002-9426-8336; Heagerty, Anthony/0000-0002-9043-2119	Biotechnology and Biological Sciences Research Council [BBS/B/02436] Funding Source: Medline; Medical Research Council [G0900414] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Chen CZ, 2002, P NATL ACAD SCI USA, V99, P15468, DOI 10.1073/pnas.202614899; Choi JH, 2000, BIOINFORMATICS, V16, P1056, DOI 10.1093/bioinformatics/16.11.1056; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DiBella LM, 2001, J BIOL CHEM, V276, P14366, DOI 10.1074/jbc.M011456200; Ding W, 2005, CANCER RES, V65, P6526, DOI 10.1158/0008-5472.CAN-04-4385; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Goldstein LSB, 2001, TRENDS CELL BIOL, V11, P477, DOI 10.1016/S0962-8924(01)02143-2; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Higgins D G, 1994, Methods Mol Biol, V25, P307; James P, 1996, GENETICS, V144, P1425; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Lux A, 2005, J BIOL CHEM, V280, P8482, DOI 10.1074/jbc.M409197200; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; Machado RD, 2003, HUM MOL GENET, V12, P3277, DOI 10.1093/hmg/ddg365; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Postiglione L, 2005, INT J ONCOL, V26, P1193; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Schmidt-Weber CB, 2005, INT IMMUNOL, V17, P921, DOI 10.1093/intimm/dxh272; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Tang Q, 2002, MOL BIOL CELL, V13, P4484, DOI 10.1091/mbc.e02-05-0245; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Williams JC, 2005, J BIOL CHEM, V280, P21981, DOI 10.1074/jbc.M414643200	49	35	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37069	37080		10.1074/jbc.M608614200	http://dx.doi.org/10.1074/jbc.M608614200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16982625	hybrid			2022-12-25	WOS:000242220800068
J	Ring, MW; Schwar, G; Thiel, V; Dickschat, JS; Kroppenstedt, RM; Schulz, S; Bode, HB				Ring, Michael W.; Schwaer, Gertrud; Thiel, Verena; Dickschat, Jeroen S.; Kroppenstedt, Reiner M.; Schulz, Stefan; Bode, Helge B.			Novel iso-branched ether lipids as specific markers of developmental sporulation in the myxobacterium Myxococcus xanthus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUITING BODY FORMATION; SER/THR KINASE CASCADE; BIOSYNTHETIC GENE-CLUSTER; CHAIN FATTY-ACIDS; STIGMATELLA-AURANTIACA; MASS-SPECTROMETRY; PHOSPHATIDYLGLYCEROL ACETAL; CLOSTRIDIUM-BUTYRICUM; MEGASPHAERA-ELSDENII; VEGETATIVE CELLS	Iso-fatty acids (FAs) are the dominant FA family in all myx-obacteria analyzed. Furthermore, it was postulated that isoFAs or compounds derived thereof are involved in fruiting body formation in Myxococcus xanthus, since mutants with a reduced level of iso-FA due to a reduced level of the precursor isovaleryl-CoA, are delayed in aggregation and produce only few myxospores. To elucidate the function of iso-FAs and their corresponding lipids we have analyzed the developmental phenotype of mutants having different levels of iso-FAs resulting in a clear correlation between the amount of iso-FAs and the delay of aggregation and reduction in spore yield. Addition of either isovalerate or 13-methyltetradecanoic acid resulted in restoration of the wild-type FA profile and normal development. Detailed analysis of the fatty acid (FA) profile during fruiting body formation in Myxococcus xanthus wildtype revealed the specific accumulation of 13-methyltetradecanal and 1-O-13-methyltetradecylglycerol which were produced specifically in the myxospores and which are derived from 1-O-(13-methyl-1-Z-tetradecenyl)-2-O-(13-methyltetradecanoyl)glycero-3-phosphatidylethanolamine(VEPE) and 1,2-di-(13-methyltetradecanoyl)-3-(13-methyltetradecyl) glycerol (TG-1), respectively. The structures of these unusual ether lipids have been determined by spectrometric methods and synthesis (for TG-1). Analysis of several mutants blocked at different stages of development indicated that the biosynthesis of TG-1 is developmentally regulated and that VEPE might be an intermediate in the TG-1 biosynthesis. Finally, addition of TG-1 to mutants blocked in the biosynthesis of isovaleryl- CoA could restore aggregation and sporulation emphasizing the important role of iso-branched lipids for myxobacterial development.	Univ Saarland, Inst Pharmazeut Biotechnol, D-66041 Saarbrucken, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Org Chem, D-38106 Braunschweig, Germany; Deutsch Sammlung von Mikroorganismen & Zellkuture, D-38124 Braunschweig, Germany	Saarland University; Braunschweig University of Technology	Bode, HB (corresponding author), Univ Saarland, Inst Pharmazeut Biotechnol, D-66041 Saarbrucken, Germany.	h.bode@mx.uni-saarland.de	Bode, Helge B/F-7022-2014	Bode, Helge B/0000-0001-6048-5909; Schafer, Gertrud/0000-0001-5159-0539; Schulz, Stefan/0000-0002-4810-324X				Alvarez HM, 2002, APPL MICROBIOL BIOT, V60, P367, DOI 10.1007/s00253-002-1135-0; Alvarez HM, 2000, APPL MICROBIOL BIOT, V54, P218, DOI 10.1007/s002530050012; Alvarez HM, 1997, FETT-LIPID, V99, P239, DOI 10.1002/lipi.19970990704; Alvarez HM, 1996, ARCH MICROBIOL, V165, P377, DOI 10.1007/s002030050341; BAILEY SJ, 1983, J CHEM SOC PERK T 1, P851, DOI 10.1039/p19830000851; Biermann J, 1999, EUR J BIOCHEM, V261, P492, DOI 10.1046/j.1432-1327.1999.00295.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bode HB, 2005, J AM CHEM SOC, V127, P532, DOI 10.1021/ja043570y; Bode HB, 2006, J BACTERIOL, V188, P6524, DOI 10.1128/JB.00825-06; Bode HB, 2006, J BACTERIOL, V188, P5632, DOI 10.1128/JB.00438-06; BRETSCHER AP, 1978, J BACTERIOL, V133, P763, DOI 10.1128/JB.133.2.763-768.1978; Brouwers JFHM, 1999, J LIPID RES, V40, P164; CAILLON E, 1983, J BACTERIOL, V153, P1348, DOI 10.1128/JB.153.3.1348-1351.1983; Cheng CF, 1998, ANAL CHEM, V70, P4417, DOI 10.1021/ac9805192; COREY EJ, 1979, TETRAHEDRON LETT, P399; de Vet ECJM, 1999, J LIPID RES, V40, P1998; Dickschat JS, 2005, CHEMBIOCHEM, V6, P2023, DOI 10.1002/cbic.200500174; Dickschat JS, 2005, ORG BIOMOL CHEM, V3, P2824, DOI 10.1039/b504889c; DOWNARD J, 1993, J BACTERIOL, V175, P7762, DOI 10.1128/JB.175.24.7762-7770.1993; DOWNARD J, 1995, MOL MICROBIOL, V16, P171, DOI 10.1111/j.1365-2958.1995.tb02290.x; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; DWORKIN M, 1964, SCIENCE, V146, P243, DOI 10.1126/science.146.3641.243; Ellehauge E, 1998, MOL MICROBIOL, V30, P807, DOI 10.1046/j.1365-2958.1998.01113.x; FAUTZ E, 1979, J BACTERIOL, V140, P852, DOI 10.1128/JB.140.3.852-858.1979; FILER D, 1977, J BACTERIOL, V131, P751, DOI 10.1128/JB.131.3.751-758.1977; Gonzalez-Pastor JE, 2003, SCIENCE, V301, P510, DOI 10.1126/science.1086462; Han XL, 1995, J AM SOC MASS SPECTR, V6, P1202, DOI 10.1016/1044-0305(95)00568-4; Hsu FF, 1999, J AM SOC MASS SPECTR, V10, P587, DOI 10.1016/S1044-0305(99)00035-5; JOHNSON RY, 1972, J BACTERIOL, V112, P849, DOI 10.1128/JB.112.2.849-855.1972; JOHNSTON NC, 1994, EUR J BIOCHEM, V223, P957, DOI 10.1111/j.1432-1033.1994.tb19073.x; JOHNSTON NC, 1988, BIOCHIM BIOPHYS ACTA, V961, P1, DOI 10.1016/0005-2760(88)90124-5; KAISER D, 1979, P NATL ACAD SCI USA, V76, P5952, DOI 10.1073/pnas.76.11.5952; Kaiser D, 2004, ANNU REV MICROBIOL, V58, P75, DOI 10.1146/annurev.micro.58.030603.123620; Kearns DB, 2001, P NATL ACAD SCI USA, V98, P13990, DOI 10.1073/pnas.251484598; KOTTEL RH, 1975, J BACTERIOL, V124, P550, DOI 10.1128/JB.124.1.550-557.1975; KROOS L, 1987, GENE DEV, V1, P840, DOI 10.1101/gad.1.8.840; KROOS L, 1986, DEV BIOL, V117, P252, DOI 10.1016/0012-1606(86)90368-4; Kunze B, 2005, J ANTIBIOT, V58, P244, DOI 10.1038/ja.2005.28; KUSPA A, 1989, P NATL ACAD SCI USA, V86, P8917, DOI 10.1073/pnas.86.22.8917; Lewis T, 2000, J MICROBIOL METH, V43, P107, DOI 10.1016/S0167-7012(00)00217-7; Licking E, 2000, J BACTERIOL, V182, P3553, DOI 10.1128/JB.182.12.3553-3558.2000; Liu LR, 2006, WORLD J GASTROENTERO, V12, P539, DOI 10.3748/wjg.v12.i4.539; Lux R, 2005, MOL MICROBIOL, V58, P345, DOI 10.1111/j.1365-2958.2005.04856.x; MACDONALD DL, 1990, BIOCHEM CELL BIOL, V68, P225, DOI 10.1139/o90-030; Mahmud T, 2002, J BIOL CHEM, V277, P32768, DOI 10.1074/jbc.M205222200; Mahmud T, 2005, CHEMBIOCHEM, V6, P322, DOI 10.1002/cbic.200400261; MALINS DC, 1968, J LIPID RES, V9, P687; MCBRIDE MJ, 1989, J BACTERIOL, V171, P6383, DOI 10.1128/jb.171.11.6383-6386.1989; MICHAL G, 1999, BIOCH PATHWAYS, V1; Mouritsen OG, 2005, FRONT COLLECT, P1, DOI 10.1007/b138577; Nariya H, 2005, MOL MICROBIOL, V58, P367, DOI 10.1111/j.1365-2958.2005.04826.x; Nariya H, 2006, MOL MICROBIOL, V60, P1205, DOI 10.1111/j.1365-2958.2006.05178.x; OCONNOR KA, 1991, J BACTERIOL, V173, P3334, DOI 10.1128/jb.173.11.3334-3341.1991; OCONNOR KA, 1988, J BACTERIOL, V170, P4103, DOI 10.1128/jb.170.9.4103-4112.1988; OCONNOR KA, 1991, J BACTERIOL, V173, P3342, DOI 10.1128/jb.173.11.3342-3355.1991; Ogawa M, 1996, MOL MICROBIOL, V22, P757, DOI 10.1046/j.1365-2958.1996.d01-1725.x; ORLOWSKI M, 1974, J BACTERIOL, V118, P96, DOI 10.1128/JB.118.1.96-102.1974; ORLOWSKI M, 1972, Journal of Bacteriology, V111, P784; ORNDORFF PE, 1980, J BACTERIOL, V141, P914, DOI 10.1128/JB.141.2.914-927.1980; Pasciak M, 2003, J BIOL CHEM, V278, P3948, DOI 10.1074/jbc.M206013200; PRINS RA, 1976, FEBS LETT, V63, P107, DOI 10.1016/0014-5793(76)80204-9; PRINS RA, 1974, BIOCHIM BIOPHYS ACTA, V348, P361, DOI 10.1016/0005-2760(74)90216-1; Pulfer M, 2003, MASS SPECTROM REV, V22, P332, DOI 10.1002/mas.10061; Reichenbach H, 1999, ENVIRON MICROBIOL, V1, P15, DOI 10.1046/j.1462-2920.1999.00016.x; ROSENBLUH A, 1989, J BACTERIOL, V171, P4521, DOI 10.1128/JB.171.8.4521-4524.1989; ROSENBLUH A, 1989, J BACTERIOL, V171, P1513, DOI 10.1128/jb.171.3.1513-1518.1989; ROSENBLUH A, 1990, J BACTERIOL, V172, P4307, DOI 10.1128/jb.172.8.4307-4314.1990; Shimkets LJ, 1999, ANNU REV MICROBIOL, V53, P525, DOI 10.1146/annurev.micro.53.1.525; Silakowski B, 2001, CHEM BIOL, V8, P59, DOI 10.1016/S1074-5521(00)00056-9; Silakowski B, 1999, J BIOL CHEM, V274, P37391, DOI 10.1074/jbc.274.52.37391; Sogaard-Andersen L, 2003, MOL MICROBIOL, V48, P1, DOI 10.1046/j.1365-2958.2003.03399.x; SogaardAndersen L, 1996, GENE DEV, V10, P740, DOI 10.1101/gad.10.6.740; STARCK JP, 1995, TETRAHEDRON, V51, P2629, DOI 10.1016/0040-4020(95)00011-V; STEIN J, 1987, Z NATURFORSCH B, V42, P1017, DOI 10.1515/znb-1987-0815; Stoveken T, 2005, J BACTERIOL, V187, P1369, DOI 10.1128/JB.187.4.1369-1376.2005; TOAL DR, 1995, MOL MICROBIOL, V16, P177, DOI 10.1111/j.1365-2958.1995.tb02291.x; Tzeng LF, 2005, P NATL ACAD SCI USA, V102, P14428, DOI 10.1073/pnas.0506969102; VANDENBOSCH H, 1993, BIOCHIMIE, V75, P183, DOI 10.1016/0300-9084(93)90076-5; VANGOLDE LM, 1973, BIOCHIM BIOPHYS ACTA, V326, P314, DOI 10.1016/0005-2760(73)90133-1; VARON M, 1984, J BACTERIOL, V160, P1146, DOI 10.1128/JB.160.3.1146-1150.1984; Wagner F, 2000, EUR J BIOCHEM, V267, P6276, DOI 10.1046/j.1432-1327.2000.01709.x; Waltermann M, 2005, MOL MICROBIOL, V55, P750, DOI 10.1111/j.1365-2958.2004.04441.x; WARE JC, 1973, J BACTERIOL, V115, P253, DOI 10.1128/JB.115.1.253-261.1973	85	52	54	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36691	36700		10.1074/jbc.M607616200	http://dx.doi.org/10.1074/jbc.M607616200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16990257	hybrid			2022-12-25	WOS:000242220800026
J	Carroll, BT; Dubyak, GR; Sedensky, MM; Morgan, PG				Carroll, Bryan T.; Dubyak, George R.; Sedensky, Margaret M.; Morgan, Phil G.			Sulfated signal from ASJ sensory neurons modulates stomatin-dependent coordination in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; MEMBRANE-PROTEIN; CHEMOSENSORY NEURONS; VOLATILE ANESTHETICS; DEGENERIN INTERACT; PLASMA-MEMBRANE; DAUER FORMATION; NERVOUS-SYSTEM; FTSH HFLB; COMPLEX	The neuronal stomatin-like proteins UNC-1 and UNC-24 play important roles in the nervous system of Caenorhabditis elegans. These neuronal stomatin-like proteins are putative chaperone proteins that can modify volatile anesthetic sensitivity and disrupt coordinated locomotion. A suppressor of unc-1 and unc-24, named ssu-1(fc73) ( for suppressor of stomatin uncoordination), suppresses three phenotypes of neuronal stomatin-like protein deficiency as follows: volatile anesthetic sensitivity, uncoordinated locomotion, and a constitutive alternative developmental phenotype known as dauer. Here we provide the first phenotypic characterization of ssu-1, predicted to be the only C. elegans cytosolic alcohol sulfotransferase, a family of enzymes that catalyze a sulfate linkage with the alcohol group of small molecules for the purposes of detoxification or modification of signaling. In vitro enzyme analysis of bacterially expressed SSU-1 demonstrates sulfotransferase activity and thus confirms the function predicted by protein sequence similarities. Whereas unc-1 is expressed in the majority of neurons of C. elegans, expression of SSU-1 protein in only the two ASJ amphid interneurons is sufficient to restore the wild type phenotype. This work demonstrates that SSU- 1 is a functional sulfotransferase that likely modifies endocrine signaling in C. elegans. The expression of SSU- 1 in the ASJ neurons refines the understanding of the function of these cells and supports their classification as endocrine tissue. The relationship of unc-1, unc-24, and ssu-1 is the first association of neuronal stomatin-like proteins sharing regulatory roles with a sulfotransferase enzyme.	Univ Hosp & Case Sch Med, Dept Anesthesiol, Cleveland, OH 44106 USA; Univ Hosp & Case Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; Case Western Reserve University; Case Western Reserve University Hospital; Case Western Reserve University; Case Western Reserve University	Morgan, PG (corresponding author), Univ Hosp & Case Sch Med, Dept Anesthesiol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	philip.morgan@uhhs.com		Carroll, Bryan T/0000-0001-5712-6307; Dubyak, George/0000-0001-9720-4226	NIGMS NIH HHS [T32 GM07250, GM-45402] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, R01GM045402] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama Y, 1999, BIOCHEMISTRY-US, V38, P11693, DOI 10.1021/bi991177c; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asikainen S, 2005, NEUROREPORT, V16, P1995, DOI 10.1097/00001756-200512190-00005; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; Barnes TM, 1996, J NEUROCHEM, V67, P46; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; BRENNER S, 1974, GENETICS, V77, P71; Fricke B, 2003, BLOOD, V102, P2268, DOI 10.1182/blood-2002-06-1705; Fricke B, 2004, BRIT J HAEMATOL, V125, P796, DOI 10.1111/j.1365-2141.2004.04965.x; Gerisch B, 2001, DEV CELL, V1, P841, DOI 10.1016/S1534-5807(01)00085-5; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Hattori K, 2006, J BIOCHEM, V139, P355, DOI 10.1093/jb/mvj041; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; Javitt NB, 2001, ENDOCRINOLOGY, V142, P2978, DOI 10.1210/en.142.7.2978; Kihara A, 1996, EMBO J, V15, P6122, DOI 10.1002/j.1460-2075.1996.tb01000.x; Kihara A, 1997, P NATL ACAD SCI USA, V94, P5544, DOI 10.1073/pnas.94.11.5544; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; Li J, 2004, DEVELOPMENT, V131, P5741, DOI 10.1242/dev.01408; Ma B, 2003, DRUG METAB DISPOS, V31, P1300, DOI 10.1124/dmd.31.11.1300; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Matyash V, 2004, PLOS BIOL, V2, P1561, DOI 10.1371/journal.pbio.0020280; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORGAN PG, 1985, ANESTHESIOLOGY, V62, P738, DOI 10.1097/00000542-198506000-00007; MORGAN PG, 1990, P NATL ACAD SCI USA, V87, P2965, DOI 10.1073/pnas.87.8.2965; Motola DL, 2006, CELL, V124, P1209, DOI 10.1016/j.cell.2006.01.037; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; PARK EC, 1986, GENETICS, V113, P821; Price MP, 2004, J BIOL CHEM, V279, P53886, DOI 10.1074/jbc.M407708200; Rajaram S, 1999, GENETICS, V153, P1673; Rajaram S, 1998, P NATL ACAD SCI USA, V95, P8761, DOI 10.1073/pnas.95.15.8761; Riddle DL, 1997, C ELEGANS, P739; Saikawa N, 2004, J STRUCT BIOL, V146, P123, DOI 10.1016/j.jsb.2003.09.020; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Sedensky MM, 2004, AM J PHYSIOL-CELL PH, V287, pC468, DOI 10.1152/ajpcell.00182.2003; Sedensky MM, 2001, AM J PHYSIOL-CELL PH, V280, pC1340, DOI 10.1152/ajpcell.2001.280.5.C1340; Steglich G, 1999, MOL CELL BIOL, V19, P3435; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; STEWART GW, 2003, NEPHRON PHYSIOL, V93, P29; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040; van Swinderen B, 2002, GENETICS, V161, P109; WAUD DR, 1972, J PHARMACOL EXP THER, V183, P577; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; Zhang SF, 2004, CURR BIOL, V14, P1888, DOI 10.1016/j.cub.2004.10.030; Zhu YW, 1999, BLOOD, V93, P2404, DOI 10.1182/blood.V93.7.2404.407k13_2404_2410	48	19	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35989	35996		10.1074/jbc.M606086200	http://dx.doi.org/10.1074/jbc.M606086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16973616	hybrid			2022-12-25	WOS:000242100500046
J	Joseph, JW; Jensen, MV; Ilkayeva, O; Palmieri, F; Alarcon, C; Rhodes, CJ; Newgard, CB				Joseph, Jamie W.; Jensen, Mette V.; Ilkayeva, Olga; Palmieri, Ferdinando; Alarcon, Cristina; Rhodes, Christopher J.; Newgard, Christopher B.			The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC COUPLING FACTORS; NMR ISOTOPOMER ANALYSIS; MALONYL-COA; PANCREATIC-ISLETS; BETA-CELLS; PYRUVATE; ATP; ADENOVIRUS; GLUTAMATE; PATHWAY	Glucose-stimulated insulin secretion (GSIS) is mediated in part by glucose metabolism-driven increases in ATP/ADP ratio, but by-products of mitochondrial glucose metabolism also play an important role. Here we investigate the role of the mitochondrial citrate/isocitrate carrier (CIC) in regulation of GSIS. Inhibition of CIC activity in INS-1-derived 832/13 cells or primary rat islets by the substrate analogue 1,2,3-benzenetricarboxylate (BTC) resulted in potent inhibition of GSIS, involving both first and second phase secretion. A recombinant adenovirus containing a CIC-specific siRNA (Ad-siCIC) dose-dependently reduced CIC expression in 832/13 cells and caused parallel inhibitory effects on citrate accumulation in the cytosol. Ad-siCIC treatment did not affect glucose utilization, glucose oxidation, or ATP/ADP ratio but did inhibit glucose incorporation into fatty acids and glucose-induced increases in NADPH/NADP(+) ratio relative to cells treated with a control siRNA virus (Ad-siControl). Ad-siCIC also inhibited GSIS in 832/13 cells, whereas overexpression of CIC enhanced GSIS and raised cytosolic citrate levels. In normal rat islets, Ad-siCIC treatment also suppressed CIC mRNA levels and inhibited GSIS. We conclude that export of citrate and/or isocitrate from the mitochondria to the cytosol is an important step in control of GSIS.	Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Independence Pk Facil, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27704 USA; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; Univ Bari, Natl Res Council, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy; Univ Chicago, Dept Med, Ctr Diabet, Chicago, IL 60637 USA; Univ Chicago, Div Endocrine, Chicago, IL 60637 USA	Duke University; Duke University; Duke University; Duke University; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Chicago; University of Chicago	Newgard, CB (corresponding author), Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Independence Pk Facil, 4321 Med Pk Dr,Suite 200, Durham, NC 27704 USA.	newga002@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42583, DK58398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Boucher A, 2004, J BIOL CHEM, V279, P27263, DOI 10.1074/jbc.M401167200; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; CAPOBIANCO L, 1995, FEBS LETT, V357, P297, DOI 10.1016/0014-5793(94)01379-F; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; Cline GW, 2004, J BIOL CHEM, V279, P44370, DOI 10.1074/jbc.M311842200; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Deeney JT, 2000, SEMIN CELL DEV BIOL, V11, P267, DOI 10.1006/scdb.2000.0175; Fox JEM, 2004, MOL ENDOCRINOL, V18, P679, DOI 10.1210/me.2003-0431; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; HENQUIN JC, 1987, HORM RES, V27, P168, DOI 10.1159/000180806; Henquin JC, 2004, DIABETES, V53, pS48, DOI 10.2337/diabetes.53.suppl_3.S48; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; Ivarsson R, 2005, DIABETES, V54, P2132, DOI 10.2337/diabetes.54.7.2132; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; Koshkin V, 2004, J BIOL CHEM, V279, P41368, DOI 10.1074/jbc.M406914200; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MacDonald PE, 2005, PHILOS T R SOC B, V360, P2211, DOI 10.1098/rstb.2005.1762; MacDonald PE, 2003, J PHYSIOL-LONDON, V546, P647, DOI 10.1113/jphysiol.2002.035709; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 2000, J PHYSIOL-LONDON, V529, P49, DOI 10.1111/j.1469-7793.2000.00049.x; Matschinsky F.M., 2001, HDB PHYSL 7, P125; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Rabaglia ME, 2005, AM J PHYSIOL-ENDOC M, V289, pE218, DOI 10.1152/ajpendo.00573.2004; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; Ronnebaum SM, 2006, J BIOL CHEM, V281, P30593, DOI 10.1074/jbc.M511908200; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; Stanley CA, 2004, MOL GENET METAB, V81, pS45, DOI 10.1016/j.ymgme.2003.10.013	49	127	132	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35624	35632		10.1074/jbc.M602606200	http://dx.doi.org/10.1074/jbc.M602606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17001083	hybrid			2022-12-25	WOS:000242100500007
J	Lampert, A; Dib-Hajj, SD; Tyrrell, L; Waxman, SG				Lampert, Angelika; Dib-Hajj, Sulayman D.; Tyrrell, Lynda; Waxman, Stephen G.			Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNEL; DEPENDENT K+ CHANNEL; FAMILIAL PERIODIC PARALYSIS; CLOSED-STATE INACTIVATION; OF-FUNCTION MUTATION; MUSCLE NA+ CHANNEL; VOLTAGE-SENSOR; S4-S5 LINKER; ALPHA-SUBUNIT; PARAMYOTONIA-CONGENITA	The Nav1.7 sodium channel is preferentially expressed in most nociceptive dorsal root ganglion neurons and in sympathetic neurons. Inherited erythromelalgia (IEM, also known as erythermalgia), an autosomal dominant neuropathy characterized by burning pain in the extremities in response to mild warmth, has been linked to mutations in Nav1.7. Recently, a substitution of Ser-241 by threonine (S241T)in the domain I S4-S5 linker of Nav1.7 was identified in a family with IEM. To investigate the possible causative role of this mutation in the pathophysiology of IEM, we used whole-cell voltage-clamp analysis to study the effects of S241T on Nav1.7 gating in HEK293 cells. We found a hyperpolarizing shift of activation midpoint by 8.4 mV, an accelerated time to peak, slowing of deactivation, and an increase in the current in response to small, slow depolarizations. Additionally, S241T produced an enhancement of slow inactivation, shifting the midpoint by -12.3 mV. Because serine and threonine have similar biochemical properties, the S241T substitution suggested that the size of the side chain at this position affected channel gating. To test this hypothesis, we investigated the effect of S241A and S241L substitutions on the gating properties of Nav1.7. Although S241A did not alter the properties of the channel, S241L mimicked the effects of S241T. We conclude that the linker between S4 and S5 in domain I of Nav1.7 modulates gating of this channel, and that a larger side chain at position 241 interferes with its gating mechanisms.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06520 USA; Vet Affairs Connecticut Healthcare Ctr, Rehabil Res Ctr, West Haven, CT 06516 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Waxman, SG (corresponding author), Yale Univ, Sch Med, Dept Neurol, LCI 707,POB 208018, New Haven, CT 06520 USA.	Stephen.Waxman@yale.edu	Waxman, Stephen/Z-2507-2019; Lampert, Angelika/F-7198-2010	Waxman, Stephen/0000-0001-5718-7177; Lampert, Angelika/0000-0001-6319-6272				Bendahhou S, 2002, NEUROLOGY, V58, P1266, DOI 10.1212/WNL.58.8.1266; Bezanilla F, 2005, TRENDS BIOCHEM SCI, V30, P166, DOI 10.1016/j.tibs.2005.02.006; Bouhours M, 2005, J PHYSIOL-LONDON, V565, P415, DOI 10.1113/jphysiol.2004.081018; Cannon SC, 2002, NEUROMUSCULAR DISORD, V12, P533, DOI 10.1016/S0960-8966(02)00007-X; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; CHOI JS, 2006, NEUROLOGY; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; Cummins TR, 1998, J NEUROSCI, V18, P9607; CUMMINS TR, 1993, NEURON, V10, P667, DOI 10.1016/0896-6273(93)90168-Q; Cummins TR, 2004, J NEUROSCI, V24, P8232, DOI 10.1523/JNEUROSCI.2695-04.2004; Dib-Hajj SD, 2005, BRAIN, V128, P1847, DOI 10.1093/brain/awh514; Drenth JPH, 2005, J INVEST DERMATOL, V124, P1333, DOI 10.1111/j.0022-202X.2005.23737.x; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; Ferrer T, 2006, J BIOL CHEM, V281, P12858, DOI 10.1074/jbc.M513518200; Filatov GN, 1998, J GEN PHYSIOL, V111, P703, DOI 10.1085/jgp.111.6.703; Fleischhauer R, 1998, PFLUG ARCH EUR J PHY, V436, P757, DOI 10.1007/s004240050699; George AL, 2005, J CLIN INVEST, V115, P1990, DOI 10.1172/JCI25505; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Han CY, 2006, ANN NEUROL, V59, P553, DOI 10.1002/ana.20776; Hayward LJ, 1999, NEUROLOGY, V52, P1447, DOI 10.1212/WNL.52.7.1447; Herzog RI, 2003, J PHYSIOL-LONDON, V551, P741, DOI 10.1113/jphysiol.2003.047357; Jiang QX, 2004, NATURE, V430, P806, DOI 10.1038/nature02735; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Lerche H, 1997, J PHYSIOL-LONDON, V505, P345, DOI 10.1111/j.1469-7793.1997.345bb.x; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; MacKinnon R, 2004, SCIENCE, V306, P1304, DOI 10.1126/science.1105528; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; Meisler MH, 2005, J CLIN INVEST, V115, P2010, DOI 10.1172/JCI25466; Meregalli PG, 2005, CARDIOVASC RES, V67, P367, DOI 10.1016/j.cardiores.2005.03.005; Michiels JJ, 2005, ARCH NEUROL-CHICAGO, V62, P1587, DOI 10.1001/archneur.62.10.1587; Mitrovic N, 1996, NEUROSCI LETT, V214, P9; O'Reilly AO, 2006, BIOCHEM J, V396, P255, DOI 10.1042/BJ20051925; Popa MO, 2004, J PHYSIOL-LONDON, V561, P39, DOI 10.1113/jphysiol.2004.065912; Richmond JE, 1997, BIOPHYS J, V73, P1896, DOI 10.1016/S0006-3495(97)78220-1; Rush AM, 2006, P NATL ACAD SCI USA, V103, P8245, DOI 10.1073/pnas.0602813103; Sangameswaran L, 1997, J BIOL CHEM, V272, P14805, DOI 10.1074/jbc.272.23.14805; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Smith MR, 1999, NEUROREPORT, V10, P3027, DOI 10.1097/00001756-199909290-00028; Smith MR, 1997, BIOPHYS J, V73, P1885, DOI 10.1016/S0006-3495(97)78219-5; Smits JPP, 2005, CARDIOVASC RES, V67, P459, DOI 10.1016/j.cardiores.2005.01.017; Sugiura Y, 2003, NEUROLOGY, V61, P914, DOI 10.1212/01.WNL.0000086820.54065.A0; Tang LH, 1996, J GEN PHYSIOL, V108, P89, DOI 10.1085/jgp.108.2.89; ToledoAral JJ, 1997, P NATL ACAD SCI USA, V94, P1527, DOI 10.1073/pnas.94.4.1527; Tottene A, 2005, J BIOL CHEM, V280, P17678, DOI 10.1074/jbc.M501110200; TRIMMER JS, 1990, DEV BIOL, V142, P360, DOI 10.1016/0012-1606(90)90356-N; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Tsujino A, 2003, P NATL ACAD SCI USA, V100, P7377, DOI 10.1073/pnas.1230273100; Vicart S, 2005, NEUROL SCI, V26, P194, DOI 10.1007/s10072-005-0461-x; Waxman SG, 2005, TRENDS MOL MED, V11, P555, DOI 10.1016/j.molmed.2005.10.004; Yamakawa K, 2005, NEUROREPORT, V16, P1, DOI 10.1097/00001756-200501190-00001; Yang Y, 2004, J MED GENET, V41, P171, DOI 10.1136/jmg.2003.012153; Yarov-Yarovoy V, 2006, P NATL ACAD SCI USA, V103, P7292, DOI 10.1073/pnas.0602350103	55	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36029	36035		10.1074/jbc.M607637200	http://dx.doi.org/10.1074/jbc.M607637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008310	hybrid			2022-12-25	WOS:000242100500051
J	Choi, SM; Choi, KO; Park, YK; Cho, H; Yang, EG; Park, H				Choi, Su Mi; Choi, Kyung-Ok; Park, Young-Kwon; Cho, Hyunju; Yang, Eun Gyeong; Park, Hyunsung			Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1 alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; ZINC CHELATOR; HIF-ALPHA; IN-VIVO; DISEASE; PROLYL; BRAIN; NEUROPROTECTION	We found that the Cu(II) and Zn(II)-specific chelator Clioquinol (10-50 mu M) increased functional hypoxia-inducible factor 1 alpha(HIF-1 alpha) protein, leading to increased expression of its target genes, vascular endothelial growth factors and erythropoietin, in SH-SY5Y cells and HepG2 cells. Clioquinol inhibited ubiquitination of HIF-1 alpha in a Cu(II)- and Zn(II)-dependent manner. It prevents FIH-1 from hydroxylating the asparagine residue (803) of HIF-1 alpha in a Cu(II)- and Zn(II)-independent fashion. Therefore, it leads to the accumulation of HIF-1 alpha that is prolyl but not asparaginyl hydroxylated. Consistent with this, co-immunoprecipitation assays showed that Clioquinol-induced HIF-1 alpha interacted with cAMP-responsive element-binding protein in normoxic cells, implying that Clioquinol stabilizes the trans-active form of HIF-1 alpha. Our results indicate that Clioquinol could be useful as an inducer of HIF-1 alpha and its target genes in ischemic diseases.	Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Korea Inst Sci & Technol, Div Life Sci, Seoul 136791, South Korea	University of Seoul; Korea Institute of Science & Technology (KIST)	Park, H (corresponding author), Univ Seoul, Dept Life Sci, 90 Cheonnong Dong, Seoul 130743, South Korea.	hspark@uos.ac.kr		Park, Young-Kwon/0000-0002-3473-7233				AGRAWAL YK, 1986, J PHARM SCI, V75, P190, DOI 10.1002/jps.2600750219; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Choi KO, 2005, MOL PHARMACOL, V68, P1803, DOI 10.1124/mol.105.015271; Choi SM, 2006, BIOCHEM BIOPH RES CO, V343, P1002, DOI 10.1016/j.bbrc.2006.03.039; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ding WQ, 2005, CANCER RES, V65, P3389, DOI 10.1158/0008-5472.CAN-04-3577; Doraiswamy PM, 2004, LANCET NEUROL, V3, P431, DOI 10.1016/S1474-4422(04)00809-9; Ehrenreich H, 2004, METAB BRAIN DIS, V19, P195, DOI 10.1023/B:MEBR.0000043969.96895.3c; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferriero DM, 2005, EPILEPSIA, V46, P45, DOI 10.1111/j.1528-1167.2005.00302.x; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li LM, 2005, CANCER RES, V65, P7249, DOI 10.1158/0008-5472.CAN-04-4426; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Natarajan R, 2006, CIRC RES, V98, P133, DOI 10.1161/01.RES.0000197816.63513.27; Nguyen T, 2005, P NATL ACAD SCI USA, V102, P11840, DOI 10.1073/pnas.0502177102; Raman B, 2005, J BIOL CHEM, V280, P16157, DOI 10.1074/jbc.M500309200; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; Simons M, 2003, NAT REV DRUG DISCOV, V2, P863, DOI 10.1038/nrd1226; Zhu W, 2005, NEUROSURGERY, V57, P325, DOI 10.1227/01.NEU.0000166682.50272.BC	42	56	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34056	34063		10.1074/jbc.M603913200	http://dx.doi.org/10.1074/jbc.M603913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973622	hybrid			2022-12-25	WOS:000241767600026
J	O'Hara, L; Han, GS; Peak-Chew, S; Grimsey, N; Carman, GM; Siniossoglou, S				O'Hara, Laura; Han, Gil-Soo; Peak-Chew, Sew; Grimsey, Neil; Carman, George M.; Siniossoglou, Symeon			Control of phospholipid synthesis by phosphorylation of the yeast lipin Pah1p/Smp2p Mg2+-dependent phosphatidate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; SACCHAROMYCES-CEREVISIAE; NUCLEAR-ENVELOPE; ENDOPLASMIC-RETICULUM; MEMBRANE; BIOSYNTHESIS; METABOLISM; COMPLEX; SUPERFAMILY; BIOGENESIS	Phosphorylation of the conserved lipin Pah1p/Smp2p in Saccharomyces cerevisiae was previously shown to control transcription of phospholipid biosynthetic genes and nuclear structure by regulating the amount of membrane present at the nuclear envelope (Santos-Rosa, H., Leung, J., Grimsey, N., Peak-Chew, S., and Siniossoglou, S. (2005) EMBO J. 24, 1931 1941). A recent report identified Pah1p as a Mg2+-dependent phosphatidate (PA) phosphatase that regulates de novo lipid synthesis (Han G.-S., Wu, W. I., and Carman, G. M. ( 2006) J. Biol. Chem. 281, 9210-9218). In this work we use a combination of mass spectrometry and systematic mutagenesis to identify seven Ser/Thr-Pro motifs within Pah1p that are phosphorylated in vivo. We show that phosphorylation on these sites is required for the efficient transcriptional derepression of key enzymes involved in phospholipid biosynthesis. The phosphorylation-deficient Pah1p exhibits higher PA phosphatase-specific activity than the wild-type Pah1p, indicating that phosphorylation of Pah1p controls PA production. Opi1p is a transcriptional repressor of phospholipid biosynthetic genes, responding to PA levels. Genetic analysis suggests that Pah1p regulates transcription of these genes through both Opi1p-dependent and -independent mechanisms. We also provide evidence that derepression of phospholipid biosynthetic genes is not sufficient to induce the nuclear membrane expansion shown in the pah1 Delta cells.	Univ Cambridge, Wellcome Trust, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; Wellcome Trust Sanger Institute; Rutgers State University New Brunswick; MRC Laboratory Molecular Biology	Siniossoglou, S (corresponding author), Univ Cambridge, Wellcome Trust, Cambridge Inst Med Res, MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	ss560@cam.ac.uk	Grimsey, Neil/B-1634-2015; Grimsey, Neil/AAB-9153-2020	Grimsey, Neil/0000-0002-0481-4920; Grimsey, Neil/0000-0002-0481-4920; O'Hara, Laura/0000-0001-7790-9261	Medical Research Council [G0701446] Funding Source: Medline; NIGMS NIH HHS [GM-28140, R37 GM028140, R01 GM028140] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athenstaedt K, 2006, CELL MOL LIFE SCI, V63, P1355, DOI 10.1007/s00018-006-6016-8; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Campbell JL, 2006, MOL BIOL CELL, V17, P1768, DOI 10.1091/mbc.E05-09-0839; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dephoure N, 2005, P NATL ACAD SCI USA, V102, P17940, DOI 10.1073/pnas.0509080102; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LIN YP, 1989, J BIOL CHEM, V264, P8641; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Madera M, 2004, NUCLEIC ACIDS RES, V32, pD235, DOI 10.1093/nar/gkh117; Mah Angie S., 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-22; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; Nunnari J, 1996, CELL, V84, P389, DOI 10.1016/S0092-8674(00)81283-0; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Prunuske AJ, 2006, CURR OPIN CELL BIOL, V18, P108, DOI 10.1016/j.ceb.2005.12.004; Ptacek J, 2005, NATURE, V438, P679, DOI 10.1038/nature04187; Pyne S, 2005, BIOCHEM SOC T, V33, P1370, DOI 10.1042/BST0331370; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Rudge SA, 2004, MOL BIOL CELL, V15, P207, DOI 10.1091/mbc.e03-04-0245; Santos-Rosa H, 2005, EMBO J, V24, P1931, DOI 10.1038/sj.emboj.7600672; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; Shemesh T, 2003, BIOPHYS J, V85, P3813, DOI 10.1016/S0006-3495(03)74796-1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siniossoglou S, 1998, EMBO J, V17, P6449, DOI 10.1093/emboj/17.22.6449; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Stensballe A, 2001, PROTEOMICS, V1, P207, DOI 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.3.CO;2-V; Tange Y, 2002, J CELL SCI, V115, P4375, DOI 10.1242/jcs.00135; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429	48	146	152	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34537	34548		10.1074/jbc.M606654200	http://dx.doi.org/10.1074/jbc.M606654200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968695	Green Accepted, hybrid			2022-12-25	WOS:000241767600074
J	Ferreira-da-Silva, F; Pereira, PJB; Gales, L; Roessle, M; Svergun, DI; Moradas-Ferreira, P; Damas, AM				Ferreira-da-Silva, Frederico; Pereira, Pedro J. B.; Gales, Luis; Roessle, Manfred; Svergun, Dmitri I.; Moradas-Ferreira, Pedro; Damas, Ana M.			The crystal and solution structures of glyceraldehyde-3-phosphate dehydrogenase reveal different quaternary structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-WALL; HOLO-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GLYCERAIDEHYDE-3-PHOSPHATE DEHYDROGENASE; KLUYVEROMYCES-MARXIANUS; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SCHISTOSOMA-MANSONI; CANDIDA-ALBICANS; PROTEIN; GENE	The presence of an isoform of glyceraldehyde-3-phosphate dehydrogenase (kmGAPDH1p) associated with the cell wall of a flocculent strain of Kluyveromyces marxianus was the first report of a non-cytosolic localization of a glycolytic enzyme, but the mechanism by which the protein is transported to the cell surface is not known. To identify structural features that could account for the multiple localizations of the protein, the three-dimensional structure of kmGAPDH1p was determined by x-ray crystallography and small angle x-ray scattering. The x-ray crystallographic structure of kmGAPDH1p revealed a dimer, although all GAPDH homologs studied thus far have a tetrameric structure with 222 symmetry. Interestingly, the structure of kmGAPDH1p in solution revealed a tetramer with a 70 degrees tilt angle between the dimers. Moreover, the separation between the centers of the dimers composing the kmGAPDH1p tetramer diminished from 34 to 30 angstrom upon NAD(+) binding, this latter value being similar to the observed in the crystallographic models of GAPDH homologs. The less compact structure of apo-kmGAPDH1p could already be the first image of the transition intermediate between the tetramer observed in solution and the dimeric form found in the crystal structure, which we postulate to exist in vivo because of the protein's multiple subcellular localizations in this yeast species.	Univ Porto, Inst Mol & Cellular Biol, P-4150180 Oporto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	Universidade do Porto; Universidade do Porto; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Damas, AM (corresponding author), Univ Porto, Inst Mol & Cellular Biol, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	amdamas@ibmc.up.pt	Pereira, Pedro/F-8972-2011; Silva, Frederico F/K-3820-2013; MORADAS-FERREIRA, PEDRO/E-6357-2012; Gales, Luis/J-8716-2013	Pereira, Pedro/0000-0003-0969-5438; Silva, Frederico F/0000-0002-8890-4228; MORADAS-FERREIRA, PEDRO/0000-0003-2994-0314; Gales, Luis/0000-0002-8352-6539; Rossle, Manfred/0000-0003-4196-0430; Svergun, Dmitri/0000-0003-0830-5696				Andrade J, 2004, BIOCHEM J, V384, P327, DOI 10.1042/BJ20040622; Angiolella L, 1996, J INFECT DIS, V173, P684, DOI 10.1093/infdis/173.3.684; Antonyuk SV, 2003, ACTA CRYSTALLOGR D, V59, P835, DOI 10.1107/S0907444903041441; Arutyunova EI, 2003, BIOCHEM BIOPH RES CO, V307, P547, DOI 10.1016/S0006-291X(03)01222-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998; Charron C, 1999, ACTA CRYSTALLOGR D, V55, P1353, DOI 10.1107/S0907444999005363; Cowan-Jacob SW, 2003, ACTA CRYSTALLOGR D, V59, P2218, DOI 10.1107/S0907444903020493; DeLano WL, 2004, PYMOL MOL GRAPHICS S; Delgado ML, 2003, YEAST, V20, P713, DOI 10.1002/yea.993; Delgado ML, 2001, MICROBIOL-SGM, V147, P411, DOI 10.1099/00221287-147-2-411; Duee E, 1996, J MOL BIOL, V257, P814, DOI 10.1006/jmbi.1996.0204; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; Falcao-Moreira R, 2000, YEAST, V16, P231; FERNANDES PA, 1995, YEAST, V11, P725, DOI 10.1002/yea.320110804; FERNANDES PA, 1993, YEAST, V9, P859, DOI 10.1002/yea.320090806; FERNANDES PA, 1992, BIOCHIM BIOPHYS ACTA, V1159, P67, DOI 10.1016/0167-4838(92)90076-P; Fleming TM, 1998, ACTA CRYSTALLOGR D, V54, P671, DOI 10.1107/S0907444997018076; GARCIA DLT, 2000, BIOPHYS J, V78, P719; GOUDOTCROZEL V, 1989, J EXP MED, V170, P2065, DOI 10.1084/jem.170.6.2065; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Ismail SA, 2005, ACTA CRYSTALLOGR D, V61, P1508, DOI 10.1107/S0907444905026740; KIHN JC, 1988, CAN J MICROBIOL, V34, P773, DOI 10.1139/m88-131; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LEE KW, 1995, MOL BIOCHEM PARASIT, V71, P221, DOI 10.1016/0166-6851(95)91598-O; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; Moreira RF, 1998, MICROBIOL-SGM, V144, P681, DOI 10.1099/00221287-144-3-681; MURTHY MRN, 1980, J MOL BIOL, V138, P859, DOI 10.1016/0022-2836(80)90069-8; Nakagawa T, 2003, J BIOL CHEM, V278, P20395, DOI 10.1074/jbc.M210824200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nombela C, 2006, TRENDS MICROBIOL, V14, P15, DOI 10.1016/j.tim.2005.11.009; Pardo M, 1999, YEAST, V15, P459, DOI 10.1002/(SICI)1097-0061(199904)15:6<459::AID-YEA387>3.0.CO;2-L; Pavao F, 2002, FEBS LETT, V520, P13, DOI 10.1016/S0014-5793(02)02700-X; Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154; Robien MA, 2006, PROTEINS, V62, P570, DOI 10.1002/prot.20801; Roitel O, 2003, J MOL BIOL, V326, P1513, DOI 10.1016/S0022-2836(03)00049-4; ROUSSEL A, 1989, TURBO FRODO SILICON; Shen YQ, 2000, J STRUCT BIOL, V130, P1, DOI 10.1006/jsbi.2000.4220; SHOEMAKER C, 1992, P NATL ACAD SCI USA, V89, P1842, DOI 10.1073/pnas.89.5.1842; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; Song SY, 1998, ACTA CRYSTALLOGR D, V54, P558, DOI 10.1107/S090744499701620X; Suresh S, 2001, J MOL BIOL, V309, P423, DOI 10.1006/jmbi.2001.4588; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2000, J BIOL CHEM, V275, P297, DOI 10.1074/jbc.275.1.297; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; Terao Y, 2006, J BIOL CHEM, V281, P14215, DOI 10.1074/jbc.M513408200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tisdale EJ, 2004, J BIOL CHEM, V279, P54046, DOI 10.1074/jbc.M409472200; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; YANG WG, 1994, MOL BIOCHEM PARASIT, V64, P253, DOI 10.1016/0166-6851(93)00020-A; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	64	23	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33433	33440		10.1074/jbc.M605267200	http://dx.doi.org/10.1074/jbc.M605267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963457	hybrid			2022-12-25	WOS:000241621400053
J	Li, L; Shaw, PE				Li, Li; Shaw, Peter E.			Elevated activity of STAT3C due to higher DNA binding affinity of phosphotyrosine dimer rather than covalent dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; TYROSINE PHOSPHORYLATION; ACTIVATION; CELLS; PROTEINS; DIMERIZATION; DOMAINS	Signal transducer and activator of transcription (STAT) proteins are involved in cell proliferation and survival, aspects of tissue differentiation and immune function. STAT3 appears to be fundamentally important for vertebrate organisms, being required for the self-renewal of embryonal stem cells in response to leukemia inhibitory factor signaling and for proliferation of some somatic cell types. Moreover, STAT3 is up-regulated in a range of tumors, and a modified version of STAT3 (STAT3C) has been shown to function as an oncogene, whereas inhibition of STAT3 can suppress tumor cell growth. The constitutive activity of oncogenic STAT3C was reported to depend on spontaneous dimerization directed by disulfide bonds in the absence of tyrosine phosphorylation. In fact, tyrosine phosphorylation consequent upon cytokine or mitogen-induced signaling events remains obligatory for STAT3C activation. Instead, the DNA-binding affinity of phospho-STAT3C is elevated resulting in a faster on-rate and slower off-rate. The faster onrate sensitizes STAT3C to cytokine stimulation, and the slower off-rate protects it from inactivation by nuclear phosphatases. These changes account for the ability of STAT3C to up- regulate persistently the expression of STAT3 target genes and promote cell cycle progression.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Ctr Biochem & Cell Biol, Nottingham NG7 2UH, England	University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Ctr Biochem & Cell Biol, Nottingham NG7 2UH, England.	shaw@nottingham.ac.uk		SHAW, Peter/0000-0002-2598-4283				Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; Chen XM, 2003, PROTEIN SCI, V12, P361, DOI 10.1110/ps.0218903; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Liddle FJ, 2006, BIOCHEMISTRY-US, V45, P5599, DOI 10.1021/bi0525674; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Neculai D, 2005, J BIOL CHEM, V280, P40782, DOI 10.1074/jbc.M507682200; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Schroder M, 2004, J LEUKOCYTE BIOL, V75, P792, DOI 10.1189/jlb.1003496; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Taylor JD, 2000, NUCLEIC ACID PROTOCOLS HANDBOOK, P745; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2005, J BIOL CHEM, V280, P34306, DOI 10.1074/jbc.M503263200; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102	39	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33172	33181		10.1074/jbc.M606940200	http://dx.doi.org/10.1074/jbc.M606940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956893	hybrid			2022-12-25	WOS:000241621400025
J	Nho, RS; Xia, H; Diebold, D; Kahm, J; Kleidon, J; White, E; Henke, CA				Nho, Richard Seonghun; Xia, Hong; Diebold, Deanna; Kahm, Judy; Kleidon, Jill; White, Eric; Henke, Craig A.			PTEN regulates fibroblast elimination during collagen matrix contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; VIABILITY SIGNALING PATHWAY; FOCAL ADHESION KINASE; GRANULATION-TISSUE; PULMONARY FIBROSIS; PROTEIN STABILITY; SURVIVAL PATHWAY; CELL-SURVIVAL; APOPTOSIS; ACTIN	During tissue repair, excess fibroblasts are eliminated by apoptosis. This physiologic process limits fibrosis and restores normal anatomic patterns. Replicating physiologic apoptosis associated with tissue repair, fibroblasts incorporated into type I collagen matrices undergo apoptosis in response to collagen matrix contraction. In this in vitro model of wound repair, fibroblasts first attach to collagen via alpha 2 beta 1 integrin. This provides a survival signal via activation of the phosphatidylinositol 3-kinase/Akt signal pathway. However, during subsequent collagen matrix contraction, the level of phosphorylated Akt progressively declines, triggering apoptosis. The mechanism underlying the fall in phosphorylated Akt is incompletely understood. Here we show that PTEN phosphatase becomes activated during collagen matrix contraction and is responsible for antagonizing phosphatidylinositol 3-kinase activity and promoting a decline in phosphorylated Akt and fibroblast apoptosis in response to collagen contraction. PTEN null fibroblasts displayed enhanced levels of phosphorylated Akt and were resistant to collagen matrix contraction-induced apoptosis. Reconstitution of PTEN in PTEN null cells conferred susceptibility to apoptosis in response to contraction of collagen matrices. Consistent with this, knockdown of PTEN in PTEN+/+ embryonic fibroblasts by small interfering RNA augmented Akt activity and suppressed apoptosis in contractile collagen matrices. Furthermore, inhibition of Akt activity restored the sensitivity of PTEN null cells to collagen contraction-induced apoptosis, indicating that the mechanism by which PTEN alters fibroblast viability is through modulation of phosphorylated Akt levels. Our work suggests that collagen matrix contraction activates PTEN by a mechanism involving cytoskeletal disassembly. Our studies indicate a key role for PTEN in regulating fibroblast viability during tissue repair.	Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan	Nho, RS (corresponding author), Univ Minnesota, Dept Med, Box 276,420 Delaware St SE, Minneapolis, MN 55455 USA.	nhoxx002@umn.edu; henke002@umn.edu		White, Eric/0000-0003-4060-8443	NHLBI NIH HHS [R01 HL085083, L30 HL074723] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berry DP, 1998, PLAST RECONSTR SURG, V102, P124, DOI 10.1097/00006534-199807000-00019; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Cooke ME, 2000, J CELL SCI, V113, P2375; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FUKUDA Y, 1987, AM J PATHOL, V126, P171; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Huang YP, 2005, ONCOGENE, V24, P3819, DOI 10.1038/sj.onc.1208527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; KUHN C, 1991, AM J PATHOL, V138, P1257; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lin YC, 1997, MOL BIOL CELL, V8, P59, DOI 10.1091/mbc.8.1.59; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yamada KM, 2001, J CELL SCI, V114, P2375	34	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33291	33301		10.1074/jbc.M606450200	http://dx.doi.org/10.1074/jbc.M606450200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963781	hybrid			2022-12-25	WOS:000241621400039
J	Samardzija, M; Wenzel, A; Aufenberg, S; Thiersch, M; Reme, C; Grimm, C				Samardzija, Marijana; Wenzel, Andreas; Aufenberg, Svenja; Thiersch, Markus; Reme, Charlotte; Grimm, Christian			Differential role of Jak-STAT signaling in retinal degenerations	FASEB JOURNAL			English	Article						apoptosis; neuroprotection; photoreceptor	CILIARY NEUROTROPHIC FACTOR; FIBRILLARY ACIDIC PROTEIN; EPITHELIUM-DERIVED FACTOR; APOPTOTIC CELL-DEATH; LIGHT-INDUCED DAMAGE; MOUSE RETINA; RAT RETINA; PHOTORECEPTOR APOPTOSIS; UP-REGULATION; MULLER CELLS	Retinal degeneration is a major cause of severe visual impairment or blindness. Understanding the underlying molecular mechanisms is a prerequisite to develop therapeutic approaches for human patients. We show in three mouse models that induced and inherited retinal degeneration induces LIF and CLC as members of the interleukin (IL)-6 family of proteins, activates proteins of the Jak-STAT signaling pathway, and up-regulates suppressors of cytokine signaling as a negative feedback loop. Inhibition of Jak2 leads to protection of photoreceptors in a model of induced but not in a model of inherited retinal degeneration. Differential activation of Akt suggests alternative pathways for cell death and/or survival in different models. Proteins induced during photoreceptor degeneration are not mainly expressed in photoreceptors but in cells of other retinal layers. This suggests a model in which photoreceptor injury is signaled to cells of the inner retina, which in turn initiate a response either to support viability or accelerate death of injured cells.	Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CIHP, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, ZNZ, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Grimm, C (corresponding author), Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CIHP, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.	cgrimm@opht.unizh.ch	Samardzija, Marijana/B-9245-2008; Thiersch, Markus/AGN-3176-2022	Samardzija, Marijana/0000-0003-0991-4653; Thiersch, Markus/0000-0002-9118-8285; Grimm, Christian/0000-0001-9318-4352				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beltran WA, 2005, MOL VIS, V11, P232; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burdelya L, 2002, MOL CANCER THER, V1, P893; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328; Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Casson RJ, 2004, INVEST OPHTH VIS SCI, V45, P685, DOI 10.1167/iovs.03-0674; Chun MH, 2000, BRAIN RES, V868, P358, DOI 10.1016/S0006-8993(00)02305-2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; deRaad S, 1996, OPHTHALMIC RES, V28, P99, DOI 10.1159/000267881; Dikdan GS, 2004, SURGERY, V136, P677, DOI 10.1016/j.surg.2004.02.005; Graham DR, 2005, INVEST OPHTH VIS SCI, V46, P2601, DOI 10.1167/iovs.05-0129; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Harada C, 2003, NEUROSCIENCE, V122, P229, DOI 10.1016/S0306-4522(03)00599-2; Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002; Harada T, 2000, NEURON, V26, P533, DOI 10.1016/S0896-6273(00)81185-X; Ikeda K, 2004, CURR EYE RES, V29, P349, DOI 10.1080/02713680490516279; Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155; Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x; Johnson LE, 2005, CELL TISSUE RES, V320, P213, DOI 10.1007/s00441-004-1046-8; Jomary C, 2006, INVEST OPHTH VIS SCI, V47, P1620, DOI 10.1167/iovs.05-1176; Kaldi I, 2003, EXP EYE RES, V76, P453, DOI 10.1016/S0014-4835(02)00334-2; Krebs DL, 2000, J CELL SCI, V113, P2813; Kueng-Hitz N, 2000, INVEST OPHTH VIS SCI, V41, P909; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Naash MI, 1996, J NEUROSCI, V16, P7853; Neophytou C, 1997, DEVELOPMENT, V124, P2345; Nir I, 1999, INVEST OPHTH VIS SCI, V40, P2383; Organisciak DT, 1999, PHOTOCHEM PHOTOBIOL, V70, P261, DOI 10.1562/0031-8655(1999)070<0261:LIDITR>2.3.CO;2; Peterson WM, 2000, J NEUROSCI, V20, P4081; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Ranchon I, 2001, INVEST OPHTH VIS SCI, V42, P1375; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Rhee KD, 2003, MOL VIS, V9, P715; Samardzija M, 2006, EUR J NEUROSCI, V23, P1028, DOI 10.1111/j.1460-9568.2006.04639.x; Sherry DM, 2005, J NEUROSCI RES, V82, P316, DOI 10.1002/jnr.20619; Song Y, 2003, INVEST OPHTH VIS SCI, V44, P4069, DOI 10.1167/iovs.02-1130; Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x; Strettoi E, 2003, VISION RES, V43, P867, DOI 10.1016/S0042-6989(02)00594-1; Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292; Valter K, 2005, INVEST OPHTH VIS SCI, V46, P1748, DOI 10.1167/iovs.04-0657; Walsh N, 2001, EXP EYE RES, V72, P495, DOI 10.1006/exer.2000.0984; Wang LH, 1999, J IMMUNOL, V162, P3897; Wang Y, 2002, CURR EYE RES, V24, P305, DOI 10.1076/ceyr.24.4.305.8408; WEN R, 1995, J NEUROSCI, V15, P7377; Wenzel A, 2003, INVEST OPHTH VIS SCI, V44, P2798, DOI 10.1167/iovs.02-1134; Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002; Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845; Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344; Zhang SSM, 2003, EXP EYE RES, V76, P421, DOI 10.1016/S0014-4835(03)00002-2	67	100	103	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2411	+		10.1096/fj.06-5895fje	http://dx.doi.org/10.1096/fj.06-5895fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	16966486				2022-12-25	WOS:000241702600037
J	Klucken, J; Outeiro, TF; Nguyen, P; McLean, PJ; Hyman, BT				Klucken, Jochen; Outeiro, Tiago F.; Nguyen, Paul; McLean, Pamela J.; Hyman, Bradley T.			Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging	FASEB JOURNAL			English	Article						Parkinson's disease; Lewy body disease; chaperone; protein aggregation	PARKINSONS-DISEASE; DROSOPHILA MODEL; IN-VITRO; PROTEIN; AGGREGATION; DYNAMICS; SUPPRESSION; PHOSPHOLIPIDS; NEUROTOXICITY; GELDANAMYCIN	Oligomerization and aggregation of alpha-synuclein molecules are believed to play a major role in neuronal dysfunction and loss in Parkinson's disease (PD) and dementia with Lewy bodies. However, alpha-synuclein oligomerization and aggregation have been detected only indirectly in cells using detergent extraction methods. Here, we show for the first time intracellular alpha-synuclein oligomerization using fluorescence lifetime imaging (FLIM). Two forms of alpha-synuclein homomeric interactions were detected: an antiparallel amino terminus-carboxyl terminus interaction between alpha-synuclein molecules, and a close amino terminus-carboxy terminus interaction within single alpha-synuclein molecules. Coexpression of the chaperone protein Hsp70, which can block alpha-synuclein toxicity in several systems, causes alpha-synuclein to adopt a different, open conformation, but Hsp70 does not alter alpha-synuclein-alpha-synuclein interactions. Thus, the neuroprotective effect of Hsp70 can be explained by its chaperone activity on alpha-synuclein molecules, rather than alteration of alpha-synuclein-alpha-synuclein interactions.	Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Alzheimers Dis Res Unit, Charlestown, MA 02129 USA; Univ Regensburg, Dept Neurol, D-8400 Regensburg, Germany	Harvard University; Massachusetts General Hospital; University of Regensburg	McLean, PJ (corresponding author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Alzheimers Dis Res Unit, 114 16th St, Charlestown, MA 02129 USA.	pmclean@partners.org	Outeiro, Tiago/L-7351-2019; Outeiro, Tiago/M-8106-2019; Outeiro, Tiago F/C-1067-2008	Outeiro, Tiago/0000-0003-1679-1727; Outeiro, Tiago F/0000-0003-1679-1727; McLean, Pamela/0000-0003-4870-5715	NINDS NIH HHS [5P50 NS38372A-06] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038372] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Berezovska O, 2003, J NEUROSCI, V23, P4560; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bertoncini CW, 2005, J BIOL CHEM, V280, P30649, DOI 10.1074/jbc.C500288200; Bussell R, 2005, PROTEIN SCI, V14, P862, DOI 10.1110/ps.041255905; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Dedmon MM, 2005, J BIOL CHEM, V280, P14733, DOI 10.1074/jbc.m413024200; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; Del Mar C, 2005, P NATL ACAD SCI USA, V102, P15477, DOI 10.1073/pnas.0507405102; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fernandez CO, 2004, EMBO J, V23, P2039, DOI 10.1038/sj.emboj.7600211; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Heise H, 2005, P NATL ACAD SCI USA, V102, P15871, DOI 10.1073/pnas.0506109102; Hoyer W, 2004, BIOCHEMISTRY-US, V43, P16233, DOI 10.1021/bi048453u; Kamp F, 2006, J BIOL CHEM, V281, P9251, DOI 10.1074/jbc.M512292200; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Klucken J, 2004, BIOCHEM BIOPH RES CO, V325, P367, DOI 10.1016/j.bbrc.2004.10.037; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kubo S, 2005, J BIOL CHEM, V280, P31664, DOI 10.1074/jbc.M504894200; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; Lee JC, 2004, P NATL ACAD SCI USA, V101, P16466, DOI 10.1073/pnas.0407307101; Leng Y, 2001, J BIOL CHEM, V276, P28212, DOI 10.1074/jbc.M011121200; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; McLean PJ, 2002, NEUROSCI LETT, V323, P219, DOI 10.1016/S0304-3940(02)00154-4; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Trostchansky A, 2006, BIOCHEM J, V393, P343, DOI 10.1042/BJ20051277; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	47	67	71	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2050	2057		10.1096/fj.05-5422com	http://dx.doi.org/10.1096/fj.05-5422com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012257				2022-12-25	WOS:000241156900013
J	Oh, KJ; Barbuto, S; Pitter, K; Morash, J; Walensky, LD; Korsmeyer, SJ				Oh, Kyoung Joon; Barbuto, Scott; Pitter, Kenneth; Morash, Joel; Walensky, Loren D.; Korsmeyer, Stanley J.			A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; CONFORMATIONAL-CHANGE; PROAPOPTOTIC BAX; CONTACT SITES; FAMILY-MEMBER; TUMOR-CELLS; BH3 DOMAINS; X-L; APOPTOSIS	The multidomain pro-apoptotic proteins BAX and BAK constitute an essential gateway to mitochondrial dysfunction and programmed cell death. Among the "BCL-2 homology (BH) 3-only" members of pro-apoptotic proteins, truncated BID (tBID) has been implicated in direct BAX activation, although an explicit molecular mechanism remains elusive. We find that BID BH3 peptide alone at submicromolar concentrations cannot activate BAX or complement BID BH3 mutant-tBID in mitochondrial and liposomal release assays. Because tBID contains structurally defined membrane association domains, we investigated whether membrane targeting of BID BH3 peptide would be sufficient to restore its pro-apoptotic activity. We developed a Ni2+-nitrilotriacetic acid liposomal assay system that efficiently conjugates histidine-tagged peptides to a simulated outer mitochondrial membrane surface. Strikingly, nanomolar concentrations of a synthetic BID BH3 peptide that is chemically tethered to the liposomal membrane activated BAX almost as efficiently as tBID itself. These results highlight the importance of membrane targeting of the BID BH3 domain in tBID-mediated BAX activation and support a model in which tBID engages BAX to trigger its pro-apoptotic activity.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol & Med,Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Oh, KJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol & Med,Howard Hughes Med Inst, 1 Jimmy Fund Way,Smith Bldg 758, Boston, MA 02115 USA.	kyoung_joon_oh@dfci.harvard.edu		Pitter, Kenneth/0000-0002-9450-313X; OH, KYOUNG JOON/0000-0002-4729-9674	NATIONAL CANCER INSTITUTE [P01CA068484, R01CA050239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074049] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA68484, R01 CA50239] Funding Source: Medline; NHLBI NIH HHS [K08 HL074049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Becattini B, 2004, CHEM BIOL, V11, P389, DOI 10.1016/j.chembiol.2004.02.020; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Hochman A, 1998, J NEUROCHEM, V71, P741; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hu X, 2003, APOPTOSIS, V8, P277, DOI 10.1023/A:1023676906857; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Ladokhin AS, 1999, J MOL BIOL, V285, P1363, DOI 10.1006/jmbi.1998.2346; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Oh KJ, 2005, J BIOL CHEM, V280, P753, DOI 10.1074/jbc.M405428200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Petros AM, 2006, J MED CHEM, V49, P656, DOI 10.1021/jm0507532; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; SCHMITT L, 1994, AM CHEM SOC, V166, P8485; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; SZOKA F, 1980, BIOCHIM BIOPHYS ACTA, V601, P559, DOI 10.1016/0005-2736(80)90558-1; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Van Mau N, 2005, J MEMBRANE BIOL, V207, P1, DOI 10.1007/s00232-005-0799-7; Vila R, 2001, J BIOL CHEM, V276, P46429, DOI 10.1074/jbc.M106952200; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	58	71	72	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36999	37008		10.1074/jbc.M602341200	http://dx.doi.org/10.1074/jbc.M602341200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16987815	hybrid			2022-12-25	WOS:000242220800061
J	Yoon, SI; Logsdon, NJ; Sheikh, F; Donnelly, RP; Walter, MR				Yoon, Sung Il; Logsdon, Naomi J.; Sheikh, Faruk; Donnelly, Raymond P.; Walter, Mark R.			Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; SOLUBLE RECEPTOR; GROWTH-HORMONE; INTERLEUKIN-22; CELLS; CHAIN; CRYSTALLIZATION; CYTOKINES; HOMOLOG	Interleukin-10 receptor 2 (IL-10R2) is a critical component of the IL-10 center dot IL-10R1 center dot IL-10R2 complex which regulates IL-10-mediated immunomodulatory responses. The ternary IL-10 signaling complex is assembled in a sequential order with the IL-10 center dot IL-10R1 interaction occurring first followed by engagement of the IL-10R2 chain. In this study we map the IL-10R2 binding site on IL-10 using surface plasmon resonance and cell-based assays. Critical IL-10R2 binding residues are located in helix A adjacent to the previously identified IL-10R1 recognition surface. Interestingly, IL-10R2 binding residues located in the N-terminal end of helix A exhibit large structural differences between unbound cIL-10 and cIL-10 center dot IL-10R1 crystal structures. This suggests IL-10R1-induced conformational changes regulate IL-10R2 binding and assembly of the ternary IL-10 center dot IL10R1 center dot IL-10R2 complex. The basic mechanistic features of the assembly process are likely shared by six additional class-2 cytokines (viral IL-10s, IL-22, IL-26, IL-28A, IL28B, and IL-29) to promote IL-10R2 binding to six additional receptor complexes. These studies highlight the importance of structure in regulating low affinity protein-protein interactions and IL-10 signal transduction.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA; US FDA, Div Therapeut Prot, Ctr Drug Evaluat & Res, Bethesda, MD 20892 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Food & Drug Administration (FDA)	Walter, MR (corresponding author), Univ Alabama, Dept Microbiol, CBSE Rm 144,1025 18th St S, Birmingham, AL 35294 USA.	walter@uab.edu	Donnelly, Raymond P./AFT-8600-2022	Donnelly, Raymond P./0000-0002-0695-5276	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047300] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47300, R01 AI047300] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beebe AM, 2002, CYTOKINE GROWTH F R, V13, P403, DOI 10.1016/S1359-6101(02)00025-4; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DE WMR, 1991, J EXP MED, V174, P1209; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Donnelly RP, 2004, J LEUKOCYTE BIOL, V76, P314, DOI 10.1189/jlb.0204117; Jones BC, 2002, P NATL ACAD SCI USA, V99, P9404, DOI 10.1073/pnas.152147499; Josephson K, 2000, J BIOL CHEM, V275, P13552, DOI 10.1074/jbc.275.18.13552; Josephson K, 2002, STRUCTURE, V10, P981, DOI 10.1016/S0969-2126(02)00791-8; Josephson K, 2001, IMMUNITY, V15, P35, DOI 10.1016/S1074-7613(01)00169-8; Josephson K, 2001, ACTA CRYSTALLOGR D, V57, P1908, DOI 10.1107/S0907444901016249; Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Krause CD, 2006, BIOCHEM BIOPH RES CO, V340, P377, DOI 10.1016/j.bbrc.2005.11.182; Li J, 2004, INT IMMUNOPHARMACOL, V4, P693, DOI 10.1016/j.intimp.2004.01.010; Liu Y, 1997, J IMMUNOL, V158, P604; Lockridge KM, 2000, VIROLOGY, V268, P272, DOI 10.1006/viro.2000.0195; Logsdon NJ, 2002, J INTERF CYTOK RES, V22, P1099, DOI 10.1089/10799900260442520; Logsdon NJ, 2004, J MOL BIOL, V342, P503, DOI 10.1016/j.jmb.2004.07.069; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; MALEFYT RD, 1991, J EXP MED, V174, P915; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nagem RAP, 2002, STRUCTURE, V10, P1051, DOI 10.1016/S0969-2126(02)00797-9; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pletnev S, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-10; Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; Usacheva A, 2002, J IMMUNOL, V169, P1302, DOI 10.4049/jimmunol.169.3.1302; Walsh STR, 2003, PROTEIN SCI, V12, P1960, DOI 10.1110/ps.03133903; Walter MR, 2004, ADV PROTEIN CHEM, V68, P171; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; WINDSOR WT, 1993, BIOCHEMISTRY-US, V32, P8807, DOI 10.1021/bi00085a011; Wolk K, 2005, GENES IMMUN, V6, P8, DOI 10.1038/sj.gene.6364144; Xu T, 2004, ACTA CRYSTALLOGR D, V60, P1295, DOI 10.1107/S0907444904010492; Yoon SI, 2005, STRUCTURE, V13, P551, DOI 10.1016/j.str.2005.01.016; Zdanov A, 1996, PROTEIN SCI, V5, P1955, DOI 10.1002/pro.5560051001	39	93	106	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35088	35096		10.1074/jbc.M606791200	http://dx.doi.org/10.1074/jbc.M606791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982608	hybrid			2022-12-25	WOS:000241933700042
J	Park, HJ; Kim, SS; Seong, YM; Kim, KH; Goo, HG; Yoon, EJ; Min, DS; Kang, S; Rhim, H				Park, Hyo-Jin; Kim, Sang-Soo; Seong, Young-Mo; Kim, Kyung-Hee; Goo, Hui Gwan; Yoon, Eun Jin; Min, Do Sik; Kang, Seongman; Rhim, Hyangshuk			beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease - Implications for the physiological function of HtrA2 in the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-APOPTOTIC PROTEIN; PROMOTES CELL-DEATH; ALZHEIMERS-DISEASE; CASPASE ACTIVATION; OMI/HTRA2; INHIBITOR; SECRETASE; INTERACTS; NEURONS; BINDING	The processing and metabolism of amyloid precursor protein (APP) is a major interest in Alzheimer disease (AD) research, because not only amyloid beta(A beta) peptide, but also cellular or mitochondrial APP are intimately involved in cellular dysfunction and AD pathogenesis. Here we demonstrate that APP is directly and efficiently cleaved by the HtrA2 serine protease in vitro and in vivo. Using several APP mutants and N-terminal amino acid sequencing, we identified that the HtrA2-mediated APP cleavage product is the C161 fragment encompassing amino acids 535 - 695 of APP695. The immunofluorescence and subcellular fractionation studies indicate that APP is partly colocalized with HtrA2 in the mitochondria where HtrA2 can cleave APP under normal conditions. The HtrA2-cleaved C161 fragment was detected in the cytosolic fraction; therefore, we postulate that the C161 fragment is released into the cytosol after cleavage of APP by HtrA2. Interestingly, the level of C161 was remarkably decreased in motor neuron degeneration (mnd2) mice in which the serine protease activity of HtrA2 was greatly reduced. These results show that the protease activity of HtrA2 is essential for the production of C161 and that processing of APP into C161 is a natural event occurring under normal physiological conditions. Our study suggests that the direct cleavage of mitochondrial APP by HtrA2 may prevent mitochondrial dysfunction caused by accumulation of APP and that the regulation of HtrA2 protease activity may be a therapeutic target in AD.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Catholic Univ, Coll Med, Dept Biomed Sci, Seoul 137701, South Korea; Catholic Univ, Coll Med, Res Inst Mol Genet, Seoul 137701, South Korea; Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea	Korea University; Catholic University of Korea; Catholic University of Korea; Pusan National University	Kang, S (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	skang@korea.ac.kr; hrhim@catholic.ac.kr	Kim, Hyung-Kwan/R-8375-2019					Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Barnes NY, 1998, J NEUROSCI, V18, P5869; Caswell MD, 1999, EUR J BIOCHEM, V266, P509, DOI 10.1046/j.1432-1327.1999.00886.x; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Citron M, 2000, ANN NY ACAD SCI, V920, P192; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Grant SM, 1999, NEUROREPORT, V10, P41, DOI 10.1097/00001756-199901180-00008; Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kienlen-Campard P, 2000, EXP GERONTOL, V35, P843, DOI 10.1016/S0531-5565(00)00170-4; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Martins LM, 2002, CELL DEATH DIFFER, V9, P699, DOI 10.1038/sj.cdd.4401044; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Park HJ, 2004, NEUROSCI LETT, V357, P63, DOI 10.1016/j.neulet.2003.11.068; Sekine K, 2005, BIOCHEM BIOPH RES CO, V330, P279, DOI 10.1016/j.bbrc.2005.02.165; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Seong YM, 2004, J BIOL CHEM, V279, P37588, DOI 10.1074/jbc.M401408200; Seong YM, 2004, PROTEIN EXPRES PURIF, V33, P200, DOI 10.1016/j.pep.2003.10.002; SIMAN R, 1990, J NEUROSCI, V10, P2400; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045; Tesco G, 2003, J BIOL CHEM, V278, P46074, DOI 10.1074/jbc.M307809200; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	35	89	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34277	34287		10.1074/jbc.M603443200	http://dx.doi.org/10.1074/jbc.M603443200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968707	hybrid			2022-12-25	WOS:000241767600048
J	Teh, CHL; Lam, KKY; Loh, CC; Loo, JM; Yan, T; Lim, TM				Teh, Christina H. L.; Lam, Kevin K. Y.; Loh, Chin C.; Loo, Jia M.; Yan, Tie; Lim, Tit Meng			Neuronal PAS domain protein 1 is a transcriptional repressor and requires arylhydrocarbon nuclear translocator for its nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH-RECEPTOR; DNA-BINDING; DROSOPHILA; CLONING; ACTIVATION; EXPRESSION; IDENTIFICATION; RECRUITMENT; SIGNAL; BRAIN	Neuronal PAS domain protein 1 (NPAS1), a basic helix-loop-helix-PAS transcription factor expressed in the central nervous system, has been suggested to be involved in neuronal differentiation. However, relatively little is known about the molecular mechanism underlying the role of NPAS1 during development. In this study we set out to characterize the different domains within NPAS1. We showed that the nuclear localization of NPAS1 is dependent on the presence of ARNT. In addition, the transcriptional potential of ARNT is not required for this localization. In the absence of ARNT, NPAS1 is excluded from the nucleus, and this exclusion is due to the presence of a nuclear export signal within the N terminus of NPAS1. The interaction between NPAS1 and ARNT is via their N termini. We found no transactivation domain within NPAS1; instead, we mapped out at least three repression domains within NPAS1, suggesting that NPAS1 acts as a repressor. Furthermore, our experiments showed that NPAS1 is able to repress the transactivation functions of ARNT and ARNT2. We suggest that NPAS1 is guided into the nucleus by ARNT via the ARNT nuclear localization signal, and NPAS1 can override the activation function of adjacent transcription factors, providing a mechanism by which NPAS1 may inhibit transcription.	Natl Univ Singapore, Dept Biol Sci, Singapore 117542, Singapore	National University of Singapore	Lim, TM (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4,Kent Ridge, Singapore 117542, Singapore.	dbsltm@nus.edu.sg		Loo, Jia Min/0000-0002-6605-4031				Brunskill EW, 1999, MECH DEVELOP, V88, P237, DOI 10.1016/S0925-4773(99)00182-3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Chee JLY, 2005, CELL MOL LIFE SCI, V62, P227, DOI 10.1007/s00018-004-4413-4; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Drutel G, 1996, BIOCHEM BIOPH RES CO, V225, P333, DOI 10.1006/bbrc.1996.1176; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Erbel-Sieler C, 2004, P NATL ACAD SCI USA, V101, P13648, DOI 10.1073/pnas.0405310101; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; JAIN S, 1994, J BIOL CHEM, V269, P31518; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; LI H, 1994, J BIOL CHEM, V269, P28098; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Ohsawa S, 2005, J NEUROSCI RES, V79, P451, DOI 10.1002/jnr.20365; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Studer L, 2000, J NEUROSCI, V20, P7377; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; Ward MP, 1998, DEVELOPMENT, V125, P1599; Wenger RH, 1997, BIOL CHEM, V378, P609; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713; Zhou ZD, 2005, EXP CELL RES, V312, P156, DOI 10.1016/j.yexcr.2005.10.012	41	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34617	34629		10.1074/jbc.M604409200	http://dx.doi.org/10.1074/jbc.M604409200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16954219	hybrid			2022-12-25	WOS:000241767600081
J	Wang, J; Yin, L; Lazar, MA				Wang, Jing; Yin, Lei; Lazar, Mitchell A.			The orphan nuclear receptor Rev-erb alpha regulates circadian expression of plasminogen activator inhibitor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-RECEPTOR; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; MYOCARDIAL-INFARCTION; ROR-ALPHA; CARDIOVASCULAR-DISEASE; OPPOSITE STRAND; TRANSGENIC MICE; PAI-1 PROMOTER; TRANSCRIPTION	Plasminogen activator inhibitor type 1 (PAI-1) is a major physiologic regulator of the fibrinolytic system and has recently gained recognition as a modulator of inflammation and atherosclerosis. PAI-1 exhibits circadian rhythmicity in its expression, peaking in the early morning, which is associated with increased risk for cardiovascular events. However, the mechanisms that determine PAI-1 circadian rhythmicity remain poorly understood. We discovered that the orphan nuclear receptor Reverb alpha, a core component of the circadian loop, represses human PAI-1 gene expression through two Rev-erb alpha binding sites in the PAI-1 promoter. Mutations of these sites, as well as RNA interference targeting endogenous Rev-erb alpha and its corepressors, led to increased expression of the PAI-1 gene. Furthermore, glycogen synthase kinase 3 beta (GSK3 beta) contributes to pai-1 repression by phosphorylating and stabilizing Rev-erb alpha protein, which can be blocked by lithium. Interestingly, serum shock generated circadian oscillations in PAI-1 mRNA in NIH3T3 cells, suggesting that PAI-1 is a direct output gene of the circadian loop. Ectopic expression of a stabilized form of Rev-erb alpha that mimics GSK3 beta phosphorylation dramatically dampened PAI-1 circadian oscillations. Thus, our results suggest that Rev-erb alpha is a major determinant of the circadian PAI-1 expression and a potential modulator of the morning susceptibility to myocardial infarction.	Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, 611 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019		NIDDK NIH HHS [DK45586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Chauvet C, 2005, MOL ENDOCRINOL, V19, P2517, DOI 10.1210/me.2005-0153; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHOMIKI N, 1994, THROMB HAEMOSTASIS, V72, P44; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Coste H, 2002, J BIOL CHEM, V277, P27120, DOI 10.1074/jbc.M203421200; De Taeye B, 2005, CURR OPIN PHARMACOL, V5, P149, DOI 10.1016/j.coph.2005.01.007; Eitzman DT, 2000, BLOOD, V96, P4212; Eren M, 2003, J THROMB HAEMOST, V1, P2389, DOI 10.1046/j.1538-7836.2003.00437.x; Eren M, 2002, CIRCULATION, V106, P491, DOI 10.1161/01.CIR.0000023186.60090.FB; Genoux A, 2005, ARTERIOSCL THROM VAS, V25, P1186, DOI 10.1161/01.ATV.0000163841.85333.83; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; Guillaumond F, 2005, J BIOL RHYTHM, V20, P391, DOI 10.1177/0748730405277232; Harding HP, 1997, MOL ENDOCRINOL, V11, P1737, DOI 10.1210/me.11.11.1737; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Kapiotis S, 1997, CIRCULATION, V96, P19; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; Ma LJ, 2004, DIABETES, V53, P336, DOI 10.2337/diabetes.53.2.336; Maemura K, 2000, J BIOL CHEM, V275, P36847, DOI 10.1074/jbc.C000629200; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; Nagoshi E, 2005, METHOD ENZYMOL, V393, P543, DOI 10.1016/S0076-6879(05)93028-0; PARAMO JA, 1990, THROMB HAEMOSTASIS, V64, P3; Pratt LA, 1996, CIRCULATION, V94, P3123, DOI 10.1161/01.CIR.94.12.3123; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Raspe E, 2002, J LIPID RES, V43, P2172, DOI 10.1194/jlr.M200386-JLR200; Samad F, 1996, MOL MED, V2, P568, DOI 10.1007/BF03401641; Schafer K, 2001, FASEB J, V15, P1840, DOI 10.1096/fj.00-0750fje; Schoenhard JA, 2003, J MOL CELL CARDIOL, V35, P473, DOI 10.1016/S0022-2828(03)00051-8; Sobel BE, 1998, CIRCULATION, V97, P2213, DOI 10.1161/01.CIR.97.22.2213; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Vaughan DE, 2005, J THROMB HAEMOST, V3, P1879, DOI 10.1111/j.1538-7836.2005.01420.x; Yin L, 2005, MOL ENDOCRINOL, V19, P1452, DOI 10.1210/me.2005-0057; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; Young ME, 2006, AM J PHYSIOL-HEART C, V290, pH1, DOI 10.1152/ajpheart.00582.2005; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835	48	101	105	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33842	33848		10.1074/jbc.M607873200	http://dx.doi.org/10.1074/jbc.M607873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968709	hybrid			2022-12-25	WOS:000241767600005
J	Chini, CCS; Chen, JJ				Chini, Claudia C. S.; Chen, Junjie			Repeated phosphopeptide motifs in human claspin are phosphorylated by Chk1 and mediate claspin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; RADIOSENSITIZING AGENT; ACTIVATION; ATR; PROTEIN; DEGRADATION; RECOVERY; BINDING; ROLES	Claspin is a checkpoint protein involved in ATR ((a) under bar taxia (t) under bar elangiectasia mutated-and (R) under bar ad3-related)-dependent Chk1 activation in Xenopus and human cells. In Xenopus, Claspin interacts with Chk1 after DNA damage through a region containing two highly conserved repeats, which becomes phosphorylated during the checkpoint response. Because this region is also conserved in human Claspin, we investigated the regulation and function of these potential phosphorylation sites in human Claspin. We found that Claspin is phosphorylated in vivo at Thr-916 in response to replication stress and UV damage. Mutation of these phosphorylation sites on Claspin inhibited Claspin-Chk1 interaction in vivo, impaired Chk1 activation, and induced premature chromatin condensation in cells, indicating a defect in replication checkpoint. In addition, we found that Thr-916 on Claspin is phosphorylated by Chk1, suggesting that Chk1 regulates Claspin during checkpoint response. These results together indicate that phosphorylation of Claspin repeats in human Claspin is important for Claspin function and the regulation of Claspin-Chk1 interaction in human cells.	Mayo Clin & Mayo Fdn, Coll Med, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, Hunter Bldg,Rm 213C,333 Cedar St, New Haven, CT 06520 USA.	Junjie.Chen@yale.edu			NATIONAL CANCER INSTITUTE [R01CA100109, R01CA089239, R01CA092312] Funding Source: NIH RePORTER; NCI NIH HHS [CA92312, CA89239, CA100109] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett LN, 2006, FEBS LETT, V580, P4176, DOI 10.1016/j.febslet.2006.06.071; Busby EC, 2000, CANCER RES, V60, P2108; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chini C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; MAMELY I, 2006, IN PRESS CURR BIOL; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9	25	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33276	33282		10.1074/jbc.M604373200	http://dx.doi.org/10.1074/jbc.M604373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963448	hybrid			2022-12-25	WOS:000241621400037
J	Liu, J; Kumar, KGS; Yu, D; Molton, SA; McMahon, M; Herlyn, M; Thomas-Tikhonenko, A; Fuchs, SY				Liu, J.; Kumar, K. G. Suresh; Yu, D.; Molton, S. A.; McMahon, M.; Herlyn, M.; Thomas-Tikhonenko, A.; Fuchs, S. Y.			Oncogenic BRAF regulates beta-Trcp expression and NF-kappa B activity in human melanoma cells	ONCOGENE			English	Article						BRAF; melanoma; beta-Trcp; NF-kappa B; I kappa B kinase	MALIGNANT-MELANOMA; SIGNALING PATHWAYS; COLORECTAL TUMORS; KINASE ACTIVATION; RAF; TRANSFORMATION; MUTATIONS; APOPTOSIS; PHOSPHORYLATION; INHIBITION	Mutational activation of BRAF is a frequent event in human malignant melanomas suggesting that BRAF-dependent signaling is conducive to melanoma cell growth and survival. Previously published work reported that melanoma cells exhibit constitutive anti-apoptotic nuclear factor kappa B (NF-kappa B) transcription factor activation triggered by proteolysis of its inhibitor I kappa B. I kappa B degradation is dependent upon its phosphorylation by the I kappa B kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase. Here, we report that melanocytes expressing a conditionally oncogenic form of BRAF(V600E) exhibit enhanced beta-Trcp expression, increased IKK activity and a concomitant increase in the rate of I kappa B alpha degradation. Conversely, inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (BAY 43-9006) or by selective knock-down of BRAF(V600E) expression by RNA interference in human melanoma cells leads to decreased IKK activity and beta-Trcp expression, stabilization of I kappa B, inhibition of NF-kappa B transcriptional activity and sensitization of these cells to apoptosis. Taken together, these data support a model in which mutational activation of BRAF in human melanomas contributes to constitutive induction of NF-kappa B activity and to increased survival of melanoma cells.	Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The Wistar Institute	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Biol Anim, 3800 Spruce St,Room 161E VET, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu	Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206; Liu, Jianghuai/0000-0002-2382-9140	NCI NIH HHS [R01 CA092900, CA092900, R01 CA102709, CA25874, CA108972, CA102709, P01 CA025874, P50 CA093372, CA93372, R01 CA108972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102709, R01CA092900, R01CA108972, P50CA093372, P01CA025874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Panka DJ, 2006, CANCER RES, V66, P1611, DOI 10.1158/0008-5472.CAN-05-0808; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smalley KSM, 2005, ANN NY ACAD SCI, V1059, P16, DOI 10.1196/annals.1339.005; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Yang JM, 2006, CLIN CANCER RES, V12, P950, DOI 10.1158/1078-0432.CCR-05-1220; Yang JM, 2001, CANCER RES, V61, P4901; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	22	70	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1954	1958		10.1038/sj.onc.1209994	http://dx.doi.org/10.1038/sj.onc.1209994			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001349	Green Accepted			2022-12-25	WOS:000245117700013
J	Wang, H; Yan, C; Asangani, I; Allgayer, H; Boyd, DD				Wang, H.; Yan, C.; Asangani, I.; Allgayer, H.; Boyd, D. D.			Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression	ONCOGENE			English	Article						urokinase receptor; enhancer; gene expression	PLASMINOGEN-ACTIVATOR RECEPTOR; TRANSCRIPTION FACTOR-BINDING; IV COLLAGENASE EXPRESSION; INVASIVE COLON-CANCER; GENE-EXPRESSION; IN-VIVO; COLORECTAL-CANCER; CELL-MIGRATION; PROTEIN-KINASE; POSTTRANSCRIPTIONAL REGULATION	The transcriptionally regulated urokinase-type plasminogen activator receptor (u-PAR) contributes to cancer progression. Although previous studies have identified multiple 50 regulatory elements, these cis motifs cannot fully account for u-PAR expression prompting a search for hitherto uncharacterized regulatory elements. DNase I hypersensitivity and chromatin immunoprecipitation assays using u-PAR-expressing colon cancer cells indicated a hypersensitive region (+665/+2068) in intron 1 enriched with acetylated histone 3 (H3) and H3 methylated at lysine 4, markers of regulatory regions. The +665/+2068 region increased transcription from a u-PAR-promoter in an orientation- and distance-independent manner fulfilling the criteria of an enhancer. Optimal stimulation of the u-PAR promoter by phorbol ester required this enhancer. Systematic truncations combined with DNase I footprinting revealed two protected regions (+1060/+1099 and +1123/+1134) with deletion of the latter practically abolishing enhancer activity. The +1123/+1134 region harbored non-consensus activator protein-1 and Ets1 binding sites bound with c-Jun (and/or the related JunD/JunB) and c-Fos (and/or the related FosB/Fra-1/Fra-2) as revealed with chromatin immunoprecipitation. Further, nuclear extract from resected colon cancers showed elevated protein binding to a +1123/_1134- spanning probe coordinate with elevated u-PAR protein. Thus, we have defined a novel intragenic enhancer in the u-PAR gene required for constitutive and inducible expression.	MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Heidelberg, Dept Expt Mol Surg, D-6900 Heidelberg, Germany	University of Texas System; UTMD Anderson Cancer Center; Ruprecht Karls University Heidelberg	Boyd, DD (corresponding author), MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org		asangani, irfan/0000-0001-5381-1702; Yan, Chunhong/0000-0002-3974-7991	NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ahnen DJ, 1998, CANCER RES, V58, P1149; Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Bass R, 2005, J BIOL CHEM, V280, P14811, DOI 10.1074/jbc.M414189200; BOS JL, 1989, CANCER RES, V49, P4682; CASEY JR, 1994, BLOOD, V84, P1151; DeLong CJ, 2005, BIOCHEM BIOPH RES CO, V338, P53, DOI 10.1016/j.bbrc.2005.07.184; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Ibanez-Tallon I, 1999, ONCOGENE, V18, P2836, DOI 10.1038/sj.onc.1202644; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; JONES LG, 1994, J BIOL CHEM, V269, P23790; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Lakka SS, 2003, CANCER RES, V63, P2454; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Lin CY, 2004, GENE, V334, P63, DOI 10.1016/j.gene.2004.03.016; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Nair RR, 2005, ONCOL RES, V15, P265, DOI 10.3727/096504005776404571; Nestl A, 2001, CANCER RES, V61, P1569; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 2002, CANCER RES, V62, P2390; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; REITER LS, 1993, INT J CANCER, V53, P444, DOI 10.1002/ijc.2910530316; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schewe DM, 2003, CLIN CANCER RES, V9, P2267; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Shetty S, 2005, MOL CELL BIOCHEM, V272, P107, DOI 10.1007/s11010-005-7644-2; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Shitoh K, 2001, GENE CHROMOSOME CANC, V30, P32, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1065>3.0.CO;2-I; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; SOZERI O, 1992, ONCOGENE, V7, P2259; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; Suzuki S, 1998, GUT, V43, P798, DOI 10.1136/gut.43.6.798; Trisciuoglio D, 2004, J BIOL CHEM, V279, P6737, DOI 10.1074/jbc.M308938200; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	66	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2058	2070		10.1038/sj.onc.1210003	http://dx.doi.org/10.1038/sj.onc.1210003			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001307				2022-12-25	WOS:000245313400008
J	Kambara, T; Komaba, S; Ikebe, M				Kambara, Taketoshi; Komaba, Shigeru; Ikebe, Mitsuo			Human myosin III is a motor having an extremely high affinity for actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUTY RATIO MOTOR; DROSOPHILA-NINAC KINASE; SMOOTH-MUSCLE MYOSIN; KINETIC MECHANISM; LIGHT ADAPTATION; PROCESSIVE MOTOR; VISUAL ARRESTIN; PROTEIN-KINASE; PHOTORECEPTORS; TRANSLOCATION	Myosin IIIA is expressed in photoreceptor cells and thought to play a critical role in phototransduction processes, yet its function on a molecular basis is largely unknown. Here we clarified the kinetic mechanism of the ATPase cycle of human myosin IIIA. The steady-state ATPase activity was markedly activated similar to 10-fold with very low actin concentration. The rate of ADP off from actomyosin IIIA was 10 times greater than the overall cycling rate, thus not a rate-determining step. The rate constant of the ATP hydrolysis step of the actin-dissociated form was very slow, but the rate was markedly accelerated by actin binding. The dissociation constant of the ATP-bound form of myosin IIIA from actin is submicromolar, which agrees well with the low K-actin. These results indicate that ATP hydrolysis predominantly takes place in the actin-bound form for actomyosin IIIA ATPase reaction. The obtained K-actin was much lower than the previously reported one, and we found that the autophosphorylation of myosin IIIA dramatically increased the K-actin, whereas the V-max was unchanged. Our kinetic model indicates that both the actin-attached hydrolysis and the P-i release steps determine the overall cycle rate of the dephosphorylated form. Although the stable steady-state intermediates of actomyosin IIIA ATPase reaction are not typical strong actin-binding intermediates, the affinity of the stable intermediates for actin is much higher than conventional weak actin binding forms. The present results suggest that myosin IIIA can spend a majority of its ATP hydrolysis cycling time on actin.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu			NIAMS NIH HHS [AR04856, AR048898] Funding Source: Medline; NIDCD NIH HHS [DC006103] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Battelle BA, 1998, J NEUROSCI, V18, P4548; Cronin MA, 2004, J CELL SCI, V117, P4797, DOI 10.1242/jcs.01371; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Dose AC, 2003, MOL BIOL CELL, V14, P1058, DOI 10.1091/mbc.E02-06-0317; Dose AC, 2002, GENOMICS, V79, P621, DOI 10.1006/geno.2002.6749; Dose AC, 2000, GENOMICS, V67, P333, DOI 10.1006/geno.2000.6256; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Erickson FL, 2003, MOL BIOL CELL, V14, P4173, DOI 10.1091/mbc.e02-10-0656; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Henn A, 2005, J BIOL CHEM, V280, P39665, DOI 10.1074/jbc.M507667200; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; KANAZAWA T, 1965, J BIOCHEM-TOKYO, V57, P604; Komaba S, 2003, J BIOL CHEM, V278, P21352, DOI 10.1074/jbc.M300757200; Kosloff M, 2003, EMBO J, V22, P459, DOI 10.1093/emboj/cdg054; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Lee SJ, 2004, NEURON, V43, P95, DOI 10.1016/j.neuron.2004.06.014; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lin-Jones J, 2004, J CELL SCI, V117, P5825, DOI 10.1242/jcs.01512; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Nalavadi V, 2005, J BIOL CHEM, V280, P38957, DOI 10.1074/jbc.M507161200; Ng KP, 1996, BIOCHEMISTRY-US, V35, P9392, DOI 10.1021/bi960181a; Nishikawa M, 2006, BIOCHEM BIOPH RES CO, V343, P1159, DOI 10.1016/j.bbrc.2006.03.057; Pate E, 1997, BIOCHEMISTRY-US, V36, P12155, DOI 10.1021/bi970996z; Peterson JJ, 2003, EXP EYE RES, V76, P553, DOI 10.1016/S0014-4835(03)00032-0; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Smith L, 1999, J BIOL CHEM, V274, P29433, DOI 10.1074/jbc.274.41.29433; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; Watanabe S, 2006, J BIOL CHEM, V281, P7151, DOI 10.1074/jbc.M511592200; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Yang Y, 2005, J BIOL CHEM, V280, P32061, DOI 10.1074/jbc.M506765200; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; YOUNT RG, 1995, BIOPHYS J, V68, pS44	45	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37291	37301		10.1074/jbc.M603823200	http://dx.doi.org/10.1074/jbc.M603823200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17012748	hybrid			2022-12-25	WOS:000242477100006
J	Ghorbel, S; Sinha-Datta, U; Dundr, M; Brown, M; Franchini, G; Nicot, C				Ghorbel, Sofiane; Sinha-Datta, Uma; Dundr, Miroslav; Brown, Megan; Franchini, Genoveffa; Nicot, Christophe			Human T-cell leukemia virus type I p30 nuclear/nucleolar retention is mediated through interactions with RNA and a constituent of the 60 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR TARGETING SIGNAL; CAULIFLOWER-MOSAIC-VIRUS; KAPPA-B PATHWAY; HTLV-I; ARABIDOPSIS-THALIANA; HUMAN ANGIOGENIN; ENTRY SITE; HIV-1 REV; PROTEIN; TRANSCRIPTION	Human T-cell leukemia virus type I is the etiological agent of adult T-cell leukemia/lymphoma, an aggressive and fatal lymphoproliferative malignancy. The virus has evolved strategies to escape immune clearance by remaining latent in most infected cells in vivo. We demonstrated previously that virally encoded p30 protein is a potent post-transcriptional inhibitor of virus replication (Nicot, C., Dundr, M., Johnson, J. M., Fullen, J. R., Alonzo, N., Fukumoto, R., Princler, G. L., Derse, D., Misteli, T., and Franchini, G. (2004) Nat. Med. 10, 197-201). p30 is unable to shuttle out of the nucleus in heterokaryon assays, suggesting the existence of specific retention signals. Because suppression of virus replication relies on nuclear retention of the tax/rex mRNA by p30, determining the retention features of p30 will offer hints to break latency in infected cells and insights into new therapeutic approaches. In this study, we used live cell imaging technologies to study the kinetics of p30 and to delineate its retention signals and their function in virus replication. Notably, this is the first study to identify p30 nucleolar retention domains. Using mutants of p30 that localized in different cellular compartments, we show that post-transcriptional control of virus replication by p30 occurs in the nucleoplasm. We further demonstrate that p30 nuclear/nucleolar retention is dependent upon de novo RNA transcripts and interactions with components of the ribosomal machinery.	Univ Kansas, Med Ctr, Dept Microbiol Immunol & Mol Genet, Kansas City, KS 66160 USA; NCI, Anim Models & Retroviral Vaccines Sect, NIH, Bethesda, MD 20892 USA; Rosalind Franklin Univ Med & Sci, Dept Cell Biol & Anat, N Chicago, IL 60064 USA	University of Kansas; University of Kansas Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rosalind Franklin University Medical & Science	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Immunol & Mol Genet, 3901 Rainbow Blvd,3025 Wahl Hall W, Kansas City, KS 66160 USA.	cnicot@kumc.edu		Ghorbel, Sofiane/0000-0001-8793-4882	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058944] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR016443] Funding Source: Medline; NIAID NIH HHS [R01 AI058944, AI058944] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bellon M, 2006, INT J CANCER, V119, P2090, DOI 10.1002/ijc.22026; Bureau M, 2004, J GEN VIROL, V85, P3765, DOI 10.1099/vir.0.80242-0; Catez F, 2002, EMBO REP, V3, P760, DOI 10.1093/embo-reports/kvf156; Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; DAgostino DM, 1997, J VIROL, V71, P75, DOI 10.1128/JVI.71.1.75-83.1997; DANG CV, 1989, AM J MED, V87, P567; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182/blood-2006-01-0067; Dhar D, 2006, ARCH VIROL, V151, P509, DOI 10.1007/s00705-005-0642-6; Dundr M, 2002, J STRUCT BIOL, V140, P92, DOI 10.1016/S1047-8477(02)00521-X; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Ji H, 2004, P NATL ACAD SCI USA, V101, P16990, DOI 10.1073/pnas.0407402101; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; Leh V, 2000, VIROLOGY, V266, P1, DOI 10.1006/viro.1999.0073; Lixin R, 2001, BIOCHEM BIOPH RES CO, V284, P185, DOI 10.1006/bbrc.2001.4953; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; MARION MJ, 1987, BIOCHEM BIOPH RES CO, V149, P1077, DOI 10.1016/0006-291X(87)90518-3; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Miyazato P, 2006, J VIROL, V80, P10683, DOI 10.1128/JVI.01009-06; MOROIANU J, 1994, BIOCHEM BIOPH RES CO, V203, P1765, DOI 10.1006/bbrc.1994.2391; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Phair RD, 2004, METHOD ENZYMOL, V375, P393; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; Pyper WR, 1998, MOL BIOCHEM PARASIT, V94, P287, DOI 10.1016/S0166-6851(98)00069-3; RICHARD N, 1994, VIROLOGY, V204, P123, DOI 10.1006/viro.1994.1516; Scheer S, 1999, J FR OPHTALMOL, V22, P859; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; Wattel E, 1996, J ACQUIR IMMUNE D S1, V13, P92; Zhang WQ, 2001, J VIROL, V75, P9885, DOI 10.1128/JVI.75.20.9885-9895.2001	34	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37150	37158		10.1074/jbc.M603981200	http://dx.doi.org/10.1074/jbc.M603981200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17008317	hybrid			2022-12-25	WOS:000242220800076
J	Kim, KW; Mutter, RW; Cao, C; Albert, JM; Freeman, M; Hallahan, DE; Lu, B				Kim, Kwang Woon; Mutter, Robert W.; Cao, Carolyn; Albert, Jeffrey M.; Freeman, Michael; Hallahan, Dennis E.; Lu, Bo			Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; PROAPOPTOTIC BAX; ENDOPLASMIC-RETICULUM; IONIZING-RADIATION; CONJUGATION SYSTEM; MALIGNANT GLIOMA; TUMOR-SUPPRESSOR; CASPASE-8; P53	Autophagy is an alternative cell death pathway that is induced by mammalian target of rapamycin ( mTOR) inhibitors and upregulated when apoptosis is defective. We investigated radiation-induced autophagy in the presence or absence of Bax/Bak with or without an mTOR inhibitor, Rad001. Two isogenic cell lines, wild type (WT) and Bak/Bak(-/-) mouse embryonic fibroblasts and tumor cell lines were used for this study. Irradiated Bak/Bak(-/-) cells had a decrease of Akt/mTOR signaling and a significant increase of pro-autophagic proteins ATG5-ATG12 COMPLEX and Beclin-1. These molecular events resulted in an up-regulation of autophagy. Bax/Bak(-/-) cells were defective in undergoing apoptosis but were more radiosensitive than the WT cells in autophagy. Both autophagy and sensitization of Bak/Bax(-/-) cells were further enhanced in the presence of Rad001. In contrast, inhibitors of autophagy rendered the Bak/Bax(-/-) cells radioresistant, whereas overexpression of ATG5 and Beclin-1 made the WT cells radiosensitive. When this novel concept of radiosensitization was tested in cancer models, small interfering RNAs against Bak/Bax also led to increased autophagy and sensitization of human breast and lung cancer cells to gamma radiation, which was further enhanced by Rad001. This is the first report to demonstrate that inhibition of pro-apoptotic proteins and induction of autophagy sensitizes cancer cells to therapy. Therapeutically targeting this novel pathway may yield significant benefits for cancer patients.	Vanderbilt Univ, Vanderbilt Clin, Dept Radiat Oncol, Sch Med,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Vanderbilt Clin, Dept Radiat Oncol, Sch Med,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010; Mutter, Robert/AAP-3996-2020	Freeman, Michael/0000-0003-1881-366X				Arafat WO, 2003, INT J RADIAT ONCOL, V55, P1037, DOI 10.1016/S0360-3016(02)04488-7; Arafat WO, 2000, MOL THER, V1, P545, DOI 10.1006/mthe.2000.0071; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bursch W, 2000, J CELL SCI, V113, P1189; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Ding HF, 2001, J PEDIAT HEMATOL ONC, V23, P185, DOI 10.1097/00043426-200103000-00014; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Held KD, 1997, APOPTOSIS, V2, P265, DOI 10.1023/A:1026485003280; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; LINSTERN T, 2000, MOL CELL, V6, P1389; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2003, INT J BIOCHEM CELL B, V35, P553, DOI 10.1016/S1357-2725(02)00343-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Paglin S, 2001, CANCER RES, V61, P439; Pataer A, 2000, CANCER RES, V60, P788; Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shinoura N, 2000, CANCER GENE THER, V7, P739, DOI 10.1038/sj.cgt.7700158; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; Verheij M, 2000, CELL TISSUE RES, V301, P133, DOI 10.1007/s004410000188; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wouters BG, 1999, ONCOGENE, V18, P6540, DOI 10.1038/sj.onc.1203053; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378; Yu L, 2004, CELL CYCLE, V3, P1124; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	33	155	163	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36883	36890		10.1074/jbc.M607094200	http://dx.doi.org/10.1074/jbc.M607094200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17005556	hybrid			2022-12-25	WOS:000242220800047
J	Lotito, SB; Frei, B				Lotito, Silvina B.; Frei, Balz			Dietary flavonoids attenuate tumor necrosis factor alpha-induced adhesion molecule expression in human aortic endothelial cells - Structure-function relationships and activity after first pass metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; RAT-LIVER; OXIDATIVE STRESS; PLANT FLAVONOIDS; INHIBITION; QUERCETIN; INFLAMMATION; MECHANISMS; PLASMA	Flavonoids have been suggested to exert human health benefits by anti-oxidant and anti-inflammatory mechanisms. In this study, we investigated whether and by what mechanisms dietary flavonoids inhibit expression of cellular adhesion molecules, which is relevant to inflammation and atherosclerosis. We found that the capacity of flavonoids to inhibit tumor necrosis factor alpha-induced adhesion molecule expression in human aortic endothelial cells was dependent on specific structural features of the flavonoids. The 5,7-dihydroxyl substitution of a flavonoid A-ring and 2,3-double bond and 4-keto group of the C-ring were the main structural requirements for inhibition of adhesion molecule expression. In striking contrast, hydroxyl substitutions of the B- and C-rings but not the A-ring were essential for antioxidant activity. Hence, only hydroxyl flavones, such as apigenin and chrysin, and flavonols, such as galangin, kaempferol, and quercetin, were able to inhibit endothelial adhesion molecule expression, whereas flavone, chromone, the flavanone, naringenin, and the flavanol, (-)-epicatechin, were ineffectual. At low concentrations, the active flavonoids significantly attenuated expression of E-selectin and intercellular adhesion molecule 1 but not vascular cell adhesion molecule 1. In addition, exposure of apigenin and kaempferol to cultured hepatocytes, mimicking first pass metabolism, greatly diminished the inhibitory effect of flavonoids on endothelial intercellular adhesion molecule 1 expression. We conclude that the effect of dietary flavonoids on endothelial adhesion molecule expression depends on their molecular structure, concentration, and metabolic transformation but not their antioxidant activity.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA	Oregon State University	Frei, B (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.	balz.frei@oregonstate.edu			NCCIH NIH HHS [AT002034] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [P01AT002034] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Choi JS, 2004, J NUTR, V134, P1013, DOI 10.1093/jn/134.5.1013; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Di Paola R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-66; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Dinkova-Kostova AT, 2005, P NATL ACAD SCI USA, V102, P4584, DOI 10.1073/pnas.0500815102; FERRIOLA PC, 1989, BIOCHEM PHARMACOL, V38, P1617, DOI 10.1016/0006-2952(89)90309-2; GERRITSEN ME, 1995, AM J PATHOL, V147, P278; Gradolatto A, 2004, DRUG METAB DISPOS, V32, P58, DOI 10.1124/dmd.32.1.58; HAGIWARA M, 1988, BIOCHEM PHARMACOL, V37, P2987; Huang MT, 2006, MOL NUTR FOOD RES, V50, P115, DOI 10.1002/mnfr.200500101; JINSART W, 1992, BIOL CHEM H-S, V373, P205, DOI 10.1515/bchm3.1992.373.1.205; JINSART W, 1991, BIOL CHEM H-S, V372, P819, DOI 10.1515/bchm3.1991.372.2.819; Kalfin R, 2002, FREE RADICAL RES, V36, P819, DOI 10.1080/1071576021000005249; Knekt P, 2002, AM J CLIN NUTR, V76, P560, DOI 10.1093/ajcn/76.3.560; Kobuchi H, 1999, AM J PHYSIOL-CELL PH, V277, pC403, DOI 10.1152/ajpcell.1999.277.3.C403; Koga T, 2001, AM J CLIN NUTR, V73, P941; Kwon HM, 2005, J AGR FOOD CHEM, V53, P5150, DOI 10.1021/jf047854d; LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U; LEE TP, 1982, LIFE SCI, V31, P2765, DOI 10.1016/0024-3205(82)90723-8; Liang YC, 2001, FEBS LETT, V496, P12, DOI 10.1016/S0014-5793(01)02393-6; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LOTITO SB, 2006, IN PRESS FREE RADIC; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; Middleton E, 2000, PHARMACOL REV, V52, P673; Morikawa K, 2003, LIFE SCI, V74, P709, DOI 10.1016/j.lfs.2003.06.036; Natsume M, 2003, FREE RADICAL BIO MED, V34, P840, DOI 10.1016/S0891-5849(02)01434-X; O'Leary KA, 2001, FEBS LETT, V503, P103, DOI 10.1016/S0014-5793(01)02684-9; Panes Julian, 1996, Microcirculation (Philadelphia), V3, P279, DOI 10.3109/10739689609148302; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; RACKER E, 1985, ARCH BIOCHEM BIOPHYS, V240, P836, DOI 10.1016/0003-9861(85)90093-1; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Shimoi K, 2001, DRUG METAB DISPOS, V29, P1521; SHOSHAN V, 1980, P NATL ACAD SCI-BIOL, V77, P4435, DOI 10.1073/pnas.77.8.4435; SHOSHAN V, 1981, J BIOL CHEM, V256, P887; Singh U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/annurev.nutr.24.012003.132446; Spencer JPE, 2004, ARCH BIOCHEM BIOPHYS, V423, P148, DOI 10.1016/j.abb.2003.11.010; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S; Williamson G, 2005, FREE RADICAL RES, V39, P457, DOI 10.1080/10715760500053610; Yodogawa S, 2003, BIOL PHARM BULL, V26, P1120, DOI 10.1248/bpb.26.1120; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001	46	143	149	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37102	37110		10.1074/jbc.M606804200	http://dx.doi.org/10.1074/jbc.M606804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16987811	hybrid			2022-12-25	WOS:000242220800071
J	Marohnic, CC; Panda, SP; Martasek, P; Masters, BS				Marohnic, Christopher C.; Panda, Satya P.; Martasek, Pavel; Masters, Bettie Sue			Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I DEFICIENCY; P450 OXIDOREDUCTASE; REDOX PROPERTIES; P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; DISORDERED STEROIDOGENESIS; ELECTRON-TRANSFER; NADPH; RIBOFLAVIN; MUTATIONS	Numerous mutations/polymorphisms of the POR gene, encoding NADPH: cytochrome P450 oxidoreductase (CYPOR), have been described in patients with Antley-Bixler syndrome (ABS), presenting with craniofacial dysmorphogenesis, and/or disordered steroidogenesis, exhibiting ambiguous genitalia. CYPOR is the obligate electron donor to 51 microsomal cytochromes P450 that catalyze critical steroidogenic and xenobiotic reactions, and to two heme oxygenase isoforms, among other redox partners. To address the molecular basis of CYPOR dysfunction in ABS patients, the soluble catalytic domain of human CYPOR was bacterially expressed. WT enzyme was green, due to air-stable FMN semiquinone ( blue) and oxidized FAD ( yellow). The ABS mutant V492E was blue-gray. Flavin analysis indicated that WT had a protein: FAD: FMN ratio of similar to 1:1: 1, whereas similar to 1:0.1:0.9 was observed for V492E, which retained 9% of the WT k(cat)/K-m in NADPH: cytochrome c reductase assays. V492E was reconstituted upon addition of FAD, post-purification, as shown by flavin analysis, activity assay, and near UV-visible CD. Both Y459H and V492E were expressed as membrane anchor-containing proteins, which also exhibited FAD deficiency. CYP4A4-catalyzed omega-hydroxylation of prostaglandin E-1 was supported by WT CYPOR but not by either of the ABS mutants. Hydroxylation activity was rescued for both Y459H and V492E upon addition of FAD to the reaction. Based on these findings, decreased FAD-binding affinity is proposed as the basis of the observed loss of CYPOR function in the Y459H and V492E POR mutations in ABS.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Charles Univ Prague, Sch Med 1, Dept Pediat, CR-11636 Prague, Czech Republic	University of Texas System; University of Texas Health San Antonio; Charles University Prague	Masters, BS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr,7760, San Antonio, TX 78229 USA.	masters@uthscsa.edu	Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [R01 GM081568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2004, AM J MED GENET A, V128A, P333, DOI 10.1002/ajmg.a.30169; Aitken AE, 2001, ARCH BIOCHEM BIOPHYS, V393, P329, DOI 10.1006/abbi.2001.2501; Antley R, 1975, Birth Defects Orig Artic Ser, V11, P397; Arlt W, 2004, LANCET, V363, P2128, DOI 10.1016/S0140-6736(04)16503-3; Auchus RJ, 1999, MOL ENDOCRINOL, V13, P1169, DOI 10.1210/me.13.7.1169; BELL RB, 1990, NEUROLOGY, V40, P1779, DOI 10.1212/WNL.40.11.1779; BERNSEN PLJA, 1993, J NEUROL SCI, V118, P181, DOI 10.1016/0022-510X(93)90108-B; Bewley MC, 2003, BIOCHEMISTRY-US, V42, P13145, DOI 10.1021/bi034915c; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BLACK SD, 1979, BIOCHEM BIOPH RES CO, V91, P1528, DOI 10.1016/0006-291X(79)91238-5; BLASS JP, 1977, NEW ENGL J MED, V297, P1367, DOI 10.1056/NEJM197712222972503; Bonina TA, 2005, BIOCHEMISTRY-MOSCOW+, V70, P357, DOI 10.1007/s10541-005-0122-3; Chun K, 1998, AM J MED GENET, V77, P219, DOI 10.1002/(SICI)1096-8628(19980518)77:3<219::AID-AJMG6>3.0.CO;2-K; Davydov DR, 2000, BIOCHEMISTRY-US, V39, P6489, DOI 10.1021/bi992936u; EDMONDSO.DE, 1971, BIOCHEMISTRY-US, V10, P113; Fluck CE, 2004, NAT GENET, V36, P228, DOI 10.1038/ng1300; Fukami M, 2005, J CLIN ENDOCR METAB, V90, P414, DOI 10.1210/jc.2004-0810; Geller DH, 1997, NAT GENET, V17, P201, DOI 10.1038/ng1097-201; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; Homma K, 2006, J CLIN ENDOCR METAB, V91, P2643, DOI 10.1210/jc.2005-2460; Huang NW, 2005, AM J HUM GENET, V76, P729, DOI 10.1086/429417; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KMOCH S, 1995, J INHERIT METAB DIS, V18, P227, DOI 10.1007/BF00711774; Kondo S, 1999, BIOCHEM BIOPH RES CO, V257, P273, DOI 10.1006/bbrc.1999.0455; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; KURZBAN GP, 1990, J BIOL CHEM, V265, P12272; KUZBAN GP, 1986, J CHROMATOGR, V358, P296; Makovec T, 2002, J STEROID BIOCHEM, V82, P89, DOI 10.1016/S0960-0760(02)00145-0; Masters B, 1967, METHOD ENZYMOL, V10, P565; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Ogle RF, 1997, J PEDIATR-US, V130, P138, DOI 10.1016/S0022-3476(97)70323-8; OPRIAN DD, 1982, J BIOL CHEM, V257, P8935; Otto DME, 2003, MOL CELL BIOL, V23, P6103, DOI 10.1128/MCB.23.17.6103-6116.2003; PASCAL TA, 1975, SCIENCE, V190, P1209, DOI 10.1126/science.1198108; PIETTA P, 1982, J CHROMATOGR, V229, P445, DOI 10.1016/S0378-4347(00)84288-7; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHOLTE HR, 1992, J INHERIT METAB DIS, V15, P331, DOI 10.1007/BF02435969; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Vergani L, 1999, BRAIN, V122, P2401, DOI 10.1093/brain/122.12.2401; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Zhang HM, 2003, BIOCHEMISTRY-US, V42, P6804, DOI 10.1021/bi030081m	46	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35975	35982		10.1074/jbc.M607095200	http://dx.doi.org/10.1074/jbc.M607095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16998238	hybrid			2022-12-25	WOS:000242100500044
J	Nagae, M; Nishi, N; Murata, T; Usui, T; Nakamura, T; Wakatsuki, S; Kato, R				Nagae, Masamichi; Nishi, Nozomu; Murata, Takeomi; Usui, Taichi; Nakamura, Takanori; Wakatsuki, Soichi; Kato, Ryuichi			Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL RECONSTITUTION; LINKER PEPTIDE; BINDING LECTIN; FAMILY; PROGRAM	The galectins are a family of beta-galactoside-binding animal lectins with a conserved carbohydrate recognition domain (CRD). They have a high affinity for small beta-galactosides, but binding specificity for complex glycoconjugates varies considerably within the family. The ligand recognition is essential for their proper function, and the structures of several galectins have suggested their mechanism of carbohydrate binding. Galectin-9 has two tandem CRDs with a short linker, and we report the crystal structures of mouse galectin-9N-terminal CRD (NCRD) in the absence and the presence of four ligand complexes. All structures form the same dimer, which is quite different from the canonical 2-fold symmetric dimer seen for galectin-1 and -2. The beta-galactoside recognition mechanism in the galectin-9 NCRD is highly conserved among other galectins. In the apo form structure, water molecules mimic the ligand hydrogen-bond network. The galectin-9 NCRD can bind both N-acetyllactosamine (Gal beta 1-4GlcNAc) and T-antigen (Gal beta 1-3GalNAc) with the proper location of Arg-64. Moreover, the structure of the N-acetyllactosamine dimer (Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc) complex shows a unique binding mode of galectin-9. Finally, surface plasmon resonance assay showed that the galectin-9 NCRD forms a homophilic dimer not only in the crystal but also in solution.	High Energy Acclerator Res Org, Photon Factory, Inst Mat Struct Sci, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan; Kagawa Univ, Fac Med, Dept Endocrinol, Kagawa 7610793, Japan; Shizuoka Univ, Fac Agr, Dept Appl Biol Chem, Suruga Ku, Shizuoka 4228529, Japan	High Energy Accelerator Research Organization (KEK); Kagawa University; Shizuoka University	Kato, R (corresponding author), High Energy Acclerator Res Org, Photon Factory, Inst Mat Struct Sci, Struct Biol Res Ctr, Tsukuba, Ibaraki 3050801, Japan.	ryuichi.kato@kek.jp		Nishi, Nozomu/0000-0001-7050-3226; Kato, Ryuichi/0000-0003-2087-2896; Nagae, Masamichi/0000-0002-5470-3807; Wakatsuki, Soichi/0000-0001-5896-7968				Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bianchet MA, 2000, PROTEINS, V40, P378, DOI 10.1002/1097-0134(20000815)40:3<378::AID-PROT40>3.0.CO;2-7; Birdsall B, 2001, BIOCHEMISTRY-US, V40, P4859, DOI 10.1021/bi002907f; Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255, DOI 10.1016/S0304-4165(02)00312-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cooper DN, 2002, BIOCHIM BIOPHYS ACTA, V1572, P198; Dunphy JL, 2002, J BIOL CHEM, V277, P14916, DOI 10.1074/jbc.M200214200; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; Hughes RC, 2001, BIOCHIMIE, V83, P667; Ideo H, 2003, GLYCOBIOLOGY, V13, P713, DOI 10.1093/glycob/cwg094; Kageshita T, 2002, INT J CANCER, V99, P809, DOI 10.1002/ijc.10436; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LealPinto E, 1997, J BIOL CHEM, V272, P617; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Lipkowitz MS, 2001, J CLIN INVEST, V107, P1103, DOI 10.1172/JCI12471; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; Lopez-Lucendo MF, 2004, J MOL BIOL, V343, P957, DOI 10.1016/j.jmb.2004.08.078; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; Mehul B, 1997, J CELL SCI, V110, P1169; Merritt EA, 1997, PROTEIN SCI, V6, P1516, DOI 10.1002/pro.5560060716; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishi N, 2005, FEBS LETT, V579, P2058, DOI 10.1016/j.febslet.2005.02.054; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelletier I, 2003, J BIOL CHEM, V278, P22223, DOI 10.1074/jbc.M302693200; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SAKAI K, 1992, J CARBOHYD CHEM, V11, P553, DOI 10.1080/07328309208016148; Sato M, 2002, GLYCOBIOLOGY, V12, P191, DOI 10.1093/glycob/12.3.191; Sato S, 2002, TRENDS GLYCOSCI GLYC, V14, P285, DOI 10.4052/tigg.14.285; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SIEBERT HC, 2003, BIOCHEMISTRY-US, V42, P14672; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Varela PF, 1999, J MOL BIOL, V294, P537, DOI 10.1006/jmbi.1999.3273; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Walser PJ, 2004, STRUCTURE, V12, P689, DOI 10.1016/j.str.2004.03.002; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	48	65	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35884	35893		10.1074/jbc.M606648200	http://dx.doi.org/10.1074/jbc.M606648200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990264	hybrid			2022-12-25	WOS:000242100500035
J	Violin, JD; DeWire, SM; Barnes, WG; Lefkowitz, RJ				Violin, Jonathan D.; DeWire, Scott M.; Barnes, William G.; Lefkowitz, Robert J.			G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1(A) receptor elucidated by diacylglycerol dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED PHOSPHORYLATION; SIGNAL-REGULATED KINASE-1; AT(1A) RECEPTOR; SELECTIVE REGULATION; CYTOPLASMIC TAIL; LIVING CELLS; ACTIVATION; BETA-ARRESTIN-2; VASOPRESSIN; HEPATOCYTES	Receptor desensitization progressively limits responsiveness of cells to chronically applied stimuli. Desensitization in the continuous presence of agonist has been difficult to study with available assay methods. Here, we used a fluorescence resonance energy transfer-based live cell assay for the second messenger diacylglycerol to measure desensitization of a model seven-transmembrane receptor, the G(q)-coupled angiotensin II type 1(A) receptor, expressed in human embryonic kidney 293 cells. In response to angiotensin II, we observed a transient diacylglycerol response reflecting activation and complete desensitization of the receptor within 2-5 min. By utilizing a variety of approaches including graded tetracycline-inducible receptor expression, mutated receptors, and overexpression or short interfering RNA-mediated silencing of putative components of the cellular desensitization machinery, we conclude that the rate and extent of receptor desensitization are critically determined by the following: receptor concentration in the plasma membrane; the presence of phosphorylation sites on the carboxyl terminus of the receptor; kinase activity of Gprotein-coupled receptor kinase 2, but not of G protein-coupled receptor kinases 3, 5, or 6; and stoichiometric expression of beta-arrestin. The findings introduce the use of the biosensor diacylglycerol reporter as a powerful means for studying G(q)-coupled receptor desensitization and document that, at the levels of receptor overexpression commonly used in such studies, the properties of the desensitization process are markedly perturbed and do not reflect normal cellular physiology.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021	DeWire, Scott/0000-0002-1357-4543	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL070631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70631, HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balmforth AJ, 1997, BRIT J PHARMACOL, V122, P1469, DOI 10.1038/sj.bjp.0701522; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BOULAY G, 1994, ENDOCRINOLOGY, V135, P2130, DOI 10.1210/en.135.5.2130; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; DEWIRE S, 2007, IN PRESS ANN REV PHY, V69; Du Y, 1996, AM J PHYSIOL-HEART C, V271, pH440, DOI 10.1152/ajpheart.1996.271.2.H440; Fareh J, 1996, CIRC RES, V78, P302, DOI 10.1161/01.RES.78.2.302; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirai K, 1998, INT J ANDROL, V21, P177; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Kostenis E, 2005, TRENDS PHARMACOL SCI, V26, P595, DOI 10.1016/j.tips.2005.09.007; Laporte SA, 1996, MOL PHARMACOL, V49, P89; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PREISS J, 1986, J BIOL CHEM, V261, P8597; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; Qian HW, 1999, BIOCHEM J, V343, P637, DOI 10.1042/0264-6021:3430637; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; SAUCERMAN JJ, 2006, P NATL ACAD SCI US; SEGALABRAMSON T, 1992, P NATL ACAD SCI USA, V89, P2336, DOI 10.1073/pnas.89.6.2336; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; STAHLS AK, 1989, SCAND J IMMUNOL, V29, P211, DOI 10.1111/j.1365-3083.1989.tb01118.x; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; VIOLIN JD, 2006, J BIOL CHEM; Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200	42	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36411	36419		10.1074/jbc.M607956200	http://dx.doi.org/10.1074/jbc.M607956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008309	hybrid			2022-12-25	WOS:000242100500092
J	Della Valle, MC; Sleat, DE; Sohar, I; Wen, T; Pintar, JE; Jadot, M; Lobel, P				Della Valle, Maria Cecilia; Sleat, David E.; Sohar, Istvan; Wen, Ting; Pintar, John E.; Jadot, Michel; Lobel, Peter			Demonstration of lysosomal localization for the mammalian ependymin-related protein using classical approaches combined with a novel density shift method	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID STORAGE DISORDER; NCTR-BALB/C MICE; MANNOSE 6-PHOSPHATE; PROTEOMIC ANALYSIS; HUMAN BRAIN; RAT-BRAIN; IDENTIFICATION; GLYCOPROTEINS; FRACTIONS; CELLS	Most newly synthesized soluble lysosomal proteins are delivered to the lysosome via the mannose 6-phosphate (Man-6-P)targeting pathway. The presence of the Man-6-P post-translational modification allows these proteins to be affinity-purified on immobilized Man-6-P receptors. This approach has formed the basis for a number of proteomic studies that identified multiple as yet uncharacterized Man-6-P glycoproteins that may represent new lysosomal proteins. Although the presence of Man-6-P is suggestive of lysosomal function, the subcellular localization of such candidates requires experimental verification. Here, we have investigated one such candidate, ependymin-related protein (EPDR). EPDR is a protein of unknown function with some sequence similarity to ependymin, a fish protein thought to play a role in memory consolidation and learning. Using classical subcellular fractionation on rat brain, EPDR co-distributes with lysosomal proteins, but there is significant overlap between lysosomal and mitochondrial markers. For more definitive localization, we have developed a novel approach based upon a selective buoyant density shift of the brain lysosomes in a mutant mouse lacking NPC2, a lysosomal protein involved in lipid transport. EPDR, in parallel with lysosomal markers, shows this density shift in gradient centrifugation experiments comparing mutant and wild type mice. This approach, combined with morphological analyses, demonstrates that EPDR resides in the lysosome. In addition, the lipidosis-induced density shift approach represents a valuable tool for identification and validation of both luminal and membrane lysosomal proteins that should be applicable to high throughput proteomic studies.	Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Dept Pharmacol, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Dept Neurosci & Cell Biol, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Fac Univ Notre Dame Paix, Unite Rech Physiol Mol, Lab Chim Physiol, B-5000 Namur, Belgium	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Namur	Lobel, P (corresponding author), Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Dept Pharmacol, Robert Wood Johnson Med Sch, 679 Hoes Ln, Piscataway, NJ 08854 USA.	lobel@cabm.rutgers.edu			NIDDK NIH HHS [DK054317] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054317] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apostolopoulos J, 2001, DNA CELL BIOL, V20, P625, DOI 10.1089/104454901753340613; BEAUFAY H, 1964, BIOCHEM J, V92, P184, DOI 10.1042/bj0920184; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BHUVANESWARAN C, 1982, AM J PATHOL, V108, P160; Bhuvaneswaran C, 2000, MOL CELL BIOCHEM, V214, P15, DOI 10.1023/A:1007180800941; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; COHEN G, 1970, ANAL BIOCHEM, V34, P30, DOI 10.1016/0003-2697(70)90083-7; Czupalla C, 2006, MOL CELL PROTEOMICS, V5, P134, DOI 10.1074/mcp.M500291-MCP200; De Duve C, 1965, Harvey Lect, V59, P49; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; Gregorio-King CC, 2002, GENE, V286, P249, DOI 10.1016/S0378-1119(02)00434-1; HOTLZMAN E, 1989, LYSOSOMES; Jadot M, 1999, J BIOL CHEM, V274, P21104, DOI 10.1074/jbc.274.30.21104; Journet A, 2000, ELECTROPHORESIS, V21, P3411, DOI 10.1002/1522-2683(20001001)21:16<3411::AID-ELPS3411>3.0.CO;2-M; Journet A, 2002, PROTEOMICS, V2, P1026, DOI 10.1002/1615-9861(200208)2:8<1026::AID-PROT1026>3.0.CO;2-I; Kollmann K, 2005, PROTEOMICS, V5, P3966, DOI 10.1002/pmic.200401247; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; PATEL CC, 1960, NATURE, V186, P803, DOI 10.1038/186803a0; SCHMIDT R, 1995, BEHAV BRAIN RES, V66, P65, DOI 10.1016/0166-4328(94)00126-Z; Scriver C.R., 2001, METABOLIC MOL BASES; SELLINGER OZ, 1971, BRAIN RES, V26, P361, DOI 10.1016/S0006-8993(71)80010-0; SHASHOUA VE, 1979, BRAIN RES, V166, P349, DOI 10.1016/0006-8993(79)90220-8; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; Sleat DE, 2006, MOL CELL PROTEOMICS, V5, P686, DOI 10.1074/mcp.M500343-MCP200; Sleat DE, 2005, PROTEOMICS, V5, P1520, DOI 10.1002/pmic.200401054; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; SLEAT DE, 2006, IN PRESS MOL CELL PR; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Tribl F, 2005, MOL CELL PROTEOMICS, V4, P945, DOI 10.1074/mcp.M400117-MCP200; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WATTIAUX R, 1963, CIBA F S LYSOSOMES, P176; YOUNG JDE, 1986, ANAL BIOCHEM, V158, P28, DOI 10.1016/0003-2697(86)90583-X	37	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35436	35445		10.1074/jbc.M606208200	http://dx.doi.org/10.1074/jbc.M606208200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16954209	hybrid			2022-12-25	WOS:000241933700077
J	Michalakis, S; Reisert, J; Geiger, H; Wetzel, C; Zong, XG; Bradley, J; Spehr, M; Huttl, S; Gerstner, A; Pfeifer, A; Hatt, H; Yau, KW; Biel, M				Michalakis, Stylianos; Reisert, Johannes; Geiger, Heidi; Wetzel, Christian; Zong, Xiangang; Bradley, Jonathan; Spehr, Marc; Huettl, Sabine; Gerstner, Andrea; Pfeifer, Alexander; Hatt, Hanns; Yau, King-Wai; Biel, Martin			Loss of CNGB1 protein leads to olfactory dysfunction and subciliary cyclic nucleotide-gated channel trapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ADENYLYL-CYCLASE; RECEPTOR NEURONS; CATION CHANNEL; ROD PHOTORECEPTOR; SENSORY NEURONS; ION CHANNELS; MICE LACKING; BETA-SUBUNIT; CALCIUM; STOICHIOMETRY	Olfactory receptor neurons (ORNs) employ a cyclic nucleotide-gated (CNG) channel to generate a receptor current in response to an odorant-induced rise in cAMP. This channel contains three types of subunits, the principal CNGA2 subunit and two modulatory subunits (CNGA4 and CNGB1b). Here, we have analyzed the functional relevance of CNGB1 for olfaction by gene targeting in mice. Electro-olfactogram responses of CNGB1-deficient (CNGB1(-/-)) mice displayed a reduced maximal amplitude and decelerated onset and recovery kinetics compared with wild-type mice. In a behavioral test, CNGB1(-/-) mice exhibited a profoundly decreased olfactory performance. Electrophysiological recordings revealed that ORNs of CNGB1(-/-) mice weakly expressed a CNG current with decreased cAMP sensitivity, very rapid flicker-gating behavior and no fast modulation by Ca2+-calmodulin. Co-immunoprecipitation confirmed the presence of a CNGA2/CNGA4 channel in the olfactory epithelium of CNGB1(-/-) mice. This CNGA2/CNGA4 channel was targeted to the plasma membrane of olfactory knobs, but failed to be trafficked into olfactory cilia. Interestingly, we observed a similar trafficking defect in mice deficient for the CNGA4 subunit. In conclusion, these results demonstrate that CNGB1 has a dual function in vivo. First, it endows the olfactory CNG channel with a variety of biophysical properties tailored to the specific requirements of olfactory transduction. Second, together with the CNGA4 subunit, CNGB1 is needed for ciliary targeting of the olfactory CNG channel.	Univ Munich, Dept Pharm, Zentrum Pharmaforsch, D-81377 Munich, Germany; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Ruhr Univ Bochum, Lehrstuhl Zell Biol, D-44780 Bochum, Germany	University of Munich; Johns Hopkins University; Ruhr University Bochum	Biel, M (corresponding author), Univ Munich, Dept Pharm Pharmakol Nat Wissensch, Butenandtstr 7, D-81377 Munich, Germany.	mbiel@cup.uni-muenchen.de	Spehr, Marc/AAK-3162-2021; Spehr, Marc/B-3140-2011; Wetzel, Christian H/N-9880-2017; Michalakis, Stylianos/W-2094-2018; Biel, Martin/G-1175-2014; Wetzel, Christian/C-2501-2009; Michalakis, Stylianos/M-4677-2019; Wetzel, Christian/F-1366-2018	Spehr, Marc/0000-0001-6616-4196; Spehr, Marc/0000-0001-6616-4196; Wetzel, Christian H/0000-0002-5762-0003; Michalakis, Stylianos/0000-0001-5092-9238; Biel, Martin/0000-0002-9974-3052; Wetzel, Christian/0000-0002-5762-0003; Michalakis, Stylianos/0000-0001-5092-9238; Bradley, Jonathan/0000-0002-6933-1153	NEI NIH HHS [R01 EY006837-18, R01 EY006837-19, R01 EY006837, R01 EY014596, R01 EY014596-02, R01 EY014596-04, R01 EY006837-16A1, R01 EY006837-20A1, R01 EY006837-17, R01 EY014596-01, R01 EY014596-03] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904-02, R01 DC006904-01, R01 DC006904, DC06904] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014596, R01EY006837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Baker H, 1999, J NEUROSCI, V19, P9313; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; Biel M, 1999, Rev Physiol Biochem Pharmacol, V135, P151, DOI 10.1007/BFb0033672; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; Bonigk W, 1999, J NEUROSCI, V19, P5332; Bradley J, 2005, CURR OPIN NEUROBIOL, V15, P343, DOI 10.1016/j.conb.2005.05.014; Bradley J, 2004, NAT NEUROSCI, V7, P705, DOI 10.1038/nn1266; Bradley J, 2001, SCIENCE, V294, P2176, DOI 10.1126/science.1063415; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; Dwyer ND, 2001, NEURON, V31, P277, DOI 10.1016/S0896-6273(01)00361-0; FINN JT, 1996, ANNU REV PHYSIOL, V58, P396; FRINGS S, 1995, NEURON, V15, P169, DOI 10.1016/0896-6273(95)90074-8; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; Huttl S, 2005, J NEUROSCI, V25, P130, DOI 10.1523/JNEUROSCI.3764-04.2005; Jenkins PM, 2006, CURR BIOL, V16, P1211, DOI 10.1016/j.cub.2006.04.034; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KELLER A, 1975, J NEUROCHEM, V24, P1101, DOI 10.1111/j.1471-4159.1975.tb03883.x; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; Matthews HR, 2003, CURR OPIN NEUROBIOL, V13, P469, DOI 10.1016/S0959-4388(03)00097-7; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; McClintock TS, 2003, NEUROREPORT, V14, P1547, DOI 10.1097/00001756-200308260-00001; Menco BPM, 1997, CHEM SENSES, V22, P295, DOI 10.1093/chemse/22.3.295; MENCO BPM, 1992, NEURON, V8, P441, DOI 10.1016/0896-6273(92)90272-F; Meyer MR, 2000, P NATL ACAD SCI USA, V97, P10595, DOI 10.1073/pnas.97.19.10595; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Munger SD, 2001, SCIENCE, V294, P2172, DOI 10.1126/science.1063224; NAKAMURA T, 1994, NEUROSCI LETT, V171, P197, DOI 10.1016/0304-3940(94)90638-6; Reisert J, 2005, NEURON, V45, P553, DOI 10.1016/j.neuron.2005.01.012; Reisert J, 2003, J GEN PHYSIOL, V122, P349, DOI 10.1085/jgp.200308888; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Spehr M, 2002, NEURON, V33, P731, DOI 10.1016/S0896-6273(02)00610-4; Washburn KB, 2002, CHEM SENSES, V27, P635, DOI 10.1093/chemse/27.7.635; Weitz D, 2002, NEURON, V36, P881, DOI 10.1016/S0896-6273(02)01098-X; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Zheng J, 2004, NEURON, V42, P411, DOI 10.1016/S0896-6273(04)00253-3; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201; Zong XG, 2005, J BIOL CHEM, V280, P34224, DOI 10.1074/jbc.M506544200	49	61	63	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35156	35166		10.1074/jbc.M606409200	http://dx.doi.org/10.1074/jbc.M606409200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980309	hybrid, Green Accepted			2022-12-25	WOS:000241933700049
J	Kriz, V; Agren, N; Lindholm, CK; Lenell, S; Saldeen, J; Mares, J; Welsh, M				Kriz, Vitezslav; Agren, Nina; Lindholm, Cecilia K.; Lenell, Samuel; Saldeen, Johan; Mares, Jaroslav; Welsh, Michael			The SHB adapter protein is required for normal maturation of mesoderm during in vitro differentiation of embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; JURKAT T-CELLS; DEFINITIVE HEMATOPOIESIS; PRIMITIVE ERYTHROPOIESIS; EXPRESSION DEFINES; ENDOTHELIAL-CELLS; COMMON PRECURSOR; ES CELLS; ENDODERM; VASCULOGENESIS	Definitive mesoderm arises from a bipotent mesendodermal population, and to study processes controlling its development at this stage, embryonic stem (ES) cells can be employed. SHB ((S) under bar rc (h) under bar omology 2 protein in beta-cells) is an adapter protein previously found to be involved in ES cell differentiation to mesoderm. To further study the role of SHB in this context, we have established ES cell lines deficient for one (SHB+/-) or both SHB alleles (SHB-/-). Differentiating embryoid bodies (EBs) derived from these ES cell lines were used for gene expression analysis. Alternatively, EBs were stained for the blood vessel marker CD31. For hematopoietic differentiation, EBs were differentiated in methylcellulose. SHB-/- EBs exhibited delayed down-regulation of the early mesodermal marker Brachyury. Later mesodermal markers relatively specific for the hematopoietic, vascular, and cardiac lineages were expressed at lower levels on day 6 or 8 of differentiation in EBs lacking SHB. The expression of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 was also reduced in SHB-/- EBs. SHB-/- EBs demonstrated impaired blood vessel formation after vascular endothelial growth factor stimulation. In addition, the SHB-/- ES cells formed fewer blood cell colonies than SHB+/+ ES cells. It is concluded that SHB is required for appropriate hematopoietic and vascular differentiation and that delayed down-regulation of Brachyury expression may play a role in this context.	Univ Uppsala, Dept Med Cell Biol, SE-75123 Uppsala, Sweden; Karolinska Univ Hosp, Dept Lab Med, Div Clin Chem, S-14186 Huddinge, Sweden; Charles Univ, Inst Biol & Med Genet, Prague 15006, Czech Republic	Uppsala University; Karolinska Institutet; Karolinska University Hospital; Charles University Prague	Welsh, M (corresponding author), Univ Uppsala, Dept Med Cell Biol, POB 571,Husargatan 3, SE-75123 Uppsala, Sweden.	michael.welsh@mcb.uu.se	Welsh, Michael/AAF-8564-2020; Kriz, Vitezslav/G-6353-2014	Welsh, Michael/0000-0002-5467-9755; Lenell, Samuel/0000-0001-8914-5086				Abe K, 1996, EXP CELL RES, V229, P27, DOI 10.1006/excr.1996.0340; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bielinska M, 1996, BLOOD, V88, P3720, DOI 10.1182/blood.V88.10.3720.bloodjournal88103720; Carlsson L, 2003, METHOD ENZYMOL, V365, P202; Choi K, 1998, DEVELOPMENT, V125, P725; Cross MJ, 2002, MOL BIOL CELL, V13, P2881, DOI 10.1091/mbc.E02-02-0103; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Drake CJ, 2000, BLOOD, V95, P1671, DOI 10.1182/blood.V95.5.1671.005k39_1671_1679; Emambokus NR, 2003, IMMUNITY, V19, P33, DOI 10.1016/S1074-7613(03)00173-0; Ferkowicz MJ, 2003, DEVELOPMENT, V130, P4393, DOI 10.1242/dev.00632; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Hallonet M, 2002, DEV BIOL, V243, P20, DOI 10.1006/dbio.2001.0536; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1996, ONCOGENE, V13, P955; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Kimelman D, 2000, CURR OPIN GENET DEV, V10, P350, DOI 10.1016/S0959-437X(00)00095-2; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Kriz V, 2003, EXP CELL RES, V286, P40, DOI 10.1016/S0014-4827(03)00099-5; Kumar M, 2003, DEV BIOL, V259, P109, DOI 10.1016/S0012-1606(03)00183-0; Lindholm CK, 1999, J BIOL CHEM, V274, P28050, DOI 10.1074/jbc.274.39.28050; Lindholm CK, 2002, EUR J BIOCHEM, V269, P3279, DOI 10.1046/j.1432-1033.2002.03008.x; Lu LG, 2002, CELL GROWTH DIFFER, V13, P141; Lu LG, 2000, EXP CELL RES, V259, P370, DOI 10.1006/excr.2000.4984; Magnusson P, 2004, J CELL SCI, V117, P1513, DOI 10.1242/jcs.00999; Magnusson PU, 2005, ARTERIOSCL THROM VAS, V25, P944, DOI 10.1161/01.ATV.0000163182.73190.f9; Mitjavila-Garcia MT, 2002, DEVELOPMENT, V129, P2003; Otani T, 2005, EXP HEMATOL, V33, P632, DOI 10.1016/j.exphem.2005.03.006; PALIS J, 1995, BLOOD, V86, P156, DOI 10.1182/blood.V86.1.156.bloodjournal861156; Rolny C, 2005, EXP CELL RES, V308, P381, DOI 10.1016/j.yexcr.2005.04.020; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soria B, 2001, DIABETOLOGIA, V44, P407, DOI 10.1007/s001250051636; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; WELSH M, 1994, ONCOGENE, V9, P19; Welsh M, 1999, MOL MED, V5, P169, DOI 10.1007/BF03402060; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Yasunaga M, 2005, NAT BIOTECHNOL, V23, P1542, DOI 10.1038/nbt1167	44	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34484	34491		10.1074/jbc.M604084200	http://dx.doi.org/10.1074/jbc.M604084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16971391	hybrid			2022-12-25	WOS:000241767600069
J	Montagna, GN; Donelson, JE; Frasch, ACC				Montagna, Georgina N.; Donelson, John E.; Frasch, Alberto C. C.			Procyclic Trypanosoma brucei expresses separate sialidase and trans-sialidase enzymes on its surface membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SEQUENCES; PROTEINS; FORMS; ACIDS	The procyclic stage of (T) under bar rypanosoma (b) under bar rucei in the insect vector expresses a surface-bound (t) under bar rans-(s) under bar ialidase (TbTS) that transfers sialic acid from glycoconjugates in the environment to glycosylphosphatidylinositol-anchored proteins on its surface membrane. RNA interference against TbTS abolished transsialidase activity in procyclic cells but did not diminish sialidase activity, suggesting the presence of a separate sialidase enzyme for hydrolyzing sialic acid. A search of the T. brucei genome sequence revealed seven other putative genes encoding proteins with varying similarity to TbTS. RNA interference directed against one of these proteins, TbSA C, greatly decreased the sialidase activity but had no effect on trans-sialidase activity. The deduced amino acid sequence of TbSA C shares only 40% identity with TbTS but conserves most of the relevant residues required for catalysis. However, the sialidase has a tryptophan substitution for a tyrosine at position 170 that is crucial in binding the terminal galactose that accepts the transferred sialic acid. When this same tryptophan substitution in the sialidase was placed into the recombinant trans-sialidase, the mutant enzyme lost almost all of its trans-sialidase activity and increased its sialidase activity, further confirming that the gene and protein identified correspond to the parasite sialidase. Thus, in contrast to all other trypanosomes analyzed to date that express either a trans-sialidase or a sialidase but not both, T. brucei expresses these two enzymatic activities in two separate proteins. These results suggest that African trypanosomes could regulate the amount of critical sialic acid residues on their surface by modulating differential expression of each of these enzymes.	Univ Gen San Martin, Inst Invest Biotechnol, Inst Tecnol Chascomus, INTI, RA-1650 San Martin, Pcia de Buenos, Argentina; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	Instituto Nacional de Tecnologia Industrial (INTI); University of Iowa	Frasch, ACC (corresponding author), Univ Gen San Martin, Inst Invest Biotechnol, Inst Tecnol Chascomus, INTI, Ave Gral Paz 5445,Edificio 24,Casilla Correo 30, RA-1650 San Martin, Pcia de Buenos, Argentina.	cfrasch@iib.unsam.edu.ar	Donelson, John E/F-5795-2010; Montagna, Georgina/D-1202-2013	Montagna, Georgina/0000-0003-0283-8977; Frasch, Alberto Carlos/0000-0001-7532-653X				Basseri HR, 2002, EXP PARASITOL, V100, P226, DOI 10.1016/S0014-4894(02)00026-7; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Buschiazzo A, 1997, GLYCOBIOLOGY, V7, P1167, DOI 10.1093/glycob/7.8.1167; Buschiazzo A, 2002, MOL CELL, V10, P757, DOI 10.1016/S1097-2765(02)00680-9; Buschiazzo A, 1996, CELL MOL BIOL, V42, P703; CREMONA ML, 1995, GENE, V160, P123, DOI 10.1016/0378-1119(95)00175-6; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; ENGLSTLER M, 1992, MOL BIOCHEM PARASIT, V54, P21; ENGLSTLER M, 1993, MOL BIOCHEM PARASIT, V61, P1; Engstler M, 1997, GLYCOBIOLOGY, V7, P955, DOI 10.1093/glycob/7.7.955; Hill KL, 1999, J CELL SCI, V112, P3091; Kamhawi S, 2004, CELL, V119, P329, DOI 10.1016/j.cell.2004.10.009; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; Montagna G, 2002, EUR J BIOCHEM, V269, P2941, DOI 10.1046/j.1432-1033.2002.02968.x; Nagamune K, 2004, J EXP MED, V199, P1445, DOI 10.1084/jem.20030635; Paris G, 2005, J MOL BIOL, V345, P923, DOI 10.1016/j.jmb.2004.09.031; Paris G, 2001, GLYCOBIOLOGY, V11, P305, DOI 10.1093/glycob/11.4.305; PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; POWELL LD, 1986, ANAL BIOCHEM, V157, P179, DOI 10.1016/0003-2697(86)90211-3; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; SCHENKMAN S, 1993, PARASITOL TODAY, V9, P218, DOI 10.1016/0169-4758(93)90017-A; Tiralongo E, 2003, BIOL CHEM, V384, P1203, DOI 10.1515/BC.2003.133; Tiralongo E, 2003, J BIOL CHEM, V278, P23301, DOI 10.1074/jbc.M212909200; Tomlinson S, 1998, PARASITOL TODAY, V14, P354, DOI 10.1016/S0169-4758(98)01295-2; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Watts AG, 2006, J BIOL CHEM, V281, P4149, DOI 10.1074/jbc.M510677200	33	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33949	33958		10.1074/jbc.M604951200	http://dx.doi.org/10.1074/jbc.M604951200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16956887	hybrid			2022-12-25	WOS:000241767600016
J	Schwender, J; Shachar-Hill, Y; Ohlrogge, JB				Schwender, Jorg; Shachar-Hill, Yair; Ohlrogge, John B.			Mitochondrial metabolism in developing embryos of Brassica napus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIZE ROOT-TIPS; CHROMATOGRAPHY-MASS-SPECTROMETRY; NUCLEAR-MAGNETIC-RESONANCE; FATTY-ACID SYNTHESIS; ATP-CITRATE LYASE; PHOSPHOENOLPYRUVATE CARBOXYLASE; OILSEED RAPE; PYRUVATE-KINASE; VICIA-NARBONENSIS; DEVELOPING SEEDS	The metabolism of developing plant seeds is directed toward transforming primary assimilatory products ( sugars and amino acids) into seed storage compounds. To understand the role of mitochondria in this metabolism, metabolic fluxes were determined in developing embryos of Brassica napus. After labeling with [1,2-C-13(2)] glucose + [U-C-13(6)] glucose, [U-C-13(3)] alanine, [U-C-13(5)] glutamine, [N-15] alanine, (amino)-[N-15] glutamine, or (amide)-[N-15] glutamine, the resulting labeling patterns in protein amino acids and in fatty acids were analyzed by gas chromatographymass spectrometry. Fluxes through mitochondrial metabolism were quantified using a steady state flux model. Labeling information from experiments using different labeled substrates was essential for model validation and reliable flux estimation. The resulting flux map shows that mitochondrial metabolism in these developing seeds is very different from that in either heterotrophic or autotrophic plant tissues or in most other organisms: (i) flux around the tricarboxylic acid cycle is absent and the small fluxes through oxidative reactions in the mitochondrion can generate (via oxidative phosphorylation) at most 22% of the ATP needed for biosynthesis; (ii) isocitrate dehydrogenase is reversible in vivo; (iii) about 40% of mitochondrial pyruvate is produced by malic enzyme rather than being imported from the cytosol; (iv) mitochondrial flux is largely devoted to providing precursors for cytosolic fatty acid elongation; and (v) the uptake of amino acids rather than anaplerosis via PEP carboxylase determines carbon flow into storage proteins.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; Michigan State University	Schwender, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	Schwender@BNL.gov	Schwender, Jorg/P-2282-2014; Shachar-Hill, Yair/B-6165-2013	Schwender, Jorg/0000-0003-1350-4171; Shachar-Hill, Yair/0000-0001-8793-5084				Asokanthan PS, 1997, PHYSIOL PLANTARUM, V101, P353, DOI 10.1034/j.1399-3054.1997.1010215.x; Bao XM, 1998, PLANT PHYSIOL, V118, P183, DOI 10.1104/pp.118.1.183; Bowsher CG, 2001, J EXP BOT, V52, P513, DOI 10.1093/jexbot/52.356.513; Chollet R, 1996, ANNU REV PLANT PHYS, V47, P273, DOI 10.1146/annurev.arplant.47.1.273; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; Dieuaide-Noubhani M, 1997, PLANT PHYSIOL, V115, P1505, DOI 10.1104/pp.115.4.1505; DIEUAIDENOUBHANI M, 1995, J BIOL CHEM, V270, P13147, DOI 10.1074/jbc.270.22.13147; DOUCE R, 1989, ANNU REV PLANT PHYS, V40, P371, DOI 10.1146/annurev.pp.40.060189.002103; Eastmond P, 1996, J EXP BOT, V47, P1763, DOI 10.1093/jxb/47.11.1763; Eastmond PJ, 1998, J EXP BOT, V49, P1105, DOI 10.1093/jexbot/49.324.1105; Eastmond PJ, 2000, PLANT PHYSIOL, V122, P767, DOI 10.1104/pp.122.3.767; Edwards S, 1998, PLANT PHYSIOL, V116, P1073, DOI 10.1104/pp.116.3.1073; Fatland BL, 2005, PLANT CELL, V17, P182, DOI 10.1105/tpc.104.026211; Fatland BL, 2002, PLANT PHYSIOL, V130, P740, DOI 10.1104/pp.008110; Fischer E, 2004, ANAL BIOCHEM, V325, P308, DOI 10.1016/j.ab.2003.10.036; GALVEZ S, 1995, PLANT SCI, V105, P1, DOI 10.1016/0168-9452(94)04041-E; Geigenberger P, 2003, CURR OPIN PLANT BIOL, V6, P247, DOI 10.1016/S1369-5266(03)00038-4; Goffman FD, 2005, PLANT PHYSIOL, V138, P2269, DOI 10.1104/pp.105.063628; Goffman FD, 2004, PLANT PHYSIOL BIOCH, V42, P703, DOI 10.1016/j.plaphy.2004.07.003; Gupta R, 1997, INDIAN J BIOCHEM BIO, V34, P288; Hernandez-Sebastia C, 2005, J EXP BOT, V56, P1951, DOI 10.1093/jxb/eri191; KANG F, 1994, PLANT J, V6, P795, DOI 10.1046/j.1365-313X.1994.6060795.x; King SP, 1998, AUST J PLANT PHYSIOL, V25, P377, DOI 10.1071/PP97157; KROMER S, 1995, ANNU REV PLANT PHYS, V46, P45, DOI 10.1146/annurev.pp.46.060195.000401; Kubis SE, 2004, J EXP BOT, V55, P1455, DOI 10.1093/jxb/erh157; Mollney M, 1999, BIOTECHNOL BIOENG, V66, P86, DOI 10.1002/(SICI)1097-0290(1999)66:2<86::AID-BIT2>3.0.CO;2-A; MURPHY DJ, 1989, J PLANT PHYSIOL, V135, P63, DOI 10.1016/S0176-1617(89)80225-1; Rees T.A.P., 1990, PLANT PHYSIOL, P106; Rolletschek H, 2005, PLANT PHYSIOL, V137, P1236, DOI 10.1104/pp.104.056523; Rolletschek H, 2004, PLANT BIOTECHNOL J, V2, P211, DOI 10.1111/j.1467-7652.2004.00064.x; Rontein D, 2002, J BIOL CHEM, V277, P43948, DOI 10.1074/jbc.M206366200; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; Ruuska SA, 2004, PLANT PHYSIOL, V136, P2700, DOI 10.1104/pp.104.047977; SALON C, 1988, J BIOL CHEM, V263, P12278; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Schwender J, 2004, NATURE, V432, P779, DOI 10.1038/nature03145; Schwender J, 2004, CURR OPIN PLANT BIOL, V7, P309, DOI 10.1016/j.pbi.2004.03.016; Schwender J, 2003, J BIOL CHEM, V278, P29442, DOI 10.1074/jbc.M303432200; Schwender J, 2002, PLANT PHYSIOL, V130, P347, DOI 10.1104/pp.004275; SINGAL HR, 1995, J BIOSCIENCE, V20, P49, DOI 10.1007/BF02711580; SINGAL HR, 1987, PLANT PHYSIOL, V83, P1043, DOI 10.1104/pp.83.4.1043; SMITH AJ, 1989, CROP SCI, V29, P349, DOI 10.2135/cropsci1989.0011183X002900020024x; Smith CR, 2000, EUR J BIOCHEM, V267, P4477, DOI 10.1046/j.1432-1327.2000.01494.x; Sriram G, 2004, PLANT PHYSIOL, V136, P3043, DOI 10.1104/pp.104.050625; STEFANOPOULOS GN, 1998, METABOLIC ENG PRINCI; SUGIMOTO T, 1989, AGR BIOL CHEM TOKYO, V53, P885, DOI 10.1080/00021369.1989.10869369; Tcherkez G, 2005, PLANT PHYSIOL, V138, P1596, DOI 10.1104/pp.105.062141; VIGEOLAS H, 2003, PLANT PHYSIOL, V133, P2048, DOI DOI 10.1104/PP.103.031963; Wiechert W, 2001, METAB ENG, V3, P265, DOI 10.1006/mben.2001.0188	49	188	189	1	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34040	34047		10.1074/jbc.M606266200	http://dx.doi.org/10.1074/jbc.M606266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16971389	hybrid			2022-12-25	WOS:000241767600024
J	Xuan, DY; Li, X; Deng, ZH; Zhang, HL; Feng, PX; Duan, XY; Jin, Y				Xuan, Dong-Ying; Li, Xin; Deng, Zhi-Hong; Zhang, Hua-Li; Feng, Pei-xun; Duan, Xiao-Yan; Jin, Yan			Identification and characterization of a novel gene, Mcpr1, and its possible function in the proliferation of embryonic palatal mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CLEFT-PALATE; TRANS-RETINOIC ACID; TGF-BETA; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; IN-VITRO; PROTEIN; TRANSCRIPTION; CHONDROGENESIS; MORPHOGENESIS	We cloned a novel mouse cDNA, Mcpr1 ((m) under bar ouse (c) under bar left (p) under bar alate-(r) under bar elated gene (1) under bar), between retinoic acid (RA)-treated murine embryonic palatal and control shelves by improved subtractive hybridization. Its transcript was identified by Northern blotting. The open reading frame encodes 132 amino acids and shows almost no identity to other genetic products. Mcpr1 expression could be detected extensively in adult mouse tissues and during murine embryonic development. It was identified to be significantly stimulated by RA in murine palatal shelves at embryonic day 12 and in palatal mesenchymal cells in vitro. We demonstrate that MCPR1 protein was localized primarily in the cytoplasm and could be synthesized and secreted by transfected COS-7 cells. Both the secretory and recombinant proteins of Mcpr1 inhibited proliferation of murine embryonic palatal mesenchymal cells and impeded the progression from the G(1) to S phase in the cell cycle. The cells were prone to apoptosis after exposure to glutathione S-transferase- MCPR1. Furthermore, knockdown of MCPR1 protein levels by antisense oligode-oxynucleotides promoted progression of cells from the G1 to S phase and completely abolished the RA-induced block of the cell cycle from the G1 to S phase. These findings suggest that Mcpr1 might function as one of the RA-up-regulated genes involved in inhibiting cell proliferation during palatogenesis and RA-induced cleft palate by regulating proliferation and apoptosis of embryonic palatal mesenchymal cells and might even play a role in the development of many other organs.	Fourth Mil Med Univ, Coll Stomatol, Dept Oral Histol & Pathol, Xian 710032, Shaanxi, Peoples R China; Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China; Fourth Mil Med Univ, Dept Otolaryngol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Jin, Y (corresponding author), Fourth Mil Med Univ, Coll Stomatol, Dept Oral Histol & Pathol, 7 Kangfu Rd, Xian 710032, Shaanxi, Peoples R China.	yanjin@fmmu.edu.cn	Jin, Yan/I-4204-2013					Abbott BD, 1999, TOXICOL SCI, V47, P62, DOI 10.1093/toxsci/47.1.62; ABBOTT BD, 1989, TERATOLOGY, V40, P533, DOI 10.1002/tera.1420400602; ABBOTT BD, 1990, TERATOLOGY, V41, P299, DOI 10.1002/tera.1420410307; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bhasin N, 2004, DEV DYNAM, V230, P201, DOI 10.1002/dvdy.20038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JL, 2004, BIRTH DEFECTS RES B, V71, P289, DOI 10.1002/bdrb.20015; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cho SH, 2003, J CELL BIOCHEM, V89, P837, DOI 10.1002/jcb.10553; Dhulipala V C, 2004, Orthod Craniofac Res, V7, P227, DOI 10.1111/j.1601-6343.2004.00299.x; Dhulipala VC, 2004, TOXICOL APPL PHARM, V194, P270, DOI 10.1016/j.taap.2003.09.014; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Fujita Y, 2006, ENDOCRINOLOGY, V147, P1377, DOI 10.1210/en.2005-0644; Hanumegowda UM, 2002, TOXICOL SCI, V66, P159, DOI 10.1093/toxsci/66.1.159; Jakowlew SB, 2000, PEPTIDES, V21, P1831, DOI 10.1016/S0196-9781(00)00344-2; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lai LH, 2003, DEVELOPMENT, V130, P6465, DOI 10.1242/dev.00887; Lane MA, 2005, PROG NEUROBIOL, V75, P275, DOI 10.1016/j.pneurobio.2005.03.002; Laudet V., 2001, NUCL RECEPTOR FACTSB; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEWIS CA, 1978, DEV BIOL, V64, P31, DOI 10.1016/0012-1606(78)90058-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LUKAS J, 1995, ONCOGENE, V10, P2125; Maeda T, 2001, J BIOL CHEM, V276, P3628, DOI 10.1074/jbc.M007898200; Makhijani NS, 2005, J CELL PHYSIOL, V202, P304, DOI 10.1002/jcp.20128; Mark M, 2003, PURE APPL CHEM, V75, P1709, DOI 10.1351/pac200375111709; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; MICHIELS L, 1993, ONCOGENE, V8, P2537; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Nishida J, 2002, J BIOCHEM, V131, P485, DOI 10.1093/oxfordjournals.jbchem.a003125; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; Nugent P, 1998, J CELL PHYSIOL, V177, P36, DOI 10.1002/(SICI)1097-4652(199810)177:1<36::AID-JCP4>3.0.CO;2-F; Pfisterer P, 2002, J BIOL CHEM, V277, P6637, DOI 10.1074/jbc.M108578200; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reynolds PR, 2003, BIRTH DEFECTS RES A, V67, P168, DOI 10.1002/bdra.10036; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasaki Y, 2004, J PEDIATR SURG, V39, P170, DOI 10.1016/j.jpedsurg.2003.10.009; SATRE MA, 1989, DEV BIOL, V133, P529, DOI 10.1016/0012-1606(89)90055-9; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shibamoto S, 2004, EXP CELL RES, V292, P11, DOI 10.1016/j.yexcr.2003.08.009; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P1954, DOI 10.1093/nar/19.8.1954; Ueno M, 2002, HISTOL HISTOPATHOL, V17, P789, DOI 10.14670/HH-17.789; Wang W, 2002, J CELL BIOL, V157, P1061, DOI 10.1083/jcb.200203014; Yano H, 1996, CLEFT PALATE-CRAN J, V33, P379, DOI 10.1597/1545-1569(1996)033<0379:COCREP>2.3.CO;2; Yu ZL, 2006, BIOCHEM BIOPH RES CO, V340, P929, DOI 10.1016/j.bbrc.2005.12.100; Yu ZL, 2005, TOXICOL SCI, V83, P349, DOI 10.1093/toxsci/kfi030; Zhao ZL, 1999, J BIOTECHNOL, V73, P35, DOI 10.1016/S0168-1656(99)00006-1; Zheng YQ, 2006, ACTA PHARMACOL SIN, V27, P111, DOI 10.1111/j.1745-7254.2006.00234.x	54	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33997	34008		10.1074/jbc.M605467200	http://dx.doi.org/10.1074/jbc.M605467200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963447	hybrid			2022-12-25	WOS:000241767600020
J	Koo, AJK; Chung, HS; Kobayashi, Y; Howe, GA				Koo, Abraham J. K.; Chung, Hoo Sun; Kobayashi, Yuichi; Howe, Gregg A.			Identification of a peroxisomal acyl-activating enzyme involved in the biosynthesis of jasmonic acid in arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; METHYL JASMONATE; BETA-OXIDATION; OCTADECANOID PRECURSORS; GENE-EXPRESSION; REVEALS; DEFENSE; MUTANTS; VISUALIZATION; SUPERFAMILY	Jasmonic acid (JA) is a lipid-derived signal that regulates a wide variety of developmental and defense-related processes in higher plants. JA is synthesized from linolenic acid via an enzymatic pathway that initiates in the plastid and terminates in peroxisomes. The C18 JA precursor 12-oxo-phytodienoic acid (OPDA) is converted in the peroxisome to 3-oxo-2-(2'-[Z]-pentenyl) cyclopentane-1-octanoic acid (OPC-8:0), which subsequently undergoes three rounds of beta-oxidation to yield JA. Although most JA biosynthetic enzymes have been identified, several key steps in the pathway remain to be elucidated. To address this knowledge gap, we employed co-expression analysis to identify genes that are coordinately regulated with known JA biosynthetic components in Arabidopsis. Among the candidate genes uncovered by this approach was a 4-coumarate-CoA ligase-like member of the acyl-activating enzyme (AAE) gene family, which we have named OPC-8:0 CoA Ligase1 (OPCL1). In response to wounding, opcl1 null mutants exhibited reduced levels of JA and hyperaccumulation of OPC-8:0. Recombinant OPCL1 was active against both OPDA and OPC-8: 0, as well as medium-to-long straight-chain fatty acids. Subcellular localization studies with green fluorescent protein-tagged OPCL1 showed that the protein is targeted to peroxisomes. These findings establish a physiological role for OPCL1 in the activation of JA biosynthetic precursors in leaf peroxisomes, and further indicate that OPC-8: 0 is a physiological substrate for the activation step. The results also demonstrate the utility of co-expression analysis for identification of factors that contribute to jasmonate homeostasis.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; Tokyo Inst Technol, Dept Biol Engn, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Tokyo Institute of Technology; Michigan State University	Howe, GA (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.	howeg@msu.edu	Koo, Abraham J/H-9721-2017; Howe, Gregg A/N-1887-2014	Howe, Gregg A/0000-0002-9218-979X; Koo, Abraham/0000-0003-2162-2987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057795] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM57795] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ainai T, 2003, J ORG CHEM, V68, P7825, DOI 10.1021/jo0348571; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Baker A, 2006, TRENDS PLANT SCI, V11, P124, DOI 10.1016/j.tplants.2006.01.005; Benning C, 2006, CURR OPIN PLANT BIOL, V9, P241, DOI 10.1016/j.pbi.2006.03.012; Buseman CM, 2006, PLANT PHYSIOL, V142, P28, DOI 10.1104/pp.106.082115; Castillo MC, 2004, PLANT PHYSIOL, V135, P85, DOI 10.1104/pp.104.039925; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Costa MA, 2005, PHYTOCHEMISTRY, V66, P2072, DOI 10.1016/j.phytochem.2005.06.022; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; Cukovic D, 2001, BIOL CHEM, V382, P645, DOI 10.1515/BC.2001.076; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Devoto A, 2005, PLANT MOL BIOL, V58, P497, DOI 10.1007/s11103-005-7306-5; Devoto A, 2005, PHYSIOL PLANTARUM, V123, P161, DOI 10.1111/j.1399-3054.2004.00418.x; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FEYS BJF, 1994, PLANT CELL, V6, P751, DOI 10.1105/tpc.6.5.751; Fliegmann J, 2003, BIOL CHEM, V384, P437, DOI 10.1515/BC.2003.049; Fulda M, 2004, PLANT CELL, V16, P394, DOI 10.1105/tpc.019646; Gfeller A, 2004, SCIENCE, V306, P1515, DOI 10.1126/science.1104352; Halitschke R, 2004, J PLANT GROWTH REGUL, V23, P238, DOI 10.1007/s00344-004-0037-z; Howe GA, 2004, PLANT HORMONES: BIOSYNTHESIS, SIGNAL TRANSDUCTION, ACTION, P610; Howe GA, 2004, J PLANT GROWTH REGUL, V23, P223, DOI 10.1007/s00344-004-0030-6; Ishiguro S, 2001, PLANT CELL, V13, P2191, DOI 10.1105/tpc.13.10.2191; Jedd G, 2002, PLANT CELL PHYSIOL, V43, P384, DOI 10.1093/pcp/pcf045; Koch T, 1999, PLANT PHYSIOL, V121, P153, DOI 10.1104/pp.121.1.153; Koo AJK, 2004, J BIOL CHEM, V279, P16101, DOI 10.1074/jbc.M311305200; Li CY, 2005, PLANT CELL, V17, P971, DOI 10.1105/tpc.104.029108; Li L, 2004, PLANT CELL, V16, P126, DOI 10.1105/tpc.017954; Mandaokar A, 2006, PLANT J, V46, P984, DOI 10.1111/j.1365-313X.2006.02756.x; Mueller MJ, 2006, PLANT J, V45, P472, DOI 10.1111/j.1365-313X.2005.02614.x; Nemhauser JL, 2006, CELL, V126, P467, DOI 10.1016/j.cell.2006.05.050; Persson S, 2005, P NATL ACAD SCI USA, V102, P8633, DOI 10.1073/pnas.0503392102; Reumann S, 2004, PLANT PHYSIOL, V136, P2587, DOI 10.1104/pp.104.043695; Reymond P, 2004, PLANT CELL, V16, P3132, DOI 10.1105/tpc.104.026120; Reymond P, 2000, PLANT CELL, V12, P707, DOI 10.1105/tpc.12.5.707; Sasaki Y, 2001, DNA RES, V8, P153, DOI 10.1093/dnares/8.4.153; Schaller F, 2000, PLANTA, V210, P979, DOI 10.1007/s004250050706; Schaller F, 2004, J PLANT GROWTH REGUL, V23, P179, DOI 10.1007/s00344-004-0047-x; Schilmiller AL, 2005, CURR OPIN PLANT BIOL, V8, P369, DOI 10.1016/j.pbi.2005.05.008; Schmelz EA, 2004, PLANT J, V39, P790, DOI 10.1111/j.1365-313X.2004.02168.x; Schneider K, 2005, J BIOL CHEM, V280, P13962, DOI 10.1074/jbc.M413578200; Schnurr JA, 2002, PLANT PHYSIOL, V129, P1700, DOI 10.1104/pp.003251; Seo HS, 2001, P NATL ACAD SCI USA, V98, P4788, DOI 10.1073/pnas.081557298; Shockey JM, 2003, PLANT PHYSIOL, V132, P1065, DOI 10.1104/pp.103.020552; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; Staswick PE, 2004, PLANT CELL, V16, P2117, DOI 10.1105/tpc.104.023549; Staswick PE, 2002, PLANT CELL, V14, P1405, DOI 10.1105/tpc.000885; Stelmach BA, 2001, J BIOL CHEM, V276, P12832, DOI 10.1074/jbc.M010743200; Stintzi A, 2001, P NATL ACAD SCI USA, V98, P12837, DOI 10.1073/pnas.211311098; Strassner J, 2002, PLANT J, V32, P585, DOI 10.1046/j.1365-313X.2002.01449.x; Taki N, 2005, PLANT PHYSIOL, V139, P1268, DOI 10.1104/pp.105.067058; Theodoulou FL, 2005, PLANT PHYSIOL, V137, P835, DOI 10.1104/pp.105.059352; Toufighi K, 2005, PLANT J, V43, P153, DOI 10.1111/j.1365-313X.2005.02437.x; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; Wallis JG, 2002, PROG LIPID RES, V41, P254, DOI 10.1016/S0163-7827(01)00027-3; Wasternack C, 2006, J PLANT PHYSIOL, V163, P297, DOI 10.1016/j.jplph.2005.10.014; Weber H, 1997, P NATL ACAD SCI USA, V94, P10473, DOI 10.1073/pnas.94.19.10473; WEILER EW, 1993, PHYTOCHEMISTRY, V32, P591, DOI 10.1016/S0031-9422(00)95142-2; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; ZIEGLER K, 1987, ARCH MICROBIOL, V149, P62, DOI 10.1007/BF00423138; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	61	141	150	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33511	33520		10.1074/jbc.M607854200	http://dx.doi.org/10.1074/jbc.M607854200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963437	hybrid			2022-12-25	WOS:000241621400062
J	Piessevaux, J; Lavens, D; Montoye, T; Wauman, J; Catteeuw, D; Vandekerckhove, J; Belsham, D; Peelman, F; Tavernier, J				Piessevaux, Julie; Lavens, Delphine; Montoye, Tony; Wauman, Joris; Catteeuw, Dominiek; Vandekerckhove, Joel; Belsham, Denise; Peelman, Frank; Tavernier, Jan			Functional cross-modulation between SOCS proteins can stimulate cytokine signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING SUPPRESSOR; CONFERS RESISTANCE; LEPTIN SENSITIVITY; KINASE-ACTIVITY; SH2 DOMAIN; BOX MOTIF; RECEPTOR; INHIBITION; PHOSPHORYLATION; BINDING	SOCS (suppressors of cytokine signaling) proteins are negative regulators of cytokine signaling that function primarily at the receptor level. Remarkably, in vitro and in vivo observations revealed both inhibitory and stimulatory effects of SOCS2 on growth hormone signaling, suggesting an additional regulatory level. In this study, we examined the possibility of direct cross-modulation between SOCS proteins and found that SOCS2 could interfere with the inhibitory actions of other SOCS proteins in growth hormone, interferon, and leptin signaling. This SOCS2 effect was SOCS box-dependent, required recruitment of the elongin BC complex, and coincided with degradation of target SOCS proteins. Detailed mammalian protein-protein interaction trap (MAPPIT) analysis indicated that SOCS2 can interact with all members of the SOCS family. SOCS2 may thus function as a molecular bridge between a ubiquitin-protein isopeptide ligase complex and SOCS proteins, targeting them for proteasomal turnover. We furthermore extended these observations to SOCS6 and SOCS7. Our findings point to a unique regulatory role for SOCS2, SOCS6, and SOCS7 within the SOCS family and provide an explanation for the unexpected phenotypes observed in SOCS2 and SOCS6 transgenic mice.	Univ Ghent VIB, Fac Med & Hlth Sci, Dept Med Prot Res, B-9000 Ghent, Belgium; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	Flanders Institute for Biotechnology (VIB); Ghent University; University of Toronto	Tavernier, J (corresponding author), Univ Ghent VIB, Fac Med & Hlth Sci, Dept Med Prot Res, Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.tavernier@ugent.be	Tavernier, Jan/AAG-3636-2019; Wauman, Joris/GZL-0902-2022					Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Belsham DD, 2004, ENDOCRINOLOGY, V145, P393, DOI 10.1210/en.2003-0946; Brender C, 2001, EXP CLIN IMMUNOGENET, V18, P80, DOI 10.1159/000049186; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Dif F, 2001, ENDOCRINOLOGY, V142, P5286, DOI 10.1210/en.142.12.5286; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Favre H, 1999, FEBS LETT, V453, P63, DOI 10.1016/S0014-5793(99)00681-X; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Greenhalgh CJ, 2002, MOL ENDOCRINOL, V16, P1394, DOI 10.1210/me.16.6.1394; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; Greenhalgh CJ, 2005, J CLIN INVEST, V115, P397, DOI 10.1172/JCI200522710; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Krebs DL, 2004, P NATL ACAD SCI USA, V101, P15446, DOI 10.1073/pnas.0406870101; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Landsman T, 2005, J BIOL CHEM, V280, P37471, DOI 10.1074/jbc.M504125200; Lavens D, 2006, J CELL SCI, V119, P2214, DOI 10.1242/jcs.02947; Li L, 2004, J BIOL CHEM, V279, P34107, DOI 10.1074/jbc.M312672200; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Montoye T, 2005, BLOOD, V105, P4264, DOI 10.1182/blood-2004-07-2733; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ouyang X, 2006, J CELL PHYSIOL, V207, P428, DOI 10.1002/jcp.20579; Pattyn E, 1999, J BIOL CHEM, V274, P34838, DOI 10.1074/jbc.274.49.34838; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; Rawlings JS, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-38; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Tannahill GM, 2005, MOL CELL BIOL, V25, P9115, DOI 10.1128/MCB.25.20.9115-9126.2005; Tavernier J, 2002, CLIN EXP ALLERGY, V32, P1397, DOI 10.1046/j.1365-2745.2002.01520.x; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; van de Geijn GJM, 2004, BLOOD, V104, P667, DOI 10.1182/blood-2003-08-2913; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	57	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					32953	32966		10.1074/jbc.M600776200	http://dx.doi.org/10.1074/jbc.M600776200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956890	hybrid			2022-12-25	WOS:000241621400004
J	Zhu, JX; Doyle, HA; Mamula, MJ; Aswad, DW				Zhu, Jeff X.; Doyle, Hester A.; Mamula, Mark J.; Aswad, Dana W.			Protein repair in the brain, proteomic analysis of endogenous substrates for protein L-isoaspartyl methyltransferase in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY MODIFIED PROTEINS; RESPONSE MEDIATOR PROTEINS; ALZHEIMERS-DISEASE BRAIN; CARBOXYL METHYLTRANSFERASE; SYNAPSIN-I; METHYL ESTERIFICATION; O-METHYLTRANSFERASE; DAMAGED PROTEINS; ALPHA-INTERNEXIN; DEAMIDATION	Protein L-isoaspartyl methyltransferase ( PIMT) catalyzes repair of L-isoaspartyl peptide bonds, a major source of protein damage under physiological conditions. PIMT knock-out ( KO) mice exhibit brain enlargement and fatal epileptic seizures. All organs accumulate isoaspartyl proteins, but only the brain manifests an overt pathology. To further explore the role of PIMT in brain function, we undertook a global analysis of endogenous substrates for PIMT in mouse brain. Extracts from PIMT-KO mice were subjected to two-dimensional gel electrophoresis and blotted onto membranes. Isoaspartyl proteins were radiolabeled on-blot using [methyl-3H] S-adenosyl-L-methionine and recombinant PIMT. Fluorography of the blot revealed 30-35 H-3-labeled proteins, 22 of which were identified by peptide mass fingerprinting. These isoaspartate-prone proteins represent a wide range of cellular functions, including neuronal development, synaptic transmission, cytoskeletal structure and dynamics, energy metabolism, nitrogen metabolism, pH homeostasis, and protein folding. The following five proteins, all of which are rich in neurons, accumulated exceptional levels of isoaspartate: collapsin response mediator protein 2 (CRMP2/ULIP2/DRP-2), dynamin 1, synapsin I, synapsin II, and tubulin. Several of the proteins identified here are prone to age-dependent oxidation in vivo, and many have been identified as autoimmune antigens, of particular interest because isoaspartate can greatly enhance the antigenicity of self-peptides. We propose that the PIMT-KO phenotype results from the cumulative effect of isoaspartate-related damage to a number of the neuron-rich proteins detected in this study. Further study of the isoaspartate-prone proteins identified here may help elucidate the molecular basis of one or more developmental and/or age-related neurological diseases.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06510 USA	University of California System; University of California Irvine; Yale University	Aswad, DW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 McGaugh Hall, Irvine, CA 92697 USA.	dwaswad@uci.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048120, R21AI048120, P01AI036529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR047759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36529, AI48120] Funding Source: Medline; NIAMS NIH HHS [F32-AR47759] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anggono V, 2006, NAT NEUROSCI, V9, P752, DOI 10.1038/nn1695; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; AXELROD J, 1965, SCIENCE, V150, P892, DOI 10.1126/science.150.3698.892; Brown M, 2004, J NEUROSCI, V24, P8994, DOI 10.1523/JNEUROSCI.3184-04.2004; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Chretien-Leprince P, 2005, ANN NY ACAD SCI, V1050, P266, DOI 10.1196/annals.1313.028; Clarke S, 2003, AGEING RES REV, V2, P263, DOI 10.1016/S1568-1637(03)00011-4; Cole AR, 2006, J BIOL CHEM, V281, P16591, DOI 10.1074/jbc.M513344200; Dale RC, 2006, J NEUROIMMUNOL, V172, P187, DOI 10.1016/j.jneuroim.2005.10.014; David CL, 1998, J BIOL CHEM, V273, P32063, DOI 10.1074/jbc.273.48.32063; DILIBERT.EJ, 1974, P NATL ACAD SCI USA, V71, P1701, DOI 10.1073/pnas.71.5.1701; Doyle HA, 2005, ANN NY ACAD SCI, V1050, P1, DOI 10.1196/annals.1313.001; Doyle HA, 2003, J IMMUNOL, V171, P2840, DOI 10.4049/jimmunol.171.6.2840; Farrar C, 2005, AGING CELL, V4, P1, DOI 10.1111/j.1474-9728.2004.00136.x; Farrar CE, 2005, J COMP NEUROL, V493, P524, DOI 10.1002/cne.20780; Ferreira A, 2000, J NEUROSCI, V20, P3736, DOI 10.1523/JNEUROSCI.20-10-03736.2000; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gitlits VM, 2001, J INVEST MED, V49, P276, DOI 10.2310/6650.2001.33973; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hattori T, 2006, INVEST OPHTH VIS SCI, V47, P249, DOI 10.1167/iovs.05-0774; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Ikegaya Y, 2001, HIPPOCAMPUS, V11, P287, DOI 10.1002/hipo.1043; Ingrosso D, 2000, EUR J BIOCHEM, V267, P4397, DOI 10.1046/j.1432-1327.2000.01485.x; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1985, BIOCHEMISTRY-US, V24, P2581, DOI 10.1021/bi00331a028; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kim E, 1999, J BIOL CHEM, V274, P20671, DOI 10.1074/jbc.274.29.20671; KIM S, 1973, ARCH BIOCHEM BIOPHYS, V157, P476, DOI 10.1016/0003-9861(73)90665-6; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lanthier J, 2002, J NEUROCHEM, V83, P581, DOI 10.1046/j.1471-4159.2002.01150.x; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Lindner H, 2001, EXP GERONTOL, V36, P1551, DOI 10.1016/S0531-5565(01)00140-1; Lowenson JD, 2001, J BIOL CHEM, V276, P20695, DOI 10.1074/jbc.M100987200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; Mor F, 2005, J IMMUNOL, V175, P3439, DOI 10.4049/jimmunol.175.5.3439; MORIN AM, 1973, BIOCHEM BIOPH RES CO, V52, P373, DOI 10.1016/0006-291X(73)90721-3; MURRAY ED, 1984, J BIOL CHEM, V259, P722; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Ochi H, 2002, FEBS LETT, V528, P197, DOI 10.1016/S0014-5793(02)03307-0; OCONNOR CM, 1985, ANAL BIOCHEM, V148, P79, DOI 10.1016/0003-2697(85)90630-X; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OHTA K, 1987, BIOCHIMIE, V69, P1227, DOI 10.1016/0300-9084(87)90150-7; OTA IM, 1990, ARCH BIOCHEM BIOPHYS, V279, P320, DOI 10.1016/0003-9861(90)90498-N; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Rajasalu T, 2004, IMMUNOL LETT, V94, P153, DOI 10.1016/j.imlet.2004.05.002; Reissner KJ, 2006, J BIOL CHEM, V281, P8389, DOI 10.1074/jbc.M510716200; Reissner KJ, 2003, CELL MOL LIFE SCI, V60, P1281, DOI 10.1007/s00018-003-2287-5; Robinson NE, 2004, J PEPT RES, V63, P426, DOI 10.1111/j.1399-3011.2004.00151.x; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Shimizu T, 2005, BIOL PHARM BULL, V28, P1590, DOI 10.1248/bpb.28.1590; Shimizu T, 2002, J NEUROSCI RES, V69, P341, DOI 10.1002/jnr.10301; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; Tanaka Y, 2006, MICROBIOL IMMUNOL, V50, P117, DOI 10.1111/j.1348-0421.2006.tb03776.x; Tontsch D, 2000, CLIN EXP IMMUNOL, V121, P270, DOI 10.1046/j.1365-2249.2000.01283.x; Vitali R, 2004, BEHAV BRAIN RES, V153, P129, DOI 10.1016/j.bbr.2003.11.007; Volkin DB, 1997, MOL BIOTECHNOL, V8, P105, DOI 10.1007/BF02752255; Yamamoto A, 1998, J NEUROSCI, V18, P2063; Yang ML, 2006, J IMMUNOL, V177, P4541, DOI 10.4049/jimmunol.177.7.4541; Young AL, 2001, J BIOL CHEM, V276, P37161, DOI 10.1074/jbc.M106682200; Young GW, 2005, J BIOL CHEM, V280, P26094, DOI 10.1074/jbc.M503624200	74	66	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33802	33813		10.1074/jbc.M606958200	http://dx.doi.org/10.1074/jbc.M606958200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959769	hybrid			2022-12-25	WOS:000241621400086
J	Candeias, MM; Powell, DJ; Roubalova, E; Apcher, S; Bourougaa, K; Vojtesek, B; Bruzzoni-Giovanelli, H; Fahraeus, R				Candeias, M. M.; Powell, D. J.; Roubalova, E.; Apcher, S.; Bourougaa, K.; Vojtesek, B.; Bruzzoni-Giovanelli, H.; Fahraeus, R.			Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation	ONCOGENE			English	Article						p53; p53/47; stress response; alternative translation initiation	RIBOSOME-ENTRY-SITE; TUMOR-SUPPRESSOR; MEDIATED TRANSLATION; PROTEIN; MDM2; INDUCTION; APOPTOSIS; ISOFORM; DOMAIN; STABILITY	P53 controls the growth and survival of cells by acting in response to a multitude of cellular stresses. It is, however, not yet fully understood how different p53 activation pathways result in either cell cycle arrest or apoptosis. We and others have described an N-terminally truncated p53 protein (p53/47) originating from a second translation initiation site in the p53 messenger RNA ( mRNA), which can interact with p53 and impose altered stability and transactivation properties to p53 complexes. Here we show that cap-dependent and cap-independent mechanisms of initiation govern the translation of the p53 mRNA. Changes in synthesis of full-length p53 or p53/47 are regulated through distinct cell stress-induced pathways acting through separate regions of the p53 mRNA. We also show that some cytotoxic drugs require the presence of full-length p53 to induce apoptosis, whereas for others p53/47 is sufficient. This indicates that by harbouring alternative translation initiation sites, the p53 mRNA gives rise to different levels of the p53 isoforms which help to orchestrate the cell biological outcome of p53 activation in response to different types of cell stress. This sheds new light into the way p53 can integrate and differentiate a large multiplicity of changes in the cellular environment.	Hop St Louis, INSERM, Inst Mol Genet, U716, F-75010 Paris, France; Masaryk Mem Canc Inst, Brno, Czech Republic	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Masaryk Memorial Cancer Institute	Fahraeus, R (corresponding author), Hop St Louis, INSERM, Inst Mol Genet, U716, 27 Rue Juliette Dodu, F-75010 Paris, France.	robinfahraeus@yahoo.co.uk	Apcher, Sebastien/P-2590-2018; Apcher, Sebastien/B-6356-2015; fahraeus, robin/K-8726-2014; Powell, Darren Jmaes/GOE-5236-2022; Hajduskova, Eva/G-9780-2014	Powell, Darren Jmaes/0000-0001-9439-5880; Bourougaa, Karima/0000-0003-0339-962X; , robin/0000-0003-0402-8492				Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Herbreteau CH, 2005, NAT STRUCT MOL BIOL, V12, P1001, DOI 10.1038/nsmb1011; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	41	79	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6936	6947		10.1038/sj.onc.1209996	http://dx.doi.org/10.1038/sj.onc.1209996			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16983332				2022-12-25	WOS:000241732300004
J	Habens, F; Lapham, AS; Dallman, CL; Pickering, BM; Michels, J; Marcusson, EG; Johnson, PWM; Packham, G				Habens, F.; Lapham, A. S.; Dallman, C. L.; Pickering, B. M.; Michels, J.; Marcusson, E. G.; Johnson, P. W. M.; Packham, G.			Distinct promoters mediate constitutive and inducible Bcl-X-L expression in malignant lymphocytes	ONCOGENE			English	Article						Bcl-X-L; Ets; lymphoma; transcription	EPSTEIN-BARR-VIRUS; REL/NF-KAPPA-B; CELL-DEATH; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC MALIGNANCIES; FAMILY PROTEINS; POOR-PROGNOSIS	Bcl-X-L is a Bcl-2-related survival protein that is essential for normal development. Bcl-X-L expression is rapidly induced by a wide range of survival signals and many cancer cells constitutively express high levels. The Bcl-X gene has a complex organization with multiple promoters giving rise to RNAs with alternate 5' non-codingexons. Here we have investigated the mechanisms that control basal and induced expression of Bcl-X-L in B-lymphoma cells. Antisense experiments demonstrated that Bcl-X-L was essential for survival of Akata6 B-lymphoma cells. The levels of RNAs containing the IB Bcl-X non-coding exon, derived from the distal 1B promoter, correlated with basal expression of Bcl-X-L in primary malignant B cells and this promoter was highly active in B-cell lines. The activity of this promoter was largely dependent on a single Ets binding site and Ets family proteins were bound at this promoter in intact cells. CD40 ligand (CD40L)-induced cell survival was associated with increased Bcl-X-L expression and accumulation of exon IA-containing RNAs, derived from the proximal 1A promoter. Nuclear factor-kappaB (NF-kappa B) inhibition prevented induction of Bcl-X-L protein and exon IA-containingRNAs by CD40L. Therefore, the distal Bcl-X 1B promoter plays a critical role in driving constitutive expression-mediated via Ets family proteins in malignant B cells, whereas NF-kappa B plays a central role in the induction of Bcl-X-L in response to CD40 signalling via the proximal 1A promoter.	Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK,Ctr Clin,Canc Sci Div, Southampton SO16 6YD, Hants, England; ISIS Pharmaceut, Antisense Drug Discovery, Carlsbad, CA 92008 USA	Cancer Research UK; University of Southampton; Isis Pharmaceuticals Inc	Packham, G (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK,Ctr Clin,Canc Sci Div, Somers Canc Res Bldg,MP824, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691; Marcusson, Eric/0000-0002-0504-8674				Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; Dallman C, 2005, METH MOLEC MED, V115, P1; de Nigris F, 2001, CANCER RES, V61, P2267; Deng G, 1998, MOL MED, V4, P158, DOI 10.1007/BF03401913; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Friess H, 1998, ANN SURG, V228, P780, DOI 10.1097/00000658-199812000-00009; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Heere-Ress E, 2002, INT J CANCER, V99, P29, DOI 10.1002/ijc.10248; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Kirito K, 2002, J BIOL CHEM, V277, P8329, DOI 10.1074/jbc.M109824200; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V149, P1449; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Lohmann CM, 2000, CYTOMETRY, V42, P61, DOI 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pallis M, 1997, LEUKEMIA, V11, P945, DOI 10.1038/sj.leu.2400705; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Pena JC, 1998, CANCER RES, V58, P2111; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tian CX, 2003, BLOOD, V101, P2235, DOI 10.1182/blood-2002-04-1217; Tu YP, 1998, CANCER RES, V58, P256; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Vega MI, 2005, ONCOGENE, V24, P8114, DOI 10.1038/sj.onc.1208954; Viegas LR, 2004, J BIOL CHEM, V279, P9831, DOI 10.1074/jbc.M312402200; WANG ZH, 1995, J IMMUNOL, V155, P3722; Wu LX, 2005, J IMMUNOL, V174, P180, DOI 10.4049/jimmunol.174.1.180; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x	55	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1910	1919		10.1038/sj.onc.1209979	http://dx.doi.org/10.1038/sj.onc.1209979			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983335				2022-12-25	WOS:000245117700008
J	Wang, F; Liu, R; Lee, SW; Sloss, CM; Couget, J; Cusack, JC				Wang, F.; Liu, R.; Lee, S. W.; Sloss, C. M.; Couget, J.; Cusack, J. C.			Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance	ONCOGENE			English	Article						HB-EGF; EGFR; NF-kappa B; c-fos; chemotherapy resistance	NF-KAPPA-B; HB-EGF; PROHB-EGF; METALLOPROTEINASE-CLEAVAGE; CELL-PROLIFERATION; SIGNALING CASCADES; CARCINOMA-CELLS; INHIBITION; CHEMORESISTANCE; ACTIVATION	We have shown that one of the principle mechanisms of chemotherapy resistance involves the activation of nuclear factor kappa-B (NF-kappa B). In an effort to identify NF- kappa-B-regulated chemotherapy response genes, we performed a microarray assay and observed that heparin-binding EGF-like growth factor (HB-EGF) was significantly upregulated by SN38 (a strong inducer of NF-kappa B activity) in colon cancer cells. Further studies revealed that HB-EGF was rapidly induced following a variety of chemotherapy treatments. Using RNA interference, we demonstrated that the chemotherapy-induced HB-EGF was largely dependent on activator protein-1 (AP-1) and NF-kappa B activation. Constitutive HB-EGF expression rescued AP-1/NF-kappa B small interfering RNA (siRNA) cells from chemotherapy-induced apoptosis. Meanwhile, we found that the enzymatic shedding of HB-EGF was also regulated by chemotherapy treatment, resulting in the elevated release of soluble HB-EGF from the cellular membrane. Induction of HB-EGF expression and ectodomain shedding synergistically led to robust epidermal growth factor receptor (EGFR) phosphorylation, whereas inhibition of HB-EGF expression by use of the HB-EGF inhibitor (CRM197) or siRNA resulted in the suppression of chemotherapyinduced EGFR phosphorylation. These results suggest that the chemotherapy-induced EGFR activation is regulated by HB-EGF. Finally, we demonstrated that overexpression of HB-EGF led to apoptotic resistance to chemotherapy, whereas suppression of HB-EGF expression by siRNA resulted in a dramatic increase in cell death. In summary, our study suggests that chemotherapy-induced HB-EGF activation represents a critical mechanism of inducible chemotherapy resistance. Therefore, therapeutic intervention aimed at inhibiting HB-EGF activity may be useful in cancer prevention and treatments.	Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University	Cusack, JC (corresponding author), Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,7th Floor, Boston, MA 02114 USA.	jcusack@partners.org			NATIONAL CANCER INSTITUTE [K08CA077278, R01CA098871] Funding Source: NIH RePORTER; NCI NIH HHS [CA98871-01, CA77278-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armant DR, 2006, DEVELOPMENT, V133, P751, DOI 10.1242/dev.02237; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; Cusack JC, 2001, CANCER RES, V61, P3535; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Ito Y, 2001, INT J PANCREATOL, V29, P47, DOI 10.1385/IJGC:29:1:47; Ito Y, 2001, ONCOL REP, V8, P903; Itoh Y, 2005, CYTOKINE, V29, P275, DOI 10.1016/j.cyto.2004.11.005; Kanda N, 2005, AM J PHYSIOL-CELL PH, V288, pC813, DOI 10.1152/ajpcell.00483.2004; Kishida O, 2005, CANCER CHEMOTH PHARM, V55, P393, DOI 10.1007/s00280-004-0904-0; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Park JM, 1999, AM J PHYSIOL-CELL PH, V277, pC294, DOI 10.1152/ajpcell.1999.277.2.C294; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Suganuma K, 2003, CANCER SCI, V94, P355, DOI 10.1111/j.1349-7006.2003.tb01446.x; Takenobu H, 2003, J BIOL CHEM, V278, P17255, DOI 10.1074/jbc.M211835200; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yang XP, 2005, MOL CELLS, V20, P263; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066	26	65	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2006	2016		10.1038/sj.onc.1209999	http://dx.doi.org/10.1038/sj.onc.1209999			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001310				2022-12-25	WOS:000245313400003
J	Hyde, TJ; Bryan, MA; Brodsky, B; Baum, J				Hyde, Timothy J.; Bryan, Michael A.; Brodsky, Barbara; Baum, Jean			Sequence dependence of renucleation after a Gly mutation in model collagen peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERIZATION; TRIPLE-HELIX FORMATION; AMINO-ACID-SEQUENCE; OSTEOGENESIS IMPERFECTA; GLYCINE SUBSTITUTIONS; FIBRILLAR COLLAGENS; I COLLAGEN; NUCLEATION; STABILITY; DISEASES	Missense mutations in the collagen triple helix that replace one Gly residue in the (Gly-X-Y)(n) repeating pattern by a larger amino acid have been shown to delay triple helix folding. One hypothesis is that such mutations interfere with the C- to N-terminal directional propagation and that the identity of the residues immediately N-terminal to the mutation site may determine the delay time and the degree of clinical severity. Model peptides are designed to clarify the role of tripeptide sequences N-terminal to the mutation site, with respect to length, stability, and nucleation propensity, to complete triple helix folding. Two sets of peptides with different N-terminal sequences, one with the natural sequence alpha 1(I) 886-900, which is just adjacent to the Gly(901) mutation, and one with a GPO(GAO)(3) sequence, which occurs at alpha 1(I) 865-879, are studied by CD and NMR. Placement of the five tripeptides of the natural alpha 1(I) collagen sequence N-terminal to the Gly to Ala mutation site results in a peptide that is folded only C-terminal to the mutation site. In contrast, the presence of the Hyp-rich sequence GPO(GAO)(3) N-terminal to the mutation allows complete refolding in the presence of the mutation. The completely folded peptide contains an ordered central region with unusual hydrogen bonding while maintaining standard triple helix structure at the N- and C-terminal ends. These peptide results suggest that the location and sequences of downstream regions favorable for renucleation could be the key factor in the completion of a triple helix N-terminal to a mutation.	Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Baum, J (corresponding author), Wright Rieman Labs, Dept Chem & Biol Chem, 610 Taylor Rd, Piscataway, NJ 08854 USA.	baum@rutchem.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008319, F31GM072149, R29GM045302, R01GM060048, R01GM045302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45302, 5 T32 GM08319, GM60048, 1F31 GM072149] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; Barth D, 2003, CHEM-EUR J, V9, P3703, DOI 10.1002/chem.200304918; Baum J., 2000, MECH PROTEIN FOLDING, V2nd, P330; Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; Bella J, 1996, CONNECT TISSUE RES, V35, P401, DOI 10.3109/03008209609029218; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; Buevich A, 2001, PHILOS T R SOC B, V356, P159, DOI 10.1098/rstb.2000.0761; Buevich AV, 2004, J BIOL CHEM, V279, P46890, DOI 10.1074/jbc.M407061200; Buevich AV, 2000, BIOCHEMISTRY-US, V39, P4299, DOI 10.1021/bi992584r; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; Byers PH, 2001, PHILOS T ROY SOC B, V356, P151, DOI 10.1098/rstb.2000.0760; Byers PH, 2002, CONNECTIVE TISSUE IT, P385; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Frank S, 2003, J BIOL CHEM, V278, P7747, DOI 10.1074/jbc.C200698200; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KILTY CM, 1993, COLLAGEN FAMILY STRU, P159; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; Liu XY, 1998, BIOCHEMISTRY-US, V37, P15528, DOI 10.1021/bi981147u; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; PROCKOP DJ, 1988, T AM CLIN CLIMAT ASS, V100, P70; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590; Xu YJ, 2003, BIOCHEMISTRY-US, V42, P8696, DOI 10.1021/bi034006n; Xu YJ, 2002, BIOCHEMISTRY-US, V41, P8143, DOI 10.1021/bi015952b; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	39	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36937	36943		10.1074/jbc.M605135200	http://dx.doi.org/10.1074/jbc.M605135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16998200	hybrid			2022-12-25	WOS:000242220800053
J	Roche, CJ; Dantsker, D; Samuni, U; Friedman, JM				Roche, Camille J.; Dantsker, David; Samuni, Uri; Friedman, Joel M.			Nitrite reductase activity of sol-gel-encapsulated deoxyhemoglobin - Influence of quaternary and tertiary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADULT HEMOGLOBIN; T-STATE; OXIDE BINDING; FUNCTIONAL-CHARACTERIZATION; GEMINATE RECOMBINATION; AFFINITY CONFORMATIONS; ALLOSTERIC REGULATION; MAXIMUM-ENTROPY; ALPHA-SUBUNIT; RED-CELL	Nitrite reductase activity of deoxyhemoglobin (HbA) in the red blood cell has been proposed as a non-nitric-oxide synthase source of deliverable nitric oxide (NO) within the vasculature. An essential element in this scheme is the dependence of this reaction on the quaternary/tertiary structure of HbA. In the present work sol-gel encapsulation is used to trap and stabilize deoxy-HbA in either the T or R quaternary state, thus allowing for the clear-cut monitoring of nitrite reductase activity as a function of quaternary state with and without effectors. The results indicate that reaction is not only R-T-dependent but also heterotropic effector-dependent within a given quaternary state. The use of the maximum entropy method to analyze carbon monoxide ( CO) recombination kinetics from fully and partially liganded sol-gel-encapsulated T-state species provides a framework for understanding effector modulation of T-state reactivity by influencing the distribution of high and low reactivity T-state conformations.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu			NHLBI NIH HHS [P01HL071064] Funding Source: Medline; NIAID NIH HHS [R01AI052258] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbruzzetti S, 2001, J NANOSCI NANOTECHNO, V1, P407, DOI 10.1166/jnn.2001.058; ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; Ackers GK, 2004, METHOD ENZYMOL, V379, P3; Ackers GK, 2002, P NATL ACAD SCI USA, V99, P9777, DOI 10.1073/pnas.152225999; ALAYASH AI, 1993, ARCH BIOCHEM BIOPHYS, V303, P332, DOI 10.1006/abbi.1993.1292; ALPERT B, 1979, CHEM PHYS LETT, V64, P11, DOI 10.1016/0009-2614(79)87265-6; Angelo M, 2006, P NATL ACAD SCI USA, V103, P8366, DOI 10.1073/pnas.0600942103; ANTONINI E, HEMOGLOBINS MYGLOBIN; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; Bonaventura C, 1999, J BIOL CHEM, V274, P8686, DOI 10.1074/jbc.274.13.8686; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; Bruno S, 2001, PROTEIN SCI, V10, P2401, DOI 10.1110/ps.20501; Colombo MF, 1996, J BIOL CHEM, V271, P4895; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; Dantsker D, 2005, J BIOL CHEM, V280, P38740, DOI 10.1074/jbc.M506333200; Das TK, 2004, J BIOL CHEM, V279, P10433, DOI 10.1074/jbc.M309590200; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; Dejam A, 2004, BLOOD CELL MOL DIS, V32, P423, DOI 10.1016/j.bcmd.2004.02.002; Dejam A, 2005, BLOOD, V106, P734, DOI 10.1182/blood-2005-02-0567; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; DUDDELL DA, 1980, PHOTOCHEM PHOTOBIOL, V31, P479, DOI 10.1111/j.1751-1097.1980.tb03732.x; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; FRIEDMAN JM, 1980, NATURE, V284, P570, DOI 10.1038/284570a0; Gladwin MT, 2005, NAT CHEM BIOL, V1, P245, DOI 10.1038/nchembio1005-245; Gladwin MT, 2005, AM J RESP CELL MOL, V32, P363, DOI 10.1165/rcmb.F294; Gladwin MT, 2004, FREE RADICAL BIO MED, V36, P707, DOI 10.1016/j.freeradbiomed.2003.11.032; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Goldbeck RA, 2004, BIOCHEMISTRY-US, V43, P12065, DOI 10.1021/bi0493923; Goldbeck RA, 2001, BIOPHYS J, V81, P2919, DOI 10.1016/S0006-3495(01)75932-2; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; Henry ER, 2002, BIOPHYS CHEM, V98, P149, DOI 10.1016/S0301-4622(02)00091-1; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; Huang KT, 2005, J BIOL CHEM, V280, P31126, DOI 10.1074/jbc.M501496200; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Huang Z, 2002, BIOCHEM BIOPH RES CO, V292, P812, DOI 10.1006/bbrc.2002.6730; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; Hui HL, 2004, BIOCHEMISTRY-US, V43, P7843, DOI 10.1021/bi030263g; Imai K, 2002, BIOPHYS CHEM, V98, P79, DOI 10.1016/S0301-4622(02)00086-8; JUSZCZAK L, 2006, RAMAN SPECTROSCOPY, V36, P350; Karasik E, 2004, BIOCHEMISTRY-US, V43, P7851, DOI 10.1021/bi0302649; Kavanaugh JS, 2005, BIOCHEMISTRY-US, V44, P6101, DOI 10.1021/bi047813a; Khan I, 2001, BIOCHEMISTRY-US, V40, P7581, DOI 10.1021/bi010051o; Khan I, 2000, BIOCHEMISTRY-US, V39, P16099, DOI 10.1021/bi000536x; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; Luchsinger BP, 2005, J INORG BIOCHEM, V99, P912, DOI 10.1016/j.jinorgbio.2004.12.010; Manjula BN, 1998, PROTEIN ENG, V11, P583, DOI 10.1093/protein/11.7.583; Miyazaki G, 1999, J MOL BIOL, V292, P1121, DOI 10.1006/jmbi.1999.3124; MOZZARELLI A, 1991, NATURE, V351, P416, DOI 10.1038/351416a0; Mueser TC, 2000, BIOCHEMISTRY-US, V39, P15353, DOI 10.1021/bi0012944; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Parsegian VA, 2002, INT REV CYTOL, V215, P1; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2163, DOI 10.1021/bi00707a026; Peterson ES, 2004, BIOCHEMISTRY-US, V43, P4832, DOI 10.1021/bi035481o; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; Salvay AG, 2003, BIOPHYS J, V84, P564, DOI 10.1016/S0006-3495(03)74876-0; Samuni U, 2006, BIOCHEMISTRY-US, V45, P2820, DOI 10.1021/bi050010i; Samuni U, 2004, BIOCHEMISTRY-US, V43, P13674, DOI 10.1021/bi048531d; Samuni U, 2003, BIOCHEMISTRY-US, V42, P8272, DOI 10.1021/bi020648j; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shibayama N, 2001, FEBS LETT, V492, P50, DOI 10.1016/S0014-5793(01)02225-6; SIEMIARCZUK A, 1990, J PHYS CHEM-US, V94, P1661, DOI 10.1021/j100367a080; SIEMIARCZUK A, 1989, J PHYS CHEM-US, V93, P7609, DOI 10.1021/j100359a017; SILVA MM, 1992, J BIOL CHEM, V267, P17248; STEINBACH PJ, 1992, BIOPHYS J, V61, P235, DOI 10.1016/S0006-3495(92)81830-1; Tsuneshige A, 2004, J BIOL CHEM, V279, P48959, DOI 10.1074/jbc.M405909200; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; Unzai S, 1996, J BIOL CHEM, V271, P12451, DOI 10.1074/jbc.271.21.12451; Viappiani C, 2004, P NATL ACAD SCI USA, V101, P14414, DOI 10.1073/pnas.0405987101	72	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36874	36882		10.1074/jbc.M603914200	http://dx.doi.org/10.1074/jbc.M603914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16984908	hybrid			2022-12-25	WOS:000242220800046
J	Bulliard, Y; Wiznerowicz, M; Barde, I; Trono, D				Bulliard, Yannick; Wiznerowicz, Maciej; Barde, Isabelle; Trono, Didier			KRAB can repress lentivirus proviral transcription independently of integration site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 INTEGRATION; GENE-EXPRESSION; HUMAN GENOME; IN-VIVO; PROMOTERS; PROTEINS; REGIONS; HP1	The KRAB transcriptional repressor domain, commonly found in zinc finger proteins, acts by inducing the formation of heterochromatin. We previously exploited this property to achieve drug-regulated transgenesis and knock down by combining doxycycline-controllable KRAB-containing fusion proteins and lentiviral vectors. Here, we asked whether KRAB-induced repression is widespread or limited to specific regions of the genome. For this, we transduced cells with a lentiviral vector expressing a target reporter and a KRAB-containing transcriptional repressor from a bicistronic mRNA. We found that similar to 1.4% of the resulting proviruses escaped repression. However, this phenotype could be reverted by expressing the KRAB-containing protein in trans. Accordingly, the irrepressible proviruses all contained, in the DNA sequence encoding the KRAB-containing effector or its upstream internal ribosomal entry site, mutations or deletions likely resulting from errors or recombination during reverse transcription. These results indicate that KRAB-induced transcriptional repression is robust and active over a variety of genomic contexts that include at least the wide range of sites targeted by lentiviral integration.	Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland; Univ Geneva, Natl Ctr Competence Res, CH-1211 Geneva, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Geneva	Trono, D (corresponding author), Ecole Polytech Fed Lausanne, Sch Life Sci, Stn 15, CH-1015 Lausanne, Switzerland.	didier.trono@epfl.ch						Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Ayyanathan K, 2000, CANCER RES, V60, P5803; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Kulkarni A, 2004, BIOCHEM BIOPH RES CO, V322, P672, DOI 10.1016/j.bbrc.2004.07.170; Lewinski MK, 2005, J VIROL, V79, P6610, DOI 10.1128/JVI.79.11.6610-6619.2005; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Papworth M, 2003, P NATL ACAD SCI USA, V100, P1621, DOI 10.1073/pnas.252773399; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784	17	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35742	35746		10.1074/jbc.M602843200	http://dx.doi.org/10.1074/jbc.M602843200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16997916	hybrid			2022-12-25	WOS:000242100500019
J	Hanes, JW; Thal, DM; Johnson, KA				Hanes, Jeremiah W.; Thal, David M.; Johnson, Kenneth A.			Incorporation and replication of 8-oxo-deoxyguanosine by the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; STEADY-STATE; OXIDATIVE STRESS; FIDELITY; REPAIR; EXONUCLEASE; EXPRESSION; EXTENSION; INSERTION; NUCLEAR	To assess the role of oxidative stress on the replication of mitochondrial DNA, we examined the kinetics of incorporation of 8-oxo-7,8-dihydroguanosine (8-oxodG) triphosphate catalyzed by the human mitochondrial DNA polymerase. Using transient state kinetic methods, we quantified the kinetics of incorporation, excision, and extension beyond a base pair containing 8-oxodG. The 8-oxodGTP was incorporated opposite dC in the template with a specificity constant of 0.005 mu M-1 s(-1), a value similar to 10,000-fold lower than that for dGTP. Once incorporated, 96% of the time 8-oxodGMP was extended by continued polymerization rather than being excised by the proofreading exonuclease. The specificity constant for incorporation of 8-oxodGTP opposite a template dA was 0.2 mu M-1 s(-1), a value 13-fold higher than incorporation opposite a template dC. The 8-oxodG: dA mispair was extended rather than excised at least 70% of the time. Examination of the kinetics of polymerization with 8-oxodG in the template strand also revealed relatively low fidelity in that dCTP would be incorporated only 90% of the time. In nearly 10% of events, dATP would be incorporated, and once incorporated dA ( opposite 8-oxodG) was extended rather than excised. The greatest fidelity was against a dTTP: 8-oxodG mismatch affording a discrimination value of only 1800. These data reveal that 8-oxodGTP is a potent mutagen. Once it is incorporated into DNA, 8-oxodGMP codes for error prone DNA synthesis. These reactions are likely to play important roles in oxidative stress in mitochondria related to aging and as compounded by nucleoside analogs used to treat human immunodeficiency virus infections.	Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, Austin, TX 78735 USA	University of Texas System; University of Texas Austin	Johnson, KA (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, 2500 Speedway,A4800, Austin, TX 78735 USA.	kajohnson@mail.utexas.edu		Thal, David/0000-0002-0325-2524	NIGMS NIH HHS [R01 GM044613] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeyev MF, 2004, CLIN SCI, V107, P355, DOI 10.1042/CS20040148; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Dufour E, 2004, BBA-BIOENERGETICS, V1658, P122, DOI 10.1016/j.bbabio.2004.04.020; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; GANNETT PM, 1993, CHEM RES TOXICOL, V6, P690, DOI 10.1021/tx00035a015; Gao DQ, 2004, AM J PHYSIOL-GASTR L, V287, pG1070, DOI 10.1152/ajpgi.00228.2004; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Herrero A, 1999, AGING-CLIN EXP RES, V11, P294, DOI 10.1007/BF03339803; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Kamiya H, 2003, NUCLEIC ACIDS RES, V31, P517, DOI 10.1093/nar/gkg137; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KATI WM, 1992, J BIOL CHEM, V267, P25988; Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Larsen NB, 2005, MITOCHONDRION, V5, P89, DOI 10.1016/j.mito.2005.02.002; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200; Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288; Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Stevnsner T, 2002, EXP GERONTOL, V37, P1189, DOI 10.1016/S0531-5565(02)00142-0; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; Xu P, 2003, J BIOL CHEM, V278, P48422, DOI 10.1074/jbc.M307888200	34	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36241	36248		10.1074/jbc.M607965200	http://dx.doi.org/10.1074/jbc.M607965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005553	hybrid			2022-12-25	WOS:000242100500076
J	Vitvitsky, V; Thomas, M; Ghorpade, A; Gendelman, HE; Banerjee, R				Vitvitsky, Victor; Thomas, Mark; Ghorpade, Anuja; Gendelman, Howard E.; Banerjee, Ruma			A functional transsulfuration pathway in the brain links to glutathione homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; HOMOCYSTEINE METABOLISM; PLASMA HOMOCYSTEINE; RISK-FACTOR; CYSTATHIONINE; ASTROCYTES; CYSTEINE; NEURONS; ACID; CULTURES	Oxidative stress and diminished glutathione pools play critical roles in the pathogenesis of neurodegenerative diseases, including Alzheimer and Parkinson disease. Synthesis of glutathione, the most abundant mammalian antioxidant, is regulated at the substrate level by cysteine, which is synthesized from homocysteine via the transsulfuration pathway. Elevated homocysteine and diminished glutathione levels, seen in Alzheimer and Parkinson disease patients suggest impairments in the transsulfuration pathway that connects these metabolites. However, the very existence of this metabolic pathway in the brain is a subject of controversy. The product of the first of two enzymes in this pathway, cystathionine, is present at higher levels in brain as compared with other organs. This, together with the reported absence of the second enzyme, gamma-cystathionase, has led to the suggestion that the transsulfuration pathway is incomplete in the brain. In this study, we incubated mouse and human neurons and astrocytes and murine brain slices in medium with [S-35] methionine and detected radiolabel incorporation into glutathione. This label transfer was sensitive to inhibition of gamma-cystathionase. In adult brain slices, similar to 40% of the glutathione was depleted within 10 h following gamma-cystathionase inhibition. In cultured human astrocytes, flux through the transsulfuration pathway increased under oxidative stress conditions, and blockade of this pathway led to reduced cell viability under oxidizing conditions. This study establishes the presence of an intact transsulfuration pathway and demonstrates its contribution to glutathione-dependent redox-buffering capacity under ex vivo conditions in brain cells and slices.	Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Banerjee, R (corresponding author), Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu	Vitvitsky, Victor/ABA-2967-2021; Gendelman, Howard E/G-8242-2012	Vitvitsky, Victor/0000-0001-6251-6115; 	NCRR NIH HHS [P20 RR17675] Funding Source: Medline; NIDDK NIH HHS [DK64959] Funding Source: Medline; NINDS NIH HHS [2 R37 NS36126] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036126] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; ASHWOODSMITH MJ, 1959, NATURE, V184, P2028, DOI 10.1038/1842028a0; BEATTY PW, 1980, ARCH BIOCHEM BIOPHYS, V204, P80, DOI 10.1016/0003-9861(80)90009-0; Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Broer A, 2006, BIOCHEM J, V393, P421, DOI 10.1042/BJ20051273; CARLSON K, 2002, MACROPHAGE, P138; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; DELUCA G, 1974, ITAL J BIOCHEM, V23, P371; Deshpande M, 2005, NEUROTOX RES, V7, P183, DOI 10.1007/BF03036448; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Dringen R, 1996, J NEUROCHEM, V67, P1375, DOI 10.1046/j.1471-4159.1996.67041375.x; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Dringen R, 1999, NEUROSCI LETT, V259, P79, DOI 10.1016/S0304-3940(98)00894-5; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GAITONDE MK, 1957, METABOLISM NERVOUS S, P449; Ghorpade A, 2003, J NEUROIMMUNOL, V141, P141, DOI 10.1016/S0165-5728(03)00222-4; GJESSING LR, 1966, SCAND J CLIN LAB INV, V18, P565, DOI 10.3109/00365516609103923; GRIFFITHS R, 1976, LIFE SCI, V19, P1217, DOI 10.1016/0024-3205(76)90257-5; Ishii I, 2004, BIOCHEM J, V381, P113, DOI 10.1042/BJ20040243; Isobe C, 2005, LIFE SCI, V77, P1836, DOI 10.1016/j.lfs.2005.02.014; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; KEY BJ, 1970, NEUROPHARMACOLOGY, V9, P349, DOI 10.1016/0028-3908(70)90032-8; Kimura H, 2002, MOL NEUROBIOL, V26, P13, DOI 10.1385/MN:26:1:013; KODAMA H, 1985, J NEUROCHEM, V44, P1207, DOI 10.1111/j.1471-4159.1985.tb08744.x; Kranich O, 1998, GLIA, V22, P11, DOI 10.1002/(SICI)1098-1136(199801)22:1<11::AID-GLIA2>3.0.CO;2-B; Lehmann M, 1999, DEMENT GERIATR COGN, V10, P12, DOI 10.1159/000017092; MAKAR TK, 1994, J NEUROCHEM, V62, P1983; MAKAR TK, 1994, J NEUROCHEM, V62, P45; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MARTENSSON J, 1992, P NATL ACAD SCI USA, V89, P11566, DOI 10.1073/pnas.89.23.11566; MEISTER A, 1995, GLUTATHIONE SYNTHETA, P1461; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Mudd S., 2001, METABOLIC MOL BASES, P2007; MUDD SH, 1989, DISORDERS TRANSSULFU, P693; OCONNOR E, 1995, BRAIN RES, V680, P157, DOI 10.1016/0006-8993(95)00257-Q; Oltean S, 2005, J BIOL CHEM, V280, P32662, DOI 10.1074/jbc.M501964200; Oltean S, 2003, J BIOL CHEM, V278, P20778, DOI 10.1074/jbc.M300845200; Rao AV, 2002, NUTR NEUROSCI, V5, P291, DOI 10.1080/1028415021000033767; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; SHIMIZU H, 1966, J NEUROCHEM, V13, P65, DOI 10.1111/j.1471-4159.1966.tb03333.x; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; STURMAN JA, 1976, J NEUROCHEM, V26, P457, DOI 10.1111/j.1471-4159.1976.tb01496.x; STURMAN JA, 1970, J NEUROCHEM, V17, P1117, DOI 10.1111/j.1471-4159.1970.tb02268.x; Takanaga H, 2005, BIOCHEM BIOPH RES CO, V337, P892, DOI 10.1016/j.bbrc.2005.09.128; TALLAN HH, 1958, J BIOL CHEM, V230, P707; Vitvitsky V, 2004, AM J PHYSIOL-REG I, V287, pR39, DOI 10.1152/ajpregu.00036.2004; VOLPE JJ, 1972, BIOL NEONATE, V20, P385; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; WERMAN R., 1966, LIFE SCI, V5, P1431, DOI 10.1016/0024-3205(66)90119-6; Zheng JL, 1999, J VIROL, V73, P8256, DOI 10.1128/JVI.73.10.8256-8267.1999	55	165	173	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35785	35793		10.1074/jbc.M602799200	http://dx.doi.org/10.1074/jbc.M602799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005561	hybrid			2022-12-25	WOS:000242100500025
J	Kubetzko, S; Balic, E; Waibel, R; Zangemeister-Wittke, U; Pluckthun, A				Kubetzko, Susanne; Balic, Ela; Waibel, Robert; Zangemeister-Wittke, Uwe; Plueckthun, Andreas			PEGylation and multimerization of the anti-p185(HER-2) single chain Fv fragment 4D5 - Effects on tumor targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ANTIBODY FRAGMENTS; IN-VIVO; ESCHERICHIA-COLI; POLYETHYLENE-GLYCOL; HIGH AVIDITY; MONOCLONAL-ANTIBODIES; MODELING ANALYSIS; BREAST-CANCER; ANTIGEN; BINDING	A major goal in antibody design for cancer therapy is to tailor the pharmacokinetic properties of the molecule according to specific treatment requirements. Key parameters determining the pharmacokinetics of therapeutic antibodies are target specificity, affinity, stability, and size. Using the p185(HER-2) (HER-2)-specific scFv 4D5 as model system, we analyzed how changes in molecular weight and valency independently affect antigen binding and tumor localization. By employing multimerization and PEGylation, four different antibody formats were generated and compared with the scFv 4D5. First, dimeric and tetrameric miniantibodies were constructed by fusion of self-associating, disulfide-linked peptides to the scFv 4D5. Second, we attached a 20-kDa PEG moiety to the monovalent scFv and to the divalent miniantibody at the respective C terminus. In all formats, serum stability and full binding reactivity of the scFv 4D5 were retained. Functional affinity, however, did change. An avidity increase was achieved by multimerization, whereas PEGylation resulted in a 5-fold decreased affinity. Nevertheless, the PEGylated monomer showed an 8.5-fold, and the PEGylated dimer even a 14.5-fold higher tumor accumulation than the corresponding scFv, 48 h post-injection, because of a significantly longer serum half-life. In comparison, the non-PEGylated bivalent and tetravalent miniantibodies showed only a moderate increase in tumor localization compared with the scFv, which correlated with the degree of multimerization. However, these non-PEGylated formats resulted in higher tumor-to-blood ratios. Both multimerization and PEGylation represent thus useful strategies to tailor the pharmacokinetic properties of therapeutic antibodies and their combined use can additively improve tumor targeting.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Univ Zurich Hosp, Dept Oncol, CH-8044 Zurich, Switzerland; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	University of Zurich; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Pluckthun, A (corresponding author), Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland.	plueckthun@bioc.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				Adams GP, 2001, CANCER RES, V61, P4750; Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; Adams GP, 2006, CLIN CANCER RES, V12, P1599, DOI 10.1158/1078-0432.CCR-05-2217; Adams GP, 1998, CANCER RES, V58, P485; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; Anderson PJ, 2005, SEMIN ARTHRITIS RHEU, V34, P19, DOI 10.1016/j.semarthrit.2005.01.005; Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; Batra SK, 2002, CURR OPIN BIOTECH, V13, P603, DOI 10.1016/S0958-1669(02)00352-X; Berndorff D, 2005, CLIN CANCER RES, V11, p7053S, DOI 10.1158/1078-0432.CCR-1004-0015; Borrebaeck Carl A. K., 2001, Current Opinion in Pharmacology, V1, P404; Caliceti P, 2003, ADV DRUG DELIVER REV, V55, P1261, DOI 10.1016/S0169-409X(03)00108-X; Carter P, 1997, CURR OPIN BIOTECH, V8, P449, DOI 10.1016/S0958-1669(97)80067-5; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; Casey JL, 1996, BRIT J CANCER, V74, P1397, DOI 10.1038/bjc.1996.555; CHANG RLS, 1975, BIOPHYS J, V15, P887, DOI 10.1016/S0006-3495(75)85863-2; Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717; Chapman AP, 2002, ADV DRUG DELIVER REV, V54, P531, DOI 10.1016/S0169-409X(02)00026-1; CHESTER KA, 1995, TRENDS BIOTECHNOL, V13, P294, DOI 10.1016/S0167-7799(00)88968-4; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Christensen EI, 2004, PEDIATR NEPHROL, V19, P714, DOI 10.1007/s00467-004-1494-0; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; CUNNINGHAMRUNDLES C, 1992, J IMMUNOL METHODS, V152, P177, DOI 10.1016/0022-1759(92)90139-K; De Lorenzo C, 2005, CARCINOGENESIS, V26, P1890, DOI 10.1093/carcin/bgi146; Deyev SM, 2003, NAT BIOTECHNOL, V21, P1486, DOI 10.1038/nbt916; FUJIMORI K, 1990, J NUCL MED, V31, P1191; FUJIMORI K, 1989, CANCER RES, V49, P5656; Ge L, 1995, ANTIBODY ENG, P229; Graff CP, 2003, CANCER RES, V63, P1288; Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Hill RB, 1998, J AM CHEM SOC, V120, P1138, DOI 10.1021/ja9733649; Horn U, 1996, APPL MICROBIOL BIOT, V46, P524, DOI 10.1007/s002530050855; Hu SZ, 1996, CANCER RES, V56, P3055; Hudson PJ, 1999, J IMMUNOL METHODS, V231, P177, DOI 10.1016/S0022-1759(99)00157-X; HUSTON JS, 1994, CELL BIOPHYS, V24-5, P267, DOI 10.1007/BF02789238; Jackson H, 1998, BRIT J CANCER, V78, P181, DOI 10.1038/bjc.1998.462; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kang N, 2000, CLIN CANCER RES, V6, P4921; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; KING DJ, 1994, CANCER RES, V54, P6176; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; Kubetzko S, 2005, MOL PHARMACOL, V68, P1439, DOI 10.1124/mol.105.014910; Le Gall F, 1999, FEBS LETT, V453, P164, DOI 10.1016/S0014-5793(99)00713-9; Lee LS, 1999, BIOCONJUGATE CHEM, V10, P973, DOI 10.1021/bc990076o; LeSauteur L, 1996, NAT BIOTECHNOL, V14, P1120, DOI 10.1038/nbt0996-1120; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; MAACK T, 1979, KIDNEY INT, V16, P251, DOI 10.1038/ki.1979.128; Miller K, 2003, J IMMUNOL, V170, P4854, DOI 10.4049/jimmunol.170.9.4854; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; Moroney S, 2005, MODERN BIOPHARMACEUT, P1147; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nahta R, 2003, ONCOLOGIST, V8, P5, DOI 10.1634/theoncologist.8-1-5; Olafsen T, 2005, CANCER RES, V65, P5907, DOI 10.1158/0008-5472.CAN-04-4472; Olafsen T, 2004, PROTEIN ENG DES SEL, V17, P315, DOI 10.1093/protein/gzh040; PACK P, 1995, J MOL BIOL, V246, P28, DOI 10.1006/jmbi.1994.0062; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Rheinnecker M, 1996, J IMMUNOL, V157, P2989; Ros R, 1998, P NATL ACAD SCI USA, V95, P7402, DOI 10.1073/pnas.95.13.7402; Ross JS, 2003, AM J CLIN PATHOL, V119, P472, DOI 10.1309/Y6LPC0LR726L9DX9; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; Schibli R, 2000, BIOCONJUGATE CHEM, V11, P345, DOI 10.1021/bc990127h; Schmiedl A, 2000, J IMMUNOL METHODS, V242, P101, DOI 10.1016/S0022-1759(00)00243-X; SCHOTT ME, 1992, CANCER RES, V52, P6413; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Trikha M, 2002, CURR OPIN BIOTECH, V13, P609, DOI 10.1016/S0958-1669(02)00348-8; Viti F, 1999, CANCER RES, V59, P347; Waibel R, 1999, NAT BIOTECHNOL, V17, P897, DOI 10.1038/12890; Weiner LM, 2005, NAT BIOTECHNOL, V23, P556, DOI 10.1038/nbt0505-556; WEINSTEIN JN, 1987, ANN NY ACAD SCI, V507, P199, DOI 10.1111/j.1749-6632.1987.tb45802.x; Werlen RC, 1996, CANCER RES, V56, P809; Willuda J, 1999, CANCER RES, V59, P5758; Willuda J, 2001, J BIOL CHEM, V276, P14385, DOI 10.1074/jbc.M011669200; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Yang K, 2003, PROTEIN ENG, V16, P761, DOI 10.1093/protein/gzg093; YOKOTA T, 1992, CANCER RES, V52, P3402	81	101	111	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35186	35201		10.1074/jbc.M604127200	http://dx.doi.org/10.1074/jbc.M604127200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16963450	hybrid			2022-12-25	WOS:000241933700052
J	Liu, JJ; Grimison, B; Lewellyn, AL; Maller, JL				Liu, Junjun; Grimison, Bryn; Lewellyn, Andrea L.; Maller, James L.			The anaphase-promoting complex/cyclosome inhibitor Emi2 is essential for meiotic but not mitotic cell cycles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSTATIC FACTOR ARREST; XENOPUS-OOCYTES; METAPHASE ARREST; REGULATED PROTEOLYSIS; DEPENDENT PROTEOLYSIS; VERTEBRATE EGGS; MEIOSIS-II; COMPLEX; KINASE; EXIT	Vertebrate oocytes awaiting fertilization are arrested at metaphase of meiosis II by cytostatic factor (CSF). This arrest is due to inhibition of the anaphase-promoting complex/cyclosome, in part by a newly identified protein, Emi2 (xErp1). Emi2 is required for maintenance of CSF arrest in egg extracts, but its function in CSF establishment in oocytes and the normal embryonic cell cycle is unknown. Here we show that during oocyte maturation, Emi2 appears only after metaphase I, and its level peaks at CSF arrest (metaphase II). In M phase, Emi2 undergoes a phosphorylation-dependent electrophoretic shift. Microinjection of antisense oligonucleotides against Emi2 into stage VI oocytes blocks progression through meiosis II and the establishment of CSF arrest. Recombinant Emi2 rescues CSF arrest in these oocytes and also causes CSF arrest in egg extracts and in blastomeres of two-cell embryos. Fertilization triggers rapid, complete degradation of Emi2, but it is resynthesized in the first embryonic cell cycle to reach levels 5-fold lower than during CSF arrest. However, depletion of the protein from cycling egg extracts does not prevent mitotic cell cycle progression. Thus, Emi2 plays an essential role in meiotic but not mitotic cell cycles.	Univ Colorado, Sch Med, Dept Pharmacol, HHMI, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, HHMI, 4200 E 9th Ave,Box C-236, Denver, CO 80262 USA.	jim.maller@uchsc.edu						Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; D'Angiolella V, 2001, CURR BIOL, V11, P1221, DOI 10.1016/S0960-9822(01)00352-9; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; Furuno N, 1997, EMBO J, V16, P3860, DOI 10.1093/emboj/16.13.3860; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Grimison B, 2006, CURR BIOL, V16, P1968, DOI 10.1016/j.cub.2006.08.055; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Hansen DV, 2006, P NATL ACAD SCI USA, V103, P608, DOI 10.1073/pnas.0509549102; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hartley RS, 1996, DEV BIOL, V173, P408, DOI 10.1006/dbio.1996.0036; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Ohsumi K, 2004, P NATL ACAD SCI USA, V101, P12531, DOI 10.1073/pnas.0405300101; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Rauh NR, 2005, NATURE, V437, P1048, DOI 10.1038/nature04093; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Roy LM, 1996, ONCOGENE, V12, P2203; Schmidt A, 2006, J CELL SCI, V119, P1213, DOI 10.1242/jcs.02919; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Shoji S, 2006, EMBO J, V25, P834, DOI 10.1038/sj.emboj.7600953; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Tung JJ, 2005, P NATL ACAD SCI USA, V102, P4318, DOI 10.1073/pnas.0501108102; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Tunquist BJ, 2002, CURR BIOL, V12, P1027, DOI 10.1016/S0960-9822(02)00894-1; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x	32	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34736	34741		10.1074/jbc.M606607200	http://dx.doi.org/10.1074/jbc.M606607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982610	hybrid			2022-12-25	WOS:000241933700004
J	Paarmann, I; Schmitt, B; Meyer, B; Karas, M; Betz, H				Paarmann, Ingo; Schmitt, Bertram; Meyer, Bjorn; Karas, Michael; Betz, Heinrich			Mass spectrometric analysis of glycine receptor-associated gephyrin splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEINS; NEUROTRANSMITTER RECEPTORS; IDENTIFICATION; MOLYBDENUM; SEQUENCE; BINDING; DOMAIN; SITES; BRAIN; RAT	Gephyrin is an ubiquitously expressed protein that, in the nervous system, is essential for synaptic anchoring of glycine receptors (GlyRs) and major GABA(A) receptor subtypes. The binding of gephyrin to the GlyR depends on an amphipathic motif within the large intracellular loop of the GlyR beta subunit. The mouse gephyrin gene consists of 30 exons. Ten of these exons, encoding cassettes of 5-40 amino acids, are subject to alternative splicing (C1-C7, C4 '-C6 '). Since one of the cassettes, C5 ', has recently been reported to exclude GlyRs from GABAergic synapses, we investigated which cassettes are found in gephyrin associated with the GlyR. Gephyrin variants were purified from rat spinal cord, brain, and liver by binding to the glutathione S-transferase-tagged GlyR beta loop or copurified with native GlyR from spinal cord by affinity chromatography and analyzed by mass spectrometry. In addition to C2 and C6 ', already known to be prominent, C4 was found to be abundant in gephyrin from all tissues examined. The nonneuronal cassette C3 was easily detected in liver but not in GlyR-associated gephyrin from spinal cord. C5 was present in brain and spinal cord polypeptides, whereas C5 ' was coisolated mainly from liver. Notably C5 '-containing gephyrin bound to the GlyR beta loop, inconsistent with its proposed selectivity for GABAA receptors. Our data show that GlyR-associated gephyrin, lacking C3, but enriched in C4 without C5, differs from other neuronal and nonneuronal gephyrin isoforms.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60438 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Betz, H (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de						Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Ding QX, 2003, PROTEOMICS, V3, P1313, DOI 10.1002/pmic.200300452; Finn RD, 2005, BIOINFORMATICS, V21, P410, DOI 10.1093/bioinformatics/bti011; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Godovac-Zimmermann J, 2005, PROTEOMICS, V5, P699, DOI 10.1002/pmic.200401051; Harris WA, 2002, RAPID COMMUN MASS SP, V16, P1714, DOI 10.1002/rcm.775; Heck S, 1997, DEV BRAIN RES, V98, P211, DOI 10.1016/S0165-3806(96)00181-2; Hermann A, 2001, BIOCHEM BIOPH RES CO, V282, P67, DOI 10.1006/bbrc.2001.4553; JOHNSON JL, 1989, INHERITED BASIS META; KIRSCH J, 1993, EUR J NEUROSCI, V5, P1109, DOI 10.1111/j.1460-9568.1993.tb00965.x; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; Meier J, 2004, J NEUROSCI, V24, P1398, DOI 10.1523/JNEUROSCI.4260-03.2004; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Nagradova N, 2003, IUBMB LIFE, V55, P459, DOI 10.1080/15216540310001602805; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; Rees MI, 2003, J BIOL CHEM, V278, P24688, DOI 10.1074/jbc.M301070200; Roth MJ, 2005, MOL CELL PROTEOMICS, V4, P1002, DOI 10.1074/mcp.M500064-MCP200; Sachs L., 1984, ANGEW STAT; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; Schrader N, 2004, J BIOL CHEM, V279, P18733, DOI 10.1074/jbc.M311245200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sola M, 2004, EMBO J, V23, P2510, DOI 10.1038/sj.emboj.7600256; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Thiede B, 2005, METHODS, V35, P237, DOI 10.1016/j.ymeth.2004.08.015; Ule J, 2005, NAT GENET, V37, P844, DOI 10.1038/ng1610; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; van Heusden GPH, 2005, IUBMB LIFE, V57, P623, DOI 10.1080/15216540500252666; Wilkins MR, 1999, J MOL BIOL, V289, P645, DOI 10.1006/jmbi.1999.2794	43	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34918	34925		10.1074/jbc.M607764200	http://dx.doi.org/10.1074/jbc.M607764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17001074	hybrid			2022-12-25	WOS:000241933700024
J	Yuan, J; Xiao, XZ; McGeehan, J; Dong, ZQ; Cali, I; Fujioka, H; Kong, QZ; Kneale, G; Gambetti, P; Zou, WQ				Yuan, Jue; Xiao, Xiangzhu; McGeehan, John; Dong, Zhiqian; Cali, Ignazio; Fujioka, Hisashi; Kong, Qingzhong; Kneale, Geoff; Gambetti, Pierluigi; Zou, Wen-Quan			Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP 27-30; SCRAPIE; DISEASE; CONFORMATION; MECHANISM; CAVEOLIN; GENE; TRANSMISSIBILITY; CLASSIFICATION; IDENTIFICATION	Aggregated prion protein (PrPSc), which is detergent-insoluble and partially proteinase K (PK)-resistant, constitutes the major component of infectious prions that cause a group of transmissible spongiform encephalopathies in animals and humans. PrPSc derives from a detergent-soluble and PK-sensitive cellular prion protein (PrPC) through an alpha-helix to beta-sheet transition. This transition confers on the PrPSc molecule unique physicochemical and biological properties, including insolubility in nondenaturing detergents, an enhanced tendency to form aggregates, resistance to PK digestion, and infectivity, which together are regarded as the basis for distinguishing PrPSc from PrPC. Here we demonstrate, using sedimentation and size exclusion chromatography, that small amounts of detergent-insoluble PrP aggregates are present in uninfected human brains. Moreover, PK-resistant PrP core fragments are detectable following PK treatment. This is the first study that provides experimental evidence supporting the hypothesis that there might be silent prions lying dormant in normal human brains.	Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA; Univ Portsmouth, Inst Biomed & Biomol Sci, Biophys Lab, Portsmouth PO1 2DT, Hants, England	Case Western Reserve University; Case Western Reserve University; University of Portsmouth	Zou, WQ (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.	wenquan.zou@case.edu	xiao, xiangzhu/B-9300-2014; Zou, Wenquan/ABF-2875-2020; cali, ignazio/AAS-1127-2020	xiao, xiangzhu/0000-0002-8013-9074; cali, ignazio/0000-0001-5770-3848; DONG, ZHIQIAN/0000-0002-8748-4532; McGeehan, John/0000-0002-6750-1462	NIA NIH HHS [AG08702, AG-14359] Funding Source: Medline; PHS HHS [UR8/CCU515004] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG014359, P50AG008702] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; Cali I, 2006, BRAIN, V129, P2266, DOI 10.1093/brain/awl224; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; Gambetti P, 2003, BRIT MED BULL, V66, P213, DOI 10.1093/bmb/66.1.213; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Grenier C, 2006, J NEUROCHEM, V97, P1456, DOI 10.1111/j.1471-4159.2006.03837.x; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Hall D, 2004, J MOL BIOL, V336, P775, DOI 10.1016/j.jmb.2003.12.004; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Kong QZ, 2005, J NEUROSCI, V25, P7944, DOI 10.1523/JNEUROSCI.2467-05.2005; Krasemann S, 1999, J BIOTECHNOL, V73, P119, DOI 10.1016/S0168-1656(99)00115-7; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Lu BY, 2002, BIOCHEM J, V364, P81, DOI 10.1042/bj3640081; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Oliver AW, 2000, J MOL BIOL, V301, P575, DOI 10.1006/jmbi.2000.3991; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2005, J VIROL, V79, P934, DOI 10.1128/JVI.79.2.934-943.2005; Pan T, 2002, J NEUROCHEM, V81, P1092, DOI 10.1046/j.1471-4159.2002.00909.x; Pastore M, 2005, AM J PATHOL, V167, P1729, DOI 10.1016/S0002-9440(10)61254-0; Pergami P, 1999, BIOCHEM BIOPH RES CO, V264, P972, DOI 10.1006/bbrc.1999.1430; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ross ED, 2005, NAT CELL BIOL, V7, P1039, DOI 10.1038/ncb1105-1039; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2005, J GEN VIROL, V86, P2913, DOI 10.1099/vir.0.80947-0; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Sokolowski F, 2003, J BIOL CHEM, V278, P40481, DOI 10.1074/jbc.M304391200; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; Tzaban S, 2002, BIOCHEMISTRY-US, V41, P12868, DOI 10.1021/bi025958g; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Williams TM, 2004, ANN MED, V36, P584, DOI 10.1080/07853890410018899; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r; Zou WQ, 2004, P NATL ACAD SCI USA, V101, P1380, DOI 10.1073/pnas.0307825100; Zou WQ, 2003, J BIOL CHEM, V278, P40429, DOI 10.1074/jbc.M308550200	62	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34848	34858		10.1074/jbc.M602238200	http://dx.doi.org/10.1074/jbc.M602238200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987816	hybrid			2022-12-25	WOS:000241933700017
J	Azad, N; Vallyathan, V; Wang, LY; Tantishaiyakul, V; Stehlik, C; Leonard, SS; Rojanasakul, Y				Azad, Neelam; Vallyathan, Val; Wang, Liying; Tantishaiyakul, Vimon; Stehlik, Christian; Leonard, Stephen S.; Rojanasakul, Yon			S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation - A novel antiapoptotic mechanism that suppresses apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LUNG-CANCER; CHROMIUM(VI)-INDUCED APOPTOSIS; PROTEIN-KINASE; UP-REGULATION; CYTOCHROME-C; CELLS; EXPRESSION; FAS; PHOSPHORYLATION	Bcl-2 is a key apoptosis regulatory protein of the mitochondrial death pathway whose function is dependent on its expression levels. Although Bcl-2 expression is controlled by various mechanisms, post-translational modifications, such as ubiquitination and proteasomal degradation, have emerged as important regulators of Bcl-2 function. However, the underlying mechanisms of this regulation are unclear. We report here that Bcl-2 undergoes S-nitrosylation by endogenous nitric oxide ( NO) in response to multiple apoptotic mediators and that this modification inhibits ubiquitin-proteasomal degradation of Bcl-2. Inhibition of NO production by the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide and by NO synthase inhibitor aminoguanidine effectively inhibited S-nitrosylation of Bcl-2, increased its ubiquitination, and promoted apoptotic cell death induced by chromium ( VI). In contrast, the NO donors dipropylenetriamine NONOate and sodium nitroprusside showed opposite effects. The effect of NO on Bcl-2 stability was shown to be independent of its dephosphorylation. Mutational analysis of Bcl-2 further showed that the two cysteine residues of Bcl-2 (Cys(158) and Cys(229)) are important in the S-nitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 S-nitrosylation. Treatment of the cells with other stress inducers, including Fas ligand and buthionine sulfoxide, also induced Bcl-2 S-nitrosylation, suggesting that this is a general phenomenon that regulates Bcl-2 stability and function under various stress conditions. These findings indicate a novel function of NO and its regulation of Bcl-2, which provides a key mechanism for the control of apoptotic cell death and cancer development.	W Virginia Univ, Dept Pharmaceut Sci, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Songkla Univ, Dept Pharmaceut Chem, Songkhla 90110, Thailand	West Virginia University; West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Prince of Songkla University	Rojanasakul, Y (corresponding author), W Virginia Univ, Dept Pharmaceut Sci, POB 9530, Morgantown, WV 26506 USA.	yrojanasakul@hsc.wvu.edu	高, 雨莉/HGU-8187-2022; Stehlik, Christian/AAG-2132-2021	Stehlik, Christian/0000-0002-3782-2484; Rojanasakul, Yon/0000-0002-8839-6462	NHLBI NIH HHS [HL076340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1990, IARC Monogr Eval Carcinog Risks Hum, V49, P1; ARIASDIAZ J, 1994, CANCER, V74, P1546, DOI 10.1002/1097-0142(19940901)74:5<1546::AID-CNCR2820740509>3.0.CO;2-F; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BENEZRA JM, 1994, AM J PATHOL, V145, P1036; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Buolamwini JK, 1999, CURR OPIN CHEM BIOL, V3, P500, DOI 10.1016/S1367-5931(99)80073-8; Carlisle DL, 2000, MOL CARCINOGEN, V28, P111, DOI 10.1002/1098-2744(200006)28:2<111::AID-MC7>3.0.CO;2-Y; Chanvorachote P, 2005, J BIOL CHEM, V280, P42044, DOI 10.1074/jbc.M510080200; Chanvorachote P, 2006, CANCER RES, V66, P6353, DOI 10.1158/0008-5472.CAN-05-4533; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; De Flora S, 2000, CARCINOGENESIS, V21, P533, DOI 10.1093/carcin/21.4.533; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; Delikouras A, 2001, TRANSPLANTATION, V71, P599, DOI 10.1097/00007890-200103150-00004; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Fujimoto H, 1997, JPN J CANCER RES, V88, P1190, DOI 10.1111/j.1349-7006.1997.tb00348.x; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griscavage J M, 1995, Adv Pharmacol, V34, P215; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Heigold S, 2002, CARCINOGENESIS, V23, P929, DOI 10.1093/carcin/23.6.929; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; IKEGAKI N, 1994, CANCER RES, V54, P6; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JIANG SX, 1995, J PATHOL, V177, P135, DOI 10.1002/path.1711770206; Jourd'Heuil D, 2002, FREE RADICAL BIO MED, V33, P676, DOI 10.1016/S0891-5849(02)00955-3; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kuzushima M, 2006, ARCH ORAL BIOL, V51, P1048, DOI 10.1016/j.archoralbio.2006.05.004; LANGARD S, 1990, AM J IND MED, V17, P189, DOI 10.1002/ajim.4700170205; LANGARD S, 1993, SCAND J WORK ENV HEA, V19, P81; Li CQ, 2004, CANCER RES, V64, P3022, DOI 10.1158/0008-5472.CAN-03-1880; Li DC, 2004, CANCER SCI, V95, P644, DOI 10.1111/j.1349-7006.2004.tb03323.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu CY, 1998, BRIT J CANCER, V78, P534, DOI 10.1038/bjc.1998.528; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Moon KH, 2005, FEBS LETT, V579, P6115, DOI 10.1016/j.febslet.2005.09.082; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Oxford SME, 2004, CURR MED CHEM, V11, P1031, DOI 10.2174/0929867043455486; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Pritchard DE, 2000, CARCINOGENESIS, V21, P2027, DOI 10.1093/carcin/21.11.2027; Reliene R, 2006, CARCINOGENESIS, V27, P240, DOI 10.1093/carcin/bgi222; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shi XL, 1999, J TOXICOL ENV HEAL B, V2, P87, DOI 10.1080/109374099281241; SIMONATO L, 1991, BRIT J IND MED, V48, P145; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang SW, 2004, MOL CELL BIOCHEM, V255, P129, DOI 10.1023/B:MCBI.0000007269.74532.98; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wink DA, 1999, METHOD ENZYMOL, V301, P201; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Zhang Z, 2001, MOL CELL BIOCHEM, V222, P77, DOI 10.1023/A:1017963307358	61	156	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34124	34134		10.1074/jbc.M602551200	http://dx.doi.org/10.1074/jbc.M602551200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980304	hybrid			2022-12-25	WOS:000241767600033
J	Lee, PA; Orriss, GL; Buchanan, G; Greene, NP; Bond, PJ; Punginelli, C; Jack, RL; Sansom, MSP; Berks, BC; Palmer, T				Lee, Philip A.; Orriss, George L.; Buchanan, Grant; Greene, Nicholas P.; Bond, Peter J.; Punginelli, Claire; Jack, Rachael L.; Sansom, Mark S. P.; Berks, Ben C.; Palmer, Tracy			Cysteine-scanning mutagenesis and disulfide mapping studies of the conserved domain of the twin-arginine translocase TatB component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC-INDEPENDENT PROTEIN; ESCHERICHIA-COLI; TRANSPORT SYSTEM; EXPORT PATHWAY; SIGNAL PEPTIDE; MEMBRANE; COMPLEXES; RESIDUES; BINDING; ASSOCIATION	The cytoplasmic membrane protein TatB is an essential component of the Escherichia coli twin-arginine (Tat) protein translocation pathway. Together with the TatC component it forms a complex that functions as a membrane receptor for substrate proteins. Structural predictions suggest that TatB is anchored to the membrane via an N-terminal transmembrane alpha-helix that precedes an amphipathic alpha-helical section of the protein. From truncation analysis it is known that both these regions of the protein are essential for function. Here we construct 31 unique cysteine substitutions in the first 42 residues of TatB. Each of the substitutions results in a TatB protein that is competent to support Tat-dependent protein translocation. Oxidant-induced disulfide cross-linking shows that both the N-terminal and amphipathic helices form contacts with at least one other TatB protomer. For the transmembrane helix these contacts are localized to one face of the helix. Molecular modeling and molecular dynamics simulations provide insight into the possible structural basis of the transmembrane helix interactions. Using variants with double cysteine substitutions in the transmembrane helix, we were able to detect cross-links between up to five TatB molecules. Protein purification showed that species containing at least four cross-linked TatB molecules are found in correctly assembled TatBC complexes. Our results suggest that the transmembrane helices of TatB protomers are in the center rather than the periphery of the TatBC complex.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Oxford; University of East Anglia	Berks, BC (corresponding author), Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.	ben.berks@bioch.ox.ac.uk; tracy.palmer@bbsrc.ac.uk	Bond, Peter J/C-4918-2009; Punginelli, Claire/M-1759-2014; Jack, Rachael L/E-2869-2017; Sansom, Mark S.P./C-5157-2009	Sansom, Mark S.P./0000-0001-6360-7959; Bond, Peter/0000-0003-2900-098X; Palmer, Tracy/0000-0001-9043-2592; Greene, Nicholas/0000-0002-3631-0380; Berks, Ben/0000-0001-9685-4067	Medical Research Council [G117/519] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G117/519] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Barrett CML, 2005, FEBS J, V272, P2261, DOI 10.1111/j.1742-4658.2005.04654.x; Barrett CML, 2003, FEBS LETT, V537, P42, DOI 10.1016/S0014-5793(03)00068-1; Behrendt J, 2004, FEMS MICROBIOL LETT, V234, P303, DOI 10.1016/j.femsle.2004.03.048; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Buchanan G, 2002, MOL MICROBIOL, V43, P1457, DOI 10.1046/j.1365-2958.2002.02853.x; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; COHEN N, 1956, ANN I PASTEUR PARIS, V91, P693; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; de Leeuw E, 2002, J MOL BIOL, V322, P1135, DOI 10.1016/S0022-2836(02)00820-3; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Fincher V, 2003, EUR J BIOCHEM, V270, P4930, DOI 10.1046/j.1432-1033.2003.03894.x; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Gerard F, 2006, J BIOL CHEM, V281, P6130, DOI 10.1074/jbc.M512733200; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; Hicks MG, 2005, J BACTERIOL, V187, P2920, DOI 10.1128/JB.187.8.2920-2925.2005; Hicks MG, 2003, FEBS LETT, V539, P61, DOI 10.1016/S0014-5793(03)00198-4; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; KI JJ, 2004, J MOL BIOL, V341, P901, DOI DOI 10.1016/J.JMB.2004.05.078; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lee PA, 2002, J BACTERIOL, V184, P5871, DOI 10.1128/JB.184.21.5871-5879.2002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma XY, 2000, J BIOL CHEM, V275, P10016, DOI 10.1074/jbc.275.14.10016; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Masip L, 2004, SCIENCE, V303, P1185, DOI 10.1126/science.1092612; McDevitt CA, 2005, BIOCHEM BIOPH RES CO, V329, P693, DOI 10.1016/j.bbrc.2005.02.038; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Oates J, 2003, J MOL BIOL, V330, P277, DOI 10.1016/S0022-2836(03)00621-1; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Richter S, 2005, J BIOL CHEM, V280, P42723, DOI 10.1074/jbc.M509570200; Russell DW, 2001, MOL CLONING LAB MANU; Sal-Man N, 2004, BIOCHEMISTRY-US, V43, P2309, DOI 10.1021/bi0356294; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stockner T, 2004, BIOPHYS J, V87, P1650, DOI 10.1529/biophysj.104.045310; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	60	49	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34072	34085		10.1074/jbc.M607295200	http://dx.doi.org/10.1074/jbc.M607295200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973610	hybrid			2022-12-25	WOS:000241767600028
J	Login, FH; Shevchik, VE				Login, Frederic H.; Shevchik, Vladimir E.			The single transmembrane segment drives self-assembly of OutC and the formation of a functional type II secretion system in Erwinia chrysanthemi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY GRADIENT CENTRIFUGATION; CATION-PI INTERACTIONS; PROTEIN SECRETION; MEMBRANE ASSOCIATION; POLAR RESIDUES; PATHWAY; DOMAINS; IDENTIFICATION; SPECIFICITY; CAROTOVORA	Many pathogenic Gram-negative bacteria secrete toxins and lytic enzymes via a multiprotein complex called the type II secretion system. This system, named Out in Erwinia chrysanthemi, consists of 14 proteins integrated or associated with the two bacterial membranes. OutC, a key player in this process, is probably implicated in the recognition of secreted proteins and signal transduction. OutC possesses a short cytoplasmic sequence, a single transmembrane segment (TMS), and a large periplasmic region carrying a putative PDZ domain. A hydrodynamic study revealed that OutC forms stable dimers of an elongated shape, whereas the PDZ domain adopts a globular shape. Bacterial two-hybrid, crosslinking, and pulldown assays revealed that the self-association of OutC is driven by the TMS, whereas the periplasmic region is dispensable for self-association. Site-directed mutagenesis of the TMS revealed that cooperative interactions between three polar residues located at the same helical face provide adequate stability for OutC self-assembly. An interhelical H-bonding mediated by Gln(29) appears to be the main driving force, and two Arg residues located at the TMS boundaries are essential for the stabilization of OutC oligomers. Stepwise mutagenesis of these residues gradually diminished OutC functionality and self-association ability. The triple OutC mutant R15V/Q29L/R36A became monomeric and nonfunctional. Self-association and functionality of the triple mutant were partially restored by the introduction of a polar residue at an alternative position in the interhelical interface. Thus, the OutC TMS is more than just a membrane anchor; it drives the protein self-association that is essential for formation of a functional secretion system.	Univ Lyon 1, INSA, CNRS, UMG UMR 5122, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Shevchik, VE (corresponding author), Univ Lyon 1, INSA, CNRS, UMG UMR 5122, Bat Lwoff,10 Rue Dubois, F-69622 Villeurbanne, France.	vladimir.shevchik@insa-lyon.fr		Shevchik, Vladimir/0000-0002-8031-8638				Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bleves S, 1999, J BACTERIOL, V181, P4012, DOI 10.1128/JB.181.13.4012-4019.1999; Bouley J, 2001, J MOL BIOL, V308, P205, DOI 10.1006/jmbi.2001.4594; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Filloux A, 2004, BBA-MOL CELL RES, V1694, P163, DOI 10.1016/j.bbamcr.2004.05.003; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gerard-Vincent M, 2002, MOL MICROBIOL, V44, P1651, DOI 10.1046/j.1365-2958.2002.02991.x; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; GROWLEY PB, 2005, PROTEINS, V59, P231; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; GURRAN AR, 2003, CURR OPIN STRUC BIOL, V13, P412; HARDING SE, 1995, ANAL BIOCHEM, V228, P131, DOI 10.1006/abio.1995.1324; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HM, 2004, J BACTERIOL, V186, P2946, DOI 10.1128/JB.186.10.2946-2955.2004; Lee HM, 2000, J BACTERIOL, V182, P1549, DOI 10.1128/JB.182.6.1549-1557.2000; Lindeberg M, 1996, MOL MICROBIOL, V20, P175, DOI 10.1111/j.1365-2958.1996.tb02499.x; Miller JH., 1972, EXPT MOL GENETICS; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Pallen MJ, 1997, MOL MICROBIOL, V26, P411, DOI 10.1046/j.1365-2958.1997.5591911.x; Peabody CR, 2003, MICROBIOL-SGM, V149, P3051, DOI 10.1099/mic.0.26364-0; Possot OM, 2000, J BACTERIOL, V182, P2142, DOI 10.1128/JB.182.8.2142-2152.2000; Possot OM, 1999, J BACTERIOL, V181, P4004, DOI 10.1128/JB.181.13.4004-4011.1999; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Py B, 2001, EMBO REP, V2, P244, DOI 10.1093/embo-reports/kve042; Ridder A, 2005, J MOL BIOL, V354, P894, DOI 10.1016/j.jmb.2005.09.084; Robert V, 2002, J BACTERIOL, V184, P1779, DOI 10.1128/JB.184.6.1779-1782.2002; Robien MA, 2003, J MOL BIOL, V333, P657, DOI 10.1016/j.jmb.2003.07.015; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SADLER JE, 1979, J BIOL CHEM, V254, P4443; Sandkvist M, 2000, J BACTERIOL, V182, P742, DOI 10.1128/JB.182.3.742-748.2000; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Shevchik VE, 1998, MICROBIOL-UK, V144, P3219, DOI 10.1099/00221287-144-11-3219; SHEVCHIK VE, 1995, MOL MICROBIOL, V16, P745, DOI 10.1111/j.1365-2958.1995.tb02435.x; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; Thomas JD, 1997, MICROBIOL-UK, V143, P713, DOI 10.1099/00221287-143-3-713; Voulhoux R, 2001, EMBO J, V20, P6735, DOI 10.1093/emboj/20.23.6735; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	50	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33152	33162		10.1074/jbc.M606245200	http://dx.doi.org/10.1074/jbc.M606245200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956883	hybrid			2022-12-25	WOS:000241621400023
J	Overton, TW; Whitehead, R; Li, Y; Snyder, LAS; Saunders, NJ; Smith, H; Cole, JA				Overton, Tim W.; Whitehead, Rebekah; Li, Ying; Snyder, Lori A. S.; Saunders, Nigel J.; Smith, Harry; Cole, Jeff A.			Coordinated regulation of the Neisseria gonorrhoeae-truncated denitrification pathway by the nitric oxide-sensitive repressor, NsrR, and nitrite-insensitive NarQ-NarP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; ANAEROBIC GROWTH; CHROMOSOMAL GENES; BLOOD-CELLS; EXPRESSION; NITRATE; ANIA; RESISTANCE; REDUCTASE	Neisseria gonorrhoeae survives anaerobically by reducing nitrite to nitrous oxide catalyzed by the nitrite and nitric oxide reductases, AniA and NorB. P-aniA is activated by FNR (regulator of fumarate and nitrate reduction), the two-component regulatory system NarQ-NarP, and induced by nitrite; P-norB is induced by NO independently of FNR by an uncharacterized mechanism. We report the results of microarray analysis, bioinformatic analysis, and chromatin immunoprecipitation, which revealed that only five genes with readily identified NarP-binding sites are differentially expressed in narP(+) and narP strains. These include three genes implicated in the truncated gonococcal denitrification pathway: aniA, norB, and narQ. We also report that (i) nitrite induces aniA transcription in a narP mutant; (ii) nitrite induction involves indirect inactivation by nitric oxide of a gonococcal repressor, NsrR, identified from a multigenome bioinformatic study; (iii) in an nsrR mutant, aniA, norB, and dnrN (encoding a putative reactive nitrogen species response protein) were expressed constitutively in the absence of nitrite, suggesting that NsrR is the only NO-sensing transcription factor in N. gonorrhoeae; and (iv) NO rather than nitrite is the ligand to which NsrR responds. When expressed in Escherichia coli, gonococcal NarQ and chimaeras of E. coli and gonococcal NarQ are ligand-insensitive and constitutively active: a "locked-on" phenotype. We conclude that genes involved in the truncated denitrification pathway of N. gonorrhoeae are key components of the small NarQP regulon, that NarP indirectly regulates PnorB by stimulating NO production by AniA, and that NsrR plays a critical role in enabling gonococci to evade NO generated as a host defense mechanism.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Sir William Dunn Sch Pathol, Bacterial Pathogenesis & Funct Genom Grp, Oxford OX1 3RE, England; Univ Birmingham, Sch Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Oxford; University of Birmingham	Cole, JA (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	j.a.cole@bham.ac.uk	Saunders, Nigel J/W-6745-2019; Overton, Tim W/F-3284-2011	Overton, Tim W/0000-0003-3050-2549; Saunders, Nigel/0000-0002-0160-4573; Snyder, Lori/0000-0003-3172-3984				Aparicio O., 2005, CURRENT PROTOCOLS MO, V21, P31; Appleman JA, 2003, J BACTERIOL, V185, P4872, DOI 10.1128/JB.185.16.4872-4882.2003; Beaumont HJE, 2004, J BACTERIOL, V186, P4417, DOI 10.1128/JB.186.13.4417-4421.2004; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; Boulanger MJ, 2002, J MOL BIOL, V315, P1111, DOI 10.1006/jmbi.2001.5251; Cairo G, 2002, FREE RADICAL BIO MED, V32, P1237, DOI 10.1016/S0891-5849(02)00825-0; Cardinale JA, 2000, INFECT IMMUN, V68, P4368, DOI 10.1128/IAI.68.7.4368-4369.2000; CLARK VL, 1987, INFECT IMMUN, V55, P1359, DOI 10.1128/IAI.55.6.1359-1364.1987; CLARK VL, 1988, MICROB PATHOGENESIS, V5, P381, DOI 10.1016/0882-4010(88)90038-1; Constantinidou C, 2006, J BIOL CHEM, V281, P4802, DOI 10.1074/jbc.M512312200; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; FRANGIPANE JV, 1993, INFECT IMMUN, V61, P1657, DOI 10.1128/IAI.61.5.1657-1666.1993; Grainger DC, 2004, J BACTERIOL, V186, P6938, DOI 10.1128/JB.186.20.6938-6943.2004; Grifantini R, 2004, MOL MICROBIOL, V54, P962, DOI 10.1111/j.1365-2958.2004.04315.x; Hartig E, 1999, J BACTERIOL, V181, P3658; Householder TC, 1999, J BACTERIOL, V181, P541, DOI 10.1128/JB.181.2.541-551.1999; Householder TC, 2000, INFECT IMMUN, V68, P5241, DOI 10.1128/IAI.68.9.5241-5246.2000; JAYARAMAN PS, 1987, J MOL BIOL, V196, P781, DOI 10.1016/0022-2836(87)90404-9; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; KNAPP JS, 1984, INFECT IMMUN, V46, P176, DOI 10.1128/IAI.46.1.176-181.1984; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Lissenden S, 2000, MOL MICROBIOL, V37, P839, DOI 10.1046/j.1365-2958.2000.02050.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Mellies J, 1997, MOL GEN GENET, V256, P525, DOI 10.1007/s004380050597; NAIRN CA, 1988, J GEN MICROBIOL, V134, P3295; PARSONS NJ, 1988, MICROB PATHOGENESIS, V5, P303, DOI 10.1016/0882-4010(88)90103-9; POPE NR, 1982, J GEN MICROBIOL, V128, P219; Rodionov DA, 2005, PLOS COMPUT BIOL, V1, P415, DOI 10.1371/journal.pcbi.0010055; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; SILVER LE, 1995, GENE, V166, P101, DOI 10.1016/0378-1119(95)00605-6; Snyder LAS, 2005, MICROBIOL-SGM, V151, P4005, DOI 10.1099/mic.0.27925-0; Snyder LAS, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-23; Snyder LAS, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-128; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; Uzzau S, 2001, P NATL ACAD SCI USA, V98, P15264, DOI 10.1073/pnas.261348198; Ward SM, 2002, MOL MICROBIOL, V44, P709, DOI 10.1046/j.1365-2958.2002.02902.x	39	79	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33115	33126		10.1074/jbc.M607056200	http://dx.doi.org/10.1074/jbc.M607056200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16954205	Green Accepted, hybrid			2022-12-25	WOS:000241621400020
J	Joshi, PP; Kulkarni, MV; Yu, BK; Smith, KR; Norton, DL; van Veelen, W; Hoppener, JWM; Franklin, DS				Joshi, P. P.; Kulkarni, M. V.; Yu, B. K.; Smith, K. R.; Norton, D. L.; van Veelen, W.; Hoppener, J. W. M.; Franklin, D. S.			Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis	ONCOGENE			English	Article						MEN; RET; cell cycle; CDKI; tumorigenesis; proliferation	MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE MUTATIONS; ENDOCRINE NEOPLASIA TYPE-2; ACTIVATED PROTEIN-KINASE; D-DEPENDENT KINASE; GROWTH-FACTOR; CELL-CYCLE; CONTACT INHIBITION; SIGNALING PATHWAY; MEN2B MUTATION	Multiple endocrine neoplasia type 2A (MEN2A) is predisposed by mutations in the RET proto-oncogene. Low expression of the cyclin-dependent kinase inhibitor (CDKI) p27(Kip1) is present in thyroid tumors, and recent evidence demonstrates p27 downregulation by the active RET mutant, RET/PTC1, found in papillary thyroid carcinoma. This implicates decreased p27 activity as an important event during thyroid tumorigenesis. However, p27(-/-) mice develop MEN-like tumors only in combination with loss of another CDKI, p18(Ink4c). This suggests that p18 and p27 functionally collaborate in suppression of tumorigenesis, that loss of both is critical in the development of MEN tumors and that both p18 and p27 are regulated by RET. We report that induction of the constitutively active MEN2A-specific RET mutant, RET2A(C634R), correlates with reduced p18/p27, and elevated cyctin D protein levels, leading to increased CDK activity, increased pRb phosphorylation and proliferation under growth arrest conditions. Mechanistically, RET2A represses p18/p27 mRNA levels while elevating cyclin D1 mRNA levels. RET2A expression also correlates with decreased p27 protein stability. RET2A-mediated regulation of p18 and p27, but not of cyclins D1 and D2, requires functional mitogen-activated protein kinase signaling. Additionally, RET2A-dependent p18 repression is required and sufficient to increase cell proliferation. Perhaps most significantly, MEN2A adrenal tumors also display these changes in cell cycle expression profile, demonstrating the biological relevance of our cell culture studies. Our results demonstrate for the first time that RET2A regulates p18, and suggest that loss of not only p27 but also of p18 expression is a key step in MEN tumorigenesis.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Univ Utrecht, Med Ctr, Dept Metab & Endocrine Dis, Utrecht, Netherlands	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Utrecht University	Franklin, DS (corresponding author), Purdue Univ, Dept Biol Sci, 205A Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	franklid@purdue.edu						ACTON D, 2004, J INTERN MED, V255, P696; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Buchwald PC, 2004, CLIN ENDOCRINOL, V60, P389, DOI 10.1111/j.1365-2265.2004.01995.x; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; CONDE E, 1992, ENDOCRINOLOGY, V131, P436, DOI 10.1210/en.131.1.436; Drosten M, 2004, JNCI-J NATL CANCER I, V96, P1231, DOI 10.1093/jnci/djh226; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 1996, ONCOGENE, V12, P481; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JUAN G, 1998, CURRENT PROTOCOLS CY, P791; Jung YD, 1999, CANCER RES, V59, P4804; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Kim HS, 1998, J NEUROSCI, V18, P8247; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marsh DJ, 1997, HORM RES, V47, P168, DOI 10.1159/000185461; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schubert WH, 2001, J HYDROMETEOROL, V2, P3, DOI 10.1175/1525-7541(2001)002<0005:>2.0.CO;2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SOZZI G, 1991, ONCOGENE, V6, P339; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TISCHLER AS, 1989, INT J DEV NEUROSCI, V7, P439, DOI 10.1016/0736-5748(89)90004-X; TONG Q, 1995, ONCOGENE, V10, P1781; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vitagliano D, 2004, CANCER RES, V64, P3823, DOI 10.1158/0008-5472.CAN-03-3918; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	54	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					554	570		10.1038/sj.onc.1209811	http://dx.doi.org/10.1038/sj.onc.1209811			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16953232				2022-12-25	WOS:000243731600008
J	Gautam, M; Shen, Y; Thirkill, TL; Douglas, GC; Barakat, AI				Gautam, Mamta; Shen, Yue; Thirkill, Twanda L.; Douglas, Gordon C.; Barakat, Abdul I.			Flow-activated chloride channels in vascular endothelium - Shear stress sensitivity, desensitization dynamics, and physiological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; ATHEROSCLEROSIS; PHOSPHORYLATION; APOPTOSIS; PULSATILE; RESPONSES; KINASE; MODEL; WALL; AKT	Although activation of outward rectifying Cl- channels is one of the fastest responses of endothelial cells (ECs) to shear stress, little is known about these channels. In this study, we used whole-cell patch clamp recordings to characterize the flow-activated Cl- current in bovine aortic ECs (BAECs). Application of shear stress induced rapid development of a Cl- current that was effectively blocked by the Cl- channel antagonist 5-nitro-2(3-phenopropylamino) benzoic acid (100 mu M). The current initiated at a shear stress as low as 0.3 dyne/cm(2), attained its peak within minutes of flow onset, and saturated above 3.5 dynes/cm(2) (similar to 2.5-3.5-fold increase over pre-flow levels). The Cl- current desensitized slowly in response to sustained flow, and step increases in shear stress elicited increased current only if the shear stress levels were below the 3.5 dynes/cm(2) saturation level. Oscillatory flow with a physiological oscillation frequency of 1 Hz, as occurs in disturbed flow zones prone to atherosclerosis, failed to elicit the Cl- current, whereas lower oscillation frequencies led to partial recovery of the current. Nonreversing pulsatile flow, generally considered protective of atherosclerosis, was as effective in eliciting the current as steady flow. Measurements using fluids of different viscosities indicated that the Cl- current is responsive to shear stress rather than shear rate. Blocking the flow-activated Cl- current abolished flow-induced Akt phosphorylation in BAECs, whereas blocking flow-sensitive K+ currents had no effect, suggesting that flow-activated Cl+ channels play an important role in regulating EC flow signaling.	Univ Calif Davis, Dept Mech & Aeronaut Engn, Davis, CA 95616 USA; Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Barakat, AI (corresponding author), Univ Calif Davis, Dept Mech & Aeronaut Engn, 1 Shields Ave, Davis, CA 95616 USA.	abarakat@ucdavis.edu	Barakat, Abdul I/AAI-3117-2020	Barakat, Abdul I/0000-0002-7551-3631				ANDO J, 1993, BIOCHEM BIOPH RES CO, V190, P716, DOI 10.1006/bbrc.1993.1108; Barakat AI, 1999, CIRC RES, V85, P820, DOI 10.1161/01.RES.85.9.820; Barakat AI, 2006, BIOMATERIALS, V27, P671, DOI 10.1016/j.biomaterials.2005.07.036; Barakat AI, 2001, J THEOR BIOL, V210, P221, DOI 10.1006/jtbi.2001.2290; Britt JC, 1997, PFLUG ARCH EUR J PHY, V434, P38, DOI 10.1007/s004240050360; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Hoger JH, 2002, P NATL ACAD SCI USA, V99, P7780, DOI 10.1073/pnas.102184999; JACOBS ER, 1995, PFLUG ARCH EUR J PHY, V431, P129, DOI 10.1007/BF00374386; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Li YSJ, 2005, J BIOMECH, V38, P1949, DOI 10.1016/j.jbiomech.2004.09.030; Lieu DK, 2004, AM J PHYSIOL-CELL PH, V286, pC1367, DOI 10.1152/ajpcell.00243.2003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKACHE M, 1988, P NATL ACAD SCI USA, V85, P1841, DOI 10.1073/pnas.85.6.1841; NEREM RM, 1992, J BIOMECH ENG-T ASME, V114, P274, DOI 10.1115/1.2891384; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; Qiu WP, 2003, AM J PHYSIOL-HEART C, V285, pH341, DOI 10.1152/ajpheart.01072.2002; Romanenko VG, 2002, AM J PHYSIOL-CELL PH, V282, pC708, DOI 10.1152/ajpcell.00247.2001; Suvatne J, 2001, AM J PHYSIOL-CELL PH, V280, pC216, DOI 10.1152/ajpcell.2001.280.1.C216; Wiesner TF, 1997, P NATL ACAD SCI USA, V94, P3726, DOI 10.1073/pnas.94.8.3726	27	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36492	36500		10.1074/jbc.M605866200	http://dx.doi.org/10.1074/jbc.M605866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16973617	hybrid			2022-12-25	WOS:000242220800004
J	Ahmad, R; Raina, D; Meyer, C; Kharbanda, S; Kufe, D				Ahmad, Rehan; Raina, Deepak; Meyer, Colin; Kharbanda, Surender; Kufe, Donald			Triterpenoid CDDO-Me blocks the NF-kappa B pathway by direct inhibition of IKK beta on Cys-179	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OIC ACID CDDO; TUMOR-NECROSIS-FACTOR; INDUCE APOPTOSIS; 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID; KINASE; CANCER; CELLS; DIFFERENTIATION; EXPRESSION; LIGAND	The novel oleanane triterpenoid 2-cyano-3,12-dioxooleana-1,9,-dien-28-oic acid ( CDDO) and the C-28 methyl ester (CDDO-Me) induce apoptosis of human tumor cells by disruption of redox balance and are currently in clinical trials. The present studies show that CDDO and CDDO-Me block tumor necrosis factor alpha-induced targeting of NF-kappa B p65 to the nucleus. CDDO- Me also blocked tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha. In concert with these results, we found that CDDO- Me inhibits I kappa B alpha kinase beta(IKK beta) activity in cells. In support of a direct mechanism, CDDO- Me inhibited recombinant IKK beta activity in vitro. The results also demonstrate that (i) CDDO and CDDO- Me form adducts with IKK beta, but not IKK beta with mutation of Cys-179 to Ala, and (ii)CDDO- Me inhibits IKK beta by a mechanism dependent on oxidation of Cys-179. These findings indicate that CDDO and CDDO-Me directly block IKK beta activity and thereby the NF-kappa B pathway by interacting with Cys-179 in the IKK beta activation loop.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Reata Pharmaceut Inc, Dallas, TX 75207 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	Rather, R A/J-3509-2019		NCI NIH HHS [CA98628, CA100707, CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA098628, P50CA100707] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernier M, 2006, J BIOL CHEM, V281, P2551, DOI 10.1074/jbc.M511878200; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Couch RD, 2005, BIOORG MED CHEM LETT, V15, P2215, DOI 10.1016/j.bmcl.2005.03.031; Dinkova-Kostova AT, 2005, P NATL ACAD SCI USA, V102, P4584, DOI 10.1073/pnas.0500815102; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Honda T, 2004, J MED CHEM, V47, P4923, DOI 10.1021/jm049727e; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Ikeda T, 2005, CELL DEATH DIFFER, V12, P523, DOI 10.1038/sj.cdd.4401574; Ikeda T, 2004, MOL CANCER THER, V3, P39, DOI 10.2463/mrms.3.39; Ikeda T, 2003, CANCER RES, V63, P5551; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kharbanda S, 1996, CANCER RES, V56, P3617; Kim KB, 2002, MOL CANCER THER, V1, P177; Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402; Konopleva M, 2002, BLOOD, V99, P326, DOI 10.1182/blood.V99.1.326; Lapillonne H, 2003, CANCER RES, V63, P5926; Liang MC, 2006, BIOCHEM PHARMACOL, V71, P634, DOI 10.1016/j.bcp.2005.11.013; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Samudio I, 2005, J BIOL CHEM, V280, P36273, DOI 10.1074/jbc.M507518200; Shishodia S, 2006, CLIN CANCER RES, V12, P1828, DOI 10.1158/1078-0432.CCR-05-2044; Stadheim TA, 2002, J BIOL CHEM, V277, P16448, DOI 10.1074/jbc.M108974200; Suh NJ, 1999, CANCER RES, V59, P336; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	30	206	240	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35764	35769		10.1074/jbc.M607160200	http://dx.doi.org/10.1074/jbc.M607160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16998237	hybrid			2022-12-25	WOS:000242100500022
J	Fujita-Becker, S; Tsiavaliaris, G; Ohkura, R; Shimada, T; Manstein, DJ; Sutoh, K				Fujita-Becker, Setsuko; Tsiavaliaris, Georgios; Ohkura, Reiko; Shimada, Takashi; Manstein, Dietmar J.; Sutoh, Kazuo			Functional characterization of the N-terminal region of myosin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MYOSIN; SMOOTH-MUSCLE MYOSIN; MOTOR DOMAIN; CRYSTAL-STRUCTURE; HEAVY-MEROMYOSIN; POWER STROKE; LIGHT-CHAIN; RELAY LOOP; 2 HEADS; ACTIN	All class 2 myosins contain an N-terminal extension of similar to 80 residues that includes an Src homology 3 (SH3)-like subdomain. To explore the functional importance of this region, which is also present in most other myosin classes, we generated truncated constructs of Dictyostelium discoideum myosin-2. Truncation at position 80 resulted in the complete loss of myosin-2 function in vivo. Actin affinity was more than 80-fold, and the rate of ADP release similar to 40-fold decreased in this mutant. In contrast, a myosin construct that lacks only the SH3-like subdomain, corresponding to residues 33-79, displayed much smaller functional defects. In complementation experiments with myosin-2 null cells, this construct rescued myosin-2-dependent processes such as cytokinesis, fruiting body formation, and sporogenesis. An 8-fold reduction in motile activity and changes of similar extent in the affinity for ADP and filamentous actin indicate the importance of the SH3-like subdomain for correct communication between the functional regions within the myosin motor domain and suggest that local perturbations in this region can play a role in modulating myosin-2 motor activity.	Hannover Med Sch, Inst Biophys Chem, D-30625 Hannover, Germany; Max Planck Inst Med Res, D-69120 Heidelberg, Germany; Univ Tokyo, Dept Life Sci, Tokyo 1538902, Japan	Hannover Medical School; Max Planck Society; University of Tokyo	Manstein, DJ (corresponding author), Hannover Med Sch, Inst Biophys Chem, OE4350,Carl Neubergstr 1, D-30625 Hannover, Germany.	manstein@bpc.mh-hannover.de	Manstein, Dietmar J. J/M-1034-2013; Manstein, Dietmar J./AAG-2640-2019	Manstein, Dietmar J. J/0000-0003-0763-0147; Manstein, Dietmar J./0000-0003-0763-0147				Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Batra R, 1999, BIOCHEMISTRY-US, V38, P6126, DOI 10.1021/bi982251e; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geeves MA, 2005, CELL MOL LIFE SCI, V62, P1462, DOI 10.1007/s00018-005-5015-5; Holmes KC, 2004, PHILOS T ROY SOC B, V359, P1819, DOI 10.1098/rstb.2004.1566; Ito K, 1999, BIOPHYS J, V76, P985, DOI 10.1016/S0006-3495(99)77262-0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kollmar M, 2002, EMBO J, V21, P2517, DOI 10.1093/emboj/21.11.2517; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Menetrey J, 2005, NATURE, V435, P779, DOI 10.1038/nature03592; Nikolaeva OP, 2002, EUR J BIOCHEM, V269, P5678, DOI 10.1046/j.1432-1033.2002.03279.x; ONISHI H, 1990, J BIOL CHEM, V265, P19362; Reubold TF, 2003, NAT STRUCT BIOL, V10, P826, DOI 10.1038/nsb987; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Terrak M, 2005, P NATL ACAD SCI USA, V102, P12718, DOI 10.1073/pnas.0503899102; Tsiavaliaris G, 2002, EMBO REP, V3, P1099, DOI 10.1093/embo-reports/kvf214; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; van Duffelen M, 2005, BIOCHEM BIOPH RES CO, V329, P563, DOI 10.1016/j.bbrc.2005.01.152; van Duffelen M, 2004, BIOPHYS J, V87, P1767, DOI 10.1529/biophysj.104.044388; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020	34	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36102	36109		10.1074/jbc.M605171200	http://dx.doi.org/10.1074/jbc.M605171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16982629	hybrid			2022-12-25	WOS:000242100500059
J	Chakraborty, S; Reineke, EL; Lam, M; Li, XF; Liu, Y; Gao, CZ; Khurana, S; Kao, HY				Chakraborty, Sharmistha; Reineke, Erin L.; Lam, Minh; Li, Xiaofang; Liu, Yu; Gao, Chengzhuo; Khurana, Simran; Kao, Hung-Ying			alpha-actinin 4 potentiates myocyte enhancer factor-2 transcription activity by antagonizing histone deacetylase 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II HISTONE DEACETYLASES; CELL MOTILITY; CROSS-LINKING; BINDING PROTEIN; NUCLEAR EXPORT; ASSOCIATION; REPRESSION; ACTININ-4; CANCER; PHOSPHORYLATION	Histone deacetylase 7 (HDAC7) is a member of class IIa HDACs that regulate myocyte enhancer factor-2 (MEF2)-mediated transcription and participate in multiple cellular processes such as T cell apoptosis. We have identified alpha-actinin 1 and 4 as class IIa HDAC-interacting proteins. The interaction domains are mapped to C terminus of alpha-actinin 4 and amino acids 72-172 of HDAC7. A point mutation in HDAC7 that disrupts its association with MEF2A also disrupts its association with alpha-actinin 4, indicating that MEF2A and alpha-actinin 4 binding sites largely overlap. We have also isolated a novel splice variant of alpha-actinin 4 that is predominantly localized in the nucleus, a pattern distinct from the full-length alpha-actinin 4, which is primarily distributed in the cytoplasm and plasma membrane. Using small interfering RNA, chromatin immunoprecipitation, and transient transfection assays, we show that alpha-actinin 4 potentiates expression of TAF55, a putative MEF2 target gene. Loss of MEF2A interaction correlates with loss of the ability of alpha-actinin 4 to potentiate TAF55 promoter activity. Ectopic expression of alpha-actinin 4, but not the mutant defective in MEF2A association, leads to disruption of HDAC7 center dot MEF2A association and enhancement of MEF2-mediated transcription. Taken together, we have identified a novel mechanism by which HDAC7 activity is negatively regulated and uncovered a previously unknown function of alpha-actinin 4.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Inst Res, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Kao, HY (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxk43@po.cwru.edu	Gao, Chengzhuo/G-6361-2010		NCI NIH HHS [T32 CA059366-11, P30 CA43703-12] Funding Source: Medline; NIDDK NIH HHS [R01 DK62985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babakov V N, 2004, Tsitologiia, V46, P1064; Berger I, 2003, J BIOL CHEM, V278, P17625, DOI 10.1074/jbc.M301646200; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gao CZ, 2006, FEBS LETT, V580, P5096, DOI 10.1016/j.febslet.2006.08.038; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Honda K, 2004, ONCOGENE, V23, P5257, DOI 10.1038/sj.onc.1207652; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Liu QY, 2004, CELL DEATH DIFFER, V11, P645, DOI 10.1038/sj.cdd.4401401; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Menez J, 2004, ONCOGENE, V23, P2630, DOI 10.1038/sj.onc.1207347; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Poch MT, 2004, TOXICOL APPL PHARM, V199, P239, DOI 10.1016/j.taap.2003.12.023; TRAVE G, 1995, EMBO J, V14, P4922, DOI 10.1002/j.1460-2075.1995.tb00175.x; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhou TY, 2001, J BIOL CHEM, V276, P25503, DOI 10.1074/jbc.M102875200	29	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35070	35080		10.1074/jbc.M602474200	http://dx.doi.org/10.1074/jbc.M602474200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980305	hybrid			2022-12-25	WOS:000241933700040
J	Schrader, R; Young, C; Kozian, D; Hoffmann, R; Lottspeich, F				Schrader, Rainer; Young, Craig; Kozian, Detlef; Hoffmann, Reinhard; Lottspeich, Friedrich			Temperature-sensitive eIF5A mutant accumulates transcripts targeted to the nonsense-mediated decay pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; DEOXYHYPUSINE SYNTHASE; SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; HYPUSINE FORMATION; GENE DISRUPTION; SHUTTLE VECTORS; YEAST GENES; AMINO-ACID; RNA	The highly conserved protein eIF5A found in Archaea and all eukaryotes uniquely contains the posttranslationally formed amino acid hypusine. Despite being essential the functions of this protein and its modification remain unclear. To gain more insight into these functions temperature-sensitive mutants of the human EIF5A1 were characterized in the yeast Saccharomyces cerevisiae. Expression of the point mutated form V81G in a Delta eIF5A strain of yeast led to a strongly temperature-sensitive phenotype and to a significantly reduced protein level at restrictive temperature. The mutant showed accumulation of a subset of mRNAs that was also observed in nonsense-mediated decay (NMD)-deficient yeast strains. After short incubation at restrictive temperature the mutant exhibited increased half-lives of the intron containing CYH2 pre-mRNA and mature transcripts of NMD-dependent genes. Reduced telomere silencing and shortening was detected in the V81G mutant further supporting similarities to NMD-deficient strains. Our data suggest that eIF5A mediates important cellular processes like cell viability and senescence through its effects on the stability of certain mRNAs.	Max Planck Inst Biochem, Dept Prot Analyt, D-82152 Martinsried, Germany; Aventis Pharma Germany GmbH, D-65929 Frankfurt, Germany; Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany	Max Planck Society; Sanofi-Aventis; University of Munich	Schrader, R (corresponding author), Max Planck Inst Biochem, Dept Prot Analyt, Klopferspitz 18, D-82152 Martinsried, Germany.	schrader@biochem.mpg.de	Hoffmann, Reinhard/I-8748-2018	Hoffmann, Reinhard/0000-0003-1514-1183				Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; Atkin AL, 1997, J BIOL CHEM, V272, P22163, DOI 10.1074/jbc.272.35.22163; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Burhans WC, 2003, MUTAT RES-FUND MOL M, V532, P227, DOI 10.1016/j.mrfmmm.2003.08.019; Caraglia M, 2001, AMINO ACIDS, V20, P91, DOI 10.1007/s007260170050; Chatterjee I, 2006, MOL GENET GENOMICS, V275, P264, DOI 10.1007/s00438-005-0086-4; Chen ZP, 1997, J CELL PHYSIOL, V170, P248, DOI 10.1002/(SICI)1097-4652(199703)170:3<248::AID-JCP5>3.0.CO;2-O; Culbertson MR, 2003, CURR OPIN GENET DEV, V13, P207, DOI 10.1016/S0959-437X(03)00014-5; Dahlseid JN, 2003, EUKARYOT CELL, V2, P134, DOI 10.1128/EC.2.1.134-142.2003; Enomoto S, 2004, MOL CELL BIOL, V24, P837, DOI 10.1128/MCB.24.2.837-845.2004; Facchiano AM, 2001, PROTEIN ENG, V14, P881, DOI 10.1093/protein/14.11.881; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HANAUSKEABEL HM, 1995, FEBS LETT, V366, P92, DOI 10.1016/0014-5793(95)00493-S; Hatfield L, 1996, MOL CELL BIOL, V16, P5830; He F, 2003, MOL CELL, V12, P1439, DOI 10.1016/S1097-2765(03)00446-5; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HODGSON VJ, 1994, FEMS MICROBIOL LETT, V120, P201, DOI [10.1111/j.1574-6968.1994.tb07031.x, 10.1016/0378-1097(94)90090-6]; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jao DLE, 2006, J CELL BIOCHEM, V97, P583, DOI 10.1002/jcb.20658; Jao DLE, 2002, J CELL BIOCHEM, V86, P590, DOI 10.1002/jcb.10235; Jin Bao-Feng, 2003, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V11, P325; KANG HA, 1994, J BIOL CHEM, V269, P3934; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; Lendvay TS, 1996, GENETICS, V144, P1399; Lew JE, 1998, MOL CELL BIOL, V18, P6121, DOI 10.1128/MCB.18.10.6121; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Liu YP, 1997, BIOL SIGNAL, V6, P166; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; MAGDOLEN V, 1994, MOL GEN GENET, V244, P646, DOI 10.1007/BF00282755; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Park MH, 2006, J BIOCHEM, V139, P161, DOI 10.1093/jb/mvj034; Park MH, 1997, BIOL SIGNAL, V6, P115; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PRKER R, 1919, GUIDE YEAST GENETICS, V149, P415; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Rosorius O, 1999, J CELL SCI, V112, P2369; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; Sherman F., 1986, METHODS YEAST GENETI; Shi XP, 1996, BBA-MOL CELL RES, V1310, P119, DOI 10.1016/0167-4889(95)00165-4; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; Taylor CA, 2004, INVEST OPHTH VIS SCI, V45, P3568, DOI 10.1167/iovs.03-1367; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; TUSHER VG, 2001, P NATL ACAD SCI USA, V98, P5115; Valentini SR, 2002, GENETICS, V160, P393; Wang TW, 2003, PLANT MOL BIOL, V52, P1223, DOI 10.1023/B:PLAN.0000004332.80792.4d; Wang TW, 2001, J BIOL CHEM, V276, P17541, DOI 10.1074/jbc.M008544200; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WOHL T, 1993, MOL GEN GENET, V241, P305; Zuk D, 1998, EMBO J, V17, P2914, DOI 10.1093/emboj/17.10.2914	63	53	59	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35336	35346		10.1074/jbc.M601460200	http://dx.doi.org/10.1074/jbc.M601460200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987817	Green Published, hybrid			2022-12-25	WOS:000241933700068
J	Shiraishi, N; Utsunomiya, H; Nishikimi, M				Shiraishi, Noriyuki; Utsunomiya, Hirotoshi; Nishikimi, Morimitsu			Combination of NADPH and copper ions generates proteinase K-resistant aggregates from recombinant prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO CONVERSION; AMINO-TERMINUS; BINDING-SITES; METAL-BINDING; FULL-LENGTH; SCRAPIE; CONFORMATION; PRP; DISEASE; DEPOLARIZATION	Recent studies have demonstrated that the octapeptide repeats of the N-terminal region of prion protein may be responsible for de novo generation of infectious prions in the absence of template. Here we demonstrate that PrP-(23-98), an N-terminal portion of PrP, is converted to aggregates upon incubation with NADPH and copper ions. Other pyridine nucleotides possessing a phosphate group on the adenine-linked ribose moiety (the reduced form of nicotinamide adenine dinucleotide 3 '-phosphate, nicotinic acid adenine dinucleotide phosphate, and NADP) were also effective in promoting aggregation, but NADH and NAD had no effect. The aggregation was attenuated by the metal chelator EDTA or by modification of histidyl residues with diethyl pyrocarbonate. The aggregates are amyloid-like as judged by the binding of thioflavin T, a fluorescent probe for amyloid, but do not exhibit fibrillar structures according to electron micrography. Interestingly the aggregates were resistant to proteinase K digestion. Likewise NADPH and zinc ions caused aggregation of PrP-(23-98), but the resulting aggregates were susceptible to degradation by proteinase K. Upon incubation with NADPH and copper ions, the full-length molecule PrP-(23-231) also formed proteinase K-resistant amyloid-like aggregates. Because it is possible that PrP, NADPH, and copper ions could associate in certain tissues, the aggregation observed in this study may be involved in prion initiation especially in the nonfamilial types of prion diseases.	Wakayama Med Univ, Dept Biochem, Wakayama 6418509, Japan; Wakayama Med Univ, Cent Res Lab, Wakayama 6418509, Japan	Wakayama Medical University; Wakayama Medical University	Shiraishi, N (corresponding author), Wakayama Med Univ, Dept Biochem, 811-1 Kimiidera, Wakayama 6418509, Japan.	nshirais@wakayamamed.ac.jp						Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2005, BIOCHEMISTRY-US, V44, P2339, DOI 10.1021/bi048322t; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 2001, J NEUROCHEM, V76, P69, DOI 10.1046/j.1471-4159.2001.00009.x; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Campbell TA, 1996, NEUROLOGY, V46, P761, DOI 10.1212/WNL.46.3.761; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Daggett V, 1998, CURR OPIN BIOTECH, V9, P359, DOI 10.1016/S0958-1669(98)80008-6; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Frankenfield KN, 2005, PROTEIN SCI, V14, P2154, DOI 10.1110/ps.051434005; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Garnett AP, 2003, J BIOL CHEM, V278, P6795, DOI 10.1074/jbc.M209280200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; HARTTER DE, 1988, SYNAPSE, V2, P412, DOI 10.1002/syn.890020408; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; Hijazi N, 2003, BRAIN RES, V993, P192, DOI 10.1016/j.brainres.2003.09.014; Hopt A, 2003, J NEUROSCI METH, V128, P159, DOI 10.1016/S0165-0270(03)00173-0; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Jones EM, 2006, J BIOL CHEM, V281, P8190, DOI 10.1074/jbc.M513417200; KARDOS J, 1989, NEUROSCI LETT, V103, P139, DOI 10.1016/0304-3940(89)90565-X; Kelleher SL, 2006, AM J PHYSIOL-REG I, V291, pR1181, DOI 10.1152/ajpregu.00206.2005; Kuczius T, 2004, BIOL CHEM, V385, P739, DOI 10.1515/BC.2004.090; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Lawson VA, 2004, J BIOL CHEM, V279, P13689, DOI 10.1074/jbc.M303697200; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; Leliveld SR, 2006, J BIOL CHEM, V281, P3268, DOI 10.1074/jbc.M510606200; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Mange A, 2004, BIOL CELL, V96, P125, DOI 10.1016/j.biolcel.2003.11.007; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Miles E W, 1977, Methods Enzymol, V47, P431; Moore RA, 2006, PROTEIN SCI, V15, P609, DOI 10.1110/ps.051822606; PATTISON IH, 1971, NATURE, V230, P115, DOI 10.1038/230115a0; Post K, 1998, BIOL CHEM, V379, P1307, DOI 10.1515/bchm.1998.379.11.1307; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; ROZELL B, 1988, EUR J CELL BIOL, V46, P470; Shiraishi N, 2005, BIOCHEM J, V387, P247, DOI 10.1042/BJ20041561; Shiraishi N, 2002, FEBS LETT, V511, P118, DOI 10.1016/S0014-5793(01)03324-5; Sigurdsson EM, 2003, J BIOL CHEM, V278, P46199, DOI 10.1074/jbc.C300303200; Stewart RS, 2005, J BIOL CHEM, V280, P15855, DOI 10.1074/jbc.M412298200; Supattapone S, 2001, J VIROL, V75, P1408, DOI 10.1128/JVI.75.3.1408-1413.2001; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wise DD, 2004, NEUROSCIENCE, V128, P263, DOI 10.1016/j.neuroscience.2004.06.058; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yang LC, 2005, P NATL ACAD SCI USA, V102, P11179, DOI 10.1073/pnas.0406547102	63	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34880	34887		10.1074/jbc.M606581200	http://dx.doi.org/10.1074/jbc.M606581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990274	hybrid			2022-12-25	WOS:000241933700020
J	Zahnd, C; Pecorari, F; Straumann, N; Wyler, E; Pluckthun, A				Zahnd, Christian; Pecorari, Frederic; Straumann, Nadine; Wyler, Emanuel; Plueckthun, Andreas			Selection and characterization of Her2 binding-designed ankyrin repeat proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; BREAST-CANCER; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; COMBINATORIAL LIBRARIES; RECEPTOR; HERCEPTIN; COMPLEX; EXPRESSION; EVOLUTION	Designed ankyrin repeat proteins (DARPins) are a novel class of binding proteins that bind their target protein with high affinity and specificity and have very favorable expression and stability properties. We describe here the in vitro selection of DARPins against human epidermal growth factor receptor 2 (Her2), an important target for cancer therapy and diagnosis. Several DARPins bind to the same epitope as trastuzumab (Herceptin), but none were selected that bind to the epitope of pertuzumab (Omnitarg). Some of the selected DARPins bind with low nanomolar affinity (K-d = 7.3 nm) to the target. Further analysis revealed that all DARPins are highly specific and do not cross-react with epidermal growth factor receptor I (EGFR1) or any other investigated protein. The selected DARPins specifically bind to strongly Her2-overexpressing cell lines such as SKBR-3 but also recognize small amounts of Her2 on weakly expressing cell lines such as MCF-7. Furthermore, the DARPins also lead to a highly specific and strong staining of plasma membranes of paraffinated sections of human mamma-carcinoma tissue. Thus, the selected DARPins might be used for the development of diagnostic tests for the status of Her2 overexpression in different adenocarcinomas, and they may be further evaluated for their potential in targeted therapy since their favorable expression properties make the construction of fusion proteins very convenient.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; ETH, Inst Cell Biol, ETH Honggerberg, CH-8093 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@bioc.unizh.ch	Plückthun, Andreas/C-2746-2009; Pecorari, Frederic/L-2942-2015	Plückthun, Andreas/0000-0003-4191-5306; Wyler, Emanuel/0000-0002-9884-1806; Pecorari, Frederic/0000-0002-7854-0643				Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Amstutz P, 2005, J BIOL CHEM, V280, P24715, DOI 10.1074/jbc.M501746200; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Forrer P, 2004, CHEMBIOCHEM, V5, P183, DOI 10.1002/cbic.200300762; Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Ge L, 1995, ANTIBODY ENG, P229; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Jacobs TW, 2000, AM J CLIN PATHOL, V113, P251, DOI 10.1309/980M-E24R-V19K-595D; Kohl A, 2003, P NATL ACAD SCI USA, V100, P1700, DOI 10.1073/pnas.0337680100; Maur AAD, 2002, J BIOL CHEM, V277, P45075, DOI 10.1074/jbc.M205264200; Mayfield S, 2001, BREAST CANCER RES TR, V70, P123, DOI 10.1023/A:1012999012192; Molina MA, 2001, CANCER RES, V61, P4744; Moroney S, 2005, MODERN BIOPHARMACEUT, P1147; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Willuda J, 2001, J BIOL CHEM, V276, P14385, DOI 10.1074/jbc.M011669200; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200	33	83	101	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35167	35175		10.1074/jbc.M602547200	http://dx.doi.org/10.1074/jbc.M602547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16963452	hybrid			2022-12-25	WOS:000241933700050
J	Hwang, WC; Lin, YQ; Santelli, E; Sui, JH; Jaroszewski, L; Stec, B; Farzan, M; Marasco, WA; Liddington, RC				Hwang, William C.; Lin, Yaqiong; Santelli, Eugenio; Sui, Jianhua; Jaroszewski, Lukasz; Stec, Boguslaw; Farzan, Michael; Marasco, Wayne A.; Liddington, Robert C.			Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARS-CORONAVIRUS; MOLECULAR REPLACEMENT; RECEPTOR; DETERMINANTS; ENTRY	Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease that caused pandemic spread in 2003. The etiological agent of SARS is a novel coronavirus (SARS-CoV). The coronaviral surface spike protein S is a type I transmembrane glycoprotein that mediates initial host binding via the cell surface receptor angiotensin-converting enzyme 2 (ACE2), as well as the subsequent membrane fusion events required for cell entry. Here we report the crystal structure of the S1 receptor binding domain (RBD) in complex with a neutralizing antibody, 80R, at 2.3 angstrom resolution, as well as the structure of the uncomplexed S1 RBD at 2.2 angstrom resolution. We show that the 80R-binding epitope on the S1 RBD overlaps very closely with the ACE2-binding site, providing a rationale for the strong binding and broad neutralizing ability of the antibody. We provide a structural basis for the differential effects of certain mutations in the spike protein on 80R versus ACE2 binding, including escape mutants, which should facilitate the design of immunotherapeutics to treat a future SARS outbreak. We further show that the RBD of S1 forms dimers via an extensive interface that is disrupted in receptor- and antibody-bound crystal structures, and we propose a role for the dimer in virus stability and infectivity.	Burnham Inst Med Res, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA	Sanford Burnham Prebys Medical Discovery Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University	Liddington, RC (corresponding author), Burnham Inst Med Res, Infect & Inflammatory Dis Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org		SUI, JIANHUA/0000-0002-1272-9662; Farzan, Michael/0000-0002-2990-5319; Stec, Boguslaw/0000-0002-8696-0349	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028785, R01AI048436, U01AI061318] Funding Source: NIH RePORTER; NIAID NIH HHS [AI053822, AI48436, AI28785, AI061318] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAGG WL, 1954, ACTA CRYSTALLOGR, V7, P409, DOI 10.1107/S0365110X54001235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chakraborti S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-73; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewicki DN, 2002, J BIOL CHEM, V277, P19727, DOI 10.1074/jbc.M201837200; Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640; Lin Y, 2004, ANTIVIR THER, V9, P287; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nurani G, 2003, J VIROL, V77, P11985, DOI 10.1128/JVI.77.22.11985-11991.2003; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102; Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101; Sui JH, 2005, J VIROL, V79, P5900, DOI 10.1128/JVI.79.10.5900-5906.2005; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang JM, 2005, ACTA CRYSTALLOGR D, V61, P67, DOI 10.1107/S0907444904026721; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200	28	143	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34610	34616		10.1074/jbc.M603275200	http://dx.doi.org/10.1074/jbc.M603275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16954221	Green Published, hybrid			2022-12-25	WOS:000241767600080
J	Pinto, MP; Grou, CP; Alencastre, IS; Oliveira, ME; Sa-Miranda, C; Fransen, M; Azevedo, JE				Pinto, Manuel P.; Grou, Claudia P.; Alencastre, Ines S.; Oliveira, Marcia E.; Sa-Miranda, Clara; Fransen, Marc; Azevedo, Jorge E.			The import competence of a peroxisomal membrane protein is determined by Pex19p before the docking step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ZELLWEGER-SYNDROME; RAT-LIVER; IN-VITRO; MAMMALIAN PEROXISOMES; SACCHAROMYCES-CEREVISIAE; POTENTIAL ROLE; PTS1 RECEPTOR; HUMAN PEX3; IDENTIFICATION	Biogenesis of the mammalian peroxisomal membrane requires the action of Pex3p and Pex16p, two proteins present in the organelle membrane, and Pex19p, a protein that displays a dual subcellular distribution (peroxisomal and cytosolic). Pex19p interacts with most peroxisomal intrinsic membrane proteins, but whether this property reflects its role as an import receptor for this class of proteins or a chaperone-like function in the assembly/ disassembly of peroxisomal membrane proteins has been the subject of much controversy. Here, we describe an in vitro system particularly suited to address this issue. It is shown that insertion of a reporter protein into the peroxisomal membrane is a Pex3p-dependent process that does not require ATP/GTP hydrolysis. The system can be programmed with recombinant versions of Pex19p, allowing us to demonstrate that Pex19p-cargo protein complexes formed in the absence of peroxisomes are the substrates for the peroxisomal docking/insertion machinery. Data suggesting that cargo-loaded Pex19p displays a much higher affinity for Pex3p than Pex19p alone are also provided. These results suggest that soluble Pex19p participates in the targeting of newly synthesized peroxisomal membrane proteins to the organelle membrane and support the existence of a cargo-induced peroxisomal targeting mechanism for Pex19p.	Univ Porto, Inst Mol & Celular Biol, P-4150180 Oporto, Portugal; Univ Porto, ICBAS, P-4099003 Oporto, Portugal; Katholieke Univ Leuven, Fac Geneeskunde, Dept Mol Celbiol, B-3000 Louvain, Belgium	Universidade do Porto; Universidade do Porto; KU Leuven	Azevedo, JE (corresponding author), Univ Porto, Inst Mol & Celular Biol, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	jazevedo@ibmc.up.pt	Grou, Claudia P/K-5472-2013; Azevedo, Jorge E/A-4113-2008; Pinto, Manuel/K-6425-2013; Fransen, Marc/C-6262-2008; sá Miranda, Maria Clara/K-3920-2013; Fransen, Marc/ADL-0723-2022	Grou, Claudia P/0000-0001-5197-2270; Azevedo, Jorge E/0000-0001-7714-5302; Pinto, Manuel/0000-0001-9778-2093; Fransen, Marc/0000-0001-9284-1197; sá Miranda, Maria Clara/0000-0003-0123-5525; Oliveira, Marcia/0000-0003-2437-2004; Alencastre, Ines/0000-0002-5591-5596				CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; Fransen M, 2005, J MOL BIOL, V346, P1275, DOI 10.1016/j.jmb.2005.01.013; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Fransen M, 1999, BIOCHEM J, V340, P561, DOI 10.1042/0264-6021:3400561; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALLAGER SR, 1999, CURRENT PROTOCOLS MO; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AMM, 1999, ANAL BIOCHEM, V274, P270, DOI 10.1006/abio.1999.4281; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Hadden DA, 2006, MOL MEMBR BIOL, V23, P325, DOI 10.1080/09687860600738221; Halbach A, 2005, J BIOL CHEM, V280, P21176, DOI 10.1074/jbc.M501750200; Halbach A, 2006, J CELL SCI, V119, P2508, DOI 10.1242/jcs.02979; Heiland I, 2005, FEBS J, V272, P2362, DOI 10.1111/j.1742-4658.2005.04690.x; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; Kim PK, 2006, J CELL BIOL, V173, P521, DOI 10.1083/jcb.200601036; KOSTER A, 1986, BIOCHEM BIOPH RES CO, V137, P626, DOI 10.1016/0006-291X(86)91124-1; Kragt A, 2005, J BIOL CHEM, V280, P34350, DOI 10.1074/jbc.M505432200; Lambkin GR, 2001, MOL BIOL CELL, V12, P3353, DOI 10.1091/mbc.12.11.3353; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 2006, J BIOL CHEM, V281, P36, DOI 10.1074/jbc.M509819200; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mayerhofer PU, 2002, BIOCHEM BIOPH RES CO, V291, P1180, DOI 10.1006/bbrc.2002.6568; Michels PAM, 2005, MOL MEMBR BIOL, V22, P133, DOI 10.1080/09687860400024186; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Muntau AC, 2000, AM J HUM GENET, V67, P967, DOI 10.1086/303071; Muntau AC, 2003, EUR J CELL BIOL, V82, P333, DOI 10.1078/0171-9335-00325; Pause B, 2000, FEBS LETT, V471, P23, DOI 10.1016/S0014-5793(00)01332-6; Pause B, 1997, FEBS LETT, V414, P95, DOI 10.1016/S0014-5793(97)00975-7; Reguenga C, 1999, BBA-GENE STRUCT EXPR, V1445, P337, DOI 10.1016/S0167-4781(99)00061-5; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; Shimozawa N, 2000, HUM MOL GENET, V9, P1995, DOI 10.1093/hmg/9.13.1995; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Tam YYC, 2005, J BIOL CHEM, V280, P34933, DOI 10.1074/jbc.M506208200; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; van der Zand A, 2006, J CELL SCI, V119, P989, DOI 10.1242/jcs.02893; Vizeacoumar FJ, 2006, J BIOL CHEM, V281, P14805, DOI 10.1074/jbc.M601808200; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Weller S, 2003, ANNU REV GENOM HUM G, V4, P165, DOI 10.1146/annurev.genom.4.070802.110424; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; Yernaux C, 2006, MOL MEMBR BIOL, V23, P157, DOI 10.1080/09687860500460124	58	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34492	34502		10.1074/jbc.M607183200	http://dx.doi.org/10.1074/jbc.M607183200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980692	hybrid			2022-12-25	WOS:000241767600070
J	Sztalryd, C; Bell, M; Lu, XY; Mertz, P; Hickenbottom, S; Chang, BHJ; Chan, L; Kimmel, AR; Londos, C				Sztalryd, Carole; Bell, Ming; Lu, Xinyue; Mertz, Pamela; Hickenbottom, Sabrina; Chang, Benny H. -J.; Chan, Lawrence; Kimmel, Alan R.; Londos, Constantine			Functional compensation for adipose differentiation-related protein (ADFP) by Tip47 in an ADFP null embryonic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID DROPLETS; PERILIPIN; LIPOLYSIS; LIPASE; LIVER; RAB18; MILK; ADRP	Ectopic accumulation of lipid droplets in non-adipose tissues correlates with the degree of insulin resistance in these tissues. Emerging evidence indicates that lipid droplets are specialized organelles that participate in lipid metabolism and intracellular trafficking. These properties are thought to derive from the lipid droplet-associated PAT protein family (perilipin, ADFP, and Tip47). The functions of the ubiquitously distributed adipose differentiation-related protein (ADFP) and Tip47 remain unknown. To evaluate the roles of ADFP and Tip47 in lipid biogenesis and metabolism, ADFP null and wild type (wt) clonal cell lines were established from ADFP null and wt mice, respectively. In ADFP null cells, Tip47 was identified as the sole lipid droplet-associated protein from the PAT family by mass spectroscopy, which was further confirmed by immunoblotting and immunocytochemistry. Following incubation with oleic acid, ADFP null cells were able to form lipid droplets to the same extent as wt cells. No statistical differences between the two cell types were observed in NEFA uptake or lipolysis. Small interference RNAs (siRNAs) against Tip47 were found to down-regulate protein levels for Tip47 by 85%. ADFP null cells treated with Tip47 siRNA retained the ability to form lipid droplets but to a lesser extent and shunted the utilization of exogenously added NEFA from triglycerides to phospholipids. These data support the hypothesis that Tip47 plays an important role in lipid metabolism. Tip47 and ADFP in peripheral tissues may play a critical role in regulating the formation and turnover, and hence metabolic consequences, of ectopic fat.	Univ Maryland, Sch Med, Geriatr Res Educ & Clin Ctr, Baltimore Vet Affairs Hlth Care Ctr,Dept Med, Baltimore, MD 21201 USA; NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Geriatric Research Education & Clinical Center; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Baylor College of Medicine; Baylor College of Medicine	Sztalryd, C (corresponding author), Vet Affairs Med Ctr, GRECC Geriatr, 10 N Greene St, Baltimore, MD 21201 USA.	csztalry@grecc.umaryland.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015609, P30DK056338, Z01DK015503, Z01DK015505] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL51586] Funding Source: Medline; NIDDK NIH HHS [DK56338] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Chang BHJ, 2006, MOL CELL BIOL, V26, P1063, DOI 10.1128/MCB.26.3.1063-1076.2006; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Meigs JB, 2002, AM J MANAG CARE, V8, pS283; Mishra R, 2004, AM J PHYSIOL-RENAL, V286, pF913, DOI 10.1152/ajprenal.00323.2003; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Ozeki S, 2005, J CELL SCI, V118, P2601, DOI 10.1242/jcs.02401; Phillips SA, 2005, OBES RES, V13, P1321, DOI 10.1038/oby.2005.160; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SZTALRYD C, 1989, CELL MOL BIOL, V35, P81; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Than NG, 2003, EUR J BIOCHEM, V270, P1176, DOI 10.1046/j.1432-1033.2003.03475.x; Wolins NE, 2005, J BIOL CHEM, V280, P19146, DOI 10.1074/jbc.M500978200; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wu CC, 2000, ELECTROPHORESIS, V21, P3470, DOI 10.1002/1522-2683(20001001)21:16<3470::AID-ELPS3470>3.3.CO;2-7; Xu GH, 2006, BBA-MOL CELL BIOL L, V1761, P83, DOI 10.1016/j.bbalip.2005.12.005; Xu GH, 2005, J BIOL CHEM, V280, P42841, DOI 10.1074/jbc.M506569200; Yamaguchi T, 2006, J BIOL CHEM, V281, P14232, DOI 10.1074/jbc.M601682200	39	98	105	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34341	34348		10.1074/jbc.M602497200	http://dx.doi.org/10.1074/jbc.M602497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968708	hybrid			2022-12-25	WOS:000241767600054
J	Fan, ACY; Bhangoo, MK; Young, JC				Fan, Anna C. Y.; Bhangoo, Melanie K.; Young, Jason C.			Hsp90 functions in the targeting and outer membrane translocation steps of Tom70-mediated mitochondrial import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; TOM CORE COMPLEX; SHOCK-PROTEIN 90; ADP/ATP CARRIER; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; INNER MEMBRANE; MAMMALIAN MITOCHONDRIA; PREPROTEIN TRANSLOCASE	The Tom70 import receptor on the mitochondrial outer membrane specifically recognizes Hsp90 and Hsc70, a critical step for the import of mitochondrial preproteins, the targeting of which depends on these cytosolic chaperones. To analyze the role of Hsp90 in mitochondrial import, the effects of the Hsp90 inhibitors geldanamycin and novobiocin were compared. Geldanamycin occludes the N-terminal ATP-binding site of Hsp90, whereas novobiocin targets the C-terminal region of the chaperone. Here, novobiocin was found to inhibit preprotein import and, in particular, targeting to the purified cytosolic fragment of Tom70. Hsp90 cross-linking to preprotein and coprecipitation of Hsp90 with Tom70 were both impaired by novobiocin. Overall, novobiocin treatment increased preprotein aggregation, contributing to reduced import competence. In contrast, geldanamycin had no apparent effect on preprotein interactions with Hsp90, formation of preprotein-chaperone complexes, Hsp90 docking onto Tom70, or preprotein association with the outer membrane. Instead, geldanamycin impaired formation of preprotein import intermediates at the outer membrane. This suggests a novel active role for Hsp90 in import steps subsequent to Tom70 targeting. Our results outline the mechanisms of Hsp90 function in preprotein targeting and transport.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Young, JC (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	jason.young2@mcgill.ca						Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Ahting U, 2005, J BIOL CHEM, V280, P48, DOI 10.1074/jbc.M410905200; Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; Ali MMU, 2006, NATURE, V440, P1013, DOI 10.1038/nature04716; Allan RK, 2006, J BIOL CHEM, V281, P7161, DOI 10.1074/jbc.M512406200; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; Beddoe T, 2004, J BIOL CHEM, V279, P46448, DOI 10.1074/jbc.M405639200; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chan NC, 2006, J MOL BIOL, V358, P1010, DOI 10.1016/j.jmb.2006.02.062; Citri A, 2004, CELL CYCLE, V3, P51; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; del Arco A, 2005, CELL MOL LIFE SCI, V62, P2204, DOI 10.1007/s00018-005-5197-x; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Kanelakis KC, 2002, J BIOL CHEM, V277, P33698, DOI 10.1074/jbc.M204164200; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; LINGELBACH KR, 1986, EUR J BIOCHEM, V161, P19, DOI 10.1111/j.1432-1033.1986.tb10119.x; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; McClellan AJ, 2005, CELL, V121, P739, DOI 10.1016/j.cell.2005.03.024; Muhlenbein N, 2004, J BIOL CHEM, V279, P13540, DOI 10.1074/jbc.M312485200; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Reichert AS, 2004, TRENDS GENET, V20, P555, DOI 10.1016/j.tig.2004.08.012; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Suzuki H, 2002, J CELL SCI, V115, P1895; Suzuki H, 2004, J BIOL CHEM, V279, P50619, DOI 10.1074/jbc.M408604200; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Terada K, 1996, MOL CELL BIOL, V16, P6103; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Vasiljev A, 2004, MOL BIOL CELL, V15, P1445, DOI 10.1091/mbc.E03-05-0272; VIJAYASARATHY C, 1989, J BIOL CHEM, V264, P7772; Webb CT, 2006, MOL CELL, V21, P123, DOI 10.1016/j.molcel.2005.11.010; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Yano M, 2000, MOL CELL BIOL, V20, P7205, DOI 10.1128/MCB.20.19.7205-7213.2000; Yano M, 1998, J BIOL CHEM, V273, P26844, DOI 10.1074/jbc.273.41.26844; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Young JC, 1996, EMBO J, V15, P172, DOI 10.1002/j.1460-2075.1996.tb00345.x; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Yun BG, 2004, BIOCHEMISTRY-US, V43, P8217, DOI 10.1021/bi0497998; ZARA V, 1992, J BIOL CHEM, V267, P12077; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	75	71	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33313	33324		10.1074/jbc.M605250200	http://dx.doi.org/10.1074/jbc.M605250200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16968702	hybrid			2022-12-25	WOS:000241621400041
J	Kim, E; Clark, AL; Kiss, A; Hahn, JW; Wesselschmidt, R; Coscia, CJ; Belcheva, MM				Kim, Eunhae; Clark, Amy L.; Kiss, Alexi; Hahn, Jason W.; Wesselschmidt, Robin; Coscia, Carmine J.; Belcheva, Mariana M.			mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; RECEPTOR GENE-EXPRESSION; EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASES; FACTOR SIGNALING PATHWAYS; SELF-RENEWAL; RETINOIC ACID; MAP KINASE; ENDODERM DIFFERENTIATION; DNA-SYNTHESIS	Growth factors, hormones, and neurotransmitters have been implicated in the regulation of stem cell fate. Since various neural precursors express functional neurotransmitter receptors, which include G protein-coupled receptors, it is anticipated that they are involved in cell fate decisions. We detected mu-opioid receptor (MOR-1) and kappa-opioid receptor (KOR-1) expression and immunoreactivity in embryonic stem (ES) cells and in retinoic acid-induced ES cell-derived, nestin-positive, neural progenitors. Moreover, these G protein-coupled receptors are functional, since [D-Ala(2), MePhe(4), Gly-ol(5)] enkephalin, a MOR-selective agonist, and U69,593, a KOR-selective agonist, induce a sustained activation of extracellular signal-regulated kinase (ERK) signaling throughout a 24-h treatment period in undifferentiated, self-renewing ES cells. Both opioids promote limited proliferation of undifferentiated ES cells via the ERK/MAP kinase signaling pathway. Importantly, biochemical and immunofluorescence data suggest that [D-Ala2, MePhe4, Gly-ol5] enkephalin and U69,593 divert ES cells from self-renewal and coax the cells to differentiate. In retinoic acid-differentiated ES cells, opioid-induced signaling features a biphasic ERK activation profile and an opioid-induced, ERK- independent inhibition of proliferation in these neural progenitors. Collectively, the data suggest that opioids may have opposite effects on ES cell self-renewal and ES cell differentiation and that ERK activation is only required by the latter. Finally, opioid modulation of ERK activity may play an important role in ES cell fate decisions by directing the cells to specific lineages.	St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Primogenix Inc, Los Angeles, CA 90033 USA	Saint Louis University	Belcheva, MM (corresponding author), St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	beltchem@slu.edu	Kiss, Alexi/AAH-6830-2021	Kiss, Alexi/0000-0003-2330-6929	NIDA NIH HHS [DA-05412, R01 DA005412, R01 DA005412-16] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA005412, R01DA005412] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Adi S, 2002, ENDOCRINOLOGY, V143, P511, DOI 10.1210/en.143.2.511; Aguado T, 2006, J NEUROSCI, V26, P1551, DOI 10.1523/JNEUROSCI.3101-05.2006; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BARG J, 1992, J NEUROCHEM, V59, P1145, DOI 10.1111/j.1471-4159.1992.tb08357.x; BARG J, 1993, J NEUROCHEM, V60, P1505, DOI 10.1111/j.1471-4159.1993.tb03314.x; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Belcheva MM, 2003, MOL PHARMACOL, V64, P1391, DOI 10.1124/mol.64.6.1391; Belcheva MM, 2005, J BIOL CHEM, V280, P27662, DOI 10.1074/jbc.M502593200; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bi J, 2001, J NEUROSCI, V21, P1590, DOI 10.1523/JNEUROSCI.21-05-01590.2001; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; Bohn LM, 2000, J NEUROCHEM, V74, P574, DOI 10.1046/j.1471-4159.2000.740574.x; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chakrabarti S, 2005, MOL BRAIN RES, V135, P217, DOI 10.1016/j.molbrainres.2004.12.016; Chen HC, 1999, NEUROSCIENCE, V92, P1143, DOI 10.1016/S0306-4522(99)00030-5; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Finley MFA, 1999, J NEUROBIOL, V40, P271, DOI 10.1002/(SICI)1097-4695(19990905)40:3<271::AID-NEU1>3.0.CO;2-C; FUKUDA M, 1995, ONCOGENE, V11, P239; GARZON J, 1995, MOL PHARMACOL, V47, P738; Gottlieb DI, 1999, CELLS TISSUES ORGANS, V165, P165, DOI 10.1159/000016696; Gottlieb DI, 2002, ANNU REV NEUROSCI, V25, P381, DOI 10.1146/annurev.neuro.25.112701.142904; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HEO IS, 2006, AM J PHYSIOL, V290, pC123; Hu XL, 2002, MOL PHARMACOL, V62, P881, DOI 10.1124/mol.62.4.881; Hwang CK, 2003, J BIOL CHEM, V278, P3742, DOI 10.1074/jbc.M208780200; Jin XW, 2003, MOL CELL BIOL, V23, P1054, DOI 10.1128/MCB.23.3.1054-1060.2003; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Kippin TE, 2005, J NEUROSCI, V25, P5815, DOI 10.1523/JNEUROSCI.1120-05.2005; Li BS, 2001, J NEUROSCI, V21, P1569, DOI 10.1523/JNEUROSCI.21-05-01569.2001; LIUCHEN LY, 1993, MOL PHARMACOL, V44, P749; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luk KC, 2003, J NEUROSCI, V23, P2239; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Nguyen L, 2001, CELL TISSUE RES, V305, P187, DOI 10.1007/s004410000343; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Park SW, 2005, J NEUROSCI, V25, P3350, DOI 10.1523/JNEUROSCI.0186-05.2005; Persson PAI, 2000, J NEUROSCI RES, V61, P371, DOI 10.1002/1097-4547(20000815)61:4<371::AID-JNR3>3.0.CO;2-H; Pevny L, 2005, CURR OPIN NEUROBIOL, V15, P7, DOI 10.1016/j.conb.2005.01.016; Ponte E, 1998, P NATL ACAD SCI USA, V95, P9360, DOI 10.1073/pnas.95.16.9360; Prudhomme W, 2004, P NATL ACAD SCI USA, V101, P2900, DOI 10.1073/pnas.0308768101; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Rohrer DK, 1998, ANNU REV PHARMACOL, V38, P351, DOI 10.1146/annurev.pharmtox.38.1.351; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Sanada K, 2005, CELL, V122, P119, DOI 10.1016/j.cell.2005.05.009; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith ER, 2004, J CELL BIOL, V164, P689, DOI 10.1083/jcb.200312028; Stavridis MP, 2003, BIOCHEM SOC T, V31, P45, DOI 10.1042/bst0310045; Tighe AP, 2004, J CELL PHYSIOL, V198, P223, DOI 10.1002/jcp.10424; Ventura C, 2005, EVID-BASED COMPL ALT, V2, P277, DOI 10.1093/ecam/neh100; Ventura C, 2000, CIRC RES, V87, P189, DOI 10.1161/01.RES.87.3.189; Ventura C, 2003, CIRC RES, V92, P623, DOI 10.1161/01.RES.0000065169.23780.0E; Ventura C, 2003, CIRC RES, V92, P617, DOI 10.1161/01.RES.0000065168.31147.5B; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wegner M, 2005, TRENDS NEUROSCI, V28, P583, DOI 10.1016/j.tins.2005.08.008; Wei LN, 2000, MOL PHARMACOL, V57, P401; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yoshida-Koide U, 2004, BIOCHEM BIOPH RES CO, V313, P475, DOI 10.1016/j.bbrc.2003.11.138	81	72	77	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33749	33760		10.1074/jbc.M603862200	http://dx.doi.org/10.1074/jbc.M603862200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16954126	Green Accepted, hybrid			2022-12-25	WOS:000241621400082
J	Urschel, S; Hoher, T; Schubert, T; Alev, C; Sohl, G; Worsdorfer, P; Asahara, T; Dermietzel, R; Weiler, R; Willecke, K				Urschel, Stephanie; Hoeher, Thorsten; Schubert, Timm; Alev, Cantas; Soehl, Goran; Woersdoerfer, Philipp; Asahara, Takayuki; Dermietzel, Rolf; Weiler, Reto; Willecke, Klaus			Protein kinase A-mediated phosphorylation of Connexin36 in mouse retina results in decreased gap junctional communication between AII amacrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE BIPOLAR CELLS; MAMMALIAN RETINA; RABBIT RETINA; ELECTRICAL SYNAPSES; NEURONAL CONNEXIN36; VISUAL TRANSMISSION; GENE CONNEXIN36; EXPRESSION; MODULATION; PATHWAYS	Gap junctions in AII amacrine cells of mammalian retina participate in the coordination of the rod and cone signaling pathway involved in visual adaptation. Upon stimulation by light, released dopamine binds to D-1 receptors on AII amacrine cells leading to increased intracellular cAMP (cyclic adenosine monophosphate) levels. AII amacrine cells express the gap junctional protein connexin36 (Cx36). Phosphorylation of Cx36 has been hypothesized to regulate gap junctional activity of AII amacrine cells. However, until now in vivo phosphorylation of Cx36 has not been reported. Indeed, it had been concluded that Cx36 in bovine retina is not phosphorylated, but in vitro phosphorylation for Cx35, the bass ortholog of Cx36, had been shown. To clarify this experimental discrepancy, we examined protein kinase A (PKA)-induced phosphorylation of Cx36 in mouse retina as a possible mechanism to modulate the extent of gap junctional coupling. The cytoplasmic domains of Cx36 and the total Cx36 protein were phosphorylated in vitro by PKA. Mass spectroscopy revealed that all four possible PKA consensus motifs were phosphorylated; however, domains point mutated at the sites in question showed a prevalent usage of Ser-110 and Ser-293. Additionally, we demonstrated that Cx36 was phosphorylated in cultured mouse retina. Furthermore, activation of PKA increased the level of phosphorylation of Cx36. cAMP-stimulated, PKA-mediated phosphorylation of Cx36 protein was accompanied by a decrease of tracer coupling between AII amacrine cells. Our results link increased phosphorylation of Cx36 to down-regulation of permeability through gap junction channels mediating light adaptation in the retina.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany; Carl von Ossietzky Univ Oldenburg, Inst Biol, D-2900 Oldenburg, Germany; RIKEN, Ctr Dev Biol, Lab Stem Cell Translat Res, Kobe, Hyogo 6500047, Japan; Int Grad Sch Neurosci, D-44780 Bochum, Germany; Ruhr Univ Bochum, Inst Neuroanat & Mol Brain Res, D-44780 Bochum, Germany	University of Bonn; Carl von Ossietzky Universitat Oldenburg; RIKEN; Ruhr University Bochum	Willecke, K (corresponding author), Univ Bonn, Inst Genet, Romer Str 164, D-53117 Bonn, Germany.	genetik@uni-bonn.de	Alev, Cantas/W-1493-2018	Alev, Cantas/0000-0002-4879-8782; Worsdorfer, Philipp/0000-0003-3398-3229				Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.3.CO;2-R; Bird GC, 2005, J PHYSIOL-LONDON, V564, P907, DOI 10.1113/jphysiol.2005.084780; BLITZER RD, 2005, SCI STKE, V280, pTR12; Bloomfield SA, 2004, VISION RES, V44, P3297, DOI 10.1016/j.visres.2004.07.012; Bloomfield SA, 1997, VISUAL NEUROSCI, V14, P565, DOI 10.1017/S0952523800012220; Bloomfield SA, 2001, PROG RETIN EYE RES, V20, P351, DOI 10.1016/S1350-9462(00)00031-8; Bortolotto ZA, 1998, NEUROPHARMACOLOGY, V37, P535, DOI 10.1016/S0028-3908(98)00058-6; Chung HJ, 2004, J NEUROSCI, V24, P10248, DOI 10.1523/JNEUROSCI.0546-04.2004; Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2; Feigenspan A, 2001, J NEUROSCI, V21, P230, DOI 10.1523/JNEUROSCI.21-01-00230.2001; Guldenagel M, 2001, J NEUROSCI, V21, P6036, DOI 10.1523/JNEUROSCI.21-16-06036.2001; HAMPSON ECGM, 1992, J NEUROSCI, V12, P4911; Han Y, 2005, P NATL ACAD SCI USA, V102, P13313, DOI 10.1073/pnas.0505067102; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; He SG, 2000, J COMP NEUROL, V418, P33, DOI 10.1002/(SICI)1096-9861(20000228)418:1<33::AID-CNE3>3.0.CO;2-J; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lin B, 2005, J NEUROSCI, V25, P6696, DOI 10.1523/JNEUROSCI.1894-05.2005; Maxeiner S, 2005, J NEUROSCI, V25, P566, DOI 10.1523/JNEUROSCI.3232-04.2005; Mills SL, 2001, J COMP NEUROL, V436, P336; MILLS SL, 1995, NATURE, V377, P734, DOI 10.1038/377734a0; O'Brien J, 2004, J NEUROSCI, V24, P5632, DOI 10.1523/JNEUROSCI.1248-04.2004; Ouyang XS, 2005, MOL BRAIN RES, V135, P1, DOI 10.1016/j.molbrainres.2004.10.045; Pang JJ, 2004, J PHYSIOL-LONDON, V558, P897, DOI 10.1113/jphysiol.2003.059543; Patel LS, 2006, CELL COMMUN ADHES, V13, P41, DOI 10.1080/15419060600631474; Sambrook J, 2001, MOL CLONING LAB MANU; Sitaramayya A, 2003, VISUAL NEUROSCI, V20, P385, DOI 10.1017/S0952523803204041; Sohl G, 2005, NAT REV NEUROSCI, V6, P191, DOI 10.1038/nrn1627; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; STRETTOI E, 1992, J COMP NEUROL, V325, P152, DOI 10.1002/cne.903250203; Teubner B, 2000, J MEMBRANE BIOL, V176, P249, DOI 10.1007/s002320001094; Veruki ML, 2002, J NEUROSCI, V22, P10558; Volgyi B, 2005, J COMP NEUROL, V492, P66, DOI 10.1002/cne.20700; Weiler R, 2000, BRAIN RES REV, V32, P121, DOI 10.1016/S0165-0173(99)00071-5; Witkovsky P, 2004, DOC OPHTHALMOL, V108, P17, DOI 10.1023/B:DOOP.0000019487.88486.0a; Xia XB, 2004, VISUAL NEUROSCI, V21, P791, DOI 10.1017/S0952523804215127; Zoidl G, 2002, J NEUROSCI RES, V69, P448, DOI 10.1002/jnr.10284	37	105	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33163	33171		10.1074/jbc.M606396200	http://dx.doi.org/10.1074/jbc.M606396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956882	hybrid			2022-12-25	WOS:000241621400024
J	Wojcik, M; Seidle, HF; Bieganowski, P; Brenner, C				Wojcik, Marzena; Seidle, Heather F.; Bieganowski, Pawel; Brenner, Charles			Glutamine-dependent NAD(+) synthetase - How a two-domain, three-substrate enzyme avoids waste	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDOTRANSFERASE DOMAIN; INTERMEDIATE; CATALYSIS	Glutamine-dependent NAD(+) synthetase, Qns1, utilizes a glutamine aminotransferase domain to supply ammonia for amidation of nicotinic acid adenine dinucleotide (NaAD(+)) to NAD(+). Earlier characterization of Qns1 suggested that glutamine consumption exceeds NAD(+) production by 40%. To explore whether Qns1 is systematically wasteful or whether additional features account for this behavior, we performed a careful kinetic and molecular genetic analysis. In fact, Qns1 possesses remarkable properties to reduce waste. The glutaminase active site is stimulated by NaAD(+) more than 50-fold such that glutamine is not appreciably consumed in the absence of NaAD(+). Glutamine consumption exceeds NAD(+) production over the whole range of glutamine and NaAD(+) substrate concentrations with greatest efficiency occurring at saturation of both substrates. Kinetic data coupled with site-directed mutagenesis of amino acids in the predicted ammonia channel indicate that NaAD(+) stimulates the glutaminase active site in the k(cat) term by a synergistic mechanism that does not require ammonia utilization by the NaAD(+) substrate. Six distinct classes of Qns1 mutants that fall within the glutaminase domain and the synthetase domain selectively inhibit components of the coordinated reaction.	Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Med Sch, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Polish Acad Sci, Ctr Mol & Macromol Studies, Dept Bioorgan Sci, PL-90363 Lodz, Poland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Polish Academy of Sciences; Centre of Molecular & Macromolecular Studies of the Polish Academy of Sciences; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Brenner, C (corresponding author), Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA.	charles.brenner@dartmouth.edu	Bieganowski, Pawel/ABC-8554-2021; Wojcik, Marzena/S-9411-2016; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226; wojcik, marzena/0000-0001-5563-8122	NATIONAL CANCER INSTITUTE [P01CA077738] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA077738-01A20003, P01 CA077738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bera AK, 2000, J BIOL CHEM, V275, P7975, DOI 10.1074/jbc.275.11.7975; Bieganowski P, 2003, J BIOL CHEM, V278, P33049, DOI 10.1074/jbc.M302257200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner C, 2002, CURR OPIN STRUC BIOL, V12, P775, DOI 10.1016/S0959-440X(02)00387-1; BRIDGER WA, 1968, BIOCHEMISTRY-US, V7, P3608, DOI 10.1021/bi00850a038; Cantoni R, 1998, J BACTERIOL, V180, P3218, DOI 10.1128/JB.180.12.3218-3221.1998; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Hans MA, 2003, BIOTECHNOL BIOENG, V82, P143, DOI 10.1002/bit.10553; Jauch R, 2005, J BIOL CHEM, V280, P15131, DOI 10.1074/jbc.M413195200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCELROY WD, 1967, SCIENCE, V157, P150, DOI 10.1126/science.157.3785.150; Miles BW, 1998, BIOCHEMISTRY-US, V37, P16773, DOI 10.1021/bi982018g; Pace HC, 2001, GENOME BIOL, V2; PREISS J, 1958, J BIOL CHEM, V233, P493; Raushel FM, 2003, ACCOUNTS CHEM RES, V36, P539, DOI 10.1021/ar020047k; Rizzi M, 1998, STRUCTURE, V6, P1129, DOI 10.1016/S0969-2126(98)00114-2; YU CK, 1972, J BIOL CHEM, V247, P4794; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	18	41	46	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33395	33402		10.1074/jbc.M607111200	http://dx.doi.org/10.1074/jbc.M607111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16954203	hybrid			2022-12-25	WOS:000241621400049
J	Gao, TY; Newton, AC				Gao, Tianyan; Newton, Alexandra C.			Invariant Leu preceding turn motif phosphorylation site controls the interaction of protein kinase C with Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; APOPTOSIS; AUTOPHOSPHORYLATION; DEPHOSPHORYLATION; DEGRADATION; DEPLETION; PATHWAYS; ISOTYPES	Heat shock proteins play important roles in regulating signal transduction in cells by associating with, and stabilizing, diverse signaling molecules, including protein kinases. Previously, we have shown that heat shock protein Hsp70 associates with protein kinase C (PKC) via an interaction that is triggered by dephosphorylation at the turn phosphorylation motif. Here we have identified an invariant residue in the carboxyl terminus of PKC that mediates the binding to Hsp70. Specifically, we show that Hsp70 binds to Leu (Leu-640) immediately preceding the conserved turn motif autophosphorylation site (Thr-641) in PKC beta II. Co-immunoprecipitation experiments reveal that mutation of Leu-640 to Gly decreases the interaction of Hsp70 with PKC beta II. This weakened interaction between Hsp70 and the mutant PKCs results in accumulation of dephosphorylated PKC in the detergent-insoluble fraction of cells. In addition, the Hsp70-binding mutant is considerably more sensitive to downregulation compared with WT PKC: disruption of Hsp70 binding leads to accelerated dephosphorylation and enhanced ubiquitination of mutant PKC upon phorbol ester treatment. Last, pulse-chase experiments demonstrate that Hsp70 preferentially binds the species of mature PKC that has become dephosphorylated compared with the newly synthesized protein that has yet to be phosphorylated. Thus, Hsp70 binds a hydrophobic residue preceding the turn motif, protecting PKC from down-regulation and sustaining the signaling lifetime of the kinase.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	anewton@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA 10209-03] Funding Source: Medline; NIDDK NIH HHS [P01 DK 54441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; CHIDA K, 1986, J BIOL CHEM, V261, P3013; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nollen EAA, 2002, J CELL SCI, V115, P2809; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200	26	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32461	32468		10.1074/jbc.M604076200	http://dx.doi.org/10.1074/jbc.M604076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954220	hybrid			2022-12-25	WOS:000241414500044
J	Efeyan, A; Collado, M; Velasco-Miguel, S; Serrano, M				Efeyan, A.; Collado, M.; Velasco-Miguel, S.; Serrano, M.			Genetic dissection of the role of p21(Cip1/Waf1) in p53-mediated tumour suppression	ONCOGENE			English	Article						p21; p53; cancer; cell cycle; apoptosis; tumour suppression	CYCLE ARREST; DNA-DAMAGE; P21; P53; INHIBITOR; CELLS; INACTIVATION; SENSITIVITY; DEFICIENCY; P21(WAF1)	Protein p21(Cip1/Waf1) is transcriptionally activated by the tumour suppressor p53 and previous studies have shown that p21 plays a role in tumour suppression. However, the involvement of p21 in p53-mediated tumour suppression remains to be directly demonstrated in vivo. Tumour suppression mediated by p53 can be measured by comparing tumour susceptibility in animals carrying two (wild-type mice) or three (super-p53 mice) copies of the p53 gene. We have taken advantage of this genetically defined system to measure p53-mediated cell-cycle arrest, apoptosis and tumorigenesis, in a p21 wild-type and in a p21-null context. The absence of p21 significantly impaired the enhanced p53-mediated cell-cycle arrest characteristic of super-p53 cells, but did not affect the enhanced apoptosis. Importantly, in an experimental model of fibrosarcoma induction, the absence of p21 significantly decreased the tumour suppression benefit of super-p53 mice. We conclude that cell-cycle arrest through p21 plays a significant role in mediating p53-dependent cancer protection.	Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Serrano, M (corresponding author), Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Collado, Manuel/K-8140-2014; Efeyan, Alejo/J-8197-2016; Serrano, Manuel/H-2634-2015	Collado, Manuel/0000-0002-0330-0880; Efeyan, Alejo/0000-0002-3806-6799; Serrano, Manuel/0000-0001-7177-9312				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Bearss DJ, 2002, CANCER RES, V62, P2077; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fotedar R, 2004, CELL CYCLE, V3, P134; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; HARPER JW, 1993, CELL, V75, P805; Jackson JF, 2002, MOLEC METH PLAN ANAL, V21, P1; Jackson RJ, 2003, CANCER RES, V63, P3021; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Martin J A, 2001, Iowa Orthop J, V21, P1; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Samuel T, 2002, CELL CYCLE, V1, P162, DOI 10.4161/cc.1.3.118; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg WC, 1999, CANCER RES, V59, P2050; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WC, 2001, CANCER RES, V61, P565	32	28	29	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1645	1649		10.1038/sj.onc.1209972	http://dx.doi.org/10.1038/sj.onc.1209972			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964282				2022-12-25	WOS:000244782500014
J	Streicher, KL; Yang, ZQ; Draghici, S; Ethier, SP				Streicher, K. L.; Yang, Z. Q.; Draghici, S.; Ethier, S. P.			Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon	ONCOGENE			English	Article						LSM1; breast cancer; chromosome 8p11-12	MESSENGER-RNA DEGRADATION; ANTISENSE GENE-THERAPY; SM-LIKE PROTEIN; ONTO-TOOLS; CELL-LINES; PANCREATIC-CANCER; EPITHELIAL-CELLS; EXPRESSION; CASM; CONTRIBUTES	Amplification of the 8p11 - 12 region occurs in 15 - 20% of breast cancers, but the driving oncogene at this locus has yet to be definitively identified. We mapped the 8p11 - 12 amplicon in breast cancer cell lines and primary human breast cancers and identified the candidate oncogene human Sm-like protein (hLsm1, LSM1) based on increases in copy number and expression level relative to human mammary epithelial cells. To examine the oncogenic role of LSM1, we overexpressed this gene in MCF10A mammary epithelial cells and inhibited its production in the SUM44 breast cancer cell line, which has a natural amplification and overexpression of LSM1. Our data confirmed that LSM1 is an oncogene from the 8p11 - 12 amplicon by showing that hLsm1 overexpression induced growth factor-independent proliferation and soft agar colony formation in MCF10A cells, and hLsm1 inhibition in SUM44 cells dramatically reduced soft agar growth. Little is known about hLsm1 function other than its involvement in mRNA degradation; therefore, we used expression microarray analysis to investigate how hLsm1 affects cell transformation in MCF10A and SUM44 cells. We identified numerous genes altered following hLsm1 overexpression common to SUM44 breast cancer cells that play important roles in cell cycle regulation, cell proliferation and other cancer-promoting processes. Future work will continue to characterize these important changes to achieve a more complete understanding of the mechanism of hLsm1's effect on cancer progression.	Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA; Karmanos Canc Inst, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Streicher, KL (corresponding author), Karmanos Canc Inst, Breast Canc Program, 4100 John R St,815 HWCRC, Detroit, MI 48201 USA.	streiche@karmanos.org	Draghici, Sorin/B-3074-2013	Draghici, Sorin/0000-0002-0786-8377	NATIONAL CANCER INSTITUTE [P30CA022453, R21CA100740, R01CA100724] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017857] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045207] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100724-01, R01 CA100724, P30 CA022453, P30 CA022453-25, R21 CA100740, R21 CA10074001, R21 CA100740-01] Funding Source: Medline; NCRR NIH HHS [1S10 RR01785701, S10 RR017857-01, S10 RR017857] Funding Source: Medline; NHGRI NIH HHS [R01 HG003491-01A1, R01 HG003491] Funding Source: Medline; NIBIB NIH HHS [R21 EB000990-01, R21 EB000990, 1R21 EB0099001] Funding Source: Medline; NINDS NIH HHS [R01 NS045207-01, 1R01NS04520701, R01 NS045207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Draghici S., 2003, DATA ANAL TOOLS DNA; ETHIER SP, 1991, BREAST CANCER RES TR, V18, P73, DOI 10.1007/BF01980969; ETHIER SP, 1991, BREAST CANCER RES TR, V17, P221, DOI 10.1007/BF01806371; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Fraser MM, 2005, CANCER RES, V65, P6228, DOI 10.1158/0008-5472.CAN-05-0650; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; Ignatoski KMW, 2005, NEOPLASIA, V7, P788, DOI 10.1593/neo.05106; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Kelley JR, 2003, ANTICANCER RES, V23, P2007; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Khatri P, 2005, NUCLEIC ACIDS RES, V33, pW762, DOI 10.1093/nar/gki472; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Schweinfest CW, 1997, CANCER RES, V57, P2961; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Yan Y, 2006, MOL THER, V13, P357, DOI 10.1016/j.ymthe.2005.06.485; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013; Zaric B, 2005, J BIOL CHEM, V280, P16066, DOI 10.1074/jbc.M414481200	30	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2104	2114		10.1038/sj.onc.1210002	http://dx.doi.org/10.1038/sj.onc.1210002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001308	Green Accepted			2022-12-25	WOS:000245313400012
J	Grenha, R; Rzechorzek, NJ; Brannigan, JA; de Jong, RN; Ab, E; Diercks, T; Truffault, V; Ladds, JC; Fogg, MJ; Bongiorni, C; Perego, M; Kaptein, R; Wilson, KS; Folkers, GE; Wilkinson, AJ				Grenha, Rosa; Rzechorzek, Neil J.; Brannigan, James A.; de Jong, Rob N.; Ab, Eiso; Diercks, Tammo; Truffault, Vincent; Ladds, Joanne C.; Fogg, Mark J.; Bongiorni, Cristina; Perego, Marta; Kaptein, Robert; Wilson, Keith S.; Folkers, Gert E.; Wilkinson, Anthony J.			Structural characterization of Spo0E-like protein-aspartic acid phosphatases that regulate sporulation in bacilli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SPO0A; TORSION ANGLE DYNAMICS; RESPONSE REGULATOR; MOLECULAR RECOGNITION; SUBTILIS SPORULATION; HISTIDINE KINASES; ESCHERICHIA-COLI; PHOSPHORELAY; ASSIGNMENT; MECHANISM	Spore formation is an extreme response of many bacterial species to starvation. In the case of pathogenic species of Bacillus and Clostridium, it is also a component of disease transmission. Entry into the pathway of sporulation in Bacillus subtilis and its relatives is controlled by an expanded two-component system in which starvation signals lead to the activation of sensor kinases and phosphorylation of the master sporulation response regulator Spo0A. Accumulation of threshold concentrations of Spo0A similar to P heralds the commitment to sporulation. Countering the activities of the sensor kinases are phosphatases such as Spo0E, which dephosphorylate Spo0A similar to P and inhibit sporulation. Spo0E-like protein-aspartic acid-phosphate phosphatases, consisting of 50-90 residues, are conserved in sporeforming bacteria and unrelated in sequence to proteins of known structure. Here we determined the structures of the Spo0A similar to P phosphatases BA1655 and BA5174 from Bacillus anthracis using nuclear magnetic resonance spectroscopy. Each is composed of two anti-parallel alpha-helices flanked by flexible regions at the termini. The signature SQELD motif (SRDLD in BA1655) is situated in the middle of helix alpha 2 with its polar residues projecting outward. BA5174 is a monomer, whereas BA1655 is a dimer. The four-helix bundle structure in the dimer is reminiscent of the phosphotransferase Spo0B and the chemotaxis phosphatase CheZ, although in contrast to these systems, the subunits in BA1655 are in head-to-tail rather than head-to-head apposition. The implications of the structures for interactions between the phosphatases and their substrate Spo0A similar to P are discussed.	Univ Utrecht, Bijvoet Ctr, NMR Dept, NL-3584 CH Utrecht, Netherlands; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Scripps Res Inst, Div Cellular Biol, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Utrecht University; University of York - UK; Scripps Research Institute	Folkers, GE (corresponding author), Univ Utrecht, Bijvoet Ctr, NMR Dept, NL-3584 CH Utrecht, Netherlands.	g.folkers@chem.uu.nl	Diercks, Tammo/G-1167-2011; Folkers, Gert E/C-2863-2009; Diercks, Tammo/AAT-3731-2021; AB, Eiso/H-8177-2012	Diercks, Tammo/0000-0002-5200-0905; Folkers, Gert E/0000-0003-1070-0505; Diercks, Tammo/0000-0002-5200-0905; Rzechorzek, Neil/0000-0003-2068-1424; Wilkinson, Anthony/0000-0003-4577-9479; AB, Eiso/0000-0002-5758-0435; Wilson, Keith/0000-0002-3581-2194; de Jong, Rob N./0000-0002-9300-6633; Fogg, Mark/0000-0002-6692-122X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055594] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52289] Funding Source: Medline; NIGMS NIH HHS [GM55594] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; BRUNGER AT, 1997, CRYSTALLOGRAPHY NMR; Brunsing RL, 2005, J BACTERIOL, V187, P6972, DOI 10.1128/JB.187.20.6972-6981.2005; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Diercks T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535; FERRARI E, 1986, J BACTERIOL, V166, P173, DOI 10.1128/JB.166.1.173-179.1986; Folkers G. E., 2004, Journal of Structural and Functional Genomics, V5, P119, DOI 10.1023/B:JSFG.0000029200.66197.0c; Goddard T. D., 2006, SPARKY 3; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jiang M, 2000, MOL MICROBIOL, V38, P535, DOI 10.1046/j.1365-2958.2000.02148.x; KOBAYASHI K, 1995, J BACTERIOL, V177, P176, DOI 10.1128/jb.177.1.176-182.1995; KOEHLER TM, 1994, J BACTERIOL, V176, P586, DOI 10.1128/jb.176.3.586-595.1994; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDEAUX JR, 1995, J BACTERIOL, V177, P166, DOI 10.1128/jb.177.1.166-175.1995; Lee SY, 2001, NAT STRUCT BIOL, V8, P52; Leutner M, 1998, J BIOMOL NMR, V11, P31, DOI 10.1023/A:1008298226961; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Lewis RJ, 2002, J MOL BIOL, V316, P235, DOI 10.1006/jmbi.2001.5331; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Madhusudan, 1996, STRUCTURE, V4, P679, DOI 10.1016/S0969-2126(96)00074-3; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Muchova K, 2004, MOL MICROBIOL, V53, P829, DOI 10.1111/j.1365-2958.2004.04171.x; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; Park SY, 2004, MOL CELL, V16, P563, DOI 10.1016/j.molcel.2004.10.018; Perego M, 1997, P NATL ACAD SCI USA, V94, P8612, DOI 10.1073/pnas.94.16.8612; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perego M, 2001, PEPTIDES, V22, P1541, DOI 10.1016/S0196-9781(01)00490-9; Perego M, 2001, MOL MICROBIOL, V42, P133, DOI 10.1046/j.1365-2958.2001.02611.x; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; Piggot PJ, 2004, CURR OPIN MICROBIOL, V7, P579, DOI 10.1016/j.mib.2004.10.001; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Poyart C, 1997, FEMS MICROBIOL LETT, V156, P193, DOI 10.1016/S0378-1097(97)00423-0; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; Stephenson K, 2002, MOL MICROBIOL, V46, P297, DOI 10.1046/j.1365-2958.2002.03186.x; Stephenson SJ, 2002, MOL MICROBIOL, V44, P1455, DOI 10.1046/j.1365-2958.2002.02974.x; Varughese KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Whitehead B, 1997, J BIOMOL NMR, V9, P313, DOI 10.1023/A:1018687127330; Zapf J, 2000, STRUCTURE, V8, P851, DOI 10.1016/S0969-2126(00)00174-X; Zapf JW, 1996, BIOCHEMISTRY-US, V35, P2926, DOI 10.1021/bi9519361; Zhao R, 2002, NAT STRUCT BIOL, V9, P570; Zimmerman DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/jmbi.1997.1052	53	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37993	38003		10.1074/jbc.M607617200	http://dx.doi.org/10.1074/jbc.M607617200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17001075	hybrid, Green Published			2022-12-25	WOS:000242477100078
J	Huff, LM; Lee, JS; Robey, RW; Fojo, T				Huff, Lyn M.; Lee, Jong-Seok; Robey, Robert W.; Fojo, Tito			Characterization of gene rearrangements leading to activation of MDR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DISTANT UPSTREAM PROMOTER; MULTIDRUG-RESISTANCE; CELL-LINE; THERAPEUTIC STRATEGIES; TOPOISOMERASE-II; P-GLYCOPROTEIN; DNA BREAKS; REPAIR; TRANSCRIPTION	Expression of the MDR-1/P-glycoprotein gene confers drug resistance both in vitro and in vivo. We previously reported that gene rearrangements resulting in a hybrid MDR-1 transcript represent a common mechanism for acquired activation of MDR-1/P-glycoprotein. We have identified hybrid MDR-1 transcripts in nine MDR-1- overexpressing cell lines and two patients with relapsed ALL. We characterize these rearrangements as follows. 1) Non-MDR-1 sequences in the hybrid MDR-1 transcripts are expressed in unselected cell lines, showing that these sequences are constitutively expressed. 2) The rearrangements occur randomly and involve partner genes (sequences) on chromosome 7 and on chromosomes other than 7. Breakpoints have been characterized in six cell lines. In one, the rearrangement occurred within intron 2 of MDR-1; in the other five, the rearrangement occurred 24 to > 96 kb 5' of the normal start of transcription of MDR-1. In one cell line, homologous recombination involving an Alu repeat was observed. However, in the remaining five cell lines, nonhomologous recombination was observed. 3) The rearrangements arise during drug selection. The acquired rearrangements are not detected in parental cells. 4) Five of the six active promoters that captured MDR-1 controlled MDR-1 from a distance of 29 to more than 110 kb 5' to MDR-1. Transcription was initiated in an antegrade or retrograde direction. We conclude that drug selection with natural products targeting DNA or microtubules leads to DNA damage, nonhomologous recombination, and acquired drug resistance, wherein MDR-1 expression is driven by a random but constitutively active promoter.	NCI, NIH, Canc Res Ctr, Med Oncol Branch, Bethesda, MD 20892 USA; Seoul Natl Univ, Bandung Hosp, Seoul 151742, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Fojo, T (corresponding author), NCI, NIH, Canc Res Ctr, Med Oncol Branch, Bldg 10,Rm 12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.	tfojo@helix.nih.gov		Robey, Rob/0000-0002-0857-3650	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC006732, Z01SC006732] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955; Barnes DJ, 2002, ACTA HAEMATOL-BASEL, V108, P180, DOI 10.1159/000065655; Binaschi M, 1997, MOL PHARMACOL, V51, P1053, DOI 10.1124/mol.51.6.1053; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133; COHEN D, 1992, J BIOL CHEM, V267, P20248; DALTON WS, 1986, CANCER RES, V46, P5125; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Eastman A, 2004, J CELL BIOCHEM, V91, P223, DOI 10.1002/jcb.10699; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Froelich JJ, 1999, CLIN CHEM LAB MED, V37, P403, DOI 10.1515/CCLM.1999.066; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Harada Taishi, 2000, International Journal of Cancer, V86, P506, DOI 10.1002/(SICI)1097-0215(20000515)86:4<506::AID-IJC10>3.0.CO;2-8; Huff LM, 2005, CANCER RES, V65, P11694; Jones I, 2003, THYROID, V13, P1057, DOI 10.1089/105072503770867228; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kotchetkov R, 2003, INT J CANCER, V104, P36, DOI 10.1002/ijc.10917; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Kuwano M, 2004, MOL CANCER THER, V3, P1485; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Li ZY, 2005, LEUKEMIA, V19, P183, DOI 10.1038/sj.leu.2403602; Mahadevan D, 2004, BLOOD, V104, P1940, DOI 10.1182/blood-2003-07-2490; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362; Mickley LA, 1998, BLOOD, V91, P1749, DOI 10.1182/blood.V91.5.1749.1749_1749_1756; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; PASQUALUCCI L, 2004, LEUKEMIA LYMPHOMA S3, V44, P5; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Rao VK, 2005, MUTAT RES-GEN TOX EN, V583, P105, DOI 10.1016/j.mrgentox.2005.01.013; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; ROTHENBERG ML, 1989, BLOOD, V74, P1388; SAMBROOK J, 1989, MOL CLONING LAB MANU, P931; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; SIEBER SM, 1978, TERATOLOGY, V18, P31, DOI 10.1002/tera.1420180107; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Tada Y, 2000, CLIN CANCER RES, V6, P4618; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; UEDA K, 1987, J BIOL CHEM, V262, P17432; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vossebeld PJM, 1999, BLOOD REV, V13, P67, DOI 10.1016/S0268-960X(99)90013-9; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; WHANGPENG J, 1984, RISK FACTORS MULTIPL, P45; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	57	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36501	36509		10.1074/jbc.M602998200	http://dx.doi.org/10.1074/jbc.M602998200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16956878	hybrid			2022-12-25	WOS:000242220800005
J	Anand, VS; Patel, SS				Anand, Vasanti Subramanian; Patel, Smita S.			Transient state kinetics of transcription elongation by T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CONFORMATIONAL-CHANGES; NTP-DRIVEN TRANSLOCATION; DNA BUBBLE DUPLEXES; STRUCTURAL BASIS; NUCLEOTIDE INCORPORATION; KLENOW FRAGMENT; REVERSE-TRANSCRIPTASE; PROMOTER CLEARANCE; MECHANISM; INITIATION	The single subunit DNA-dependent RNA polymerase ( RNAP) from bacteriophage T7 catalyzes both promoter-dependent transcription initiation and promoter-independent elongation. Using a promoter-free substrate, we have dissected the kinetic pathway of single nucleotide incorporation during elongation. We show that T7 RNAP undergoes a slow conformational change (0.01-0.03 s(-1)) to form an elongation competent complex with the promoter-free substrate ( dissociation constant (K-d) of 96 nM). The complex binds to a correct NTP ( Kd of 80 mu M) and incorporates the nucleoside monophosphate (NMP) into RNA primer very efficiently ( 220 s(-1) at 25 degrees C). An overall free energy change (-5.5 kcal/mol) and internal free energy change (-3.7 kcal/mol) of single NMP incorporation was calculated from the measured equilibrium constants. In the presence of inorganic pyrophosphate (PPi), the elongation complex catalyzes the reverse pyrophosphorolysis reaction at a maximum rate of 0.8 s(-1) with PPi K-d of 1.2 mM. Several experiments were designed to investigate the rate-limiting step in the pathway of single nucleotide addition. Acid-quench and pulse-chase kinetics indicated that an isomerization step before chemistry is rate-limiting. The very similar rate constants of sequential incorporation of two nucleotides indicated that the steps after chemistry are fast. Based on available data, we propose that the preinsertion to insertion isomerization of NTP observed in the crystallographic studies of T7 RNAP is a likely candidate for the rate-limiting step. The studies here provide a kinetic framework to investigate structure-function and fidelity of RNA synthesis and to further explore the role of the conformational change in nucleotide selection during RNA synthesis.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NIGMS NIH HHS [GM51966, R37 GM051966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051966, R37GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5126, DOI 10.1021/bi035212y; Bandwar RP, 2006, J MOL BIOL, V360, P466, DOI 10.1016/j.jmb.2006.05.029; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; Burton ZF, 2005, BIOCHEM CELL BIOL, V83, P486, DOI 10.1139/O05-059; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; Datta K, 2006, J MOL BIOL, V360, P800, DOI 10.1016/j.jmb.2006.05.053; DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Guillerez J, 2005, P NATL ACAD SCI USA, V102, P5958, DOI 10.1073/pnas.0407141102; Guo Q, 2006, J MOL BIOL, V358, P241, DOI 10.1016/j.jmb.2006.02.001; Guo Q, 2005, J MOL BIOL, V353, P256, DOI 10.1016/j.jmb.2005.08.016; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; KUCHTA RD, 1988, BIOCHEM SOC T, V16, P947, DOI 10.1042/bst0160947; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ma KY, 2005, P NATL ACAD SCI USA, V102, P17612, DOI 10.1073/pnas.0508865102; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Pandey M, 2004, J BIOL CHEM, V279, P47840, DOI 10.1074/jbc.M406019200; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Steitz TA, 2004, CURR OPIN STRUC BIOL, V14, P4, DOI 10.1016/j.sbi.2004.01.006; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Temiakov D, 2002, J BIOL CHEM, V277, P47035, DOI 10.1074/jbc.M208923200; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	41	53	61	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35677	35685		10.1074/jbc.M608180200	http://dx.doi.org/10.1074/jbc.M608180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005565	hybrid			2022-12-25	WOS:000242100500012
J	Ledin, J; Ringvall, M; Thuveson, M; Eriksson, I; Wilen, M; Kusche-Gullberg, M; Forsberg, E; Kjellen, L				Ledin, Johan; Ringvall, Maria; Thuveson, Maria; Eriksson, Inger; Wilen, Maria; Kusche-Gullberg, Marion; Forsberg, Erik; Kjellen, Lena			Enzymatically active N-deacetylase/N-sulfotransferase-2 is present in liver but does not contribute to heparan sulfate N-sulfation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE/N-SULFOTRANSFERASE ISOZYMES; FIBROBLAST GROWTH-FACTOR; NEONATAL LETHALITY; TUMOR SUPPRESSORS; LIGAND-BINDING; IDURONIC ACID; MOUSE; BIOSYNTHESIS; CELLS; MICE	Heparan sulfate (HS) proteoglycans influence embryonic development through interactions with growth factors and morphogens. The interactions depend on HS structure, which is largely determined during biosynthesis by Golgi enzymes. NDST ( glucosaminyl N-deacetylase/N-sulfotransferase), responsible for HSN-sulfation, is a key enzyme directing further modifications including O-sulfation. To elucidate the roles of the different NDST isoforms in HS biosynthesis, we took advantage of mice with targeted mutations in NDST1 and NDST2 and used liver as our model organ. Of the four NDST isoforms, only NDST1 and NDST2 transcripts were shown to be expressed in control liver. The absence of NDST1 or NDST2 in the knock-out mice did not affect transcript levels of other NDST isoforms or other HS modification enzymes. Although the sulfation level of HS synthesized in NDST1(-/-) mice was drastically lowered, liver HS from wild-type mice, from NDST1(-/-), NDST2(-/-), and NDST1(-/-), NDST2(-/-) mice all had the same structure despite greatly reduced NDST enzyme activity (30% of control levels in NDST1(-/-) NDST2(-/-) embryonic day 18.5 embryos). Enzymatically active NDST2 was shown to be present in similar amounts in wild-type, NDST1(-/-), and NDST1(-/-) embryonic day 18.5 liver. Despite the substantial contribution of NDST2 to total NDST enzyme activity in embryonic day 18.5 liver (approximate to 40%), its presence did not appear to affect HS structure as long as NDST1 was also present. In NDST1(-/-) embryonic day 18.5 liver, in contrast, NDST2 was responsible for N-sulfation of the low sulfated HS. A tentative model to explain these results is presented.	Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, SE-75123 Uppsala, Sweden	Uppsala University	Kjellen, L (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden.	lena.kjellen@imbim.uu.se	Kjellen, Lena/F-1362-2011; Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695; Ledin, Johan/0000-0002-7319-7735				Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Grobe K, 2005, DEVELOPMENT, V132, P3777, DOI 10.1242/dev.01935; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Grobe K, 2002, J BIOL CHEM, V277, P30699, DOI 10.1074/jbc.M111904200; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Holmborn K, 2004, J BIOL CHEM, V279, P42355, DOI 10.1074/jbc.C400373200; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; KATO M, 1994, J BIOL CHEM, V269, P18881; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; van den Born J, 2003, GLYCOBIOLOGY, V13, P1, DOI 10.1093/glycob/cwg011; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; Zako M, 2003, J BIOL CHEM, V278, P13561, DOI 10.1074/jbc.M209658200	38	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35727	35734		10.1074/jbc.M604113200	http://dx.doi.org/10.1074/jbc.M604113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16984905	hybrid			2022-12-25	WOS:000242100500017
J	Sikora, B; Eoff, RL; Matson, SW; Raney, KD				Sikora, Bartek; Eoff, Robert L.; Matson, Steven W.; Raney, Kevin D.			DNA unwinding by Escherichia coli DNA helicase I (Tral) provides evidence for a processive monomeric molecular motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T4 DDA HELICASE; STEP-SIZE; RECBCD ENZYME; TURNOVER KINETICS; MECHANISM; PROTEIN; TRANSLOCATION; REVEALS; MACHINES	The F plasmid TraI protein ( DNA helicase I) plays an essential role in conjugative DNA transfer as both a transesterase and a helicase. Previous work has shown that the 192-kDa TraI protein is a highly processive helicase, catalytically separating > 850 bp under steady-state conditions. In this report, we examine the kinetic mechanism describing DNA unwinding of TraI. The kinetic step size of TraI was measured under both single turnover and pre-steady-state conditions. The resulting kinetic stepsize estimate was similar to 6-8 bp step(-1). TraI can separate double-stranded DNA at a rate of similar to 1100 bp s(-1), similar to the measured unwinding rate of the RecBCD helicase, and appears to dissociate very slowly from the 3' terminus following translocation and strand-separation events. Analyses of pre-steady-state burst amplitudes indicate that TraI can function as a monomer, similar to the bacteriophage T4 helicase, Dda. However, unlike Dda, TraI is a highly processive monomeric helicase, making it unique among the DNA helicases characterized thus far.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ N Carolina, Dept Biol, Curriculum Genet & Mol Biol, Program Mol & Cellular BIophys, Chapel Hill, NC 27599 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; University of North Carolina Chapel Hill	Raney, KD (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	raneykevind@uams.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059400, R01GM061020] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM61020, R01 GM059400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1977, J MOL BIOL, V110, P667, DOI 10.1016/S0022-2836(77)80083-1; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Byrd AK, 2005, BIOCHEMISTRY-US, V44, P12990, DOI 10.1021/bi050703z; Byrd AK, 2004, NAT STRUCT MOL BIOL, V11, P531, DOI 10.1038/nsmb774; Byrd DR, 2002, J BIOL CHEM, V277, P42645, DOI 10.1074/jbc.M205984200; Csitkovits VC, 2003, J BIOL CHEM, V278, P48696, DOI 10.1074/jbc.M310025200; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; Eoff RL, 2006, NAT STRUCT MOL BIOL, V13, P242, DOI 10.1038/nsmb1055; Galletto R, 2004, J MOL BIOL, V343, P83, DOI 10.1016/j.jmb.2004.07.055; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Lisal J, 2005, J BIOL CHEM, V280, P23157, DOI 10.1074/jbc.M502658200; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; Lucius AL, 2002, J MOL BIOL, V324, P409, DOI 10.1016/S0022-2836(02)01067-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Matson SW, 2005, J BACTERIOL, V187, P697, DOI 10.1128/JB.187.2.697-706.2005; Matson SW, 2001, J BIOL CHEM, V276, P2372, DOI 10.1074/jbc.M008728200; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2004, NAT STRUCT MOL BIOL, V11, P494, DOI 10.1038/nsmb0604-494; WILLIAMS MMR, 1979, ANN NUCL ENERGY, V6, P145, DOI 10.1016/0306-4549(79)90082-3	34	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36110	36116		10.1074/jbc.M604412200	http://dx.doi.org/10.1074/jbc.M604412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16984922	hybrid, Green Published			2022-12-25	WOS:000242100500060
J	Amer, A; Franchi, L; Kanneganti, TD; Body-Malapel, M; Ozoren, N; Brady, G; Meshinchi, S; Jagirdar, R; Gewirtz, A; Akira, S; Nunez, G				Amer, Amal; Franchi, Luigi; Kanneganti, Thirumala-Devi; Body-Malapel, Mathilde; Ozoren, Nesrin; Brady, Graham; Meshinchi, Sasha; Jagirdar, Rajesh; Gewirtz, Andrew; Akira, Shizuo; Nunez, Gabriel			Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; LEGIONNAIRES-DISEASE; PNEUMOPHILA INFECTION; HUMAN-MONOCYTES; A/J MICE; INTERLEUKIN-1-BETA; CASPASE-1; BACTERIUM; GENE; SUSCEPTIBILITY	Legionella pneumophila is an intracellular bacterium that causes an acute form of pneumonia called Legionnaires' disease. After infection of human macrophages, the Legionella-containing phagosome (LCP) avoids fusion with the lysosome allowing intracellular replication of the bacterium. In macrophages derived from most mouse strains, the LCP is delivered to the lysosome resulting in Legionella degradation and restricted bacterial growth. Mouse macrophages lacking the NLR protein Ipaf or its downstream effector caspase-1 are permissive to intracellular Legionella replication. However, the mechanism by which Ipaf restricts Legionella replication is not well understood. Here we demonstrate that the presence of flagellin and a competent type IV secretion system are critical for Legionella to activate caspase-1 in macrophages. Activation of caspase-1 in response to Legionella infection also required host Ipaf, but not TLR5. In the absence of Ipaf or caspase-1 activation, the LCP acquired endoplasmic reticulum-derived vesicles, avoided fusion with the lysosome, and allowed Legionella replication. Accordingly a Legionella mutant lacking flagellin did not activate caspase-1, avoided degradation, and replicated in wild-type macrophages. The regulation of phagosome maturation by Ipaf occurred within 2 h after infection and was independent of macrophage cell death. In vivo studies confirmed that flagellin and Ipaf play an important role in the control of Legionella clearance. These results reveal that Ipaf restricts Legionella replication through the regulation of phagosome maturation, providing a novel function for NLR proteins in host defense against an intracellular bacterium.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Unit, Atlanta, GA 30322 USA; Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Emory University; Osaka University	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4215 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bclx@umich.edu	Jagirdar, Rajesh/AAO-2327-2021; Ozoren, Nesrin/AAS-3279-2020; Body-Malapel, Mathilde/K-9981-2018; Akira, Shizuo/C-3134-2009; Kanneganti, Thirumala-Devi/M-9435-2018; Nuñez, Gabriel/A-7160-2014; Kanneganti, Thirumala-Devi/Y-2503-2019; Amer, Amal/E-2643-2011	Jagirdar, Rajesh/0000-0001-7005-7772; Body-Malapel, Mathilde/0000-0003-3392-4229; Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Kanneganti, Thirumala-Devi/0000-0002-6395-6443; OZOREN, NESRIN/0000-0002-8580-618X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063331, R56AI063331, R37AI063331, R01AI064748] Funding Source: NIH RePORTER; NHLBI NIH HHS [5/T32/HL007517] Funding Source: Medline; NIAID NIH HHS [AI063331, AI064748] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amer AO, 2005, CELL MICROBIOL, V7, P765, DOI 10.1111/j.1462-5822.2005.00509.x; BERGER KH, 1994, MOL MICROBIOL, V14, P809, DOI 10.1111/j.1365-2958.1994.tb01317.x; BRIELAND J, 1994, AM J PATHOL, V145, P1537; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Coers J, 2000, MOL MICROBIOL, V38, P719, DOI 10.1046/j.1365-2958.2000.02176.x; DIETRICH WF, 1995, GENOMICS, V26, P443, DOI 10.1016/0888-7543(95)80161-E; Diez E, 2003, NAT GENET, V33, P55, DOI 10.1038/ng1065; Fortier A, 2005, TRENDS MICROBIOL, V13, P328, DOI 10.1016/j.tim.2005.05.007; Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346; Gerhardt H, 2000, FEMS MICROBIOL LETT, V192, P145, DOI 10.1111/j.1574-6968.2000.tb09373.x; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1983, J EXP MED, V158, P2108, DOI 10.1084/jem.158.6.2108; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Kagan JC, 2004, J EXP MED, V199, P1201, DOI 10.1084/jem.20031706; Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; MCDADE JE, 1977, NEW ENGL J MED, V297, P1197, DOI 10.1056/NEJM197712012972202; Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344; Molofsky AB, 2005, INFECT IMMUN, V73, P5720, DOI 10.1128/IAI.73.9.5720-5734.2005; Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Ren T, 2006, PLOS PATHOG, V2, P175, DOI 10.1371/journal.ppat.0020018; Sturgill-Koszycki S, 2000, J EXP MED, V192, P1261, DOI 10.1084/jem.192.9.1261; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tilney LG, 2001, J CELL SCI, V114, P4637; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498; Wright EK, 2003, CURR BIOL, V13, P27, DOI 10.1016/S0960-9822(02)01359-3; YAMAMOTO Y, 1988, INFECT IMMUN, V56, P370, DOI 10.1128/IAI.56.2.370-375.1988; Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305	37	369	378	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35217	35223		10.1074/jbc.M604933200	http://dx.doi.org/10.1074/jbc.M604933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984919	hybrid			2022-12-25	WOS:000241933700055
J	Meley, D; Bauvy, C; Houben-Weerts, JHPM; Dubbelhuis, PF; Helmond, MTJ; Codogno, P; Meijer, AJ				Meley, Daniel; Bauvy, Chantal; Houben-Weerts, Judith H. P. M.; Dubbelhuis, Peter F.; Helmond, Mariette T. J.; Codogno, Patrice; Meijer, Alfred J.			AMP-activated protein kinase and the regulation of autophagic proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE; SKELETAL-MUSCLE; LIPID KINASE; HT-29 CELLS; S6 KINASE; IN-VITRO; INHIBITION; PHOSPHORYLATION; METFORMIN	Interruption of mTOR-dependent signaling by rapamycin is known to stimulate autophagy, both in mammalian cells and in yeast. Because activation of AMPK also inhibits mTOR-dependent signaling one would expect stimulation of autophagy by AMPK activation. According to the literature, this is true for yeast but, unexpectedly, not for mammalian cells on the basis of the use of AICAR, a pharmacological activator of AMPK. In the present study, carried out with hepatocytes, HT-29 cells, and HeLa cells, we have reexamined the possible role of AMPK in the control of mammalian autophagy. Inhibition of AMPK activity by compound C or by transfection with a dominant negative form of AMPK almost completely inhibited autophagy. These results suggest that the inhibition of autophagy by AICAR is not related to its ability to activate AMPK. We conclude that in mammalian cells, as in yeast, AMPK is required for autophagy.	Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands; Univ Paris 11, Fac Pharm, INSERM U756, F-92296 Chatenay Malabry, France	University of Amsterdam; Academic Medical Center Amsterdam; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Meijer, AJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	a.j.meijer@amc.uva.nl		Meley, Daniel/0000-0002-0708-2139				Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Fryer LGD, 2002, FEBS LETT, V531, P189, DOI 10.1016/S0014-5793(02)03501-9; Guigas B, 2006, DIABETES, V55, P865, DOI 10.2337/diabetes.55.04.06.db05-1178; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; HOYVIK H, 1986, EXP CELL RES, V166, P1, DOI 10.1016/0014-4827(86)90503-3; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jhun BS, 2004, BIOCHEM BIOPH RES CO, V318, P372, DOI 10.1016/j.bbrc.2004.04.035; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Leverve XM, 2003, DIABETES METAB, V29, pS88; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Luiken JJFP, 1996, EUR J BIOCHEM, V235, P564; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; Meijer AJ, 2004, BIOCHEM BIOPH RES CO, V313, P397, DOI 10.1016/j.bbrc.2003.07.012; Moller MTN, 2004, TOXICOL SCI, V82, P628, DOI 10.1093/toxsci/kfh273; MOLLER TN, 2004, AUTOPHAGY, P48; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Munafo DB, 2001, J CELL SCI, V114, P3619; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; PLOMP PJAM, 1989, J BIOL CHEM, V264, P6699; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Samari HR, 1998, J BIOL CHEM, V273, P23758, DOI 10.1074/jbc.273.37.23758; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; VINCENT MF, 1992, BIOCHEM J, V281, P267, DOI 10.1042/bj2810267; Vincent MF, 1996, BIOCHEM PHARMACOL, V52, P999, DOI 10.1016/0006-2952(96)00413-3; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001; Williamson J R, 1979, Methods Enzymol, V55, P200; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Wu GY, 1996, BIOL REPROD, V54, P1261, DOI 10.1093/biolreprod/54.6.1261; Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	50	376	389	3	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34870	34879		10.1074/jbc.M605488200	http://dx.doi.org/10.1074/jbc.M605488200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990266	hybrid			2022-12-25	WOS:000241933700019
J	Moses, DN; Harreld, JH; Stucky, GD; Waite, JH				Moses, Dana N.; Harreld, John H.; Stucky, Galen D.; Waite, J. Herbert			Melanin and glycera jaws - Emerging dark side of a robust biocomposite structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CHARACTERIZATION; SEPIA MELANIN; 5,6-DIHYDROXYINDOLE-2-CARBOXYLIC ACID; OXIDATIVE-DEGRADATION; MASS-SPECTROMETRY; INSECT CUTICLE; PYRROLE ACIDS; ION-EXCHANGE; COPPER; EUMELANIN	Defining the design principles guiding the fabrication of superior biocomposite structures from an assemblage of ordinary molecules is a key goal of biomimetics. Considering their low degree of mineralization, Glycera jaws have been shown to be extraordinarily resistant to abrasion based on the metric hardness(3)/Young's modulus(2). The jaws also exhibit an impressive chemical inertness withstanding boiling concentrated hydrochloric acid as well as boiling concentrated sodium hydroxide. A major organic component largely responsible for the chemical inertness of the jaws has been characterized using a spectrophotometric assay for melanin content, C-13 solid state nuclear magnetic resonance, IR spectroscopy, and laser desorption ionization-time of flight mass spectrometry and is identified here as a melanin-like network. Although melanin is widely distributed as a pigment in tissues and other structural biomaterials, to our knowledge, Glycera jaws represent the first known integument to exploit melanin as a cohesive load- and shape-bearing material.	Univ Calif Santa Barbara, Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Moses, DN (corresponding author), Univ Calif Santa Barbara, Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA.	moses@lifesci.ucsb.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014672] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 014672] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adhyaru BB, 2003, MAGN RESON CHEM, V41, P466, DOI 10.1002/mrc.1193; Alaluf S, 2002, PIGM CELL RES, V15, P112, DOI 10.1034/j.1600-0749.2002.1o071.x; Balooch M, 1998, J BIOMED MATER RES, V40, P539, DOI 10.1002/(SICI)1097-4636(19980615)40:4<539::AID-JBM4>3.3.CO;2-O; BARDANI L, 1982, BIOCHIM BIOPHYS ACTA, V716, P8, DOI 10.1016/0304-4165(82)90196-9; BARR FE, 1983, MED HYPOTHESES, V11, P1, DOI 10.1016/0306-9877(83)90122-6; BERNARDS MA, 1995, J BIOL CHEM, V270, P7382, DOI 10.1074/jbc.270.13.7382; Bilinska B, 1996, SPECTROCHIM ACTA A, V52, P1157, DOI 10.1016/0584-8539(96)01691-1; Birkedal H, 2006, CHEMBIOCHEM, V7, P1392, DOI 10.1002/cbic.200600160; BRATOSIN S, 1973, J INVEST DERMATOL, V60, P224, DOI 10.1111/1523-1747.ep12724518; Bridelli MG, 1999, FEBS LETT, V457, P18, DOI 10.1016/S0014-5793(99)01001-7; Broomell CC, 2006, J EXP BIOL, V209, P3219, DOI 10.1242/jeb.02373; Butler M, 2004, J EXP BIOL, V207, P285, DOI 10.1242/jeb.00746; CHENG J, 1994, PIGM CELL RES, V7, P255, DOI 10.1111/j.1600-0749.1994.tb00060.x; CHENG J, 1994, PIGM CELL RES, V7, P263, DOI 10.1111/j.1600-0749.1994.tb00061.x; CLANCY CMR, 2005, BIOCHEMISTRY-US, V40, P13353; Di JW, 2003, SPECTROCHIM ACTA A, V59, P3075, DOI 10.1016/S1386-1425(03)00127-6; Doss RP, 2003, PHYTOCHEMISTRY, V63, P687, DOI 10.1016/S0031-9422(03)00323-6; Eisenman HC, 2005, BIOCHEMISTRY-US, V44, P3683, DOI 10.1021/bi047731m; GIBBS PE, 1980, J MAR BIOL ASSOC UK, V60, P205, DOI 10.1017/S0025315400024267; HACKMAN RH, 1971, ANAL BIOCHEM, V41, P279, DOI 10.1016/0003-2697(71)90214-4; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; Hutchison KA, 2002, MYCOL RES, V106, P729, DOI 10.1017/S095375620200597X; ITO S, 1993, ANAL BIOCHEM, V215, P273, DOI 10.1006/abio.1993.1586; ITO S, 1986, BIOCHIM BIOPHYS ACTA, V883, P155, DOI 10.1016/0304-4165(86)90146-7; Kronstrand R, 1999, CLIN CHEM, V45, P1485; Lichtenegger HC, 2002, SCIENCE, V298, P389, DOI 10.1126/science.1075433; Liu Y, 2005, PIGM CELL RES, V18, P42, DOI 10.1111/j.1600-0749.2004.00197.x; Liu Y, 2004, PIGM CELL RES, V17, P262, DOI 10.1111/j.1600-0749.2004.00140.x; Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180; McGraw KJ, 2005, FUNCT ECOL, V19, P816, DOI 10.1111/j.1365-2435.2005.01032.x; MICHEL C, 1973, Bulletin Biologique de la France et de la Belgique, V107, P301; Money NP, 1996, FUNGAL GENET BIOL, V20, P217, DOI 10.1006/fgbi.1996.0037; Money NP, 1998, FUNGAL GENET BIOL, V24, P240, DOI 10.1006/fgbi.1998.1052; Moses DN, 2006, ACTA BIOMATER, V2, P521, DOI 10.1016/j.actbio.2006.05.002; NAPOLITANO A, 1995, TETRAHEDRON, V51, P5913, DOI 10.1016/0040-4020(95)00259-B; Napolitano A, 1996, TETRAHEDRON, V52, P8775, DOI 10.1016/0040-4020(96)00418-8; NICOLAUS RA, 1968, CHEM NATURAL PRODUCT, P9; Ozeki H, 1997, ANAL BIOCHEM, V248, P149, DOI 10.1006/abio.1997.2079; Pezzella A, 1997, RAPID COMMUN MASS SP, V11, P368, DOI 10.1002/(SICI)1097-0231(19970228)11:4<368::AID-RCM859>3.0.CO;2-E; Pezzella A, 1997, TETRAHEDRON, V53, P8281, DOI 10.1016/S0040-4020(97)00494-8; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; RILEY PA, 1992, PIGM CELL RES, V5, P101, DOI 10.1111/j.1600-0749.1992.tb00005.x; SARNA T, 1976, SCIENCE, V192, P1132, DOI 10.1126/science.179142; SERAGLIA R, 1993, BIOL MASS SPECTROM, V22, P687, DOI 10.1002/bms.1200221204; Smith-Thomas LC, 2000, CURR EYE RES, V21, P518, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT518; STEPIEN KB, 1989, BIOCHIM BIOPHYS ACTA, V997, P49, DOI 10.1016/0167-4838(89)90134-9; SUGUMARAN M, 1987, BIOORG CHEM, V15, P194, DOI 10.1016/0045-2068(87)90019-8; Szpoganicz B, 2002, J INORG BIOCHEM, V89, P45, DOI 10.1016/S0162-0134(01)00406-8; Tai KS, 2005, J MATER SCI-MATER M, V16, P947, DOI 10.1007/s10856-005-4429-9; THATHACHARI YT, 1976, PIGMENT CELL, V3, P64; Voss-Foucart M.-F., 1973, Biochemical Syst, V1, P119, DOI 10.1016/0305-1978(73)90025-2; Waite JH, 2004, BIOCHEMISTRY-US, V43, P7653, DOI 10.1021/bi049380h; Wakamatsu K, 2003, J NEUROCHEM, V86, P1015, DOI 10.1046/j.1471-4159.2003.01917.x; WATTS KP, 1981, CANCER RES, V41, P467; Wegst UGK, 2004, PHILOS MAG, V84, P2167, DOI 10.1080/14786430410001680935	55	42	42	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34826	34832		10.1074/jbc.M603429200	http://dx.doi.org/10.1074/jbc.M603429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984906	hybrid			2022-12-25	WOS:000241933700015
J	Wei, YZ; Sowers, JR; Nistala, R; Gong, HP; Uptergrove, GME; Clark, SE; Morris, EM; Szary, N; Manrique, C; Stump, CS				Wei, Yongzhong; Sowers, James R.; Nistala, Ravi; Gong, Heping; Uptergrove, Grace M. -E.; Clark, Suzanne E.; Morris, E. Matthew; Szary, Nicholas; Manrique, Camila; Stump, Craig S.			Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; OXIDATIVE STRESS; NAD(P)H OXIDASE; RECEPTOR SUBSTRATE-1; GLUT4 TRANSLOCATION; CARDIOVASCULAR MORBIDITY; DIABETES-MELLITUS; 3T3-L1 ADIPOCYTES; DOWN-REGULATION; GLUCOSE-UPTAKE	The renin-angiotensin system (RAS) and reactive oxygen species (ROS) have been implicated in the development of insulin resistance and its related complications. There is also evidence that angiotensin II (Ang II)-induced generation of ROS contributes to the development of insulin resistance in skeletal muscle, although the precise mechanisms remain unknown. In the present study, we found that Ang II markedly enhanced NADPH oxidase activity and consequent ROS generation in L6 myo-tubes. These effects were blocked by the angiotensin II type 1 receptor blocker losartan, and by the NADPH oxidase inhibitor apocynin. Ang II also promoted the translocation of NADPH oxidase cytosolic subunits p47(phox) and p67(phox) to the plasma membrane within 15 min. Furthermore, Ang II abolished insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS1), activation of protein kinase B (Akt), and glucose transporter-4 (GLUT4) translocation to the plasma membrane, which was reversed by pretreating myotubes with losartan or apocynin. Finally, small interfering RNA (siRNA)-specific gene silencing targeted specifically against p47(phox) (p47siRNA), in both L6 and primary myotubes, reduced the cognate protein expression, decreased NADPH oxidase activity, restored Ang II-impaired IRS1 and Akt activation as well as GLUT4 translocation by insulin. These results suggest a pivotal role for NADPH oxidase activation and ROS generation in Ang II-induced inhibition of insulin signaling in skeletal muscle cells.	Univ Missouri, Dept Internal Med, Columbia, MO 65212 USA; Univ Missouri, Dept Physiol & Pharmacol, Columbia, MO 65212 USA; Harry S Truman Mem Vet Med Ctr, Columbia, MO 65201 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital	Stump, CS (corresponding author), Univ Arizona, Dept Med, Diabet Res Ctr, 1656 E Mabel St,PO 245218, Tucson, AZ 85724 USA.	stumpc@email.arizona.edu		Morris, E. Matthew/0000-0001-7046-3623	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073101] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R01 HL073101-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Bays H, 2004, J CLIN ENDOCR METAB, V89, P463, DOI 10.1210/jc.2003-030723; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; Blendea MC, 2005, AM J PHYSIOL-ENDOC M, V288, pE353, DOI 10.1152/ajpendo.00402.2004; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; DEADAMS MI, 1996, EMBO J, V15, P1211; Dikalova A, 2005, CIRCULATION, V112, P2668, DOI 10.1161/CIRCULATIONAHA.105.538934; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Henriksen EJ, 2003, EXERC SPORT SCI REV, V31, P79, DOI 10.1097/00003677-200304000-00005; Henriksen EJ, 2001, HYPERTENSION, V38, P884, DOI 10.1161/hy1101.092970; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; Hsieh TJ, 2004, J ENDOCRINOL, V183, P535, DOI 10.1677/joe.1.05871; Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Izawa Y, 2005, EXP CELL RES, V308, P291, DOI 10.1016/j.yexcr.2005.04.028; Javesghani D, 2002, AM J RESP CRIT CARE, V165, P412, DOI 10.1164/ajrccm.165.3.2103028; Katovich MJ, 2001, J HYPERTENS, V19, P1553, DOI 10.1097/00004872-200109000-00006; Kinnick TR, 2002, J APPL PHYSIOL, V93, P805, DOI 10.1152/japplphysiol.00236.2002; Kjeldsen SE, 2002, JAMA-J AM MED ASSOC, V288, P1491, DOI 10.1001/jama.288.12.1491; Landmesser U, 2002, HYPERTENSION, V40, P511, DOI 10.1161/01.HYP.0000032100.23772.98; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Laufs U, 2003, J BIOL CHEM, V278, P5956, DOI 10.1074/jbc.M209813200; Maddux BA, 2001, DIABETES, V50, P404, DOI 10.2337/diabetes.50.2.404; McFarlane SI, 2001, J CLIN ENDOCR METAB, V86, P713, DOI 10.1210/jc.86.2.713; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; Mizuki K, 2005, ARCH BIOCHEM BIOPHYS, V444, P185, DOI 10.1016/j.abb.2005.10.012; Motley ED, 2003, HYPERTENSION, V41, P775, DOI 10.1161/01.HYP.0000051891.90321.12; NouroozZadeh J, 1997, DIABETOLOGIA, V40, P647, DOI 10.1007/s001250050729; Ogihara T, 2002, HYPERTENSION, V40, P872, DOI 10.1161/01.HYP.0000040262.48405.A8; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; RICHEY JM, 1999, AM J PHYSIOL, V277, pR920; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; SECHI LA, 1992, METABOLISM, V41, P1261, DOI 10.1016/0026-0495(92)90019-7; Shiuchi T, 2004, HYPERTENSION, V43, P1003, DOI 10.1161/01.HYP.0000125142.41703.64; Sloniger JA, 2005, AM J PHYSIOL-ENDOC M, V288, pE1074, DOI 10.1152/ajpendo.00396.2004; Sowers JR, 2004, AM J PHYSIOL-HEART C, V286, pH1597, DOI 10.1152/ajpheart.00026.2004; Sowers JR, 2002, NEW ENGL J MED, V346, P1999, DOI 10.1056/NEJMe020054; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100; Szocs K, 2002, ARTERIOSCL THROM VAS, V22, P21, DOI 10.1161/hq0102.102189; Taniyama Y, 2005, ARTERIOSCL THROM VAS, V25, P1142, DOI 10.1161/01.ATV.0000164313.17167.df; Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595; Tojo T, 2005, CIRCULATION, V111, P2347, DOI 10.1161/01.CIR.0000164261.62586.14; Touyz RM, 2005, ARTERIOSCL THROM VAS, V25, P512, DOI 10.1161/01.ATV.0000154141.66879.98; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Touyz RM, 2002, CIRC RES, V90, P1205, DOI 10.1161/01.RES.0000020404.01971.2F; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; vanKats JP, 1997, HYPERTENSION, V30, P42, DOI 10.1161/01.HYP.30.1.42; VUORINENMARKKOLA H, 1995, METABOLISM, V44, P85, DOI 10.1016/0026-0495(95)90293-7; Watanabe Y, 2006, COMPUT BIOL CHEM, V30, P303, DOI 10.1016/j.compbiolchem.2006.04.004; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Yusuf S, 2000, NEW ENGL J MED, V342, P145	59	235	247	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35137	35146		10.1074/jbc.M601320200	http://dx.doi.org/10.1074/jbc.M601320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982630	hybrid			2022-12-25	WOS:000241933700047
J	Hiesberger, T; Gourley, E; Erickson, A; Koulen, P; Ward, CJ; Masyuk, TV; Larusso, NF; Harris, PC; Igarashi, P				Hiesberger, Thomas; Gourley, Eric; Erickson, Andrea; Koulen, Peter; Ward, Christopher J.; Masyuk, Tatyana V.; Larusso, Nicholas F.; Harris, Peter C.; Igarashi, Peter			Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CILIUM; GENE; DISEASE; PKHD1; TRANSCRIPTION; EXPRESSION; RECEPTORS; STIMULATION; MUTATION; ENCODES	Fibrocystin, a type I membrane protein of unknown function, is the protein affected in the autosomal recessive form of polycystic kidney disease. Here we show that fibrocystin undergoes regulated proteolysis. Several proteolytic cleavages occur within the predicted ectodomain, whereas at least one cleavage occurs within the cytoplasmic portion. The latter generates a C-terminal intracellular fragment that harbors the nuclear localization signal KRKVSRLAVTGERTATPAPKIPRIT and translocates to the nucleus. Proteolytic cleavage of fibrocystin occurs constitutively in long term cultures of polarized inner medullary collecting duct cells (mIMCD-3). Activation of protein kinase C and release of intracellular Ca2+ are required for proteolysis under these conditions. In short term cultures of human embryonic kidney 293 cells (HEK-293), proteolytic cleavage of fibrocystin can be elicited by stimulation of intracellular Ca2+ release or activation of protein kinase C. These results identify a novel Ca2+-dependent pathway that signals from fibrocystin located in the cell membrane to the nucleus.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Basic Sci, Dallas, TX 75390 USA; Univ N Texas, Hlth Sci Ctr, Ft Worth, TX 76107 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Nephrol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Internal Med, Rochester, MN 55905 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Texas System; University of North Texas Health Science Center; Mayo Clinic; Mayo Clinic	Hiesberger, T (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Hiesberger@UTSouthwestern.edu		Igarashi, Peter/0000-0001-8698-1185; Masyuk, Tatyana/0000-0003-3290-9879	NIA NIH HHS [P01 AG22550, P01 AG022550] Funding Source: Medline; NIDDK NIH HHS [R01 DK-67565, R01 DK067565] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022550] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; Hiesberger T, 2004, J CLIN INVEST, V113, P814, DOI 10.1172/JCI200420083; Hiesberger T, 2005, J BIOL CHEM, V280, P10578, DOI 10.1074/jbc.M414121200; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Landman N, 2004, CYTOKINE GROWTH F R, V15, P337, DOI 10.1016/j.cytogfr.2004.04.001; Leung AKL, 2003, CRIT REV EUKAR GENE, V13, P39, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.40; LIEBERMAN E, 1971, MEDICINE, V50, P277, DOI 10.1097/00005792-197107000-00003; Masyuk TV, 2003, GASTROENTEROLOGY, V125, P1303, DOI 10.1016/j.gastro.2003.09.001; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Menezes LFC, 2004, KIDNEY INT, V66, P1345, DOI 10.1111/j.1523-1755.2004.00844.x; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Onuchic LF, 2002, AM J HUM GENET, V70, P1305, DOI 10.1086/340448; Querfurth HW, 1998, BIOCHEM J, V334, P79, DOI 10.1042/bj3340079; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Wang SX, 2004, J AM SOC NEPHROL, V15, P592, DOI 10.1097/01.ASN.0000113793.12558.1D; Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833; Ward CJ, 2003, HUM MOL GENET, V12, P2703, DOI 10.1093/hmg/ddg274; Xiong HQ, 2002, GENOMICS, V80, P96, DOI 10.1006/geno.2002.6802; YANG J, 1995, MOL PHARMACOL, V48, P477; Young HS, 2004, J MEMBRANE BIOL, V198, P55, DOI 10.1007/s00232-004-0666-y; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429	25	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34357	34364		10.1074/jbc.M606740200	http://dx.doi.org/10.1074/jbc.M606740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16956880	hybrid			2022-12-25	WOS:000241767600056
J	Hunter, I; Nixon, GF				Hunter, Irene; Nixon, Graeme F.			Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells - Lipid rafts are essential for TNF-alpha-mediated activation of RhoA but dispensable for the activation of the NF-kappa B and MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; PLASMA-MEMBRANE; CAVEOLAE; PROTEIN; COMPLEX; TRANSDUCTION; RECRUITMENT; MOLECULES; APOPTOSIS; DOMAIN	Tumor necrosis factor (TNF)-alpha-induced activation of RhoA, mediated by TNF receptor 1 (TNFR1), is a prerequisite step in a pathway that leads to increased 20-kDa light chain of myosin (MLC20) phosphorylation and airway smooth muscle contraction. In this study, we have investigated the proximal events in TNF-alpha-induced RhoA activation. TNFR1 is localized to both lipid raft and nonraft regions of the plasma membrane in primary human airway smooth muscle cells. TNF-alpha engagement of TNFR1 recruited the adaptor proteins TRADD, TRAF-2, and RIP into lipid rafts and activated RhoA, NF-kappa B, and MAPK pathways. Depletion of cholesterol from rafts with methyl-beta-cyclodextrin caused a redistribution of TNFR1 to nonraft plasma membrane and prevented ligand-induced RhoA activation. By contrast, TNF-alpha-induced activation of NF-kappa B and MAPKs was unaffected by methyl-beta-cyclodextrin indicating that, in airway smooth muscle cells, activation of these pathways occurred independently of lipid rafts. Targeted knockdown of caveolin-1 completely abrogated TNF-alpha-induced RhoA activation, identifying this raft-resident protein as a positive regulator of the activation process. The signaling adaptors TRADD and RIP were also found to be necessary for ligand-induced RhoA activation. Taken together, our results suggest that in airway smooth muscle cells, spatial compartmentalization of TNFR1 provides a mechanism for generating distinct signaling outcomes in response to ligand engagement and define a mechanistic role for lipid rafts and caveolin-1 in TNF-alpha-induced activation of RhoA.	Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Hunter, I (corresponding author), Univ Aberdeen, Sch Med Sci, IMS Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland.	i.hunter@abdn.ac.uk		Nixon, Graeme/0000-0002-9581-3332	Wellcome Trust [074107] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Amrani Y, 1997, AM J PHYSIOL-LUNG C, V273, pL1020, DOI 10.1152/ajplung.1997.273.5.L1020; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; D'Alessio A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2; Dienz O, 2003, J IMMUNOL, V170, P365, DOI 10.4049/jimmunol.170.1.365; Doan JES, 2004, J IMMUNOL, V172, P7654, DOI 10.4049/jimmunol.172.12.7654; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Fessler MB, 2004, J BIOL CHEM, V279, P39989, DOI 10.1074/jbc.M401080200; Fu Y, 2004, J BIOL CHEM, V279, P14140, DOI 10.1074/jbc.M311061200; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Hoeller D, 2005, CURR OPIN CELL BIOL, V17, P107, DOI 10.1016/j.ceb.2005.01.001; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hunter I, 2003, MOL PHARMACOL, V63, P714, DOI 10.1124/mol.63.3.714; Jaksits S, 2004, J IMMUNOL, V173, P1628, DOI 10.4049/jimmunol.173.3.1628; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Jupp OJ, 2001, BIOCHEM J, V359, P525, DOI 10.1042/0264-6021:3590525; Karacsonyi C, 2005, J LEUKOCYTE BIOL, V78, P1097, DOI 10.1189/jlb.0405189; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim KB, 2004, PROTEOMICS, V4, P3527, DOI 10.1002/pmic.200401001; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Ko YG, 1999, J IMMUNOL, V162, P7217; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li HY, 2004, AM J PHYSIOL-RENAL, V286, pF711, DOI 10.1152/ajprenal.00308.2003; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; MacLellan DL, 2005, PROTEOMICS, V5, P4733, DOI 10.1002/pmic.200500044; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Papakonstanti EA, 2004, MOL BIOL CELL, V15, P1273, DOI 10.1091/mbc.E03-07-0491; PARAHARALAMBUS C, 2005, J BIOL CHEM, V280, P18790; Parris JRM, 1999, J PHYSIOL-LONDON, V518, P561, DOI 10.1111/j.1469-7793.1999.0561p.x; Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005; Pike LJ, 2005, J BIOL CHEM, V280, P26796, DOI 10.1074/jbc.M503805200; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Puls A, 1999, J CELL SCI, V112, P2983; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Sebald A, 2005, EUR J IMMUNOL, V35, P318, DOI 10.1002/eji.200425024; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Yamaga M, 2004, GENES CELLS, V9, P25, DOI 10.1111/j.1356-9597.2004.00698.x; ZOU L, 2005, ARTERIOSCLER THROMB, V25, P1824	66	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34705	34715		10.1074/jbc.M605738200	http://dx.doi.org/10.1074/jbc.M605738200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16982613	Green Accepted, hybrid			2022-12-25	WOS:000241767600089
J	Zhang, DY; Song, L; Li, JX; Wu, KJ; Huang, CS				Zhang, Dongyun; Song, Lun; Li, Jingxia; Wu, Kangjian; Huang, Chuanshu			Coordination of JNK1 and JNK2 is critical for GADD45 alpha induction and its mediated cell apoptosis in arsenite responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACUTE PROMYELOCYTIC LEUKEMIA; KAPPA-B; SODIUM ARSENITE; DNA-REPAIR; ACTIVATION; EXPRESSION; PATHWAYS; GENE; PHOSPHORYLATION	Arsenite is a well documented environmental pathogen, whereas it has also been applied as medication to treat various neoplasmas. The pathogenic and therapeutic effects of arsenite are associated with cellular apoptotic responses. However, the molecular mechanisms of arsenite-induced apoptosis are not very well understood. Our previous study has shown that arsenite exposure is able to activate JNKs, which subsequently mediate the apoptotic outcome. The present study further revealed that the coordination of JNK1 and JNK2 was critical for the arsenite-induced expression of GADD45 alpha ( growth arrest and DNA damage 45 alpha), which in turn mediated the cellular apoptosis. The arsenite-induced apoptosis and GADD45 alpha expression were significantly impaired in mouse embryonic fibroblasts deficient in either jnk1 (JNK1(-/-)) or jnk2 (JNK2(-/-)). Knockdown of GADD45 alpha by its specific small interfering RNA also dramatically reduced the apoptotic responses, and overexpression of GADD45 alpha in either JNK1(-/-) or JNK2(-/-) mouse embryonic fibroblasts partially resensitized the cell death. Furthermore, it was found that the regulation of GADD45 alpha by JNK1 and JNK2 was achieved through mediating the activation of c-Jun, since in the JNK1(-/-) and JNK2(-/-) cells the c-Jun activation was impaired, and overexpression of the dominant negative mutant of c-Jun (TAM67) in wild type cells could also block GADD45 alpha induction as well as cellular apoptosis. Our results demonstrate that the coordination of JNK1 and JNK2 is critical for c-Jun/GADD45 alpha-mediated cellular apoptosis induced by arsenite.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA	New York University	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R01CA112557, R01CA103180, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260, R01ES012451] Funding Source: NIH RePORTER; NCI NIH HHS [CA103180, CA094964, CA112557] Funding Source: Medline; NIEHS NIH HHS [ES012451, ES000260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; BETTLEY FR, 1975, BRIT J DERMATOL, V92, P563; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Chou RH, 2002, J CELL BIOCHEM, V84, P615; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cooper SJ, 2003, MOL CANCER RES, V1, P848; Das T, 1999, BIOCHEM BIOPH RES CO, V260, P105, DOI 10.1006/bbrc.1999.0712; Davison K, 2004, BLOOD, V103, P3496, DOI 10.1182/blood-2003-05-1412; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dong ZG, 2002, ENVIRON HEALTH PERSP, V110, P757, DOI 10.1289/ehp.02110s5757; FUENTE HD, 2002, CLIN EXP IMMUNOL, V129, P69; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang CS, 1999, CANCER RES, V59, P3053; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 2001, ANTICANCER RES, V21, P261; Huang SC, 2000, BIOCHEM PHARMACOL, V60, P771, DOI 10.1016/S0006-2952(00)00397-X; *INT AG RES CANC, 1980, LYON IARC, V23, P39; Ivanov VN, 2004, J BIOL CHEM, V279, P22747, DOI 10.1074/jbc.M314131200; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lau ATY, 2004, CARCINOGENESIS, V25, P21, DOI 10.1093/carcin/bgg179; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li JX, 2004, MOL CARCINOGEN, V40, P104, DOI 10.1002/mc.20020; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; McCabe MJ, 2000, J PHARMACOL EXP THER, V295, P724; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Muscarella DE, 2003, TOXICOL SCI, V74, P66, DOI 10.1093/toxsci/kfg052; Muscarella DE, 2002, TOXICOL SCI, V68, P82, DOI 10.1093/toxsci/68.1.82; MUYAO L, 2002, J CELL BIOCHEM, V87, P29; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Namgung U, 2001, TOXICOL APPL PHARM, V174, P130, DOI 10.1006/taap.2001.9200; Nuntharatanapong N, 2005, AM J PHYSIOL-HEART C, V289, pH99, DOI 10.1152/ajpheart.00901.2004; Nutt LK, 2005, CANCER BIOL THER, V4, P459; Ouyang WM, 2005, CANCER RES, V65, P9287, DOI 10.1158/0008-5472.CAN-05-0469; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Pawate S, 2006, ANTIOXID REDOX SIGN, V8, P903, DOI 10.1089/ars.2006.8.903; Qu W, 2002, CARCINOGENESIS, V23, P151, DOI 10.1093/carcin/23.1.151; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sciandrello G, 2002, MUTAGENESIS, V17, P99, DOI 10.1093/mutage/17.2.99; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Solary E, 2003, LEUKEMIA LYMPHOMA, V44, P563, DOI 10.1080/1042819021000038001; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tuncman G, 2006, P NATL ACAD SCI USA, V103, P10741, DOI 10.1073/pnas.0603509103; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WANG Y, 2006, IN PRESS BIOCH J; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	65	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34113	34123		10.1074/jbc.M602821200	http://dx.doi.org/10.1074/jbc.M602821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973625	hybrid			2022-12-25	WOS:000241767600032
J	Rostovtseva, TK; Kazemi, N; Weinrich, M; Bezrukov, SM				Rostovtseva, Tatiana K.; Kazemi, Namdar; Weinrich, Michael; Bezrukov, Sergey M.			Voltage gating of VDAC is regulated by nonlamellar lipids of mitochondrial membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE CHANNEL; CYTOCHROME-C RELEASE; OUTER-MEMBRANE; NEUROSPORA-CRASSA; PHOSPHATIDYLSERINE BILAYERS; MECHANOSENSITIVE CHANNELS; TRANSMEMBRANE CHANNEL; GRAMICIDIN CHANNELS; YEAST MITOCHONDRIA; LATERAL PRESSURE	Evidence is accumulating that lipids play important roles in permeabilization of the mitochondria outer membrane (MOM) at the early stage of apoptosis. Lamellar phosphatidylcholine (PC) and nonlamellar phosphatidylethanolamine (PE) lipids are the major membrane components of the MOM. Cardiolipin (CL), the characteristic lipid from the mitochondrial inner membrane, is another nonlamellar lipid recently shown to play a role in MOM permeabilization. We investigate the effect of these three key lipids on the gating properties of the voltage-dependent anion channel (VDAC), the major channel in MOM. We find that PE induces voltage asymmetry in VDAC current-voltage characteristics by promoting channel closure at cis negative applied potentials. Significant asymmetry is also induced by CL. The observed differences in VDAC behavior in PC and PE membranes cannot be explained by differences in the insertion orientation of VDAC in these membranes. Rather, it is clear that the two nonlamellar lipids affect VDAC gating. Using gramicidin A channels as a tool to probe bilayer mechanics, we show that VDAC channels are much more sensitive to the presence of CL than could be expected from the experiments with gramicidin channels. We suggest that this is due to the preferential insertion of VDAC into CL-rich domains. We propose that the specific lipid composition of the mitochondria outer membrane and/or of contact sites might influence MOM permeability by regulating VDAC gating.	NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA; NICHD, Natl Ctr Med Rehabil Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rostovtseva, TK (corresponding author), NICHD, Lab Phys & Struct Biol, NIH, Bldg 9,Rm 1E-106, Bethesda, MD 20892 USA.	rostovtt@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000072] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000072] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Bezrukov SM, 2000, CURR OPIN COLLOID IN, V5, P237, DOI 10.1016/S1359-0294(00)00061-3; Bezrukov SM, 1998, FARADAY DISCUSS, V111, P173; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; Booth PJ, 2005, CURR OPIN STRUC BIOL, V15, P435, DOI 10.1016/j.sbi.2005.06.002; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Cantor RS, 1999, BIOPHYS J, V76, P2625, DOI 10.1016/S0006-3495(99)77415-1; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V693, P1, DOI 10.1016/0005-2736(82)90464-3; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DORING C, 1985, J MEMBRANE BIOL, V83, P81, DOI 10.1007/BF01868740; EHRENSTEIN G, 1970, J GEN PHYSIOL, V55, P119, DOI 10.1085/jgp.55.1.119; ELLIOTT JR, 1983, BIOCHIM BIOPHYS ACTA, V735, P95, DOI 10.1016/0005-2736(83)90264-X; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; Garofalo T, 2005, CELL DEATH DIFFER, V12, P1378, DOI 10.1038/sj.cdd.4401672; GAWRISCH K, 1992, BIOCHEMISTRY-US, V31, P2856, DOI 10.1021/bi00126a003; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P614, DOI 10.1038/sj.cdd.4401571; Goulian M, 1998, BIOPHYS J, V74, P328, DOI 10.1016/S0006-3495(98)77790-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; Gullingsrud J, 2004, BIOPHYS J, V86, P3496, DOI 10.1529/biophysj.103.034322; Gurnev PA, 2006, J MOL BIOL, V359, P1447, DOI 10.1016/j.jmb.2006.04.034; Harroun TA, 1999, BIOPHYS J, V76, P3176, DOI 10.1016/S0006-3495(99)77469-2; HAUSER H, 1981, J BIOL CHEM, V256, P1377; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Hong HD, 2004, P NATL ACAD SCI USA, V101, P4065, DOI 10.1073/pnas.0400358101; HUANG HW, 1986, BIOPHYS J, V50, P1061, DOI 10.1016/S0006-3495(86)83550-0; Huster D, 1999, BIOPHYS J, V77, P879, DOI 10.1016/S0006-3495(99)76939-0; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; Karginov VA, 2005, P NATL ACAD SCI USA, V102, P15075, DOI 10.1073/pnas.0507488102; KELLER SL, 1993, BIOPHYS J, V65, P23, DOI 10.1016/S0006-3495(93)81040-3; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LEMASTER JJ, 2005, BIOCHIM BIOPHYS ACTA, V1762, P181; Levadny V, 2002, BIOPHYS J, V82, P1773, DOI 10.1016/S0006-3495(02)75528-8; Lundbaek JA, 1996, BIOCHEMISTRY-US, V35, P3825, DOI 10.1021/bi952250b; Lundbaek JA, 2005, MOL PHARMACOL, V68, P680, DOI 10.1124/mol.105.013573; Lundbaek JA, 1999, BIOPHYS J, V76, P889, DOI 10.1016/S0006-3495(99)77252-8; Lundbaek JA, 1997, BIOCHEMISTRY-US, V36, P5695, DOI 10.1021/bi9619841; Lundbaek JA, 2006, J PHYS-CONDENS MAT, V18, pS1305, DOI 10.1088/0953-8984/18/28/S13; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; McIntosh TJ, 2006, ANNU REV BIOPH BIOM, V35, P177, DOI 10.1146/annurev.biophys.35.040405.102022; Merzlyak PG, 1999, BIOPHYS J, V77, P3023, DOI 10.1016/S0006-3495(99)77133-X; Nestorovich EM, 2006, J BIOL CHEM, V281, P16230, DOI 10.1074/jbc.M600650200; Nestorovich EM, 2002, P NATL ACAD SCI USA, V99, P9789, DOI 10.1073/pnas.152206799; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Petrache HI, 2004, BIOPHYS J, V86, P1574, DOI 10.1016/S0006-3495(04)74225-3; Polcic P, 2005, CELL DEATH DIFFER, V12, P310, DOI 10.1038/sj.cdd.4401566; POWELL GL, 1987, BIOCHEMISTRY-US, V26, P8138, DOI 10.1021/bi00399a018; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; Rokitskaya TI, 1997, BIOPHYS J, V73, P850, DOI 10.1016/S0006-3495(97)78117-7; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva TK, 1998, BIOPHYS J, V74, P2365, DOI 10.1016/S0006-3495(98)77945-7; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Rostovtseva TK, 2002, BIOPHYS J, V82, P193, DOI 10.1016/S0006-3495(02)75386-1; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; Song JM, 1998, BIOPHYS J, V74, P2926, DOI 10.1016/S0006-3495(98)78000-2; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Templer RH, 1998, FARADAY DISCUSS, V111, P41; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; Tristram-Nagle S, 1998, BIOPHYS J, V75, P917, DOI 10.1016/S0006-3495(98)77580-0; URRY DW, 1971, P NATL ACAD SCI USA, V68, P1907, DOI 10.1073/pnas.68.8.1907; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Xu X, 2001, J MEMBRANE BIOL, V180, P73, DOI 10.1007/s002320010060; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; ZAMBROWICZ EB, 1993, BIOPHYS J, V65, P1093, DOI 10.1016/S0006-3495(93)81148-2; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIZI M, 1995, J MEMBRANE BIOL, V144, P121; Zizi M, 1998, BIOPHYS J, V75, P704, DOI 10.1016/S0006-3495(98)77560-5	92	106	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37496	37506		10.1074/jbc.M602548200	http://dx.doi.org/10.1074/jbc.M602548200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16990283	hybrid			2022-12-25	WOS:000242477100026
J	Bundschu, K; Walter, U; Schuh, K				Bundschu, Karin; Walter, Ulrich; Schuh, Kai			The VASP-Spred-Sprouty domain puzzle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							VASODILATOR-STIMULATED PHOSPHOPROTEIN; PROTEIN-KINASE PHOSPHORYLATION; INTACT HUMAN PLATELETS; RICH FOCAL ADHESION; TYROSINE KINASE; ERK ACTIVATION; EVH1 DOMAIN; MAP KINASE; TRANSLOCATION DOMAIN; SIGNALING PATHWAYS	Sprouty-related proteins with an EVH1 domain (Spreds) belong to a new protein family harboring a conserved N-terminal EVH1 domain, which is related to the VASP (vasodilator-stimulated phosphoprotein) EVH1 domain (Enabled/VASP homology 1 domain) and a C-terminal Sprouty-related domain, typical for Sprouty proteins. Spreds were, like Sproutys, initially discovered as inhibitors of the Ras/MAPK pathway, and the SPR (Sprouty-related) domains of both protein families seem to be very important for many protein interactions and cellular processes. VASP was initially characterized as a proline-rich substrate of protein kinases A and G in human platelets and later shown to be a scaffold protein, regulating both signal transduction pathways and the actin filament system. The VASP-EVH1 domain is known to bind specifically to a FP4 binding motif, which is, for example, present in the focal adhesion proteins vinculin and zyxin. In this review we give a structural and functional overview on these three protein families and ask whether nature plays a modular protein domain puzzle with stable exchangeable elements or if these closely related domains have various functions when pasted in a different protein context.	Univ Ulm, Abt Biochem & Mol Biol, D-89081 Ulm, Germany; Univ Wurzburg, Int Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany	Ulm University; University of Wurzburg; University of Wurzburg	Bundschu, K (corresponding author), Univ Ulm, Abt Biochem & Mol Biol, D-89081 Ulm, Germany.	karin.bundschu@gmx.de	Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307				ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Anteby EY, 2005, PLACENTA, V26, P476, DOI 10.1016/j.placenta.2004.08.008; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Brading AF, 2005, NAT CLIN PRACT UROL, V2, P546, DOI 10.1038/ncpuro0340; Bundschu K, 2005, J BIOL CHEM, V280, P28572, DOI 10.1074/jbc.M503640200; Bundschu K, 2006, GENE EXPR PATTERNS, V6, P247, DOI 10.1016/j.modgep.2005.08.003; BUTT E, 1994, J BIOL CHEM, V269, P14509; Cabrita MA, 2003, THROMB HAEMOSTASIS, V90, P586, DOI 10.1160/TH03-04-0217; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; Chitaley K, 2004, FEBS LETT, V556, P211, DOI 10.1016/S0014-5793(03)01435-2; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; de Alvaro C, 2005, MOL BIOL CELL, V16, P4454, DOI 10.1091/mbc.E05-05-0419; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; DeMille MMC, 1996, GENE, V183, P103, DOI 10.1016/S0378-1119(96)00506-9; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Engelhardt CM, 2004, HISTOCHEM CELL BIOL, V122, P527, DOI 10.1007/s00418-004-0725-6; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; Haimov-Kochman R, 2005, MOL HUM REPROD, V11, P537, DOI 10.1093/molehr/gah203; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hanani M, 2000, ACTA PHYSIOL SCAND, V170, P177, DOI 10.1111/j.1365-201X.2000.00769.x; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Harmer NJ, 2005, FEBS LETT, V579, P1161, DOI 10.1016/j.febslet.2004.11.114; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616; Jarvis LA, 2006, DEVELOPMENT, V133, P1133, DOI 10.1242/dev.02255; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; King JAJ, 2006, J HEPATOL, V44, P758, DOI 10.1016/j.jhep.2005.10.031; King JAJ, 2005, BIOCHEM J, V388, P445, DOI 10.1042/BJ20041284; Klostermann A, 2000, J BIOL CHEM, V275, P39647, DOI 10.1074/jbc.M006316200; Kramer S, 1999, DEVELOPMENT, V126, P2515; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Kuhnel K, 2004, P NATL ACAD SCI USA, V101, P17027, DOI 10.1073/pnas.0403069101; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Mason JM, 2004, MOL BIOL CELL, V15, P2176, DOI 10.1091/mbc.E03-07-0503; Massberg S, 2004, BLOOD, V103, P136, DOI 10.1182/blood-2002-11-3417; Menzies AS, 2004, J NEUROSCI, V24, P8029, DOI 10.1523/JNEUROSCI.1057-04.2004; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nobuhisa I, 2004, J EXP MED, V199, P737, DOI 10.1084/jem.20030830; Nonami A, 2005, GENES CELLS, V10, P887, DOI 10.1111/j.1365-2443.2005.00886.x; Nonami A, 2004, J BIOL CHEM, V279, P52543, DOI 10.1074/jbc.M405189200; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; Ozaki K, 2005, J CELL SCI, V118, P5861, DOI 10.1242/jcs.02711; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Reich A, 1999, DEVELOPMENT, V126, P4139; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Rubin C, 2005, J BIOL CHEM, V280, P9735, DOI 10.1074/jbc.M408308200; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schirenbeck A, 2006, P NATL ACAD SCI USA, V103, P7694, DOI 10.1073/pnas.0511243103; Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009; Sivak JM, 2005, DEV CELL, V8, P689, DOI 10.1016/j.devcel.2005.02.011; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Tsumura Y, 2005, BIOCHEM J, V387, P627, DOI 10.1042/BJ20041181; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Zhang CX, 2005, ARTERIOSCL THROM VAS, V25, P533, DOI 10.1161/01.ATV.0000155461.50450.5a; Zhuang SH, 2004, J BIOL CHEM, V279, P10397, DOI 10.1074/jbc.M313048200; Zimmermann J, 2004, J BIOMOL NMR, V29, P435, DOI 10.1023/B:JNMR.0000032526.17586.8c	95	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36477	36481		10.1074/jbc.R600023200	http://dx.doi.org/10.1074/jbc.R600023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16987806	hybrid			2022-12-25	WOS:000242220800002
J	Bjursell, MK; Martens, EC; Gordon, JI				Bjursell, Magnus K.; Martens, Eric C.; Gordon, Jeffrey I.			Functional genomic and metabolic studies of the adaptations of a prominent adult human gut symbiont, Bacteroides thetaiotaomicron, to the suckling period	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENSIVE DNA INVERSIONS; OUTER-MEMBRANE PROTEINS; INTESTINAL FLORA; MICROBIAL DIVERSITY; FECAL MICROFLORA; CELL-SURFACE; HUMAN-MILK; IN-VIVO; STARCH; GENE	The adult human gut microbiota is dominated by two divisions of Bacteria, the Bacteroidetes and the Firmicutes. Assembly of this community begins at birth through processes that remain largely undefined. In this report, we examine the adaptations of Bacteroides thetaiotaomicron, a prominent member of the adult distal intestinal microbiota, during the suckling and weaning periods. Germ-free NMRI mice were colonized at birth from their gnotobiotic mothers, who harbored this anaerobic Gram-negative saccharolytic bacterium. B. thetaiotaomicron was then harvested from the ceca of these hosts during the suckling period ( postnatal day 17) and after weaning ( postnatal day 30). Whole genome transcriptional profiles were obtained at these two time points using custom B. thetaiotaomicron Gene-Chips. Transcriptome-based in silico reconstructions of bacterial metabolism and gas chromatography-mass spectrometry and biochemical assays of carbohydrate utilization in vivo indicated that in the suckling gut B. thetaiotaomicron prefers host-derived polysaccharides, as well as mono-and oligosaccharides present in mother's milk. After weaning, B. thetaiotaomicron expands its metabolism to exploit abundant, plant-derived dietary polysaccharides. The bacterium's responses to postnatal alterations in its nutrient landscape involve expression of gene clusters encoding environmental sensors, outer membrane proteins involved in binding and import of glycans, and glycoside hydrolases. These expression changes are interpreted in light of a phylogenetic analysis that revealed unique expansions of related polysaccharide utilization loci in three human alimentary tract-associated Bacteroidetes, expansions that likely reflect the evolutionary adaptations of these species to different nutrient niches.	Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci, Campus Box 8510,4444 Forest Pk Ave, St Louis, MO 63108 USA.	jgordon@wustl.edu			NICHD NIH HHS [T32 HD07409] Funding Source: Medline; NIDDK NIH HHS [DK30292] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALMER SE, 1989, ARCH DIS CHILD, V64, P1678, DOI 10.1136/adc.64.12.1678; Braun V, 2006, BIOMETALS, V19, P103, DOI 10.1007/s10534-005-8253-y; Caspi R, 2006, NUCLEIC ACIDS RES, V34, pD511, DOI 10.1093/nar/gkj128; Cerdeno-Tarraga AM, 2005, SCIENCE, V307, P1463, DOI 10.1126/science.1107008; Cho KH, 2001, J BACTERIOL, V183, P7198, DOI 10.1128/JB.183.24.7198-7205.2001; Coyne MJ, 2005, SCIENCE, V307, P1778, DOI 10.1126/science.1106469; DElla JN, 1996, J BACTERIOL, V178, P7173; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Engfer MB, 2000, AM J CLIN NUTR, V71, P1589; George Mary, 1996, Upsala Journal of Medical Sciences, V101, P233; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Hall LMC, 2005, INFECT IMMUN, V73, P4253, DOI 10.1128/IAI.73.7.4253-4262.2005; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Koebnik R, 2005, TRENDS MICROBIOL, V13, P343, DOI 10.1016/j.tim.2005.06.005; Kunz C, 2000, ANNU REV NUTR, V20, P699, DOI 10.1146/annurev.nutr.20.1.699; Kuwahara T, 2004, P NATL ACAD SCI USA, V101, P14919, DOI 10.1073/pnas.0404172101; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Mandar R, 1996, BIOL NEONATE, V69, P30; Murata T, 2005, SCIENCE, V308, P654, DOI 10.1126/science.1110064; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P85; Rawls JF, 2006, CELL, V127, P423, DOI 10.1016/j.cell.2006.08.043; Reeves AR, 1996, J BACTERIOL, V178, P823, DOI 10.1128/jb.178.3.823-830.1996; Reeves AR, 1997, J BACTERIOL, V179, P643, DOI 10.1128/jb.179.3.643-649.1997; ROBERTS AK, 1992, ACTA PAEDIATR, V81, P119, DOI 10.1111/j.1651-2227.1992.tb12186.x; SAKATA H, 1985, EUR J PEDIATR, V144, P186, DOI 10.1007/BF00451911; Samuel BS, 2006, P NATL ACAD SCI USA, V103, P10011, DOI 10.1073/pnas.0602187103; Shipman JA, 2000, J BACTERIOL, V182, P5365, DOI 10.1128/JB.182.19.5365-5372.2000; Sonnenburg ED, 2006, P NATL ACAD SCI USA, V103, P8834, DOI 10.1073/pnas.0603249103; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; Steuber J, 2002, EUR J BIOCHEM, V269, P1287, DOI 10.1046/j.1432-1033.2002.02770.x; Swofford D.L., 2002, PAUP PHYLOGENETIC AN, DOI 10.1111/j.0014-3820.2002.tb00191.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSAI MH, 1995, RES MICROBIOL, V146, P397, DOI 10.1016/0923-2508(96)80285-3; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vorwerk S, 2004, TRENDS PLANT SCI, V9, P203, DOI 10.1016/j.tplants.2004.02.005; Westover BP, 2005, BIOINFORMATICS, V21, P880, DOI 10.1093/bioinformatics/bti123; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; YOSHIOKA H, 1983, PEDIATRICS, V72, P317; Zoetendal Erwin G., 2001, Microbial Ecology in Health and Disease, V13, P129, DOI 10.1080/089106001750462669	45	203	213	2	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36269	36279		10.1074/jbc.M606509200	http://dx.doi.org/10.1074/jbc.M606509200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16968696	hybrid			2022-12-25	WOS:000242100500079
J	Razumova, MV; Shaffer, JF; Tu, AY; Flint, GV; Regnier, M; Harris, SP				Razumova, Maria V.; Shaffer, Justin F.; Tu, An-Yue; Flint, Galina V.; Regnier, Michael; Harris, Samantha P.			Effects of the N-terminal domains of myosin binding protein-C in an in vitro motility assay - Evidence for long-lived cross-bridges	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; THIN-FILAMENT; SHORTENING VELOCITY; F-ACTIN; HYPERTROPHIC CARDIOMYOPATHY; REGULATED ACTIN; CARDIAC-MUSCLE; MYBP-C; ACTIVATION; SMOOTH	Myosin binding protein-C ( MyBP-C) is a thick-filament protein whose precise function within the sarcomere is not known. However, recent evidence from cMyBP-C knock-out mice that lack MyBP-C in the heart suggest that cMyBP-C normally slows cross-bridge cycling rates and reduces myocyte power output. To investigate possible mechanisms by which cMyBP-C limits cross-bridge cycling kinetics we assessed effects of recombinant N-terminal domains of MyBP-C on the ability of heavy meromyosin (HMM) to support movement of actin filaments using in vitro motility assays. Here we show that N-terminal domains of cMyBP-C containing the MyBP-C "motif," a sequence of similar to 110 amino acids, which is conserved across all MyBP-C isoforms, reduced actin filament velocity under conditions where filaments are maximally activated (i.e. either in the absence of thin filament regulatory proteins or in the presence of troponin and tropomyosin and high [Ca2+]). By contrast, under conditions where thin filament sliding speed is submaximal (i.e. in the presence of troponin and tropomyosin and low [Ca2+]), proteins containing the motif increased filament speed. Recombinant N-terminal proteins also bound to F-actin and inhibited acto-HMM ATPase rates in solution. The results suggest that N-terminal domains of MyBP-C slow cross-bridge cycling kinetics by reducing rates of cross-bridge detachment.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Harris, SP (corresponding author), Univ Washington, Dept Bioengn, Box 355061, Seattle, WA 98195 USA.	spharris@u.washington.edu			NHLBI NIH HHS [R01 HL080367, HL080367, HL61683, R01 HL065497] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061683, R01HL065497, R01HL080367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alahyan M, 2006, J BIOL CHEM, V281, P19433, DOI 10.1074/jbc.M507602200; Amann KJ, 1998, J BIOL CHEM, V273, P28419, DOI 10.1074/jbc.273.43.28419; Bobkov AA, 1997, BIOCHEMISTRY-US, V36, P7733, DOI 10.1021/bi963185o; Calaghan SC, 2000, J PHYSIOL-LONDON, V528, P151, DOI 10.1111/j.1469-7793.2000.00151.x; Clemmens EW, 2004, J MUSCLE RES CELL M, V25, P515, DOI 10.1007/s10974-004-3787-0; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; DAVIS JS, 1988, J MUSCLE RES CELL M, V9, P174, DOI 10.1007/BF01773739; ElMezgueldi M, 1996, J BIOL CHEM, V271, P28161, DOI 10.1074/jbc.271.45.28161; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Gordon AM, 1997, BIOPHYS J, V72, P1295, DOI 10.1016/S0006-3495(97)78776-9; Gorga JA, 2003, BIOPHYS J, V85, P2484, DOI 10.1016/S0006-3495(03)74671-2; Gruen M, 1999, J MOL BIOL, V286, P933, DOI 10.1006/jmbi.1998.2522; Haeberle JR, 1999, J MUSCLE RES CELL M, V20, P363, DOI 10.1023/A:1005408402323; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Harris SP, 2004, CIRC RES, V95, P930, DOI 10.1161/01.RES.0000147312.02673.56; Harris SP, 2002, CIRC RES, V90, P594, DOI 10.1161/01.RES.0000012222.70819.64; Herron TJ, 2006, CIRC RES, V98, P1290, DOI 10.1161/01.RES.0000222059.54917.ef; HOFMANN PA, 1991, J PHYSIOL-LONDON, V439, P701, DOI 10.1113/jphysiol.1991.sp018689; HOMSHER E, 1993, ADV EXP MED BIOL, V332, P279; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Korte FS, 2003, CIRC RES, V93, P752, DOI 10.1161/01.RES.0000096363.85588.9A; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Kulikovskaya I, 2003, J GEN PHYSIOL, V122, P761, DOI 10.1085/jgp.200308941; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; LI QN, 1995, BIOPHYS J, V69, P1508, DOI 10.1016/S0006-3495(95)80021-4; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MOOS C, 1978, J MOL BIOL, V124, P571, DOI 10.1016/0022-2836(78)90172-9; MOOS C, 1981, J CELL BIOL, V90, P25, DOI 10.1083/jcb.90.1.25; Moss RL, 2004, CIRC RES, V94, P1290, DOI 10.1161/01.RES.0000127125.61647.4F; MOSS RL, 1986, J PHYSIOL-LONDON, V377, P487, DOI 10.1113/jphysiol.1986.sp016199; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Regnier M, 2000, CIRC RES, V86, P1211, DOI 10.1161/01.RES.86.12.1211; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Squire JM, 2003, J MOL BIOL, V331, P713, DOI 10.1016/S0022-2836(03)00781-2; Stelzer JE, 2006, CIRC RES, V98, P1212, DOI 10.1161/01.RES.0000219863.94390.ce; Stelzer JE, 2006, BIOPHYS J, V90, P4119, DOI 10.1529/biophysj.105.078147; Swartz DR, 2001, J PHYSIOL-LONDON, V533, P357, DOI 10.1111/j.1469-7793.2001.0357a.x; Weisberg A, 1996, P NATL ACAD SCI USA, V93, P8999, DOI 10.1073/pnas.93.17.8999; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; YAMAMOTO K, 1986, FEBS LETT, V208, P123, DOI 10.1016/0014-5793(86)81545-9	45	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35846	35854		10.1074/jbc.M606949200	http://dx.doi.org/10.1074/jbc.M606949200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012744	hybrid			2022-12-25	WOS:000242100500031
J	Soskine, M; Mark, S; Tayer, N; Mizrachi, R; Schuldiner, S				Soskine, Misha; Mark, Shirley; Tayer, Naama; Mizrachi, Roy; Schuldiner, Shimon			On parallel and antiparallel topology of a homodimeric multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; ESCHERICHIA-COLI; MEMBRANE-PROTEINS; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; LIGAND-BINDING; CROSS-LINKING; EMRE; REVEALS; IDENTIFICATION	The recently suggested antiparallel topology of EmrE has intriguing implications for many aspects of the biology of ion-coupled transporters. However, it is at odds with biochemical data that demonstrated the same topology for all protomers in the intact cell and with extensive cross-linking studies. To examine this apparent contradiction we chemically cross-linked dimers with a rigid bifunctional maleimide using Cys replacements at positions not permissible by an antiparallel topology. A purified cross-linked dimer binds substrate and transports it in proteoliposomes with kinetic constants similar to those of the non-cross-linked dimer. The cross-linked dimers do not interact with non-cross-linked dimers as judged from the fact that inactive mutants do not affect their activity ( negative dominance). The results support the contention that EmrE with parallel topology is fully functional. We show that the detergents used in crystallization increase the fraction of monomers in solution. We suggest that the antiparallel orientation observed is a result of the arrangement of the monomers in the crystal. Functionality of EmrE with the suggested antiparallel orientation of the monomers remains to be characterized.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237; Soskine, Misha/0000-0002-2198-9466	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Andersen OS, 1999, NAT STRUCT BIOL, V6, P609, DOI 10.1038/10648; Bowie JU, 2006, NAT STRUCT MOL BIOL, V13, P94, DOI 10.1038/nsmb0206-94; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Daley DO, 2005, SCIENCE, V308, P1321, DOI 10.1126/science.1109730; Davidson AL, 2005, SCIENCE, V308, P963, DOI 10.1126/science.1113414; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Elbaz Y, 2005, BIOCHEMISTRY-US, V44, P7369, DOI 10.1021/bi050356t; Elbaz Y, 2004, P NATL ACAD SCI USA, V101, P1519, DOI 10.1073/pnas.0306533101; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Gouaux E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Locher KP, 2003, SCIENCE, V301, P603, DOI 10.1126/science.1088621; LOLKEMA JS, 1983, EUR J BIOCHEM, V130, P287, DOI 10.1111/j.1432-1033.1983.tb07149.x; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; Molteni V, 2001, ACTA CRYSTALLOGR D, V57, P536, DOI 10.1107/S0907444901001652; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Ninio S, 2004, FEBS LETT, V562, P193, DOI 10.1016/S0014-5793(04)00240-6; Pornillos O, 2006, FEBS LETT, V580, P358, DOI 10.1016/j.febslet.2005.12.054; Pornillos O, 2005, SCIENCE, V310, P1950, DOI 10.1126/science.1119776; Rapp M, 2006, NAT STRUCT MOL BIOL, V13, P112, DOI 10.1038/nsmb1057; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Sikora CW, 2005, BIOPHYS J, V88, P475, DOI 10.1529/biophysj.104.049247; Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899; Steiner-Mordoch S., 1999, J BIOL CHEM, V274, P19480; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2003, J MOL BIOL, V332, P229, DOI 10.1016/S0022-2836(03)00895-7; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200	35	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36205	36212		10.1074/jbc.M607186200	http://dx.doi.org/10.1074/jbc.M607186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003034	hybrid			2022-12-25	WOS:000242100500071
J	Zerbinatti, CV; Wahrle, SE; Kim, H; Cam, JA; Bales, K; Paul, SM; Holtzman, DM; Bu, GJ				Zerbinatti, Celina V.; Wahrle, Suzanne E.; Kim, Hyungjin; Cam, Judy A.; Bales, Kelly; Paul, Steven M.; Holtzman, David M.; Bu, Guojun			Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal A beta 42 accumulation in amyloid model mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; A-BETA; PRECURSOR PROTEIN; LDL-RECEPTOR; SECRETED APOE; DEPOSITION; PEPTIDE; LRP; NEURONS	The low density lipoprotein receptor-related protein (LRP) is highly expressed in the brain and has been shown to alter the metabolism of amyloid precursor protein and amyloid-beta peptide (A beta) in vitro. Previously we developed mice that overexpress a functional LRP minireceptor (mLRP2) in their brains and crossed them to the PDAPP mouse model of Alzheimer disease. Overexpression of mLRP2 in 22-month-old PDAPP mice with amyloid plaques increased a pool of carbonate-soluble A beta in the brain and worsened memory-related behavior. In the current study, we examined the effects of mLRP2 overexpression on 3-month-old PDAPP mice that had not yet developed amyloid plaques. We found significantly higher levels of membrane-associated A beta 42 in the hippocampus of mice that overexpressed mLRP2. Using immunohistochemical methods, we observed significant intraneuronal A beta 42 in the hippocampus and frontal cortex of PDAPP mice, which frequently co-localized with the lysosomal marker LAMP-1. Interestingly, PDAPP mice lacking apolipoprotein E ( apoE) had much less intraneuronal A beta 42. We also found that PC12 cells overexpressing mLRP2 cleared A beta 42 and A beta 40 more rapidly from media than PC12 cells transfected with the vector only. Preincubation of apoE3 or apoE4 with A beta 42 increased the rate of A beta clearance, and this effect was partially blocked by receptor- associated protein. Our results support the hypothesis that LRP binds and endocytoses A beta 42 both directly and via apoE but that endocytosed A beta 42 is not completely degraded and accumulates in intraneuronal lysosomes.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Lilly Res Labs, Neurosci Discovery Res, Indianapolis, IN 46285 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Eli Lilly	Bu, GJ (corresponding author), Campus Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	bu@wustl.edu	Paul, Steve/ABE-5400-2020	Schindler, Suzanne/0000-0002-1680-1465	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS041872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027924] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG027924] Funding Source: Medline; NINDS NIH HHS [F32-NS41872] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 1998, J BIOL CHEM, V273, P13359, DOI 10.1074/jbc.273.21.13359; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Cataldo AM, 2004, NEUROBIOL AGING, V25, P1263, DOI 10.1016/j.neurobiolaging.2004.02.027; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364; Du YS, 1997, J NEUROCHEM, V69, P299; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Harris-White ME, 2004, J NEUROSCI RES, V77, P217, DOI 10.1002/jnr.20149; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LaDu MJ, 2006, BIOCHEMISTRY-US, V45, P381, DOI 10.1021/bi051765s; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Langui D, 2004, AM J PATHOL, V165, P1465, DOI 10.1016/S0002-9440(10)63405-0; Mochizuki A, 2000, LANCET, V355, P42, DOI 10.1016/S0140-6736(99)04937-5; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pasternak SH, 2004, J ALZHEIMERS DIS, V6, P53; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Ruiz J, 2005, J LIPID RES, V46, P1721, DOI 10.1194/jlr.M500114-JLR200; Shie FS, 2003, NEUROREPORT, V14, P123, DOI 10.1097/00001756-200301200-00023; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	46	102	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36180	36186		10.1074/jbc.M604436200	http://dx.doi.org/10.1074/jbc.M604436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012232	hybrid			2022-12-25	WOS:000242100500068
J	Wilczynska, KM; Gopalan, SM; Bugno, M; Kasza, A; Konik, BS; Bryan, L; Wright, S; Griswold-Prenner, I; Kordula, T				Wilczynska, Katarzyna M.; Gopalan, Sunita M.; Bugno, Marcin; Kasza, Aneta; Konik, Barbara S.; Bryan, Lauren; Wright, Sarah; Griswold-Prenner, Irene; Kordula, Tomasz			A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; ONCOSTATIN-M; MATRIX-METALLOPROTEINASE; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; GENE; ALPHA; TIMP-1	Reactive astrogliosis is the gliotic response to brain injury with activated astrocytes and microglia being the major effector cells. These cells secrete inflammatory cytokines, proteinases, and proteinase inhibitors that influence extracellular matrix (ECM) remodeling. In astrocytes, the expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) is up-regulated by interleukin-1 (IL-1), which is a major neuroinflammatory cytokine. We report that IL-1 activates TIMP-1 expression via both the IKK/NF-kappa B and MEK3/6/p38/ATF-2 pathways in astrocytes. The activation of the TIMP-1 gene can be blocked by using pharmacological inhibitors, including BAY11-7082 and SB202190, overexpression of the dominant-negative inhibitor of NF-kappa B (I kappa B alpha SR), or by the knock-down of p65 subunit of NF-kappa B. Binding of activated NF-kappa B (p50/p65 heterodimer) and ATF-2 (homodimer) to two novel regulatory elements located -2.7 and -2.2 kb upstream of the TIMP-1 transcription start site, respectively, is required for full IL-1-responsiveness. Mutational analysis of these regulatory elements and their weak activity when linked to the minimal tk promoter suggest that cooperative binding is required to activate transcription. In contrast to astrocytes, we observed that TIMP-1 is expressed at lower levels in gliomas and is not regulated by IL-1. We provide evidence that the lack of TIMP-1 activation in gliomas results from either dysfunctional IKK/NF-kappa B or MEK3/6/p38/ATF-2 activation by IL-1. In summary, we propose a novel mechanism of TIMP-1 regulation, which ensures an increased supply of the inhibitor after brain injury, and limits ECM degradation. This mechanism does not function in gliomas, and may in part explain the increased invasiveness of glioma cells.	Virginia Commonwealth Univ, Dept Biochem, Sch Med, Richmond, VA 23298 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Elan Pharmaceut, San Francisco, CA 94080 USA; Jagiellonian Univ, Fac Biotechnol, Dept Cell Biochem, Krakow, Poland	Virginia Commonwealth University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Jagiellonian University	Kordula, T (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Sch Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.	tkordula@vcu.edu	Paugh, Barbara/B-3625-2009		NINDS NIH HHS [NS044118, NS046280] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R15NS046280, R01NS044118] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bertrand-Philippe M, 2004, J BIOL CHEM, V279, P24530, DOI 10.1074/jbc.M311804200; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Bugno M, 1999, FEBS LETT, V448, P9, DOI 10.1016/S0014-5793(99)00323-3; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Dean G, 2000, J BIOL CHEM, V275, P32664, DOI 10.1074/jbc.275.42.32664; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700; Ditsworth D, 2004, CANCER BIOL THER, V3, P1214, DOI 10.4161/cbt.3.12.1391; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Edwards DR, 2000, TISSUE INHIBITORS OF METALLOPROTEINASES IN DEVELOPMENT AND DISEASE, PROCEEDINGS, P13; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Funakoshi M, 2001, BIOCHEM BIOPH RES CO, V283, P248, DOI 10.1006/bbrc.2001.4759; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Gopalan S, 2005, J NEUROCHEM, V94, P763, DOI 10.1111/j.1471-4159.2005.03204.x; Gopalan SM, 2006, J BIOL CHEM, V281, P1956, DOI 10.1074/jbc.M510935200; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Groft LL, 2001, BRIT J CANCER, V85, P55, DOI 10.1054/bjoc.2001.1854; Guo CJ, 2004, GLIA, V48, P259, DOI 10.1002/glia.20079; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Han R, 2005, J IMMUNOL, V174, P3072, DOI 10.4049/jimmunol.174.5.3072; Hiramitsu T, 2006, RHEUMATOLOGY, V45, P824, DOI 10.1093/rheumatology/kel026; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kasza A, 2002, J NEUROCHEM, V83, P696, DOI 10.1046/j.1471-4159.2002.01163.x; Kiss DL, 2005, J NEUROCHEM, V92, P730, DOI 10.1111/j.1471-4159.2004.02900.x; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Moynagh PN, 2005, J ANAT, V207, P265, DOI 10.1111/j.1469-7580.2005.00445.x; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagase H, 1999, ANN NY ACAD SCI, V878, P1, DOI 10.1111/j.1749-6632.1999.tb07670.x; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Russell JS, 2002, MOL BIOL CELL, V13, P3431, DOI 10.1091/mbc.E02-05-0252; Saporta S, 1992, J Fla Med Assoc, V79, P645; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Suryadevara R, 2003, GLIA, V44, P47, DOI 10.1002/glia.10266; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; UEDA A, 1994, J IMMUNOL, V153, P2052; Valter MM, 1999, INT J DEV NEUROSCI, V17, P565, DOI 10.1016/S0736-5748(99)00048-9; VanMeter TE, 2001, J NEURO-ONCOL, V53, P213, DOI 10.1023/A:1012280925031; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yang EV, 2002, J NEUROIMMUNOL, V133, P144, DOI 10.1016/S0165-5728(02)00270-9; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	53	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34955	34964		10.1074/jbc.M604616200	http://dx.doi.org/10.1074/jbc.M604616200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17012236	hybrid, Green Published			2022-12-25	WOS:000241933700028
J	Macey, TA; Lowe, JD; Chavkin, C				Macey, Tara A.; Lowe, Janet D.; Chavkin, Charles			Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESENSITIZATION; KINASE; MORPHINE; PHOSPHORYLATION; INTERNALIZATION; EFFICACY; RESENSITIZATION; ENDOCYTOSIS; EXPRESSION; TOLERANCE	In this study we investigated the mechanisms responsible for MAP kinase ERK1/2 activation following agonist activation of endogenous mu opioid receptors (MOR) normally expressed in cultured striatal neurons. Treatment with the MOR agonist fentanyl caused significant activation of ERK1/2 in neurons derived from wild type mice. Fentanyl effects were blocked by the opioid antagonist naloxone and were not evident in neurons derived from MOR knock-out (-/-) mice. In contrast, ERK1/2 activation by fentanyl was not evident in neurons from GRK3(-/-) mice or neurons pretreated with small inhibitory RNA for arrestin3. Consistent with this observation, treatment with the opiate morphine (which is less able to activate arrestin) did not elicit ERK1/2 activation in wild type neurons; however, transfection of arrestin3-(R170E) (a dominant positive form of arrestin that does not require receptor phosphorylation for activation) enabled morphine activation of ERK1/2. In addition, activation of ERK1/2 by fentanyl and morphine was rescued in GRK3(-/-) neurons following transfection with dominant positive arrestin3(R170E). The activation of ERK1/2 appeared to be selective as p38 MAP kinase activation was not increased by either fentanyl or morphine treatment in neurons from wild type, MOR-/-, or GRK3(-/-) mice. In addition, U0126 (a selective inhibitor of MEK kinase responsible for ERK phosphorylation) blocked ERK1/2 activation by fentanyl. These results support the hypothesis that MOR activation of ERK1/2 requires opioid receptor phosphorylation by GRK3 and association of arrestin3 to initiate the cascade resulting in ERK1/2 phosphorylation in striatal neurons.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Box 357280,1959 Pacific Ave NE, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010		NIDA NIH HHS [R37 DA011672-08, R01DA11672, R37 DA011672, R37 DA011672-07, R01 DA016898-05, R01 DA016898, R37 DA011672-06, R01 DA011672] Funding Source: Medline; NINDS NIH HHS [T32NS07332, T32 NS007332] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA011672, R01DA011672, R01DA016898] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Bruchas MR, 2006, J BIOL CHEM, V281, P18081, DOI 10.1074/jbc.M513640200; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Clark MJ, 2004, J PHARMACOL EXP THER, V310, P215, DOI 10.1124/jpet.103.064824; Dang VC, 2005, MOL PHARMACOL, V68, P1127, DOI 10.1124/mol.105.013185; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Kovoor A, 1998, MOL PHARMACOL, V54, P704; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Ma WY, 2001, EUR J NEUROSCI, V14, P1091, DOI 10.1046/j.0953-816x.2001.01731.x; Macey TA, 2004, MOL PHARMACOL, V66, P1635, DOI 10.1124/mol.104.001495; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Narita M, 2002, NEUROSCI LETT, V324, P97, DOI 10.1016/S0304-3940(02)00141-6; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706; Schulz R, 2004, EUR J PHARMACOL, V500, P487, DOI 10.1016/j.ejphar.2004.07.010; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Terman GW, 2004, BRIT J PHARMACOL, V141, P55, DOI 10.1038/sj.bjp.0705595; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	32	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34515	34524		10.1074/jbc.M604278200	http://dx.doi.org/10.1074/jbc.M604278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16982618	Green Accepted, hybrid			2022-12-25	WOS:000241767600072
J	O'Connor, MN; Smethurst, PA; Davies, LW; Joutsi-Korhonen, L; Onley, DJ; Herr, AB; Farndale, RW; Ouwehand, WH				O'Connor, Marie N.; Smethurst, Peter A.; Davies, Lorna W.; Joutsi-Korhonen, Lotta; Onley, David J.; Herr, Andrew B.; Farndale, Richard W.; Ouwehand, Willem H.			Selective blockade of glycoprotein VI clustering on collagen helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; INDUCED THROMBUS FORMATION; PLATELET COLLAGEN; IMMUNOGLOBULIN SUPERFAMILY; TYROSINE PHOSPHORYLATION; BINDING; ALPHA(2)BETA(1); ACTIVATION; RESPONSES; ANTIBODY	Platelet activation by collagen relies on the interaction of the receptor glycoprotein VI ( GPVI) with collagen helices. We have previously generated two recombinant single chain human antibodies (scFvs) to human GPVI. The first, 10B12, binds to the collagen-binding site on the apical surface between the two immunoglobulin-like domains (D1D2) of the receptor and so directly inhibits GPVI function. The second, 1C3, binds D1D2 independently of 10B12 and has been shown to have a more subtle effect on platelet responses to collagen. Here we have shown that 1C3 potentiates the effect of 10B12 on platelet aggregation induced by collagen and cross-linked collagen-related peptide (CRP-XL). We investigated this by measuring the effect of both scFvs on the binding of D1D2 to immobilized collagen and CRP. As expected, 10B12 completely inhibited binding of GPVI to each ligand in a dose-dependent manner. However, 1C3 inhibited only a proportion of GPVI binding to its ligands, implying that it interferes with another aspect of ligand recognition by GPVI. To further understand the mode of inhibition, we used a unique set of CRPs in which the content of critical glycine-proline-hydroxyproline (GPO) triplets was varied in relation to an "inert" scaffold sequence of GPP motifs. We observed that a stepwise increase in D1D2 binding with (GPO) 2 content was blocked by 1C3. Together these results indicate that 1C3 inhibits clustering of the immunoglobulin- like domains of GPVI on collagen/CRPs, a conclusion that is supported by mapping the 1C3 epitope to the region including isoleucine 148 in D2.	Univ Cambridge, Dept Haematol, Div Transfus Med, Cambridge CB2 2PT, England; Natl Blood Serv Cambridge, Cambridge CB2 2PT, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Cambridge; University of Cambridge; University System of Ohio; University of Cincinnati	Smethurst, PA (corresponding author), Univ Cambridge, Dept Haematol, Div Transfus Med, Long Rd, Cambridge CB2 2PT, England.	pas28@cam.ac.uk	Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399	Medical Research Council [G0400701] Funding Source: Medline; MRC [G0400701] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asselin J, 1999, BIOCHEM J, V339, P413, DOI 10.1042/0264-6021:3390413; BERNATOWICZ MS, 1986, ANAL BIOCHEM, V155, P95, DOI 10.1016/0003-2697(86)90231-9; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; DeLano WL, 2002, PYMOL USERS MANUAL; Farndale RW, 2003, BIOCHEM SOC SYMP, V70, P81, DOI 10.1042/bss0700081; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; Horii K, 2006, BLOOD, V108, P936, DOI 10.1182/blood-2006-01-010215; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JENNINGS NS, 2006, IN PRESS J IMMUNOL M; Joutsi-Korhonen L, 2003, BLOOD, V101, P4372, DOI 10.1182/blood-2002-08-2591; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Miura Y, 2002, J BIOL CHEM, V277, P46197, DOI 10.1074/jbc.M204029200; Montigiani S, 1996, J MOL BIOL, V258, P6, DOI 10.1006/jmbi.1996.0229; O'Connor MN, 2006, J THROMB HAEMOST, V4, P869, DOI 10.1111/j.1538-7836.2005.01764.x; Penz S, 2005, FASEB J, V19, P898, DOI 10.1096/fj.04-2748com; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; Perret S, 2003, J BIOL CHEM, V278, P29873, DOI 10.1074/jbc.M304073200; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; Smethurst PA, 2004, BLOOD, V103, P903, DOI 10.1182/blood-2003-01-0308; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Watkins NA, 2006, J THROMB HAEMOST, V4, P1197, DOI 10.1111/j.1538-7836.2006.01937.x; Watkins NA, 2000, TISSUE ANTIGENS, V55, P219, DOI 10.1034/j.1399-0039.2000.550305.x	26	21	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33505	33510		10.1074/jbc.M606480200	http://dx.doi.org/10.1074/jbc.M606480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956881	hybrid			2022-12-25	WOS:000241621400061
J	Palazuelos, J; Aguado, T; Egia, A; Mechoulam, R; Guzman, M; Galve-Roperh, I				Palazuelos, Javier; Aguado, Tania; Egia, Ainara; Mechoulam, Raphael; Guzman, Manuel; Galve-Roperh, Ismael			Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation	FASEB JOURNAL			English	Article						signaling systems; hippocampus; neurogenesis	RECEPTOR; BRAIN; NEUROGENESIS; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION; INVOLVEMENT; ACTIVATION; MIGRATION	Cannabinoids, the active components of marijuana and their endogenous counterparts, act on the brain and many other organs through the widely expressed CB1 cannabinoid receptor. In contrast, the CB2 cannabinoid receptor is abundant in the immune system and shows a restricted expression pattern in brain cells. CB2-selective agonists are, therefore, very attractive therapeutic agents as they do not cause CB1-mediated psychoactive effects. CB2 receptor expression in brain has been partially examined in differentiated cells, while its presence and function in neural progenitor cells remain unknown. Here we show that the CB2 receptor is expressed, both in vitro and in vivo, in neural progenitors from late embryonic stages to adult brain. Selective pharmacological activation of the CB2 receptor in vitro promotes neural progenitor cell proliferation and neurosphere generation, an action that is impaired in CB2-deficient cells. Accordingly, in vivo experiments evidence that hippocampal progenitor proliferation is increased by administration of the CB2-selective agonist HU-308. Moreover, impaired progenitor proliferation was observed in CB2-deficient mice both in normal conditions and on kainate-induced excitotoxicity. These findings provide a novel physiological role for the CB2 cannabinoid receptor and open a novel therapeutic avenue for manipulating neural progenitor cell fate.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel	Complutense University of Madrid; Hebrew University of Jerusalem	Guzman, M (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.	mgp@bbm1.ucm.es; igr@quim.ucm.es	PALAZUELOS, JAVIER/D-1211-2013; PALAZUELOS, JAVIER/AAD-7313-2020; Aguado, Tania/AAE-3972-2019; AGUADO SANCHEZ, TANIA/ABD-6975-2021; Galve-Roperh, Ismael/AAG-2369-2020	PALAZUELOS, JAVIER/0000-0002-0409-1398; AGUADO SANCHEZ, TANIA/0000-0003-4339-0443; Guzman, Manuel/0000-0001-7475-118X				Aguado T, 2005, FASEB J, V19, P1704, DOI 10.1096/fj.05-3995fje; Aguado T, 2006, J NEUROSCI, V26, P1551, DOI 10.1523/JNEUROSCI.3101-05.2006; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Ashton JC, 2006, NEUROSCI LETT, V396, P113, DOI 10.1016/j.neulet.2005.11.038; Berghuis P, 2005, P NATL ACAD SCI USA, V102, P19115, DOI 10.1073/pnas.0509494102; Bernard C, 2005, P NATL ACAD SCI USA, V102, P9388, DOI 10.1073/pnas.0409641102; Bilkei-Gorzo A, 2005, P NATL ACAD SCI USA, V102, P15670, DOI 10.1073/pnas.0504640102; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carayon P, 1998, BLOOD, V92, P3605, DOI 10.1182/blood.V92.10.3605.422k05_3605_3615; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Ibrahim MM, 2005, P NATL ACAD SCI USA, V102, P3093, DOI 10.1073/pnas.0409888102; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jorda MA, 2004, BLOOD, V104, P526, DOI 10.1182/blood-2003-12-4257; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nunez E, 2004, SYNAPSE, V53, P208, DOI 10.1002/syn.20050; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Sanchez C, 2001, CANCER RES, V61, P5784; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sinha D, 1998, J NEUROIMMUNOL, V82, P13, DOI 10.1016/S0165-5728(97)00181-1; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Villa A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/exnr.1999.7237; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667	40	166	173	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2405	+		10.1096/fj.06-6164fje	http://dx.doi.org/10.1096/fj.06-6164fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015409				2022-12-25	WOS:000241702600035
J	Yakovleva, T; Bazov, I; Cebers, G; Marinova, Z; Hara, Y; Ahmed, A; Vlaskovska, M; Johansson, BR; Hochgeschwender, U; Singh, IN; Bruce-Keller, AJ; Hurd, YL; Kaneko, T; Terenius, L; Ekstrom, TJ; Hauser, KF; Pickel, VM; Bakalkin, G				Yakovleva, Tatiana; Bazov, Igor; Cebers, Gvido; Marinova, Zoya; Hara, Yuko; Ahmed, Aisha; Vlaskovska, Mila; Johansson, Bjo Rn; Hochgeschwender, Ute; Singh, Indrapal N.; Bruce-Keller, Annadora J.; Hurd, Yasmin L.; Kaneko, Takeshi; Terenius, Lars; Ekstrom, Tomas J.; Hauser, Kurt F.; Pickel, Virginia M.; Bakalkin, Georgy			Prodynorphin storage and processing in axon terminals and dendrites	FASEB JOURNAL			English	Article							TRANS-GOLGI NETWORK; MESSENGER-RNA EXPRESSION; RAT NUCLEUS-ACCUMBENS; SECRETORY GRANULES; BIG DYNORPHIN; IMMUNOCYTOCHEMISTRY; CLEAVAGE; NEURONS; CELL; PROOPIOMELANOCORTIN	The classical view postulates that neuropeptide precursors in neurons are processed into mature neuropeptides in the somatic trans-Golgi network (TGN) and in secretory vesicles during axonal transport. Here we show that prodynorphin (PDYN), precursor to dynorphin opioid peptides, is predominantly located in axon terminals and dendrites in hippocampal and striatal neurons. The molar content of unprocessed PDYN was much greater than that of dynorphin peptides in axon terminals of PDYN-containing neurons projecting to the CA3 region of the hippocampus and in the striatal projections to the ventral tegmental area. Electron microscopy showed coexistence of PDYN and dynorphins in the same axon terminals with occasional codistribution in individual dense core vesicles. Thus, the precursor protein is apparently stored at presynaptic sites. In comparison with the hippocampus and striatum, PDYN and dynorphins were more equally distributed between neuronal somata and processes in the amygdala and cerebral cortex, suggesting regional differences in the regulation of trafficking and processing of the precursor protein. Potassium-induced depolarization activated PDYN processing and secretion of opioid peptides in neuronal cultures and in a model cell line. Regulation of PDYN storage and processing at synapses by neuronal activity or extracellular stimuli may provide a local mechanism for regulation of synaptic transmission.	Karolinska Inst, Expt Alcohol & Drug Addict Res Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA; Kyoto Univ, Dept Morphol Brain Sci, Kyoto, Japan	Karolinska Institutet; Cornell University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Kentucky; Kyoto University	Bakalkin, G (corresponding author), Karolinska Inst, Expt Alcohol & Drug Addict Res Sect, Dept Clin Neurosci, CMM L8-01, S-17176 Stockholm, Sweden.	georgy.bakalkin@ki.se	Ahmed, Aisha S/J-4619-2012; Bruce-Keller, Annadora/N-1954-2017; Hara, Yuko/B-9172-2012; Hauser, Kurt/AAX-8361-2020; Ekström, Tomas/B-7764-2013	Hara, Yuko/0000-0001-5828-442X; Bakalkin, Georgy/0000-0002-8074-9833; Bazov, Igor/0000-0003-4388-1656; Hauser, Kurt/0000-0001-7886-0332; Ahmed, Aisha/0000-0002-8483-5309	NIDA NIH HHS [DA-13278, DA-313312, DA-004600] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004600] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BAKALKIN GY, 1993, MOL BRAIN RES, V20, P137, DOI 10.1016/0169-328X(93)90119-A; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; Cawley NX, 2000, FEBS LETT, V481, P37, DOI 10.1016/S0014-5793(00)01961-X; CHAN J, 1990, J NEUROSCI METH, V33, P113, DOI 10.1016/0165-0270(90)90015-8; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; Costigan M, 2002, CELL, V108, P297, DOI 10.1016/S0092-8674(02)00640-2; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; DAY R, 1989, ENDOCRINOLOGY, V124, P2392, DOI 10.1210/endo-124-5-2392; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; De Vries TJ, 2002, J NEUROSCI, V22, P3321; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; DRAKE CT, 1994, J NEUROSCI, V14, P3736; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; FALLON JH, 1986, J COMP NEUROL, V249, P293, DOI 10.1002/cne.902490302; GAINER H, 1977, SCIENCE, V195, P1354, DOI 10.1126/science.65791; GAINER H, 1977, J CELL BIOL, V73, P366, DOI 10.1083/jcb.73.2.366; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Hara Y, 2006, SYNAPSE, V60, P1, DOI 10.1002/syn.20273; Hokfelt T, 2000, NEUROPHARMACOLOGY, V39, P1337, DOI 10.1016/S0028-3908(00)00010-1; Hopkins KJ, 2000, BRAIN RES, V864, P69, DOI 10.1016/S0006-8993(00)02137-5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hurd YL, 1996, NEUROSCIENCE, V72, P767, DOI 10.1016/0306-4522(96)00002-4; Hurd YL, 2002, MOL PSYCHIATR, V7, P75, DOI 10.1038/sj/mp/4000930; Josefsen K, 1998, ENDOCRINOLOGY, V139, P4329, DOI 10.1210/en.139.10.4329; KHACHATURIAN H, 1982, PEPTIDES, V3, P941, DOI 10.1016/0196-9781(82)90063-8; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; Kreek MJ, 2001, ANN NY ACAD SCI, V937, P27; Kuzmin A, 2006, NEUROPSYCHOPHARMACOL, V31, P1928, DOI 10.1038/sj.npp.1300959; Lee T, 1997, J COMP NEUROL, V386, P229, DOI 10.1002/(SICI)1096-9861(19970922)386:2<229::AID-CNE5>3.0.CO;2-3; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; LERANTH C, 1989, NEUROANATOMICAL TRAC, V2, P29; LEWIS RV, 1980, SCIENCE, V208, P1459, DOI 10.1126/science.7384787; Ludwig M, 1998, J NEUROENDOCRINOL, V10, P881; MANSOUR A, 1994, MOL CELL NEUROSCI, V5, P124, DOI 10.1006/mcne.1994.1015; Merg F, 2006, J NEUROCHEM, V97, P292, DOI 10.1111/j.1471-4159.2006.03732.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Morris JF, 1998, PROG BRAIN RES, V119, P21; MORRISON JH, 1984, BRAIN RES, V292, P269, DOI 10.1016/0006-8993(84)90763-7; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nguyen XV, 2005, BEHAV BRAIN RES, V161, P254, DOI 10.1016/j.bbr.2005.02.010; NYBERG F, 1986, BRAIN RES, V371, P278, DOI 10.1016/0006-8993(86)90363-X; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLETIER G, 1981, BRAIN RES, V210, P356, DOI 10.1016/0006-8993(81)90909-4; PETERS A, 1991, FINE STRUCTURE NERVO, P1; Pierce JP, 1999, HIPPOCAMPUS, V9, P255, DOI 10.1002/(SICI)1098-1063(1999)9:3<255::AID-HIPO6>3.3.CO;2-J; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Sharifi N, 2001, MOL BRAIN RES, V86, P70, DOI 10.1016/S0169-328X(00)00264-3; Svensson P, 1998, MOL BRAIN RES, V56, P162, DOI 10.1016/S0169-328X(98)00041-2; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; Tanaka S, 1997, J HISTOCHEM CYTOCHEM, V45, P425, DOI 10.1177/002215549704500310; Thureson-Klein A K, 1990, Int Rev Cytol, V121, P67, DOI 10.1016/S0074-7696(08)60659-2; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; VANBOCKSTAELE EJ, 1994, J COMP NEUROL, V341, P1, DOI 10.1002/cne.903410102; Vlaskovska M, 1997, J NEUROCHEM, V68, P517; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Winsky-Sommerer P, 2000, J COMP NEUROL, V424, P439, DOI 10.1002/1096-9861(20000828)424:3<439::AID-CNE4>3.0.CO;2-1; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; Zhang BF, 1997, J APPL POULTRY RES, V6, P94, DOI 10.1093/japr/6.1.94; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	63	41	43	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2124	+		10.1096/fj.06-6174fje	http://dx.doi.org/10.1096/fj.06-6174fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16966485				2022-12-25	WOS:000241156900027
J	Reiter, F; Hartl, M; Karagiannidis, AI; Bister, K				Reiter, F.; Hartl, M.; Karagiannidis, A. I.; Bister, K.			WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential	ONCOGENE			English	Article						cell transformation; gene expression; C/EBP; Pmel17; GPNMB	DOXYCYCLINE-CONTROLLED EXPRESSION; CONDITIONAL CELL-TRANSFORMATION; C-MYC; V-MYC; C/EBP-ALPHA; ACTIVATION; JUN; DNA; ONCOPROTEIN; METASTASIS	We have isolated a gene (WS5) that is specifically expressed at the mRNA and protein level in avian fibroblasts transformed by the v-myc oncogene of avian acute leukemia virus MC29. In a conditional cell transformation system, WS5 gene expression was tightly correlated with v-myc activation. The WS5 gene contains 11 exons, encoding a 733-amino acid protein with a transmembrane region and a polycystic kidney disease (PKD) domain. Near the transcriptional start site, the WS5 promoter contains a cluster of four binding sites for the Myc-Max complex and a binding site for transcription factor C/EBP alpha. Electrophoretic mobility shift assays and chromatin immunoprecipitation showed that Myc, Max and C/EBP alpha bind specifically to these sites. Functional promoter analyses revealed that both the Myc-binding site cluster and the C/EBP alpha-binding site are essential for strong transcriptional activation, and that Myc and C/EBP alpha synergistically activate the WS5 promoter. Ectopic expression of WS5 led to cell transformation documented by anchorage-independent growth. The human melanoma antigen Pmel17, a type I transmembrane glycoprotein, is the mammalian protein with the highest amino acid sequence identity (38%) to WS5. The Pmel17 gene is regulated by the MITF protein, a bHLHZip transcription factor with DNA binding specificities similar to those of Myc/Max. WS5 is also related to human glycoprotein GPNMB expressed in metastatic melanoma cells and implicated in the progression of brain and liver tumors.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria; Univ Innsbruck, Ctr Mol Biosci Innsbruck, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Bister, K (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	klaus.bister@uibk.ac.at	Hartl, Markus/O-4655-2014; Bister, Klaus/AFA-9400-2022	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653	Austrian Science Fund FWF [P 18148, P 17041] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Clark LA, 2006, P NATL ACAD SCI USA, V103, P1376, DOI 10.1073/pnas.0506940103; Dang CV, 1999, MOL CELL BIOL, V19, P1; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Grabe Niels, 2002, In Silico Biology, V2, pS1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hartl M, 2006, ONCOGENE, V25, P4043, DOI 10.1038/sj.onc.1209441; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; Hartl M, 2003, J MOL BIOL, V333, P33, DOI 10.1016/j.jmb.2003.08.018; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Jing H, 2002, STRUCTURE, V10, P1453, DOI 10.1016/S0969-2126(02)00840-7; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; Theos AC, 2005, PIGM CELL RES, V18, P322, DOI 10.1111/j.1600-0749.2005.00269.x; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	47	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1769	1779		10.1038/sj.onc.1209975	http://dx.doi.org/10.1038/sj.onc.1209975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964280				2022-12-25	WOS:000244955600011
J	Salzameda, B; Facemyer, KC; Beck, BW; Cremo, CR				Salzameda, Bridget; Facemyer, Kevin C.; Beck, Brian W.; Cremo, Christine R.			The N-terminal lobes of both regulatory light chains interact with the tail domain in the 10 S-inhibited conformation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; CHICKEN GIZZARD MUSCLE; ATOMIC FORCE MICROSCOPY; BRUSH-BORDER MYOSIN; HEAVY-MEROMYOSIN; ATPASE ACTIVITY; VERTEBRATE NONMUSCLE; ENZYMATIC-PROPERTIES; STRIATED-MUSCLE; EQUILIBRIUM	In the presence of ATP, unphosphorylated smooth muscle myosin can form a catalytically inactive monomer that sediments at 10 Svedbergs (10 S). The tail of 10 S bends into thirds and interacts with the regulatory domain. ADP-P-i is "trapped" at the active site, and consequently the ATPase activity is extremely low. We are interested in the structural basis for maintenance of this off state. Our prior photocross-linking work with 10 S showed that tail residues 1554-1583 are proximal to position 108 in the C-terminal lobe of one of the two regulatory light chains (Olney, J. J., Sellers, J. R., and Cremo, C. R. (1996) J. Biol. Chem. 271, 20375-20384). These data suggested that the tail interacts with only one of the two regulatory light chains. Here we present data, using a photocross-linker on position 59 on the N-terminal lobe of the regulatory light chain (RLC), demonstrating that both regulatory light chains of a single molecule can cross-link to the light meromyosin portion of the tail. Mass spectrometric data show four specific cross-linked regions spanning residues 1428-1571 in the light meromyosin portion of the tail, consistent with cross-linking two RLC to one light meromyosin. In addition, we find that position 59 can cross-link internally to residues 42-45 within the same RLC subunit. The internal cross-link only forms in 10 S and not in unphosphorylated heavy meromyosin (lacking the light meromyosin), suggesting a structural rearrangement within the RLC attributed to the interaction of the tail with the head.	Univ Nevada, Sch Med, Dept Biochem & Mol Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Cremo, CR (corresponding author), Univ Nevada, Sch Med, Dept Biochem & Mol Biol, 330,1664 N Virginia St, Reno, NV 89557 USA.	cremo@unr.edu	Beck, Brian/H-5530-2018	Beck, Brian/0000-0002-7731-3457	NCRR NIH HHS [P20 RR 016405, 1P20 RR 018751] Funding Source: Medline; NIAMS NIH HHS [R01 AR 40917] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040917] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; BARYLKO B, 1986, EUR J BIOCHEM, V158, P271, DOI 10.1111/j.1432-1033.1986.tb09747.x; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CITI S, 1989, J CELL BIOL, V109, P549, DOI 10.1083/jcb.109.2.549; CITI S, 1986, J MOL BIOL, V188, P369, DOI 10.1016/0022-2836(86)90161-0; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; CROSS RA, 1992, J STRUCT BIOL, V109, P208, DOI 10.1016/1047-8477(92)90033-7; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; CROSS RA, 1986, EMBO J, V5, P2637, DOI 10.1002/j.1460-2075.1986.tb04545.x; CROSS RA, 1988, J MUSCLE RES CELL M, V9, P108, DOI 10.1007/BF01682153; CROSS RA, 1991, J MOL BIOL, V222, P455, DOI 10.1016/0022-2836(91)90487-Q; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; FARUQI AR, 1993, ADV EXP MED BIOL, V332, P81; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HELBING D, 1993, EUR J CELL BIOL, V60, P228; HIGASHIHARA M, 1989, BIOCHEMISTRY-US, V28, P1642, DOI 10.1021/bi00430a032; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HOROWITZ A, 1994, J CELL BIOL, V126, P1195, DOI 10.1083/jcb.126.5.1195; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; Katoh T, 1998, J BIOL CHEM, V273, P11436, DOI 10.1074/jbc.273.19.11436; KENDRICKJONES J, 1987, J MOL BIOL, V198, P241, DOI 10.1016/0022-2836(87)90310-X; Konishi K, 1998, J BIOCHEM-TOKYO, V124, P163, DOI 10.1093/oxfordjournals.jbchem.a022075; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; Liu J, 2003, J MOL BIOL, V329, P963, DOI 10.1016/S0022-2836(03)00516-3; Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719; Macht M, 2004, RAPID COMMUN MASS SP, V18, P2093, DOI 10.1002/rcm.1589; Mazhari SM, 2004, J BIOL CHEM, V279, P39905, DOI 10.1074/jbc.M407062200; Offer G, 1996, J MOL BIOL, V256, P407, DOI 10.1006/jmbi.1996.0096; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; ONISHI H, 1984, J BIOCHEM-TOKYO, V95, P903, DOI 10.1093/oxfordjournals.jbchem.a134686; ONISHI H, 1983, J BIOCHEM-TOKYO, V94, P1147, DOI 10.1093/oxfordjournals.jbchem.a134459; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; Sheng ST, 2003, J BIOL CHEM, V278, P39892, DOI 10.1074/jbc.M306094200; Stoffler HE, 1998, J BIOL CHEM, V273, P14605, DOI 10.1074/jbc.273.23.14605; SUZUKI H, 1985, J BIOL CHEM, V260, P4810; TAKAHASHI M, 1989, J BIOCHEM-TOKYO, V105, P149, DOI 10.1093/oxfordjournals.jbchem.a122628; Takahashi T, 1999, J BIOCHEM-TOKYO, V126, P34, DOI 10.1093/oxfordjournals.jbchem.a022433; TAKEUCHI K, 1985, J BIOCHEM-TOKYO, V97, P1695, DOI 10.1093/oxfordjournals.jbchem.a135228; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Wahlstrom JL, 2003, J BIOL CHEM, V278, P5123, DOI 10.1074/jbc.M206963200; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098; Woodhead JL, 2005, NATURE, V436, P1195, DOI 10.1038/nature03920; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328; Xu JQ, 1996, J CELL BIOL, V134, P53, DOI 10.1083/jcb.134.1.53; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097; Zhang YY, 1997, BIOPHYS J, V72, P1308, DOI 10.1016/S0006-3495(97)78777-0	62	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38801	38811		10.1074/jbc.M606555200	http://dx.doi.org/10.1074/jbc.M606555200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17012238	hybrid			2022-12-25	WOS:000242709500078
J	Barquera, B; Ramirez-Silva, L; Morgan, JE; Nilges, MJ				Barquera, Blanca; Ramirez-Silva, Leticia; Morgan, Joel E.; Nilges, Mark J.			A new flavin radical signal in the Na+-pumping NADH : quinone oxidoreductase from Vibrio cholerae - An EPR/electron nuclear double resonance investigation of the role of the covalently bound flavins in subunits B and C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING NADH; UBIQUINONE OXIDOREDUCTASE; DNA PHOTOLYASE; NQRC SUBUNITS; ALGINOLYTICUS; REDUCTASE; EPR; SPECTROSCOPY; PURIFICATION; MUTAGENESIS	The Na+ pumping NADH-ubiquinone oxidoreductase has six polypeptide subunits (NqrA-F) and a number of redox cofactors, including a noncovalently bound FAD and a 2Fe-2S center in subunit F, covalently bound FMNs in subunits B and C, and a noncovalently bound riboflavin in an undisclosed location. The FMN cofactors in subunits B and C are bound to threonine residues by phosphoester linkages. A neutral flavin-semiquinone radical is observed in the oxidized enzyme, whereas an anionic flavin-semiquinone has been reported in the reduced enzyme. For this work, we have altered the binding ligands of the FMNs in subunits B and C by replacing the threonine ligands with other amino acids, and we studied the resulting mutants by EPR and electron nuclear double resonance spectroscopy. We conclude that the sodium-translocating NADH: quinone oxidoreductase forms three spectroscopically distinct flavin radicals as follows: 1) a neutral radical in the oxidized enzyme, which is observed in all of the mutants and most likely arises from the riboflavin; 2) an anionic radical observed in the fully reduced enzyme, which is present in wild type, and the NqrC-T225Y mutant but not the NqrB-T236Y mutant; 3) a second anionic radical, seen primarily under weakly reducing conditions, which is present in wild type, and the NqrB-T236Y mutant but not the NqrC-T225Y mutant. Thus, we can tentatively assign the first anionic radical to the FMN in subunit B and the second to the FMN in subunit C. The second anionic radical has not been reported previously. In electron nuclear double resonance spectra, it exhibits a larger line width and larger 8 alpha-methyl proton splittings, compared with the first anionic radical.	Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA; Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Troy, NY 12180 USA; Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico; Illinois EPR Res Ctr, Urbana, IL 61801 USA	Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; Universidad Nacional Autonoma de Mexico	Barquera, B (corresponding author), Rensselaer Polytech Inst, Dept Biol, 110 8th St, Troy, NY 12180 USA.	barqub@rpi.edu; mjnilges@uiuc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016101, R37HL016101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069936] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16101] Funding Source: Medline; NIGMS NIH HHS [R01-GM069936] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIVERTI A, 1995, FEBS LETT, V368, P220, DOI 10.1016/0014-5793(95)00648-S; Barquera B, 2001, FEBS LETT, V492, P45, DOI 10.1016/S0014-5793(01)02224-4; Barquera B, 2002, P NATL ACAD SCI USA, V99, P10322, DOI 10.1073/pnas.162361299; Barquera B, 2004, BIOCHEMISTRY-US, V43, P12322, DOI 10.1021/bi048689y; Barquera B, 2002, BIOCHEMISTRY-US, V41, P3781, DOI 10.1021/bi011873o; Barquera B, 2003, J AM CHEM SOC, V125, P265, DOI 10.1021/ja0207201; Bogachev AV, 2005, BIOCHEMISTRY-MOSCOW+, V70, P143, DOI 10.1007/s10541-005-0093-4; Bogachev AV, 2002, BBA-BIOENERGETICS, V1556, P113, DOI 10.1016/S0005-2728(02)00342-0; Bogachev AV, 2006, BIOCHEMISTRY-US, V45, P3421, DOI 10.1021/bi052422x; Bogachev AV, 1997, FEBS LETT, V409, P475, DOI 10.1016/S0014-5793(97)00536-X; EDMONDSON DE, 1978, BIOL MAGN RESON, P205; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; Hayashi M, 2001, BBA-BIOENERGETICS, V1505, P37, DOI 10.1016/S0005-2728(00)00275-9; Hayashi M, 2001, FEBS LETT, V488, P5, DOI 10.1016/S0014-5793(00)02404-2; Hayashi M, 1996, FEBS LETT, V381, P174, DOI 10.1016/0014-5793(96)00114-7; Kay CWM, 1999, BIOCHEMISTRY-US, V38, P16740, DOI 10.1021/bi991442u; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; Nakayama Y, 2000, FEBS LETT, V474, P165, DOI 10.1016/S0014-5793(00)01595-7; Nilges M. J., 1979, THESIS U ILLINOIS UR; PfenningerLi XD, 1996, BIOCHEMISTRY-US, V35, P6233, DOI 10.1021/bi953032l; TOKUDA H, 1984, J BIOL CHEM, V259, P7785; Turk K, 2004, J BIOL CHEM, V279, P21349, DOI 10.1074/jbc.M311692200; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m; Wunsch P, 2005, J BACTERIOL, V187, P1992, DOI 10.1128/JB.187.6.1992-2001.2005; Zhou WD, 1999, BIOCHEMISTRY-US, V38, P16246, DOI 10.1021/bi991664s	25	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36482	36491		10.1074/jbc.M605765200	http://dx.doi.org/10.1074/jbc.M605765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16973619	hybrid			2022-12-25	WOS:000242220800003
J	Davis, CW; Mattei, LM; Nguyen, HY; Ansarah-Sobrinho, C; Doms, RW; Pierson, TC				Davis, Carl W.; Mattei, Lisa M.; Nguyen, Hai-Yen; Ansarah-Sobrinho, Camilo; Doms, Robert W.; Pierson, Theodore C.			The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS ENVELOPE PROTEINS; RECEPTORS DC-SIGN; C-TYPE LECTIN; DENGUE VIRUS; EXTRACELLULAR GLYCOSIDASES; CARBOHYDRATE-RECOGNITION; DIPLOCOCCUS PNEUMONIAE; STRUCTURAL BASIS; LIGAND-BINDING; HIGH-MANNOSE	Mammalian cell-derived West Nile virus preferentially infects cells expressing the C-type lectin CD209L (dendritic cell-specific ICAM-3 grabbing nonintegrin-related protein; liver- and lymph node-specific ICAM-3 grabbing nonintegrin) but not cells expressing CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). In contrast, Dengue virus infection is enhanced in cells expressing either attachment factor. The West Nile virus envelope (E) protein contains a single N-linked glycosylation site at residue 154, whereas Dengue virus E contains sites at residues 153 and 67. We introduced a glycosylation site at position 67 into West Nile virus E. Reporter virus particles pseudotyped with this E protein infected cells using either CD209 or CD209L. We also introduced glycosylation sites at several novel positions. All sites allowed CD209L-mediated infection, but only a subset promoted CD209 use. As seen for other viruses, mannose-rich glycans on West Nile virus were required for its interactions with CD209. Surprisingly, however, mannose-rich glycans were not required for CD209L-mediated infection. Complex glycans, particularly N-acetylglucosamine-terminated structures, were able to mediate reporter virus particle interactions with CD209L. We propose that CD209L recognizes glycosylated flaviviruses with broad specificity, whereas CD209 is selective for flaviviruses bearing mannose-rich glycans. The location of the N-linked glycosylation sites on a virion determines the types of glycans incorporated, thus controlling viral tropism for CD209-expressing cells.	NIH, Viral Dis Lab, Viral Pathogenesis Sect, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; University of Pennsylvania	Pierson, TC (corresponding author), NIH, Viral Dis Lab, Viral Pathogenesis Sect, 4 Ctr Dr,Bldg 4,Room 216, Bethesda, MD 20892 USA.	piersontc@mail.nih.gov		Mattei, Lisa/0000-0002-2238-0281	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [U54 AI57168, T32 AI07632, AI50469] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI001022, U54AI057168, R01AI050469, T32AI007632] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Bashirova AA, 2003, J VIROL, V77, P217, DOI 10.1128/JVI.77.1.217-227.2003; Beasley DWC, 2005, J VIROL, V79, P8339, DOI 10.1128/JVI.79.13.8339-8347.2005; Beasley DWC, 2004, EMERG INFECT DIS, V10, P2221, DOI 10.3201/eid1012.040647; Beasley DWC, 2004, ARCH VIROL, P35; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Chambers TJ, 1998, J GEN VIROL, V79, P2375, DOI 10.1099/0022-1317-79-10-2375; CHU FK, 1986, J BIOL CHEM, V261, P172; Davis BS, 2001, J VIROL, V75, P4040, DOI 10.1128/JVI.75.9.4040-4047.2001; Davis CW, 2006, J VIROL, V80, P1290, DOI 10.1128/JVI.80.3.1290-1301.2006; Drickamer K, 1996, BIOCHEM SOC T, V24, P146, DOI 10.1042/bst0240146; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; Gehrke R, 2003, J VIROL, V77, P8924, DOI 10.1128/JVI.77.16.8924-8933.2003; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Granelli-Piperno A, 2005, J IMMUNOL, V175, P4265, DOI 10.4049/jimmunol.175.7.4265; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Hanna SL, 2005, J VIROL, V79, P13262, DOI 10.1128/JVI.79.21.13262-13274.2005; HSIEH P, 1984, J BIOL CHEM, V259, P2375; HUGHES RC, 1964, BIOCHEMISTRY-US, V3, P1535, DOI 10.1021/bi00898a025; HUGHES RC, 1964, BIOCHEMISTRY-US, V3, P1543, DOI 10.1021/bi00898a026; Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101; Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043; JOHNSON AJ, 1994, VIROLOGY, V203, P241, DOI 10.1006/viro.1994.1481; Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034; Keelapang P, 2004, J VIROL, V78, P2367, DOI 10.1128/JVI.78.5.2367-2381.2004; Khromykh AA, 1998, J VIROL, V72, P5967, DOI 10.1128/JVI.72.7.5967-5977.1998; Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003; Koppel EA, 2005, CELL MICROBIOL, V7, P157, DOI 10.1111/J.1462-5822.2004.00480.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Lee B, 2001, J VIROL, V75, P12028, DOI 10.1128/JVI.75.24.12028-12038.2001; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Pierson TC, 2006, VIROLOGY, V346, P53, DOI 10.1016/j.virol.2005.10.030; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; Rosen L, 1999, AM J TROP MED HYG, V61, P720, DOI 10.4269/ajtmh.1999.61.720; Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550; Scherret JH, 2001, ANN NY ACAD SCI, V951, P361, DOI 10.1111/j.1749-6632.2001.tb02719.x; Scholle F, 2004, J VIROL, V78, P11605, DOI 10.1128/JVI.78.21.11605-11614.2004; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; WENGLER G, 1989, J VIROL, V63, P2521, DOI 10.1128/JVI.63.6.2521-2526.1989; Wu L, 2002, P NATL ACAD SCI USA, V99, P1568, DOI 10.1073/pnas.032654399; Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553; YAMASHITA K, 1981, BIOCHEM BIOPH RES CO, V100, P226, DOI 10.1016/S0006-291X(81)80086-1; Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270	63	78	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37183	37194		10.1074/jbc.M605429200	http://dx.doi.org/10.1074/jbc.M605429200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17001080	hybrid			2022-12-25	WOS:000242220800079
J	Kasashima, K; Ohta, E; Kagawa, Y; Endo, H				Kasashima, Katsumi; Ohta, Eriko; Kagawa, Yasuo; Endo, Hitoshi			Mitochondrial functions and estrogen receptor-dependent nuclear translocation of pleiotropic human prohibitin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATIVE LIFE-SPAN; TRANSCRIPTIONAL ACTIVITY; INTRACELLULAR PROTEIN; ACTIVITY REA; CELL-DEATH; FAMILY; HAX-1; GENE; REPRESSOR; RB	Proteins with multiple cellular functions provide biological diversity to eukaryotic cells. In the current studies, we identified the mitochondrial functions of human prohibitin 2 (PHB2), which was initially identified as a repressor of estrogen-dependent transcriptional activity. The mitochondrial complex of PHB2 consists of PHB1, voltage-dependent anion channel 2, adenine nucleotide translocator 2, and the anti-apoptotic Hax-1, which is a novel binding partner for PHB2. RNA interference-mediated knockdown of PHB2 in HeLa cells resulted in caspase-dependent apoptosis through down-regulation of Hax-1 and fragmentation of mitochondria. We also found that, although PHB2 is predominantly expressed in the mitochondria of HeLa cells, it translocates to nucleus in the presence of estrogen receptor alpha and estradiol. Here, we first demonstrated the roles of mammalian PHB2 in mitochondria and the molecular mechanism of its nuclear targeting and showed that PHB2 is a possible molecule directly coupling nuclear-mitochondrial interaction.	Jichi Med Univ, Dept Biochem, Shimotsuke, Tochigi 3290498, Japan	Jichi Medical University	Endo, H (corresponding author), Jichi Med Univ, Dept Biochem, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	hendo@jichi.ac.jp						Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Chen JQ, 2005, BBA-MOL CELL RES, V1746, P1, DOI 10.1016/j.bbamcr.2005.08.001; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; EVELETH DD, 1986, NUCLEIC ACIDS RES, V14, P6169, DOI 10.1093/nar/14.15.6169; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; Kurtev V, 2004, J BIOL CHEM, V279, P24834, DOI 10.1074/jbc.M312300200; Loukas A, 1998, DNA SEQUENCE, V9, P323; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Mirmohammadsadegh A, 2003, J INVEST DERMATOL, V120, P1045, DOI 10.1046/j.1523-1747.2003.12247.x; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Park SE, 2005, MOL CELL BIOL, V25, P1989, DOI 10.1128/MCB.25.5.1989-1999.2005; Piper PW, 2002, AGING CELL, V1, P149, DOI 10.1046/j.1474-9728.2002.00018.x; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; SATO T, 1992, CANCER RES, V52, P1643; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Sharp TV, 2002, J VIROL, V76, P802, DOI 10.1128/JVI.76.2.802-816.2002; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Snedden WA, 1997, PLANT MOL BIOL, V33, P753, DOI 10.1023/A:1005737026289; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 1997, J IMMUNOL, V158, P2736; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684	40	149	161	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36401	36410		10.1074/jbc.M605260200	http://dx.doi.org/10.1074/jbc.M605260200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008324	hybrid			2022-12-25	WOS:000242100500091
J	Abid, MR; Shih, SC; Otu, HH; Spokes, KC; Okada, Y; Curiel, DT; Minami, T; Aird, WC				Abid, Md. Ruhul; Shih, Shu-Ching; Otu, Hasan H.; Spokes, Katherine C.; Okada, Yoshiaki; Curiel, David T.; Minami, Takashi; Aird, William C.			A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FOXO3A; PHOSPHOINOSITIDE 3-KINASE PATHWAY; PROTEIN-KINASE-C; SIGNALING PATHWAY; OXIDATIVE STRESS; CELL GROWTH; FACTOR FKHR; PHOSPHOENOLPYRUVATE CARBOXYKINASE; TERMINAL FRAGMENT; KAPPA-B	Recently, we have shown that transient phosphorylation and inhibition of the pro-apoptotic transcription factor, forkhead, by vascular endothelial growth factor (VEGF) is essential for endothelial cell (EC) survival and proliferation. The goal of the present study was to determine whether forkhead (FKHR) also plays a positive role in agonist-mediated gene induction. Human coronary artery ECs were transduced with adenovirus overexpressing constitutively active phosphorylation-resistant triple mutant FKHR or transfected with small interference RNA (siRNA) against FKHR. The cells were then treated in the absence or presence of VEGF and assayed for gene expression using quantitative real-time PCR and Northern blots analyses. The data revealed a novel set of VEGF-responsive genes that require FKHR activity for optimal expression in ECs, including bone morphogenic protein 2, cbp/p300-interacting transactivator 2, decay accelerating factor (DAF), vascular cell adhesion molecule-1 (VCAM-1), manganese superoxide dismutase, endothelial-specific molecule-1, RING1 and YY1-binding protein, and matrix metalloproteinase-10. Consistent with a positive role for FKHR in mediating VEGF induction of DAF and VCAM-1 mRNA, siRNA against FKHR attenuated the effect of VEGF on complement-mediated EC lysis and monocyte adhesion, respectively. VEGF induction of the forkhead-dependent genes was down-regulated by the NF-kappa B inhibitor, constitutively active Ad-I kappa B, and in some cases by the nuclear factor of activated T-cells (NF-AT) inhibitor, cyclosporin. Together, these findings suggest that the VEGF-forkhead signaling axis plays an important functional role in ECs beyond the regulation of cell survival/apoptosis and cell cycle.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Genom Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Mol & Vasc Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Univ Alabama Birmingham, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Obstet & Gynecol, Div Human Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Div Human Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Div Human Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gene Therapy Ctr, Birmingham, AL 35294 USA; Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo 153, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Tokyo	Abid, MR (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Genom Ctr, E-RW-663,330 Brookline Ave, Boston, MA 02215 USA.	rabid@bidmc.harvard.edu	Okada, Yoshiaki/M-8718-2017	Otu, Hasan/0000-0002-9253-8152	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL077348, R01 HL077348] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2004, J BIOL CHEM, V279, P44030, DOI 10.1074/jbc.M408285200; Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bilbao G, 1999, J VIROL, V73, P6992, DOI 10.1128/JVI.73.8.6992-7000.1999; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen ZQ, 1997, CANCER RES, V57, P2013; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Mason JC, 2004, J BIOL CHEM, V279, P41611, DOI 10.1074/jbc.M407981200; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Mukhopadhyay D, 2004, MOL CELL BIOCHEM, V264, P51, DOI 10.1023/B:MCBI.0000044374.85095.df; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Stupack DG, 2004, CURR TOP DEV BIOL, V64, P207, DOI 10.1016/S0070-2153(04)64009-9; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yanase S, 2002, MECH AGEING DEV, V123, P1579, DOI 10.1016/S0047-6374(02)00093-3; Zachary I, 2000, ARTERIOSCL THROM VAS, V20, P1512, DOI 10.1161/01.ATV.20.6.1512	49	43	43	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35544	35553		10.1074/jbc.M608620200	http://dx.doi.org/10.1074/jbc.M608620200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980307	hybrid			2022-12-25	WOS:000241933700087
J	Sehgal, BU; DeBiase, PJ; Matzno, S; Chew, TL; Claiborne, JN; Hopkinson, SB; Russell, A; Marinkovich, MP; Jones, JCR				Sehgal, Bernd U.; DeBiase, Phillip J.; Matzno, Sumio; Chew, Teng-Leong; Claiborne, Jessica N.; Hopkinson, Susan B.; Russell, Alan; Marinkovich, M. Peter; Jones, Jonathan C. R.			Integrin beta 4 regulates migratory behavior of keratinocytes by determining laminin-332 organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-3-BETA-1 INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; EPITHELIAL-CELLS; LIM-KINASE; MATRIX METALLOPROTEASE-2; PLASMINOGEN-ACTIVATOR; BETA(4) SUBUNIT; GAMMA-2 CHAIN; RHO-GTPASES; COFILIN	hether alpha 6 beta 4 integrin regulates migration remains controversial. beta 4 integrin-deficient (JEB) keratinocytes display aberrant migration in that they move in circles, a behavior that mirrors the circular arrays of laminin (LM)-332 in their matrix. In contrast, wild-type keratinocytes and JEB keratinocytes, induced to express beta 4 integrin, assemble laminin-332 in linear tracks over which they migrate. Moreover, laminin-332-dependent migration of JEB keratinocytes along linear tracks is restored when cells are plated on wild-type keratinocyte matrix, whereas wild-type keratinocytes show rotation over circular arrays of laminn-332 in JEB keratinocyte matrix. The activities of Rac1 and the actin cytoskeleton-severing protein cofilin are low in JEB keratinocytes compared with wild-type cells but are rescued following expression of wild-type beta 4 integrin in JEB cells. Additionally, in wild-type keratinocytes Rac1 is complexed with alpha 6 beta 4 integrin. Moreover, Rac1 or cofilin inactivation induces wild-type keratinocytes to move in circles over rings of laminin-332 in their matrix. Together these data indicate that laminin-332 matrix organization is determined by the alpha 6 beta 4 integrin/actin cytoskeleton via Rac1/cofilin signaling. Furthermore, our results imply that the organizational state of laminin-332 is a key determinant of the motility behavior of keratinocytes, an essential element of skin wound healing and the successful invasion of epidermal-derived tumor cells.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Cytokinet Inc, Dept Mol & Cell Biol, San Francisco, CA 94080 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA	Northwestern University; Feinberg School of Medicine; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Jones, JCR (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	j-jones3@northwestern.edu	Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922; Russell, Alan/0000-0001-7545-5008	NIAMS NIH HHS [T32 AR007593, R01 AR054184, R01 AR054184-17, R01 AR054184-18] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007593, R01AR054184] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; BANNON LJ, 2001, CELL ADHESION, P324; Baudoin C, 2005, J INVEST DERMATOL, V125, P883, DOI 10.1111/j.0022-202X.2005.23881.x; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; Cancelas JA, 2005, NAT MED, V11, P886, DOI 10.1038/nm1274; CARTER BZ, 1991, LAB INVEST, V65, P610; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Danen EHJ, 2005, J CELL BIOL, V169, P515, DOI 10.1083/jcb.200412081; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; DeHart GW, 2003, EXP CELL RES, V283, P67, DOI 10.1016/S0014-4827(02)00028-9; deHart GW, 2004, CELL MOTIL CYTOSKEL, V57, P107, DOI 10.1002/cm.10161; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Henry MD, 2001, J CELL SCI, V114, P1137; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kainulainen T, 1997, BRIT J DERMATOL, V136, P331, DOI 10.1046/j.1365-2133.1997.5581514.x; Katayama M, 2004, J MOL HISTOL, V35, P277; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; Kosmehl H, 1999, BRIT J CANCER, V81, P1071, DOI 10.1038/sj.bjc.6690809; LANGHOFER M, 1993, J CELL SCI, V105, P753; Litjens SHM, 2003, MOL BIOL CELL, V14, P4039, DOI 10.1091/mbc.E03-05-0268; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; McGowan KA, 2000, MICROSC RES TECHNIQ, V51, P262, DOI 10.1002/1097-0029(20001101)51:3<262::AID-JEMT6>3.0.CO;2-V; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Niki T, 2002, AM J PATHOL, V160, P1129, DOI 10.1016/S0002-9440(10)64933-4; Nikolopoulos SN, 2005, MOL CELL BIOL, V25, P6090, DOI 10.1128/MCB.25.14.6090-6102.2005; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Ortiz-Urda S, 2005, SCIENCE, V307, P1773, DOI 10.1126/science.1106209; PILCHER BK, 2002, CELL INVASION, P148; PYKE C, 1995, CANCER RES, V55, P4132; Rabinovitz I, 2001, MOL BIOL CELL, V12, P4030, DOI 10.1091/mbc.12.12.4030; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Raymond K, 2005, J CELL SCI, V118, P1045, DOI 10.1242/jcs.01689; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Tsuruta D, 2003, J BIOL CHEM, V278, P38707, DOI 10.1074/jbc.M301637200; Tsuruta D, 2003, CELL MOTIL CYTOSKEL, V54, P122, DOI 10.1002/cm.10089; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; Wang H, 2004, J CELL BIOL, V164, P935, DOI 10.1083/jcb.200309112; Wiche G, 1998, J CELL SCI, V111, P2477; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	69	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35487	35498		10.1074/jbc.M606317200	http://dx.doi.org/10.1074/jbc.M606317200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973601	Green Accepted, hybrid			2022-12-25	WOS:000241933700082
J	Parameswaran, N; Pao, CS; Leonhard, KS; Kang, DS; Kratz, M; Ley, SC; Benovic, JL				Parameswaran, Narayanan; Pao, Christina S.; Leonhard, Kristi S.; Kang, Dong Soo; Kratz, Michelle; Ley, Steven C.; Benovic, Jeffrey L.			Arrestin-2 and G protein-coupled receptor kinase 5 interact with NF kappa B1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COUPLED RECEPTOR KINASE; TOLL-LIKE RECEPTORS; BETA-ARRESTIN; INNATE IMMUNITY; PROTEIN-KINASE; PATHOGEN RECOGNITION; SIGNALING PATHWAYS; CLATHRIN ADAPTER; PHOSPHORYLATION	Toll-like receptors (TLRs) are a recently described receptor class involved in the regulation of innate and adaptive immunity. Here, we demonstrate that arrestin-2 and GRK5 (G protein-coupled receptor kinase 5), proteins that regulate G protein-coupled receptor signaling, play a negative role in TLR4 signaling in Raw264.7 macrophages. We find that lipopolysaccharide (LPS)-induced ERK1/2 phosphorylation is significantly enhanced in arrestin-2 and GRK5 knockdown cells. To elucidate the mechanisms involved, we tested the effect of arrestin-2 and GRK5 knockdown on LPS-stimulated signaling components that are upstream of ERK phosphorylation. Upon LPS stimulation, I kappa B kinase promotes phosphorylation and degradation of NF kappa B1 p105 (p105), which releases TPL2 (a MAP3K), which phosphorylates MEK1/2, which in turn phosphorylates ERK1/2. We demonstrate that knockdown of arrestin-2 leads to enhanced LPS-induced phosphorylation and degradation of p105, enhanced TPL2 release, and enhanced MEK1/2 phosphorylation. GRK5 knockdown also results in enhanced I kappa B kinase-mediated p105 phosphorylation and degradation, whereas GRK2 and GRK6 knockdown have no effect on this pathway. In vitro analysis demonstrates that arrestin-2 directly binds to the COOH-terminal domain of p105, whereas GRK5 binds to and phosphorylates p105. Taken together, these results suggest that p105 phosphorylation by GRK5 and binding of arrestin-2 negatively regulates LPS-stimulated ERK activation. These results reveal that arrestin-2 and GRK5 are important negative regulatory components in TLR4 signaling.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England	Jefferson University; MRC National Institute for Medical Research	Benovic, JL (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.	benovic@mail.jci.tju.edu	Parameswaran, Narayanan/V-1969-2019	Parameswaran, Narayanan/0000-0002-8894-5564	NIDDK NIH HHS [T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM44944, GM47417] Funding Source: Medline; Medical Research Council [U117532003] Funding Source: researchfish; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944, R01GM047417, R37GM047417] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; AOKI M, 1991, ONCOGENE, V6, P1515; Babu GR, 2006, BBA-MOL CELL RES, V1763, P174, DOI 10.1016/j.bbamcr.2005.12.010; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Beutler B, 2005, IMMUNOGENETICS, V57, P385, DOI 10.1007/s00251-005-0011-3; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Day PW, 2004, METHOD ENZYMOL, V390, P295; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Freeman JLR, 2002, BIOCHEMISTRY-US, V41, P12850, DOI 10.1021/bi020145d; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hunton DL, 2005, MOL PHARMACOL, V67, P1229, DOI 10.1124/mol.104.006270; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kawai T, 2005, ARTHRITIS RES THER, V7, P12, DOI 10.1186/ar1469; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Mochida Y, 2000, J BIOL CHEM, V275, P32747, DOI 10.1074/jbc.M003042200; Moorthy AK, 2003, J BIOL CHEM, V278, P556, DOI 10.1074/jbc.M207515200; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Pao CS, 2005, J BIOL CHEM, V280, P11052, DOI 10.1074/jbc.M412996200; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Piu F, 2006, ONCOGENE, V25, P218, DOI 10.1038/sj.onc.1209024; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sanz-Rosa D, 2005, J HYPERTENS, V23, P1167, DOI 10.1097/01.hjh.0000170379.08214.5a; Shi L, 2002, AM J PHYSIOL-CELL PH, V282, pC1205, DOI 10.1152/ajpcell.00511.2001; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Symons A, 2006, TRENDS IMMUNOL, V27, P40, DOI 10.1016/j.it.2005.11.007; Wang YY, 2006, NAT IMMUNOL, V7, P139, DOI 10.1038/ni1294; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Zughaier SM, 2005, INFECT IMMUN, V73, P2940, DOI 10.1128/IAI.73.5.2940-2950.2005	55	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34159	34170		10.1074/jbc.M605376200	http://dx.doi.org/10.1074/jbc.M605376200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980301	hybrid			2022-12-25	WOS:000241767600036
J	Szeszel-Fedorowicz, W; Talukdar, I; Griffith, BN; Walsh, CM; Salati, LM				Szeszel-Fedorowicz, Wioletta; Talukdar, Indrani; Griffith, Brian N.; Walsh, Callee M.; Salati, Lisa M.			An exonic splicing silencer is involved in the regulated splicing of glucose 6-phosphate dehydrogenase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POSTTRANSCRIPTIONAL MECHANISM; IMMUNODEFICIENCY-VIRUS TYPE-1; POLYUNSATURATED FATTY-ACIDS; HNRNP A/B PROTEINS; SR PROTEINS; RIBONUCLEOPROTEIN-PARTICLES; NUTRITIONAL REGULATION; SPLICEOSOMAL COMPLEX; RAT-LIVER; IDENTIFICATION	The inhibition of glucose-6-phosphate dehydrogenase (G6PD) expression by arachidonic acid occurs by changes in the rate of pre-mRNA splicing. Here, we have identified a cis-acting RNA element required for regulated splicing of G6PD mRNA. Using transfection of G6PD RNA reporter constructs into rat hepatocytes, the cis-acting RNA element involved in this regulation was localized to nucleotides 43 - 72 of exon 12 in the G6PD mRNA. In in vitro splicing assays, RNA substrates containing exon 12 were not spliced. In contrast, RNA substrates containing other regions ( exons 8 and 9 or exons 10 and 11) of the G6PD mRNA were efficiently spliced. Furthermore, exon 12 can inhibit splicing when substituted for other exons in RNA substrates that are readily spliced. This activity of the exon 12 regulatory element suggests that it is an exonic splicing silencer. Consistent with its activity as a splicing silencer, spliceosome assembly was inhibited on RNA substrates containing exon 12 compared with RNAs representing other regions of the G6PD transcript. Elimination of nucleotides 43 - 72 of exon 12 did not restore splicing of exon 12-containing RNA; thus, the 30-nucleotide element may not be exclusively a silencer. The binding of heterogeneous nuclear ribonucleoproteins K, L, and A2/B1 from both HeLa and hepatocyte nuclear extracts to the element further supports its activity as a silencer. In addition, SR proteins bind to the element, consistent with the presence of enhancer activity within this sequence. Thus, an exonic splicing silencer is involved in the inhibition of splicing of a constitutively spliced exon in the G6PD mRNA.	W Virginia Univ, Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA	West Virginia University	Salati, LM (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Biochem & Mol Pharmacol, POB 9142, Morgantown, WV 26506 USA.	Lsalati@hsc.wvu.edu		Walsh, Callee/0000-0002-3368-9209	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046897, R56DK046897, R01DK046897] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR016440] Funding Source: Medline; NIDDK NIH HHS [DK46897, R01 DK046897] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amir-Ahmady B, 2001, J BIOL CHEM, V276, P10514, DOI 10.1074/jbc.M010535200; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cochran W.G., 1967, STAT METHODS; Das R, 2000, MOL CELL, V5, P779, DOI 10.1016/S1097-2765(00)80318-4; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; Furuyama S, 2002, MOL CELL BIOL, V22, P5337, DOI 10.1128/MCB.22.15.5337-5346.2002; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Grabowski PJ, 2004, BIOCHEM SOC T, V32, P924, DOI 10.1042/BST0320924; Hertel KJ, 2005, TRENDS BIOCHEM SCI, V30, P115, DOI 10.1016/j.tibs.2005.01.002; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Hodge DL, 1997, ARCH BIOCHEM BIOPHYS, V348, P303, DOI 10.1006/abbi.1997.0373; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kamma H, 2001, IMMUNOL LETT, V76, P49, DOI 10.1016/S0165-2478(00)00318-7; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LANGLAND JO, 1995, PROTEIN EXPRES PURIF, V6, P25, DOI 10.1006/prep.1995.1004; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopato S, 1996, P NATL ACAD SCI USA, V93, P3074, DOI 10.1073/pnas.93.7.3074; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P315; Mayeda A, 1999, METH MOL B, V118, P309; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MOONEY RA, 1981, J BIOL CHEM, V256, P1724; Ostrowski J, 2001, P NATL ACAD SCI USA, V98, P9044, DOI 10.1073/pnas.161284098; Patel NA, 2005, J BIOL CHEM, V280, P14302, DOI 10.1074/jbc.M411485200; Query CC, 1997, MOL CELL BIOL, V17, P2944, DOI 10.1128/MCB.17.5.2944; Reed R, 1999, METHODS, V18, P3, DOI 10.1006/meth.1999.0751; Rothrock CR, 2005, EMBO J, V24, P2792, DOI 10.1038/sj.emboj.7600745; Schaal TD, 1999, MOL CELL BIOL, V19, P261; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; Siculella L, 2004, J LIPID RES, V45, P1333, DOI 10.1194/jlr.M400061-JLR200; Stabile LP, 1998, J LIPID RES, V39, P1951; Stabile LP, 1996, ARCH BIOCHEM BIOPHYS, V332, P269, DOI 10.1006/abbi.1996.0342; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Talukdar I, 2005, J BIOL CHEM, V280, P40660, DOI 10.1074/jbc.M505531200; Tao HM, 2002, J BIOL CHEM, V277, P31270, DOI 10.1074/jbc.M203196200; Tong A, 2005, J BIOL CHEM, V280, P38297, DOI 10.1074/jbc.M508123200; Walker JD, 1996, ENDOCRINOLOGY, V137, P2293, DOI 10.1210/en.137.6.2293; Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; Zhang XHF, 2004, GENE DEV, V18, P1241, DOI 10.1101/gad.1195304; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	57	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34146	34158		10.1074/jbc.M603825200	http://dx.doi.org/10.1074/jbc.M603825200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980303	Green Published, hybrid			2022-12-25	WOS:000241767600035
J	Abdulrahman, M; Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Wiesener, MS; Richards, FM; Johnson, CM; Latif, F; Maher, ER				Abdulrahman, M.; Maina, E. N.; Morris, M. R.; Zatyka, M.; Raval, R. R.; Banks, R. E.; Wiesener, M. S.; Richards, F. M.; Johnson, C. M.; Latif, F.; Maher, E. R.			Identification of novel VHL targets that are associated with the development of renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; VHL; microarray; gene expression	HIPPEL-LINDAU-DISEASE; PROTEINASE-ACTIVATED RECEPTOR-2; HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; CYCLIN D1; DIFFERENTIAL EXPRESSION; GERMLINE MUTATIONS; ENDOTHELIAL-CELLS; THYMOSIN BETA(4); MOUSE MODEL	von Hippel-Lindau (VHL) disease is a dominantly inherited family cancer syndrome characterized by the development of retinal and central nervous system haemangioblastomas, renal cell carcinoma (RCC) and phaeochromocytoma. Specific germline VHL mutations may predispose to haemangioblastomas, RCC and phaeochromocytoma to a varying extent. Although dysregulation of the hypoxia-inducible transcription factor-2 and JunB have been linked to the development of RCC and phaeochromocytoma, respectively, the precise basis for genotype-phenotype correlations in VHL disease have not been defined. To gain insights into the pathogenesis of RCC in VHL disease we compared gene expression microarray profiles in a RCC cell line expressing a Type 1 or Type 2B mutant pVHL (RCC-associated) to those of a Type 2A or 2C mutant (not associated with RCC). We identified 19 differentially expressed novel VHL target genes linked to RCC development. Eight targets were studied in detail by quantitative real-time polymerase chain reaction (three downregulated and five upregulated by wild-type VHL) and for six genes the effect of VHL inactivation was mimicked by hypoxia (but hypoxic-induction of smooth muscle alpha-actin 2 was specific for a RCC cell line). The potential role of four RCC-associated VHL target genes was assessed in vitro. NB thymosin beta (TMSNB) and proteinase-activated receptor 2 (PAR2) (both downregulated by wt pVHL) increased cell growth and motility in a RCC cell line, but aldehyde dehydrogenase (ALDH)1 and ALDH7 had no effect. These findings implicate TMSNB and PAR2 candidate oncogenes in the pathogenesis of VHL-associated RCC.	Univ Birmingham, Sch Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; St James Univ Hosp, Canc Res UK, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England; Univ Erlangen Nurnberg, Interdisciplinary Ctr Clin Res, IZKF, Erlangen, Germany; Pfizer Globaol R&D, Discovery Biol, Sandwich, Kent, England	University of Birmingham; Cancer Research UK; University of Birmingham; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Saint James's University Hospital; University of Erlangen Nuremberg; Pfizer	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Zatyka, Malgorzata/D-9340-2017	MAHER, EAMONN R/0000-0002-6226-6918; Zatyka, Malgorzata/0000-0003-3427-1653; Banks, Rosamonde/0000-0002-0042-8715; Johnson, Claire/0000-0003-4428-3594; Morris, Mark/0000-0002-0700-355X; Abdulrahman, Mahera/0000-0001-6271-3776				Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Bertog M, 1999, J PHYSIOL-LONDON, V521, P3, DOI 10.1111/j.1469-7793.1999.00003.x; Bindra RS, 2002, CANCER RES, V62, P3014; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHA HJ, 2003, J NATL CANCER I, P1674; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cocks TM, 1999, GASTROENTEROLOGY, V116, P586, DOI 10.1016/S0016-5085(99)70180-0; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Frungieri MB, 2002, P NATL ACAD SCI USA, V99, P15072, DOI 10.1073/pnas.232422999; GRANT DS, 1995, J CELL SCI, V108, P3685; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hollenberg MD, 2002, AM J PHYSIOL-CELL PH, V283, pC1347, DOI 10.1152/ajpcell.00304.2002; Hoogerwerf WA, 2001, J NEUROSCI, V21, P9036, DOI 10.1523/JNEUROSCI.21-22-09036.2001; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Iguchi K, 1999, BIOCHEM PHARMACOL, V57, P1105, DOI 10.1016/S0006-2952(99)00030-1; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Li DS, 2004, MOL CELL BIOL, V24, P3838, DOI 10.1128/MCB.24.9.3838-3848.2004; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Maina EN, 2005, ONCOGENE, V24, P4549, DOI 10.1038/sj.onc.1208649; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Milia AF, 2002, CIRC RES, V91, P346, DOI 10.1161/01.RES.0000031958.92781.9E; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Niu M, 2000, CELL ADHES COMMUN, V7, P311, DOI 10.3109/15419060009015002; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Webster AR, 1998, AM J HUM GENET, V63, P1025, DOI 10.1086/302037; Wiesener MS, 2001, CANCER RES, V61, P5215; Woodward ER, 1997, HUM MOL GENET, V6, P1051, DOI 10.1093/hmg/6.7.1051; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Zatyka M, 2002, CANCER RES, V62, P3803; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	57	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1661	1672		10.1038/sj.onc.1209932	http://dx.doi.org/10.1038/sj.onc.1209932			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	17001320	Bronze			2022-12-25	WOS:000244782500017
J	Nakai-Murakami, C; Shimura, M; Kinomoto, M; Takizawa, Y; Tokunaga, K; Taguchi, T; Hoshino, S; Miyagawa, K; Sata, T; Kurumizaka, H; Yuo, A; Ishizaka, Y				Nakai-Murakami, C.; Shimura, M.; Kinomoto, M.; Takizawa, Y.; Tokunaga, K.; Taguchi, T.; Hoshino, S.; Miyagawa, K.; Sata, T.; Kurumizaka, H.; Yuo, A.; Ishizaka, Y.			HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination	ONCOGENE			English	Article						HIV-1; Vpr; DNA double-strand breaks; homologous recombination; non-AIDS defining malignancies	VIRUS TYPE-1 VPR; AIDS-DEFINING CANCERS; DOUBLE-STRAND BREAKS; VIRAL-PROTEIN-R; DNA-DAMAGE; MICRONUCLEI FORMATION; ACCESSORY GENE; CYCLE ARREST; EARLY STEPS; P53	An ATM-dependent cellular signal, a DNA-damage response, has been shown to be involved during infection of human immunodeficiency virus type-1 (HIV-1), and a high incidence of malignant tumor development has been observed in HIV-1-positive patients. Vpr, an accessory gene product of HIV-1, delays the progression of the cell cycle at the G2/M phase, and ATR-Chk1-Wee-1, another DNA-damage signal, is a proposed cellular pathway responsible for the Vpr-induced cell cycle arrest. In this study, we present evidence that Vpr also activates ATM, and induces expression of gamma-H2AX and phosphorylation of Chk2. Strikingly, Vpr was found to stimulate the focus formation of Rad51 and BRCA1, which are involved in repair of DNA double-strand breaks (DSBs) by homologous recombination (1411), and biochemical analysis revealed that Vpr dissociates the interaction of p53 and Rad51 in the chromatin fraction, as observed under irradiation-induced DSBs. Vpr was consistently found to increase the rate of HR in the locus of I-Scel, a rare cutting-enzyme site that had been introduced into the genome. An increase of the HR rate enhanced by Vpr was attenuated by an ATM inhibitor, KU55933, suggesting that Vpr-induced DSBs activate ATM-dependent cellular signal that enhances the intracellular recombination potential. In context with a recent report that KU55933 attenuated the integration of HIV-1 into host genomes, we discuss the possible role of Vpr-induced DSBs in viral integration and also in HIV-1 associated malignancy.	Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, Tokyo 1628655, Japan; Int Med Ctr Japan, Dept Hematol, Shinjuku Ku, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 169, Japan; Univ Tokyo, Grad Sch Med, Sect Radiat Biol, Bunkyo Ku, Tokyo, Japan	National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Waseda University; University of Tokyo	Ishizaka, Y (corresponding author), Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	zakay@ri.imcj.go.jp	Takizawa, Yoshimasa/G-2956-2015; Tokunaga, Kenzo/Q-9914-2018	Takizawa, Yoshimasa/0000-0002-6265-4830; Tokunaga, Kenzo/0000-0002-2625-5322; Kurumizaka, Hitoshi/0000-0001-7412-3722				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Anglana M, 1999, NUCLEIC ACIDS RES, V27, P4276, DOI 10.1093/nar/27.21.4276; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Biggar RJ, 1996, INT J CANCER, V68, P754; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Burgi A, 2005, CANCER-AM CANCER SOC, V104, P1505, DOI 10.1002/cncr.21334; Chadburn A, 1997, SEMIN DIAGN PATHOL, V14, P15; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Daniel R, 2005, J VIROL, V79, P2058, DOI 10.1128/JVI.79.4.2058-2065.2005; Daniel R, 2004, J VIROL, V78, P8573, DOI 10.1128/JVI.78.16.8573-8581.2004; Daniel R, 2003, P NATL ACAD SCI USA, V100, P4778, DOI 10.1073/pnas.0730887100; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Elder RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD349, DOI 10.2741/elder; ElenitobaJohnson KSJ, 1997, SEMIN DIAGN PATHOL, V14, P35; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Groschel B, 2005, J VIROL, V79, P5695, DOI 10.1128/JVI.79.9.5695-5704.2005; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096; HOSHINO S, 2006, UNPUB; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; HUANG X, 2006, CYTOMETER A, V67, P222; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Knowles DM, 2003, HEMATOL ONCOL CLIN N, V17, P785, DOI 10.1016/S0889-8588(03)00050-9; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Lai MY, 2005, J VIROL, V79, P15443, DOI 10.1128/JVI.79.24.15443-15451.2005; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Lau A, 2004, EMBO J, V23, P3421, DOI 10.1038/sj.emboj.7600348; LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635; LEVYDN, 1994, P NATL ACAD SCI USA, V91, P10873; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Lim Soon Thye, 2005, Curr HIV/AIDS Rep, V2, P146, DOI 10.1007/s11904-005-0008-4; Linke SP, 2003, CANCER RES, V63, P2596; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MAYER V, 1995, EUR J CANCER PREV, V4, P211, DOI 10.1097/00008469-199506000-00001; Nunnari G, 2005, VIROLOGY, V335, P177, DOI 10.1016/j.virol.2005.02.015; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shimura M, 2005, AIDS, V19, P1434, DOI 10.1097/01.aids.0000180788.92627.e7; Shimura M, 1999, CANCER RES, V59, P2259; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; Slebos RJC, 2001, BIOCHEM BIOPH RES CO, V281, P212, DOI 10.1006/bbrc.2001.4335; Straus D J, 2001, Curr Oncol Rep, V3, P260, DOI 10.1007/s11912-001-0059-7; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; Taguchi T, 2004, BIOCHEM BIOPH RES CO, V320, P18, DOI 10.1016/j.bbrc.2004.05.126; Tokunaga K, 2001, J VIROL, V75, P6776, DOI 10.1128/JVI.75.15.6776-6785.2001; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Yuan HD, 2004, J VIROL, V78, P8183, DOI 10.1128/JVI.78.15.8183-8190.2004; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zimmerman ES, 2004, MOL CELL BIOL, V24, P9286, DOI 10.1128/MCB.24.21.9286-9294.2004	67	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					477	486		10.1038/sj.onc.1209831	http://dx.doi.org/10.1038/sj.onc.1209831			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16983346				2022-12-25	WOS:000243731600001
J	Chen, F; Lu, YJ; Castranova, V; Li, ZW; Karin, M				Chen, Fei; Lu, Yongju; Castranova, Vince; Li, Zhiwei; Karin, Michael			Loss of Ikk beta promotes migration and proliferation of mouse embryo fibroblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; KINASE ACTIVATION; JNK ACTIVATION; CANCER-THERAPY; MESSENGER-RNA; ALPHA; TNF	The I kappa B kinase complex (IKK) is central to the activation of NF-kappa B, a critical transcription factor governing expression of genes involved in cell proliferation and anti-apoptotic responses. Mice with genetic disruptions of the Ikk beta or Ikk gamma gene loci die during embryogenesis because of severe hepatic apoptosis. We now show that Ikk beta gene deficiency promotes migration and proliferation of mouse embryo fibroblast cells. Morphological analyses revealed an unusual protrusion of the cytoplasm in Ikk beta(-/-) cells when cultured at a lower density. In a Boyden chamber assay, Ikk beta(-/-) cells exhibited a high rate of invasion and migration. Enhanced formation of actin stress fibers was also observed in the Ikk beta(-/-) cells. Mechanistic studies indicated that IKK beta affects the expression of proteins involved in the assembly of cytoskeleton and cell movement. Furthermore, re-expression of Ikk beta and antioxidant treatment in Ikk beta(-/-) cells caused a reversal of protrusive phenotype and high motility, respectively. Furthermore, elimination of reactive oxygen species (ROS) blocked expression of snail and subsequently derepressed E-cadherin expression. Although the underlying mechanism is likely entangled and complicated, the data presented indicate that generation of ROS played a key role in the morphological and mobility changes in Ikk beta(-/-) cells. These data thus suggest that IKK beta provides inhibitory signals for cell mobility and growth. Deficiency in the Ikk gamma gene promotes cell mobilization, at least partially, through a ROS-dependent mechanism.	NIOSH, PPRB, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of California System; University of California San Diego	Chen, F (corresponding author), NIOSH, PPRB, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	lfd3@cdc.gov	Chen, Fei/A-3056-2008					Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Cazals V, 1999, BBA-MOL CELL RES, V1448, P349, DOI 10.1016/S0167-4889(98)00095-0; Chen F, 1999, CLIN CHEM, V45, P7; Chen F, 2003, CANCER RES, V63, P7689; Chen F, 2002, J BIOL CHEM, V277, P3342, DOI 10.1074/jbc.M101089200; Chen F, 2002, CRIT REV ONCOL HEMAT, V42, P105, DOI 10.1016/S1040-8428(01)00211-6; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Eichten A, 2004, VIROLOGY, V319, P81, DOI 10.1016/j.virol.2003.11.008; Gapuzan MER, 2005, ONCOGENE, V24, P6574, DOI 10.1038/sj.onc.1208809; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gringhuis SI, 2005, MOL CELL BIOL, V25, P6454, DOI 10.1128/MCB.25.15.6454-6463.2005; Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee SH, 2004, P NATL ACAD SCI USA, V101, P17416, DOI 10.1073/pnas.0408061101; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Otey CA, 2005, INT REV CYTOL, V246, P31, DOI 10.1016/S0074-7696(05)46002-7; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; REDDEL RR, 1988, CANCER RES, V48, P1904; Rupec RA, 2005, IMMUNITY, V22, P479, DOI 10.1016/j.immuni.2005.02.009; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zheng X, 2005, BIOCHEM BIOPH RES CO, V329, P95, DOI 10.1016/j.bbrc.2005.01.105	51	28	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37142	37149		10.1074/jbc.M603631200	http://dx.doi.org/10.1074/jbc.M603631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16966325	hybrid			2022-12-25	WOS:000242220800075
J	Leung, KW; Pon, YL; Wong, RNS; Wong, AST				Leung, Kar Wah; Pon, Yuen Lam; Wong, Ricky N. S.; Wong, Alice S. T.			Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; IN-VITRO; ANGIOGENESIS; RG(1); WNT; GENE; ACTIVATION; MECHANISM; ADHESION; GINSENG	Ginsenoside-Rg1, the most prevalent active constituent of ginseng, is a potent proangiogenic factor of vascular endothelial cells. This suggests that Rg1 may be a new modality for angiotherapy. Rg1 can activate the glucocorticoid receptor (GR). However, the regulatory steps downstream from GR that promote Rg1-induced angiogenesis have not been elucidated. Here we showed for the first time that Rg1 was a potent stimulator of vascular endothelial growth factor ( VEGF) expression in human umbilical vein endothelial cells, and importantly this induction was mediated through a phosphatidylinositol 3-kinase (PI3K)/Akt and beta-catenin/T-cell factor-dependent pathway via the GR. Rg1 stimulation resulted in an increase in the level of beta-catenin, culminating its nuclear accumulation, and subsequent activation of VEGF expression. Transfection of a stable form of beta-catenin (S37A) or the use of a glycogen synthase kinase 3 beta inhibitor to stabilize beta-catenin induced VEGF synthesis, whereas small interfering RNA-mediated down-regulation of beta-catenin did not, confirming that the effect was beta-catenin-specific. Using a luciferase reporter gene assay, we observed that Rg1 increased T-cell factor/lymphoid enhancer factor transcriptional activity. These events were mediated via a PI3K-dependent phosphorylation of the inhibitory Ser9 residue of glycogen synthase kinase 3 beta. In addition, the GR antagonist RU486 was able to inhibit Rg1-induced PI3K/Akt and beta-catenin activation. These findings provide new insights into the mechanism responsible for Rg1 functions.	Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Hong Kong Baptist Univ, Dept Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Hong Kong Baptist University	Wong, AST (corresponding author), Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bartholome B, 2004, FASEB J, V18, P70, DOI 10.1096/fj.03-0328com; Blazquez C, 2004, CANCER RES, V64, P5617, DOI 10.1158/0008-5472.CAN-03-3927; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Easwaran V, 2003, CANCER RES, V63, P3145; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Goodwin A. M., 2002, Angiogenesis, V5, P1, DOI 10.1023/A:1021563510866; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Han M, 2006, ACTA PHARMACOL SIN, V27, P499, DOI 10.1111/j.1745-7254.2006.00303.x; Helms Steve, 2004, Altern Med Rev, V9, P259; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Lee YJ, 1997, MOL CELL ENDOCRINOL, V133, P135, DOI 10.1016/S0303-7207(97)00160-3; Leung KW, 2006, FEBS LETT, V580, P3211, DOI 10.1016/j.febslet.2006.04.080; Liang HC, 2005, TISSUE ENG, V11, P835, DOI 10.1089/ten.2005.11.835; Liebner S, 2004, J CELL BIOL, V166, P359, DOI 10.1083/jcb.200403050; LIU CX, 1992, J ETHNOPHARMACOL, V36, P27, DOI 10.1016/0378-8741(92)90057-X; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Monkley SJ, 1996, DEVELOPMENT, V122, P3343; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Radad K, 2004, BRAIN RES, V1021, P41, DOI 10.1016/j.brainres.2004.06.030; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Sengupta S, 2004, CIRCULATION, V110, P1219, DOI 10.1161/01.CIR.0000140676.88412.CF; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Song IH, 2006, MOL CELL ENDOCRINOL, V246, P142, DOI 10.1016/j.mce.2005.11.012; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Xu QF, 2003, J ETHNOPHARMACOL, V84, P187, DOI 10.1016/S0378-8741(02)00317-3; Zhang XB, 2001, CANCER RES, V61, P6050	38	109	119	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36280	36288		10.1074/jbc.M606698200	http://dx.doi.org/10.1074/jbc.M606698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008323	hybrid			2022-12-25	WOS:000242100500080
J	Heinrich, A; Woyda, K; Brauburger, K; Meiss, G; Detsch, C; Stulke, J; Forchhammer, K				Heinrich, Annette; Woyda, Kathrin; Brauburger, Katja; Meiss, Gregor; Detsch, Christian; Stuelke, Joerg; Forchhammer, Karl			Interaction of the membrane-bound GlnK-AmtB complex with the master regulator of nitrogen metabolism TnrA in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; PHOSPHOPROTEIN P-II; ESCHERICHIA-COLI; MECHANISTIC FEATURES; GENE-EXPRESSION; PII; BINDING; OPERON; PHOSPHORYLATION; SEQUESTRATION	P-II proteins are widespread and highly conserved signal transduction proteins occurring in bacteria, Archaea, and plants and play pivotal roles in controlling nitrogen assimilatory metabolism. This study reports on biochemical properties of the P-II-homologue GlnK (originally termed NrgB) in Bacillus subtilis (BsGlnK). Like other P-II proteins, the native BsGlnK protein has a trimeric structure and readily binds ATP in the absence of divalent cations, whereas 2-oxoglutarate is only weakly bound. In contrast to other P-II-like proteins, Mg2+ severely affects its ATP-binding properties. BsGlnK forms a tight complex with the membrane-bound ammonium transporter AmtB (NrgA), from which it can be relieved by millimolar concentrations of ATP. Immunoprecipitation and co-localization experiments identified a novel interaction between the BsGlnK-AmtB complex and the major transcription factor of nitrogen metabolism, TnrA. In vitro in the absence of ATP, TnrA is completely tethered to membrane (AmtB)-bound GlnK, whereas in extracts from BsGlnK- or AmtB-deficient cells, TnrA is entirely soluble. The presence of 4 mM ATP leads to concomitant solubilization of BsGlnK and TnrA. This ATP-dependent membrane re-localization of TnrA by BsGlnK/AmtB may present a novel mechanism to control the global nitrogen-responsive transcription regulator TnrA in B. subtilis under certain physiological conditions.	Univ Giessen, Inst Mikrobiol & Mol Biol, D-35392 Giessen, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Erlangen Nurnberg, Inst Mikrobiol Biochem & Genet, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; University of Erlangen Nuremberg; University of Gottingen	Forchhammer, K (corresponding author), Univ Giessen, Inst Mikrobiol & Mol Biol, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.	Karl.Forchhammer@mikro.bio.uni-giessen.de	Stülke, Jörg/AAD-1600-2021	Stulke, Jorg/0000-0001-5881-5390				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Belitsky BR, 2000, J BACTERIOL, V182, P5939, DOI 10.1128/JB.182.21.5939-5947.2000; Benelli EM, 2002, EUR J BIOCHEM, V269, P3296, DOI 10.1046/j.1432-1033.2002.03011.x; Bohm A, 2004, CURR OPIN MICROBIOL, V7, P151, DOI 10.1016/j.mib.2004.02.009; Detsch C, 2003, MICROBIOL-SGM, V149, P3289, DOI 10.1099/mic.0.26512-0; Dixon R, 2004, NAT REV MICROBIOL, V2, P621, DOI 10.1038/nrmicro954; Dodsworth JA, 2006, P NATL ACAD SCI USA, V103, P9779, DOI 10.1073/pnas.0602278103; Ehlers C, 2005, MOL MICROBIOL, V55, P1841, DOI 10.1111/j.1365-2958.2005.04511.x; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; Fisher SH, 2002, J BACTERIOL, V184, P4636, DOI 10.1128/JB.184.16.4636-4639.2002; Forchhammer K, 1997, EUR J BIOCHEM, V244, P869, DOI 10.1111/j.1432-1033.1997.00869.x; FORCHHAMMER K, 1995, J BACTERIOL, V177, P2033, DOI 10.1128/jb.177.8.2033-2040.1995; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; Gorke B, 2005, NUCLEIC ACIDS RES, V33, P2504, DOI 10.1093/nar/gki549; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Hesketh A, 2002, MOL MICROBIOL, V46, P319, DOI 10.1046/j.1365-2958.2002.03149.x; Huergo LF, 2006, MOL MICROBIOL, V59, P326, DOI 10.1111/j.1365-2958.2005.04944.x; Javelle A, 2004, J BIOL CHEM, V279, P8530, DOI 10.1074/jbc.M312399200; KAMBEROV ES, 1995, J BIOL CHEM, V270, P17797, DOI 10.1074/jbc.270.30.17797; Kessler PS, 2001, J BACTERIOL, V183, P882, DOI 10.1128/JB.183.3.882-889.2001; Maheswaran M, 2004, J BIOL CHEM, V279, P55202, DOI 10.1074/jbc.M410971200; Mahren S, 2002, J BACTERIOL, V184, P3704, DOI 10.1128/JB.184.13.3704-3711.2002; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; MOORHEAD GBG, 2003, PLANT PHYSIOL, V133, P1; Nakano MM, 1998, J BACTERIOL, V180, P5344, DOI 10.1128/JB.180.20.5344-5350.1998; Ninfa AJ, 2005, CURR OPIN MICROBIOL, V8, P168, DOI 10.1016/j.mib.2005.02.011; Palinska KA, 2002, MICROBIOL-SGM, V148, P2405, DOI 10.1099/00221287-148-8-2405; Reitzer L, 2003, ANNU REV MICROBIOL, V57, P155, DOI 10.1146/annurev.micro.57.030502.090820; Ruppert U, 2002, MOL MICROBIOL, V44, P855, DOI 10.1046/j.1365-2958.2002.02927.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIER HJ, 1989, J MOL BIOL, V210, P51, DOI 10.1016/0022-2836(89)90290-8; Smith CS, 2004, BBA-PROTEINS PROTEOM, V1699, P145, DOI 10.1016/j.bbapap.2004.02.009; Smith CS, 2003, PLANT J, V33, P353, DOI 10.1046/j.1365-313X.2003.01634.x; Strosser J, 2004, MOL MICROBIOL, V54, P132, DOI 10.1111/j.1365-2958.2004.04247.x; VOELKER U, 1995, J BACTERIOL, V177, P3771, DOI 10.1128/jb.177.13.3771-3780.1995; WRAY LV, 1994, J BACTERIOL, V176, P108, DOI 10.1128/JB.176.1.108-114.1994; Wray LV, 1996, P NATL ACAD SCI USA, V93, P8841, DOI 10.1073/pnas.93.17.8841; Wray LV, 1997, J BACTERIOL, V179, P5494, DOI 10.1128/jb.179.17.5494-5501.1997; Wray LV, 2001, CELL, V107, P427, DOI 10.1016/S0092-8674(01)00572-4; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Yoshida K, 2003, MOL MICROBIOL, V49, P157, DOI 10.1046/j.1365-2958.2003.03567.x; Zhang SY, 2005, J BACTERIOL, V187, P7554, DOI 10.1128/JB.187.22.7554-7560.2005	43	67	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34909	34917		10.1074/jbc.M607582200	http://dx.doi.org/10.1074/jbc.M607582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17001076	hybrid			2022-12-25	WOS:000241933700023
J	Joly, N; Schumacher, J; Buck, M				Joly, Nicolas; Schumacher, Jorg; Buck, Martin			Heterogeneous nucleotide occupancy stimulates functionality of phage shock protein F, an AAA plus transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER DNA COMPLEX; ESCHERICHIA-COLI; RNA-POLYMERASE; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; STRUCTURAL BASIS; IN-VITRO; ATP; DOMAIN; BINDING	The catalytic AAA+ domain (PspF(1-275)) of an enhancer-binding protein is necessary and sufficient to contact sigma 54-RNA polymerase holoenzyme (E sigma(54)), remodel it, and in so doing catalyze open promoter complex formation. Whether ATP binding and hydrolysis is coordinated between subunits of PspF and the precise nature of the nucleotide(s) bound to the oligomeric forms responsible for substrate remodeling are unknown. We demonstrate that ADP stimulates the intrinsic ATPase activity of PspF(1-275) and propose that this heterogeneous nucleotide occupancy in a PspF(1-275) hexamer is functionally important for specific activity. Binding of ADP and ATP triggers the formation of functional PspF(1-275) hexamers as shown by a gain of specific activity. Furthermore, ATP concentrations congruent with stoichiometric ATP binding to PspF(1-275) inhibit ATP hydrolysis and E sigma(54)-promoter open complex formation. Demonstration of a heterogeneous nucleotide-bound state of a functional PspF(1-275)center dot E sigma(54) complex provides clear biochemical evidence for heterogeneous nucleotide occupancy in this AAA+ protein. Based on our data, we propose a stochastic nucleotide binding and a coordinated hydrolysis mechanism in PspF(1-275) hexamers.	Univ London Imperial Coll Sci Technol & Med, Div Biol, London SW7 2AZ, England	Imperial College London	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	m.buck@imperial.ac.uk	Joly, Nicolas/H-6851-2018	Joly, Nicolas/0000-0003-2731-3827				Ades SE, 2006, CURR BIOL, V16, pR46, DOI 10.1016/j.cub.2006.01.005; BERGER DK, 1995, J BACTERIOL, V177, P191, DOI 10.1128/jb.177.1.191-199.1995; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Burrows PC, 2004, EMBO J, V23, P4253, DOI 10.1038/sj.emboj.7600406; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Cannon WV, 2004, NUCLEIC ACIDS RES, V32, P4596, DOI 10.1093/nar/gkh755; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Darwin AJ, 2005, MOL MICROBIOL, V57, P621, DOI 10.1111/j.1365-2958.2005.04694.x; De Carlo S, 2006, GENE DEV, V20, P1485, DOI 10.1101/gad.1418306; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Elderkin S, 2002, J MOL BIOL, V320, P23, DOI 10.1016/S0022-2836(02)00404-7; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Jovanovic G, 1999, J MOL BIOL, V285, P469, DOI 10.1006/jmbi.1998.2263; Jovanovic G, 2006, J BIOL CHEM, V281, P21147, DOI 10.1074/jbc.M602323200; Kazmirski SL, 2004, P NATL ACAD SCI USA, V101, P16750, DOI 10.1073/pnas.0407904101; Kirstein J, 2006, EMBO J, V25, P1481, DOI 10.1038/sj.emboj.7601042; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lloyd LJ, 2004, J BIOL CHEM, V279, P55707, DOI 10.1074/jbc.M408994200; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Martin A, 2005, NATURE, V437, P1115, DOI 10.1038/nature04031; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pelton JG, 1999, J MOL BIOL, V292, P1095, DOI 10.1006/jmbi.1999.3140; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; Rappas M, 2006, J MOL BIOL, V357, P481, DOI 10.1016/j.jmb.2005.12.052; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; Rombel I, 1999, J BACTERIOL, V181, P4628, DOI 10.1128/JB.181.15.4628-4638.1999; Sallai L, 2005, J STRUCT BIOL, V151, P160, DOI 10.1016/j.jsb.2005.05.006; Schneider DA, 2004, J BIOL CHEM, V279, P8262, DOI 10.1074/jbc.M311996200; Schumacher J, 2004, J MOL BIOL, V338, P863, DOI 10.1016/j.jmb.2004.02.071; SCHUMACHER J, 2006, IN PRESS J STRUCT BI; Studholme DJ, 2003, J BACTERIOL, V185, P1757, DOI 10.1128/JB.185.6.1757-1767.2003; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Wigneshweplaraj SR, 2005, PROG NUCLEIC ACID RE, V79, P339, DOI 10.1016/S0079-6603(04)79007-8; Wigneshweraraj SR, 2005, J BIOL CHEM, V280, P36176, DOI 10.1074/jbc.M506416200; Wigneshweraraj SR, 2003, METHOD ENZYMOL, V370, P646; Wikstrom P, 2001, J MOL BIOL, V314, P971, DOI 10.1006/jmbi.2000.5212; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Xu H, 2004, J BACTERIOL, V186, P3499, DOI 10.1128/JB.186.11.3499-3507.2004; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	49	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34997	35007		10.1074/jbc.M606628200	http://dx.doi.org/10.1074/jbc.M606628200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973614	hybrid			2022-12-25	WOS:000241933700033
J	Xu, LJ; Deng, XM				Xu, Lijun; Deng, Xingming			Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION; GROWTH; ZYMOGRAPHY; APOPTOSIS; PROTEASES; MEMBRANE; CLEAVAGE	The mu-and m-calpains are major members of the calpain family that play an essential role in regulating cell motility. We have recently discovered that nicotine-activated protein kinase C i enhances calpain phosphorylation in association with enhanced calpain activity and accelerated migration and invasion of human lung cancer cells. Here we found that specific disruption of protein phosphatase 2A (PP2A) activity by expression of SV40 small tumor antigen up-regulates phosphorylation of mu-and m-calpains whereas C2-ceramide, a potent PP2A activator, reduces nicotine-induced calpain phosphorylation, suggesting that PP2A may function as a physiological calpain phosphatase. PP2A co-localizes and interacts with mu-and m-calpains. Purified, active PP2A directly dephosphorylates mu-and m-calpains in vitro. Overexpression of the PP2A catalytic subunit (PP2A/C) suppresses nicotine-stimulated phosphorylation of mu-and m-calpains, which is associated with inhibition of calpain activity, wound healing, cell migration, and invasion. By contrast, depletion of PP2A/C by RNA interference enhances calpain phosphorylation, calpain activity, cell migration, and invasion. Importantly, C2-ceramide-induced suppression of calpain phosphorylation results in decreased secretion of mu-and m-calpains from lung cancer cells into culture medium, which may have potential clinic relevance in controlling metastasis of lung cancer. These findings reveal a novel role for PP2A as a physiological calpain phosphatase that not only directly dephosphorylates but also inactivates mu-and m-calpains, leading to suppression of migration and invasion of human lung cancer cells.	Univ Florida, Shands Canc Ctr, Dept Med, Hlth Sci Ctr, Gainesville, FL 32610 USA; Univ Florida, Hlth Sci Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, Hlth Sci Ctr, 1376 Mowry Rd,Canc Genet Res Complex,Rm 262,POB 1, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu			NCI NIH HHS [R01 CA112183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; Arthur JSC, 2000, METH MOL B, V144, P109; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Gomez DE, 1999, ONCOL REP, V6, P1363; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; HEINO J, 2002, CELL INVASION MED IN, V33, P1; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Mamoune A, 2003, CANCER RES, V63, P4632; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Palecek SP, 1998, J CELL SCI, V111, P929; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; REPESH LA, 1989, INVAS METAST, V9, P192; Rita M, 2003, INT J CANCER, V103, P38, DOI 10.1002/ijc.10772; Shao HS, 2006, MOL CELL BIOL, V26, P5481, DOI 10.1128/MCB.02243-05; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Witkowski JM, 2002, BLOOD, V100, P1802, DOI 10.1182/blood-2001-11-0073; Wu MQ, 2006, FEBS LETT, V580, P3246, DOI 10.1016/j.febslet.2006.05.003; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Xu LJ, 2006, J BIOL CHEM, V281, P4457, DOI 10.1074/jbc.M510721200; Xu LJ, 2004, J BIOL CHEM, V279, P53683, DOI 10.1074/jbc.M409889200; Young MRI, 2002, INT J CANCER, V100, P276, DOI 10.1002/ijc.10491	33	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35567	35575		10.1074/jbc.M607702200	http://dx.doi.org/10.1074/jbc.M607702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982626	hybrid			2022-12-25	WOS:000241933700089
J	Li, QF; Spinelli, AM; Wang, RP; Anfinogenova, Y; Singer, HA; Tang, DD				Li, Qing-Fen; Spinelli, Amy M.; Wang, Ruping; Anfinogenova, Yana; Singer, Harold A.; Tang, Dale D.			Critical role of vimentin phosphorylation at Ser-56 by p21-activated kinase in vimentin cytoskeleton signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; INTERMEDIATE-FILAMENT NETWORK; PROTEIN-KINASE; CONTRACTILE STIMULATION; ACTIN POLYMERIZATION; TENSION DEVELOPMENT; ANGIOTENSIN-II; LD4 MOTIF; PAK; REORGANIZATION	Phosphorylation and spatial reorganization of the vimentin network have been implicated in mediating smooth muscle contraction, cell migration, and mitosis. In this study, stimulation of cultured smooth muscle cells with 5-hydroxytryptamine (5-HT) induced PAK1 phosphorylation at Thr-423 (an indication of p21-activated kinase (PAK) activation). Treatment with PAK led to disassembly of wild-type (but not mutant S56A) vimentin filaments as assessed by an in vitro filament assembly assay. Furthermore, stimulation with 5-HT resulted in the dissociation of Crk-associated substrate (CAS; an adapter protein associated with smooth muscle force development) from cytoskeletal vimentin. Expression of mutant S56A vimentin in cells inhibited the increase in phosphorylation at Ser-56 and in the ratios of soluble to insoluble vimentin (an index of vimentin disassembly) and the dissociation of CAS from cytoskeletal vimentin in response to 5-HT activation compared with cells expressing wild-type vimentin. Because CAS may be involved in PAK activation, PAK phosphorylation was evaluated in cells expressing the S56A mutant. Expression of mutant S56A vimentin depressed PAK phosphorylation at Thr-423 induced by 5-HT. Expression of the S56A mutant also inhibited the spatial reorientation of vimentin filaments in cells in response to 5-HT stimulation. Our results suggest that vimentin phosphorylation at Ser-56 may inversely regulate PAK activation possibly via the increase in the amount of soluble CAS upon agonist stimulation of smooth muscle cells. Additionally, vimentin phosphorylation at this position is critical for vimentin filament spatial rearrangement elicited by agonists.	Albany Med Coll, Ctr Cardiovasc Res, Albany, NY 12208 USA	Albany Medical College	Tang, DD (corresponding author), Albany Med Coll, Ctr Cardiovasc Res, 47 New Scotland Ave,MC-8, Albany, NY 12208 USA.	tangd@mail.amc.edu	T, Dale/AAE-9643-2020; Anfinogenova, Nina D./E-7458-2014; Anfinogenova, Yana/AAH-3946-2021	T, Dale/0000-0002-7339-9249; Anfinogenova, Nina D./0000-0003-1106-0730; Anfinogenova, Yana/0000-0003-1106-0730; Wang, Ruping/0000-0003-4233-7755	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075388] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL075388, HL-75388] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Bruel A, 2001, ANTICANCER RES, V21, P3973; Chan W, 2002, EUR J CELL BIOL, V81, P692, DOI 10.1078/0171-9335-00281; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Dechert MA, 2001, AM J PHYSIOL-CELL PH, V281, pC123, DOI 10.1152/ajpcell.2001.281.1.C123; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Finley NL, 2004, J BIOL CHEM, V279, P54833, DOI 10.1074/jbc.M408304200; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Li QF, 2006, FASEB J, V20, pA1243; Marganski WA, 2005, CIRC RES, V97, P541, DOI 10.1161/01.RES.0000182630.29093.0d; McFawn PK, 2003, AM J PHYSIOL-LUNG C, V284, pL863, DOI 10.1152/ajplung.00068.2002; Meriane M, 2000, J BIOL CHEM, V275, P33046, DOI 10.1074/jbc.M001566200; OGDEN K, 2006, IN PRESS AM J PHYSL; PARROTT DP, 1991, ATHEROSCLEROSIS, V88, P213, DOI 10.1016/0021-9150(91)90083-F; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; SMALL JV, 1995, BIOESSAYS, V17, P785, DOI 10.1002/bies.950170908; Tang DD, 2005, J BIOL CHEM, V280, P23380, DOI 10.1074/jbc.M413390200; Tang DD, 2005, BIOCHEM J, V388, P773, DOI 10.1042/BJ20050065; Tang DD, 2004, J BIOL CHEM, V279, P51722, DOI 10.1074/jbc.M408351200; Tang DD, 2003, HYPERTENSION, V42, P858, DOI 10.1161/01.HYP.0000085333.76141.33; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Wang RP, 2006, AM J PHYSIOL-CELL PH, V291, pC483, DOI 10.1152/ajpcell.00097.2006; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Woolfolk EA, 2005, AM J PHYSIOL-CELL PH, V289, pC1286, DOI 10.1152/ajpcell.00448.2004	31	109	114	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34716	34724		10.1074/jbc.M607715200	http://dx.doi.org/10.1074/jbc.M607715200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16990256	hybrid, Green Accepted			2022-12-25	WOS:000241767600090
J	Sudo, Y; Furutani, Y; Kandori, H; Spudich, JL				Sudo, Yuki; Furutani, Yuji; Kandori, Hideki; Spudich, John L.			Functional importance of the interhelical hydrogen bond between Thr(204) and Tyr(174) of sensory rhodopsin II and its alteration during the signaling process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROXIMAL DOMAIN; PHARAONIS PHOBORHODOPSIN; NATRONOBACTERIUM-PHARAONIS; STRUCTURAL-CHANGES; COGNATE TRANSDUCER; FTIR SPECTROSCOPY; HTRI TRANSDUCER; LINKER REGION; COMPLEX; PHOTOISOMERIZATION	Sensory rhodopsin II (SRII), a receptor for negative phototaxis in haloarchaea, transmits light signals through changes in protein-protein interaction with its transducer HtrII. Light-induced structural changes throughout the SRII-HtrII interface, which spans the periplasmic region, membrane-embedded domains, and cytoplasmic domains near the membrane, have been identified by several studies. Here we demonstrate by site-specific mutagenesis and analysis of phototaxis behavior that two residues in SRII near the membrane-embedded interface (Tyr(174) on helix F and Thr(204) on helix G) are essential for signaling by the SRII-HtrII complex. These residues, which are the first in SRII shown to be required for phototaxis function, provide biological significance to the previous observation that the hydrogen bond between them is strengthened upon the formation of the earliest SRII photointermediate (SRIIK) only when SRII is complexed with HtrII. Here we report frequency changes of the S-H stretch of a cysteine substituted for SRII Thr(204) in the signaling state intermediates of the SRII photocycle, as well as an influence of HtrII on the hydrogen bond strength, supporting a direct role of the hydrogen bond in SRII-HtrII signal relay chemistry. Our results suggest that the light signal is transmitted to HtrII from the energized interhelical hydrogen bond between Thr(204) and Tyr(174), which is located at both the retinal chromophore pocket and in helices F and G that form the membrane-embedded interaction surface to the signal-bearing second transmembrane helix of HtrII. The results argue for a critical process in signal relay occurring at this membrane interfacial region of the complex.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA; Nagoya Inst Technol, Dept Mat Sci & Engn, Showa Ku, Nagoya, Aichi 4668555, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kyoto 6068502, Japan	University of Texas System; University of Texas Health Science Center Houston; Nagoya Institute of Technology; Japan Science & Technology Agency (JST)	Spudich, JL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu	Furutani, Yuji/J-8337-2019; Sudo, Yuki/AGY-0493-2022	Furutani, Yuji/0000-0001-5284-8773; Sudo, Yuki/0000-0001-8155-9356	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergo VB, 2005, J BIOL CHEM, V280, P28365, DOI 10.1074/jbc.M505555200; Bordignon E, 2005, J BIOL CHEM, V280, P38767, DOI 10.1074/jbc.M509391200; Chen XP, 2004, J BIOL CHEM, V279, P42964, DOI 10.1074/jbc.M406503200; Chizhov I, 1998, BIOPHYS J, V75, P999, DOI 10.1016/S0006-3495(98)77588-5; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P2909, DOI 10.1021/bi047893i; Furutani Y, 2004, BIOCHEMISTRY-US, V43, P5204, DOI 10.1021/bi036316b; Furutani Y, 2003, BIOCHEMISTRY-US, V42, P4837, DOI 10.1021/bi034317y; Furutani Y, 2002, BIOPHYS J, V83, P3482, DOI 10.1016/S0006-3495(02)75347-2; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; HE YW, 1993, BIOCHEMISTRY-US, V32, P2282, DOI 10.1021/bi00060a021; Hippler-Mreyen S, 2003, J MOL BIOL, V330, P1203, DOI 10.1016/S0022-2836(03)00656-9; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Iwamoto M, 2005, BIOPHYS J, V88, P1215, DOI 10.1529/biophysj.104.045583; Jung KH, 1996, P NATL ACAD SCI USA, V93, P6557, DOI 10.1073/pnas.93.13.6557; Jung KH, 2001, J BACTERIOL, V183, P6365, DOI 10.1128/JB.183.21.6365-6371.2001; Kamo N, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1277, DOI 10.1023/A:1013187403599; Kandori H, 2000, P NATL ACAD SCI USA, V97, P4643, DOI 10.1073/pnas.080064797; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Kandori H, 1999, BIOCHEMISTRY-US, V38, P9676, DOI 10.1021/bi990713y; Kandori H, 1998, J AM CHEM SOC, V120, P5828, DOI 10.1021/ja980837i; Klare JP, 2004, PHOTOCH PHOTOBIO SCI, V3, P543, DOI 10.1039/b402656j; Klare JP, 2002, BIOPHYS J, V82, P2156, DOI 10.1016/S0006-3495(02)75562-8; Krebs MP, 1995, PROTEIN EXPRES PURIF, V6, P780, DOI 10.1006/prep.1995.0009; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Moukhametzianov R, 2006, NATURE, V440, P115, DOI 10.1038/nature04520; OLSON KD, 1993, BIOPHYS J, V65, P2578, DOI 10.1016/S0006-3495(93)81295-5; Pebay-Peyroula E, 2002, BBA-BIOMEMBRANES, V1565, P196, DOI 10.1016/S0005-2736(02)00569-2; Perazzona B, 1996, J BACTERIOL, V178, P6475, DOI 10.1128/jb.178.22.6475-6478.1996; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Sasaki J, 1999, BIOPHYS J, V77, P2145, DOI 10.1016/S0006-3495(99)77055-4; Shimono K, 2003, J BIOL CHEM, V278, P23882, DOI 10.1074/jbc.M301200200; Spudich J, 2002, NAT STRUCT BIOL, V9, P797, DOI 10.1038/nsb1102-797; Spudich JL, 2002, CURR OPIN STRUC BIOL, V12, P540, DOI 10.1016/S0959-440X(02)00359-7; Sudo Y, 2006, J MOL BIOL, V357, P1274, DOI 10.1016/j.jmb.2006.01.061; Sudo Y, 2005, J AM CHEM SOC, V127, P16036, DOI 10.1021/ja056203a; Sudo Y, 2005, BIOCHEMISTRY-US, V44, P6144, DOI 10.1021/bi047573z; Sudo Y, 2003, BIOCHEMISTRY-US, V42, P14166, DOI 10.1021/bi035678g; Sudo Y, 2003, PHOTOCHEM PHOTOBIOL, V78, P511, DOI 10.1562/0031-8655(2003)078<0511:IONPPS>2.0.CO;2; Sudo Y, 2002, BIOPHYS J, V83, P427, DOI 10.1016/S0006-3495(02)75180-1; Sudo Y, 2001, PHOTOCHEM PHOTOBIOL, V74, P489, DOI 10.1562/0031-8655(2001)074<0489:PPBTIC>2.0.CO;2; Sudo Y., 2004, RECENT RES DEV BIOPH, V3, P1; SUDO Y, 2006, IN PRESS P NATL ACAD; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Wegener AA, 2001, EMBO J, V20, P5312, DOI 10.1093/emboj/20.19.5312; Yang CS, 2004, J BIOL CHEM, V279, P42970, DOI 10.1074/jbc.M406504200; Yang CS, 2001, BIOCHEMISTRY-US, V40, P14207, DOI 10.1021/bi010985c	46	47	47	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34239	34245		10.1074/jbc.M605907200	http://dx.doi.org/10.1074/jbc.M605907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968701	hybrid			2022-12-25	WOS:000241767600044
J	Hentschke, M; Kurth, I; Borgmeyer, U; Hubner, CA				Hentschke, Moritz; Kurth, Ingo; Borgmeyer, Uwe; Huebner, Christian A.			Germ cell nuclear factor is a repressor of CRIPTO-1 and CRIPTO-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PROTAMINE GENES; ORPHAN RECEPTOR; DNA-BINDING; RETINOIC ACID; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; OCT4 EXPRESSION; THYROID-HORMONE; STEM-CELLS; TERATOCARCINOMA	The pluripotency of embryonic stem and embryonic carcinoma cells is maintained by the expression of a set of "stemness" genes. Whereas these genes are down-regulated upon induction of differentiation, the germ cell nuclear factor (GCNF) is transiently up-regulated and represses several pluripotency genes. CRIPTO-1, a co-receptor for the morphogen nodal, is strongly expressed in undifferentiated cells and is rapidly down-regulated during retinoic acid-induced differentiation. Although CRIPTO-1 is expressed at very low levels in adult tissues under normal conditions, it is found highly expressed in a broad range of tumors, where it acts as a potent oncogene. We show that expression of CRIPTO-1 is directly repressed by GCNF during differentiation of the human teratocarcinoma cell line, NT2. GCNF bound to a DR0 element of the CRIPTO-1 promoter in vitro, as shown by electrophoretic mobility shift assays, and in vivo, as demonstrated by chromatin immunoprecipitation. Reporter gene assays demonstrated that GCNF-mediated repression of the CRIPTO-1 promoter is dependent upon the DR0 site. Overexpression of GCNF in NT2 cells resulted in repression of CRIPTO-1 transcription, whereas expression of the transcription-activating fusion construct GCNF-VP16 led to an induction of theCRIPTO-1 gene and prevented its retinoic acid-induced down-regulation. Furthermore, we demonstrated that CRIPTO-3, a processed pseudogene of CRIPTO-1 on the X chromosome, is expressed in undifferentiated NT2 cells and is regulated by GCNF in parallel to CRIPTO-1. Thus, our study supports the hypothesis of GCNF playing a central role during differentiation of stem cells by repression of stem cell-specific genes.	Univ Med Ctr Hamburg Eppendorf, Inst Med Microbiol, D-20246 Hamburg, Germany; Univ Med Ctr Hamburg Eppendorf, Inst Human Genet, D-22529 Hamburg, Germany; Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20251 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Hentschke, M (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Med Microbiol, Martinistr 52, D-20246 Hamburg, Germany.	m.hentschke@uke.uni-hamburg.de; c.huebner@uke.uni-hamburg.de	Borgmeyer, Uwe/D-4662-2012; Hübner, Christian/A-2950-2017	Borgmeyer, Uwe/0000-0003-3727-4083; Hübner, Christian/0000-0002-1030-4943; Kurth, Ingo/0000-0002-5642-8378				Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Barreto G, 2003, DEV BIOL, V257, P329, DOI 10.1016/S0012-1606(03)00109-X; Bianco C, 2005, J NATL CANCER I, V97, P132, DOI 10.1093/jnci/dji011; Bianco C, 2004, GROWTH FACTORS, V22, P133, DOI 10.1080/08977190410001723290; Borgmeyer U, 1997, EUR J BIOCHEM, V244, P120, DOI 10.1111/j.1432-1033.1997.00120.x; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; Chung ACK, 2001, MOL CELL BIOL, V21, P663, DOI 10.1128/MCB.21.2.663-677.2001; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1991, AM J HUM GENET, V49, P555; Elliman SJ, 2006, J BIOL CHEM, V281, P16, DOI 10.1074/jbc.C500415200; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Greschik H, 1999, MOL CELL BIOL, V19, P690; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gu PL, 2005, MOL CELL BIOL, V25, P8507, DOI 10.1128/MCB.25.19.8507-8519.2005; Gu PL, 2005, J BIOL CHEM, V280, P31818, DOI 10.1074/jbc.M501924200; Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005; Hart AH, 2005, CANCER, V104, P2092, DOI 10.1002/cncr.21435; Heinzer C, 1998, BIOL CHEM, V379, P349, DOI 10.1515/bchm.1998.379.3.349; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hummelke GC, 2004, MOL REPROD DEV, V68, P394, DOI 10.1002/mrd.20092; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Lan ZJ, 2003, EMBO J, V22, P4070, DOI 10.1093/emboj/cdg405; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Minchiotti G, 2005, ONCOGENE, V24, P5668, DOI 10.1038/sj.onc.1208917; Minchiotti G, 2002, GENE, V287, P33, DOI 10.1016/S0378-1119(01)00892-7; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Niemeyer CC, 1998, CELL DEATH DIFFER, V5, P440, DOI 10.1038/sj.cdd.4400368; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Pain D, 2005, J BIOL CHEM, V280, P6265, DOI 10.1074/jbc.C400587200; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; Rajkovic M, 2004, J BIOL CHEM, V279, P52493, DOI 10.1074/jbc.M404467200; Sattler U, 2004, MOL ENDOCRINOL, V18, P2714, DOI 10.1210/me.2004-0251; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schmitz TP, 1999, BBA-GENE STRUCT EXPR, V1446, P173, DOI 10.1016/S0167-4781(99)00079-2; Scognamiglio B, 1999, CYTOGENET CELL GENET, V84, P220, DOI 10.1159/000015263; Shen MM, 2003, J CLIN INVEST, V112, P500, DOI 10.1172/JCI200319546; Strizzi L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Xu CH, 1999, DEVELOPMENT, V126, P483; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yan ZJ, 2000, J BIOL CHEM, V275, P35077, DOI 10.1074/jbc.M005566200; Yan ZJ, 2002, J BIOL CHEM, V277, P32379, DOI 10.1074/jbc.M203475200	51	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33497	33504		10.1074/jbc.M606975200	http://dx.doi.org/10.1074/jbc.M606975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16954206	hybrid			2022-12-25	WOS:000241621400060
J	Perotti, MA; Clarke, HK; Turner, BD; Braig, HR				Perotti, M. Alejandra; Clarke, Heather K.; Turner, Bryan D.; Braig, Henk R.			Rickettsia as obligate and mycetomic bacteria	FASEB JOURNAL			English	Article						evolution; development; Liposcelis bostrychophila; Cerobasis guestfalica; Psocoptera	APHID ACYRTHOSIPHON-PISUM; PHYLOGENETIC ANALYSIS; CHROMOSOME-NUMBERS; MULTIPLE ORIGINS; TICK-BORNE; WOLBACHIA; INSECT; ENDOSYMBIONTS; HOST; SYMBIONTS	Rickettsiae are well known as intracellular pathogens of animals, humans, and plants and facultative and unorganized symbionts of invertebrates. No close relative of mitochondria has yet been associated with nutritional or developmental dependency of its host cell or organism. We have found a mycetomic Rickettsia that is a strict obligatory symbiont of the parthenogenetic booklouse Liposcelis bostrychophila (Psocoptera). These rickettsiae show an evolutionary transition from a solitary to a primary mycetomic bacterium adapted to the development of its host. These intracellular and intranuclear bacteria reside in specialized cells in several tissues. Their distribution changes markedly with the development of their host. The most advanced phenotype is a paired mycetome in the abdomen, described for the first time for Rickettsia and this host order. The mycetomic rickettsiae of two parthenogenetic book lice species are in the spotted fever group and in the basal limoniae group. While mycetomic bacteria are well known for their metabolic or light-emitting functions, these rickettsiae have an essential role in the early development of the oocyte. Removal of the Rickettsia stops egg production and reproduction in the book louse. In two phylogenetically distant psocopteran species, Rickettsia are shown to be associated with four transitional stages from free bacteria, infected cells, through single mycetocytes to organ-forming mycetomes.	Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Kings Coll London, Dept Life Sci, London WC2R 2LS, England	Bangor University; University of London; King's College London	Braig, HR (corresponding author), Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.	bss40c@bangor.ac.uk	Braig, Henk/I-5477-2013	Braig, Henk/0000-0001-9592-1141				AKSOY S, 1995, INT J SYST BACTERIOL, V45, P848, DOI 10.1099/00207713-45-4-848; Andersson SGE, 2004, INT J MED MICROBIOL, V293, P463, DOI 10.1078/1438-4221-00304; BADONNEL ANDRE, 1934, BULL BIOL FRANCE ET BELGIQUE SUPPL, V18, P1; Batut J, 2004, NAT REV MICROBIOL, V2, P933, DOI 10.1038/nrmicro1044; BAUMANN P, 2000, PROKARYOTES EVOLVING; Bourtzis K, 2003, CONT T ENT, P217; Braendle C, 2003, PLOS BIOL, V1, P70, DOI 10.1371/journal.pbio.0000021; Braig HR, 1998, J BACTERIOL, V180, P2373, DOI 10.1128/JB.180.9.2373-2378.1998; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Chapman GB, 2003, INVERTEBR BIOL, V122, P52, DOI 10.1111/j.1744-7410.2003.tb00072.x; Chen DQ, 1996, CURR MICROBIOL, V33, P123, DOI 10.1007/s002849900086; Corsaro D, 1999, CRIT REV MICROBIOL, V25, P39, DOI 10.1080/10408419991299167; Cowdry EV, 1923, J EXP MED, V37, P431, DOI 10.1084/jem.37.4.431; Davis MJ, 1998, CURR MICROBIOL, V36, P80, DOI 10.1007/s002849900283; Dobson SL, 1999, INSECT BIOCHEM MOLEC, V29, P153, DOI 10.1016/S0965-1748(98)00119-2; DOUGLAS AE, 1989, BIOL REV, V64, P409, DOI 10.1111/j.1469-185X.1989.tb00682.x; Dykova I, 2003, FOLIA PARASIT, V50, P161, DOI 10.14411/fp.2003.030; FINLAYSON LH, 1949, P ZOOL SOC LOND, V119, P301; Fukatsu T, 1999, APPL ENTOMOL ZOOL, V34, P391, DOI 10.1303/aez.34.391; Gil R, 2004, ENVIRON MICROBIOL, V6, P1109, DOI 10.1111/j.1462-2920.2004.00691.x; Goebel W, 2001, TRENDS MICROBIOL, V9, P267, DOI 10.1016/S0966-842X(01)02040-6; Gomez-Valero L, 2004, J BACTERIOL, V186, P6626, DOI 10.1128/JB.186.19.6626-6633.2004; GOSS RICHARD J., 1954, ANN ENT SOC AMER, V47, P190; GOSS RJ, 1953, J MORPHOL, V92, P157, DOI 10.1002/jmor.1050920106; GOSS RJ, 1952, J MORPHOL, V91, P135, DOI 10.1002/jmor.1050910107; GOSTEVA VV, 1991, ACTA VIROL, V35, P174; Gottlieb Y, 2006, APPL ENVIRON MICROB, V72, P3646, DOI 10.1128/AEM.72.5.3646-3652.2006; Grandi G, 1997, J SUBMICR CYTOL PATH, V29, P281; Hagimori T, 2006, CURR MICROBIOL, V52, P97, DOI 10.1007/s00284-005-0092-0; Heddi A, 2005, CELL MICROBIOL, V7, P293, DOI 10.1111/j.1462-5822.2004.00461.x; Heddi A, 1999, P NATL ACAD SCI USA, V96, P6814, DOI 10.1073/pnas.96.12.6814; Heinzen RA, 1999, INFECT IMMUN, V67, P4201, DOI 10.1128/IAI.67.8.4201-4207.1999; Hertig M, 1924, J MED RES, V44, P329; Hoy MA, 2005, BIOL CONTROL, V32, P427, DOI 10.1016/j.biocontrol.2004.12.012; Iturbe-Ormaetxe I, 2005, J BACTERIOL, V187, P5136, DOI 10.1128/JB.187.15.5136-5145.2005; Johnson KP, 2004, P ROY SOC B-BIOL SCI, V271, P1771, DOI 10.1098/rspb.2004.2798; JOSTES RF, 1975, CYTOLOGIA, V40, P553; Kikuchi Y, 2005, MICROBIAL ECOL, V49, P265, DOI 10.1007/s00248-004-0140-5; Koivisto RKK, 2003, BIOL J LINN SOC, V79, P43, DOI 10.1046/j.1095-8312.2003.00185.x; Lawson ET, 2001, HEREDITY, V86, P497, DOI 10.1046/j.1365-2540.2001.00848.x; LYAL CHC, 1985, SYST ENTOMOL, V10, P145; Majerus MEN, 1997, ENTOMOPHAGA, V42, P13, DOI 10.1007/BF02769875; Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795; Montllor CB, 2002, ECOL ENTOMOL, V27, P189, DOI 10.1046/j.1365-2311.2002.00393.x; Moran NA, 2005, APPL ENVIRON MICROB, V71, P3302, DOI 10.1128/AEM.71.6.3302-3310.2005; Moran NA, 1998, BIOSCIENCE, V48, P295, DOI 10.2307/1313356; MUNGOMBA LM, 1989, PARASITOL RES, V75, P167, DOI 10.1007/BF00931269; Murrell A, 2005, PARASITOL RES, V97, P274, DOI 10.1007/s00436-005-1413-8; Niebylski ML, 1999, APPL ENVIRON MICROB, V65, P773; Noda H, 1997, APPL ENVIRON MICROB, V63, P3926, DOI 10.1128/AEM.63.10.3926-3932.1997; Noland R. C., 1924, Transactions of the Wisconsin Academy of Sciences Arts and Letters, V21, P195; Ogata H, 2005, PLOS BIOL, V3, P1391, DOI 10.1371/journal.pbio.0030248; Ogata H, 2006, PLOS GENET, V2, P733, DOI 10.1371/journal.pgen.0020076; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; Parola P, 2005, VET RES, V36, P469, DOI 10.1051/vetres:2005004; Perotti MA, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-10; Perotti Maria Alejandra, 2005, Phytophaga - Palermo, V14, P457; Pongponratn E, 1998, TROP MED INT HEALTH, V3, P242, DOI 10.1046/j.1365-3156.1998.00231.x; Ries E., 1931, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V20, P233, DOI 10.1007/BF00444101; Rigaud T, 1997, INFLUENTIAL PASSENGERS, P81; Sakurai M, 2005, APPL ENVIRON MICROB, V71, P4069, DOI 10.1128/AEM.71.7.4069-4075.2005; Seeger W, 1979, STUTTGARTER BEITRA A, V329, P1; SIKORA H., 1920, Archiv fur Schiffs- und Tropenhygiene, V24, P347; Simser JA, 2002, APPL ENVIRON MICROB, V68, P4559, DOI 10.1128/AEM.68.9.4559-4566.2002; SUTAKOVA G, 1986, MYCOPLASMA MYCOPLASM, V22, P43; Tamas I, 2001, FEBS LETT, V498, P135, DOI 10.1016/S0014-5793(01)02459-0; Veneti Z, 2005, SCIENCE, V307, P1461, DOI 10.1126/science.1107182; WERREN JH, 1994, J BACTERIOL, V176, P388, DOI 10.1128/JB.176.2.388-394.1994; WEYDA F, 1991, ACTA ENTOMOL BOHEMOS, V88, P95; Whiting MF, 1997, SYST BIOL, V46, P1, DOI 10.1093/sysbio/46.1.1; Whitworth T, 2003, ANN NY ACAD SCI, V990, P67, DOI 10.1111/j.1749-6632.2003.tb07339.x; WONG S K, 1970, New Zealand Entomologist, V4, P66; WONG SK, 1966, NATURE, V211, P214, DOI 10.1038/211214a0; Yano Y, 2004, MICROBIOL IMMUNOL, V48, P535, DOI 10.1111/j.1348-0421.2004.tb03549.x; Yoshizawa K, 2003, MOL PHYLOGENET EVOL, V29, P102, DOI 10.1016/S1055-7903(03)00073-3; YU XJ, 2003, PROKARYOTES EVOLVING; Yusuf M, 2004, J STORED PROD RES, V40, P207, DOI 10.1016/S0022-474X(02)00098-X; Yusuf M, 2000, J STORED PROD RES, V36, P169, DOI 10.1016/S0022-474X(99)00037-5; Zchori-Fein E, 2001, P NATL ACAD SCI USA, V98, P12555, DOI 10.1073/pnas.221467498; Zientz E, 2004, MICROBIOL MOL BIOL R, V68, P745, DOI 10.1128/MMBR.68.4.745-770.2004	80	84	86	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2372	+		10.1096/fj.06-5870fje	http://dx.doi.org/10.1096/fj.06-5870fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012243				2022-12-25	WOS:000241702600024
J	Kontrogianni-Konstantopoulos, A; Catino, DH; Strong, JC; Sutter, S; Borisov, AB; Pumplin, DW; Russell, MW; Bloch, RJ				Kontrogianni-Konstantopoulos, Aikaterini; Catino, Dawn H.; Strong, John C.; Sutter, Sarah; Borisov, Andrei B.; Pumplin, David W.; Russell, Mark W.; Bloch, Robert J.			Obscurin modulates the assembly and organization of sarcomeres and the sarcoplasmic reticulum	FASEB JOURNAL			English	Article						obscurin; myosin; myomesin; titin; small ankyrin 1; A-band; M-band	M-LINE; PROTEIN; TITIN; MYOFIBRILLOGENESIS; EXPRESSION; MYOSIN; GIANT; DIFFERENTIATION; MLCK; IDENTIFICATION	Obscurin (similar to 800 kDa) in striated muscle closely surrounds sarcomeres at the level of the M-band and Z-disk where, we hypothesize, it participates in the assembly of the contractile apparatus and membrane systems required for Ca2+ homeostasis. In this study, we used small inhibitory RNA (siRNA) technology to reduce the levels of obscurin in primary cultures of skeletal myotubes to study its role in myofibrillogenesis and the organization of the sarcoplasmic reticulum (SR). siRNA-treated myotubes showed a specific and dramatic reduction in the similar to 800 kDa form of obscurin by reverse transcription-polymerase chain reaction, immunoblotting, and immunofluorescence. M-bands and A-bands, but not Z-disks or I-bands, were disrupted when the synthesis of obscurin was inhibited. Small ankyrin 1, an integral protein of the network SR that binds to obscurin, also failed to align around developing sarcomeres in treated myotubes. Myosin and myomesin levels were significantly reduced in treated myotubes but alpha-actinin was not, suggesting that down-regulation of obscurin destabilizes proteins of the M-band and A-band but not of the Z-disk. Our findings suggest that obscurin is required for the assembly of the M-band and A-band and for the regular alignment of the network SR around the contractile apparatus.	Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA; Univ Maryland, Dept Anat & Neurobiol, Sch Med, Baltimore, MD 21201 USA; Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan	Kontrogianni-Konstantopoulos, A (corresponding author), Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA.	akons001@umaryland.edu			NHLBI NIH HHS [R01 HL 075093-01, R01 HL 64304] Funding Source: Medline; NIAMS NIH HHS [R01 AR52768-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064304, R01HL075093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052768] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarkova I, 2003, J MUSCLE RES CELL M, V24, P191, DOI 10.1023/A:1026094924677; Auerbach D, 1997, CELL STRUCT FUNCT, V22, P139, DOI 10.1247/csf.22.139; Bagnato P, 2003, J CELL BIOL, V160, P245, DOI 10.1083/jcb.200208109; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Barral JM, 1999, BIOESSAYS, V21, P813, DOI 10.1002/(SICI)1521-1878(199910)21:10<813::AID-BIES3>3.0.CO;2-0; Benian GM, 1996, J CELL BIOL, V132, P835, DOI 10.1083/jcb.132.5.835; Borisov AB, 2006, HISTOCHEM CELL BIOL, V125, P227, DOI 10.1007/s00418-005-0069-x; Borisov AB, 2004, J HISTOCHEM CYTOCHEM, V52, P1117, DOI 10.1369/jhc.3A6183.2004; Borisov AB, 2003, BIOCHEM BIOPH RES CO, V310, P910, DOI 10.1016/j.bbrc.2003.09.035; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493; De Deyne PG, 1998, J CELL SCI, V111, P2729; Du AP, 2003, DEV BIOL, V257, P382, DOI 10.1016/S0012-1606(03)00104-0; Ehler E, 1999, J CELL SCI, V112, P1529; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Furst DO, 1999, REV PHYSIOL BIOCH P, V138, P163, DOI 10.1007/BF02346663; Gautel M, 1999, REV PHYSIOL BIOCH P, V138, P97, DOI 10.1007/BF02346661; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; Kontrogianni-Konstantopoulos A, 2006, AM J PHYSIOL-CELL PH, V290, pC626, DOI 10.1152/ajpcell.00442.2005; Kontrogianni-Konstantopoulos A, 2004, AM J PHYSIOL-CELL PH, V287, pC209, DOI 10.1152/ajpcell.00497.2003; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; KONTROGIANNIKON.A, 2005, IN PRESS J MUSCLE RE; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; Mason P, 1999, BIOCHEM BIOPH RES CO, V257, P699, DOI 10.1006/bbrc.1999.0531; McElhinny AS, 2003, TRENDS CARDIOVAS MED, V13, P195, DOI 10.1016/S1050-1738(03)00076-8; Miller G, 2003, J CELL SCI, V116, P4811, DOI 10.1242/jcs.00768; Ojima K, 1999, J CELL SCI, V112, P4101; RHEE D, 1994, CELL MOTIL CYTOSKEL, V28, P1, DOI 10.1002/cm.970280102; Russell MW, 2002, GENE, V282, P237, DOI 10.1016/S0378-1119(01)00795-8; Sanger JW, 2002, CLIN ORTHOP RELAT R, pS153, DOI 10.1097/01.blo.0000031973.69509.21; SCHULTHEISS T, 1990, J CELL BIOL, V110, P1159, DOI 10.1083/jcb.110.4.1159; Small TM, 2004, J MOL BIOL, V342, P91, DOI 10.1016/j.jmb.2004.07.006; TAKEKURA H, 1993, J MUSCLE RES CELL M, V14, P633, DOI 10.1007/BF00141560; Takekura H, 2001, DEV BIOL, V239, P204, DOI 10.1006/dbio.2001.0437; Van der Ven PFM, 1998, J MUSCLE RES CELL M, V19, P767, DOI 10.1023/A:1005443203238; Van der Ven PFM, 1999, J MUSCLE RES CELL M, V20, P569, DOI 10.1023/A:1005569225773; Wang SM, 1998, J CELL BIOCHEM, V71, P82, DOI 10.1002/(SICI)1097-4644(19981001)71:1<82::AID-JCB9>3.0.CO;2-Y; Wright C, 1997, J APPL PHYSIOL, V83, P1389, DOI 10.1152/jappl.1997.83.4.1389; WRIGHT J, 1993, J MUSCLE RES CELL M, V14, P476, DOI 10.1007/BF00297210; Yang YG, 2000, CELL STRUCT FUNCT, V25, P177, DOI 10.1247/csf.25.177; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621	43	81	81	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2102	2111		10.1096/fj.06-5761com	http://dx.doi.org/10.1096/fj.06-5761com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012262	Green Submitted			2022-12-25	WOS:000241156900018
J	Perez-Caro, M; Gutierrez-Cianca, N; Gonzalez-Herrero, I; Lopez-Hernandez, I; Flores, T; Orfao, A; Sanchez-Martin, M; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I				Perez-Caro, M.; Gutierrez-Cianca, N.; Gonzalez-Herrero, I.; Lopez-Hernandez, I.; Flores, T.; Orfao, A.; Sanchez-Martin, M.; Gutierrez-Adan, A.; Pintado, B.; Sanchez-Garcia, I.			Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice	ONCOGENE			English	Article						cancer maintenance; dox regulation; fusion genes; cancer stem cell; mouse models	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; COMPLETE CYTOGENETIC REMISSION; IMATINIB MESYLATE TREATMENT; BCR-ABL; PHILADELPHIA-CHROMOSOME; IN-VIVO; HEMATOPOIETIC PROGENITORS; CANCER DEVELOPMENT	Pharmacological inactivation of cancer genes or products is being used as a strategy for therapy in oncology. To investigate the potential role of BCR-ABLp190 cessation in leukaemia development, we generated mice carrying a tetracycline-repressible BCR-ABLp190 transgene. These mice were morphologically normal at birth, and developed leukaemias. Disease was characterized by the presence of B-cell blasts co-expressingmyeloid markers, reminiscent of the human counterpart. BCR-ABLp190 activation can initiate leukaemia in both young and adult mice. Transitory expression of BCR-ABLp190 is enough to develop leukaemia. Suppression of the BCR-ABLp190 transgene in leukaemic CombitTA-p190 mice did not rescue the malignant phenotype, indicating that BCR-ABLp190 is not required to maintain the disease in mice. Similar results were obtained by inactivation of BCR-ABLp190 with STI571 (Gleevec; Novartis, East Hanover, NJ, USA) in leukaemic CombitTA-p190 mice. However, gradual suppression of BCR-ABLp190 in leukaemic CombitTA-p190 mice identified a minimum level of BCR-ABLp190 expression necessary to revert the specific block in B-cell differentiation in the leukaemic cells. Overall, the findings indicate that BCR-ABLp190 appears to cause epigenetic and/or genetic changes in tumour-maintaining cells that render them insensitive to BCR-ABLp190 inactivation.	Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Lab 13, E-37007 Salamanca, Spain; Univ Salamanca, Serv Anat Patol, E-37007 Salamanca, Spain; Univ Salamanca, Serv Citometria, E-37007 Salamanca, Spain; Univ Salamanca, Dept Med, E-37007 Salamanca, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Lab 13, Campus Unamuno S-N, E-37007 Salamanca, Spain.	isg@usal.es	Sanchez-Martin, Manuel/N-5327-2016; Gutierrez-Adan, Alfonso/A-1485-2014; 2007, Secribsal/A-1556-2012; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; González-Herrero, Inés/G-8546-2015; Orfao, Alberto/B-5801-2017; Pintado, Belen/N-3233-2014	Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; González-Herrero, Inés/0000-0003-1142-4362; Pintado, Belen/0000-0002-8485-2520; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; Chu S, 2005, BLOOD, V105, P2093, DOI 10.1182/blood-2004-03-1114; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Cobaleda C, 1998, BIOESSAYS, V20, P922, DOI 10.1002/(SICI)1521-1878(199811)20:11<922::AID-BIES7>3.0.CO;2-O; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GarciaHernandez B, 1997, P NATL ACAD SCI USA, V94, P13239, DOI 10.1073/pnas.94.24.13239; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Mauro MJ, 2001, ONCOLOGIST, V6, P233, DOI 10.1634/theoncologist.6-3-233; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; O'Dwyer ME, 2001, CURR CANCER DRUG TAR, V1, P49, DOI 10.2174/1568009013334250; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; Perez-Caro M, 2005, CURR GENOMICS, V6, P81, DOI 10.2174/1389202053642276; Perez-Mancera PA, 2005, HUM MOL GENET, V14, P3449, DOI 10.1093/hmg/ddi373; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SECKERWALKER LM, 1991, GENE CHROMOSOME CANC, V3, P320; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Tabernero MD, 2001, LEUKEMIA, V15, P406, DOI 10.1038/sj.leu.2402060; Towatari M, 2004, BLOOD, V104, P3507, DOI 10.1182/blood-2004-04-1389; Van Etten R A, 2001, Curr Oncol Rep, V3, P228; Wendel HG, 2006, P NATL ACAD SCI USA, V103, P7444, DOI 10.1073/pnas.0602402103; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	48	20	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1702	1713		10.1038/sj.onc.1209968	http://dx.doi.org/10.1038/sj.onc.1209968			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983340				2022-12-25	WOS:000244955600004
J	Bradley, KJ; Bowl, MR; Williams, SE; Ahmad, BN; Partridge, CJ; Patmanidi, AL; Kennedy, AM; Loh, NY; Thakker, RV				Bradley, K. J.; Bowl, M. R.; Williams, S. E.; Ahmad, B. N.; Partridge, C. J.; Patmanidi, A. L.; Kennedy, A. M.; Loh, N. Y.; Thakker, R. V.			Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal	ONCOGENE			English	Article						parathyroid cancer; tumour suppressor gene; uterine tumours; renal tumours; ossifying fibromas	JAW TUMOR SYNDROME; PARATHYROID CARCINOMA; GENE-PRODUCT; HUMAN PAF1; HYPERPARATHYROIDISM; HRPT2; MUTATIONS; RETINOBLASTOMA; IDENTIFICATION; DYSPLASIA	Parafibromin is a nuclear protein with a tumour suppressor role in the development of non-hereditary and hereditary parathyroid carcinomas, and the hyperparathyroidism-jaw tumour (HPT-JT) syndrome, which is associated with renal and uterine tumours. Nuclear localization signal( s), (NLS(s)), of the 61kDa parafibromin remain to be defined. Utilization of computer-prediction programmes, identified five NLSs (three bipartite ( BP) and two monopartite ( MP)). To investigate their functionality, wild-type (WT) and mutant parafibromin constructs tagged with enhanced green fluorescent protein or cMyc were transiently expressed in COS-7 cells, or human embryonic kidney 293 (HEK293) cells, and their subcellular locations determined by confocal fluorescence microscopy. Western blot analyses of nuclear and cytoplasmic fractions from the transfected cells were also performed. WT parafibromin localized to the nucleus and deletions or mutations of the three predicted BP and one of the predicted MP NLSs did not affect this localization. In contrast, deletions or mutations of a MP NLS, at residues 136-139, resulted in loss of nuclear localization. Furthermore, the critical basic residues, KKXR, of this MP NLS were found to be evolutionarily conserved, and over 60% of all parafibromin mutations lead to a loss of this NLS. Thus, an important functional domain of parafibromin, consisting of an evolutionarily conserved MP NLS, has been identified.	Univ Oxford, OCDEM, Nuffield Dept Clin Med, Acad Endocrine Unit,Churchil Hosp, Oxford OX3 7LJ, England; Univ Oxford, Diabet Res Labs, Nuffield Dept Clin Med, Dept Clin Med,Churchill Hosp,OCDEM, Oxford OX3 7LJ, England	University of Oxford; University of Oxford	Thakker, RV (corresponding author), Univ Oxford, OCDEM, Nuffield Dept Clin Med, Acad Endocrine Unit,Churchil Hosp, Oxford OX3 7LJ, England.	rajesh.thakker@ndm.ox.ac.uk		Kennedy, Ann/0000-0003-0290-396X; Piret, Sian/0000-0002-3586-7654; Patmanidi, Alexandra/0000-0003-0773-2020; Bowl, Michael/0000-0001-7971-445X; Thakker, Rajesh/0000-0002-1438-3220	Medical Research Council [G9825289] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9825289] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bradley KJ, 2006, CLIN ENDOCRINOL, V64, P299, DOI 10.1111/j.1365-2265.2006.02460.x; Bradley KJ, 2005, J INTERN MED, V257, P18, DOI 10.1111/j.1365-2796.2004.01421.x; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kennedy AM, 2005, J CLIN INVEST, V115, P2832, DOI 10.1172/JCI22900; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Krauer K, 2004, J GEN VIROL, V85, P165, DOI 10.1099/vir.0.19549-0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; Quadrini KJ, 2002, J BIOL CHEM, V277, P32243, DOI 10.1074/jbc.M205677200; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; SZABO J, 1995, AM J HUM GENET, V56, P944; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; THAKKER RV, 2006, ENDOCRINOLOGY, V2, P1511; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	30	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1213	1221		10.1038/sj.onc.1209893	http://dx.doi.org/10.1038/sj.onc.1209893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16964291				2022-12-25	WOS:000244406400011
J	Taubert, H; Greither, T; Kaushal, D; Wurl, P; Bache, M; Bartel, F; Kehlen, A; Lautenschlager, C; Harris, L; Kraemer, K; Meye, A; Kappler, M; Schmidt, H; Holzhausen, HJ; Hauptmann, S				Taubert, H.; Greither, T.; Kaushal, D.; Wuerl, P.; Bache, M.; Bartel, F.; Kehlen, A.; Lautenschlaeger, C.; Harris, L.; Kraemer, K.; Meye, A.; Kappler, M.; Schmidt, H.; Holzhausen, H-J; Hauptmann, S.			Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma	ONCOGENE			English	Article						Hiwi; stem cell self-renewal; soft-tissue sarcoma; prognosis; Piwi domain; mRNA expression	PIWI; PROTEINS; RECOGNITION; HOMOLOG; CANCER	Self-renewal is considered as a common property of stem cells. Dysregulation of stem cell self-renewal is likely a requirement for the development of cancer. Hiwi, the human Piwi gene, encodes a protein responsible for stem cell self-renewal. In this study, we investigated the expression of Hiwi at the RNA level by real-time quantitative PCR in 65 primary soft-tissue sarcomas (STS) and ascertained its impact on prognosis for STS patients. In a multivariate Cox's proportional hazards regression model, we found that an increased expression of Hiwi mRNA is a significant negative prognostic factor for patients with STS (P=0.017; relative risk 4.6, 95% confidence interval (CI) 1.3 - 16.1) compared to medium expression of Hiwi transcript. However, a low expression of Hiwi transcript is correlated with a 2.4- fold ( CI 0.7-8.0) increased risk, but this effect was not significant (P=0.17). Altogether, high-level expression of Hiwi mRNA identifies STS patients at high risk of tumour-related death. This is the first report showing a correlation between expression of a gene involved in stem cell self-renewal and prognosis of cancer patients.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle, Germany; St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Ulm, Clin Gen & Transplantat Surg, D-89069 Ulm, Germany; Univ Halle Wittenberg, Dept Radiotherapy, D-4010 Halle, Germany; Probiodrug AG, Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, Halle, Germany; St Jude Childrens Hosp, Memphis, TN 38105 USA; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany; Univ Halle Wittenberg, Inst Pathol, Jr Res Grp, Halle, Germany	Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Ulm University; Martin Luther University Halle Wittenberg; Vivoryon Therapeutics; Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Technische Universitat Dresden; Martin Luther University Halle Wittenberg	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle, Germany.	helge.taubert@medizin.uni-halle.de	Greither, Thomas/M-5334-2019; Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271				Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cox DN, 2000, DEVELOPMENT, V127, P503; Fetzer CP, 2002, NUCLEIC ACIDS RES, V30, P4380, DOI 10.1093/nar/gkf579; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Lingel A, 2005, CURR OPIN STRUC BIOL, V15, P107, DOI 10.1016/j.sbi.2005.01.010; Liu XY, 2006, INT J CANCER, V118, P1922, DOI 10.1002/ijc.21575; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; Qiao D, 2002, ONCOGENE, V21, P3988, DOI 10.1038/sj.onc.1205505; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Soltysova A, 2005, NEOPLASMA, V52, P435; VANUNNIK JAM, 1995, HEMATOL ONCOL CLIN N, V9, P677, DOI 10.1016/S0889-8588(18)30091-1; WITTEKIND C, 1997, UICC TNM KLASSIFIKAT; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4	14	111	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1098	1100		10.1038/sj.onc.1209880	http://dx.doi.org/10.1038/sj.onc.1209880			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16953229				2022-12-25	WOS:000244245400016
J	Godoy, A; Ormazabal, V; Moraga-Cid, G; Zuniga, FA; Sotomayor, P; Barra, V; Vasquez, O; Montecinos, V; Mardones, L; Guzman, C; Villagran, M; Aguayo, LG; Onate, SA; Reyes, AM; Carcamo, JG; Rivas, CI; Vera, JC				Godoy, Alejandro; Ormazabal, Valeska; Moraga-Cid, Gustavo; Zuniga, Felipe A.; Sotomayor, Paula; Barra, Valeria; Vasquez, Osman; Montecinos, Viviana; Mardones, Lorena; Guzman, Catherine; Villagran, Marcelo; Aguayo, Luis G.; Onate, Sergio A.; Reyes, Alejandro M.; Carcamo, Juan G.; Rivas, Coralia I.; Vera, Juan Carlos			Mechanistic insights and functional determinants of the transport cycle of the ascorbic acid transporter SVCT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENOMEDULLARY CHROMAFFIN CELLS; DEHYDROASCORBIC ACID; FACILITATED TRANSPORT; LACTOSE PERMEASE; ESCHERICHIA-COLI; EXPRESSION; FAMILY; NOMENCLATURE; SECRETION; AFFINITY	We characterized the human Na+-ascorbic acid transporter SVCT2 and developed a basic model for the transport cycle that challenges the current view that it functions as a Na+-dependent transporter. The properties of SVCT2 are modulated by Ca2+/Mg2+ and a reciprocal functional interaction between Na+ and ascorbic acid that defines the substrate binding order and the transport stoichiometry. Na+ increased the ascorbic acid transport rate in a cooperative manner, decreasing the transport K-m without affecting the V-max, thus converting a low affinity form of the transporter into a high affinity transporter. Inversely, ascorbic acid affected in a bimodal and concentration-dependent manner the Na+ cooperativity, with absence of cooperativity at low and high ascorbic acid concentrations. Our data are consistent with a transport cycle characterized by a Na+:ascorbic acid stoichiometry of 2:1 and a substrate binding order of the type Na+:ascorbic acid:Na+. However, SVCT2 is not electrogenic. SVCT2 showed an absolute requirement for Ca2+/Mg2+ for function, with both cations switching the transporter from an inactive into an active conformation by increasing the transport V-max without affecting the transport K-m or the Na+ cooperativity. Our data indicate that SVCT2 may switch between a number of states with characteristic properties, including an inactive conformation in the absence of Ca2+/Mg2+. At least three active states can be envisioned, including a low affinity conformation at Na+ concentrations below 20 mM and two high affinity conformations at elevated Na+ concentrations whose Na+ cooperativity is modulated by ascorbic acid. Thus, SVCT2 is a Ca2+/Mg2+-dependent transporter.	Univ Concepcion, Fac Ciencias Biol, Dept Fisiopatol, Concepcion, Chile; Univ Concepcion, Fac Ciencias Biol, Dept Fisiol, Concepcion, Chile; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Univ Austral Chile, Fac Ciencias, Inst Bioquim, Valdivia, Chile	Universidad de Concepcion; Universidad de Concepcion; Roswell Park Cancer Institute; Universidad Austral de Chile	Vera, JC (corresponding author), Univ Concepcion, Fac Ciencias Biol, Dept Fisiopatol, Barrio Univ S-N,Casilla 160C, Concepcion, Chile.	juvera@udec.cl	Moraga-Cid, Gustavo/AAC-3314-2021; Zuniga, Felipe A/L-7885-2013; Godoy, Alejandro/GPS-4942-2022; Zuniga, Felipe/Q-8035-2019; Mardones, Lorena/Z-4896-2019; Villagran, Marcelo/AAP-1171-2020	Mardones, Lorena/0000-0001-8037-4296; Carcamo, Juan Guillermo/0000-0002-2595-4375; Villagran, Marcelo/0000-0003-3645-5659; Zuniga, Felipe A./0000-0003-0286-565X				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Castro M, 2001, J NEUROCHEM, V78, P815, DOI 10.1046/j.1471-4159.2001.00461.x; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V3rd, DOI [10.1016/B978-0-408-10617-7.50013-4/, DOI 10.1016/B978-0-408-10617-7.50013-4]; DANIELS AJ, 1983, MOL PHARMACOL, V23, P437; DANIELS AJ, 1982, SCIENCE, V216, P737, DOI 10.1126/science.7079733; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; DILIBERTO EJ, 1983, J BIOL CHEM, V258, P2886; Garcia MDA, 2001, J CELL BIOCHEM, V80, P491; Guan L, 2004, P NATL ACAD SCI USA, V101, P12148, DOI 10.1073/pnas.0404936101; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Joost HG, 2002, AM J PHYSIOL-ENDOC M, V282, pE974, DOI 10.1152/ajpendo.00407.2001; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; Maulen NP, 2003, J BIOL CHEM, V278, P9035, DOI 10.1074/jbc.M205119200; Nualart F, 1999, BRAIN RES, V824, P97, DOI 10.1016/S0006-8993(99)01078-1; QUAMME GA, 1993, AM J PHYSIOL, V264, pG383, DOI 10.1152/ajpgi.1993.264.2.G383; Rajan DP, 1999, BIOCHEM BIOPH RES CO, V262, P762, DOI 10.1006/bbrc.1999.1272; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; SMITHMAXWELL C, 1990, AM J PHYSIOL, V258, pC234, DOI 10.1152/ajpcell.1990.258.2.C234; Spielholz C, 1997, CANCER RES, V57, P2529; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Vayro S, 1998, BIOCHEM J, V332, P119, DOI 10.1042/bj3320119; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang HP, 1999, BBA-BIOMEMBRANES, V1461, P1, DOI 10.1016/S0005-2736(99)00182-0; Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929	30	72	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					615	624		10.1074/jbc.M608300200	http://dx.doi.org/10.1074/jbc.M608300200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17012227	hybrid			2022-12-25	WOS:000243166500067
J	Straight, SW; Pieczynski, JN; Whiteman, EL; Liu, CJ; Margolis, B				Straight, Samuel W.; Pieczynski, Jay N.; Whiteman, Eileen L.; Liu, Chia-Jen; Margolis, Ben			Mammalian Lin-7 stabilizes polarity protein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS VULVAR INDUCTION; CELL-CELL JUNCTIONS; EPITHELIAL-CELLS; TIGHT JUNCTIONS; BASOLATERAL SURFACE; DROSOPHILA STARDUST; PLASMA-MEMBRANE; MAGUK FAMILY; PDZ PROTEINS; DISCS LOST	Mammalian Lin-7 forms a complex with several proteins, including PALS1, that have a role in polarity determination in epithelial cells. In this study we have found that loss of Lin-7 protein from the polarized epithelial cell line Madin-Darby canine kidney II by small hairpin RNA results in defects in tight junction formation as indicated by lowered transepithelial electrical resistance and mislocalization of the tight junction protein ZO-1 after calcium switch. The knock down of Lin-7 also resulted in the loss of expression of several Lin-7 binding partners, including PALS1 and the polarity protein PATJ. The effects of Lin-7 knock down were rescued by the exogenous expression of murine Lin-7 constructs that contained the L27 domain, but not the PDZ domain alone. Furthermore, exogenously expressed PALS1, but not other Lin-7 binding partners, also rescued the effects of Lin-7 knock down, including the restoration of PATJ protein in rescued cell lines. Finally, the effects of Lin-7 knock down appeared to be due to instability of PALS1 protein in the absence of Lin-7, as indicated by an increased rate of PALS1 protein degradation. Taken together, these results indicate that Lin-7 functions in tight junction formation by stabilizing its membrane-associated guanylate kinase binding partner PALS1.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1528 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu			NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255, P60DK020572, R01DK058208] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09676] Funding Source: Medline; NIDDK NIH HHS [DK39255, 5P60 DK20572, DK58208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachmann A, 2004, J CELL SCI, V117, P1899, DOI 10.1242/jcs.01029; Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Feng W, 2004, NAT STRUCT MOL BIOL, V11, P475, DOI 10.1038/nsmb751; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Konig C, 1999, MECH DEVELOP, V86, P17, DOI 10.1016/S0925-4773(99)00098-2; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Lemmers C, 2002, J BIOL CHEM, V277, P25408, DOI 10.1074/jbc.M202196200; Li YH, 2004, EMBO J, V23, P2723, DOI 10.1038/sj.emboj.7600294; Makarova O, 2003, GENE, V302, P21, DOI 10.1016/S0378111902010843; Marshall OJ, 2004, BIOINFORMATICS, V20, P2471, DOI 10.1093/bioinformatics/bth254; Olsen O, 2005, AM J PHYSIOL-RENAL, V288, pF345, DOI 10.1152/ajprenal.00235.2004; Olsen O, 2005, J CELL BIOL, V170, P1127, DOI 10.1083/jcb.200503011; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Petrosky KY, 2005, J BIOL CHEM, V280, P38528, DOI 10.1074/jbc.M506536200; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Roh MH, 2003, J CELL SCI, V116, P2895, DOI 10.1242/jcs.00500; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Rohr S, 2006, DEVELOPMENT, V133, P107, DOI 10.1242/dev.02182; Shelly M, 2003, DEV CELL, V5, P475, DOI 10.1016/j.devcel.2003.08.001; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; Straight SW, 2000, AM J PHYSIOL-RENAL, V278, pF464, DOI 10.1152/ajprenal.2000.278.3.F464	39	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37738	37747		10.1074/jbc.M607059200	http://dx.doi.org/10.1074/jbc.M607059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17012742	hybrid			2022-12-25	WOS:000242477100051
J	Palecek, J; Vidot, S; Feng, M; Doherty, AJ; Lehmann, AR				Palecek, Jan; Vidot, Susanne; Feng, Min; Doherty, Aidan J.; Lehmann, Alan R.			The Smc5-Smc6 DNA repair complex - Bridging of the Smc5-Smc6 heads by the kleisin, Nse4, and non-kleisin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMC PROTEINS; SUMO LIGASE; FISSION YEAST; COMPONENT; COHESIN; DAMAGE; ARCHITECTURE; CHROMOSOME; RESPONSES; GENOME	Structural maintenance of chromosomes (SMC) proteins play fundamental roles in many aspects of chromosome organization and dynamics. The SMC complexes form unique structures with long coiled-coil arms folded at a hinge domain, so that the globular N-and C-terminal domains are brought together to form a "head." Within the Smc5-Smc6 complex, we previously identified two subcomplexes containing Smc6-Smc5-Nse2 and Nse1-Nse3-Nse4. A third subcomplex containing Nse5 and -6 has also been identified recently. We present evidence that Nse4 is the kleisin component of the complex, which bridges the heads of Smc5 and -6. The C-terminal part of Nse4 interacts with the head domain of Smc5, and structural predictions for Nse4 proteins suggest similar motifs that are shared within the kleisin family. Specific mutations within a predicted winged helix motif of Nse4 destroy the interaction with Smc5. We propose that Nse4 and its orthologs form the delta-kleisin subfamily. We further show that Nse3, as well as Nse5 and Nse6, also bridge the heads of Smc5 and -6. The Nse1-Nse3-Nse4 and Nse5-Nse6 subcomplexes bind to the Smc5-Smc6 heads domain at different sites.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sussex	Lehmann, AR (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	a.r.lehmann@sussex.ac.uk	Palecek, Jan/D-6864-2012	Palecek, Jan/0000-0002-6223-5169; Doherty, Aidan/0000-0002-6370-1109	Medical Research Council [G0300662B] Funding Source: researchfish; MRC [G0501450] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D522746/1] Funding Source: Medline; Cancer Research UK [A5451] Funding Source: Medline; Medical Research Council [G0501450] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Andrews EA, 2005, MOL CELL BIOL, V25, P185, DOI 10.1128/MCB.25.1.185-196.2005; Fousteri MI, 2000, EMBO J, V19, P1691, DOI 10.1093/emboj/19.7.1691; Fujioka Y, 2002, J BIOL CHEM, V277, P21585, DOI 10.1074/jbc.M201523200; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Haering CH, 2004, MOL CELL, V15, P951, DOI 10.1016/j.molcel.2004.08.030; Harvey SH, 2004, MOL CELL BIOL, V24, P662, DOI 10.1128/MCB.24.2.662-674.2004; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hirano T, 2006, NAT REV MOL CELL BIO, V7, P311, DOI 10.1038/nrm1909; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hu B, 2005, MOL MICROBIOL, V55, P1735, DOI 10.1111/j.1365-2958.2005.04531.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lehmann AR, 2005, DNA REPAIR, V4, P309, DOI 10.1016/j.dnarep.2004.07.009; Losada A, 2005, GENE DEV, V19, P1269, DOI 10.1101/gad.1320505; McDonald WH, 2003, J BIOL CHEM, V278, P45460, DOI 10.1074/jbc.M308828200; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Morikawa H, 2004, MOL CELL BIOL, V24, P9401, DOI 10.1128/MCB.24.21.9401-9413.2004; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Pebernard S, 2006, MOL CELL BIOL, V26, P1617, DOI 10.1128/MCB.26.5.1617-1630.2006; Pebernard S, 2004, MOL BIOL CELL, V15, P4866, DOI 10.1091/mbc.E04-05-0436; Potts PR, 2005, MOL CELL BIOL, V25, P7021, DOI 10.1128/MCB.25.16.7021-7032.2005; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sergeant J, 2005, MOL CELL BIOL, V25, P172, DOI 10.1128/MCB.25.1.172-184.2005; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	27	78	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36952	36959		10.1074/jbc.M608004200	http://dx.doi.org/10.1074/jbc.M608004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17005570	hybrid			2022-12-25	WOS:000242220800055
J	Taylor, RM; Baniulis, D; Burritt, JB; Gripentrog, JM; Lord, CI; Riesselman, MH; Maaty, WS; Bothner, BP; Angel, TE; Dratz, EA; Linton, GF; Malech, HL; Jesaitis, AJ				Taylor, Ross M.; Baniulis, Danas; Burritt, James B.; Gripentrog, Jeannie M.; Lord, Connie I.; Riesselman, Marcia H.; Maaty, Walid S.; Bothner, Brian P.; Angel, Thomas E.; Dratz, Edward A.; Linton, Gilda F.; Malech, Harry L.; Jesaitis, Algirdas J.			Analysis of human phagocyte flavocytochrome b(558) by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; LASER-DESORPTION/IONIZATION-TIME; NEUTROPHIL CYTOCHROME-B; NADPH OXIDASE; GLYCOSYLATION SITES; SUPEROXIDE; MEMBRANE; IDENTIFICATION; P22(PHOX); PROTEINS	The catalytic core of the phagocyte NADPH oxidase is a heterodimeric integral membrane protein (flavocytochrome b (Cyt b)) that generates superoxide and initiates a cascade of reactive oxygen species critical for the host inflammatory response. In order to facilitate structural characterization, the present study reports the first direct analysis of human phagocyte Cyt b by matrix-assisted laser desorption/ionization and nanoelectrospray mass spectrometry. Mass analysis of in-gel tryptic digest samples provided 73% total sequence coverage of the gp91(phox) subunit, including three of the six proposed transmembrane domains. Similar analysis of the p22(phox) subunit provided 72% total sequence coverage, including assignment of the hydrophobic N-terminal region and residues that are polymorphic in the human population. To initiate mass analysis of Cyt b post-translational modifications, the isolated gp91phox subunit was subject to sequential in-gel digestion with Flavobacterium meningosepticum peptide N-glycosidase F and trypsin, with matrix-assisted laser desorption/ionization and liquid chromatography-mass spectrometry/mass spectrometry used to demonstrate that Asn-132, -149, and -240 are genuinely modified by N-linked glycans in human neutrophils. Since the PLB-985 cell line represents an important model system for analysis of the NADPH oxidase, methods were developed for the purification of Cyt b from PLB-985 membrane fractions in order to confirm the appropriate modification of N-linked glycosylation sites on the recombinant gp91phox subunit. This study reports extensive sequence coverage of the integral membrane protein Cyt b by mass spectrometry and provides analytical methods that will be useful for evaluating post-translational modifications involved in the regulation of superoxide production.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Taylor, RM (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.	rosst@montana.edu	Baniulis, Danas/AAA-9458-2021	Baniulis, Danas/0000-0002-2693-2020; Malech, Harry/0000-0001-5874-5775; Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064107, Z01AI000644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062547] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 64107] Funding Source: Medline; NIGMS NIH HHS [R01 GM 62547] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams ER, 1997, BIOCHEM J, V325, P249, DOI 10.1042/bj3250249; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Barnidge DR, 1997, PROTEIN SCI, V6, P816; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; Bjorgvinsdottir H, 1996, BLOOD, V87, P2005, DOI 10.1182/blood.V87.5.2005.bloodjournal8752005; Brenner S, 2003, BLOOD, V102, P2789, DOI 10.1182/blood-2002-05-1482; Buetler TM, 2004, NEWS PHYSIOL SCI, V19, P120, DOI 10.1152/nips.01514.2003; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; Burritt JB, 2003, J IMMUNOL, V170, P6082, DOI 10.4049/jimmunol.170.12.6082; Burritt JB, 2001, J BIOL CHEM, V276, P2053, DOI 10.1074/jbc.M006236200; Carroll J, 2005, MOL CELL PROTEOMICS, V4, P693, DOI 10.1074/mcp.M500014-MCP200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; Davis AR, 1998, J LEUKOCYTE BIOL, V64, P114, DOI 10.1002/jlb.64.1.114; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; Domon B, 2006, SCIENCE, V312, P212, DOI 10.1126/science.1124619; DOUSSIERE J, 1995, BIOCHEMISTRY-US, V34, P1760, DOI 10.1021/bi00005a033; Elsbach P, 1999, INFLAMMATION BASIC P, P801; Foubert TR, 2001, J BIOL CHEM, V276, P38852, DOI 10.1074/jbc.M104373200; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Guzik TJ, 2000, CIRCULATION, V102, P1744; Hagglund P, 2004, J PROTEOME RES, V3, P556, DOI 10.1021/pr034112b; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Jacobsen RB, 2006, PROTEIN SCI, V15, P1303, DOI 10.1110/ps.052040406; Kawahara T, 2005, J BIOL CHEM, V280, P31859, DOI 10.1074/jbc.M501882200; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; Kraft P, 2001, ANAL BIOCHEM, V292, P76, DOI 10.1006/abio.2001.5072; Leite JF, 2003, P NATL ACAD SCI USA, V100, P13054, DOI 10.1073/pnas.2133028100; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Li XJ, 2005, J BIOL CHEM, V280, P14962, DOI 10.1074/jbc.M500226200; Melley DD, 2005, CLIN SCI, V108, P413, DOI 10.1042/CS20040228; Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q; Ogura K, 2006, J BIOL CHEM, V281, P3660, DOI 10.1074/jbc.M505193200; Paclet MH, 2004, BIOCHEM J, V382, P981, DOI 10.1042/BJ20040954; Park MY, 1997, BIOCHEM BIOPH RES CO, V234, P531, DOI 10.1006/bbrc.1997.6672; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; Quach TTT, 2003, J PROTEOME RES, V2, P543, DOI 10.1021/pr0340126; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; Rae J, 2000, BLOOD, V96, P1106, DOI 10.1182/blood.V96.3.1106.015k44_1106_1112; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Regier DS, 1999, J BIOL CHEM, V274, P36601, DOI 10.1074/jbc.274.51.36601; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Sinz A, 2006, MASS SPECTROM REV, V25, P663, DOI 10.1002/mas.20082; Taylor RM, 2004, J IMMUNOL, V173, P7349, DOI 10.4049/jimmunol.173.12.7349; Taylor RM, 2004, BBA-BIOMEMBRANES, V1663, P201, DOI 10.1016/j.bbamem.2004.03.009; Taylor RM, 2003, BBA-BIOMEMBRANES, V1612, P65, DOI 10.1016/S0005-2736(03)00086-5; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; TUCKER KA, 1987, BLOOD, V70, P372; Ueno N, 2005, J BIOL CHEM, V280, P23328, DOI 10.1074/jbc.M414548200; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Whitelegge JP, 2006, J EXP BOT, V57, P1515, DOI 10.1093/jxb/erj163; Wyche KE, 2004, HYPERTENSION, V43, P1246, DOI 10.1161/01.HYP.0000126579.50711.62; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288	62	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37045	37056		10.1074/jbc.M607354200	http://dx.doi.org/10.1074/jbc.M607354200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17015440	hybrid			2022-12-25	WOS:000242220800066
J	Ray, S; Yumak, H; Domashevskiy, A; Khan, MA; Gallie, DR; Goss, DJ				Ray, Sibnath; Yumak, Hasan; Domashevskiy, Artem; Khan, Mateen A.; Gallie, Daniel R.; Goss, Dixie J.			Tobacco etch virus mRNA preferentially binds wheat germ eukaryotic initiation factor (eIF) 4G rather than eIFiso4G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-INDEPENDENT TRANSLATION; LINKED PROTEIN VPG; FACTOR 4F; INTERNAL INITIATION; POLYRIBOSOMAL RNA; ISOZYME FORM; 5' LEADER; IDENTIFICATION; AFFINITY; ENTRY	The 5'-leader of tobacco etch virus (TEV) genomic RNA directs the efficient translation from the naturally uncapped viral RNA. The TEV 143-nt 5'-leader folds into a structure that contains two domains, each of which contains RNA pseudoknots. The 5'-proximal pseudoknot 1 (PK1) is necessary to promote cap-independent translation (Zeenko,V., and Gallie, D. R. ( 2005) J. Biol. Chem. 280, 26813-26824). During the translation initiation of cellular mRNAs, eIF4G functions as an adapter that recruits many of the factors involved in stimulating 40 S ribosomal subunit binding to an mRNA. Two related but highly distinct eIF4G proteins are expressed in plants, animals, and yeast. The two plant eIF4G isoforms, referred to as eIF4G and eIFiso4G, differ in size ( 165 and 86 kDa, respectively) and their functional differences are still unclear. Although eIF4G is required for the translation of TEV mRNA, it is not known if eIF4G binds directly to the TEV RNA itself or if other factors are required. To determine whether binding affinity and isoform preference correlates with translational efficiency, fluorescence spectroscopy was used to measure the binding of eIF4G, eIFiso4G, and their complexes( eIF4F and eIFiso4F, respectively) to the TEV 143-nt 5'-leader (TEV1-143) and a shorter RNA that contained PK1. A mutant (i.e. S1-3) in which the stem of PK1 was disrupted resulting in impaired cap-independent translation, was also tested. These studies demonstrate that eIF4G binds TEV1-143 and PK1 RNA with similar to 22-30-fold stronger affinity than eIFiso4G. eIF4G and eIF4F bind TEV1- 143 with similar affinity, whereas eIFiso4F binds with similar to 6-fold higher affinity than eIFiso4G. The binding affinity of eIF4G, eIF4F, and eIFiso4G to S1-3 was reduced by 3-5-fold, consistent with the reduction in the ability of this mutant to promote cap-independent translation. Temperature-dependent binding studies revealed that binding of the TEV 5'-leader to these initiation factors has a large entropic contribution. Overall, these results demonstrate the first direct interaction of eIF4G with the TEV 5'-leader in the absence of other initiation factors. These data correlate well with the observed translational data and provide more detailed information on the translational strategy of polyviruses.	CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; CUNY Hunter Coll, Grad Ctr, New York, NY 10021 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); University of California System; University of California Riverside	Goss, DJ (corresponding author), 695 Pk Ave, New York, NY 10021 USA.	dgoss@hunter.cuny.edu	Ray, Sibnath/C-7369-2008	Ray, Sibnath/0000-0002-6313-3930; Domashevskiy, Artem/0000-0001-7511-8191; Khan, Mateen A./0000-0002-2300-4595	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALLISON RF, 1985, P NATL ACAD SCI USA, V82, P3969, DOI 10.1073/pnas.82.12.3969; Borman AM, 1997, VIROLOGY, V237, P129, DOI 10.1006/viro.1997.8761; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; Dobrikova EY, 2006, J VIROL, V80, P3310, DOI 10.1128/JVI.80.7.3310-3321.2006; DOUGHERTY WG, 1988, ANNU REV PHYTOPATHOL, V26, P123, DOI 10.1146/annurev.py.26.090188.001011; Dunoyer P, 2004, J VIROL, V78, P2301, DOI 10.1128/JVI.78.5.2301-2309.2004; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; Gallie DR, 2002, PLANT MOL BIOL, V50, P949, DOI 10.1023/A:1021220910664; GALLIE DR, 1995, GENE, V165, P233, DOI 10.1016/0378-1119(95)00521-7; Gallie DR, 2001, J VIROL, V75, P12141, DOI 10.1128/JVI.75.24.12141-12152.2001; Gallie DR, 2001, J BIOL CHEM, V276, P36951, DOI 10.1074/jbc.M103869200; Gao ZH, 2004, PLANT J, V40, P376, DOI 10.1111/j.1365-313X.2004.02215.x; Gottesfeld JM, 2002, J MOL BIOL, V321, P249, DOI 10.1016/S0022-2836(02)00598-3; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; HEWLETT MJ, 1976, P NATL ACAD SCI USA, V73, P327, DOI 10.1073/pnas.73.2.327; Khan MA, 2005, BIOCHEMISTRY-US, V44, P4510, DOI 10.1021/bi047298g; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, J BIOL CHEM, V261, P5632; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Lellis AD, 2002, CURR BIOL, V12, P1046, DOI 10.1016/S0960-9822(02)00898-9; Luo YJ, 2001, J BIOL CHEM, V276, P43083, DOI 10.1074/jbc.M104970200; Merrick WC., 1996, TRANSLATION CONTROL, P31; Michon T, 2006, FEBS J, V273, P1312, DOI 10.1111/j.1742-4658.2006.05156.x; Miyoshi H, 2006, BIOCHIMIE, V88, P329, DOI 10.1016/j.biochi.2005.09.002; Niepel M, 1999, J VIROL, V73, P9080, DOI 10.1128/JVI.73.11.9080-9088.1999; NOMOTO A, 1976, P NATL ACAD SCI USA, V73, P375, DOI 10.1073/pnas.73.2.375; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; PETTERSSON RF, 1977, NATURE, V268, P270, DOI 10.1038/268270a0; Pilipenko EV, 2000, GENE DEV, V14, P2028; Rambo RP, 2004, BIOCHEMISTRY-US, V43, P6486, DOI 10.1021/bi049912u; Ray S, 2004, MOL MEMBR BIOL, V21, P93, DOI 10.1080/09687680310001625800; Robaglia C, 2006, TRENDS PLANT SCI, V11, P40, DOI 10.1016/j.tplants.2005.11.004; SONENBERG N, 1996, TRANSLATIONAL CONTRO, P271; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Zeenko V, 2005, J BIOL CHEM, V280, P26813, DOI 10.1074/jbc.M503576200	43	34	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35826	35834		10.1074/jbc.M605762200	http://dx.doi.org/10.1074/jbc.M605762200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012235	hybrid			2022-12-25	WOS:000242100500029
J	Johnson, DJD; Langdown, J; Li, W; Luis, SA; Baglin, TP; Huntington, JA				Johnson, Daniel J. D.; Langdown, Jonathan; Li, Wei; Luis, Stephan A.; Baglin, Trevor P.; Huntington, James A.			Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN AFFINITY; TERNARY COMPLEX; FACTOR XA; ACTIVATION; MECHANISM; SERPIN; SPECIFICITY; SUBSTRATE; ALLOSTERY; BINDING	The poor inhibitory activity of circulating antithrombin ( AT) is critical to the formation of blood clots at sites of vascular damage. AT becomes an efficient inhibitor of the coagulation proteases only after binding to a specific heparin pentasaccharide, which alters the conformation of the reactive center loop (RCL). The molecular basis of this activation event lies at the heart of the regulation of hemostasis and accounts for the anticoagulant properties of the low molecular weight heparins. Although several structures of AT have been solved, the conformation of the RCL in native AT remains unknown because of the obligate crystal contact between the RCL of native AT and its latent counterpart. Here we report the crystallographic structure of a variant of AT in its monomeric native state. The RCL shifted similar to 20 angstrom, and a salt bridge was observed between the P1 residue (Arg-393) and Glu-237. This contact explains the effect of mutations at the P1 position on the affinity of AT for heparin and also the properties of AT-Truro (E237K). The relevance of the observed conformation was verified through mutagenesis studies and by solving structures of the same variant in different crystal forms. We conclude that the poor inhibitory activity of the circulating form of AT is partially conferred by intramolecular contacts that restrain the RCL, orient the P1 residue away from attacking proteases, and additionally block the exosite utilized in protease recognition.	Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Div Struct Med,Thrombosis Res Unit, Cambridge CB2 2XY, England	University of Cambridge	Huntington, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Div Struct Med,Thrombosis Res Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			Medical Research Council [G117/444] Funding Source: Medline; NHLBI NIH HHS [R01 HL068629-06, R01 HL068629, R01 HL68629] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068629] Funding Source: NIH RePORTER; MRC [G117/444] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; Huntington J. A., 2005, CHEM BIOL HEPARIN HE, P367; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2006, EMBO J, V25, P2029, DOI 10.1038/sj.emboj.7601089; Johnson DJD, 2004, J BIOL CHEM, V279, P4913, DOI 10.1074/jbc.M311644200; Johnson DJD, 2003, BIOCHEMISTRY-US, V42, P8712, DOI 10.1021/bi034524y; LESLIE AWG, 1992, JOINT CCP4 ESFEACMB; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; McCoy AJ, 2003, J MOL BIOL, V326, P823, DOI 10.1016/S0022-2836(02)01382-7; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mushunje A, 2003, BLOOD, V102, P4028, DOI 10.1182/blood-2003-05-1560; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; OWEN MC, 1988, FEBS LETT, V231, P317, DOI 10.1016/0014-5793(88)80841-X; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Zhou AW, 2003, J BIOL CHEM, V278, P15116, DOI 10.1074/jbc.M211663200	28	53	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35478	35486		10.1074/jbc.M607204200	http://dx.doi.org/10.1074/jbc.M607204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973611	Green Accepted, hybrid			2022-12-25	WOS:000241933700081
J	Khurana, A; Nakayama, K; Williams, S; Davis, RJ; Mustelin, T; Ronai, Z				Khurana, Ashwani; Nakayama, Koh; Williams, Scott; Davis, Roger J.; Mustelin, Tomas; Ronai, Ze'ev			Regulation of the ring finger E3 ligase Siah2 by p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL-HYDROXYLASES; STABILITY; ACTIVATION; PATHWAY; EXPRESSION; PROTEINS	The RING finger ubiquitin ligase Siah2 controls the stability of various substrates involved in stress and hypoxia responses, including the PHD3, which controls the stability of HIF-1 alpha. In the present study we determined the role of Siah2 phosphorylation in the regulation of its activity toward PHD3. We show that Siah2 is subject to phosphorylation by p38 MAPK, which increases Siah2-mediated degradation of PHD3. Consistent with these findings, MKK3/MKK6 double-deficient cells, which cannot activate p38 kinases, exhibit impaired Siah2-dependent degradation of PHD3. Phosphopeptide mapping identified T24 and S29 as the primary phospho-acceptor sites. Phospho-mutant forms of Siah2 (S29A or T24A/S29A) exhibit impaired degradation of PHD3, particularly after hypoxia. Conversely, a phospho-mimic form of Siah2 (T24E/S29D) exhibits stronger degradation of PHD3, compared with wild type Siah2. Whereas phospho-mutant Siah2 exhibits weaker association with PHD3, phospho-mimic Siah2 associates as well as wild type and is localized within the perinuclear region, suggesting that phosphorylation of Siah2 affects its subcellular localization and, consequently, the degree of its association with PHD3. In all, our findings reveal the phosphorylation of Siah2 by p38 and the implications of such phosphorylation for Siah2 activity toward PHD3.	Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Ronai, Z (corresponding author), Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@burnham.org	Nakayama, Koh/U-9232-2019	Mustelin, Tomas/0000-0001-5912-8840; RONAI, ZEEV/0000-0002-3859-0400; Davis, Roger/0000-0002-0130-1652	NATIONAL CANCER INSTITUTE [R01CA111515] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111515-03, R01-CA111515, R01 CA111515] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gutierrez GJ, 2006, NAT CELL BIOL, V8, P1084, DOI 10.1038/ncb1472; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hu G, 1999, MOL CELL BIOL, V19, P724; HU G, 1997, GENE DEV, V15, P2401; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LUO K, 1990, ONCOGENE, V5, P921; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; NAKAYAMA K, 2006, IN PRESS BIOCH J; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Shemirani B, 2002, ORAL ONCOL, V38, P251, DOI 10.1016/S1368-8375(01)00052-5; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Xu ZH, 2006, J BIOL CHEM, V281, P303, DOI 10.1074/jbc.M509060200; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	32	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35316	35326		10.1074/jbc.M606568200	http://dx.doi.org/10.1074/jbc.M606568200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17003045	Green Accepted, hybrid			2022-12-25	WOS:000241933700066
J	Lewin, A; Crow, A; Oubrie, A; Le Brun, NE				Lewin, Allison; Crow, Allister; Oubrie, Arthur; Le Brun, Nick E.			Molecular basis for specificity of the extracytoplasmic thioredoxin ResA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; THIOL-DISULFIDE OXIDOREDUCTASES; ACTIVE-SITE CYSTEINE; STRUCTURAL BASIS; CRYSTAL-STRUCTURES; REDOX PROPERTIES; PK(A) VALUES; REACTIVITY; DSBA; IONIZATION	ResA, an extracytoplasmic thioredoxin from Bacillus subtilis, acts in cytochrome c maturation by reducing the disulfide bond present in apocytochromes prior to covalent attachment of heme. This reaction is (and has to be) specific, as broad substrate specificity would result in unproductive shortcircuiting with the general oxidizing thioredoxin(s) present in the same compartment. Using mutational analysis and subsequent biochemical and structural characterization of active site variants, we show that reduced ResA displays unusually low reactivity at neutral pH, consistent with the observed high pK(a) values > 8 for both active site cysteines. Residue Glu(80) is shown to play a key role in controlling the acid-base properties of the active site. A model in which substrate binding dramatically enhances the reactivity of the active site cysteines is proposed to account for the specificity of the protein. Such a substrate-mediated activation mechanism is likely to have wide relevance for extracytoplasmic thioredoxins.	Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia	Le Brun, NE (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England.	n.le-brun@uea.ac.uk	Crow, Allister/F-2147-2018	Crow, Allister/0000-0001-6856-5962; Oubrie, Arthur/0000-0001-6765-9246; Le Brun, Nick/0000-0001-9780-4061	Biotechnology and Biological Sciences Research Council [BB/C503597/1] Funding Source: Medline; Wellcome Trust [076017/Z/04/Z] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Aslund F, 1999, J BACTERIOL, V181, P1375; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERGLUND O, 1970, J BIOL CHEM, V245, P6030; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P14985, DOI 10.1021/bi970071j; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; Colbert CL, 2006, P NATL ACAD SCI USA, V103, P4410, DOI 10.1073/PNAS.0600552103; Crow A, 2005, BIOCHEM SOC T, V33, P149, DOI 10.1042/BST0330149; Crow A, 2004, J BIOL CHEM, V279, P23654, DOI 10.1074/jbc.M402823200; Dillet V, 1998, BIOCHEMISTRY-US, V37, P10298, DOI 10.1021/bi980333x; Dorenbos R, 2002, J BIOL CHEM, V277, P16682, DOI 10.1074/jbc.M201158200; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Edeling MA, 2004, J BACTERIOL, V186, P4030, DOI 10.1128/JB.186.12.4030-4033.2004; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Erlendsson LS, 2004, J BACTERIOL, V186, P6230, DOI 10.1128/JB.186.18.6230-6238.2004; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; Erlendsson LS, 2002, J BACTERIOL, V184, P1423, DOI 10.1128/JB.184.5.1423-1429.2002; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Forsyth WR, 2002, PROTEINS, V48, P388, DOI 10.1002/prot.10174; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Hansen RE, 2005, BIOCHEMISTRY-US, V44, P5899, DOI 10.1021/bi0500372; HAUGLAND RP, 2005, HBD GUIDE FLUORESCNE; Hutchings MI, 2000, J BACTERIOL, V182, P6434, DOI 10.1128/JB.182.22.6434-6439.2000; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JOCELYN PC, 1972, BIOCH SH GROUP, P51; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; KALLIS GB, 1980, J BIOL CHEM, V255, P261; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Brun NE, 2000, MOL MICROBIOL, V36, P638, DOI 10.1046/j.1365-2958.2000.01883.x; LeMaster DM, 1997, J BIOL CHEM, V272, P29998, DOI 10.1074/jbc.272.48.29998; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Mossner E, 2000, FEBS LETT, V477, P21, DOI 10.1016/S0014-5793(00)01738-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; Nordstrand K, 1999, FEBS LETT, V449, P196, DOI 10.1016/S0014-5793(99)00401-9; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rozhkova A, 2004, EMBO J, V23, P1709, DOI 10.1038/sj.emboj.7600178; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; Stirnimann CU, 2006, J MOL BIOL, V358, P829, DOI 10.1016/j.jmb.2006.02.030; Stirnimann CU, 2005, STRUCTURE, V13, P985, DOI 10.1016/j.str.2005.04.014; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503	54	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35467	35477		10.1074/jbc.M607047200	http://dx.doi.org/10.1074/jbc.M607047200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16971393	hybrid			2022-12-25	WOS:000241933700080
J	Kim, M; Li, D; Cui, YX; Mueller, K; Chears, WC; DeJong, J				Kim, MinJung; Li, Dan; Cui, Yunxia; Mueller, Konrad; Chears, William C.; DeJong, Jeff			Regulatory factor interactions and somatic silencing of the germ cell-specific ALF gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H1T GENE; TRANSCRIPTION FACTOR SP1; BINDING PROTEIN; DNA-BINDING; PROXIMAL PROMOTER; FACTOR TFIIA; TESTIS; EXPRESSION; SPERMATOGENESIS; CTCF	Germ cell-specific genes are active in oocytes and spermatocytes but are silent in all other cell types. To understand the basis for this seemingly simple pattern of regulation, we characterized factors that recognize the promoter-proximal region of the germ cell-specific TFIIA alpha/beta-like factor (ALF) gene. Two of the protein-DNA complexes formed with liver extracts (C4 and C5) are due to the zinc finger proteins Sp1 and Sp3, respectively, whereas another complex (C6) is due to the transcription factor RFX1. Two additional complexes (C1 and C3) are due to the multivalent zinc finger protein CTCF, a factor that plays a role in gene silencing and chromatin insulation. An investigation of CTCF binding revealed a recognition site of only 17 bp that overlaps with the Sp1/Sp3 site. This site is predictive of other genomic CTCF sites and can be aligned to create a functional consensus. Studies on the activity of the ALF promoter in somatic 293 cells revealed mutations that result in increased reporter activity. In addition, RNAi-mediated down-regulation of CTCF is associated with activation of the endogenous ALF gene, and both CTCF and Sp3 repress the promoter in transient transfection assays. Overall, the results suggest a role for several factors, including the multivalent zinc finger chromatin insulator protein CTCF, in mediating somatic repression of the ALF gene. Release of such repression, perhaps in conjunction with other members of the CTCF, RFX, and Sp1 families of transcription factors, could be an important aspect of germ cell gene activation.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA	University of Texas System; University of Texas Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, 2601 N Floyd Rd, Richardson, TX 75080 USA.	dejong@utdallas.edu		Li, Dan/0000-0002-8841-8991				Acharya KK, 2006, DEV BIOL, V295, P781, DOI 10.1016/j.ydbio.2006.04.443; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bonny C, 1998, BIOL REPROD, V58, P754, DOI 10.1095/biolreprod58.3.754; Clare SE, 1997, J BIOL CHEM, V272, P33028, DOI 10.1074/jbc.272.52.33028; DeJong J, 2006, GENE, V366, P39, DOI 10.1016/j.gene.2005.10.012; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Filippova GN, 2002, CANCER RES, V62, P48; Grimes SR, 2005, J CELL BIOCHEM, V94, P317, DOI 10.1002/jcb.20320; Han SY, 2004, BIOL REPROD, V71, P933, DOI 10.1095/biolreprod.104.030247; Han SY, 2003, J BIOL CHEM, V278, P45586, DOI 10.1074/jbc.M302884200; Han SY, 2001, BIOL REPROD, V64, P507, DOI 10.1095/biolreprod64.2.507; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Horvath GC, 2004, BIOL REPROD, V71, P1551, DOI 10.1095/biolreprod.104.032268; Horvath GC, 2001, BIOL REPROD, V65, P1074, DOI 10.1095/biolreprod65.4.1074; Huang M, 2006, INT J MOL MED, V17, P599; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; Jethanandani P, 2001, J BIOL CHEM, V276, P35414, DOI 10.1074/jbc.M101269200; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; MacLean JA, 2005, CURR TOP DEV BIOL, V71, P131, DOI 10.1016/S0070-2153(05)71005-X; MIZUNO K, 1992, GENE, V119, P293, DOI 10.1016/0378-1119(92)90286-X; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Nakayama A, 2003, J BIOL CHEM, V278, P233, DOI 10.1074/jbc.M209574200; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Ozer J, 2000, J BIOL CHEM, V275, P122, DOI 10.1074/jbc.275.1.122; Peaston AE, 2004, DEV CELL, V7, P597, DOI 10.1016/j.devcel.2004.09.004; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Pohlers M, 2005, CURR BIOL, V15, P1051, DOI 10.1016/j.cub.2005.04.060; Reddi PP, 2003, DEV BIOL, V262, P173, DOI 10.1016/S0012-1606(03)00349-X; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; Santti H, 2003, BIOCHEM BIOPH RES CO, V308, P139, DOI 10.1016/S0006-291X(03)01339-1; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; Shima JE, 2004, BIOL REPROD, V71, P319, DOI 10.1095/biolreprod.103.026880; SIERRA F, 1990, LAB GUIDE IN VITRO T, P29; Storre J, 2005, J BIOL CHEM, V280, P41380, DOI 10.1074/jbc.M506797200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Thomas K, 2005, BIOL REPROD, V72, P898, DOI 10.1095/biolreprod.104.030528; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Upadhyaya AB, 2002, J BIOL CHEM, V277, P34208, DOI 10.1074/jbc.M204808200; Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Wilkerson DC, 2002, BIOL REPROD, V67, P1157, DOI 10.1095/biolreprod67.4.1157; Xie WS, 2002, J BIOL CHEM, V277, P17765, DOI 10.1074/jbc.M200954200; Zhang LP, 1999, BIOL REPROD, V60, P1329, DOI 10.1095/biolreprod60.6.1329	48	23	23	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34288	34298		10.1074/jbc.M607168200	http://dx.doi.org/10.1074/jbc.M607168200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966320	hybrid			2022-12-25	WOS:000241767600049
J	Pan, S; Wang, R; Zhou, X; He, G; Koomen, J; Kobayashi, R; Sun, L; Corvera, J; Gallick, GE; Kuang, J				Pan, Shujuan; Wang, Ruoning; Zhou, Xi; He, Guangan; Koomen, John; Kobayashi, Ryuji; Sun, Le; Corvera, Joe; Gallick, Gary E.; Kuang, Jian			Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BINDING PARTNER; INTERACTS; BRO1; PHALLOIDIN; APOPTOSIS; PATHWAY; ALG-2; GENE; TUMORIGENICITY	The conserved adaptor protein Alix, also called AIP1 or Hp95, promotes flattening and alignment of cultured mammalian fibroblasts; however, the mechanism by which Alix regulates fibroblast morphology is not understood. Here we demonstrate that Alix in WI38 cells, which require Alix expression for maintaining typical fibroblast morphology, associates with filamentous actin (F-actin) and F-actin-based structures lamellipodia and stress fibers. Reducing Alix expression by small interfering RNA (siRNA) decreases F-actin content and inhibits stress fiber assembly. In cell-free systems, Alix directly interacts with F-actin at both the N-terminal Bro1 domain and the C-terminal proline-rich domain. In Alix immunoprecipitates from WI38 cell lysates, actin is the most abundant partner protein of Alix. In addition, the N-terminal half of the middle region of Alix binds cortactin, an activator of the ARP2/3 complex-mediated initiation of actin polymerization. Alix is required for lamellipodial localization of cortactin. The C-terminal half of the middle region of Alix interacts with alpha-actinin, a key factor that bundles F-actin in stress fibers. Alix knockdown decreases the amount of alpha-actinin that associates with F-actin. These findings establish crucial involvement of Alix in actin cytoskeleton assembly.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; A&G Pharmaceut Inc, Baltimore, MD 21202 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuang, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 019, Houston, TX 77030 USA.	jkuang@mdanderson.org	Wang, Ruoning/C-1683-2014; Koomen, John/D-1844-2013; Zhou, Xi/J-1902-2012	Zhou, Xi/0000-0002-3846-5079	NCI NIH HHS [1 R01 CA93941, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093941, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANKWAH KS, 1994, EXP CELL RES, V210, P315, DOI 10.1006/excr.1994.1044; Banan A, 2000, GUT, V46, P830, DOI 10.1136/gut.46.6.830; BEREITERHAHN J, 1988, HISTOCHEMISTRY, V90, P271, DOI 10.1007/BF00495970; Blystone SD, 2004, BBA-MOL CELL RES, V1692, P47, DOI 10.1016/j.bbamcr.2004.04.011; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Cabezas A, 2005, J CELL SCI, V118, P2625, DOI 10.1242/jcs.02382; CARTER CA, 1994, EXP CELL RES, V212, P141, DOI 10.1006/excr.1994.1128; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; KAHN P, 1983, CYTOGENET CELL GENET, V36, P605, DOI 10.1159/000131983; Katoh K, 2003, J BIOL CHEM, V278, P39104, DOI 10.1074/jbc.M301604200; Kim JW, 2005, DEV CELL, V8, P937, DOI 10.1016/j.devcel.2005.04.001; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Krebs J, 2000, BBA-MOL CELL RES, V1498, P153, DOI 10.1016/S0167-4889(00)00091-4; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Labat-Robert J, 2002, SEMIN CANCER BIOL, V12, P187, DOI 10.1016/S1044-579X(02)00022-6; LENGSFEL.AM, 1974, P NATL ACAD SCI USA, V71, P2803, DOI 10.1073/pnas.71.7.2803; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamura K, 1999, FEBS LETT, V445, P9, DOI 10.1016/S0014-5793(99)00087-3; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Peck JW, 2002, J BIOL CHEM, V277, P43924, DOI 10.1074/jbc.M203569200; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Sadoul R, 2006, BIOL CELL, V98, P69, DOI 10.1042/BC20050007; Schmidt MHH, 2003, J CELL SCI, V116, P2845, DOI 10.1242/jcs.00522; Shibata H, 2004, J BIOCHEM, V135, P117, DOI 10.1093/jb/mvh014; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Trioulier Y, 2004, J BIOL CHEM, V279, P2046, DOI 10.1074/jbc.M309243200; VERDERAME M, 1980, P NATL ACAD SCI-BIOL, V77, P6624, DOI 10.1073/pnas.77.11.6624; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Weaver AM, 2003, CURR OPIN CELL BIOL, V15, P23, DOI 10.1016/S0955-0674(02)00015-7; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x; Wu Y, 2002, ONCOGENE, V21, P6801, DOI 10.1038/sj.onc.1205849; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; Yates-Siilata KE, 2004, CELL BIOL INT, V28, P33, DOI 10.1016/j.cellbi.2003.09.003	47	52	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34640	34650		10.1074/jbc.M602263200	http://dx.doi.org/10.1074/jbc.M602263200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966331	hybrid			2022-12-25	WOS:000241767600083
J	Chong, YP; Chan, AS; Chan, KC; Williamson, NA; Lerner, EC; Smithgall, TE; Bjorge, JD; Fujita, DJ; Purcell, AW; Scholz, G; Mulhern, TD; Cheng, HC				Chong, Yuh-Ping; Chan, Andrew S.; Chan, Khai-Chew; Williamson, Nicholas A.; Lerner, Edwina C.; Smithgall, Thomas E.; Bjorge, Jeffrey D.; Fujita, Donald J.; Purcell, Anthony W.; Scholz, Glen; Mulhern, Terrence D.; Cheng, Heung-Chin			C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SH2 DOMAIN; CRYSTAL-STRUCTURE; PROTEIN-KINASES; CELL BEHAVIOR; ACTIVATION; HCK; PHOSPHORYLATION; BINDING; AUTOPHOSPHORYLATION	The Src family of protein kinases (SFKs) mediates mitogenic signal transduction, and constitutive SFK activation is associated with tumorigenesis. To prevent constitutive SFK activation, the catalytic activity of SFKs in normal mammalian cells is suppressed mainly by two inhibitors called C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK), which inactivate SFKs by phosphorylating a consensus tyrosine near the C terminus of SFKs (Y-T). The phosphorylated Y-T intramolecularly binds to the SH2 domain of SFKs. This interaction, known as pY(T)/SH2 interaction, together with binding between the SH2 kinase linker and the SH3 domain of SFKs (linker/SH3 interaction) stabilizes SFKs in a "closed" inactive conformation. We previously discovered an alternative mechanism CHK employs to inhibit SFKs. This mechanism, referred to as the non-catalytic inhibitory mechanism, involves tight binding of CHK to SFKs; the binding alone is sufficient to inhibit SFKs. Herein, we constructed multiple active conformations of an SFK member, Hck, by systematically disrupting the two inhibitory interactions. We found that CHK employs the non-catalytic mechanism to inactivate these active conformations of Hck. However, CHK does not bind Hck when it adopts the inactive conformation in which both inhibitory interactions are intact. These data indicate that binding of CHK to SFKs via the non-catalytic mechanism is governed by the conformations of SFKs. Although CSK is also an inhibitor of SFKs, it does not inhibit SFKs by a similar non-catalytic mechanism. Thus, the non-catalytic inhibitory mechanism is a unique property of CHK that allows it to down-regulate multiple active conformations of SFKs.	Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Melbourne; University of Melbourne; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Mulhern, TD (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3010, Australia.	tmulhern@unimelb.edu.au; heung@unimelb.edu.au	Mulhern, Terrence/A-1206-2007; Purcell, Anthony/AAH-1942-2019; Williamson, Nicholas A/O-9812-2016	Purcell, Anthony/0000-0003-0532-8331; Williamson, Nicholas A/0000-0002-2173-3452; Mulhern, Terrence/0000-0002-1609-7498; Scholz, Glen/0000-0003-2722-6344; Cheng, Heung-Chin/0000-0002-4965-7148; Chong, Yuh Ping/0000-0002-9596-3242				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P9083, DOI 10.1021/bi973147k; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHENG HC, 2006, AFCS NATURE MOL PAGE, DOI DOI 10.1038/MP.A000705.01; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Chong YP, 2004, J BIOL CHEM, V279, P20752, DOI 10.1074/jbc.M309865200; Chong YP, 2005, BBA-PROTEINS PROTEOM, V1754, P210, DOI 10.1016/j.bbapap.2005.07.027; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; Johnson TM, 1997, J PEPT RES, V50, P365; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Lerner EC, 2005, J BIOL CHEM, V280, P40832, DOI 10.1074/jbc.M508782200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lim WA, 2002, CURR OPIN STRUC BIOL, V12, P61, DOI 10.1016/S0959-440X(02)00290-7; Miller WT, 2003, ACCOUNTS CHEM RES, V36, P393, DOI 10.1021/ar020116v; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mulhern TD, 2002, J BIOMOL NMR, V24, P363, DOI 10.1023/A:1021657406480; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; Nitabach MN, 2002, J NEUROSCI, V22, P7913; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schulte RJ, 2003, BIOCHEMISTRY-US, V42, P9424, DOI 10.1021/bi034519u; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sicilia RJ, 1998, J BIOL CHEM, V273, P16756, DOI 10.1074/jbc.273.27.16756; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Trible RP, 2006, J BIOL CHEM, V281, P27029, DOI 10.1074/jbc.M601128200; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					32988	32999		10.1074/jbc.M602951200	http://dx.doi.org/10.1074/jbc.M602951200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959780	hybrid			2022-12-25	WOS:000241621400007
J	Weller, K; Foitzik, K; Paus, R; Syska, W; Maurer, M				Weller, Karsten; Foitzik, Kerstin; Paus, Ralf; Syska, Wolfgang; Maurer, Marcus			Mast cells are required for normal healing of skin wounds in mice	FASEB JOURNAL			English	Article						inflammation; neutrophil	TUMOR-NECROSIS-FACTOR; TNF-ALPHA; EXOGENOUS HISTAMINE; LATE-PHASE; PROLIFERATION; DEFICIENT; MEDIATORS; MOUSE; INFLAMMATION; ANGIOGENESIS	Mast cells (MCs) have recently been reported to play a pivotal role in the elicitation of inflammatory reactions that are beneficial to the host, e. g., during innate immune responses to bacteria. To explore whether MCs also contribute to wound repair, we studied experimentally induced skin wounds in MC-deficient Kit(W)/Kit(W-v) mice, normal Kit+/+ mice, and MC-reconstituted Kit(W)/Kit(W-v) mice. Wound closure was significantly impaired in the absence of MCs during the first 6 days of wound healing and histomorphometric analyses of MC degranulation at the wound edges revealed distance-dependent MC activation, i.e., MC degranulation was most prominent directly adjacent to the wound. In addition, Kit(W)/Kit(W-v) mice showed impaired extravasation and recruitment of neutrophils to the wounded areas. Notably, wound closure, extravasation, and neutrophil recruitment were found to be normal in MC-reconstituted Kit(W)/Kit(W-v) mice. Therefore, we examined whether MCs promote wound healing by releasing histamine or TNF-alpha. Interestingly, wound closure was reduced in mice treated with an H-1-receptor antagonist but not after treatment with an H-2-receptor antagonist or in the absence of TNF-alpha. Taken together, our findings indicate that MC activation and histamine release are required for normal cutaneous wound healing.	Univ Med Berlin, Dept Dermatol & Allergy, Charite, Allergie Ctr, D-10117 Berlin, Germany; Univ Hosp Wurzburg, Dept Dermatol, Wurzburg, Germany; Univ Hosp Hamburg Eppendorf, Dept Dermatol, Hamburg, Germany; Univ Hosp Lubeck, Dept Dermatol, Lubeck, Germany; Univ Hosp Mainz, Dept Dermatol, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University Hospital Mainz	Maurer, M (corresponding author), Univ Med Berlin, Dept Dermatol & Allergy, Charite, Allergie Ctr, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020; Paus, Ralf/F-6243-2011	Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313				Abraham SN, 1997, INFECT IMMUN, V65, P3501, DOI 10.1128/IAI.65.9.3501-3508.1997; Artuc M, 1999, EXP DERMATOL, V8, P1, DOI 10.1111/j.1600-0625.1999.tb00342.x; BAIRY K L, 1991, Indian Journal of Physiology and Pharmacology, V35, P180; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Biro T, 2005, EXP DERMATOL, V14, P225, DOI 10.1111/j.0906-6705.2005.0321a.x; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cregar L, 1999, ARCH BIOCHEM BIOPHYS, V366, P125, DOI 10.1006/abbi.1999.1220; DABROWSKI R, 1975, AGENTS ACTIONS, V5, P311, DOI 10.1007/BF02205236; Deiters U, 2004, EXP DERMATOL, V13, P731, DOI 10.1111/j.0906-6705.2004.00233.x; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Egozi EI, 2003, WOUND REPAIR REGEN, V11, P46, DOI 10.1046/j.1524-475X.2003.11108.x; Gailit J, 2001, J INVEST DERMATOL, V117, P1113, DOI 10.1046/j.1523-1747.2001.15211.x; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GRABBE J, 1994, HAUTARZT, V45, P55; GRUBER BL, 1995, BLOOD, V86, P2488; HEBDA PA, 1993, DERMATOL CLIN, V11, P685, DOI 10.1016/S0733-8635(18)30221-3; Iba Y, 2004, INT IMMUNOPHARMACOL, V4, P1873, DOI 10.1016/j.intimp.2004.08.009; Kanbe N, 1999, EUR J IMMUNOL, V29, P2645; KATAYAMA I, 1992, INT ARCH ALLERGY IMM, V98, P410, DOI 10.1159/000236218; Kauhanen P, 1998, THROMB HAEMOSTASIS, V79, P843, DOI 10.1055/s-0037-1615075; LEVISCHAFFER F, 1990, EXP CELL RES, V188, P42, DOI 10.1016/0014-4827(90)90275-F; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LI L, 1994, J IMMUNOL, V153, P3967; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Maurer M, 1997, J DERMATOL SCI, V16, P79, DOI 10.1016/S0923-1811(97)00043-1; Maurer M, 2005, EXP DERMATOL, V14, P923, DOI 10.1111/j.1600-0625.2005.00369.x; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Maurer M, 1997, LAB INVEST, V77, P319; Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x; MOLLER A, 1993, J IMMUNOL, V151, P3261; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Noli C, 2001, VET DERMATOL, V12, P303, DOI 10.1046/j.0959-4493.2001.00272.x; NORRBY K, 1986, VIRCHOWS ARCH B, V52, P195, DOI 10.1007/BF02889963; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; Peters EMJ, 2003, J INVEST DERMATOL, V121, P976, DOI 10.1046/j.1523-1747.2003.12478.x; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; RAMOS BF, 1992, J PHARMACOL EXP THER, V262, P559; Singh LK, 1999, J PHARMACOL EXP THER, V288, P1349; Takanami I, 2000, CANCER, V88, P2686, DOI 10.1002/1097-0142(20000615)88:12<2686::AID-CNCR6>3.0.CO;2-6; TRABUCCHI E, 1988, INT J TISSUE REACT, V10, P367; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; ULOGOL A, 1996, YONSEI MED J, V37, P97; von Stebut E, 2003, BLOOD, V101, P210, DOI 10.1182/blood-2002-03-0921; WEBER A, 2003, BRIT J DERMATOL, V148, P625; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; YAMATODANI A, 1982, BIOCHEM PHARMACOL, V31, P305; YOSHIDA S, 1989, P SOC EXP BIOL MED, V191, P90; ZHANG Y, 1992, IMMUNOLOGY, V77, P422	55	209	220	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2366	+		10.1096/fj.06-5837fje	http://dx.doi.org/10.1096/fj.06-5837fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	16966487				2022-12-25	WOS:000241702600022
J	Gamble, SC; Chotai, D; Odontiadis, M; Dart, DA; Brooke, GN; Powell, SM; Reebye, V; Varela-Carver, A; Kawano, Y; Waxman, J; Bevan, CL				Gamble, S. C.; Chotai, D.; Odontiadis, M.; Dart, D. A.; Brooke, G. N.; Powell, S. M.; Reebye, V.; Varela-Carver, A.; Kawano, Y.; Waxman, J.; Bevan, C. L.			Prohibitin, a protein downregulated by androgens, represses androgen receptor activity	ONCOGENE			English	Article						prohibitin; prostate cancer; androgen receptor; corepressor; cell cycle	PROSTATE-CANCER CELLS; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTOR; N-COR; MITOCHONDRIAL PROTEINS; TUMOR-SUPPRESSOR; BINDING; DOMAIN; COACTIVATOR	Prohibitin (PHB) is a cell cycle regulatory protein, known to repress E2F1-mediated gene activation via recruitment of transcriptional regulatory factors such as retinoblastoma and histone deacetylase 1 (HDAC1). We previously identified PHB as a target protein of androgen signaling in prostate cancer cells and showed that downregulation of PHB is required for androgen-induced cell cycle entry in these cells. We now present evidence that PHB, which has 54% homology at the protein level to the oestrogen receptor corepressor REA (repressor of oestrogen receptor activity), can repress androgen receptor (AR)mediated transcription and androgen-dependent cell growth. Depletion of endogenous PHB resulted in an increase in expression of the androgen-regulated prostatespecific antigen gene. The repression appears to be specific to androgen and closely related receptors, as it is also evident for the glucocorticoid and progesterone, but not oestrogen, receptors. In spite of interaction of PHB with HDAC1, HDAC activity is not required for this repression. Although AR and PHB could be co-immunoprecipitated, no direct interaction was detectable, suggesting that PHB forms part of a repressive complex with the AR. Competition with the co-activator SRC1 further suggests that formation of a complex with AR, PHB and other cofactors is the mechanism by which repression is achieved. It appears then that repression of AR activity is one mechanism by which PHB inhibits androgen-dependent growth of prostate cells. Further, this study implies that the AR itself could, by mediating downregulation of a corepressor, be involved in the progression of prostate tumours to the hormone refractory stage.	Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Harris Lab Prostate Canc Res, London W12 0NN, England	Imperial College London	Bevan, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Harris Lab Prostate Canc Res, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Bevan, Charlotte L/K-2276-2012; Brooke, Greg/ABF-4859-2020; Bevan, Charlotte/T-7769-2019; Brooke, Greg/C-9426-2013	Bevan, Charlotte L/0000-0002-7533-0552; Brooke, Greg/0000-0003-4501-4134	Medical Research Council [MC_U120084164] Funding Source: Medline; Worldwide Cancer Research [05-0613] Funding Source: Medline; MRC [MC_U120084164] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Worldwide Cancer Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adegbola O, 2005, BIOCHEM BIOPH RES CO, V334, P702, DOI 10.1016/j.bbrc.2005.06.153; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Berrevoets CA, 2004, BIOCHEM J, V379, P731, DOI 10.1042/BJ20031456; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng ST, 2002, MOL ENDOCRINOL, V16, P1492, DOI 10.1210/me.16.7.1492; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Joshi B, 2003, BIOCHEM BIOPH RES CO, V312, P459, DOI 10.1016/j.bbrc.2003.10.148; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; KALKHOVEN E, 1994, MOL CELL ENDOCRINOL, V102, P45, DOI 10.1016/0303-7207(94)90096-5; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Smith JR, 1997, IEEE MULTIMEDIA, V4, P12, DOI 10.1109/93.621578; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Thompson WE, 2001, ENDOCRINOLOGY, V142, P4076, DOI 10.1210/en.142.9.4076; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Whitaker HC, 2004, CLIN CANCER RES, V10, P7392, DOI 10.1158/1078-0432.CCR-04-0388; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	44	56	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1757	1768		10.1038/sj.onc.1209967	http://dx.doi.org/10.1038/sj.onc.1209967			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964284				2022-12-25	WOS:000244955600010
J	Ding, J; Zhang, XH; Li, JX; Song, L; Ouyang, W; Zhang, DY; Xue, CF; Costa, M; Melendez, JA; Huang, CS				Ding, Jin; Zhang, Xinhai; Li, Jingxia; Song, Lun; Ouyang, Weiming; Zhang, Dongyun; Xue, Caifang; Costa, Max; Melendez, J. Andres; Huang, Chuanshu			Nickel compounds render anti-apoptotic effect to human bronchial epithelial Beas-2B cells by induction of cyclooxygenase-2 through an IKK beta/p65-dependent and IKK alpha- and p50-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; NUCLEAR-FACTOR; COX-2 EXPRESSION; CANCER; ACTIVATION; INHIBITION; TARGET; KINASE; DEATH	The carcinogenicity of nickel compounds has been well documented both in vitro and in vivo; however, the molecular mechanisms by which nickel compounds cause cancers are far from understood. Because suppression of apoptosis is thought to contribute to carcinogenesis, we investigated the mechanisms implicated in nickel-induced anti-apoptotic effect in human bronchial epithelial (Beas-2B) cells. We found that exposure of Beas-2B cells to nickel compounds resulted in increased cyclooxygenase-2 (COX-2) expression and that small interfering RNA (siCOX-2) knockdown of COX-2 expression resulted in increased cell sensitivity to nickel-triggered cell apoptosis, demonstrating that COX-2 induction has an anti-apoptotic effect on Beas-2B cells. Overexpression of IKK beta-KM, a kinase inactive mutant of IKK beta, blocked NF-kappa B activation and COX-2 induction by nickel compounds, indicating that activated NF-kappa B may be a mediator for COX-2 induction. To further explore the contribution of the NF-kappa B pathway in COX-2 induction and in protection from nickel exposure, mouse embryonic fibroblasts deficient in IKK beta, IKK beta, p65, and p50 were analyzed. Loss of IKK beta impaired COX-2 induction by nickel exposure, whereas knockout of IKK beta had a marginal effect. Moreover, the NF-kappa B p65, and not the p50 subunit, was critical for nickel-induced COX-2 expression. In addition, a deficiency of IKK beta or p65 rendered cells more sensitive to nickel-induced apoptosis as compared with those in wild type cells. Finally, it was shown that reactive oxygen species H2O2 were involved in both NF-kappa B activation and COX-2 expression. Collectively, our results demonstrate that COX-2 induction by nickel compounds occurs via an IKK beta/p65 NF-kappa B-dependent but IKK beta and p50-independent pathway and plays a crucial role in antagonizing nickel-induced cell apoptosis in Beas-2B cells.	NYU, Nelson Inst Environm Med, Sch Med, Tuxedo Pk, NY 10987 USA; Fourth Mil Med Univ, Dept Etiol, Xian 710032, Peoples R China; Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	New York University; Air Force Military Medical University; Albany Medical College	Huang, CS (corresponding author), NYU, Nelson Inst Environm Med, Sch Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu	costa, max/H-1754-2012	Melendez, Juan/0000-0001-8021-3097; Huang, Chuanshu/0000-0003-4133-5096	NCI NIH HHS [R01 CA112557, R01 CA103180, R01 CA094964] Funding Source: Medline; NIEHS NIH HHS [R01 ES012451] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112557, R01CA103180, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; BURSCH W, 1993, BRIT J CANCER, V67, P531, DOI 10.1038/bjc.1993.98; Cangul H, 2002, TOXICOL LETT, V127, P69, DOI 10.1016/S0378-4274(01)00485-4; Chang PY, 2006, MOL CANCER RES, V4, P101, DOI 10.1158/1541-7786.MCR-05-0259; Clarke A R, 2000, Symp Soc Exp Biol, V52, P265; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Correa P, 1998, BRIT MED BULL, V54, P151; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Denkhaus E, 2002, CRIT REV ONCOL HEMAT, V42, P35, DOI 10.1016/S1040-8428(01)00214-1; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Harris GK, 2003, MUTAT RES-FUND MOL M, V533, P183, DOI 10.1016/j.mrfmmm.2003.08.025; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang CS, 2001, CANCER RES, V61, P8051; Huang Y, 2002, ENVIRON HEALTH PERSP, V110, P835, DOI 10.1289/ehp.02110s5835; INT AGCY RES CANC, 1990, IARC MONOG EVAL CARC, V49, P257; Kang J, 2003, TOXICOL SCI, V74, P279, DOI 10.1093/toxsci/kfg137; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kasprzak KS, 2003, MUTAT RES-FUND MOL M, V533, P67, DOI 10.1016/j.mrfmmm.2003.08.021; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Li JX, 2004, CANCER RES, V64, P94, DOI 10.1158/0008-5472.CAN-03-0737; Li LY, 2003, RADIAT RES, V160, P617, DOI 10.1667/RR3076; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu ZG, 2001, METHOD CELL BIOL, V66, P187; Lu HT, 2005, MOL CELL BIOCHEM, V279, P45, DOI 10.1007/s11010-005-8215-2; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Moynagh Paul N, 2005, J Cell Sci, V118, P4589, DOI 10.1242/jcs.02579; Ouyang WM, 2005, CANCER RES, V65, P9287, DOI 10.1158/0008-5472.CAN-05-0469; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Riedl K, 2004, DRUG RESIST UPDATE, V7, P169, DOI 10.1016/j.drup.2004.04.003; Roberts RA, 1995, TOXICOL APPL PHARM, V135, P192, DOI 10.1006/taap.1995.1223; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; SALDANA M, IN PRESS EUR NEUROPS; Salnikow Konstantin, 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P307; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SCHULTEHERMANN R, 1990, CANCER RES, V50, P5127; Scott KA, 2003, MOL CANCER THER, V2, P445; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Sivulka DJ, 2005, REGUL TOXICOL PHARM, V43, P117, DOI 10.1016/j.yrtph.2005.06.014; SNYDER RD, 1995, CANCER RES, V55, P3702; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; von Knethen A, 1999, J IMMUNOL, V163, P2858; Weng MW, 2004, TOXICOL LETT, V151, P345, DOI 10.1016/j.toxlet.2004.03.007; Wyllie AH, 1999, BRIT J CANCER, V80, P34; Yoon JM, 2005, LUNG CANCER, V48, P201, DOI 10.1016/j.lungcan.2004.11.005	59	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39022	39032		10.1074/jbc.M604798200	http://dx.doi.org/10.1074/jbc.M604798200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	16982623	hybrid			2022-12-25	WOS:000242898700008
J	Forquer, I; Covian, R; Bowman, MK; Trumpower, BL; Kramer, DM				Forquer, Isaac; Covian, Raul; Bowman, Michael K.; Trumpower, Bernard L.; Kramer, David M.			Similar transition states mediate the Q-cycle and superoxide production by the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; COUPLED ELECTRON-TRANSFER; PROTONMOTIVE Q-CYCLE; Q(O) SITE; UBIQUINOL OXIDATION; BC COMPLEXES; SACCHAROMYCES-CEREVISIAE; BYPASS REACTIONS; DOMAIN MOVEMENT; UBIHYDROQUINONE OXIDATION	The cytochrome bc complexes found in mitochondria, chloroplasts and many bacteria play critical roles in their respective electron transport chains. The quinol oxidase (Q(o)) site in this complex oxidizes a hydroquinone ( quinol), reducing two one-electron carriers, a low potential cytochrome b heme and the "Rieske" iron-sulfur cluster. The overall electron transfer reactions are coupled to transmembrane translocation of protons via a "Q-cycle" mechanism, which generates proton motive force for ATP synthesis. Since semiquinone intermediates of quinol oxidation are generally highly reactive, one of the key questions in this field is: how does the Q(o) site oxidize quinol without the production of deleterious side reactions including superoxide production? We attempt to test three possible general models to account for this behavior: 1) The Q(o) site semiquinone ( or quinol-imidazolate complex) is unstable and thus occurs at a very low steady-state concentration, limiting O-2 reduction; 2) the Q(o) site semiquinone is highly stabilized making it unreactive toward oxygen; and 3) the Q(o) site catalyzes a quantum mechanically coupled two-electron/two-proton transfer without a semiquinone intermediate. Enthalpies of activation were found to be almost identical between the uninhibited Q-cycle and superoxide production in the presence of antimycin A in wild type. This behavior was also preserved in a series of mutants with altered driving forces for quinol oxidation. Overall, the data support models where the rate-limiting step for both Q-cycle and superoxide production is essentially identical, consistent with model 1 but requiring modifications to models 2 and 3.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Battelle NW Lab, Richland, WA 99352 USA	Washington State University; Dartmouth College; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Kramer, DM (corresponding author), Washington State Univ, Inst Biol Chem, 299 Clark Hall, Pullman, WA 99164 USA.	dkramer@wsu.edu	Bowman, Michael/F-4265-2011; Kramer, David/B-9588-2016	Bowman, Michael/0000-0003-3464-9409; Kramer, David/0000-0003-2181-6888	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061904, R01GM020379, R37GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379, GM 61904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berry EA, 1999, J BIOENERG BIOMEMBR, V31, P177, DOI 10.1023/A:1005459426843; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; Brasseur G, 2004, J BIOL CHEM, V279, P24203, DOI 10.1074/jbc.M311576200; Brasseur G, 2001, BBA-BIOENERGETICS, V1506, P89, DOI 10.1016/S0005-2728(01)00186-4; Cape JL, 2006, TRENDS PLANT SCI, V11, P46, DOI 10.1016/j.tplants.2005.11.007; Cape JL, 2005, J BIOL CHEM, V280, P34654, DOI 10.1074/jbc.M507616200; Cooley JW, 2005, BIOCHEMISTRY-US, V44, P10520, DOI 10.1021/bi050571+; Cooley JW, 2004, BIOCHEMISTRY-US, V43, P2217, DOI 10.1021/bi035938u; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Crofts AR, 2006, BBA-BIOENERGETICS, V1757, P1019, DOI 10.1016/j.bbabio.2006.02.009; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 2004, BBA-BIOENERGETICS, V1655, P77, DOI 10.1016/j.bbabio.2003.10.012; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Crofts AR, 2002, BBA-BIOENERGETICS, V1555, P48, DOI 10.1016/S0005-2728(02)00253-0; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2004, PHOTOSYNTH RES, V79, P25, DOI 10.1023/B:PRES.0000011926.47778.4e; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; FORQUER I, 2004, PHOTOSYNTHESIS FUNDA; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; Guergova-Kuras M, 2000, BIOCHEMISTRY-US, V39, P7436, DOI 10.1021/bi992491+; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kessl JJ, 2005, J BIOL CHEM, V280, P17142, DOI 10.1074/jbc.M500388200; Kramer D, 2004, METHOD ENZYMOL, V382, P21; KRAMER DM, 1994, BBA-BIOENERGETICS, V1184, P251, DOI 10.1016/0005-2728(94)90230-5; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Osyczka A, 2005, TRENDS BIOCHEM SCI, V30, P176, DOI 10.1016/j.tibs.2005.02.001; Osyczka A, 2004, NATURE, V427, P607, DOI 10.1038/nature02242; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; Schutz M, 2000, J MOL BIOL, V300, P663, DOI 10.1006/jmbi.2000.3915; Snyder CH, 1999, J BIOENERG BIOMEMBR, V31, P235, DOI 10.1023/A:1005419712731; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Zhang H, 2004, METH MOL B, V274, P67; Zhang L, 2002, BBA-BIOENERGETICS, V1556, P226, DOI 10.1016/S0005-2728(02)00368-7; Zhang Z, 2000, Subcell Biochem, V35, P541; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zusman LD, 1996, J CHEM PHYS, V105, P165, DOI 10.1063/1.471862	57	58	62	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38459	38465		10.1074/jbc.M605119200	http://dx.doi.org/10.1074/jbc.M605119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17008316	hybrid			2022-12-25	WOS:000242709500039
J	Mukhopadhyay, I; Sausville, EA; Doroshow, JH; Roy, KK				Mukhopadhyay, Indranil; Sausville, Edward A.; Doroshow, James H.; Roy, Krishnendu K.			Molecular mechanism of adaphostin-mediated G(1) arrest in prostate cancer (PC-3) cells - Signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN LEUKEMIA-CELLS; TYROSINE KINASE; IN-VITRO; INDUCED APOPTOSIS; TUMOR-CELLS; INHIBITOR; EXPRESSION; INDUCTION; NUCLEOPHOSMIN/B23	Adaphostin (NSC680410), a small molecule congener of tyrphostin AG957, has been demonstrated previously to have significant anti-proliferative effects in several leukemia models. However, this effect of adaphostin in adherent cells/solid tumor models has not been examined. In this study, we investigated the anti-proliferative effects of adaphostin in the human prostate cancer cell line PC-3. Specifically, we explored the potential molecular mechanism(s) by which adaphostin elicits its anti-proliferative effect(s). We demonstrate that adaphostin inhibits the proliferation of PC-3 cells by inducing a G(1) phase cell cycle arrest. This adaphostin-induced G(1) arrest was associated with an increase in the expression of p21 and p27 and a decrease in the expression of G(1)-specific cyclins (cyclin A, D1, and D3) and cyclin-dependent kinases 4 and 6. Consequently, a dramatic decrease in the phosphorylation of retinoblastoma protein was also observed. Additionally, we found that adaphostin treatment induced a decrease in the phosphorylation of nucleophosmin, a major nuclear phosphoprotein, and that this decreased phosphorylation was a result of the p21- and p27-mediated inactivation of cyclin E-cyclin-dependent kinase 2 complex kinase activity. Furthermore, we have determined that the adaphostin-mediated cell cycle arrest of PC-3 cells is dependent upon activation of the p38 MAPK. We also demonstrate that the hepatocyte growth factor receptor-c-Met is involved in the adaphostin-mediated signaling events that regulate p38 MAPK. Taken together, these results identify for the first time a signaling cascade of adaphostin-mediated G(1) phase-specific cell cycle arrest in PC-3 cells. These findings suggest that the tyrphostin member has a broader spectrum of activity than originally predicted.	NCI, Lab Clin Tials Unit, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore	Roy, KK (corresponding author), NCI, Lab Clin Tials Unit, Div Canc Treatment & Diag, NIH, 37 Convent Dr,Bldg 37,Rm 1052, Bethesda, MD 20892 USA.	kr91w@nih.gov						Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Aichberger KJ, 2005, CANCER RES, V65, P9436, DOI 10.1158/0008-5472.CAN-05-0972; Avramis IA, 2002, CANCER CHEMOTH PHARM, V50, P479, DOI 10.1007/s00280-002-0507-6; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blagden S, 2005, CURR DRUG TARGETS, V6, P325, DOI 10.2174/1389450053765824; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; Chattopadhyay N, 2002, MOL BRAIN RES, V102, P73, DOI 10.1016/S0169-328X(02)00215-2; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; Christensen JG, 2003, CANCER RES, V63, P7345; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Dasmahapatra G, 2006, BLOOD, V107, P232, DOI 10.1182/blood-2005-06-2302; Dasmahapatra G, 2006, LEUKEMIA RES, V30, P1263, DOI 10.1016/j.leukres.2006.01.005; Dasmahapatra GP, 2004, CLIN CANCER RES, V10, P5242, DOI 10.1158/1078-0432.CCR-03-0534; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; George J, 2005, EXP MOL PATHOL, V78, P233, DOI 10.1016/j.yexmp.2004.11.003; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GRANA X, 1995, ONCOGENE, V11, P211; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Hayami R, 2005, CANCER RES, V65, P6; Hose C, 2005, CLIN CANCER RES, V11, P6370, DOI 10.1158/1078-0432.CCR-05-0291; Hurle RA, 2005, HISTOL HISTOPATHOL, V20, P1339, DOI 10.14670/HH-20.1339; Kaur G, 2005, BIOORGAN MED CHEM, V13, P1749, DOI 10.1016/j.bmc.2004.12.003; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liu TZ, 2006, FOOD CHEM TOXICOL, V44, P227, DOI 10.1016/j.fct.2005.07.003; Losada A, 2004, BRIT J CANCER, V91, P1405, DOI 10.1038/sj.bjc.6602166; Losiewicz MD, 1999, BIOCHEM PHARMACOL, V57, P281, DOI 10.1016/S0006-2952(98)00293-7; Maulik G, 2002, J CELL MOL MED, V6, P539, DOI 10.1111/j.1582-4934.2002.tb00453.x; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Miura S, 2005, ATHEROSCLEROSIS, V182, P267, DOI 10.1016/j.atherosclerosis.2005.02.017; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakashiro K, 2000, AM J PATHOL, V157, P795, DOI 10.1016/S0002-9440(10)64593-2; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ribatti D, 2005, CURR CANCER DRUG TAR, V5, P573, DOI 10.2174/156800905774932806; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Sattler M, 2003, CANCER RES, V63, P5462; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Shanafelt TD, 2005, BLOOD, V105, P2099, DOI 10.1182/blood-2004-06-2205; Shen YH, 2005, BIOORGAN MED CHEM, V13, P4960, DOI 10.1016/j.bmc.2005.05.038; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CANCER RES, V60, P3689; Subong ENP, 1999, PROSTATE, V39, P298; Svingen PA, 2000, CLIN CANCER RES, V6, P237; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; TSAI LH, 1993, ONCOGENE, V8, P1593; Vlahovic G, 2003, ONCOLOGIST, V8, P531, DOI 10.1634/theoncologist.8-6-531; Wang X, 2004, J BIOL CHEM, V279, P5237, DOI 10.1074/jbc.M309271200; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yim D, 2005, CANCER RES, V65, P1035; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248	66	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37330	37344		10.1074/jbc.M605569200	http://dx.doi.org/10.1074/jbc.M605569200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16956884	hybrid			2022-12-25	WOS:000242477100010
J	Wang, L; Zuercher, WJ; Consler, TG; Lambert, MH; Miller, AB; Orband-Miller, LA; McKee, DD; Willson, TM; Nolte, RT				Wang, Liping; Zuercher, William J.; Consler, Thomas G.; Lambert, Millard H.; Miller, Aaron B.; Orband-Miller, Lisa A.; McKee, David D.; Willson, Timothy M.; Nolte, Robert T.			X-ray crystal structures of the estrogen-related receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT TRANSCRIPTIONAL ACTIVATION; IDENTIFICATION; 4-HYDROXYTAMOXIFEN; DETERMINANTS; ANTAGONISM; AGONISTS; ALPHA; BETA	X-ray crystal structures of the ligand binding domain (LBD) of the estrogen-related receptor-gamma (ERR gamma) were determined that describe this receptor in three distinct states: unliganded, inverse agonist bound, and agonist bound. Two structures were solved for the unliganded state, the ERR gamma LBD alone, and in complex with a coregulator peptide representing a portion of receptor interacting protein140(RIP140). No significant differences were seen between these structures that both exhibited the conformation of ERR gamma seen in studies with other coactivators. Two structures were obtained describing the inverse agonist-bound state, the ERR gamma LBD with 4-hydroxytamoxifen (4-OHT), and the ERR gamma LBD with 4-OHT and a peptide representing a portion of the silencing mediator of retinoid and thyroid hormone action protein (SMRT). The 4-OHT structure was similar to other reported inverse agonist bound structures, showing reorientation of phenylalanine 435 and a displacement of the AF-2 helix relative to the unliganded structures with little other rearrangement occurring. No significant changes to the LBD appear to be induced by peptide binding with the addition of the SMRT peptide to the ERR gamma plus 4-OHT complex. The observed agonist-bound state contains the ERR gamma LBD, a ligand (GSK4716), and the RIP140 peptide and reveals an unexpected rearrangement of the phenol-binding residues. Thermal stability studies show that agonist binding leads to global stabilization of the ligand binding domain. In contrast to the conventional mechanism of nuclear receptor ligand activation, activation of ERR gamma by GSK4716 does not appear to involve a major rearrangement or significant stabilization of the C-terminal helix.	GlaxoSmithKline Inc, Discovery Res, Res Triangle Pk, NC 27909 USA	GlaxoSmithKline	Nolte, RT (corresponding author), GlaxoSmithKline Inc, Computat Analyt & Struct Sci Dept, 5 Moore Dr, Res Triangle Pk, NC 27909 USA.	robert.t.nolte@gsk.com	feinstein, doug/M-9414-2019					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Farnegardh M, 2003, J BIOL CHEM, V278, P38821, DOI 10.1074/jbc.M304842200; Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Hentschke M, 2002, EUR J BIOCHEM, V269, P4086, DOI 10.1046/j.1432-1033.2002.03102.x; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; LAMBERT MH, 1997, PRACTICAL APPL COMPU, P243; Lu DS, 2001, CANCER RES, V61, P6755; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1992, MOL REPLACEMENT, P87; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Zuercher WJ, 2005, J MED CHEM, V48, P3107, DOI 10.1021/jm050161j	26	101	104	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37773	37781		10.1074/jbc.M608410200	http://dx.doi.org/10.1074/jbc.M608410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16990259	hybrid			2022-12-25	WOS:000242477100054
J	Qin, BM; He, M; Chen, X; Pei, DQ				Qin, Baoming; He, Miao; Chen, Xiao; Pei, Duanqing			Sorting nexin 10 induces giant vacuoles in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-COMPLEX; BREFELDIN-A; CRYSTAL-STRUCTURE; MEMBRANE; PROTEIN; TRANSPORT; RECEPTOR; BINDING; LOCALIZATION; MECHANISMS	Eukaryotic cells maintain a sophisticated network of intracellular membranous system to ensure the proper distribution and compartmentalization of cellular proteins critical for diverse functions such as cell division or cell-cell communication. Yet, little is known about the mechanism that regulates the homeostasis of this system. While analyzing the impact of sorting nexins on the trafficking of membrane type matrix metalloproteinases, we unexpectedly discovered that the expression of SNX10 induced the formation of giant vacuoles in mammalian cells. This vacuolizing activity is sensitive to mutations at the putative phosphoinositide 3-phosphate binding residue Arg53. Domain-swap experiments with SNX3 demonstrate that the PX domain of SNX10 alone is insufficient to generate vacuoles and the downstream C-terminal domain is required for vacuolization. Brefeldin A, a chemical known to block the endoplasmic reticulum to Golgi transport, inhibited the vacuolization process. Together, these results suggest that SNX10 activity may be involved in the regulation of endosome homeostasis.	Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510663, Peoples R China	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Pei, DQ (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510663, Peoples R China.	pei_duanqing@gibh.ac.cn	zhou, xingru/G-4442-2012; He, Miao/AAQ-1044-2020; Qin, Baoming/G-1553-2015	He, Miao/0000-0003-0731-6801; Qin, Baoming/0000-0001-7652-161X				Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Cui P, 2004, EXP CELL RES, V293, P154, DOI 10.1016/j.yexcr.2003.09.023; Dacks JB, 2001, CELL, V107, P419, DOI 10.1016/S0092-8674(01)00584-0; De Matteis MA, 2005, BBA-MOL CELL RES, V1744, P396, DOI 10.1016/j.bbamcr.2005.04.013; De Matteis MA, 2004, BBA-BIOMEMBRANES, V1666, P264, DOI 10.1016/j.bbamem.2004.07.002; De Matteis MA, 2004, NAT CELL BIOL, V6, P487, DOI 10.1038/ncb0604-487; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; HUNZIKER W, 1992, FEBS LETT, V307, P93, DOI 10.1016/0014-5793(92)80908-Y; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Munro S, 2004, NAT CELL BIOL, V6, P469, DOI 10.1038/ncb0604-469; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Roberts RL, 1999, J CELL SCI, V112, P3667; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Zhou CZ, 2003, J BIOL CHEM, V278, P50371, DOI 10.1074/jbc.M304392200	27	53	58	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36891	36896		10.1074/jbc.M608884200	http://dx.doi.org/10.1074/jbc.M608884200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17012226	hybrid			2022-12-25	WOS:000242220800048
J	Sun, F; Zhang, RL; Gong, XY; Geng, XH; Drain, PF; Frizzell, RA				Sun, Fei; Zhang, Ruilin; Gong, Xiaoyan; Geng, Xuehui; Drain, Peter F.; Frizzell, Raymond A.			Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; MISFOLDED PROTEINS; UBIQUITIN LIGASE; QUALITY-CONTROL; ER; PROTEASOME; COMPLEX; RETROTRANSLOCATION; DISLOCATION; INHIBITION	A complex involving Derlin-1 and p97 mediates the retrotranslocation and endoplasmic reticulum (ER)-associated degradation of misfolded proteins in yeast and is used by certain viruses to promote host cell protein degradation (Romisch, K. (2005) Annu. Rev. Cell Dev. Biol. 21, 435-456; Lilley, B. N., and Ploegh, H. L. (2004) Nature 429, 834-840; Ye, Y., Shibata, Y., Yun, C., Ron, D., and Rapoport, T. A. (2004) Nature 429, 841 847). We asked whether the components of this pathway are involved in the endoplasmic reticulum-associated degradation of the mammalian integral membrane protein, the cystic fibrosis transmembrane conductance regulator (CFTR), a substrate for the ubiquitin-proteasome system. We report that Derlin-1 and p97 formed complexes with CFTR in human airway epithelial cells. Derlin-1 interacted with nonubiquitylated CFTR, whereas p97 associated with ubiquitylated CFTR. Exogenous expression of Derlin-1 led to its co-localization with CFTR in the ER where it reduced wild type (WT) CFTR expression and efficiently degraded the disease-associated CFTR folding mutants, Delta F508 and G85E (> 90%). Consistent with this, Derlin-1 also reduced the amount of WT or Delta F508 CFTR appearing in detergent-insoluble aggregates. An similar to 70% knockdown of endogenous Derlin-1 by RNA interference increased the steady-state levels of WT and Delta F508 CFTR by 10-15-fold, reflecting its significant role in CFTR degradation. Derlin-1 mediated the degradation of N-terminal CFTR fragments corresponding to the first transmembrane domain of CFTR, but CFTR fragments that incorporated additional domains were degraded less efficiently. These findings suggest that Derlin-1 recognizes misfolded, nonubiquitylated CFTR to initiate its dislocation and degradation early in the course of CFTR biogenesis, perhaps by detecting structural instability within the first transmembrane domain.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072506, R01DK068196] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK68196, DK72506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amaral MD, 2005, PEDIATR PULM, V39, P479, DOI 10.1002/ppul.20168; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hassink G, 2005, BIOCHEM J, V388, P647, DOI 10.1042/BJ20041241; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kleizen B, 2005, MOL CELL, V20, P277, DOI 10.1016/j.molcel.2005.09.007; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Loo TW, 2006, BIOCHEM J, V395, P537, DOI 10.1042/BJ20060013; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Neuber O, 2005, NAT CELL BIOL, V7, P993, DOI 10.1038/ncb1298; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; PIND S, 1994, J BIOL CHEM, V269, P12784; RIORDAN JR, 1989, SCIENCE, V245, P1066; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Vij N, 2006, J BIOL CHEM, V281, P17369, DOI 10.1074/jbc.M600509200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang H, 2006, J BIOL CHEM, V281, P11312, DOI 10.1074/jbc.M512013200	43	114	117	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36856	36863		10.1074/jbc.M607085200	http://dx.doi.org/10.1074/jbc.M607085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16954204	hybrid			2022-12-25	WOS:000242220800044
J	Cornett, J; Smith, L; Friedman, M; Shin, JY; Li, XJ; Li, SH				Cornett, Jonathan; Smith, Lauren; Friedman, Meyer; Shin, Ji-Yeon; Li, Xiao-Jiang; Li, Shi-Hua			Context-dependent dysregulation of transcription by mutant huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; GENE-EXPRESSION CHANGES; MOUSE MODELS; POLYGLUTAMINE EXPANSION; CELLULAR TOXICITY; NUCLEAR; DISEASE; PROTEIN; SP1; MICE	Huntington disease (HD) is an adult-onset neurodegenerative disease caused by expansion of a polyglutamine ( poly( Q) tract in the N-terminal region of huntingtin (htt). Although the precise mechanisms leading to neurodegeneration in HD have not been fully elucidated, transcriptional dysregulation has been implicated in disease pathogenesis. In HD, multiple N-terminal mutant htt fragments smaller than the first 500 amino acids have been found to accumulate in the nucleus and adversely affect gene transcription. It is unknown whether different htt fragments in the nucleus can differentially bind transcription factors and affect transcription. Here, we report that shorter N-terminal htt fragments, which are more prone to misfolding and aggregation, are more competent to bind Sp1 and inhibit its activity. These effects can be reversed by Hsp40, a molecular chaperone that reduces the misfolding of mutant htt. Our results provide insight into the beneficial effects of molecular chaperones and suggest that context dependent transcriptional dysregulation may contribute to differential toxicity of various N-terminal htt fragments.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA	Emory University	Li, XJ (corresponding author), 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu; shihual@genetics.emory.edu			NIA NIH HHS [AG19206] Funding Source: Medline; NINDS NIH HHS [NS41669, NS045016] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045016, R01NS041669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benn CL, 2005, HUM MOL GENET, V14, P3065, DOI 10.1093/hmg/ddi340; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chan EYW, 2002, HUM MOL GENET, V11, P1939, DOI 10.1093/hmg/11.17.1939; Chen-Plotkin AS, 2006, NEUROBIOL DIS, V22, P233, DOI 10.1016/j.nbd.2005.11.001; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cornett J, 2005, NAT GENET, V37, P198, DOI 10.1038/ng1503; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Ellerby LM, 2006, NATURE, V442, P641, DOI 10.1038/442641a; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Li SH, 1999, J NEUROSCI, V19, P5159; Li SH, 2000, HUM MOL GENET, V9, P2859, DOI 10.1093/hmg/9.19.2859; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1927, DOI 10.1093/hmg/11.17.1927; Michalik A, 2001, BIOTECHNIQUES, V31, P250, DOI 10.2144/01312bm02; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Poukka H, 1996, BIOCHEM BIOPH RES CO, V229, P565, DOI 10.1006/bbrc.1996.1844; Qiu ZH, 2006, J BIOL CHEM, V281, P16672, DOI 10.1074/jbc.M511648200; Ryu H, 2003, J NEUROSCI, V23, P3597; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Schilling G, 2004, HUM MOL GENET, V13, P1599, DOI 10.1093/hmg/ddh175; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Sipione S, 2002, HUM MOL GENET, V11, P1953, DOI 10.1093/hmg/11.17.1953; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Yu ZX, 2002, HUM MOL GENET, V11, P905, DOI 10.1093/hmg/11.8.905; Yu ZX, 2003, J NEUROSCI, V23, P2193; Zhai WG, 2005, CELL, V123, P1241, DOI 10.1016/j.cell.2005.10.030; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200	42	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36198	36204		10.1074/jbc.M607839200	http://dx.doi.org/10.1074/jbc.M607839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012230	hybrid			2022-12-25	WOS:000242100500070
J	Landry, YD; Denis, M; Nandi, S; Bell, S; Vaughan, AM; Zha, XH				Landry, Yves D.; Denis, Maxime; Nandi, Shilpi; Bell, Stephanie; Vaughan, Ashley M.; Zha, Xiaohui			ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELL-MEMBRANES; GPI-ANCHORED PROTEINS; CHOLESTEROL EFFLUX; LIPID EFFLUX; PHOSPHOLIPID EFFLUX; MEDIATED TRANSPORT; TANGIER-DISEASE; GOLGI-COMPLEX; APOA-I; ABCA1	ATP-binding cassette transporter A1(ABCA1) is known to mediate cholesterol efflux to lipid-poor apolipoprotein A-I. In addition, ABCA1 has been shown to influence functions of the plasma membrane, such as endocytosis and phagocytosis. Here, we report that ABCA1 expression results in a significant redistribution of cholesterol and sphingomyelin from rafts to non-rafts. Caveolin, a raft/caveolae marker also redistributes from punctate caveolae-like structures to the general area of the plasma membrane upon ABCA1 expression. Furthermore, we observed significant reduction of Akt activation in ABCA1-expressing cells, consistent with raft disruption. Cholesterol content in the plasma membrane is, however, notaltered. Moreover, we provide evidence that a non-functional ABCA1 with mutation in an ATP-binding domain, A937V, fails to redistribute cholesterol, sphingomyelin, or caveolin. A937V also fails to influence Akt activation. Finally, we show that apolipoprotein A-I preferentially associates with non-raft membranes in ABCA1-expressing cells. Our results thus demonstrate that ABCA1 causes a change in overall lipid packing of the plasma membrane, likely through its ATPase-related functions. Such reorganization by ABCA1 effectively expands the non-raft membrane fractions and, consequentially, pre-conditions cells for cholesterol efflux.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4E9, Canada; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Washington; University of Washington Seattle	Zha, XH (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	xzha@ohri.ca						Alder-Baerens N, 2005, J BIOL CHEM, V280, P26321, DOI 10.1074/jbc.M413993200; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Duong PT, 2006, J LIPID RES, V47, P832, DOI 10.1194/jlr.M500531-JLR200; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Fu Y, 2004, J BIOL CHEM, V279, P14140, DOI 10.1074/jbc.M311061200; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Kiss RS, 2005, J LIPID RES, V46, P1877, DOI 10.1194/jlr.M400482-JLR200; Lange Y, 2004, P NATL ACAD SCI USA, V101, P11664, DOI 10.1073/pnas.0404766101; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Mayor S, 2004, TRAFFIC, V5, P231, DOI 10.1111/j.1600-0854.2004.00172.x; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; Pol A, 2005, MOL BIOL CELL, V16, P2091, DOI 10.1091/mbc.E04-08-0737; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Thorn H, 2003, MOL BIOL CELL, V14, P3967, DOI 10.1091/mbc.E03-01-0050; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang MM, 2004, BIOCHEMISTRY-US, V43, P2159, DOI 10.1021/bi035982+; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200; Zhuang LY, 2002, CANCER RES, V62, P2227	42	176	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36091	36101		10.1074/jbc.M602247200	http://dx.doi.org/10.1074/jbc.M602247200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16984907	hybrid			2022-12-25	WOS:000242100500058
J	Toth, B; Balla, A; Ma, H; Knight, ZA; Shokat, KM; Balla, T				Toth, Balazs; Balla, Andras; Ma, Hui; Knight, Zachary A.; Shokat, Kevan M.; Balla, Tamas			Phosphatidylinositol 4-kinase III beta regulates the transport of ceramide between the endoplasmic reticulum and Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; PLECKSTRIN HOMOLOGY DOMAINS; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; MOLECULAR MACHINERY; 4-KINASE ACTIVITY; CELL-SURFACE; GENE ENCODES; YEAST; SECRETION	The recently identified ceramide transfer protein, CERT, is responsible for the bulk of ceramide transport from the endoplasmic reticulum ( ER) to the Golgi. CERT has a C-terminal START domain for ceramide binding and an N-terminal pleckstrin homology domain that binds phosphatidylinositol 4-phosphate suggesting that phosphatidylinositol ( PI) 4-kinases are involved in the regulation of CERT-mediated ceramide transport. In the present study fluorescent analogues were used to follow the ER to Golgi transport of ceramide to determine which of the four mammalian PI 4-kinases are involved in this process. Overexpression of pleckstrin homology domains that bind phosphatidylinositol 4-phosphate strongly inhibited the transport of C5-BODIPY-ceramide to the Golgi. A newly identified PI3-kinase inhibitor, PIK93 that selectively inhibits the type III PI4-kinase beta enzyme, and small interfering RNA-mediated down-regulation of the individual PI4-kinase enzymes, revealed that PI4-kinase beta has a dominant role in ceramide transport between the ER and Golgi. Accordingly, inhibition of PI4-kinase III beta either by wortmannin or PIK93 inhibited the conversion of [H-3] serine-labeled endogenous ceramide to sphingomyelin. Therefore, PI4-kinase beta is a key enzyme in the control of spingomyelin synthesis by controlling the flow of ceramide from the ER to the Golgi compartment.	NICHD, Sect Mol Signal Transduct, NIH, Bethesda, MD 20892 USA; Univ Calif San Francisco, Program Chem & Chem Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Balla, T (corresponding author), Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.	ballat@mail.nih.gov	Toth, Balazs/B-4252-2012	Balla, Andras/0000-0002-6450-2793; Balla, Tamas/0000-0002-9077-3335; Knight, Zachary/0000-0001-7621-1478	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI044009] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Balla A, 2005, MOL BIOL CELL, V16, P1282, DOI 10.1091/mbc.E04-07-0578; Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Bodennec J, 2000, J LIPID RES, V41, P1524; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Han GS, 2002, J BIOL CHEM, V277, P47709, DOI 10.1074/jbc.M207996200; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hanada K, 2006, MOL CELL BIOCHEM, V286, P23, DOI 10.1007/s11010-005-9044-z; Im YJ, 2005, NATURE, V437, P154, DOI 10.1038/nature03923; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; Mayor S, 2004, TRAFFIC, V5, P231, DOI 10.1111/j.1600-0854.2004.00172.x; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; Perry RJ, 2005, BBA-MOL CELL BIOL L, V1734, P220, DOI 10.1016/j.bbalip.2005.04.001; Perry RJ, 2006, MOL BIOL CELL, V17, P2604, DOI 10.1091/mbc.E06-01-0060; Raychaudhuri S, 2006, J CELL BIOL, V173, P107, DOI 10.1083/jcb.200510084; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P57, DOI 10.1016/0005-2760(95)00010-A; Routt SM, 2005, TRAFFIC, V6, P1157, DOI 10.1111/j.1600-0854.2005.00350.x; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Tabuchi M, 2006, MOL CELL BIOL, V26, P5861, DOI 10.1128/MCB.02403-05; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Voelker DR, 2005, TRENDS BIOCHEM SCI, V30, P396, DOI 10.1016/j.tibs.2005.05.008; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Weixel KM, 2005, J BIOL CHEM, V280, P10501, DOI 10.1074/jbc.M414304200; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x	39	110	116	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36369	36377		10.1074/jbc.M604935200	http://dx.doi.org/10.1074/jbc.M604935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003043	hybrid			2022-12-25	WOS:000242100500088
J	Smirnova, TI; Chadwick, TG; MacArthur, R; Poluektov, O; Song, L; Ryan, MM; Schaaf, G; Bankaitis, VA				Smirnova, Tatyana I.; Chadwick, Thomas G.; MacArthur, Ryan; Poluektov, Oleg; Song, Likai; Ryan, Margaret M.; Schaaf, Gabriel; Bankaitis, Vytas A.			The chemistry of phospholipid binding by the Saccharomyces cerevisiae phosphatidylinositol transfer protein Sec14p as determined by EPR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FIELD EPR; ELECTRON-SPIN-RESONANCE; NITROXIDE SIDE-CHAINS; CONFORMATIONAL-CHANGES; T4 LYSOZYME; SITE; DYNAMICS; CHANNEL; DOMAIN; ACCESSIBILITY	The major yeast phosphatidylinositol/phosphatidylcholine transfer protein Sec14p is the founding member of a large eukaryotic protein superfamily. Functional analyses indicate Sec14p integrates phospholipid metabolism with the membrane trafficking activity of yeast Golgi membranes. In this regard, the ability of Sec14p to rapidly exchange bound phospholipid with phospholipid monomers that reside in stable membrane bilayers is considered to be important for Sec14p function in cells. How Sec14p-like proteins bind phospholipids remains unclear. Herein, we describe the application of EPR spectroscopy to probe the local dynamics and the electrostatic microenvironment of phosphatidylcholine (PtdCho) bound by Sec14p in a soluble protein-PtdCho complex. We demonstrate that PtdCho movement within the Sec14p binding pocket is both anisotropic and highly restricted and that the C-5 region of the sn-2 acyl chain of bound PtdCho is highly shielded from solvent, whereas the distal region of that same acyl chain is more accessible. Finally, high field EPR reports on a heterogeneous polarity profile experienced by a phospholipid bound to Sec14p. Taken together, the data suggest a headgroup-out orientation of Sec14p-bound PtdCho. The data further suggest that the Sec14p phospholipid binding pocket provides a polarity gradient that we propose is a primary thermodynamic factor that powers the ability of Sec14p to abstract a phospholipid from a membrane bilayer.	N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA; Argonne Natl Lab, Argonne, IL 60439 USA; Florida State Univ, Tallahassee, FL 32310 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; North Carolina State University; United States Department of Energy (DOE); Argonne National Laboratory; State University System of Florida; Florida State University; University of North Carolina; University of North Carolina Chapel Hill	Smirnova, TI (corresponding author), N Carolina State Univ, Dept Chem, 2620 Yarborough Dr, Raleigh, NC 27695 USA.	Tatyana_Smirnova@ncsu.edu; vytas@med.unc.edu	Schaaf, Gabriel/F-1956-2014	Schaaf, Gabriel/0000-0001-9022-4515; Smirnova, Tatyana/0000-0001-7867-7116	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001980] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB001980] Funding Source: Medline; NIGMS NIH HHS [GM44530] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alb JG, 2003, J BIOL CHEM, V278, P33501, DOI 10.1074/jbc.M303591200; Altenbach C, 2005, BIOPHYS J, V89, P2103, DOI 10.1529/biophysj.105.059063; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Bartucci R, 2003, CHEM PHYS LIPIDS, V124, P111, DOI 10.1016/S0009-3084(03)00047-1; Bomar JM, 2003, NAT GENET, V35, P264, DOI 10.1038/ng1255; CARMENLOPEZ M, 1994, J CELL BIOL, V124, P113; CHEN SC, 1982, BIOCHEMISTRY-US, V21, P5096, DOI 10.1021/bi00263a038; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; Ding Z, 2001, J CHEM PHYS, V115, P10685, DOI 10.1063/1.1416177; EARLE KA, 1994, BIOPHYS J, V66, P1213, DOI 10.1016/S0006-3495(94)80905-1; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Griffith O.H., 1976, SPIN LABELING THEORY, P454; Gulla AF, 2001, J PHYS CHEM B, V105, P8056, DOI 10.1021/jp0109224; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HERSCHEL WH, 1917, 100 US DEP COMM BUR; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; KAWAMURA T, 1967, B CHEM SOC JPN, V40, P1111, DOI 10.1246/bcsj.40.1111; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Merianos HJ, 2000, NAT STRUCT BIOL, V7, P205; Monteoliva L, 1996, YEAST, V12, P1097, DOI 10.1002/(SICI)1097-0061(19960915)12:11<1097::AID-YEA990>3.0.CO;2-E; Nielsen RD, 2005, J AM CHEM SOC, V127, P6430, DOI 10.1021/ja042782s; Oh KJ, 2000, METH MOL B, V145, P147; Owenius R, 2001, J PHYS CHEM A, V105, P10967, DOI 10.1021/jp0116914; Perozo E, 2002, STRUCTURE, V10, P1027, DOI 10.1016/S0969-2126(02)00812-2; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Phillips SE, 2006, CRIT REV BIOCHEM MOL, V41, P21, DOI 10.1080/10409230500519573; Plato M, 2002, MOL PHYS, V100, P3711, DOI 10.1080/00268970210166246; Pyka J, 2005, BIOPHYS J, V89, P2059, DOI 10.1529/biophysj.105.059055; ROBINSON BH, 1994, SCIENCE, V263, P490, DOI 10.1126/science.8290958; Schorn K, 1997, SPECTROCHIM ACTA A, V53, P2235, DOI 10.1016/S1386-1425(97)00136-4; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; SMIRNOV AI, 1995, J MAGN RESON SER A, V113, P65, DOI 10.1006/jmra.1995.1057; Smirnova TI, 2003, J PHYS CHEM B, V107, P7212, DOI 10.1021/jp0349637; SMIRNOVA TI, 1995, MAGNET RESON MED, V33, P801, DOI 10.1002/mrm.1910330610; Smirnova TI, 1998, J AM CHEM SOC, V120, P5060, DOI 10.1021/ja973427n; Steinhoff HJ, 2000, BBA-BIOENERGETICS, V1457, P253, DOI 10.1016/S0005-2728(00)00106-7; Tilley SJ, 2004, STRUCTURE, V12, P317, DOI 10.1016/j.str.2004.01.013; Vincent P, 2005, J CELL BIOL, V168, P801, DOI 10.1083/jcb.200412074; Wegener C, 2001, APPL MAGN RESON, V21, P441, DOI 10.1007/BF03162419; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200; Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098	45	13	13	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34897	34908		10.1074/jbc.M603054200	http://dx.doi.org/10.1074/jbc.M603054200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16997918	Green Published, hybrid			2022-12-25	WOS:000241933700022
J	Fearns, C; Pan, Q; Mathison, JC; Chuang, TH				Fearns, Colleen; Pan, Qilin; Mathison, John C.; Chuang, Tsung-Hsien			Triad3A regulates ubiquitination and proteasomal degradation of RIP1 following disruption of Hsp90 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTORS; INTERACTING PROTEIN RIP; DEATH DOMAIN KINASE; SIGNAL-TRANSDUCTION; IMMUNE-RESPONSES; INNATE IMMUNITY; ACTIVATION; NECROSIS; APOPTOSIS	Toll-like receptors (TLRs) play a crucial role in innate immunity by recognizing microbial pathogens. Triad3A is an E3 ubiquitin-protein ligase that interacts with the Toll/interleukin-1 receptor domain of TLRs and promotes their proteolytic degradation. In the present study, we further investigated its activity on signaling molecules downstream of TLRs and tumor necrosis factor (TNF) receptor 1. Triad3A promoted down-regulation of two TIR domain-containing adapter proteins, TIRAP and TRIF, as well as a RIP1 but had no effect on other adapter molecules in either the TLRs or TNF-alpha signaling pathways. Multiple sequence alignment analysis suggested that RIP1 contains a TIR homologous domain, and mutation of amino acid residues in this domain identified three residues critical for its interaction with Triad3A. Moreover, Triad3A acted as a negative regulator in TNF-alpha signaling. Reduction of Triad3A expression by small interference RNAs rendered cells hyperresponsive to TNF-alpha stimulation. Conversely, overexpression of Triad3A in cells blocked TNF-alpha-induced cell activation. This negative regulation was effected independently of changes in the cellular protein level of RIP1. Further studies indicated that RIP1 formed a complex with Triad3A and heat shock protein 90 (Hsp90), which is a chaperone protein capable of maintaining the stability of its client proteins. Treatment of cells with geldanamycin to disrupt the Hsp90 complex led to proteasomal degradation of RIP1. Depletion of Triad3A by small interference RNA treatment inhibited geldanamycin-activated ubiquitination and proteolytic degradation of RIP1. These results suggest that Triad3A is an E3 ubiquitin-protein ligase to RIP1 and that Hsp90 and Triad3A cooperatively maintain the homeostasis of RIP1.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Chuang, TH (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chuang@scripps.edu	Chuang, Tsung-Hsien/F-9679-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069652] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ardley HC, 2005, ESSAYS BIOCHEM, V41, P15, DOI 10.1042/EB0410015; Beutler B, 2004, MICROBES INFECT, V6, P1374, DOI 10.1016/j.micinf.2004.08.017; Beutler B, 2003, ANNU REV PHARMACOL, V43, P609, DOI 10.1146/annurev.pharmtox.43.100901.135729; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Chiosis G, 2003, CURR CANCER DRUG TAR, V3, P371, DOI 10.2174/1568009033481778; Chuang TH, 2004, NAT IMMUNOL, V5, P495, DOI 10.1038/ni1066; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Daun JM, 2000, J INTERF CYTOK RES, V20, P843, DOI 10.1089/10799900050163217; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Imler J L, 2000, Rev Immunogenet, V2, P294; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Park SM, 2004, FEBS LETT, V566, P151, DOI 10.1016/j.feblset.2004.04.021; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268; Schmidt M, 2005, BIOL CHEM, V386, P725, DOI 10.1515/BC.2005.085; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Younes A., 2005, FUTURE ONCOLOGY, V1, P273; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006	40	70	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34592	34600		10.1074/jbc.M604019200	http://dx.doi.org/10.1074/jbc.M604019200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968706	hybrid			2022-12-25	WOS:000241767600078
J	Garza-Sanchez, F; Janssen, BD; Hayes, CS				Garza-Sanchez, Fernando; Janssen, Brian D.; Hayes, Christopher S.			Prolyl-tRNA(Pro) in the A-site of SecM-arrested ribosomes inhibits the recruitment of transfer-messenger RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSLATION ARREST; BACILLUS-SUBTILIS; NASCENT-PEPTIDE; QUALITY-CONTROL; DEGRADATION; PROTEIN; EXPRESSION; CLEAVAGE; CODON	Translational pausing can lead to cleavage of the A-site codon and facilitate recruitment of the transfer-messenger RNA (tmRNA) (SsrA) quality control system to distressed ribosomes. We asked whether aminoacyl-tRNA binding site (A-site) mRNA cleavage occurs during regulatory translational pausing using the Escherichia coli SecM-mediated ribosome arrest as a model. We find that SecM ribosome arrest does not elicit efficient A-site cleavage, but instead allows degradation of downstream mRNA to the 3'-edge of the arrested ribosome. Characterization of SecM-arrested ribosomes shows the nascent peptide is covalently linked via glycine 165 to tRNA(3)(Gly) in the peptidyl-tRNA binding site, and prolyl-tRNA(2)(Pro) is bound to the A-site. Although A-site-cleaved mRNAs were not detected, tmRNA-mediated ssrA tagging after SecM glycine 165 was observed. This tmRNA activity results from sequestration of prolyl-tRNA(2)(Pro) on overexpressed SecM-arrested ribosomes, which produces a second population of stalled ribosomes with unoccupied A-sites. Indeed, compensatory overexpression of tRNA(2)(Pro) readily inhibits ssrA tagging after glycine 165, but has no effect on the duration of SecM ribosome arrest. We conclude that, under physiological conditions, the architecture of SecM-arrested ribosomes allows regulated translational pausing without interference from A-site cleavage or tmRNA activities. Moreover, it seems likely that A-site mRNA cleavage is generally avoided or inhibited during regulated ribosome pauses.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Hayes, CS (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Life Sci Technol Bldg,Rm 3105, Santa Barbara, CA 93106 USA.	chayes@lifesci.ucsb.edu	Hayes, Christopher/A-5505-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078634] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM078634-01, R01 GM078634] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; BECHHOFER DH, 1989, J BACTERIOL, V171, P5803, DOI 10.1128/jb.171.11.5803-5811.1989; BRUCKNER R, 1987, MOL GEN GENET, V207, P486, DOI 10.1007/BF00331619; Butkus ME, 2003, J BACTERIOL, V185, P6719, DOI 10.1128/JB.185.22.6719-6722.2003; Carpousis AJ, 2002, BIOCHEM SOC T, V30, P150, DOI 10.1042/bst0300150; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; Collier J, 2004, J BIOL CHEM, V279, P54193, DOI 10.1074/jbc.M314012200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; DREHER J, 1991, MOL MICROBIOL, V5, P3025, DOI 10.1111/j.1365-2958.1991.tb01862.x; DUBNAU D, 1985, EMBO J, V4, P533, DOI 10.1002/j.1460-2075.1985.tb03661.x; Fredrick K, 2002, MOL CELL, V9, P1125, DOI 10.1016/S1097-2765(02)00523-3; HAHN J, 1982, MOL GEN GENET, V186, P204, DOI 10.1007/BF00331851; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Hayes CS, 2002, P NATL ACAD SCI USA, V99, P3440, DOI 10.1073/pnas.052707199; Ivanova N, 2004, J MOL BIOL, V338, P33, DOI 10.1016/j.jmb.2004.02.043; Jerinic O, 2000, J MOL BIOL, V304, P707, DOI 10.1006/jmbi.2000.4269; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Li Y, 2003, P NATL ACAD SCI USA, V100, P13213, DOI 10.1073/pnas.2235589100; Loomis WP, 2001, MOL MICROBIOL, V39, P693, DOI 10.1046/j.1365-2958.2001.02241.x; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; LOVETT PS, 1990, J BACTERIOL, V172, P1, DOI 10.1128/JB.172.1.1-6.1990; McNicholas P, 1997, J MOL BIOL, V265, P128, DOI 10.1006/jmbi.1996.0723; Mitra K, 2006, MOL CELL, V22, P533, DOI 10.1016/j.molcel.2006.05.003; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Murakami A, 2004, P NATL ACAD SCI USA, V101, P12330, DOI 10.1073/pnas.0404907101; Muto H, 2006, MOL CELL, V22, P545, DOI 10.1016/j.molcel.2006.03.033; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Nakatogawa H, 2005, GENE DEV, V19, P436, DOI 10.1101/gad.1259505; Nakatogawa H, 2004, CURR OPIN MICROBIOL, V7, P145, DOI 10.1016/j.mib.2004.01.001; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Regnier P, 2000, BIOESSAYS, V22, P235; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sunohara T, 2004, J BIOL CHEM, V279, P15368, DOI 10.1074/jbc.M312805200; Sunohara T, 2004, RNA, V10, P378, DOI 10.1261/rna.5169404; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Yamamoto Y, 2003, RNA, V9, P408, DOI 10.1261/rna.2174803; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZURAWSKI G, 1978, P NATL ACAD SCI USA, V75, P5988, DOI 10.1073/pnas.75.12.5988	47	75	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34258	34268		10.1074/jbc.M608052200	http://dx.doi.org/10.1074/jbc.M608052200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968693	Green Accepted, hybrid			2022-12-25	WOS:000241767600046
J	Nakajima, S; Lan, L; Kanno, SI; Usami, N; Kobayashi, K; Mori, M; Shiomi, T; Yasui, A				Nakajima, Satoshi; Lan, Li; Kanno, Shin-ichiro; Usami, Noriko; Kobayashi, Katsumi; Mori, Masahiko; Shiomi, Tadahiro; Yasui, Akira			Replication-dependent and -independent responses of RAD18 to DNA damage in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; DEFECTIVE POSTREPLICATION REPAIR; RING FINGER PROTEINS; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; YEAST RAD6; POLYMERASE-ETA; GENE; PCNA; SUMO	Postreplication repair facilitates tolerance of DNA damage during replication, overcoming termination of replication at sites of DNA damage. A major post-replication repair pathway in mammalian cells is translesion synthesis, which is carried out by specialized polymerase(s), such as polymerase eta, and is identified by focus formation by the polymerase after irradiation with UVC light. The formation of these foci depends on RAD18, which ubiquitinates PCNA for the exchange of polymerases. To understand the initial processes in translesion synthesis, we have here analyzed the response to damage of RAD18 in human cells. We find that human RAD18 accumulates very rapidly and remains for a long period of time at sites of different types of DNA damage, including UVC light-induced lesions, and x-ray microbeam- and laser-induced single-strand breaks, in a cell cycle-independent manner. The accumulation of RAD18 at DNA damage is observed even when DNA replication is inhibited, and a small region containing a zinc finger motif located in the middle of RAD18 is essential and sufficient for the replication-independent damage accumulation. The zinc finger motif of RAD18 is not necessary for UV-induced polymerase eta focus formation, but another SAP (SAF-A/B, Acinus and PIAS) motif near the zinc finger is required. These data indicate that RAD18 responds to DNA damage in two distinct ways, one replication-dependent and one replication-independent, involving the SAP and zinc finger motifs, respectively.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Natl Inst Radiol Sci, KEK, IMSS, Photon Factory, Chiba 2638555, Japan; Natl Inst Radiol Sci, Low Dose Radiat Effects Project, Chiba 2638555, Japan	Tohoku University; High Energy Accelerator Research Organization (KEK); National Institutes for Quantum Science & Technology; National Institutes for Quantum Science & Technology	Yasui, A (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan.	ayasui@idac.tohoku.ac.jp	Kanno, Shin-ichiro/AAE-4549-2019	Usami, Noriko/0000-0002-6157-8418				Akhtar A, 2001, EMBO REP, V2, P113, DOI 10.1093/embo-reports/kve022; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Bohm F, 2005, NUCLEIC ACIDS RES, V33, P1101, DOI 10.1093/nar/gki258; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Hishida T, 2002, EMBO J, V21, P2019, DOI 10.1093/emboj/21.8.2019; Hishida T, 2001, P NATL ACAD SCI USA, V98, P8283, DOI 10.1073/pnas.121009098; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Katsumi S, 2001, J INVEST DERMATOL, V117, P1156, DOI 10.1046/j.0022-202x.2001.01540.x; Kawabe Y, 2001, J BIOL CHEM, V276, P20364, DOI 10.1074/jbc.C100035200; KOBAYASHI K, 2006, IN PRESS J BIOMED NA; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; Lan L, 2004, P NATL ACAD SCI USA, V101, P13738, DOI 10.1073/pnas.0406048101; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Lehmann AR, 2005, FEBS LETT, V579, P873, DOI 10.1016/j.febslet.2004.11.029; Lehmann AR, 2002, MUTAT RES-FUND MOL M, V509, P23, DOI 10.1016/S0027-5107(02)00227-0; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; Miyase S, 2005, J BIOL CHEM, V280, P515, DOI 10.1074/jbc.M409219200; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Murakumo Y, 2006, GENES CELLS, V11, P193, DOI 10.1111/j.1365-2443.2006.00938.x; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Roest HP, 2004, MOL CELL BIOL, V24, P5485, DOI 10.1128/MCB.24.12.5485-5495.2004; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Tateishi S, 2003, MOL CELL BIOL, V23, P474, DOI 10.1128/MCB.23.2.474-481.2003; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847	48	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34687	34695		10.1074/jbc.M605545200	http://dx.doi.org/10.1074/jbc.M605545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980296	hybrid			2022-12-25	WOS:000241767600087
J	Pierobon, N; Renard-Rooney, DC; Gaspers, LD; Thomas, AP				Pierobon, Nicola; Renard-Rooney, Dominique C.; Gaspers, Lawrence D.; Thomas, Andrew P.			Ryanodine receptors in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CYTOSOLIC CALCIUM OSCILLATIONS; CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; RAT-LIVER; BINDING-SITES; ENDOPLASMIC-RETICULUM; HEPATOCYTES; CELLS	The ryanodine receptor has been mainly regarded as the Ca2+ release channel from sarcoplasmic reticulum controlling skeletal and cardiac muscle contraction. However, many studies have shown that it is widely expressed, with functions not restricted to muscular contraction. This study examined whether ryanodine receptor plays a role in calcium signaling in the liver. RTPCR analysis of isolated hepatocytes showed expression of a truncated type 1 ryanodine receptor, but no type 2 or type 3 message was detected. We also detected binding sites for [H-3]ryanodine in the microsomal cellular fraction and in permeabilized hepatocytes. This binding was displaced by caffeine and dantrolene, but not by ruthenium red, heparin or cyclic ADP-Ribose. Ryanodine, by itself, did not trigger Ca2+ oscillations in either primary cultured hepatocytes or hepatocytes within the intact perfused rat liver. In both preparations, however, ryanodine significantly increased the frequency of the cytosolic free [Ca2+] oscillations evoked by an alpha(1) adrenergic receptor agonist. Experiments in permeabilized hepatocytes showed that both ryanodine and cyclic ADP-ribose evoked a slow Ca2+ leak from intracellular stores and were able to increase the Ca2+-released response to a subthreshold dose of inositol 1,4,5-trisphosphate. Our findings suggest the presence of a novel truncated form of the type 1 ryanodine receptor in rat hepatocytes. Ryanodine modulates the pattern of cytosolic free [Ca2+] oscillations by increasing oscillation frequency. We propose that the Ca2+ released from ryanodine receptors on the endoplasmic reticulum provides an increased pool of Ca2+ for positive feedback on inositol 1,4,5-trisphosphate receptors.	Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Thomas, AP (corresponding author), Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.	thomasap@umdnj.edu	Thomas, Andrew/C-6755-2013; Gaspers, Lawrence/W-8766-2019	Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA014980] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA014980] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASSIMACOPOULOSJEANNET FD, 1977, J BIOL CHEM, V252, P2662; BAZOTTE RB, 1991, BIOCHEM PHARMACOL, V42, P1799, DOI 10.1016/0006-2952(91)90518-A; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Beutner G, 2001, J BIOL CHEM, V276, P21482, DOI 10.1074/jbc.M101486200; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; ELLINGSON JS, 1991, BIOCHIM BIOPHYS ACTA, V1062, P199, DOI 10.1016/0005-2736(91)90393-M; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Fitzsimmons TJ, 2000, BIOCHEM J, V351, P265, DOI 10.1042/0264-6021:3510265; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Gaspers LD, 2005, CELL CALCIUM, V38, P329, DOI 10.1016/j.ceca.2005.06.009; Gerasimenko J, 2003, BIOCHEM SOC T, V31, P76, DOI 10.1042/bst0310076; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; Hirata K, 2002, GASTROENTEROLOGY, V122, P1088, DOI 10.1053/gast.2002.32363; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; Khoo KM, 2000, ARCH BIOCHEM BIOPHYS, V373, P35, DOI 10.1006/abbi.1999.1526; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lee BS, 2002, J MEMBRANE BIOL, V189, P181, DOI 10.1007/s00232-002-1012-x; LILLY LB, 1995, AM J PHYSIOL-GASTR L, V268, pG1017, DOI 10.1152/ajpgi.1995.268.6.G1017; Mackenzie L, 2004, BIOL RES, V37, P553, DOI 10.4067/S0716-97602004000400008; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; Morgan AJ, 1999, METH MOL B, V114, P93; NATHANSON MH, 1994, AM J PHYSIOL, V267, pG338, DOI 10.1152/ajpgi.1994.267.3.G338; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SANCHEZBUENO A, 1994, BIOCHEM BIOPH RES CO, V198, P728, DOI 10.1006/bbrc.1994.1105; Sei Y, 1999, J BIOL CHEM, V274, P5995, DOI 10.1074/jbc.274.9.5995; SHOSHANBARMATZ V, 1991, BIOCHEM J, V276, P41, DOI 10.1042/bj2760041; SHOSHANBARMATZ V, 1990, FEBS LETT, V263, P317, DOI 10.1016/0014-5793(90)81403-B; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TARASCHI TF, 1985, BIOCHEMISTRY-US, V24, P7096, DOI 10.1021/bi00346a012; Tunwell REA, 1996, J BIOL CHEM, V271, P29583, DOI 10.1074/jbc.271.47.29583; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; Zhang XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1306, DOI 10.1152/ajpcell.1997.273.4.C1306	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34086	34095		10.1074/jbc.M607788200	http://dx.doi.org/10.1074/jbc.M607788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973607	hybrid			2022-12-25	WOS:000241767600029
J	Unoki, M; Shen, JC; Zheng, ZM; Harris, CC				Unoki, Motoko; Shen, Jiang Cheng; Zheng, Zhi-Ming; Harris, Curtis C.			Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; MESSENGER-RNA; PHD FINGER; BINDING; PROTEINS; ACTIVATION; EXPRESSION; CYTOPLASM; ENHANCER; FAMILY	The ING4 gene is a candidate tumor suppressor gene that functions in cell proliferation, contact inhibition, and angiogenesis. We identified three novel splice variants of ING4 with differing activities in controlling cell proliferation, cell spreading, and cell migration. ING4_v1 (the longest splice variant), originally identified as ING4, encodes an intact nuclear localization signal (NLS), whereas the other three splice variants (ING4_v2, ING4_v3, and ING4_v4) lack the full NLS, resulting in increased cytoplasmic localization of these proteins. We found that one of the three ING4 variants, ING4_v2, is expressed at the same level as the original ING4 (ING4_v1), suggesting that ING4 variants may have significant biological functions. Growth suppressive effects of the variants that have a partial NLS (ING4_v2 and ING4_v4) were attenuated by a weaker effect of the variants on p21(WAF1) promoter activation. ING4_v4 lost cell spreading and migration suppressive effects; on the other hand, ING4_v2 retained a cell migration suppressive effect but lost a cell spreading suppressive effect. Therefore, ING4_v2, which localized primarily into cytoplasm, might have an important role in the regulation of cell migration. We also found that ING4_v4 played dominant-negative roles in the induction of p21(WAF1) promoter activation and in the suppression of cell motility by ING4_v1. In addition, ING4 variants had different binding affinities to two cytoplasmic proteins, protein-tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1, and G3BP2a. Understanding the functions of the four splice variants may aid in defining their roles in human carcinogenesis.	NCI, Human Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; NCI, HIV & AIDS Malignancy Branch, CCR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, CCR, NIH, 37 Convent Dr,Bldg 37,Rm 3068, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	Zheng, Zhi-Ming/L-6383-2019; Unoki, Motoko/X-3285-2019	Zheng, Zhi-Ming/0000-0001-5547-7912; Unoki, Motoko/0000-0002-9629-3818	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Ladd AN, 2002, GENOME BIOL, V3; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Liu SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI 10.1016/S1368-7646(03)00044-X; Liu XF, 2003, J VIROL, V77, P2105, DOI 10.1128/JVI.77.3.2105-2115.2003; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Miller KE, 2005, CURR BIOL, V15, P684, DOI 10.1016/j.cub.2005.02.061; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Parker F, 1996, MOL CELL BIOL, V16, P2561; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Serra-Pages C, 2005, BIOCHEMISTRY-US, V44, P15715, DOI 10.1021/bi051434f; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiseki M, 2003, CANCER RES, V63, P2373; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Zhang X, 2005, BIOCHEM BIOPH RES CO, V331, P1032, DOI 10.1016/j.bbrc.2005.04.023; Zhang X, 2004, FEBS LETT, V570, P7, DOI 10.1016/j.febslet.2004.06.010; Zheng ZM, 2004, J BIOMED SCI, V11, P278, DOI 10.1159/000077096	34	82	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34677	34686		10.1074/jbc.M606296200	http://dx.doi.org/10.1074/jbc.M606296200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973615	hybrid			2022-12-25	WOS:000241767600086
J	Liu, H; Liu, L; Fletcher, BS; Visner, GA				Liu, Hanzhong; Liu, Li; Fletcher, Bradley S.; Visner, Gary A.			Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis	FASEB JOURNAL			English	Article						lung transplantation; nonviral gene therapy	BRONCHIOLITIS OBLITERANS SYNDROME; GROWTH-FACTOR-BETA; TRANSPLANT RECIPIENTS; PHENOTYPIC CORRECTION; ACTIVE GENES; LAVAGE FLUID; TRYPTOPHAN; RISK; INTEGRATION; TRANSPOSON	Sleeping Beauty (SB) transposon is a natural nonviral gene transfer system that can mediate long-term transgene expression. Its potential utility in treating organ transplantation-associated long-term complications has not yet been explored. In the present study we generated an improved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that possesses both T cell-suppressive and antioxidant properties and selectively delivered the SB transposon in combination with a hyperactive transposase plasmid to donor lung using the cationic polymer polyethylenimine (PEI) as transfection reagent. This nonviral gene therapeutic approach led to persistent and uniform transgene expression in the rat lung tissue without noticeable toxicity and inflammation. Importantly, IDO activity produced by hIDO transgene showed a remarkable therapeutic response, as evident by near normal pulmonary function ( peak airway pressure and oxygenation), histological appearance, and reduced collagen content in lung allografts. In addition, we established a hIDO-overexpressing type II cell line using the SB-based gene transfer system and found that hIDO-overexpressing lung cells effectively inhibited transforming growth factor-beta-stimulated fibroblast proliferation in vitro. In summary, the SB-based gene therapy with hIDO represents a new strategy for treating lung transplantation-associated chronic complications, e.g., obliterative bronchiolitis.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA; Dept Vet Affairs Med Ctr, Med Res Serv, Gainesville, FL USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; State University System of Florida; University of Florida	Visner, GA (corresponding author), Childrens Hosp Philadelphia, Div Pulm Med, 34th & Civic Ctr Blvd,Abramson Res Bldg,916D, Philadelphia, PA 19104 USA.	visner@email.chop.edu	Marzocchi, Warner/J-9299-2012	Marzocchi, Warner/0000-0002-9114-1516				Baus J, 2005, MOL THER, V12, P1148, DOI 10.1016/j.ymthe.2005.06.484; de Lima MCP, 2003, CURR MED CHEM, V10, P1221, DOI 10.2174/0929867033457430; de Perrot M, 2003, AM J RESP CELL MOL, V28, P616, DOI 10.1165/rcmb.2002-0109OC; DiGiovine B, 1996, J IMMUNOL, V157, P4194; El-Gamel A, 1999, J HEART LUNG TRANSPL, V18, P828, DOI 10.1016/S1053-2498(99)00047-9; Elssner A, 2000, TRANSPLANTATION, V70, P362, DOI 10.1097/00007890-200007270-00022; Estenne M, 2002, AM J RESP CRIT CARE, V166, P440, DOI 10.1164/rccm.200201-003PP; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hirsch J, 1999, AM J RESP CRIT CARE, V160, P1640, DOI 10.1164/ajrccm.160.5.9902012; Hopkins PM, 2004, AM J RESP CRIT CARE, V170, P1022, DOI 10.1164/rccm.200302-165oc; Husain AN, 1999, AM J RESP CRIT CARE, V159, P829, DOI 10.1164/ajrccm.159.3.9607099; Izsvak Z, 2004, MOL THER, V9, P147, DOI 10.1016/j.ymthe.2003.11.009; Jia SF, 2003, CLIN CANCER RES, V9, P3462; Khalifah AP, 2004, AM J RESP CRIT CARE, V170, P181, DOI 10.1164/rccm.200310-1359OC; Khalifah AP, 2005, AM J TRANSPLANT, V5, P2022, DOI 10.1111/j.1600-6143.2005.00953.x; Koshkina NV, 2003, MOL THER, V8, P249, DOI 10.1016/S1525-0016(03)00177-1; Leuchte HH, 2004, AM J RESP CRIT CARE, V170, P360, DOI 10.1164/rccm.200308-1142OC; Liu HZ, 2006, AM J RESP CRIT CARE, V173, P566, DOI 10.1164/rccm.200509-1413OC; Liu HZ, 2005, AM J TRANSPLANT, V5, P1256, DOI 10.1111/j.1600-6143.2005.00876.x; Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006; Liu L, 2006, MOL THER, V13, P1006, DOI 10.1016/j.ymthe.2005.11.021; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Moffett JR, 2003, IMMUNOL CELL BIOL, V81, P247, DOI 10.1046/j.1440-1711.2003.t01-1-01177.x; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Neurohr C, 2005, AM J TRANSPLANT, V5, P2982, DOI 10.1111/j.1600-6143.2005.01103.x; Ohlfest JR, 2005, BLOOD, V105, P2691, DOI 10.1182/blood-2004-09-3496; Platten M, 2005, SCIENCE, V310, P850, DOI 10.1126/science.1117634; Riise GC, 1998, EUR RESPIR J, V12, P82, DOI 10.1183/09031936.98.12010082; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shoji F, 2003, GENE THER, V10, P213, DOI 10.1038/sj.gt.3301847; Swanson KA, 2004, AM J RESP CELL MOL, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Wilkes DS, 2005, AM J RESP CRIT CARE, V172, P944, DOI 10.1164/rccm.200501-098WS; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; YASUI H, 1986, P NATL ACAD SCI USA, V83, P6622, DOI 10.1073/pnas.83.17.6622; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100	37	67	70	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2384	+		10.1096/fj.06-6228fje	http://dx.doi.org/10.1096/fj.06-6228fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015408				2022-12-25	WOS:000241702600028
J	Zhang, L; Wang, C				Zhang, L.; Wang, C.			Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain	ONCOGENE			English	Article						oncogene; rhabdomyosarcoma; transcription; chromosomal translocation	ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; FUSION PROTEIN; MYOGENIN GENE; EXPRESSION; DIFFERENTIATION; EMBRYOGENESIS; ACTIVATION; CELLS; TRANSLOCATION	Alveolar rhabdomyosarcoma (aRMS), an aggressive skeletal muscle cancer, carries a unique t(2;13) chromosomal translocation resulting in the formation of a chimeric transcription factor PAX3-FKHR. This fusion protein contains the intact DNA-binding domains (PD:paired box binding domain; HD: paired-type homeodomain) of Pax3 fused to the activation domain of FKHR. Cells expressing Pax3 and PAX3-FKHR show vastly different gene expression patterns, despite that they share the same DNA-binding domains. We present evidence of a gain of function mechanism that allows the fusion protein to recognize and transcriptionally activate response elements containing a PD-specific binding site. This DNA recognition specificity is in contrast to the requirement for Pax3-specific target sequences that must contain a composite of PD-and HD-binding sites. Domain swapping studies suggest that an increased structural flexibility could account for the relaxed DNA targeting specificity in PAX3-FKHR. Here, we identify myogenin gene as a direct target of PD- dependent PAX3-FKHR activation pathway in vitro and in vivo. We demonstrate that PAX3-FKHR could induce myogenin expression in undifferentiated myoblasts by a MyoD independent pathway, and that PAX3-FKHR is directly involved in myogenin expression in aRMS cells.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,Room 530E,M-C 860, Chicago, IL 60612 USA.	chiayeng@uic.edu			NATIONAL CANCER INSTITUTE [R01CA074907, R29CA074907] Funding Source: NIH RePORTER; NCI NIH HHS [CA074907, R29 CA074907, R01 CA074907, R01 CA074907-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; De Pitta C, 2006, INT J CANCER, V118, P2772, DOI 10.1002/ijc.21698; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Folpe AL, 2002, ADV ANAT PATHOL, V9, P198, DOI 10.1097/00125480-200205000-00003; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hostein I, 2004, CANCER-AM CANCER SOC, V101, P2817, DOI 10.1002/cncr.20711; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Lam PYP, 1999, MOL CELL BIOL, V19, P594; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; Michelagnoli MP, 2003, MED PEDIATR ONCOL, V40, P1, DOI 10.1002/mpo.10201; Puri PL, 2000, GENE DEV, V14, P574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Wang-Wuu S, 1988, Cancer Res, V48, P983; Weintraub M, 1997, Sarcoma, V1, P135, DOI 10.1080/13577149778218; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286	39	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1595	1605		10.1038/sj.onc.1209958	http://dx.doi.org/10.1038/sj.onc.1209958			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964289	Green Accepted			2022-12-25	WOS:000244782500009
J	Karp, CM; Shukla, MN; Buckley, DJ; Buckley, AR				Karp, C. M.; Shukla, M. N.; Buckley, D. J.; Buckley, A. R.			HRPAP20: a novel calmodulin-binding protein that increases breast cancer cell invasion	ONCOGENE			English	Article						HRPAP20; calmodulin; MMP-9; tumor invasion; metastasis; breast cancer	MMP-9 IMMUNOREACTIVE PROTEIN; LIGHT-CHAIN KINASE; IN-VITRO; TARGET RECOGNITION; PROGNOSTIC VALUE; TUMOR-CELLS; MATRIX; EXPRESSION; GROWTH; IDENTIFICATION	We previously reported the identification of HRPAP20 (hormone-regulated proliferation-associated protein 20), a novel hormone-regulated, proliferation-associated protein. In tumor cell lines, constitutive HRPAP20 expression enhanced proliferation and suppressed apoptosis, characteristics frequently associated with malignant progression. Here, we report that highly invasive breast cancer cell lines and human breast tumor specimens express elevated HRPAP20, which in transfection experiments in MCF-7 and MDA-MB-231 cells, increased invasion. Results from mechanistic studies revealed that HRPAP20 bound to calmodulin (CaM) via a conserved CaM-binding motif. Transfection of MCF-7 breast cancer cells with HRPAP20 harboring a mutated CaM-binding motif (HRPAP20K73A) inhibited its interaction with CaM and failed to increase invasion. Other experiments revealed that transfection with HRPAP20, but not HRPAP20K73A, increased secretion of matrix metallo-proteinase-9 (MMP-9). Moreover, knockdown of HRPAP20 with small interfering RNA in MCF-7/HRPAP20 transfectants and wild-type MDA-MB-231 cells reduced invasion and inhibited secretion of MMP-9. Together these observations suggest that HRPAP20 may be an important regulator of breast tumor cell invasion by a CaM-mediated mechanism that leads to increased MMP-9 secretion. We conclude that dysregulation of HRPAP20 expression in tumor cells may contribute to the observed phenotypic changes associated with breast cancer progression.	Univ Cincinnati, Acad Hlth Ctr, Coll Pharm, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Buckley, AR (corresponding author), Univ Cincinnati, Acad Hlth Ctr, Coll Pharm, 3223 Eden Ave, Cincinnati, OH 45267 USA.	arthur.buckley@uc.edu						Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; ALBINI A, 1987, CANCER RES, V47, P3239; ARAFAH BM, 1986, CANCER RES, V46, P3268; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; Bartsch JE, 2003, J SURG RES, V110, P383, DOI 10.1016/S0022-4804(03)00007-6; Boehning D, 2004, J BIOL CHEM, V279, P30927, DOI 10.1074/jbc.C400222200; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Di Carlo A, 2005, INT J ONCOL, V26, P1363; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Ellis MJ, 2003, ADV EXP MED BIOL, V532, P223; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; Garbett EA, 2000, J CLIN PATHOL-MOL PA, V53, P99, DOI 10.1136/mp.53.2.99; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Haupt LM, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-18; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Karp CM, 2004, CANCER RES, V64, P1016, DOI 10.1158/0008-5472.CAN-03-0023; La Rocca G, 2004, BRIT J CANCER, V90, P1414, DOI 10.1038/sj.bjc.6601725; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; Li HC, 2004, BREAST CANCER RES TR, V88, P75, DOI 10.1007/s10549-004-1200-8; Mariani G, 2005, ANN ONCOL, V16, P191, DOI 10.1093/annonc/mdi719; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; MIYAZAKI K, 1994, NATURE, V368, P695, DOI 10.1038/368695b0; MURPHY G, 1989, INT J CANCER, V44, P757, DOI 10.1002/ijc.2910440434; NAKAJIMA M, 1987, CANCER RES, V47, P4869; Paquette B, 2005, INT J CANCER, V113, P706, DOI 10.1002/ijc.20647; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; PRZYBLOWSKA K, BREAST CANC RES TREA, V95, P65; Rahko E, 2004, ANTICANCER RES, V24, P4247; Ranuncolo SM, 2003, INT J CANCER, V106, P745, DOI 10.1002/ijc.11288; REICH R, 1988, CANCER RES, V48, P3307; REPESH LA, 1989, INVAS METAST, V9, P192; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Schmitt M, 1990, Blood Coagul Fibrinolysis, V1, P695; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Subramaniam Deepa S, 2005, Curr Treat Options Oncol, V6, P147, DOI 10.1007/s11864-005-0022-1; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Talvensaari-Mattila A, 2005, CANCER LETT, V217, P237, DOI 10.1016/j.canlet.2004.06.056; Weigelt B, 2004, BRIT J CANCER, V90, P1531, DOI 10.1038/sj.bjc.6601659; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	45	17	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1780	1788		10.1038/sj.onc.1209980	http://dx.doi.org/10.1038/sj.onc.1209980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001319				2022-12-25	WOS:000244955600012
J	Lindtner, S; Zolotukhin, AS; Uranishi, H; Bear, J; Kulkarni, V; Smulevitch, S; Samiotaki, M; Panayotou, G; Felber, BK; Pavlakis, GN				Lindtner, Susan; Zolotukhin, Andrei S.; Uranishi, Hiroaki; Bear, Jenifer; Kulkarni, Viraj; Smulevitch, Sergey; Samiotaki, Martina; Panayotou, George; Felber, Barbara K.; Pavlakis, George N.			RNA-binding motif protein 15 binds to the RNA transport element RTE and provides a direct link to the NXF1 export pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MEDIATED POSTTRANSCRIPTIONAL REGULATION; SIMIAN RETROVIRUS TYPE-1; EXON JUNCTION COMPLEX; INTRON-CONTAINING RNA; VIRAL MESSENGER-RNA; NUCLEAR EXPORT; MAMMALIAN-CELLS; MEGAKARYOBLASTIC LEUKEMIA; NUCLEOCYTOPLASMIC EXPORT	Retroviruses/retroelements provide tools enabling the identification and dissection of basic steps for post-transcriptional regulation of cellular mRNAs. The RNA transport element (RTE) identified in mouse retrotransposons is functionally equivalent to constitutive transport element of Type D retroviruses, yet does not bind directly to the mRNA export receptor NXF1. Here, we report that the RNA-binding motif protein 15 (RBM15) recognizes RTE directly and specifically in vitro and stimulates export and expression of RTE-containing reporter mRNAs in vivo. Tethering of RBM15 to a reporter mRNA showed that RBM15 acts by promoting mRNA export from the nucleus. We also found that RBM15 binds to NXF1 and the two proteins cooperate in stimulating RTE-mediated mRNA export and expression. Thus, RBM15 is a novel mRNA export factor and is part of the NXF1 pathway. We propose that RTE evolved as a high affinity RBM15 ligand to provide a splicing-independent link to NXF1, thereby ensuring efficient nuclear export and expression of retrotransposon transcripts.	NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Canc Res Ctr,NIH, Ft Detrick, MD 21702 USA; NCI, Human Retrovirus Sect, Vaccine Branch, Canc Res Ctr,NIH, Ft Detrick, MD 21702 USA; Alexander Fleming Biomed Sci Res Ctr, Vari 16672, Greece	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Alexander Fleming Biomedical Sciences Research Center	Felber, BK (corresponding author), NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Canc Res Ctr,NIH, Bldg 535,Rm 209, Ft Detrick, MD 21702 USA.	felber@ncifcrf.gov	Samiotaki, Martina/B-3851-2018	Samiotaki, Martina/0000-0001-9952-0636	DIVISION OF BASIC SCIENCES - NCI [Z01BC010397] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010750, Z01BC010750, ZIABC010334, Z01BC010334] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariyoshi M, 2003, GENE DEV, V17, P1909, DOI 10.1101/gad.266203; Bear J, 1999, MOL CELL BIOL, V19, P6306; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; De Gregorio E, 2001, RNA, V7, P106, DOI 10.1017/S1355838201000577; Dewannieux M, 2004, NAT GENET, V36, P534, DOI 10.1038/ng1353; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Herold A, 2003, EMBO J, V22, P2472, DOI 10.1093/emboj/cdg233; Herold A, 2001, RNA, V7, P1768; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Hiriart E, 2005, J BIOL CHEM, V280, P36935, DOI 10.1074/jbc.M501725200; Hsiao HH, 2005, AM J HEMATOL, V79, P43, DOI 10.1002/ajh.20298; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; Huang YQ, 2005, MOL CELL, V17, P613, DOI 10.1016/j.molcel.2005.02.020; Huang YQ, 2004, P NATL ACAD SCI USA, V101, P9666, DOI 10.1073/pnas.0403533101; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Izaurralde Elisa, 2002, Results Probl Cell Differ, V35, P133; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Jin L, 2003, GENE DEV, V17, P3075, DOI 10.1101/gad.1155703; Kawaguchi H, 2005, LEUKEMIA, V19, P1492, DOI 10.1038/sj.leu.2403812; Lai MC, 2004, J BIOL CHEM, V279, P31745, DOI 10.1074/jbc.C400173200; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Levesque L, 2001, J BIOL CHEM, V276, P44953, DOI 10.1074/jbc.M106558200; Lindtner S, 2002, RNA, V8, P345, DOI 10.1017/S1355838202027759; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; Mercher T, 2002, GENE CHROMOSOME CANC, V33, P22, DOI 10.1002/gcc.1208; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Nappi F, 2001, J VIROL, V75, P4558, DOI 10.1128/JVI.75.10.4558-4569.2001; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; Saridaki A, 2005, GROWTH FACTORS, V23, P223, DOI 10.1080/08977190500178836; Sasaki M, 2005, GENOMICS, V85, P641, DOI 10.1016/j.ygeno.2005.01.003; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Smulevitch S, 2005, J VIROL, V79, P2356, DOI 10.1128/JVI.79.4.2356-2365.2005; Smulevitch S, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-6; Srinivasakumar N, 1997, J VIROL, V71, P5841, DOI 10.1128/JVI.71.8.5841-5848.1997; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Tabernero C, 1997, J VIROL, V71, P95, DOI 10.1128/JVI.71.1.95-101.1997; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; Tan W, 2005, NUCLEIC ACIDS RES, V33, P3855, DOI 10.1093/nar/gki706; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Tang HL, 2000, J BIOL CHEM, V275, P32694, DOI 10.1074/jbc.M003933200; Tang HL, 1997, VIROLOGY, V228, P333, DOI 10.1006/viro.1996.8407; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Tretyakova I, 2005, J BIOL CHEM, V280, P31981, DOI 10.1074/jbc.M502736200; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Yang JP, 2001, J BIOL CHEM, V276, P30694, DOI 10.1074/jbc.M102809200; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994; Zolotukhin AS, 2003, MOL CELL BIOL, V23, P6618, DOI 10.1128/MCB.23.18.6618-6630.2003; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200; Zolotukhin AS, 1997, J BIOL CHEM, V272, P11356, DOI 10.1074/jbc.272.17.11356	78	47	49	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36915	36928		10.1074/jbc.M608745200	http://dx.doi.org/10.1074/jbc.M608745200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17001072	hybrid			2022-12-25	WOS:000242220800051
J	Hayashi, R; Goto, Y; Ikeda, R; Yokoyama, KK; Yoshida, K				Hayashi, Reiko; Goto, Yuya; Ikeda, Ryuji; Yokoyama, Kazunari K.; Yoshida, Kenichi			CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; IN-VIVO; REPRESSES TRANSCRIPTION; GROWTH SUPPRESSION; CYCLE PROGRESSION; GENE-PRODUCT; TARGET GENES; TRIP-BR	The TRIP-Br1/p34(SEI-1) family proteins participate in cell cycle progression by coactivating E2F1- or p53-dependent transcriptional activation. Here, we report the identification of human CDCA4 ( also know as SEI-3/Hepp) as a novel target gene of transcription factor E2F and as a repressor of E2F-dependent transcriptional activation. Analysis of CDCA4 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the E2F1-4 induced activation of CDCA4 gene transcription. Chromatin immunoprecipitation analysis demonstrated that E2F1 and E2F4 bound to an E2F-responsive sequence of the human CDCA4 gene. Like TRIP-Br1/p34SEI-1 and TRIP-Br2 (SEI-2), the transactivation domain of CDCA4 was mapped within C-terminal acidic region 175-241. The transactivation function of the CDCA4 protein was inhibited by E2F1-4 and DP2, but not by E2F5-8. Inhibition of CDCA4 transactivation activity by E2F1 partially interfered with retinoblastoma protein overexpression. Conversely, CDCA4 suppressed E2F1-3-induced reporter activity. CDCA4 ( but not acidic region-deleted CDCA4) suppressed E2F1- regulated gene promoter activity. These findings suggest that the CDCA4 protein functions as a suppressor at the E2F-responsive promoter. Small interfering RNA-mediated knockdown of CDCA4 expression in cancer cells resulted in up-regulation of cell growth rates and DNA synthesis. The CDCA4 protein was detected in several human cells and was induced as cells entered the G(1)/S phase of the cell cycle. Taken together, our results suggest that CDCA4 participates in the regulation of cell proliferation, mainly through the E2F/retinoblastoma protein pathway.	Meiji Univ, Sch Agr, Dept Life Sci, Mol & Cellular Biol Lab,Tama Ku, Kawasaki, Kanagawa 2148571, Japan; Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, Kagoshima 8908520, Japan; RIKEN, Tsukuba Inst, Bioresource Ctr, Dept Biol Syst,Gene Engn Div, Tsukuba, Ibaraki 3050074, Japan	Meiji University; Kagoshima University; RIKEN	Yoshida, K (corresponding author), Meiji Univ, Sch Agr, Dept Life Sci, Mol & Cellular Biol Lab,Tama Ku, 1-1-1 Higashimita, Kawasaki, Kanagawa 2148571, Japan.	yoshida@isc.meiji.ac.jp						Abdullah JM, 2001, BLOOD CELL MOL DIS, V27, P667, DOI 10.1006/bcmd.2001.0434; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Bennetts JS, 2006, GENE, V374, P153, DOI 10.1016/j.gene.2006.01.027; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Calgaro S, 2002, GENETICS, V160, P547; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Cho JM, 2000, NUCLEIC ACIDS RES, V28, P3478, DOI 10.1093/nar/28.18.3478; Christensen J, 2005, NUCLEIC ACIDS RES, V33, P5458, DOI 10.1093/nar/gki855; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Goto Y, 2006, BBA-GENE STRUCT EXPR, V1759, P60, DOI 10.1016/j.bbaexp.2006.02.004; Gupta S, 2003, VIROLOGY, V317, P155, DOI 10.1016/j.virol.2003.08.008; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hirose T, 2003, INT J MOL MED, V11, P705; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KITAGAWA M, 1995, ONCOGENE, V10, P229; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Li J, 2004, BIOCHEMISTRY-US, V43, P4394, DOI 10.1021/bi035601s; Li JN, 2005, BIOCHEMISTRY-US, V44, P13246, DOI 10.1021/bi0504658; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Logan N, 2005, ONCOGENE, V24, P5000, DOI 10.1038/sj.onc.1208703; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAY E, 1991, ONCOGENE, V6, P1363; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sim KG, 2004, CELL CYCLE, V3, P1296, DOI 10.4161/cc.3.10.1157; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; TAKAHASHI Y, 2002, GENE DEV, V14, P804; Takashima T, 1997, INT J CANCER, V72, P31, DOI 10.1002/(SICI)1097-0215(19970703)72:1<31::AID-IJC4>3.0.CO;2-5; Tang DJ, 2005, CANCER RES, V65, P6504, DOI 10.1158/0008-5472.CAN-05-0351; Tang TCM, 2002, CANCER RES, V62, P7157; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Walker MG, 2001, CURR CANCER DRUG TAR, V1, P73, DOI 10.2174/1568009013334241; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Watanabe-Fukunaga R, 2005, GENES CELLS, V10, P851, DOI 10.1111/j.1365-2443.2005.00881.x; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yoshida K, 2005, BIOCHEM BIOPH RES CO, V331, P669, DOI 10.1016/j.bbrc.2005.03.222; Yoshida K, 2004, ONCOGENE, V23, P6250, DOI 10.1038/sj.onc.1207829; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488	76	58	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35633	35648		10.1074/jbc.M603800200	http://dx.doi.org/10.1074/jbc.M603800200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16984923	hybrid			2022-12-25	WOS:000242100500008
J	Montero, E; Gonzalez, LM; Rodriguez, M; Oksov, Y; Blackman, MJ; Lobo, CA				Montero, Estrella; Gonzalez, Luis Miguel; Rodriguez, Marilis; Oksov, Yelena; Blackman, Michael J.; Lobo, Cheryl A.			A conserved subtilisin protease identified in Babesia divergens merozoites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL INVASION; TOXOPLASMA-GONDII; MALARIA PARASITE; SERINE-PROTEASE; DATABASE; DISEASE; ORGANELLES; INFECTION; SEQUENCE	Invasion of erythrocytes is an integral part of the Babesia divergens life cycle. Serine proteases have been shown to play an important role in invasion by related Apicomplexan parasites such as the malaria parasite Plasmodium falciparum. Here we demonstrate the presence of two dominant serine proteases in asexual B. divergens using a biotinylated fluorophosphonate probe. One of these active serine proteases (p48) and its precursors were recognized by anti-PfSUB1 antibodies. These antibodies were used to clone the gene encoding a serine protease using a B. divergens cDNA library. BdSub-1 is a single copy gene with no introns. The deduced gene product (BdSUB-1) clearly belongs to the subtilisin superfamily and shows significant homology to Plasmodium subtilisins, with the highest degree of sequence identity around the four catalytic residues. Like subtilisin proteases in other Apicomplexan parasites, BdSUB-1 undergoes two steps of processing during activation in the secretory pathway being finally converted to an active form ( p48). The mature protease is concentrated in merozoite dense granules, apical secretory organelles involved in erythrocyte invasion. Anti-PfSUB1 antibodies have a potent inhibitory effect on erythrocyte invasion by B. divergens merozoites in vitro. This report demonstrates conservation of the molecular machinery involved in erythrocyte invasion by these two Apicomplexan parasites and paves the way for a comparative analysis of other molecules that participate in this process in the two parasites.	New York Blood Ctr, Lindsley F Kimball Res Inst, Dept Mol Parasitol, New York, NY 10032 USA; Inst Salud Carlos III, Div Parasitol, Madrid 28220, Spain; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England	New York Blood Center; Instituto de Salud Carlos III; MRC National Institute for Medical Research	Lobo, CA (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Dept Mol Parasitol, 310 E 67th St, New York, NY 10032 USA.	clobo@nybloodcenter.org	Montero, Estrella/M-3648-2018; Gonzalez, Luis Miguel/O-6377-2018	Montero, Estrella/0000-0002-3852-960X; Gonzalez, Luis Miguel/0000-0002-9107-2450	MRC [MC_U117532063] Funding Source: UKRI; Medical Research Council [MC_U117532063] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barale JC, 1999, P NATL ACAD SCI USA, V96, P6445, DOI 10.1073/pnas.96.11.6445; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Blackman Michael J., 2000, Current Drug Targets, V1, P59, DOI 10.2174/1389450003349461; Blackman MJ, 2004, CELL MICROBIOL, V6, P893, DOI 10.1111/j.1462-5822.2004.00437.x; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; Carruthers VB, 2002, ACTA TROP, V81, P111, DOI 10.1016/S0001-706X(01)00201-7; DAMMIN GJ, 1981, HUM PATHOL, V12, P398, DOI 10.1016/S0046-8177(81)80020-2; DVORAK JA, 1975, SCIENCE, V187, P748, DOI 10.1126/science.803712; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; GARNHAM PCC, 1980, T ROY SOC TROP MED H, V74, P153, DOI 10.1016/0035-9203(80)90232-1; GORENFLOT A, 1991, PARASITOL RES, V77, P3, DOI 10.1007/BF00934377; Harris PK, 2005, PLOS PATHOG, V1, P241, DOI 10.1371/journal.ppat.0010029; Hermentin P, 1984, Behring Inst Mitt, P121; Herwaldt BL, 1996, ANN INTERN MED, V124, P643, DOI 10.7326/0003-4819-124-7-199604010-00004; Holman PJ, 2002, MOL BIOCHEM PARASIT, V119, P295, DOI 10.1016/S0166-6851(01)00423-6; Homer MJ, 2000, CLIN MICROBIOL REV, V13, P451, DOI 10.1128/CMR.13.3.451-469.2000; Jack R. M., 1981, Babesiosis. (Internat. Conf. on malaria and babesiosis, Mexico City, 30 Apr. -- 4 May 1979)., P445; Jean L, 2003, J BIOL CHEM, V278, P28572, DOI 10.1074/jbc.M303827200; Kim K, 2004, ACTA TROP, V91, P69, DOI 10.1016/j.actaropia.2003.11.016; Kjemtrup AM, 2000, INT J PARASITOL, V30, P1323, DOI 10.1016/S0020-7519(00)00137-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; Lantos PM, 2002, PEDIATR ANN, V31, P192, DOI 10.3928/0090-4481-20020301-10; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Lobo CA, 2005, INFECT IMMUN, V73, P649, DOI 10.1128/IAI.73.1.649-651.2005; Louie K, 1999, MOL BIOCHEM PARASIT, V103, P211, DOI 10.1016/S0166-6851(99)00127-9; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; McQuiston JH, 2000, TRANSFUSION, V40, P274, DOI 10.1046/j.1537-2995.2000.40030274.x; Miller SA, 2001, J BIOL CHEM, V276, P45341, DOI 10.1074/jbc.M106665200; PERSING DH, 1995, NEW ENGL J MED, V332, P298, DOI 10.1056/NEJM199502023320504; PRECIGOUT E, 1993, EXP PARASITOL, V77, P425, DOI 10.1006/expr.1993.1102; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Rudzinska M. A., 1981, Babesiosis. (Internat. Conf. on malaria and babesiosis, Mexico City, 30 Apr. -- 4 May 1979)., P87; RUEBUSH TK, 1977, NEW ENGL J MED, V297, P825, DOI 10.1056/NEJM197710132971511; Sajid M, 2000, J BIOL CHEM, V275, P631, DOI 10.1074/jbc.275.1.631; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; Withers-Martinez C, 2004, MOL MICROBIOL, V53, P55, DOI 10.1111/j.1365-2958.2004.04144.x; Withers-Martinez C, 2002, J BIOL CHEM, V277, P29698, DOI 10.1074/jbc.M203088200	39	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35717	35726		10.1074/jbc.M604344200	http://dx.doi.org/10.1074/jbc.M604344200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16982617	hybrid			2022-12-25	WOS:000242100500016
J	Yamamoto-Furusho, JK; Barnich, N; Xavier, R; Hisamatsu, T; Podolsky, DK				Yamamoto-Furusho, Jesus K.; Barnich, Nicolas; Xavier, Ramnik; Hisamatsu, Tadakazu; Podolsky, Daniel K.			Centaurin beta 1 down-regulates nucleotide-binding oligomerization domains 1- and 2-dependent NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; NOD2; EXPRESSION; INNATE; SUSCEPTIBILITY; PROTEINS; MUTATION; ERBIN; GENE	Centaurin beta 1 (CENTB1), a GTPase-activating protein, is a member of the ADP-ribosylation factor family encoded by a gene located on the short arm of human chromosome 17. A yeast two-hybrid screen first suggested a direct interaction between CENTB1 and NOD2. Co-immunoprecipitation experiments confirmed direct interaction between CENTB1 and NOD2 and demonstrated similar interaction between CENTB1 and NOD1. We also demonstrate that endogenous CENTB1 interacts with endogenous NOD2 and NOD1 in SW480 and HT-29 intestinal epithelial cells. CENTB1 partially co-localized with NOD2 and NOD1 proteins in the cytoplasm of mammalian cells. CENTB1 expression in epithelial cells was highly induced by tumor necrosis factor alpha,interleukin 1 beta, and the NOD1 and NOD2 ligands (gamma-D-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively). In addition, CENTB1 mRNA level is increased in the inflamed mucosa of patients with inflammatory bowel disease. Functionally, CENTB1 overexpression inhibited NOD1- and NOD2-dependent activation of NF-kappa B, whereas small inhibitory RNA against CENTB1 increased NF-kappa B activation following NOD1- or NOD2-mediated recognition of the bacterial components gamma-D-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively. In contrast, CENTB1 had no effect on NF-kappa B activation induced by Toll-like receptors. In conclusion, CENTB1 selectively down-regulates NF-kappa B activation via NODs pathways, creating a "feedback" loop and suggesting a novel role of CENTB1 in innate immune responses to bacteria and inflammatory responses.	Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Ctr Study Inflammatory Bowel Dis, 55 Fruit St, Boston, MA 02114 USA.	dpodolsky@partners.org	Yamamoto-Furusho, Jesus K./AAQ-4998-2020	Yamamoto-Furusho, Jesus K./0000-0002-5247-5812; Barnich, Nicolas/0000-0001-9465-7844	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069344, P30DK043351] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43351, DK069344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Barnich N, 2005, J BIOL CHEM, V280, P19021, DOI 10.1074/jbc.M413776200; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941; Elewaut D, 1999, J IMMUNOL, V163, P1457; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hayashi H, 2006, J BIOL CHEM, V281, P1332, DOI 10.1074/jbc.M505905200; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hisamatsu T, 2003, J BIOL CHEM, V278, P32962, DOI 10.1074/jbc.M304355200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kufer TA, 2006, INFECT IMMUN, V74, P3115, DOI 10.1128/IAI.00035-06; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Martin RK, 2005, BIOCHEM SOC T, V33, P1282, DOI 10.1042/BST0331282; McDonald C, 2005, J BIOL CHEM, V280, P40301, DOI 10.1074/jbc.M508538200; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Neurath MF, 1998, ANN NY ACAD SCI, V859, P149, DOI 10.1111/j.1749-6632.1998.tb11119.x; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Reiser G, 2004, NEUROREPORT, V15, P147, DOI 10.1097/00001756-200401190-00028; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092	34	61	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36060	36070		10.1074/jbc.M602383200	http://dx.doi.org/10.1074/jbc.M602383200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005562	hybrid			2022-12-25	WOS:000242100500055
J	Zhou, GL; Tucker, DF; Bae, SS; Bhatheja, K; Birnbaum, MJ; Field, J				Zhou, Guo-Lei; Tucker, David F.; Bae, Sun Sik; Bhatheja, Kanav; Birnbaum, Morris J.; Field, Jeffrey			Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE PAK1; ADAPTER PROTEIN; MICE LACKING; GROWTH; ACTIN; PHOSPHORYLATION; ACTIVATION; BINDING; SURVIVAL; MOTILITY	The Akt/PKB isoforms have different roles in animals, with Akt2 primarily regulating metabolic signaling and Akt1 regulating growth and survival. Here we show distinct roles for Akt1 and Akt2 in mouse embryo fibroblast cell migration and regulation of the cytoskeleton. Akt1-deficient cells responded poorly to platelet-derived growth factor while Akt2-deficient cells had a dramatically enhanced response, resulting in a substantial increase in dorsal ruffling. Swapping domains between Akt1 and Akt2 demonstrated that the N-terminal region containing the pleckstrin homology domain and a linker region distinguishes the two isoforms, while the catalytic domains are interchangeable. Akt2 knock-out cells also migrated faster than wild-type cells, especially through extracellular matrix (ECM), while Akt1 knock-out cells migrated more slowly than wild-type cells. Consistently, Akt2 knock-out cells had elevated Pak1 and Rac activities, suggesting that Akt2 inhibits Rac and Pak1. Both Akt2 and Akt1 associated in complexes with Pak1, but only Akt2 inhibited Pak1 in kinase assays, suggesting an underlying molecular basis for the different cellular phenotypes. Together these data provide evidence for an unexpected functional link between Akt2 and Pak1 that opposes the actions of Akt1 on cell migration.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Field, J (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 6320 Hamilton Walk, Philadelphia, PA 19104 USA.	field@pharm.med.upenn.edu		Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048241] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56886] Funding Source: Medline; NIGMS NIH HHS [R01 GM048241, GM48241] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROMBIE M, 1970, EXP CELL RES, V60, P437, DOI 10.1016/0014-4827(70)90537-9; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Alberts AS, 2005, J BIOL CHEM, V280, P12152, DOI 10.1074/jbc.M405073200; ALI SA, 1995, BIOTECHNIQUES, V18, P746; Arboleda MJ, 2003, CANCER RES, V63, P196; Arguinzonis MIG, 2002, J BIOL CHEM, V277, P45604, DOI 10.1074/jbc.M202873200; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Figueroa C, 2003, J BIOL CHEM, V278, P47922, DOI 10.1074/jbc.M307357200; Fryer BH, 2006, J BIOL CHEM, V281, P11487, DOI 10.1074/jbc.M600279200; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Menard RE, 2004, FEBS LETT, V556, P187, DOI 10.1016/S0014-5793(03)01406-6; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yuan ZQ, 2005, J BIOL CHEM, V280, P21483, DOI 10.1074/jbc.M500097200; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	59	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36443	36453		10.1074/jbc.M600788200	http://dx.doi.org/10.1074/jbc.M600788200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012749	hybrid			2022-12-25	WOS:000242100500095
J	Leifer, CA; Brooks, JC; Hoelzer, K; Lopez, J; Kennedy, MN; Mazzoni, A; Segal, DM				Leifer, Cynthia A.; Brooks, James C.; Hoelzer, Karin; Lopez, Jody; Kennedy, Margaret N.; Mazzoni, Alessandra; Segal, David M.			Cytoplasmic targeting motifs control localization of toll-like receptor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CPG-DNA; INTRACELLULAR COMPARTMENTS; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; DENDRITIC CELLS; CUTTING EDGE; DOMAIN; TLR9; RECOGNITION; ACTIVATION	Toll-like receptors (TLRs) are essential for host defense. Although several TLRs reside on the cell surface, nucleic acid recognition of TLRs occurs intracellularly. For example, the receptor for CpG containing bacterial and viral DNA, TLR9, is retained in the endoplasmic reticulum. Recent evidence suggests that the localization of TLR9 is critical for appropriate ligand recognition. Here we have defined which structural features of the TLR9 molecule control its intracellular localization. Both the cytoplasmic and ectodomains of TLR9 contain sufficient information, whereas the transmembrane domain plays no role in intracellular localization. We identify a 14-amino acid stretch that directs TLR9 intracellularly and confers intracellular localization to the normally cell surface-expressed TLR4. Truncation or mutation of the cytoplasmic tail of TLR9 reveals a vesicle localization motif that targets early endosomes. We propose a model whereby modification of the cytoplasmic tail of TLR9 results in trafficking to early endosomes where it encounters CpG DNA.	Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Leifer, CA (corresponding author), Cornell Univ, Coll Vet Med, VMC C5-153, Ithaca, NY 14853 USA.	cal59@cornell.edu	Hoelzer, Karin/A-8230-2010		Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [K22 CA113705-03, K22 CA113705] Funding Source: Medline; NIAID NIH HHS [T32 AI007643] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009255, K22CA113705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007643] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Bauer M, 2001, J IMMUNOL, V166, P5000, DOI 10.4049/jimmunol.166.8.5000; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gursel M, 2006, J IMMUNOL, V177, P1575, DOI 10.4049/jimmunol.177.3.1575; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Kajita E, 2006, BIOCHEM BIOPH RES CO, V343, P578, DOI 10.1016/j.bbrc.2006.03.014; Khan JA, 2004, J BIOL CHEM, V279, P31664, DOI 10.1074/jbc.M403434200; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Nishiya T, 2005, J BIOL CHEM, V280, P37107, DOI 10.1074/jbc.M504951200; Sanjuan MA, 2006, J CELL BIOL, V172, P1057, DOI 10.1083/jcb.200508058; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; UCHIYAMA T, 1981, J IMMUNOL, V126, P1398; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	31	74	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35585	35592		10.1074/jbc.M607511200	http://dx.doi.org/10.1074/jbc.M607511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990271	Green Accepted, hybrid			2022-12-25	WOS:000241933700091
J	Liu, Y; Wang, Y; Wu, C; Liu, Y; Zheng, P				Liu, Yan; Wang, Yin; Wu, Cindy; Liu, Yang; Zheng, Pan			Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3 beta phosphorylation, and Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MYOCLONUS EPILEPSY; DUAL-SPECIFICITY PHOSPHATASE; CARBOHYDRATE-BINDING DOMAIN; DISEASE; GLYCOGEN; MUTATIONS; ISOFORM; SUBUNIT; COMPLEX; TARGETS	Epilepsy of progressive myoclonus type 2 gene A (EPM2A) encodes a dual specificity protein phosphatase called Laforin. Laforin is also a tumor suppressor that dephosphorylates GSK3 beta at the critical Ser(9) position and regulates Wnt signaling. The epilepsy-causing mutations have a deleterious effect on phosphatase activity, regardless of whether they locate in the carbohydrate-binding domain (CBD) at the N terminus or the dual specificity phosphatase domain (DSPD) at the C terminus. How mutations outside the DSPD reduce the phosphatase activity of Laforin remains unexplained. Here we report that Laforin expressed in mammalian cells forms dimers that are highly resistant to SDS treatment. Deleting CBD completely abolished the dimerization and phosphatase activity of Laforin. Moreover, all of the naturally occurring Laforin mutations tested impaired laforin dimerization, GSK3 beta dephosphorylation at Ser(9) and beta-catenin accumulation in nucleus. Our results demonstrate a critical role of dimerization in Laforin function and suggest an important new dimension in protein phosphatase function and in molecular pathogenesis of Lafora's disease.	Univ Michigan, Program Mol Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; Ohio State University	Zheng, P (corresponding author), Univ Michigan, Program Mol Med, Dept Surg, Div Immunotherapy, Ann Arbor, MI 48109 USA.	panz@umich.edu	Zheng, Pan/E-8691-2011	Zheng, Pan/0000-0003-2598-3544; Liu, Yang/0000-0002-9442-700X				Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Cavanagh JB, 1999, BRAIN RES REV, V29, P265, DOI 10.1016/S0165-0173(99)00003-X; Chan EM, 2003, NAT GENET, V35, P125, DOI 10.1038/ng1238; Fernandez-Sanchez ME, 2003, HUM MOL GENET, V12, P3161, DOI 10.1093/hmg/ddg340; GAMBETTI P, 1971, ARCH NEUROL-CHICAGO, V25, P483, DOI 10.1001/archneur.1971.00490060017002; Ganesh S, 2000, HUM MOL GENET, V9, P2251, DOI 10.1093/oxfordjournals.hmg.a018916; Ganesh S, 2004, BIOCHEM BIOPH RES CO, V313, P1101, DOI 10.1016/j.bbrc.2003.12.043; Gentry MS, 2005, P NATL ACAD SCI USA, V102, P8501, DOI 10.1073/pnas.0503285102; Ianzano L, 2004, HUM MUTAT, V23, P170, DOI 10.1002/humu.10306; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Lohi H, 2005, HUM MOL GENET, V14, P2727, DOI 10.1093/hmg/ddi306; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; SCHWARZ GA, 1965, ARCH NEUROL-CHICAGO, V13, P427, DOI 10.1001/archneur.1965.00470040093015; Stanton T, 2003, P NATL ACAD SCI USA, V100, P5997, DOI 10.1073/pnas.0931490100; Wang JY, 2002, J BIOL CHEM, V277, P2377, DOI 10.1074/jbc.C100686200; Wang Y, 2006, CANCER CELL, V10, P179, DOI 10.1016/j.ccr.2006.08.008; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Worby CA, 2006, J BIOL CHEM, V281, P30412, DOI 10.1074/jbc.M606117200; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822	21	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34768	34774		10.1074/jbc.M607778200	http://dx.doi.org/10.1074/jbc.M607778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16971387	hybrid			2022-12-25	WOS:000241933700008
J	Scott, DJ; Layfield, S; Yan, Y; Sudo, S; Hsueh, AJW; Tregear, GW; Bathgate, RAD				Scott, Daniel J.; Layfield, Sharon; Yan, Yan; Sudo, Satoko; Hsueh, Aaron J. W.; Tregear, Geoffrey W.; Bathgate, Ross A. D.			Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST BINDING; MONOCLONAL-ANTIBODIES; PASSIVE-IMMUNIZATION; MYOMETRIAL ACTIVITY; MESSENGER-RNA; RAT RELAXIN; H3 RELAXIN; CLONING; EXPRESSION; PREGNANCY	The relaxin and insulin-like peptide 3 receptors, LGR7 and LGR8, respectively, are unique members of the leucine-rich repeat-containing G-protein-coupled receptor (LGR) family, because they possess an N-terminal motif with homology to the low density lipoprotein class A (LDLa) modules. By characterizing several LGR7 and LGR8 splice variants, we have revealed that the LDLa module directs ligand-activated cAMP signaling. The LGR8-short variant encodes an LGR8 receptor lacking the LDLa module, whereas LGR7-truncate, LGR7-truncate-2, and LGR7-truncate-3 all encode truncated secreted proteins retaining the LGR7 LDLa module. LGR8-short and an engineered LGR7 variant missing its LDLa module, LGR7-short, bound to their respective ligands with high affinity but lost their ability to signal via stimulation of intracellular cAMP accumulation. Conversely, secreted LGR7-truncate protein with the LDLa module was able to block relaxin-induced LGR7 cAMP signaling and did so without compromising the ability of LGR7 to bind to relaxin or be expressed on the cell membrane. Although the LDLa module of LGR7 was N-glycosylated at position Asn-14, an LGR7 N14Q mutant retained relaxin binding affinity and cAMP signaling, implying that glycosylation is not essential for optimal LDLa function. Using real-time PCR, the expression of mouse LGR7-truncate was detected to be high in, and specific to, the uterus of pregnant mice. The differential expression and evolutionary conservation of LGR7-truncate further suggests that it may also play an important role in vivo. This study highlights the essential role of the LDLa module in LGR7 and LGR8 function and introduces a novel model of GPCR regulation.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; Stanford Univ, Sch Med, Div Reprod Biol, Dept Obstet & Gynecol, Stanford, CA 94305 USA; Peking Univ, Coll Life Sci, Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Stanford University; Peking University	Bathgate, RAD (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia.	r.bathgate@hfi.unimelb.edu.au	Yan, Yan/A-3720-2009; Scott, Daniel J/B-9880-2017; Bathgate, Ross/ABE-6471-2020	Yan, Yan/0000-0003-2938-4063; Scott, Daniel J/0000-0001-6332-2793; Bathgate, Ross/0000-0001-6301-861X				Bathgate R. A. D., 2006, PHYSL REPROD, P679; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Burger LL, 1998, ENDOCRINOLOGY, V139, P3984, DOI 10.1210/en.139.9.3984; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Devlin MG, 2002, J NEUROCHEM, V80, P1095, DOI 10.1046/j.0022-3042.2002.00797.x; DOWNING SJ, 1980, BIOL REPROD, V23, P899, DOI 10.1095/biolreprod23.5.899; Fu P, 2004, J PEPT RES, V63, P91, DOI 10.1111/j.1399-3011.2003.00118.x; Goldsmith LT, 2004, P NATL ACAD SCI USA, V101, P4685, DOI 10.1073/pnas.0400776101; GRAVES PN, 1992, BIOCHEM BIOPH RES CO, V187, P1135, DOI 10.1016/0006-291X(92)91315-H; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; Hann V, 2004, INFLAMM RES, V53, pS67, DOI 10.1007/s00011-003-0332-3; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Huang CJ, 1997, ANIM REPROD SCI, V46, P149, DOI 10.1016/S0378-4320(96)01593-X; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; HWANG JJ, 1991, ENDOCRINOLOGY, V129, P3034, DOI 10.1210/endo-129-6-3034; Hwang JJ, 1996, J CLIN ENDOCR METAB, V81, P3379, DOI 10.1210/jc.81.9.3379; Kawamura K, 2004, P NATL ACAD SCI USA, V101, P7323, DOI 10.1073/pnas.0307061101; Kraaij R, 1998, J ENDOCRINOL, V158, P127, DOI 10.1677/joe.0.1580127; KUENZI MJ, 1992, ENDOCRINOLOGY, V131, P1841, DOI 10.1210/en.131.4.1841; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Min GS, 1997, ENDOCRINOLOGY, V138, P560, DOI 10.1210/en.138.2.560; Misrahi M, 1996, MOL CELL ENDOCRINOL, V125, P161, DOI 10.1016/S0303-7207(96)03953-6; Muda M, 2005, MOL HUM REPROD, V11, P591, DOI 10.1093/molehr/gah205; Nakamura K, 2004, MOL ENDOCRINOL, V18, P1461, DOI 10.1210/me.2003-0489; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Palejwala S, 2001, ENDOCRINOLOGY, V142, P3405, DOI 10.1210/en.142.8.3405; PORTER DG, 1971, J REPROD FERTIL, V26, P251; Rai T, 2005, J VIROL, V79, P14962, DOI 10.1128/JVI.79.23.14962-14966.2005; SCHLEGEL JR, 1986, BIOCHEM PHARMACOL, V35, P1943, DOI 10.1016/0006-2952(86)90725-2; Scott DJ, 2005, ANN NY ACAD SCI, V1041, P22, DOI 10.1196/annals.1282.005; Scott DJ, 2003, LETT PEPT SCI, V10, P393, DOI 10.1007/BF02442569; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; SZELE FG, 1993, MOL PHARMACOL, V43, P915; Tena-Sempere M, 1999, BIOL REPROD, V60, P1515, DOI 10.1095/biolreprod60.6.1515; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; Van Der Westhuizen ET, 2005, ANN NY ACAD SCI, V1041, P332, DOI 10.1196/annals.1282.053; Wilkinson T. N., 2005, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V5, P369, DOI 10.2174/156801305774322411; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14; WIQVIST N, 1959, Acta Endocrinol Suppl (Copenh), V32(Suppl 46), P15; Zhao L, 2000, BIOL REPROD, V63, P697, DOI 10.1095/biolreprod63.3.697; Zhao L, 1999, ENDOCRINOLOGY, V140, P445, DOI 10.1210/en.140.1.445; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	46	114	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34942	34954		10.1074/jbc.M602728200	http://dx.doi.org/10.1074/jbc.M602728200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16963451	hybrid			2022-12-25	WOS:000241933700027
J	Zhou, XY; Davis, DR; Sigmund, CD				Zhou, Xiyou; Davis, Deborah R.; Sigmund, Curt D.			The human renin kidney enhancer is required to maintain base-line renin expression but is dispensable for tissue-specific, cell-specific, and regulated expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; BLOOD-PRESSURE; MESSENGER-RNA; ANGIOTENSIN SYSTEM; DEFICIENT MICE; TRANSCRIPTION; PROMOTER; ELEMENTS; CAMP; IDENTIFICATION	Renin is the rate-limiting enzyme in the renin-angiotensin system and thus dictates the level of the pressor hormone angiotensinII. The classical site of renin expression and secretion is the renal juxtaglomerular cell, where its expression is tightly regulated by physiological cues. An evolutionarily conserved transcriptional enhancer located 11 kb upstream of the human RENIN gene has been reported to markedly enhance transcription in renin expressing cells in vitro. However, its importance in vivo remains unclear. We tested whether this enhancer is required for appropriate tissue- and cell-specific expression, or for physiological regulation of the human RENIN gene. To accomplish this, we used a retrofitting technique employing homologous recombination in bacteria to delete the enhancer from a 160-kb P1-artificial chromosome containing human RENIN, two upstream genes and one downstream gene, and then generated two lines of transgenic mice. We previously showed that human renin expression in transgenic mice containing the wild type construct is tightly regulated as is expression of the linked genes. Deletion of the enhancer had no effect on tissue- specific expression of human RENIN, but using the downstream gene as an internal control, found that human RENIN mRNA levels were 3-10-fold decreased compared with constructs containing the enhancer. Despite this decrease in expression, renin protein remained localized to renal juxtaglomerular cells and was appropriately regulated by cues that either increase or decrease expression of renin. Our results suggest that sequences other than the enhancer may be necessary for tissue- specific, cell-specific, and regulated expression of human RENIN.	Univ Iowa, Med Educ & Biomed Res Facil 3181B, Roy J & Lucille A Carver Coll Med, Mol & Cellular Biol Grad Program,Dept Internal Me, Iowa City, IA 52242 USA; Univ Iowa, Dept Mol Physiol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Sigmund, CD (corresponding author), Univ Iowa, Med Educ & Biomed Res Facil 3181B, Roy J & Lucille A Carver Coll Med, Mol & Cellular Biol Grad Program,Dept Internal Me, Iowa City, IA 52242 USA.	curt-sigmund@uiowa.edu	Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NHLBI NIH HHS [HL48058, HL61446, HL55006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006, R01HL048058, R37HL048058, R01HL061446] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams DJ, 2006, J BIOL CHEM, V281, P31753, DOI 10.1074/jbc.M605720200; Adams DJ, 2003, J BIOL CHEM, V278, P44894, DOI 10.1074/jbc.M307782200; AHU XG, 2000, MOL CELL BIOL, V20, P2604; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; Castrop H, 2006, PHYSIOL GENOMICS, V25, P277, DOI 10.1152/physiolgenomics.00302.2005; CHEN L, 2006, IN PRESS AM J PHYSL; Davisson RL, 1997, J CLIN INVEST, V99, P1258, DOI 10.1172/JCI119283; Germain S, 1998, J BIOL CHEM, V273, P25292, DOI 10.1074/jbc.273.39.25292; GILBERT MT, 1994, J BIOL CHEM, V269, P28049; Gribouval O, 2005, NAT GENET, V37, P964, DOI 10.1038/ng1623; Harris JM, 1997, MICROSC RES TECHNIQ, V39, P211, DOI 10.1002/(SICI)1097-0029(19971101)39:3<211::AID-JEMT2>3.0.CO;2-N; Jessen JR, 1998, P NATL ACAD SCI USA, V95, P5121, DOI 10.1073/pnas.95.9.5121; Keen HL, 2001, HYPERTENSION, V37, P403, DOI 10.1161/01.HYP.37.2.403; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; Klar J, 2005, HYPERTENSION, V46, P1340, DOI 10.1161/01.HYP.0000192025.86189.46; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Lavoie JL, 2004, AM J PHYSIOL-RENAL, V286, pF965, DOI 10.1152/ajprenal.00402.2003; LIU X, 2006, IN PRESS ENDOCRINOLO; Liu XB, 2003, CIRC RES, V92, P1033, DOI 10.1161/01.RES.0000071355.82009.43; Lochard N, 2003, J BIOL CHEM, V278, P2184, DOI 10.1074/jbc.M209933200; Lopez MLSS, 2004, DEV CELL, V6, P719; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; Nistala R, 2004, PHYSIOL GENOMICS, V17, P4, DOI 10.1152/physiolgenomics.00205.2003; Nistala R, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e41; Oliverio MI, 1998, AM J PHYSIOL-RENAL, V274, pF43, DOI 10.1152/ajprenal.1998.274.1.F43; Oliverio MI, 1997, AM J PHYSIOL-RENAL, V272, pF515, DOI 10.1152/ajprenal.1997.272.4.F515; Pan L, 2005, J BIOL CHEM, V280, P20860, DOI 10.1074/jbc.M414618200; Pan L, 2005, AM J PHYSIOL-RENAL, V288, pF117, DOI 10.1152/ajprenal.00333.2003; Pan L, 2003, BBA-GENE STRUCT EXPR, V1625, P280, DOI 10.1016/S0167-4781(03)00016-2; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; Shi Q, 2001, HYPERTENSION, V38, P332, DOI 10.1161/01.HYP.38.3.332; Shi Q, 2001, J BIOL CHEM, V276, P3597, DOI 10.1074/jbc.M008361200; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; Sinn PL, 2000, PHYSIOL GENOMICS, V3, P25, DOI 10.1152/physiolgenomics.2000.3.1.25; Sinn PL, 2000, V CH MO CAR, V1, P259; Sinn PL, 1999, AM J PHYSIOL-RENAL, V277, pF634, DOI 10.1152/ajprenal.1999.277.4.F634; Sinn PL, 1999, HYPERTENSION, V33, P900, DOI 10.1161/01.HYP.33.3.900; Sinn PL, 1999, J BIOL CHEM, V274, P35785, DOI 10.1074/jbc.274.50.35785; Sinn PL, 2000, REGUL PEPTIDES, V86, P77, DOI 10.1016/S0167-0115(99)00097-X; Skalweit A, 2003, CIRC RES, V92, P419, DOI 10.1161/01.RES.0000059300.67152.4E; SUN JD, 1994, CIRC RES, V75, P624, DOI 10.1161/01.RES.75.4.624; Takahashi N, 2005, J AM SOC NEPHROL, V16, P125, DOI 10.1681/ASN.2004060490; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; Todorov VT, 2005, J BIOL CHEM, V280, P24356, DOI 10.1074/jbc.M502968200; Todorov VT, 2004, J BIOL CHEM, V279, P1458, DOI 10.1074/jbc.M308697200; Tomita S, 1999, CIRC RES, V84, P1059, DOI 10.1161/01.RES.84.9.1059; Yan Y, 1998, HYPERTENSION, V32, P205, DOI 10.1161/01.HYP.32.2.205; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558; Zhang Y, 2001, MOL ENDOCRINOL, V15, P1891, DOI 10.1210/me.15.11.1891	53	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35296	35304		10.1074/jbc.M608055200	http://dx.doi.org/10.1074/jbc.M608055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990260	hybrid			2022-12-25	WOS:000241933700064
J	Goto, M; Hayashi, H; Miyahara, I; Hirotsu, K; Yoshida, M; Oikawa, T				Goto, Masaru; Hayashi, Hideyuki; Miyahara, Ikuko; Hirotsu, Ken; Yoshida, Masahiro; Oikawa, Tadao			Crystal structures of nonoxidative zinc-dependent 2,6-dihydroxybenzoate (gamma-resorcylate) decarboxylase from Rhizobium sp strain MTP-10005	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSIBLE 4-HYDROXYBENZOATE DECARBOXYLASE; 2,3-DIHYDROXYBENZOIC ACID DECARBOXYLASE; BINUCLEAR METAL CENTER; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; MOLECULAR-STRUCTURE; D-AMINOACYLASE; MALIC ENZYME; ACTIVE-SITE; PURIFICATION	Reversible 2,6-dihydroxybenzoate decarboxylase from Rhizobium sp. strain MTP-10005 belongs to a nonoxidative decarboxylase family. We have determined the structures of the following three forms of the enzyme: the native form, the complex with the true substrate (2,6-dihydroxybenzoate), and the complex with 2,3-dihydroxybenzaldehyde at 1.7-, 1.9-, and 1.7-angstrom resolution, respectively. The enzyme exists as a tetramer, and the subunit consists of one (alpha beta)(8) triose-phosphate isomerase-barrel domain with three functional linkers and one C-terminal tail. The native enzyme possesses one Zn2+ ion liganded by Glu(8), His(10), His(164), Asp(287), and a water molecule at the active site center, although the enzyme has been reported to require no cofactor for its catalysis. The substrate carboxylate takes the place of the water molecule and is coordinated to the Zn2+ ion. The 2-hydroxy group of the substrate is hydrogen-bonded to Asp(287), which forms a triad together with His(218) and Glu(221) and is assumed to be the catalytic base. On the basis of the geometrical consideration, substrate specificity is uncovered, and the catalytic mechanism is proposed for the novel Zn2+-dependent decarboxylation.	Osaka City Univ, Dept Chem, Grad Sch Sci, Osaka 5588585, Japan; Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan; Kansai Univ, Fac Engn, Dept Biotechnol, Osaka 5648680, Japan; Kansai Univ, High Technol Res Ctr, Osaka 5648680, Japan	Osaka Metropolitan University; Osaka Medical College; Kansai University; Kansai University	Hirotsu, K (corresponding author), Osaka City Univ, Dept Chem, Grad Sch Sci, Osaka 5588585, Japan.	hirotsu@sci.osaka-cu.ac.jp						ANDERSON JJ, 1981, J BACTERIOL, V146, P291, DOI 10.1128/JB.146.1.291-297.1981; Appleby TC, 2000, P NATL ACAD SCI USA, V97, P2005, DOI 10.1073/pnas.259441296; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benini S, 1998, J BIOL INORG CHEM, V3, P268, DOI 10.1007/s007750050231; BENNING MM, 1995, BIOCHEMISTRY-US, V34, P7973, DOI 10.1021/bi00025a002; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANDY JM, 1994, BIOCHEM J, V300, P7, DOI 10.1042/bj3000007; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; GRANT DJW, 1969, ANTON VAN LEE J M S, V35, P325, DOI 10.1007/BF02219153; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; He ZQ, 1996, J BACTERIOL, V178, P3539, DOI 10.1128/jb.178.12.3539-3543.1996; HE ZQ, 1995, EUR J BIOCHEM, V229, P77, DOI 10.1111/j.1432-1033.1995.tb20440.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Huang JB, 1999, J BACTERIOL, V181, P5119, DOI 10.1128/JB.181.16.5119-5122.1999; Ireton GC, 2002, J MOL BIOL, V315, P687, DOI 10.1006/jmbi.2001.5277; Ishii Y, 2004, BIOCHEM BIOPH RES CO, V324, P611, DOI 10.1016/j.bbrc.2004.09.091; IWAKURA M, 1979, J BIOCHEM-TOKYO, V85, P1355; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jozic D, 2003, J MOL BIOL, V332, P243, DOI 10.1016/S0022-2836(03)00845-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMATH AV, 1987, BIOCHEM BIOPH RES CO, V145, P586, DOI 10.1016/0006-291X(87)91361-1; Kishan KVR, 2005, J MOL BIOL, V347, P95, DOI 10.1016/j.jmb.2005.01.025; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lai WL, 2004, J BIOL CHEM, V279, P13962, DOI 10.1074/jbc.M308849200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liaw SH, 2003, J BIOL CHEM, V278, P4957, DOI 10.1074/jbc.M210795200; Martynowski D, 2006, BIOCHEMISTRY-US, V45, P10412, DOI 10.1021/bi060903q; MATSUI T, 2006, IN PRESS APPL MICROB; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller BG, 2000, P NATL ACAD SCI USA, V97, P2011, DOI 10.1073/pnas.030409797; NAKAMATSU T, 1993, Patent No. 0552912; NAKAZAWA T, 1978, APPL ENVIRON MICROB, V36, P264, DOI 10.1128/AEM.36.2.264-269.1978; Nitanai Y, 2002, J MOL BIOL, V321, P177, DOI 10.1016/S0022-2836(02)00632-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK SL, 1973, J BACTERIOL, V116, P263, DOI 10.1128/JB.116.1.263-270.1973; PUJAR BG, 1985, APPL ENVIRON MICROB, V49, P374, DOI 10.1128/AEM.49.2.374-376.1985; RAMACHANDRAN A, 1979, FEMS MICROBIOL LETT, V5, P421, DOI 10.1111/j.1574-6968.1979.tb03372.x; RECSEI PA, 1983, J BIOL CHEM, V258, P439; RECSEI PA, 1970, BIOCHEMISTRY-US, V9, P1492, DOI 10.1021/bi00809a003; REID J, 1951, BRIT MED J, V4727, P321; RIBBONS DW, 1960, BIOCHEM J, V76, P310, DOI 10.1042/bj0760310; SAGAWA M, 2000, Patent No. 12323016; Santha R, 1996, BBA-PROTEIN STRUCT M, V1293, P191, DOI 10.1016/0167-4838(95)00242-1; SANTHA R, 1995, EUR J BIOCHEM, V230, P104, DOI 10.1111/j.1432-1033.1995.0104i.x; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; Tao X, 2003, STRUCTURE, V11, P1141, DOI 10.1016/S0969-2126(03)00168-0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thoden JB, 2001, BIOCHEMISTRY-US, V40, P6989, DOI 10.1021/bi010682i; TOSHIMOTO M, 1996, Patent No. 08272035; Vincent F, 2004, J BIOL CHEM, V279, P2809, DOI 10.1074/jbc.M310165200; Wang ZM, 1998, BIOCHEMISTRY-US, V37, P8314, DOI 10.1021/bi980324o; WU JY, 1973, J BIOL CHEM, V248, P3029; Yoshida M, 2004, J BACTERIOL, V186, P6855, DOI 10.1128/JB.186.20.6855-6863.2004; Yoshida T, 2004, ARCH MICROBIOL, V181, P391, DOI 10.1007/s00203-004-0668-2	58	37	38	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34365	34373		10.1074/jbc.M607270200	http://dx.doi.org/10.1074/jbc.M607270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963440	hybrid			2022-12-25	WOS:000241767600057
J	Nojiri, H; Shimizu, T; Funakoshi, M; Yamaguchi, O; Zhou, H; Kawakami, S; Ohta, Y; Sami, M; Tachibana, T; Ishikawa, H; Kurosawa, H; Kahn, RC; Otsu, K; Shirasawa, T				Nojiri, Hidetoshi; Shimizu, Takahiko; Funakoshi, Masabumi; Yamaguchi, Osamu; Zhou, Heying; Kawakami, Satoru; Ohta, Yutaka; Sami, Manabu; Tachibana, Toshiaki; Ishikawa, Hiroshi; Kurosawa, Hisashi; Kahn, Ronald C.; Otsu, Kinya; Shirasawa, Takuji			Oxidative stress causes heart failure with impaired mitochondrial respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; GENE-EXPRESSION; MUTANT MICE; LIFE-SPAN; IN-VIVO; OXYGEN; APOPTOSIS; PROTEIN	Elderly people insidiously manifest the symptoms of heart failure, such as dyspnea and/or physical disabilities in an age-dependent manner. Although previous studies suggested that oxidative stress plays a pathological role in the development of heart failure, no direct evidence has been documented so far. In order to investigate the pathological significance of oxidative stress in the heart, we generated heart/muscle-specific manganese superoxide dismutase-deficient mice. The mutant mice developed progressive congestive heart failure with specific molecular defects in mitochondrial respiration. In this paper, we showed for the first time that the oxidative stress caused specific morphological changes of mitochondria, excess formation of superoxide (O-2(center dot)), reduction of ATP, and transcriptional alterations of genes associated with heart failure in respect to cardiac contractility. Accordingly, administration of a superoxide dismutase mimetic significantly ameliorated the symptoms. These results implied that O-2(center dot) generated in mitochondria played a pivotal role in the development and progression of heart failure. We here present a bona fide model for human cardiac failure with oxidative stress valuable for therapeutic interventions.	Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Itabashi Ku, Tokyo 1730015, Japan; Juntendo Univ, Sch Med, Dept Orthoped, Bunkyo Ku, Tokyo 1138421, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Asahi Brewery Co Ltd, Fundamental Res Lab, Moriya, Ibaraki 3020106, Japan; Jikei Univ, Sch Med, Dept Anat 2, Minato Ku, Tokyo 1058461, Japan; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Tokyo Univ Agr & Technol, United Grad Sch Agr Sci, Fuchu, Tokyo 1838509, Japan; Anti Aging Sci Inc, Chiyoda Ku, Tokyo 1000001, Japan	Tokyo Metropolitan Institute of Gerontology; Juntendo University; Tokyo Metropolitan University; Osaka University; Asahi Group Holdings Ltd.; Jikei University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Tokyo University of Agriculture & Technology	Shirasawa, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Itabashi Ku, 35-2 Sakaesho, Tokyo 1730015, Japan.	sirasawa@tmig.or.jp	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Yamaguchi, Osamu/0000-0002-7461-369X				Alameddine Fadi M F, 2002, Congest Heart Fail, V8, P157, DOI 10.1111/j.1527-5299.2002.00719.x; Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0; Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; BROQVIST M, 1994, EUR HEART J, V15, P1641, DOI 10.1093/oxfordjournals.eurheartj.a060447; BROWN JM, 1988, J CLIN INVEST, V81, P1297, DOI 10.1172/JCI113448; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; DiazVelez CR, 1996, AM HEART J, V131, P146, DOI 10.1016/S0002-8703(96)90063-0; Dieterich S, 2000, CIRCULATION, V101, P33, DOI 10.1161/01.CIR.101.1.33; Giordano FJ, 2005, J CLIN INVEST, V115, P500, DOI 10.1172/JCI200524408; Givertz MM, 1998, LANCET, V352, P34; Hiroi S, 1999, BIOCHEM BIOPH RES CO, V261, P332, DOI 10.1006/bbrc.1999.1036; Ide T, 2000, CIRC RES, V86, P152, DOI 10.1161/01.RES.86.2.152; Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529; Ikegami T, 2002, BIOCHEM BIOPH RES CO, V296, P729, DOI 10.1016/S0006-291X(02)00933-6; JABR RI, 1995, CIRC RES, V76, P812, DOI 10.1161/01.RES.76.5.812; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; Khaper N, 2003, MOL CELL BIOCHEM, V251, P9, DOI 10.1023/A:1025448908694; Kong BW, 2003, BBA-GENE STRUCT EXPR, V1625, P98, DOI 10.1016/S0167-4781(02)00593-6; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li J, 1999, J CELL BIOL, V147, P1391, DOI 10.1083/jcb.147.7.1391; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liew CC, 2004, NAT REV GENET, V5, P811, DOI 10.1038/nrg1470; Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 2001, J NEUROSCI, V21, P8348, DOI 10.1523/JNEUROSCI.21-21-08348.2001; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Morten KJ, 2006, J BIOL CHEM, V281, P3354, DOI 10.1074/jbc.M509261200; Nakai D, 2004, AGING CELL, V3, P273, DOI 10.1111/j.1474-9728.2004.00116.x; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Shimizu T, 2002, J NEUROSCI RES, V69, P341, DOI 10.1002/jnr.10301; Shirasawa T, 2003, J BIOL CHEM, V278, P5035, DOI 10.1074/jbc.M211110200; Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009; SUZUKI S, 1991, BIOCHIM BIOPHYS ACTA, V1074, P95, DOI 10.1016/0304-4165(91)90045-I; Tang WW, 2003, EXPERT OPIN INV DRUG, V12, P1791, DOI 10.1517/13543784.12.11.1791; Valenti L, 2004, J MED GENET, V41, P946, DOI 10.1136/jmg.2004.019588; Wallace Douglas C, 2002, Methods Mol Biol, V197, P3, DOI 10.1385/1-59259-284-8:003; Yamaguchi O, 2003, P NATL ACAD SCI USA, V100, P15883, DOI 10.1073/pnas.2136717100; Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661	45	169	172	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33789	33801		10.1074/jbc.M602118200	http://dx.doi.org/10.1074/jbc.M602118200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959785	hybrid			2022-12-25	WOS:000241621400085
J	Burgers, WA; Blanchon, L; Pradhan, S; de Launoit, Y; Kouzarides, T; Fuks, F				Burgers, W. A.; Blanchon, L.; Pradhan, S.; de Launoit, Y.; Kouzarides, T.; Fuks, F.			Viral oncoproteins target the DNA methyltransferases	ONCOGENE			English	Article						E1A; E7; Dnmt1; DNA methyltransferase; viral oncoproteins	RETINOBLASTOMA GENE-PRODUCT; CYTOSINE-5 METHYLTRANSFERASE; ACETYLTRANSFERASE ACTIVITY; CELLULAR-TRANSFORMATION; HISTONE DEACETYLASE; DE-NOVO; E1A; METHYLATION; TRANSCRIPTION; EXPRESSION	Small DNA tumour viruses have evolved a number of mechanisms to drive nondividing cells into S phase. Virally encoded oncoproteins such as adenovirus E1A and human papillomavirus (HPV) E7 can bind an array of cellular proteins to override proliferation arrest. The DNA methyltransferase Dnmt1 is the major mammalian enzyme responsible for maintaining CpG methylation patterns in the cell following replication. One of the hallmarks of tumour cells is disrupted DNA methylation patterns, highlighting the importance of the proper regulation of DNA methyltransferases in normal cell proliferation. Here, we show that adenovirus 5 E1A and HPV-16 E7 associate in vitro and in vivo with the DNA methyltransferase Dnmt1. Consistent with this interaction, we find that E1A and E7 can purify DNA methyltransferase activity from nuclear extracts. These associations are direct and mediated by the extreme N-terminus of E1A and the CR3 zinc-finger domain of E7. Furthermore, we find that a point mutant at leucine 20 of E1A, a residue known to be critical for its transformation functions, is unable to bind Dnmt1 and DNA methyltransferase activity. Finally, both E1A and E7 can stimulate the methyltransferase activity of Dnmt1 in vitro. Our results provide the first indication that viral oncoproteins bind and regulate Dnmt1 enzymatic activity. These observations open up the possibility that this association may be used to control cellular proliferation pathways and suggest a new mechanism by which small DNA tumour viruses can steer cells through the cell cycle.	Free Univ Brussels, Fac Med, Lab Canc Epigenet, B-1070 Brussels, Belgium; Univ Cambridge, CRUK Gurdon Inst, Wellcome Trust, Cambridge CB2 1TN, England; Univ Cape Town, Fac Hlth Sci, Div Med Virol, ZA-7925 Cape Town, South Africa; Univ Lille 1, CNRS, Inst Pasteur, Inst Biol Lille,UMR 8161, Lille, France; Univ Lille 2, CNRS, Inst Pasteur, Inst Biol Lille,UMR 8161, F-59800 Lille, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Cambridge; Wellcome Trust Sanger Institute; University of Cape Town; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Fuks, F (corresponding author), Free Univ Brussels, Fac Med, Lab Canc Epigenet, 808 Route Lennik, B-1070 Brussels, Belgium.	ffuks@ulb.ac.be		Burgers, Wendy/0000-0003-3396-9398; BLANCHON, LOIC/0000-0001-8842-0162; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust [092096] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gowher H, 2005, J BIOL CHEM, V280, P13341, DOI 10.1074/jbc.M413412200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; McCance DJ, 2005, CURR OPIN GENET DEV, V15, P515, DOI 10.1016/j.gde.2005.08.003; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; Ordway JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-19; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	24	194	202	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1650	1655		10.1038/sj.onc.1209950	http://dx.doi.org/10.1038/sj.onc.1209950			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983344	Green Accepted, Bronze			2022-12-25	WOS:000244782500015
J	Nieto, M; Barradas, M; Criado, LM; Flores, JM; Serrano, M; Llano, E				Nieto, M.; Barradas, M.; Criado, L. M.; Flores, J. M.; Serrano, M.; Llano, E.			Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1)	ONCOGENE			English	Article						Ris1; Ras; senescence; tumor suppression; mouse models	ONCOGENIC RAS; TUMOR SUPPRESSION; CARCINOGENESIS; IDENTIFICATION; TUMORIGENESIS; GENES; P53	Oncogenic Ras triggers a permanent cell-cycle arrest known as oncogene-induced senescence (OIS) that constitutes a relevant tumor suppressor mechanism. Ris1 (Ras-induced senescence-1) is a novel gene that was identified in a screen as specifically upregulated during Ras-induced senescence, and that is located at a chromosomal region, 3p21.3, frequently lost in human cancer. Moreover, Ris1 is highly conserved in vertebrates, does not present paralogs, and its sequence does not reveal similarities with other proteins or domains. To analyse the physiological function of Ris1 and test its putative role as a tumor suppressor gene, we have generated mutant mice deficient for this gene. Ris1-null mice are viable, fertile, develop normally and do not display any obvious abnormalities. Of relevance, Ris1-deficient mice had a normal lifespan and did not exhibit predisposition to spontaneous tumors or to tumors induced by chemical carcinogens. Finally, Ris1-deficient embryonic fibroblasts were indistinguishable from wild-type cells regarding their proliferation properties, immortalization, senescence and oncogenic transformation. These findings do not support a role of Ris1 in tumor suppression or in OIS.	Spanish Natl Canc Ctr, Dept Mol Oncol, CNIO, E-28029 Madrid, Spain; Spanish Natl Canc Ctr, Tumor Suppress Grp, CNIO, E-28029 Madrid, Spain; Univ Complutense, Sch Vet, Dept Anim Surg & Med, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr, Dept Mol Oncol, CNIO, 3 Melchor Fernandez Almagro St, E-28029 Madrid, Spain.	mserrano@cnio.es	Llano, Elena/K-1723-2014; Serrano, Manuel/H-2634-2015; Llano, Elena/AAS-5517-2021	Llano, Elena/0000-0002-2626-5723; Serrano, Manuel/0000-0001-7177-9312; Llano, Elena/0000-0002-2626-5723				Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Hama T, 2001, J BIOL CHEM, V276, P31929, DOI 10.1074/jbc.M100617200; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Petursdottir TE, 2004, GENE CHROMOSOME CANC, V41, P232, DOI 10.1002/gcc.20072; Qin ZH, 2002, J EXP MED, V195, P1479, DOI 10.1084/jem.20011887; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Silva J, 2006, MUTAT RES-FUND MOL M, V594, P78, DOI 10.1016/j.mrfmmm.2005.07.017; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Xiang RH, 2002, CANCER RES, V62, P2637	21	5	6	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1673	1680		10.1038/sj.onc.1209978	http://dx.doi.org/10.1038/sj.onc.1209978			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964279				2022-12-25	WOS:000244955600001
J	Rinaldo, F; Li, J; Wang, E; Muders, M; Datta, K				Rinaldo, F.; Li, J.; Wang, E.; Muders, M.; Datta, K.			RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation	ONCOGENE			English	Article						RalA; VEGF-C; androgen; reactive oxygen species; prostate cancer	LYMPH-NODE METASTASIS; TUMOR LYMPHANGIOGENESIS; OXIDATIVE STRESS; EPITHELIAL-CELLS; EXPRESSION; RAS; PATHWAY; INVOLVEMENT; ACTIVATION; RECEPTOR-3	Prostate cancer mortality is primarily due to failure to cure patients with metastatic disease. In its early stages, prostate cancer growth is enhanced by androgens. As such, the primary therapy for advanced (locally extensive or metastatic) prostate cancer consists of androgen deprivation therapy by pharmacotherapeutic or surgical means. Eventually, the tumor recurs owing to a transition from androgen-dependence to a highly metastatic and androgen refractory (androgen depletion-independent) phenotype. As the detailed molecular mechanism underlying this transition to a more aggressive phenotype is poorly understood, it has been difficult to develop effective treatments for this advanced stage of the disease. We have previously reported an increase in vascular endothelial growth factor-C (VEGF-C) express ion in human prostate cancer cells after androgen withdrawal. We have also shown increased expression of the androgen receptor coactivator BAG-1L by VEGF-C, suggesting the involvement of this growth factor in transactivation of the androgen receptor, even at low concentrations of androgen. In our present study, we show that androgen deprivation of human prostate carcinoma cells activates the small GTPase, RalA, a molecule important for human oncogenesis. RalA activation leads to VEGF-C upregulation. We also show that elevated levels of intracellular reactive oxygen species in prostate cancer cells under androgen-ablated conditions is the major inducer of RalA activation and VEGF-C synthesis.	Mayo Clin Fdn, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Datta, K (corresponding author), Mayo Clin Fdn, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, Gugg 1401B,200 1st St SW, Rochester, MN 55905 USA.	datta.kaustubh@mayo.edu	Muders, Michael/AAU-6443-2020		PHS HHS [1 PSOCA91956-3] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jennbacken K, 2005, PROSTATE, V65, P110, DOI 10.1002/pros.20276; Jia YT, 2004, WORLD J GASTROENTERO, V10, P3261, DOI 10.3748/wjg.v10.i22.3261; Karpanen T, 2001, CANCER RES, V61, P1786; Kimura Y, 2003, ONCOL REP, V10, P1747; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Li JP, 2005, ONCOGENE, V24, P5510, DOI 10.1038/sj.onc.1208693; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Neuchrist C, 2003, HEAD NECK-J SCI SPEC, V25, P464, DOI 10.1002/hed.10235; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Sipos B, 2004, AM J PATHOL, V165, P1187, DOI 10.1016/S0002-9440(10)63379-2; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Tam NNC, 2003, AM J PATHOL, V163, P2513, DOI 10.1016/S0002-9440(10)63606-1; Tchevkina E, 2005, ONCOGENE, V24, P329, DOI 10.1038/sj.onc.1208094; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Ulku AS, 2003, MOL CANCER RES, V1, P1077; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Zeng YP, 2005, PROSTATE, V65, P222, DOI 10.1002/pros.20288	30	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1731	1738		10.1038/sj.onc.1209971	http://dx.doi.org/10.1038/sj.onc.1209971			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964283				2022-12-25	WOS:000244955600007
J	Zucman-Rossi, J; Benhamouche, S; Godard, C; Boyault, S; Grimber, G; Balabaud, C; Cunha, AS; Bioulac-Sage, P; Perret, C				Zucman-Rossi, J.; Benhamouche, S.; Godard, C.; Boyault, S.; Grimber, G.; Balabaud, C.; Cunha, A. S.; Bioulac-Sage, P.; Perret, C.			Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; beta-catenin; Axin1; target genes; Wnt pathway	COLON-CARCINOMA; PROTEIN-KINASE; CYCLIN D1; GENE; COMPLEX; VIRUS; LIVER; IDENTIFICATION; EXPRESSION; FREQUENT	Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of b-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated b-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR) 49 and glutamate transporter (GLT)-1 (P = 0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of b-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. beta-Catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.	Univ Paris 05, INSERM, U567,Inst Cochin, CNRS,UMR 8104,Dept EMC,Fac Med Cochin Port Royal, F-75014 Paris, France; INSERM, U674, IFR105, CEPH, Paris, France; Ctr Hosp Univ Bordeaux, Dept Hepatol, Bordeaux, France; Ctr Hosp Univ Bordeaux, Hop Pellegrin, Serv Anat Pathol, Bordeaux, France; Univ Bordeaux 2, INSERM, E362, GREF, F-33076 Bordeaux, France; CHU Bordeaux, Hop St Andre, Serv Chirurg Digest, Bordeaux, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux	Perret, C (corresponding author), Univ Paris 05, INSERM, U567,Inst Cochin, CNRS,UMR 8104,Dept EMC,Fac Med Cochin Port Royal, 24,Bat Fac,Rue Faubourg St Jacques, F-75014 Paris, France.	perret@cochin.inserm.fr	Perret-Mayeux, Christine/L-3297-2017; j, zucman-rossi/AAV-3594-2021; cunha, antonio sa/B-5781-2012; zucman-rossi, Jessica/B-5098-2009	j, zucman-rossi/0000-0002-5687-0334; cunha, antonio sa/0000-0003-4015-5368; zucman-rossi, Jessica/0000-0002-5687-0334; Godard, Cecile/0000-0003-3016-0980; perret, christine/0000-0003-4710-7051				Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Miyoshi Y, 1998, CANCER RES, V58, P2524; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueta T, 2002, ONCOL REP, V9, P1197; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	26	191	196	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					774	780		10.1038/sj.onc.1209824	http://dx.doi.org/10.1038/sj.onc.1209824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16964294				2022-12-25	WOS:000243902200014
J	Li, L; Cook, PF				Li, Lei; Cook, Paul F.			The 2 '-phosphate of NADP is responsible for proper orientation of the nicotinamide ring in the oxidative decarboxylation reaction catalyzed by sheep liver 6-phosphogluconate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-UTILIS; SUBSTRATE-BINDING; MECHANISM; ENZYME; COENZYME	Sheep liver 6-phosphogluconate dehydrogenase shows a high specificity for NADP, with a much lower affinity for NAD. Discrimination between NADP and NAD suggests that the interactions between the 2'-phosphate and 6-phosphogluconate dehydrogenase contribute most of the binding energy for NADP. There are three active site residues, Asn-32, Arg-33, and Thr-34, that hydrogen-bond to the 2'-phosphate of NADP according to the crystal structure of the E center dot Nbr(8)ADP complex. In this study alanine mutagenesis was used to probe the contribution of each of the three residues to binding the cofactor and to catalysis. All mutant enzymes exhibit no significant change in V/E-t or K-6PG but an increase in K-NADP that ranges from 6- to 80-fold. All mutant enzymes also exhibit at least a 7-fold increase in the primary kinetic C-13-isotope effect-1, indicating that the decarboxylation step has become more rate-limiting. Data are consistent with significant roles for Asn-32, Arg-33, and Thr-34 in providing binding energy for NADP, and more importantly, the 2 alpha-phosphate of NADP is required for proper orientation of the cofactor to allow rotation about the N-glycosidic bond as it is reduced in the hydride transfer step.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Cook, PF (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Norman, OK 73019 USA.	pcook@chemdept.chem.ou.edu						ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; BERDIS AJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P551, DOI 10.1006/abbi.1993.1460; BERDIS AJ, 1993, BIOCHEMISTRY-US, V32, P2041, DOI 10.1021/bi00059a022; BERDIS AJ, 1993, BIOCHEMISTRY-US, V32, P2036, DOI 10.1021/bi00059a021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cervellati C, 2005, BIOCHEMISTRY-US, V44, P2432, DOI 10.1021/bi0476679; Chooback L, 1998, PROTEIN EXPRES PURIF, V13, P251, DOI 10.1006/prep.1998.0896; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1980, BIOCHEMISTRY-US, V19, P4853, DOI 10.1021/bi00562a023; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P15698, DOI 10.1021/bi981288w; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P12596, DOI 10.1021/bi980611s; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Karsten WE, 1998, BIOCHEMISTRY-US, V37, P15691, DOI 10.1021/bi9812827; Lei Z, 1999, BIOCHEMISTRY-US, V38, P11231, DOI 10.1021/bi990433i; Li L, 2006, J BIOL CHEM, V281, P25568, DOI 10.1074/jbc.M601154200; O'Leary M H, 1980, Methods Enzymol, V64, P83; PARKIN DW, 1991, ENZYME MECH ISOTOPE, P284; Price NE, 1996, ARCH BIOCHEM BIOPHYS, V336, P215, DOI 10.1006/abbi.1996.0551; Tetaud E, 1999, BIOCHEM J, V338, P55, DOI 10.1042/0264-6021:3380055; Weiss PM, 1991, ENZYME MECH ISOTOPE, P291	22	14	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36803	36810		10.1074/jbc.M604609200	http://dx.doi.org/10.1074/jbc.M604609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16959777	hybrid			2022-12-25	WOS:000242220800038
J	van Rossum, DB; Patterson, RL; Cheung, KH; Barrow, RK; Syrovatkina, V; Gessell, GS; Burkholder, SG; Watkins, DN; Foskett, JK; Snyder, SH				van Rossum, Damian B.; Patterson, Randen L.; Cheung, King-Ho; Barrow, Roxanne K.; Syrovatkina, Viktoriya; Gessell, Gregory S.; Burkholder, Scott G.; Watkins, D. Neil; Foskett, J. Kevin; Snyder, Solomon H.			DANGER, a novel regulatory protein of inositol 1,4,5-trisphosphate-receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL KINETICS; PURKINJE NEURONS; CALCIUM-RELEASE; CA2+ RELEASE; TRISPHOSPHATE; RECEPTORS; CELLS; INACTIVATION; APOPTOSIS; BINDS	We report the cloning and characterization of DANGER, a novel protein which physiologically binds to inositol 1,4,5-trisphosphate receptors (IP3R). DANGER is a membrane-associated protein predicted to contain a partial MAB-21 domain. It is expressed in a wide variety of neuronal cell lineages where it localizes to membranes in the cell periphery together with IP3R. DANGER interacts with IP3R in vitro and co-immunoprecipitates with IP3R from cellular preparations. DANGER robustly enhances Ca2+-mediated inhibition of IP3R Ca2+ release without affecting IP3 binding in microsomal assays and inhibits gating in single-channel recordings of IP3R. DANGER appears to allosterically modulate the sensitivity of IP3R to Ca2+ inhibition, which likely alters IP3R-mediated Ca2+ dynamics in cells where DANGER and IP3R are co-expressed.	Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Penn State Univ, Sch Med, Dept Physiol, University Pk, PA 16802 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania State University - University Park	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu	Watkins, David N/I-6113-2013; Foskett, Kevin/R-2549-2019; /B-3424-2011	/0000-0001-8683-1654; van Rossum, Damian/0000-0003-1011-2586; Foskett, J. Kevin/0000-0002-8854-0268	NIDA NIH HHS [DA-00074] Funding Source: Medline; NIDDK NIH HHS [GM/DK-56328] Funding Source: Medline; NIGMS NIH HHS [R01 GM056328] Funding Source: Medline; NIMH NIH HHS [MH-68830] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068830] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Hernjak N, 2005, BIOPHYS J, V89, P3790, DOI 10.1529/biophysj.105.065771; Ionescu L, 2006, J PHYSIOL-LONDON, V573, P645, DOI 10.1113/jphysiol.2006.109504; Joseph SK, 2000, J BIOL CHEM, V275, P16084, DOI 10.1074/jbc.M000506200; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Nagase T, 2001, DNA RES, V8, P319, DOI 10.1093/dnares/8.6.319; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Patterson RL, 2004, P NATL ACAD SCI USA, V101, P2328, DOI 10.1073/pnas.0308567100; Qin F, 2000, BIOPHYS J, V79, P1915, DOI 10.1016/S0006-3495(00)76441-1; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Womack MD, 2000, J GEN PHYSIOL, V115, P339, DOI 10.1085/jgp.115.3.339	17	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37111	37116		10.1074/jbc.M608760200	http://dx.doi.org/10.1074/jbc.M608760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16990268	hybrid			2022-12-25	WOS:000242220800072
J	Yakovleva, L; Lai, J; Kool, ET; Shuman, S				Yakovleva, Lyudmila; Lai, Jacob; Kool, Eric T.; Shuman, Stewart			Nonpolar nucleobase analogs illuminate requirements for site-specific DNA cleavage by vaccinia topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; TRANSESTERIFICATION; MECHANISM; CATALYSIS; CONTACTS; ADENINE; DUPLEX; DIFLUOROTOLUENE; SUBSTRATE; ADDUCTS	Vaccinia DNA topoisomerase forms a covalent DNA-(3'-phosphotyrosyl)-enzyme intermediate at a specific target site 5'-C(+5)C(+4)C(+3)T(+2)T(+1)p down arrow N-1 in duplex DNA. Here we study the effects of nonpolar pyrimidine isosteres difluorotoluene ( F) and monofluorotoluene ( D) and the nonpolar purine analog indole at individual positions of the scissile and nonscissile strands on the rate of single-turnover DNA transesterification and the cleavage-religation equilibrium. Comparison of the effects of nonpolar base substitution to the effects of abasic lesions reported previously allowed us to surmise the relative contributions of base-stacking and polar edge interactions to the DNA transesterification reactions. For example, the deleterious effects of eliminating the +2T base on the scissile strand were rectified by introducing the nonpolar F isostere, whereas the requirement for the +1T base was not elided by F substitution. We impute a role for +1T in recruiting the catalytic residue Lys-167 to the active site. Topoisomerase is especially sensitive to suppression of DNA cleavage upon elimination of the +4G and +3G bases of the nonscissile strand. Indole provided little or no gain of function relative to abasic lesions. Inosine substitutions for +4G and +3G had no effect on transesterification rate, implying that the guanine exocyclic amine is not a critical determinant of DNA cleavage. Prior studies of 2-aminopurine and 7-deazaguanine effects had shown that the O6 and N7 of guanine were also not critical. These findings suggest that either the topoisomerase makes functionally redundant contacts with polar atoms ( likely via Tyr-136, a residue important for pre-cleavage active site assembly) or that it relies on contacts to N1 or N3 of the purine ring. The cleavage-religation equilibrium is strongly skewed toward trapping of the covalent intermediate by elimination of the +1A base of the nonscissile strand; the reaction equilibrium is restored by +1 indole, signifying that base stacking flanking the nick is critical for the religation step. Our findings highlight base isosteres as valuable tools for the analysis of proteins that act on DNA in a site-specific manner.	Sloan Kettering INst, Program Mol Biol, New York, NY 10021 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Memorial Sloan Kettering Cancer Center; Stanford University	Shuman, S (corresponding author), Sloan Kettering INst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Kool, Eric/0000-0002-7310-2935	NIGMS NIH HHS [GM46330, GM072705] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330, R01GM072705] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; DELANO WL, 2002, PYMOL SOFTWARE; Francis AW, 2003, J AM CHEM SOC, V125, P16235, DOI 10.1021/ja0374426; Guckian KM, 1998, NAT STRUCT BIOL, V5, P954, DOI 10.1038/2930; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; Hwang Y, 1999, J BIOL CHEM, V274, P9160, DOI 10.1074/jbc.274.14.9160; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; LAI J, 2005, THESIS STANFORD U; Lai JS, 2004, J AM CHEM SOC, V126, P3040, DOI 10.1021/ja039571s; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Nagarajan R, 2006, BIOCHEMISTRY-US, V45, P5775, DOI 10.1021/bi060133i; Patel A, 2006, J BIOL CHEM, V281, P6030, DOI 10.1074/jbc.M512332200; Perry K, 2006, MOL CELL, V23, P343, DOI 10.1016/j.molcel.2006.06.015; Rausch JW, 2003, P NATL ACAD SCI USA, V100, P11279, DOI 10.1073/pnas.1932546100; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; TIAN L, 2006, IN PRESS VIROLOGY; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Tian LG, 2005, STRUCTURE, V13, P513, DOI 10.1016/j.str.2005.02.001; Tian LG, 2004, J BIOL CHEM, V279, P39718, DOI 10.1074/jbc.M407376200; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tian LG, 2003, MOL CELL, V12, P199, DOI 10.1016/S1097-2765(03)00263-6; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Yakovleva L, 2004, J BIOL CHEM, V279, P23335, DOI 10.1074/jbc.M401203200; Yakovleva L, 2003, J BIOL CHEM, V278, P42170, DOI 10.1074/jbc.M308079200; Yakovleva L, 2006, BIOCHEMISTRY-US, V45, P7644, DOI 10.1021/bi060158h	39	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35914	35921		10.1074/jbc.M608349200	http://dx.doi.org/10.1074/jbc.M608349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005552	hybrid			2022-12-25	WOS:000242100500038
J	Nooh, MM; Aziz, RK; Kotb, M; Eroshkin, A; Chuang, WJ; Proft, T; Kansal, R				Nooh, Mohammed M.; Aziz, Ramy K.; Kotb, Malak; Eroshkin, Alexey; Chuang, Woei-Jer; Proft, Thomas; Kansal, Rita			Streptococcal mitogenic exotoxin, SmeZ, is the most susceptible M1T1 streptococcal superantigen to degradation by the streptococcal cysteine protease, SpeB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; GENOME SEQUENCE; INFECTIONS; PYOGENES; SURFACE; PATHOGENESIS; INVOLVEMENT; PROTEOLYSIS; EXPRESSION; STRAIN	Superantigens (SAgs) play an important role in the pathogenesis of severe invasive infections caused by Group A Streptococcus (GAS). We had shown earlier that the expression of streptococcal cysteine protease SpeB results in partial loss of the immune-stimulating activity of the native secreted GAS SAgs, namely the streptococcal pyrogenic exotoxins produced by the globally disseminated M1T1 GAS strain, associated with invasive infections worldwide. In this study, we examined the susceptibility of each of the M1T1 recombinant SAgs to degradation by rSpeB. Whereas SmeZ was degraded completely within 30 min of incubation with rSpeB, SpeG, and SpeA were more resistant and SpeJ was completely unaffected by the proteolytic effects of this protease. Proteomic analyses demonstrated that the order of susceptibility of the M1T1 SAgs to SpeB proteolysis is unaltered when they are present in a mixture that reflects their native physiological status. As expected, the degradation of SmeZ abolished its immune stimulatory activity. In silico sequence disorder and structural analyses revealed that SmeZ, unlike the three other structurally related SAgs, possesses a putative SpeB cleavage site within an area of the protein likely to be exposed to the surface. The study provides evidence for the effect of subtle structural differences between highly similar SAgs on their biological activity.	Vet Affairs Med Ctr, Res Ctr, Res Serv 151, Memphis, TN 38104 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; Burnham Inst, La Jolla, CA 92037 USA; Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Sanford Burnham Prebys Medical Discovery Institute; National Cheng Kung University; University of Auckland	Kansal, R (corresponding author), Vet Affairs Med Ctr, Res Ctr, Res Serv 151, 1030 Jefferson Ave, Memphis, TN 38104 USA.	rkansal@utmem.edu	Proft, Thomas/H-4686-2019; Aziz, Ramy/B-2918-2009	Proft, Thomas/0000-0002-9275-5042; Nooh, Mohammed/0000-0001-9794-4099; Aziz, Ramy/0000-0002-4448-7100	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040198] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aziz RK, 2004, MOL MICROBIOL, V51, P123, DOI 10.1046/j.1365-2958.2003.03797.x; Basma H, 1999, INFECT IMMUN, V67, P1871; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; Chen CY, 2003, J BIOL CHEM, V278, P17336, DOI 10.1074/jbc.M209038200; CHERCHI GB, 1992, EUR J CLIN MICROBIOL, V11, P836, DOI 10.1007/BF01960886; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Collin M, 2003, INFECT IMMUN, V71, P2983, DOI 10.1128/IAI.71.6.2983-2992.2003; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Green NM, 2005, J INFECT DIS, V192, P760, DOI 10.1086/430618; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; Kagawa TF, 2000, P NATL ACAD SCI USA, V97, P2235, DOI 10.1073/pnas.040549997; Kansal RG, 2003, J INFECT DIS, V187, P398, DOI 10.1086/368022; Kazmi SU, 2001, INFECT IMMUN, V69, P4988, DOI 10.1128/IAI.69.8.4988-4995.2001; Kim SW, 2004, J NEUROPSYCH CLIN N, V16, P252, DOI 10.1176/appi.neuropsych.16.3.252; KOTB M, 1995, CLIN MICROBIOL REV, V8, P411, DOI 10.1128/CMR.8.3.411; Kotb M, 2002, NAT MED, V8, P1398, DOI 10.1038/nm800; Kreikemeyer B, 2003, TRENDS MICROBIOL, V11, P224, DOI 10.1016/S0966-842X(03)00098-2; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Nomizu M, 2001, J BIOL CHEM, V276, P44551, DOI 10.1074/jbc.M106306200; Norrby-Teglund A, 2000, J MED MICROBIOL, V49, P849, DOI 10.1099/0022-1317-49-10-849; Norrby-Teglund A, 2001, J INFECT DIS, V184, P853, DOI 10.1086/323443; NorrbyTeglund A, 1996, J IMMUNOL, V156, P3057; Proft T, 2003, EMERG INFECT DIS, V9, P1211; Proft T, 1999, J EXP MED, V189, P89, DOI 10.1084/jem.189.1.89; Raeder R, 1998, RES MICROBIOL, V149, P539, DOI 10.1016/S0923-2508(99)80001-1; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; Rasmussen M, 2002, MOL MICROBIOL, V43, P537, DOI 10.1046/j.1365-2958.2002.02766.x; Rasmussen M, 1999, J BIOL CHEM, V274, P15336, DOI 10.1074/jbc.274.22.15336; Rosch JW, 2005, MOL MICROBIOL, V58, P959, DOI 10.1111/j.1365-2958.2005.04887.x; SCHLIEVERT PM, 1993, J INFECT DIS, V167, P997, DOI 10.1093/infdis/167.5.997; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sumby P, 2006, PLOS PATHOG, V2, P41, DOI 10.1371/journal.ppat.0020005; Unnikrishnan M, 2002, J IMMUNOL, V169, P2561, DOI 10.4049/jimmunol.169.5.2561; Ward JJ, 2004, BIOINFORMATICS, V20, P2138, DOI 10.1093/bioinformatics/bth195; WATANABEOHNISHI R, 1995, J INFECT DIS, V171, P74, DOI 10.1093/infdis/171.1.74; Yang L, 2005, J CLIN MICROBIOL, V43, P3570, DOI 10.1128/JCM.43.7.3570-3573.2005; YU CE, 1989, INFECT IMMUN, V57, P3715, DOI 10.1128/IAI.57.12.3715-3719.1989	39	23	23	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35281	35288		10.1074/jbc.M605544200	http://dx.doi.org/10.1074/jbc.M605544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980693	hybrid			2022-12-25	WOS:000241933700062
J	Kvist, AJ; Johnson, AE; Morgelin, M; Gustafsson, E; Bengtsson, E; Lindblom, K; Aszodi, A; Fassler, R; Sasaki, T; Timpl, R; Aspberg, A				Kvist, Alexander J.; Johnson, Anna E.; Moergelin, Matthias; Gustafsson, Erika; Bengtsson, Eva; Lindblom, Karin; Aszodi, Attila; Faessler, Reinhard; Sasaki, Takako; Timpl, Rupert; Aspberg, Anders			Chondroitin sulfate perlecan enhances collagen fibril formation - Implications for perlecan chondrodysplasias	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWARTZ-JAMPEL-SYNDROME; GLYCOSAMINOGLYCAN MODIFICATION; MATRIX PROTEIN; II COLLAGEN; CHONDROGENIC ACTIVITY; DERMATAN SULFATE; DOMAIN V; PROTEOGLYCAN; CARTILAGE; INHIBITION	Inactivation of the perlecan gene leads to perinatal lethal chondrodysplasia. The similarity to the phenotypes of the Col2A1 knock-out and the disproportionate micromelia mutation suggests perlecan involvement in cartilage collagen matrix assembly. We now present a mechanism for the defect in collagen type II fibril assembly by perlecan-null chondrocytes. Cartilage perlecan is a heparin sulfate or a mixed heparan sulfate/ chondroitin sulfate proteoglycan. The latter form binds collagen and accelerates fibril formation in vitro, with more defined fibril morphology and increased fibril diameters produced in the presence of perlecan. Interestingly, the enhancement of collagen fibril formation is independent on the core protein and is mimicked by chondroitin sulfate E but neither by chondroitin sulfate D nor dextran sulfate. Furthermore, perlecan chondroitin sulfate contains the 4,6-disulfated disaccharides typical for chondroitin sulfate E. Indeed, purified glycosaminoglycans from perlecan-enriched fractions of cartilage extracts contain elevated levels of 4,6-disulfated chondroitin sulfate disaccharides and enhance collagen fibril formation. The effect on collagen assembly is proportional to the content of the 4,6- disulfated disaccharide in the different cartilage extracts, with growth plate cartilage glycosaminoglycan being the most efficient enhancer. These findings demonstrate a role for perlecan chondroitin sulfate side chains in cartilage extracellular matrix assembly and provide an explanation for the perlecan-null chondrodysplasia.	Lund Univ, Dept Expt Med Sci, SE-22184 Lund, Sweden; Lund Univ, Dept Clin Sci, SE-22184 Lund, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lund University; Lund University; Max Planck Society	Aspberg, A (corresponding author), Univ Copenhagen, Inst Mol Biol & Physiol, August Krogh Bldg,Univ Parken 13, DK-2100 Copenhagen OE, Denmark.	aaspberg@aki.ku.dk	Bengtsson, Eva/AGH-2754-2022; Bengtsson, Eva/AAA-1968-2019	Bengtsson, Eva/0000-0001-7075-1772; Aspberg, Anders/0000-0002-6588-6944				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Arikawa-Hirasawa E, 2002, AM J HUM GENET, V70, P1368, DOI 10.1086/340390; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; French MM, 1999, J CELL BIOL, V145, P1103, DOI 10.1083/jcb.145.5.1103; French MM, 2002, J BONE MINER RES, V17, P48, DOI 10.1359/jbmr.2002.17.1.48; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; GAVRIEL P, 1988, BIOCHEMISTRY-US, V27, P2811, DOI 10.1021/bi00408a022; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; Govindraj P, 2002, J BIOL CHEM, V277, P19461, DOI 10.1074/jbc.M200786200; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; Gustafsson E, 2003, ANN NY ACAD SCI, V995, P140, DOI 10.1111/j.1749-6632.2003.tb03217.x; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; JACKSON D. S., 1967, METHODS BIOCHEM ANAL, V15, P25, DOI 10.1002/9780470110331.ch2; KUIJER R, 1988, CONNECT TISSUE RES, V17, P83, DOI 10.3109/03008208809015022; Lauder RM, 2000, GLYCOBIOLOGY, V10, P393, DOI 10.1093/glycob/10.4.393; MACBEATH JRE, 1993, J BIOL CHEM, V268, P19826; MATHEWS MB, 1968, BIOCHEM J, V109, P517, DOI 10.1042/bj1090517; Mo JA, 1996, J IMMUNOL, V157, P2440; Nicole S, 2000, NAT GENET, V26, P480, DOI 10.1038/82638; OBRINK B, 1973, EUR J BIOCHEM, V34, P129, DOI 10.1111/j.1432-1033.1973.tb02739.x; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; Rossi M, 2003, EMBO J, V22, P236, DOI 10.1093/emboj/cdg019; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; Sasaki T, 2002, EUR J BIOCHEM, V269, P431, DOI 10.1046/j.0014-2956.2001.02663.x; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Takagaki K, 2002, J BIOL CHEM, V277, P8882, DOI 10.1074/jbc.M106479200; Tapanadechopone P, 1999, BIOCHEM BIOPH RES CO, V265, P680, DOI 10.1006/bbrc.1999.1714; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WOOD GC, 1960, BIOCHEM J, V75, P605, DOI 10.1042/bj0750605; Zaucke F, 2001, BIOCHEM J, V358, P17, DOI 10.1042/0264-6021:3580017	47	81	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33127	33139		10.1074/jbc.M607892200	http://dx.doi.org/10.1074/jbc.M607892200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956876	hybrid			2022-12-25	WOS:000241621400021
J	Moore, LJ; Mettert, EL; Kiley, PJ				Moore, Laura J.; Mettert, Erin L.; Kiley, Patricia J.			Regulation of FNR dimerization by subunit charge repulsion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FNR; CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; DNA-BINDING; 4FE-4S CLUSTER; OXYGEN; COOA; SULFUR; MUTANT; INTERSUBUNIT	Dimerization of the global anaerobic transcription factor FNR is essential for FNR activity. Under aerobic conditions FNR is an inactive monomeric species because it lacks the oxygen labile [4Fe-4S] cluster required for dimerization. In this study, we investigated the protein side chains that inhibit FNR dimerization under aerobic conditions. Substitution of Asp(154) within the predicted dimerization helix with residues containing neutral or positively charged side chains increased FNR activity under aerobic conditions, whereas replacement of Asp(154) with Glu inhibited FNR activity similar to WT-FNR. Similar results were obtained when making analogous substitutions of Glu(150). In vitro analysis of representative FNR mutant proteins indicated that their increased activity under aerobic conditions resulted from an [4Fe-4S] independent mechanism of dimerization. In addition, simultaneous substitution of residues 150 and 154 with Lys restored inhibition of FNR activity under aerobic growth conditions. Collectively, these data indicate that charge repulsion by side chains at positions 150 and 154 is necessary to inhibit dimerization under aerobic conditions. They also suggest that a [4Fe-4S]-dependent conformational change overcomes charge repulsion between subunits under anaerobic conditions. Comparison of the trypsin sensitivity of [4Fe-4S]-FNR and apoFNR indicated that there are no major differences in protease sensitivity between these forms, whereas circular dichroism suggested that small changes in secondary structure occur between the cluster-containing FNR and apoFNR. Thus, the [4Fe-4S]-dependent conformational change necessary to overcome inter-subunit charge repulsion and create a subunit interface more favorable for dimerization must be small.	Monmouth Coll, Dept Chem, Monmouth, IL 61462 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	Monmouth College; University of Wisconsin System; University of Wisconsin Madison	Moore, LJ (corresponding author), 700 E Broadway, Monmouth, IL 61462 USA.	lmoore@monm.edu		Kiley, Patricia/0000-0002-8771-1782	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045844] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45844, GM19792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama S, 2004, J MOL BIOL, V341, P651, DOI 10.1016/j.jmb.2004.06.040; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bates DM, 2000, J BIOL CHEM, V275, P6234, DOI 10.1074/jbc.275.9.6234; BATES DM, 1995, J BACTERIOL, V177, P3972, DOI 10.1128/jb.177.14.3972-3978.1995; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BROWN AM, 1989, P NATL ACAD SCI USA, V86, P7387, DOI 10.1073/pnas.86.19.7387; CHENG XD, 1993, BIOCHEMISTRY-US, V32, P8130, DOI 10.1021/bi00083a011; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; Dong AC, 2002, BIOCHEMISTRY-US, V41, P6660, DOI 10.1021/bi020036z; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Guest John R., 1996, P317; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; Kerby RL, 2003, J MOL BIOL, V325, P809, DOI 10.1016/S0022-2836(02)01203-2; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Korner H, 2003, FEMS MICROBIOL REV, V27, P559, DOI 10.1016/S0168-6445(03)00066-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mettert EL, 2005, J MOL BIOL, V354, P220, DOI 10.1016/j.jmb.2005.09.066; Moore LJ, 2001, J BIOL CHEM, V276, P45744, DOI 10.1074/jbc.M106569200; MOUSSET S, 1969, NATURE, V221, P242, DOI 10.1038/221242a0; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Patschkowski T, 2000, BACTERIAL STRESS RESPONSES, P61; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Shi Y, 2000, BIOCHEMISTRY-US, V39, P7300, DOI 10.1021/bi000225m; Shi Y, 1999, J BIOL CHEM, V274, P6946, DOI 10.1074/jbc.274.11.6946; Sutton VR, 2004, BIOCHEMISTRY-US, V43, P791, DOI 10.1021/bi0357053; Sutton VR, 2003, METHOD ENZYMOL, V370, P300; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; Yamashita T, 2004, J BIOL CHEM, V279, P47320, DOI 10.1074/jbc.M407766200; Youn H, 2006, J BIOL CHEM, V281, P1119, DOI 10.1074/jbc.M509421200	42	33	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33268	33275		10.1074/jbc.M608331200	http://dx.doi.org/10.1074/jbc.M608331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959764	hybrid			2022-12-25	WOS:000241621400036
J	Ikeda, K; Maegawa, H; Ugi, S; Tao, Y; Nishio, Y; Tsukada, S; Maeda, S; Kashiwagi, A				Ikeda, Kazuhiro; Maegawa, Hiroshi; Ugi, Satoshi; Tao, Yukari; Nishio, Yoshihiko; Tsukada, Shuichi; Maeda, Shiro; Kashiwagi, Atsunori			Transcription factor activating enhancer-binding protein-2 beta - A negative regulator of adiponectin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-SPECIFIC PROTEIN; FATTY-ACID OXIDATION; CAUSE CHAR-SYNDROME; FACTOR AP-2; INSULIN-RESISTANCE; 3T3-L1 ADIPOCYTES; PLASMA-CONCENTRATIONS; MAMMARY-CARCINOMA; ALPHA GENE; HTLV-I	We previously reported the association between the activating enhancer-binding protein-2 beta (AP-2 beta) transcription factor gene and type 2 diabetes. This gene is preferentially expressed in adipose tissue, and subjects with the disease-susceptible allele of AP-2 beta showed stronger expression in adipose tissue than those without the susceptible allele. Furthermore, overexpression of AP-2 beta leads to lipid accumulation by enhancing glucose transport and inducing insulin resistance in 3T3-L1 adipocytes. In this study we demonstrated that overexpression of AP-2 beta in 3T3-L1 adipocytes decreased the expression and secretion of adiponectin and increased those of interleukin-6 (IL-6). Interestingly, the effects of AP-2 beta on the expressions of adiponectin and IL-6 and the mechanisms by which AP-2 beta modulated their expressions were different. We found that the promoter activity of adiponectin gene was inhibited by AP-2 beta overexpression and enhanced by knockdown of endogenous AP-2 beta, whereas IL-6 was unaffected. Electrophoretic mobility shift assays revealed the existence of putative responsive elements for AP-2 beta and NF-YA in human and mouse adiponectin promoter regions, and mutation of this AP-2 beta binding site abolished the inhibitory effect of AP-2 beta. Furthermore, chromatin immunoprecipitation assays demonstrated that AP-2 beta and NF-YA competitively bind to the same region of the adiponectin promoter. Our results clearly demonstrated that AP-2 beta directly inhibits adiponectin gene expression by displacing NF-YA and binding to its promoter. We conclude that AP-2 beta might modulate the expression of adiponectin by directly inhibiting its transcriptional activity.	Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan; Inst Phys & Chem Res, Lab Diabet Nephrol, SNP Res Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Shiga University of Medical Science; RIKEN	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan.	maegawa@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Azuma K, 2003, OBES RES, V11, P997, DOI 10.1038/oby.2003.137; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Fasshauer M, 2003, BIOCHEM BIOPH RES CO, V301, P1045, DOI 10.1016/S0006-291X(03)00090-1; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Hashimoto T, 2005, J BIOL CHEM, V280, P1893, DOI 10.1074/jbc.M410759200; Hosoda K, 1996, BIOCHEM BIOPH RES CO, V221, P234, DOI 10.1006/bbrc.1996.0579; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Kadowaki T, 2003, EXP BIOL MED, V228, P1111, DOI 10.1177/153537020322801003; Latasa MJ, 2003, MOL CELL BIOL, V23, P5896, DOI 10.1128/MCB.23.16.5896-5907.2003; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Maeda S, 2005, J HUM GENET, V50, P283, DOI 10.1007/s10038-005-0253-9; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Matsuzawa Yuji, 2005, Semin Vasc Med, V5, P34, DOI 10.1055/s-2005-871744; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MOSER M, 1995, DEVELOPMENT, V121, P2779; MUCHARDT C, 1992, NEW BIOL, V4, P541; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; Okamoto Y, 2006, CLIN SCI, V110, P267, DOI 10.1042/CS20050182; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Park SK, 2004, DIABETES, V53, P2757, DOI 10.2337/diabetes.53.11.2757; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Seo JB, 2004, J BIOL CHEM, V279, P22108, DOI 10.1074/jbc.M400238200; Tao Y, 2006, ENDOCRINOLOGY, V147, P1685, DOI 10.1210/en.2005-1304; Tsukada S, 2006, MOL ENDOCRINOL, V20, P1104, DOI 10.1210/me.2005-0311; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhao F, 2001, AM J HUM GENET, V69, P695, DOI 10.1086/323410	46	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2006	281	42					31245	31253		10.1074/jbc.M605132200	http://dx.doi.org/10.1074/jbc.M605132200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	094JI	16954217				2022-12-25	WOS:000241235300009
J	Cotroneo, MS; Haag, JD; Zan, Y; Lopez, CC; Thuwajit, P; Petukhova, GV; Camerini-Otero, RD; Gendron-Fitzpatrick, A; Griep, AE; Murphy, CJ; Dubielzig, RR; Gould, MN				Cotroneo, M. S.; Haag, J. D.; Zan, Y.; Lopez, C. C.; Thuwajit, P.; Petukhova, G. V.; Camerini-Otero, R. D.; Gendron-Fitzpatrick, A.; Griep, A. E.; Murphy, C. J.; Dubielzig, R. R.; Gould, M. N.			Characterizing a rat Brca2 knockout model	ONCOGENE			English	Article						Brca2; knockout; rat; carcinogenesis; tumors	DOUBLE-STRAND BREAKS; DNA-REPAIR; SYNAPTONEMAL COMPLEX; MEIOTIC CHROMOSOMES; MICE; RECOMBINATION; LOCALIZATION; RADIATION; CANCER; SUSCEPTIBILITY	Evidence exists that BRCA2 carriers may have an elevated risk of breast, ovarian, colon, prostate, and pancreatic cancer. In general, carriers are defined as individuals with protein truncating mutations within the BRCA2 gene. Many Brca2 knockout lines have been produced and characterized in the mouse. We previously produced a rat Brca2 knockout strain in which there is a nonsense mutation in exon 11 between BRC repeats 2 and 3, and a truncated protein is produced. Interestingly, while such a mutation in homozygous mice would lead to limited survival of approximately 3 months, the Brca2(-/-) rats are 100% viable and the vast majority live to over 1 year of age. Brca2(-/-) rats show a phenotype of growth inhibition and sterility in both sexes. Aspermatogenesis in the Brca2(-/-) rats is due to a failure of homologous chromosome synapsis. Long-term phenotypes include underdeveloped mammary glands, cataract formation and lifespan shortening due to the development of tumors and cancers in multiple organs. The establishment of the rat Brca2 knockout model provides a means to study the role of Brca2 in increasing cancer susceptibility and inducing a novel ocular phenotype not previously associated with this gene.	Univ Wisconsin, Canc Res Lab, Madison, WI 53706 USA; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD USA; Univ Wisconsin, Res Anim Resource Ctr, Comparat Pathol Lab, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gould, MN (corresponding author), Univ Wisconsin, Canc Res Lab, 1400 Univ Ave, Madison, WI 53706 USA.	gould@oncology.wisc.edu	Griep, Anne/ABA-9636-2020; Thuwajit, Peti/AAD-1014-2021; Gould, Michael N/C-7414-2014	Thuwajit, Peti/0000-0003-0798-1510	NATIONAL CANCER INSTITUTE [R01CA106216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008, Z01DK052033, ZIADK052033] Funding Source: NIH RePORTER; NCI NIH HHS [CA106216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Barlow C, 1998, DEVELOPMENT, V125, P4007; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bigsby RM, 1999, P NATL ACAD SCI USA, V96, P9328, DOI 10.1073/pnas.96.16.9328; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cucinotta FA, 2001, RADIAT RES, V156, P460, DOI 10.1667/0033-7587(2001)156[0460:SRACIA]2.0.CO;2; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Dynlacht JR, 2006, RADIAT RES, V165, P9, DOI 10.1667/RR3481.1; Eijpe M, 2000, CHROMOSOMA, V109, P123, DOI 10.1007/s004120050420; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Friedman LS, 1998, CANCER RES, V58, P1338; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219; Liu JG, 1996, EXP CELL RES, V226, P11, DOI 10.1006/excr.1996.0197; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; McAllister KA, 2002, CANCER RES, V62, P990; McAllister KA, 2006, TOXICOL PATHOL, V34, P187, DOI 10.1080/01926230600611794; Moens PB, 1998, CURR TOP DEV BIOL, V37, P241; Mohr U., 1994, PATHOBIOLOGY AGING R, V2; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Nakazawa M, 2001, EXP ANIM TOKYO, V50, P99, DOI 10.1538/expanim.50.99; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Samuelson DJ, 2003, CARCINOGENESIS, V24, P1455, DOI 10.1093/carcin/bgg112; Sarkisian CJ, 2001, J BIOL CHEM, V276, P37640, DOI 10.1074/jbc.M106281200; Schulze W, 1999, HUM REPROD, V14, P82, DOI 10.1093/humrep/14.suppl_1.82; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008; Siaud N, 2004, EMBO J, V23, P1392, DOI 10.1038/sj.emboj.7600146; Villeneuve AM, 2001, CELL, V106, P647, DOI 10.1016/S0092-8674(01)00500-1; WORGUL BV, 1991, MUTAGENESIS, V6, P495, DOI 10.1093/mutage/6.6.495; Worgul BV, 2002, P NATL ACAD SCI USA, V99, P9836, DOI 10.1073/pnas.162349699; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zan YH, 2003, NAT BIOTECHNOL, V21, P645, DOI 10.1038/nbt830; Zhoucun A, 2006, EUR J OBSTET GYN R B, V124, P61, DOI 10.1016/j.ejogrb.2005.09.001; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; Zierhut D, 2000, INT J RADIAT ONCOL, V46, P131, DOI 10.1016/S0360-3016(99)00354-5	43	23	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1626	1635		10.1038/sj.onc.1209960	http://dx.doi.org/10.1038/sj.onc.1209960			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964288				2022-12-25	WOS:000244782500012
J	Liu, B; Lee, KW; Anzo, M; Zhang, B; Zi, X; Tao, Y; Shiry, L; Pollak, M; Lin, S; Cohen, P				Liu, B.; Lee, K. -W; Anzo, M.; Zhang, B.; Zi, X.; Tao, Y.; Shiry, L.; Pollak, M.; Lin, S.; Cohen, P.			Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis	ONCOGENE			English	Article						insulin-like growth factor-binding protein-3; prostate cancer; angiogenesis; apoptosis	FACTOR IGF; ENDOTHELIAL-CELLS; TARGETED DISRUPTION; TUMOR ANGIOGENESIS; BREAST-CANCER; EXPRESSION; IGFBP-3; INDUCTION; ZEBRAFISH; APOPTOSIS	Insulin-like growth factor-binding protein-3 (IGFBP-3) is a multifunctional protein that induces apoptosis utilizing both insulin-like growth factor receptor (IGF)-dependent and -independent mechanisms. We investigated the effects of IGFBP-3 on tumor growth and angiogenesis utilizing a human CaP xenograft model in severe-combined immunodeficiency mice. A 16-day course of IGFBP-3 injections reduced tumor size and increased apoptosis and also led to a reduction in the number of vessels stained with CD31. In vitro, IGFBP-3 inhibited both vascular endothelial growth factor- and IGF-stimulated human umbilical vein endothelial cells vascular network formation in a matrigel assay. This action is primarily IGF independent as shown by studies utilizing the non-IGFBP-binding IGF-1 analog Long-R3. Additionally, we used a fibroblast growth factor- enriched matrigel-plug assay and chick allantoic membrane assays to show that IGFBP-3 has potent antiangiogenic actions in vivo. Finally, overexpression of IGFBP-3 or the non-IGF-binding GGG-IGFBP-3 mutant in Zebrafish embryos confirmed that both IGFBP-3 and the non-IGF-binding mutant inhibited vessel formation in vivo, indicating that the antiangiogenic effect of IGFBP-3 is an IGF-independent phenomenon. Together, these studies provide the first evidence that IGFBP-3 has direct, IGF-independent inhibitory effects on angiogenesis providing an additional mechanism by which it exerts its tumor suppressive effects and further supporting its development for clinical use in the therapy of patients with prostate cancer.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Endocrinol, Dept Pediat,Mattel Childrens Hosp, Los Angeles, CA 90095 USA; Peking Univ, Coll Life Sci, Ctr Dev Biol & Genet, Beijing 100871, Peoples R China; UCI, Dept Urol, Irvine, CA USA; UCI, Chao Family Comprehens Canc Ctr, Irvine, CA USA; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H2W 1S4, Canada; McGill Univ, Dept Oncol, Montreal, PQ H2W 1S4, Canada; INSMED Corp, Charlottesville, VA USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Peking University; University of California System; University of California Irvine; University of California System; University of California Irvine; McGill University; McGill University; University of California System; University of California Los Angeles	Cohen, P (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Endocrinol, Dept Pediat,Mattel Childrens Hosp, Los Angeles, CA 90095 USA.	hassy@mednet.ucla.edu	Zi, Xiaolin/D-3924-2009; Zhang, Bo/K-7162-2012; Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD034610] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100938, P50CA092131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020954] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA92131, R01CA100938] Funding Source: Medline; NIA NIH HHS [R01AG20954] Funding Source: Medline; NICHD NIH HHS [2K12HD34610] Funding Source: Medline; NIDDK NIH HHS [R01DK054508] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acker T, 2003, CELL TISSUE RES, V314, P145, DOI 10.1007/s00441-003-0763-8; Arakawa A, 1997, PROSTATE CANCER P D, V1, P32, DOI 10.1038/sj.pcan.4500204; Bagheri-Yarmand R, 1999, CANCER RES, V59, P507; Bettencourt MC, 1998, J UROLOGY, V160, P459, DOI 10.1016/S0022-5347(01)62925-2; Bono AV, 2002, PROSTATE CANCER P D, V5, P123, DOI 10.1038/sj.pcan.4500572; Booth BA, 1996, GROWTH REGULAT, V6, P206; Brown TA, 2001, DOMEST ANIM ENDOCRIN, V20, P203, DOI 10.1016/S0739-7240(01)00092-3; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chan SSY, 2005, J CLIN ENDOCR METAB, V90, P6588, DOI 10.1210/jc.2005-0595; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Delafontaine P, 1996, BIOCHEM BIOPH RES CO, V222, P478, DOI 10.1006/bbrc.1996.0769; Diaz-Gonzalez JA, 2005, CANCER BIOL THER, V4, P1055, DOI 10.4161/cbt.4.10.2195; Eivers E, 2004, INT J DEV BIOL, V48, P1131, DOI 10.1387/ijdb.041913ee; ERICKSON GF, 1993, ENDOCRINOLOGY, V133, P1147, DOI 10.1210/en.133.3.1147; Erondu NE, 1996, GROWTH REGULAT, V6, P1; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 1998, HUM REPROD, V13, P2180, DOI 10.1093/humrep/13.8.2180; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Grimberg A, 2005, J CLIN ENDOCR METAB, V90, P3568, DOI 10.1210/jc.2004-1213; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Iwatsuki K, 2005, ONCOGENE, V24, P1129, DOI 10.1038/sj.onc.1208287; Jackson MW, 1997, J UROLOGY, V157, P2323, DOI 10.1016/S0022-5347(01)64774-8; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jones HE, 2005, ENDOCR-RELAT CANCER, V12, pS173, DOI 10.1677/erc.1.01004; Klauber N, 1997, CANCER RES, V57, P81; Koong AC, 2000, CANCER RES, V60, P883; LEE HS, 1999, J INJECTION MOLDING, V3, P11; Lee HY, 2002, CANCER RES, V62, P3530; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu BR, 2005, CLIN CANCER RES, V11, P4851, DOI 10.1158/1078-0432.CCR-04-2160; Odenthal J, 1996, DEVELOPMENT, V123, P103; Oh SH, 2006, CLIN CANCER RES, V12, P653, DOI 10.1158/1078-0432.CCR-05-1725; OLNEY RC, 1995, J ENDOCRINOL, V146, P279, DOI 10.1677/joe.0.1460279; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; Schmitt HJ, 2003, LANCET INFECT DIS, V3, P103, DOI 10.1016/S1473-3099(03)00519-X; Singh RP, 2003, CANCER EPIDEM BIOMAR, V12, P933; Singh RP, 2004, CLIN CANCER RES, V10, P244, DOI 10.1158/1078-0432.CCR-1080-3; Singh RP, 2004, INT J CANCER, V108, P733, DOI 10.1002/ijc.11620; Tucci M, 1998, J ENDOCRINOL, V157, P13, DOI 10.1677/joe.0.1570013; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Voskuil DW, 2005, CANCER EPIDEM BIOMAR, V14, P195; WEIDNER N, 1993, AM J PATHOL, V143, P401; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069	54	81	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1811	1819		10.1038/sj.onc.1209977	http://dx.doi.org/10.1038/sj.onc.1209977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983336				2022-12-25	WOS:000244955600015
J	Zapatka, M; Zboralski, D; Radacz, Y; Bockmann, M; Arnold, C; Schoneck, A; Hoppe, S; Tannapfel, A; Schmiegel, W; Simon-Assmann, P; Schwarte-Waldhoff, I				Zapatka, M.; Zboralski, D.; Radacz, Y.; Boeckmann, M.; Arnold, C.; Schoeneck, A.; Hoppe, S.; Tannapfel, A.; Schmiegel, W.; Simon-Assmann, P.; Schwarte-Waldhoff, I.			Basement membrane component laminin-5 is a target of the tumor suppressor Smad4	ONCOGENE			English	Article						tumor suppressor Smad4; TGF-beta; laminin-5; invasion; basement membrane	STABLE RNA INTERFERENCE; GAMMA-2 CHAIN; COLORECTAL-CANCER; CARCINOMA CELLS; EXPRESSION; INVASION; DPC4; METASTASIS; LAMC2; LINES	The tumor suppressor Smad4 is involved in carcinogenesis mainly of the pancreas and colon. Functional inactivation of Smad4 is a genetically late event that occurs upon transition from premalignant stages to invasive and metastatic growth. Smad4 encodes an intracellular messenger common to all signalling cascades induced by members of the transforming growth factor-beta (TGF-beta) superfamily of cytokines. Despite extensive knowledge about the mechanisms of TGF-beta/Smadsignal transduction, little is known about Smad4 targets involved in the transition to malignancy. The hallmark of invasive growth is a breakdown of the basement membrane ( BM), a specialized sheet of extracellular matrix produced through of epithelial and stromal cells. Laminin-5, a heterotrimeric epithelial-derived BM component, is commonly lost in carcinomas but not in premalignant tumors. Herein, we report that in human colon and pancreatic tumor cells, Smad4 functions as a positive transcriptional regulator of all three genes encoding laminin-5. Coordinate re-expression of the three laminin-5 chains induced by reconstitution of Smad4 leads to secretion and deposition of the heterotrimeric molecule in BM-like structures. These data de. ne the expression control of an essential BM component as a novel function for the tumor suppressor Smad4.	Ruhr Univ Bochum, Dept Internal Med, Knappschaftskrankenhaus, IMBL, D-44892 Bochum, Germany; Univ Strasbourg, INSERM, U682, Strasbourg, France; Ruhr Univ Bochum, Inst Pathol, BG Kliniken Bergmannsheil, D-4630 Bochum, Germany; Ruhr Univ Bochum, Dept Gastroenterol & Hepatol, Kliniken Bergmannsheil, D-4630 Bochum, Germany	Ruhr University Bochum; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Ruhr University Bochum; Ruhr University Bochum	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Dept Internal Med, Knappschaftskrankenhaus, IMBL, Schornau 23-25, D-44892 Bochum, Germany.	Irmgard.Schwarte-Waldhoff@ruhr-uni-bochum.de	Zapatka, Marc/G-9896-2013	Zapatka, Marc/0000-0001-8287-5967; Zboralski, Dirk/0000-0002-2224-2452				Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; BOUZIGES F, 1991, INT J CANCER, V48, P101; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Giannelli G, 2001, CLIN EXP METASTAS, V18, P439; Givant-Horwitz V, 2005, CANCER LETT, V223, P1, DOI 10.1016/j.canlet.2004.08.030; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hlubek F, 2001, CANCER RES, V61, P8089; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Jonson T, 2003, GENE CHROMOSOME CANC, V36, P340, DOI 10.1002/gcc.10179; Katayama M, 2004, J MOL HISTOL, V35, P277; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Lu W, 2001, HISTOCHEM J, V33, P629, DOI 10.1023/A:1016350316926; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Olsen J, 2003, BIOCHEM J, V371, P211, DOI 10.1042/BJ20021454; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1994, AM J PATHOL, V145, P782; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Simon-Assmann P, 1998, ANN NY ACAD SCI, V859, P46, DOI 10.1111/j.1749-6632.1998.tb11110.x; Sordat I, 2000, INT J CANCER, V88, P708, DOI 10.1002/1097-0215(20001201)88:5<708::AID-IJC5>3.0.CO;2-J; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; Takahashi H, 2004, CLIN CANCER RES, V10, P3772, DOI 10.1158/1078-0432.CCR-03-0120; Takahashi S, 2002, CANCER, V94, P1894, DOI 10.1002/cncr.10395; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TELLER IC, 2001, EXPERT REV MOL MED, P1; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Volmer MW, 2004, PROTEOMICS, V4, P1324, DOI 10.1002/pmic.200300703; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; Wilentz RE, 2000, CANCER RES, V60, P2002; Yuen HW, 2005, EXP CELL RES, V309, P198, DOI 10.1016/j.yexcr.2005.05.013	41	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1417	1427		10.1038/sj.onc.1209918	http://dx.doi.org/10.1038/sj.onc.1209918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953227				2022-12-25	WOS:000244558800006
J	Bhattacharjee, RN; Park, KS; Kumagai, Y; Okada, K; Yamamoto, M; Uematsu, S; Matsui, K; Kumar, H; Kawai, T; Iida, T; Honda, T; Takeuchi, O; Akira, S				Bhattacharjee, Rabindra N.; Park, Kwon-Sam; Kumagai, Yutaro; Okada, Kazuhisa; Yamamoto, Masahiro; Uematsu, Satoshi; Matsui, Kosuke; Kumar, Himanshu; Kawai, Taro; Iida, Tetsuya; Honda, Takeshi; Takeuchi, Osamu; Akira, Shizuo			VP1686, a Vibrio type III secretion protein, induces Toll-like receptor-independent apoptosis in macrophage through NF-kappa B inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INNATE IMMUNITY; PARAHAEMOLYTICUS; ACTIVATION; EXPRESSION; TOLL-LIKE-RECEPTOR-4; SUPPRESSION; INDUCTION; CHOLERAE; PATHWAY	Vibrio parahaemolyticus, causative agent of human gastrointestinal diseases, possesses several virulent machineries including thermostable direct hemolysin and type III secretion systems (TTSS1 and -2). In this report, we establish that TTSS1-dependent secretion and translocation of a V. parahaemolyticus effector protein VP1686 into the cytosol induces DNA fragmentation in macrophages. We performed yeast two-hybrid screening to identify the molecules involved in VP1686-mediated cell death pathways and showed that nuclear factor RelA p65/NF-kappa B physically interacts with VP1686. To understand the impact of this interaction on the kappa F-kappa B DNA binding activities in infected macrophages, we analyzed a series of deletion mutants for the TTSS and its secreted proteins. Induction of DNA binding activity of NF-kappa B was significantly suppressed, and increased macrophage apoptosis has been associated with V. parahaemolyticus strain, which contains both VP1686 and TTSS1. Macrophages lacking Toll-like receptor adaptor molecules MyD88 (myeloid differentiation primary response protein 88) or TRIF (TIR domain-containing adapter- inducing interferon beta) showed similar sensitivity to VP1686. As a consequence of NF-kappa B suppression, microarray analysis has revealed that VP1686 translocation alerted the expression of many genes that have known functions in cellular responses to apoptosis, cell growth, and transcriptional regulation. Our results suggest an important role for Vibrio effector protein VP1686 that activate a conserved apoptotic pathway in macrophages through suppression of NF-kappa B activation independent of Toll-like receptor signaling.	Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Bacterial Infect, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, Explorat Res Adv Technol, Akira Innate Immun Project, Kunsan 573701, South Korea; Kunsan Natl Univ, Coll Ocean Sci & Technol, Food Sci & Biotechnol Major, Kunsan 573701, South Korea	Osaka University; Osaka University; Kunsan National University	Akira, S (corresponding author), Osaka Univ, Dept Host Def, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	sakira@biken.osaka-u.ac.jp	Kumagai, Yutaro/L-7732-2018; Kumar, Himanshu/A-8070-2010; Akira, Shizuo/C-3134-2009; Takeuchi, Osamu/AAG-9359-2019; Takeuchi, Osamu/D-6007-2011; Kumar, Himanshu/J-4494-2012	Kumagai, Yutaro/0000-0002-5039-3979; Takeuchi, Osamu/0000-0002-1260-6232; Kumar, Himanshu/0000-0001-5246-2694; Kawai, Taro/0000-0001-7510-4662; Okada, Kazuhisa/0000-0002-1225-7933				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bhattacharjee RN, 2005, BIOCHEM BIOPH RES CO, V335, P328, DOI 10.1016/j.bbrc.2005.07.080; Bhattacharjee RN, 2005, FEBS LETT, V579, P6604, DOI 10.1016/j.febslet.2005.10.053; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Haase R, 2003, J IMMUNOL, V171, P4294, DOI 10.4049/jimmunol.171.8.4294; Hauf N, 2003, J IMMUNOL, V170, P2074, DOI 10.4049/jimmunol.170.4.2074; Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Makino K, 2003, LANCET, V361, P743, DOI 10.1016/S0140-6736(03)12659-1; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Nasu H, 2000, J CLIN MICROBIOL, V38, P2156; Ono T, 2006, INFECT IMMUN, V74, P1032, DOI 10.1128/IAI.74.2.1032-1042.2006; Park KS, 2005, INFECT IMMUN, V73, P5754, DOI 10.1128/IAI.73.9.5754-5761.2005; Park KS, 2004, INFECT IMMUN, V72, P6659, DOI 10.1128/IAI.72.11.6659-6665.2004; Park KS, 2004, MICROBIOL IMMUNOL, V48, P313, DOI 10.1111/j.1348-0421.2004.tb03512.x; Ruckdeschel K, 2001, J IMMUNOL, V166, P1823, DOI 10.4049/jimmunol.166.3.1823; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262	25	58	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36897	36904		10.1074/jbc.M605493200	http://dx.doi.org/10.1074/jbc.M605493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16984916	hybrid			2022-12-25	WOS:000242220800049
J	Hallay, H; Locker, N; Ayadi, L; Ropers, D; Guittet, E; Branlant, C				Hallay, Houda; Locker, Nicolas; Ayadi, Lilia; Ropers, Delphine; Guittet, Eric; Branlant, Christiane			Biochemical and NMR study on the competition between proteins SC35, SRp40, and heterogeneous nuclear ribonucleoprotein A1 at the HIV-1 tat Exon 2 splicing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RNA-BINDING-PROTEINS; HNRNP A/B PROTEINS; MESSENGER-RNA; REGULATORY ELEMENTS; COOPERATIVE BINDING; CRYSTAL-STRUCTURE; SILENCER ELEMENT; BRANCH SITE; IN-VITRO	The human immunodeficiency virus, type 1, Tat protein plays a key role in virus multiplication. Because of its apoptotic property, its production is highly controlled. It depends upon the A3 splicing site utilization. A key control of site A3 activity is the ESS2 splicing silencer, which is located within the long stem-loop structure 3 (SLS3), far downstream from site A3. Here, by enzymatic footprints, we demonstrate the presence of several heterogeneous nuclear ribonucleoprotein (hnRNP) A1-binding sites on SLS3 and show the importance of the C-terminal Gly domain of hnRNP A1 in the formation of stable complexes containing several hnRNP A1 molecules bound on SLS3. Mutations in each of the UAG triplets in ESS2 strongly reduce the overall hnRNP A1 binding, showing the central role of ESS2 in hnRNP A1 assembly on SLS2-SLS3. Using NMR spectroscopy, we demonstrate the direct interaction of ESS2 with the RNA recognition motifs domains of hnRNP A1. This interaction has limited effect on the RNA two-dimensional structure. The SR proteins SC35 and SRp40 were found previously to be strong activators of site A3 utilization. By enzymatic and chemical footprints, we delineate their respective binding sites on SLS2 and SLS3 and find a strong similarity between the hnRNP A1-, SC35-, and SRp40-binding sites. The strongest SC35-binding site only has a modest contribution to site A3 activation. Hence, the main role of SR proteins at site A3 is to counteract hnRNP A1 binding on ESS2 and ESE2. Indeed, we found that ESE2 has inhibitory properties because of its ability to bind hnRNP A1.	Univ Nancy 1, Lab Matuat ARN & Enzymol Mol, UMR 7567, F-54506 Vandoeuvre Les Nancy, France; CNRS, ICSN, Lab Chim & Biol Struct, F-91198 Gif Sur Yvette, France	Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Branlant, C (corresponding author), Univ Nancy 1, Lab Matuat ARN & Enzymol Mol, UMR 7567, BP 239, F-54506 Vandoeuvre Les Nancy, France.	christiane.branlant@maem.uhp-nancy.fr		Branlant, Christiane/0000-0003-4728-5499; Guittet, Eric/0000-0002-8368-6719; Locker, Nicolas/0000-0002-0053-2897; Ropers, Delphine/0000-0003-2659-3003				AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Beriault V, 2004, J BIOL CHEM, V279, P44141, DOI 10.1074/jbc.M404691200; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Bonavia R, 2001, BIOCHEM BIOPH RES CO, V288, P301, DOI 10.1006/bbrc.2001.5743; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Collin D, 2000, NUCLEIC ACIDS RES, V28, P3386, DOI 10.1093/nar/28.17.3386; Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075; Damier L, 1997, BIOCHEM BIOPH RES CO, V237, P182, DOI 10.1006/bbrc.1997.7091; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Dingley AJ, 1998, J AM CHEM SOC, V120, P8293, DOI 10.1021/ja981513x; DYHRMIKKELSEN H, 1995, J BIOL CHEM, V270, P24060, DOI 10.1074/jbc.270.41.24060; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; Jacquenet S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-33; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Jacquenet S, 2001, NUCLEIC ACIDS RES, V29, P464, DOI 10.1093/nar/29.2.464; Kao C, 1999, RNA, V5, P1268, DOI 10.1017/S1355838299991033; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; Mayeda A, 1998, RNA, V4, P1111, DOI 10.1017/S135583829898089X; Mouland AJ, 2001, MOL CELL BIOL, V21, P2133, DOI 10.1128/MCB.21.6.2133-2143.2001; OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Ropers D, 2004, J BIOL CHEM, V279, P29963, DOI 10.1074/jbc.M404452200; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; Stoltzfus CM, 2006, CURR HIV RES, V4, P43, DOI 10.2174/157016206775197655; Swanson AK, 1998, J BIOL CHEM, V273, P34551, DOI 10.1074/jbc.273.51.34551; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200	41	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37159	37174		10.1074/jbc.M603864200	http://dx.doi.org/10.1074/jbc.M603864200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16990281	hybrid			2022-12-25	WOS:000242220800077
J	Neves, AR; Pool, WA; Castro, R; Mingote, A; Santos, F; Kok, J; Kuipers, OP; Santos, H				Neves, Ana R.; Pool, Wietske A.; Castro, Rute; Mingote, Ana; Santos, Filipe; Kok, Jan; Kuipers, Oscar P.; Santos, Helena			The alpha-phosphoglucomutase of Lactococcus lactis is unrelated to the alpha-D-phosphohexomutase superfamily and is encoded by the essential gene pgmH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; BETA-PHOSPHOGLUCOMUTASE; LIPOPOLYSACCHARIDE BIOSYNTHESIS; EXOPOLYSACCHARIDE BIOSYNTHESIS; GALACTOSE UTILIZATION; METABOLISM; SEQUENCE; KINETICS; PLASMID; IDENTIFICATION	alpha-Phosphoglucomutase (alpha-PGM) plays an important role in carbohydrate metabolism by catalyzing the reversible conversion of alpha-glucose 1-phosphate to glucose 6-phosphate. Isolation of alpha-PGM activity from cell extracts of Lactococcus lactis strain MG1363 led to the conclusion that this activity is encoded by yfgH, herein renamed pgmH. Its gene product has no sequence homology to proteins in the alpha-D-phosphohexomutase superfamily and is instead related to the eukaryotic phosphomannomutases within the haloacid dehalogenase superfamily. In contrast to known bacterial alpha-PGMs, this 28-kDa enzyme is highly specific for alpha-glucose 1-phosphate and glucose 6-phosphate and showed no activity for mannose phosphate. To elucidate the function of pgmH, the metabolism of glucose and galactose was characterized in mutants overproducing or with a deficiency of alpha-PGM activity. Overproduction of alpha-PGM led to increased glycolytic flux and growth rate on galactose. Despite several attempts, we failed to obtain a deletion mutant of pgmH. The essentiality of this gene was proven by using a conditional knock- out strain in which a native copy of the gene was provided in trans under the control of the nisin promoter. Growth of this strain was severely impaired when alpha-PGM activity was below the control level. We show that the novel L. lactis alpha-PGM is the only enzyme that mediates the interconversion of alpha-glucose 1-phosphate to glucose 6-phosphate and is essential for growth.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Univ Nova Lisboa, Inst Biol Expt & Tecnol, P-2780156 Oeiras, Portugal; Univ Groningen, Dept Mol Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	Universidade Nova de Lisboa; Universidade Nova de Lisboa; University of Groningen	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande,6 Apartado 127, P-2780156 Oeiras, Portugal.	santos@itqb.unl.pt	Kok, Jan/C-9972-2012; Santos, Filipe/M-7709-2013; Kuipers, Oscar/B-6752-2009; Neves, Ana/B-9476-2008; Santos, Helena/B-9141-2011	Santos, Filipe/0000-0001-7316-1479; Kuipers, Oscar/0000-0001-5596-7735; Neves, Ana/0000-0003-4896-9585; Santos, Helena/0000-0002-8050-9485; Castro, Rute/0000-0002-0899-0649; Branco dos Santos, Filipe/0000-0002-4268-8080				Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; Andersson U, 2001, J BIOL CHEM, V276, P42707, DOI 10.1074/jbc.M108279200; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; Boels IC, 2001, APPL ENVIRON MICROB, V67, P3033, DOI 10.1128/AEM.67.7.3033-3040.2001; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chandrapati S, 2002, MOL MICROBIOL, V46, P467, DOI 10.1046/j.1365-2958.2002.03163.x; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; COYNE MJ, 1994, J BACTERIOL, V176, P3500, DOI 10.1128/JB.176.12.3500-3507.1994; Delcour J, 1999, ANTON LEEUW INT J G, V76, P159, DOI 10.1023/A:1002089722581; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Gaona G, 2004, FEMS MICROBIOL LETT, V238, P199, DOI 10.1016/j.femsle.2004.07.044; GASSON MJ, 1983, J BACTERIOL, V154, P1; Grossiord B, 1998, LAIT, V78, P77, DOI 10.1051/lait:1998110; Grossiord BP, 2003, J BACTERIOL, V185, P870, DOI 10.1128/JB.185.3.870-878.2003; Hardy GG, 2000, J BACTERIOL, V182, P1854, DOI 10.1128/JB.182.7.1854-1863.2000; Hardy GG, 2001, INFECT IMMUN, V69, P2309, DOI 10.1128/IAI.69.4.2309-2317.2001; Holo H, 1995, Methods Mol Biol, V47, P195; JOHANSEN E, 1992, PLASMID, V27, P200, DOI 10.1016/0147-619X(92)90022-3; Kleerebezem M, 1999, ANTON LEEUW INT J G, V76, P357, DOI 10.1023/A:1002084822851; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; Kramer NE, 2006, ANTIMICROB AGENTS CH, V50, P1753, DOI 10.1128/AAC.50.5.1753-1761.2006; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lahiri SD, 2004, BIOCHEMISTRY-US, V43, P2812, DOI 10.1021/bi0356810; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Lazarevic V, 2005, APPL ENVIRON MICROB, V71, P39, DOI 10.1128/AEM.71.1.39-45.2005; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Levander F, 2001, APPL ENVIRON MICROB, V67, P2734, DOI 10.1128/AEM.67.6.2734-2738.2001; Levander F, 2001, APPL ENVIRON MICROB, V67, P4546, DOI 10.1128/AEM.67.10.4546-4553.2001; LU M, 1994, J BACTERIOL, V176, P5847, DOI 10.1128/JB.176.18.5847-5851.1994; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; McKay GA, 2003, INFECT IMMUN, V71, P3068, DOI 10.1128/IAI.71.6.3068-3075.2003; Monteiro MA, 2003, CARBOHYD RES, V338, P2905, DOI 10.1016/j.carres.2003.08.014; Neves AR, 1999, BIOTECHNOL BIOENG, V64, P200, DOI 10.1002/(SICI)1097-0290(19990720)64:2&lt;200::AID-BIT9&gt;3.0.CO;2-K; Neves AR, 2000, EUR J BIOCHEM, V267, P3859, DOI 10.1046/j.1432-1327.2000.01424.x; Neves AR, 2002, MICROBIOL-SGM, V148, P3467, DOI 10.1099/00221287-148-11-3467; Neves AR, 2002, J BIOL CHEM, V277, P28088, DOI 10.1074/jbc.M202573200; Neves AR, 2002, APPL ENVIRON MICROB, V68, P6332, DOI 10.1128/AEM.68.12.6332-6342.2002; Neves AR, 2005, FEMS MICROBIOL REV, V29, P531, DOI 10.1016/j.femsre.2005.04.005; Pirard M, 1999, BIOCHEM J, V339, P201, DOI 10.1042/0264-6021:3390201; Pirard M, 1997, FEBS LETT, V411, P251, DOI 10.1016/S0014-5793(97)00704-7; QIAN N, 1994, J BACTERIOL, V176, P5304, DOI 10.1128/JB.176.17.5304-5311.1994; Ramos A, 2001, APPL ENVIRON MICROB, V67, P33, DOI 10.1128/AEM.67.1.33-41.2001; Roberts A, 2005, PROTEINS, V58, P790, DOI 10.1002/prot.20267; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders JW, 1998, MOL GEN GENET, V257, P681, DOI 10.1007/s004380050697; Shackelford GS, 2004, PROTEIN SCI, V13, P2130, DOI 10.1110/ps.04801104; Silvaggi NR, 2006, J BIOL CHEM, V281, P14918, DOI 10.1074/jbc.M601505200; Steen A, 2005, FEBS J, V272, P2854, DOI 10.1111/j.1742-4658.2005.04706.x; Steen A, 2005, J BACTERIOL, V187, P114, DOI 10.1128/JB.187.1.114-124.2005; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vaughan EE, 1998, J BACTERIOL, V180, P4893, DOI 10.1128/JB.180.18.4893-4902.1998; Videira PA, 2000, APPL ENVIRON MICROB, V66, P2252, DOI 10.1128/AEM.66.5.2252-2258.2000; West NP, 2000, INFECT IMMUN, V68, P4673, DOI 10.1128/IAI.68.8.4673-4680.2000; Whitehouse DB, 1998, MOL BIOL EVOL, V15, P456, DOI 10.1093/oxfordjournals.molbev.a025942; Zhang GF, 2005, BIOCHEMISTRY-US, V44, P9404, DOI 10.1021/bi050558p	58	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36864	36873		10.1074/jbc.M607044200	http://dx.doi.org/10.1074/jbc.M607044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16980299	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000242220800045
J	Dehay, B; Bertolotti, A				Dehay, Benjamin; Bertolotti, Anne			Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; PROLYL ISOMERASE PIN1; POLYGLUTAMINE EXPANSION; IN-VITRO; PROTEIN; CHAPERONE; EXPRESSION; TOXICITY; FRAGMENT; HSP70	Nine neurodegenerative diseases, such as Huntington, are caused by a polyglutamine ( poly( Q)) expansion in otherwise unrelated proteins. Although poly( Q) expansion causes aggregation of the affected proteins, the protein context might determine the selective neuronal vulnerability found in each disease. Here we have report that, although expression of Huntingtin derivatives with a pathological poly( Q) expansion are innocuous in yeast, deletion of the flanking proline-rich region alters the shape and number of poly( Q) inclusions and unmasks toxic properties. Strikingly, deletion of Hsp104 increases the size of inclusions formed by expanded poly( Q) lacking the proline-rich region and abolishes toxicity. Overexpression of the chaperones Hsp104 or Hsp70 rescues growth defects in affected cells without resolving inclusions. However, aggregates formed by nontoxic Huntingtin derivatives or by toxic derivatives cured by chaperones are physically distinct from aggregates formed by toxic proteins. This study identifies the proline-rich region in Huntingtin as a profound cis-acting modulator of expanded poly( Q) toxicity and distinguishes between aggregates of toxic or non-toxic proteins.	Ecole Normale Super, CNRS, UMR 8541, Genet Mol Lab, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bertolotti, A (corresponding author), MRC, Div Neurobiol, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	aberto@mrc-lmb.cam.ac.uk	DEHAY, Benjamin/I-4713-2016	DEHAY, Benjamin/0000-0003-1723-9045				Bhattacharyya A, 2006, J MOL BIOL, V355, P524, DOI 10.1016/j.jmb.2005.10.053; Burke D., 2000, COLD SPRING HARBOR L; Chacinska A, 2001, CURR GENET, V39, P62, DOI 10.1007/s002940000180; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11045, DOI 10.1073/pnas.0604547103; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Gellera C, 1996, AM J HUM GENET, V59, P475; Gietz R Daniel, 2006, Methods Mol Biol, V313, P107; Gokhale KC, 2005, J BIOL CHEM, V280, P22809, DOI 10.1074/jbc.M500390200; Hazeki N, 2000, BIOCHEM BIOPH RES CO, V277, P386, DOI 10.1006/bbrc.2000.3682; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Khoshnan A, 2002, P NATL ACAD SCI USA, V99, P1002, DOI 10.1073/pnas.022631799; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Passani LA, 2000, HUM MOL GENET, V9, P2175, DOI 10.1093/hmg/9.14.2175; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Qin ZH, 2004, J NEUROSCI, V24, P269, DOI 10.1523/JNEUROSCI.1409-03.2004; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Rousseau E, 2004, P NATL ACAD SCI USA, V101, P9648, DOI 10.1073/pnas.0403015101; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schroedel Andrea, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-10; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389; Zhai WG, 2005, CELL, V123, P1241, DOI 10.1016/j.cell.2005.10.030; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	34	100	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35608	35615		10.1074/jbc.M605558200	http://dx.doi.org/10.1074/jbc.M605558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16973603	hybrid			2022-12-25	WOS:000242100500005
J	Schoehn, G; Vellieux, FMD; Dura, MA; Receveur-Brechot, V; Fabry, CMS; Ruigrok, RWH; Ebel, C; Roussel, A; Franzetti, B				Schoehn, Guy; Vellieux, Frederic M. D.; Dura, M. Asuncion; Receveur-Brechot, Veronique; Fabry, Celine M. S.; Ruigrok, Rob W. H.; Ebel, Christine; Roussel, Alain; Franzetti, Bruno			An archaeal peptidase assembles into two different quaternary structures - A tetrahedron and a giant octahedron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-COMPARTMENTALIZING PROTEASE; PYROCOCCUS-HORIKOSHII; CRYSTAL-STRUCTURE; TRICORN PROTEASE; DEBLOCKING AMINOPEPTIDASE; AEROMONAS-PROTEOLYTICA; ANGSTROM RESOLUTION; SECONDARY-STRUCTURE; DEGRADATION; COMPLEX	Cellular proteolysis involves large oligomeric peptidases that play key roles in the regulation of many cellular processes. The cobalt-activated peptidase TET1 from the hyperthermophilic Archaea Pyrococcus horikoshii (PhTET1) was found to assemble as a 12-subunit tetrahedron and as a 24-subunit octahedral particle. Both quaternary structures were solved by combining x-ray crystallography and cryoelectron microscopy data. The internal organization of the PhTET1 particles reveals highly self-compartmentalized systems made of networks of access channels extended by vast catalytic chambers. The two edifices display aminopeptidase activity, and their organizations indicate substrate navigation mechanisms different from those described in other large peptidase complexes. Compared with the tetrahedron, the octahedron forms a more expanded hollow structure, representing a new type of giant peptidase complex. PhTET1 assembles into two different quaternary structures because of quasi-equivalent contacts that previously have only been identified in viral capsids.	UJF, CNRS,UMR 5075, CEA, Lab Mol Biophys,Inst Biol Struct JB Ebel, F-38027 Grenoble, France; UJF, CNRS, EMBL, Lab Virol Mol & Struct,FRE 2854, F-38042 Grenoble, France; Univ Aix Marseille 1, CNRS, UMR 6098, F-13288 Marseille, France; Univ Aix Marseille 2, CNRS, UMR 6098, F-13288 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Franzetti, B (corresponding author), UJF, CNRS,UMR 5075, CEA, Lab Mol Biophys,Inst Biol Struct JB Ebel, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	franzetti@ibs.fr	Vellieux, Frederic/J-4829-2019	Vellieux, Frederic/0000-0002-1922-5707; Schoehn, Guy/0000-0002-1459-3201; Ebel, Christine/0000-0002-6912-500X; Receveur-Brechot, Veronique/0000-0002-7464-6192				Ando S, 1999, FEBS LETT, V447, P25, DOI 10.1016/S0014-5793(99)00257-4; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Borissenko L, 2005, J MOL BIOL, V346, P1207, DOI 10.1016/j.jmb.2004.12.056; BOTBOL V, 1991, J BIOL CHEM, V266, P2151; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1992, J MOL BIOL, V224, P113, DOI 10.1016/0022-2836(92)90580-D; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Conway JF, 1999, J STRUCT BIOL, V128, P106, DOI 10.1006/jsbi.1999.4168; DeLano WL, 2002, PYMOL USERS MANUAL; Dura MA, 2005, BIOCHEMISTRY-US, V44, P3477, DOI 10.1021/bi047736j; Fabry CMS, 2005, EMBO J, V24, P1645, DOI 10.1038/sj.emboj.7600653; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Franzetti B, 2002, EMBO J, V21, P2132, DOI 10.1093/emboj/21.9.2132; Gonzales T, 1996, FEMS MICROBIOL REV, V18, P319, DOI 10.1111/j.1574-6976.1996.tb00247.x; Gonzalez JM, 1998, EXTREMOPHILES, V2, P123, DOI 10.1007/s007920050051; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Greenblatt HM, 1997, J MOL BIOL, V265, P620, DOI 10.1006/jmbi.1996.0729; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim JS, 2002, J MOL BIOL, V324, P1041, DOI 10.1016/S0022-2836(02)01153-1; Kirschner M, 1999, TRENDS CELL BIOL, V9, pM42, DOI 10.1016/S0962-8924(99)01666-9; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Navaza J, 2002, ACTA CRYSTALLOGR D, V58, P1820, DOI 10.1107/S0907444902013707; Onoe S, 2002, BIOCHEM BIOPH RES CO, V290, P994, DOI 10.1006/bbrc.2001.6327; Porciero S, 2005, ACTA CRYSTALLOGR F, V61, P239, DOI 10.1107/S1744309105001910; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Remaut H, 2001, NAT STRUCT BIOL, V8, P674, DOI 10.1038/90380; Rockel B, 2005, P NATL ACAD SCI USA, V102, P10135, DOI 10.1073/pnas.0504569102; Rossmann M. G., 1972, MOL REPLACEMENT METH; Russo S, 2004, J BIOL CHEM, V279, P51275, DOI 10.1074/jbc.M409455200; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Schut GJ, 2003, J BACTERIOL, V185, P3935, DOI 10.1128/JB.185.13.3935-3947.2003; Stamper C, 2001, BIOCHEMISTRY-US, V40, P7035, DOI 10.1021/bi0100891; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; Walz J, 1999, J STRUCT BIOL, V128, P65, DOI 10.1006/jsbi.1999.4169; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; Wriggers W, 2001, J STRUCT BIOL, V133, P193, DOI 10.1006/jsbi.2000.4350; Yao TT, 1999, CURR BIOL, V9, pR551, DOI 10.1016/S0960-9822(99)80352-2	48	34	36	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36327	36337		10.1074/jbc.M604417200	http://dx.doi.org/10.1074/jbc.M604417200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16973604	hybrid			2022-12-25	WOS:000242100500084
J	Pelis, RM; Zhang, XH; Dangprapai, YY; Wright, SH				Pelis, Ryan M.; Zhang, Xiaohong; Dangprapai, Yodying; Wright, Stephen H.			Cysteine accessibility in the hydrophilic cleft of human organic cation transporter 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING REGION; LACTOSE PERMEASE; ESCHERICHIA-COLI; RAT-KIDNEY; CONTRALUMINAL TRANSPORT; PROXIMAL TUBULE; AMINO-ACIDS; ANION; TETRAETHYLAMMONIUM; LOCALIZATION	Organic cation transporters (OCTs) are involved in the renal elimination of many cationic drugs and toxins. A hypothetical three-dimensional structure of OCT2 based on a homology model that used the Escherichia coli glycerol 3-phosphate transporter as a template has been described (Zhang, X., Shirahatti, N. V., Mahadevan, D., and Wright, S. H. (2005) J. Biol. Chem. 280, 34813-34822). To further define OCT structure, the accessibility to hydrophilic thiol-reactive reagents of the 13 cysteine residues contained in the human ortholog of OCT2 was examined. Maleimide-PEO2-biotin precipitated (surface biotinylation followed by Western blotting) and reduced tetraethylammonium transport by OCT2 expressed in Chinese hamster ovary cells, effects that were largely reversed by co-exposure to substrates and transport inhibitors, suggesting interaction with cysteines that are near to or part of a substrate-binding surface. Cysteines at amino acid position 437, 451, 470, and 474 were identified from the model as being located in transmembrane helices that participate in forming the hydrophilic cleft, the proposed region of substrate-protein interaction. To determine which residues are exposed to the solvent, a mutant with all four of these cysteines converted to alanine, along with four variants of this mutant each with an individual cysteine restored, were created. Maleimide-PEO2-biotin was only effective at precipitating and reducing transport by wild-type OCT2 and the mutant with cysteine 474 restored. Additionally, the smaller thiol-reactive reagent, methanethiosulfonate ethylsulfonate, reduced transport by wild-type OCT2 and the mutant with cysteine 474 restored. These data demonstrate that cysteine 474 of OCT2 is exposed to the aqueous milieu of the cleft and contributes to forming a pathway for organic cation transport.	Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85743 USA	University of Arizona	Pelis, RM (corresponding author), Univ Arizona, Coll Med, Dept Physiol, POB 245051, Tucson, AZ 85743 USA.	rpelis@email.arizona.edu			NHLBI NIH HHS [HL07249] Funding Source: Medline; NIDDK NIH HHS [DK58251, DK075242] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK075242, R01DK058251, R56DK058251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bednarczyk D, 2003, MOL PHARMACOL, V63, P489, DOI 10.1124/mol.63.3.489; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Bleasby K, 2002, FASEB J, V16, pA459; Dodd JR, 2005, J BIOL CHEM, V280, P32649, DOI 10.1074/jbc.M506723200; Dresser MJ, 2001, J PHARM SCI, V90, P397, DOI 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.3.CO;2-4; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Gorboulev V, 2005, MOL PHARMACOL, V67, P1612, DOI 10.1124/mol.104.008821; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Karbach U, 2000, AM J PHYSIOL-RENAL, V279, pF679, DOI 10.1152/ajprenal.2000.279.4.F679; Koepsell H, 2004, REV PHYSIOL BIOCH P, V150, P36, DOI 10.1007/s10254-003-0017-x; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Pelis RM, 2006, AM J PHYSIOL-RENAL, V290, pF1118, DOI 10.1152/ajprenal.00462.2005; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; Pritchard JB, 1996, KIDNEY INT, V49, P1649, DOI 10.1038/ki.1996.240; Suhre WM, 2005, MOL PHARMACOL, V67, P1067, DOI 10.1124/mol.104.004713; Thomas MC, 2004, J PHARMACOL EXP THER, V311, P456, DOI 10.1124/jpet.104.070672; ULLRICH KJ, 1993, PFLUG ARCH EUR J PHY, V425, P300, DOI 10.1007/BF00374180; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; ULLRICH KJ, 1992, PFLUG ARCH EUR J PHY, V420, P29, DOI 10.1007/BF00378638; ULLRICH KJ, 1993, PFLUG ARCH EUR J PHY, V425, P280, DOI 10.1007/BF00374179; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Wright SH, 2005, TOXICOL APPL PHARM, V204, P309, DOI 10.1016/j.taap.2004.10.021; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Zhang XH, 2005, J BIOL CHEM, V280, P34813, DOI 10.1074/jbc.M506342200	27	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35272	35280		10.1074/jbc.M606561200	http://dx.doi.org/10.1074/jbc.M606561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990275	hybrid			2022-12-25	WOS:000241933700061
J	Zegzouti, H; Li, W; Lorenz, TC; Xie, MT; Payne, CT; Smith, K; Glenny, S; Payne, GS; Christensen, SK				Zegzouti, Hicham; Li, Wei; Lorenz, Todd C.; Xie, Mingtang; Payne, C. Thomas; Smith, Kelly; Glenny, Scott; Payne, Gregory S.; Christensen, Sioux K.			Structural and functional insights into the regulation of Arabidopsis AGC VIIIa kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT HAIR-GROWTH; PROTEIN-KINASES; SIGNALING PATHWAY; PDK1; DOMAIN; PHOSPHORYLATION; ADAPTER; CELLS	The AGCVIIIa kinases of Arabidopsis are members of the eukaryotic PKA, PKG, and PKC group of regulatory kinases. One AGCVIIIa kinase, PINOID (PID), plays a fundamental role in the asymmetrical localization of membrane proteins during polar auxin transport. The remaining 16 AGCVIIIa genes have not been associated with single mutant phenotypes, suggesting that the corresponding kinases function redundantly. Consistent with this idea, we find that the genes encoding the Arabidopsis AGCVIIIa kinases have spatially distinct, but overlapping, expression domains. Here we show that the majority of Arabidopsis AGCVIIIa kinases are substrates for the 3-phosphoinositide-dependent kinase 1 (PDK1) and that trans-phosphorylation by PDK1 correlates with activation of substrate AGCVIIIa kinases. Mutational analysis of two conserved regulatory domains was used to demonstrate that sequences located outside of the C-terminal PDK1 interaction (PIF) domain and the activation loop are required for functional interactions between PDK1 and its substrates. A subset of GFP-tagged AGCVIIIa kinases expressed in Saccharomyces cerevisiae and tobacco BY-2 cells were preferentially localized to the cytoplasm (AGC1-7), nucleus (WAG1 and KIPK), and the cell periphery (PID). We present evidence that PID insertion domain sequences are sufficient to direct the observed peripheral localization. We find that PID specifically but non-selectively binds to phosphoinositides and phosphatidic acid, suggesting that PID might directly interact with the plasma membrane through protein-lipid interactions. The initial characterization of the AGCVIIIa kinases presented here provides a framework for elucidating the physiological roles of these kinases in planta.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Christensen, SK (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, David Geffen Sch Med, POB 951606, Los Angeles, CA 90095 USA.	sioux@ucla.edu		Zegzouti, Hicham/0000-0002-0989-6195; Xie, Mingtang/0000-0002-2797-0598; Lorenz, Todd/0000-0001-7847-7325	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064584, R01GM039040] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM64584, R01 GM39040] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Benjamins R, 2001, DEVELOPMENT, V128, P4057; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bogre L, 2003, TRENDS PLANT SCI, V8, P424, DOI 10.1016/S1360-1385(03)00188-2; Briggs WR, 2002, TRENDS PLANT SCI, V7, P204, DOI 10.1016/S1360-1385(02)02245-8; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Champion A., 2004, Functional & Integrative Genomics, V4, P163, DOI 10.1007/s10142-003-0096-4; Christensen SK, 2000, CELL, V100, P469, DOI 10.1016/S0092-8674(00)80682-0; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Day IS, 2000, J BIOL CHEM, V275, P13737, DOI 10.1074/jbc.275.18.13737; Devarenne TP, 2006, EMBO J, V25, P255, DOI 10.1038/sj.emboj.7600910; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Force A, 1999, GENETICS, V151, P1531; Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lee SH, 2006, PLANT CELL, V18, P1604, DOI 10.1105/tpc.105.035972; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Oyama T, 2002, PLANT J, V30, P289, DOI 10.1046/j.1365-313X.2002.01290.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Santner AA, 2006, PLANT J, V45, P752, DOI 10.1111/j.1365-313X.2005.02641.x; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Turck F, 2004, PLANT PHYSIOL, V134, P1527, DOI 10.1104/pp.103.035873; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Zegzouti H, 2006, P NATL ACAD SCI USA, V103, P6404, DOI 10.1073/pnas.0510283103; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	37	66	72	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35520	35530		10.1074/jbc.M605167200	http://dx.doi.org/10.1074/jbc.M605167200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973627	hybrid			2022-12-25	WOS:000241933700085
J	An, HJ; Maeng, O; Kang, KH; Lee, JO; Kim, YS; Paik, SG; Lee, H				An, Hyun-Jung; Maeng, Oky; Kang, Kyoung-Hee; Lee, Jie-Oh; Kim, Young-Sang; Paik, Sang-Gi; Lee, Hayyoung			Activation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; GUANINE-NUCLEOTIDE EXCHANGE; C-HA-RAS; PROTEIN BNIP3; SURVIVAL RESPONSIVENESS; PANCREATIC-CANCER; GENE-EXPRESSION; BH3 DOMAIN; MACROPHAGES; HYPOXIA	Nitric oxide ( NO) produced by NO synthases causes nitration and nitrosylation of cellular factors. We have shown previously that endogenously produced or exogenously added NO induces expression of BNIP3 (Bcl-2/adenovirus E1B 19kDa-interacting protein 3), leading to death of macrophages (Yook, Y.-H., Kang, K.-H., Maeng, O., Kim, T.-R., Lee, J.-O., Kang, K.-i., Kim, Y.-S., Paik, S.-G., and Lee, H. ( 2004) Biochem. Biophys. Res. Commun. 321, 298-305). We now provide evidence that Ras mediates NO-induced BNIP3 expression via the MEK/ERK/hypoxia-inducible factor (HIF)-1 pathway. (a)ras-Q61L, a constitutively active form of Ras, up-regulated BNIP3 protein expression by enhancing Bnip3 promoter activity, and ras-S17N, a dominant-negative form, and ras-C118S, an S-nitrosylation mutant, blocked NO-induced BNIP3 expression, suggesting that Ras acts downstream of NO and that NO activates Ras by nitrosylation. (b) U0126, a specific MEK inhibitor, completely abolished BNIP3 expression and the stimulation of promoter activity by NO and Ras, whereas 1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one, SB203580, and wortmannin, specific inhibitors of soluble guanylyl cyclase, p38 MAPK, and phosphatidylinositol 3-kinase, respectively, had no effect. Ras, MEK1/2, and ERK1/2 were sequentially activated by NO treatment of macrophages. ( c) Mutation of the HIF-1-binding site (hypoxia-response element) in the Bnip3 promoter abolished BNIP3 induction, and HIF-1 alpha was strongly induced by NO. (d) Transient expression of activated Ras promoted macrophage death, as did NO, and this Ras-mediated cell death was inhibited by silencing BNIP3 expression. These results suggest that NO-induced death of macrophages is mediated, at least in part, by BNIP3 induction.	Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Chungnam Natl Univ, Dept Biochem, Sch Biosci & Biotechnol, Taejon 305764, South Korea; Chungnam Natl Univ, Inst Biotechnol, Taejon 305764, South Korea; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea	Chungnam National University; Chungnam National University; Chungnam National University; Korea Advanced Institute of Science & Technology (KAIST)	Paik, SG (corresponding author), Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea.	sgpaik@cnu.ac.kr; hlee@cnu.ac.kr	Lee, Jie-Oh/C-1581-2011; Lee, Jie-Oh/AAG-4302-2020	Lee, Jie-Oh/0000-0001-6519-6049				Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chang FM, 2003, INT J ONCOL, V22, P469; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; Drosopoulos KG, 2005, J BIOL CHEM, V280, P22856, DOI 10.1074/jbc.M412483200; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Jeong HS, 2002, J NEURO-ONCOL, V60, P97; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kasuno K, 2004, J BIOL CHEM, V279, P2550, DOI 10.1074/jbc.M308197200; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Kim SO, 2001, J ENDOTOXIN RES, V7, P292, DOI 10.1179/096805101101532873; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Klampfer L, 2005, ONCOGENE, V24, P3932, DOI 10.1038/sj.onc.1208552; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Messmer UK, 1996, FEBS LETT, V384, P162; MESSMER UK, 1994, FEBS LETT, V355, P23; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Mott HR, 1997, BIOCHEMISTRY-US, V36, P3640, DOI 10.1021/bi962790o; Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422; Murai M, 2005, CLIN CANCER RES, V11, P1021; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sowter HM, 2001, CANCER RES, V61, P6669; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wan J, 2003, IMMUNOLOGY, V110, P10, DOI 10.1046/j.1365-2567.2003.01710.x; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yook YH, 2004, BIOCHEM BIOPH RES CO, V321, P298, DOI 10.1016/j.bbrc.2004.06.144; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	49	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33939	33948		10.1074/jbc.M605819200	http://dx.doi.org/10.1074/jbc.M605819200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16954213	hybrid			2022-12-25	WOS:000241767600015
J	Archbold, JK; Macdonald, WA; Miles, JJ; Brennan, RM; Kjer-Nielsen, L; McCluskey, J; Burrows, SR; Rossjohn, J				Archbold, Julia K.; Macdonald, Whitney A.; Miles, John J.; Brennan, Rebekah M.; Kjer-Nielsen, Lars; McCluskey, James; Burrows, Scott R.; Rossjohn, Jamie			Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is the result of highly focused, peptide-dependent structural mimicry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL EPITOPE; MHC CLASS-I; CRYSTAL-STRUCTURE; RECEPTOR; RECOGNITION; AFFINITY; CTL; IDENTIFICATION; ALLORESPONSE	Our understanding of the molecular mechanisms of T cell alloreactivity remains limited by the lack of systems for which both the T cell receptor allo-and cognate ligand are known. Here we provide evidence that a single alloreactive T cell receptor interacts with analogous structural regions of its cognate ligand, HLA-B*0801(FLRGRAYGL), as its allogeneic ligand, HLA-B*3501(KPIVVLHGY). The crystal structures of the binary peptide-major histocompatibility complexes show marked differences in the conformation of the heavy chains as well as the bound peptides. Nevertheless, both epitopes possess a prominent solvent-exposed aromatic residue at position 7 flanked by a small glycine at position 8 of the peptide determinant. Moreover, regions of close structural homology between the heavy chains of HLA B8 and HLA B35 coincided with regions that have previously been implicated in "hot spots" of T cell receptor recognition. The avidity of this human T cell receptor was also comparable for the allo- and cognate ligand, consistent with the modes of T cell receptor binding being broadly similar for these complexes. Collectively, it appears that highly focused structural mimicry against a diverse structural background provides a basis for the observed alloreactivity in this system. This cross-reactivity underpins the T cell degeneracy inherent in the limited mature T cell repertoire that must respond to a vast diversity of microbial antigens.	Queensland Inst Med Res, Cellular Immunol Lab, Brisbane, Qld 4029, Australia; Monash Univ, Sch Biomed Sci, Prot Crystallog Unit, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia	QIMR Berghofer Medical Research Institute; Monash University; University of Melbourne	Burrows, SR (corresponding author), Queensland Inst Med Res, Cellular Immunol Lab, Brisbane, Qld 4029, Australia.	Scott.Burrows@qimr.edu.au; jamie.rossjohn@med.monash.edu.au	Archbold, Julia/N-2884-2013; Engel, Rebekah/AAQ-2644-2020; Miles, John J/ABC-1105-2020; Brennan, Rebekah/C-6172-2013; Rossjohn, Jamie/F-9032-2013; Burrows, Scott/G-2050-2011; McCluskey, James/A-1291-2007	Archbold, Julia/0000-0002-7768-4784; Engel, Rebekah/0000-0003-1951-547X; Miles, John J/0000-0001-5506-6304; Rossjohn, Jamie/0000-0002-2020-7522; Burrows, Scott/0000-0002-1430-0472; McCluskey, James/0000-0002-8597-815X				ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335; Auchincloss Hugh Jr., 1993, P1099; Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, 1993, J IMMUNOL, V151, P3943; Borg NA, 2005, NAT IMMUNOL, V6, P171, DOI 10.1038/ni1155; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURROWS SR, 1990, J EXP MED, V171, P345, DOI 10.1084/jem.171.1.345; Burrows SR, 1997, EUR J IMMUNOL, V27, P1726, DOI 10.1002/eji.1830270720; BURROWS SR, 1995, J EXP MED, V182, P1703, DOI 10.1084/jem.182.6.1703; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; CHATTOPADHYAY S, 1994, J EXP MED, V179, P213, DOI 10.1084/jem.179.1.213; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; Housset D, 2003, TRENDS IMMUNOL, V24, P429, DOI 10.1016/S1471-4906(03)00180-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kedzierska K, 2005, P NATL ACAD SCI USA, V102, P11432, DOI 10.1073/pnas.0504851102; KEEVER CA, 1994, BONE MARROW TRANSPL, V14, P137; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; Kjer-Nielsen L, 2002, J IMMUNOL, V169, P5153, DOI 10.4049/jimmunol.169.9.5153; Kjer-Nielsen L, 2002, STRUCTURE, V10, P1521, DOI 10.1016/S0969-2126(02)00878-X; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Luz JG, 2002, J EXP MED, V195, P1175, DOI 10.1084/jem.20011644; Macdonald W, 2002, FEBS LETT, V527, P27, DOI 10.1016/S0014-5793(02)03149-6; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; Miles JJ, 2005, J IMMUNOL, V175, P3826, DOI 10.4049/jimmunol.175.6.3826; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Obst R, 2000, J EXP MED, V191, P805, DOI 10.1084/jem.191.5.805; Pittet MJ, 2006, J IMMUNOL, V176, P2330, DOI 10.4049/jimmunol.176.4.2330; Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SHERMAN LA, 1982, J EXP MED, V155, P380, DOI 10.1084/jem.155.2.380; Smith KJ, 1996, IMMUNITY, V4, P203, DOI 10.1016/S1074-7613(00)80429-X; Smith PA, 1997, J EXP MED, V185, P1023, DOI 10.1084/jem.185.6.1023; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; Tynan FE, 2005, NAT IMMUNOL, V6, P1114, DOI 10.1038/ni1257; Tynan FE, 2005, J BIOL CHEM, V280, P23900, DOI 10.1074/jbc.M503060200; Tynan FE, 2005, J EXP MED, V202, P1249, DOI 10.1084/jem.20050864; VILLADANGOS JA, 1994, J IMMUNOL, V152, P2317; Yee C, 1999, J IMMUNOL, V162, P2227; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	49	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34324	34332		10.1074/jbc.M606755200	http://dx.doi.org/10.1074/jbc.M606755200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963442	hybrid			2022-12-25	WOS:000241767600052
J	Keil, C; Grobe, T; Oei, SL				Keil, Claudia; Groebe, Tina; Oei, Shiao Li			MNNG-induced cell death is controlled by interactions between PARP-1, poly(ADP-ribose) glycohydrolase, and XRCC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; BASE EXCISION-REPAIR; SISTER-CHROMATID EXCHANGE; OXIDATIVE DNA-DAMAGE; MAMMALIAN-CELLS; LIGASE-III; IN-VITRO; POLYMERASE; ATP; METABOLISM	PARP-1 (poly(ADP-ribose) polymerases) modifies proteins with poly(ADP-ribose), which is an important signal for genomic stability. ADP-ribose polymers also mediate cell death and are degraded by poly(ADP-ribose) glycohydrolase (PARG). Here we show that the catalytic domain of PARG interacts with the automodification domain of PARP-1. Furthermore, PARG can directly down-regulate PARP-1 activity. PARG also interacts with XRCC1, a DNA repair factor that is recruited by DNA damage-activated PARP-1. We investigated the role of XRCC1 in cell death after treatment with supralethal doses of the alkylating agent MNNG. Only in XRCC1-proficient cells MNNG induced a considerable accumulation of poly(ADP-ribose). Similarly, extracts of XRCC1-deficient cells produced large ADPribose polymers if supplemented with XRCC1. Consequently, MNNG triggered in XRCC1-proficient cells the translocation of the apoptosis inducing factor from mitochondria to the nucleus followed by caspase-independent cell death. In XRCC1-deficient cells, the same MNNG treatment caused non-apoptotic cell death without accumulation of poly(ADP-ribose). Thus, XRCC1 seems to be involved in regulating a poly(ADP-ribose)mediated apoptotic cell death.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Free University of Berlin	Oei, SL (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.	lity@chemie.fu-berlin.de		Keil, Claudia/0000-0003-0317-0905				Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; Bonicalzi ME, 2003, BIOL CELL, V95, P635, DOI 10.1016/j.biolcel.2003.10.003; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Cortes U, 2004, MOL CELL BIOL, V24, P7163, DOI 10.1128/MCB.24.16.7163-7178.2004; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Davidovic L, 2001, EXP CELL RES, V268, P7, DOI 10.1006/excr.2001.5263; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Gagne JP, 2005, BIOCHEM J, V392, P499, DOI 10.1042/BJ20050792; GOTHGOLDSTEIN R, 1987, MUTAT RES, V177, P267, DOI 10.1016/0027-5107(87)90010-8; Griesenbeck J, 1997, BIOCHEMISTRY-US, V36, P7297, DOI 10.1021/bi962710g; Griesenbeck J, 1999, FEBS LETT, V443, P20, DOI 10.1016/S0014-5793(98)01671-8; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hanai S, 2004, P NATL ACAD SCI USA, V101, P82, DOI 10.1073/pnas.2237114100; IKEJIMA M, 1984, MUTAT RES, V128, P213, DOI 10.1016/0027-5107(84)90109-X; Jacobson EL, 1997, METHOD ENZYMOL, V280, P221; James P, 1996, GENETICS, V144, P1425; Keil C, 2004, ARCH BIOCHEM BIOPHYS, V425, P115, DOI 10.1016/j.abb.2004.02.024; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; Kun E, 2004, BIOCHEMISTRY-US, V43, P210, DOI 10.1021/bi0301791; Lan L, 2004, P NATL ACAD SCI USA, V101, P13738, DOI 10.1073/pnas.0406048101; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; MALANGA M, 1994, J BIOL CHEM, V269, P17691; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MENARD L, 1990, BIOCHIM BIOPHYS ACTA, V1049, P45, DOI 10.1016/0167-4781(90)90083-E; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Meyer RG, 2003, GENE, V314, P181, DOI 10.1016/S0378-1119(03)00738-8; Meyer-Ficca ML, 2004, EXP CELL RES, V297, P521, DOI 10.1016/j.yexcr.2004.03.050; Nakamura J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng105; Oei SL, 2005, BIOCHEM CELL BIOL, V83, P263, DOI 10.1139/o05-039; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Ohashi S, 2003, BIOCHEM BIOPH RES CO, V307, P915, DOI 10.1016/S0006-291X(03)01272-5; Oka S, 2006, J BIOL CHEM, V281, P705, DOI 10.1074/jbc.M510290200; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Patel CN, 2005, BIOCHEM J, V388, P493, DOI 10.1042/BJ20040942; Petermann E, 2005, CELL MOL LIFE SCI, V62, P731, DOI 10.1007/s00018-004-4504-2; Petermann E, 2003, DNA REPAIR, V2, P1101, DOI 10.1016/S1568-7864(03)00117-4; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rossi L, 2002, BIOCHIMIE, V84, P1229; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanaka S, 2005, J NEUROCHEM, V95, P179, DOI 10.1111/j.1471-4159.2005.03353.x; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	58	45	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34394	34405		10.1074/jbc.M606470200	http://dx.doi.org/10.1074/jbc.M606470200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963444	hybrid			2022-12-25	WOS:000241767600060
J	Kundu, P; Mukhopadhyay, AK; Patra, R; Banerjee, A; Berg, DE; Swarnakar, S				Kundu, Parag; Mukhopadhyay, Asish K.; Patra, Rajashree; Banerjee, Aditi; Berg, Douglas E.; Swarnakar, Snehasikta			Cag pathogenicity island-independent up-regulation of matrix metalloproteinases-9 and -2 secretion and expression in mice by Helicobacter pylori infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; IN-VITRO; INFLAMMATORY RESPONSE; VIRULENCE FACTORS; MOUSE MODEL; STRAIN SS1; COLONIZATION; TIMP-1	Helicobacter pylori cag pathogenicity island (PAI) is a major determinant of gastric injury via induction of several matrix metalloproteinases (MMPs). In the present study, we examined the influence of the cag PAI on gastric infection and MMP-9 production in mice and in cultured cells. A new mouse colonizing Indian H. pylori strain (AM1) that lacks the cag PAI was used to study the cag PAI importance in inflammation. Groups of C57BL/6 mice were inoculated separately with H. pylori strains AM1 and SS1 (cag(+)), gastric tissues were histologically examined, and bacterial colonization was scored by quantitative culture. Mice infected with either cag(+) or cag(-) H. pylori strains showed gastric inflammation and elevated MMP-3 production. Significant up-regulation of pro-MMP-9 secretion and gene expression in H. pylori infected gastric tissues indicate dispensability of cag PAI for increased pro-MMP-9 secretion and synthesis in mice. In agreement, cell culture studies revealed that both AM1 and SS1 were equipotent in pro-MMP-9 induction in human gastric epithelial cells. Both strains showed moderate increase in MMP-2 activity in vivo and in vitro. In addition, increased secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and IL-6 induced pro-MMP-9 secretion and synthesis in AM1 or SS1 strain-infected mice suggesting elicitation of pro-inflammatory cytokines by both cag(-) and cag(+) genotype. Moreover, tissue inhibitors of metalloproteinase-1 expression were decreased with increase in pro-MMP-9 induction. These data show that H. pylori may act through different pathways other than cag PAI-mediated for gastric inflammation and contribute to upregulation of MMP-9 via pro-inflammatory cytokines.	Indian Inst Chem Biol, Dept Physiol, Kolkata 700032, W Bengal, India; Natl Inst Cholera & Enter Dis, Kolkata 700010, W Bengal, India; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); Washington University (WUSTL)	Swarnakar, S (corresponding author), Indian Inst Chem Biol, Dept Physiol, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	snehasiktas@hotmail.com	Das, Rajashree/AAS-4747-2020; Mukhopadhyay, Asish/ABE-7697-2020; Das, Rajashree/D-1755-2017	Das, Rajashree/0000-0003-1202-4942; Swarnakar, Snehasikta/0000-0002-7139-9683; Kundu, Parag/0000-0002-8684-7530				Achtman M, 1999, MOL MICROBIOL, V32, P459, DOI 10.1046/j.1365-2958.1999.01382.x; Atherton JC, 1998, BRIT MED BULL, V54, P105; Audibert C, 2001, INFECT IMMUN, V69, P1625, DOI 10.1128/IAI.69.3.1625-1629.2001; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Bergin PJ, 2005, FEMS IMMUNOL MED MIC, V45, P159, DOI 10.1016/j.femsim.2005.03.008; Bergin PJ, 2004, HELICOBACTER, V9, P201, DOI 10.1111/j.1083-4389.2004.00232.x; Blaser MJ, 1999, P NATL ACAD SCI USA, V96, P8359, DOI 10.1073/pnas.96.15.8359; BLASER MJ, 1995, CANCER RES, V55, P2111; Campbell S, 1997, INFECT IMMUN, V65, P3708, DOI 10.1128/IAI.65.9.3708-3712.1997; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLEMENS J, 1995, J INFECT DIS, V171, P1653, DOI 10.1093/infdis/171.6.1653; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; Crabtree JE, 2002, HELICOBACTER, V7, P139, DOI 10.1046/j.1083-4389.2002.00071.x; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; Dale A, 1998, J PEDIATR GASTR NUTR, V26, P393, DOI 10.1097/00005176-199804000-00006; Datta S, 2003, J CLIN MICROBIOL, V41, P3737, DOI 10.1128/JCM.41.8.3737-3743.2003; Eaton KA, 2002, INFECT IMMUN, V70, P771, DOI 10.1128/IAI.70.2.771-778.2002; Eaton KA, 2001, INFECT IMMUN, V69, P2902, DOI 10.1128/IAI.69.5.2902-2908.2001; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Ferrero RL, 1998, INFECT IMMUN, V66, P1349, DOI 10.1128/IAI.66.4.1349-1355.1998; Gambero A, 2003, FEMS IMMUNOL MED MIC, V38, P193, DOI 10.1016/S0928-8244(03)00171-8; Ganguly K, 2006, FREE RADICAL BIO MED, V41, P911, DOI 10.1016/j.freeradbiomed.2006.04.022; GIONCHETTI P, 1994, AM J GASTROENTEROL, V89, P883; Go M F, 1996, Helicobacter, V1, P107, DOI 10.1111/j.1523-5378.1996.tb00019.x; Gooz M, 2003, GUT, V52, P1250, DOI 10.1136/gut.52.9.1250; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; Graham DY, 2000, HELICOBACTER, V5, pS3; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Ishiguro N, 1999, J RHEUMATOL, V26, P34; Kabashima A, 2000, CLIN CANCER RES, V6, P3581; Kauser F, 2004, J CLIN MICROBIOL, V42, P5302, DOI 10.1128/JCM.42.11.5302-5308.2004; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kodama K, 1999, J GASTROENTEROL, V34, P6; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; Krueger S, 2006, J BIOL CHEM, V281, P2868, DOI 10.1074/jbc.m511053200; LEE A, 1990, GASTROENTEROLOGY, V99, P1315, DOI 10.1016/0016-5085(90)91156-Z; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; Lempinen M, 2000, EUR SURG RES, V32, P169, DOI 10.1159/000008759; Lindholm C, 1998, INFECT IMMUN, V66, P5964, DOI 10.1128/IAI.66.12.5964-5971.1998; Maeda S, 1997, DIGEST DIS SCI, V42, P1841, DOI 10.1023/A:1018846723379; Maeda S, 1999, GUT, V44, P336, DOI 10.1136/gut.44.3.336; MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116; Menges M, 2000, Z GASTROENTEROL, V38, P887, DOI 10.1055/s-2000-10300; MOBLEY LTH, 2001, HELICOBACTER PYLORI; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Mukhopadhyay AK, 2000, J BACTERIOL, V182, P3219, DOI 10.1128/JB.182.11.3219-3227.2000; Murphy G, 1995, ACTA ORTHOP SCAND, V66, P55, DOI 10.3109/17453679509157648; Nolan KJ, 2002, INFECT IMMUN, V70, P685, DOI 10.1128/IAI.70.2.685-691.2002; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ohnita K, 2005, WORLD J GASTROENTERO, V11, P1549; Parks WC, 1998, BIOL EXTRAC, P263; Peek RM, 1999, CANCER RES, V59, P6124; Peek RM, 1995, LAB INVEST, V73, P760; Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Swarnakar S, 2005, J BIOL CHEM, V280, P9409, DOI 10.1074/jbc.M413398200; Thompson LJ, 2004, INFECT IMMUN, V72, P4668, DOI 10.1128/IAI.72.8.4668-4679.2004; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Doorn LJ, 1999, GASTROENTEROLOGY, V116, P823, DOI 10.1016/S0016-5085(99)70065-X; von Lampe B, 2000, GUT, V47, P63, DOI 10.1136/gut.47.1.63; Westblom TU, 1999, CURR TOP MICROBIOL, V241, P215; Yanagisawa N, 2005, FEMS IMMUNOL MED MIC, V44, P197, DOI 10.1016/j.femsim.2004.11.009; Yokoyama T, 2000, ALIMENT PHARM THERAP, V14, P193, DOI 10.1046/j.1365-2036.2000.014s1193.x; Zhang YH, 1998, J IMMUNOL, V161, P3071	69	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34651	34662		10.1074/jbc.M604574200	http://dx.doi.org/10.1074/jbc.M604574200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966323	hybrid			2022-12-25	WOS:000241767600084
J	Vallon, M; Essler, M				Vallon, Mario; Essler, Markus			Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin alpha(v)beta(3) to glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADHESION; BINDING; SURFACE; CD97	Tumor endothelial marker (TEM) 5 is a member of the adhesion family of G-protein-coupled receptors and up-regulated in endothelial cells during tumor and physiologic angiogenesis. Here, we report that TEM5 is expressed on the surface of endothelial cells. A soluble TEM5(sTEM5) fragment is shed by endothelial cells during capillary-like network formation and upon growth factor stimulation. We found that sTEM5 binds to several glycosaminoglycans. Furthermore, sequence analysis and functional and biochemical studies revealed that sTEM5 contains a cryptic RGD-binding site for integrin alpha(v)beta(3). Matrix metalloprotease 9-processed, but not full-length, sTEM5 mediated endothelial cell adhesion by direct interaction with integrin alpha(v)beta(3). Adhesion to proteolytically processed sTEM5 (ppsTEM5) or glycosaminoglycan-bound ppsTEM5 promoted survival of growth factor deprived endothelial cells. ppsTEM5-mediated cell survival was inhibited by a function blocking integrin alpha(v)beta(3) antibody. Based on our results we conclude that sTEM5 is shed by endothelial cells during angiogenesis and binds to glycosaminoglycans present on extracellular matrix and cell surface proteoglycans. Further proteolytic processing of sTEM5 leads to exposure of its RGD motif mediating endothelial cell survival by linking integrin alpha(v)beta(3) to glycosaminoglycans.	Tech Univ Munich, Dept Nucl Med, D-81675 Munich, Germany	Technical University of Munich; University of Munich	Essler, M (corresponding author), Tech Univ Munich, Dept Nucl Med, Ismaninger Str 22, D-81675 Munich, Germany.	markus.essler@gmx.de						Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Gray JX, 1996, J IMMUNOL, V157, P5438; Kaur B, 2005, ONCOGENE, V24, P3632, DOI 10.1038/sj.onc.1208317; Lee HK, 2006, FEBS LETT, V580, P2253, DOI 10.1016/j.febslet.2006.03.033; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; St Croix B, 2000, SCIENCE, V289, P1197; Varner Judith A., 1996, P69; Wang T, 2005, BLOOD, V105, P2836, DOI 10.1182/blood-2004-07-2878; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495	17	65	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34179	34188		10.1074/jbc.M605291200	http://dx.doi.org/10.1074/jbc.M605291200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16982628	hybrid			2022-12-25	WOS:000241767600038
J	Yan, FF; Casey, J; Shyng, SL				Yan, Fei-Fei; Casey, Jillene; Shyng, Show-Ling			Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING MUTATIONS; SUBUNIT STOICHIOMETRY; INSULIN-SECRETION; TOLBUTAMIDE SITE; KIR6.2; RECEPTOR; SUR1; GLIBENCLAMIDE; IDENTIFICATION; REPAGLINIDE	ATP-sensitive potassium (K-ATP) channels mediate glucose-induced insulin secretion by coupling metabolic signals to beta-cell membrane potential and the secretory machinery. Reduced K-ATP channel expression caused by mutations in the channel proteins: sulfonylurea receptor 1 (SUR1) and Kir6.2, results in loss of channel function as seen in congenital hyperinsulinism. Previously, we reported that sulfonylureas, oral hypoglycemic drugs widely used to treat type II diabetes, correct the endoplasmic reticulum to the plasma membrane trafficking defect caused by two SUR1 mutations, A116P and V187D. In this study, we investigated the mechanism by which sulfonylureas rescue these mutants. We found that glinides, another class of SUR-binding hypoglycemic drugs, also markedly increased surface expression of the trafficking mutants. Attenuating or abolishing the ability of mutant SUR1 to bind sulfonylureas or glinides by the following mutations: Y230A, S1238Y, or both, accordingly diminished the rescuing effects of the drugs. Interestingly, rescue of the trafficking defects requires mutant SUR1 to be co-expressed with Kir6.2, suggesting that the channel complex, rather than SUR1 alone, is the drug target. Observations that sulfonylureas also reverse trafficking defects caused by neonatal diabetes-associated Kir6.2 mutations in a way that is dependent on intact sulfonylurea binding sites in SUR1 further support this notion. Our results provide insight into the mechanistic and structural basis on which sulfonylureas rescue K-ATP channel surface expression defects caused by channel mutations.	Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA	Oregon Health & Science University	Shyng, SL (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	shyngs@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57699, R01 DK057699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 2006, BIOCHEM SOC T, V34, P243, DOI 10.1042/BST0340243; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 2006, NEW ENGL J MED, V355, P456, DOI 10.1056/NEJMoa055068; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Babenko AP, 2002, J BIOL CHEM, V277, P43997, DOI 10.1074/jbc.M208085200; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; BROWN GR, 1984, J MED CHEM, V27, P79, DOI 10.1021/jm00367a016; Bryan J, 2004, DIABETES, V53, pS104, DOI 10.2337/diabetes.53.suppl_3.S104; Cartier EA, 2003, J BIOL CHEM, V278, P7081, DOI 10.1074/jbc.M211395200; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Crane A, 2004, J BIOL CHEM, V279, P9080, DOI 10.1074/jbc.M311079200; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Grell W, 1998, J MED CHEM, V41, P5219, DOI 10.1021/jm9810349; Gribble FM, 2003, DIABETOLOGIA, V46, P875, DOI 10.1007/s00125-003-1143-3; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gros L, 1999, BIOCHEM BIOPH RES CO, V257, P766, DOI 10.1006/bbrc.1999.0529; Hansen AMK, 2005, BRIT J PHARMACOL, V144, P551, DOI 10.1038/sj.bjp.0706082; Hattersley AT, 2005, DIABETES, V54, P2503, DOI 10.2337/diabetes.54.9.2503; Hoy M, 2000, J PHYSIOL-LONDON, V527, P109, DOI 10.1111/j.1469-7793.2000.00109.x; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; Lin CW, 2006, DIABETES, V55, P1738, DOI 10.2337/db05-1571; Melander A, 2004, DIABETES, V53, pS151, DOI 10.2337/diabetes.53.suppl_3.S151; Mikhailov MV, 2002, BIOCHEM SOC T, V30, P323, DOI 10.1042/BST0300323; Mikhailov MV, 2000, J BIOL CHEM, V275, P3360, DOI 10.1074/jbc.275.5.3360; Mikhailov MV, 2001, FEBS LETT, V499, P154, DOI 10.1016/S0014-5793(01)02538-8; Neagoe I, 2005, J MOL CELL CARDIOL, V38, P887, DOI 10.1016/j.yjmcc.2004.11.023; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; Pearson ER, 2006, NEW ENGL J MED, V355, P467, DOI 10.1056/NEJMoa061759; Perlmutter DH, 2002, PEDIATR RES, V52, P832, DOI 10.1203/01.PDR.0000036878.28942.14; Proks P, 2006, HUM MOL GENET, V15, P1793, DOI 10.1093/hmg/ddl101; Quast U, 2004, DIABETES, V53, pS156, DOI 10.2337/diabetes.53.suppl_3.S156; Reimann F, 1999, J PHYSIOL-LONDON, V518, P325, DOI 10.1111/j.1469-7793.1999.0325p.x; Renstrom E, 2002, DIABETES, V51, pS33, DOI 10.2337/diabetes.51.2007.S33; Robinson JM, 2005, NEURON, V45, P223, DOI 10.1016/j.neuron.2004.12.043; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Tonini G, 2006, DIABETOLOGIA, V49, P2210, DOI 10.1007/s00125-006-0329-x; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Yan FF, 2005, AM J PHYSIOL-CELL PH, V289, pC1351, DOI 10.1152/ajpcell.00240.2005; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	49	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33403	33413		10.1074/jbc.M605195200	http://dx.doi.org/10.1074/jbc.M605195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956886	hybrid			2022-12-25	WOS:000241621400050
J	Yamasaki, K; Schauber, J; Coda, A; Lin, H; Dorschner, RA; Schechter, NM; Bonnart, C; Descargues, P; Hovnanian, A; Gallo, RL				Yamasaki, Kenshi; Schauber, Jurgen; Coda, Alvin; Lin, Henry; Dorschner, Robert A.; Schechter, Norman M.; Bonnart, Chrystelle; Descargues, Pascal; Hovnanian, Alain; Gallo, Richard L.			Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin	FASEB JOURNAL			English	Article						antimicrobial peptide; stratum corneum tryptic enzyme; stratum corneum chymotryptic protease; lympho-epithelial Kazal-type related inhibitor; SELDI-TOF-MS	ANTIBACTERIAL PEPTIDE LL-37; CORNEUM CHYMOTRYPTIC ENZYME; SERINE-PROTEASE INHIBITOR; NETHERTON-SYNDROME; INNATE IMMUNITY; CUTTING EDGE; EXPRESSION; GENE; MUTATIONS; DEFENSE	The presence of cathelicidin antimicrobial peptides provides an important mechanism for prevention of infection against a wide variety of microbial pathogens. The activity of cathelicidin is controlled by enzymatic processing of the proform (hCAP18 in humans) to a mature peptide (LL-37 in human neutrophils). In this study, elements important to the processing of cathelicidin in the skin were examined. Unique cathelicidin peptides distinct from LL-37 were identified in normal skin. Through the use of selective inhibitors, SELDI-TOF-MS, Western blot, and siRNA, the serine proteases stratum corneum tryptic enzyme (SCTE, kallikrein 5) and stratum corneum chymotryptic protease (SCCE, kallikrein 7) were shown to control activation of the human cathelicidin precursor protein hCAP18 and also influence further processing to smaller peptides with alternate biological activity. The importance of this serine protease activity to antimicrobial activity in vivo was illustrated in SPINK5-deficent mice that lack the serine protease inhibitor LEKTI. Epidermal extracts of these animals show a significant increase in antimicrobial activity compared with controls, and immunoabsorption of cathelicidin diminished antimicrobial activity. These observations demonstrate that the balance of proteolytic activity at an epithelial interface will control innate immune defense.	Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA; VA San Diego Hlth Care Syst, San Diego, CA USA; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; Inserm U563, F-31300 Toulouse, France; Univ Toulouse 3, F-31062 Toulouse, France; CHU Purpan, Dept Genet, Toulouse, France	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Pennsylvania; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Gallo, RL (corresponding author), MC 9111B,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rgallo@ucsd.edu	Yamasaki, Kenshi/C-8905-2018; BONNART, Chrystelle/A-1309-2011; Hovnanian, Alain/I-4711-2017; Gallo, Richard L/A-8931-2009	Yamasaki, Kenshi/0000-0002-5495-4956; Hovnanian, Alain/0000-0003-3412-7512; Gallo, Richard L/0000-0002-1401-7861	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, R37AI052453, R21AI048176, N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57345] Funding Source: Medline; NIAID NIH HHS [N01-AI-40029, R01-AI052453, AI48176] Funding Source: Medline; NIAMS NIH HHS [R01-AR45676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Bitoun E, 2002, J INVEST DERMATOL, V118, P352, DOI 10.1046/j.1523-1747.2002.01603.x; Braff MH, 2005, J INVEST DERMATOL, V125, P9, DOI 10.1111/j.0022-202X.2004.23587.x; Braff MH, 2005, J INVEST DERMATOL, V124, P394, DOI 10.1111/j.0022-202X.2004.23443.x; Braff MH, 2005, J IMMUNOL, V174, P4271, DOI 10.4049/jimmunol.174.7.4271; Chang CI, 2005, INFECT IMMUN, V73, P5053, DOI 10.1128/IAI.73.8.5053-5064.2005; Chao SC, 2005, BRIT J DERMATOL, V152, P159, DOI 10.1111/J.1365-2133.2005.06337.X; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; Franzke CW, 1996, J BIOL CHEM, V271, P21886, DOI 10.1074/jbc.271.36.21886; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Ishida-Yamamoto A, 2005, J INVEST DERMATOL, V124, P360, DOI 10.1111/j.0022-202X.2004.23583.x; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Komatsu N, 2003, J INVEST DERMATOL, V121, P542, DOI 10.1046/j.1523-1747.2003.12363.x; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; Raghunath M, 2004, J INVEST DERMATOL, V123, P474, DOI 10.1111/j.0022-202X.2004.23220.x; Rosenberger CM, 2004, P NATL ACAD SCI USA, V101, P2422, DOI 10.1073/pnas.0304455101; Sayama K, 2005, EUR J IMMUNOL, V35, P1886, DOI 10.1002/eji.200425827; Schechter NM, 2005, BIOL CHEM, V386, P1173, DOI 10.1515/BC.2005.134; Sorensen OE, 2003, J BIOL CHEM, V278, P28540, DOI 10.1074/jbc.M301608200; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Strub MP, 2003, STRUCTURE, V11, P1359, DOI 10.1016/j.str.2003.09.014; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; van Dijk A, 2005, VET IMMUNOL IMMUNOP, V106, P321, DOI 10.1016/j.vetimm.2005.03.003; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; WIEDOW O, 1991, BIOCHEM BIOPH RES CO, V174, P6, DOI 10.1016/0006-291X(91)90476-N; Wu H, 2000, INFECT IMMUN, V68, P5552, DOI 10.1128/IAI.68.10.5552-5558.2000; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zaiou M, 2002, J MOL MED, V80, P549, DOI 10.1007/s00109-002-0350-6; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179, DOI 10.21775/cimb.007.179; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147	51	343	361	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2068	2080		10.1096/fj.06-6075com	http://dx.doi.org/10.1096/fj.06-6075com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012259				2022-12-25	WOS:000241156900015
J	Oliveira, C; Velho, S; Moutinho, C; Ferreira, A; Preto, A; Domingo, E; Capelinha, AF; Duval, A; Hamelin, R; Machado, JC; Schwartz, S; Carneiro, F; Seruca, R				Oliveira, C.; Velho, S.; Moutinho, C.; Ferreira, A.; Preto, A.; Domingo, E.; Capelinha, A. F.; Duval, A.; Hamelin, R.; Machado, J. C.; Schwartz, S., Jr.; Carneiro, F.; Seruca, R.			KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression	ONCOGENE			English	Article						KRAS; BRAF; colorectal carcinoma; instability; MAP kinase; lymph node metastases	RAS POINT MUTATIONS; CELL-CYCLE ARREST; K-RAS; COLON-CANCER; WILD-TYPE; EXPRESSION; ASSOCIATION; ACTIVATION; MELANOMA; PATTERNS	In sporadic colorectal cancer (CRC), KRAS are alternative to BRAF mutations and occur, respectively, in 30 and 10% of cases. Few reports addressed the association between KRAS - BRAF mutations and tumour progression specifically in sporadic microsatellite-stable (MSS) CRC. We screened KRAS and BRAF in 250 MSS primary CRC and 45 lymph node (LN) metastases and analysed the pathological features of the cases to understand the involvement of KRAS - BRAF activation in progression and metastasis. Forty-five per cent of primary MSS CRCs carried mutations in at least one of these genes and mutations were associated with wall invasion (P = 0.02), presence and number of LN metastases (P = 0.02 and P = 0.03, respectively), distant metastases (P = 0.004) and advanced stage (P = 0.01). We demonstrated that KRAS and BRAF are alternative events in Tis and T1 MSS CRC and, KRAS rather than BRAF mutations, contributed to the progression of MSS CRC. The frequency of KRAS and/or BRAF mutations was higher in LN metastases than in primary carcinomas (P = 0.0002). Mutated LN metastases displayed KRAS associated or not with BRAF mutations. BRAF mutations were never present as a single event. Concomitant KRAS and BRAF mutations increased along progression of MSS CRCs, suggesting that activation of both genes is likely to harbour a synergistic effect.	Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4200465 Oporto, Portugal; Hosp Univ Vall Hebron, CIBBIM, Barcelona, Spain; Hosp Sao Joao, Dept Pathol, Oporto, Portugal; INSERM, U762, CEPH, Paris, France; Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Hospital Universitari Vall d'Hebron; Sao Joao Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade do Porto	Seruca, R (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.	rseruca@ipatimup.pt	Oliveira, Carla/F-8188-2011; Carneiro, Fatima/AAV-8677-2021; Preto, Ana/H-8112-2012; seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012; Machado, Jose Carlos/C-5907-2009; Velho, Sérgia/B-8501-2013; Domingo, Enric/A-9099-2018; Carneiro, Fatima/J-6432-2013	Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; Preto, Ana/0000-0002-7302-0630; Machado, Jose Carlos/0000-0003-4741-8415; Velho, Sérgia/0000-0002-7104-8234; Domingo, Enric/0000-0003-4390-8767; Carneiro, Fatima/0000-0002-1964-1006; Seruca, Raquel/0000-0002-8851-4166; Ferreira, Ana/0000-0001-6290-1320; Schwartz, Simo/0000-0001-8297-7971				Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, CANCER, V71, P3827, DOI 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N; Fransen K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ikehara N, 2005, INT J CANCER, V115, P943, DOI 10.1002/ijc.20957; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; Kerkhoff E, 1998, CANCER RES, V58, P1636; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; Lipton L, 2003, CANCER RES, V63, P7595; Lubomierski N, 2005, CANCER-AM CANCER SOC, V104, P952, DOI 10.1002/cncr.21266; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; MOERKERK P, 1994, CANCER RES, V54, P3376; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Oliveira C, 2004, HUM MOL GENET, V13, P2303, DOI 10.1093/hmg/ddh238; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Schramm K, 2000, INT J CANCER, V87, P155, DOI 10.1002/1097-0215(20000715)87:2<155::AID-IJC1>3.0.CO;2-J; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Span M, 1996, INT J CANCER, V69, P241, DOI 10.1002/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.3.CO;2-D; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang L, 2003, CANCER RES, V63, P5209; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Yuen ST, 2002, CANCER RES, V62, P6451	52	139	143	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					158	163		10.1038/sj.onc.1209758	http://dx.doi.org/10.1038/sj.onc.1209758			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16953233				2022-12-25	WOS:000243236500016
J	Gherghe, C; Weeks, KM				Gherghe, Cristina; Weeks, Kevin M.			The SL1-SL2 (stem-loop) domain is the primary determinant for stability of the gamma retroviral genomic RNA dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE-LEUKEMIA-VIRUS; ENCAPSIDATION SIGNAL; DIMERIZATION; RECOMBINATION; SEQUENCES; VIRIONS; REGION; COMPLEMENTARITY; IDENTIFICATION; PREDICTION	Retroviral genomes are assembled from two sense-strand RNAs by noncovalent interactions at their 5' ends, forming a dimer. The RNA dimerization domain is a potential target for antiretroviral therapy and represents a compelling RNA folding problem. The fundamental dimerization unit for the Moloney murine sarcoma gamma retrovirus spans a 170-nucleotide minimal dimerization active sequence. In the dimer, two self-complementary sequences, PAL1 and PAL2, form intermolecular duplexes, and an SL1-SL2 (stem-loop) domain forms loop-loop base pairs, mediated by GACG tetraloops, and extensive tertiary interactions. To develop a framework for assembly of the retroviral RNA dimer, we quantified the stability of and established nucleotide resolution secondary structure models for sequence variants in which each motif was compromised. Base pairing and tertiary interactions between SL1-SL2 domains contribute a large free energy increment of -10 kcal/mol. In contrast, even though the PAL1 and PAL2 intermolecular duplexes span 10 and 16 bp in the dimer, respectively, they contribute only -2.5 kcal/mol to stability, roughly equal to a single new base pair. First, these results emphasize that the energetic costs for disrupting interactions in the monomer state nearly balance the PAL1 and PAL2 base pairing interactions that form in the dimer. Second, intermolecular duplex formation plays a biological role distinct from simply stabilizing the structure of the retroviral genomic RNA dimer.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Weeks, KM (corresponding author), Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.	weeks@unc.edu			NIGMS NIH HHS [GM064803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM MA, 1988, J VIROL, V62, P3802, DOI 10.1128/JVI.62.10.3802-3806.1988; Badorrek CS, 2006, BIOCHEMISTRY-US, V45, P12664, DOI 10.1021/bi060521k; Badorrek CS, 2006, P NATL ACAD SCI USA, V103, P13640, DOI 10.1073/pnas.0606156103; Badorrek CS, 2005, NAT CHEM BIOL, V1, P104, DOI 10.1038/nchembio712; BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; Coffin J, 1997, RETROVIRUSES; D'Souza V, 2005, NAT REV MICROBIOL, V3, P643, DOI 10.1038/nrmicro1210; D'Souza V, 2004, J MOL BIOL, V337, P427, DOI 10.1016/j.jmb.2004.01.037; D'Souza V, 2004, NATURE, V431, P586, DOI 10.1038/nature02944; Das R, 2005, RNA, V11, P344, DOI 10.1261/rna.7214405; De Tapia M, 1998, BIOCHEMISTRY-US, V37, P6077, DOI 10.1021/bi9800303; Evans MJ, 2004, J VIROL, V78, P7677, DOI 10.1128/JVI.78.14.7677-7684.2004; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; GIRARD PM, 1995, BIOCHEMISTRY-US, V34, P9785, DOI 10.1021/bi00030a016; Hibbert CS, 2005, J VIROL, V79, P8142, DOI 10.1128/JVI.79.13.8142-8148.2005; Hibbert CS, 2004, J VIROL, V78, P10927, DOI 10.1128/JVI.78.20.10927-10938.2004; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697; KONINGS DAM, 1992, J VIROL, V66, P632, DOI 10.1128/JVI.66.2.632-640.1992; Ly H, 2002, J VIROL, V76, P3135, DOI 10.1128/JVI.76.7.3135-3144.2002; Ly H, 1999, J VIROL, V73, P7255, DOI 10.1128/JVI.73.9.7255-7261.1999; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; Merino EJ, 2005, J AM CHEM SOC, V127, P4223, DOI 10.1021/ja043822v; Mikkelsen JG, 2004, NUCLEIC ACIDS RES, V32, P102, DOI 10.1093/nar/gkh159; Monie TP, 2005, BIOCHEMISTRY-US, V44, P294, DOI 10.1021/bi048529m; Mougel M, 1997, J VIROL, V71, P8061, DOI 10.1128/JVI.71.10.8061-8065.1997; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; Oroudjev EM, 1999, J MOL BIOL, V291, P603, DOI 10.1006/jmbi.1999.2984; Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903; Paillart JC, 1996, BIOCHIMIE, V78, P639, DOI 10.1016/S0300-9084(96)80010-1; Rasmussen SV, 2004, VIROLOGY, V329, P440, DOI 10.1016/j.virol.2004.08.027; Rasmussen SV, 2002, J MOL BIOL, V323, P613, DOI 10.1016/S0022-2836(02)00966-X; Sakuragi J, 2001, J VIROL, V75, P2557, DOI 10.1128/JVI.75.6.2557-2565.2001; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; TOUNEKTI N, 1992, J MOL BIOL, V223, P205, DOI 10.1016/0022-2836(92)90726-Z; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; Wilkinson KA, 2005, J AM CHEM SOC, V127, P4659, DOI 10.1021/ja0436749; WILKINSON KA, 2006, IN PRESS NAT PROTOCO, V1; YANG SL, 1994, EMBO J, V13, P713, DOI 10.1002/j.1460-2075.1994.tb06311.x	41	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37952	37961		10.1074/jbc.M607380200	http://dx.doi.org/10.1074/jbc.M607380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16984912	hybrid, Green Published			2022-12-25	WOS:000242477100074
J	Canton, DA; Olsten, MEK; Niederstrasser, H; Cooper, JA; Litchfield, DW				Canton, David A.; Olsten, Mary Ellen K.; Niederstrasser, Hanspeter; Cooper, John A.; Litchfield, David W.			The role of CKIP-1 in cell morphology depends on its interaction with actin-capping protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; FILAMENT BARBED END; BETA-ACTININ; KINASE CK2; IN-VITRO; CAPZ; POLYMERIZATION; MUSCLE; IDENTIFICATION; MOTILITY	CKIP-1 is a pleckstrin homology domain-containing protein that induces alterations of the actin cytoskeleton and cell morphology when expressed in human osteosarcoma cells. CKIP-1 interacts with the heterodimeric actin-capping protein in cells, so we postulated that this interaction was responsible for the observed cytoskeletal and morphological effects of CKIP-1. To test this postulate, we used peptide "walking arrays" and alignments of CKIP-1 with CARMIL, another CP-binding protein, to identify Arg-155 and Arg-157 of CKIP-1 as residues potentially required for its interactions with CP. CKIP-1 mutants harboring Arg-155 and Arg-157 substitutions exhibited greatly decreased CP binding, while retaining wild-type localization, the ability to interact with protein kinase CK2,and self-association. To examine the phenotype associated with expression of these mutants, we generated tetracycline-inducible human osteosarcoma cells lines expressing R155E, R157E mutants of CKIP-1. Examination of these cell lines reveals that CKIP-1 R155E, R157E did not induce the distinct changes in cell morphology and the actin cytoskeleton that are characteristic of wild-type CKIP-1 demonstrating that the interaction between CKIP-1 and CP is required for these cellular effects.	Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent,Siebens Drake Med Res Ins, Regulatory Biol & Funct Genom Res Grp, London, ON N6A 5C1, Canada; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Western University (University of Western Ontario); Washington University (WUSTL)	Litchfield, DW (corresponding author), Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent,Siebens Drake Med Res Ins, Regulatory Biol & Funct Genom Res Grp, Med Sci Bldg, London, ON N6A 5C1, Canada.	litchfi@uwo.ca	Litchfield, David/E-4636-2015; Cooper, John/E-9389-2012; Canton, David/N-7463-2015; Cooper, John/D-4448-2014	Litchfield, David/0000-0002-2425-6620; Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038542] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038542-20, R01 GM038542, GM38542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alto N, 2002, DIABETES, V51, pS385, DOI 10.2337/diabetes.51.2007.S385; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; Bhattacharya N, 2006, J BIOL CHEM, V281, P31021, DOI 10.1074/jbc.M606278200; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Bruck S, 2006, J BIOL CHEM, V281, P19196, DOI 10.1074/jbc.M600166200; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; Canton DA, 2005, MOL CELL BIOL, V25, P3519, DOI 10.1128/MCB.25.9.3519-3534.2005; CASELLA JF, 1986, J BIOL CHEM, V261, P915; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; DiNubile MJ, 1997, BBA-MOL CELL RES, V1358, P261, DOI 10.1016/S0167-4889(97)00076-1; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Eyers CE, 2005, BIOCHEM J, V389, P127, DOI 10.1042/BJ20050387; Falck S, 2004, EMBO J, V23, P3010, DOI 10.1038/sj.emboj.7600310; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; HAUS U, 1991, BIOCHEM BIOPH RES CO, V181, P833, DOI 10.1016/0006-291X(91)91265-E; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; Kim K, 2004, J CELL BIOL, V164, P567, DOI 10.1083/jcb.200308061; Kitazawa M, 2005, BIOCHEM BIOPH RES CO, V331, P181, DOI 10.1016/j.bbrc.2005.03.127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MARUYAMA K, 1990, J BIOL CHEM, V265, P8712; Olsten MEK, 2004, J BIOL CHEM, V279, P42114, DOI 10.1074/jbc.M407628200; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Remmert K, 2004, J BIOL CHEM, V279, P3068, DOI 10.1074/jbc.M308829200; Safi A, 2004, MOL CELL BIOL, V24, P1245, DOI 10.1128/MCB.24.3.1245-1255.2004; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Soeno Y, 1998, J MUSCLE RES CELL M, V19, P639, DOI 10.1023/A:1005329114263; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Tegge WJ, 1998, METH MOL B, V87, P99; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Yang CS, 2005, DEV CELL, V9, P209, DOI 10.1016/j.devcel.2005.06.008; Zhang LQ, 2005, EMBO J, V24, P766, DOI 10.1038/sj.emboj.7600532	42	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36347	36359		10.1074/jbc.M607595200	http://dx.doi.org/10.1074/jbc.M607595200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16987810	Green Accepted, hybrid			2022-12-25	WOS:000242100500086
J	Ding, MG; di Rago, JP; Trumpower, BL				Ding, Martina G.; di Rago, Jean-Paul; Trumpower, Bernard L.			Investigating the Q(n) site of the cytochrome bc(1) complex in Saccharomyces cerevisiae with mutants resistant to ilicicolin H, a novel Q(n) site inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BC(1) COMPLEX; C REDUCTASE; ELECTRON-TRANSFER; SEQUENCE-ANALYSIS; DIURON-RESISTANT; MOLECULAR-BASIS; QI SITE; Q-CYCLE; B GENE; ANTIMYCIN	The cytochrome bc(1) complex resides in the inner membrane of mitochondria and transfers electrons from ubiquinol to cytochrome c. This electron transfer is coupled to the translocation of protons across the membrane by the protonmotive Q cycle mechanism. This mechanism topographically separates reduction of quinone and reoxidation of quinol at sites on opposite sites of the membrane, referred to as center N (Q(n) site) and center P (Q(p) site), respectively. Both are located on cytochrome b, a transmembrane protein of the bc1 complex that is encoded on the mitochondrial genome. To better understand the parameters that affect ligand binding at the Qn site, we applied the Qn site inhibitor ilicicolin H to select for mutations conferring resistance in Saccharomyces cerevisiae. The screen resulted in seven different single amino acid substitutions in cytochrome b rendering the yeast resistant to the inhibitor. Six of the seven mutations have not been previously linked to inhibitor resistance. Ubiquinol-cytochrome c reductase activities of mitochondrial membranes isolated from the mutants confirmed that the differences in sensitivity toward ilicicolin H originated in the cytochrome bc1 complex. Comparative in vivo studies using the known Qn site inhibitors antimycin and funiculosin showed little cross-resistance, indicating different modes of binding of these inhibitors at center N of the bc1 complex.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Victor Segalen, Inst Biochim & Genet Cellulaires, CNRS, F-33077 Bordeaux, France	Dartmouth College; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Trumpower, BL (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO K, 1969, J ANTIBIOT, V22, P189, DOI 10.7164/antibiotics.22.189; Baggish AL, 2002, ANTIMICROB AGENTS CH, V46, P1163, DOI 10.1128/AAC.46.5.1163-1173.2002; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BRASSEUR G, 1994, FEBS LETT, V354, P23, DOI 10.1016/0014-5793(94)01077-3; BRIQUET M, 1981, EUR J BIOCHEM, V117, P333, DOI 10.1111/j.1432-1033.1981.tb06342.x; BURGER G, 1976, BIOCHEM BIOPH RES CO, V72, P1201, DOI 10.1016/S0006-291X(76)80258-6; COLSON AM, 1979, MOL GEN GENET, V167, P287, DOI 10.1007/BF00267421; CORIA R, 1989, MOL MICROBIOL, V11, P1599; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DIRAGO JP, 1990, FEBS LETT, V263, P93, DOI 10.1016/0014-5793(90)80713-S; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; DIRAGO JP, 1986, FEBS LETT, V208, P208, DOI 10.1016/0014-5793(86)81019-5; ENDO T, 1970, J ANTIBIOT, V23, P91, DOI 10.7164/antibiotics.23.91; ESPOSTI MD, 1992, ARCH BIOCHEM BIOPHYS, V295, P198, DOI 10.1016/0003-9861(92)90506-R; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gutierrez-Cirlos EB, 2004, J BIOL CHEM, V279, P8708, DOI 10.1074/jbc.M311805200; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Kessl JJ, 2003, J BIOL CHEM, V278, P31312, DOI 10.1074/jbc.M304042200; Kim H, 1999, J AM CHEM SOC, V121, P4902, DOI 10.1021/ja990190h; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; MICHAELIS G, 1976, MOL GEN GENET, V146, P133, DOI 10.1007/BF00268081; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; PRATJE E, 1977, MOL GEN GENET, V152, P167, DOI 10.1007/BF00268814; RAPER RB, 1949, MANUAL PENICILLIA, P216; SCHMITT ME, 1991, J BIOL CHEM, V266, P14958; SIDHU A, 1983, J BIOL CHEM, V258, P649; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P102; TRUMPOWER BL, 2004, ENCY BIOL CHEM, V1, P528; TSAI AL, 1985, BIOCHIM BIOPHYS ACTA, V806, P418, DOI 10.1016/0005-2728(85)90249-X; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253	35	19	19	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36036	36043		10.1074/jbc.M608026200	http://dx.doi.org/10.1074/jbc.M608026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16987808	hybrid			2022-12-25	WOS:000242100500052
J	Fass, E; Shvets, E; Degani, I; Hirschberg, K; Elazar, Z				Fass, Ephraim; Shvets, Elena; Degani, Ilan; Hirschberg, Koret; Elazar, Zvulun			Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; TRANSPORT MODULATOR; MEMBRANE-TRANSPORT; CELLS; GATE-16; VACUOLES; GABARAP; MUTANTS	Autophagy is a major catabolic pathway in eukaryotic cells whereby the lack of amino acids induces the formation of autophagosomes, double-bilayer membrane vesicles that mediate delivery of cytosolic proteins and organelles for lysosomal degradation. The biogenesis and turnover of autophagosomes in mammalian cells as well as the molecular mechanisms underlying induction of autophagy and trafficking of these vesicles are poorly understood. Here we utilized different autophagic markers to determine the involvement of microtubules in the autophagic process. We show that autophagosomes associate with microtubules and concentrate near the microtubule-organizing center. Moreover, we demonstrate that autophagosomes, but not phagophores, move along these tracks en route for degradation. Disruption of microtubules leads to a significant reduction in the number of mature autophagosomes but does not affect their life span or their fusion with lysosomes. We propose that microtubules serve to deliver only mature autophagosomes for degradation, thus providing a spatial barrier between phagophores and lysosomes.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Chem Phys, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmzevi@wicc.weizmann.ac.il						APLIN A, 1992, J CELL PHYSIOL, V152, P458, DOI 10.1002/jcp.1041520304; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; HAMMING RW, 1991, ART PROBABILITY SCI, P145; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; KOVACS AL, 1982, ACTA BIOL MED GER, V41, P125; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mousavi SA, 2001, BBA-BIOMEMBRANES, V1510, P243, DOI 10.1016/S0005-2736(00)00354-0; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; PUNNONEN EL, 1990, EXP MOL PATHOL, V52, P87, DOI 10.1016/0014-4800(90)90061-H; Ravikumar B, 2005, NAT GENET, V37, P771, DOI 10.1038/ng1591; REUNANEN H, 1988, EXP MOL PATHOL, V48, P97, DOI 10.1016/0014-4800(88)90048-2; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SCHEEL J, 1990, J CELL SCI, V96, P711; Scherz-Shouval R, 2003, J BIOL CHEM, V278, P14053, DOI 10.1074/jbc.M212108200; Seglen PO, 1996, ADV EXP MED BIOL, V389, P103; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shorer H, 2005, J BIOL CHEM, V280, P16219, DOI 10.1074/jbc.M500554200; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33	44	225	232	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36303	36316		10.1074/jbc.M607031200	http://dx.doi.org/10.1074/jbc.M607031200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16963441	hybrid			2022-12-25	WOS:000242100500082
J	Heurgue-Hamard, V; Graille, M; Scrima, N; Ulryck, N; Champ, S; van Tilbeurgh, H; Buckingham, RH				Heurgue-Hamard, Valerie; Graille, Marc; Scrima, Nathalie; Ulryck, Nathalie; Champ, Stephanie; van Tilbeurgh, Herman; Buckingham, Richard H.			The zinc finger protein Ynr046w is plurifunctional and a component of the eRF1 methyltransferase in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE FACTOR ERF1; TRANSFER-RNA HYDROLYSIS; CONSERVED GGQ MOTIF; TRANSLATION TERMINATION; CRYSTAL-STRUCTURES; MESSENGER-RNA; GTP-BINDING; FACTORS RF1; STOP CODON; COMPLEX	Protein release factor eRF1 in Saccharomyces cerevisiae, in complex with eRF3 and GTP,is methylated on a functionally crucial Gln residue by the S-adenosylmethionine-dependent methyltransferase Ydr140w. Here we show that eRF1 methylation, in addition to these previously characterized components, requires a 15-kDa zinc-binding protein, Ynr046w. Co-expression in Escherichia coli of Ynr046w and Ydr140w allows the latter to be recovered in soluble form rather than as inclusion bodies, and the two proteins co-purify on nickel-nitrilotriacetic acid chromatography when Ydr140w alone carries a His tag. The crystal structure of Ynr046w has been determined to 1.7 angstrom resolution. It comprises a zinc-binding domain built from both the N-and C-terminal sequences and an inserted domain, absent from bacterial and archaeal orthologs of the protein, composed of three alpha-helices. The active methyltransferase is the heterodimer Ydr140w(.)Ynr046w, but when alone, both in solution and in crystals, Ynr046w appears to be a homodimer. The Ynr046w eRF1 methyltransferase subunit is shared by the tRNA methyltransferase Trm11p and probably by two other enzymes containing a Rossman fold.	CNRS, IBPC, UPR 9073, F-75005 Paris, France; Univ Paris 11, Inst Biochim & Biohys Mol & Cellulaire, CNRS, UMR8619, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), CNRS, IBPC, UPR 9073, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.	herman.van-tilbeurgh@ibbmc.u-psud.fr; richard.buckingham@ibpc.fr	GRAILLE, Marc/D-3242-2014	GRAILLE, Marc/0000-0002-7853-5852; HEURGUE-HAMARD, VALERIE/0000-0003-1576-7231; Buckingham, Richard/0000-0002-8567-4500				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Alexandrov A, 2002, RNA, V8, P1253, DOI 10.1017/S1355838202024019; Alkalaeva EZ, 2006, CELL, V125, P1125, DOI 10.1016/j.cell.2006.04.035; Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Das K, 2004, P NATL ACAD SCI USA, V101, P4041, DOI 10.1073/pnas.0400189101; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Dincbas-Renqvist V, 2000, EMBO J, V19, P6900, DOI 10.1093/emboj/19.24.6900; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Graille M, 2005, MOL CELL, V20, P917, DOI 10.1016/j.molcel.2005.10.025; Hauryliuk V, 2006, BIOCHIMIE, V88, P747, DOI 10.1016/j.biochi.2006.06.001; Heurgue-Hamard V, 2005, J BIOL CHEM, V280, P2439, DOI 10.1074/jbc.M407252200; Heurgue-Hamard V, 2002, EMBO J, V21, P769, DOI 10.1093/emboj/21.4.769; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kalhor HR, 2003, MOL CELL BIOL, V23, P9283, DOI 10.1128/MCB.23.24.9283-9292.2003; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Kisselev L, 2002, STRUCTURE, V10, P8, DOI 10.1016/S0969-2126(01)00703-1; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Kobayashi T, 2004, J BIOL CHEM, V279, P45693, DOI 10.1074/jbc.M405163200; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Nakamura Y, 2003, TRENDS BIOCHEM SCI, V28, P99, DOI 10.1016/S0968-0004(03)00006-9; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petry S, 2005, CELL, V123, P1255, DOI 10.1016/j.cell.2005.09.039; Polevoda B, 2006, J BIOL CHEM, V281, P2562, DOI 10.1074/jbc.M507651200; Purushothaman SK, 2005, MOL CELL BIOL, V25, P4359, DOI 10.1128/MCB.25.11.4359-4370.2005; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; STORTS DR, 1987, J BACTERIOL, V169, P416, DOI 10.1128/jb.169.1.416-418.1987; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6	38	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36140	36148		10.1074/jbc.M608571200	http://dx.doi.org/10.1074/jbc.M608571200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008308	Green Published, hybrid			2022-12-25	WOS:000242100500064
J	Mori, H; Ito, K				Mori, Hiroyuki; Ito, Koreaki			The long alpha-helix of SecA is important for the ATPase coupling of translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CONDUCTING CHANNEL; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; DIMERIC SECA; MEMBRANE; SECYEG; COMPONENT; INSERTION; SUBUNIT; DOMAINS	SecA contains two ATPase folds (NBF1 and NBF2) and other interaction/regulatory domains, all of which are connected by a long helical scaffold domain (HSD) running along the molecule. Here we identified a functionally important and spatially adjacent pair of SecA residues, Arg-642 on HSD and Glu-400 on NBF1. A charge-reversing substitution at either position as well as disulfide tethering of these positions inactivated the translocation activity. Interestingly, however, the translocation-inactive SecA variants fully retained the ability to up-regulate the ATPase in response to a preprotein and the SecYEG translocon. The translocation defect was suppressible by second site alterations at the hinge-forming boundary of NBF2 and HSD. Based on these results, we propose that the motor function of SecA is realized by ligand-activated ATPase engine and its HSD-mediated conversion into the mechanical work of preprotein translocation.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp		Mori, Hiroyuki/0000-0002-0429-1269				AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; Chou YT, 2005, J BIOL CHEM, V280, P32753, DOI 10.1074/jbc.M507532200; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; de Keyzer J, 2005, J BIOL CHEM, V280, P35255, DOI 10.1074/jbc.M506157200; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jilaveanu LB, 2006, J BACTERIOL, V188, P335, DOI 10.1128/JB.188.1.335-338.2006; Jilaveanu LB, 2005, P NATL ACAD SCI USA, V102, P7511, DOI 10.1073/pnas.0502774102; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Matsuo E, 1998, J BIOL CHEM, V273, P18835, DOI 10.1074/jbc.273.30.18835; MCFARLAND L, 1993, J BACTERIOL, V175, P2255, DOI 10.1128/JB.175.8.2255-2262.1993; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Mori H, 2003, J BACTERIOL, V185, P405, DOI 10.1128/JB.185.2.405-412.2003; Mori H, 2001, P NATL ACAD SCI USA, V98, P5128, DOI 10.1073/pnas.081617398; MORI H, 2006, IN PRESS P NATL ACAD; Murakami A, 2004, P NATL ACAD SCI USA, V101, P12330, DOI 10.1073/pnas.0404907101; Nakatogawa H, 2005, GENE DEV, V19, P436, DOI 10.1101/gad.1259505; Natale P, 2005, BIOCHEMISTRY-US, V44, P6424, DOI 10.1021/bi047488r; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; Papanikou E, 2005, J BIOL CHEM, V280, P43209, DOI 10.1074/jbc.M509990200; Ritz D, 2001, SCIENCE, V294, P158, DOI 10.1126/science.1063143; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VASSYLYEV DG, 2006, IN PRESS J MOL BIOL; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Vrontou E, 2004, J BIOL CHEM, V279, P22490, DOI 10.1074/jbc.M401008200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429; ZIMMER J, 2006, IN PRESS J MOL BIOL	37	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36249	36256		10.1074/jbc.M606906200	http://dx.doi.org/10.1074/jbc.M606906200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005557	hybrid			2022-12-25	WOS:000242100500077
J	Chmelar, RS; Nathanson, NM				Chmelar, Renee S.; Nathanson, Neil M.			Identification of a novel apical sorting motif and mechanism of targeting of the M-2 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLARIZED EPITHELIAL-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; GPI-ANCHORED PROTEINS; TRANS-GOLGI NETWORK; MDCK CELLS; PLASMA-MEMBRANE; CYTOPLASMIC DOMAIN; N-GLYCOSYLATION	Previous studies have shown that the M-2 receptor is localized at steady state to the apical domain in Madin-Darby canine kidney (MDCK) epithelial cells. In this study, we identify the molecular determinants governing the localization and the route of apical delivery of the M-2 receptor. First, by confocal analysis of a transiently transfected glycosylation mutant in which the three putative glycosylation sites were mutated, we determined that N-glycans are not necessary for the apical targeting of the M-2 receptor. Next, using a chimeric receptor strategy, we found that two independent sequences within the M-2 third intracellular loop can confer apical targeting to the basolaterally targeted M-4 receptor, Val(270)-Lys(280) and Lys(280)-Ser(350). Experiments using Triton X-100 extraction followed by OptiPrep (TM) density gradient centrifugation and cholera toxin beta-subunit-induced patching demonstrate that apical targeting is not because of association with lipid rafts. S-35-Metabolic labeling experiments with domain-specific surface biotinylation as well as immunocytochemical analysis of the time course of surface appearance of newly transfected confluent MDCK cells expressing FLAG-M(2)(-)GFP demonstrate that the M-2 receptor achieves its apical localization after first appearing on the basolateral domain. Domain-specific application of tannic acid of newly transfected cells indicates that initial basolateral plasma membrane expression is required for subsequent apical localization. This is the first demonstration that a G-protein-coupled receptor achieves its apical localization in MDCK cells via transcytosis.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.	nathanso@u.washington.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS26920] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adair-Kirk TL, 2003, J CELL SCI, V116, P655, DOI 10.1242/jcs.00260; Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; Barman S, 2001, VIRUS RES, V77, P61, DOI 10.1016/S0168-1702(01)00266-0; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; Bastaki M, 2002, MOL BIOL CELL, V13, P225, DOI 10.1091/mbc.01-07-0376; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Breuza L, 2002, EXP CELL RES, V273, P178, DOI 10.1006/excr.2001.5442; Brown A, 2004, AM J PHYSIOL-CELL PH, V286, pC1071, DOI 10.1152/ajpcell.00291.2003; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burgos PV, 2004, P NATL ACAD SCI USA, V101, P3845, DOI 10.1073/pnas.0400295101; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Cheng CL, 2002, J NEUROSCI, V22, P10643; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Corbeil D, 1999, J CELL SCI, V112, P1023; Dempsey PJ, 2003, EXP CELL RES, V285, P159, DOI 10.1016/S0014-4827(03)00035-1; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Francesconi A, 2002, J NEUROSCI, V22, P2196, DOI 10.1523/JNEUROSCI.22-06-02196.2002; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; Goldman PS, 1996, J BIOL CHEM, V271, P4215; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; Gut A, 1998, J BIOL CHEM, V273, P29381, DOI 10.1074/jbc.273.45.29381; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hamilton SE, 1997, P NATL ACAD SCI USA, V94, P13311, DOI 10.1073/pnas.94.24.13311; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hodson CA, 2006, TRAFFIC, V7, P456, DOI 10.1111/j.1600-0854.2006.00398.x; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Inukai K, 2004, MOL ENDOCRINOL, V18, P339, DOI 10.1210/me.2003-0089; Iverson HA, 2005, J BIOL CHEM, V280, P24568, DOI 10.1074/jbc.M501264200; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jolimay N, 2000, J NEUROSCI, V20, P9111; Karim-Jimenez Z, 2000, P NATL ACAD SCI USA, V97, P2916, DOI 10.1073/pnas.97.6.2916; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P6892, DOI 10.1021/bi00396a003; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; Marzolo MP, 2003, TRAFFIC, V4, P273, DOI 10.1034/j.1600-0854.2003.00081.x; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Matthews P, 2000, SIGHT SOUND, V10, P42; Meerson NR, 2000, J CELL SCI, V113, P4193; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Nadler LS, 2001, J BIOL CHEM, V276, P10539, DOI 10.1074/jbc.M007190200; Newman TM, 1996, AM J RESP CELL MOL, V15, P529, DOI 10.1165/ajrcmb.15.4.8879187; Nies AT, 2002, EUR J BIOCHEM, V269, P1866, DOI 10.1046/j.1432-1033.2002.02832.x; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; Paladino S, 2006, J CELL BIOL, V172, P1023, DOI 10.1083/jcb.200507116; Pang S, 2004, J CELL SCI, V117, P5079, DOI 10.1242/jcs.01386; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PETERSON GL, 1986, BIOCHEMISTRY-US, V25, P3189, DOI 10.1021/bi00359a017; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Prydz K, 2001, BIOCHEM J, V357, P11, DOI 10.1042/0264-6021:3570011; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Regeer RR, 2004, AM J PHYSIOL-CELL PH, V287, pC365, DOI 10.1152/ajpcell.00502.2003; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTH MG, 1979, P NATL ACAD SCI USA, V76, P6430, DOI 10.1073/pnas.76.12.6430; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saunders C, 1998, J BIOL CHEM, V273, P24196, DOI 10.1074/jbc.273.37.24196; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Slimane TA, 2001, EXP CELL RES, V270, P45, DOI 10.1006/excr.2001.5337; Spodsberg N, 2001, J BIOL CHEM, V276, P46597, DOI 10.1074/jbc.M108187200; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Vagin O, 2005, J BIOL CHEM, V280, P43159, DOI 10.1074/jbc.M508262200; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Westlake CJ, 2003, BIOCHEMISTRY-US, V42, P14099, DOI 10.1021/bi035333y; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596	96	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35381	35396		10.1074/jbc.M605954200	http://dx.doi.org/10.1074/jbc.M605954200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16968700	hybrid			2022-12-25	WOS:000241933700072
J	Han, JW; Leeper, L; Rivero, F; Chung, CY				Han, Ji W.; Leeper, Laura; Rivero, Francisco; Chung, Chang Y.			Role of RacC for the regulation of WASP and phosphatidylinositol 3-kinase during chemotaxis of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-WASP; ACTIN POLYMERIZATION; CELL POLARITY; RHO-GTPASES; PROTEIN FAMILY; LEADING-EDGE; DISCOIDEUM; COMPLEX; MEMBER; COMPLEMENTARY	WASP family proteins are key players for connecting multiple signaling pathways to F-actin polymerization. To dissect the highly integrated signaling pathways controlling WASP activity, we identified a Rac protein that binds to the GTPase binding domain of WASP. Using two-hybrid and FRET-based functional assays, we identified RacC as a major regulator of WASP. RacC stimulates F-actin assembly in cell-free systems in a WASP-dependent manner. A FRET-based microscopy approach showed local activation of RacC at the leading edge of chemotaxing cells. Cells overexpressing RacC exhibit a significant increase in the level of F-actin polymerization upon cAMP stimulation, which can be blocked by a phosphatidylinositol (PI) 3-kinase inhibitor. Membrane translocation of PI 3-kinase and PI 3,4,5-trisphosphate reporter is absent in racC null cells. Cells overexpressing dominant negative RacC mutants and racC null cells move at a significantly slower speed and show a poor directionality during chemotaxis. Our results suggest that RacC plays an important role in PI 3-kinase activation and WASP activation for dynamic regulation of F-actin assembly during Dictyostelium chemotaxis.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Univ Cologne, Fak Med, Zentrum Biochem, D-50931 Cologne, Germany; Univ Cologne, Fak Med, Zentrum Mol Med, D-50931 Cologne, Germany	Vanderbilt University; University of Cologne; University of Cologne	Chung, CY (corresponding author), 468 Robinson Res Bldg,MRB 1,1215 21st Ave S Pierc, Nashville, TN 37232 USA.	chang.chung@vanderbilt.edu	Chung, Chang Y/G-7522-2012; Rivero, Francisco/N-2969-2013	Rivero, Francisco/0000-0001-5435-6991	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068097] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM068097-04, GM068097, R01 GM068097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Buck M, 2004, J MOL BIOL, V338, P271, DOI 10.1016/j.jmb.2004.02.036; BUSH J, 1993, GENE, V136, P61, DOI 10.1016/0378-1119(93)90448-C; Chen LF, 2003, MOL BIOL CELL, V14, P5028, DOI 10.1091/mbc.E03-05-0339; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; de la Roche M, 2005, MOL BIOL CELL, V16, P238, DOI 10.1091/mbc.E04-06-0534; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dumontier M, 2000, J CELL SCI, V113, P2253; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; FUTRELLE RP, 1982, J CELL BIOL, V92, P807, DOI 10.1083/jcb.92.3.807; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; Janetopoulos C, 2004, P NATL ACAD SCI USA, V101, P8951, DOI 10.1073/pnas.0402152101; Kato M, 2005, BIOCHEM BIOPH RES CO, V328, P1058, DOI 10.1016/j.bbrc.2005.01.058; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; Lee E, 2003, EUKARYOT CELL, V2, P474, DOI 10.1128/EC.2.3.474-485.2003; Lorenz M, 2004, CURR BIOL, V14, P697, DOI 10.1016/j.cub.2004.04.008; Ma L, 2004, BIOPHYS J, V87, P3764, DOI 10.1529/biophysj.104.045484; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Myers SA, 2005, MOL BIOL CELL, V16, P2191, DOI 10.1091/mbc.E04-09-0844; Palmieri SJ, 2000, CELL MOTIL CYTOSKEL, V46, P285, DOI 10.1002/1097-0169(200008)46:4<285::AID-CM6>3.0.CO;2-N; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Park KC, 2004, EMBO J, V23, P4177, DOI 10.1038/sj.emboj.7600368; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rivero F, 1999, MOL BIOL CELL, V10, P1205, DOI 10.1091/mbc.10.4.1205; Rivero F, 2002, J MUSCLE RES CELL M, V23, P737, DOI 10.1023/A:1024423611223; Rivero F, 2001, NUCLEIC ACIDS RES, V29, P1068, DOI 10.1093/nar/29.5.1068; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sasaki AT, 2004, J CELL BIOL, V167, P505, DOI 10.1083/jcb.200406177; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Seastone DJ, 1998, MOL BIOL CELL, V9, P2891, DOI 10.1091/mbc.9.10.2891; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Stradal TEB, 2004, TRENDS CELL BIOL, V14, P303, DOI 10.1016/j.tcb.2004.04.007; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Takenawa T, 2001, J CELL SCI, V114, P1801; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Ward ME, 2004, P NATL ACAD SCI USA, V101, P970, DOI 10.1073/pnas.0306258101; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	50	36	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35224	35234		10.1074/jbc.M605997200	http://dx.doi.org/10.1074/jbc.M605997200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16968699	Green Accepted, hybrid			2022-12-25	WOS:000241933700056
J	Roh, JB; Lee, MA; Lee, HJ; Kim, SM; Cho, Y; Kim, YJ; Seok, YJ; Park, SJ; Lee, KH				Roh, Jong-Bok; Lee, Mi-Ae; Lee, Hyun-Jung; Kim, Sung-Min; Cho, Yona; Kim, You-Jin; Seok, Yeong-Jae; Park, Soon-Jung; Lee, Kyu-Ho			Transcriptional regulatory cascade for elastase production in Vibrio vulnificus - LuxO activates luxT expression and LuxT represses smcR expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; QUORUM-SENSING SYSTEM; GENE-EXPRESSION; ELASTOLYTIC PROTEASE; HARVEYI LUXR; CHOLERAE; VIRULENCE; PROMOTER; METALLOPROTEASE; ANGUILLARUM	Vibrio vulnificus causes diseases through actions of various virulence factors, including the elastase encoded by the vvpE gene. Through transposon mutagenesis of V. vulnificus, vvpE expression was shown to be increased by luxO mutation. Since the vvpE gene is known to be positively regulated by SmcR via direct binding to the vvpE promoter, the role of LuxO in smcR expression was investigated. The luxAB-transcriptional fusions containing different lengths of the smcR promoter region indicated that the smcR transcription was negatively regulated by LuxO and that a specific upstream region of the smcR gene was required for this repression. Since LuxO is a known member of positive regulators, the negative regulation of smcR transcription by LuxO prompted us to identify the factor(s) linking LuxO and smcR transcription. LuxT was isolated in a ligand fishing experiment using the smcR upstream region as bait, and smcR expression was increased by luxT mutation. Recombinant LuxT bound to a specific upstream region of the smcR gene, -154 to -129 relative to the smcR transcription start site. The expression of luxT was positively regulated by LuxO, and the luxT promoter region contained a putative LuxO-binding site. Mutagenesis of the LuxO-binding site in the luxT promoter region resulted in a loss of transcriptional control by LuxO. Therefore, this study demonstrates a transcriptional regulatory cascade for elastase production, where LuxO activates luxT transcription and LuxT represses smcR transcription.	Hankuk Univ Foreign Studies, Dept Environm Sci, Yongin 449791, Kyunggi Do, South Korea; Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea; Yonsei Univ, Coll Med, Brain Korea Project 21, Dept Parasitol, Seoul 133791, South Korea	Hankuk University Foreign Studies; Seoul National University (SNU); Yonsei University; Yonsei University Health System	Lee, KH (corresponding author), Hankuk Univ Foreign Studies, Dept Environm Sci, Yongin 449791, Kyunggi Do, South Korea.	khlee@hufs.ac.kr		Seok, Yeong-Jae/0000-0003-0379-3619; Park, Soon-Jung/0000-0002-0423-1944				[Anonymous], 2001, MOL CLONING LAB MANU; BERMAN S, 1961, J BACTERIOL, V82, P582, DOI 10.1128/JB.82.4.582-588.1961; Croxatto A, 2004, MOL MICROBIOL, V52, P1677, DOI 10.1111/j.1365-2958.2004.04083.x; Croxatto A, 2002, J BACTERIOL, V184, P1617, DOI 10.1128/JB.184.6.1617-1629.2002; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; Enos-Berlage JL, 2000, J BACTERIOL, V182, P5513, DOI 10.1128/JB.182.19.5513-5520.2000; Freeman JA, 1999, J BACTERIOL, V181, P899, DOI 10.1128/JB.181.3.899-906.1999; Freeman JA, 1999, MOL MICROBIOL, V31, P665, DOI 10.1046/j.1365-2958.1999.01208.x; GREENBERG EP, 1979, ARCH MICROBIOL, V120, P87, DOI 10.1007/BF00409093; Henke JM, 2004, J BACTERIOL, V186, P6902, DOI 10.1128/JB.186.20.6902-6914.2004; Jeong HS, 2003, J BIOL CHEM, V278, P45072, DOI 10.1074/jbc.M308184200; Jeong HS, 2001, J BIOL CHEM, V276, P13875, DOI 10.1074/jbc.M010567200; Jeong JY, 2004, J BIOL CHEM, V279, P38513, DOI 10.1074/jbc.M406667200; Jeong KC, 2000, INFECT IMMUN, V68, P5096, DOI 10.1128/IAI.68.9.5096-5106.2000; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim SY, 2003, MOL MICROBIOL, V48, P1647, DOI 10.1046/j.1365-2958.2003.03536.x; KOTHARY MH, 1985, INFECT IMMUN, V50, P534, DOI 10.1128/IAI.50.2.534-540.1985; Lee HJ, 2003, J BACTERIOL, V185, P5891, DOI 10.1128/JB.185.19.5891-5896.2003; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Lilley BN, 2000, MOL MICROBIOL, V36, P940, DOI 10.1046/j.1365-2958.2000.01913.x; Lin W, 2005, J BACTERIOL, V187, P3013, DOI 10.1128/JB.187.9.3013-3019.2005; Lin YH, 2000, BBA-GENE STRUCT EXPR, V1494, P226, DOI 10.1016/S0167-4781(00)00236-0; Lin YH, 2000, PROTEIN EXPRES PURIF, V20, P87, DOI 10.1006/prep.2000.1285; Liu Z, 2006, J BACTERIOL, V188, P2446, DOI 10.1128/JB.188.7.2446-2453.2006; MARTIN M, 1989, J BACTERIOL, V171, P2406, DOI 10.1128/jb.171.5.2406-2414.1989; McDougald D, 2000, GENE, V248, P213, DOI 10.1016/S0378-1119(00)00117-7; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Milton DL, 1996, J BACTERIOL, V178, P1310, DOI 10.1128/jb.178.5.1310-1319.1996; Miyamoto CM, 2003, MOL MICROBIOL, V48, P537, DOI 10.1046/j.1365-2958.2003.03453.x; Miyoshi S, 1998, INFECT IMMUN, V66, P4851, DOI 10.1128/IAI.66.10.4851-4855.1998; Miyoshi S, 2000, MICROBES INFECT, V2, P91, DOI 10.1016/S1286-4579(00)00280-X; OLIVER JD, 1986, DIAGN MICR INFEC DIS, V5, P99, DOI 10.1016/0732-8893(86)90112-4; Park KJ, 2004, J BACTERIOL, V186, P3304, DOI 10.1128/JB.186.11.3304-3312.2004; Reitzer L, 2001, MICROBIOL MOL BIOL R, V65, P422, DOI 10.1128/MMBR.65.3.422-444.2001; Rhee JE, 2002, FEMS MICROBIOL LETT, V208, P245; SCHMIDT TM, 1988, APPL ENVIRON MICROB, V54, P2793, DOI 10.1128/AEM.54.11.2793-2797.1988; Shao CP, 2001, J BACTERIOL, V183, P1369, DOI 10.1128/JB.183.4.1369-1375.2001; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Strom MS, 2000, MICROBES INFECT, V2, P177, DOI 10.1016/S1286-4579(00)00270-7; Vance RE, 2003, INFECT IMMUN, V71, P2571, DOI 10.1128/IAI.71.5.2571-2576.2003; WRIGHT AC, 1985, INFECT IMMUN, V50, P922, DOI 10.1128/IAI.50.3.922-924.1985; Zhu J, 2002, P NATL ACAD SCI USA, V99, P3129, DOI 10.1073/pnas.052694299	42	39	40	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34775	34784		10.1074/jbc.M607844200	http://dx.doi.org/10.1074/jbc.M607844200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16971386	hybrid			2022-12-25	WOS:000241933700009
J	Wietek, C; Cleaver, CS; Ludbrook, V; Wilde, J; White, J; Bell, DJ; Lee, M; Dickson, M; Ray, KP; O'Neill, LAJ				Wietek, Claudia; Cleaver, Catherine S.; Ludbrook, Valerie; Wilde, Jonathan; White, Julia; Bell, David J.; Lee, Michael; Dickson, Marion; Ray, Keith P.; O'Neill, Luke A. J.			I kappa B kinase epsilon interacts with p52 and promotes transactivation via p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-EPSILON; NF-KAPPA-B2 P100; SPLENIC MICROARCHITECTURE; SIGNALING PATHWAY; ONCOPROTEIN BCL-3; VIRAL-INFECTION; GENE-EXPRESSION; DNA-BINDING; ACTIVATION; PHOSPHORYLATION	The members of the NF-kappa B transcription factor family are key regulators of gene expression in the immune response. Different combinations of NF-kappa B subunits not only diverge in timing to induce transcription but also recognize varying sequences of the NF-kappa B-binding site of their target genes. The p52 subunit is generated as a result of processing of NF-kappa B2 p100. Here, we demonstrate that the non-canonical I kappa B kinase is an element of(IKK is an element of) directly interacts with p100. In a transactivation assay, IKK is an element of promoted the ability of p52 to transactivate gene expression. This effect was indirect, requiring p65, which was shown to be part of the IKK is an element of-p52 complex and to be phosphorylated by IKK is an element of. These novel interactions reveal a hitherto unknown function of IKK is an element of in the regulation of the alternative NF-kappa B activation pathway involving p52 and p65.	Trinity Coll Dublin, Sch Biochem & Immunol, Dublin 2, Ireland; GlaxoSmithKline Inc, Med Res Ctr, Dept Dis Biol Rheumatol & Inflammat, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline Inc, Med Res Ctr, Dept Pathway Genom Genom & Proteom Sci, Stevenage SG1 2NY, Herts, England	Trinity College Dublin; GlaxoSmithKline; GlaxoSmithKline	Wietek, C (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Dublin 2, Ireland.	wietekc@gmail.com		O'Neill, Luke/0000-0002-4333-2748				Alcamo E, 2002, J EXP MED, V195, P233, DOI 10.1084/jem.20011885; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Civas A, 2006, J BIOL CHEM, V281, P4856, DOI 10.1074/jbc.M506812200; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Fuller KJ, 1998, BIOTECHNIQUES, V25, P85, DOI 10.2144/98251st04; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Kuai J, 2004, J BIOL CHEM, V279, P53266, DOI 10.1074/jbc.M411037200; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; Lo JC, 2006, BLOOD, V107, P1048, DOI 10.1182/blood-2005-06-2452; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Marienfeld R, 2003, J BIOL CHEM, V278, P19852, DOI 10.1074/jbc.M301945200; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Nijnik A, 2003, NUCLEIC ACIDS RES, V31, P1497, DOI 10.1093/nar/gkg231; Nomura F, 2000, GENES CELLS, V5, P191; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Qing GL, 2005, J BIOL CHEM, V280, P18, DOI 10.1074/jbc.M406619200; Qing GL, 2005, J BIOL CHEM, V280, P9765, DOI 10.1074/jbc.C400502200; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Takeuchi O, 2004, J ENDOTOXIN RES, V10, P252, DOI 10.1179/096805104225005896; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	54	23	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34973	34981		10.1074/jbc.M607018200	http://dx.doi.org/10.1074/jbc.M607018200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17003035	hybrid, Green Published			2022-12-25	WOS:000241933700030
J	Wang, JH; Wu, XS; Simonavicius, N; Tian, H; Ling, L				Wang, Jinghong; Wu, Xiaosu; Simonavicius, Nicole; Tian, Hui; Ling, Lei			Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE; CELLS; IDENTIFICATION; SECRETION; RESPONSES; OBESITY; GPR120; GPR40; ASSAY; IL-12	Free fatty acids (FFAs) play important physiological roles in many tissues as an energy source and as signaling molecules in various cellular processes. Elevated levels of circulating FFAs are associated with obesity, dyslipidemia, and diabetes. Here we show that GPR84, a previously orphan G protein-coupled receptor, functions as a receptor for medium-chain FFAs with carbon chain lengths of 9 - 14. Medium-chain FFAs elicit calcium mobilization, inhibit 3', 5'-cyclic AMP production, and stimulate [S-35] guanosine 5(')-O-(3-thiotriphosphate) binding in a GPR84-dependent manner. The activation of GPR84 by medium-chain FFAs couples primarily to a pertussis toxin-sensitive G(i/o) pathway. In addition, we show that GPR84 is selectively expressed in leukocytes and markedly induced in monocytes/macrophages upon activation by lipopolysaccharide. Furthermore, we demonstrate that medium-chain FFAs amplify lipopolysaccharide-stimulated production of the proinflammatory cytokine interleukin-12 p40 through GPR84. Our results indicate a role for GPR84 in directly linking fatty acid metabolism to immunological regulation.	Amgen Inc, San Francisco, CA 94080 USA	Amgen	Ling, L (corresponding author), Amgen Inc, San Francisco, CA 94080 USA.	lling@amgen.com						AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Boden Guenther, 1998, Frontiers in Bioscience, V3, pD169; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Hwang D, 2000, ANNU REV NUTR, V20, P431, DOI 10.1146/annurev.nutr.20.1.431; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jump DB, 2004, CRIT REV CL LAB SCI, V41, P41, DOI 10.1080/10408360490278341; Katsuma S, 2005, J BIOL CHEM, V280, P19507, DOI 10.1074/jbc.M412385200; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; Nunez EA, 1997, PROSTAG LEUKOTR ESS, V57, P107, DOI 10.1016/S0952-3278(97)90500-7; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SPECTOR AA, 1975, SCIENCE, V190, P490, DOI 10.1126/science.1166323; Sperling RI, 1998, P NUTR SOC, V57, P527, DOI 10.1079/PNS19980077; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Takeda S, 2003, LIFE SCI, V74, P367, DOI 10.1016/j.lfs.2003.09.030; Venkataraman C, 2005, IMMUNOL LETT, V101, P144, DOI 10.1016/j.imlet.2005.05.010; Wang JH, 2006, J BIOL CHEM, V281, P22021, DOI 10.1074/jbc.M603503200; Wanten G, 2006, CURR OPIN CLIN NUTR, V9, P79, DOI 10.1097/01.mco.0000214563.21697.55; Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Yousefi S, 2001, J LEUKOCYTE BIOL, V69, P1045	36	267	289	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34457	34464		10.1074/jbc.M608019200	http://dx.doi.org/10.1074/jbc.M608019200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966319	hybrid			2022-12-25	WOS:000241767600066
J	Xu, LM; Harada, H; Taniguchi, A				Xu, Liming; Harada, Hidemitsu; Taniguchi, Akiyoshi			The exon 6ABC region of amelogenin mRNA contribute to increased levels of amelogenin mRNA through amelogenin protein-enhanced mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE SPLICE PRODUCTS; MOUSE AMELOGENIN; CODING REGION; UNTRANSLATED REGION; PORCINE AMELOGENIN; CELL LINE; EXPRESSION; STABILITY; SEQUENCE; ALPHA	We recently demonstrated that the reuptake of full-length amelogenin protein results in increased levels of amelogenin mRNA through enhanced mRNA stabilization (Xu, L., Harada, H., Tamaki, T. Y., Matsumoto, S., Tanaka, J., and Taniguchi, A. (2006) J. Biol. Chem. 281, 2257-2262). Here, we examined the molecular mechanism of enhanced amelogenin mRNA stabilization. To identify the cis-regulatory region within amelogenin mRNA, we tested various reporter systems using a deletion series of reporter plasmids. A deletion at exon 6ABC of amelogenin mRNA resulted in a 2.5-fold increase in the amelogenin mRNA expression level when compared with that of full-length mRNA, indicating that a cis-element exists in exon 6ABC of amelogenin mRNA. Furthermore, Northwestern analysis demonstrated that amelogenin protein binds directly to its mRNA in vitro, suggesting that amelogenin protein acts as a trans-acting protein that specifically binds to this cis-element. Moreover, recombinant mouse amelogenin protein extended the half-life of full-length amelogenin mRNA but did not significantly alter the half-life of exon 6ABC-deletion mutant mRNA. The splice products produced by deletion of exon 6ABC are known as leucine-rich amelogenin peptides and have signaling effects on cells. Our findings also suggest that the regulation of full-length amelogenin protein expression differs from the regulation of leucine-rich amelogenin peptide expression.	Natl Inst Mat Sci, Ctr Biomat, Cell Engn Technol Grp, Tsukuba, Ibaraki 3050044, Japan; Iwate Med Univ, Dept Oral Anat 2, Sch Dent, Morioka, Iwate 0208505, Japan	National Institute for Materials Science; Iwate Medical University	Taniguchi, A (corresponding author), Natl Inst Mat Sci, Ctr Biomat, Cell Engn Technol Grp, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.	Taniguchi.Akiyoshi@nims.go.jp	TANIGUCHI, Akiyoshi/H-2896-2011; Wada, Ken-Ichi/GVS-5955-2022; Harada, Hidemitsu/P-5692-2017	Wada, Ken-Ichi/0000-0001-5144-905X; Harada, Hidemitsu/0000-0002-9724-8568				Boabaid F, 2004, J PERIODONTOL, V75, P1126, DOI 10.1902/jop.2004.75.8.1126; BONASS WA, 1994, BBA-GENE STRUCT EXPR, V1219, P690, DOI 10.1016/0167-4781(94)90228-3; BROOKES SJ, 1995, ARCH ORAL BIOL, V40, P1, DOI 10.1016/0003-9969(94)00135-X; Cannons AC, 2002, PLANTA, V214, P488, DOI 10.1007/s00425-001-0679-z; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; GIBSON CW, 1992, BIOCHEMISTRY-US, V31, P8384, DOI 10.1021/bi00150a036; Hu CC, 1996, J DENT RES, V75, P1735, DOI 10.1177/00220345960750100501; Ikawa T, 2005, J DENT RES, V84, P144, DOI 10.1177/154405910508400207; Ishibashi Y, 2005, GLYCOCONJUGATE J, V22, P53, DOI 10.1007/s10719-005-0292-7; Kawano S, 2002, CONNECT TISSUE RES, V43, P409, DOI 10.1080/03008200290000637; Koga T, 1999, P NATL ACAD SCI USA, V96, P5680, DOI 10.1073/pnas.96.10.5680; Kurosawa Y, 2005, TISSUE ENG, V11, P1650, DOI 10.1089/ten.2005.11.1650; LAU EC, 1992, BIOCHEM BIOPH RES CO, V188, P1253, DOI 10.1016/0006-291X(92)91366-X; LAU EC, 1989, GENOMICS, V4, P162, DOI 10.1016/0888-7543(89)90295-4; Li R, 1995, J DENT RES, V74, P1880, DOI 10.1177/00220345950740121101; MoradianOldak J, 1995, CONNECT TISSUE RES, V32, P125, DOI 10.3109/03008209509013714; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; Papagerakis P, 2005, J DENT RES, V84, P613, DOI 10.1177/154405910508400706; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMER JP, 1994, CALCIFIED TISSUE INT, V55, P302, DOI 10.1007/BF00310410; Simmer JP, 1995, CONNECT TISSUE RES, V32, P131, DOI 10.3109/03008209509013715; Taguchi T, 2005, BIOMATERIALS, V26, P1247, DOI 10.1016/j.biomaterials.2004.04.029; Tompkins K, 2006, BONE, V38, P172, DOI 10.1016/j.bone.2005.08.013; Tompkins K, 2005, J BONE MINER RES, V20, P341, DOI 10.1359/JBMR.041107; Veis A, 2003, CELL MOL LIFE SCI, V60, P38, DOI 10.1007/s000180300003; Veis A, 2000, J BIOL CHEM, V275, P41263, DOI 10.1074/jbc.M002308200; Viswanathan HL, 2003, J PERIODONTOL, V74, P1423, DOI 10.1902/jop.2003.74.10.1423; Wang HJ, 2005, J BONE MINER RES, V20, P1032, DOI 10.1359/JBMR.050111; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Xu LM, 2006, J BIOL CHEM, V281, P2257, DOI 10.1074/jbc.M507695200; Yu J, 2001, MOL CELL BIOL, V21, P5879, DOI 10.1128/MCB.21.17.5879-5888.2001; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200; Zhou YL, 2000, J BIOL CHEM, V275, P12273, DOI 10.1074/jbc.275.16.12273	38	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32439	32444		10.1074/jbc.M605406200	http://dx.doi.org/10.1074/jbc.M605406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954216	hybrid			2022-12-25	WOS:000241414500041
J	Endeward, V; Musa-Aziz, R; Cooper, GJ; Chen, LM; Pelletier, MF; Virkki, LV; Supuran, CT; King, LS; Boron, WF; Gros, G				Endeward, V.; Musa-Aziz, R.; Cooper, G. J.; Chen, L. -M.; Pelletier, M. F.; Virkki, L. V.; Supuran, C. T.; King, L. S.; Boron, W. F.; Gros, G.			Evidence that aquaporin 1 is a major pathway for CO2 transport across the human erythrocyte membrane	FASEB JOURNAL			English	Article						human red cell membrane; CO2 permeability; pCMBS; DIDS	CARBON-DIOXIDE PERMEABILITY; RED-BLOOD-CELLS; INTRACELLULAR PH; WATER CHANNEL; INHIBITORS; DIFFUSION; ANHYDRASE; EXCHANGE; PCMBS; CHIP	We report here the application of a previously described method to directly determine the CO2 permeability (P-CO2) of the cell membranes of normal human red blood cells (RBCs) vs. those deficient in aquaporin 1 (AQP1), as well as AQP1-expressing Xenopus laevis oocytes. This method measures the exchange of O-18 between CO2, HCO3-, and H2O in cell suspensions. In addition, we measure the alkaline surface pH (pH(S)) transients caused by the dominant effect of entry of CO2 vs. HCO3- into oocytes exposed to step increases in [CO2]. We report that 1) AQP1 constitutes the major pathway for molecular CO2 in human RBCs; lack of AQP1 reduces P-CO2 from the normal value of 0.15 +/- 0.08 (SD; n = 85) cm/s by 60% to 0.06 cm/s. Expression of AQP1 in oocytes increases P-CO2 2-fold and doubles the alkaline pHS gradient. 2) pCMBS, an inhibitor of the AQP1 water channel, reduces P-CO2 of RBCs solely by action on AQP1 as it has no effect in AQP1-deficient RBCs. 3) P-CO2 determinations of RBCs and pH(S) measurements of oocytes indicate that DIDS inhibits the CO2 pathway of AQP1 by half. 4) RBCs have at least one other DIDS-sensitive pathway for CO2. We conclude that AQP1 is responsible for 60% of the high P-CO2 of red cells and that another, so far unidentified, CO2 pathway is present in this membrane that may account for at least 30% of total P-CO2.	Hannover Med Sch, Zentrum Physiol, Abt Vegetat Physiol, D-30625 Hannover, Germany; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Florence, Dipartimento Chim, Chim Bioorgan Lab, Florence, Italy; Johns Hopkins Univ, Dept Med, Baltimore, MD USA	Hannover Medical School; Yale University; University of Florence; Johns Hopkins University	Gros, G (corresponding author), Hannover Med Sch, Zentrum Physiol, Abt Vegetat Physiol, D-30625 Hannover, Germany.	gros.gerolf@mh-hannover.de	Supuran, Claudiu T/A-5151-2008; Musa-Aziz, Raif/F-3434-2013; Gros, Gerolf/K-8421-2012; Chen, Li-Ming/AAU-2363-2021; Boron, Walter/ABI-1564-2020	Musa-Aziz, Raif/0000-0002-0386-4248; Chen, Li-Ming/0000-0002-8129-9563; Boron, Walter/0000-0003-4741-7287; Supuran, Claudiu/0000-0003-4262-0323				BENGA G, 1992, EUR J CELL BIOL, V59, P219; BENGA G, 1983, J MEMBRANE BIOL, V76, P129, DOI 10.1007/BF02000613; Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; Casey JR, 2004, J MED CHEM, V47, P2337, DOI 10.1021/jm031079w; CHESLER M, 1986, J PHYSIOL-LONDON, V381, P241, DOI 10.1113/jphysiol.1986.sp016325; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; DEHEMPTINNE A, 1984, J PHYSIOL-LONDON, V347, P581, DOI 10.1113/jphysiol.1984.sp015084; EDSALL JT, 1966, CO2 CHEM BIOCH PHYSL; Endeward V, 2005, J PHYSIOL-LONDON, V567, P253, DOI 10.1113/jphysiol.2005.085761; Forster RE, 1998, P NATL ACAD SCI USA, V95, P15815, DOI 10.1073/pnas.95.26.15815; Forster RE, 1964, HDB PHYSIOLOGY     3, V1, P827; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GROS G, 1971, PFLUG ARCH EUR J PHY, V324, P249, DOI 10.1007/BF00586422; GROS G, 1979, Pfluegers Archiv European Journal of Physiology, V382, pR21; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; ITADA N, 1977, J BIOL CHEM, V252, P3881; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Moore W. J., 1962, PHYS CHEM; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Prasad Ramjee, 1998, IEEE Communications Surveys & Tutorials, V1, P2, DOI 10.1109/COMST.1998.5340404; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; THEWS G, 1960, PFLUG ARCH GES PHYS, V271, P227, DOI 10.1007/BF00363006; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; Uehlein N, 2003, NATURE, V425, P734, DOI 10.1038/nature02027; Virkki LV, 2002, J BIOL CHEM, V277, P40610, DOI 10.1074/jbc.M206157200; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; Weast R. C., 1977, CRC HDB CHEM PHYS; Wunder M, 1998, ISOT ENVIRON HEALT S, V34, P197, DOI 10.1080/10256019808036371; Wunder MA, 1998, ISOT ENVIRON HEALT S, V34, P303, DOI 10.1080/10256019808234064; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Yool AJ, 2002, NEWS PHYSIOL SCI, V17, P68, DOI 10.1152/nips.01372.2001; ZHANG ZH, 1992, BIOCHIM BIOPHYS ACTA, V1106, P31, DOI 10.1016/0005-2736(92)90218-B	37	160	168	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1974	1981		10.1096/fj.04-3300com	http://dx.doi.org/10.1096/fj.04-3300com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012249				2022-12-25	WOS:000241156900005
J	Wan, X; Harkavy, B; Shen, N; Grohar, P; Helman, LJ				Wan, X.; Harkavy, B.; Shen, N.; Grohar, P.; Helman, L. J.			Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism	ONCOGENE			English	Article						mTOR; rapamycin; Akt; IGF-1R; rhabdomyosarcoma	GROWTH-FACTOR-II; INSULIN-RESISTANCE; MTOR; RECEPTOR; PHOSPHORYLATION; SURVIVAL; PATHWAY; TARGET; RHABDOMYOSARCOMA; DOWNSTREAM	Rapamycin and several analogs, such as CCI-779 and RAD001, are currently undergoing clinical evaluation as anticancer agents. In this study, we show that inhibition of mammalian target of rapamycin ( mTOR) signaling by rapamycin leads to an increase of Akt phosphorylation in Rh30 and RD human rhabdomyosarcoma cell lines and xenografts, and insulin-like growth factor (IGF)-II-treated C2C12 mouse myoblasts and IGF-II-overexpressing Chinese hamster ovary cells. RNA interference-mediated knockdown of S6K1 also results in an increase of Akt phosphorylation. These data suggest that mTOR/S6K1 inhibition either by rapamycin or small interfering RNA ( siRNA) triggers a negative feedback loop, resulting in the activation of Akt signaling. We next sought to investigate the mechanism of this negative feedback regulation from mTOR to Akt. Suppression of insulin receptor substrate (IRS)-1 and tuberous sclerosis complex-1 by siRNAs failed to abrogate rapamycin-induced upregulation of Akt phosphorylation in both Rh30 and RD cells. However, pretreatment with h7C10 antibody directed against insulin-like growth factor-1 receptor (IGF-1R) led to a blockade of rapamycin-induced Akt activation. Combined mTOR and IGF-1R inhibition with rapamycin and h7C10 antibody, respectively, resulted in additive inhibition of cell growth and survival. These data suggest that rapamycin mediates Akt activation through an IGF-1R-dependent mechanism. Thus, combining an mTOR inhibitor and an IGF-1R antibody/inhibitor may be an appropriate strategy to enhance mTOR-targeted anticancer therapy.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH,Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wan, X (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH,Ctr Canc Res, Bldg 10,Rm CRC 1W 3750, Bethesda, MD 20892 USA.	xiaolinw@mail.nih.gov	Grohar, Patrick/V-2557-2018		NATIONAL CANCER INSTITUTE [ZIASC006892, Z01SC006892] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Dagher R, 1999, Oncologist, V4, P34; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Lawlor MA, 2001, J CELL SCI, V114, P2903; LeRoith D, 1995, ANN NY ACAD SCI, V766, P402, DOI 10.1111/j.1749-6632.1995.tb26689.x; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINNITI CP, 1995, CELL GROWTH DIFFER, V6, P263; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; PAPPO AS, 1995, J CLIN ONCOL, V13, P2123, DOI 10.1200/JCO.1995.13.8.2123; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Womer RB, 2000, CURR OPIN ONCOL, V12, P337, DOI 10.1097/00001622-200007000-00010; Zhang LJ, 1999, J BIOL CHEM, V274, P13118, DOI 10.1074/jbc.274.19.13118	37	611	632	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1932	1940		10.1038/sj.onc.1209990	http://dx.doi.org/10.1038/sj.onc.1209990			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001314				2022-12-25	WOS:000245117700010
J	Rose, PP; Carroll, JM; Carroll, PA; DeFilippis, VR; Lagunoff, M; Moses, AV; Roberts, CT; Fruh, K				Rose, P. P.; Carroll, J. M.; Carroll, P. A.; DeFilippis, V. R.; Lagunoff, M.; Moses, A. V.; Roberts, C. T., Jr.; Fruh, K.			The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma	ONCOGENE			English	Article						Kaposi's sarcoma; endothelial cell; tumorigenesis; insulin; insulin-like growth factor	GENE-EXPRESSION; ENDOTHELIAL-CELLS; IGF-II; HERPESVIRUS; GROWTH; TRANSFORMATION; INFECTION; ISOFORM; ESTABLISHMENT; DISEASES	Kaposi sarcoma (KS), a multifocal neoplasm of the skin that can spread to visceral organs, is the most prevalent malignant tumor in acquired immuno deficiency syndrome (AIDS) patients. KS-associated herpesvirus (KSHV or HHV8) is considered the primary etiological factor of this malignancy, as well as of primary effusion lymphoma and multicentric Castleman's disease. KS lesions are characterized by proliferating spindle cells of endothelial cell (EC) origin. The action of the insulin-like growth factor (IGF) system has been implicated in many malignancies, and recent data have demonstrated that the IGF-I receptor (IGF-IR) is required for in vitro growth of the KS-derived KSIMM cell line. To examine whether the IGF pathway is also involved in KSHV-mediated transformation of ECs, we examined the expression and function of the IGF system in KSHV-infected, immortalized dermal microvascular EC (E-DMVEC). The expression of the insulin receptor (IR) was strongly induced in latently infected E-DMVEC, whereas the expression levels of the IGF-IR remained unchanged. Gene knockdown of IR, but not IGF-IR, prevented the characteristic focus formation seen in KSHV-infected E-DMVEC. Similarly, treatment with the IR-specific small-molecule inhibitor HNMPA-(AM(3)) inhibited post-confluent growth. These data suggest a role for the IR, but not the IGF-IR, in KSHV-induced transformation of vascular ECs.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Oregon Health & Science University; University of Washington; University of Washington Seattle	Fruh, K (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th ave, Beaverton, OR 97006 USA.	fruehk@ohsu.edu	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772; Frueh, Klaus/0000-0001-8014-3877; Carroll, Patrick/0000-0001-8147-5750	NATIONAL CANCER INSTITUTE [R01CA099906] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007781] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA099906, R01 CA097934] Funding Source: Medline; NHLBI NIH HHS [T32 HL007781-13] Funding Source: Medline; NCHHSTP CDC HHS [PS1-RR00163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCHHSTP CDC HHS		Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Denley A, 2004, MOL ENDOCRINOL, V18, P2502, DOI 10.1210/me.2004-0183; Denley A, 2003, HORM METAB RES, V35, P778; Flamand L, 1996, J ACQ IMMUN DEF SYND, V13, P194, DOI 10.1097/00042560-199610010-00011; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Hailey J, 2002, MOL CANCER THER, V1, P1349; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; McAllister SC, 2004, BLOOD, V103, P3465, DOI 10.1182/blood-2003-08-2781; Moses AV, 2002, J VIROL, V76, P8383, DOI 10.1128/JVI.76.16.8383-8399.2002; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Sharma-Walia N, 2005, J VIROL, V79, P10308, DOI 10.1128/JVI.79.16.10308-10329.2005; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384	31	29	30	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					1995	2005		10.1038/sj.onc.1210006	http://dx.doi.org/10.1038/sj.onc.1210006			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001305				2022-12-25	WOS:000245313400002
J	Trivedi, AK; Bararia, D; Christopeit, M; PeerZada, AA; Singh, SM; Kieser, A; Hiddemann, W; Behre, HM; Behre, G				Trivedi, A. K.; Bararia, D.; Christopeit, M.; PeerZada, A. A.; Singh, S. M.; Kieser, A.; Hiddemann, W.; Behre, H. M.; Behre, G.			Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBP alpha by inhibiting its ubiquitination	ONCOGENE			English	Article						JNK1; C/EBP alpha; ubiquitination; AML and proteomics	BINDING-PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; C-JUN EXPRESSION; GRANULOCYTIC DIFFERENTIATION; DNA-BINDING; TRANSCRIPTION FACTORS; LINEAGE COMMITMENT; DOWN-REGULATION; PHOSPHORYLATION; KINASE	Functional inactivation of transcription factors in hematopoietic stem cell development is involved in the pathogenesis of acute myeloid leukemia (AML). Stem cell regulator C/enhancer binding protein (EBP)alpha is among such transcription factors known to be inactive in AML. This is either due to mutations or inhibition by protein-protein interactions. Here, we applied a mass spectrometry-based proteomic approach to systematically identify putative co-activator proteins interacting with the DNA-binding domain (DBD) of C/EBP transcription factors. In our proteomic screen, we identified c-Jun N-terminal kinase (JNK) 1 among others such as PAK6, MADP-1, calmodulin-like skin proteins and ZNF45 as proteins interacting with DBD of C/EBPs from nuclear extract of myelomonocytic U937 cells. We show that kinase JNK1 physically interacts with DBD of C/EBP alpha in vitro and in vivo. Furthermore, we show that active JNK1 inhibits ubiquitination of C/EBP alpha possibly by phosphorylating in its DBD. Consequently, JNK1 prolongs C/EBP alpha protein half-life leading to its enhanced transactivation and DNA-binding capacity. In certain AML patients, however, the JNK1 mRNA expression and its kinase activity is decreased which suggests a possible reason for C/EBP alpha inactivation in AML. Thus, we report the first proteomic screen of C/EBP-interacting proteins, which identifies JNK1 as positive regulator of C/EBP alpha.	Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med 4, State Ctr Cell & Gene Therapy, Halle, SA, Germany; GSF Natl Res Ctr Environm & Hlth, Dept Gene Vectors, Munich, Germany; Univ Munich, Dept Internal Med 3, D-80539 Munich, Germany; Univ Halle Wittenberg, Androl Sect, D-4010 Halle, Germany	Martin Luther University Halle Wittenberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Martin Luther University Halle Wittenberg	Behre, G (corresponding author), Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med 4, State Ctr Cell & Gene Therapy, Halle, SA, Germany.	gerhard.behre@medizin.uni-halle.de	Kieser, Arnd/M-4616-2014; Trivedi, Arun Kumar/W-1883-2019	Kieser, Arnd/0000-0003-0783-1950; Trivedi, Arun Kumar/0000-0002-6316-0947; Christopeit, Maximilian/0000-0003-4627-0412				BALKHI MY, 2006, EPUB ONCOGENE, V29; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Behre Gerhard, 2002, Expert Opin Ther Targets, V6, P491, DOI 10.1517/14728222.6.4.491; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Cleaves R, 2004, ONCOGENE, V23, P716, DOI 10.1038/sj.onc.1207172; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Friedman AD, 1996, CANCER RES, V56, P3250; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Perrotti D, 2004, J CLIN ONCOL, V22, P582, DOI 10.1200/JCO.2004.12.965; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Ronai Z, 2004, MOL CELL, V15, P843, DOI 10.1016/j.molcel.2004.09.011; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; SCOTT LM, 1992, BLOOD, V80, P1725; Shim M, 2003, J BIOL CHEM, V278, P19674, DOI 10.1074/jbc.M301356200; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Smith ML, 2004, NEW ENGL J MED, V351, P2403, DOI 10.1056/NEJMoa041331; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; TERRANCE A, 2002, LEUKEMIA RES, V26, P55; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	53	43	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1789	1801		10.1038/sj.onc.1209964	http://dx.doi.org/10.1038/sj.onc.1209964			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983342				2022-12-25	WOS:000244955600013
J	Han, Q; Robinson, H; Gao, YG; Vogelaar, N; Wilson, SR; Rizzi, M; Li, JY				Han, Qian; Robinson, Howard; Gao, Yi Gui; Vogelaar, Nancy; Wilson, Scott R.; Rizzi, Menico; Li, Jianyong			Crystal structures of Aedes aegypti alanine glyoxylate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMBIAE 3-HYDROXYKYNURENINE TRANSAMINASE; PRIMARY HYPEROXALURIA TYPE-1; YELLOW-FEVER MOSQUITO; MAJOR BRANCH PATHWAY; KYNURENINE AMINOTRANSFERASE; XANTHURENIC ACID; PROTEIN; EVOLUTION; MALARIA; ENZYME	Mosquitoes are unique in having evolved two alanine glyoxylate aminotransferases (AGTs). One is 3-hydroxykynurenine transaminase (HKT), which is primarily responsible for catalyzing the transamination of 3-hydroxykynurenine (3-HK) to xanthurenic acid (XA). Interestingly, XA is used by malaria parasites as a chemical trigger for their development within the mosquito. This 3-HK to XA conversion is considered the major mechanism mosquitoes use to detoxify the chemically reactive and potentially toxic 3-HK. The other AGT is a typical dipteran insect AGT and is specific for converting glyoxylic acid to glycine. Here we report the 1.75 angstrom high-resolution three-dimensional crystal structure of AGT from the mosquito Aedes aegypti (AeAGT) and structures of its complexes with reactants glyoxylic acid and alanine at 1.75 and 2.1 angstrom resolution, respectively. This is the first time that the three-dimensional crystal structures of an AGT with its amino acceptor, glyoxylic acid, and amino donor, alanine, have been determined. The protein is dimeric and adopts the type I-fold of pyridoxal 5-phosphate (PLP)-dependent aminotransferases. The PLP co-factor is covalently bound to the active site in the crystal structure, and its binding site is similar to those of other AGTs. The comparison of the AeAGT-glyoxylic acid structure with other AGT structures revealed that these glyoxylic acid binding residues are conserved in most AGTs. Comparison of the AeAGT-alanine structure with that of the Anopheles HKT-inhibitor complex suggests that a Ser-Asn-Phe motif in the latter may be responsible for the substrate specificity of HKT enzymes for 3-HK.	Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA; Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA; Univ Peimonte Orientale Novara, Struct Biol Unit, I-28100 Novara, Italy	Virginia Polytechnic Institute & State University; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Illinois System; University of Illinois Urbana-Champaign; Virginia Polytechnic Institute & State University; University of Eastern Piedmont Amedeo Avogadro	Li, JY (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA.	lij@vt.edu	Han, Qian/AAS-2134-2020; Han, Qian/J-8696-2014	Han, Qian/0000-0001-6245-5252	NIAID NIH HHS [R01 AI44399] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044399] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Birdsey GM, 2004, MOL BIOL EVOL, V21, P632, DOI 10.1093/molbev/msh054; Birdsey GM, 2005, P ROY SOC B-BIOL SCI, V272, P833, DOI 10.1098/rspb.2004.3011; Danpure C. J., 2001, METABOLIC MOL BASES, V2, P3323; Danpure CJ, 1997, BIOESSAYS, V19, P317, DOI 10.1002/bies.950190409; Danpure CJ, 1996, ANN NY ACAD SCI, V804, P477, DOI 10.1111/j.1749-6632.1996.tb18638.x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fang J, 2002, INSECT BIOCHEM MOLEC, V32, P943, DOI 10.1016/S0965-1748(02)00032-2; Garcia GE, 1998, J BIOL CHEM, V273, P12003, DOI 10.1074/jbc.273.20.12003; Guidetti P, 1997, J NEUROSCI RES, V50, P457; Han GW, 2005, PROTEINS, V58, P971; Han Q, 2005, FEBS J, V272, P2198, DOI 10.1111/j.1742-4658.2005.04643.x; Han Q, 2004, FEBS LETT, V577, P381, DOI 10.1016/j.febslet.2004.09.088; Han Q, 2002, J BIOL CHEM, V277, P15781, DOI 10.1074/jbc.M201202200; Han Q, 2002, FEBS LETT, V527, P199, DOI 10.1016/S0014-5793(02)03229-5; Han Q, 2006, BIOCHEM J, V397, P473, DOI 10.1042/BJ20060469; Holbrook JD, 2002, J BIOL CHEM, V277, P2336, DOI 10.1074/jbc.M107047200; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li JY, 1997, INSECT BIOCHEM MOLEC, V27, P859, DOI 10.1016/S0965-1748(97)00068-4; Li JY, 1999, INSECT BIOCHEM MOLEC, V29, P329, DOI 10.1016/S0965-1748(99)00007-7; Liepman AH, 2001, PLANT J, V25, P487, DOI 10.1046/j.1365-313x.2001.00961.x; Meyer P, 2005, BIOCHIMIE, V87, P1041, DOI 10.1016/j.biochi.2005.09.001; Minor W., 1993, XDISPLAYF PROGRAM; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 1999, BIOCHEMISTRY-US, V38, P2413, DOI 10.1021/bi9819881; Okamoto A, 1998, J MOL BIOL, V280, P443, DOI 10.1006/jmbi.1998.1869; OKUNO E, 1980, BIOCHEM J, V189, P581, DOI 10.1042/bj1890581; OKUNO E, 1991, BRAIN RES, V542, P307, DOI 10.1016/0006-8993(91)91583-M; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT, P80; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; REHFELD DW, 1972, J BIOL CHEM, V247, P4803; Rossi F, 2006, P NATL ACAD SCI USA, V103, P5711, DOI 10.1073/pnas.0510233103; Rossi F, 2005, FEBS J, V272, P5653, DOI 10.1111/j.1742-4658.2005.04961.x; Schlosser T, 2004, YEAST, V21, P63, DOI 10.1002/yea.1058; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Takayama T, 2003, J AM SOC NEPHROL, V14, P939, DOI 10.1097/01.ASN.0000059310.67812.4F; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WATTS RWE, 1992, ADV ENZYME REGUL, V32, P309; Zhang XX, 2003, J MOL BIOL, V331, P643, DOI 10.1016/S0022-2836(03)00791-5	43	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37175	37182		10.1074/jbc.M607032200	http://dx.doi.org/10.1074/jbc.M607032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16990263	hybrid			2022-12-25	WOS:000242220800078
J	Melrose, J; Roughley, P; Knox, S; Smith, S; Lord, M; Whitelock, J				Melrose, James; Roughley, Peter; Knox, Sarah; Smith, Susan; Lord, Megan; Whitelock, John			The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN-RECEPTOR; FIBROBLAST-GROWTH-FACTOR; SCHWARTZ-JAMPEL-SYNDROME; SILVERMAN-HANDMAKER TYPE; CELL-ADHESION MOLECULES; BASEMENT-MEMBRANES; PROTEIN CORE; DOMAIN-I; GLYCOSAMINOGLYCAN MODIFICATION	The aim of this study was to immunolocalize perlecan in human fetal, postnatal, and mature hyaline cartilages and to determine information on the structure and function of chondrocyte perlecan. Perlecan is a prominent component of human fetal (12-14 week) finger, toe, knee, and elbow cartilages; it was localized diffusely in the interterritorial extracellular matrix, densely in the pericellular matrix around chondrocytes, and to small blood vessels in the joint capsules and perichondrium. Aggrecan had a more intense distribution in the marginal regions of the joint rudiments and in para-articular structures. Perlecan also had a strong pericellular localization pattern in postnatal (2-7 month) and mature (55-64 year) femoral cartilages, whereas aggrecan had a prominent extracellular matrix distribution in these tissues. Western blotting identified multiple perlecan core protein species in extracts of the postnatal and mature cartilages, some of which were substituted with heparan sulfate and/or chondroitin sulfate and some were devoid of glycosaminoglycan substitution. Some perlecan core proteins were smaller than intact perlecan, suggesting that proteolytic processing or alternative splicing had occurred. Surface plasmon resonance and quartz crystal microbalance with dissipation experiments demonstrated that chondrocyte perlecan bound fibroblast growth factor (FGF)-1 and -9 less efficiently than endothelial cell perlecan. The latter perlecan supported the proliferation of Baf-32 cells transfected with FGFR3c equally well with FGF-1 and -9, whereas chondrocyte perlecan only supported Baf-32 cell proliferation with FGF-9. The function of perlecan therefore may not be universal but may vary with its cellular origin and presumably its structure.	Univ Sydney, Inst Bone & Joint Res, Raymond Purves Res Labs, St Leonards, NSW, Australia; Univ Sydney, Kolling Inst Med Res, St Leonards, NSW, Australia; Royal N Shore Hosp, St Leonards, NSW 2065, Australia; Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; Univ New S Wales, Grad Sch Biomed Engn, Sydney, NSW 2052, Australia	University of Sydney; University of Sydney; Kolling Institute of Medical Research; Royal North Shore Hospital; McGill University; University of New South Wales Sydney	Melrose, J (corresponding author), Univ Clin, Royal N Shore Hosp, Level 5,Bldg B26, St Leonards, NSW 2065, Australia.	jmelrose@med.usyd.edu.au	Melrose, James/AAG-5445-2019; Lord, Megan/D-4673-2013; Knox, Sarah Monica/GNW-5445-2022	Melrose, James/0000-0001-9237-0524; Lord, Megan/0000-0002-0506-9811; Whitelock, John/0000-0003-1835-802X; Knox, Sarah/0000-0002-7567-083X				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Arikawa-Hirasawa E, 2002, AM J HUM GENET, V70, P1368, DOI 10.1086/340390; Arikawa-Hirasawa E, 2001, AM J MED GENET, V106, P254, DOI 10.1002/ajmg.10229.abs; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; Balasubramani M, 2004, MATRIX BIOL, V23, P143, DOI 10.1016/j.matbio.2004.04.001; Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Clayton A, 2001, KIDNEY INT, V59, P2084, DOI 10.1046/j.1523-1755.2001.00723.x; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; DODGE G, 2002, ORTHOP RES SOC, V27, P358; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; Eriksen GV, 1999, BIOCHEM J, V340, P613, DOI 10.1042/0264-6021:3400613; French MM, 1999, J CELL BIOL, V145, P1103, DOI 10.1083/jcb.145.5.1103; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; Ghiselli G, 2001, BIOCHEM J, V359, P153, DOI 10.1042/0264-6021:3590153; Gomes RR, 2004, CELLS TISSUES ORGANS, V176, P79, DOI 10.1159/000075029; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; Govindraj P, 2002, J BIOL CHEM, V277, P19461, DOI 10.1074/jbc.M200786200; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; Handley CJ, 2002, MATRIX BIOL, V21, P579, DOI 10.1016/S0945-053X(02)00078-1; Hart M, 2001, J PATHOL, V194, P262, DOI 10.1002/1096-9896(200106)194:2<262::AID-PATH882>3.0.CO;2-W; Ho Nicola C, 2003, BMC Neurol, V3, P3, DOI 10.1186/1471-2377-3-3; Hopf M, 2001, J MOL BIOL, V311, P529, DOI 10.1006/jmbi.2001.4878; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; Knox S, 2005, FEBS LETT, V579, P5019, DOI 10.1016/j.febslet.2005.07.090; Knox S, 2001, PROTEOMICS, V1, P1534, DOI 10.1002/1615-9861(200111)1:12<1534::AID-PROT1534>3.0.CO;2-A; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; KOKENYESI R, 1995, BIOCHEM BIOPH RES CO, V211, P262, DOI 10.1006/bbrc.1995.1805; Melrose J, 2005, HISTOCHEM CELL BIOL, V123, P561, DOI 10.1007/s00418-005-0789-y; Melrose J, 2003, J HISTOCHEM CYTOCHEM, V51, P1331, DOI 10.1177/002215540305101010; Melrose J, 2003, EUR SPINE J, V12, P57, DOI 10.1007/s00586-002-0434-6; Melrose J, 2002, HISTOCHEM CELL BIOL, V118, P269, DOI 10.1007/s00418-002-0049-4; Melrose J, 1998, J VASC SURG, V28, P676, DOI 10.1016/S0741-5214(98)70094-1; Miosge N, 2003, J HISTOCHEM CYTOCHEM, V51, P285, DOI 10.1177/002215540305100303; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nicole S, 2000, NAT GENET, V26, P480, DOI 10.1038/82638; Nishida T, 2003, J CELL PHYSIOL, V196, P265, DOI 10.1002/jcp.10277; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; Oda O, 1996, CLIN CHIM ACTA, V255, P119, DOI 10.1016/0009-8981(96)06395-4; Olsen BR, 1999, J CELL BIOL, V147, P909, DOI 10.1083/jcb.147.5.909; Ornitz DM, 2001, GENOME BIOL, V2; Patel MI, 1996, J VASC SURG, V24, P82, DOI 10.1016/S0741-5214(96)70148-9; RODAHL M, 1995, REV SCI INSTRUM, V66, P3924, DOI 10.1063/1.1145396; Rossi M, 2003, EMBO J, V22, P236, DOI 10.1093/emboj/cdg019; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; Schofield KP, 1999, BIOCHEM J, V343, P663, DOI 10.1042/0264-6021:3430663; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Tapanadechopone P, 2001, BIOCHEM J, V355, P517, DOI 10.1042/0264-6021:3550517; Tapanadechopone P, 1999, BIOCHEM BIOPH RES CO, V265, P680, DOI 10.1006/bbrc.1999.1714; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; Voinova MV, 1999, PHYS SCRIPTA, V59, P391, DOI 10.1238/Physica.Regular.059a00391; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Whitelock JM, 2002, METHOD CELL BIOL, V69, P53, DOI 10.1016/S0091-679X(02)69007-7; Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1	67	76	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36905	36914		10.1074/jbc.M608462200	http://dx.doi.org/10.1074/jbc.M608462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16984910	hybrid			2022-12-25	WOS:000242220800050
J	Goepfert, S; Hiltunen, JK; Poirier, Y				Goepfert, Simon; Hiltunen, J. Kalervo; Poirier, Yves			Identification and functional characterization of a monofunctional peroxisomal enoyl-CoA hydratase 2 that participates in the degradation of even cis-unsaturated fatty acids in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; COENZYME-A HYDRATASE; BETA-OXIDATION; RAT-LIVER; MULTIFUNCTIONAL ENZYME; ESCHERICHIA-COLI; POLYHYDROXYALKANOATE SYNTHESIS; 2-ENOYL-COA HYDRATASE; ISOMERASE ACTIVITIES; PLANT PEROXISOMES	A gene, named AtECH2, has been identified in Arabidopsis thaliana to encode a monofunctional peroxisomal enoyl-CoA hydratase 2. Homologues of AtECH2 are present in several angiosperms belonging to the Monocotyledon and Dicotyledon classes, as well as in a gymnosperm. In vitro enzyme assays demonstrated that AtECH2 catalyzed the reversible conversion of 2E-enoyl-CoA to 3R-hydroxyacyl-CoA. AtECH2 was also demonstrated to have enoyl-CoA hydratase 2 activity in an in vivo assay relying on the synthesis of polyhydroxyalkanoate from the polymerization of 3R-hydroxyacyl-CoA in the peroxisomes of Saccharomyces cerevisiae. AtECH2 contained a peroxisome targeting signal at the C-terminal end, was addressed to the peroxisome in S. cerevisiae, and a fusion protein between AtECH2 and a fluorescent protein was targeted to peroxisomes in onion cells. AtECH2 gene expression was strongest in tissues with high beta-oxidation activity, such as germinating seedlings and senescing leaves. The contribution of AtECH2 to the degradation of unsaturated fatty acids was assessed by analyzing the carbon flux through the beta-oxidation cycle in plants that synthesize peroxisomal polyhydroxyalkanoate and that were over-or under-expressing the AtECH2 gene. These studies revealed that AtECH2 participates in vivo to the conversion of the intermediate 3R-hydroxyacyl-CoA, generated by the metabolism of fatty acids with a cis(Z)-unsaturated bond on an even-numbered carbon, to the 2E-enoyl-CoA for further degradation through the core beta-oxidation cycle.	Univ Lausanne, Dept Biol Mol Vegetale, CH-1015 Lausanne, Switzerland; Oulu Univ, Bioctr Oulu, FIN-90014 Oulu, Finland; Oulu Univ, Dept Biochem, FIN-90014 Oulu, Finland	University of Lausanne; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Poirier, Y (corresponding author), Univ Lausanne, Dept Biol Mol Vegetale, Biophore Bldg, CH-1015 Lausanne, Switzerland.	yves.poirier@unil.ch						Allenbach L, 2000, PLANT PHYSIOL, V124, P1159, DOI 10.1104/pp.124.3.1159; BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P170, DOI 10.1016/0003-9861(88)90625-X; CHU CH, 1984, BIOCHEM BIOPH RES CO, V118, P162, DOI 10.1016/0006-291X(84)91081-7; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979; ENGELAND K, 1991, EUR J BIOCHEM, V200, P171, DOI 10.1111/j.1432-1033.1991.tb21064.x; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Froman BE, 2000, PLANT PHYSIOL, V123, P733, DOI 10.1104/pp.123.2.733; Fukui T, 1998, J BACTERIOL, V180, P667, DOI 10.1128/JB.180.3.667-673.1998; Fulda M, 2002, PLANT J, V32, P93, DOI 10.1046/j.1365-313X.2002.01405.x; GERHARDT B, 1992, PROG LIPID RES, V31, P417, DOI 10.1016/0163-7827(92)90004-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goepfert S, 2005, PLANT PHYSIOL, V138, P1947, DOI 10.1104/pp.105.064311; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; Gurvitz A, 1998, J BIOL CHEM, V273, P31366, DOI 10.1074/jbc.273.47.31366; Hilson P, 2004, GENOME RES, V14, P2176, DOI 10.1101/gr.2544504; Hiltunen JK, 2000, BBA-MOL CELL BIOL L, V1484, P117, DOI 10.1016/S1388-1981(00)00013-5; Hiltunen JK, 2003, FEMS MICROBIOL REV, V27, P35, DOI 10.1016/S0168-6445(03)00017-2; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; Huyghe S, 2006, BBA-MOL CELL BIOL L, V1761, P973, DOI 10.1016/j.bbalip.2006.04.006; Karimi M, 2005, TRENDS PLANT SCI, V10, P103, DOI 10.1016/j.tplants.2005.01.008; Koski MK, 2004, J BIOL CHEM, V279, P24666, DOI 10.1074/jbc.M400293200; Marchesini S, 2003, APPL ENVIRON MICROB, V69, P6495, DOI 10.1128/AEM.69.11.6495-6499.2003; Mittendorf V, 1999, PLANT J, V20, P45, DOI 10.1046/j.1365-313X.1999.00572.x; Mittendorf V, 1998, P NATL ACAD SCI USA, V95, P13397, DOI 10.1073/pnas.95.23.13397; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Poirier Y, 1999, PLANT PHYSIOL, V121, P1359, DOI 10.1104/pp.121.4.1359; Poirier Y, 2002, PROG LIPID RES, V41, P131, DOI 10.1016/S0163-7827(01)00018-2; Poirier Y, 2001, APPL ENVIRON MICROB, V67, P5254, DOI 10.1128/AEM.67.11.5254-5260.2001; PREISIGMULLER R, 1994, J BIOL CHEM, V269, P20475; Qin YM, 2000, J BIOL CHEM, V275, P4965, DOI 10.1074/jbc.275.7.4965; Qin YM, 1997, BIOCHEM J, V321, P21, DOI 10.1042/bj3210021; Reumann S, 2004, PLANT PHYSIOL, V136, P2587, DOI 10.1104/pp.104.043695; Reumann S, 2004, PLANT PHYSIOL, V135, P783, DOI 10.1104/pp.103.035584; Robert J, 2005, BBA-MOL CELL BIOL L, V1734, P169, DOI 10.1016/j.bbalip.2005.02.010; Sambrook J, 2001, MOL CLONING LAB MANU; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SCHULZ H, 1983, BIOCHEMISTRY-US, V22, P1827, DOI 10.1021/bi00277a013; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuge T, 2000, FEMS MICROBIOL LETT, V184, P193, DOI 10.1111/j.1574-6968.2000.tb09013.x; WAN CY, 1994, ANAL BIOCHEM, V223, P7, DOI 10.1006/abio.1994.1538; YANG SY, 1995, BIOCHEMISTRY-US, V34, P6441, DOI 10.1021/bi00019a025; YANG SY, 1993, J BIOL CHEM, V268, P6588; YANG SY, 1986, J BIOL CHEM, V261, P5390	48	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35894	35903		10.1074/jbc.M606383200	http://dx.doi.org/10.1074/jbc.M606383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16982622	hybrid			2022-12-25	WOS:000242100500036
J	Kissova, I; Plamondon, LT; Brisson, L; Priault, M; Renouf, V; Schaeffer, J; Camougrand, N; Manon, S				Kissova, Ingrid; Plamondon, Louis-Thomas; Brisson, Louise; Priault, Muriel; Renouf, Vincent; Schaeffer, Jacques; Camougrand, Nadine; Manon, Stephen			Evaluation of the roles of apoptosis, autophagy, and mitophagy in the loss of plating efficiency induced by Bax expression in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; MITOCHONDRIAL AUTOPHAGY; REGULATES APOPTOSIS; OXIDATIVE STRESS; BCL-2; PROTEINS; DISTINCT; RELEASE; GENE	We found recently that, in yeast cells, the heterologous expression of Bax induces a loss of plating efficiency different from that induced by acute stress because it is associated with the maintenance of plasma membrane integrity (Camougrand, N., Grelaud-Coq, A., Marza, E., Priault, M., Bessoule, J. J., and Manon ,S. ( 2003) Mol. Microbiol. 47, 495-506). Bax effects were neither dependent on the presence of the yeast metacaspase Yca1p and the apoptosis-inducing factor homolog nor associated with the appearance of typical apoptotic markers such as metacaspase activation, annexin V binding, and DNA cleavage. Yeast cells expressing Bax instead displayed autophagic features, including increased accumulation of Atg8p, activation of vacuolar alkaline phosphatase, and the presence of auto-phagosomes and autophagic bodies. However, the inactivation of autophagy did not prevent and actually slightly accelerated Bax-induced loss of plating efficiency. On the other hand, Bax expression induced a fragmentation of the mitochondrial network, which retained, however, some level of organization in wild-type cells. However, when expressed in cells inactivated for the gene UTH1, previously shown to be involved in mitophagy, Bax induced a complete disorganization of the mitochondrial network. Interestingly, although mitochondrially targeted green fluorescent protein was slowly degraded in the wild-type strain, it remained unaffected in the mutant. Furthermore, the slow loss of plating efficiency in the mutant strain correlated with a loss of plasma membrane integrity. These data suggest that Bax-induced loss of growth capacity is associated with maintenance of plasma membrane integrity dependent on UTH1, suggesting that selective degradation of altered mitochondria is required for a regulated loss of growth capacity.	Univ Bordeaux 2, CNRS, UMR5095, F-33077 Bordeaux, France; Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia; Univ Laval, Dept Biochem & Microbiol, Ste Foy, PQ G1K 7P4, Canada; Univ Bordeaux 2, Serv Commun Microscopie, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Comenius University Bratislava; Laval University; UDICE-French Research Universities; Universite de Bordeaux	Camougrand, N (corresponding author), Univ Bordeaux 2, CNRS, UMR5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	n.camougrand@ibgc.cnrs.fr; stephen.manon@ibgc.cnrs.fr	Manon, Stéphen/C-7088-2017; Bhatia, Ingrid/H-7016-2016; Priault, Muriel/HHT-0658-2022	Priault, Muriel/0000-0001-8193-0389; Manon, Stephen/0000-0002-5792-1084				Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Abudugupur A, 2002, CELL DEATH DIFFER, V9, P158, DOI 10.1038/sj.cdd.4400942; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Arnoult D, 2002, CELL DEATH DIFFER, V9, P65, DOI 10.1038/sj.cdd.4400951; Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; Arokium H, 2004, J BIOL CHEM, V279, P52566, DOI 10.1074/jbc.M408373200; Belhocine S, 2004, CELL DEATH DIFFER, V11, P946, DOI 10.1038/sj.cdd.4401422; BONNEU M, 1991, ANAL BIOCHEM, V193, P225, DOI 10.1016/0003-2697(91)90013-J; Camougrand N, 2003, MOL MICROBIOL, V47, P495, DOI 10.1046/j.1365-2958.2003.03311.x; Camougrand NM, 2000, ARCH BIOCHEM BIOPHYS, V375, P154, DOI 10.1006/abbi.1999.1655; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Clow A, 1998, EUR J BIOCHEM, V258, P19, DOI 10.1046/j.1432-1327.1998.2580019.x; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Dimitrova I, 2004, FEBS LETT, V566, P100, DOI 10.1016/j.febslet.2004.04.012; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Golstein P, 2005, CELL DEATH DIFFER, V12, P1490, DOI 10.1038/sj.cdd.4401607; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Guscetti F, 2005, FASEB J, V19, P464, DOI 10.1096/fj.04-2316fje; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hauptmann P, 2006, MOL MICROBIOL, V59, P765, DOI 10.1111/j.1365-2958.2005.04981.x; Hazan R, 2004, APPL ENVIRON MICROB, V70, P4449, DOI 10.1128/AEM.70.8.4449-4457.2004; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Khan MAS, 2005, P NATL ACAD SCI USA, V102, P17326, DOI 10.1073/pnas.0508120102; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kissova I, 2000, FEBS LETT, V471, P113, DOI 10.1016/S0014-5793(00)01379-X; Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200; Kosta A, 2004, J BIOL CHEM, V279, P48404, DOI 10.1074/jbc.M408924200; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kundu M, 2005, CELL DEATH DIFFER, V12, P1484, DOI 10.1038/sj.cdd.4401780; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levraud JP, 2003, J CELL BIOL, V160, P1105, DOI 10.1083/jcb.200212104; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ludovico P, 2005, IUBMB LIFE, V57, P129, DOI 10.1080/15216540500090553; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marza E, 2002, FEBS LETT, V521, P47, DOI 10.1016/S0014-5793(02)02819-3; Mazzoni C, 2005, EMBO REP, V6, P1076, DOI 10.1038/sj.embor.7400514; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Mitsui K, 2005, FEBS LETT, V579, P723, DOI 10.1016/j.febslet.2004.12.051; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pinan-Lucarre B, 2005, EUKARYOT CELL, V4, P1765, DOI 10.1128/EC.4.11.1765-1774.2005; Pinan-Lucarre R, 2003, MOL MICROBIOL, V47, P321, DOI 10.1046/j.1365-2958.2003.03208.x; Pozniakovsky AI, 2005, J CELL BIOL, V168, P257, DOI 10.1083/jcb.200408145; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 2003, FEMS YEAST RES, V4, P15, DOI 10.1016/S1567-1356(03)00143-0; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Priault M, 2002, EUR J BIOCHEM, V269, P5440, DOI 10.1046/j.1432-1033.2002.03234.x; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Skulachev VP, 2002, FEBS LETT, V528, P23, DOI 10.1016/S0014-5793(02)03319-7; Thompson AR, 2005, CURR OPIN PLANT BIOL, V8, P165, DOI 10.1016/j.pbi.2005.01.013; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Wysocki R, 2004, J CELL BIOL, V166, P311, DOI 10.1083/jcb.200405016; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zadrag R, 2006, CELL BIOL INT, V30, P205, DOI 10.1016/j.cellbi.2005.10.023; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	78	53	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36187	36197		10.1074/jbc.M607444200	http://dx.doi.org/10.1074/jbc.M607444200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990272	hybrid			2022-12-25	WOS:000242100500069
J	Li, TW; Santockyte, R; Shen, RF; Tekle, E; Wang, GH; Yang, DCH; Chock, PB				Li, Tianwei; Santockyte, Rasa; Shen, Rong-Fong; Tekle, Ephrem; Wang, Guanghui; Yang, David C. H.; Chock, P. Boon			Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELLULAR SENESCENCE; HUMAN HOMOLOG; UBIQUITIN; PROTEINS; APOPTOSIS; NUCLEAR; CELLS; E1A	Three highly homologous small ubiquitin-related modifier ( SUMO) proteins have been identified in mammals. Modifications of proteins by SUMO-1 have been shown to regulate transcription, nucleocytoplasmic transport, protein stability, and protein-protein interactions. Relative to SUMO-1, little is known about the functions of SUMO-2 or SUMO-3 ( referred to as SUMO-2/3). Here, stable cell lines overexpressing processed forms of SUMO-2/3 (SUMO-2/3GG) as well as their non-conjugatable derivatives, SUMO-2/3 Delta GG, were established. Cells overexpressing SUMO-2/3GG showed a premature senescence phenotype as revealed by cellular morphology and senescence-associated galactosidase activity. The senescence pathway protein p21 was up-regulated in cells overexpressing SUMO-2/3GG. In contrast, cells overexpressing non-conjugatable forms of SUMO-2/3 Delta GG showed neither an apparent senescent phenotype nor elevated p21. Both p53 and pRB were found to be modified by SUMO-2/3. Site-directed mutagenesis studies showed that Lys-386 of p53, the SUMO- 1 modification site, is also the modification site for SUMO-2/3. In addition, H2O2 treatment of untransfected cells caused an increase in p53 sumoylation by SUMO-2/3, whereas that by SUMO- 1 remained unchanged. Moreover, knocking down tumor suppressor proteins p53 or pRB using small interfering RNA significantly alleviated the premature senescence phenotypes in SUMO-2/3GG overexpressing cells. Together, our results reveal that p53 and pRB can be sumoylated by SUMO-2/3 in vivo, and such modification of p53 and pRB may play roles in premature senescence and stress response.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Proteom Core Facil, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Dept Chem, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Chock, PB (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 50,Rm 2134,50 S Dr,MSC-8012, Bethesda, MD 20892 USA.	bchock@nih.gov	Santockyte, Rasa/ABD-2254-2021; Yang, David/A-7294-2009	Santockyte, Rasa/0000-0002-5610-9051; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000202, Z01HL000202] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayaydin F, 2004, MOL BIOL CELL, V15, P5208, DOI 10.1091/mbc.E04-07-0589; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bischof O, 2006, MOL CELL, V22, P783, DOI 10.1016/j.molcel.2006.05.016; Campisi J, 2003, EXP GERONTOL, V38, P5, DOI 10.1016/S0531-5565(02)00152-3; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Li TW, 2006, ARCH BIOCHEM BIOPHYS, V453, P70, DOI 10.1016/j.abb.2006.03.002; Li TW, 2004, P NATL ACAD SCI USA, V101, P8551, DOI 10.1073/pnas.0402889101; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Xu Z, 2005, BIOCHEM J, V386, P325, DOI 10.1042/BJ20041210; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	28	87	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36221	36227		10.1074/jbc.M608236200	http://dx.doi.org/10.1074/jbc.M608236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012228	hybrid			2022-12-25	WOS:000242100500073
J	Nie, YL; Smirnova, I; Kasho, V; Kaback, HR				Nie, Yiling; Smirnova, Irina; Kasho, Vladimir; Kaback, H. Ronald			Energetics of ligand-induced conformational flexibility in the lactose permease of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; MEMBRANE-TRANSPORT PROTEIN; SUBSTRATE-BINDING; RECOGNITION; MECHANISM; SUGAR; SPECTROSCOPY; ENTHALPY; ANTIBODY; SITE	Isothermal titration calorimetry has been applied to characterize the thermodynamics of ligand binding to wild-type lactose permease ( LacY) and a mutant (C154G) that strongly favors an inward facing conformation. The affinity of wildtype or mutant LacY for ligand and the change in free energy (Delta G) upon binding are similar. However, with the wild type, the change in free energy upon binding is due primarily to an increase in the entropic free energy component (T Delta S), whereas in marked contrast, an increase in enthalpy (Delta H) is responsible for Delta G in the mutant. Thus, wild-type LacY behaves as if there are multiple ligand-bound conformational states, whereas the mutant is severely restricted. The findings also indicate that the structure of the mutant represents a conformational intermediate in the overall transport cycle.	Univ Calif Los Angeles, MacDonald Res Labs, Dept Physiol & Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Immunol & Mol Genet, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kaback, HR (corresponding author), Univ Calif Los Angeles, MacDonald Res Labs, Dept Physiol & Microbiol, Rm 6720,675 Charles E Young Dr S, Los Angeles, CA 90095 USA.	rkaback@mednet.ucla.edu			NIDDK NIH HHS [R01 DK051131-09, R01 DK051131-08, R01 DK051131-04, R01 DK051131-13, R01 DK051131-10, R01 DK051131-07, R01 DK051131, R01 DK051131-14, DK51131, R01 DK051131-06, R01 DK051131-05, R56 DK069463, R01 DK069463, R01 DK051131-12, R56 DK051131, R01 DK051131-11] Funding Source: Medline; NIGMS NIH HHS [P50 GM073210] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK069463, R56DK051131, R01DK051131, R01DK069463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM073210] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BERES L, 1971, BIOCHEMISTRY-US, V10, P2120; BUNDLE DR, 1994, METHOD ENZYMOL, V247, P288; CHRISTENSEN JJ, 1976, HDB PROTON IONIZATIO, P148; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; Ermolova NV, 2005, BIOCHEMISTRY-US, V44, P7669, DOI 10.1021/bi0502801; Guan L, 2003, BIOCHEMISTRY-US, V42, P1377, DOI 10.1021/bi027152m; Guan L, 2006, P NATL ACAD SCI USA, V103, P1723, DOI 10.1073/pnas.0510922103; Guan L, 2006, ANNU REV BIOPH BIOM, V35, P67, DOI 10.1146/annurev.biophys.35.040405.102005; Indyk L, 1998, METHOD ENZYMOL, V295, P350; Janin J, 1997, STRUCTURE, V5, P473, DOI 10.1016/S0969-2126(97)00204-9; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaback HR, 2005, CR BIOL, V328, P557, DOI 10.1016/j.crvi.2005.03.008; le Coutre J, 1998, P NATL ACAD SCI USA, V95, P6114, DOI 10.1073/pnas.95.11.6114; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P162, DOI 10.1016/0006-291X(85)91002-2; MIRZA O, 2006, EMBO J; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; RAMAN CS, 1995, BIOCHEMISTRY-US, V34, P5831, DOI 10.1021/bi00017a015; RUDNICK G, 1976, BIOCHEMISTRY-US, V15, P5126, DOI 10.1021/bi00668a028; Sahin-Toth M, 2000, BIOCHEMISTRY-US, V39, P5097, DOI 10.1021/bi0000263; Sahin-Toth M, 2001, BIOCHEMISTRY-US, V40, P13015, DOI 10.1021/bi011233l; Sahin-Toth M, 2001, P NATL ACAD SCI USA, V98, P6068, DOI 10.1073/pnas.111139698; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; Smirnova IN, 2003, BIOCHEMISTRY-US, V42, P3025, DOI 10.1021/bi027329c; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; VANIWAARDEN PR, 1993, BIOCHEMISTRY-US, V32, P5419, DOI 10.1021/bi00071a017; Vazquez-Ibar JL, 2004, J BIOL CHEM, V279, P49214, DOI 10.1074/jbc.M407408200; Vazquez-Ibar JL, 2003, P NATL ACAD SCI USA, V100, P12706, DOI 10.1073/pnas.1835645100; Wang CY, 2001, J MOL BIOL, V313, P873, DOI 10.1006/jmbi.2001.5083; Weinglass A, 2004, J BIOL CHEM, V279, P41858, DOI 10.1074/jbc.M407555200; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7	32	45	45	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35779	35784		10.1074/jbc.M607232200	http://dx.doi.org/10.1074/jbc.M607232200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003033	hybrid, Green Accepted			2022-12-25	WOS:000242100500024
J	Zheng, SS; Hausmann, S; Hausmann, P; Liu, QS; Ghosh, A; Schwer, B; Lima, CD; Shuman, S				Zheng, Sushuang; Hausmann, Stephane; Hausmann, Phane; Liu, Quansheng; Ghosh, Agnidipta; Schwer, Beate; Lima, Christopher D.; Shuman, Stewart			Mutational analysis of Encephalitozoon cuniculi mRNA cap (guanine-N7) methyltransferase, structure of the enzyme bound to sinefungin, and evidence that cap methyltransferase is the target of sinefungin's antifungal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING APPARATUS; DNA METHYLTRANSFERASE; (GUANINE-7-)-METHYLTRANSFERASE; MECHANISM; COFACTOR; MUTANTS; CLONING; BRUCEI; GROWTH; A9145	Cap (guanine-N7) methylation is an essential step in eukaryal mRNA synthesis and a potential target for antiviral, antifungal, and antiprotozoal drug discovery. Previous mutational and structural analyses of Encephalitozoon cuniculi Ecm1, a prototypal cellular cap methyltransferase, identified amino acids required for cap methylation in vivo, but also underscored the nonessentiality of many side chains that contact the cap and AdoMet substrates. Here we tested new mutations in residues that comprise the guanine-binding pocket, alone and in combination. The outcomes indicate that the shape of the guanine binding pocket is more crucial than particular base edge interactions, and they highlight the contributions of the aliphatic carbons of Phe-141 and Tyr-145 that engage in multiple van der Waals contacts with guanosine and S-adenosylmethionine ( AdoMet), respectively. We purified 45 Ecm1 mutant proteins and assayed them for methylation of GpppA in vitro. Of the 21 mutations that resulted in unconditional lethality in vivo, 14 reduced activity in vitro to <= 2% of the wild-type level and 5 reduced methyltransferase activity to between 4 and 9% of wild- type Ecm1. The natural product antibiotic sinefungin is an AdoMet analog that inhibits Ecm1 with modest potency. The crystal structure of an Ecm1-sinefungin binary complex reveals sinefungin-specific polar contacts with main-chain and side-chain atoms that can explain the 3-fold higher affinity of Ecm1 for sinefungin versus AdoMet or S-adenosylhomocysteine ( AdoHcy). In contrast, sinefungin is an extremely potent inhibitor of the yeast cap methyltransferase Abd1, to which sinefungin binds 900-fold more avidly than AdoHcy or AdoMet. We find that the sensitivity of Saccharomyces cerevisiae to growth inhibition by sinefungin is diminished when Abd1 is overexpressed. These results highlight cap methylation as a principal target of the antifungal activity of sinefungin.	Cornell Univ, Weill Coll Med, Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Coll Med, Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Coll Med, Dept Immunol & Microbiol, Struct Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Cornell Univ, Weill Coll Med, Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Ghosh, Agnidipta/0000-0002-7753-0240; Lima, Christopher/0000-0002-9163-6092	NIGMS NIH HHS [GM52470, GM61906] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470, R01GM061906] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRASSEUR P, 1993, ANTIMICROB AGENTS CH, V37, P889, DOI 10.1128/AAC.37.4.889; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chrebet G, 2005, J BIOMOL SCREEN, V10, P355, DOI 10.1177/1087057104273333; DECLERCQ E, 2005, NUCLEOS NUCLEOT, V24, P1295; DUBE DK, 1983, AM J TROP MED HYG, V32, P31, DOI 10.4269/ajtmh.1983.32.31; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; FERRANTE A, 1984, T ROY SOC TROP MED H, V78, P837, DOI 10.1016/0035-9203(84)90039-7; GORDEE RS, 1973, J ANTIBIOT, V26, P466, DOI 10.7164/antibiotics.26.466; Hall MP, 2006, RNA, V12, P488, DOI 10.1261/rna.2250606; HAMILL RL, 1973, J ANTIBIOT, V26, P463, DOI 10.7164/antibiotics.26.463; HAUGHAN PA, 1993, EXP PARASITOL, V77, P147, DOI 10.1006/expr.1993.1071; Hausmann S, 2005, J BIOL CHEM, V280, P20404, DOI 10.1074/jbc.M501073200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Horton JR, 2005, CELL, V121, P349, DOI 10.1016/j.cell.2005.02.021; INSELBURG J, 1984, MOL BIOCHEM PARASIT, V10, P89, DOI 10.1016/0166-6851(84)90021-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMINSKY R, 1989, ANTIMICROB AGENTS CH, V33, P881, DOI 10.1128/AAC.33.6.881; Lawrence F, 1998, MOL BIOCHEM PARASIT, V92, P99, DOI 10.1016/S0166-6851(97)00235-1; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; MESSIKA E, 1990, TROP MED PARASITOL, V41, P273; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez-Pertejo Y, 2006, BBA-GEN SUBJECTS, V1760, P10, DOI 10.1016/j.bbagen.2005.09.003; PHELOUZAT MA, 1993, PARASITOL RES, V79, P683, DOI 10.1007/BF00932511; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Schluckebier G, 1999, J MOL BIOL, V289, P277, DOI 10.1006/jmbi.1999.2788; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; Schwer B, 2001, J BIOL CHEM, V276, P1857, DOI 10.1074/jbc.M006072200; Schwer B, 2000, GENETICS, V155, P1561; Schwer B, 2006, J BIOL CHEM, V281, P18953, DOI 10.1074/jbc.M602867200; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SIBLEY LD, 1992, GENETICS, V132, P1003; Takata Y, 2003, BIOCHEMISTRY-US, V42, P8394, DOI 10.1021/bi034245a; Thomas CB, 2003, J BIOL CHEM, V278, P26094, DOI 10.1074/jbc.M303751200; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Yamada-Okabe T, 1999, MICROBIOL-UK, V145, P3023, DOI 10.1099/00221287-145-11-3023; Yokoska J, 2000, BIOCHEM BIOPH RES CO, V268, P617, DOI 10.1006/bbrc.2000.2188	44	27	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35904	35913		10.1074/jbc.M607292200	http://dx.doi.org/10.1074/jbc.M607292200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16971388	hybrid			2022-12-25	WOS:000242100500037
J	Gui, LQ; Wojciechowski, K; Gildner, CD; Nedelkovska, H; Hocking, DC				Gui, Liqiong; Wojciechowski, Katherine; Gildner, Candace D.; Nedelkovska, Hristina; Hocking, Denise C.			Identification of the heparin-binding determinants within fibronectin repeat III - Role in cell spreading and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; PLASMA FIBRONECTIN; CYCLE PROGRESSION; MEMBRANE TENSION; ACTIN-FILAMENTS; POLYMERIZATION; MODULE; DOMAIN; SITE; CONTRACTILITY	Fibronectins are high molecular mass glycoproteins that circulate as soluble molecules in the blood, and are also found in an insoluble, multimeric form in extracellular matrices throughout the body. Soluble fibronectins are polymerized into insoluble extracellular matrix (ECM) fibrils via a cell-dependent process. Recent studies indicate that the interaction of cells with the ECM form of fibronectin promotes actin organization and cell contractility, increases cell growth and migration, and enhances the tensile strength of artificial tissue constructs; ligation of integrins alone is insufficient to trigger these responses. Evidence suggests that the effect of ECM fibronectin on cell function is mediated in part by a matricryptic heparin-binding site within the first III1 repeat (FNIII1). In this study, we localized the heparin- binding activity of FNIII1 to a cluster of basic amino acids, Arg(613), Trp(614), Arg(615), and Lys(617). Site- directed mutagenesis of a recombinant fibronectin construct engineered to mimic the ECM form of fibronectin demonstrates that these residues are also critical for stimulating cell spreading and increasing cell proliferation. Cell proliferation has been tightly correlated with cell area. Using integrin-and heparin-binding fibronectin mutants, we found a positive correlation between cell spreading and growth when cells were submaximally spread on ECM protein-coated surfaces at the time of treatment. However, cells maximally spread on vitronectin or fibronectin still responded to the fibronectin matrix mimetic with an increase in growth, indicating that an absolute change in cell area is not required for the increase in cell proliferation induced by the matricryptic site of FNIII1.	Univ Rochester, Med Ctr, Dept Biomed Engn, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Hocking, DC (corresponding author), Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.	denise_hocking@urmc.rochester.edu	Hocking, Denise/H-7903-2012	Hocking, Denise/0000-0003-2337-0357	NHLBI NIH HHS [HL64074] Funding Source: Medline; NIBIB NIH HHS [EB00986] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000986] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Baneyx G, 2002, P NATL ACAD SCI USA, V99, P5139, DOI 10.1073/pnas.072650799; Baneyx G, 2001, P NATL ACAD SCI USA, V98, P14464, DOI 10.1073/pnas.251422998; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Briknarova K, 2003, J MOL BIOL, V332, P205, DOI 10.1016/S0022-2836(03)00890-8; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Davey G, 1999, J CELL SCI, V112, P4663; Dubin-Thaler BJ, 2004, BIOPHYS J, V86, P1794, DOI 10.1016/S0006-3495(04)74246-0; DUNN GA, 1995, J CELL SCI, V108, P1239; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fransson LA, 2003, INT J BIOCHEM CELL B, V35, P125, DOI 10.1016/S1357-2725(02)00095-X; Gao M, 2003, P NATL ACAD SCI USA, V100, P14784, DOI 10.1073/pnas.2334390100; Gildner CD, 2004, AM J PHYSIOL-HEART C, V287, pH46, DOI 10.1152/ajpheart.00859.2003; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; Hocking DC, 2000, J BIOL CHEM, V275, P10673, DOI 10.1074/jbc.275.14.10673; Hocking DC, 2003, AM J PHYSIOL-LUNG C, V285, pL169, DOI 10.1152/ajplung.00371.2002; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hocking DC, 2002, J CELL BIOL, V158, P175, DOI 10.1083/jcb.200112031; Hynes RO, 1999, P NATL ACAD SCI USA, V96, P2588, DOI 10.1073/pnas.96.6.2588; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LITVINOVICH SV, 1992, BIOCHIM BIOPHYS ACTA, V1119, P57, DOI 10.1016/0167-4838(92)90234-5; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Miller TM, 1997, J BIOL CHEM, V272, P9847; MOONEY DJ, 1995, J CELL SCI, V108, P2311; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; Oberhauser AF, 2002, J MOL BIOL, V319, P433, DOI 10.1016/S0022-2836(02)00306-6; Ohashi T, 1999, P NATL ACAD SCI USA, V96, P2153, DOI 10.1073/pnas.96.5.2153; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sheetz MP, 1996, TRENDS CELL BIOL, V6, P85, DOI 10.1016/0962-8924(96)80993-7; Sottile J, 1998, J CELL SCI, V111, P2933; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Sottile J, 2000, J CELL SCI, V113, P4287; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Woods A, 2001, J CLIN INVEST, V107, P935, DOI 10.1172/JCI12802; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	53	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34816	34825		10.1074/jbc.M608611200	http://dx.doi.org/10.1074/jbc.M608611200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982604	hybrid			2022-12-25	WOS:000241933700014
J	Cavalier, DM; Keegstra, K				Cavalier, David M.; Keegstra, Kenneth			Two xyloglucan xylosyltransferases catalyze the addition of multiple xylosyl residues to cellohexaose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED SOYBEAN CELLS; BETA-GLUCAN SYNTHETASE; GOLGI MEMBRANES; UDP-XYLOSE; BIOSYNTHESIS; WALL; PEA; GALACTOSYLTRANSFERASE; POLYSACCHARIDE; OLIGOSACCHARIDES	Xyloglucan (XyG) is the principal hemicellulose found in the primary cell walls of most plants. XyG is composed of a beta-(1,4)glucan backbone that is substituted in a regular pattern with xylosyl residues, which are added by at least one and likely two or three xylosyltransferase (XT) enzymes. Previous work identified seven Arabidopsis thaliana candidate genes, one of which (AtXT1) was shown to encode a protein with XT activity (Faik, A., Price, N. J., Raikhel, N. V., and Keegstra, K. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7797 - 7802). We expressed both AtXT1 and a second closely related gene, now called AtXT2, in insect cells and demonstrated that both have XT activity for cellopentaose and cellohexaose acceptor substrates. Moreover, we showed that cellohexaose was a significantly better acceptor substrate than cellopentaose. Product structural characterization showed that AtXT1 and AtXT2 preferentially added the first xylosyl residue to the fourth glucosyl residue from the reducing end of both acceptors. Furthermore, when the ratio of UDP-xylose to cellohexaose and the reaction time were increased, both AtXT1 and AtXT2 added a second xylosyl residue adjacent to the first, which generated dixylosylated cellohexaose. On the basis of these results, we concluded that AtXT1 and AtXT2 have the same acceptor specificities and generate the same products in vitro. The implications of these results for understanding in vivo XyG biosynthesis are considered.	Michigan State Univ, Dept Energy Plant, Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University	Cavalier, DM (corresponding author), Michigan State Univ, Dept Energy Plant, Res Lab, 110 Plant Biol Bldg,178 Wilson Rd, E Lansing, MI 48824 USA.	cavalie8@msu.edu						BRUMMELL DA, 1990, J CELL SCI, V96, P705; EDWARDS M, 1992, PLANTA, V187, P67, DOI 10.1007/BF00201625; Edwards ME, 1999, PLANT J, V19, P691, DOI 10.1046/j.1365-313x.1999.00566.x; Edwards ME, 2002, PLANT PHYSIOL, V129, P1391, DOI 10.1104/pp.002592; Faik A, 2000, J BIOL CHEM, V275, P15082, DOI 10.1074/jbc.M000677200; Faik A, 2002, P NATL ACAD SCI USA, V99, P7797, DOI 10.1073/pnas.102644799; Fort S, 2000, J AM CHEM SOC, V122, P5429, DOI 10.1021/ja9936520; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; GORDON R, 1989, PLANT PHYSIOL, V91, P373, DOI 10.1104/pp.91.1.373; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHI T, 1981, J BIOCHEM-TOKYO, V89, P325, DOI 10.1093/oxfordjournals.jbchem.a133198; HAYASHI T, 1984, AGR BIOL CHEM TOKYO, V48, P1023, DOI 10.1080/00021369.1984.10866244; HAYASHI T, 1981, PLANT CELL PHYSIOL, V22, P1571, DOI 10.1093/oxfordjournals.pcp.a076310; HAYASHI T, 1981, PLANT CELL PHYSIOL, V22, P517; HAYASHI T, 1989, ANNU REV PLANT PHYS, V40, P139, DOI 10.1146/annurev.pp.40.060189.001035; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; Hoffman M, 2005, CARBOHYD RES, V340, P1826, DOI 10.1016/j.carres.2005.04.016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lerouxel O, 2002, PLANT PHYSIOL, V130, P1754, DOI 10.1104/pp.011965; Madson M, 2003, PLANT CELL, V15, P1662, DOI 10.1105/tpc.009837; Marry M, 2003, CARBOHYD POLYM, V51, P347, DOI 10.1016/S0144-8617(02)00189-3; ONEILL MA, 2003, PLANT CELL WALL, V8, P1; Perrin RM, 1999, SCIENCE, V284, P1976, DOI 10.1126/science.284.5422.1976; RAY PM, 1969, P NATL ACAD SCI USA, V64, P605, DOI 10.1073/pnas.64.2.605; RAY PM, 1980, BIOCHIM BIOPHYS ACTA, V629, P431, DOI 10.1016/0304-4165(80)90149-X; REID JSG, 1995, PLANTA, V195, P489, DOI 10.1007/BF00195705; Reiter WD, 1997, PLANT J, V12, P335, DOI 10.1046/j.1365-313X.1997.12020335.x; Somerville C, 2004, SCIENCE, V306, P2206, DOI 10.1126/science.1102765; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; WHITE AR, 1993, BIOCHEM J, V294, P231, DOI 10.1042/bj2940231	31	86	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34197	34207		10.1074/jbc.M606379200	http://dx.doi.org/10.1074/jbc.M606379200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16982611	hybrid			2022-12-25	WOS:000241767600040
J	Xu, L; Renaud, L; Muller, JG; Baicu, CF; Bonnema, DD; Zhou, H; Kappler, CS; Kubalak, SW; Zile, MR; Conway, SJ; Menick, DR				Xu, Lin; Renaud, Ludivine; Mueller, Joachim G.; Baicu, Catalin F.; Bonnema, D. Dirk; Zhou, Hongming; Kappler, Christiana S.; Kubalak, Steven W.; Zile, Michael R.; Conway, Simon J.; Menick, Donald R.			Regulation of Ncx1 expression - Identification of regulatory elements mediating cardiac-specific expression and up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; SERUM RESPONSE FACTOR; GENE-EXPRESSION; PRESSURE-OVERLOAD; IN-VIVO; TRANSCRIPTION; HYPERTROPHY; GATA-4; CARDIOMYOCYTES; ORGANIZATION	The Na+-Ca2+ exchanger (NCX1) is up-regulated in hypertrophy and is often found up-regulated in end-stage heart failure. Studies have shown that the change in its expression contributes to contractile dysfunction. We have previously shown that the 1831-bp Ncx1 H1 (1831Ncx1) promoter directs cardiac-specific expression of the exchanger in both development and in the adult, and is sufficient for the up-regulation of Ncx1 in response to pressure overload. Here, we utilized adenoviral mediated gene transfer and transgenics to identify minimal regions and response elements that mediate Ncx1 expression in the heart. We demonstrate that the proximal 184 bp of the Ncx1 H1 (184Ncx1) promoter is sufficient for expression of reporter genes in adult cardiomyocytes and for the correct spatiotemporal pattern of Ncx1 expression in development but not for up-regulation in response to pressure overload. Mutational analysis revealed that both the -80 CArG and the -50 GATA elements were required for expression in isolated adult cardiomyocytes. Chromatin immunoprecipitation assays in adult cardiocytes demonstrate that SRF and GATA4 are associated with the proximal region of the endogenous Ncx1 promoter. Transgenic lines were established for the 1831Ncx1 promoter-luciferase containing mutations in the -80 CArG or -50 GATA element. No luciferase activity was detected during development, in the adult, or after pressure overload in any of the -80 CArG transgenic lines. The Ncx1 -50 GATA mutant promoter was sufficient for driving the normal spatiotemporal pattern of Ncx1 expression in development and for up-regulation in response to pressure overload but importantly, expression was no longer cardiac restricted. This work is the first in vivo study that demonstrates which cis elements are important for Ncx1 regulation.	Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Charleston, SC 29425 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Res, Cardiovasc Dev Grp, Indianapolis, IN 46202 USA	Medical University of South Carolina; Indiana University System; Indiana University-Purdue University Indianapolis	Menick, DR (corresponding author), 114 Doughty St, Charleston, SC 29425 USA.	menickd@musc.edu	Renaud, Ludivine/T-1209-2019	Zile, Michael/0000-0001-7076-221X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063714, T32HL007260, P01HL048788, R01HL060714, R01HL066223] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07260, HL066223, R01 HL063714-04, P01 HL48788, HL60714, R01 HL066223, P01 HL048788, R01 HL063714, R01 HL060714] Funding Source: Medline; PHS HHS [NCRR16434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Conway SJ, 2002, ANN NY ACAD SCI, V976, P268; de Krom M, 2002, MOL CELL, V9, P1319, DOI 10.1016/S1097-2765(02)00558-0; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; KENT RL, 1989, AM J PHYSIOL, V257, pH1717, DOI 10.1152/ajpheart.1989.257.5.H1717; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; Koushik SV, 1999, MECH DEVELOP, V88, P119, DOI 10.1016/S0925-4773(99)00177-X; Koushik SV, 2001, FASEB J, V15, P1209, DOI 10.1096/fj.00-0696fje; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, J MOL CELL CARDIOL, V34, P611, DOI 10.1006/jmcc.2002.2011; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; Martin DIK, 2001, TRENDS GENET, V17, P444, DOI 10.1016/S0168-9525(01)02368-X; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Muller JG, 2002, J MOL CELL CARDIOL, V34, P807, DOI 10.1006/jmcc.2002.2019; Muller JG, 2002, CIRC RES, V90, P158, DOI 10.1161/hh0202.103231; Nelson TJ, 2005, J MOL CELL CARDIOL, V39, P479, DOI 10.1016/j.yjmcc.2005.05.004; Pogwizd SM, 1999, CIRC RES, V85, P1009; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Roten L, 2000, J MOL CELL CARDIOL, V32, P109, DOI 10.1006/jmcc.1999.1052; Scheller T, 1998, J BIOL CHEM, V273, P7643, DOI 10.1074/jbc.273.13.7643; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Wang ZY, 2001, J BIOL CHEM, V276, P17706, DOI 10.1074/jbc.M100544200; Xu L, 2005, J MOL CELL CARDIOL, V38, P735, DOI 10.1016/j.yjmcc.2005.03.002	33	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34430	34440		10.1074/jbc.M607446200	http://dx.doi.org/10.1074/jbc.M607446200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966329	hybrid, Green Accepted			2022-12-25	WOS:000241767600063
J	Jeske, NA; Patwardhan, AM; Gamper, N; Price, TJ; Akopian, AN; Hargreaves, KM				Jeske, Nathaniel A.; Patwardhan, Amol M.; Gamper, Nikita; Price, Theodore J.; Akopian, Armen N.; Hargreaves, Kenneth M.			Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; POTENTIAL VANILLOID-1 TRPV1; DEPENDENT PROTEIN-KINASE; MESENTERIC ARTERIAL BED; CAPSAICIN RECEPTOR VR1; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CALCIUM; NEUROPEPTIDE RELEASE; THERMAL HYPERALGESIA; ION CHANNELS	Cannabinoids are known to have multiple sites of action in the nociceptive system, leading to reduced pain sensation. However, the peripheral mechanism(s) by which this phenomenon occurs remains an issue that has yet to be resolved. Because phosphorylation of TRPV1 ((t) under bar ransient (r) under bar eceptor (p) under bar otential subtype (V1) under bar) plays a key role in the induction of thermal hyperalgesia in inflammatory pain models, we evaluated whether the cannabinoid agonist WIN 55,212-2 (WIN) regulates the phosphorylation state of TRPV1. Here, we show that treatment of primary rat trigeminal ganglion cultures with WIN led to dephosphorylation of TRPV1, specifically at threonine residues. Utilizing Chinese hamster ovary cell lines, we demonstrate that Thr(144) and Thr(370) were dephosphorylated, leading to desensitization of the TRPV1 receptor. This post- translational modification occurred through activation of the phosphatase calcineurin (protein phosphatase 2B) following WIN treatment. Furthermore, knockdown of TRPA1 ((t) under bar ransient (r) under bar eceptor (p) under bar otential subtype (A1) under bar) expression in sensory neurons by specific small interfering RNA abolished the WIN effect on TRPV1 dephosphorylation, suggesting that WIN acts through TRPA1. We also confirm the importance of TRPA1 in WIN-induced dephosphorylation of TRPV1 in Chinese hamster ovary cells through targeted expression of one or both receptor channels. These results imply that the cannabinoid WIN modulates the sensitivity of sensory neurons to TRPV1 activation by altering receptor phosphorylation. In addition, our data could serve as a useful strategy in determining the potential use of certain cannabinoids as peripheral analgesics.	Univ Texas, Hlth Sci Ctr, Dept Endodont, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Hargreaves, KM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Endodont, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Hargreaves@UTHSCSA.edu	Price, Theodore/A-5094-2010; Price, Theodore/M-3810-2018	Price, Theodore/0000-0002-6971-6221; Gamper, Nikita/0000-0001-5806-0207	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE014928, F32DE016500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA006085, R01DA019585] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA 19585, R01 DA019585, F31 DA006085-03, F31 DA006085] Funding Source: Medline; NIDCR NIH HHS [F32 DE016500-01, R21 DE014928, F32 DE 016500, R21 DE 014928, F32 DE016500] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; Baker CL, 2004, BRIT J PHARMACOL, V142, P1361, DOI 10.1038/sj.bjp.0705902; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bhave G, 2003, P NATL ACAD SCI USA, V100, P12480, DOI 10.1073/pnas.2032100100; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bridges D, 2003, NEUROSCIENCE, V119, P803, DOI 10.1016/S0306-4522(03)00200-8; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1999, P NATL ACAD SCI USA, V96, P7658, DOI 10.1073/pnas.96.14.7658; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Chin CN, 1999, J PHARMACOL EXP THER, V291, P837; Costa B, 2004, BRIT J PHARMACOL, V143, P247, DOI 10.1038/sj.bjp.0705920; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DELRIO E, 1994, J NEUROCHEM, V63, P535; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; Duncan M, 2004, J PHARMACOL EXP THER, V311, P411, DOI 10.1124/jpet.104.067587; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; HARGREAVES KM, 1992, J ENDODONT, V18, P597, DOI 10.1016/S0099-2399(06)81329-4; Helyes Z, 2003, LIFE SCI, V73, P2345, DOI 10.1016/S0024-3205(03)00651-9; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Ibrahim MM, 2005, P NATL ACAD SCI USA, V102, P3093, DOI 10.1073/pnas.0409888102; Jeske NA, 2004, J NEUROCHEM, V90, P819, DOI 10.1111/j.1471-4159.2004.02557.x; Johanek LM, 2001, PAIN, V93, P303, DOI 10.1016/S0304-3959(01)00336-0; Johanek LM, 2004, PAIN, V109, P432, DOI 10.1016/j.pain.2004.02.020; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Jung JY, 2004, J BIOL CHEM, V279, P7048, DOI 10.1074/jbc.M311448200; Khasabova IA, 2004, J NEUROSCI, V24, P1744, DOI 10.1523/JNEUROSCI.4298-03.2004; Koplas PA, 1997, J NEUROSCI, V17, P3525; KUSTER JE, 1993, J PHARMACOL EXP THER, V264, P1352; Lauckner JE, 2005, P NATL ACAD SCI USA, V102, P19144, DOI 10.1073/pnas.0509588102; Li J, 1999, PAIN, V81, P25, DOI 10.1016/S0304-3959(98)00263-2; Lizanecz E, 2006, MOL PHARMACOL, V69, P1015, DOI 10.1124/mol.105.015644; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; Malan TP, 2003, CURR OPIN PHARMACOL, V3, P62, DOI 10.1016/S1471-4892(02)00004-8; Malan TP, 2001, PAIN, V93, P239, DOI 10.1016/S0304-3959(01)00321-9; Mandadi S, 2004, CELL CALCIUM, V35, P471, DOI 10.1016/j.ceca.2003.11.003; Mohapatra DP, 2005, J BIOL CHEM, V280, P13424, DOI 10.1074/jbc.M410917200; Mohapatra DP, 2003, MOL CELL NEUROSCI, V23, P314, DOI 10.1016/S1044-7431(03)00054-X; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Patwardhan AM, 2006, P NATL ACAD SCI USA, V103, P11393, DOI 10.1073/pnas.0603861103; Premkumar LS, 2002, J PHYSIOL-LONDON, V545, P107, DOI 10.1113/jphysiol.2002.016352; Price TJ, 2004, BRIT J PHARMACOL, V141, P1118, DOI 10.1038/sj.bjp.0705711; Price TJ, 2003, NEUROSCIENCE, V120, P155, DOI 10.1016/S0306-4522(03)00333-6; Price TJ, 2004, BRIT J PHARMACOL, V142, P257, DOI 10.1038/sj.bjp.0705778; Ralevic V, 2001, EUR J PHARMACOL, V418, P117, DOI 10.1016/S0014-2999(01)00940-2; Rathee PK, 2002, J NEUROSCI, V22, P4740, DOI 10.1523/JNEUROSCI.22-11-04740.2002; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; RUMSFIELD JA, 1991, DICP ANN PHARMAC, V25, P381, DOI 10.1177/106002809102500409; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; STOEHR SJ, 1986, J NEUROCHEM, V46, P637, DOI 10.1111/j.1471-4159.1986.tb13014.x; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	57	115	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32879	32890		10.1074/jbc.M603220200	http://dx.doi.org/10.1074/jbc.M603220200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954222	Green Accepted, hybrid			2022-12-25	WOS:000241414500086
J	Klegeris, A; Giasson, BI; Zhang, H; Maguire, J; Pelech, S; McGeer, PL				Klegeris, Andis; Giasson, Benoit I.; Zhang, Hong; Maguire, John; Pelech, Steven; McGeer, Patrick L.			Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells	FASEB JOURNAL			English	Article						c-Jun N-terminal kinase; MAPK/ERK kinase; neuroinflammation; p38 mitogen-activated protein kinase; Parkinson disease	PARKINSONS-DISEASE; WILD-TYPE; DEGENERATION PROCESS; NEUROBLASTOMA-CELLS; OXIDATIVE STRESS; LEWY BODIES; KINASE; EXPRESSION; SYSTEM; ACTIVATION	Autosomal dominant Parkinson disease (PD) is caused by duplication or triplication of the alpha-synuclein gene as well as by the A30P, E46K, and A53T mutations. The mechanisms are unknown. Reactive astrocytes in the substantia nigra of PD and MPTP-treated monkeys display high levels of the inflammatory mediator intercellular adhesion molecule-1 (ICAM-1), indicating that chronic inflammation contributes to the degeneration. Here we report that alpha-synuclein strongly stimulates human astrocytes as well as human U-373 MG astrocytoma cells to up-regulate both interleukin (IL)-6 and ICAM-1 (ED50 = 5 mu g ml(-1)). The mutated forms are more potent stimulators than wild-type (WT) alpha-synuclein in these assays. We demonstrate by immunoblotting analysis that this up-regulation is associated with activation of the major mitogen-activated protein kinase (MAPK) pathways. It is also attenuated by PD 98059, an inhibitor of the MAPK/extracellular-regulated kinase kinase MEK1/2, SP 600125, an inhibitor of c-Jun N-terminal kinase (JNK), and SB 202190, an inhibitor of p38 MAPK. The inhibitory effects on human astrocytes have IC50 values of 2, 5, and 1.5 mu M respectively. We hypothesize that the neuroinflammation stimulated by release of an excess of normal alpha-synuclein or by release of its mutated forms can be involved in the pathobiology of PD.	Univ British Columbia, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Kinexus Bioinformat Corp, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of Pennsylvania	Klegeris, A (corresponding author), Univ British Columbia, Kinsmen Lab Neurol Res, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	aklegeri@interchange.ubc.ca						AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Betarbet R, 2005, EXP NEUROL, V191, pS17, DOI 10.1016/j.expneurol.2004.08.021; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Croisier E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-14; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; De Groot CJA, 2000, BRAIN RES PROTOC, V5, P85, DOI 10.1016/S1385-299X(99)00059-8; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Frasier M, 2005, EXP NEUROL, V192, P274, DOI 10.1016/j.expneurol.2004.07.016; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gasser T, 2005, CURR OPIN NEUROL, V18, P363, DOI 10.1097/01.wco.0000170951.08924.3d; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hosokawa M, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-17; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Iseki E, 2000, NEUROSCI LETT, V286, P69, DOI 10.1016/S0304-3940(00)01090-9; Ishizawa K, 2004, J NEUROPATH EXP NEUR, V63, P43, DOI 10.1093/jnen/63.1.43; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Klegeris A, 2000, BIOCHEM PHARMACOL, V59, P1305, DOI 10.1016/S0006-2952(00)00252-5; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Klegeris A, 2001, NEUROSCI LETT, V313, P41, DOI 10.1016/S0304-3940(01)02251-0; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Martin FL, 2003, J NEUROCHEM, V87, P620, DOI 10.1046/j.1471-4159.2003.02013.x; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; Miklossy J, 2006, EXP NEUROL, V197, P275, DOI 10.1016/j.expneurol.2005.10.034; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nishioka K, 2006, ANN NEUROL, V59, P298, DOI 10.1002/ana.20753; Norris EH, 2004, CURR TOP DEV BIOL, V60, P17; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Stefanova N, 2005, AM J PATHOL, V166, P869, DOI 10.1016/S0002-9440(10)62307-3; Suh HS, 2005, J IMMUNOL, V174, P2712, DOI 10.4049/jimmunol.174.5.2712; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; Tanji K, 2001, NEUROREPORT, V12, P1909, DOI 10.1097/00001756-200107030-00028; Togo T, 2001, J NEUROL SCI, V184, P71, DOI 10.1016/S0022-510X(00)00498-6; von Bohlen und Halbach O, 2004, CELL TISSUE RES, V318, P163, DOI 10.1007/s00441-004-0921-7; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P14, DOI 10.1007/PL00007400; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com; Zhu JH, 2003, BRAIN PATHOL, V13, P473; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	56	106	110	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2000	2008		10.1096/fj.06-6183com	http://dx.doi.org/10.1096/fj.06-6183com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012252				2022-12-25	WOS:000241156900008
J	Cronauer, MV; Ince, Y; Engers, R; Rinnab, L; Weidemann, W; Suschek, CV; Burchardt, M; Kleinert, H; Wiedenmann, J; Sies, H; Ackermann, R; Kroncke, KD				Cronauer, M. V.; Ince, Y.; Engers, R.; Rinnab, L.; Weidemann, W.; Suschek, C. V.; Burchardt, M.; Kleinert, H.; Wiedenmann, J.; Sies, H.; Ackermann, R.; Kroencke, K.-D.			Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression	ONCOGENE			English	Article						androgen receptor; nitric oxide; prostate cancer; prostate specific antigen; zinc-finger	CARCINOMA-CELL LINE; GROWTH-FACTOR; UP-REGULATION; ZINC RELEASE; TUMOR-GROWTH; SYNTHASE-II; EXPRESSION; TRANSCRIPTION; PROTEIN; METALLOTHIONEIN	Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase ( iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro, NO inhibits androgen receptor-dependent promoter activity and prostate specific antigen production as well as DNA-binding activity of the androgen receptor (AR) in a concentration-dependent manner. Inhibition of the activity of androgen receptor-dependent reporter constructs is neither owing to diminished AR protein levels nor owing to an inhibition of its nuclear import. In addition, NO inhibits the proliferation of androgen receptor-positive prostate cancer cells significantly more efficiently than proliferation of androgen receptor-negative prostate cancer cells. In summary, our findings suggest that intratumoral iNOS activity favors development of prostate cancer cells that are able to proliferate androgen receptor-independently, thereby promoting prostate tumor progression.	Univ Dusseldorf, Inst Biochem & Mol Biol 1, Dept Urol, D-40225 Dusseldorf, Germany; Univ Ulm, Dept Gen Zool & Endocrinol, D-89069 Ulm, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Univ Ulm, Dept Urol & Pediat Urol, D-89069 Ulm, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 2, D-4000 Dusseldorf, Germany; Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-6500 Mainz, Germany	Heinrich Heine University Dusseldorf; Ulm University; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Ulm University; Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz	Kroncke, KD (corresponding author), Univ Dusseldorf, Inst Biochem & Mol Biol 1, Dept Urol, Univ Str 1, D-40225 Dusseldorf, Germany.	kroencke@uni-duesseldorf.de	Cronauer, Marcus/AAG-7457-2021; Kleinert, Hartmut/M-2988-2018; Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Kleinert, Hartmut/0000-0003-2202-3548; Sies, Helmut/0000-0002-1000-3198				Aaltomaa SH, 2001, ANTICANCER RES, V21, P3101; Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Attardi BJ, 2004, MOL CELL ENDOCRINOL, V222, P121, DOI 10.1016/j.mce.2004.04.013; Baltaci S, 2001, BJU INT, V88, P100, DOI 10.1046/j.1464-410x.2001.02231.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bronte V, 2005, J EXP MED, V201, P1257, DOI 10.1084/jem.20042028; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Craft N, 1999, CANCER RES, V59, P5030; Cronauer MV, 2000, BRIT J CANCER, V82, P39; Cronauer MV, 2005, INT J ONCOL, V26, P1033; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Cronauer MV, 2003, INT J ONCOL, V23, P1095; Ekmekcioglu S, 2005, CURR CANCER DRUG TAR, V5, P103, DOI 10.2174/1568009053202072; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Garban HJ, 2005, P NATL ACAD SCI USA, V102, P2632, DOI 10.1073/pnas.0409854102; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; Gradini R, 1999, J PATHOL, V189, P224; Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X; Hobisch A, 1996, PROSTATE, V28, P129; Hobisch A, 1998, CANCER RES, V58, P4640; Hongo F, 2005, BIOCHEM BIOPH RES CO, V336, P692, DOI 10.1016/j.bbrc.2005.08.150; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hrabie JA, 2000, J ORG CHEM, V65, P5745, DOI 10.1021/jo000600g; Huguenin S, 2004, PROSTATE, V61, P132, DOI 10.1002/pros.20081; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Klotz T, 1998, CANCER, V82, P1897, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1897::AID-CNCR12>3.0.CO;2-O; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Kroncke KD, 2000, FASEB J, V14, P166; Kroncke KD, 2001, NITRIC OXIDE-BIOL CH, V5, P289, DOI 10.1006/niox.2001.0354; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Le XD, 2005, P NATL ACAD SCI USA, V102, P8758, DOI 10.1073/pnas.0409581102; MARTH C, 1990, CANCER RES, V50, P7037; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nelson William G, 2004, J Urol, V172, pS6, DOI 10.1097/01.ju.0000142058.99614.ff; Nienhaus GU, 2006, PHOTOCHEM PHOTOBIOL, V82, P351, DOI 10.1562/2005-05-19-RA-533; Olson MV, 2006, CANCER GENE THER, V13, P676, DOI 10.1038/sj.cgt.7700941; PARK JG, 1987, CANCER RES, V47, P6710; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Royle JS, 2004, J UROLOGY, V172, P338, DOI 10.1097/01.ju.0000132367.02834.41; Rudeck M, 2000, IUBMB LIFE, V49, P451; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tepper CG, 2002, CANCER RES, V62, P6606; Thomsen LL, 1998, CANCER METAST REV, V17, P107, DOI 10.1023/A:1005912906436; Wang JZ, 2003, UROL ONCOL-SEMIN ORI, V21, P117, DOI 10.1016/S1078-1439(02)00208-9; Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101	50	54	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1875	1884		10.1038/sj.onc.1209984	http://dx.doi.org/10.1038/sj.onc.1209984			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983333				2022-12-25	WOS:000245117700005
J	Cameroni, E; De Virgilio, C; Deloche, O				Cameroni, Elisabetta; De Virgilio, Claudio; Deloche, Olivier			Phosphatidylinositol 4-phosphate is required for translation initiation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DEPENDENT TRANSLATION; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; SIGNALING PATHWAY; CLATHRIN ADAPTER; VACUOLAR PROTEIN; DISTINCT ROLES; CELL-GROWTH	The small natural product wortmannin inhibits protein synthesis by modulating several phosphatidylinositol (PI) metabolic pathways. A primary target of wortmannin in yeast is the plasma membrane-associated PI4-kinase (PI4K) Stt4p, which is required for actin cytoskeleton organization. Here we show that wortmannin treatment or inactivation of Stt4p, but not disorganization of the actin cytoskeleton per se, leads to a rapid attenuation of translation initiation. Interestingly, inactivation of Pik1p, a wortmannin-insensitive, functionally distinct PI4K, implicated in the regulation of Golgi functions and secretion, also results in severe translation initiation defects with a marked increase of the phosphorylation of the translation initiation factor eIF2 alpha. Because wortmannin largely phenocopies the effects of rapamycin (e.g. it triggers nuclear accumulation of Gln3p), it likely also inhibits the PI kinase-related, target of rapamycin (TOR) kinases. Importantly, however, neither inactivation of Stt4p nor Pik1p significantly affects TOR-controlled readouts other than translation initiation, indicating that these PI4Ks do not simply function upstream of TOR. Together, our results reveal the existence of a novel translation initiation control mechanism in yeast that is tightly coupled to the synthesis of distinct PI4P pools.	Univ Geneva, Ctr Med Univ, Dept Microbiol & Mol Med, CH-1211 Geneva, Switzerland	University of Geneva	Deloche, O (corresponding author), Univ Geneva, Ctr Med Univ, Dept Microbiol & Mol Med, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	olivier.deloche@medecine.unige.ch	De Virgilio, Claudio/B-4707-2012	De Virgilio, Claudio/0000-0001-8826-4323				Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; Chang HJ, 2004, GENETICS, V168, P1899, DOI 10.1534/genetics.104.032961; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Chuang JS, 1996, J CELL BIOL, V135, P597, DOI 10.1083/jcb.135.3.597; Cosentino GP, 2000, MOL CELL BIOL, V20, P4604, DOI 10.1128/MCB.20.13.4604-4613.2000; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; Deloche O, 2004, MOL CELL, V13, P357, DOI 10.1016/S1097-2765(04)00008-5; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DEVIRGILIO C, 1993, EUR J BIOCHEM, V212, P315; Dubouloz F, 2005, MOL CELL, V19, P15, DOI 10.1016/j.molcel.2005.05.020; Efe JA, 2005, J CELL SCI, V118, P4751, DOI 10.1242/jcs.02599; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gall WE, 2002, CURR BIOL, V12, P1623, DOI 10.1016/S0960-9822(02)01148-X; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Han GS, 2002, J BIOL CHEM, V277, P47709, DOI 10.1074/jbc.M207996200; Haynes LP, 2005, J BIOL CHEM, V280, P6047, DOI 10.1074/jbc.M413090200; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Meier KD, 2006, MOL BIOL CELL, V17, P1164, DOI 10.1091/mbc.E05-11-1039; Mendelsohn BA, 2003, NUCLEIC ACIDS RES, V31, P5838, DOI 10.1093/nar/gkg810; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Patil CK, 2004, PLOS BIOL, V2, P1208, DOI 10.1371/journal.pbio.0020246; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; Roberg KJ, 1997, GENETICS, V147, P1569; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sciorra VA, 2005, MOL BIOL CELL, V16, P776, DOI 10.1091/mbc.e04-08-0700; Shelton SN, 2003, BIOCHEM J, V371, P533, DOI 10.1042/BJ20021407; STACK JH, 1994, J BIOL CHEM, V269, P31552; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Valenzuela L, 2001, J BACTERIOL, V183, P2331, DOI 10.1128/JB.183.7.2331-2334.2001; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Weixel KM, 2005, J BIOL CHEM, V280, P10501, DOI 10.1074/jbc.M414304200; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zewail A, 2003, P NATL ACAD SCI USA, V100, P3345, DOI 10.1073/pnas.0530118100	79	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38139	38149		10.1074/jbc.M601060200	http://dx.doi.org/10.1074/jbc.M601060200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17005563	hybrid			2022-12-25	WOS:000242709500006
J	Adio, S; Bloemink, M; Hartel, M; Leier, S; Geeves, MA; Woehlke, G				Adio, Sarah; Bloemink, Marieke; Hartel, Michaela; Leier, Sven; Geeves, Michael A.; Woehlke, Guenther			Kinetic and mechanistic basis of the nonprocessive kinesin-3 motor NcKin3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-BASED MOTILITY; STIMULATED ATP HYDROLYSIS; SINGLE-MOLECULE BEHAVIOR; FUNGUS NEUROSPORA-CRASSA; DIMERIC KINESIN; MEMBRANE-TRANSPORT; PROTEIN KIF1A; COILED COILS; WILD-TYPE; K-LOOP	Kinesin-3 motors have been shown to transport cellular cargo along microtubules and to function according to mechanisms that differ from the conventional hand-over-hand mechanism. To find out whether the mechanisms described for Kif1A and CeUnc104 cover the full spectrum of Kinesin-3 motors, we characterize here NcKin3, a novel member of the Kinesin-3 family that localizes to mitochondria of ascomycetes. We show that NcKin3 does not move in a K-loop-dependent way as Kif1A or in a cluster-dependent way as CeUnc104. Its in vitro gliding velocity ranges between 0.30 and 0.64 mu m/s and correlates positively with motor density. The processivity index (k(bi,ratio)) of similar to 3 reveals that not more than three ATP molecules are hydrolyzed per productive microtubule encounter. The NcKin3 duty ratio of 0.03 indicates that the motor spends only a minute fraction of the ATPase cycle attached to the filament. Unlike other Kinesin-3 family members, NcKin3 forms stable dimers, but only one subunit releases ADP in a microtubule-dependent fashion. Together, these data exclude a processive hand-over-hand mechanism of movement and suggest a power-stroke mechanism where nucleotide-dependent structural changes in a single motor domain lead to displacement of the motor along the filament. Thus, NcKin3 is the first plus end-directed kinesin motor that is dimeric but moves in a nonprocessive fashion to its destination.	Univ Munich, Inst Cell Biol, D-80336 Munich, Germany; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Munich; University of Kent	Woehlke, G (corresponding author), Univ Munich, Inst Cell Biol, Schillerstr 42, D-80336 Munich, Germany.	guenther.woehlke@lrz.uni-muenchen.de	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898; Bloemink, Marieke Johanna/0000-0001-9441-2783; Adio, Sarah/0000-0002-6555-0850; Woehlke, Gunther/0000-0001-8462-9962				Andrews P, 1970, Methods Biochem Anal, V18, P1, DOI 10.1002/9780470110362.ch1; Bathe F, 2005, MOL BIOL CELL, V16, P3529, DOI 10.1091/mbc.E04-11-0957; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P591; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 2004, EMBO J, V23, P23, DOI 10.1038/sj.emboj.7600042; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; deCastro MJ, 2000, NAT CELL BIOL, V2, P724, DOI 10.1038/35036357; deCastro MJ, 1999, BIOCHEMISTRY-US, V38, P5076, DOI 10.1021/bi9829175; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Endres NF, 2006, NATURE, V439, P875, DOI 10.1038/nature04320; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; Foster KA, 2001, J BIOL CHEM, V276, P19259, DOI 10.1074/jbc.M008347200; Fuchs F, 2005, MOL BIOL CELL, V16, P153, DOI 10.1091/mbc.E04-05-0413; Fuchs F, 2002, J CELL SCI, V115, P1931; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J., 2001, MECH MOTOR PROTEINS; HUANG TG, 1994, J BIOL CHEM, V269, P16493; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; Kallipolitou A, 2001, EMBO J, V20, P6226, DOI 10.1093/emboj/20.22.6226; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Mackey AT, 2000, BIOCHEMISTRY-US, V39, P1346, DOI 10.1021/bi991918+; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; McDonnell AV, 2006, BIOINFORMATICS, V22, P356, DOI 10.1093/bioinformatics/bti797; Nitta R, 2004, SCIENCE, V305, P678, DOI 10.1126/science.1096621; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 2003, NATURE, V424, P574, DOI 10.1038/nature01804; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; ORBACH MJ, 1994, GENE, V150, P159, DOI 10.1016/0378-1119(94)90877-X; Pechatnikova E, 1999, BIOPHYS J, V77, P1003, DOI 10.1016/S0006-3495(99)76951-1; Pierce DW, 1999, BIOCHEMISTRY-US, V38, P5412, DOI 10.1021/bi9830009; Pollock N, 1999, J CELL BIOL, V147, P493, DOI 10.1083/jcb.147.3.493; Pollock N, 1998, CELL MOTIL CYTOSKEL, V40, P304, DOI 10.1002/(SICI)1097-0169(1998)40:3<304::AID-CM8>3.0.CO;2-C; Rashid DJ, 2005, J PEPT RES, V65, P538, DOI 10.1111/j.1399-3011.2005.00255.x; Rogers KR, 2001, EMBO J, V20, P5101, DOI 10.1093/emboj/20.18.5101; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Schafer F, 2003, EMBO J, V22, P450, DOI 10.1093/emboj/cdg036; Schoch CL, 2003, FUNGAL GENET BIOL, V39, P1, DOI 10.1016/S1087-1845(03)00022-7; Shimizu T, 2000, BIOCHEMISTRY-US, V39, P5265, DOI 10.1021/bi9928344; STEINBERG G, 1993, J CELL SCI, V106, P555; Stone DB, 1999, BIOCHEMISTRY-US, V38, P4938, DOI 10.1021/bi982374z; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tomishige M, 2002, SCIENCE, V297, P2263, DOI 10.1126/science.1073386; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Wendt TG, 2002, EMBO J, V21, P5969, DOI 10.1093/emboj/cdf622; Westermann B, 2002, FUNGAL GENET BIOL, V36, P91, DOI 10.1016/S1087-1845(02)00019-1; Yun M, 2003, EMBO J, V22, P5382, DOI 10.1093/emboj/cdg531	59	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37782	37793		10.1074/jbc.M605061200	http://dx.doi.org/10.1074/jbc.M605061200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17012747	hybrid			2022-12-25	WOS:000242477100055
J	Montalvo, GB; Artalejo, AR; Gilabert, JA				Montalvo, Gema B.; Artalejo, Antonio R.; Gilabert, Juan A.			ATP from subplasmalemmal mitochondria controls Ca2+ dependent inactivation of CRAC channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; CURRENT I-CRAC; HUMAN T-CELLS; MAST-CELLS; DEPLETION; LYMPHOCYTES; INFLUX; MICRODOMAINS; MODULATION; INHIBITION	A sustained Ca2+ entry is the primary signal for T lymphocyte activation after antigen recognition. This Ca2+ entry mainly occurs through store-operated Ca2+ channels responsible for a highly selective Ca2+ current known as I-CRAC. Ca2+ ions act as negative feedback regulators of I-CRAC, promoting its inactivation. Mitochondria, which act as intracellular Ca2+ buffers, have been proposed to control all stages of CRAC current and, hence, intracellular Ca2+ signaling in several types of non-excitable cells. Using the whole-cell configuration of the patch clamp technique, which allows control of the intracellular environment, we report here that respiring mitochondria located close to CRAC channels can regulate slow Ca2+-dependent inactivation of I-CRAC by increasing the Ca2+-buffering capacity beneath the plasma membrane, mainly through the release of ATP.	Univ Complutense Madrid, Fac Vet, Inst Farmacol & Toxicol, Dept Pharmacol & Toxicol, E-28040 Madrid, Spain	Complutense University of Madrid	Gilabert, JA (corresponding author), Univ Complutense Madrid, Fac Vet, Inst Farmacol & Toxicol, Dept Pharmacol & Toxicol, Ave Puerta de Hierro,S-N, E-28040 Madrid, Spain.	jagilabe@vet.ucm.es	Artalejo, Antonio R./ABG-2009-2020; Artalejo, Antonio R./H-4378-2015	Artalejo, Antonio R./0000-0001-9720-9190; Artalejo, Antonio R./0000-0001-9720-9190; Gilabert, Juan Antonio/0000-0003-2717-1718				Aneiros E, 2005, J IMMUNOL, V174, P119, DOI 10.4049/jimmunol.174.1.119; Bakowski D, 2001, BIOCHEM J, V353, P561, DOI 10.1042/0264-6021:3530561; Bautista DM, 2004, J PHYSIOL-LONDON, V556, P805, DOI 10.1113/jphysiol.2003.060004; Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; Makowska A, 2000, EUR J BIOCHEM, V267, P877, DOI 10.1046/j.1432-1327.2000.01066.x; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Naraghi M, 1997, J NEUROSCI, V17, P6961; Neher E., 1986, CALCIUM ELECTROGENES, V14, P80; Parekh AB, 2003, NEWS PHYSIOL SCI, V18, P252, DOI 10.1152/nips.01458.2003; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Tiffert T, 2001, CELL CALCIUM, V30, P337, DOI 10.1054/ceca.2001.0241; Varadi A, 2004, CELL CALCIUM, V36, P499, DOI 10.1016/j.ceca.2004.05.003; VILLALBA M, 1994, J BIOL CHEM, V269, P2468; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	36	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35616	35623		10.1074/jbc.M603518200	http://dx.doi.org/10.1074/jbc.M603518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16982621	hybrid			2022-12-25	WOS:000242100500006
J	Peng, J; Tan, CB; Roberts, GJ; Nikolaeva, O; Zhang, Z; Lapolla, SM; Primorac, S; Andrews, DW; Lin, JL				Peng, Jun; Tan, Chibing; Roberts, G. Jane; Nikolaeva, Olga; Zhang, Zhi; Lapolla, Suzanne M.; Primorac, Steve; Andrews, David W.; Lin, Jialing			tBid elicits a conformational alteration in membrane-bound Bcl-2 such that it inhibits Bax pore formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIAPOPTOTIC PROTEIN BCL-2; CYTOCHROME-C RELEASE; MITOCHONDRIAL-MEMBRANE; CELL-DEATH; X-L; BIOPHYSICAL CHARACTERIZATION; HYDROPHOBIC HELICES; BH3-ONLY PROTEINS; DIPHTHERIA-TOXIN; FAMILY PROTEINS	During initiation of apoptosis, Bcl-2 family proteins regulate the permeability of mitochondrial outer membrane. BH3-only protein, tBid,activates pro-apoptotic Bax to release cytochrome c from mitochondria. tBid also activates anti-apoptotic Bcl-2 in the mitochondrial outer membrane, changing it from a single-spanning to a multispanning conformation that binds the active Bax and inhibits cytochrome c release. However, it is not known whether other mitochondrial proteins are required to elicit the tBid-induced Bcl-2 conformational alteration. To define the minimal components that are required for the functionally important Bcl-2 conformational alteration, we reconstituted the reaction using purified proteins and liposomes. We found that purified tBid was sufficient to induce a conformational alteration in the liposome-tethered, but not cytosolic Bcl-2, resulting in a multispanning form that is similar to the one found in the mitochondrial outer membrane of drug-treated cells. Mutations that abolished tBid/Bcl-2 interaction also abolished the conformational alteration, demonstrating that a direct tBid/Bcl-2 interaction at the membrane is both required and sufficient to elicit the conformational alteration. Furthermore, active Bax also elicited the Bcl-2 conformational alteration. Bcl-2 mutants that displayed increased or decreased activity in the conformational alteration assay showed corresponding activities in inhibiting pore formation by Bax in vitro and in preventing apoptosis in vivo. Thus, there is a strong correlation between the direct interaction of membrane-bound Bcl-2 and tBid with activation of Bcl-2 in vitro and in vivo.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada	University of Oklahoma System; University of Oklahoma Health Sciences Center; McMaster University	Lin, JL (corresponding author), 940 Stanton L Young Blvd,BMSB 935,POB 26901, Oklahoma City, OK 73190 USA.	jialing-lin@ouhsc.edu		Andrews, David/0000-0002-9266-7157	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062964] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM062964, R01 GM062964, R01 GM062964-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Caputo GA, 2004, BIOCHEMISTRY-US, V43, P8794, DOI 10.1021/bi049696p; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126; Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Johnson AE, 2005, TRAFFIC, V6, P1078, DOI 10.1111/j.1600-0854.2005.00340.x; Kim KM, 2001, BIOCHEMISTRY-US, V40, P4911, DOI 10.1021/bi002368e; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P488; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; Lew S, 2000, BIOCHEMISTRY-US, V39, P9632, DOI 10.1021/bi000694o; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; O'Neill J, 2004, BBA-REV CANCER, V1705, P43, DOI 10.1016/j.bbcan.2004.09.004; O'Neill JW, 2006, J MOL BIOL, V356, P367, DOI 10.1016/j.jmb.2005.11.032; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Venturoli D, 2005, AM J PHYSIOL-RENAL, V288, pF605, DOI 10.1152/ajprenal.00171.2004; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Woo JS, 2003, CELL DEATH DIFFER, V10, P1310, DOI 10.1038/sj.cdd.4401303; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhang Z, 2004, J BIOL CHEM, V279, P43920, DOI 10.1074/jbc.M406412200; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	53	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35802	35811		10.1074/jbc.M608303200	http://dx.doi.org/10.1074/jbc.M608303200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005564	hybrid, Green Accepted			2022-12-25	WOS:000242100500027
J	Zhang, AL; Lyu, YL; Lin, CP; Zhou, N; Azarova, AM; Wood, LM; Liu, LF				Zhang, Ailing; Lyu, Yi Lisa; Lin, Chao-Po; Zhou, Nai; Azarova, Anna M.; Wood, Laurence M.; Liu, Leroy F.			A protease pathway for the repair of topoisomerase II-DNA covalent complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SISTER-CHROMATID EXCHANGES; CHROMOSOMAL-ABERRATIONS; CLEAVABLE COMPLEXES; KAPPA-B; CELLS; BETA; YEAST; DEGRADATION; EXPRESSION	Despite rapid advances in the field of DNA repair, little is known about the repair of protein-DNA adducts. Previous studies have demonstrated that topoisomerase II (TopII)-DNA adducts (TopII-DNA covalent complexes) are rapidly degraded by the proteasome. It has been hypothesized that proteasomal degradation of TopII-DNA covalent adducts exposes TopII-concealed DNA double-strand breaks (DSBs)for repair. To test this hypothesis, the anticancer drug, VP-16 ( etoposide), was employed to induce TopII-DNA covalent complexes in mammalian cells, and the involvement of proteasome in processing TopII-DNA covalent complexes into DSBs was investigated. Consistent with the hypothesis, VP-16-induced DSBs as monitored by neutral comet assay, as well as DNA damage signals ( e. g. gamma-H2AX) were significantly reduced in the presence of the proteasome inhibitor, MG132. Using both top2 beta knock-out mouse embryonic fibroblasts and Top2 beta small interfering RNA knockdown PC12 cells, as well as postmitotic neurons in which TopII alpha was absent, we showed that VP-16-induced DNA damage signals were attenuated upon proteasome inhibition, suggesting the involvement of proteasome in the repair/processing of both TopII alpha-DNA and TopII beta-DNA adducts. By contrast, hydrogen peroxide-induced gamma-H2AX was unaffected upon proteasome inhibition, suggesting a specific requirement of the proteasome pathway in the processing of TopII-DNA covalent complexes into DNA damage.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	lliu@umdnj.edu		Azarova, Anna/0000-0002-2901-732X; Liu, Leroy/0000-0001-9396-763X; Lin, Chao-Po/0000-0002-1457-1635	NCI NIH HHS [R01 CA39662, R01 CA102463] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102463, R01CA039662] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andriollo M, 2003, ARCH BIOCHEM BIOPHYS, V413, P75, DOI 10.1016/S0003-9861(03)00114-0; Baldwin E. L., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P363, DOI 10.2174/1568011054222364; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Boland MP, 2000, J BIOL CHEM, V275, P25231, DOI 10.1074/jbc.275.33.25231; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Clifford B, 2003, CANCER RES, V63, P4074; Cuvier O, 2003, J CELL BIOL, V160, P645, DOI 10.1083/jcb.200209023; DARPA P, 1990, CANCER RES, V50, P6919; Degrassi Francesca, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P317, DOI 10.2174/1568011043352920; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Desai SD, 2001, CANCER RES, V61, P5926; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KEENEY S, 1995, P NATL ACAD SCI USA, V92, P11274, DOI 10.1073/pnas.92.24.11274; Kurose A, 2005, CYTOM PART A, V68A, P1, DOI 10.1002/cyto.a.20186; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; Lyu YL, 2006, MOL CELL BIOL, V26, P7929, DOI 10.1128/MCB.00617-06; Lyu YL, 2003, P NATL ACAD SCI USA, V100, P7123, DOI 10.1073/pnas.1232376100; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Neale MJ, 2005, NATURE, V436, P1053, DOI 10.1038/nature03872; Niimi A, 2001, CHROMOSOMA, V110, P102, DOI 10.1007/s004120100140; Nitiss KC, 2006, P NATL ACAD SCI USA, V103, P8953, DOI 10.1073/pnas.0603455103; NOVIELLO E, 1994, MUTAT RES-FUND MOL M, V311, P21, DOI 10.1016/0027-5107(94)90069-8; POMMIER Y, 1988, CANCER RES, V48, P512; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Tsutsui K, 2001, J BIOL CHEM, V276, P5769, DOI 10.1074/jbc.M008517200; TSUTSUI K, 1993, J BIOL CHEM, V268, P19076; Tsutsui K, 2001, J COMP NEUROL, V431, P228, DOI 10.1002/1096-9861(20010305)431:2<228::AID-CNE1067>3.0.CO;2-M; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WATANABE M, 1994, NEUROSCI RES, V19, P51, DOI 10.1016/0168-0102(94)90007-8; Willmore E, 1998, MOL PHARMACOL, V54, P78, DOI 10.1124/mol.54.1.78; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200	45	105	105	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35997	36003		10.1074/jbc.M604149200	http://dx.doi.org/10.1074/jbc.M604149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16973621	hybrid			2022-12-25	WOS:000242100500047
J	Csutora, P; Zarayskiy, V; Peter, K; Monje, F; Smani, T; Zakharov, SI; Litvinov, D; Bolotina, VM				Csutora, Peter; Zarayskiy, Vladislav; Peter, Krisztina; Monje, Francisco; Smani, Tarik; Zakharov, Sergey I.; Litvinov, Dmitry; Bolotina, Victoria M.			Activation mechanism for CRAC current and store-operated Ca2+ entry - Calcium influx factor and Ca2+-independent phospholipase A(2)beta-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PHOSPHOLIPASE; ARACHIDONIC-ACID; A(2); IDENTIFICATION; PURIFICATION; INHIBITION; EXPRESSION; CHANNELS; IPLA(2); CELLS	Here we tested the role of calcium influx factor (CIF) and calcium-independent phospholipase A(2) (iPLA(2)) in activation of Ca2+ release-activated Ca2+ (CRAC) channels and store-operated Ca2+ entry in rat basophilic leukemia (RBL-2H3) cells. We demonstrate that 1) endogenous CIF production may be triggered by Ca2+ release (net loss) as well as by simple buffering of free Ca2+ within the stores, 2) a specific 82-kDa variant of iPLA(2)beta and its corresponding activity are present in membrane fraction of RBL cells, 3) exogenous CIF (extracted from other species) mimics the effects of endogenous CIF and activates iPLA(2)beta when applied to cell homogenates but not intact cells, 4) activation of I-CRAC can be triggered in resting RBL cells by dialysis with exogenous CIF, 5) molecular or functional inhibition of iPLA(2)beta prevents activation of I-CRAC, which could be rescued by cell dialysis with a human recombinant iPLA(2)beta, 6) dependence of ICRAC on intracellular pH strictly follows pH dependence of iPLA(2)beta activity, and 7) (S)-BEL, a chiral enantiomer of suicidal substrate specific for iPLA(2)beta, could be effectively used for pharmacological inhibition of I-CRAC and store-operated Ca2+ entry. These findings validate and significantly advance our understanding of the CIF-iPLA(2)-dependent mechanism of activation of I-CRAC and store-operated Ca2+ entry.	Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University	Bolotina, VM (corresponding author), EBRC, Ion Channel & Calcium Signaling Unit, X-704,650 Albany St, Boston, MA 02118 USA.	bolotina@bu.edu	Zakharov, Sergey/L-8511-2014; Hajami, Tarik Smani/D-5372-2016; IBIS, CARDIOVASCULAR/P-3910-2015; Litvinov, Dmitry Y/Q-4561-2016	Zakharov, Sergey/0000-0001-9864-8304; Hajami, Tarik Smani/0000-0002-1877-7438; Litvinov, Dmitry Y/0000-0003-4778-6648; Bolotina, Victoria/0000-0001-5862-181X	NHLBI NIH HHS [HL71793, HL54150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054150, R01HL071793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao SZ, 2004, DIABETES, V53, pS186, DOI 10.2337/diabetes.53.2007.S186; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Bolotina VM, 2005, TRENDS BIOCHEM SCI, V30, P378, DOI 10.1016/j.tibs.2005.05.009; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Ma JJ, 2003, CELL CALCIUM, V33, P375, DOI 10.1016/S0143-4160(03)00050-2; Martinez J, 2005, BIOCHEM PHARMACOL, V70, P733, DOI 10.1016/j.bcp.2005.04.045; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Shin KJ, 2002, TOXICOL APPL PHARM, V178, P37, DOI 10.1006/taap.2001.9317; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Song HW, 2004, J AM SOC MASS SPECTR, V15, P1780, DOI 10.1016/j.jasms.2004.08.012; Tay HK, 2004, J BIOL CHEM, V279, P22505, DOI 10.1074/jbc.M308788200; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Turk J, 2004, CAN J PHYSIOL PHARM, V82, P824, DOI 10.1139/Y04-064; Vanden Abeele F, 2004, J BIOL CHEM, V279, P30326, DOI 10.1074/jbc.M400106200; Vanden Abeele F, 2003, CELL CALCIUM, V33, P357, DOI 10.1016/S0143-4160(03)00049-6; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Yang HC, 1999, J NEUROCHEM, V73, P1278, DOI 10.1046/j.1471-4159.1999.0731278.x; Zablocki K, 2000, ACTA BIOCHIM POL, V47, P591	36	46	47	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34926	34935		10.1074/jbc.M606504200	http://dx.doi.org/10.1074/jbc.M606504200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17003039	hybrid			2022-12-25	WOS:000241933700025
J	Sharpley, MS; Hirst, J				Sharpley, Mark S.; Hirst, Judy			The inhibition of mitochondrial complex I (NADH : ubiquinone oxidoreductase) by Zn2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ACTIVE/DE-ACTIVE TRANSITION; BACTERIAL REACTION CENTERS; BOVINE HEART-MITOCHONDRIA; IRON-SULFUR CLUSTERS; ZINC IONS INHIBIT; PROTON-TRANSFER; SUPEROXIDE-PRODUCTION; DEPENDENT INHIBITION; INACTIVE TRANSITION	NADH: ubiquinone oxidoreductase (complex I) from bovine heart mitochondria is a highly complicated, membrane-bound enzyme. It is central to energy transduction, an important source of cellular reactive oxygen species, and its dysfunction is implicated in neurodegenerative and muscular diseases and in aging. Here, we describe the effects of Zn2+ on complex I to define whether complex I may contribute to mediating the pathological effects of zinc in states such as ischemia and to determine how Zn2+ can be used to probe the mechanism of complex I. Zn2+ inhibits complex I more strongly than Mg2+, Ca2+, Ba2+, and Mn2+ to Cu2+ or Cd2+. It does not inhibit NADH oxidation or intramolecular electron transfer, so it probably inhibits either proton transfer to bound quinone or proton translocation. Thus, zinc represents a new class of complex I inhibitor clearly distinct from the many ubiquinone site inhibitors. No evidence for increased superoxide production by zinc-inhibited complex I was detected. Zinc binding to complex I is mechanistically complicated. During catalysis, zinc binds slowly and progressively, but it binds rapidly and tightly to the resting state(s) of the enzyme. Reactivation of the inhibited enzyme upon the addition of EDTA is slow, and inhibition is only partially reversible. The IC50 value for the Zn2+ inhibition of complex I is high (10-50 mu M, depending on the enzyme state); therefore, complex I is unlikely to be a major site for zinc inhibition of the electron transport chain. However, the slow response of complex I to a change in Zn2+ concentration may enhance any physiological consequences.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Hirst, J (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jh@mrc-dunn.cam.ac.uk	Hirst, Judy/F-4803-2011	Hirst, Judy/0000-0001-8667-6797	Medical Research Council [MC_U105663141] Funding Source: Medline; MRC [MC_U105663141] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aagaard A, 2002, BBA-BIOENERGETICS, V1555, P133, DOI 10.1016/S0005-2728(02)00268-2; Aagaard A, 2001, FEBS LETT, V494, P157, DOI 10.1016/S0014-5793(01)02299-2; Axelrod HL, 2000, P NATL ACAD SCI USA, V97, P1542, DOI 10.1073/pnas.97.4.1542; Berry EA, 2000, BBA-BIOENERGETICS, V1459, P440, DOI 10.1016/S0005-2728(00)00182-1; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Brown AM, 2000, J BIOL CHEM, V275, P13441, DOI 10.1074/jbc.275.18.13441; BRUNORI M, 1979, J BIOL CHEM, V254, P769; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; Chen TY, 1998, J GEN PHYSIOL, V112, P715, DOI 10.1085/jgp.112.6.715; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Daniel RM, 2001, TRENDS BIOCHEM SCI, V26, P223, DOI 10.1016/S0968-0004(01)01803-5; DeCoursey TE, 2000, BBA-BIOENERGETICS, V1458, P104, DOI 10.1016/S0005-2728(00)00062-1; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Duffield MD, 2005, J PHYSIOL-LONDON, V568, P5, DOI 10.1113/jphysiol.2005.091777; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; Faxen K, 2006, BBA-BIOENERGETICS, V1757, P388, DOI 10.1016/j.bbabio.2006.05.010; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; Galkin A, 2005, J BIOL CHEM, V280, P30129, DOI 10.1074/jbc.M504709200; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; Gavrikova EV, 1999, FEBS LETT, V455, P36, DOI 10.1016/S0014-5793(99)00850-9; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; Grivennikova VG, 2001, J BIOL CHEM, V276, P9038, DOI 10.1074/jbc.M009661200; Hinchliffe P, 2005, SCIENCE, V309, P771, DOI 10.1126/science.1113988; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; HUNTER FE, 1955, J BIOL CHEM, V216, P357; Hwang PM, 2004, P NATL ACAD SCI USA, V101, P9618, DOI 10.1073/pnas.0402324101; Jancura D, 2006, J BIOL CHEM, V281, P30319, DOI 10.1074/jbc.M605955200; Kannt A, 2001, FEBS LETT, V503, P142, DOI 10.1016/S0014-5793(01)02719-3; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; KOTLYAR AB, 1990, BIOCHIM BIOPHYS ACTA, V1019, P151, DOI 10.1016/0005-2728(90)90137-S; KOTLYAR AB, 1992, BIOCHIM BIOPHYS ACTA, V1098, P144, DOI 10.1016/S0005-2728(05)80329-9; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103; Kuznetsova SS, 2005, BIOCHEMISTRY-MOSCOW+, V70, P128, DOI 10.1007/s10541-005-0091-6; Kwong JQ, 2006, J NEUROCHEM, V97, P1659, DOI 10.1111/j.1471-4159.2006.03990.x; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; LINK TA, 1995, J BIOL CHEM, V270, P25001, DOI 10.1074/jbc.270.42.25001; LORUSSO M, 1991, EUR J BIOCHEM, V197, P555, DOI 10.1111/j.1432-1033.1991.tb15944.x; Maklashina E, 2003, BBA-BIOENERGETICS, V1606, P95, DOI 10.1016/S0005-2728(03)00087-2; Maklashina E, 2002, BBA-BIOENERGETICS, V1556, P6, DOI 10.1016/S0005-2728(02)00280-3; Malaiyandi LM, 2005, J NEUROSCI, V25, P9507, DOI 10.1523/JNEUROSCI.0868-05.2005; Mills DA, 2005, BIOCHEMISTRY-US, V44, P4656, DOI 10.1021/bi0475774; Mills DA, 2002, J BIOL CHEM, V277, P14894, DOI 10.1074/jbc.M111922200; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Paddock ML, 1999, P NATL ACAD SCI USA, V96, P6183, DOI 10.1073/pnas.96.11.6183; Sadek HA, 2004, BIOCHEMISTRY-US, V43, P8494, DOI 10.1021/bi049803f; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Sculley MJ, 1996, BBA-PROTEIN STRUCT M, V1298, P78, DOI 10.1016/S0167-4838(96)00118-5; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sharpley MS, 2006, BIOCHEMISTRY-US, V45, P241, DOI 10.1021/bi051809x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SKULACHE.VP, 1967, BIOCHEM BIOPH RES CO, V26, P1, DOI 10.1016/0006-291X(67)90242-2; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Vinogradov AD, 1998, BBA-BIOENERGETICS, V1364, P169, DOI 10.1016/S0005-2728(98)00026-7; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Whitehead SJ, 2005, FEBS LETT, V579, P2863, DOI 10.1016/j.febslet.2005.04.026; Wikstrom M, 2002, BBA-BIOENERGETICS, V1555, P128, DOI 10.1016/S0005-2728(02)00267-0; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	68	59	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34803	34809		10.1074/jbc.M607389200	http://dx.doi.org/10.1074/jbc.M607389200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980308	hybrid			2022-12-25	WOS:000241933700012
J	Sheng, Y; Tsai-Morris, CH; Gutti, R; Maeda, Y; Dufau, ML				Sheng, Yi; Tsai-Morris, Chon-Hwa; Gutti, Ravi; Maeda, Yuji; Dufau, Maria L.			Gonadotropin-regulated testicular RNA helicase (GRTH/Ddx25) is a transport protein involved in gene-specific mRNA export and protein translation during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAD-BOX PROTEINS; NUCLEAR-EXPORT; PGK-2 ISOZYMES; MOUSE; EXPRESSION; FAMILY; CELLS; DBP5; MRNP	Gonadotropin-regulated testicular RNA helicase (GRTH/Ddx25), a member of the DEAD-box protein family, is essential for completion of spermatogenesis. GRTH is present in the cytoplasm and nucleus of meiotic spermatocytes and round spermatids and functions as a component of mRNP particles, implicating its post-transcriptional regulatory roles in germ cells. In this study, GRTH antibodies specific to N- or C- terminal sequences showed differential subcellular expression of GRTH 56- and 61-kDa species in nucleus and cytoplasm, respectively, of rodent testis and transfected COS1 cells. The 56-kDa nuclear species interacted with CRM1 and participated in mRNA transport. The phosphorylated cytoplasmic 61-kDa species was associated with polyribosomes. Confocal studies on COS-1 cells showed that GRTH-GFP was retained in the nucleus by treatment with a RNA polymerase inhibitor or the nuclear protein export inhibitor. This indicated that GRTH is a shuttling protein associated with RNA export. The N- terminal leucine-rich region (61-74 amino acids) was identified as the nuclear export signal that participated in CRM1-dependent nuclear export pathway. Deletion analysis identified a 14-amino acid GRTH sequence (100-114 amino acids) as a nuclear localization signal. GRTH selectively regulated the translation of specific genes including histone 4 and HMG2 in germ cells. In addition, GRTH participated in the nuclear export of RNA messages (PGK2, tACE, and TP2) in a gene-specific manner. These studies strongly indicate that the mammalian GRTH/Ddx25 gene is a multifunctional RNA helicase that is an essential regulator of sperm maturation.	NICHD, Sect Mol Endocrinol, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHD, Sect Mol Endocrinol, ERRB, NIH, Bldg 49,Rm 6A-36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.	dufaum@mail.nih.gov		Gutti, Ravi Kumar/0000-0002-0912-5796; Tsai Morris, Chon Hwa/0000-0002-8113-0979	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000150] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000150] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdelhaleem M, 2005, CLIN BIOCHEM, V38, P499, DOI 10.1016/j.clinbiochem.2005.01.010; Askjaer P, 2000, J BIOL CHEM, V275, P11561, DOI 10.1074/jbc.275.16.11561; BUCCI LR, 1986, BIOL REPROD, V34, P195, DOI 10.1095/biolreprod34.1.195; Carrera P, 2000, MOL CELL, V5, P181, DOI 10.1016/S1097-2765(00)80414-1; Coller JM, 2001, RNA, V7, P1717, DOI 10.1017/S135583820101994X; DAY RN, 1989, J BIOL CHEM, V264, P431; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Eddy EM, 2002, RECENT PROG HORM RES, V57, P103, DOI 10.1210/rp.57.1.103; KRAMER JM, 1981, DEV BIOL, V87, P37, DOI 10.1016/0012-1606(81)90058-0; KRAMER JM, 1981, DEV BIOL, V87, P30, DOI 10.1016/0012-1606(81)90057-9; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; Linder P, 2001, CURR BIOL, V11, pR961, DOI 10.1016/S0960-9822(01)00574-7; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Minshall N, 2001, RNA, V7, P1728, DOI 10.1017/S135583820101158X; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rollenhagen C, 2004, MOL CELL BIOL, V24, P4869, DOI 10.1128/MCB.24.11.4869-4879.2004; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Sheng Y, 2003, J BIOL CHEM, V278, P27796, DOI 10.1074/jbc.M302411200; Shibata N, 2004, MOL REPROD DEV, V67, P1, DOI 10.1002/mrd.20009; SIBONY M, 1994, BIOL REPROD, V50, P1015, DOI 10.1095/biolreprod50.5.1015; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; Smillie DA, 2002, J CELL SCI, V115, P395; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Steger K, 2001, ANAT EMBRYOL, V203, P323, DOI 10.1007/s004290100176; Suntharalingam M, 2004, J BIOL CHEM, V279, P35384, DOI 10.1074/jbc.M402044200; Tang PZ, 1999, J BIOL CHEM, V274, P37932, DOI 10.1074/jbc.274.53.37932; Tsai-Morris CH, 2004, P NATL ACAD SCI USA, V101, P6373, DOI 10.1073/pnas.0401855101; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Weirich CS, 2004, MOL CELL, V16, P749, DOI 10.1016/j.molcel.2004.10.032; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; Zhao J, 2002, EMBO J, V21, P1177, DOI 10.1093/emboj/21.5.1177	34	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35048	35056		10.1074/jbc.M605086200	http://dx.doi.org/10.1074/jbc.M605086200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16968703	hybrid			2022-12-25	WOS:000241933700038
J	Suetsugu, S; Murayama, K; Sakamoto, A; Hanawa-Suetsugu, K; Seto, A; Oikawa, T; Mishima, C; Shirouzu, M; Takenawa, T; Yokoyama, S				Suetsugu, Shiro; Murayama, Kazutaka; Sakamoto, Ayako; Hanawa-Suetsugu, Kyoko; Seto, Azusa; Oikawa, Tsukasa; Mishima, Chiemi; Shirouzu, Mikako; Takenawa, Tadaomi; Yokoyama, Shigeyuki			The RAC binding domain/IRSp53-MIM homology domain of IRSp53 induces RAC-dependent membrane deformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE; HIGH-CURVATURE MEMBRANES; ACTIN CYTOSKELETON; STRUCTURAL BASIS; FILOPODIA; PROTEIN; AMPHIPHYSIN; BAR	The concave surface of the crescent-shaped Bin-amphiphysin-Rvs (BAR) domain is postulated to bind to the cell membrane to induce membrane deformation of a specific curvature. The Rac binding (RCB) domain/IRSp53-MIM homology domain (IMD) has a dimeric structure that is similar to the structure of the BAR domain; however, the RCB domain/IMD has a "zeppelin-shaped" dimer. Interestingly, the RCB domain/IMD of IRSp53 possesses Rac binding, membrane binding, and actin filament binding abilities. Here we report that the RCB domain/IMD of IRSp53 induces membrane deformation independent of the actin filaments in a Rac-dependent manner. In contrast to the BAR domain, the RCB domain/IMD did not cause long tubulation of the artificial liposomes; however, the Rac binding domain caused the formation of small buds on the liposomal surface. When expressed in cells, the Rac binding domain induced outward protrusion of the plasma membrane in a direction opposite to that induced by the BAR domain. Mapping of the amino acids responsible for membrane deformation suggests that the convex surface of the Rac binding domain binds to the membrane in a Rac-dependent manner, which may explain the mechanism of the membrane deformation induced by the RCB domain/IMD.	Univ Tokyo, Dept Biochem, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2230045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; RIKEN; University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Dept Biochem, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Shirouzu, Mikako/A-6521-2016; Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/ABB-6033-2020; Oikawa, Tsukasa/B-7718-2013; Suetsugu, Shiro/AAF-4427-2019; Yokoyama, Shigeyuki/N-6911-2015	Suetsugu, Shiro/0000-0002-4612-0628; Oikawa, Tsukasa/0000-0003-2694-2699; Suetsugu, Shiro/0000-0002-4612-0628; Yokoyama, Shigeyuki/0000-0003-3133-7338				Alvarez CE, 2002, J BIOL CHEM, V277, P24728, DOI 10.1074/jbc.M202512200; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Choi J, 2005, J NEUROSCI, V25, P869, DOI 10.1523/JNEUROSCI.3212-04.2005; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakagawa H, 2003, J CELL SCI, V116, P2577, DOI 10.1242/jcs.00462; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oikawa T, 2004, NAT CELL BIOL, V6, P420, DOI 10.1038/ncb1125; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Razzaq A, 2001, GENE DEV, V15, P2967, DOI 10.1101/gad.207801; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Suetsugu S, 2006, J CELL BIOL, V173, P571, DOI 10.1083/jcb.200509067; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200	26	129	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35347	35358		10.1074/jbc.M606814200	http://dx.doi.org/10.1074/jbc.M606814200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17003044	hybrid			2022-12-25	WOS:000241933700069
J	Augustus, AM; Reardon, PN; Heller, WT; Spicer, LD				Augustus, Anne Marie; Reardon, Patrick N.; Heller, William T.; Spicer, Leonard D.			Structural basis for the differential regulation of DNA by the methionine repressor MetJ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; S-ADENOSYLMETHIONINE; OPERATOR BINDING; SCATTERING; GENE; BIOSYNTHESIS; RECOGNITION; COREPRESSOR; EVOLUTION; REVEALS	The Met regulon in Escherichia coli encodes several proteins responsible for the biosynthesis of methionine. Regulation of the expression of most of these proteins is governed by the methionine repressor protein MetJ and its co-repressor, the methionine derivative S-adenosylmethionine. Genes controlled by MetJ contain from two to five sequential copies of a homologous 8-bp sequence called the metbox. A crystal structure for one of the complexes, the repressor tetramer bound to two metboxes, has been reported (Somers, W. S., and S. E. Phillips (1992) Nature 359, 387 - 393), but little structural work on the larger assemblies has been done presumably because of the difficulties in crystallization and the variability in the number and sequences of metboxes for the various genes. Small angle neutron scattering was used to study complexes of MetJ and S-adenosylmethionine with double-stranded DNA containing two, three, and five metboxes. Our results demonstrate that the crystal structure of the two-metbox complex is not the native solution conformation of the complex. Instead, the system adopts a less compact conformation in which there is decreased interaction between the adjacent MetJ dimers. Models built of the higher order complexes from the scattering data show that the three-metbox complex is organized much like the two-metbox complex. However, the five-metbox complex differs significantly from the smaller complexes, providing much closer packing of the adjacent MetJ dimers and allowing additional contacts not available in the crystal structure. The results suggest that there is a structural basis for the differences observed in the regulatory effectiveness of MetJ for the various genes of the Met regulon.	Oak Ridge Natl Lab, Ctr Struct Mol Biol, Oak Ridge, TN 37831 USA; Oak Ridge Natl Lab, Div Chem Sci, Oak Ridge, TN 37831 USA; Duke Univ, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; Duke University; Duke University	Heller, WT (corresponding author), Oak Ridge Natl Lab, Ctr Struct Mol Biol, POB 2008,MS-6142, Oak Ridge, TN 37831 USA.	hellerwt@ornl.gov; spicer@biochem.duke.edu	Heller, William/ABE-1104-2020	Heller, William/0000-0001-6456-2975; Reardon, Patrick/0000-0002-6858-0086				BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; DAVIDSON BE, 1989, MOL MICROBIOL, V3, P1639, DOI 10.1111/j.1365-2958.1989.tb00149.x; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Gal J, 2002, J BACTERIOL, V184, P4930, DOI 10.1128/JB.184.17.4930-4932.2002; Glinka CJ, 1998, J APPL CRYSTALLOGR, V31, P430, DOI 10.1107/S0021889897017020; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; HE YY, 1992, NATURE, V359, P431, DOI 10.1038/359431a0; He YY, 1996, J MOL BIOL, V255, P55, DOI 10.1006/jmbi.1996.0006; He YY, 2002, J MOL BIOL, V320, P39, DOI 10.1016/S0022-2836(02)00423-0; Heller WT, 2003, BIOCHEMISTRY-US, V42, P10579, DOI 10.1021/bi0348664; HYRE DE, 1995, BIOCHEMISTRY-US, V34, P3212, DOI 10.1021/bi00010a010; Lawrenson ID, 2004, FEBS LETT, V564, P136, DOI 10.1016/S0014-5793(04)00336-9; Marincs F, 2006, BIOCHEM J, V396, P227, DOI 10.1042/BJ20060021; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; OLD IG, 1991, PROG BIOPHYS MOL BIO, V56, P145, DOI 10.1016/0079-6107(91)90012-H; Olson WK, 2001, J MOL BIOL, V313, P229, DOI 10.1006/jmbi.2001.4987; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; SAINTGIRONS I, 1986, J BIOL CHEM, V261, P936; SHOEMAN R, 1985, P NATL ACAD SCI USA, V82, P3601, DOI 10.1073/pnas.82.11.3601; SMITH AA, 1985, P NATL ACAD SCI USA, V82, P6104, DOI 10.1073/pnas.82.18.6104; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; WIGNALL GD, 1987, J APPL CRYSTALLOGR, V20, P28, DOI 10.1107/S0021889887087181; Wild CM, 1996, MOL MICROBIOL, V21, P1125, DOI 10.1046/j.1365-2958.1996.00055.x; WU WF, 1993, FEMS MICROBIOL LETT, V108, P145, DOI 10.1016/0378-1097(93)90576-N	25	17	18	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34269	34276		10.1074/jbc.M605763200	http://dx.doi.org/10.1074/jbc.M605763200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963446	hybrid			2022-12-25	WOS:000241767600047
J	Burza, AM; Pekala, I; Sikora, J; Siedlecki, P; Malagocki, P; Bucholc, M; Koper, L; Zielenkiewicz, P; Dadlez, M; Dobrowolska, G				Burza, Anna Maria; Pekala, Izabela; Sikora, Jacek; Siedlecki, Pawel; Malagocki, Pawel; Bucholc, Maria; Koper, Luiza; Zielenkiewicz, Piotr; Dadlez, Michal; Dobrowolska, Grazyna			Nicotiana tabacum osmotic stress-activated kinase is regulated by phosphorylation on Ser-154 and Ser-158 in the kinase activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PROTEIN-KINASE; ABSCISIC-ACID; HYPEROSMOTIC STRESS; SIGNAL-TRANSDUCTION; STOMATAL CLOSURE; STRUCTURAL BASIS; GENE-EXPRESSION; IDENTIFICATION; HOMOLOG; FAMILY	NtOSAK (Nicotiana tabacum osmotic stress-activated protein kinase), a member of the SnRK2 subfamily, is activated rapidly in response to hyperosmotic stress. Our previous results as well as data presented by others indicate that phosphorylation is involved in activation of SnRK2 kinases. Here, we have mapped the regulatory phosphorylation sites of NtOSAK by mass spectrometry with collision-induced peptide fragmentation. We show that active NtOSAK, isolated from NaCl-treated tobacco BY-2 cells, is phosphorylated on Ser-154 and Ser-158 in the kinase activation loop. Prediction of the NtOSAK three-dimensional structure indicates that phosphorylation of Ser-154 and Ser-158 triggers changes in enzyme conformation resulting in its activation. The involvement of Ser-154 and Ser-158 phosphorylation in regulation of NtOSAK activity was confirmed by site-directed mutagenesis of NtOSAK expressed in bacteria and in maize protoplasts. Our data reveal that phosphorylation of Ser-158 is essential for NtOSAK activation, whereas phosphorylation of Ser-154 most probably facilitates Ser-158 phosphorylation. The time course of NtOSAK phosphorylation on Ser-154 and Ser-158 in BY-2 cells subjected to osmotic stress correlates with NtOSAK activity, indicating that NtOSAK is regulated by reversible phosphorylation of these residues in vivo. Importantly, Ser-154 and Ser-158 are conserved in all SnRK2 subfamily members, suggesting that phosphorylation at these sites may be a general mechanism for SnRK2 activation.	Polish Acad Sci, Dept Plant Biochem, PL-02106 Warsaw, Poland; Polish Acad Sci, Dept Bioinformat, PL-02106 Warsaw, Poland; Polish Acad Sci, Mass Spectrometry Lab, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Warsaw Univ, Fac Biol, PL-02096 Warsaw, Poland; Warsaw Univ, Plant Mol Biol Lab, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Polish Academy of Sciences; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; University of Warsaw; University of Warsaw	Dobrowolska, G (corresponding author), Polish Acad Sci, Dept Plant Biochem, Ul Pawinskiego 5A, PL-02106 Warsaw, Poland.	dobrowol@ibb.waw.pl	Bucholc, Maria/ABF-5097-2020; Siedlecki, Pawel/Q-3265-2017	Siedlecki, Pawel/0000-0002-7482-1341; Zielenkiewicz, Piotr/0000-0001-8151-6874; Malagocki, Pawel/0000-0002-5534-9731; Bucholc, Maria/0000-0003-0237-1131; Dadlez, Michal/0000-0001-8811-5176; Dobrowolska, Grazyna/0000-0002-2598-9666				Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Belin C, 2006, PLANT PHYSIOL, V141, P1316, DOI 10.1104/pp.106.079327; Boudsocq M, 2005, PLANT PHYSIOL, V138, P1185, DOI 10.1104/pp.105.061275; Boudsocq M, 2004, J BIOL CHEM, V279, P41758, DOI 10.1074/jbc.M405259200; Chinnusamy V, 2004, J EXP BOT, V55, P225, DOI 10.1093/jxb/erh005; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Gong DM, 2004, PLANT PHYSIOL, V134, P919, DOI 10.1104/pp.103.037440; Gong DM, 2002, J BIOL CHEM, V277, P42088, DOI 10.1074/jbc.M205504200; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1999, BIOCHEM SOC SYMP, P13; HARMON AC, 2003, GRAVIT SPACE BIOL B, V16, P1; HOLAPPA LD, 1995, PLANT PHYSIOL, V108, P1203, DOI 10.1104/pp.108.3.1203; Hoyos ME, 2000, PLANT PHYSIOL, V122, P1355, DOI 10.1104/pp.122.4.1355; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kelner A, 2004, PLANT PHYSIOL, V136, P3255, DOI 10.1104/pp.104.046151; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kobayashi Y, 2004, PLANT CELL, V16, P1163, DOI 10.1105/tpc.019943; Lamotte O, 2006, FREE RADICAL BIO MED, V40, P1369, DOI 10.1016/j.freeradbiomed.2005.12.006; Li JX, 1996, PLANT CELL, V8, P2359, DOI 10.1105/tpc.8.12.2359; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; Luciano BS, 2004, J BIOL CHEM, V279, P52117, DOI 10.1074/jbc.M403716200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mikolajczyk M, 2000, PLANT CELL, V12, P165, DOI 10.1105/tpc.12.1.165; Monks DE, 2001, PLANT CELL, V13, P1205, DOI 10.1105/tpc.13.5.1205; Mustilli AC, 2002, PLANT CELL, V14, P3089, DOI 10.1105/tpc.007906; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; Sheen J, 2001, PLANT PHYSIOL, V127, P1466, DOI 10.1104/pp.010820; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Umezawa T, 2004, P NATL ACAD SCI USA, V101, P17306, DOI 10.1073/pnas.0407758101; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Yoon HW, 1997, MOL GEN GENET, V255, P359, DOI 10.1007/s004380050507; Yoshida R, 2006, J BIOL CHEM, V281, P5310, DOI 10.1074/jbc.M509820200; Yoshida R, 2002, PLANT CELL PHYSIOL, V43, P1473, DOI 10.1093/pcp/pcf188; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	48	39	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34299	34311		10.1074/jbc.M601977200	http://dx.doi.org/10.1074/jbc.M601977200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980311	hybrid			2022-12-25	WOS:000241767600050
J	Busam, RD; Thorsell, AG; Flores, A; Hammarstrom, M; Persson, C; Hallberg, BM				Busam, Robert D.; Thorsell, Ann-Gerd; Flores, Alex; Hammarstrom, Martin; Persson, Camilla; Hallberg, B. Martin			First structure of a eukaryotic phosphohistidine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN HISTIDINE PHOSPHATASE; HETEROTRIMERIC G-PROTEINS; KINASE NDPK B; CRYSTAL-STRUCTURE; BETA-SUBUNITS; PHOSPHORYLATION; ALIGNMENT; ACTIVATION; SUBSTRATE; ACCURACY	Phosphatases are a diverse group of enzymes that regulate numerous cellular processes. Much of what is known relates to the tyrosine, threonine, and serine phosphatases, whereas the histidine phosphatases have not been studied as much. The structure of phosphohistidine phosphatase (PHPT1), the first identified eukaryotic-protein histidine phosphatase, has been determined to a resolution of 1.9 angstrom using multiple-wavelength anomalous dispersion methods. This enzyme can dephosphorylate a variety of proteins (e. g. ATP-citrate lyase and the beta-subunit of G proteins). A putative active site has been identified by its electrostatic character, ion binding, and conserved protein residues. Histidine 53 is proposed to play a major role in histidine dephosphorylation based on these observations and previous mutational studies. Models of peptide binding are discussed to suggest possible mechanisms for substrate recognition.	Karolinska Inst, Struct Genom Consortium, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet	Hallberg, BM (corresponding author), Karolinska Inst, Struct Genom Consortium, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	Martin.Hallberg@ki.se	Hallberg, B. Martin/C-5361-2009	Hallberg, B. Martin/0000-0002-6781-0345	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Besant PG, 2005, BBA-PROTEINS PROTEOM, V1754, P281, DOI 10.1016/j.bbapap.2005.07.026; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; Cuello F, 2003, J BIOL CHEM, V278, P7220, DOI 10.1074/jbc.M210304200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ek P, 2002, EUR J BIOCHEM, V269, P5016, DOI 10.1046/j.1432-1033.2002.03206.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Hamada K, 2005, GENES CELLS, V10, P1, DOI 10.1111/j.1365-2443.2005.00817.x; Hippe HJ, 2003, J BIOL CHEM, V278, P7227, DOI 10.1074/jbc.M210305200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Klumpp S, 2002, J CEREBR BLOOD F MET, V22, P1420, DOI 10.1097/01.wcb.0000045041.03034.99; Klumpp S, 2005, BBA-PROTEINS PROTEOM, V1754, P291, DOI 10.1016/j.bbapap.2005.07.035; Klumpp S, 2003, BIOCHEM BIOPH RES CO, V306, P110, DOI 10.1016/S0006-291X(03)00920-3; Kowluru A, 1996, BIOCHEM J, V313, P97, DOI 10.1042/bj3130097; Li H, 2005, PROTEINS, V61, P704, DOI 10.1002/prot.20660; Ma RX, 2005, BIOCHEM BIOPH RES CO, V337, P887, DOI 10.1016/j.bbrc.2005.09.134; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; Maurer A, 2005, BIOCHEM BIOPH RES CO, V334, P1115, DOI 10.1016/j.bbrc.2005.06.200; Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WIELAND T, 1993, J BIOL CHEM, V268, P18111	33	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33830	33834		10.1074/jbc.C600231200	http://dx.doi.org/10.1074/jbc.C600231200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16990267	hybrid			2022-12-25	WOS:000241767600003
J	Shiou, SR; Datta, PK; Dhawan, P; Law, BK; Yingling, JM; Dixon, DA; Beauchamp, RD				Shiou, Sheng-Ru; Datta, Pran K.; Dhawan, Punita; Law, Brian K.; Yingling, Jonathan M.; Dixon, Dan A.; Beauchamp, R. Daniel			Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER MDA-MB-231 CELLS; PROTEIN-KINASE-C; TGF-BETA; BREAST-CANCER; MESSENGER-RNA; INHIBITOR TYPE-1; II RECEPTOR; MESENCHYMAL TRANSITION; GENE-EXPRESSION; TUMOR INVASION	Metastasis is a primary cause of mortality due to cancer. Early metastatic growth involves both a remodeling of the extracellular matrix surrounding tumors and invasion of tumors across the basement membrane. Up-regulation of extracellular matrix degrading proteases such as urokinase plasminogen activator (uPA) and matrix metalloproteinases has been reported to facilitate tumor cell invasion. Autocrine transforming growth factor-beta (TGF-beta) signaling may play an important role in cancer cell invasion and metastasis; however, the underlying mechanisms remain unclear. In the present study, we report that autocrine TGF-beta supports cancer cell invasion by maintaining uPA levels through protein secretion. Interestingly, treatment of paracrine/exogenous TGF-beta at higher concentrations than autocrine TGF-beta further enhanced uPA expression and cell invasion. The enhanced uPA expression by exogenous TGF-beta is a result of increased uPA mRNA expression due to RNA stabilization. We observed that both autocrine and paracrine TGF-beta mediated regulation of uPA levels was lost upon depletion of Smad4 protein by RNA interference. Thus, through the Smad pathway, autocrine TGF-beta maintains uPA expression through facilitated protein secretion, thereby supporting tumor cell invasiveness, whereas exogenous TGF-beta further enhances uPA expression through mRNA stabilization leading to even greater invasiveness of the cancer cells.	Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32611 USA; Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; State University System of Florida; University of Florida; Eli Lilly; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Beauchamp, RD (corresponding author), Vanderbilt Univ, Med Ctr, Sect Surg Sci, 1161 21st Ave S,D-4316 Med Ctr N, Nashville, TN 37232 USA.	daniel.beauchamp@vanderbilt.edu	Law, Brian/L-6043-2019	Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [R01CA095195, P50CA095103, R01CA093651, R01CA069457, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052334] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093651, P30 CA68485, CA69457, R01 CA95195, P50 CA95103] Funding Source: Medline; NIDDK NIH HHS [DK52334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; BARICOS WH, 1995, KIDNEY INT, V47, P1039, DOI 10.1038/ki.1995.150; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; Farina AR, 1996, BIOTECHNIQUES, V21, P904; Farina AR, 1998, INT J CANCER, V75, P721; Fisher JL, 2000, BREAST CANCER RES TR, V61, P1, DOI 10.1023/A:1006445129195; Frandsen TL, 2001, CANCER RES, V61, P532; Frey RS, 1997, CANCER RES, V57, P628; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HUANG F, 1995, CELL GROWTH DIFFER, V6, P1635; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; Kojima S, 2000, BLOOD, V95, P1309; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; Li HY, 2006, J MED CHEM, V49, P2138, DOI 10.1021/jm058209g; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Martinez-Carpio PA, 1999, CELL SIGNAL, V11, P753, DOI 10.1016/S0898-6568(99)00048-0; Martinez-Carpio PA, 1999, CANCER LETT, V147, P25, DOI 10.1016/S0304-3835(99)00261-X; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; MATRISIAN LM, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P152; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Moses H L, 1991, Princess Takamatsu Symp, V22, P183; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nanbu R, 1997, EUR J BIOCHEM, V247, P169, DOI 10.1111/j.1432-1033.1997.00169.x; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Peng SB, 2005, BIOCHEMISTRY-US, V44, P2293, DOI 10.1021/bi048851x; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Ray D, 2005, MOL CELL BIOL, V25, P3338, DOI 10.1128/MCB.25.8.3338-3347.2005; Reuning U, 1998, INT J ONCOL, V13, P893; Roman CD, 2002, J GASTROINTEST SURG, V6, P304, DOI 10.1016/S1091-255X(01)00041-5; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV M, 2001, SCI STKE, pRE11; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsukada S, 2005, J BIOL CHEM, V280, P10055, DOI 10.1074/jbc.M409381200; Vrana JA, 1996, CANCER RES, V56, P5063; WALKER RA, 1994, BRIT J CANCER, V69, P1160, DOI 10.1038/bjc.1994.228; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WUN TC, 1987, J BIOL CHEM, V262, P3646; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	70	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33971	33981		10.1074/jbc.M607010200	http://dx.doi.org/10.1074/jbc.M607010200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16959768	hybrid			2022-12-25	WOS:000241767600018
J	Singleton, PA; Dudek, SM; Ma, SF; Garcia, JGN				Singleton, Patrick A.; Dudek, Steven M.; Ma, Shwu-Fan; Garcia, Joe G. N.			Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation - Novel role for hyaluronan and CD44 receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; IP3 RECEPTOR; LIPID RAFTS; KINASE; ENHANCEMENT; EXPRESSION; TISSUE; ACID; RHO; SPHINGOSINE-1-PHOSPHATE	The role for hyaluronan (HA) and CD44 in vascular barrier regulation is unknown. We examined high and low molecular weight HA (HMW-HA, similar to 1,000 kDa; LMW- HA, similar to 2.5 kDa) effects on human transendothelial monolayer electrical resistance (TER). HMW-HA increased TER, whereas LMW- HA induced biphasic TER changes ultimately resulting in EC barrier disruption. HMW-HA induced the association of the CD44s isoform with, and AKT-mediated phosphorylation of, the barrier-promoting sphingosine 1-phosphate receptor (S1P(1)) within caveolin-enriched lipid raft microdomains, whereas LMW- HA induced brief CD44s association with S1P1 followed by sustained association of the CD44v10 isoform with, and Src and ROCK 1/2-mediated phosphorylation of, the barrier-disrupting S1P(3) receptor. HA-induced EC cytoskeletal reorganization and TER alterations were abolished by either disruption of lipid raft formation, CD44 blocking antibody or siRNA-mediated reductions in expression of CD44 isoforms. Silencing S1P1, AKT1, or Rac1 blocked the barrier enhancing effects of HA whereas silencing S1P(3), Src, ROCK1/2, or RhoA blocked the barrier disruption induced by LMW- HA. In summary, HA regulates EC barrier function through novel differential CD44 isoform interaction with S1P receptors, S1P receptor transactivation, and RhoA/Rac1 signaling to the EC cytoskeleton.	Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA	University of Chicago	Garcia, JGN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, 5841 S Maryland Ave,W604, Chicago, IL 60637 USA.	jgarcia@medicine.bsd.uchicago.edu	Garcia, Joe GN/E-8862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL068472] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL68472] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bensadoun ES, 1996, AM J RESP CRIT CARE, V154, P1819, DOI 10.1164/ajrccm.154.6.8970376; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Cantor JO, 2004, CHEST, V125, P288, DOI 10.1378/chest.125.1.288; CARNENISCH TD, 2000, J CLIN INVEST, V106, P349; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Dentener MA, 2005, THORAX, V60, P114, DOI 10.1136/thx.2003.020842; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gee K, 2004, ARCH IMMUNOL THER EX, V52, P13; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; HIRANO H, 1994, INT IMMUNOL, V6, P49, DOI 10.1093/intimm/6.1.49; Konttinen Y, 2001, J PATHOL, V194, P384, DOI 10.1002/1096-9896(200107)194:3<384::AID-PATH896>3.0.CO;2-8; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Luscher TF, 1997, CLIN CARDIOL, V20, P3; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Mucha DR, 2003, AM J PHYSIOL-HEART C, V284, pH994, DOI 10.1152/ajpheart.00862.2002; NETTELBLADT O, 1989, AM REV RESPIR DIS, V140, P1028, DOI 10.1164/ajrccm/140.4.1028; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; PEARSON JD, 1991, RADIOLOGY, V179, P9, DOI 10.1148/radiology.179.1.2006310; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Scott JE, 2002, BIOMACROMOLECULES, V3, P547, DOI 10.1021/bm010170j; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stern R, 2003, GLYCOBIOLOGY, V13, p105R, DOI 10.1093/glycob/cwg112; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Teder P, 1997, AM J RESP CELL MOL, V17, P376, DOI 10.1165/ajrcmb.17.3.2698; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Waeber C, 2004, DRUG NEWS PERSPECT, V17, P365, DOI 10.1358/dnp.2004.17.6.829028; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702	49	143	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34381	34393		10.1074/jbc.M603680200	http://dx.doi.org/10.1074/jbc.M603680200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963454	hybrid			2022-12-25	WOS:000241767600059
J	Yogev, O; Anzi, S; Inoue, K; Shaulian, E				Yogev, Orli; Anzi, Shira; Inoue, Kazushi; Shaulian, Eitan			Induction of transcriptionally active jun proteins regulates drug-induced senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; MAMMALIAN UV RESPONSE; C-JUN; DNA-DAMAGE; HUMAN FIBROBLASTS; MESSENGER-RNA; GROWTH ARREST; AP-1 ACTIVITY; TARGET GENES; HYDROXYUREA	The drug hydroxyurea (HU) is used for cancer therapy and treatment of sickle cell anemia. It inhibits cell cycle progression by blocking DNA synthesis and drives cells to undergo apoptosis or enter senescence. We demonstrate here that HU induces the expression of two AP-1 proteins, c-Jun and JunB, which exert antagonistic effects on the cell cycle. Moreover, the induction of c-Jun is observed following treatment with two other drugs that inhibit the cell cycle in S phase, aphidicolin and camptothecin. The induction of c-Jun, which promotes cell cycle progression, up-regulates expression of cyclin D after exposure of cells to HU. Deficiency in c-jun prevents elevation of cyclin D expression and extends entrance into HU-induced senescence but also renders cells more resistant to HU-dependent apoptosis. The induction of c-Jun is independent of JNK activity, and additionally, of c-Jun autoregulatory activity but is inhibited upon inhibition of protein kinase C activity. Therefore, we suggest that c-Jun activity prevents drug-induced senescence. Conversely, the JunB target gene, tumor suppressor p16(INK4a), a cyclin-dependent kinase inhibitor essential for the induction of drug-induced senescence, is also up-regulated by HU in a JunB-dependent manner. Constitutive expression of JunB up-regulates p16(INK4a) and increases the sensitivity of mouse fibroblasts to drug-induced senescence. Thus, we suggest that in contrast to c-Jun, JunB drives cells to enter HU-dependent senescence. The effect of HU treatment, which regulates the intricate web of AP-1 transcription, depends on the balance between c-Jun and JunB activities.	Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel; Wake Forest Univ, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27157 USA	Hebrew University of Jerusalem; Wake Forest University; Wake Forest University	Shaulian, E (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel.	eshaulian@md.huji.ac.il						ADUNYAH SE, 1995, BBA-GENE STRUCT EXPR, V1263, P123; Ahn JS, 2003, ANN NY ACAD SCI, V1010, P493, DOI 10.1196/annals.1299.090; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baker GL, 2005, CELL CYCLE, V4, P330; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bulgin D, 2006, THYROID, V16, P217, DOI 10.1089/thy.2006.16.217; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Davies SC, 2003, BLOOD REV, V17, P99, DOI 10.1016/S0268-960X(02)00074-7; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dosch J, 1996, ONCOGENE, V13, P1927; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LI JC, 1987, CANCER RES, V47, P2755; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAOKA T, 1995, J BIOL CHEM, V270, P12147, DOI 10.1074/jbc.270.20.12147; NAKAOKA T, 1993, J BIOCHEM-TOKYO, V114, P449, DOI 10.1093/oxfordjournals.jbchem.a124196; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Navarra P, 1999, CRIT REV ONCOL HEMAT, V29, P249, DOI 10.1016/S1040-8428(98)00032-8; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Park JI, 2000, J CANCER RES CLIN, V126, P455, DOI 10.1007/s004320050013; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Queralt E, 2005, GENETICS, V171, P1485, DOI 10.1534/genetics.105.045005; ROSENTHAL F., 1928, KLIN WOCHENSCHR, V7, P972, DOI 10.1007/BF01716922; Sakano K, 2001, JPN J CANCER RES, V92, P1166, DOI 10.1111/j.1349-7006.2001.tb02136.x; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; WANG E, 1995, CANCER RES, V55, P2284; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yeo EJ, 2000, EXP GERONTOL, V35, P553, DOI 10.1016/S0531-5565(00)00108-X	58	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34475	34483		10.1074/jbc.M602865200	http://dx.doi.org/10.1074/jbc.M602865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966326	hybrid			2022-12-25	WOS:000241767600068
J	Karkhanis, VA; Boniecki, MT; Poruri, K; Martinis, SA				Karkhanis, Vrajesh A.; Boniecki, Michal T.; Poruri, Kiranmai; Martinis, Susan A.			A viable amino acid editing activity in the leucyl-tRNA synthetase CP1-splicing domain is not required in the yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I TRANSFER-RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; SPLICING FUNCTION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELL VIABILITY; DISCRIMINATION; ISOLEUCINE	Aminoacyl-tRNA synthetases are a family of enzymes that are responsible for translating the genetic code in the first step of protein synthesis. Some aminoacyl-tRNA synthetases have editing activities to clear their mistakes and enhance fidelity. Leucyl-tRNA synthetases have a hydrolytic active site that resides in a discrete amino acid editing domain called CP1. Mutational analysis within yeast mitochondrial leucyl-tRNA synthetase showed that the enzyme has maintained an editing active site that is competent for post-transfer editing of mischarged tRNA similar to other leucyl-tRNA synthetases. These mutations that altered or abolished leucyl-tRNA synthetase editing were introduced into complementation assays. Cell viability and mitochondrial function were largely unaffected in the presence of high levels of non-leucine amino acids. In contrast, these editing-defective mutations limited cell viability in Escherichia coli. It is possible that the yeast mitochondria have evolved to tolerate lower levels of fidelity in protein synthesis or have developed alternate mechanisms to enhance discrimination of leucine from non-cognate amino acids that can be misactivated by leucyl-tRNA synthetase.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Martinis, SA (corresponding author), Univ Illinois, Dept Biochem, 419 Roger Adams Lab,Box B-4,600 S Matthews Ave, Urbana, IL 61801 USA.	martinis@life.uiuc.edu		poruri, kiran/0000-0002-3127-0244; Martinis, Susan/0000-0001-5730-8346	NIGMS NIH HHS [GM63107, GM63789, R01 GM063789] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063789, R01GM063107] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SG, 2004, J BIOL CHEM, V279, P42359, DOI 10.1074/jbc.C400304200; Apostol I, 1997, J BIOL CHEM, V272, P28980, DOI 10.1074/jbc.272.46.28980; Augustin S, 2005, J BIOL CHEM, V280, P2691, DOI 10.1074/jbc.M410609200; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FINZI E, 1985, MEMBRANE BIOCHEM, V5, P291, DOI 10.3109/09687688509150283; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; Fukunaga R, 2005, NAT STRUCT MOL BIOL, V12, P915, DOI 10.1038/nsmb985; Fukunaga R, 2005, J BIOL CHEM, V280, P29937, DOI 10.1074/jbc.M502668200; Fukunaga R, 2005, J MOL BIOL, V346, P57, DOI 10.1016/j.jmb.2004.11.060; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; Hendrickson TL, 2004, ANNU REV BIOCHEM, V73, P147, DOI 10.1146/annurev.biochem.73.012803.092429; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; Houman F, 2000, P NATL ACAD SCI USA, V97, P13743, DOI 10.1073/pnas.240465597; Hsu JL, 2006, J BIOL CHEM, V281, P23075, DOI 10.1074/jbc.M601606200; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; Li GY, 1996, MOL GEN GENET, V252, P667, DOI 10.1007/BF02173972; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; LINCECUM TL, 2005, AMINOACYL TRNA SYNTH, P36; Liu YQ, 2006, BIOCHEM J, V394, P399, DOI 10.1042/BJ20051249; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; LOW B, 1971, J BACTERIOL, V108, P742, DOI 10.1128/JB.108.2.742-750.1971; Lue SW, 2005, BIOCHEMISTRY-US, V44, P3010, DOI 10.1021/bi047901v; Martinis S A, 1997, Nucleic Acids Symp Ser, V36, P125; Martinis SA, 1999, BIOCHIMIE, V81, P683, DOI 10.1016/S0300-9084(99)80126-6; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, V1, P887; MESSENGUY F, 1980, EUR J BIOCHEM, V108, P439, DOI 10.1111/j.1432-1033.1980.tb04740.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mursinna RS, 2004, BIOCHEMISTRY-US, V43, P155, DOI 10.1021/bi034919h; Mursinna RS, 2002, J AM CHEM SOC, V124, P7286, DOI 10.1021/ja025879s; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; Nangle LA, 2002, J BIOL CHEM, V277, P45729, DOI 10.1074/jbc.M208093200; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Passarella S, 2003, MITOCHONDRION, V2, P319, DOI 10.1016/S1567-7249(03)00008-4; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Rho SB, 2002, EMBO J, V21, P6874, DOI 10.1093/emboj/cdf671; Rho SB, 2000, RNA, V6, P1882, DOI 10.1017/S1355838200001254; Roy H, 2005, J BIOL CHEM, V280, P38186, DOI 10.1074/jbc.M508281200; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tang Y, 2002, BIOCHEMISTRY-US, V41, P10635, DOI 10.1021/bi026130x; Tang Y, 2001, J AM CHEM SOC, V123, P11089, DOI 10.1021/ja016652k; VONHEIJNE G, 1986, FEBS LETT, V198, P1, DOI 10.1016/0014-5793(86)81172-3; Xu MG, 2004, BIOCHEM BIOPH RES CO, V318, P11, DOI 10.1016/j.bbrc.2004.03.180; Zhai YX, 2005, BIOCHEMISTRY-US, V44, P15437, DOI 10.1021/bi0514461	61	28	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33217	33225		10.1074/jbc.M607406200	http://dx.doi.org/10.1074/jbc.M607406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956879	hybrid			2022-12-25	WOS:000241621400030
J	Netzel-Arnett, S; Currie, BM; Szabo, R; Lin, CY; Chen, LM; Chai, KX; Antalis, TM; Bugge, TH; List, K				Netzel-Arnett, Sarah; Currie, Brooke M.; Szabo, Roman; Lin, Chen-Yong; Chen, Li-Mei; Chai, Karl X.; Antalis, Toni M.; Bugge, Thomas H.; List, Karin			Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; BARRIER FUNCTION; OVARIAN-CANCER; NETHERTON-SYNDROME; CELLULAR-LOCALIZATION; EPITHELIAL-CELLS; STRATUM-CORNEUM; MESSENGER-RNA; BREAST-CANCER; IN-VIVO	Recent gene ablation studies in mice have shown that matriptase, a type II transmembrane serine protease, and prostasin, a glycosylphosphatidylinositol-anchored membrane serine protease, are both required for processing of the epidermis-specific polyprotein, profilaggrin, stratum corneum formation, and acquisition of epidermal barrier function. Here we present evidence that matriptase acts upstream of prostasin in a zymogen activation cascade that regulates terminal epidermal differentiation and is required for prostasin zymogen activation. Enzymatic gene trapping of matriptase combined with prostasin immunohistochemistry revealed that matriptase was co-localized with prostasin in transitional layer cells of the epidermis and that the developmental onset of expression of the two membrane proteases was coordinated and correlated with acquisition of epidermal barrier function. Purified soluble matriptase efficiently converted soluble prostasin zymogen to an active two-chain form that formed SDS-stable complexes with the serpin protease nexin-1. Whereas two forms of prostasin with molecular weights corresponding to the prostasin zymogen and active prostasin were present in wild type epidermis, prostasin was exclusively found in the zymogen form in matriptase-deficient epidermis. These data suggest that matriptase, an autoactivating protease, acts upstream from prostasin to initiate a zymogen cascade that is essential for epidermal differentiation.	NIDCR, Proteases & Tissue Remodeling Unit, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Washington, DC 20201 USA; Univ Maryland, Sch Med, Dept Physiol, Washington, DC 20201 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Georgetown University; State University System of Florida; University of Central Florida	Bugge, TH (corresponding author), NIDCR, Proteases & Tissue Remodeling Unit, NIH, 30 Convent Dr,Rm 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov			Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01-CA-104944, R01 CA098369, R01-CA-096851, CA098369] Funding Source: Medline; NHLBI NIH HHS [HL07698, R01 HL084387] Funding Source: Medline; NICHD NIH HHS [HD40241] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD040241] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA096851, R01CA104944, R56CA098369, R01CA098369] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007698, R01HL084387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chen LM, 2006, AM J PHYSIOL-RENAL, V291, pF567, DOI 10.1152/ajprenal.00047.2006; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; Fukushima K, 2004, J GASTROENTEROL, V39, P940, DOI 10.1007/s00535-004-1425-7; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Hewett DR, 2005, HUM MOL GENET, V14, P335, DOI 10.1093/hmg/ddi030; Hoang CD, 2004, CHEST, V125, P1843, DOI 10.1378/chest.125.5.1843; Kang JY, 2003, CANCER RES, V63, P1101; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Oberst MD, 2003, J HISTOCHEM CYTOCHEM, V51, P1017, DOI 10.1177/002215540305100805; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Pearton DJ, 2001, EXP DERMATOL, V10, P193, DOI 10.1034/j.1600-0625.2001.010003193.x; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; RESING KA, 1993, BIOCHEMISTRY-US, V32, P10036, DOI 10.1021/bi00089a020; RESING KA, 1995, J BIOL CHEM, V270, P28193; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanimoto H, 2005, BRIT J CANCER, V92, P278, DOI 10.1038/sj.bjc.6602320; Yang T, 2004, GENE DEV, V18, P2354, DOI 10.1101/gad.1232104; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388	43	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					32941	32945		10.1074/jbc.C600208200	http://dx.doi.org/10.1074/jbc.C600208200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16980306	hybrid, Green Submitted			2022-12-25	WOS:000241621400002
J	Ren, SM; Higashi, H; Lu, HS; Azuma, T; Hatakeyama, M				Ren, Shumei; Higashi, Hideaki; Lu, Huaisheng; Azuma, Takeshi; Hatakeyama, Masanori			Structural basis and functional consequence of Helicobacter pylori CagA multimerization in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; VIRULENCE FACTOR CAGA; TYROSINE PHOSPHORYLATION; BIOLOGICAL-ACTIVITY; IV SECRETION; PROTEIN; SHP-2; TRANSLOCATION; PHOSPHATASE; ANTIGEN	Helicobacter pylori cagA-positive strains are associated with gastric adenocarcinoma. The cagA gene product CagA is delivered into gastric epithelial cells where it localizes to the plasma membrane and undergoes tyrosine phosphorylation at the EPIYA-repeat region, which contains the EPIYA-A segment, EPIYA-B segment, and Western CagA-specific EPIYA-C or East Asian CagA-specific EPIYA-D segment. In host cells, CagA specifically binds to and deregulates SHP-2 phosphatase via the tyrosine-phosphorylated EPIYA-C or EPIYA-D segment, thereby inducing an elongated cell shape known as the hummingbird phenotype. In this study, we found that CagA multimerizes in cells in a manner independent of its tyrosine phosphorylation. Using a series of CagA mutants, we identified a conserved amino acid sequence motif (FPLXRXXXVXDL-SKVG), which mediates CagA multimerization, within the EPIYA-C segment as well as in a sequence that located immediately downstream of the EPIYA-C or EPIYA-D segment. We also found that a phosphorylation-resistant CagA, which multimerizes but cannot bind SHP-2, inhibits the wild-type CagA-SHP-2 complex formation and abolishes induction of the hummingbird phenotype. Thus, SHP-2 binds to a preformed and tyrosine-phosphorylated CagA multimer via its two Src homology 2 domains. These results, in turn, indicate that CagA multimerization is a prerequisite for CagA-SHP-2 interaction and subsequent deregulation of SHP-2. The present work raises the possibility that inhibition of CagA multimerization abolishes pathophysiological activities of CagA that promote gastric carcinogenesis.	Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Kobe Univ, Grad Sch Med, Internal Ctr Med Res, Kobe, Hyogo 6500017, Japan	Hokkaido University; Kobe University	Hatakeyama, M (corresponding author), Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012					Argent RH, 2004, GASTROENTEROLOGY, V127, P514, DOI 10.1053/j.gastro.2004.06.006; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Azuma T, 2004, J INFECT DIS, V189, P820, DOI 10.1086/381782; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; BLASER MJ, 1995, CANCER RES, V55, P2111; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; De Souza D, 2002, BIOCHEMISTRY-US, V41, P9229, DOI 10.1021/bi0259507; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Higashi H, 2005, J BIOL CHEM, V280, P23130, DOI 10.1074/jbc.M503583200; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Naito M, 2006, GASTROENTEROLOGY, V130, P1181, DOI 10.1053/j.gastro.2005.12.038; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Rugge M, 1999, CANCER-AM CANCER SOC, V85, P2506, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2506::AID-CNCR3>3.3.CO;2-9; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993	25	96	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32344	32352		10.1074/jbc.M606172200	http://dx.doi.org/10.1074/jbc.M606172200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954210	hybrid			2022-12-25	WOS:000241414500032
J	Browne, CD; Hindmarsh, EJ; Smith, JW				Browne, Cecille D.; Hindmarsh, Elizabeth J.; Smith, Jeffrey W.			Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor	FASEB JOURNAL			English	Article						VEGF; KDR; neovascularization	GROWTH-FACTOR; ANTITUMOR-ACTIVITY; FAS EXPRESSION; CANCER; OVEREXPRESSION; ARCHITECTURE; SYNTHETASE; APOPTOSIS; COMPLEX; MODEL	Orlistat, an antiobesity drug, is cytostatic and cytotoxic to tumor cells (1). The antitumor activity of orlistat can be attributed to its ability to inhibit the thioesterase domain of fatty acid synthase (FAS). The objective of the present study was to test the effect of orlistat on endothelial cell proliferation and angiogenesis. Orlistat inhibits endothelial cell FAS, blocks the synthesis of fatty acids, and prevents endothelial cell proliferation. More significantly, orlistat inhibits human neovascularization in an ex vivo assay, which suggests that it may be useful as an antiangiogenic drug. The mechanism of these effects can be traced to the fact that orlistat prevents the display of the vascular endothelial growth factor (VEGF) receptor (VEGFR2/KDR/Flk1) on the endothelial cell surface. Thus, orlistat is an antiangiogenic agent with a novel mechanism of action.	Burke Med Res Inst, Canc Res Ctr, La Jolla, CA 92037 USA		Smith, JW (corresponding author), Burke Med Res Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	liesa.hindmarsh@anu.edu.au; jsmith@burnham.org			NCI NIH HHS [P01 CA82713-06, R01 CA106582-02] Funding Source: Medline; NCRR NIH HHS [U54 RR020843-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106582, P01CA082713] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Bandyopadhyay S, 2005, ONCOGENE, V24, P5389, DOI 10.1038/sj.onc.1208555; Brown KJ, 1996, LAB INVEST, V75, P539; Chirala SS, 2001, P NATL ACAD SCI USA, V98, P3104, DOI 10.1073/pnas.051635998; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DEMETRI GDV, 2005, 2005 ASCO ANN M ORL; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Furuya Y, 1997, ANTICANCER RES, V17, P4589; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Heiligtag SJ, 2002, CELL DEATH DIFFER, V9, P1017, DOI 10.1038/sj.cdd.4401055; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Li JN, 2001, CANCER RES, V61, P1493; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; MATTICK JS, 1983, J BIOL CHEM, V258, P5300; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Menendez JA, 2005, MED HYPOTHESES, V64, P997, DOI 10.1016/j.mehy.2004.09.027; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; MOTZER RJB, 2005, 2005 ASCO ANN M ORL; Nakamura I, 1999, INT J MOL MED, V4, P381; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Rossi S, 2003, MOL CANCER RES, V1, P707; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; *USFDA, 2004, FDA NEWS; Wang Y, 2001, CANCER LETT, V167, P99, DOI 10.1016/S0304-3835(01)00464-5; WITTE K, 1998, HLTH RISK COMMUNICAT, V2, P1; Zeng HY, 2003, J BIOL CHEM, V278, P20738, DOI 10.1074/jbc.M209712200	36	76	85	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2027	2035		10.1096/fj.05-5404com	http://dx.doi.org/10.1096/fj.05-5404com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012255				2022-12-25	WOS:000241156900011
J	Chin, SF; Wang, Y; Thorne, NP; Teschendorff, AE; Pinder, SE; Vias, M; Naderi, A; Roberts, I; Barbosa-Morais, NL; Garcia, MJ; Iyer, NG; Kranjac, T; Robertson, JFR; Aparicio, S; Tavare, S; Ellis, I; Brenton, JD; Caldas, C				Chin, S-F; Wang, Y.; Thorne, N. P.; Teschendorff, A. E.; Pinder, S. E.; Vias, M.; Naderi, A.; Roberts, I.; Barbosa-Morais, N. L.; Garcia, M. J.; Iyer, N. G.; Kranjac, T.; Robertson, J. F. R.; Aparicio, S.; Tavare, S.; Ellis, I.; Brenton, J. D.; Caldas, C.			Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers	ONCOGENE			English	Article						breast cancer; array-CGH; amplification; deletion	HISTOLOGICAL GRADE; GENE; MICROARRAY; IDENTIFICATION; CARCINOMAS; PATTERNS; AMPLIFICATION; SUBGROUPS; REVEALS; CGH	We analysed 148 primary breast cancers using BAC-arrays containing 287 clones representing cancer-related gene/loci to obtain genomic molecular portraits. Gains were detected in 136 tumors (91.9%) and losses in 123 tumors (83.1%). Eight tumors (5.4%) did not have any genomic aberrations in the 281 clones analysed. Common (more than 15% of the samples) gains were observed at 8q11-qtel, 1q21-qtel, 17q11-q12 and 11q13, whereas common losses were observed at 16q12-qtel, 11ptel-p15.5, 1p36-ptel, 17p11.2-p12 and 8ptel-p22. Patients with tumors registering either less than 5% (median value) or less than 11% (third quartile) total copy number changes had a better overall survival (log-rank test: P = 0.0417 and P = 0.0375, respectively). Unsupervised hierarchical clustering based on copy number changes identified four clusters. Women with tumors from the cluster with amplification of three regions containing known breast oncogenes (11q13, 17q12 and 20q13) had a worse prognosis. The good prognosis group (Nottingham Prognostic Index (NPI) <= 3.4) tumors had frequent loss of 16q24-qtel. Genes significantly associated with estrogen receptor (ER), Grade and NPI were used to build k-nearest neighbor (KNN) classifiers that predicted ER, Grade and NPI status in the test set with an average misclassification rate of 24.7, 25.7 and 35.7%, respectively. These data raise the prospect of generating a molecular taxonomy of breast cancer based on copy number pro. ling using tumor DNA, which may be more generally applicable than expression microarray analysis.	Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Genom Program, Cambridge CB2 2XZ, Cambs, England; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England; Hutchison MRC, Res Ctr, Canc Cell Unit, Cambridge, England; Inst Mol Med, Lisbon, Portugal; Univ Nottingham, Nottingham NG7 2RD, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universidade de Lisboa; University of Nottingham	Caldas, C (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Genom Program, Hill Rd, Cambridge CB2 2XZ, Cambs, England.	cc234@cam.ac.uk	Caldas, Carlos/A-7543-2008; García, María J/G-1361-2016; Wang, Yanzhong/GRY-3114-2022; Barbosa-Morais, Nuno L/I-2743-2013; Brenton, James D/B-3174-2008; Caldas, Carlos/U-7250-2019	García, María J/0000-0002-2236-9912; Barbosa-Morais, Nuno L/0000-0002-1215-0538; Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; Naderi, Ali/0000-0001-7142-7616; Aparicio, Samuel/0000-0002-0487-9599; /0000-0003-4167-8910; Ellis, Ian/0000-0001-5292-8474; Wang, Yanzhong/0000-0002-0768-1676; chin, suet-feung/0000-0001-5697-1082				Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Bogliolo M, 2002, MUTAGENESIS, V17, P529, DOI 10.1093/mutage/17.6.529; Callagy G, 2005, J PATHOL, V205, P388, DOI 10.1002/path.1694; Chin SF, 2001, BRIT J CANCER, V84, P193, DOI 10.1054/bjoc.2000.1577; Cingoz S, 2003, CANCER GENET CYTOGEN, V145, P108, DOI 10.1016/S0165-4608(03)00094-3; Daigo Y, 2001, AM J PATHOL, V158, P1623, DOI 10.1016/S0002-9440(10)64118-1; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; GILCHRIST KW, 1985, BREAST CANCER RES TR, V5, P3, DOI 10.1007/BF01807642; Glinsky GV, 2004, CLIN CANCER RES, V10, P2272, DOI 10.1158/1078-0432.CCR-03-0522; Gunther K, 2001, J PATHOL, V193, P40, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH745>3.0.CO;2-N; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Jones C, 2004, CLIN CANCER RES, V10, P5988, DOI 10.1158/1078-0432.CCR-03-0731; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Korsching E, 2004, BRIT J CANCER, V90, P1422, DOI 10.1038/sj.bjc.6601658; Landi MT, 2005, J NATL CANCER I, V97, P998, DOI 10.1093/jnci/dji176; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Maass N, 2002, CANCER LETT, V185, P219, DOI 10.1016/S0304-3835(02)00286-0; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Nessling M, 2005, CANCER RES, V65, P439; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PIPER J, 2002, P 3 EUR QUANT MOL CY, P109; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rennstam K, 2003, CANCER RES, V63, P8861; Reyal F, 2005, CANCER RES, V65, P1376, DOI 10.1158/0008-5472.CAN-04-2706; Roylance R, 1999, CANCER RES, V59, P1433; Smyth Gordon K, 2003, Methods Mol Biol, V224, P111; Soares R, 2004, MOL ENDOCRINOL, V18, P2333, DOI 10.1210/me.2003-0362; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tsarouha H, 1999, CANCER GENET CYTOGEN, V113, P156, DOI 10.1016/S0165-4608(99)00016-3; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	44	83	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1959	1970		10.1038/sj.onc.1209985	http://dx.doi.org/10.1038/sj.onc.1209985			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001317				2022-12-25	WOS:000245117700014
J	Rother, K; Kirschner, R; Sanger, K; Bohlig, L; Mossner, J; Engeland, K				Rother, K.; Kirschner, R.; Saenger, K.; Boehlig, L.; Moessner, J.; Engeland, K.			p53 downregulates expression of the G(1)/S cell cycle phosphatase Cdc25A	ONCOGENE			English	Article						p53; Cdc25A; G(1) to S transition; repression; tumor suppressor; transcription	SUPPRESSOR PROTEIN P53; P63; HOMOLOG; TRANSCRIPTION; ACTIVATION; PHOSPHORYLATION; P73; IDENTIFICATION; REQUIREMENT; INHIBITION	Overexpression of Cdc25A phosphatase is often observed in cancer and results in poor prognosis. Cdc25A mainly dephosphorylates and thereby activates Cyclin-dependent kinase 2 and thus induces progression in the cell cycle from G(1) to S phase. Here, we demonstrate that the tumor suppressor p53 downregulates expression from the Cdc25A gene. In a p53-inducible cell system, Cdc25A expression on the mRNA and protein level is downregulated upon p53 expression. Promoter-reporter assays show that this regulation is dependent on the Cdc25A promoter. Mutant p53 fails to reduce Cdc25A transcription. In contrast to p53, neither p63 nor p73 can repress Cdc25A transcription. The Cdc25A promoter displays no p53 binding site, and p53 does not bind directly to the promoter DNA as shown by chromatin immunoprecipitation assays. Previously, the contribution of p53 to G1/S arrest has been mostly linked to activating the expression of the Cdk inhibitor p21(WAF1/CIP1). By downregulating Cdc25A expression, p53 may impair transition from G1 to S phase independently of p21(WAF1/CIP1). Therefore, the data suggest that, as long as p53 is intact, Cdc25A transcriptional downregulation might play a role in cancer prevention.	Univ Leipzig, Med Klin & Poliklin 2, Max Burger Forschungszentrum, D-04103 Leipzig, Germany; Univ Leipzig, IZKF, Max Burger Forschungszentrum, D-7010 Leipzig, Germany	Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University	Engeland, K (corresponding author), Univ Leipzig, Med Klin & Poliklin 2, Max Burger Forschungszentrum, Johannisallee, D-04103 Leipzig, Germany.	engeland@medizin.uni-leipzig.de	Engeland, Kurt/AAW-9965-2020; Rother, Karen/GQI-3786-2022	Engeland, Kurt/0000-0003-3525-0440; Rother, Karen/0000-0002-0074-7329				Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Broggini M, 2000, ANTICANCER RES, V20, P4835; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lammer C, 1998, J CELL SCI, V111, P2445; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; NAGATA A, 1991, NEW BIOL, V3, P959; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Tschop K, 2006, FEBS J, V273, P1681, DOI 10.1111/j.1742-4658.2006.05184.x; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wasner M, 2003, GENE, V312, P225, DOI 10.1016/S0378-1119(03)00618-8; Wasner M, 2003, FEBS LETT, V536, P66, DOI 10.1016/S0014-5793(03)00028-0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu JH, 1998, CANCER RES, V58, P5061	45	49	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1949	1953		10.1038/sj.onc.1209989	http://dx.doi.org/10.1038/sj.onc.1209989			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001315				2022-12-25	WOS:000245117700012
J	Mattison, K; Wilbur, JS; So, M; Brennan, RG				Mattison, Kirsten; Wilbur, J. Scott; So, Magdalene; Brennan, Richard G.			Structure of FitAB from Neisseria gonorrhoeae bound to DNA reveals a tetramer of toxin-antitoxin heterodimers containing pin domains and ribbon-helix-helix motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENINE TRACT; RNA DECAY; INFECTION; ALIGNMENT; COMPLEX; SYSTEM; TOOL; RECOGNITION; DODECAMER	Neisseria gonorrhoeae is a sexually transmitted pathogen that initiates infections in humans by adhering to the mucosal epithelium of the urogenital tract. The bacterium then enters the apical region of the cell and traffics across the cell to exit into the subepithelial matrix. Mutations in the fast intracellular trafficking (fitAB) locus cause the bacteria to transit a polarized epithelial monolayer more quickly than the wild-type parent and to replicate within cells at an accelerated rate. Here, we describe the crystal structure of the toxin-antitoxin heterodimer, FitAB, bound to a high affinity 36-bp DNA fragment from the fitAB promoter. FitA, the antitoxin, binds DNA through its ribbon-helix-helix motif and is tethered to FitB, the toxin, to form a heterodimer by the insertion of a four turn alpha-helix into an extensive FitB hydrophobic pocket. FitB is composed of a PIN (PilT N terminus) domain, with a central, twisted, 5-stranded parallel beta-sheet that is open on one side and flanked by five alpha-helices. FitB in the context of the FitAB complex does not display nuclease activity against tested PIN substrates. The FitAB complex points to the mechanism by which antitoxins with RHH motifs can block the activity of toxins with PIN domains. Interactions between two FitB molecules result in the formation of a tetramer of FitAB heterodimers, which binds to the 36-bp DNA fragment and provides an explanation for how FitB enhances the DNA binding affinity of FitA.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Brennan, RG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 100, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rgbrenna@mdanderson.org	So, Magdalene/ABB-8918-2020	So, Magdalene/0000-0001-8301-0674; Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047260] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47260] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXEEV DG, 1987, NATURE, V325, P821, DOI 10.1038/325821a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anantharaman V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-12-r81; Apicella MA, 1996, J INFECT DIS, V173, P636, DOI 10.1093/infdis/173.3.636; Arcus VL, 2005, TRENDS MICROBIOL, V13, P360, DOI 10.1016/j.tim.2005.06.008; Arcus VL, 2004, J BIOL CHEM, V279, P16471, DOI 10.1074/jbc.M313833200; Brendler T, 2004, J BACTERIOL, V186, P2504, DOI 10.1128/JB.186.8.2504-2507.2004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Clissold PM, 2000, CURR BIOL, V10, pR888, DOI 10.1016/S0960-9822(00)00858-7; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; Edwards JL, 2004, CLIN MICROBIOL REV, V17, P965, DOI 10.1128/CMR.17.4.965-981.2004; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Han GW, 1997, J MOL BIOL, V269, P811, DOI 10.1006/jmbi.1997.1085; Hanekamp T, 1997, FEBS LETT, V415, P40, DOI 10.1016/S0014-5793(97)01089-2; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HOLMES KH, 1971, ANN INTERN MED, V74, P979, DOI 10.7326/0003-4819-74-6-979; Hopper S, 2000, INFECT IMMUN, V68, P896, DOI 10.1128/IAI.68.2.896-905.2000; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamada K, 2005, MOL CELL, V19, P497, DOI 10.1016/j.molcel.2005.07.004; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lan RT, 2003, INFECT IMMUN, V71, P6298, DOI 10.1128/IAI.71.11.6298-6306.2003; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEROY JL, 1988, BIOCHEMISTRY-US, V27, P8894, DOI 10.1021/bi00425a004; Makarova KS, 2002, NUCLEIC ACIDS RES, V30, P482, DOI 10.1093/nar/30.2.482; Makarova KS, 1999, GENOME RES, V9, P608; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pandey DP, 2005, NUCLEIC ACIDS RES, V33, P966, DOI 10.1093/nar/gki201; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; PULLINGER GD, 1992, MOL MICROBIOL, V6, P1631, DOI 10.1111/j.1365-2958.1992.tb00888.x; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Takagi H, 2005, NAT STRUCT MOL BIOL, V12, P327, DOI 10.1038/nsmb911; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turner CF, 2002, JAMA-J AM MED ASSOC, V287, P726, DOI 10.1001/jama.287.6.726; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Wall D, 1999, MOL MICROBIOL, V32, P1, DOI 10.1046/j.1365-2958.1999.01339.x; Watkins RE, 2003, BIOCHEMISTRY-US, V42, P1430, DOI 10.1021/bi0268753; Wilbur JS, 2005, BIOCHEMISTRY-US, V44, P12515, DOI 10.1021/bi0511080; Zhang YX, 2004, CELL RES, V14, P208, DOI 10.1038/sj.cr.7290221	48	106	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37942	37951		10.1074/jbc.M605198200	http://dx.doi.org/10.1074/jbc.M605198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16982615	hybrid			2022-12-25	WOS:000242477100073
J	Okuda, K; Nakamura, T; Sugita, M; Shimizu, T; Shikanai, T				Okuda, Kenji; Nakamura, Takahiro; Sugita, Mamoru; Shimizu, Toshiyuki; Shikanai, Toshiharu			A pentatricopeptide repeat protein is a site recognition factor in chloroplast RNA editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEUS-ENCODED FACTOR; PSBL MESSENGER-RNA; MITOCHONDRIAL GENOME; RESTORES FERTILITY; PLANT-MITOCHONDRIA; GENE-EXPRESSION; PPR MOTIF; TOBACCO; MAIZE; TRANSLATION	In higher plants, RNA editing is a post-transcriptional process that converts C to U in organelle mRNAs. We have previously shown that an Arabidopsis thaliana crr4 mutant is defective with respect to RNA editing for creating the translational initial codon of the plastid ndhD gene ( the ndhD-1 site). CRR4 contains 11 pentatricopeptide repeat motifs but does not contain any domains that are likely to be involved in the editing activity. The green fluorescent protein fused to the putative transit peptide of CRR4 targeted the plastid. The recombinant CRR4 expressed in Escherichia coli specifically bound to the 25 nucleotides of the upstream and the 10 nucleotides of the downstream sequences surrounding the editing site of ndhD-1. The target C nucleotide of this editing is not essential for the binding of CRR4. Taken together with the genetic evidence, we conclude that the pentatricopeptide repeat protein CRR4 is a sequence-specific RNA-binding protein that acts as a site recognition factor in plastid RNA editing.	Kyushu Univ, Grad Sch Agr, Higashi Ku, Fukuoka 8128581, Japan; Nagoya Univ, Ctr Gene Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Yokohama City Univ, Int Grad Sch Arts & Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Kyushu University; Nagoya University; Yokohama City University	Shikanai, T (corresponding author), Kyushu Univ, Grad Sch Agr, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	shikanai@agr.kyushu-u.ac.jp	Shikanai, Toshiharu/AAK-9112-2020					BARKAN A, 1994, EMBO J, V13, P3170, DOI 10.1002/j.1460-2075.1994.tb06616.x; Bentolila S, 2002, P NATL ACAD SCI USA, V99, P10887, DOI 10.1073/pnas.102301599; Bock R, 1996, EMBO J, V15, P5052, DOI 10.1002/j.1460-2075.1996.tb00885.x; Bock R, 2000, BIOCHIMIE, V82, P549, DOI 10.1016/S0300-9084(00)00610-6; BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/j.1460-2075.1994.tb06784.x; Brennicke A, 1999, FEMS MICROBIOL REV, V23, P297, DOI 10.1111/j.1574-6976.1999.tb00401.x; CHAUDHURI S, 1995, EMBO J, V14, P2951, DOI 10.1002/j.1460-2075.1995.tb07295.x; Chaudhuri S, 1996, EMBO J, V15, P5958, DOI 10.1002/j.1460-2075.1996.tb00982.x; Farre JC, 2001, NUCLEIC ACIDS RES, V29, P2484, DOI 10.1093/nar/29.12.2484; Fisk DG, 1999, EMBO J, V18, P2621, DOI 10.1093/emboj/18.9.2621; Giege P, 1999, P NATL ACAD SCI USA, V96, P15324, DOI 10.1073/pnas.96.26.15324; Handa H, 2003, NUCLEIC ACIDS RES, V31, P5907, DOI 10.1093/nar/gkg795; Hashimoto M, 2003, PLANT J, V36, P541, DOI 10.1046/j.1365-313X.2003.01900.x; Hirose T, 2001, EMBO J, V20, P1144, DOI 10.1093/emboj/20.5.1144; Karcher D, 1998, NUCLEIC ACIDS RES, V26, P1185, DOI 10.1093/nar/26.5.1185; Kazama T, 2003, FEBS LETT, V544, P99, DOI 10.1016/S0014-5793(03)00480-0; Koizuka N, 2003, PLANT J, V34, P407, DOI 10.1046/j.1365-313X.2003.01735.x; Kotera E, 2005, NATURE, V433, P326, DOI 10.1038/nature03229; Lurin C, 2004, PLANT CELL, V16, P2089, DOI 10.1105/tpc.104.022236; Maier RM, 1996, PLANT MOL BIOL, V32, P343, DOI 10.1007/BF00039390; Meierhoff K, 2003, PLANT CELL, V15, P1480, DOI 10.1105/tpc.010397; Miyamoto T, 2004, P NATL ACAD SCI USA, V101, P48, DOI 10.1073/pnas.0307163101; Miyamoto T, 2002, MOL CELL BIOL, V22, P6726, DOI 10.1128/MCB.22.19.6726-6734.2002; Munekaga Y, 2004, NATURE, V429, P579, DOI 10.1038/nature02598; Nakamura T, 2003, EUR J BIOCHEM, V270, P4070, DOI 10.1046/j.1432-1033.2003.03796.x; Notsu Y, 2002, MOL GENET GENOMICS, V268, P434, DOI 10.1007/s00438-002-0767-1; REED ML, 2001, NUCLEIC ACIDS RES, V29, P6948; Rivals E, 2006, PLANT PHYSIOL, V141, P825, DOI 10.1104/pp.106.077826; Sasaki Y, 2001, J BIOL CHEM, V276, P3937, DOI 10.1074/jbc.M008166200; Schmitz-Linneweber C, 2005, PLANT CELL, V17, P2791, DOI 10.1105/tpc.105.034454; Schmitz-Linneweber C, 2001, EMBO J, V20, P4874, DOI 10.1093/emboj/20.17.4874; Shikanai T, 2006, CELL MOL LIFE SCI, V63, P698, DOI 10.1007/s00018-005-5449-9; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; Smith HC, 1997, RNA, V3, P1105; Takenaka M, 2004, NUCLEIC ACIDS RES, V32, P4137, DOI 10.1093/nar/gkh763; Tsudzuki T, 2001, J MOL EVOL, V53, P327, DOI 10.1007/s002390010222; Wang ZH, 2006, PLANT CELL, V18, P676, DOI 10.1105/tpc.105.038240; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Yamazaki H, 2004, PLANT J, V38, P152, DOI 10.1111/j.1365-313X.2004.02035.x; Zito F, 1997, PLANT MOL BIOL, V33, P79, DOI 10.1023/A:1005734809834	40	165	181	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37661	37667		10.1074/jbc.M608184200	http://dx.doi.org/10.1074/jbc.M608184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17015439	hybrid			2022-12-25	WOS:000242477100043
J	Panda, K; Haque, MM; Garcin-Hosfield, ED; Durra, D; Getzoff, ED; Stuehr, DJ				Panda, Koustubh; Haque, Mohammad Mahfuzul; Garcin-Hosfield, Elsa D.; Durra, Deborah; Getzoff, Elizabeth D.; Stuehr, Dennis J.			Surface charge interactions of the FMN module govern catalysis by nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NO COMPLEX-FORMATION; ELECTRON-TRANSFER; REDUCTASE DOMAIN; ACIDIC RESIDUES; HEME REDUCTION; CALMODULIN; NADPH; FLAVODOXIN; BINDING; CYTOCHROME-P450	The FMN module of nitric-oxide synthase (NOS) plays a pivotal role by transferring NADPH-derived electrons to the enzyme heme for use in oxygen activation. The process may involve a swinging mechanism in which the same face of the FMN module accepts and provides electrons during catalysis. Crystal structure shows that this face of the FMN module is electronegative, whereas the complementary interacting surface is electropositive, implying that charge interactions enable function. We used site-directed mutagenesis to investigate the roles of six electronegative surface residues of the FMN module in electron transfer and catalysis in neuronal NOS. Results are interpreted in light of crystal structures of NOS and related flavoproteins. Neutralizing or reversing the negative charge of each residue altered the NO synthesis, NADPH oxidase, and cytochrome c reductase activities of neuronal NOS and also altered heme reduction. The largest effects occurred at the NOS-specific charged residue Glu762. Together, the results suggest that electrostatic interactions of the FMN module help to regulate electron transfer and to minimize flavin autoxidation and the generation of reactive oxygen species during NOS catalysis.	Cleveland Clin, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44195 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute	Stuehr, DJ (corresponding author), Cleveland Clin, Dept Pathobiol, Lerner Res Inst, NC22,9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Garcin, Elsa D/C-1556-2013; Panda, Koustubh/E-5273-2017	Garcin, Elsa D/0000-0003-0501-8421; HAQUE, MOHAMMAD/0000-0003-0852-6368; Panda, Koustubh/0000-0002-4783-2221	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL58883, HL76491] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076491, R01HL058883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Chen PF, 2003, J BIOL CHEM, V278, P52392, DOI 10.1074/jbc.M305469200; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/bst0310502; Finn RD, 2003, EUR J BIOCHEM, V270, P1164, DOI 10.1046/j.1432-1033.2003.03474.x; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GOVINDARAJ S, 1995, BIOCHEMISTRY-US, V34, P11221, DOI 10.1021/bi00035a031; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Grunau A, 2006, BIOCHEMISTRY-US, V45, P1421, DOI 10.1021/bi052115r; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Hanley SC, 2004, BIOCHEM BIOPH RES CO, V325, P1418, DOI 10.1016/j.bbrc.2004.10.189; KLATT P, 1992, J BIOL CHEM, V267, P11374; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Olteanu H, 2004, BIOCHEMISTRY-US, V43, P1988, DOI 10.1021/bi035910i; Panda K, 2004, J BIOL CHEM, V279, P18323, DOI 10.1074/jbc.M310391200; Porasuphatana S, 2003, COMP BIOCHEM PHYS C, V134, P281, DOI 10.1016/S1532-0456(02)00271-5; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Schrammel A, 1998, BBA-PROTEIN STRUCT M, V1387, P257, DOI 10.1016/S0167-4838(98)00138-1; Sevrioukova I, 1996, BIOCHEMISTRY-US, V35, P7058, DOI 10.1021/bi960060a; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Sibille N, 2005, BIOCHEMISTRY-US, V44, P9086, DOI 10.1021/bi050437p; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Tiso M, 2005, J BIOL CHEM, V280, P39208, DOI 10.1074/jbc.M507775200; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	41	53	54	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36819	36827		10.1074/jbc.M606129200	http://dx.doi.org/10.1074/jbc.M606129200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17001078	hybrid			2022-12-25	WOS:000242220800040
J	Mendiratta, SS; Sekulic, N; Hernandez-Guzman, FG; Close, BE; Lavie, A; Colley, KJ				Mendiratta, Shalu Shiv; Sekulic, Nikolina; Hernandez-Guzman, Francisco G.; Close, Brett E.; Lavie, Arnon; Colley, Karen J.			A novel alpha-helix in the first fibronectin type III repeat of the neural cell adhesion molecule is critical for N-glycan polysialylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; AMINO-ACIDS; RECOGNITION; POLYSIALYLTRANSFERASES; GLYCOPROTEIN; GROWTH; ACETYLGALACTOSAMINE; AUTOPOLYSIALYLATION; OLIGOSACCHARIDES; REFINEMENT	Polysialic acid is a developmentally regulated, anti-adhesive glycan that is added to the neural cell adhesion molecule, NCAM. Polysialylated NCAM is critical for brain development and plays roles in synaptic plasticity, axon guidance, and cell migration. The first fibronectin type III repeat of NCAM, FN1, is necessary for the polysialylation of N-glycans on the adjacent immunoglobulin domain. This repeat cannot be replaced by other fibronectin type III repeats. We solved the crystal structure of human NCAM FN1 and found that, in addition to a unique acidic surface patch, it possesses a novel alpha-helix that links strands 4 and 5 of its beta-sandwich structure. Replacement of the alpha-helix did not eliminate polysialyltransferase recognition, but shifted the addition of polysialic acid from the N-glycans modifying the adjacent immunoglobulin domain to O-glycans modifying FN1. Other experiments demonstrated that replacement of residues in the acidic surface patch alter the polysialylation of both N-and O-glycans in the same way, while the alpha-helix is only required for the polysialylation of N-glycans. Our data are consistent with a model in which the FN1 alpha-helix is involved in an Ig5-FN1 interaction that is critical for the correct positioning of Ig5N-glycans for polysialylation.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Accelrys Inc, San Diego, CA 92121 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; BIOVIA	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	karenc@uic.edu	Sekulic, Nikolina/N-5550-2016; Sekulic, Nikolina/F-8911-2013; Lavie, Arnon/H-4927-2012	Sekulic, Nikolina/0000-0001-7555-3222; Lavie, Arnon/0000-0001-5591-8722	NIGMS NIH HHS [R01 GM63843] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063843] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 2004, J BIOL CHEM, V279, P32603, DOI 10.1074/jbc.M403429200; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; Durbec P, 2001, MOL NEUROBIOL, V24, P53; Gluer S, 1998, J PEDIATR SURG, V33, P1516, DOI 10.1016/S0022-3468(98)90488-2; Goridis C, 1992, Semin Cell Biol, V3, P189; Hildebrandt H, 1998, CANCER RES, V58, P779; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kiss JZ, 2001, BRAIN RES REV, V36, P175, DOI 10.1016/S0165-0173(01)00093-5; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mendiratta SS, 2005, J BIOL CHEM, V280, P32340, DOI 10.1074/jbc.M506217200; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MICHALIDES R, 1994, INT J CANCER, P34; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oldfield TJ, 2001, ACTA CRYSTALLOGR D, V57, P82, DOI 10.1107/S0907444900014098; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; Tanaka F, 2000, CANCER RES, V60, P3072; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; Weinhold B, 2004, GLYCOBIOLOGY, V14, P1141; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; ZUBER C, 1992, J BIOL CHEM, V267, P9965	43	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36052	36059		10.1074/jbc.M608073200	http://dx.doi.org/10.1074/jbc.M608073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003032	hybrid			2022-12-25	WOS:000242100500054
J	Mosyak, L; Wood, A; Dwyer, B; Buddha, M; Johnson, M; Aulabaugh, A; Zhong, XT; Presman, E; Benard, S; Kelleher, K; Wilhelm, J; Stahl, ML; Kriz, R; Gao, Y; Cao, ZX; Ling, HP; Pangalos, MN; Walsh, FS; Somers, WS				Mosyak, Lidia; Wood, Andrew; Dwyer, Brian; Buddha, Madhavan; Johnson, Mark; Aulabaugh, Ann; Zhong, Xiaotian; Presman, Eleonora; Benard, Susan; Kelleher, Kerry; Wilhelm, James; Stahl, Mark L.; Kriz, Ron; Gao, Ying; Cao, Zixuan; Ling, Huai-Ping; Pangalos, Menelas N.; Walsh, Frank S.; Somers, William S.			The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR FAMILY-MEMBER; CRYSTAL-STRUCTURE; AXONAL REGENERATION; NOGO-66 RECEPTOR; ADHESION; COMPLEX; PROTEIN; RECOGNITION; OLIGODENDROCYTES; DIFFERENTIATION	Nogo receptor (NgR)-mediated control of axon growth relies on the central nervous system-specific type I transmembrane protein Lingo-1. Interactions between Lingo-1 and NgR, along with a complementary co-receptor, result in neurite and axonal collapse. In addition, the inhibitory role of Lingo-1 is particularly important in regulation of oligodendrocyte differentiation and myelination, suggesting that pharmacological modulation of Lingo-1 function could be a novel approach for nerve repair and remyelination therapies. Here we report on the crystal structure of the ligand-binding ectodomain of human Lingo-1 and show it has a bimodular, kinked structure composed of leucine-rich repeat (LRR) and immunoglobulin (Ig)-like modules. The structure, together with biophysical analysis of its solution properties, reveals that in the crystals and in solution Lingo-1 persistently associates with itself to form a stable tetramer and that it is its LRR-Ig-composite fold that drives such assembly. Specifically, in the crystal structure protomers of Lingo-1 associate in a ring-shaped tetramer, with each LRR domain filling an open cleft in an adjacent protomer. The tetramer buries a large surface area ( 9,200 A 2) and may serve as an efficient scaffold to simultaneously bind and assemble the NgR complex components during activation on a membrane. Potential functional binding sites that can be identified on the ectodomain surface, including the site of self-recognition, suggest a model for protein assembly on the membrane.	Wyeth Res, Dept Chem & Screening Sci, Cambridge, MA 02140 USA; Wyeth Res, Princeton, NJ 08852 USA; Wyeth Res, Pearl River, NY 10965 USA; Wyeth Res, Collegeville, PA 19426 USA	Pfizer; Pfizer; Pfizer; Pfizer	Mosyak, L (corresponding author), Wyeth Res, Dept Chem & Screening Sci, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	lmosyak@wyeth.com; wsomers@wyeth.com						BANDTLOW C, 2004, SCI STKE, P24; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; Barton WA, 2003, EMBO J, V22, P3291, DOI 10.1093/emboj/cdg325; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Carim-Todd L, 2003, EUR J NEUROSCI, V18, P3167, DOI 10.1111/j.1460-9568.2003.03003.x; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dumas JJ, 2003, SCIENCE, V301, P222, DOI 10.1126/science.1083917; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Lo Conte L, 1999, J MOL BIOL, V285, P2177; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Park PSH, 2004, BIOCHEMISTRY-US, V43, P15643, DOI 10.1021/bi047907k; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Schubert WD, 2002, CELL, V111, P825, DOI 10.1016/S0092-8674(02)01136-4; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Sharma S. K., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P311, DOI 10.2174/1568011023354191; Soroka V, 2003, STRUCTURE, V11, P1291, DOI 10.1016/j.str.2003.09.006; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; YPHANTIS D, 1997, WINNONLIN PROGRAM; Zhong XT, 2005, BBA-GEN SUBJECTS, V1723, P143, DOI 10.1016/j.bbagen.2005.01.010	38	66	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36378	36390		10.1074/jbc.M607314200	http://dx.doi.org/10.1074/jbc.M607314200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005555	hybrid			2022-12-25	WOS:000242100500089
J	Sai, JQ; Walker, G; Wikswo, J; Richmond, A				Sai, Jiqing; Walker, Glenn; Wikswo, John; Richmond, Ann			The IL sequence in the LLKIL motif in CXCR2 is required for full ligand-induced activation of Erk, Akt, and chemotaxis in HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTORS CXCR1; FORMYL PEPTIDE RECEPTOR; BETA-ARRESTIN; POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTOR; INTERLEUKIN-8 RECEPTOR; NEUTROPHIL CHEMOTAXIS; TERMINAL DOMAIN; MAP-KINASE; INTERNALIZATION	The chemotaxis of differentiated HL60 cells stably expressing CXCR2 was examined in a microfluidic gradient device where the steepness of the CXCL8 chemokine gradient was varied from 2 pg/ml/mu m (0-1 ng/ml over a width of 500 mu m) to 50 pg/ml/mu m (0-25 ng/ml over 500 mu m). The differentiated HL60 cells stably expressing CXCR2 exhibited little chemotaxis in response to a 0-1 ng/ml gradient, but displayed an increasing chemotactic response as the gradient steepness increased from 0 to 5, 0 to 10, and 0 to 25 ng/ml, demonstrating that steepness of gradient is a major determinant of the relative ability of cells to persistently migrate up a chemotactic gradient. When HL60 cells expressed CXCR2 mutated in the C terminus LLKIL motif (IL to AA), ligand-induced internalization of receptors was reduced 50%, whereas cell migration along the gradient of CXCL8 was completely lost. Although both mutant and wildtype receptors could mediate Akt and Erk activation in response to CXCL8, the level of activation of these two kinases was much lower in the cell line expressing the mutant receptors. These data imply that the IL amino acid residues in the LLKIL motif are very important for activation of the signal transduction cascade, which is necessary for cells to sense the chemokine gradient and respond with chemotaxis. Moreover, because mutation of the IL residues in the LLKIL motif resulted in only 50% reduction in receptor internalization, and a 50% reduction in Akt and Erk phosphorylation, but a complete loss of chemotactic response, the data imply that IL amino acid residues in the LLKIL motif are key either for amplification or oscillation of crucial signaling events or for establishment of a threshold for signals required for chemotaxis.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Vet Affairs, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biomed Engn, Vanderbilt Inst Integrat Biosyst Res & Educ, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Phys & Astron, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	ann.richmond@vanderbilt.edu	Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [R01 CA034590-21, U54 CA113007, CA68485, P30 CA068485, R01 CA034590-23, CA34590, R01 CA034590, P50 CA113007, R01 CA034590-22] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA113007, R23CA034590, P30CA068485, R01CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; BEHAR TN, 1994, J NEUROSCI, V14, P29; BHALLA K, 1985, CANCER RES, V45, P3657; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; Cooper CR, 2003, CANCER-AM CANCER SOC, V97, P739, DOI 10.1002/cncr.11181; Cross AK, 1997, CYTOKINE, V9, P521, DOI 10.1006/cyto.1996.0196; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fernandis AZ, 2002, J BIOL CHEM, V277, P18111, DOI 10.1074/jbc.M200750200; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Fuhler GM, 2005, J LEUKOCYTE BIOL, V77, P257, DOI 10.1189/jlb.0504306; Fujita T, 2005, CELL SIGNAL, V17, P167, DOI 10.1016/j.cellsig.2004.06.008; GALLAGHER RE, 1985, LEUKEMIA RES, V9, P967, DOI 10.1016/0145-2126(85)90067-0; GRIMES GJ, 1973, EXP CELL RES, V79, P375, DOI 10.1016/0014-4827(73)90457-6; HARRIS H, 1954, PHYSIOL REV, V34, P529, DOI 10.1152/physrev.1954.34.3.529; HERSH EM, 1970, ANNU REV MED, V21, P105, DOI 10.1146/annurev.me.21.020170.000541; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Jeon NL, 2002, NAT BIOTECHNOL, V20, P826, DOI 10.1038/nbt712; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Lin F, 2004, BIOCHEM BIOPH RES CO, V319, P576, DOI 10.1016/j.bbrc.2004.05.029; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; PEREZ HD, 1989, J CLIN INVEST, V83, P1963, DOI 10.1172/JCI114105; RAMSEY WS, 1974, EXP CELL RES, V86, P184, DOI 10.1016/0014-4827(74)90669-7; Richardson RM, 2003, J IMMUNOL, V170, P2904, DOI 10.4049/jimmunol.170.6.2904; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; Rose JJ, 2004, J BIOL CHEM, V279, P24372, DOI 10.1074/jbc.M401364200; Sai JQ, 2004, J CELL SCI, V117, P5489, DOI 10.1242/jcs.01398; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Sambrano GR, 1999, J BIOL CHEM, V274, P20178, DOI 10.1074/jbc.274.29.20178; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Su YJ, 2005, J IMMUNOL, V175, P5396, DOI 10.4049/jimmunol.175.8.5396; VANLINT J, 1993, MOL CELL BIOCHEM, V128, P171, DOI 10.1007/BF01076768; Walker GM, 2005, LAB CHIP, V5, P611, DOI 10.1039/b417245k; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606	49	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35931	35941		10.1074/jbc.M605883200	http://dx.doi.org/10.1074/jbc.M605883200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990258	hybrid, Green Accepted			2022-12-25	WOS:000242100500040
J	Kodama, Y; Sano, H				Kodama, Yutaka; Sano, Hiroshi			Evolution of a basic helix-loop-helix protein from a transcriptional repressor to a plastid-resident regulatory factor - Involvement in hypersensitive cell death in tobacco plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSAIC-VIRUS; DNA-BINDING; CHLOROPHYLL DEGRADATION; METHYL JASMONATE; SUBCELLULAR-LOCALIZATION; NEGATIVE REGULATOR; ENVELOPE MEMBRANE; CYSTEINE SYNTHASE; MOLECULAR-CLONING; FACTOR FAMILY	The tobacco gene NtWIN4 (Nicotiana tabacum wound-induced clone 4) is transiently up-regulated in response not only to wounding but also to pathogen attack. NtWIN4 encodes a putative basic helix-loop-helix protein with an apparent molecular mass of 28 kDa that exhibited clear nuclear transcription repression activity in Dual-Luciferase assays. However, immunoblotting indicated the existence of a 17-kDa form of NtWIN4 localized exclusively in tobacco leaf chloroplasts. Subsequent peptide dissection analyses with green fluorescent protein fusions revealed that a polypeptide of 81 amino acids starting at position 13 from the N terminus is maximally necessary for this localization. Further fine dissection analysis strongly suggested that the protein actually begins at the second Met located at position 27, yielding a signal peptide of 67 amino acids. However, the last C-terminal 15 amino acids overlap with the conserved basic region critical for DNA binding, so NtWIN4 presumably does not function as a transcription factor in planta. Transgenic tobacco plants constitutively over-expressing NtWIN4 demonstrated mortality with abnormal features, including albinism, and transient expression upon agroinfiltration resulted in distinct necrosis with a sharp decrease in chlorophyll content, consistent with the phenomenon known as chlorosis. Transgenic RNA interference tobacco plants exhibited reduced hypersensitive cell death, showing delayed tissue necrosis upon pathogen infection. These results suggest that NtWIN4 arose by divergence, becoming a chloroplast-resident factor from a nuclear transcriptional repressor by obtaining a transit peptide sequence, and that, upon translocation, it interacts with chloroplast components to induce hypersensitive cell death through chloroplast disruption, thereby contributing to plant stress responses.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300192, Japan	Nara Institute of Science & Technology	Sano, H (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300192, Japan.	sano@gtc.naist.jp						Arkus KAJ, 2005, ARCH BIOCHEM BIOPHYS, V438, P146, DOI 10.1016/j.abb.2005.04.019; Benedetti CE, 1998, PLANT PHYSIOL, V116, P1037, DOI 10.1104/pp.116.3.1037; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Benkova E, 1999, PLANT PHYSIOL, V121, P245, DOI 10.1104/pp.121.1.245; Buchanan B.B., 2000, BIOCH MOL BIOL PLANT; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CORBIN DR, 1987, MOL CELL BIOL, V7, P4337, DOI 10.1128/MCB.7.12.4337; Culver JN, 2002, ANNU REV PHYTOPATHOL, V40, P287, DOI 10.1146/annurev.phyto.40.120301.102400; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Fan L, 1999, PLANT PHYSIOL, V119, P1371, DOI 10.1104/pp.119.4.1371; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GIANINAZZI S, 1970, CR ACAD SCI D NAT, V270, P2383; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; Hara K, 2000, PLANT CELL PHYSIOL, V41, P684, DOI 10.1093/pcp/41.6.684; Heim MA, 2003, MOL BIOL EVOL, V20, P735, DOI 10.1093/molbev/msg088; HENDRY GAF, 1987, NEW PHYTOL, V107, P255, DOI 10.1111/j.1469-8137.1987.tb00181.x; HESSE H, 1995, PLANT PHYSIOL, V108, P851, DOI 10.1104/pp.108.2.851; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Hortensteiner S, 2006, ANNU REV PLANT BIOL, V57, P55, DOI 10.1146/annurev.arplant.57.032905.105212; Horton P, 2006, SER ADV BIOINFORM, V3, P39, DOI 10.1142/9781860947292_0007; Jacob-Wilk D, 1999, PLANT J, V20, P653, DOI 10.1046/j.1365-313X.1999.00637.x; Kariola T, 2005, PLANT CELL, V17, P282, DOI 10.1105/tpc.104.025817; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Ledent V, 2001, GENOME RES, V11, P754, DOI 10.1101/gr.177001; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; Matile P, 1999, ANNU REV PLANT PHYS, V50, P67, DOI 10.1146/annurev.arplant.50.1.67; Monosov EZ, 1996, J HISTOCHEM CYTOCHEM, V44, P581, DOI 10.1177/44.6.8666743; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGATA T, 1981, MOL GEN GENET, V184, P161, DOI 10.1007/BF00272899; Nakamura T, 2000, EUR J BIOCHEM, V267, P5621, DOI 10.1046/j.1432-1327.2000.01633.x; Nakano T, 1997, PLANT CELL, V9, P1673, DOI 10.1105/tpc.9.9.1673; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; Quail PH, 2000, SEMIN CELL DEV BIOL, V11, P457, DOI 10.1006/scdb.2000.0199; Sato N, 2001, NUCLEIC ACIDS RES, V29, P2244, DOI 10.1093/nar/29.11.2244; Sato N, 2001, TRENDS PLANT SCI, V6, P151, DOI 10.1016/S1360-1385(01)01888-X; Sato N, 1998, PLANT CELL, V10, P859, DOI 10.1105/tpc.10.5.859; SATO N, 1993, EMBO J, V12, P555, DOI 10.1002/j.1460-2075.1993.tb05687.x; SATO N, 1995, PHOTOSYNTHESIS LIGHT, V3, P635; Schilmiller AL, 2005, CURR OPIN PLANT BIOL, V8, P369, DOI 10.1016/j.pbi.2005.05.008; Seo S, 2000, PLANT CELL, V12, P917, DOI 10.1105/tpc.12.6.917; Sugimoto M, 2004, PLANT MOL BIOL, V56, P973, DOI 10.1007/s11103-004-6459-y; Takamiya K, 2000, TRENDS PLANT SCI, V5, P426, DOI 10.1016/S1360-1385(00)01735-0; Tamura T, 2003, PLANT PHYSIOL, V131, P454, DOI 10.1104/pp.102.011007; Tang L, 2004, Z NATURFORSCH C, V59, P415; Toledo-Ortiz G, 2003, PLANT CELL, V15, P1749, DOI 10.1105/tpc.013839; Tsuchiya T, 1999, P NATL ACAD SCI USA, V96, P15362, DOI 10.1073/pnas.96.26.15362; Ueda H, 2006, PLANT MOL BIOL, V61, P31, DOI 10.1007/s11103-005-5817-8; Uefuji H, 2005, PLANT MOL BIOL, V59, P221, DOI 10.1007/s11103-005-8520-x; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; Wada Y, 2003, J BIOL CHEM, V278, P42386, DOI 10.1074/jbc.M303892200; Waller F, 2006, PLANT CELL PHYSIOL, V47, P1169, DOI 10.1093/pcp/pcj079; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Yamaguchi Y, 2000, PLANT CELL PHYSIOL, V41, P465, DOI 10.1093/pcp/41.4.465; Yamamoto YY, 1998, PLANT BIOTECHNOL-NAR, V15, P217; Yasuno R, 1998, PLANT PHYSIOL, V118, P935, DOI 10.1104/pp.118.3.935; Yoda H, 2002, MOL GENET GENOMICS, V267, P154, DOI 10.1007/s00438-002-0651-z	65	15	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35369	35380		10.1074/jbc.M604140200	http://dx.doi.org/10.1074/jbc.M604140200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16966334	hybrid			2022-12-25	WOS:000241933700071
J	Zehelein, J; Kathoefer, S; Khalil, M; Alter, M; Thomas, D; Brockmeier, K; Ulmer, HE; Katus, HA; Koenen, M				Zehelein, Joerg; Kathoefer, Sven; Khalil, Markus; Alter, Markus; Thomas, Dierk; Brockmeier, Konrad; Ulmer, Herbert E.; Katus, Hugo A.; Koenen, Michael			Skipping of exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; INHERITED CARDIAC-ARRHYTHMIAS; POTASSIUM CHANNEL GENE; ROMANO-WARD-SYNDROME; CARDIOAUDITORY SYNDROME; MOLECULAR-BASIS; MUTATIONS; KVLQT1; HERG; ISK	The Jervell and Lange-Nielsen syndrome (JLNS) is a rare autosomal recessive form of the long QT syndrome linked with a profound hearing loss caused by mutations affecting both alleles of either the KCNQ1 or the KCNE1 gene. We carried out a mutant screening of the KCNQ1 and KCNE1 genes in a clinical diagnosed German family with JLNS. Family members were examined by single strand conformation polymorphism analysis and PCR and amplified products were characterized by DNA sequence analysis. We identified a splice donor mutation of exon 1 in the KCNQ1 gene (G477 + 1A). Analysis of lymphocyte RNA by RT-PCR revealed that two symptomatic patients, homozygous for the mutant allele, exclusively produce KCNQ1 transcripts lacking exon 1 leading to a frameshift that introduced a premature termination codon at exon 4. Mutant subunits, functionally characterized in Xenpous oocytes, were unable to form homomeric channels but strongly reduced I-Ks (slowly activating delayed rectifier potassium current) in vitro (mutant isoforms 1 and 2 by 62 and 86%, respectively), a fact supposed to lead to severely affected heterozygous individuals. However, individuals heterozygous for the mutant allele exhibit an asymptomatic cardiac phenotype. Thus, the observed dominant-negative effect of mutant subunits in vitro is absent in vivo leaving heterozygous individuals unaffected. These data suggest mechanisms that prevent production of truncated KCNQ1 channel subunits in cardiomyocytes of individuals heterozygous for the mutant allele.	Max Planck Inst Med Res, Zellphysiol Abt, D-69120 Heidelberg, Germany; Univ Klinikum Heidelberg, Innere Med 3, D-69120 Heidelberg, Germany; Univ Klinikum Heidelberg, Kinderheilkunde 2, D-69120 Heidelberg, Germany; Klinikum Univ Koln, Abt Kinderkardiol, D-50931 Cologne, Germany	Max Planck Society; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Cologne	Koenen, M (corresponding author), Max Planck Inst Med Res, Zellphysiol Abt, Jahnstr 29, D-69120 Heidelberg, Germany.	koenen@mpimf-heidelberg.mpg.de	Thomas, Dierk/ABA-4706-2021; Thomas, Dierk/V-3940-2017; Khalil, Markus/AFS-7292-2022	Thomas, Dierk/0000-0002-5687-7843; Khalil, Markus/0000-0001-8897-7200				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Ackerman MJ, 2004, NAT MED, V10, P463, DOI 10.1038/nm0504-463; Ackerman MJ, 1999, MAYO CLIN PROC, V74, P1088, DOI 10.4065/74.11.1088; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Chouabe C, 2000, CARDIOVASC RES, V45, P971, DOI 10.1016/S0008-6363(99)00411-3; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Huang LQ, 2001, CARDIOVASC RES, V51, P670, DOI 10.1016/S0008-6363(01)00350-9; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; Mohammad-Panah R, 1999, AM J HUM GENET, V64, P1015, DOI 10.1086/302346; Neuhaus EM, 1998, J STRUCT BIOL, V121, P326, DOI 10.1006/jsbi.1998.3971; Neyroud N, 1999, CIRC RES, V84, P290, DOI 10.1161/01.RES.84.3.290; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schmitt N, 2000, EMBO J, V19, P332, DOI 10.1093/emboj/19.3.332; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Schwartz PJ, 2006, CIRCULATION, V113, P783, DOI 10.1161/CIRCULATIONAHA.105.592899; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Tester DJ, 2005, HEART RHYTHM, V2, P507, DOI 10.1016/j.hrthm.2005.01.020; Thomas D, 2005, CARDIOVASC RES, V67, P487, DOI 10.1016/j.cardiores.2005.05.003; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Tyson J, 2000, HUM GENET, V107, P499, DOI 10.1007/s004390000402; Van Langen IM, 2003, J MED GENET, V40, P141, DOI 10.1136/jmg.40.2.141; Wagner E, 2002, J CELL SCI, V115, P3033; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wang ZQ, 2002, MOL GENET METAB, V75, P308, DOI 10.1016/S1096-7192(02)00007-0; Zehelein J, 2004, BBA-MOL BASIS DIS, V1690, P185, DOI 10.1016/j.bbadis.2004.06.024	31	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35397	35403		10.1074/jbc.M603433200	http://dx.doi.org/10.1074/jbc.M603433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987820	hybrid, Green Published			2022-12-25	WOS:000241933700073
J	Felton-Edkins, ZA; Kondrashov, A; Karali, D; Fairley, JA; Dawson, CW; Arrand, JR; Young, LS; White, RJ				Felton-Edkins, Zoe A.; Kondrashov, Alexander; Karali, Dimitra; Fairley, Jennifer A.; Dawson, Christopher W.; Arrand, John R.; Young, Lawrence S.; White, Robert J.			Epstein-Barr virus induces cellular transcription factors to allow active expression of EBER genes by RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN 1; ENCODED SMALL RNAS; BURKITTS-LYMPHOMA; NASOPHARYNGEAL CARCINOMA; DIFFERENTIAL REGULATION; UPSTREAM SEQUENCES; LINE AKATA; IN-VITRO; CELLS; ACTIVATION	The EBER genes of Epstein-Barr virus (EBV) are transcribed by RNA polymerase (pol) III to produce untranslated RNAs that are implicated in oncogenesis. These EBER transcripts are the most highly expressed viral gene products in EBV-transformed cells. We have identified changes to the cellular transcription machinery that may contribute to the high levels of EBER RNA. These include phosphorylation of ATF2, which interacts with EBER promoters. A second is induction of TFIIIC, a pol III-specific factor that activates EBER genes; all five subunits of TFIIIC are overexpressed in EBV-positive cells. In addition, EBV induces BDP1, a subunit of the pol III-specific factor TFIIIB. Although BDP1 is the only TFIIIB subunit induced by EBV, its induction is sufficient to stimulate EBER expression in vivo, implying a limiting function. The elevated levels of BDP1 and TFIIIC in EBV-positive cells stimulate production of tRNA, 7SL, and 5S rRNA. Abnormally high expression of these cellular pol III products may contribute to the ability of EBV to enhance growth potential.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Cancer Research UK; University of Birmingham; Beatson Institute	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@udcf.gla.ac.uk	Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298; Kondrashov, Alexander/0000-0003-3428-5975				Adamson AL, 2000, J VIROL, V74, P1224, DOI 10.1128/JVI.74.3.1224-1233.2000; ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; ARRAND JR, 2000, EBV REP, V7, P145; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Daly NL, 2005, ONCOGENE, V24, P880, DOI 10.1038/sj.onc.1208031; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Greifenegger N, 1998, J VIROL, V72, P9323, DOI 10.1128/JVI.72.11.9323-9328.1998; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; HOWE JG, 1993, MOL CELL BIOL, V13, P2655, DOI 10.1128/MCB.13.5.2655; Innes F, 2006, NUCLEIC ACIDS RES, V34, P3399, DOI 10.1093/nar/gkl432; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; KHAN G, 1992, J CLIN PATHOL, V45, P616, DOI 10.1136/jcp.45.7.616; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KLEINERT H, 1988, J BIOL CHEM, V263, P11511; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Laing KG, 2002, VIROLOGY, V297, P253, DOI 10.1006/viro.2002.1354; LAING KG, 1995, BIOCH SOC T S, V23, P311; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Muller J, 1999, BIOCHEM CELL BIOL, V77, P431, DOI 10.1139/bcb-77-5-431; Murray PG, 1996, J PATHOL, V178, P44, DOI 10.1002/(SICI)1096-9896(199601)178:1<44::AID-PATH471>3.0.CO;2-0; NILLER HH, 2003, MED SCI MONITOR, V9, P1; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROONEY C, 1989, J VIROL, V63, P1531, DOI 10.1128/JVI.63.4.1531-1539.1989; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; Sriuranpong V, 2004, CLIN CANCER RES, V10, P4944, DOI 10.1158/1078-0432.CCR-03-0757; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; TAKIMOTO T, 1984, J NATL CANCER I, V73, P711; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wensing B, 2001, J VIROL, V75, P6235, DOI 10.1128/JVI.75.13.6235-6241.2001; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WHITE RJ, 2002, LANDES BIOSCIENCE; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; ZEUTHEN J, 1983, J CANCER RES CLIN, V106, P1, DOI 10.1007/BF00399890; ZEUTHEN J, 1983, ADV VIRAL ONCOL, V3, P183	59	38	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					33871	33880		10.1074/jbc.M600468200	http://dx.doi.org/10.1074/jbc.M600468200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16956891	hybrid			2022-12-25	WOS:000241767600008
J	Tahiri-Alaoui, A; Sim, VL; Caughey, B; James, W				Tahiri-Alaoui, Abdessamad; Sim, Valerie L.; Caughey, Byron; James, William			Molecular heterosis of prion protein beta-oligomers - A potential mechanism of human resistance to disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; SOLUBLE OLIGOMERS; IN-VITRO; RECOMBINANT; POLYMORPHISM; CONVERSION; GENE; PRP; STABILITY; SUSCEPTIBILITY	The gene encoding prion protein is polymorphic in human populations, with over 40% of native Europeans, for example, being heterozygous for the Met-129 and Val-129 alleles. The polymorphism affects both the incidence and the clinical presentation of a range of prion diseases, with heterozygotes generally showing the highest levels of resistance. It has been suggested that an earlier epidemic of prion diseases exerted balancing selection on the two alleles, and we have previously demonstrated that the two encoded proteins have potentially compensating tendencies to form amyloid and soluble beta-oligomers, respectively, in vitro. More strikingly, here we demonstrate that mixed oligomers, composed of both allelic forms, show an extreme sluggishness in converting to amyloid in comparison with oligomers homogenous for either allele. It may be that this example of molecular heterosis in vitro provides the basis for maintenance of the polymorphism in the population and that beta-oligomers represent a form of PrP sequestered from pathogenic amyloid formation in vivo.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; NIAID, Rocky Mt Lab, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA	University of Oxford; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	James, W (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Pk Rd, Oxford OX1 3RE, England.	abdou.tahiri-alaoui@bbsrc.ac.uk; William.james@path.ox.ac.uk	james, william/H-4289-2013; Sim, Valerie/C-4137-2013	james, william/0000-0002-2506-1198; Sim, Valerie/0000-0002-0088-8666	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000580, Z01AI000580] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Apetri AC, 2005, BIOCHEMISTRY-US, V44, P15880, DOI 10.1021/bi051455+; Baskakov I, 2005, FEBS LETT, V579, P2589, DOI 10.1016/j.febslet.2005.03.075; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, PROTEIN SCI, V13, P586, DOI 10.1110/ps.03457204; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; Calzolai L, 2003, J BIOL CHEM, V278, P35592, DOI 10.1074/jbc.M303005200; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kovacs GG, 2000, NEUROPATH APPL NEURO, V26, P463, DOI 10.1046/j.1365-2990.2000.00279.x; LAPLANCHE JL, 1994, NEUROLOGY, V44, P2347, DOI 10.1212/WNL.44.12.2347; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; MacDonald ST, 1996, NEUROPATH APPL NEURO, V22, P285, DOI 10.1111/j.1365-2990.1996.tb01106.x; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; Mitrova E, 2005, EUR J NEUROL, V12, P998, DOI 10.1111/j.1468-1331.2005.01110.x; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; NOVITSKAYA V, 2006, J BIOL CHEM; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OWEN F, 1990, AM J HUM GENET, V46, P1215; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Rezaei H, 2005, J MOL BIOL, V347, P665, DOI 10.1016/j.jmb.2005.01.043; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Sokolowski F, 2003, J BIOL CHEM, V278, P40481, DOI 10.1074/jbc.M304391200; Soldevila M, 2005, TRENDS GENET, V21, P389, DOI 10.1016/j.tig.2005.05.001; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Tahiri-Alaoui A, 2005, PROTEIN SCI, V14, P942, DOI 10.1110/ps.041000905; Tahiri-Alaoui A, 2004, J BIOL CHEM, V279, P31390, DOI 10.1074/jbc.M401754200; Tattum MH, 2006, J MOL BIOL, V357, P975, DOI 10.1016/j.jmb.2006.01.052; Vendrely C, 2005, BBA-GEN SUBJECTS, V1724, P355, DOI 10.1016/j.bbagen.2005.05.017; Welker E, 2002, J BIOL CHEM, V277, P33477, DOI 10.1074/jbc.M204273200	41	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34171	34178		10.1074/jbc.M606606200	http://dx.doi.org/10.1074/jbc.M606606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980300	hybrid			2022-12-25	WOS:000241767600037
J	Kim, EJ; Sung, JY; Lee, HJ; Rhim, H; Hasegawa, M; Iwatsubo, T; Min, DS; Kim, J; Paik, SR; Chung, KC				Kim, Eun Joo; Sung, Jee Young; Lee, Hyun Jung; Rhim, Hyewhon; Hasegawa, Masato; Iwatsubo, Takeshi; Min, Do Sik; Kim, Jongsun; Paik, Seung R.; Chung, Kwang Chul			Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PROGENITOR CELLS; ELEMENT-BINDING PROTEIN; A-BETA COMPONENT; DOWN-SYNDROME; PARKINSONS-DISEASE; ALZHEIMER-DISEASE; LEWY BODIES; NEURONAL DIFFERENTIATION; PRECURSOR PROTEIN; SRC-FAMILY	Lewy bodies (LBs) are pathological hallmarks of Parkinson disease (PD) but also occur in Alzheimer disease (AD) and dementia of LBs. alpha-Synuclein, the major component of LBs, is observed in the brain of Down syndrome (DS) patients with AD. Dyrk1A, a dual specificity tyrosine-regulated kinase (Dyrk) family member, is the mammalian ortholog of the Drosophila minibrain (Mnb) gene, essential for normal postembryonic neurogenesis. The Dyrk1A gene resides in the human chromosome 21q22.2 region, which is associated with DS anomalies, including mental retardation. In this study, we examined whether Dyrk1A interacts with alpha-synuclein and subsequently affects intracellular alpha-synuclein inclusion formation in immortalized hippocampal neuronal (H19-7) cells. Dyrk1A selectively binds to alpha-synuclein in transformed and primary neuronal cells. alpha-Synuclein overexpression, followed by basic fibroblast growth factor-induced neuronal differentiation, resulted in cell death. We observed that accompanying cell death was increased alpha-synuclein phosphorylation and intracytoplasmic aggregation. In addition, the transfection of kinase-inactive Dyrk1A or Dyrk1A small interfering RNA blocked alpha-synuclein phosphorylation and aggregate formation. In vitro kinaseassay of anti-Dyrk1A immunocomplexes demonstrated that Dyrk1A could phosphorylate alpha-synuclein at Ser-87. Furthermore, aggregates formed by phosphorylated alpha-synuclein have a distinct morphology and are more neurotoxic compared with aggregates composed of unmodified wild type alpha-synuclein. These findings suggest alpha-synuclein inclusion formation regulated by Dyrk1A, potentially affecting neuronal cell viability.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Seoul Natl Univ, Coll Engn, Sch Chem & Biol Engn, Seoul 151744, South Korea; Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136701, South Korea; Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; Tokyo Inst Psychiat, Tokyo 1568585, Japan; Univ Tokyo, Dept Neuropathol & Neurosci, Tokyo 1130033, Japan	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Korea Institute of Science & Technology (KIST); Pusan National University; Tokyo Institute of Psychiatry; University of Tokyo	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr						Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Dorval V, 2006, J BIOL CHEM, V281, P9919, DOI 10.1074/jbc.M510127200; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Eves EM, 1996, J NEUROCHEM, V67, P1908; Ferrer I, 2005, NEUROBIOL DIS, V20, P392, DOI 10.1016/j.nbd.2005.03.020; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Galceran J, 2003, J NEURAL TRANSM-SUPP, P139; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; Hashimoto M, 2004, J MOL NEUROSCI, V24, P343, DOI 10.1385/JMN:24:3:343; Hodara R, 2004, J BIOL CHEM, V279, P47746, DOI 10.1074/jbc.M408906200; Kang JE, 2005, J NEUROSCI RES, V81, P62, DOI 10.1002/jnr.20534; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim J, 1997, MOL CELLS, V7, P78; Kim SJ, 2003, J BIOL CHEM, V278, P41890, DOI 10.1074/jbc.M306017200; KORENBERG JR, 1994, P NATL ACAD SCI USA, V91, P4997, DOI 10.1073/pnas.91.11.4997; LEJEUNE J., 1959, BULL ACAD NATL MED [PARIS], V143, P256; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Nakamura T, 2002, FEBS LETT, V521, P190, DOI 10.1016/S0014-5793(02)02861-2; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; PATTERSON D, 1987, SCI AM, V257, P52, DOI 10.1038/scientificamerican0887-52; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Pulsifer M B, 1996, J Int Neuropsychol Soc, V2, P159; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Simard M, 2001, INT J GERIATR PSYCH, V16, P311; Sitz JH, 2004, MOL CELL BIOL, V24, P5821, DOI 10.1128/MCB.24.13.5821-5834.2004; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Sung JY, 2001, J BIOL CHEM, V276, P27441, DOI 10.1074/jbc.M101318200; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Yang EJ, 2004, J BIOL CHEM, V279, P1827, DOI 10.1074/jbc.M308722200; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	41	79	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33250	33257		10.1074/jbc.M606147200	http://dx.doi.org/10.1074/jbc.M606147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959772	hybrid			2022-12-25	WOS:000241621400034
J	Lee, J; Kosaras, B; Aleyasin, H; Han, JA; Park, DS; Ratan, RR; Kowall, NW; Ferrante, RJ; Lee, SW; Ryu, H				Lee, Junghee; Kosaras, Bela; Aleyasin, Hossein; Han, Jeong A.; Park, David S.; Ratan, Rajiv R.; Kowall, Neil W.; Ferrante, Robert J.; Lee, Sam W.; Ryu, Hoon			Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response	FASEB JOURNAL			English	Article						oxidative stress; neuronal survival	MESSENGER-RNA; LATE-PHASE; CORTICAL-NEURONS; BINDING PROTEIN; C/EBP-BETA; RAT-BRAIN; EXPRESSION; COX-2; ISCHEMIA; INJURY	Cyclooxygenase-2 (COX-2) has been implicated in neuronal survival and death. However, the precise regulatory mechanisms involved in COX-2 function are unclear. In the present study we found that COX-2 is induced in response to glutathione depletion-induced oxidative stress in primary cortical neurons. Two proximal specific Sp1 and Sp3 binding sites are responsible for the COX-2 promoter activity under normal as well as oxidative stress conditions through enhanced Sp1 and Sp3 DNA binding activity. Site-directed mutagenesis confirmed that -268/-267 positions serve as specific Sp1 and Sp3 recognition sites under oxidative stress. Enforced expression of Sp1 and Sp3 using HSV vectors increased the promoter activity, transcription, and protein level of COX-2 in cortical neurons. The dominant negative form of Sp1 abrogated the oxidative stress-induced promoter activity and expression of COX-2. We also demonstrated that adenovirus-mediated COX-2 gene delivery protected neurons from DNA damage induced by oxidative, genotoxic, and excitotoxic stresses and by ischemic injury. Moreover, COX-2(-/-) cortical neurons were more susceptible to DNA damage-induced cell death. These results indicate that in primary neurons Sp1 and Sp3 play an essential role in the modulation of COX-2 transcription, which mediates neuronal homeostasis and survival by preventing DNA damage in response to neuronal stress.	VA Med Ctr, GRECC, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Res Program, Ottawa, ON, Canada; Harvard Univ, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA; Cornell Univ, Weill Med Coll, Dept Neurol, White Plains, NY USA; Burke Cornell Med Res Inst, White Plains, NY USA	Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; University of Ottawa; Ottawa Hospital Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Cornell University	Ryu, H (corresponding author), VA Med Ctr, GRECC, 200 Springs Rd,Unit 182B, Bedford, MA 01730 USA.	hoonryu@bu.edu	Kowall, Neil/M-5378-2019	Kowall, Neil/0000-0002-6624-0213; Aleyasin, Hossein/0000-0002-0021-2586; Park, David/0000-0002-4490-3784; Ryu, Hoon/0000-0001-6544-3732	NATIONAL CANCER INSTITUTE [R01CA085214, R01CA097216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS045806, R01NS052724, P01NS045242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013846] Funding Source: NIH RePORTER; NCI NIH HHS [CA097216, CA8521406] Funding Source: Medline; NIA NIH HHS [P30 AG13846] Funding Source: Medline; NINDS NIH HHS [NS045242, NS045806, NS52724-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Anderson I, 2001, BIOCHEM SOC SYMP, V67, P141, DOI 10.1042/bss0670141; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; Bolli R, 2002, CARDIOVASC RES, V55, P506, DOI 10.1016/S0008-6363(02)00414-5; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Camilleri M, 2001, Rev Gastroenterol Disord, V1, P2; Chang JW, 1996, NEUROBIOL AGING, V17, P801; Dowd NP, 2001, J CLIN INVEST, V108, P585, DOI 10.1172/JCI11334; FENG JF, 1995, NEURAL PROCESS LETT, V2, P9, DOI 10.1007/BF02309009; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Ho L, 1999, J NEUROSCI RES, V57, P295; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; Hoozemans JJM, 2001, EXP GERONTOL, V36, P559, DOI 10.1016/S0531-5565(00)00226-6; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Mukutmoni M, 2001, PROSTAG LEUKOTR ESS, V65, P123, DOI 10.1054/plef.2001.0300; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Ohtsuki T, 1996, BRAIN RES, V736, P353, DOI 10.1016/S0006-8993(96)00948-1; Planas AM, 1999, NEUROSCI LETT, V275, P141, DOI 10.1016/S0304-3940(99)00756-9; Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013; Rocha JL, 2001, LANCET, V357, P1946, DOI 10.1016/S0140-6736(00)05083-2; Rudnick DA, 2001, P NATL ACAD SCI USA, V98, P8885, DOI 10.1073/pnas.151217998; Ryu H, 2003, J NEUROSCI, V23, P3597; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Shinmura K, 2000, P NATL ACAD SCI USA, V97, P10197, DOI 10.1073/pnas.97.18.10197; Shinmura K, 2002, CIRC RES, V90, P602, DOI 10.1161/01.RES.0000012202.52809.40; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Tocco G, 1997, EXP NEUROL, V144, P339, DOI 10.1006/exnr.1997.6429; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yermakova A, 2000, CURR PHARM DESIGN, V6, P1755, DOI 10.2174/1381612003398672	44	46	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2375	+		10.1096/fj.06-5957fje	http://dx.doi.org/10.1096/fj.06-5957fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17012241				2022-12-25	WOS:000241702600025
J	Anand, M; Balar, B; Ulloque, R; Gross, SR; Kinzy, TG				Anand, Monika; Balar, Bharvi; Ulloque, Rory; Gross, Stephane R.; Kinzy, Terri Goss			Domain and nucleotide dependence of the interaction between Saccharomyces cerevisiae translation elongation factors 3 and 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING; TRANSFER-RNA; FACTOR-III; EF-TU; FUNCTIONAL INTERACTIONS; CRYSTAL-STRUCTURE; ABC TRANSPORTERS; RIBOSOMAL ATPASE; FACTOR 1A; E-SITE	Eukaryotic translation elongation factor 3 (eEF3) is a fungal-specific ATPase proposed to catalyze the release of deacylated-tRNA from the ribosomal E-site. In addition, it has been shown to interact with the aminoacyl-tRNA binding GTPase elongation factor 1A (eEF1A), perhaps linking the E and A sites. Domain mapping demonstrates that amino acids 775-980 contain the eEF1A binding sites. Domain III of eEF1A, which is also involved in actin-related functions, is the site of eEF3 binding. The binding of eEF3 to eEF1A is enhanced by ADP, indicating the interaction is favored post-ATP hydrolysis but is not dependent on the eEF1A-bound nucleotide. A temperature-sensitive P915L mutant in the eEF1A binding site of eEF3 has reduced ATPase activity and affinity for eEF1A. These results support the model that upon ATP hydrolysis, eEF3 interacts with eEF1A to help catalyze the delivery of aminoacyl-tRNA at the A-site of the ribosome. The dynamics of when eEF3 interacts with eEF1A may be part of the signal for transition of the post to pre-translocational ribosomal state in yeast.	UMDNJ, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Kinzy, TG (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	kinzytg@umdnj.edu		gross, stephane/0000-0002-0867-8866; Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57483, R01 GM057483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2003, J BIOL CHEM, V278, P6985, DOI 10.1074/jbc.M209224200; Andersen CF, 2004, ACTA CRYSTALLOGR D, V60, P1304, DOI 10.1107/S0907444904010716; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2001, NAT STRUCT BIOL, V8, P531, DOI 10.1038/88598; Blakely G, 2001, J BACTERIOL, V183, P2241, DOI 10.1128/JB.183.7.2241-2248.2001; Carr-Schmid A, 1999, J BIOL CHEM, V274, P30297, DOI 10.1074/jbc.274.42.30297; Chakraburtty K, 2001, RES MICROBIOL, V152, P391, DOI 10.1016/S0923-2508(01)01210-4; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; DASMAHAPATRA B, 1981, J BIOL CHEM, V256, P9999; DIDOMENICO BJ, 1992, YEAST, V8, P337, DOI 10.1002/yea.320080502; Dinman JD, 1997, RNA, V3, P870; Dinos G, 2005, NUCLEIC ACIDS RES, V33, P5291, DOI 10.1093/nar/gki833; Dong JS, 2005, MOL CELL BIOL, V25, P9859, DOI 10.1128/MCB.25.22.9859-9873.2005; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Elskaya AV, 1997, BIOCHEMISTRY-US, V36, P10492, DOI 10.1021/bi970631e; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Ganoza MC, 2001, ANTIMICROB AGENTS CH, V45, P2813, DOI 10.1128/AAC.45.10.2813-2819.2001; Gontarek RR, 1998, J BIOL CHEM, V273, P10249, DOI 10.1074/jbc.273.17.10249; Gross SR, 2005, NAT STRUCT MOL BIOL, V12, P772, DOI 10.1038/nsmb979; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kambampati R, 1997, J BIOL CHEM, V272, P6377, DOI 10.1074/jbc.272.10.6377; Kambampati R, 2000, J BIOL CHEM, V275, P16963, DOI 10.1074/jbc.M001157200; Kambampati R, 1997, PROTEIN EXPRES PURIF, V10, P209, DOI 10.1006/prep.1997.0728; Kiel MC, 2001, EUR J BIOCHEM, V268, P278, DOI 10.1046/j.1432-1327.2001.01873.x; KIEL MC, 1999, BIOCHIMIE, V77, P713; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KOVALCHUKE O, 1994, EUR J BIOCHEM, V226, P133, DOI 10.1111/j.1432-1033.1994.tb20034.x; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; McKeegan KS, 2003, TRENDS MICROBIOL, V11, P21, DOI 10.1016/S0966-842X(02)00010-0; MERRICK WC, 2000, TRANSLATIONAL CONTRO, P98; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; Nikaido H, 2002, P NATL ACAD SCI USA, V99, P9609, DOI 10.1073/pnas.162375699; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Sarthy AV, 1998, YEAST, V14, P239, DOI 10.1002/(SICI)1097-0061(199802)14:3<239::AID-YEA219>3.0.CO;2-B; Sherman F., 1986, METHODS YEAST GENETI; Shin BS, 2002, CELL, V111, P1015, DOI 10.1016/S0092-8674(02)01171-6; SKOGERSON L, 1976, P NATL ACAD SCI USA, V73, P73, DOI 10.1073/pnas.73.1.73; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sturtevant Joy, 2002, Expert Opin Ther Targets, V6, P545, DOI 10.1517/14728222.6.5.545; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang HM, 1996, BBA-MOL CELL RES, V1310, P303, DOI 10.1016/0167-4889(95)00179-4; YPMAWONG MF, 1992, INFECT IMMUN, V60, P4140, DOI 10.1128/IAI.60.10.4140-4145.1992	47	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32318	32326		10.1074/jbc.M601899200	http://dx.doi.org/10.1074/jbc.M601899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954224	hybrid, Green Accepted			2022-12-25	WOS:000241414500029
J	Bindra, RS; Glazer, PM				Bindra, R. S.; Glazer, P. M.			Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia	ONCOGENE			English	Article						Rad51; homologous recombination; hypoxia; E2F4/p130	CELL-CYCLE ARREST; DNA-REPAIR; DIFFERENTIAL REGULATION; POCKET PROTEINS; DOWN-REGULATION; STRESS; INSTABILITY; P107; DEPHOSPHORYLATION; E2F	We and others have shown that the dysregulation of DNA repair pathways can contribute to the phenomenon of hypoxia-induced genetic instability within the tumor microenvironment. Several studies have revealed that the recombinational repair genes, RAD51 and BRCA1, and the DNA mismatch repair genes, MLH1 and MSH2, are decreased in expression in response to hypoxic stress, prompting interest in elucidating the mechanistic basis for these responses. Here we report that the downregulation of RAD51 by hypoxia is specically mediated by repressive E2F4/p130 complexes that bind to a single E2F site in the proximal promoter of the gene. Intriguingly, this E2F site is conserved in the promoter of the BRCA1 gene, which is also regulated by a similar mechanism in hypoxia. Mechanistically, we have found that hypoxia induces substantial p130 dephosphorylation and nuclear accumulation, leading to the formation of E2F4/p130 complexes and increased occupancy of E2F4 and p130 at the RAD51 and BRCA1 promoters. These findings reveal a coordinated transcriptional program mediated by the formation of repressive E2F4/p130 complexes that represents an integral response to hypoxic stress. In addition, this co-regulation of key factors within the homology-dependent DNA repair pathway provides a further basis for understanding genetic instability in tumors and may guide the design of new therapeutic strategies for cancer.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Expt Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Geriatr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Glazer, PM (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 208040, New Haven, CT 06520 USA.	peter.glazer@yale.edu	Glazer, Peter/S-7651-2019	Bindra, Randip/0000-0003-1552-9057; Glazer, Peter/0000-0003-4525-5560	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005775, R01ES005775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05775] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; DuPree EL, 2004, CANCER RES, V64, P4390, DOI 10.1158/0008-5472.CAN-03-3695; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Garriga J, 2004, CELL CYCLE, V3, P1320, DOI 10.4161/cc.3.10.1183; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Li CY, 2001, CANCER RES, V61, P428; Lin WC, 2001, GENE DEV, V15, P1833; Meng AX, 2005, RADIOTHER ONCOL, V76, P168, DOI 10.1016/j.radonc.2005.06.025; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; North S, 2005, CANCER LETT, V218, P1, DOI 10.1016/j.canlet.2004.08.007; PAQUETTE B, 1994, CANCER RES, V54, P3173; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Reynolds TY, 1996, CANCER RES, V56, P5754; Roth ME, 2004, NAT BIOTECHNOL, V22, P418, DOI 10.1038/nbt948; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Stevceva L, 2004, CURR HIV RES, V2, P1, DOI 10.2174/1570162043485004; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533; Yuan JL, 2000, CANCER RES, V60, P4372; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	40	121	122	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2048	2057		10.1038/sj.onc.1210001	http://dx.doi.org/10.1038/sj.onc.1210001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001309				2022-12-25	WOS:000245313400007
J	Rangarajan, ES; Proteau, A; Wagner, J; Hung, MN; Matte, A; Cygler, M				Rangarajan, Erumbi S.; Proteau, Ariane; Wagner, John; Hung, Ming-Ni; Matte, Allan; Cygler, Miroslaw			Structural snapshots of Escherichia coli histidinol phosphate phosphatase along the reaction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOACID DEHALOGENASE FOLD; CRYSTAL-STRUCTURE; SALMONELLA-TYPHIMURIUM; PHOSPHOSERINE PHOSPHATASE; DEPENDENT PHOSPHOHYDROLASES; SUPERFAMILY; ENZYME; DEHYDRATASE; EVOLUTION; BACTERIAL	HisB from Escherichia coli is a bifunctional enzyme catalyzing the sixth and eighth steps of L-histidine biosynthesis. The N-terminal domain (HisB-N) possesses histidinol phosphate phosphatase activity, and its crystal structure shows a single domain with fold similarity to the haloacid dehalogenase (HAD) enzyme family. HisB-N forms dimers in the crystal and in solution. The structure shows the presence of a structural Zn2+ ion stabilizing the conformation of an extended loop. Two metal binding sites were also identified in the active site. Their presence was further confirmed by isothermal titration calorimetry. HisB-N is active in the presence of Mg2+, Mn2+, Co2+, or Zn2+, but Ca2+ has an inhibitory effect. We have determined structures of several intermediate states corresponding to snapshots along the reaction pathway, including that of the phosphoaspartate intermediate. A catalytic mechanism, different from that described for other HAD enzymes, is proposed requiring the presence of the second metal ion not found in the active sites of previously characterized HAD enzymes, to complete the second half-reaction. The proposed mechanism is reminiscent of two-Mg2+ ion catalysis utilized by DNA and RNA polymerases and many nucleases. The structure also provides an explanation for the inhibitory effect of Ca2+.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	National Research Council Canada; McGill University; McGill University	Matte, A (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	allan.matte@nrc-cnrc.gc.ca; mirek.cygler@nrc-cnrc.gc.ca						Alifano P, 1996, MICROBIOL REV, V60, P44, DOI 10.1128/MMBR.60.1.44-69.1996; Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; AMES BN, 1960, J GEN MICROBIOL, V22, P369, DOI 10.1099/00221287-22-2-369; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Bernstein NK, 2005, MOL CELL, V17, P657, DOI 10.1016/j.molcel.2005.02.012; BRADY DR, 1973, J BIOL CHEM, V248, P2588; Brilli M, 2004, J MOL EVOL, V58, P225, DOI 10.1007/s00239-003-2547-x; Calderone V, 2006, J MOL BIOL, V355, P708, DOI 10.1016/j.jmb.2005.10.068; Calderone V, 2004, J MOL BIOL, V335, P761, DOI 10.1016/j.jmb.2003.10.050; CARLOMAGNO MS, 1988, J MOL BIOL, V203, P585, DOI 10.1016/0022-2836(88)90194-5; CHIARIOTTI L, 1986, MOL GEN GENET, V202, P42, DOI 10.1007/BF00330514; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Deshpande RA, 2004, BIOCHEMISTRY-US, V43, P8579, DOI 10.1021/bi049434n; Glynn SE, 2005, STRUCTURE, V13, P1809, DOI 10.1016/j.str.2005.08.012; HOUSTON LL, 1974, ARCH BIOCHEM BIOPHYS, V162, P513, DOI 10.1016/0003-9861(74)90211-2; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOPER JC, 1961, P NATL ACAD SCI USA, V47, P1440, DOI 10.1073/pnas.47.9.1440; Lu ZB, 2005, BIOCHEMISTRY-US, V44, P8684, DOI 10.1021/bi050009j; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Omi R, 2004, ACTA CRYSTALLOGR D, V60, P574, DOI 10.1107/S0907444904000277; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; Peeraer Y, 2004, EUR J BIOCHEM, V271, P3421, DOI 10.1111/j.0014-2956.2004.04277.x; Peisach E, 2004, BIOCHEMISTRY-US, V43, P12770, DOI 10.1021/bi0490688; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rinaldo-Matthis A, 2002, NAT STRUCT BIOL, V9, P779, DOI 10.1038/nsb846; ROTH JR, 1981, J MOL BIOL, V145, P697, DOI 10.1016/0022-2836(81)90310-7; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Selengut JD, 2001, BIOCHEMISTRY-US, V40, P12704, DOI 10.1021/bi011405e; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Shin DH, 2003, PROTEIN SCI, V12, P1464, DOI 10.1110/ps.0302703; Sinha SC, 2004, J BIOL CHEM, V279, P15491, DOI 10.1074/jbc.M312733200; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Winkler ME, 1996, ESCHERICHIA COLI SAL, P485; Yang W, 2006, MOL CELL, V22, P5, DOI 10.1016/j.molcel.2006.03.013	45	34	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37930	37941		10.1074/jbc.M604916200	http://dx.doi.org/10.1074/jbc.M604916200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16966333	hybrid			2022-12-25	WOS:000242477100072
J	Kanneganti, TD; Body-Malapel, M; Amer, A; Park, JH; Whitfield, J; Franchi, L; Taraporewala, ZF; Miller, D; Patton, JT; Inohara, N; Nunez, G				Kanneganti, Thirumala-Devi; Body-Malapel, Mathilde; Amer, Amal; Park, Jong-Hwan; Whitfield, Joel; Franchi, Luigi; Taraporewala, Zenobia F.; Miller, David; Patton, John T.; Inohara, Naohiro; Nunez, Gabriel			Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; VACCINIA VIRUS-INFECTION; NF-KAPPA-B; ANTIVIRAL RESPONSE; HUMAN MACROPHAGES; GENE-EXPRESSION; RIG-I; IMMUNITY; INFLAMMASOME; INNATE	Viralinfection induces the production of interleukin (IL)-1 ss and IL-18 in macrophages through the activation of caspase-1, but the mechanism by which host cells sense viruses to induce caspase-1 activation is unknown. In this report, we have identified a signaling pathway leading to caspase-1 activation that is induced by double-stranded RNA (dsRNA) and viral infection that is mediated by Cryopyrin/Nalp3. Stimulation of macrophages with dsRNA, viral RNA, or its analog poly(I:C) induced the secretion of IL-1 ss and IL-18 in a cryopyrin-dependent manner. Consistently, caspase-1 activation triggered by poly(I:C), dsRNA, and viral RNA was abrogated in macrophages lacking cryopyrin or the adaptor ASC (apoptosis-associated speck-like protein containing a caspase-activating and recruitment domain) but proceeded normally in macrophages deficient in Toll-like receptor 3 or 7. We have also shown that infection with Sendai and influenza viruses activates the cryopyrin inflammasome. Finally, cryopyrin was required for IL-1 ss production in response to poly(I:C) in vivo. These results identify a mechanism mediated by cryopyrin and ASC that links dsRNA and viral infection to caspase-1 activation resulting in IL-1 ss and IL-18 production.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4215 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bclx@umich.edu	Amer, Amal/E-2643-2011; Nuñez, Gabriel/A-7160-2014; Kanneganti, Thirumala-Devi/M-9435-2018; Kanneganti, Thirumala-Devi/Y-2503-2019; Body-Malapel, Mathilde/K-9981-2018; Patton, John T/P-1390-2014; Patton, John/V-7651-2018	Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Body-Malapel, Mathilde/0000-0003-3392-4229; Patton, John/0000-0003-1572-0732	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI064748, AI063331] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063331, R56AI063331, Z01AI000754, R01AI064748, R37AI063331] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BALL LA, 1994, P NATL ACAD SCI USA, V91, P12443, DOI 10.1073/pnas.91.26.12443; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; Dowds TA, 2004, J BIOL CHEM, V279, P21924, DOI 10.1074/jbc.M401178200; DUNN JJ, 1982, GENE, V245, P213; Fujioka N, 1999, J VIROL, V73, P2401, DOI 10.1128/JVI.73.3.2401-2409.1999; Gherardi MM, 2003, J GEN VIROL, V84, P1961, DOI 10.1099/vir.0.19120-0; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Johnston JB, 2005, IMMUNITY, V23, P587, DOI 10.1016/j.immuni.2005.10.003; Julkunen I, 2001, CYTOKINE GROWTH F R, V12, P171, DOI 10.1016/S1359-6101(00)00026-5; Kampmueller KM, 2005, J VIROL, V79, P6827, DOI 10.1128/JVI.79.11.6827-6837.2005; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Liu BX, 2004, J GEN VIROL, V85, P423, DOI 10.1099/vir.0.19596-0; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Netea MG, 2000, EUR J IMMUNOL, V30, P3057, DOI 10.1002/1521-4141(200010)30:10<3057::AID-IMMU3057>3.0.CO;2-P; Ozoren N, 2006, J IMMUNOL, V176, P4337, DOI 10.4049/jimmunol.176.7.4337; Patton JT, 1996, J VIROL, V70, P3961, DOI 10.1128/JVI.70.6.3961-3971.1996; Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615; Pirhonen J, 2001, EUR J IMMUNOL, V31, P726, DOI 10.1002/1521-4141(200103)31:3<726::AID-IMMU726>3.0.CO;2-5; Pirhonen J, 1999, J IMMUNOL, V162, P7322; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stojanov S, 2005, CURR OPIN RHEUMATOL, V17, P586, DOI 10.1097/bor.0000174210.78449.6b; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Takaoka A, 2003, CANCER SCI, V94, P405, DOI 10.1111/j.1349-7006.2003.tb01455.x; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Tanaka-Kataoka M, 1999, CYTOKINE, V11, P593, DOI 10.1006/cyto.1998.0453; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Xiang Y, 1999, P NATL ACAD SCI USA, V96, P11537, DOI 10.1073/pnas.96.20.11537; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	58	524	542	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36560	36568		10.1074/jbc.M607594200	http://dx.doi.org/10.1074/jbc.M607594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17008311	hybrid			2022-12-25	WOS:000242220800012
J	Suzuki, H; Ohnishi, Y; Furusho, Y; Sakuda, S; Horinouchi, S				Suzuki, Hirokazu; Ohnishi, Yasuo; Furusho, Yasuhide; Sakuda, Shohei; Horinouchi, Sueharu			Novel benzene ring biosynthesis from C-3 and C-4 primary metabolites by two enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III POLYKETIDE SYNTHASES; 3-AMINO-4-HYDROXYBENZOIC ACID; CRYSTAL-STRUCTURE; STREPTOMYCES; EXPRESSION; MANUMYCIN; PATHWAY; GENE; SEMIALDEHYDE; ASUKAMYCIN	The shikimate pathway, including seven enzymatic steps for production of chorismate via shikimate from phosphoenolpyruvate and erythrose-4-phosphate, is common in various organisms for the biosynthesis of not only aromatic amino acids but also most biogenic benzene derivatives. 3-Amino-4-hydroxybenzoic acid (3,4-AHBA) is a benzene derivative serving as a precursor for several secondary metabolites produced by Streptomyces, including grixazone produced by Streptomyces griseus. Our study on the biosynthesis pathway of grixazone led to identification of the biosynthesis pathway of 3,4-AHBA from two primary metabolites. Two genes, griI and griH, within the grixazone biosynthesis gene cluster were found to be responsible for the biosynthesis of 3,4-AHBA; the two genes conferred the in vivo production of 3,4-AHBA even on Escherichia coli. In vitro analysis showed that GriI catalyzed aldol condensation between two primary metabolites, L-aspartate-4-semialdehyde and dihydroxyacetone phosphate, to form a 7-carbon product, 2-amino4,5-dihydroxy-6-one-heptanoic acid-7-phosphate, which was subsequently converted to 3,4-AHBA by GriH. The latter reaction required Mn2+ ion but not any cofactors involved in reduction or oxidation. This pathway is independent of the shikimate pathway, representing a novel, simple enzyme system responsible for the synthesis of a benzene ring from the C-3 and C-4 primary metabolites.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp	Suzuki, Hirokazu/AAG-2285-2020	Suzuki, Hirokazu/0000-0002-9507-6467; Sakuda, Shohei/0000-0001-7966-1167; Ohnishi, Yasuo/0000-0001-7633-9236				Arakawa K, 2002, J AM CHEM SOC, V124, P10644, DOI 10.1021/ja0206339; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; BLACK S, 1955, J BIOL CHEM, V213, P39; Carpenter EP, 1998, NATURE, V394, P299, DOI 10.1038/28431; Copeland RA, 2000, ENZYMES PRACTICAL IN, P109; Funa N, 2006, P NATL ACAD SCI USA, V103, P6356, DOI 10.1073/pnas.0511227103; Gould SJ, 1996, J AM CHEM SOC, V118, P9228, DOI 10.1021/ja9524356; HILLIS LR, 1985, J AM CHEM SOC, V107, P4593, DOI 10.1021/ja00301a061; HOWPOOD DA, 1985, GENETIC MANIPULATION; Hu YD, 2004, J AM CHEM SOC, V126, P3837, DOI 10.1021/ja039336+; Hu YD, 1997, J AM CHEM SOC, V119, P4301, DOI 10.1021/ja9701016; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; Knaggs AR, 2003, NAT PROD REP, V20, P119, DOI 10.1039/b100399m; Li YF, 2000, TETRAHEDRON LETT, V41, P5181, DOI 10.1016/S0040-4039(00)00772-3; Lorentzen E, 2003, J BIOL CHEM, V278, P47253, DOI 10.1074/jbc.M305922200; Maniatis T., 1982, MOL CLONING LAB MANU; Martyn DC, 2003, ORG BIOMOL CHEM, V1, P2103, DOI 10.1039/b302411c; Ohnishi Y, 2004, J ANTIBIOT, V57, P218, DOI 10.7164/antibiotics.57.218; Rascher A, 2005, APPL ENVIRON MICROB, V71, P4862, DOI 10.1128/AEM.71.8.4862-4871.2005; Suzuki H, 2006, J BIOL CHEM, V281, P824, DOI 10.1074/jbc.M505806200; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; THIERICKE R, 1990, J AM CHEM SOC, V112, P3979, DOI 10.1021/ja00166a039; Wang XL, 2001, PLANT PHYSIOL, V125, P1778, DOI 10.1104/pp.125.4.1778; Westwood IM, 2005, BIOCHEM J, V385, P605, DOI 10.1042/BJ20041330; White RH, 2004, BIOCHEMISTRY-US, V43, P7618, DOI 10.1021/bi0495127; Woodard RW, 2004, BIOORG CHEM, V32, P309, DOI 10.1016/j.bioorg.2004.06.003; Yeh JI, 2002, BIOCHEMISTRY-US, V41, P11649, DOI 10.1021/bi026292t	27	56	65	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36944	36951		10.1074/jbc.M608103200	http://dx.doi.org/10.1074/jbc.M608103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17003031	hybrid			2022-12-25	WOS:000242220800054
J	Herbert, SP; Walker, JH				Herbert, Shane P.; Walker, John H.			Group VIA calcium-independent phospholipase A(2) mediates endothelial cell S phase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED DISCRIMINATION; ARACHIDONIC-ACID METABOLISM; SIGNAL-TRANSDUCTION; DNA-REPLICATION; CYCLIN-A; A(2); PROLIFERATION; ANGIOGENESIS; GROWTH; INHIBITION	Arachidonic acid and its metabolites have been previously implicated in the regulation of endothelial cell proliferation. Arachidonic acid may be liberated from cellular phospholipids by the action of group VIA calcium-independent phospholipase A(2) (iPLA(2)-VIA). Consequently, we tested the hypothesis that iPLA(2)-VIA activity is linked to the regulation of endothelial cell proliferation. Inhibition of iPLA(2) activity by bromoenol lactone (BEL) was sufficient to entirely block endothelial cell growth. BEL dose-dependently inhibited endothelial cell DNA synthesis in a manner that was reversed upon the exogenous addition of arachidonic acid. DNA synthesis was inhibited by the S-isomer and not by the R-isomer of BEL, demonstrating that endothelial cell proliferation is mediated specifically by iPLA(2)-VIA. iPLA(2)-VIA activity was critical to the progression of endothelial cells through S phase and is required for the expression of the cyclin A/cdk2 complex. Thus, inhibition of iPLA(2)-VIA blocks S phase progression and results in exit from the cell cycle. Inhibition of iPLA(2)-VIA-mediated endothelial cell proliferation is sufficient to block angiogenic tubule formation in co-culture assays. Consequently, iPLA(2)-VIA is a novel regulator of endothelial cell S phase progression, cell cycle residence, and angiogenesis.	Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Walker, JH (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England.	j.h.walker@leeds.ac.uk		Herbert, Shane/0000-0003-2517-1845				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Akiba S, 2004, BIOL PHARM BULL, V27, P1174, DOI 10.1248/bpb.27.1174; Antoniotti S, 2003, J CELL PHYSIOL, V197, P370, DOI 10.1002/jcp.10359; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Bao SZ, 2006, J BIOL CHEM, V281, P187, DOI 10.1074/jbc.M509105200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Choudhury QG, 2000, BRIT J PHARMACOL, V131, P255, DOI 10.1038/sj.bjp.0703573; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GERDES J, 1984, J IMMUNOL, V133, P1710; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Herbert SP, 2005, MOL BIOL CELL, V16, P3800, DOI 10.1091/mbc.E05-02-0164; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; Howell GJ, 2004, MOL MEMBR BIOL, V21, P413, DOI 10.1080/09687860400011571; Jackson CJ, 1997, INT J BIOCHEM CELL B, V29, P1167, DOI 10.1016/S1357-2725(97)00061-7; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Ma ZM, 2001, LIPIDS, V36, P689, DOI 10.1007/s11745-001-0774-9; Manguikian AD, 2004, J BIOL CHEM, V279, P52881, DOI 10.1074/jbc.M410659200; McHowat J, 2001, BIOCHEMISTRY-US, V40, P14921, DOI 10.1021/bi0156153; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Rickard A, 2005, AM J PHYSIOL-RENAL, V288, pF714, DOI 10.1152/ajprenal.00288.2004; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Sanchez T, 2002, J CELL PHYSIOL, V193, P293, DOI 10.1002/jcp.10162; Sanchez T, 2001, BIOCHEM PHARMACOL, V61, P811, DOI 10.1016/S0006-2952(01)00555-X; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Staton CA, 2004, INT J EXP PATHOL, V85, P233, DOI 10.1111/j.0959-9673.2004.00396.x; TAKAHASHI T, 1993, J NEUROCYTOL, V22, P1096, DOI 10.1007/BF01235751; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANE JR, 1990, NEW ENGL J MED, V323, P27; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200	48	30	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35709	35716		10.1074/jbc.M600699200	http://dx.doi.org/10.1074/jbc.M600699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16966332	hybrid			2022-12-25	WOS:000242100500015
J	Lamant, M; Smih, F; Harmancey, R; Philip-Couderc, P; Pathak, A; Roncalli, J; Galinier, M; Collet, X; Massabuau, P; Senard, JM; Rouet, P				Lamant, Matthieu; Smih, Fatima; Harmancey, Romain; Philip-Couderc, Pierre; Pathak, Atul; Roncalli, Jerome; Galinier, Michel; Collet, Xavier; Massabuau, Pierre; Senard, Jean-Michel; Rouet, Philippe			ApoO, a novel apolipoprotein, is an original glycoprotein up-regulated by diabetes in human heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LINKED MENTAL-RETARDATION; B-CONTAINING LIPOPROTEINS; A-I; CARDIOVASCULAR-DISEASE; CELLULAR CHOLESTEROL; CHONDROITIN SULFATE; LIPID-ACCUMULATION; OBESITY; CELLS	Obesity is an independent risk factor for cardiac failure. Obesity promotes excessive deposition of fat in adipose and nonadipose tissues. Intramyocardial lipid overload is a relatively common finding in nonischemic heart failure, especially in obese and diabetic patients, and promotes lipoapoptosis that contributes to the alteration of cardiac function. Lipoprotein production has been proposed as a heart-protective mechanism through the unloading of surplus cellular lipids. We previously analyzed the heart transcriptome in a dog nutritional model of obesity, and we identified a new apolipoprotein, regulated by obesity in heart, which is the subject of this study. We detected this new protein in the following lipoproteins: high density lipoprotein, low density lipoprotein, and very low density lipoprotein. We designated it apolipoprotein O. Apolipoprotein O is a 198-amino acid protein that contains a 23-amino acid-long signal peptide. The apolipoprotein O gene is expressed in a set of human tissues. Confocal immunofluorescence microscopy colocalized apolipoprotein O and perilipins, a cellular marker of the lipid droplet. Chondroitinase ABC deglycosylation analysis or cell incubation with p-nitrophenyl-beta-D-xyloside indicated that apolipoprotein O belongs to the proteoglycan family. Naringenin or CP-346086 treatments indicated that apolipoprotein O secretion requires microsomal triglyceride transfer protein activity. Apolipoprotein O gene expression is up-regulated in the human diabetic heart. Apolipoprotein O promoted cholesterol efflux from macrophage cells. To our knowledge, apolipoprotein O is the first chondroitin sulfate chain containing apolipoprotein. Apolipoprotein O may be involved in myocardium-protective mechanisms against lipid accumulation, or it may have specific properties mediated by its unique glycosylation pattern.	UPS, CHU Rangueil, Unite Rech Obes, INSERM,U586,Inst Louis Bugnard,IFR 31, F-31432 Toulouse 4, France; Hop Purpan, INSERM, U563, F-31432 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Rouet, P (corresponding author), Fac Med Toulouse, INSERM, U586, Lab Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31073 Toulouse, France.	Philippe.rouet@Toulouse.inserm.fr	Pathak, Atul/ABC-5223-2020; Pathak, Atul/E-7532-2010; Collet, Xavier/M-6938-2017	Pathak, Atul/0000-0001-6151-0096; GALINIER, Michel/0000-0003-1735-3390; Senard, Jean-Michel/0000-0001-7679-1281; Rouet, Philippe/0000-0001-6204-2079				ARN P, 1994, HUM GENET, V93, P389; Basdevant A, 2000, ANN ENDOCRINOL-PARIS, V61, P6; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Bienvenu T, 2002, HUM MOL GENET, V11, P981, DOI 10.1093/hmg/11.8.981; Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200; Campos H, 2001, J LIPID RES, V42, P1239; CARPENTER HM, 1962, AM HEART J, V63, P491, DOI 10.1016/0002-8703(62)90305-8; Chandler CE, 2003, J LIPID RES, V44, P1887, DOI 10.1194/jlr.M300094-JLR200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Christoffersen C, 2003, ENDOCRINOLOGY, V144, P3483, DOI 10.1210/en.2003-0242; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; COLLET X, 1990, BIOCHIM BIOPHYS ACTA, V1043, P301, DOI 10.1016/0005-2760(90)90031-R; Contaldo F, 2002, NUTR METAB CARDIOVAS, V12, P190; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Daugherty DL, 1998, J BIOL CHEM, V273, P33961, DOI 10.1074/jbc.273.51.33961; Duk M, 1997, ANAL BIOCHEM, V253, P98, DOI 10.1006/abio.1997.9994; GALANAKIS DK, 1994, J CLIN INVEST, V93, P303, DOI 10.1172/JCI116960; Gambino R, 1999, CHEM PHYS LIPIDS, V103, P161, DOI 10.1016/S0009-3084(99)00108-5; HALL JE, 1993, HYPERTENSION, V22, P292, DOI 10.1161/01.HYP.22.3.292; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Harsha HC, 2005, NAT GENET, V37, P331, DOI 10.1038/ng0405-331; Hirabayashi J, 2002, J CHROMATOGR B, V771, P67, DOI 10.1016/S1570-0232(02)00057-0; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KAGAYA Y, 1990, CIRCULATION, V81, P1353, DOI 10.1161/01.CIR.81.4.1353; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lee Y, 2004, P NATL ACAD SCI USA, V101, P13624, DOI 10.1073/pnas.0405499101; LEE Y, 2001, J BIOL CHEM, V276, P5629; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Listenberger LL, 2002, TRENDS CARDIOVAS MED, V12, P134, DOI 10.1016/S1050-1738(02)00152-4; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; MYKKANEN L, 1993, DIABETOLOGIA, V36, P553, DOI 10.1007/BF02743273; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen LB, 2002, SCAND J CLIN LAB INV, V62, P35, DOI 10.1080/003655102762377475; Nielsen LB, 2002, J BIOL CHEM, V277, P27014, DOI 10.1074/jbc.M203458200; Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; O'Bryan MK, 2004, ENDOCRINOLOGY, V145, P5231, DOI 10.1210/en.2004-0630; Oganesyan Natalia, 2005, Journal of Structural and Functional Genomics, V6, P177, DOI 10.1007/s10969-005-2827-3; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; Oram JF, 1996, J LIPID RES, V37, P2473; Oynebraten I, 2000, J LEUKOCYTE BIOL, V67, P183, DOI 10.1002/jlb.67.2.183; Panagotopulos SE, 2002, PROTEIN EXPRES PURIF, V25, P353, DOI 10.1016/S1046-5928(02)00020-7; Philip-Couderc P, 2004, PHYSIOL GENOMICS, V19, P32, DOI 10.1152/physiolgenomics.00001.2004; Philip-Couderc P, 2003, HYPERTENSION, V41, P414, DOI 10.1161/01.HYP.0000057573.32425.95; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; ROUET P, 1992, J BIOL CHEM, V267, P20765; Sacks Frank M., 1994, Current Opinion in Lipidology, V5, P236, DOI 10.1097/00041433-199405030-00012; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Saphir O, 1933, ARCH INTERN MED, V52, P410, DOI 10.1001/archinte.1933.00160030071006; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9231; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sharma S, 2004, FASEB J, V18, P1692, DOI 10.1096/fj.04-2263com; Silva EPP, 2004, CELL BIOCHEM FUNCT, V22, P23, DOI 10.1002/cbf.1048; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; Smith HL, 1933, ARCH INTERN MED, V52, P911, DOI 10.1001/archinte.1933.00160060085007; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; Stromme P, 1999, J MED GENET, V36, P374; Su X, 2005, BIOCHEMISTRY-US, V44, P5234, DOI 10.1021/bi047773a; Szczepaniak LS, 2003, MAGN RESON MED, V49, P417, DOI 10.1002/mrm.10372; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Veniant MM, 1999, TRENDS CARDIOVAS MED, V9, P103, DOI 10.1016/S1050-1738(99)00011-0; Verwaerde P, 1999, J HYPERTENS, V17, P1135, DOI 10.1097/00004872-199917080-00013; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wilcox LJ, 2001, J LIPID RES, V42, P725; Williams KJ, 2001, CURR OPIN LIPIDOL, V12, P477, DOI 10.1097/00041433-200110000-00002; WOOD KM, 1976, BIOCHEM J, V158, P39, DOI 10.1042/bj1580039; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	75	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36289	36302		10.1074/jbc.M510861200	http://dx.doi.org/10.1074/jbc.M510861200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16956892	hybrid			2022-12-25	WOS:000242100500081
J	Nishiyama, KI; Ikegami, A; Moser, M; Schiltz, E; Tokuda, H; Muller, M				Nishiyama, Ken-ichi; Ikegami, Ayao; Moser, Michael; Schiltz, Emile; Tokuda, Hajime; Mueller, Matthias			A derivative of lipid A is involved in signal recognition particle/SecYEG-dependent and -independent membrane integrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION ACTIVITY; COLI MANNITOL PERMEASE; F1F0 ATP SYNTHASE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; PURIFIED COMPONENTS; DIGLYCERIDE KINASE; SECRETORY PROTEINS; SECYEG TRANSLOCON; SUBUNIT-C	A cell-free system was developed that allows the correct integration of single and multispanning membrane proteins of Escherichia coli into proteoliposomes. We found that physiological levels of diacylglycerol were required to prevent spontaneous integration into liposomes even of the polytopic mannitol permease. Using diacylglycerol-containing proteoliposomes, we identified a novel integration-stimulating factor. Integration of mannitol permease was dependent on both the SecYEG translocon and this factor and was mediated by signal recognition particle and signal recognition particle receptor. Integration of M13 procoat, which is independent of both signal recognition particle/signal recognition particle receptor and SecYEG, was also promoted by this factor. Furthermore, the factor stimulated the post-translational translocation of presecretory proteins, suggesting that it also mediates integration of a signal sequence. This factor was found to be a lipid A-derived membrane component possessing a peptide moiety.	Univ Freiburg, Ctr Biochem & Mol Cell Res, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	University of Freiburg; University of Tokyo; University of Freiburg	Nishiyama, KI (corresponding author), Univ Freiburg, Ctr Biochem & Mol Cell Res, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	unishiy@mail.ecc.u-tokyo.ac.jp; matthias.mueller@biochemie.uni-freiburg.de						AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Angelini S, 2005, EMBO REP, V6, P476, DOI 10.1038/sj.embor.7400385; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Celebi N, 2006, J MOL BIOL, V357, P1428, DOI 10.1016/j.jmb.2006.01.030; CHANG YY, 1967, J BIOL CHEM, V242, P516; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; du Plessis DJF, 2006, J BIOL CHEM, V281, P12248, DOI 10.1074/jbc.M600048200; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; GELLER BL, 1985, J BIOL CHEM, V260, P3281; GERRITS PO, 1992, J NEUROSCI METH, V45, P99, DOI 10.1016/0165-0270(92)90047-H; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsumoto G, 2000, J BACTERIOL, V182, P3377, DOI 10.1128/JB.182.12.3377-3382.2000; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MONNER DA, 1971, J BACTERIOL, V107, P420, DOI 10.1128/JB.107.2.420-432.1971; MULLER M, 1987, EMBO J, V6, P3855, DOI 10.1002/j.1460-2075.1987.tb02723.x; Nagamori S, 2004, J CELL BIOL, V165, P53, DOI 10.1083/jcb.200402067; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; NISHIYAMA K, 1992, J BIOL CHEM, V267, P7170; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; RAETZ CRH, 1978, J BIOL CHEM, V253, P3882; ROTERING H, 1983, J BIOL CHEM, V258, P8068; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Soekarjo M, 1996, BIOCHEMISTRY-US, V35, P1232, DOI 10.1021/bi951087h; Spiekermann P, 1999, ARCH MICROBIOL, V171, P73, DOI 10.1007/s002030050681; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; SWIDERSKY UE, 1992, EUR J BIOCHEM, V207, P803, DOI 10.1111/j.1432-1033.1992.tb17111.x; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; van Bloois E, 2006, J BIOL CHEM, V281, P10002, DOI 10.1074/jbc.M511357200; van Dalen A, 2002, FEBS LETT, V511, P51, DOI 10.1016/S0014-5793(01)03278-1; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2004, J BIOL CHEM, V279, P1659, DOI 10.1074/jbc.M306527200; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; Vervoort EB, 2005, J MOL BIOL, V346, P733, DOI 10.1016/j.jmb.2004.12.011; WALSH JP, 1986, J BIOL CHEM, V261, P1021; WERNER PK, 1992, J BIOL CHEM, V267, P24523; Yi L, 2004, J BIOL CHEM, V279, P39260, DOI 10.1074/jbc.M405490200	56	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35667	35676		10.1074/jbc.M608228200	http://dx.doi.org/10.1074/jbc.M608228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008318	hybrid			2022-12-25	WOS:000242100500011
J	Sharma, N; Timmers, C; Trikha, P; Saavedra, HI; Obery, A; Leone, G				Sharma, Nidhi; Timmers, Cynthia; Trikha, Prashant; Saavedra, Harold I.; Obery, Amanda; Leone, Gustavo			Control of the p53-p21(CIP1) axis by E2f1, E2f2, and E2f3 is essential for G(1)/S progression and cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FAMILY; CYCLE PROGRESSION; DNA-REPLICATION; BLADDER-CANCER; PROLIFERATION; PROTEINS; GROWTH; ROLES; OVEREXPRESSION; AMPLIFICATION	The E2F family of transcription factors is believed to have an essential role in the control of cellular proliferation by regulating the transcription of genes involved in cell cycle progression. Previous work has demonstrated that the targeted inactivation of E2f1, E2f2, and E2f3 results in elevated p21(CIP1) protein levels, loss of E2F target gene expression, and cell cycle arrest at G(1)/S and G(2/)M, suggesting a strict requirement for these E2Fs in the control of normal cellular proliferation. We now demonstrate that E2f1, E2f2, and E2f3 are also required for oncogene-mediated transformation of mouse embryonic fibroblasts. Analysis of synchronized populations of mouse embryonic fibroblasts revealed that the inactivation of p21CIP1 restores the ability of E2f1-3-deficient cells to enter and transit through G(1)/S ( but not G(2)/M). In contrast, loss of p53 restored the ability of these cells to progress through both G(1)/S and mitosis, leading to their continued proliferation. The inactivation of p53 ( but not p21(CIP1)) rendered E2f1-3-deficient cells sensitive to transformation and tumorigenesis. These results suggest that the negative regulation of the p53-p21CIP1 axis by the E2F1-3 factors is critical for cell cycle progression and cellular transformation.	Ohio State Univ, Ctr Comprehens Canc, Dept Mol Genet,Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Leone, G (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Mol Genet,Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	gustavo.leone@osumc.edu	Obery, Amanda/B-5602-2017; Trikha, Prashant/B-5897-2012; Obery, Amanda/ABC-3452-2021	Obery, Amanda/0000-0002-5202-4798; Obery, Amanda/0000-0002-5202-4798	NCI NIH HHS [P01CA097189, R01CA82259, R01 CA85619, K01CA104079] Funding Source: Medline; NICHD NIH HHS [R01HD047470] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047470] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K01CA104079, R01CA082259, P01CA097189, R01CA085619] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cayirlioglu P, 2003, MOL CELL BIOL, V23, P2123, DOI 10.1128/MCB.23.6.2123-2134.2003; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; He SS, 2004, PLANT MOL BIOL, V56, P171, DOI 10.1007/s11103-004-2748-8; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VEYLDER LD, 2002, EMBO J, V21, P1360; WEINBERG RA, 1989, CANCER RES, V49, P3713; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	32	55	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36124	36131		10.1074/jbc.M604152200	http://dx.doi.org/10.1074/jbc.M604152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008321	hybrid			2022-12-25	WOS:000242100500062
J	Amiott, EA; Jaehning, JA				Amiott, Elizabeth A.; Jaehning, Judith A.			Sensitivity of the yeast mitochondrial RNA polymerase to+1 and+2 initiating nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SPECIFICITY FACTOR; TRANSCRIPTION INITIATION; CHAIN INITIATION; PROMOTER; BACTERIOPHAGE-T7; MECHANISM; KINETICS	Despite a simple consensus sequence, there is considerable variation of promoter strengths, transcription rates, and the kinetics of initiating nucleotide incorporation among the promoters found in the Saccharomyces cerevisiae mitochondrial genome. We asked how changes in the initiating (+1 and +2) nucleotides, conformation of the promoter DNA template, and mutation of the mitochondrial RNA polymerase (mtRNAP) affect the kinetics of nucleotide (NTP) utilization. Using a highly purified in vitro mitochondrial transcription system, we found that 1) the mtRNAP requires the highest concentrations of the +1 and +2 initiating NTPs, intermediate concentrations of NTPs at positions 5 to 11, and low concentrations of elongating NTPs; 2) the mtRNAP requires a higher concentration of the +2 NTP than the +1 NTP for initiation; 3) the kinetics of +2 NTP utilization are altered by a point mutation in the mtRNAP subunit Mtf1; and 4) a supercoiled or pre-melted promoter DNA template restores normal +2 NTP utilization by the Mtf1 mutant. Based on comparisons to the structural and biochemical properties of the bacterial RNAP and the closely related T7 RNAP, we propose that initiating nucleotides, particularly the +2 NTP, are required at high concentrations to drive mitochondrial promoter opening or to stabilize a productive open complex.	Univ Colorado, Dept Biochem & Mol Genet, Denver, CO 80202 USA; Hlth Sci Ctr, Aurora, CO 80045 USA; Univ Colorado, Program Mol Biol, Denver, CO 80202 USA	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Jaehning, JA (corresponding author), Univ Colorado, Dept Biochem & Mol Genet, Mail Stop 8101,POB 6511, Denver, CO 80202 USA.	Judith.Jaehning@UCHSC.edu						Amiott EA, 2006, MOL CELL, V22, P329, DOI 10.1016/j.molcel.2006.03.031; Biswas TK, 1999, BIOCHEMISTRY-US, V38, P9693, DOI 10.1021/bi982804l; BISWAS TK, 1986, P NATL ACAD SCI USA, V83, P270, DOI 10.1073/pnas.83.2.270; BISWAS TK, 1990, P NATL ACAD SCI USA, V87, P9338, DOI 10.1073/pnas.87.23.9338; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; BISWAS TK, 1985, P NATL ACAD SCI USA, V82, P1954, DOI 10.1073/pnas.82.7.1954; Cliften PF, 1997, GENE DEV, V11, P2897, DOI 10.1101/gad.11.21.2897; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Huang JB, 1999, J MOL BIOL, V293, P457, DOI 10.1006/jmbi.1999.3135; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JANG SH, 1991, J BIOL CHEM, V266, P22671; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; Karlok MA, 2002, J BIOL CHEM, V277, P28143, DOI 10.1074/jbc.M204123200; KELLY JL, 1986, J BIOL CHEM, V261, P348; Kuzmine I, 2001, J MOL BIOL, V305, P559, DOI 10.1006/jmbi.2000.4316; Lew CM, 2004, BIOCHEMISTRY-US, V43, P12660, DOI 10.1021/bi0492814; Lew CM, 2004, J BIOL CHEM, V279, P19481, DOI 10.1074/jbc.M401285200; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Matsunaga M, 2004, J BIOL CHEM, V279, P44239, DOI 10.1074/jbc.C400384200; Matsunaga M, 2004, PROTEIN EXPRES PURIF, V35, P126, DOI 10.1016/j.pep.2003.12.022; MCALLISTER WT, 1993, CELL MOL BIOL RES, V39, P385; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; MUELLER DM, 1986, J BIOL CHEM, V261, P1756; NIERMAN WC, 1979, J BIOL CHEM, V254, P7921; NIERMAN WC, 1980, J BIOL CHEM, V255, P1819; Paul BJ, 2004, CELL, V118, P311, DOI 10.1016/j.cell.2004.07.009; Schneider DA, 2003, CURR OPIN MICROBIOL, V6, P151, DOI 10.1016/S1369-5274(03)00038-9; Schneider DA, 2002, P NATL ACAD SCI USA, V99, P8602, DOI 10.1073/pnas.132285199; Schubot FD, 2001, PROTEIN SCI, V10, P1980, DOI 10.1110/ps.11201; Shadel GS, 2004, TRENDS GENET, V20, P513, DOI 10.1016/j.tig.2004.08.005; Stano NM, 2004, J BIOL CHEM, V279, P16136, DOI 10.1074/jbc.M400139200; Stano NM, 2002, J BIOL CHEM, V277, P37292, DOI 10.1074/jbc.M201600200; ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; WETTSTEINEDWARDS J, 1986, J BIOL CHEM, V261, P2905; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214	38	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34982	34988		10.1074/jbc.M608638200	http://dx.doi.org/10.1074/jbc.M608638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17003030	hybrid			2022-12-25	WOS:000241933700031
J	Kujawa, M; Ebner, H; Leitner, C; Hallberg, BM; Prongjit, M; Sucharitakul, J; Ludwig, R; Rudsander, U; Peterbauer, C; Chaiyen, P; Haltrich, D; Divne, C				Kujawa, Magdalena; Ebner, Heidemarie; Leitner, Christian; Hallberg, B. Martin; Prongjit, Methinee; Sucharitakul, Jeerus; Ludwig, Roland; Rudsander, Ulla; Peterbauer, Clemens; Chaiyen, Pimchai; Haltrich, Dietmar; Divne, Christina			Structural basis for substrate binding and regioselective oxidation of monosaccharides at C3 by pyranose 2-oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER FLAVOPROTEIN; P-CRESOL METHYLHYDROXYLASE; FUNGUS TRAMETES-MULTICOLOR; CRYSTAL-STRUCTURE; PHANEROCHAETE-CHRYSOSPORIUM; CELLOBIOSE DEHYDROGENASE; ALCOHOL OXIDASE; COVALENT FLAVINYLATION; CATALYTIC MECHANISM; LIGNIN DEGRADATION	Pyranose2-oxidase(P2Ox) participates in fungal lignin degradation by producing the H2O2 needed for lignin-degrading peroxidases. The enzyme oxidizes cellulose- and hemicellulose-derived aldopyranoses at C2 preferentially, but also on C3, to the corresponding ketoaldoses. To investigate the structural determinants of catalysis, covalent flavinylation, substrate binding, and regios-electivity, wild-type and mutant P2Ox enzymes were produced and characterized biochemically and structurally. Removal of the histidyl-FAD linkage resulted in a catalytically competent enzyme containing tightly, but noncovalently bound FAD. This mutant (H167A) is characterized by a 5-fold lower k(cat), and a 35-mV lower redox potential, although no significant structural changes were seen in its crystal structure. In previous structures of P2Ox, the substrate loop (residues 452-457) covering the active site has been either disordered or in a conformation incompatible with carbohydrate binding. We present here the crystal structure of H167A in complex with a slow substrate, 2-fluoro-2-deoxy-D-glucose. Based on the details of 2-fluoro-2-deoxy-D-glucose binding in position for oxidation at C3, we also outline a probable binding mode for D-glucose positioned for regioselective oxidation at C2. The tentative determinant for discriminating between the two binding modes is the position of the O6 hydroxyl group, which in the C2-oxidation mode can make favorable interactions with Asp(452) in the substrate loop and, possibly, a nearby arginine residue (Arg(472)). We also substantiate our hypothesis with steady-state kinetics data for the alanine replacements of Asp(452) and Arg(472) as well as the double alanine 452/472 mutant.	Royal Inst Technol, Sch Biotechnol, Albanova Univ Ctr, SE-10691 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand; Mahidol Univ, Fac Sci, Ctr Excellence Prot Struct & Funct, Bangkok 10400, Thailand; Univ Nat Resources & Appl Life Sci, Dept Food Sci & Technol, A-1190 Vienna, Austria	Royal Institute of Technology; Karolinska Institutet; Mahidol University; Mahidol University; University of Natural Resources & Life Sciences, Vienna	Divne, C (corresponding author), Royal Inst Technol, Sch Biotechnol, Albanova Univ Ctr, SE-10691 Stockholm, Sweden.	divne@biotech.kth.se	Haltrich, Dietmar/N-2624-2019; Chaiyen, Pimchai/R-5052-2019; Chaiyen, Pimchai/A-8236-2010; Divne, Christina/E-8646-2010; Hallberg, B. Martin/C-5361-2009	Haltrich, Dietmar/0000-0002-8722-8176; Chaiyen, Pimchai/0000-0002-8533-1604; Divne, Christina/0000-0002-5805-2693; Hallberg, B. Martin/0000-0002-6781-0345; Ludwig, Roland/0000-0002-5058-5874; Peterbauer, Clemens/0000-0002-8033-198X	Austrian Science Fund FWF [L 213] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Albrecht M, 2003, BIOINFORMATICS, V19, P1216, DOI 10.1093/bioinformatics/btg140; Ander P, 1997, J BIOTECHNOL, V53, P115, DOI 10.1016/S0168-1656(97)01680-5; Artolozaga MJ, 1997, APPL MICROBIOL BIOT, V47, P508, DOI 10.1007/s002530050964; Ausubel F.M., 2002, SHORT PROTOCOLS MOL, V1; Bannwarth M, 2004, BIOCHEMISTRY-US, V43, P11683, DOI 10.1021/bi048609q; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; DANIEL G, 1994, APPL ENVIRON MICROB, V60, P2524, DOI 10.1128/AEM.60.7.2524-2532.1994; DANNEEL HJ, 1993, EUR J BIOCHEM, V214, P795, DOI 10.1111/j.1432-1033.1993.tb17982.x; Efimov I, 2004, BIOCHEMISTRY-US, V43, P10532, DOI 10.1021/bi049375d; Efimov I, 2001, BIOCHEMISTRY-US, V40, P2155, DOI 10.1021/bi001644m; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fan F, 2005, J AM CHEM SOC, V127, P2067, DOI 10.1021/ja044541q; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Freimund S, 1998, CHEM-EUR J, V4, P2442, DOI 10.1002/(SICI)1521-3765(19981204)4:12<2442::AID-CHEM2442>3.3.CO;2-1; Ghanem M, 2005, BIOCHEMISTRY-US, V44, P893, DOI 10.1021/bi048056j; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; Halada P, 2003, ANAL BIOCHEM, V314, P235, DOI 10.1016/S0003-2697(02)00661-9; Hallberg BM, 2004, J MOL BIOL, V341, P781, DOI 10.1016/j.jmb.2004.06.033; Hallberg BM, 2004, ACTA CRYSTALLOGR D, V60, P197, DOI 10.1107/S0907444903024922; Hallberg BM, 2003, J BIOL CHEM, V278, P7160, DOI 10.1074/jbc.M210961200; Hallberg BM, 2002, J MOL BIOL, V315, P421, DOI 10.1006/jmbi.2001.5246; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Leitner C, 2001, APPL ENVIRON MICROB, V67, P3636, DOI 10.1128/AEM.67.8.3636-3644.2001; Leitner C, 1998, APPL BIOCHEM BIOTECH, V70-2, P237, DOI 10.1007/BF02920140; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MENON V, 1995, BIOORG CHEM, V23, P42, DOI 10.1006/bioo.1995.1004; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; Rotsaert FAJ, 2003, BIOCHEMISTRY-US, V42, P4049, DOI 10.1021/bi027092k; Salazar D, 1997, J BIOL CHEM, V272, P26425, DOI 10.1074/jbc.272.42.26425; Schafer A, 1996, APPL ENVIRON MICROB, V62, P2586, DOI 10.1128/AEM.62.7.2586-2592.1996; ten Have R, 2001, CHEM REV, V101, P3397, DOI 10.1021/cr000115l; Vecerek B, 2004, APPL MICROBIOL BIOT, V64, P525, DOI 10.1007/s00253-003-1516-z; Volc J, 1996, ARCH MICROBIOL, V165, P421, DOI 10.1007/s002030050348; VOLC J, 1985, FOLIA MICROBIOL, V30, P141, DOI 10.1007/BF02922207; Volc Jindrich, 1995, Carbohydrate Research, V278, P59, DOI 10.1016/0008-6215(95)00247-3; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9	44	70	72	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35104	35115		10.1074/jbc.M604718200	http://dx.doi.org/10.1074/jbc.M604718200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984920	hybrid			2022-12-25	WOS:000241933700044
J	Peters, GA; Li, SD; Sen, GC				Peters, Gregory A.; Li, Shoudong; Sen, Ganes C.			Phosphorylation of specific serine residues in the PKR activation domain of PACT is essential for its ability to mediate apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PROTEIN-KINASE PKR; NF-KAPPA-B; IN-VITRO; CELLULAR ACTIVATOR; INTERFERON; BINDING; STRESS; PATHWAYS; INHIBITION	Activation of the latent protein kinase, PKR, by extracellular stresses and triggering of resultant cellular apoptosis are mediated by the protein, PACT, which itself gets phosphorylated in stressed cells. We have analyzed the underlying biochemical mechanism by carrying out alanine-scanning mutagenesis of the PKR activation domain of PACT. Among the indispensable residues identified were two serine residues, whose phosphorylation was essential for the cellular actions of PACT. Two-dimensional gel analysis, Western analysis using phosphoamino acid-specific antiserum, and in vivo P-32 labeling of PACT demonstrated that constitutive phosphorylation of one of the two residues, Ser(246), was required for stress-induced phosphorylation of the other, Ser(287). Substitution of either of them by threonine or aspartic acid, but not alanine, was tolerated. Substitution of both residues with the phosphoserine mimetic, aspartic acid, produced a mutant PACT that, unlike the wild-type protein, caused PKR activation and apoptosis, even in unstressed cells. These results indicate that phosphorylation of specific serine residues in the activation domain of PACT is the major mode of transmission of cellular stress response to PKR.	Cleveland Clin Fdn, Dept Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Grad Program Mol Virol, Sch Med, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Sen, GC (corresponding author), Cleveland Clin Fdn, Dept Mol Genet, Lerner Res Inst, NE 20,9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org		Peters, Gregory/0000-0001-6914-7316	NCI NIH HHS [CA-68782, R01 CA068782, P01 CA062220, CA-62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068782, P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett RL, 2004, J BIOL CHEM, V279, P42687, DOI 10.1074/jbc.M403321200; BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DACQUISTO F, 2001, SCI STKE; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Li SD, 2006, P NATL ACAD SCI USA, V103, P10005, DOI 10.1073/pnas.0602317103; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peters GA, 2002, J VIROL, V76, P11054, DOI 10.1128/JVI.76.21.11054-11064.2002; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Pogulis R J, 1996, Methods Mol Biol, V57, P167; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Rowe TM, 2006, P NATL ACAD SCI USA, V103, P5823, DOI 10.1073/pnas.0601287103; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Williams B.R., 2001, SCI STKE, V2001, pre2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000	27	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35129	35136		10.1074/jbc.M607714200	http://dx.doi.org/10.1074/jbc.M607714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982605	hybrid			2022-12-25	WOS:000241933700046
J	Tarutina, M; Ryjenkov, DA; Gomelsky, M				Tarutina, Marina; Ryjenkov, Dmitri A.; Gomelsky, Mark			An unorthodox bacteriophytochrome from Rhodobacter sphaeroides involved in turnover of the second messenger c-di-GMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC DIGUANYLIC ACID; ACETOBACTER-XYLINUM; CYCLIC DIGUANYLATE; AGROBACTERIUM-TUMEFACIENS; PHYTOCHROME SUPERFAMILY; CELLULOSE SYNTHESIS; ALLOSTERIC CONTROL; HISTIDINE KINASES; PROTEIN DOMAIN; LIGHT	Bacteriophytochromes are bacterial photoreceptors that sense red/far red light using the biliverdin chromophore. Most bacteriophytochromes work as photoactivated protein kinases. The Rhodobacter sphaeroides bacteriophytochrome BphG1 is unconventional in that it has GGDEF and EAL output domains, which are involved, respectively, in synthesis (diguanylate cyclase) and degradation (phosphodiesterase) of the bacterial second messenger c-di-GMP. The GGDEF-EAL proteins studied to date displayed either diguanylate cyclase or phosphodiesterase activity but not both. To elucidate the function of BphG1, the holoprotein was purified from an Escherichia coli overexpression system designed to produce biliverdin. The holoprotein contained covalently bound biliverdin and interconverted between the red (dark) and far red (light-activated) forms. BphG1 had c-di-GMP-specific phosphodiesterase activity. Unexpectedly for a photochromic protein, this activity was essentially light-independent. BphG1 expressed in E. coli was found to undergo partial cleavage into two species. The smaller species was identified as the EAL domain of BphG1. It possessed c-di-GMP phosphodiesterase activity. Surprisingly, the larger species lacking EAL possessed diguanylate cyclase activity, which was dependent on biliverdin and strongly activated by light. BphG1 therefore is the first phytochrome with a non-kinase photoactivated enzymatic activity. This shows that the photosensory modules of phytochromes can transmit light signals to various outputs. BphG1 is potentially the first "bifunctional" enzyme capable of both c-di-GMP synthesis and hydrolysis. A model for the regulation of the "opposite" activities of BphG1 is presented.	Univ Wyoming, Dept Mol Biol, Dept 3944, Laramie, WY 82071 USA	University of Wyoming	Gomelsky, M (corresponding author), Univ Wyoming, Dept Mol Biol, Dept 3944, 1000 E Univ Ave, Laramie, WY 82071 USA.	gomelsky@uwyo.edu	Tarutina, Marina/AAG-1691-2021; gomelsky, mark/F-6209-2010	Gomelsky, Mark/0000-0003-4077-3932				AMIKAM D, 1995, BIOCHEM J, V311, P921, DOI 10.1042/bj3110921; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Braslavsky SE, 1997, PLANT CELL ENVIRON, V20, P700, DOI 10.1046/j.1365-3040.1997.d01-101.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Chen M, 2005, CURR BIOL, V15, P637, DOI 10.1016/j.cub.2005.02.028; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Esteban B, 2005, BIOCHEMISTRY-US, V44, P450, DOI 10.1021/bi0484365; Franklin KA, 2005, INT J DEV BIOL, V49, P653, DOI 10.1387/ijdb.051989kf; Galperin MY, 2005, ASM NEWS, V71, P326; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Galperin MY, 2004, ENVIRON MICROBIOL, V6, P552, DOI 10.1111/j.1462-2920.2004.00633.x; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; Giraud E, 2005, J BIOL CHEM, V280, P32389, DOI 10.1074/jbc.M506890200; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Karaolis DKR, 2005, BIOCHEM BIOPH RES CO, V329, P40, DOI 10.1016/j.bbrc.2005.01.093; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Karniol B, 2003, P NATL ACAD SCI USA, V100, P2807, DOI 10.1073/pnas.0437914100; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kulesekara H, 2006, P NATL ACAD SCI USA, V103, P2839, DOI 10.1073/pnas.0511090103; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Lamparter T, 2001, EUR J BIOCHEM, V268, P4720, DOI 10.1046/j.1432-1327.2001.02395.x; Montgomery BL, 2002, TRENDS PLANT SCI, V7, P357, DOI 10.1016/S1360-1385(02)02304-X; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Rockwell NC, 2006, ANNU REV PLANT BIOL, V57, P837, DOI 10.1146/annurev.arplant.56.032604.144208; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Steinberger O, 1999, FEBS LETT, V444, P125, DOI 10.1016/S0014-5793(99)00036-8; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; Tasler R, 2005, FEBS J, V272, P1927, DOI 10.1111/j.1742-4658.2005.04623.x; Van der Horst MA, 2004, ACCOUNTS CHEM RES, V37, P13, DOI 10.1021/ar020219d; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Wilde A, 2002, MOL MICROBIOL, V44, P981, DOI 10.1046/j.1365-2958.2002.02923.x; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	45	118	126	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34751	34758		10.1074/jbc.M604819200	http://dx.doi.org/10.1074/jbc.M604819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16968704	hybrid			2022-12-25	WOS:000241933700006
J	Hanano, A; Burcklen, M; Flenet, M; Ivancich, A; Louwagie, M; Garin, J; Blee, E				Hanano, Abdulsamie; Burcklen, Michel; Flenet, Martine; Ivancich, Anabella; Louwagie, Mathilde; Garin, Jerome; Blee, Elizabeth			Plant seed peroxygenase is an original heme-oxygenase with an EF-hand calcium binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE-DEPENDENT OXYGENASE; ELECTRON-PARAMAGNETIC-RESONANCE; UNSATURATED FATTY-ACIDS; HORSERADISH-PEROXIDASE; OIL BODIES; LIPID BODIES; ARABIDOPSIS-THALIANA; LINOLEIC-ACID; PROTEINS; SITE	A growing body of evidence indicates that phytooxylipins play important roles in plant defense responses. However, many enzymes involved in the biosynthesis of these metabolites are still elusive. We have purified one of these enzymes, the peroxygenase (PXG), from oat microsomes and lipid droplets. It is an integral membrane protein requiring detergent for its solubilization. Proteinase K digestion showed that PXG is probably deeply buried in lipid droplets or microsomes with only about 2 kDa at the C-terminal region accessible to proteolytic digestion. Sequencing of the N terminus of the purified protein showed that PXG had no sequence similarity with either a peroxidase or a cytochrome P450 but, rather, with caleosins, i. e. calcium-binding proteins. In agreement with this finding, we demonstrated that recombinant thale cress and rice caleosins, expressed in yeast, catalyze hydroperoxide-dependent mono-oxygenation reactions that are characteristic of PXG. Calcium was also found to be crucial for peroxygenase activity, whereas phosphorylation of the protein had no impact on catalysis. Site-directed mutagenesis studies revealed that PXG catalytic activity is dependent on two highly conserved histidines, the 9 GHz EPR spectrum being consistent with a high spin pentacoordinated ferric heme.	CNRS, UPR 2357, Inst Biol Mol Plantes, Lab Phytooxlipines, F-67083 Strasbourg, France; CEA Saclay, Dept Biol Joliot Curie, CNRS URA 2096, Serv Bioenerget, F-91191 Gif Sur Yvette, France; Commisariat Energie Atom Saclay, INSERM, ERM 0201, Lab Chim Prot, F-38054 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Blee, E (corresponding author), CNRS, UPR 2357, Inst Biol Mol Plantes, Lab Phytooxlipines, 28 Rue Goethe, F-67083 Strasbourg, France.	elizabeth.blee@ibmp-ulp.u-strasbg.fr	Hanano, Abdulsamie/V-6835-2019; Hanano, Abdulsamie/G-2623-2014	Ivancich, Anabella/0000-0002-4275-0980; Hanano, Abdulsamie/0000-0002-1699-106X				Autieri MV, 2005, EXP CELL RES, V307, P204, DOI 10.1016/j.yexcr.2005.03.002; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; Baltzer L, 1998, CURR OPIN STRUC BIOL, V8, P466, DOI 10.1016/S0959-440X(98)80124-3; BANCI L, 1997, J BIOTECHNOL, V53, P897; BLEE E, 1993, PLANT J, V4, P113, DOI 10.1046/j.1365-313X.1993.04010113.x; BLEE E, 1986, BIOCHEM BIOPH RES CO, V135, P922, DOI 10.1016/0006-291X(86)91016-8; BLEE E, 1993, J BIOL CHEM, V268, P1708; BLEE E, 1990, J BIOL CHEM, V265, P12887; BLEE E, 1987, ARCH BIOCHEM BIOPHYS, V254, P43, DOI 10.1016/0003-9861(87)90079-8; BLEE E, 1989, BIOCHEMISTRY-US, V28, P4962, DOI 10.1021/bi00438a009; Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Blee Elizabeth, 1996, P138, DOI 10.1201/9781439831977.ch8; Chen ECF, 1998, PLANT CELL PHYSIOL, V39, P935, DOI 10.1093/oxfordjournals.pcp.a029457; Chen JCF, 1999, PLANT CELL PHYSIOL, V40, P1079, DOI 10.1093/oxfordjournals.pcp.a029490; Chen MCM, 2004, J AGR FOOD CHEM, V52, P3982, DOI 10.1021/jf035533g; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; Dunford B.H., 1999, HEME PEROXIDASES; Einhauer A, 2001, J BIOCHEM BIOPH METH, V49, P455, DOI 10.1016/S0165-022X(01)00213-5; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Frandsen G, 1996, J BIOL CHEM, V271, P343, DOI 10.1074/jbc.271.1.343; Frandsen GI, 2001, PHYSIOL PLANTARUM, V112, P301, DOI 10.1034/j.1399-3054.2001.1120301.x; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gutierrez-Ford C, 2003, BIOCHEMISTRY-US, V42, P14553, DOI 10.1021/bi034870f; Hamberg M, 1996, PLANT PHYSIOL, V110, P807, DOI 10.1104/pp.110.3.807; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; HAMBERG M, 1991, LIPIDS, V26, P407, DOI 10.1007/BF02536065; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; Huang AHC, 1996, PLANT PHYSIOL, V110, P1055, DOI 10.1104/pp.110.4.1055; ISHIMARU A, 1977, J BIOL CHEM, V252, P6118; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Jakopitsch C, 2006, J INORG BIOCHEM, V100, P1091, DOI 10.1016/j.jinorgbio.2006.02.009; KATO T, 1993, BIOSCI BIOTECH BIOCH, V57, P283, DOI 10.1271/bbb.57.283; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; Lequeu J, 2003, PLANT J, V36, P155, DOI 10.1046/j.1365-313X.2003.01865.x; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; Matsunaga I, 2002, FEBS LETT, V528, P90, DOI 10.1016/S0014-5793(02)03261-1; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; MORISHIMA I, 1986, J BIOL CHEM, V261, P9391; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Murphy DJ, 2001, J PLANT PHYSIOL, V158, P471, DOI 10.1078/0176-1617-00359; Naested H, 2000, PLANT MOL BIOL, V44, P463, DOI 10.1023/A:1026564411918; NAMAI T, 1993, BIOSCI BIOTECH BIOCH, V57, P611, DOI 10.1271/bbb.57.611; Noordermeer MA, 2000, EUR J BIOCHEM, V267, P2473, DOI 10.1046/j.1432-1327.2000.01283.x; Nuccio ML, 1999, PLANT MOL BIOL, V39, P1153, DOI 10.1023/A:1006101404867; OHTA H, 1990, PLANT CELL PHYSIOL, V31, P1117; PALMER G, 1983, IRON PORPHYRINS 2, P43; Reedy CJ, 2004, CHEM REV, V104, P617, DOI 10.1021/cr0206115; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shin K, 2001, BIOCHEM BIOPH RES CO, V281, P1024, DOI 10.1006/bbrc.2001.4448; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Takahashi J, 2000, IEEE T NUCL SCI, V47, P903, DOI 10.1109/23.856715; Tanaka M, 1996, BIOCHEM BIOPH RES CO, V227, P393, DOI 10.1006/bbrc.1996.1518; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; Ting JTL, 1997, J BIOL CHEM, V272, P3699, DOI 10.1074/jbc.272.6.3699; Toorop PE, 2005, PLANTA, V221, P637, DOI 10.1007/s00425-004-1477-1; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Yi XW, 1999, P NATL ACAD SCI USA, V96, P12412, DOI 10.1073/pnas.96.22.12412	60	114	122	4	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33140	33151		10.1074/jbc.M605395200	http://dx.doi.org/10.1074/jbc.M605395200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956885	hybrid			2022-12-25	WOS:000241621400022
J	Isaji, T; Sato, Y; Zhao, YY; Miyoshi, E; Wada, Y; Taniguchi, N; Gu, JG				Isaji, Tomoya; Sato, Yuya; Zhao, Yanyang; Miyoshi, Eiji; Wada, Yoshinao; Taniguchi, Naoyuki; Gu, Jianguo			N-glycosylation of the beta-propeller domain of the integrin alpha 5 subunit is essential for alpha 5 beta 1 heterodimerization, expression on the cell surface, and its biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID FIBRONECTIN RECEPTORS; ENDOPLASMIC-RETICULUM; EXTRACELLULAR SEGMENT; ADHESION RECEPTORS; MESODERMAL DEFECTS; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; QUALITY-CONTROL; LIGAND-BINDING; DEFICIENT MICE	The N-glycosylation of integrin alpha 5 beta 1 is thought to play crucial roles in cell spreading, cell migration, ligand binding, and dimer formation, but the underlying mechanism remains unclear. To investigate the importance of the N-glycans of this integrin in detail, sequential site-directed mutagenesis was carried out to remove single or combined putative N-glycosylationsitesonthe alpha 5 integrin. Removal of the putative N-glycosylation sites on the beta-propeller, Thigh, Calf-1, or Calf-2 domains of the alpha 5 subunit resulted in a decrease in molecular weight compared with the wild type, suggesting that all of these domains contain attached N-glycans. Importantly, the absence of N-glycosylation sites (sites1-5) on the beta-propeller resulted in the persistent association of integrin subunit with calnexin in the endoplasmic reticulum, which subsequently blocked heterodimerization and its expression on the cell surface. Interestingly, the activities for cell spreading and migration for the alpha 5 subunit carrying only three potential N-glycosylationsites(3-5sites) on the beta-propellerwerecomparablewiththose of the wild type. In contrast, mutation of these three sites resulted in a significant decrease in cell spreading as well as functional expression, although the total expression level of the Delta 3-5 mutant on the cell surface was comparable with that of wild type. Furthermore, we found that site 5 is a most important site for its expression on the cell surface, whereas the S5 mutant did not show any biological functions. Taken together, this study reveals for the first time that the N-glycosylation on the beta-propeller domain of the alpha 5 subunit is essential for heterodimerization and biological functions of alpha 5 beta 1 integrin and might also be useful for studies of the molecular structure.	Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Inst Mol Biomembrane & Glycobiol, Aoba Ku, Sendai, Miyagi 9818558, Japan; Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Med Ctr, Dept Mol Med, Osaka 5941101, Japan; Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; Osaka Univ, Dept Dis Glycom, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan	Tohoku Medical & Pharmaceutical University; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University	Gu, JG (corresponding author), Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Inst Mol Biomembrane & Glycobiol, Aoba Ku, Sendai, Miyagi 9818558, Japan.	jgu@tohoku.pharm.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Isaji, Tomoya/ABC-9285-2021; Taniguchi, Naoyuki/A-7086-2016; Gu, Jianguo/ABC-9257-2020	Taniguchi, Naoyuki/0000-0001-5889-5968; 				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Bellis SL, 2004, BBA-BIOMEMBRANES, V1663, P52, DOI 10.1016/j.bbamem.2004.03.012; Berditchevski F, 2001, J CELL SCI, V114, P4143; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; Cao ZJ, 1998, J BIOL CHEM, V273, P31670, DOI 10.1074/jbc.273.48.31670; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; Dennis JW, 2002, BBA-GEN SUBJECTS, V1573, P414, DOI 10.1016/S0304-4165(02)00411-7; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ethier M, 2005, RAPID COMMUN MASS SP, V19, P721, DOI 10.1002/rcm.1844; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIPSON IK, 1984, DEV BIOL, V101, P212, DOI 10.1016/0012-1606(84)90131-3; Goh KL, 1997, DEVELOPMENT, V124, P4309; Gu JG, 2004, GLYCOBIOLOGY, V14, P177, DOI 10.1093/glycob/cwh016; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; Guo HB, 2002, CANCER RES, V62, P6837; Guo L, 2002, J BIOL CHEM, V277, P50776, DOI 10.1074/jbc.M209900200; HEINO J, 1989, J BIOL CHEM, V264, P380; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hoffmeister KM, 2003, SCIENCE, V301, P1531, DOI 10.1126/science.1085322; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Jasiulionis MG, 1996, CANCER RES, V56, P1682; Josefsson EC, 2005, J BIOL CHEM, V280, P18025, DOI 10.1074/jbc.M501178200; Karamyshev AL, 2005, J BIOL CHEM, V280, P40489, DOI 10.1074/jbc.M509168200; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; LENTER M, 1994, J BIOL CHEM, V269, P12263; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Miyoshi E, 1999, CANCER RES, V59, P2237; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Saxon E, 2001, ANNU REV CELL DEV BI, V17, P1, DOI 10.1146/annurev.cellbio.17.1.1; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Seales EC, 2005, J BIOL CHEM, V280, P37610, DOI 10.1074/jbc.M508476200; Semel AC, 2002, J BIOL CHEM, V277, P32830, DOI 10.1074/jbc.M202493200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Williams DB, 2006, J CELL SCI, V119, P615, DOI 10.1242/jcs.02856; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; YANG JT, 1993, DEVELOPMENT, V119, P1093; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yoshida Y, 2005, EMBO REP, V6, P239, DOI 10.1038/sj.embor.7400351; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	54	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33258	33267		10.1074/jbc.M607771200	http://dx.doi.org/10.1074/jbc.M607771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959765	hybrid			2022-12-25	WOS:000241621400035
J	Mero, P; Zhang, CY; Huang, ZY; Kim, MK; Schreiber, AD; Grinstein, S; Booth, JW				Mero, Patricia; Zhang, Christine Y.; Huang, Zhen-Yu; Kim, Moo-Kyung; Schreiber, Alan D.; Grinstein, Sergio; Booth, James W.			Phosphorylation-independent ubiquitylation and endocytosis of Fc gamma RIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; UBIQUITIN-BINDING PROTEINS; TYROSINE PHOSPHORYLATION; CELL-LINE; RECEPTOR; PHAGOCYTOSIS; INTERNALIZATION; DEGRADATION; ENDOSOMES; KINASES	Endocytosis of the Fc receptor Fc gamma RIIA depends on a functional ubiquitin conjugation system, and the receptor becomes ubiquitylated upon ligand binding. Phosphorylation of tyrosines in Fc gamma RIIA by Src family kinases is thought to be the initiating event in its signaling. However, although the Src family kinase inhibitor PP1 inhibited both ligand-induced phosphorylation of Fc gamma RIIA and phagocytosis in ts20 cells expressing Fc gamma RIIA, it did not inhibit receptor ubiquitylation or endocytosis of soluble ligands. Conversely, genistein and the proteasomal inhibitor MG132 did not inhibit receptor phosphorylation but strongly inhibited both receptor ubiquitylation and endocytosis. A region of the receptor lying within the immunoreceptor tyrosine-based activation motif was found to be necessary for both ubiquitylation and endocytosis. Ubiquitylation occurs at the plasma membrane before internalization. Endocytosis of Fc gamma RIIA is dependent on clathrin but independent of the adaptor protein AP-2. These findings point to a novel mechanism for ubiquitylation and endocytosis of this immunoreceptor.	Sunnybrook Res Inst, Mol & Cellular Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Booth, JW (corresponding author), Sunnybrook Res Inst, Mol & Cellular Biol Res, 2075 Bayview Ave,Rm S-116, Toronto, ON M4N 3M5, Canada.	James.Booth@sunnybrook.ca						Barriere H, 2006, TRAFFIC, V7, P282, DOI 10.1111/j.1600-0854.2006.00384.x; Belouzard S, 2006, EMBO J, V25, P932, DOI 10.1038/sj.emboj.7600989; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; Cannons JL, 2004, CURR OPIN IMMUNOL, V16, P296, DOI 10.1016/j.coi.2004.03.011; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; Gold ES, 1999, J EXP MED, V190, P1849, DOI 10.1084/jem.190.12.1849; GRABER M, 1992, INT IMMUNOL, V4, P1201, DOI 10.1093/intimm/4.11.1201; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hawryluk MJ, 2006, TRAFFIC, V7, P262, DOI 10.1111/j.1600-0854.2006.00383.x; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; Kelm KB, 2004, TRAFFIC, V5, P165, DOI 10.1111/j.1600-0854.2004.00168.x; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Leithe E, 2004, J BIOL CHEM, V279, P50089, DOI 10.1074/jbc.M402006200; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Tse SML, 2003, J BIOL CHEM, V278, P3331, DOI 10.1074/jbc.M207966200; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33242	33249		10.1074/jbc.M605372200	http://dx.doi.org/10.1074/jbc.M605372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959774	hybrid			2022-12-25	WOS:000241621400033
J	Ramana, KV; Fadl, AA; Tammali, R; Reddy, ABM; Chopra, AK; Srivastava, SK				Ramana, Kota V.; Fadl, Amin A.; Tammali, Ravinder; Reddy, Aramati B. M.; Chopra, Ashok K.; Srivastava, Satish K.			Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages (Publication with Expression of Concern. See vol. 294, pg. 1633, 2019)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Publication with Expression of Concern							TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; MULTIPLE ORGAN DYSFUNCTION; SMOOTH-MUSCLE-CELLS; INDUCED EXPRESSION; UP-REGULATION; SEPTIC SHOCK; IN-VITRO; ACTIVATION; RESPONSES	Abnormal production of inflammatory cytokines and chemokines is a key feature of bacterial endotoxin, lipopolysaccharide (LPS)-induced inflammation, and cytotoxicity; however, the mechanisms regulating production of inflammatory markers remain unclear. Herein, we show that inhibition of the aldehyde-metabolizing enzyme aldose reductase (AR; AKR1B3) modulates NF-kappa B-dependent activation of inflammatory cytokines and chemokines in mouse serum, liver, heart, and spleen. Pharmacological inhibition or small interfering RNA ablation of AR prevented the biosynthesis of tumor necrosis factor-alpha, interleukin 1 beta, interleukin-6, macrophage-chemoattractant protein-1, and cyclooxygenase-2 and prostaglandin E-2 in LPS-activated RAW264.7 murine macrophages. The AR inhibition or ablation significantly attenuated LPS-induced activation of protein kinase C (PKC) and phospholipase C (PLC), nuclear translocation of NF-kappa B, and phosphorylation and proteolytic degradation of I kappa B kappa in macrophages. Furthermore, treatment of macrophages with 4-hydroxy-trans-2-nonenal (HNE), and cell-permeable esters of glutathionyl-4-hydroxynonanal (GS-HNE) and glutathionyl-1,4-dihydroxynonane (GSDHN) activated NF-kappa B and PLC/PKC. Pharmacological inhibition or antisense ablation of AR that catalyzes the reduction of GS-HNE to GS-DHN prevented PLC, PKC, IKK alpha/beta, and NF-kappa B activation caused by HNE and GS-HNE, but not by GS-DHN, suggesting that reduced GS-lipid aldehydes catalyzed by AR propagate LPS-induced production of inflammatory markers. Collectively, these data provide evidence that inhibition of AR may be a significant therapeutic approach in preventing bacterial endotoxin-induced sepsis and tissue damage.	Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Ramana, KV (corresponding author), Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.	kvramana@utmb.edu	Ramana, Kota/C-5460-2012	Ramana, Kota/0000-0001-6502-7800	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041611, R01AI064389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071036] Funding Source: NIH RePORTER; NIAID NIH HHS [AI041611, AI064389] Funding Source: Medline; NIDDK NIH HHS [DK36118] Funding Source: Medline; NIGMS NIH HHS [GM71036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Antonicelli F, 2004, AM J PHYSIOL-LUNG C, V286, pL1319, DOI 10.1152/ajplung.00329.2003; Balk RA, 2000, CRIT CARE CLIN, V16, P337, DOI 10.1016/S0749-0704(05)70113-5; Beutler B, 1995, J CARDIOVASC PHARM, V25, pS1, DOI 10.1097/00005344-199500252-00002; Bluth MH, 2006, CRIT CARE MED, V34, P188, DOI 10.1097/01.CCM.0000196212.56885.50; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Eriksson U, 2003, CIRCULATION, V107, P320, DOI 10.1161/01.CIR.0000043802.38699.66; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Goode S, 2006, GUT, V55, P590, DOI 10.1136/gut.2005.085449; Hall AJ, 1999, J BIOL CHEM, V274, P376, DOI 10.1074/jbc.274.1.376; Hsu BG, 2004, J BIOMED SCI, V11, P152, DOI 10.1159/000076027; Hulten LM, 1998, TRANSPLANTATION, V66, P364, DOI 10.1097/00007890-199808150-00014; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Kobayashi M, 2006, CURR DRUG TARGETS, V7, P119, DOI 10.2174/138945006775270169; Kubota T, 1997, J Card Fail, V3, P117, DOI 10.1016/S1071-9164(97)90045-2; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Lindros KO, 2005, METAB BRAIN DIS, V20, P393, DOI 10.1007/s11011-005-7924-2; MOHLER KM, 1993, J IMMUNOL, V151, P1548; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Neveu PJ, 2003, STRESS, V6, P5, DOI 10.1080/1025389031000087472; Pittard A J, 1994, Clin Intensive Care, V5, P186; Pollara G, 2006, SCAND J IMMUNOL, V63, P151, DOI 10.1111/j.1365-3083.2006.01727.x; Ramana KV, 2006, J BIOL CHEM, V281, P17652, DOI 10.1074/jbc.M600270200; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Ramana KV, 2005, DIABETES, V54, P818, DOI 10.2337/diabetes.54.3.818; Ramana KV, 2004, FASEB J, V18, P1209, DOI 10.1096/fj.04-1650com; Ramana KV, 2004, DIABETES, V53, P2910, DOI 10.2337/diabetes.53.11.2910; Ramana KV, 2002, FASEB J, V16, P315, DOI 10.1096/fj.02-0568fje; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Sablotzki A, 2001, THORAC CARDIOV SURG, V49, P273, DOI 10.1055/s-2001-17803; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 2006, DIABETES, V55, P901, DOI 10.2337/diabetes.55.04.06.db05-0932; Srivastava SK, 2005, ENDOCR REV, V26, P380, DOI 10.1210/er.2004-0028; Triantafilou M, 2005, J ENDOTOXIN RES, V11, P5, DOI 10.1179/096805105225006641; Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007; Velasco M, 1997, J BIOL CHEM, V272, P23025, DOI 10.1074/jbc.272.37.23025; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414	39	129	137	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33019	33029		10.1074/jbc.M603819200	http://dx.doi.org/10.1074/jbc.M603819200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956889	hybrid			2022-12-25	WOS:000241621400010
J	Erkeland, SJ; Aarts, LH; Irandoust, M; Roovers, O; Klomp, A; Valkhof, M; Gits, J; Eyckerman, S; Tavernier, J; Touw, IP				Erkeland, S. J.; Aarts, L. H.; Irandoust, M.; Roovers, O.; Klomp, A.; Valkhof, M.; Gits, J.; Eyckerman, S.; Tavernier, J.; Touw, I. P.			Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling	ONCOGENE			English	Article						WD40 and SOCS box protein; G-CSF receptor; steady-state distribution; forward routing; proliferation-differentiation balance	NEUTROPENIA/ACUTE MYELOID-LEUKEMIA; DISTINCT CYTOPLASMIC REGIONS; UBIQUITIN; ACTIVATION; INTERNALIZATION; GROWTH; DOMAIN; SUPPRESSION; INDUCTION; SURVIVAL	Signals induced by granulocyte colony-stimulating factor (G-CSF), the major cytokine involved in neutrophil development, are tightly controlled by ligand-induced receptor internalization. Truncated G-CSF receptors(GCSF-Rs) that fail to internalize show sustained proliferation and defective differentiation signaling. Steady-state forward routing also determines cell surface levels of cytokine receptors, but mechanisms controlling this are poorly understood. Here, we show that WD40 and suppressor of cytokine signaling (SOCS) box protein-2 (Wsb-2), an SOCS box-containing WD40 protein with currently unknown function, bindsto the COOH-terminal region of G-CSF-R. Removal of this region did not affect internalization, yet resulted in increased membrane expression of G-CSF-R and enhanced proliferation signaling at the expense of differentiation induction. Conversely, Wsb-2 binding to the G-CSF-R reduced its cell surface expression and inhibited proliferation signaling. These effects depended on the SOCS box involved in ubiquitylation and on cytosolic lysines of G-CSF-R and imply a major role for ubiquitylation through the G-CSFR C-terminusin forward routing of the receptor. Importantly, the Wsb-2 gene iscommonly disrupted by virus integrations in mouse leukemia. We conclude that control of forward routing of G-CSF-R is essential for a balanced response of myeloid progenitors to G-CSF and suggest that disturbance of this balance may contribute to myeloid leukemia.	Erasmus Univ, Ctr Med, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Univ Ghent, Flanders Interuniv Inst Biotechnol, Dept Med Prot Res, Ghent, Belgium	Erasmus University Rotterdam; Ghent University	Touw, IP (corresponding author), Erasmus Univ, Ctr Med, Dept Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	i.touw@erasmusmc.nl	Tavernier, Jan/AAG-3636-2019	Erkeland, Stefan/0000-0002-1019-7957				Aarts LHJ, 2004, BLOOD, V103, P571, DOI 10.1182/blood-2003-07-2250; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DEMETRI GD, 1991, BLOOD, V78, P2791; Dentice M, 2005, NAT CELL BIOL, V7, P698, DOI 10.1038/ncb1272; Dong F, 1998, J IMMUNOL, V161, P6503; Dong F, 2001, J IMMUNOL, V167, P6447, DOI 10.4049/jimmunol.167.11.6447; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; Eyckerman Sven, 2002, Sci STKE, V2002, ppl18; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; Heuze ML, 2005, J BIOL CHEM, V280, P5468, DOI 10.1074/jbc.M413040200; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; James P, 1996, GENETICS, V144, P1425; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; McLemore ML, 1998, J CLIN INVEST, V102, P483, DOI 10.1172/JCI3216; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; Reynolds A, 2006, RNA, V12, P988, DOI 10.1261/rna.2340906; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Tavernier J, 2002, CLIN EXP ALLERGY, V32, P1397, DOI 10.1046/j.1365-2745.2002.01520.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van de Geijn GJM, 2004, BLOOD, V104, P667, DOI 10.1182/blood-2003-08-2913; van de Geijn GJM, 2004, REV PHYSIOL BIOCH P, V149, P53; van Zon A, 2002, BIOCHEM BIOPH RES CO, V291, P535, DOI 10.1006/bbrc.2002.6472; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956	41	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					1985	1994		10.1038/sj.onc.1210004	http://dx.doi.org/10.1038/sj.onc.1210004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001306				2022-12-25	WOS:000245313400001
J	Kikuchi, R; Murakami, M; Sobue, S; Iwasaki, T; Hagiwara, K; Takagi, A; Kojima, T; Asano, H; Suzuki, M; Banno, Y; Nozawa, Y; Murate, T				Kikuchi, R.; Murakami, M.; Sobue, S.; Iwasaki, T.; Hagiwara, K.; Takagi, A.; Kojima, T.; Asano, H.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T.			Ewing's sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5 ' promoter	ONCOGENE			English	Article						Ewing's sarcoma; EWS/Fli-1; PLD; gene expression; promoter analysis	PHOSPHOLIPASE D2; CELL; SPECIFICITY; INHIBITION; FAMILY	It was reported that short interfering RNA (siRNA) of EWS/Fli-1 downregulated phospholipase D (PLD)2 in Ewing's sarcoma (EWS) cell line, suggesting that PLD2 is the target of aberrant transcription factor, EWS/Fli-1. Here, we further investigated the regulation of PLD2 gene expression by EWS/Fli-1 and Fli-1 in another EWS cell line, and also in EWS/Fli-1- or Fli-1-transfected cell line. EWS/Fli-1- or Fli-1-overexpressed cells showed higher PLD2 but not PLD1 protein expression and enhanced cell proliferation as compared to mock transfectant. The treatment of these cells with 1-butanol or siRNA of PLD2 inhibited cell growth, suggesting the pivotal role of PLD in cell growth promotion. PLD2 but not PLD1 mRNA level was also increased in EWS/Fli-1 or Fli-1-transfectants. After determining the transcription initiation points, we cloned the 50 promoter of both PLD1 and PLD2 and analysed promoter activities. Results showed that EWS/Fli-1 and Fli- 1 increase PLD2 gene expression by binding to an erythroblast transformation-specific domain (-126 to -120 bp from the transcription initiation site) of PLD2 promoter, which is the minimal and most powerful region. Electrophoresis mobility shift assay using truncated proteins showed that both DNA-binding domain and trans-activating domain were necessary for the enhanced gene expression of PLD2.	Nagoya Univ, Sch Hlth Sci, Higashi Ku, Nagoya, Aichi 4618673, Japan	Nagoya University	Murate, T (corresponding author), Nagoya Univ, Sch Hlth Sci, Higashi Ku, Daiko Minami 1-1-20, Nagoya, Aichi 4618673, Japan.	murate@met.nagoya-u.ac.jp	Kojima, Tetsuhito/I-6271-2014; Kikuchi, Ryosuke/AAX-4971-2021; Suzuki, Motoshi/I-7246-2014	Kojima, Tetsuhito/0000-0002-1905-1065; Suzuki, Motoshi/0000-0003-0682-5006				Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; CARNERO A, 1994, ONCOGENE, V9, P1387; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Foster DA, 2003, MOL CANCER RES, V1, P789; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; LISCOVITCH M, 2000, BIOCHEM J, V345, P410; MAO XH, 1994, J BIOL CHEM, V269, P18216; Nakamura S, 2003, REC RES DEV MAGNET M, V1, P1; Nozawa S, 2005, J BIOL CHEM, V280, P27544, DOI 10.1074/jbc.M411626200; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; RAMUGOUNDER R, 2004, ONCOGENE, V23, P1; Redina OE, 1998, GENE, V222, P53, DOI 10.1016/S0378-1119(98)00465-X; REDINA OE, 1998, BIOCHEM J, V331, P173; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sobue S, 2005, J NEUROCHEM, V95, P940, DOI 10.1111/j.1471-4159.2005.03399.x; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	22	20	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1802	1810		10.1038/sj.onc.1209973	http://dx.doi.org/10.1038/sj.onc.1209973			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964281				2022-12-25	WOS:000244955600014
J	Scharf, S; Zech, J; Bursen, A; Schraets, D; Oliver, PL; Kliem, S; Pfitzner, E; Gillert, E; Dingermann, T; Marschalek, R				Scharf, S.; Zech, J.; Bursen, A.; Schraets, D.; Oliver, P. L.; Kliem, S.; Pfitzner, E.; Gillert, E.; Dingermann, T.; Marschalek, R.			Transcription linked to recombination: a gene-internal promoter coincides with the recombination hot spot II of the human MLL gene	ONCOGENE			English	Article						MLL gene; acute leukaemia; transcription; gene-internal promoter	BREAKPOINT-CLUSTER REGION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; DNA CLEAVAGE; REARRANGEMENTS; EXPRESSION; INHIBITORS; ETOPOSIDE; APOPTOSIS; T(4/11)	The MLL gene is frequently involved in chromosomal translocations associated with high-risk acute leukaemia. Infant and therapy-related acute leukaemia patients display chromosomal breakpoints preferentially clustered in the telomeric portion of the MLL breakpoint cluster region (SCII). Here, we demonstrate that SCII colocalizes with a gene-internal promoter element in the mouse and human MLL gene, respectively. The mRNA generated encodes an N-terminally truncated version of MLL that still exhibits many functional regions, including the C-terminal SET-domain. Etoposide-induced DNA double-strand breaks colocalize with the binding site of RNA polymerase II and the transcription initiation region, but not with a nearby Topo II consensus sequence. Thus, the observed genomic instability of the human MLL gene is presumably linked to transcriptional processes. The consequences of this novel finding for the creation of chromosomal translocations, the biology of the MLL protein and for MLL-mediated acute leukaemia are discussed.	Univ Frankfurt, Inst Pharmaceut Biol, ZAFES, Bioctr, D-60439 Frankfurt, Germany; Univ Oxford, Res Council Funct Genet Unit, Dept Physiol Anat & Genet, Oxford, England; Procompliance Verlag GmbH, Erlangen, Germany	Goethe University Frankfurt; University of Oxford	Marschalek, R (corresponding author), Univ Frankfurt, Inst Pharmaceut Biol, ZAFES, Bioctr, Marie Curie Str 9, D-60439 Frankfurt, Germany.	rolf.marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Pfitzner, Edith/AAU-7927-2021; Oliver, Peter/F-1453-2010; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Pfitzner, Edith/0000-0002-3484-9649; Dingermann, Theodor/0000-0002-2788-1085; Oliver, Peter/0000-0003-3347-2461				Andersen MK, 2001, BRIT J HAEMATOL, V114, P539, DOI 10.1046/j.1365-2141.2001.03000.x; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Betti CJ, 2005, LEUKEMIA, V19, P2289, DOI 10.1038/sj.leu.2403966; Betti CJ, 2001, CANCER RES, V61, P4550; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GOTO H, 1994, INT J HEMATOL, V60, P145; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Khobta A, 2004, CANCER RES, V64, P2656, DOI 10.1158/0008-5472.CAN-03-1126; Libura J, 2005, BLOOD, V105, P2124, DOI 10.1182/blood-2004-07-2683; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Mitterbauer-Hohendanner G, 2004, EUR J CLIN INVEST, V34, P12, DOI 10.1111/j.0960-135X.2004.01366.x; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nasr F, 1997, LEUKEMIA LYMPHOMA, V25, P399, DOI 10.3109/10428199709114180; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	28	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1361	1371		10.1038/sj.onc.1209948	http://dx.doi.org/10.1038/sj.onc.1209948			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16983345				2022-12-25	WOS:000244558800001
J	Bai, Y; Liu, YJ; Wang, H; Xu, Y; Stamenkovic, I; Yu, Q				Bai, Y.; Liu, Y-j; Wang, H.; Xu, Y.; Stamenkovic, I.; Yu, Q.			Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin	ONCOGENE			English	Article						CD44; hyaluronan; merlin; tumor suppressor; schwannoma growth	TYPE-2 GENE-PRODUCT; MEDIATES CONTACT INHIBITION; GERM-LINE MUTATIONS; MUTANT NF2 PROTEIN; NEUROFIBROMATOSIS TYPE-2; INCREASED EXPRESSION; SIGNALING PATHWAY; GLYCOPROTEIN CD44; HOMING RECEPTOR; CARCINOMA-CELLS	Mutation or loss of expression of merlin is responsible for neurofibromatosis type 2 (NF2), which is characterized by the development of schwannomas and other tumors of the nervous system. Like the ERM(ezrin-radixin-moesin) proteins, merlin interacts with CD44, a cell-surface receptor for hyaluronan (HA) that promotes tumorigenesis. However, the relationship between merlin and CD44 and the mechanism by which merlin exerts its tumor-suppressor function have not been elucidated. In the present study, we show that increased expression of wildtype merlin in Tr6BC1 schwannoma cells inhibits HA binding to CD44. Furthermore, we demonstrate that the residues required for this inhibitory effect and the interaction between CD44 and merlin lie within the first 50 amino acids of merlin. Overexpression of merlin inhibited subcutaneous growth of Tr6BC1 cells in immunocompromised Rag1 mice. In contrast, knocking down expression of endogenous merlin promoted tumor cell growth, as did overexpression of a merlin deletion mutant (merlinDel-1) that lacks the first 50 amino acids but not of other NH2-terminal deletion mutants. Together, our results demonstrate that inhibition of the CD44-HA interaction contributes to the tumor-suppressor function of merlin, and they suggest that merlin inhibits tumor growth, at least in part, by negatively regulating CD44 function.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Lausanne, Inst Pathol, Div Expt Pathol, CH-1015 Lausanne, Switzerland	University of Pennsylvania; University of Lausanne	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenne.edu			NCI NIH HHS [R01 CA116510, R01 CA135158] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Evans DGR, 1998, J MED GENET, V35, P450, DOI 10.1136/jmg.35.6.450; EVANS DGR, 1992, Q J MED, V84, P603; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUTMANN DH, 1994, CURR OPIN NEUROL, V7, P166, DOI 10.1097/00019052-199404000-00014; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hannon Gregory J, 2004, Methods Mol Biol, V257, P255, DOI 10.1385/1-59259-750-5:255; HARA T, 1994, CANCER RES, V54, P330; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huynh DP, 1996, ONCOGENE, V13, P73; Kang BS, 2002, ACTA CRYSTALLOGR D, V58, P381, DOI 10.1107/S0907444901021175; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Parry DM, 1996, AM J HUM GENET, V59, P529; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; RONG R, 2004, ONCOGENE, V4, P1; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Sainio M, 1997, J CELL SCI, V110, P2249; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Stickney JT, 2004, CANCER RES, V64, P2717, DOI 10.1158/0008-5472.CAN-03-3798; TROFATTER JA, 1993, CELL, V72, P1; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 2001, AM J PATHOL, V158, P563, DOI 10.1016/S0002-9440(10)63998-3; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	68	63	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					836	850		10.1038/sj.onc.1209849	http://dx.doi.org/10.1038/sj.onc.1209849			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16953231				2022-12-25	WOS:000244063800005
J	Nduati, V; Yan, YT; Dalmasso, G; Driss, A; Sitaraman, S; Merlin, D				Nduati, Vivienne; Yan, Yutao; Dalmasso, Guillaume; Driss, Adel; Sitaraman, Shanthi; Merlin, Didier			Leptin transcriptionally enhances peptide transporter (hPepT1) expression and activity via the cAMP-response element-binding protein and Cdx2 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; RAT SMALL-INTESTINE; EPITHELIAL TRANSPORT; LUMINAL LEPTIN; HUMAN STOMACH; OBESE GENE; CELLS; SECRETION; RECEPTOR; LOCALIZATION	PepT1 is an intestinal epithelial apical membrane transporter that is expressed in the small intestine, with little or no expression in the normal colon. However, we previously demonstrated that colonic PepT1 may be expressed during chronic inflammation. To begin elucidating inflammatory hPepT1 signaling, we herein investigated the long term leptin treatments, on PepT1 expression and activity in Caco2-BBE cells, and began to reveal the involved signaling pathways. We successfully cloned the 723-bp hPepT1 promoter region and identified the human transcription initiation site 86 bp upstream from the translation start site. Leptin treatment dose- and time-dependently increased hPepT1 promoter and transport activities in Caco2-BBE cells, with maximal activity observed in cells treated with 100 nM leptin for 8 h. Under these conditions, we observed 2-fold increases in hPepT1 mRNA and protein expression, as well as increased transport activity. Our molecular analyses of possible signal- transduction pathways revealed that leptin treatment enhanced the intracellular levels of cAMP and phosphorylated cAMP-response element-binding protein (CREB) protein in Caco2-BBE cells, whereas our deletion, mutation, and CDX2 overexpression analyses demonstrated that interaction of the Cdx2 and phosphorylated CREB transcription factors was essential for leptin-induced hPepT1 transcription in Caco2-BBE cells. Our results indicate that leptin, which is increased in inflamed colonic mucosa, triggers colonic expression of hPepT1 via the CREB and Cdx2 transcription factors. These findings provide important new insights into the mechanisms of intestinal inflammation and may suggest new therapeutic modalities in the future.	Emory Univ, Dept Med, Div Digest Dis, Sch Med, Atlanta, GA 30322 USA	Emory University	Merlin, D (corresponding author), Emory Univ, Dept Med, Div Digest Dis, Sch Med, 615 Michael St, Atlanta, GA 30322 USA.	dmerlin@emory.edu	Driss, Adel/X-6772-2019; Driss, Adel/A-4151-2008; Dalmasso, Guillaume/N-2443-2018	Dalmasso, Guillaume/0000-0002-3433-870X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK055850, R01DK061941, R01DK071594] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK071594, R24-DK-064399, R01-DK061941, R01-DK55850] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adibi SA, 2003, AM J PHYSIOL-GASTR L, V285, pG779, DOI 10.1152/ajpgi.00056.2003; Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4; Ahren B, 1999, AM J PHYSIOL-REG I, V277, pR959, DOI 10.1152/ajpregu.1999.277.4.R959; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Buyse M, 2002, J BIOL CHEM, V277, P28182, DOI 10.1074/jbc.M203281200; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Charrier L, 2006, LAB INVEST, V86, P490, DOI 10.1038/labinvest.3700413; Charrier L, 2006, LAB INVEST, V86, P538, DOI 10.1038/labinvest.3700423; Couce ME, 1997, NEUROENDOCRINOLOGY, V66, P145, DOI 10.1159/000127232; Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4; Daniel H, 2004, ANNU REV PHYSIOL, V66, P361, DOI 10.1146/annurev.physiol.66.032102.144149; Doi T, 2001, AM J PHYSIOL-REG I, V281, pR753, DOI 10.1152/ajpregu.2001.281.3.R753; Fei YJ, 2000, BBA-GENE STRUCT EXPR, V1492, P145, DOI 10.1016/S0167-4781(00)00101-9; Fei YJ, 1998, PROG NUCLEIC ACID RE, V58, P239; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Goodman RH, 2000, GENE DEV, V14, P1553; Hill RA, 1998, INT J OBESITY, V22, P765, DOI 10.1038/sj.ijo.0800656; Jin L, 2000, ENDOCRINOLOGY, V141, P333, DOI 10.1210/en.141.1.333; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lostao MP, 1998, FEBS LETT, V423, P302, DOI 10.1016/S0014-5793(98)00110-0; Meredith D, 2000, CELL MOL LIFE SCI, V57, P754, DOI 10.1007/s000180050040; Merlin D, 1998, J CLIN INVEST, V102, P2011, DOI 10.1172/JCI4179; Merlin D, 2001, GASTROENTEROLOGY, V120, P1666, DOI 10.1053/gast.2001.24845; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Mutoh H, 2005, INT J DEV BIOL, V49, P867, DOI 10.1387/ijdb.052016hm; Ogihara H, 1999, HISTOCHEM J, V31, P169, DOI 10.1023/A:1003515413550; Ogihara H, 1996, BIOCHEM BIOPH RES CO, V220, P848, DOI 10.1006/bbrc.1996.0493; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Schneider R, 2001, HORM METAB RES, V33, P1, DOI 10.1055/s-2001-12617; Shimakura J, 2005, AM J PHYSIOL-GASTR L, V289, pG471, DOI 10.1152/ajpgi.00025.2005; Shiraga T, 1999, GASTROENTEROLOGY, V116, P354, DOI 10.1016/S0016-5085(99)70132-0; Sitaraman S, 2004, FASEB J, V18, P696, DOI 10.1096/fj.03-0422fje; Sobhani I, 2000, GUT, V47, P178, DOI 10.1136/gut.47.2.178; Sobhani I, 2002, GASTROENTEROLOGY, V122, P259, DOI 10.1053/gast.2002.31385; Stan S, 2001, FEBS LETT, V508, P80, DOI 10.1016/S0014-5793(01)03032-0; Sweeney G, 2001, ENDOCRINOLOGY, V142, P4806, DOI 10.1210/en.142.11.4806; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Vavricka SR, 2004, GASTROENTEROLOGY, V127, P1401, DOI 10.1053/j.gastro.2004.07.024; Wang X, 1996, AM J PHYSIOL-HEART C, V270, pH476, DOI 10.1152/ajpheart.1996.270.2.H476; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Ziegler TR, 2002, AM J CLIN NUTR, V75, P922, DOI 10.1093/ajcn/75.5.922	44	38	41	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1359	1373		10.1074/jbc.M604267200	http://dx.doi.org/10.1074/jbc.M604267200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	16963449	hybrid			2022-12-25	WOS:000243295200062
J	Winteringham, LN; Endersby, R; Kobelke, S; McCulloch, RK; Williams, JH; Stillitano, J; Cornwall, SM; Ingley, E; Klinken, SP				Winteringham, Louise N.; Endersby, Raelene; Kobelke, Simon; McCulloch, Ross K.; Williams, James H.; Stillitano, Justin; Cornwall, Scott M.; Ingley, Evan; Klinken, S. Peter			Myeloid leukemia factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U-like molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ERYTHROPOIETIN-INDUCED DIFFERENTIATION; HEMATOPOIETIC LINEAGE SWITCH; J2E ERYTHROID-CELLS; HNRNP-U; TRANSCRIPTION FACTOR; CHROMOSOMAL LOCALIZATION; MYELODYSPLASTIC SYNDROME; ATTACHMENT REGION; DEPENDENT MANNER	Myeloid leukemia factor 1 (MLF1) is an oncoprotein associated with hemopoietic lineage commitment and acute myeloid leukemia. Here we show that Mlf1 associated with a novel binding partner, Mlf1-associated nuclear protein (Manp), a new heterogenous nuclear ribonucleoprotein (hnRNP) family member, related to hnRNP-U. Manp localized exclusively in the nucleus and could redirect Mlf1 from the cytoplasm into the nucleus. The nuclear content of Mlf1 was also regulated by 14-3-3 binding to a canonical 14-3-3 binding motif within theNterminus of Mlf1. Significantly Mlf1 contains a functional nuclear export signal and localized primarily to the nuclei of hemopoietic cells. Mlf1 was capable of binding DNA, and microarray analysis revealed that it affected the expression of several genes, including transcription factors. In summary, this study reveals that Mlf1 translocates between nucleus and cytoplasm, associates with a novel hnRNP, and influences gene expression.	Western Australian Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia	University of Western Australia	Klinken, SP (corresponding author), Western Australian Med Res, Lab Canc Med, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Ingley, Evan/C-2401-2013; Endersby, Raelene/A-2969-2013; Winteringham, Louise/H-6105-2014	Ingley, Evan/0000-0002-8112-9134; Endersby, Raelene/0000-0003-3554-2769; Winteringham, Louise/0000-0002-8117-5069; Williams, James/0000-0002-0950-1958				Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUSFIELD SJ, 1992, BLOOD, V80, P412; Campbell JK, 1997, BIOCHEMISTRY-US, V36, P15363, DOI 10.1021/bi9708085; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Craparo A, 1997, J BIOL CHEM, V272, P11663; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; Fukuda S, 2002, J BIOCHEM, V131, P349, DOI 10.1093/oxfordjournals.jbchem.a003109; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hanissian SH, 2004, ONCOGENE, V23, P3700, DOI 10.1038/sj.onc.1207448; Helbig R, 2003, CHROMOSOMA, V112, P173, DOI 10.1007/s00412-003-0258-0; Hirose F, 1996, J BIOL CHEM, V271, P3930; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; Howell M, 2004, J BIOL CHEM, V279, P26300, DOI 10.1074/jbc.M401070200; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Ko MSH, 2000, DEVELOPMENT, V127, P1737; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Leaw CL, 2004, CELL MOL LIFE SCI, V61, P2264, DOI 10.1007/s00018-004-4205-x; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lodge AP, 1999, EUR J BIOCHEM, V261, P137, DOI 10.1046/j.1432-1327.1999.00246.x; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; Mahajan MC, 2005, P NATL ACAD SCI USA, V102, P15012, DOI 10.1073/pnas.0507596102; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Ohno K, 2000, GENE, V260, P133, DOI 10.1016/S0378-1119(00)00447-9; Ohshima N, 2003, J BIOL CHEM, V278, P22928, DOI 10.1074/jbc.M303109200; Ougolkov A, 2004, JNCI-J NATL CANCER I, V96, P1161, DOI 10.1093/jnci/djh219; Pan HY, 2003, J VIROL, V77, P9758, DOI 10.1128/JVI.77.18.9758-9768.2003; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; PhiVan L, 1996, BIOCHEMISTRY-US, V35, P10735, DOI 10.1021/bi9603783; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schoen TJ, 1997, BBA-GENE STRUCT EXPR, V1353, P39, DOI 10.1016/S0167-4781(97)00041-9; Schubeler D, 1996, BIOCHEMISTRY-US, V35, P11160, DOI 10.1021/bi960930o; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Winteringham LN, 2004, ONCOGENE, V23, P5105, DOI 10.1038/sj.onc.1207661; Yoneda-Kato N, 2005, EMBO J, V24, P1739, DOI 10.1038/sj.emboj.7600656; YonedaKato N, 1996, ONCOGENE, V12, P265; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	62	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38791	38800		10.1074/jbc.M605401200	http://dx.doi.org/10.1074/jbc.M605401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17008314	Green Published, hybrid			2022-12-25	WOS:000242709500077
J	Schweinfest, CW; Spyropoulos, DD; Henderson, KW; Kim, JH; Chapman, JM; Barone, S; Worrell, RT; Wang, ZH; Soleimani, M				Schweinfest, Clifford W.; Spyropoulos, Demetri D.; Henderson, Kelly W.; Kim, Jae-Ho; Chapman, Jeannie M.; Barone, Sharon; Worrell, Roger T.; Wang, Zhaohui; Soleimani, Manoocher			slc26a3 (dra)-deficient mice display chloride-losing diarrhea, enhanced colonic proliferation, and distinct up-regulation of ion transporters in the colon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABERRANT CRYPT FOCI; PUTATIVE ANION TRANSPORTER; DRA GENE ENCODES; ADENOMA DRA; SULFATE TRANSPORTER; CL-/HCO3-EXCHANGER; FUNCTIONAL-CHARACTERIZATION; CELLS; IDENTIFICATION; MEMBRANE	Mutations in the SLC26A3 (DRA (down-regulated in adenoma)) gene constitute the molecular etiology of congenital chloride-losing diarrhea in humans. To ascertain its role in intestinal physiology, gene targeting was used to prepare mice lacking slc26a3. slc26a3-deficient animals displayed postpartum lethality at low penetrance. Surviving dra-deficient mice exhibited high chloride content diarrhea, volume depletion, and growth retardation. In addition, the large intestinal loops were distended, with colonic mucosa exhibiting an aberrant growth pattern and the colonic crypt proliferative zone being greatly expanded in slc26a3-null mice. Apical membrane chloride/base exchange activity was sharply reduced, and luminal content was more acidic in slc26a3-null mouse colon. The epithelial cells in the colon displayed unique adaptive regulation of ion transporters; NHE3 expression was enhanced in the proximal and distal colon, whereas colonic H, K-ATPase and the epithelial sodium channel showed massive up-regulation in the distal colon. Plasma aldosterone was increased in slc26a3- null mice. We conclude that slc26a3 is the major apical chloride/base exchanger and is essential for the absorption of chloride in the colon. In addition, slc26a3 regulates colonic crypt proliferation. Deletion of slc26a3 results in chloride-rich diarrhea and is associated with compensatory adaptive up-regulation of ion-absorbing transporters.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Univ Cincinnati, Dept Med, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Cincinnati, OH 45220 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	Soleimani, M (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Rm 321-A,86 Jonathan Lucas St, Charleston, SC 29425 USA.	Manoocher.Soleimani@uc.edu			NCI NIH HHS [R01 CA095172] Funding Source: Medline; NIDDK NIH HHS [R01 DK62809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alrefai WA, 2001, AM J PHYSIOL-GASTR L, V280, pG603, DOI 10.1152/ajpgi.2001.280.4.G603; Antalis TM, 1998, CLIN CANCER RES, V4, P1857; BISSIG M, 1994, J BIOL CHEM, V269, P3017; Byeon MK, 1998, PROTEIN EXPRES PURIF, V12, P67, DOI 10.1006/prep.1997.0809; Byeon MK, 1996, ONCOGENE, V12, P387; Chapman JM, 2002, CANCER RES, V62, P5083; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Greeley T, 2001, AM J PHYSIOL-GASTR L, V281, pG1301, DOI 10.1152/ajpgi.2001.281.5.G1301; Haila S, 2000, HISTOCHEM CELL BIOL, V113, P279, DOI 10.1007/s004180000131; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOGAN B, 1986, MANIPULATING MOUSE E; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; HOLMBERG C, 1986, CLIN GASTROENTEROL, V15, P583; Jacob P, 2002, GASTROENTEROLOGY, V122, P709, DOI 10.1053/gast.2002.31875; Jiang Z, 2002, J BIOL CHEM, V277, P33963, DOI 10.1074/jbc.M202660200; Lamprecht G, 2006, PFLUG ARCH EUR J PHY, V452, P307, DOI 10.1007/s00424-006-0049-6; Lee CH, 2003, J CELL PHYSIOL, V195, P61, DOI 10.1002/jcp.10225; Lohi H, 2002, J BIOL CHEM, V277, P14246, DOI 10.1074/jbc.M111802200; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; Papanikolaou A, 1998, CANCER LETT, V130, P29, DOI 10.1016/S0304-3835(98)00101-3; Papanikolaou A, 2000, CARCINOGENESIS, V21, P1567, DOI 10.1093/carcin/21.8.1567; Paulsen JE, 2000, SCAND J GASTROENTERO, V35, P534; Paulsen JE, 2001, CANCER RES, V61, P5010; Pereira MA, 1999, ADV EXP MED BIOL, V470, P55; Petrovic S, 2003, AM J PHYSIOL-GASTR L, V284, pG1093, DOI 10.1152/ajpgi.00454.2002; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Rajendran VM, 1999, AM J PHYSIOL-GASTR L, V276, pG132, DOI 10.1152/ajpgi.1999.276.1.G132; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; Shcheynikov N, 2006, J GEN PHYSIOL, V127, P511, DOI 10.1085/jgp.200509392; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; Soleimani M, 2001, AM J PHYSIOL-RENAL, V280, pF356, DOI 10.1152/ajprenal.2001.280.2.F356; SOLEIMANI M, 1992, J CLIN INVEST, V90, P211, DOI 10.1172/JCI115838; Song J, 2000, CANCER RES, V60, P5434; Spicer Z, 2001, AM J PHYSIOL-GASTR L, V281, pG1369, DOI 10.1152/ajpgi.2001.281.6.G1369; Tyagi S, 2001, EXP BIOL MED, V226, P912, DOI 10.1177/153537020122601006; Vincourt JB, 2003, FASEB J, V17, P890, DOI 10.1096/fj.02-0787fje; Vincourt JB, 2002, GENOMICS, V79, P249, DOI 10.1006/geno.2002.6689; Wang ZH, 2005, AM J PHYSIOL-CELL PH, V288, pC957, DOI 10.1152/ajpcell.00505.2004; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; Winter DC, 2000, BRIT J SURG, V87, P1684, DOI 10.1046/j.1365-2168.2000.01584.x; Xie QH, 2002, AM J PHYSIOL-RENAL, V283, pF826, DOI 10.1152/ajprenal.00079.2002; Xu J, 2005, AM J PHYSIOL-CELL PH, V289, pC493, DOI 10.1152/ajpcell.00030.2005; Xu J, 2006, J AM SOC NEPHROL, V17, P956, DOI 10.1681/ASN.2005111174; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	48	157	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37962	37971		10.1074/jbc.M607527200	http://dx.doi.org/10.1074/jbc.M607527200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17001077	hybrid			2022-12-25	WOS:000242477100075
J	Cobine, PA; Pierrel, F; Bestwick, ML; Winge, DR				Cobine, Paul A.; Pierrel, Fabien; Bestwick, Megan L.; Winge, Dennis R.			Mitochondrial matrix copper complex used in metallation of cytochrome oxidase and superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN-SUPEROXIDE DISMUTASE; TRANSPORTER; METALLOCHAPERONE; TRAFFICKING; IRON; PROTEINS; COX17; SOD1	A mitochondrial matrix copper ligand (CuL) complex, conserved in mammalian cells, is the likely source of copper for assembly of cytochrome c oxidase (CcO) and superoxide dismutase 1 (Sod1) within the intermembrane space (IMS) in yeast. Targeting the copper-binding proteins human Sod1 and Crs5 to the mitochondrial matrix results in growth impairment on non-fermentable medium caused by decreased levels of CcO. This effect is reversed by copper supplementation. Matrix-targeted Crs5 diminished Sod1 protein within the IMS and impaired activity of an inner membrane tethered human Sod1. Copper binding by the matrix-targeted proteins attenuates levels of the CuL complex without affecting total mitochondrial copper. These data suggest that attenuation of the matrix CuL complex via heterologous competitors limits available copper for metallation of CcO and Sod1 within the IMS. The ligand also exists in the cytoplasm in an apparent metal-free state.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Cobine, Paul A/G-3107-2011; Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010; PIERREL, Fabien/M-6016-2014	Cobine, Paul A/0000-0001-6012-0985; Cobine, Paul/0000-0001-6012-0985; PIERREL, Fabien/0000-0003-2083-3002; Bestwick, Megan/0000-0003-3670-5507	NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Cobine PA, 2004, J BIOL CHEM, V279, P14447, DOI 10.1074/jbc.M312693200; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Field LS, 2002, J BIOENERG BIOMEMBR, V34, P373, DOI 10.1023/A:1021202119942; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GELLER BL, 1982, J BIOL CHEM, V257, P8945; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Kim HJ, 2004, SCIENCE, V305, P1612, DOI 10.1126/science.1098322; Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Luk E, 2003, P NATL ACAD SCI USA, V100, P10353, DOI 10.1073/pnas.1632471100; Marobbio CMT, 2003, EMBO J, V22, P5975, DOI 10.1093/emboj/cdg574; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Yang LC, 2005, P NATL ACAD SCI USA, V102, P11179, DOI 10.1073/pnas.0406547102; Yang M, 2006, EMBO J, V25, P1775, DOI 10.1038/sj.emboj.7601064; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200	28	103	104	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36552	36559		10.1074/jbc.M606839200	http://dx.doi.org/10.1074/jbc.M606839200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17008312	Green Submitted, hybrid			2022-12-25	WOS:000242220800011
J	Iliev, AI; Ganesan, S; Bunt, G; Wouters, FS				Iliev, Asparouh Iliev; Ganesan, Sundar; Bunt, Gertrude; Wouters, Fred Silvester			Removal of pattern-breaking sequences in microtubule binding repeats produces instantaneous tau aggregation and toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; BETA-STRUCTURE; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; PROTEIN; TAUOPATHY; CELLS; NEURODEGENERATION; CONFORMATION; ASSOCIATION	Aggregated and highly phosphorylated tau protein is a pathological hallmark of Alzheimer's disease (AD) and other tauopathies. We identified motifs of alternating polar and apolar amino acids within the microtubule-binding repeats of tau which were interrupted by small breaking stretches. Minimal mutation of these breaking sequences yielded a unique instantly aggregating tau mutant containing longer stretches of polar/apolar amino acids without losing its microtubule-binding capacity. These modifications produced rapid aggregation and cytotoxicity with accompanying occurrence of pathologic tau phosphoepitopes (AT8, AT180, AT270, AT100, Ser(422), and PHF-1) and conformational epitopes (MC-1 and Alz50) in cells. Similar to pathological tau in the pretangle state, toxicity appeared to occur early without the requirement for extensive fibril formation. Thus, our mutant protein provides a novel platform for the investigation of the molecular mechanisms for toxicity and cellular behavior of pathologically aggregated tau proteins and the identification of its interaction partners.	European Neurosci Inst, Cell Biophys Grp, D-37073 Gottingen, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	Max Planck Society	Iliev, AI (corresponding author), European Neurosci Inst, Cell Biophys Grp, Waldweg 33, D-37073 Gottingen, Germany.	ailiev@gwdg.de; fred.wouters@gwdg.de	Iliev, Asparouh/D-2222-2015					Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Broome BM, 2000, J MOL BIOL, V296, P961, DOI 10.1006/jmbi.2000.3514; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P15009, DOI 10.1021/bi035722s; Gordon-Krajcer W, 2000, BRAIN RES, V856, P163, DOI 10.1016/S0006-8993(99)02391-4; Gotz J, 2001, BRAIN RES REV, V35, P266, DOI 10.1016/S0165-0173(01)00055-8; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GUTTMANN RP, 1995, J NEUROCHEM, V64, P1209; Hall GF, 2005, BBA-MOL BASIS DIS, V1739, P224, DOI 10.1016/j.bbadis.2004.10.002; Humbel BM, 1998, MICROSC RES TECHNIQ, V42, P43, DOI 10.1002/(SICI)1097-0029(19980701)42:1<43::AID-JEMT6>3.3.CO;2-4; Iliev AI, 2003, FASEB J, V17, P412, DOI 10.1096/fj.03-0670fje; Jicha GA, 1999, J NEUROSCI RES, V55, P713, DOI 10.1002/(SICI)1097-4547(19990315)55:6<713::AID-JNR6>3.0.CO;2-G; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; Kraemer BC, 2003, P NATL ACAD SCI USA, V100, P9980, DOI 10.1073/pnas.1533448100; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; Mukrasch MD, 2005, J BIOL CHEM, V280, P24978, DOI 10.1074/jbc.M501565200; Perez M, 2002, EUR J BIOCHEM, V269, P1484, DOI 10.1046/j.1432-1033.2002.02794.x; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Saito Y, 2002, NEUROLOGY, V58, P811, DOI 10.1212/WNL.58.5.811; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P1037, DOI 10.1073/pnas.78.2.1037; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; von Bergen M, 2005, BBA-MOL BASIS DIS, V1739, P158, DOI 10.1016/j.bbadis.2004.09.010; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382	35	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37195	37204		10.1074/jbc.M604863200	http://dx.doi.org/10.1074/jbc.M604863200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17008320	hybrid			2022-12-25	WOS:000242220800080
J	Mochida, Y; Parisuthiman, D; Kaku, M; Hanai, J; Sukhatme, VP; Yamauchi, M				Mochida, Yoshiyuki; Parisuthiman, Duenpim; Kaku, Masaru; Hanai, Jun-ichi; Sukhatme, Vikas P.; Yamauchi, Mitsuo			Nephrocan, a novel member of the small leucine-rich repeat protein family, is an inhibitor of transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I COLLAGEN; TYROSINE SULFATION; BINDING-SITES; DECORIN BINDS; PROTEOGLYCANS; BIGLYCAN; MATRIX; FIBRILLOGENESIS; DIFFERENTIATION; IDENTIFICATION	In a search of new, small leucine-rich repeat proteoglycan/protein (SLRP) family members, a novel gene, nephrocan (NPN), has been identified. The gene consists of three exons, and based on the deduced amino acid sequence, NPN has 17 leucine-rich repeat motifs and unique cysteine-rich clusters both in the N and C termini, indicating that this gene belongs to a new class of SLRP family. NPN mRNA was predominantly expressed in kidney in adult mice, and during mouse embryogenesis, the expression was markedly increased in 11-day-old embryos at a time when early kidney development takes place. In the adult mouse kidney, NPN protein was located in distal tubules and collecting ducts. When NPN was overexpressed in cell culture, the protein was detected in the cultured medium, and upon treatment with N-glycosidase F, the molecular mass was lowered by similar to 14 kDa, indicating that NPN is a secreted N-glycosylated protein. Furthermore, transforming growth factor-beta(TGF-beta)-responsive 3TP promoter luciferase activity was down-regulated, and TGF-beta-induced Smad3 phosphorylation was also inhibited by NPN, suggesting that NPN suppresses TGF-beta/Smad signaling. Taken together, NPN is a novel member of the SLRP family that may play important roles in kidney development and pathophysiology by functioning as an endogenous inhibitor of TGF-beta signaling.	Univ N Carolina, Dent Res Ctr, Chapel Hill, NC 27599 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Study Tumor Microenvironm,Div Nephrol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Study Tumor Microenvironm,Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Study Tumor Microenvironm,Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Study Tumor Microenvironm,Dept Pathol, Boston, MA 02215 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Yamauchi, M (corresponding author), Univ N Carolina, Dent Res Ctr, CB 7455, Chapel Hill, NC 27599 USA.	Mitsuo_Yamauchi@dentistry.unc.edu	Sukhatme, Vikas/W-2776-2019; Kaku, Masaru/S-7309-2017; Kaku, Masaru/K-5041-2019	Kaku, Masaru/0000-0002-7988-6435; Kaku, Masaru/0000-0002-7988-6435; Mochida, Yoshiyuki/0000-0002-2115-4303	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR052824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010489] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR052824] Funding Source: Medline; NIDCR NIH HHS [DE10489] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Atsawasuwan P, 2005, BIOCHEM BIOPH RES CO, V327, P1042, DOI 10.1016/j.bbrc.2004.12.119; Barasch J, 1996, AM J PHYSIOL-RENAL, V271, pF50, DOI 10.1152/ajprenal.1996.271.1.F50; Barasch J, 2001, CURR OPIN NEPHROL HY, V10, P429, DOI 10.1097/00041552-200105000-00021; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Chen XD, 2004, FASEB J, V18, P948, DOI 10.1096/fj.03-0899com; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769; Nili N, 2003, AM J PATHOL, V163, P869, DOI 10.1016/S0002-9440(10)63447-5; Ohta K, 2004, DEV CELL, V7, P347, DOI 10.1016/j.devcel.2004.08.014; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Plisov SY, 2001, DEVELOPMENT, V128, P1045; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; Schonherr E, 2005, J BIOL CHEM, V280, P15767, DOI 10.1074/jbc.M500451200; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Shimizu-Hirota R, 2004, FEBS LETT, V563, P69, DOI 10.1016/S0014-5793(04)00250-9; Sini P, 1997, GLYCOCONJUGATE J, V14, P871, DOI 10.1023/A:1018550307649; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; Tasheva E, 2004, MOL VIS, V10, P758; Tenni R, 2002, EUR J BIOCHEM, V269, P1428, DOI 10.1046/j.1432-1033.2002.02784.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vainio S, 2002, NAT REV GENET, V3, P533, DOI 10.1038/nrg842; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wilson IBH, 2004, CELL MOL LIFE SCI, V61, P794, DOI 10.1007/s00018-003-3278-2; Wu HW, 2000, NAT STRUCT BIOL, V7, P575; Yu L, 2003, KIDNEY INT, V64, P844, DOI 10.1046/j.1523-1755.2003.00162.x; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zhang ZL, 2004, CURR OPIN GENET DEV, V14, P328, DOI 10.1016/j.gde.2004.06.003	50	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36044	36051		10.1074/jbc.M604787200	http://dx.doi.org/10.1074/jbc.M604787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16990280	hybrid, Green Published			2022-12-25	WOS:000242100500053
J	Qian, Y; Prehoda, KE				Qian, Yi; Prehoda, Kenneth E.			Interdomain interactions in the tumor suppressor discs large regulate binding to the synaptic protein GukHolder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE KINASE DOMAINS; PDZ DOMAIN; INTRAMOLECULAR INTERACTION; CRYSTAL-STRUCTURE; CELL-JUNCTIONS; GENE DLG; DROSOPHILA; COMPLEX; PSD-95; IDENTIFICATION	Multidomain scaffolding proteins are central components of many signaling pathways and are commonly found at membrane specializations. Here we have shown that multiple interdomain interactions in the scaffold Discs Large (Dlg) regulate binding to the synaptic protein GukHolder (GukH). GukH binds the Src homology 3 (SH3) and guanylate kinase-like (GK) protein interaction domains of Dlg, whereas an intramolecular interaction between the two domains inhibits association with GukH. Regulation occurs through a PDZ domain adjacent to the SH3 that allows GukH to interact with the composite SH3-GK binding site, but PDZ ligands inhibit GukH binding such that Dlg forms mutually exclusive PDZ ligand and GukH cellular complexes. The PDZ-SH3-GK module is a common feature of membrane associate guanylate kinase scaffolds such as Dlg, and these results indicate that its supramodular architecture leads to regulation of Dlg complexes.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Prehoda, KE (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	prehoda@molbio.uoregon.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068032] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM068032-05, R01 GM068032, R01 GM068032-01, R01 GM068032-03, R01 GM068032-02, R01 GM068032-04, GM068032] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Brenman JE, 1998, J NEUROSCI, V18, P8805; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; FERRELL JE, 2000, SCI STKE, pPE1; Harris BZ, 2001, J CELL SCI, V114, P3219; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Katoh M, 2004, INT J ONCOL, V24, P1033; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lise MF, 2006, CELL MOL LIFE SCI, V63, P1833, DOI 10.1007/s00018-006-6061-3; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Montgomery JM, 2004, CELL MOL LIFE SCI, V61, P911, DOI 10.1007/s00018-003-3364-5; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Passafaro M, 1999, NAT NEUROSCI, V2, P1063, DOI 10.1038/15990; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Penkert RR, 2004, NAT STRUCT MOL BIOL, V11, P1122, DOI 10.1038/nsmb839; Sharma S, 2006, HUM MOL GENET, V15, P1972, DOI 10.1093/hmg/ddl120; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Vondriska TM, 2004, J MOL CELL CARDIOL, V37, P391, DOI 10.1016/j.yjmcc.2004.04.021; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wilken C, 2004, CELL, V117, P483, DOI 10.1016/S0092-8674(04)00454-4; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	32	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35757	35763		10.1074/jbc.M607057200	http://dx.doi.org/10.1074/jbc.M607057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16982606	Green Accepted, hybrid			2022-12-25	WOS:000242100500021
J	Vukmirica, J; Monzo, P; Le Marchand-Brustel, Y; Cormont, M				Vukmirica, Jelena; Monzo, Pascale; Le Marchand-Brustel, Yannick; Cormont, Mireille			The Rab4A effector protein Rabip4 is involved in migration of NIH 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; FYVE-FINGER; EARLY ENDOSOMES; INTEGRINS; ALPHA-V-BETA-3; TRANSPORT; EEA1; ALPHA-5-BETA-1; ANGIOGENESIS; TRAFFICKING	The small GTP-binding protein Rab4 has been involved in the recycling of alpha v beta 3 integrins in response to platelet-derived growth factor ( PDGF) stimulation suggesting a role for Rab4 in cell adhesion and migration. In this study, we explored the role of Rabip4 and Rabip4, two Rab4 effector proteins, in migration of NIH 3T3 fibroblasts. In these cells, Rabip4 and Rabip4', collectively named Rabip4s, were partially co-localized with the early endosomal marker EEA1. PDGF treatment re-distributed endogenous Rabip4s toward the cell periphery where they co-localized with F-actin. In cells expressing green fluorescent protein (GFP)-Rabip4 or GFP-Rabip4', constitutive appearance of GFP-Rabip4s at the cell periphery was accompanied by local increase in cortical F-actin in membrane ruffles at the leading edge. The expression of GFP-Rabip4 induced an increased migration compared with control cells expressing GFP alone, even in the absence of PDGF stimulation. On the contrary, in cells expressing a mutated form of Rabip4s unable to interact with Rab4, lack of typical leading edge was observed. Furthermore, PDGF treatment did not stimulate the migration of these cells. Furthermore, down-regulation of the expression of Rabip4s inhibited PDGF-stimulated cell migration. Endogenous Rabip4s were localized with alpha v integrins at the leading edge following PDGF treatment, whereas in cells expressing GFP-Rabip4s, alpha v integrins, together with GFP-Rabip4s, were constitutively localized at the leading edge. In contrast, reduction in Rabip4s expression levels using small interfering RNA was associated with impaired PDGF-induced translocation of alpha v integrins toward the leading edge. Taken together, our data provide evidence that Rabip4s, possibly via their interaction with Rab4, regulate integrin trafficking and are involved in the migration of NIH 3T3 fibroblasts.	UFR Med, INSERM, U568, F-06107 Nice 02, France; Univ Nice Sophia Antipolis, UFR Sci, F-06002 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Cormont, M (corresponding author), UFR Med, INSERM, U568, F-06107 Nice 02, France.	cormont@unice.fr		CORMONT, Mireille/0000-0001-6918-2410				BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Fouraux MA, 2004, MOL BIOL CELL, V15, P611, DOI 10.1091/mbc.E03-05-0343; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Kerr JS, 2002, EXPERT OPIN INV DRUG, V11, P1765, DOI 10.1517/13543784.11.12.1765; Kumar CC, 2003, CURR DRUG TARGETS, V4, P123, DOI 10.2174/1389450033346830; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Mari M, 2006, J CELL SCI, V119, P1297, DOI 10.1242/jcs.02850; Mari M, 2001, J BIOL CHEM, V276, P42501, DOI 10.1074/jbc.M104885200; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; Monzo P, 2005, METHOD ENZYMOL, V403, P107, DOI 10.1016/S0076-6879(05)03010-7; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Spaargaren M, 1999, MOL BIOL CELL, V10, P3239, DOI 10.1091/mbc.10.10.3239; Stenmark H, 1999, J CELL SCI, V112, P4175; Tucker GC, 2002, CURR OPIN PHARMACOL, V2, P394, DOI 10.1016/S1471-4892(02)00175-3; Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	39	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36360	36368		10.1074/jbc.M602920200	http://dx.doi.org/10.1074/jbc.M602920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17001082	hybrid			2022-12-25	WOS:000242100500087
J	Butler, MW; Robertson, I; Greene, CM; O'Neill, SJ; Taggart, CC; McElvaney, NG				Butler, Marcus W.; Robertson, Ian; Greene, Catherine M.; O'Neill, Shane J.; Taggart, Clifford C.; McElvaney, Noel G.			Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappa B activation via an effect on the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; SIGNAL-TRANSDUCTION; CHEMOKINE RECEPTOR; ALPHA DEGRADATION; KINASE ACTIVATION; EPITHELIAL-CELLS; GENE-EXPRESSION; PRE-ELAFIN; INHIBITOR; INDUCTION	The serine anti-protease elafin is expressed by monocytes, alveolar macrophages, neutrophils, and at mucosal surfaces and possesses antimicrobial activity. It is also known to reduce lipopolysaccharide-induced neutrophil influx into murine alveoli as well as to abrogate lipopolysaccharide-induced production of matrix metalloprotease 9, macrophage inhibitory protein 2, and tumor necrosis factor-alpha by as-yet unidentified mechanisms. In this report we have shown that elafin inhibits the lipopolysaccharide-induced production of monocyte chemoattractant protein-1 in monocytes by inhibiting AP-1 and NF-kappa B activation. Elafin prevented lipopolysaccharide-induced phosphorylation of AP-1, c-Jun, and JNK but had no effect on phosphorylation of p38. The lipopolysaccharide-induced degradation of IL-1R-associated kinase 1, I kappa B alpha, and I kappa B beta was inhibited by elafin but phosphorylation of I kappa B alpha was unaffected. Polyubiquitinated protein including polyubiquitinated I kappa B alpha was shown to accumulate in the presence of elafin. These results suggest that inhibition by elafin of lipopolysaccharide-induced AP-1 and NF-kappa B activation occurs via an effect on the ubiquitin-proteasome pathway.	Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Dept Med,Pulm Res Div, Dublin 9, Ireland	Royal College of Surgeons - Ireland	Taggart, CC (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Dept Med,Pulm Res Div, Dublin 9, Ireland.	ctaggart@rcsi.ie	Greene, Catherine M/D-3513-2012; Taggart, Clifford C/G-4492-2014; McElvaney, Noel/A-6809-2010; Poubelle, Patrice E/G-6537-2013	Greene, Catherine M/0000-0003-2549-2569; Butler, Marcus/0000-0003-2026-7709; Taggart, Clifford/0000-0002-9930-2978; mcelvaney, Noel/0000-0002-0152-4370				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Arndt PG, 2004, J BIOL CHEM, V279, P10883, DOI 10.1074/jbc.M309901200; Bingle L, 2001, AM J RESP CELL MOL, V25, P84, DOI 10.1165/ajrcmb.25.1.4341; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Gao YH, 2000, J CLIN INVEST, V106, P439, DOI 10.1172/JCI9826; Greene CM, 2004, INFECT IMMUN, V72, P3684, DOI 10.1128/IAI.72.6.3684-3687.2004; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guyot N, 2005, BIOL CHEM, V386, P391, DOI 10.1515/BC.2005.047; Hall DJ, 2005, J IMMUNOL, V174, P8056, DOI 10.4049/jimmunol.174.12.8056; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; MCELVANEY NG, 2005, CHRONIC OBSTRUCTIVE, P343; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Rollins BJ, 1996, MOL MED TODAY, V2, P198, DOI 10.1016/1357-4310(96)88772-7; Schalkwijk J, 1999, BIOCHEM J, V340, P569, DOI 10.1042/0264-6021:3400569; Simpson AJ, 1999, FEBS LETT, V452, P309, DOI 10.1016/S0014-5793(99)00670-5; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; Taggart CC, 2005, J EXP MED, V202, P1659, DOI 10.1084/jem.20050768; Taggart CC, 2002, J BIOL CHEM, V277, P33648, DOI 10.1074/jbc.M203710200; Vachon E, 2002, BIOL CHEM, V383, P1249, DOI 10.1515/BC.2002.138; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; ZHANG M, 1995, CANCER RES, V55, P2537; Zhong J, 2004, MOL CELL BIOL, V24, P9165, DOI 10.1128/MCB.24.20.9165-9175.2004	29	62	70	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34730	34735		10.1074/jbc.M604844200	http://dx.doi.org/10.1074/jbc.M604844200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980310	hybrid			2022-12-25	WOS:000241933700003
J	Milakovic, T; Quintanilla, RA; Johnson, GVW				Milakovic, Tamara; Quintanilla, Rodrigo A.; Johnson, Gail V. W.			Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells - Functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION; CYTOCHROME-C; DISEASE; CA2+; BRAIN; DYSFUNCTION; IMPAIRMENT; TRANSPORT; CHANNELS; SUPPORT	Huntington disease (HD) is caused by a pathological elongation of CAG repeats in the huntingtin protein gene and is characterized by atrophy and neuronal loss primarily in the striatum. Mitochondrial dysfunction and impaired Ca2+ homeostasis in HD have been suggested previously. Here, we elucidate the effects of Ca2+ on mitochondria from the wild type (STHdh(Q7/Q7)) and mutant (STHdh(Q111/Q111)) huntingtin-expressing cells of striatal origin. When treated with increasing Ca2+ concentrations, mitochondria from mutant huntingtin-expressing cells showed enhanced sensitivity to Ca2+, as they were more sensitive to Ca2+ -induced decreases in state 3 respiration and Delta Psi m, than mitochondria from wild type cells. Further, mutant huntingtin-expressing cells had a reduced mitochondrial Ca2+ uptake capacity in comparison with wild type cells. Decreases in state 3 respiration were associated with increased mitochondrial membrane permeability. The Delta Psi m defect was attenuated in the presence of ADP and the decreases in Ca2+ uptake capacity were abolished in the presence of Permeability Transition Pore (PTP) inhibitors. These findings clearly indicate that mutant huntingtin-expressing cells have mitochondrial Ca2+ handling defects that result in respiratory deficits and that the increased sensitivity to Ca2+ induced mitochondrial permeabilization maybe a contributing mechanism to the mitochondrial dysfunction in HD.	Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama Birmingham, Dept Psychiat, 1720 7th Ave S,SC 1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012; QUINTANILLA, RODRIGO/ABG-8829-2021	Johnson, Gail V.W./0000-0003-3464-0404; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS041744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramov AY, 2003, CELL CALCIUM, V33, P101, DOI 10.1016/S0143-4160(02)00203-8; Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140; BEAL MF, 1993, J NEUROSCI, V13, P4181; BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Calabresi P, 2001, J NEUROSCI, V21, P5110, DOI 10.1523/JNEUROSCI.21-14-05110.2001; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Choo YS, 2004, HUM MOL GENET, V13, P1407, DOI 10.1093/hmg/ddh162; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; Esposti MD, 1999, J BIOL CHEM, V274, P29831, DOI 10.1074/jbc.274.42.29831; Forte M, 2005, J BIOENERG BIOMEMBR, V37, P121, DOI 10.1007/s10863-005-6565-9; Gizatullina ZZ, 2006, ANN NEUROL, V59, P407, DOI 10.1002/ana.20754; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Guidetti P, 2001, EXP NEUROL, V169, P340, DOI 10.1006/exnr.2000.7626; HENSHAW R, 1994, BRAIN RES, V647, P161, DOI 10.1016/0006-8993(94)91412-5; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; Krysko DV, 2001, J HISTOCHEM CYTOCHEM, V49, P1277, DOI 10.1177/002215540104901010; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; La Piana G, 2005, ARCH BIOCHEM BIOPHYS, V436, P91, DOI 10.1016/j.abb.2004.12.029; La Piana G, 2003, ARCH BIOCHEM BIOPHYS, V410, P201, DOI 10.1016/S0003-9861(02)00687-2; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Leegwater-Kim Julie, 2004, NeuroRx, V1, P128, DOI 10.1602/neurorx.1.1.128; Lemeshko VV, 2001, ARCH BIOCHEM BIOPHYS, V388, P60, DOI 10.1006/abbi.2000.2214; Leski ML, 2002, SYNAPSE, V43, P30, DOI 10.1002/syn.10015; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MANN VM, 1990, LANCET, V336, P749, DOI 10.1016/0140-6736(90)92242-A; Milakovic T, 2005, J BIOL CHEM, V280, P30773, DOI 10.1074/jbc.M504749200; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P4028; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2003, CELL CALCIUM, V34, P407, DOI 10.1016/S0143-4160(03)00144-1; Panov A, 1999, ANN NY ACAD SCI, V893, P365, DOI 10.1111/j.1749-6632.1999.tb07856.x; Panov AV, 2004, ARCH BIOCHEM BIOPHYS, V424, P44, DOI 10.1016/j.abb.2004.01.013; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Paschen W, 1996, J NEUROCHEM, V67, P1735; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Ruan QM, 2004, HUM MOL GENET, V13, P669, DOI 10.1093/hmg/ddh082; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Valera AG, 2005, NEUROSCIENTIST, V11, P583, DOI 10.1177/1073858405280639; Vergun O, 2005, BBA-BIOENERGETICS, V1709, P127, DOI 10.1016/j.bbabio.2005.07.006; VOET D, 1995, BIOCHEMISTRY-US, P798; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	49	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34785	34795		10.1074/jbc.M603845200	http://dx.doi.org/10.1074/jbc.M603845200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973623	hybrid			2022-12-25	WOS:000241933700010
J	Sommer, F; Drepper, F; Haehnel, W; Hippler, M				Sommer, Frederik; Drepper, Friedel; Haehnel, Wolfgang; Hippler, Michael			Identification of precise electrostatic recognition sites between cytochrome c(6) and the photosystem I subunit PsaF using mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; DIRECTED MUTAGENESIS; SPINACH PLASTOCYANIN; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; SWISS-MODEL; BINDING; PROTEINS; COMPLEX; REDUCTION	The reduction of the photo-oxidized special chlorophyll pair P700 of photosystem I (PSI) in the photosynthetic electron transport chain of eukaryotic organisms is facilitated by the soluble copper-containing protein plastocyanin (pc). In the absence of copper, pc is functionally replaced by the heme-containing protein cytochrome c(6) (cyt c(6)) in the green alga Chlamydomonas reinhardtii. Binding and electron transfer between both donors and PSI follows a two-step mechanism that depends on electrostatic and hydrophobic recognition between the partners. Although the electrostatic and hydrophobic recognition sites on pc and PSI are well known, the precise electrostatic recognition site on cyt c(6) is unknown. To specify the interaction sites on a molecular level, we cross-linked cyt c(6) and PSI using a zero-length cross-linker and obtained a cross-linked complex competent in fast and efficient electron transfer. As shown previously, cyt c(6) cross-links specifically with the PsaF subunit of PSI. Mass spectrometric analysis of tryptic peptides from the cross-linked product revealed specific interaction sites between residues Lys(27) of PsaF and Glu(69) of cyt c(6) and between Lys(23) of PsaF and Glu(69)/Glu(70) of cyt c(6). Using these new data, we present a molecular model of the intermolecular electron transfer complex between eukaryotic cyt c(6) and PSI.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Univ Freiburg, D-79104 Freiburg, Germany	University of Pennsylvania; University of Freiburg	Hippler, M (corresponding author), Univ Munster, Inst Plant Biochem & Biotechnol, Dept Biol, Hindenburgpl 55, D-48143 Munster, Germany.	mhippler@uni-muenster.de		Michael, Hippler/0000-0001-9670-6101; Drepper, Friedel/0000-0002-2043-5795				Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; Finazzi G, 2005, P NATL ACAD SCI USA, V102, P7031, DOI 10.1073/pnas.0406288102; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Harris E., 1989, CHLAMYDOMONAS SOURCE, P575; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 2002, PROTIST, V153, P197, DOI 10.1078/1434-4610-00098; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; Jolley C, 2005, J BIOL CHEM, V280, P33627, DOI 10.1074/jbc.M500937200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BH, 1995, J BIOCHEM, V117, P1209; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Molina-Heredia FP, 1999, J BIOL CHEM, V274, P33565, DOI 10.1074/jbc.274.47.33565; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Naumann B, 2005, J BIOL CHEM, V280, P20431, DOI 10.1074/jbc.M414486200; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REDINBO MR, 1993, BIOCHEMISTRY-US, V32, P10560, DOI 10.1021/bi00091a005; SANDMANN G, 1986, ARCH MICROBIOL, V21, P6366; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sommer F, 2004, J BIOL CHEM, V279, P20009, DOI 10.1074/jbc.M313986200; Sommer F, 2002, J BIOL CHEM, V277, P6573, DOI 10.1074/jbc.M110633200; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Sun J, 1999, J BIOL CHEM, V274, P19048, DOI 10.1074/jbc.274.27.19048; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; XU QA, 1994, J BIOL CHEM, V269, P3205	37	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35097	35103		10.1074/jbc.M607384200	http://dx.doi.org/10.1074/jbc.M607384200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984911	hybrid			2022-12-25	WOS:000241933700043
J	Umesh, A; Thompson, MA; Chini, EN; Yip, KP; Sham, JSK				Umesh, Anita; Thompson, Michael A.; Chini, Eduardo N.; Yip, Kay-Pong; Sham, James S. K.			Integrin ligands mobilize Ca2+ from ryanodine receptor-gated stores and lysosome-related acidic organelles in pulmonary arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE PHOSPHATE; ARG-GLY-ASP; ALPHA(V)BETA(3) INTEGRIN; ADHESION RECEPTORS; INTRACELLULAR CA2+; PANCREATIC ACINAR; MEDIATED CALCIUM; FOCAL ADHESION; TENASCIN-C	Extracellular matrix (ECM) protein receptors, or integrins, participate in vascular remodeling and the systemic myogenic response. Synthetic ligands and ECM fragments regulate the vascular smooth muscle cell contractile state by altering intracellular Ca2+ levels ([Ca2+](i)). Information on the Ca2+ effect of integrins in vascular smooth muscle cells is limited, but nonexistent in pulmonary arterial smooth muscle cells (PASMCs). We therefore characterized integrin expression in endothelium-denuded pulmonary arteries, and explored [Ca2+] i mobilization pathways induced by soluble ligands in rat PASMCs. Reverse transcriptase-PCR showed mRNA expression of integrins alpha(1), alpha(2), alpha(3), alpha(4), alpha(5), alpha(7), alpha(8), alpha(v), beta(1), beta(3), and beta(4), and immunoblots of alpha(5), alpha(v), beta(1), and beta(3) confirmed protein expression. Exposure of PASMCs to integrin-binding peptides (0.5 mM) containing the arginine-glycine-aspartate (RGD) motif elicited [Ca2+](i) responses with an order of potency of GRGDNP > GRGDSP > GRGDTP = cyclo-RGD. Pharmacological analysis revealed that the GRGDSP-induced Ca2+ response was unrelated to Ca2+ influx and the inositol triphosphate receptor-gated Ca2+ store, but partially blocked by ryanodine or inhibition of lysosome-related acidic organelles with bafilomycin A1. Simultaneous inhibition of both pathways was necessary to abolish the response. GRGDSP treatment increased cyclic ADP-ribose, the endogenous activator of ryanodine receptors, by 70%. GRGDSP also rapidly reduced Lysotracker Red accumulation, confirming direct modulation of acidic organelles. These data are the first demonstration of integrin-mediated Ca2+ regulation in PASMCs. The presence of an array of integrins, and activation of ryanodine-sensitive Ca2+ stores and lysosome-like organelles by GRGDSP suggest important roles for integrin- dependent Ca2+ signaling in regulating PASMC function.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA; Mayo Clin Rochester, Dept Anesthesiol, Rochester, MN 55905 USA; Univ S Florida, Dept Physiol & Biophys, Tampa, FL 33612 USA	Johns Hopkins University; Mayo Clinic; State University System of Florida; University of South Florida	Sham, JSK (corresponding author), JHAAC, Hopkins Bayview Circle, Baltimore, MD 21224 USA.	jsks@welchlink.welch.jhu.edu	Yip, Kay-Pong D/H-4639-2012	Yip, Kay-Pong D/0000-0003-4364-6701; Sham, James/0000-0002-3571-8712	NHLBI NIH HHS [HL071835, HL075134] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075134, R56HL071835, R01HL071835] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhattacharya S, 2000, CIRC RES, V86, P456, DOI 10.1161/01.RES.86.4.456; Boittin FX, 2002, CIRC RES, V91, P1168, DOI 10.1161/01.RES.0000047507.22487.85; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Buck CA, 1996, CELL ADHES COMMUN, V4, P69, DOI 10.3109/15419069609010764; Campbell S, 2003, ENDOCRINOLOGY, V144, P1486, DOI 10.1210/en.2002-220903; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Ceni C, 2006, BIOCHEM J, V395, P417, DOI 10.1042/BJ20051321; Ceni C, 2003, J BIOL CHEM, V278, P40670, DOI 10.1074/jbc.M301196200; Chan WL, 2001, AM J PHYSIOL-CELL PH, V280, pC593, DOI 10.1152/ajpcell.2001.280.3.C593; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Christensen KA, 2002, J CELL SCI, V115, P599; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DAMJANOVICH L, 1992, AM J RESP CELL MOL, V6, P197, DOI 10.1165/ajrcmb/6.2.197; DAngelo G, 1997, AM J PHYSIOL-HEART C, V272, pH2065, DOI 10.1152/ajpheart.1997.272.4.H2065; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Deshpande DA, 2004, AM J RESP CELL MOL, V31, P36, DOI 10.1165/rcmb.2003-0313OC; Dogan S, 2004, BIOL REPROD, V71, P97, DOI 10.1095/biolreprod.103.026245; Evans AM, 2005, PHARMACOL THERAPEUT, V107, P286, DOI 10.1016/j.pharmthera.2005.03.003; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Green LJ, 1998, INT J BIOCHEM CELL B, V30, P179, DOI 10.1016/S1357-2725(97)00107-6; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Higashida H, 2001, PHARMACOL THERAPEUT, V90, P283, DOI 10.1016/S0163-7258(01)00142-5; Hohenegger M, 2002, BIOCHEM J, V367, P423, DOI 10.1042/BJ20020584; Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087; JADOT M, 1990, BIOCHIM BIOPHYS ACTA, V1027, P205, DOI 10.1016/0005-2736(90)90086-4; JADOT M, 1984, BIOCHEM J, V219, P965, DOI 10.1042/bj2190965; Jones PL, 1999, J CELL SCI, V112, P435; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Mandegar M, 2004, MICROVASC RES, V68, P75, DOI 10.1016/j.mvr.2004.06.001; Martinez-Lemus LA, 2005, AM J PHYSIOL-HEART C, V289, pH322, DOI 10.1152/ajpheart.00923.2003; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; Medhora MM, 2000, AM J PHYSIOL-HEART C, V279, pH382, DOI 10.1152/ajpheart.2000.279.1.H382; Mogford JE, 1996, CIRC RES, V79, P821, DOI 10.1161/01.RES.79.4.821; Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Rabinovitch M, 2001, CLIN CHEST MED, V22, P433, DOI 10.1016/S0272-5231(05)70282-3; SCHNAPP LM, 1995, J CELL SCI, V108, P537; Schottelndreier H, 2001, CELL SIGNAL, V13, P895, DOI 10.1016/S0898-6568(01)00225-X; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Singh B, 2000, AM J PHYSIOL-LUNG C, V278, pL217, DOI 10.1152/ajplung.2000.278.1.L217; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Sjaastad MD, 1996, MOL BIOL CELL, V7, P1025, DOI 10.1091/mbc.7.7.1025; Thompson M, 2004, AM J PHYSIOL-ENDOC M, V287, pE1142, DOI 10.1152/ajpendo.00122.2004; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; van der Wees CGC, 2006, PFLUG ARCH EUR J PHY, V451, P588, DOI 10.1007/s00424-005-1402-x; Waitkus-Edwards KR, 2002, CIRC RES, V90, P473, DOI 10.1161/hh0402.105899; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu X, 2001, J BIOL CHEM, V276, P30285, DOI 10.1074/jbc.M102436200; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200; Yao CC, 1997, J CELL SCI, V110, P1477; Yip KP, 1997, AM J PHYSIOL-RENAL, V273, pF768, DOI 10.1152/ajprenal.1997.273.5.F768; Young GS, 2006, BIOCHEM BIOPH RES CO, V346, P188, DOI 10.1016/j.bbrc.2006.05.100; Zhang WM, 2003, AM J PHYSIOL-LUNG C, V285, pL680, DOI 10.1152/ajplung.00067.2003	69	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34312	34323		10.1074/jbc.M606765200	http://dx.doi.org/10.1074/jbc.M606765200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963791	hybrid			2022-12-25	WOS:000241767600051
J	Funderburk, CD; Bowling, KM; Xu, D; Huang, ZN; O'Donnell, JM				Funderburk, Christopher D.; Bowling, Kevin M.; Xu, Dong; Huang, Zhinong; O'Donnell, Janis M.			Atypical N-terminal extensions confer novel regulatory properties on GTP cyclohydrolase isoforms in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE; HEREDITARY PROGRESSIVE DYSTONIA; PROTEIN-KINASE-C; NITRIC-OXIDE; PUNCH LOCUS; TETRAHYDROBIOPTERIN DEFICIENCY; TYROSINE-HYDROXYLASE; BLOOD-PRESSURE; GENE-TRANSFER; I INHIBITION	The cofactor tetrahydrobiopterin plays critical roles in the modulation of the signaling molecules dopamine, serotonin, and nitric oxide. Deficits in cofactor synthesis have been associated with several human hereditary diseases. Responsibility for the regulation of cofactor pools resides with the first enzyme in its biosynthetic pathway, GTP cyclohydrolase I. Because organisms must be able to rapidly respond to environmental and developmental cues to adjust output of these signaling molecules, complex regulatory mechanisms are vital for signal modulation. Mammalian GTP cyclohydrolase is subject to end-product inhibition via an associated regulatory protein and to positive regulation via phosphorylation, although target residues are unknown. GTP cyclohydrolase is composed of a highly conserved homodecameric catalytic core and non-conserved N-terminal domains proposed to be regulatory sites. We demonstrate for the first time in any organism that the N-terminal arms of the protein serve regulatory functions. We identify two different modes of regulation of the enzyme mediated through the N-terminal domains. The first is end-product feedback inhibition, catalytically similar to that of the mammalian enzyme, except that feedback inhibition by the cofactor requires sequences in the N-terminal arms rather than a separate regulatory protein. The second is a novel inhibitory interaction between the N-terminal arms and the active sites, which can be alleviated through the phosphorylation of serine residues within the N termini. Both mechanisms allow for acute and highly responsive regulation of cofactor production as required by downstream signaling pathways.	Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA	University of Alabama System; University of Alabama Tuscaloosa	O'Donnell, JM (corresponding author), Univ Alabama, Dept Biol Sci, Box 870344,411 Hackberry Lane, Tuscaloosa, AL 35487 USA.	jodonnel@bama.ua.edu	Funderburk, Christopher D./X-5473-2019; Funderburk, Christopher D./R-4092-2019; Huang, Zhinong/A-1906-2008	Funderburk, Christopher D./0000-0001-5502-1456; 	NIGMS NIH HHS [GM62879] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062879] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Bader G, 2001, J MOL BIOL, V312, P1051, DOI 10.1006/jmbi.2001.5011; BARFORD PA, 1984, J NEUROL NEUROSUR PS, V47, P736, DOI 10.1136/jnnp.47.7.736; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOTTIGLIERI T, 1992, PSYCHOL MED, V22, P871, DOI 10.1017/S0033291700038447; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown G. M., 1985, FOLATES PTERINS, P115; CHEN XY, 1994, J CELL SCI, V107, P3501; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; COTTON RGH, 1986, J INHERIT METAB DIS, V9, P4, DOI 10.1007/BF01813895; Curtius H C, 1984, Adv Neurol, V40, P463; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Futahashi R, 2006, INSECT BIOCHEM MOLEC, V36, P63, DOI 10.1016/j.ibmb.2005.11.002; GUTLICH M, 1994, BIOCHEM J, V302, P215, DOI 10.1042/bj3020215; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hesslinger C, 1998, J BIOL CHEM, V273, P21616, DOI 10.1074/jbc.273.34.21616; Higashi Y, 2006, ATHEROSCLEROSIS, V186, P390, DOI 10.1016/j.atherosclerosis.2005.07.025; Hirano M, 1998, ANN NEUROL, V44, P365, DOI 10.1002/ana.410440312; Hwu WL, 2003, BIOCHEM BIOPH RES CO, V306, P937, DOI 10.1016/S0006-291X(03)01091-X; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; KAPATOS G, 1992, J NEUROCHEM, V59, P2048; Kase H, 2005, J HYPERTENS, V23, P1375, DOI 10.1097/01.hjh.0000173520.13976.7d; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; KAUFMAN S, 1990, BIOCHIM BIOPHYS ACTA, V1040, P19, DOI 10.1016/0167-4838(90)90141-2; Kolinsky MA, 2004, J BIOL CHEM, V279, P40677, DOI 10.1074/jbc.M405370200; KOLINSKY MA, 2004, PTERINS FOLATES NEUR, P22; Krishnakumar S, 2000, J NEUROGENET, V14, P1, DOI 10.3109/01677060009083474; Kure S, 1999, J PEDIATR-US, V135, P375, DOI 10.1016/S0022-3476(99)70138-1; KWON NS, 1989, J BIOL CHEM, V264, P20496; Lapize C, 1998, BIOCHEM BIOPH RES CO, V251, P802, DOI 10.1006/bbrc.1998.9552; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MACKAY WJ, 1983, GENETICS, V105, P35; MACKAY WJ, 1985, GENETICS, V111, P885; Maita N, 2004, J BIOL CHEM, V279, P51534, DOI 10.1074/jbc.M409440200; Maita N, 2001, ACTA CRYSTALLOGR D, V57, P1153, DOI 10.1107/S0907444901005558; MCLEAN JR, 1993, J BIOL CHEM, V268, P27191; Meininger CJ, 2004, FASEB J, V18, P1900, DOI 10.1096/fj.04-1702fje; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; Mitchell BM, 2004, J CARDIOVASC PHARM, V43, P758, DOI 10.1097/00005344-200406000-00004; Mitchell BM, 2003, AM J PHYSIOL-HEART C, V285, pH2165, DOI 10.1152/ajpheart.00253.2003; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Nagatsu T, 1997, J NEURAL TRANSM-SUPP, P203; REYNOLDS ER, 1988, GENETICS, V119, P609; SCHOEDON G, 1989, EUR J BIOCHEM, V178, P627, DOI 10.1111/j.1432-1033.1989.tb14491.x; Shinozaki K, 2005, J CARDIOVASC PHARM, V46, P505, DOI 10.1097/01.fjc.0000177981.91434.ba; SUZUKI S, 1988, BRAIN RES, V446, P1, DOI 10.1016/0006-8993(88)91290-5; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Thony B, 1997, HUM MUTAT, V10, P11; TIETZ A, 1964, J BIOL CHEM, V239, P4081; TOGARI A, 1992, BIOCHEM BIOPH RES CO, V187, P359, DOI 10.1016/S0006-291X(05)81501-3; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; WEISBERG EP, 1986, J BIOL CHEM, V261, P1453; Xie LJ, 1998, J BIOL CHEM, V273, P21091, DOI 10.1074/jbc.273.33.21091	56	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33302	33312		10.1074/jbc.M602196200	http://dx.doi.org/10.1074/jbc.M602196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16966327	hybrid			2022-12-25	WOS:000241621400040
J	Gan, ZJ; Zhao, LY; Yang, L; Huang, P; Zhao, F; Li, WJ; Liu, Y				Gan, Zhenji; Zhao, Liyun; Yang, Liu; Huang, Ping; Zhao, Feng; Li, Wenjun; Liu, Yong			RNA editing by ADAR2 is metabolically regulated in pancreatic islets and beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DEAMINASE ADAR1; SPLICE-SITE VARIANTS; PRE-MESSENGER-RNA; GLUTAMATE-RECEPTOR; INSULIN-SECRETION; BINDING DOMAINS; INTERFERON; GLUCOSE; EXPRESSION; RESISTANCE	RNA editing via the conversion of adenosine (A) to inosine (I) is catalyzed by two major families of adenosine deaminases acting on RNA (ADARs), ADAR1 and ADAR2. This genetic recoding process is known to play essential roles in the brain, due in part to changes in functional activities of edited neurotransmitter receptors and ion channels. Little is known, however, about the physiological regulation and function of A to I RNA editing in peripheral tissues and other biological processes. Here, we report that both ADAR1 and ADAR2 are expressed in the murine pancreatic islets, and ADAR2 is primarily localized in the islet endocrine cells. In contrast to ADAR1, ADAR2 transcripts in the pancreatic islets exhibit a nearly 2-fold increase in insulin-resistant mice chronically fed a high fat diet. Concurrent with this diet-induced metabolic stress, RNA editing in the islets is dramatically enhanced for the RNA transcripts encoding the ionotropic glutamate receptor subunit B. Moreover, ADAR2 protein expression is repressed in the islets under fuel deficiency condition during fasting, and this repression can be completely reversed by refeeding. We also show that, specifically in pancreatic beta-cell lines, not only the expression of ADAR2 but also the glutamate receptor subunit B editing and ADAR2 self-editing are markedly augmented in response to glucose at the physiological concentration for insulin secretion stimulation. Thus, RNA editing by ADAR2 in pancreatic islets and beta-cells is metabolically regulated by nutritional and energy status, suggesting that A to I RNA editing is most likely involved in the modulation of pancreatic islet and beta-cell function.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Grad Sch, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Liu, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Grad Sch, Shanghai 200031, Peoples R China.	liuy@sibs.ac.cn		Gan, Zhenji/0000-0001-5940-207X				Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; Bhalla T, 2004, NAT STRUCT MOL BIOL, V11, P950, DOI 10.1038/nsmb825; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Cui YX, 2004, MOL CELL BIOL, V24, P258, DOI 10.1128/MCB.24.1.258-269.2004; Feng Y, 2006, MOL CELL BIOL, V26, P480, DOI 10.1128/MCB.26.2.480-488.2006; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; George CX, 2005, J BIOL CHEM, V280, P15020, DOI 10.1074/jbc.M500476200; GONOI T, 1994, J BIOL CHEM, V269, P16989; Gurevich I, 2002, NEURON, V34, P349, DOI 10.1016/S0896-6273(02)00660-8; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kawahara Y, 2005, GENE, V363, P193, DOI 10.1016/j.gene.2005.07.028; Keegan LP, 2005, EMBO J, V24, P2183, DOI 10.1038/sj.emboj.7600691; Kmiec Z, 2005, GERONTOLOGY, V51, P357, DOI 10.1159/000088698; Komatsu M, 2001, ENDOCR J, V48, P275, DOI 10.1507/endocrj.48.275; Koster JC, 2005, DIABETES, V54, P3065, DOI 10.2337/diabetes.54.11.3065; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lawrence MC, 2005, J BIOL CHEM, V280, P26751, DOI 10.1074/jbc.M503158200; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Liu Y, 1999, J BIOL CHEM, V274, P5070, DOI 10.1074/jbc.274.8.5070; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 2003, J BIOL CHEM, V278, P1391, DOI 10.1074/jbc.R200025200; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Moriyama Y, 2003, TRENDS PHARMACOL SCI, V24, P511, DOI 10.1016/j.tips.2003.08.002; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025; Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P1; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Straub SG, 2004, DIABETES MELLITUS FU, P3; UNGER RH, 2004, DIABETES MELLITUS FU, P141; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977; Weir GC, 2004, NAT BIOTECHNOL, V22, P1095, DOI 10.1038/nbt0904-1095; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	51	49	51	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33386	33394		10.1074/jbc.M604484200	http://dx.doi.org/10.1074/jbc.M604484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16956888	hybrid			2022-12-25	WOS:000241621400048
J	Mylonis, I; Chachami, G; Samiotaki, M; Panayotou, G; Paraskeva, E; Kalousi, A; Georgatsou, E; Bonanou, S; Simos, G				Mylonis, Ilias; Chachami, Georgia; Samiotaki, Martina; Panayotou, George; Paraskeva, Efrosini; Kalousi, Alkmini; Georgatsou, Eleni; Bonanou, Sofia; Simos, George			Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; NUCLEAR-CYTOPLASMIC TRAFFICKING; ARYL-HYDROCARBON RECEPTOR; GROWTH-FACTOR EXPRESSION; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; PROLYL HYDROXYLATION; SIGNAL-TRANSDUCTION; FACTOR 1-ALPHA	Hypoxia-inducible factor 1 (HIF-1) controls the expression of most genes induced by hypoxic conditions. Regulation of expression and activity of its inducible subunit, HIF-1 alpha, involves several post-translational modifications. To study HIF-1 alpha phosphorylation, we have used human full-length recombinant HIF-1 alpha as a substrate in kinase assays. We show that at least two different nuclear protein kinases, one of them identified as p42/p44MAPK, can modify HIF-1 alpha. Analysis of in vitro phosphorylated HIF-1 alpha by mass spectroscopy revealed residues Ser-641 and Ser-643 as possible MAPK phosphorylation sites. Site-directed mutagenesis of these residues reduced significantly the phosphorylation of HIF-1 alpha. When these mutant forms of HIF-1 alpha were expressed in HeLa cells, they exhibited much lower transcriptional activity than the wild-type form. However, expression of the same mutants in yeast revealed that their capacity to stimulate transcription was not significantly compromised. Localization of the green fluorescent protein-tagged HIF-1 alpha mutants in HeLa cells showed their exclusion from the nucleus in contrast to wild-type HIF-1 alpha. Treatment of the cells with leptomycin B, an inhibitor of the major exportin CRM1, reversed this exclusion and led to nuclear accumulation and partial recovery of the activity of the HIF-1 alpha mutants. Moreover, inhibition of the MAPK pathway by PD98059 impaired the phosphorylation, nuclear accumulation, and activity of wild-type GFP-HIF-1 alpha. Overall, these data suggest that phosphorylation of Ser-641/643 by MAPK promotes the nuclear accumulation and transcriptional activity of HIF-1 alpha by blocking its CRM1-dependent nuclear export.	Univ Thessaloniki, Dept Med, Biochem Lab, GR-41222 Larisa, Greece; Univ Thessaloniki, Dept Med, Physiol Lab, GR-41222 Larisa, Greece; Biomed Sci Res Ctr Alexander Flemingt, Prot Chem Lab, GR-16672 Vari, Greece	Aristotle University of Thessaloniki; Aristotle University of Thessaloniki	Simos, G (corresponding author), 22 Papakyriazi Str, GR-41222 Larisa, Greece.	simos@med.uth.gr	Simos, George/AAH-2596-2021; Paraskeva, Efrosyni/E-6449-2015; Samiotaki, Martina/B-3851-2018	Paraskeva, Efrosyni/0000-0002-1312-0322; Samiotaki, Martina/0000-0001-9952-0636; Chachami, Georgia/0000-0002-4771-4196; Mylonis, Ilias/0000-0002-0893-6618; Simos, George/0000-0001-5453-3185				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Braliou GG, 2006, BIOCHEM BIOPH RES CO, V346, P1289, DOI 10.1016/j.bbrc.2006.06.043; Bruick RK, 2002, SCIENCE, V295, P807, DOI 10.1126/science.1069825; Carr SA, 2005, METHOD ENZYMOL, V405, P82, DOI 10.1016/S0076-6879(05)05005-6; Chachami G, 2005, BIOCHEM BIOPH RES CO, V331, P464, DOI 10.1016/j.bbrc.2005.03.193; Chachami G, 2004, AM J RESP CELL MOL, V31, P544, DOI 10.1165/rcmb.2003-0426OC; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gradin K, 2002, J BIOL CHEM, V277, P23508, DOI 10.1074/jbc.M201307200; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ikuta T, 2004, J BIOL CHEM, V279, P19209, DOI 10.1074/jbc.M310492200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kubis HP, 2005, BBA-MOL CELL RES, V1745, P187, DOI 10.1016/j.bbamcr.2005.05.007; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Lancaster DE, 2004, BIOCHEM J, V383, P429, DOI 10.1042/BJ20040735; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Lee S, 1999, MOL CELL BIOL, V19, P1486; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Petosa C, 2004, MOL CELL, V16, P761, DOI 10.1016/j.molcel.2004.11.018; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sodhi A, 2000, CANCER RES, V60, P4873; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	58	212	222	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33095	33106		10.1074/jbc.M605058200	http://dx.doi.org/10.1074/jbc.M605058200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16954218	hybrid			2022-12-25	WOS:000241621400018
J	Soubias, O; Teague, WE; Gawrisch, K				Soubias, Olivier; Teague, Walter E.; Gawrisch, Klaus			Evidence for specificity in lipid-rhodopsin interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SEGMENT DISK MEMBRANES; SARCOPLASMIC-RETICULUM; RECOMBINANT MEMBRANES; CANNABINOID RECEPTOR; ANGSTROM RESOLUTION; PHOSPHOLIPIDS; BOVINE; NMR; BACTERIORHODOPSIN	The interaction of bovine rhodopsin with poly- and monounsaturated lipids was studied by H-1 MAS NMR with magnetization transfer from rhodopsin to lipid. Experiments were conducted on bovine rod outer segment (ROS) disks and on recombinant membranes containing lipids with polyunsaturated, docosahexaenoyl (DHA) chains. Poly- and monounsaturated lipids interact specifically with different sites on the rhodopsin surface. Rates of magnetization transfer from protein to DHA are lipid headgroup-dependent and increased in the sequence PC < PS < PE. Boundary lipids are in fast exchange with the lipid matrix on a time scale of milliseconds or shorter. All rhodopsin photointermediates transferred magnetization preferentially to DHA-containing lipids, but highest rates were observed for Meta-III rhodopsin. The experiments show clearly that the surface of rhodopsin has sites for specific interaction with lipids. Current theories of lipid-protein interaction do not account for such surface heterogeneity.	NIAAA, NMR Sect, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Gawrisch, K (corresponding author), NIAAA, NMR Sect, Lab Membrane Biochem & Biophys, NIH, 5625 Fishers Lane, Bethesda, MD 20892 USA.	gawrisch@helix.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000003, ZIAAA000003] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Albert AD, 1998, BBA-BIOMEMBRANES, V1368, P52, DOI 10.1016/S0005-2736(97)00200-9; Alves ID, 2005, BIOPHYS J, V88, P198, DOI 10.1529/biophj.104.046722; Andersson AS, 1998, BIOPHYS J, V75, P2877, DOI 10.1016/S0006-3495(98)77730-6; ARNOLD K, 1979, STUD BIOPHYS, V75, P189; BALGAVY P, 1984, BIOCHIM BIOPHYS ACTA, V772, P58, DOI 10.1016/0005-2736(84)90517-0; BELRHALI H, 1999, J MOL BIOL, V7, P909; Botelho AV, 2002, BIOCHEMISTRY-US, V41, P6354, DOI 10.1021/bi011995g; BROWN MF, 1977, BIOCHEMISTRY-US, V16, P2640, DOI 10.1021/bi00631a010; Cantor RS, 1997, J PHYS CHEM B, V101, P1723, DOI 10.1021/jp963911x; DEESE AJ, 1982, BIOPHYS J, V37, P207, DOI 10.1016/S0006-3495(82)84670-5; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Feller SE, 2003, J AM CHEM SOC, V125, P4434, DOI 10.1021/ja0345874; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Gaede HC, 2004, LANGMUIR, V20, P7711, DOI 10.1021/la0493114; Gaede HC, 2003, BIOPHYS J, V85, P1734, DOI 10.1016/S0006-3495(03)74603-7; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Grossfield A, 2006, P NATL ACAD SCI USA, V103, P4888, DOI 10.1073/pnas.0508352103; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; Huster D, 1999, J PHYS CHEM B, V103, P243, DOI 10.1021/jp983428h; JENSEN JW, 1984, BIOCHEMISTRY-US, V23, P1115, DOI 10.1021/bi00301a012; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Marsh D, 1998, BBA-REV BIOMEMBRANES, V1376, P267, DOI 10.1016/S0304-4157(98)00009-4; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; Mitchell DC, 2003, LIPIDS, V38, P437, DOI 10.1007/s11745-003-1081-1; Mitsuoka K, 1999, J MOL BIOL, V286, P861, DOI 10.1006/jmbi.1998.2529; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; NAVARRO J, 1984, BIOCHEMISTRY-US, V23, P130, DOI 10.1021/bi00296a021; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; Niu SL, 2002, J BIOL CHEM, V277, P20139, DOI 10.1074/jbc.M200594200; OBRIEN DF, 1977, BIOCHEMISTRY-US, V16, P1295, DOI 10.1021/bi00626a009; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P2459, DOI 10.1021/bi00175a014; Polozova A, 2000, BIOPHYS J, V79, P2632, DOI 10.1016/S0006-3495(00)76502-7; Ritter E, 2004, J BIOL CHEM, V279, P48102, DOI 10.1074/jbc.M406857200; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Soubias O, 2005, J AM CHEM SOC, V127, P13110, DOI 10.1021/ja0538942; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Vogel R, 2004, BIOCHEMISTRY-US, V43, P9457, DOI 10.1021/bi049337u; Wang Y, 2002, J AM CHEM SOC, V124, P7690, DOI 10.1021/ja0200488; WIEDMANN TS, 1988, BIOCHEMISTRY-US, V27, P6469, DOI 10.1021/bi00417a041; Yau WM, 2000, J AM CHEM SOC, V122, P3971, DOI 10.1021/ja9944756; Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200	47	76	77	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33233	33241		10.1074/jbc.M603059200	http://dx.doi.org/10.1074/jbc.M603059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959786	hybrid			2022-12-25	WOS:000241621400032
J	Oleksy, A; Opalinski, L; Derewenda, U; Derewenda, ZS; Otlewski, J				Oleksy, Arkadiusz; Opalinski, Lukasz; Derewenda, Urszula; Derewenda, Zygmunt S.; Otlewski, Jacek			The molecular basis of RhoA specificity in the guanine nucleotide exchange factor PDZ-RhoGEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; STRUCTURAL BASIS; P115 RHOGEF; GTPASES; FAMILY; DOMAIN; COMPLEX; BINDING; ACTIVATION	The Dbl homology nucleotide exchange factors (GEFs) activate Rho family cytosolic GTPases in a variety of physiological and pathophysiological events. These signaling molecules typically act downstream of tyrosine kinase receptors and often facilitate nucleotide exchange on more than one member of the Rho GTPase superfamily. Three unique GEFs, i.e. p115, PDZ-RhoGEF, and LARG, are activated by the G-protein coupled receptors via the G alpha(12/13), and exhibit very selective activation of RhoA, although the mechanism by which this is accomplished is not fully understood. Based on the recently solved crystal structure of the DH-PH tandem of PDZ-RhoGEF in complex with RhoA (Derewenda, U., Oleksy, A., Stevenson, A. S., Korczynska, J., Dauter, Z., Somlyo, A. P., Otlewski, J., Somlyo, A. V., and Derewenda, Z. S. (2004) Structure (Lond.) 12, 1955-1965), we conducted extensive mutational and functional studies of the molecular basis of the RhoA selectivity in PDZ-RhoGEF. We show that while Trp(58) of RhoA is intimately involved in the interaction with the DH domain, it is not a selectivity determinant, and its interaction with PDZ-RhoGEF is unfavorable. The key selectivity determinants are dominated by polar contacts involving residues unique to RhoA. We find that selectivity for RhoA versus Cdc42 is defined by a small number of interactions.	Univ Wroclaw, Inst Biochem & Mol Biol, PL-50137 Wroclaw, Poland; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Wroclaw; University of Virginia	Otlewski, J (corresponding author), Univ Wroclaw, Inst Biochem & Mol Biol, PL-50137 Wroclaw, Poland.	otlewski@protein.pl	Otlewski, Jacek/B-6340-2008	Opalinski, Lukasz/0000-0001-9656-8714	NHLBI NIH HHS [P01 HL 48807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200; Chen Z, 2005, NAT STRUCT MOL BIOL, V12, P191, DOI 10.1038/nsmb888; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Derewenda U, 2004, STRUCTURE, V12, P1955, DOI 10.1016/j.str.2004.09.003; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kristelly R, 2004, J BIOL CHEM, V279, P47352, DOI 10.1074/jbc.M406056200; Oleksy A, 2004, ACTA CRYSTALLOGR D, V60, P740, DOI 10.1107/S0907444904002318; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Rossman KL, 2002, J BIOL CHEM, V277, P50893, DOI 10.1074/jbc.M208580200; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200	32	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32891	32897		10.1074/jbc.M606220200	http://dx.doi.org/10.1074/jbc.M606220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954208	hybrid			2022-12-25	WOS:000241414500087
J	Hirakawa, M; Oike, M; Watanabe, M; Karashima, Y; Ito, Y				Hirakawa, Masakazu; Oike, Masahiro; Watanabe, Michi; Karashima, Yuji; Ito, Yushi			Pivotal role of integrin alpha 5 beta 1 in hypotonic stress-induced responses of human endothelium	FASEB JOURNAL			English	Article						ATP release; tyrosine kinase; RhoA; actin cytoskeleton	FOCAL ADHESION KINASE; INDUCED ATP RELEASE; SHEAR-STRESS; CELL-ADHESION; ACTIVATION; FLOW; RHO; REORGANIZATION; MECHANISM	We have previously reported that both hypotonic stress (HTS) and lysophosphatidic acid (LPA) induce ATP release and a transient reorganization of actin through sequential activation of RhoA/Rho-kinase and focal adhesion kinase F-actin (FAK)/paxillin in human umbilical cord vein endothelial cells (HUVECs). LPA is known to induce the activation of RhoA via its specific receptors, but the mechanisms by which HTS initiates these intracellular signals are not known. The present study aimed to identify the molecule(s) that are unique to the sensing and/or transducing the mechanical stress. Reverse transcriptase-polymerase chain reaction revealed the expression of several integrin subunits in HUVECs. Anti-integrin alpha 5 beta 1 antibody (Ab), but not anti-integrin alpha 2, alpha 6, alpha v, or beta 4 antibodies, inhibited HTS-induced RhoA translocation, tyrosine phosphorylation of FAK and paxillin, ATP release, and actin reorganization. However, the LPA-induced ATP release and actin reorganization were not inhibited by any of these anti-integrin antibodies, indicating that integrin alpha 5 beta 1 plays a pivotal role in the HTS-induced but not in the LPA-induced responses. It is therefore reasonable to assume that this particular subtype of integrin is involved in the initiation of the responses induced by mechanical stimuli in HUVECs.	Kyushu Univ, Grad Sch Med Sci, Dept Pharmacol, Fukuoka 8128582, Japan	Kyushu University	Oike, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Pharmacol, Fukuoka 8128582, Japan.	moike@pharmaco.med.kyushu-u.ac.jp	Karashima, Yuji/AGY-5391-2022	Karashima, Yuji/0000-0002-2866-8999				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Ashida N, 2003, J BIOL CHEM, V278, P9327, DOI 10.1074/jbc.M212316200; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; HAMASAKI K, 1995, BIOCHEM BIOPH RES CO, V212, P544, DOI 10.1006/bbrc.1995.2004; HASSESSIAN H, 1993, BRIT J PHARMACOL, V109, P466, DOI 10.1111/j.1476-5381.1993.tb13592.x; Hirakawa M, 2004, J PHYSIOL-LONDON, V558, P479, DOI 10.1113/jphysiol.2004.065334; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jans D, 2002, J PHYSIOL-LONDON, V545, P543, DOI 10.1113/jphysiol.2002.026641; Kalinowski L, 2003, CIRCULATION, V107, P2747, DOI 10.1161/01.CIR.0000066912.58385.DE; Knight GE, 2002, AM J PHYSIOL-RENAL, V282, pF281, DOI 10.1152/ajprenal.00293.2000; Knudsen HL, 1997, AM J PHYSIOL-HEART C, V273, pH347, DOI 10.1152/ajpheart.1997.273.1.H347; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Kranenburg O, 1997, J CELL SCI, V110, P2417; Li S, 1999, J CLIN INVEST, V103, P1141, DOI 10.1172/JCI5367; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Malek AM, 1996, J CELL SCI, V109, P713; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Oike M, 2000, AM J PHYSIOL-HEART C, V279, pH630, DOI 10.1152/ajpheart.2000.279.2.H630; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Urbich C, 2002, ARTERIOSCL THROM VAS, V22, P69, DOI 10.1161/hq0102.101518; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002	33	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1992	1999		10.1096/fj.05-5580com	http://dx.doi.org/10.1096/fj.05-5580com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012251				2022-12-25	WOS:000241156900007
J	Evans, MK; Yu, CR; Lohani, A; Mahdi, RM; Liu, X; Trzeciak, AR; Egwuagu, CE				Evans, M. K.; Yu, C-R; Lohani, A.; Mahdi, R. M.; Liu, X.; Trzeciak, A. R.; Egwuagu, C. E.			Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals	ONCOGENE			English	Article						breast-cancer cells; SOCS; breast cancer; STAT; BRCA1; DNA hypermethylation; interferon	ISLAND METHYLATOR PHENOTYPE; DNA-DAMAGE; IFN-GAMMA; BRCA1; TRANSCRIPTION; ACTIVATION; CARCINOMA; HYPERMETHYLATION; TUMORIGENESIS; COACTIVATOR	DNA-hypermethylation of SOCS genes in breast, ovarian, squamous cell and hepatocellular carcinoma has led to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by IFN gamma, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breast-cancer cell lines (MCF-7, HCC1937) and three prostate cancer cell lines. Compared to normal breast cells, we observe a high level constitutive expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 genes in the human cancer cells. In MCF-7 and HCC1937 breast-cancer cells, transcription of SOCS1 is dramatically up-regulated by IFN gamma and/or ionizing-radiation while SOCS3 is transiently down-regulated by IFN gamma and IGF-1, suggesting that SOCS genes are not silenced in these cells by the epigenetic mechanism of DNA-hypermethylation. We further show that the kinetics of SOCS1-mediated feedback inhibition of IFN gamma signaling is comparable to normal breast cells, indicating that the SOCS1 protein in breast-cancer cells is functional. We provide direct evidence that STAT3 pathways are constitutively activated in MCF-7 and HCC1937 cells and may drive the aberrant persistent activation of SOCS genes in breast-cancer cells. Our data therefore suggest that elevated expression of SOCS genes is a specific lesion of breast-cancer cells that may confer resistance to proinflammatory cytokines and trophic factors, by shutting down STAT1/STAT5 signaling that mediate essential functions in the mammary gland.	NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Evans, MK (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.	evansmi@grc.nia.nih.gov; egwuaguc@nei.nih.gov	Evans, Michele Kim/AAE-4776-2019	Evans, Michele/0000-0002-8546-2831; Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [ZIAEY000372, Z01EY000372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000730] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brender C, 2005, LEUKEMIA, V19, P209, DOI 10.1038/sj.leu.2403610; Campbell IL, 2005, BRAIN RES REV, V48, P166, DOI 10.1016/j.brainresrev.2004.12.006; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Cui JQ, 1998, ONCOL REP, V5, P591; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Le Provost F, 2005, BIOCHEM BIOPH RES CO, V338, P1696, DOI 10.1016/j.bbrc.2005.10.138; Medina D, 2005, ENDOCR-RELAT CANCER, V12, P483, DOI 10.1677/erc.1.00804; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Raccurt M, 2003, BRIT J CANCER, V89, P524, DOI 10.1038/sj.bjc.6601115; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Yu CR, 2004, J IMMUNOL, V173, P737, DOI 10.4049/jimmunol.173.2.737	33	62	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1941	1948		10.1038/sj.onc.1209993	http://dx.doi.org/10.1038/sj.onc.1209993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001312				2022-12-25	WOS:000245117700011
J	Neesse, A; Gangeswaran, R; Luettges, J; Feakins, R; Weeks, ME; Lemoine, NR; Crnogorac-Jurcevic, T				Neesse, A.; Gangeswaran, R.; Luettges, J.; Feakins, R.; Weeks, M. E.; Lemoine, N. R.; Crnogorac-Jurcevic, T.			Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells	ONCOGENE			English	Article						SPAG1; pancreatic adenocarcinoma; PanIN; lesions; motility	TESTIS ANTIGENS; CANCER/TESTIS ANTIGENS; SIGNALING PATHWAY; GENE-EXPRESSION; CARCINOMA; ADENOCARCINOMA; ACTIVATION; MIGRATION; PROTEINS; LINES	Sperm-associated antigen 1 (SPAG1) was recently identified in a rare form of infertility where anti-SPAG1 antibodies derived from the serum of an infertile woman were reported to cause sperm agglutination. Except for its expression and potential role in spermatogenesis, the function of SPAG1 is completely unknown. The unexpected finding of high levels of SPAG1 expression in pancreatic adenocarcinoma compared to normal pancreatic tissue in our previous cDNA array experiments prompted us to look in more detail at the expression and role of this gene in a panel of normal and malignant human tissues as well as in a larger series of pancreatic cancer specimens. We have generated an SPAG1-specific monoclonal antibody and showed high levels of SPAG1 protein in testis and in a large proportion of pancreatic ductal adenocarcinomas (PDAC). In the latter, SPAG1 expression was predominantly cytoplasmic and confined to malignant cells. Furthermore, the extent and intensity of SPAG1 expression was shown to be associated with stage and tumour nodal status, while analysis of precursor lesions, pancreatic intraepithelial neoplasias (PanINs), demonstrated its increased immunoreactivity with increasing PanIN grade, suggesting that SPAG1 is a novel marker of PDAC progression. Immunocytochemical analysis demonstrated colocalization of SPAG1 with microtubules, and their association was confirmed by co-immunoprecipitation; subsequent motility assays further substantiated a potential role of SPAG1 in cancer cell motility. Combined with the finding of its early expression in PDAC development, our data suggest that SPAG1 could contribute to the early spread and poor prognosis of pancreatic adenocarcinoma.	Queen Marys Univ, Barts & London Sch Med & Dent, Canc Res UK, John Vane Sci Ctr,Mol Oncol Unit, London WC1M 6BQ, England; Klinikum Saarbrucken, Dept Pathol, Saarbrucken, Germany; Royal London Hosp, Dept Histopathol, London E1 1BB, England	Cancer Research UK; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Crnogorac-Jurcevic, T (corresponding author), Queen Marys Univ, Barts & London Sch Med & Dent, Canc Res UK, John Vane Sci Ctr,Mol Oncol Unit, Charterhouse Sq, London WC1M 6BQ, England.	t.c.jurcevic@qmul.ac.uk	weeks, Mark/AAT-7258-2021; Feakins, Roger/AAO-5570-2020; /C-2531-2011; Feakins, Roger/J-6782-2019	/0000-0002-6576-8809; 				Coral S, 2002, CLIN CANCER RES, V8, P2690; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Cutillas PR, 2004, AM J PHYSIOL-RENAL, V287, pF353, DOI 10.1152/ajprenal.00018.2004; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Furukawa T, 1996, AM J PATHOL, V148, P1763; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Grutzmann R, 2005, ONCOGENE, V24, P5079, DOI 10.1038/sj.onc.1208696; Hustinx SR, 2004, CANCER BIOL THER, V3, P1254, DOI 10.4161/cbt.3.12.1238; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kalejs M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-4; Kubuschok B, 2004, INT J CANCER, V109, P568, DOI 10.1002/ijc.20006; Lin W, 2001, MOL HUM REPROD, V7, P811, DOI 10.1093/molehr/7.9.811; Logsdon CD, 2003, CANCER RES, V63, P2649; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Missiaglia E, 2004, INT J CANCER, V112, P100, DOI 10.1002/ijc.20376; Old L J, 2001, Cancer Immun, V1, P1; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Takimoto M, 2002, BRIT J CANCER, V86, P1757, DOI 10.1038/sj.bjc.6600328; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; Vasiliev JM, 2004, INT J DEV BIOL, V48, P425, DOI 10.1387/ijdb.041806jv; ZHANG ML, 1992, CHINESE MED J-PEKING, V105, P998; Zhang YT, 2004, CHINESE PHYS LETT, V21, P166, DOI 10.1088/0256-307X/21/1/050	30	24	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1533	1545		10.1038/sj.onc.1209961	http://dx.doi.org/10.1038/sj.onc.1209961			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983343				2022-12-25	WOS:000244782500003
J	Balasubramanian, S; Zhu, L; Eckert, RL				Balasubramanian, Sivaprakasam; Zhu, Ling; Eckert, Richard L.			Apigenin inhibition of involucrin gene expression is associated with a specific reduction in phosphorylation of protein kinase C delta Tyr(311)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN TEA POLYPHENOL; EPSILON TRANSGENIC MICE; GROWTH-FACTOR RECEPTOR; CELL-CYCLE ARREST; CHEMOPREVENTIVE FLAVONOID APIGENIN; EPIDERMAL ORNITHINE DECARBOXYLASE; DISTAL REGULATORY REGION; SKIN TUMOR-PROMOTION; SKH-1 HAIRLESS MICE; FACTOR-KAPPA-B	Apigenin is a plant-derived flavanoid that has significant promise as a skin cancer chemopreventive agent. In the present study, we examine the mechanism whereby apigenin regulates normal human keratinocyte differentiation. Expression of involucrin (hINV), a marker of keratinocyte differentiation, is increased by differentiating agents via a protein kinase C delta(PKC delta), Ras, MEKK1, MEK3 cascade that increases AP1 factor level and AP1 factor binding to DNA elements in the hINV promoter. We show that apigenin inhibits this response. Apigenin suppresses the 12-O-tetradeconylphorbol-13- acetate-dependent increase in AP1 factor expression and binding to the hINV promoter and the increase in hINV promoter activity. Apigenin also inhibits the increase in promoter activity observed following overexpression of PKC delta, constitutively active Ras, or MEKK1. The suppression of PKC delta activity is associated with reduced phosphorylation of PKC delta-Y311. The physiological importance of this phosphorylation event was confirmed by showing that the PKC delta phosphorylation-defective mutant, PKC delta-Y311F, is less able to increase hINV promoter activity. Activation of hINV promoter activity by the green tea polyphenol, (-)-epigellocathecin-3-gallate, is also inhibited by apigenin, suggesting that the two chemopreventive agents can produce opposing actions in keratinocytes. Additional studies show that the apigenin-dependent suppression of differentiation is associated with reduced cell proliferation but that there is no evidence of apoptosis.	Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, 2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; AGARWAL R, 1993, PHOTOCHEM PHOTOBIOL, V58, P695, DOI 10.1111/j.1751-1097.1993.tb04954.x; Balasubramanian S, 2005, ONCOGENE, V24, P4257, DOI 10.1038/sj.onc.1208586; Balasubramanian S, 2005, CARCINOGENESIS, V26, P1100, DOI 10.1093/carcin/bgi048; Balasubramanian S, 2004, J BIOL CHEM, V279, P24007, DOI 10.1074/jbc.M314331200; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Birt DF, 1997, ANTICANCER RES, V17, P85; CHAUMONTET C, 1994, CARCINOGENESIS, V15, P2325, DOI 10.1093/carcin/15.10.2325; Chen CC, 2004, MOL PHARMACOL, V66, P683; Chen D, 2005, BIOCHEM PHARMACOL, V69, P1421, DOI 10.1016/j.bcp.2005.02.022; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; Crish JF, 2002, ONCOGENE, V21, P738, DOI 10.1038/sj.onc.1205038; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Denning MF, 2000, EXP DERMATOL, V9, P192, DOI 10.1034/j.1600-0625.2000.009003192.x; Denning MF, 2004, INT J BIOCHEM CELL B, V36, P1141, DOI 10.1016/j.biocel.2003.12.004; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; Droillard MJ, 2004, FEBS LETT, V574, P42, DOI 10.1016/j.febslet.2004.08.001; Eckert RL, 2006, MOL NUTR FOOD RES, V50, P123, DOI 10.1002/mnfr.200500125; Eckert RL, 2004, BIOCHEM PHARMACOL, V68, P1125, DOI 10.1016/j.bcp.2004.04.029; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; ENGELHARDT UH, 1993, Z LEBENSM UNTERS FOR, V197, P239, DOI 10.1007/BF01185278; Fotsis T, 1997, CANCER RES, V57, P2916; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; GEAHLEN RL, 1989, J NAT PROD, V52, P982, DOI 10.1021/np50065a011; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; HERTOG MGL, 1994, NUTR CANCER, V22, P175, DOI 10.1080/01635589409514342; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; Hollman PCH, 1999, P SOC EXP BIOL MED, V220, P198, DOI 10.1046/j.1525-1373.1999.d01-33.x; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang YT, 1996, EUR J CANCER, V32A, P146, DOI 10.1016/0959-8049(95)00540-4; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; Jansen AP, 2001, CANCER RES, V61, P808; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Kim AL, 2005, J INVEST DERMATOL, V124, P1318, DOI 10.1111/j.0022-202X.2005.23747.x; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lepley DM, 1997, MOL CARCINOGEN, V19, P74, DOI 10.1002/(SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L; Lepley DM, 1996, CARCINOGENESIS, V17, P2367, DOI 10.1093/carcin/17.11.2367; Lin JK, 1997, J CELL BIOCHEM, P39; Llorens F, 2004, EXP CELL RES, V299, P15, DOI 10.1016/j.yexcr.2004.05.006; MATERN U, 1983, EUR J BIOCHEM, V133, P439, DOI 10.1111/j.1432-1033.1983.tb07483.x; McVean M, 2002, MOL CARCINOGEN, V33, P36, DOI 10.1002/mc.10016; McVean M, 2000, CARCINOGENESIS, V21, P633, DOI 10.1093/carcin/21.4.633; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Mukhtar H, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P209; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; PERYT B, 1992, MUTAT RES, V269, P201, DOI 10.1016/0027-5107(92)90201-C; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Rutberg SE, 1996, ONCOGENE, V13, P167; Rybin VO, 2004, J BIOL CHEM, V279, P19350, DOI 10.1074/jbc.M311096200; STONER GD, 1995, J CELL BIOCHEM, P169; Van Dross R, 2003, J NUTR, V133, p3800S, DOI 10.1093/jn/133.11.3800S; Van Dross RT, 2005, MOL CARCINOGEN, V44, P83, DOI 10.1002/mc.20123; Wang WQ, 2000, MOL CARCINOGEN, V28, P102; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Way TD, 2004, J BIOL CHEM, V279, P4479, DOI 10.1074/jbc.M305529200; WEI HC, 1990, CANCER RES, V50, P499; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Wheeler DL, 2003, CANCER RES, V63, P6547; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; Yin F, 2001, ANTICANCER RES, V21, P413; Yin F, 1999, THYROID, V9, P369, DOI 10.1089/thy.1999.9.369	85	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36162	36172		10.1074/jbc.M605368200	http://dx.doi.org/10.1074/jbc.M605368200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16982614	hybrid			2022-12-25	WOS:000242100500066
J	Boraston, AB; Wang, D; Burke, RD				Boraston, Alisdair B.; Wang, Diana; Burke, Robert D.			Blood group antigen recognition by a Streptococcus pneumoniae virulence factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING MODULES; ISOTHERMAL TITRATION CALORIMETRY; LIGAND-BINDING; LECTIN; COEFFICIENTS; SPECIFICITY; REFINEMENT; PROTEINS; SEQUENCE	The Streptococcus pneumoniae fucose utilization operon includes a gene encoding a virulence factor that belongs to family 98 in the glycoside hydrolase classification. This protein contains a C-terminal triplet of fucose binding modules that have significant amino acid sequence identity with the Anguilla anguilla fucolectin. Functional studies of these fucose binding modules reveal binding to fucosylated oligosaccharides and suggest the importance of multivalent binding. The high resolution crystal structures of ligand bound forms of one fucose binding module uncovers the molecular basis of fucose, ABH blood group antigen, and Lewis(y) antigen binding. These studies are extended by fluorescence microscopy to show specific binding to mouse lung tissue. These modules define a new family of carbohydrate binding modules now classified as family 47.	Univ Victoria, Victoria, BC V8W 3P6, Canada; Univ Victoria, Victoria, BC V8W 3N5, Canada	University of Victoria; University of Victoria	Boraston, AB (corresponding author), Univ Victoria, POB 3055 CSC, Victoria, BC V8W 3P6, Canada.	boraston@uvic.ca		Boraston, Alisdair/0000-0001-6417-0592; Burke, Robert/0000-0001-5527-4410				Anderson KM, 2005, J BIOL CHEM, V280, P7720, DOI 10.1074/jbc.M414099200; Baldus SE, 1996, GLYCOCONJUGATE J, V13, P585, DOI 10.1007/BF00731446; Bianchet MA, 2002, NAT STRUCT BIOL, V9, P628, DOI 10.1038/nsb817; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P6240, DOI 10.1021/bi0101695; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chan PF, 2003, J BACTERIOL, V185, P2051, DOI 10.1128/JB.185.6.2051-2058.2003; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; Doern GV, 1999, EMERG INFECT DIS, V5, P757, DOI 10.3201/eid0506.990603; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.t01-1-03106.x; Henshaw J, 2006, J BIOL CHEM, V281, P17099, DOI 10.1074/jbc.M600702200; Imberty A, 2004, MICROBES INFECT, V6, P221, DOI 10.1016/j.micinf.2003.10.016; Kadioglu A, 2004, TRENDS IMMUNOL, V25, P143, DOI 10.1016/j.it.2003.12.006; Kostlanova N, 2005, J BIOL CHEM, V280, P27839, DOI 10.1074/jbc.M505184200; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; van Bueren AL, 2005, J BIOL CHEM, V280, P530, DOI 10.1074/jbc.M410113200; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	28	48	48	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35263	35271		10.1074/jbc.M607620200	http://dx.doi.org/10.1074/jbc.M607620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987809	hybrid			2022-12-25	WOS:000241933700060
J	del Rey, A; Renigunta, V; Dalpke, AH; Leipziger, J; Matos, JE; Robaye, B; Zuzarte, M; Kavelaars, A; Hanley, PJ				del Rey, Adriana; Renigunta, Vijay; Dalpke, Alexander H.; Leipziger, Jens; Matos, Joana E.; Robaye, Bernard; Zuzarte, Marylou; Kavelaars, Annemieke; Hanley, Peter J.			Knock-out mice reveal the contributions of P2Y and P2X receptors to nucleotide-induced Ca2+ signaling in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP; DESENSITIZATION; AGONIST; RELEASE; ACTIVATION; MECHANISMS; MEMBRANE; CELLS; PHOSPHORYLATION; MOLECULES	Immune cell function is modulated by changes in extracellular nucleotide levels. Here we used reverse transcription-PCR analyses, single cell Ca2+ imaging, and knock-out mice to define the receptors mediating nucleotide-induced Ca2+ signaling in resident peritoneal macrophages. In Ca2+-free buffer, the potent (K-0.5 < 1 mu m) stimulatory effect of UTP (or ATP) on endoplasmic reticulum (ER) Ca2+ release was abolished in cells isolated from P2Y(2)/P2Y(4) double knock-out mice. Moreover, P2Y(4)(0/-), but not P2Y(2)(-/-), macrophages responded to UTP. In P2Y(2)(-/-) macrophages, we could elicit Ca2+ responses to "pure" P2X receptor activation by applying ATP in buffer containing Ca2+. Purified UDP and ADP were ineffective agonists, although modest UDP-induced Ca2+ responses could be elicited in macrophages after "activation" with lipopolysaccharide and interferon-gamma. Notably, in Ca2+-free buffer, UTP-induced Ca2+ transients decayed within 1 min, and there was no response to repeated agonist challenge. Measurements of ER [Ca2+] with mag-fluo-4 showed that ER Ca2+ stores were depleted under these conditions. When extracellular Ca2+ was available, ER Ca2+ stores refilled, but Ca2+ increased to only similar to 40% of the initial value upon repeated UTP challenge. This apparent receptor desensitization persisted in GRK2(+/-) and GRK6(-/-) macrophages and after inhibition of candidate kinases protein kinase C and calmodulin-dependent kinase II. Initial challenge with UTP also reduced Ca2+ mobilization by complement component C5a (and vice versa). In conclusion, homologous receptor desensitization is not the major mechanism that rapidly dampens Ca2+ signaling mediated by P2Y(2), the sole G(q)-coupled receptor for UTP or ATP in macrophages. UDP responsiveness (P2Y(6) receptor expression) increases following macrophage activation.	Univ Marburg, Inst Physiol, D-35037 Marburg, Germany; Heidelberg Univ, Dept Hyg & Med Microbiol, D-69120 Heidelberg, Germany; Aarhus Univ, Inst Physiol & Biophys, DK-8000 Aarhus, Denmark; Univ Libre Bruxelles, Inst Biol & Med Mol, Inst Interdisciplinary Res, B-6041 Charleroi, Gosselies, Belgium; Univ Utrecht, Med Ctr, Lab Psychoneuroimmunol, NL-3584 EA Utrecht, Netherlands	Philipps University Marburg; Ruprecht Karls University Heidelberg; Aarhus University; Universite Libre de Bruxelles; Utrecht University	Hanley, PJ (corresponding author), Univ Marburg, Inst Physiol, Deutschhausstr 2, D-35037 Marburg, Germany.	hanley@mailer.uni-marburg.de	Hanley, Peter J/H-4915-2017	Leipziger, Jens/0000-0002-6719-7034				Bowler JW, 2003, BRIT J PHARMACOL, V140, P567, DOI 10.1038/sj.bjp.0705459; Cho H, 2005, P NATL ACAD SCI USA, V102, P15241, DOI 10.1073/pnas.0408851102; Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909; Coutinho-Silva R, 2005, BIOCHEM PHARMACOL, V69, P641, DOI 10.1016/j.bcp.2004.11.012; Davignon I, 2000, MOL CELL BIOL, V20, P797, DOI 10.1128/MCB.20.3.797-804.2000; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Flores RV, 2005, MOL CELL BIOCHEM, V280, P35, DOI 10.1007/s11010-005-8050-5; Gachet C, 2006, ANNU REV PHARMACOL, V46, P277, DOI 10.1146/annurev.pharmtox.46.120604.141207; Gallo EM, 2006, NAT IMMUNOL, V7, P25, DOI 10.1038/ni1295; Hanley PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/pnas.0400733101; Harden TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7; Hardy AR, 2005, BLOOD, V105, P3552, DOI 10.1182/blood-2004-07-2893; Hasko G, 1998, BIOCHEM PHARMACOL, V56, P1079, DOI 10.1016/S0006-2952(98)00153-1; Herold CL, 2004, J BIOL CHEM, V279, P11456, DOI 10.1074/jbc.M301734200; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Kaufmann A, 2005, J BIOL CHEM, V280, P32459, DOI 10.1074/jbc.M505301200; Koizumi S, 2002, LIFE SCI, V72, P431, DOI 10.1016/S0024-3205(02)02273-7; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lazarowski ER, 2001, J PHARMACOL EXP THER, V297, P43; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; Marteau F, 2004, J LEUKOCYTE BIOL, V76, P796, DOI 10.1189/jlb.0104032; Matos JE, 2005, J PHYSIOL-LONDON, V564, P269, DOI 10.1113/jphysiol.2004.080002; Montecino-Rodriguez E, 2006, NAT IMMUNOL, V7, P293, DOI 10.1038/ni1301; Nicke A, 2005, J NEUROCHEM, V92, P925, DOI 10.1111/j.1471-4159.2004.02939.x; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Otero M, 2000, MOL CELL BIOCHEM, V205, P115, DOI 10.1023/A:1007018001735; Robaye B, 2003, MOL PHARMACOL, V63, P777, DOI 10.1124/mol.63.4.777; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Tulapurkar ME, 2006, J NEUROCHEM, V96, P624, DOI 10.1111/j.1471-4159.2005.03594.x; Vroon A, 2005, J IMMUNOL, V174, P4400, DOI 10.4049/jimmunol.174.7.4400; Westfall DP, 2002, J PHARMACOL EXP THER, V303, P439, DOI 10.1124/jpet.102.035113; Yoshioka K, 2001, P NATL ACAD SCI USA, V98, P7617, DOI 10.1073/pnas.121587098; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	40	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35147	35155		10.1074/jbc.M607713200	http://dx.doi.org/10.1074/jbc.M607713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980298	hybrid			2022-12-25	WOS:000241933700048
J	Gonzalez, A; Ruiz, A; Serrano, R; Arino, J; Casamayor, A				Gonzalez, Asier; Ruiz, Amparo; Serrano, Raquel; Arino, Joaquin; Casamayor, Antonio			Transcriptional profiling of the protein phosphatase 2C family in yeast provides insights into the unique functional roles of ptc1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; VACUOLAR H+-ATPASE; INTEGRITY SIGNALING PATHWAY; EXPRESSION DATA-ANALYSIS; GENE-EXPRESSION; CELL INTEGRITY; BUDDING YEAST; WIDE ANALYSIS; SER/THR PHOSPHATASE; ALTERED SENSITIVITY	Type 2C protein phosphatases are encoded in Saccharomyces cerevisiae by several related genes (PTC1-5 and PTC7). To gain insight into the functions attributable to specific members of this gene family, we have investigated the transcriptional profiles of ptc1- 5 mutants. Two main patterns were obtained as follows: the one generated by the ptc1 mutation and the one resulting from the lack of Ptc2-5. ptc4 and ptc5 profiles were quite similar, whereas that of ptc2 was less related to this group. Mutation of PTC1 resulted in increased expression of numerous genes that are also induced by cell wall damage, such as YKL161c, SED1, or CRH1, as well as in higher amounts of active Slt2 mitogen-activated protein kinase, indicating that lack of the phosphatase activates the cell wall integrity pathway. ptc1 cells were even more sensitive than slt2 mutants to a number of cell wall-damaging agents, and both mutations had additive effects. The sensitivity of ptc1 cells was not dependent on Hog1. Besides these phenotypes, we observed that calcineurin was hyperactivated in ptc1 cells, which were also highly sensitive to calcium ions, heavy metals, and alkaline pH, and exhibited a random haploid budding pattern. Remarkably, many of these traits are found in certain mutants with impaired vacuolar function. As ptc1 cells also display fragmented vacuoles, we hypothesized that lack of Ptc1 would primarily cause vacuolar malfunction, from which other phenotypes would derive. In agreement with this scenario, overexpression of VPS73, a gene of unknown function involved in vacuolar protein sorting, largely rescues not only vacuolar fragmentation but also sensitivity to cell wall damage, high calcium, alkaline pH, as well as other ptc1-specific phenotypes.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Catalonia, Spain	Autonomous University of Barcelona	Casamayor, A (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Edificio 5, E-08193 Barcelona, Catalonia, Spain.	Antonio.Casamayor@uab.es	Ruiz, Amparo/AAZ-2317-2021; Casamayor, Antonio/C-2509-2017; Arino, Joaquin/D-3756-2011; Casamayor, Antonio/A-3190-2012; González, Asier/A-7064-2012	Ruiz, Amparo/0000-0002-3947-4540; Arino, Joaquin/0000-0002-6774-2987; Casamayor, Antonio/0000-0003-2788-7329; Arino Carmona, Joaquin/0000-0002-0390-4270				Alberola TM, 2004, INT MICROBIOL, V7, P199; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bilsland E, 1998, YEAST, V14, P655, DOI 10.1002/(SICI)1097-0061(199805)14:7<655::AID-YEA257>3.0.CO;2-X; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; Boorsma A, 2004, YEAST, V21, P413, DOI 10.1002/yea.1109; Brazma A, 2000, FEBS LETT, V480, P17, DOI 10.1016/S0014-5793(00)01772-5; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Cohen PTW, 2004, TOP CURR GENET, V5, P1; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eide DJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r77; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enyenihi AH, 2003, GENETICS, V163, P47; Gaits F, 1999, MOL BIOL CELL, V10, P2647, DOI 10.1091/mbc.10.8.2647; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Garcia-Rodriguez LJ, 2005, FEBS LETT, V579, P6186, DOI 10.1016/j.febslet.2005.10.001; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; HALACHMI D, 1989, FEBS LETT, V256, P55, DOI 10.1016/0014-5793(89)81717-X; Herrero J, 2003, NUCLEIC ACIDS RES, V31, P3461, DOI 10.1093/nar/gkg591; HUANG KN, 1995, GENETICS, V141, P1275; JIANG B, 1995, MOL GEN GENET, V248, P260, DOI 10.1007/BF02191592; Jiang LH, 2002, FEBS LETT, V527, P323, DOI 10.1016/S0014-5793(02)03247-7; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Lesage G, 2004, GENETICS, V167, P35, DOI 10.1534/genetics.167.1.35; Lussier M, 1997, GENETICS, V147, P435; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; Mapes J, 2004, EMBO J, V23, P302, DOI 10.1038/sj.emboj.7600036; Markovich S, 2004, ANTIMICROB AGENTS CH, V48, P3871, DOI 10.1128/AAC.48.10.3871-3876.2004; Marsolier MC, 2000, GENETICS, V154, P1523; Martin H, 2005, MOL MICROBIOL, V58, P6, DOI 10.1111/j.1365-2958.2005.04822.x; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Munoz I, 2003, YEAST, V20, P157, DOI 10.1002/yea.938; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Ni L, 2001, MOL BIOL CELL, V12, P2147, DOI 10.1091/mbc.12.7.2147; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Page N, 2003, GENETICS, V163, P875; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; Roeder AD, 1998, MOL BIOL CELL, V9, P917, DOI 10.1091/mbc.9.4.917; Ruepp A, 2004, NUCLEIC ACIDS RES, V32, P5539, DOI 10.1093/nar/gkh894; Ruiz A, 2003, EUKARYOT CELL, V2, P937, DOI 10.1128/EC.2.5.937-948.2003; Ruiz A, 2006, MOL MICROBIOL, V62, P263, DOI 10.1111/j.1365-2958.2006.05370.x; Saito H, 2004, J BIOCHEM, V136, P267, DOI 10.1093/jb/mvh135; Sakumoto N, 2002, YEAST, V19, P587, DOI 10.1002/yea.860; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; Sambade M, 2005, GENETICS, V170, P1539, DOI 10.1534/genetics.105.042812; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Sen Gupta S, 2003, J BIOL CHEM, V278, P28831, DOI 10.1074/jbc.M303300200; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Serrano R, 2004, J BIOL CHEM, V279, P19698, DOI 10.1074/jbc.M313746200; Shitamukai A, 2004, J BIOL CHEM, V279, P3651, DOI 10.1074/jbc.M306098200; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; Tahirovic S, 2005, TRAFFIC, V6, P116, DOI 10.1111/j.1600-0854.2004.00255.x; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; van Voorst F, 2006, YEAST, V23, P351, DOI 10.1002/yea.1359; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Viladevall L, 2004, J BIOL CHEM, V279, P43614, DOI 10.1074/jbc.M403606200; Vissi E, 2001, YEAST, V18, P115, DOI 10.1002/1097-0061(20010130)18:2<115::AID-YEA653>3.0.CO;2-G; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Young C, 2002, EUKARYOT CELL, V1, P1032, DOI 10.1128/EC.1.6.1032-1040.2002; Zakrzewska A, 2005, EUKARYOT CELL, V4, P703, DOI 10.1128/EC.4.4.703-715.2005; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	75	50	51	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35057	35069		10.1074/jbc.M607919200	http://dx.doi.org/10.1074/jbc.M607919200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973600	hybrid			2022-12-25	WOS:000241933700039
J	Hammond, MSL; Sims, C; Parameshwaran, K; Suppiramaniam, V; Schachner, M; Dityatev, A				Hammond, Martin S. L.; Sims, Catrina; Parameshwaran, Kodeeswaran; Suppiramaniam, Vishnu; Schachner, Melitta; Dityatev, Alexander			Neural cell adhesion molecule-associated polysialic acid inhibits NR2B-containing N-methyl-D-aspartate receptors and prevents glutamate-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NMDA RECEPTORS; SUBUNIT COMPOSITION; PSA-NCAM; EXPRESSION; BINDING; SYSTEM; BRAIN; L1; NEURODEGENERATION	The neural cell adhesion molecule (NCAM) and its associated glycan polysialic acid play important roles in the development of the nervous system and N-methyl-D-aspartat(NMDA) receptor-dependent synaptic plasticity in the adult. Here, we investigated the influence of polysialic acid on NMDA receptor activity. We found that glutamate-elicited NMDA receptor currents in cultured hippocampal neurons were reduced by approximate to 30% with the application of polysialic acid or polysialylated NCAM but not by the sialic acid monomer, chondroitin sulfate, or non-polysialylated NCAM. Polysialic acid inhibited NMDA receptor currents elicited by 3 mu M glutamate but not by 30 mu M glutamate, suggesting that polysialic acid acts as a competitive antagonist, possibly at the glutamate binding site. The polysialic acid induced effects were mimicked and fully occluded by the NR2B subunit specific antagonist, ifenprodil. Recordings from single synaptosomal NMDA receptors reconstituted in lipid bilayers revealed that polysialic acid reduced open probability but not the conductance of NR2B-containing NMDA receptors in a polysialic acid and glutamate concentration-dependent manner. The activity of single NR2B-lacking synaptosomal NMDA receptors was not affected by polysialic acid. Application of polysialic acid to hippocampal cultures reduced excitotoxic cell death induced by low micromolar concentration of glutamate via activation of NR2B-containing NMDA receptors, whereas enzymatic removal of polysialic acid resulted in increased cell death that occluded glutamate-induced excitotoxicity. These observations indicate that the cell adhesion molecule-associated glycan polysialic acid is able to prevent excitotoxicity via inhibition of NR2B subunit-containing NMDA receptors.	Auburn Univ, Harrison Sch Pharm, Dept Pharmacal Sci, Auburn, AL 36849 USA; Univ Hamburg, Klinikum Eppendorf, Inst Neurophysiol & Pathophysiol, D-20246 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany; Dalian Med Univ, Dalian 116023, Peoples R China	Auburn University System; Auburn University; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Dalian Medical University	Suppiramaniam, V (corresponding author), Auburn Univ, Harrison Sch Pharm, Dept Pharmacal Sci, Auburn, AL 36849 USA.	suppivd@auburn.edu; melitta.schachner@zmnh.uni-hamburg.de	Dityatev, Alexander/A-4034-2008	Dityatev, Alexander/0000-0002-0472-0553; Robinson, Catrina/0000-0003-4776-5839				Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; Berger C, 2004, NERVENARZT, V75, P113, DOI 10.1007/s00115-003-1627-x; BHAVANANDAN VP, 1993, ANAL BIOCHEM, V213, P438, DOI 10.1006/abio.1993.1445; BOCK E, 1987, FEBS LETT, V225, P33, DOI 10.1016/0014-5793(87)81126-2; Bouzioukh F, 2001, J NEUROSCI, V21, P4721, DOI 10.1523/JNEUROSCI.21-13-04721.2001; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Dityatev A, 2004, J NEUROSCI, V24, P9372, DOI 10.1523/JNEUROSCI.1702-04.2004; Dityatev A, 2000, NEURON, V26, P207, DOI 10.1016/S0896-6273(00)81151-4; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Endo A, 1998, NEUROSCI LETT, V246, P37, DOI 10.1016/S0304-3940(98)00204-3; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Fux CM, 2003, MOL CELL NEUROSCI, V24, P939, DOI 10.1016/j.mcn.2003.07.001; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; HALLENBECK PC, 1987, ANAL BIOCHEM, V161, P181, DOI 10.1016/0003-2697(87)90670-1; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hatton CJ, 2005, NEURON, V46, P261, DOI 10.1016/j.neuron.2005.03.005; Hayrinen J, 2002, MOL IMMUNOL, V39, P399, DOI 10.1016/S0161-5890(02)00202-X; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; Hoffman KB, 1998, BRAIN RES, V811, P152, DOI 10.1016/S0006-8993(98)00907-X; Johnson MW, 1997, J NEUROSCI METH, V77, P151, DOI 10.1016/S0165-0270(97)00120-9; Kalus I, 2006, J NEUROCHEM, V98, P78, DOI 10.1111/j.1471-4159.2006.03847.x; Kinarsky L, 2005, J PHARMACOL EXP THER, V313, P1066, DOI 10.1124/jpet.104.082990; Kirson ED, 1999, J PHYSIOL-LONDON, V521, P99, DOI 10.1111/j.1469-7793.1999.00099.x; Kiss JZ, 2001, REV NEUROSCIENCE, V12, P297; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Kohr G, 2003, J NEUROSCI, V23, P10791; Kundrotiene J, 2004, J NEUROTRAUM, V21, P83, DOI 10.1089/089771504772695977; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Li LJ, 2003, NEUROBIOL AGING, V24, P1113, DOI 10.1016/j.neurobiolaging.2003.04.003; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nagy J, 2004, IDRUGS, V7, P339; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; Ritz MF, 2004, BRAIN RES, V1022, P157, DOI 10.1016/j.brainres.2004.07.004; ROCK DM, 1995, ANNU REV PHARMACOL, V35, P463; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Sherwin AL, 1999, NEUROCHEM RES, V24, P1385, DOI 10.1023/A:1022580506443; SHIMODA Y, 1994, BIOCHEMISTRY-US, V33, P1202, DOI 10.1021/bi00171a020; Strekalova H, 2006, NEUROBIOL AGING, V27, P1, DOI 10.1016/j.neurobiolaging.2004.11.013; Sytnyk V, 2006, J CELL BIOL, V174, P1071, DOI 10.1083/jcb.200604145; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tsvetkov E, 2002, NEURON, V34, P289, DOI 10.1016/S0896-6273(02)00645-1; Ueda Y, 2001, J NEUROCHEM, V76, P892, DOI 10.1046/j.1471-4159.2001.00087.x; Vaithianathan H, 2005, CELL BIOCHEM BIOPHYS, V42, P75, DOI 10.1385/CBB:42:1:075; Vaithianathan T, 2004, J BIOL CHEM, V279, P47975, DOI 10.1074/jbc.M407138200; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; Zhou M, 2006, J NEUROSCI, V26, P2956, DOI 10.1523/JNEUROSCI.4299-05.2006	56	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34859	34869		10.1074/jbc.M602568200	http://dx.doi.org/10.1074/jbc.M602568200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987814	hybrid			2022-12-25	WOS:000241933700018
J	Hu, YF; Li, Y; Zhang, XX; Guo, XR; Xia, B; Jin, CW				Hu, Yunfei; Li, You; Zhang, Xinxin; Guo, Xianrong; Xia, Bin; Jin, Changwen			Solution structures and backbone dynamics of a flavodoxin MioC from Escherichia coli in both apo- and holo-forms - Implications for cofactor binding and electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BEIJERINCKII FLAVODOXIN; MAGNETIC-RESONANCE RELAXATION; TORSION ANGLE DYNAMICS; MODEL-FREE APPROACH; METHIONINE SYNTHASE; DESULFOVIBRIO-VULGARIS; CRYSTAL-STRUCTURES; CHROMOSOMAL REPLICATION; ANABAENA APOFLAVODOXIN; AZOTOBACTER-VINELANDII	Flavodoxins play central roles in the electron transfer involving various biological processes in microorganisms. The mioC gene of Escherichia coli encodes a 16-kDa flavodoxin and locates next to the chromosomal replication initiation origin (oriC). Extensive researches have been carried out to investigate the relationship between mioC transcription and replication initiation. Recently, the MioC protein was proposed to be essential for the biotin synthase activity in vitro. Nevertheless, the exact role of MioC in biotin synthesis and its physiological function in vivo remain elusive. In order to understand the molecular basis of the biological functions of MioC and the cofactor-binding mechanisms of flavodoxins, we have determined the solution structures of both the apo- and holo-forms of E. coli MioC protein at high resolution by nuclear magnetic resonance spectroscopy. The overall structures of both forms consist of an alpha/beta sandwich, which highly resembles the classical flavodoxin fold. However, significant diversities are observed between the two forms, especially the stabilization of the FMN-binding loops and the notable extension of secondary structures upon FMN binding. Structural comparison reveals fewer negative charged and aromatic residues near the FMN-binding site of MioC, as compared with that of flavodoxin 1 from E. coli, which may affect both the redox potentials and the redox partner interactions. Furthermore, the backbone dynamics studies reveal the conformational flexibility at different time scales for both apo- and holo-forms of MioC, which may play important roles for cofactor binding and electron transfer.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	zhang, xinxin/E-8629-2012					Alagaratnam S, 2005, PROTEIN SCI, V14, P2284, DOI 10.1110/ps.051582605; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Artali R, 2002, ACTA CRYSTALLOGR D, V58, P1787, DOI 10.1107/S0907444902012234; ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; Atkinson RA, 2004, PROG NUCL MAG RES SP, V44, P141, DOI 10.1016/j.pnmrs.2004.01.001; Barsukov I, 1997, J BIOMOL NMR, V10, P63, DOI 10.1023/A:1018313830207; Bates DB, 1997, P NATL ACAD SCI USA, V94, P12497, DOI 10.1073/pnas.94.23.12497; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Birch OM, 2000, J BIOL CHEM, V275, P32277, DOI 10.1074/jbc.M004497200; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; Bogan JA, 1996, J BACTERIOL, V178, P3201, DOI 10.1128/jb.178.11.3201-3206.1996; Bollen YJM, 2005, J BIOL CHEM, V280, P7836, DOI 10.1074/jbc.M412871200; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chang FC, 1999, BIOCHEMISTRY-US, V38, P7168, DOI 10.1021/bi982203u; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; EDMONDSON DE, 1971, BIOCHEMISTRY-US, V10, P124; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Freigang J, 2002, PROTEIN SCI, V11, P253, DOI 10.1110/ps.28602; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Gangeswaran R, 1996, BIOCHEM J, V317, P103, DOI 10.1042/bj3170103; Genzor CG, 1996, NAT STRUCT BIOL, V3, P329, DOI 10.1038/nsb0496-329; Gerstein M, 2004, CURR OPIN CHEM BIOL, V8, P14, DOI 10.1016/j.cbpa.2003.12.006; Gorman J, 2005, PROTEIN SCI, V14, P3004, DOI 10.1110/ps.051680805; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Hall DA, 2000, BIOCHEMISTRY-US, V39, P10711, DOI 10.1021/bi001096c; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Hoover DM, 1997, BIOCHEMISTRY-US, V36, P127, DOI 10.1021/bi961693s; Jarrett JT, 1998, BIOCHEMISTRY-US, V37, P5372, DOI 10.1021/bi9730893; Jarymowycz VA, 2006, CHEM REV, V106, P1624, DOI 10.1021/cr040421p; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kasim M, 2000, BIOCHEMISTRY-US, V39, P15322, DOI 10.1021/bi001519a; Kasim M, 2001, BIOCHEMISTRY-US, V40, P13548, DOI 10.1021/bi011587c; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KOLLING R, 1988, MOL GEN GENET, V212, P99, DOI 10.1007/BF00322450; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Langdon GM, 2001, PROTEINS, V43, P476, DOI 10.1002/prot.1059; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lawson RJ, 2004, BIOCHEMISTRY-US, V43, P12390, DOI 10.1021/bi049131t; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LOBNEROLESEN A, 1992, NUCLEIC ACIDS RES, V20, P3029, DOI 10.1093/nar/20.12.3029; LOBNEROLESEN A, 1987, J BACTERIOL, V169, P2835, DOI 10.1128/jb.169.6.2835-2842.1987; Lopez-Llano J, 2004, J BIOL CHEM, V279, P47184, DOI 10.1074/jbc.M405791200; Lopez-Llano J, 2004, J BIOL CHEM, V279, P47177, DOI 10.1074/jbc.M405792200; Lostao A, 2003, J BIOL CHEM, V278, P24053, DOI 10.1074/jbc.M301049200; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; McCarthy AA, 2002, BIOCHEMISTRY-US, V41, P10950, DOI 10.1021/bi020225h; McIver L, 1998, EUR J BIOCHEM, V257, P577, DOI 10.1046/j.1432-1327.1998.2570577.x; Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; Mulliez E, 2001, BIOCHEMISTRY-US, V40, P3730, DOI 10.1021/bi001746c; NISIMOTO Y, 1986, J BIOL CHEM, V261, P14232; O'Farrell PA, 1998, BIOCHEMISTRY-US, V37, P8405, DOI 10.1021/bi973193k; OGAWA T, 1994, J BACTERIOL, V176, P1609, DOI 10.1128/jb.176.6.1609-1615.1994; OGAWA T, 1991, MOL GEN GENET, V230, P193, DOI 10.1007/BF00290668; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Puan KJ, 2005, FEBS LETT, V579, P3802, DOI 10.1016/j.febslet.2005.05.047; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; Sancho J, 2006, CELL MOL LIFE SCI, V63, P855, DOI 10.1007/s00018-005-5514-4; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sawers G, 1998, MOL MICROBIOL, V29, P945, DOI 10.1046/j.1365-2958.1998.00941.x; Setif P, 2001, BBA-BIOENERGETICS, V1507, P161, DOI 10.1016/S0005-2728(01)00205-5; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Sibille N, 2005, BIOCHEMISTRY-US, V44, P9086, DOI 10.1021/bi050437p; SMILLIE RM, 1965, BIOCHEM BIOPH RES CO, V20, P621, DOI 10.1016/0006-291X(65)90445-6; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; Stok JE, 2000, ARCH BIOCHEM BIOPHYS, V384, P351, DOI 10.1006/abbi.2000.2067; Su'etsugu M, 2003, GENES CELLS, V8, P731, DOI 10.1046/j.1365-2443.2003.00671.x; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	91	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35454	35466		10.1074/jbc.M607336200	http://dx.doi.org/10.1074/jbc.M607336200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16963438	hybrid			2022-12-25	WOS:000241933700079
J	Oliveira, MJ; Costa, AC; Costa, AM; Henriques, L; Suriano, G; Atherton, JC; Machado, JC; Carneiro, F; Seruca, R; Mareel, M; Leroy, A; Figueiredo, C				Oliveira, Maria J.; Costa, Ana C.; Costa, Angela M.; Henriques, Lara; Suriano, Gianpaolo; Atherton, John C.; Machado, Jose C.; Carneiro, Fatima; Seruca, Raquel; Mareel, Marc; Leroy, Ancy; Figueiredo, Ceu			Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; MATRIX METALLOPROTEINASES; CAGA; VACA; ACTIVATION; INDUCTION; RECEPTOR; TOXIN; TRANSACTIVATION; DISRUPTION	Helicobacter pylori interacts with gastric epithelial cells, activating signaling pathways important for carcinogenesis. In this study we examined the role of H. pylori on cell invasion and the molecular mechanisms underlying this process. The relevance of H. pylori cag pathogenicity island-encoded type IV secretion system (T4SS), CagA, and VacA for cell invasion was also investigated. We found that H. pylori induces AGS cell invasion in collagen type I and in Matrigel invasion assays. H. pylori-induced cell invasion requires the direct contact between bacteria and cancer cells. H. pylori-mediated cell invasion was dependent on the activation of the c-Met receptor and on increased MMP-2 and MMP-9 activity. The abrogation of the c-Met receptor using the specific NK4 inhibitor or the silencing of c-Met expression with small interference RNA suppressed both cell invasion and MMP activity. Studies with different H. pylori strains revealed that cell invasion, c-Met tyrosine phosphorylation, and increased MMP-2 and MMP-9 activity were all dependent on the presence of a functional bacterial T4SS, but not on VacA cytotoxicity. Our findings demonstrate that H. pylori strains with a functional T4SS stimulate gastric epithelial cell invasion through a c-Met-dependent signaling pathway that comprises an increase in MMP-2 and MMP-9 activity.	Univ Porto, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal; Fac Med Porto, P-4200465 Oporto, Portugal; Univ Nottingham, Inst Infect Immun & Inflammat, Nottingham NG7 2UH, England; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Universidade do Porto; Universidade do Porto; University of Nottingham; Ghent University; Ghent University Hospital	Figueiredo, C (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	cfigueiredo@ipatimup.pt	Figueiredo, Ceu/B-8776-2008; Carneiro, Fatima/AAV-8677-2021; Carneiro, Fatima/J-6432-2013; Machado, Jose Carlos/C-5907-2009; Costa, Ana/X-6874-2019; Costa, Ana C./K-5354-2013; seruca, raquel/F-8187-2011; Oliveira, Maria Jose/K-3275-2013	Figueiredo, Ceu/0000-0001-5247-840X; Carneiro, Fatima/0000-0002-1964-1006; Carneiro, Fatima/0000-0002-1964-1006; Machado, Jose Carlos/0000-0003-4741-8415; Costa, Ana/0000-0003-0062-8714; Costa, Ana C./0000-0003-0062-8714; Costa, Angela/0000-0002-8911-1043; Oliveira, Maria Jose/0000-0002-0724-0272; /0000-0001-6180-0042; Seruca, Raquel/0000-0002-8851-4166				Al-Ghoul L, 2004, BIOCHEM BIOPH RES CO, V322, P860, DOI 10.1016/j.bbrc.2004.07.199; ALBINI A, 1987, CANCER RES, V47, P3239; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bebb JR, 2003, GUT, V52, P1408, DOI 10.1136/gut.52.10.1408; Bebb JR, 2003, INFECT IMMUN, V71, P3623, DOI 10.1128/IAI.71.6.3623-3627.2003; BLASER MJ, 1995, CANCER RES, V55, P2111; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Cover TL, 2005, NAT REV MICROBIOL, V3, P320, DOI 10.1038/nrmicro1095; COVER TL, 1992, J BIOL CHEM, V267, P10570; CRABTREE JE, 1995, J CLIN PATHOL, V48, P967, DOI 10.1136/jcp.48.10.967; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Debruyne PR, 2002, ONCOGENE, V21, P6740, DOI 10.1038/sj.onc.1205729; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; El-Etr SH, 2004, J INFECT DIS, V190, P1516, DOI 10.1086/424526; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; GRIGIONI WF, 1994, MODERN PATHOL, V7, P220; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Nogueira C, 2001, AM J PATHOL, V158, P647, DOI 10.1016/S0002-9440(10)64006-0; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Oliveira MJ, 2005, J CANCER RES CLIN, V131, P49, DOI 10.1007/s00432-004-0601-8; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 2000, GASTROENTEROLOGY, V118, P48, DOI 10.1016/S0016-5085(00)70413-6; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374; Suriano G, 2003, ONCOGENE, V22, P5716, DOI 10.1038/sj.onc.1206672; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VAKAET L, 1991, INVAS METAST, V11, P249; van Doorn LJ, 1998, GASTROENTEROLOGY, V115, P58, DOI 10.1016/S0016-5085(98)70365-8; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Wroblewski LE, 2003, J CELL SCI, V116, P3017, DOI 10.1242/jcs.00518; Yanagisawa N, 2005, FEMS IMMUNOL MED MIC, V44, P197, DOI 10.1016/j.femsim.2004.11.009	47	80	87	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34888	34896		10.1074/jbc.M607067200	http://dx.doi.org/10.1074/jbc.M607067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16990273	hybrid			2022-12-25	WOS:000241933700021
J	Gomez, I; Arenas, I; Benitez, I; Miranda-Rios, J; Becerril, B; Grande, R; Almagro, JC; Bravo, A; Soberon, M				Gomez, Isabel; Arenas, Ivan; Benitez, Itzel; Miranda-Rios, Juan; Becerril, Baltazar; Grande, Ricardo; Carlos Almagro, Juan; Bravo, Alejandra; Soberon, Mario			Specific epitopes of domains II and III of Bacillus thuringiensis Cry1Ab toxin involved in the sequential interaction with cadherin and aminopeptidase-N receptors in Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMATION ACTIVITY; DELTA-ENDOTOXIN; CRYSTAL-STRUCTURE; HELIOTHIS-VIRESCENS; INSECTICIDAL TOXIN; BT-R-1 RECEPTOR; BOMBYX-MORI; BINDING; MEMBRANE; MIDGUT	The Bacillus thuringiensis Cry toxins are specific to different insects. In Manduca sexta cadherin (Bt-R-1) and aminopeptidase-N (APN) proteins are recognized as Cry1A receptors. Previous work showed that Cry1Ab binds to Bt-R1 promoting the formation of a pre-pore oligomer that binds to APN leading to membrane insertion. In this work we characterized the binding epitopes involved in the sequential interaction of Cry1Ab with Bt-R1 and APN. A Cry1Ab immune M13 phage repertoire was constructed using antibody gene transcripts of bone marrow or spleen from a rabbit immunized with Cry1Ab. We identified antibodies that recognize domain II loop 3 (scFvL3-3) or beta 16-beta 22 (scFvM22) in domain III. Enzyme-linked immunosorbent assay and toxin overlay binding competition assays in the presence of scFvL3-3, scFvM22, or synthetic peptides showed that domain II loop 3 is an important epitope for interaction with Bt-R1 receptor, whereas domain III beta 16 is involved in the interaction with APN. Both scFvL3-3 and scFvM22 lowered the toxicity of Cry1Ab to M. sexta larvae indicating that interaction with both receptors is important for in vivo toxicity. scFvL3-3 and anti-loop2 scFv (scFv73) promoted the formation of the pre-pore oligomer in contrast to scFvM22. In addition, scFvL3-3 and scFv73 preferentially recognized the monomeric toxin rather than the pre-pore suggesting a conformational change in domain II loops upon oligomerization. These results indicate for the first time that both receptor molecules participate in Cry1Ab toxin action in vivo: first the monomeric toxin binds to Bt-R1 through loops 2 and 3 of domain II promoting the formation of the pre-pore inducing some structural changes, then the pre-pore interacts with APN through beta-16 of domain III promoting membrane insertion and cell death.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Mol Microbiol, Cuernavaca 62250, Morelos, Mexico; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Cuernavaca 62250, Morelos, Mexico; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Ingn Celular & Biocatalisis, Cuernavaca 62250, Morelos, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Soberon, M (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Mol Microbiol, Cuernavaca 62250, Morelos, Mexico.	mario@ibt.unam.mx	Miranda Ríos, Juan/ABB-7767-2021; Almagro, Juan/O-2468-2019; de la Parra, Maria Alejandra Bravo/R-6740-2017	ARENAS, IVAN/0000-0003-0384-7437; Almagro, Juan Carlos/0000-0001-9420-1310; Bravo, Alejandra/0000-0002-7573-7475				ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Atsumi S, 2005, APPL ENVIRON MICROB, V71, P3966, DOI 10.1128/AEM.71.7.3966-3977.2005; Boonserm P, 2006, J BACTERIOL, V188, P3391, DOI 10.1128/JB.188.9.3391-3401.2006; Boonserm P, 2005, J MOL BIOL, V348, P363, DOI 10.1016/j.jmb.2005.02.013; Bravo A, 2004, BBA-BIOMEMBRANES, V1667, P38, DOI 10.1016/j.bbamem.2004.08.013; Bravo A, 2002, BBA-BIOMEMBRANES, V1562, P63, DOI 10.1016/S0005-2736(02)00360-7; Bravo A., 2005, BACILLUS THURINGIENS, P175, DOI DOI 10.1016/B0-44-451924-6/00081-8; Ferre J, 2002, ANNU REV ENTOMOL, V47, P501, DOI 10.1146/annurev.ento.47.091201.145234; Galitsky N, 2001, ACTA CRYSTALLOGR D, V57, P1101, DOI 10.1107/S0907444901008186; Gomez I, 2003, BIOCHEMISTRY-US, V42, P10482, DOI 10.1021/bi034440p; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, J BIOL CHEM, V277, P30137, DOI 10.1074/jbc.M203121200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Hawlisch H, 2000, J IMMUNOL METHODS, V236, P117, DOI 10.1016/S0022-1759(99)00229-X; Hua G, 2004, J BIOL CHEM, V279, P28051, DOI 10.1074/jbc.M400237200; Jenkins J L, 2000, Genet Eng (N Y), V22, P33; Jenkins JL, 2000, J BIOL CHEM, V275, P14423, DOI 10.1074/jbc.275.19.14423; Keeton TP, 1998, APPL ENVIRON MICROB, V64, P2158; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; Lee MK, 1999, APPL ENVIRON MICROB, V65, P4513; LERECLUS D, 1995, BIO-TECHNOL, V13, P67, DOI 10.1038/nbt0195-67; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Lorence A, 1997, FEBS LETT, V414, P303, DOI 10.1016/S0014-5793(97)01014-4; MASSON L, 1995, J BIOL CHEM, V270, P20309, DOI 10.1074/jbc.270.35.20309; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; Nakanishi K, 2002, FEBS LETT, V519, P215, DOI 10.1016/S0014-5793(02)02708-4; Rausell C, 2004, BIOCHEMISTRY-US, V43, P166, DOI 10.1021/bi035527d; Soberon M, 2000, FEMS MICROBIOL LETT, V191, P221, DOI 10.1016/S0378-1097(00)00394-3; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; Xie RY, 2005, J BIOL CHEM, V280, P8416, DOI 10.1074/jbc.M408403200; Zhang X, 2005, CELL DEATH DIFFER, V12, P1407, DOI 10.1038/sj.cdd.4401675; Zhang XB, 2006, P NATL ACAD SCI USA, V103, P9897, DOI 10.1073/pnas.0604017103; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	35	78	90	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34032	34039		10.1074/jbc.M604721200	http://dx.doi.org/10.1074/jbc.M604721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16968705	hybrid			2022-12-25	WOS:000241767600023
J	Jaen, C; Doupnik, CA				Jaen, Cristina; Doupnik, Craig A.			RGS3 and RGS4 differentially associate with G protein-coupled receptor-Kir3 channel signaling complexes revealing two modes of RGS modulation - Precoupling and collision coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; RECTIFYING POTASSIUM CHANNELS; TERMINAL CYSTEINE RESIDUES; P-INDUCED INHIBITION; END RULE PATHWAY; K+ CHANNEL; DEPENDENT RELAXATION; GENE-EXPRESSION; GIRK CHANNELS	RGS3 and RGS4 are GTPase-activating proteins expressed in the brain and heart that accelerate the termination of G(i/o)- and G(q)-mediated signaling. We report here the determinants mediating selective association of RGS4 with several G protein-coupled receptors (GPCRs) that form macromolecular complexes with neuronal G protein-gated inwardly rectifying potassium (Kir3 or GIRK) channels. Kir3 channels are instrumental in regulating neuronal firing in the central and peripheral nervous system and pacemaker activity in the heart. By using an epitope-tagged degradation-resistant RGS4 mutant, RGS4(C2V), immunoprecipitation of several hemagglutinin-tagged Gi/o- coupled and G(q)-coupled receptors expressed in Chinese hamster ovary (CHO-K1) cells readily co-precipitated both Kir3.1/Kir3.2a channels and RGS401(C2V). In contrast to RGS4(C2V), the closely related and functionally active RGS3 "short" isoform (RGS3s) did not interact with any of the GPCR-Kir3 channel complexes examined. Deletion and chimeric RGS constructs indicate both the N-terminal domain and the RGS domain of RGS4(C2V) are necessary for association with m2 receptor-Kir3.1/Kir3.2a channel complexes, where the GPCR was found to be the major target for RGS4(C2V) interaction. The functional impact of RGS4(C2V) "precoupling" to the GPCR-Kir3 channel complex versus RGS3s "collision coupling" was a 100-fold greater potency in the acceleration of G protein-dependent Kir3 channel-gating kinetics with no attenuation in current amplitude. These findings demonstrate that RGS4, a highly regulated modulator and susceptibility gene for schizophrenia, can directly associate with multiple GPCR-Kir3 channel complexes and may affect a wide range of neurotransmitter-mediated inhibitory and excitatory events in the nervous and cardiovascular systems.	Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Doupnik, CA (corresponding author), Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, 12901 Bruce B Downs Blvd,MDC8, Tampa, FL 33612 USA.	cdoupnik@health.usf.edu	Doupnik, Craig A/I-3617-2012	Doupnik, Craig A/0000-0002-7314-0747				Benians A, 2005, J BIOL CHEM, V280, P13383, DOI 10.1074/jbc.M410163200; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bishop GB, 2002, NEUROBIOL DIS, V10, P334, DOI 10.1006/nbdi.2002.0518; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chidiac P, 2003, RECEPTOR CHANNEL, V9, P135, DOI 10.3109/10606820308244; Chowdari KV, 2002, HUM MOL GENET, V11, P1373, DOI 10.1093/hmg/11.12.1373; Clancy SM, 2005, MOL CELL NEUROSCI, V28, P375, DOI 10.1016/j.mcn.2004.10.009; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; Delling M, 2002, J NEUROSCI, V22, P7154; Ding J, 2006, NAT NEUROSCI, V9, P832, DOI 10.1038/nn1700; Doupnik CA, 2004, METHOD ENZYMOL, V389, P131; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Drake CT, 1997, P NATL ACAD SCI USA, V94, P1007, DOI 10.1073/pnas.94.3.1007; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Fujita S, 2000, J PHYSIOL-LONDON, V526, P341, DOI 10.1111/j.1469-7793.2000.00341.x; Garnier M, 2003, J PHARMACOL EXP THER, V304, P1299, DOI 10.1124/jpet.102.043471; Garzon J, 2005, NEUROPHARMACOLOGY, V48, P853, DOI 10.1016/j.neuropharm.2005.01.004; Georgoussi Z, 2006, CELL SIGNAL, V18, P771, DOI 10.1016/j.cellsig.2005.07.003; Geurts M, 2003, BIOCHEM PHARMACOL, V66, P1163, DOI 10.1016/S0006-2952(03)00447-7; Geurts M, 2002, NEUROSCI LETT, V333, P146, DOI 10.1016/S0304-3940(02)01004-2; Goin JC, 2006, J BIOL CHEM, V281, P5416, DOI 10.1074/jbc.M507476200; Gold SJ, 2003, EUR J NEUROSCI, V17, P971, DOI 10.1046/j.1460-9568.2003.02529.x; Gold SJ, 2002, J NEUROCHEM, V82, P828, DOI 10.1046/j.1471-4159.2002.01002.x; Gold SJ, 1997, J NEUROSCI, V17, P8024; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hu RG, 2005, NATURE, V437, P981, DOI 10.1038/nature04027; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Inanobe A, 2001, J PHYSIOL-LONDON, V535, P133, DOI 10.1111/j.1469-7793.2001.t01-1-00133.x; Ivanina T, 2004, J BIOL CHEM, V279, P17260, DOI 10.1074/jbc.M313425200; Jaen C, 2005, NEUROPHARMACOLOGY, V49, P465, DOI 10.1016/j.neuropharm.2005.04.010; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koike-Tani M, 2005, J PHYSIOL-LONDON, V564, P489, DOI 10.1113/jphysiol.2004.079285; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Krumins AM, 2004, J BIOL CHEM, V279, P2593, DOI 10.1074/jbc.M311600200; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Mirnics K, 2001, MOL PSYCHIATR, V6, P293, DOI 10.1038/sj.mp.4000866; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Muma NA, 2003, SYNAPSE, V47, P58, DOI 10.1002/syn.10153; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; Ni YG, 1999, J NEUROSCI, V19, P3674; Nikolov EN, 2004, J BIOL CHEM, V279, P23630, DOI 10.1074/jbc.M312861200; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; Papoucheva E, 2004, J BIOL CHEM, V279, P3280, DOI 10.1074/jbc.M308177200; Ponce A, 1996, J NEUROSCI, V16, P1990; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Stanfield PR, 2002, REV PHYSIOL BIOCH P, V145, P47, DOI 10.1007/BFb0116431; Taymans JM, 2003, J NEUROCHEM, V84, P1118, DOI 10.1046/j.1471-4159.2003.01610.x; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 2003, PHARMACOL THERAPEUT, V97, P95, DOI 10.1016/S0163-7258(02)00326-1; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yamada M, 1998, PHARMACOL REV, V50, P723; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	74	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34549	34560		10.1074/jbc.M603177200	http://dx.doi.org/10.1074/jbc.M603177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973624	hybrid			2022-12-25	WOS:000241767600075
J	Ke, YH; Lesperance, J; Zhang, EE; Bard-Chapeau, EA; Oshima, RG; Muller, WJ; Feng, GS				Ke, Yuehai; Lesperance, Jacqueline; Zhang, Eric E.; Bard-Chapeau, Emilie A.; Oshima, Robert G.; Muller, William J.; Feng, Gen-Sheng			Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHATASE; CELL-DIFFERENTIATION; PROLACTIN RECEPTOR; TRANSGENIC MICE; PROLIFERATION; REGULATOR; APOPTOSIS; PATHWAY; DEPHOSPHORYLATION; PHOSPHORYLATION	Stat5 and Stat3, two members of the Stat (signal transducer and activator of transcription) family, are known to play critical roles in mammopoiesis/lactogenesis and involution, respectively, in the mammary gland. Phosphotyrosine phosphatase Shp2 has been shown to dephosphorylate and thus inactivate both Stat5 and Stat3 in vitro. Paradoxically, cell culture studies also suggest a positive role of Shp2 in promoting prolactin-stimulated Stat5 activation. We have shown here that selective deletion of Shp2 in mouse mammary glands suppresses Stat5 activity during pregnancy and lactation, resulting in significant impairment of lobulo-alveolar outgrowth and lactation. In contrast, Stat3 activity was slightly up-regulated shortly before/ at involution, leading to normal epithelial cell apoptosis/involution in Shp2-deficient mammary gland. Thus, Shp2 acts to promote Stat5 activation by the JAK2(.)prolactin receptor complex, while negatively modulating Stat3 activity before the onset of involution. This is the first demonstration that Shp2 manipulates Stat5 and Stat3 activities reciprocally in mammary epithelial cells, providing novel insight into the complex mechanisms for regulation of various Stat family members by a cytoplasmic tyrosine phosphatase.	Burnham Inst Med Res, Ctr Canc, La Jolla, CA 92037 USA; Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Sanford Burnham Prebys Medical Discovery Institute; McGill University; Royal Victoria Hospital	Feng, GS (corresponding author), Burnham Inst Med Res, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gfeng@burnham.org	Bard-Chapeau, Emilie/H-6091-2011	Zhang, Eric/0000-0002-4472-7493	NCI NIH HHS [P01 CA102583, R01 CA078606, CA078606, R01 CA098778, CA102583] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078606, R01CA098778, P01CA102583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali S, 2003, J BIOL CHEM, V278, P52021, DOI 10.1074/jbc.M306758200; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Chan RJ, 2003, BLOOD, V102, P2074, DOI 10.1182/blood-2003-04-1171; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Groner B, 2000, BREAST CANCER RES, V2, P149, DOI 10.1186/bcr47; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Humphreys RC, 2002, ENDOCRINOLOGY, V143, P3641, DOI 10.1210/en.2002-220224; Huntington ND, 2004, IMMUNOL LETT, V94, P167, DOI 10.1016/j.imlet.2004.05.011; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kritikou EA, 2003, DEVELOPMENT, V130, P3459, DOI 10.1242/dev.00578; Lai LA, 2003, PROTEIN PHOSPHATASES, P275; Li G, 2002, DEVELOPMENT, V129, P4159; Lindeman GJ, 2001, GENE DEV, V15, P1631, DOI 10.1101/gad.880801; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; Qu CK, 1998, ONCOGENE, V17, P433, DOI 10.1038/sj.onc.1201920; Radisky DC, 2003, TRENDS CELL BIOL, V13, P426, DOI 10.1016/S0962-8924(03)00146-6; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yamada S, 2003, FEBS LETT, V534, P190, DOI 10.1016/S0014-5793(02)03842-5; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101	34	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34374	34380		10.1074/jbc.M607325200	http://dx.doi.org/10.1074/jbc.M607325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16959766	Green Accepted, hybrid			2022-12-25	WOS:000241767600058
J	Mateos, JL; Luppi, JP; Ogorodnikova, OB; Sineshchekov, VA; Yanovsky, MJ; Braslavsky, SE; Gartner, W; Casal, JJ				Mateos, Julieta L.; Luppi, Juan Pablo; Ogorodnikova, Ouliana B.; Sineshchekov, Vitaly A.; Yanovsky, Marcelo J.; Braslavsky, Silvia E.; Gaertner, Wolfgang; Casal, Jorge J.			Functional and biochemical analysis of the N-terminal domain of phytochrome A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOPHORE POCKET; LIGHT SENSITIVITY; SEED-GERMINATION; PEA PHYTOCHROME; ARABIDOPSIS; LOCALIZATION; DEGRADATION; BILIVERDIN; DEFICIENT; MUTATIONS	Phytochrome A (phyA) is a versatile plant photoreceptor that mediates responses to brief light exposures (very low fluence responses, VLFR) as well as to prolonged irradiation (high irradiance responses, HIR). We identified the phyA-303 mutant allele of Arabidopsis thaliana bearing an R384K substitution in the GAF subdomain of the N-terminal half of phyA. phyA-303 showed reduced phyA spectral activity, almost normal VLFR, and severely impaired HIR. Recombinant N-terminal half oat of PHYA bearing the phyA-303 mutation showed poor incorporation of chromophore in vitro, despite the predicted relatively long distance (> 13 angstrom) between the mutation and the closest ring of the chromophore. Fusion proteins bearing the N-terminal domain of oat phyA, beta-glucuronidase, green fluorescent protein, and a nuclear localization signal showed physiological activity in darkness and mediated VLFR but not HIR. At equal protein levels, the phyA-303 mutation caused slightly less activity than the fusions containing the wild-type sequence. Taken together, these studies highlight the role of the N-terminal domain of phyA in signaling and of distant residues of the GAF subdomain in the regulation of phytochrome bilin-lyase activity.	Univ Buenos Aires, Fac Agron, IFEVA, RA-1417 Buenos Aires, DF, Argentina; Max Planck Inst Bioanorgan Chem, D-45413 Mulheim, Germany; Moscow MV Lomonosov State Univ, Dept Biol, Moscow 119992, Russia	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Max Planck Society; Lomonosov Moscow State University	Casal, JJ (corresponding author), Univ Buenos Aires, Fac Agron, IFEVA, Ave San Martin 4453, RA-1417 Buenos Aires, DF, Argentina.	casal@ifeva.edu.ar	Braslavsky, Silvia E/E-2276-2016; Sineshchekov, Vitaly/AAV-4640-2021	Braslavsky, Silvia E/0000-0002-2796-8586; Gartner, Wolfgang/0000-0002-6898-7011; Mateos, Julieta Lisa/0000-0002-1156-6662; Casal, Jorge/0000-0001-6525-8414				ALCONADAMAGLIAN.T, 2004, PHOTOCHEM PHOTOBIOL, V3, P612; Botto JF, 1996, PLANT PHYSIOL, V110, P439, DOI 10.1104/pp.110.2.439; Casal JJ, 2004, TRENDS PLANT SCI, V9, P309, DOI 10.1016/j.tplants.2004.04.007; Casal JJ, 2000, PHOTOCHEM PHOTOBIOL, V71, P481, DOI 10.1562/0031-8655(2000)071&lt;0481:TPPOPA&gt;2.0.CO;2; Cerdan PD, 2000, PLANT CELL, V12, P1203, DOI 10.1105/tpc.12.7.1203; Chen M, 2004, ANNU REV GENET, V38, P87, DOI 10.1146/annurev.genet.38.072902.092259; CHERRY JR, 1993, PLANT CELL, V5, P565, DOI 10.1105/tpc.5.5.565; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; Clough RC, 1999, PLANT J, V17, P155, DOI 10.1046/j.1365-313X.1999.00360.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Davis SJ, 1999, P NATL ACAD SCI USA, V96, P6541, DOI 10.1073/pnas.96.11.6541; DEFORCE L, 1993, BIOCHEMISTRY-US, V32, P14165, DOI 10.1021/bi00214a014; Dieterle M, 2005, PLANT J, V41, P146, DOI 10.1111/j.1365-313X.2004.02286.x; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; ELICH TD, 1989, J BIOL CHEM, V264, P12902; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Gartner W, 2003, COMP SER PHOTOCHEM, V3, P136; Hennig L, 2000, PLANT CELL ENVIRON, V23, P727, DOI 10.1046/j.1365-3040.2000.00587.x; Hisada A, 2000, PLANT CELL, V12, P1063, DOI 10.1105/tpc.12.7.1063; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; KUFER W, 1979, H-S Z PHYSIOL CHEM, V360, P935, DOI 10.1515/bchm2.1979.360.2.935; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LI LM, 1992, J BIOL CHEM, V267, P19204; Maloof JN, 2001, NAT GENET, V29, P441, DOI 10.1038/ng777; Martinez-Garcia JF, 1999, PLANT J, V20, P251, DOI 10.1046/j.1365-313x.1999.00579.x; Matsushita T, 2003, NATURE, V424, P571, DOI 10.1038/nature01837; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; NAGATANI A, 1993, PLANT PHYSIOL, V102, P269, DOI 10.1104/pp.102.1.269; Oka Y, 2004, PLANT CELL, V16, P2104, DOI 10.1105/tpc.104.022350; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; Remberg A, 1999, EUR J BIOCHEM, V266, P201, DOI 10.1046/j.1432-1327.1999.00844.x; Rockwell NC, 2006, PLANT CELL, V18, P4, DOI 10.1105/tpc.105.038513; Ruddat A, 1997, BIOCHEMISTRY-US, V36, P103, DOI 10.1021/bi962012w; Ryu JS, 2005, CELL, V120, P395, DOI 10.1016/j.cell.2004.12.019; Sch_afer E, 2006, PHOTOMORPHOGENESIS P, V3; Schmidt P, 1998, PHOTOCHEM PHOTOBIOL, V68, P754, DOI 10.1111/j.1751-1097.1998.tb02541.x; Shinomura T, 1996, P NATL ACAD SCI USA, V93, P8129, DOI 10.1073/pnas.93.15.8129; Wagner D, 1996, P NATL ACAD SCI USA, V93, P4011, DOI 10.1073/pnas.93.9.4011; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; XU Y, 1995, PLANT CELL, V7, P1433, DOI 10.1105/tpc.7.9.1433; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; YANOVSKY MJ, 1995, PLANT CELL ENVIRON, V18, P788, DOI 10.1111/j.1365-3040.1995.tb00582.x; Yanovsky MJ, 2002, PLANT CELL, V14, P1591, DOI 10.1105/tpc.000521; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	51	31	33	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34421	34429		10.1074/jbc.M603538200	http://dx.doi.org/10.1074/jbc.M603538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16966335	hybrid, Green Published			2022-12-25	WOS:000241767600062
J	Petrushenko, ZM; Lai, CH; Rybenkov, VV				Petrushenko, Zoya M.; Lai, Chien-Hung; Rybenkov, Valentin V.			Antagonistic interactions of kleisins and DNA with bacterial condensin MukB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHROMOSOME CONDENSATION; SMC PROTEINS; ELECTRON-MICROSCOPY; MITOTIC CHROMOSOME; COHESIN COMPLEX; SUPERCOILED DNA; ATP HYDROLYSIS; HINGE; CONFORMATIONS	MukBEF is a bacterial SMC (structural maintenance of chromosome) complex required for faithful chromosome segregation in Escherichia coli. The SMC subunit of the complex, MukB, promotes DNA condensation in vitro and in vivo; however, all three subunits are required for the function of MukBEF. We report here that MukEF disrupts MukB center dot DNA complex. Pre-assembled MukBEF was inert in DNA binding or reshaping. Similarly, the association of MukEF with DNA-bound MukB served to displace MukB from DNA. When purified from cells, MukBEF existed as a mixture of MukEF-saturated and unsaturated complexes. The holoenzyme was unstable and could only bind DNA upon dissociation of MukEF. The DNA reshaping properties of unsaturated MukBEF were identical to those of MukB. Furthermore, the unsaturated MukBEF was stable and proficient in DNA binding. These results support the view that kleisins are not directly involved in DNA binding but rather bridge distant DNA-bound MukBs.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Rybenkov, VV (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Norman, OK 73019 USA.	valya@ou.edu			NIGMS NIH HHS [R01 GM063786, GM63786] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063786] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Arumugam P, 2003, CURR BIOL, V13, P1941, DOI 10.1016/j.cub.2003.10.036; Cann JR, 1998, ELECTROPHORESIS, V19, P127, DOI 10.1002/elps.1150190202; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P549; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Connelly JC, 2003, DNA REPAIR, V2, P795, DOI 10.1016/S1568-7864(03)00063-6; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Fennell-Fezzie R, 2005, EMBO J, V24, P1921, DOI 10.1038/sj.emboj.7600680; Folta-Stogniew Ewa, 2006, V328, P97; Haering CH, 2004, MOL CELL, V15, P951, DOI 10.1016/j.molcel.2004.08.030; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hiraga S, 2000, ANNU REV GENET, V34, P21, DOI 10.1146/annurev.genet.34.1.21; Hirano M, 2004, EMBO J, V23, P2664, DOI 10.1038/sj.emboj.7600264; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lammens A, 2004, CURR BIOL, V14, P1778, DOI 10.1016/j.cub.2004.09.044; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Matoba K, 2005, BIOCHEM BIOPH RES CO, V333, P694, DOI 10.1016/j.bbrc.2005.05.163; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; Ohsumi K, 2001, MOL MICROBIOL, V40, P835, DOI 10.1046/j.1365-2958.2001.02447.x; Petrushenko ZM, 2006, J BIOL CHEM, V281, P4606, DOI 10.1074/jbc.M504754200; Rybenkov VV, 1997, J MOL BIOL, V267, P312, DOI 10.1006/jmbi.1996.0877; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Sherratt DJ, 2003, SCIENCE, V301, P780, DOI 10.1126/science.1084780; Soppa J, 2002, MOL MICROBIOL, V45, P59, DOI 10.1046/j.1365-2958.2002.03012.x; Stray JE, 2005, J BIOL CHEM, V280, P34723, DOI 10.1074/jbc.M506589200; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Wang Q, 2006, J BACTERIOL, V188, P4431, DOI 10.1128/JB.00313-06; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitzer S, 2003, CURR BIOL, V13, P1930, DOI 10.1016/j.cub.2003.10.030; Yamanaka K, 1996, MOL GEN GENET, V250, P241; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873; Zechiedrich EL, 1999, METH MOL B, V94, P99	43	50	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34208	34217		10.1074/jbc.M606723200	http://dx.doi.org/10.1074/jbc.M606723200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16982609	hybrid, Green Accepted			2022-12-25	WOS:000241767600041
J	Watanabe, K; Nureki, O; Fukai, S; Endo, Y; Hori, H				Watanabe, Kazunori; Nureki, Osamu; Fukai, Shuya; Endo, Yaeta; Hori, Hiroyuki			Functional categorization of the conserved basic amino acid residues in TrmH (tRNA (Gm18) methyltansferase) enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEEP TREFOIL KNOT; 23S RIBOSOMAL-RNA; THERMUS-THERMOPHILUS HB27; ESCHERICHIA-COLI; M(7)G46 METHYLTRANSFERASE; CRYSTAL-STRUCTURE; AQUIFEX-AEOLICUS; RECOGNITION MECHANISM; MODIFICATION DATABASE; SEQUENCE MOTIFS	Transfer RNA (Gm18) methyltransferase (TrmH) catalyzes the methyl transfer from S-adenosyl-L-methionine (AdoMet) to the 2'-OH group of the G18 ribose in tRNA. To identify amino acid residues responsible for the tRNA recognition, we have carried out the alanine substitution mutagenesis of the basic amino acid residues that are conserved only in TrmH enzymes and not in the other SpoU proteins. We analyzed the mutant proteins by S-adenosyl-L-homocysteine affinity column chromatography, gel mobility shift assay, and kinetic assay of the methyl transfer reaction. Based on these biochemical studies and the crystal structure of TrmH, we found that the conserved residues can be categorized according to their role (i) in the catalytic center (Arg-41), (ii) in the initial site of tRNA binding (Lys-90, Arg-166, Arg-168, and Arg-176), (iii) in the tRNA binding site required for continuation the catalytic cycle (Arg-8, Arg-19, and Lys-32), (iv) in the structural element involved in release of S-adenosyl-L- homocysteine (Arg-11-His-71-Met-147 interaction), (v) in the assisted phosphate binding site (His-34), or (vi) in an unknown function (Arg-109). Furthermore, the difference between the K-d and K-m values for tRNA suggests that the affinity for tRNA is enhanced in the presence of AdoMet. To confirm this idea, we carried out the kinetic studies, a gel mobility shift assay with a mutant protein disrupted in the catalytic center, and the analytical gel-filtration chromatography. Our experimental results clearly show that the enzyme has a semi-ordered sequential mechanism in which AdoMet both enhances the affinity for tRNA and induces formation of the tetramer structure.	Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Ehime Univ, Venture Business Lab, Matsuyama, Ehime 7908577, Japan; Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime 7908577, Japan	Ehime University; Tokyo Institute of Technology; Ehime University; Ehime University	Hori, H (corresponding author), Ehime Univ, Fac Engn, Dept Appl Chem, Bunkyo 3, Matsuyama, Ehime 7908577, Japan.	hori@eng.ehime-u.ac.jp	Watanabe, Kazunori/G-6671-2012; Hori, Hiroyuki/AAB-3911-2021; Fukai, Shuya/X-4838-2018; NUREKI, OSAMU/G-4960-2014	Watanabe, Kazunori/0000-0003-3678-636X; Fukai, Shuya/0000-0002-1241-1443; 				Ahn HJ, 2003, EMBO J, V22, P2593, DOI 10.1093/emboj/cdg269; Alexandrov A, 2002, RNA, V8, P1253, DOI 10.1017/S1355838202024019; Anantharaman V, 2002, J MOL MICROB BIOTECH, V4, P71; ASCHHOFF HJ, 1976, NUCLEIC ACIDS RES, V3, P3109, DOI 10.1093/nar/3.11.3109; Basturea GN, 2006, RNA, V12, P426, DOI 10.1261/rna.2283106; Cavaille J, 1999, RNA, V5, P66, DOI 10.1017/S1355838299981475; Clouet-d'Orval B, 2005, BIOCHIMIE, V87, P889, DOI 10.1016/j.biochi.2005.02.004; De Bie LGS, 2003, J BACTERIOL, V185, P3238, DOI 10.1128/JB.185.10.3238-3243.2003; Elkins PA, 2003, J MOL BIOL, V333, P931, DOI 10.1016/j.jmb.2003.09.011; Forouhar F, 2003, PROTEINS, V53, P329, DOI 10.1002/prot.10510; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; Hori H, 2003, J BIOL CHEM, V278, P25081, DOI 10.1074/jbc.M212577200; Hori H, 2002, GENES CELLS, V7, P259, DOI 10.1046/j.1365-2443.2002.00520.x; Hori H, 1998, J BIOL CHEM, V273, P25721, DOI 10.1074/jbc.273.40.25721; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KIM SH, 1974, P NATL ACAD SCI USA, V71, P4970, DOI 10.1073/pnas.71.12.4970; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; Lim K, 2003, PROTEINS, V51, P56, DOI 10.1002/prot.10323; Lovgren JM, 2001, J BACTERIOL, V183, P6957, DOI 10.1128/JB.183.23.6957-6960.2001; Mallam AL, 2005, J MOL BIOL, V346, P1409, DOI 10.1016/j.jmb.2004.12.055; MATSUMOTO T, 1990, J BIOCHEM-TOKYO, V107, P331, DOI 10.1093/oxfordjournals.jbchem.a123047; McCloskey JA, 1998, NUCLEIC ACIDS RES, V26, P196, DOI 10.1093/nar/26.1.196; Michel G, 2002, STRUCTURE, V10, P1303, DOI 10.1016/S0969-2126(02)00852-3; Mosbacher TG, 2005, J MOL BIOL, V345, P535, DOI 10.1016/j.jmb.2004.10.051; Nureki O, 2004, STRUCTURE, V12, P593, DOI 10.1016/j.str.2004.03.003; Nureki O, 2002, ACTA CRYSTALLOGR D, V58, P1129, DOI 10.1107/S0907444902006601; Okamoto H, 2004, J BIOL CHEM, V279, P49151, DOI 10.1074/jbc.M408209200; Persson B. C., 1997, NUCLEIC ACIDS RES, V25, P3969, DOI [10.1093/nar/25.20.4093, DOI 10.1093/NAR/25.20.4093]; Pleshe E, 2005, ACTA CRYSTALLOGR F, V61, P722, DOI 10.1107/S1744309105022980; Renalier MH, 2005, RNA, V11, P1051, DOI 10.1261/rna.2110805; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; Treede I, 2003, MOL MICROBIOL, V49, P309, DOI 10.1046/j.1365-2958.2003.03558.x; Urbonavicius J, 2002, J BACTERIOL, V184, P5348, DOI 10.1128/JB.184.19.5348-5357.2002; Watanabe K, 2005, J BIOL CHEM, V280, P10368, DOI 10.1074/jbc.M411209200; Zarembinski TI, 2003, PROTEINS, V50, P177, DOI 10.1002/prot.10311; Zegers I, 2006, NUCLEIC ACIDS RES, V34, P1925, DOI 10.1093/nar/gkl116; Ziesche SM, 2004, MOL MICROBIOL, V54, P980, DOI 10.1111/j.1365-2958.2004.04319.x	42	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34630	34639		10.1074/jbc.M606141200	http://dx.doi.org/10.1074/jbc.M606141200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16963456	hybrid			2022-12-25	WOS:000241767600082
J	Hsu, YHR; Sarker, KP; Pot, I; Chan, A; Netherton, SJ; Bonni, S				Hsu, Ying-Han R.; Sarker, Krishna P.; Pot, Isabelle; Chan, Angela; Netherton, Stuart J.; Bonni, Shirin			Sumoylated SnoN represses transcription in a promoter-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HISTONE DEACETYLASE COMPLEX; TGF-BETA; SUMO-1 MODIFICATION; TRANSFORMING ACTIVITY; TUMOR-SUPPRESSOR; SKI ONCOPROTEIN; BINDING PROTEIN; DNA-BINDING; PHOSPHORYLATION	The transcriptional modulator SnoN controls a diverse set of biological processes, including cell proliferation and differentiation. The mechanisms by which SnoN regulates these processes remain incompletely understood. Recent studies have shown that SnoN exerts positive or negative regulatory effects on transcription. Because post-translational modification of proteins by small ubiquitin-like modifier (SUMO) represents an important mechanism in the control of the activity of transcriptional regulators, we asked if this modification regulates SnoN function. Here, we show that SnoN is sumoylated. Our data demonstrate that the SUMO-conjugating E2 enzyme Ubc9 is critical for SnoN sumoylation and that the SUMO E3 ligase PIAS1 selectively interacts with and enhances the sumoylation of SnoN. We identify lysine residues 50 and 383 as the SUMO acceptor sites in SnoN. Analyses of SUMO "loss-of-function" and " gain-of-function" SnoN mutants in transcriptional reporter assays reveal that sumoylation of SnoN contributes to the ability of SnoN to repress gene expression in a promoter-specific manner. Although this modification has little effect on SnoN repression of the plasminogen activator inhibitor-1 promoter and only modestly potentiates SnoN repression of the p21 promoter, SnoN sumoylation robustly augments the ability of SnoN to suppress transcription of the myogenesis master regulatory gene myogenin. In addition, we show that the SnoN SUMO E3 ligase, PIAS1, at its endogenous levels, suppresses myogenin transcription. Collectively, our findings suggest that SnoN is directly regulated by sumoylation leading to the enhancement of the ability of SnoN to repress transcription in a promoter-specific manner. Our study also points to a physiological role for SnoN sumoylation in the control of myogenin expression in differentiating muscle cells.	Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Bonni, S (corresponding author), Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada.	sbonni@ucalgary.ca						Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Berberich-Siebelt F, 2006, J IMMUNOL, V176, P4843, DOI 10.4049/jimmunol.176.8.4843; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; BLAU HM, 1985, ADV EXP MED BIOL, V182, P231; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; BOYER PL, 1993, ONCOGENE, V8, P457; Cohen SB, 1998, ONCOGENE, V17, P2505, DOI 10.1038/sj.onc.1202177; Cohen SB, 1999, NUCLEIC ACIDS RES, V27, P1006, DOI 10.1093/nar/27.4.1006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Edmiston JS, 2005, CANCER RES, V65, P4782, DOI 10.1158/0008-5472.CAN-04-4354; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kuo HY, 2005, P NATL ACAD SCI USA, V102, P16973, DOI 10.1073/pnas.0504460102; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mimura N, 1996, FEBS LETT, V397, P253, DOI 10.1016/S0014-5793(96)01165-9; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Riquelme C, 2006, J CELL MOL MED, V10, P132, DOI 10.1111/j.1582-4934.2006.tb00295.x; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Sarker KP, 2005, J BIOL CHEM, V280, P13037, DOI 10.1074/jbc.M409367200; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stegmuller J, 2006, NEURON, V50, P389, DOI 10.1016/j.neuron.2006.03.034; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P3168, DOI 10.1021/bi026861x; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Weston AD, 2003, J CELL SCI, V116, P2885, DOI 10.1242/jcs.00525; Wilson JJ, 2004, STRUCTURE, V12, P785, DOI 10.1016/S0969-2126(04)00118-2; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Zhang F, 2003, CANCER RES, V63, P5005	63	44	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33008	33018		10.1074/jbc.M604380200	http://dx.doi.org/10.1074/jbc.M604380200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16966324	hybrid			2022-12-25	WOS:000241621400009
J	Kane, TA; White, CL; DeAngelis, PL				Kane, Tasha A.; White, Carissa L.; DeAngelis, Paul L.			Functional characterization of PmHS1, a Pasteurella multocida heparosan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULE GENE-CLUSTER; 2 ACTIVE-SITES; HYALURONAN SYNTHASE; ESCHERICHIA-COLI; MOLECULAR-CLONING; HEPARAN-SULFATE; IDENTIFICATION; BIOSYNTHESIS; GLYCOSYLTRANSFERASES; POLYSACCHARIDE	Heparosan synthase 1 (PmHS1) from Pasteurella multocida Type D is a dual action glycosyltransferase enzyme that transfers monosaccharide units from uridine diphospho (UDP) sugar precursors to form the polysaccharide heparosan (N-acetylheparosan), which is composed of alternating (-alpha 4-GlcNAc-beta 1,4-GlcUA-1-) repeats. We have used molecular genetic means to remove regions nonessential for catalytic activity from the amino and the carboxyl-terminal regions as well as characterized the functional regions involved in GlcUA-transferase activity and in GlcNAc-transferase activity. Mutation of either one of the two regions containing aspartate-X-aspartate (DXD) residue-containing motifs resulted in complete or substantial loss of heparosan polymerizing activity. However, certain mutant proteins retained only GlcUA-transferase activity while some constructs possessed only GlcNAc-transferase activity. Therefore, it appears that the PmHS1 polypeptide is composed of two types of glycosyltransferases in a single polypeptide as was found for the Pasteurella multocida Type A PmHAS, the hyaluronan synthase that makes the alternating (-beta 3-GlcNAc-beta 1,4-GlcUA-1-) polymer. However, there is low amino acid similarity between the PmHAS and PmHS1 enzymes, and the relative placement of the GlcUA-transferase and GlcNAc-transferase domains within the two polypeptides is reversed. Even though the monosaccharide compositions of hyaluronan and heparosan are identical, such differences in the sequences of the catalysts are expected because the PmHAS employs only inverting sugar transfer mechanisms whereas PmHS1 requires both retaining and inverting mechanisms.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu						Breton C, 1998, J BIOCHEM, V123, P1000; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 2004, J BACTERIOL, V186, P8529, DOI 10.1128/JB.186.24.8529-8532.2004; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; DeAngelis PL, 2002, CARBOHYD RES, V337, P1547, DOI 10.1016/S0008-6215(02)00219-7; DeAngelis PL, 2002, J BIOL CHEM, V277, P7209, DOI 10.1074/jbc.M112130200; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; Hodson N, 2000, J BIOL CHEM, V275, P27311; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Jing W, 2003, GLYCOBIOLOGY, V13, P661, DOI 10.1093/glycob/cwg085; Negishi M, 2003, BIOCHEM BIOPH RES CO, V303, P393, DOI 10.1016/S0006-291X(03)00356-5; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Whitfield C, 2006, ANNU REV BIOCHEM, V75, P39, DOI 10.1146/annurev.biochem.75.103004.142545; Williams KJ, 2006, J BIOL CHEM, V281, P5391, DOI 10.1074/jbc.M510439200	20	28	33	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33192	33197		10.1074/jbc.M606897200	http://dx.doi.org/10.1074/jbc.M606897200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959770	hybrid			2022-12-25	WOS:000241621400027
J	Cordero, CL; Kudryashov, DS; Reisler, E; Satchell, KJF				Cordero, Christina L.; Kudryashov, Dmitry S.; Reisler, Emil; Satchell, Karla J. Fullner			The actin cross-linking domain of the Vibrio cholerae RTX toxin directly catalyzes the covalent cross-linking of actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; PROTECTIVE ANTIGEN; ANTHRAX TOXIN; TISSUE TRANSGLUTAMINASE; MAMMALIAN-CELLS; LETHAL FACTOR; IDENTIFICATION; NUCLEOTIDE; OLIGOMERS; ATP	Vibrio cholerae is a Gram-negative bacterial pathogen that exports enterotoxins to alter host cells and to elicit diarrheal disease. Among the secreted toxins is the multifunctional RTX toxin, which causes cell rounding and actin depolymerization by covalently cross-linking actin monomers into dimers, trimers, and higher multimers. The region of the toxin responsible for cross-linking activity is the actin cross-linking domain (ACD). In this study, we further investigated the role of the ACD in the actin cross-linking reaction. We show that the RTX toxin cross-links actin independently of tissue transglutaminase, thus eliminating an indirect model of ACD activity. We demonstrate that a fusion protein of the ACD and the N-terminal portion of lethal factor from Bacillus anthracis (LF(N)ACD) has cross-linking activity in vivo and in crude cell extracts. Furthermore, we determined that LF(N)ACD directly catalyzes the formation of covalent linkages between actin molecules in vitro and that Mg2+ and ATP are essential cofactors for the cross-linking reaction. In addition, G-actin is proposed as a cytoskeletal substrate of the RTX toxin in vivo. Future studies of the in vitro cross-linking reaction will facilitate characterization of the enzymatic properties of the ACD and contribute to our knowledge of the novel mechanism of covalent actin cross-linking.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Northwestern University; Feinberg School of Medicine; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Satchell, KJF (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave,Tarry 3-713, Chicago, IL 60611 USA.	k-satchell@northwestern.edu	Kudryashov, Dmitri/P-9004-2014; Satchell, Karla/GSN-3100-2022	Kudryashov, Dmitri/0000-0003-1782-3305	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI052490, R01AI051490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077190] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI051490, AI 051490, F31 AI 52490, F31 AI052490, R01 AI051490-04] Funding Source: Medline; NIGMS NIH HHS [GM 077190, R01 GM077190] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRI AK, 1991, J BIOL CHEM, V266, P6815; Bai RL, 2001, MOL PHARMACOL, V59, P462, DOI 10.1124/mol.59.3.462; Boardman BK, 2004, J BACTERIOL, V186, P8137, DOI 10.1128/JB.186.23.8137-8143.2004; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chow KH, 2001, J CLIN MICROBIOL, V39, P2594, DOI 10.1128/JCM.39.7.2594-2597.2001; COOKE R, 1975, BIOCHEMISTRY-US, V14, P3250, DOI 10.1021/bi00685a035; Dalsgaard A, 2001, J CLIN MICROBIOL, V39, P4086, DOI 10.1128/JCM.39.11.4086-4092.2001; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Fullner KJ, 2000, EMBO J, V19, P5315, DOI 10.1093/emboj/19.20.5315; Fullner KJ, 2001, INFECT IMMUN, V69, P6310, DOI 10.1128/IAI.69.10.6310-6317.2001; GERSHMAN LC, 1989, BIOCHIM BIOPHYS ACTA, V995, P109, DOI 10.1016/0167-4838(89)90068-X; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; HANDEL SE, 1990, J CELL SCI, V97, P325; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; Kudryashov DS, 2003, BIOPHYS J, V85, P2466, DOI 10.1016/S0006-3495(03)74669-4; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lin W, 1999, P NATL ACAD SCI USA, V96, P1071, DOI 10.1073/pnas.96.3.1071; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Oda T, 2003, J MOL BIOL, V328, P319, DOI 10.1016/S0022-2836(03)00306-1; Pukatzki S, 2006, P NATL ACAD SCI USA, V103, P1528, DOI 10.1073/pnas.0510322103; Sambrook J, 2001, MOL CLONING LAB MANU; Sheahan KL, 2004, P NATL ACAD SCI USA, V101, P9798, DOI 10.1073/pnas.0401104101; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Spyres LM, 2001, INFECT IMMUN, V69, P599, DOI 10.1128/IAI.69.1.599-601.2001; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; Voth DE, 2005, CELL MICROBIOL, V7, P1139, DOI 10.1111/j.1462-5822.2005.00539.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	39	69	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32366	32374		10.1074/jbc.M605275200	http://dx.doi.org/10.1074/jbc.M605275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16954226	Green Accepted, hybrid			2022-12-25	WOS:000241414500034
J	Arredondo, J; Chernyavsky, AI; Jolkovsky, DL; Pinkerton, KE; Grando, SA				Arredondo, Juan; Chernyavsky, Alexander I.; Jolkovsky, David L.; Pinkerton, Kent E.; Grando, Sergei A.			Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha 7 nicotinic receptor in oral keratinocytes	FASEB JOURNAL			English	Article						nicotinic ACh receptors; gene expression; oral cancer; periodontal therapy	ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; CANCER CELL-LINES; ACETYLCHOLINE-RECEPTOR; GENE-EXPRESSION; KAPPA-B; SMOKE EXPOSURE; C-MYC; DIFFERENTIATION; SECRETION	The use of tobacco products is associated with an increased incidence of periodontal disease, poor response to periodontal therapy, and a high risk for developing head and neck cancer. Nicotine and tobacco-derived nitrosamines have been shown to exhibit their pathobiologic effects due in part to activation of the nicotinic acetylcholine (ACh) receptors (nAChRs), mainly alpha 7 nAChR, expressed by oral keratinocytes (KCs). This study was designed to gain mechanistic insight into alpha 7-mediated morbidity of tobacco products in the oral cavity. We investigated the signaling pathways downstream of alpha 7 nAChR in monolayers of oral KCs exposed for 24 h to aged and diluted sidestream cigarette smoke (ADSS) or an equivalent concentration of pure nicotine. By both real-time polymerase chain reaction (PCR) and In-cell Western, the KCs stimulated with ADSS or nicotine showed multifold increases of STAT-3. These effects could be completely blocked or significantly (P < 0.05) diminished if the cells were pretreated with the alpha 7 antagonist alpha-bungarotoxin (alpha BTX) or transfected with anti-alpha 7 small interfering RNA (siRNA-alpha 7). The use of pathway inhibitors revealed that signaling through the Ras/Raf-1/MEK1/ERK steps mediated alpha 7-dependent up-regulation of STAT-3. Targeted mutation of the alpha 7 gene prevented ERK1/2 activation by nicotine. Using the gel mobility shift assay, we demonstrated that an increased protein binding activity of STAT-3 caused by ADSS or pure nicotine was mediated by janus-activated kinase (JAK)-2. Activation of JAK-2/STAT-3 pathway could be prevented by alpha BTX or siRNA-alpha 7. Thus, nuclear transactivation of STAT-3 in KCs exposed to tobacco products is mediated via intracellular signaling downstream from alpha 7, which proceeds via two complementary pathways. The Ras/Raf-1/MEK1/ERK cascade culminates in up-regulated expression of the gene encoding STAT-3, whereas recruitment and activation of tyrosine kinase JAK-2 phosphorylates it. Elucidation of this novel mechanism of nicotine-dependent nuclear transactivation of STAT-3 identifies oral alpha 7 nAChR as a promising molecular target to prevent, reverse, or retard tobacco-related periodontal disease and progression of head and neck cancer by receptor inhibitors.	Univ Calif Davis, Dept Dermatol, Med Ctr, Sacramento, CA 95816 USA; Univ Calif Davis, Ctr Hlth & Environm, Sacramento, CA 95816 USA; Univ Calif Los Angeles, Sch Dent, Sect Periodont, Los Angeles, CA 90024 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Los Angeles	Grando, SA (corresponding author), Univ Calif Davis, Dept Dermatol, Med Ctr, 3301 C St,Ste 1400, Sacramento, CA 95816 USA.	sagrando@ucdavis.edu			NATIONAL CANCER INSTITUTE [R03CA117327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014173] Funding Source: NIH RePORTER; NCI NIH HHS [CA117327] Funding Source: Medline; NIDCR NIH HHS [DE14173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; Arredondo J, 2002, J CELL BIOL, V159, P325, DOI 10.1083/jcb.200206096; Arredondo J, 2005, J INVEST DERMATOL, V125, P1236, DOI 10.1111/j.0022-202X.2005.23973.x; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; Arredondo J, 2003, LIFE SCI, V72, P2063, DOI 10.1016/S0024-3205(03)00084-5; Arredondo J, 2001, LAB INVEST, V81, P1653, DOI 10.1038/labinvest.3780379; Benowitz N L, 1997, Adv Dent Res, V11, P336; BERGSTROM J, 1989, COMMUNITY DENT ORAL, V17, P245, DOI 10.1111/j.1600-0528.1989.tb00626.x; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; Cattaneo MG, 1997, BIOCHEM J, V328, P499; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen BC, 2004, J IMMUNOL, V173, P5219, DOI 10.4049/jimmunol.173.8.5219; Chernyavsky AI, 2005, J BIOL CHEM, V280, P39220, DOI 10.1074/jbc.M504407200; Chernyavsky AI, 2004, J CELL SCI, V117, P5665, DOI 10.1242/jcs.01492; CODIGNOLA A, 1994, FEBS LETT, V342, P286, DOI 10.1016/0014-5793(94)80518-0; Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Cox ME, 1997, J NEUROCHEM, V69, P1119; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; Dunckley T, 2003, J BIOL CHEM, V278, P15633, DOI 10.1074/jbc.M210389200; Ehrhardt A, 2003, J CANCER RES CLIN, V129, P71, DOI 10.1007/s00432-002-0400-z; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Genersch E, 2000, J CELL SCI, V113, P4319; Grando SA, 2003, LIFE SCI, V72, P2009, DOI 10.1016/S0024-3205(03)00063-8; Gueorguiev VD, 2000, J NEUROCHEM, V75, P1997, DOI 10.1046/j.1471-4159.2000.0751997.x; Haber J, 1994, Compendium, V15, P1004; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; HOFFMANN D, 1981, CANCER RES, V41, P4305; JOAD JP, 1993, PEDIATR PULM, V16, P281, DOI 10.1002/ppul.1950160503; JOAD JP, 1995, TOXICOL APPL PHARM, V132, P63, DOI 10.1006/taap.1995.1087; Johnson Georgia K., 1993, Pediatric Dentistry, V15, P169; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kwon OS, 1999, SKIN PHARMACOL APPL, V12, P227, DOI 10.1159/000066247; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li JM, 2004, ARTERIOSCL THROM VAS, V24, P80, DOI 10.1161/01.ATV.0000104007.17365.1c; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; LINDELL G, 1993, SCAND J GASTROENTERO, V28, P487, DOI 10.3109/00365529309098254; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; MANDEL I, 1994, J AM DENT ASSOC, V125, P872, DOI 10.14219/jada.archive.1994.0192; MANECKJEE R, 1994, CELL GROWTH DIFFER, V5, P1033; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nguyen VT, 2000, J DENT RES, V79, P939; Onoda N, 2001, HEAD NECK-J SCI SPEC, V23, P860, DOI 10.1002/hed.1125; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; Plummer HK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-29; Quik M, 1997, MOL PHARMACOL, V51, P499; RUSSELL MAH, 1980, BMJ-BRIT MED J, V280, P972, DOI 10.1136/bmj.280.6219.972; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Shaw S, 2002, J BIOL CHEM, V277, P44920, DOI 10.1074/jbc.M204610200; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; Sugar Janos Iidiko Vereczkey, 1996, Journal of Environmental Pathology Toxicology and Oncology, V15, P195; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; THEILIG C, 1994, SKIN PHARMACOL, V7, P307; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wityak J, 2004, BIOORG MED CHEM LETT, V14, P1483, DOI 10.1016/j.bmcl.2004.01.012; Ye YN, 2004, J PHARMACOL EXP THER, V311, P123, DOI 10.1124/jpet.104.068031; Zhang SL, 2001, PHYSIOL GENOMICS, V5, P187, DOI 10.1152/physiolgenomics.2001.5.4.187; Zhang SL, 2001, ATHEROSCLEROSIS, V154, P277, DOI 10.1016/S0021-9150(00)00475-5; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	77	161	166	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2093	2101		10.1096/fj.06-6191com	http://dx.doi.org/10.1096/fj.06-6191com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012261				2022-12-25	WOS:000241156900017
J	Borras, C; Gambini, J; Gomez-Cabrera, MC; Sastre, J; Pallardo, FV; Mann, GE; Vina, J				Borras, Consuelo; Gambini, Juan; Gomez-Cabrera, M. Carmen; Sastre, Juan; Pallardo, Federico V.; Mann, Giovanni E.; Vina, Jose			Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2, and NF kappa B	FASEB JOURNAL			English	Article						phytoestrogens; aging; oxidative stress; redox signaling	PHYTOESTROGENS; WOMEN	We have previously reported that estrogens up-regulate longevity-associated genes. As recent evidence has shown that estrogen replacement therapy is associated with an increased risk of cardiovascular disease, we have studied the effects of genistein, a soy isoflavone with a similar structure to estradiol, on the expression of antioxidant, longevity-related genes. MCF-7 cells ( human mammary gland tumor cell line) were incubated for 48 h with 0.5 mu M genistein, a concentration found in the plasma of populations consuming diets rich in soy protein. Peroxide levels were determined by fluorimetry, activation of extracellular-signal regulated kinase (ERK1/2), and nuclear factor kappa B (NF kappa B)-signaling pathways by Western blot analysis and ELISA, respectively, and mRNA expression of antioxidant genes by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Inhibition of basal peroxide levels in MCF-7 cells by genistein was prevented by pretreatment of cells with the estrogen receptor antagonist tamoxifen. Phosphorylation of extracellular regulated kinase (ERK)1/2 led to an activation of NF kappa B, as indicated by increased p50 subunit expression in nuclear extracts, and increased mRNA levels of the antioxidant enzyme manganese-superoxide dismutase (MnSOD). Inhibition of ERK1/2 abrogated genistein-mediated NF kappa B activation and elevated expression of MnSOD. Our molecular studies may provide a basis to determine the effects of genistein and other soy protein-derived products on longevity in both animals and the human population.	Univ Valencia, Dept Physiol, Sch Med, Avda Blasco Ibanez 17, Valencia 46010, Spain; Catholic Univ Valencia, Valencia, Spain; Kings Coll London, Div Cardiovasc, London WC2R 2LS, England	University of Valencia; Universidad Catolica de Valencia San Vicente Martir; University of London; King's College London	Vina, J (corresponding author), Univ Valencia, Dept Physiol, Sch Med, Avda Blasco Ibanez 17, Valencia 46010, Spain.	jose.vina@uv.es	Gomez-Cabrera, Mari Carmen/O-3109-2019; Gomez-Cabrera, Maria Carmen/H-6911-2018; borras, consuelo/Y-3407-2019; Pallardo, Federico V./T-1156-2017; SASTRE, JUAN/AAB-2344-2019; Vina, Jose/AAB-3069-2021	Gomez-Cabrera, Mari Carmen/0000-0003-4000-1684; Gomez-Cabrera, Maria Carmen/0000-0003-4000-1684; borras, consuelo/0000-0003-4606-1792; Pallardo, Federico V./0000-0003-3715-1980; SASTRE, JUAN/0000-0002-4260-6604; Vina, Jose/0000-0001-9709-0089; Mann, Giovanni/0000-0001-7311-2044; Gambini, Juan/0000-0001-8979-2865					0	125	134	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2136	2138		10.1096/fj.05-5522fje	http://dx.doi.org/10.1096/fj.05-5522fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	16966488				2022-12-25	WOS:000241156900035
J	Concannon, CG; Koehler, BF; Reimertz, C; Murphy, BM; Bonner, C; Thurow, N; Ward, MW; Villunger, A; Strasser, A; Kogel, D; Prehn, JHM				Concannon, C. G.; Koehler, B. F.; Reimertz, Claus; Murphy, B. M.; Bonner, C.; Thurow, N.; Ward, M. W.; Villunger, A.; Strasser, A.; Koegel, D.; Prehn, J. H. M.			Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway	ONCOGENE			English	Article						proteasome; apoptosis; epoxomicin; Bcl-2 family; BH3-only protein; p53	NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; PHASE-I TRIAL; BH3-ONLY PROTEINS; MULTIPLE-MYELOMA; TARGET GENES; GLIOMA-CELLS; SOLID TUMORS; C-MYC; P53	The proteasome has emerged as a novel target for antineoplastic treatment of hematological malignancies and solid tumors, including those of the central nervous system. To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). Prolonged exposure to Epoxo was associated with increased levels of poly-ubiquitinylated proteins and p53, release of cytochrome c from the mitochondria, and activation of caspases. Analysis of global gene expression using high-density oligonucleotide microarrays revealed that Epoxo triggered transcriptional activation of the two Bcl-2-homology domain-3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim. Subsequent studies in PUMA- and Bim-deficient cells indicated that Epoxo-induced caspase activation and apoptosis was predominantly PUMA- dependent. Further characterization of the transcriptional response to Epoxo in HCT116 human colon cancer cells demonstrated that PUMA induction was p53-dependent; with deficiency in either p53 or PUMA significantly protected HCT116 cells against Epoxo-induced apoptosis. Our data suggest that p53 activation and the transcriptional induction of its target gene PUMA play an important role in the sensitivity of cancer cells to apoptosis induced by proteasome inhibition, and imply that antineoplastic therapies with PIs might be especially useful in cancers with functional p53.	Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; Johann Wolfgang Goethe Univ Clin, Ctr Neurol & Neurosurg, Frankfurt, Germany; Innsbruck Med Univ, Bioctr, Div Expt Pathophysiol & Immunol, Innsbruck, Austria; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal College of Surgeons - Ireland; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Medical University of Innsbruck; Walter & Eliza Hall Institute	Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	prehn@rcsi.ie	Strasser, Andreas/C-7581-2013; Murphy, Brona/P-2544-2019; Prehn, Jochen HM/A-3928-2010; Concannon, Caoimhin/B-2075-2010; Murphy, Brona/D-4873-2012; Pattou, Francois/O-6151-2017; Bonner, Caroline/A-9819-2015	Strasser, Andreas/0000-0002-5020-4891; Murphy, Brona/0000-0002-6740-8858; Prehn, Jochen HM/0000-0003-3479-7794; Murphy, Brona/0000-0002-6740-8858; Pattou, Francois/0000-0001-8388-3766; Bonner, Caroline/0000-0002-4430-8280; Ward, Manus/0000-0002-7085-9668; Kogel, Donat/0000-0003-1209-0210				Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Aghajanian C, 2002, CLIN CANCER RES, V8, P2505; Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Biswas SC, 2005, NEUROCHEM RES, V30, P839, DOI 10.1007/s11064-005-6877-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Ceballos E, 2005, ONCOGENE, V24, P4559, DOI 10.1038/sj.onc.1208652; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; HANADA M, 1992, J ANTIBIOT, V45, P1746, DOI 10.7164/antibiotics.45.1746; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kikuchi S, 2003, BRAIN RES, V964, P228, DOI 10.1016/S0006-8993(02)04030-1; Kurland JF, 2001, INT J CANCER, V96, P327, DOI 10.1002/ijc.1040; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Masdehors P, 2000, BLOOD, V96, P269, DOI 10.1182/blood.V96.1.269.013k10_269_274; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MITSIADES N, 2002, MOL SEQUELAE PROTEAS, V99, P14374; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nikrad M, 2005, MOL CANCER THER, V4, P443; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106; Park DJ, 2004, ANN MED, V36, P296, DOI 10.1080/07853890410029031; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132; Wagenknecht B, 2000, J NEUROCHEM, V75, P2288, DOI 10.1046/j.1471-4159.2000.0752288.x; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	55	76	79	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1681	1692		10.1038/sj.onc.1209974	http://dx.doi.org/10.1038/sj.onc.1209974			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983338				2022-12-25	WOS:000244955600002
J	Yang, G; Rosen, DG; Colacino, JA; Mercado-Uribe, I; Liu, J				Yang, G.; Rosen, D. G.; Colacino, J. A.; Mercado-Uribe, I.; Liu, J.			Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells	ONCOGENE			English	Article						human ovarian surface epithelial cells; immortalization; siRNA; pRb; hTERT	HUMAN-PAPILLOMAVIRUS TYPE-16; GENOMIC INSTABILITY; GENE-EXPRESSION; CANCER; GROWTH; PROTEIN; P53; TRANSFORMATION; RETROVIRUS; BREAST	The risk of developing ovarian cancer is about 1% over a lifetime, but it is the most deadly gynecologic cancer, in part due to lack of diagnostic markers for early-stage disease and cell model system for studying early neoplastic changes. Most existing immortal human ovarian surface epithelial cells were achieved by using viral protein such as SV40 T/t antigen or E6/E7, which inactivate multiple cellular pathways. In the current study, we used a small interfering RNA ( siRNA) against the retinoblastoma gene (pRb) and ectopic expression of human telomerase reverse transcriptase ( hTERT) to immortalize the primary ovarian epithelial cell line OSE137 and two additional human ovarian surface epithelial cells. The immortalized OSE137 showed increased telomerase activity, lengthened telomeres, increased G(2)/M phase, altered cell-cycle regulatory proteins but nontumorigenic. As both Rb and hTERT pathways are commonly altered in human ovarian cancer and these genetic changes are faithfully modeled in these cells without using viral protein, these immortal cells represent an authentic in vitro model system with which to study the initiation and progression of human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Liu, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jliu@mdanderson.org			NCI NIH HHS [CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Band V, 1998, INT J ONCOL, V12, P499; Bantounas I, 2004, J MOL ENDOCRINOL, V33, P545, DOI 10.1677/jme.1.01582; BERNUES J, 1991, GENE, V108, P269, DOI 10.1016/0378-1119(91)90444-G; Chun YM, 2002, ANN OTO RHINOL LARYN, V111, P507, DOI 10.1177/000348940211100606; D'Andrilli G, 2004, CLIN CANCER RES, V10, P8132, DOI 10.1158/1078-0432.CCR-04-0886; Davies BR, 2003, EXP CELL RES, V288, P390, DOI 10.1016/S0014-4827(03)00218-0; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Gao QS, 2001, J VIROL, V75, P4459, DOI 10.1128/JVI.75.9.4459-4466.2001; Hashiguchi Y, 2001, HUM PATHOL, V32, P988, DOI 10.1053/hupa.2001.27115; Hayflick L, 1973, TISSUE CULTURE METHO, P220, DOI DOI 10.1016/B978-0-12-427150-0.50060-7; Hu YM, 2005, J BIOL CHEM, V280, P39485, DOI 10.1074/jbc.M503296200; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Jarrard DF, 1999, CANCER RES, V59, P2957; Kauff ND, 2005, JNCI-J NATL CANCER I, V97, P1382, DOI 10.1093/jnci/dji281; Kusakari T, 2003, BRIT J CANCER, V89, P2293, DOI 10.1038/sj.bjc.6601423; Kusume T, 1999, CLIN CANCER RES, V5, P4152; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Liu J, 2001, CANCER CYTOPATHOL, V93, P390, DOI 10.1002/cncr.10141; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; McDougall J K, 2001, Dev Biol (Basel), V106, P267; McDougall JK, 2001, DEV BIOL BASEL, V106; MCDOUGALL JK, 2001, DEV BIOL BASEL, V106, P272; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Plug-Demaggio AW, 2002, ONCOGENE, V21, P7507, DOI 10.1038/sj.onc.1205903; Prowse A, 2003, ACS A CLIN ONCOL SER, P49; Rosen DG, 2005, CLIN CANCER RES, V11, P632; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SANKARANARAYANA.R, 2006, BEST PRACT RES CLIN, V20, P1; Takebayashi T, 2003, J BIOL CHEM, V278, P14897, DOI 10.1074/jbc.M210849200; Tammela J, 2004, Minerva Ginecol, V56, P495; Terasawa K, 1999, CANCER LETT, V142, P207, DOI 10.1016/S0304-3835(99)00170-6; Vasey PA, 2003, BRIT J CANCER, V89, pS23, DOI 10.1038/sj.bjc.6601497; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zou GM, 2005, BIOL CELL, V97, P211	41	16	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1492	1498		10.1038/sj.onc.1209905	http://dx.doi.org/10.1038/sj.onc.1209905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953228				2022-12-25	WOS:000244558800014
J	Rafi, S; Novichenok, P; Kolappan, S; Zhang, XJ; Stratton, CF; Rawat, R; Kisker, C; Simmerling, C; Tonge, PJ				Rafi, Salma; Novichenok, Polina; Kolappan, Subramaniapillai; Zhang, Xujie; Stratton, Christopher F.; Rawat, Richa; Kisker, Caroline; Simmerling, Carlos; Tonge, Peter J.			Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; MYCOBACTERIUM-TUBERCULOSIS; GENERALIZED BORN; MOLECULAR MECHANICS; TRICLOSAN ACTIVITY; DIELECTRIC MEDIUM; ATOMIC CHARGES; ACP REDUCTASE; ACTIVE-SITE; FORCE-FIELD	Acyl carrier proteins play a central role in metabolism by transporting substrates in a wide variety of pathways including the biosynthesis of fatty acids and polyketides. However, despite their importance, there is a paucity of direct structural information concerning the interaction of ACPs with enzymes in these pathways. Here we report the structure of an acyl-ACP substrate bound to the Escherichia coli fatty acid biosynthesis enoyl reductase enzyme (FabI), based on a combination of x-ray crystallography and molecular dynamics simulation. The structural data are in agreement with kinetic studies on wild-type and mutant FabIs, and reveal that the complex is primarily stabilized by interactions between acidic residues in the ACP helix alpha 2 and a patch of basic residues adjacent to the FabI substrate-binding loop. Unexpectedly, the acyl-pantetheine thioester carbonyl is not hydrogen-bonded to Tyr(156), a conserved component of the short chain alcohol dehydrogenase/reductase superfamily active site triad. FabI is a proven target for drug discovery and the present structure provides insight into the molecular determinants that regulate the interaction of ACPs with target proteins.	SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Biochem & Struct Biol Grad Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kisker, C (corresponding author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.	caroline.kisker@virchow.uni-wuerzburg.de; carlos.simmerling@sunysb.edu; peter.tonge@sunysb.edu	Tonge, Peter J/A-7443-2009; Kisker, Caroline/T-1724-2019	Tonge, Peter J/0000-0003-1606-3471; Kisker, Caroline/0000-0002-0216-6026	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044639, R21AI044639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061678] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44639, R01 AI044639, R21 AI044639] Funding Source: Medline; NIGMS NIH HHS [R01 GM061678, R01 GM061678-06A1, GM6167803] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cane DE, 1999, CHEM BIOL, V6, pR319, DOI 10.1016/S1074-5521(00)80001-0; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; DeLano W, 2002, PYMOL 0 99; Feig M, 2004, J COMPUT CHEM, V25, P265, DOI 10.1002/jcc.10378; Fillgrove KL, 2000, BIOCHEMISTRY-US, V39, P7001, DOI 10.1021/bi0000566; Fillgrove KL, 2001, BIOCHEMISTRY-US, V40, P12412, DOI 10.1021/bi0111606; Geney R, 2006, J CHEM THEORY COMPUT, V2, P115, DOI 10.1021/ct050183l; Haas JA, 2000, PROTEIN EXPRES PURIF, V20, P274, DOI 10.1006/prep.2000.1293; Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n; HAWKINS GD, 1995, CHEM PHYS LETT, V246, P122, DOI 10.1016/0009-2614(95)01082-K; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; Hornak V, 2006, J AM CHEM SOC, V128, P2812, DOI 10.1021/ja058211x; Hornak V, 2006, P NATL ACAD SCI USA, V103, P915, DOI 10.1073/pnas.0508452103; Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123; Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Majerus P W, 1967, Adv Lipid Res, V5, P1; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nesbitt NM, 2005, PROTEIN EXPRES PURIF, V39, P269, DOI 10.1016/j.pep.2004.10.021; Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Pavelites JJ, 1997, J COMPUT CHEM, V18, P221, DOI 10.1002/(SICI)1096-987X(19970130)18:2<221::AID-JCC7>3.0.CO;2-X; Qiu XY, 1999, PROTEIN SCI, V8, P2529, DOI 10.1110/ps.8.11.2529; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; Roujeinikova A, 2002, STRUCTURE, V10, P825, DOI 10.1016/S0969-2126(02)00775-X; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Schaeffer ML, 2001, BBA-MOL CELL BIOL L, V1532, P67, DOI 10.1016/S1388-1981(01)00116-0; Sivaraman S, 2003, BIOCHEMISTRY-US, V42, P4406, DOI 10.1021/bi0300229; Sivaraman S, 2004, J MED CHEM, V47, P509, DOI 10.1021/jm030182i; Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Sullivan TJ, 2006, ACS CHEM BIOL, V1, P43, DOI 10.1021/cb0500042; Sweet CR, 2004, J BIOL CHEM, V279, P25411, DOI 10.1074/jbc.M400597200; Tang LJ, 1997, J BACTERIOL, V179, P3697, DOI 10.1128/jb.179.11.3697-3705.1997; VAGELOS PR, 1966, FED PROC, V25, P1485; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Walker RC, 2002, J PHYS CHEM B, V106, P11658, DOI 10.1021/jp0261814; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200; Zagrovic B, 2003, J COMPUT CHEM, V24, P1432, DOI 10.1002/jcc.10297; Zhang YM, 2003, J BIOL CHEM, V278, P52935, DOI 10.1074/jbc.M309874200; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	64	88	99	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39285	39293		10.1074/jbc.M608758200	http://dx.doi.org/10.1074/jbc.M608758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17012233	Green Accepted, hybrid			2022-12-25	WOS:000242898700035
J	Hopner, S; Dickhaut, K; Hofstatter, M; Kramer, H; Ruckerl, D; Soderhall, JA; Gupta, S; Marin-Esteban, V; Kuhne, R; Freund, C; Jung, G; Falk, K; Rotzschke, O				Hoepner, Sabine; Dickhaut, Katharina; Hofstaetter, Maria; Kraemer, Heiko; Rueckerl, Dominik; Soederhaell, J. Arvid; Gupta, Shashank; Marin-Esteban, Viviana; Kuehne, Ronald; Freund, Christian; Jung, Guenther; Falk, Kirsten; Roetzschke, Olaf			Small organic compounds enhance antigen loading of class II major histocompatibility complex proteins by targeting the polymorphic P1 pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE DENDRITIC CELLS; PEPTIDE-RECEPTIVE STATE; MYELIN BASIC-PROTEIN; HLA-DR MOLECULES; RHEUMATOID-ARTHRITIS; CRYSTAL-STRUCTURE; MHC MOLECULES; DM; BINDING; SUSCEPTIBILITY	Major histocompatibility complex (MHC) molecules are a key element of the cellular immune response. Encoded by the MHC they are a family of highly polymorphic peptide receptors presenting peptide antigens for the surveillance by T cells. We have shown that certain organic compounds can amplify immune responses by catalyzing the peptide loading of human class II MHC molecules HLA-DR. Here we show now that they achieve this by interacting with a defined binding site of the HLA-DR peptide receptor. Screening of a compound library revealed a set of adamantane derivatives that strongly accelerated the peptide loading rate. The effect was evident only for an allelic subset and strictly correlated with the presence of glycine at the dimorphic position beta 86 of the HLA-DR molecule. The residue forms the floor of the conserved pocket P1, located in the peptide binding site of MHC molecule. Apparently, transient occupation of this pocket by the organic compound stabilizes the peptide-receptive conformation permitting rapid antigen loading. This interaction appeared restricted to the larger Gly(beta 86) pocket and allowed striking enhancements of T cell responses for antigens presented by these "adamantyl-susceptible" MHC molecules. As catalysts of antigen loading, compounds targeting P1 may be useful molecular tools to amplify the immune response. The observation, however, that the ligand repertoire can be affected through polymorphic sites form the outside may also imply that environmental factors could induce allergic or autoimmune reactions in an allele-selective manner.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Forsch Inst Mol Pharmacol, D-13125 Berlin, Germany; Free Univ Berlin, D-14195 Berlin, Germany; Univ Tubingen, D-72076 Tubingen, Germany; Univ Med Berlin, Charite, D-10117 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Falk, K (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	falk@mdc-berlin.de; roetzsch@mdc-berlin.de	Roetzschke, Olaf/GXH-0012-2022; Marin-Esteban, Viviana/A-8856-2014	Ruckerl, Dominik/0000-0002-0206-1451				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Boes M, 2004, NATURE, V430, P264, DOI 10.1038/nature02762; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; D'Cruz D, 2000, TOXICOL LETT, V112, P421, DOI 10.1016/S0378-4274(99)00220-9; De Wall SL, 2006, NAT CHEM BIOL, V2, P197, DOI 10.1038/nchembio773; FALK K, 1994, IMMUNOGENETICS, V39, P230; Falk K, 2002, J BIOL CHEM, V277, P2709, DOI 10.1074/jbc.M109098200; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Gibert M, 2003, HUM IMMUNOL, V64, P930, DOI 10.1016/S0198-8859(03)00186-1; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; Jones EY, 2006, NAT REV IMMUNOL, V6, P271, DOI 10.1038/nri1805; Joshi RV, 2000, BIOCHEMISTRY-US, V39, P3751, DOI 10.1021/bi9923656; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; Marin-Esteban V, 2004, J BIOL CHEM, V279, P50684, DOI 10.1074/jbc.M407598200; Marin-Esteban V, 2003, J AUTOIMMUN, V20, P63, DOI 10.1016/S0896-8411(02)00107-5; Nicholson MJ, 2006, J IMMUNOL, V176, P4208, DOI 10.4049/jimmunol.176.7.4208; ONG B, 1991, P NATL ACAD SCI USA, V88, P7343, DOI 10.1073/pnas.88.16.7343; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; RAMMENSEE HG, 1997, MHC LIGANDS PEPTIDE, P55; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Rosloniec EF, 1997, J EXP MED, V185, P1113, DOI 10.1084/jem.185.6.1113; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15050, DOI 10.1073/pnas.96.26.15050; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Teutsch SM, 1999, HUM IMMUNOL, V60, P715, DOI 10.1016/S0198-8859(99)00033-6; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Watts C, 2001, CURR OPIN IMMUNOL, V13, P26, DOI 10.1016/S0952-7915(00)00177-1; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	34	37	42	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38535	38542		10.1074/jbc.M606437200	http://dx.doi.org/10.1074/jbc.M606437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17005558	hybrid			2022-12-25	WOS:000242709500048
J	Navati, MS; Friedman, JM				Navati, Mahantesh S.; Friedman, Joel M.			Sugar-derived glasses support thermal and photo-initiated electron transfer processes over macroscopic distances	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOM-TEMPERATURE; TREHALOSE GLASS; PROTEIN; MYOGLOBIN; FLUORESCENCE; SPECTROSCOPY; STABILITY; GLYCEROL/WATER; PHOTOREDUCTION; ANHYDROBIOSIS	Trehalose-derived glasses are shown to support long range electron transfer reactions between spatially well separated donors and protein acceptors. The results indicate that these matrices can be used not only to greatly stabilize protein structures but also to facilitate both thermal and photo-initiated hemeprotein reduction over large macroscopic distances. To date the promise of exciting new protein-based technologies that can harness the exceptional tunability of protein functionality has been significantly thwarted by both intrinsic instability and stringent solvent/environment requirements for the expression of functional properties. The presented results raise the prospect of overcoming these limitations with respect to incorporating redox active proteins into solid state devices such as tunable batteries, switches, and solar cells. The findings also have implications for formulations intended to enhance long term storage of biomaterials, new protein-based synthetic strategies, and biophysical studies of functional intermediates trapped under nonequilibrium conditions. In addition, the study shows that certain sugars such as glucose or tagatose, when added to redox-inactive glassy matrices, can be used as a source of thermal electrons that can be harvested by suitable redox active proteins, raising the prospect of using common sugars as an electron source in solid state thermal fuel cells.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu						Abbruzzetti S, 2005, CELL BIOCHEM BIOPHYS, V43, P431, DOI 10.1385/CBB:43:3:431; Agmon N, 2005, J PHYS CHEM A, V109, P13, DOI 10.1021/jp047465m; Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102; Christian JF, 1997, BIOCHEMISTRY-US, V36, P11198, DOI 10.1021/bi9710075; Cordone L, 2005, BBA-PROTEINS PROTEOM, V1749, P252, DOI 10.1016/j.bbapap.2005.03.004; Cordone L, 1998, EUR BIOPHYS J BIOPHY, V27, P173, DOI 10.1007/s002490050123; Crowe JH, 1998, ANNU REV PHYSIOL, V60, P73, DOI 10.1146/annurev.physiol.60.1.73; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; CROWE LM, 1966, BIOPHYS J, V7, P2087; D'Alfonso L, 2003, EUR J BIOCHEM, V270, P2497, DOI 10.1046/j.1432-1033.2003.03621.x; Dantsker D, 2005, BBA-PROTEINS PROTEOM, V1749, P234, DOI 10.1016/j.bbapap.2005.04.002; Dashnau JL, 2005, BIOPHYS CHEM, V114, P71, DOI 10.1016/j.bpc.2004.10.003; Garzon-Rodriguez W, 2004, J PHARM SCI-US, V93, P684, DOI 10.1002/jps.10587; Gottfried DS, 1996, J PHYS CHEM-US, V100, P12034, DOI 10.1021/jp9609489; Gray HB, 2005, P NATL ACAD SCI USA, V102, P3534, DOI 10.1073/pnas.0408029102; HAGEN SJ, 1995, SCIENCE, V269, P959, DOI 10.1126/science.7638618; Heller MC, 1999, BIOTECHNOL BIOENG, V63, P166, DOI 10.1002/(SICI)1097-0290(19990420)63:2<166::AID-BIT5>3.0.CO;2-H; Hoffman BM, 2005, P NATL ACAD SCI USA, V102, P3564, DOI 10.1073/pnas.0408767102; Librizzi F, 1999, BIOPHYS J, V76, P2727, DOI 10.1016/S0006-3495(99)77425-4; Liu WJ, 2005, INT J BIOL MACROMOL, V37, P232, DOI 10.1016/j.ijbiomac.2005.11.007; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; Newman Y M, 1993, Biotechnol Genet Eng Rev, V11, P263; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; Ray A, 2002, J AM CHEM SOC, V124, P7270, DOI 10.1021/ja0201348; Sakai H, 2000, BIOCHEMISTRY-US, V39, P14595, DOI 10.1021/bi0014204; Sastry GM, 1997, BIOCHEMISTRY-US, V36, P7097, DOI 10.1021/bi9626057; Wright WW, 2002, ANAL BIOCHEM, V307, P167, DOI 10.1016/S0003-2697(02)00034-9; Wright WW, 2003, BIOPHYS J, V85, P1980, DOI 10.1016/S0006-3495(03)74626-8	30	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36021	36028		10.1074/jbc.M606866200	http://dx.doi.org/10.1074/jbc.M606866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005567	hybrid			2022-12-25	WOS:000242100500050
J	Porras-Yakushi, TR; Whitelegge, JP; Clarke, S				Porras-Yakushi, Tanya R.; Whitelegge, Julian P.; Clarke, Steven			A novel SET domain methyltransferase in yeast - Rkm2-dependent trimethylation of ribosomal protein L12ab at lysine 10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC ANALYSIS; RIBOSOMAL-PROTEINS; HISTONE H3; METHYLATION; SUBUNIT; SUBSTRATE; FINGER; PRMT3	The ribosomal protein L12ab ( Rpl12ab) in Saccharomyces cerevisiae is modified by methylation at both arginine and lysine residues. Although the enzyme responsible for the modification reaction at arginine 66 has been identified (Rmt2), the enzyme(s) responsible for the lysine modification( s) has not been found, and the site( s) of methylation has not been determined. Here we demonstrate, using a combination of mass spectrometry and labeling assays, that the yeast gene YDR198c encodes the enzyme responsible for the predominant epsilon-trimethylation at lysine 10 in Rpl12ab. An additional site of predominant epsilon-dimethylation is observed at lysine 3; the enzyme catalyzing this modification is not known. The YDR198c gene encodes a SET domain similar to that of the Rkm1 enzyme responsible for modifying Rpl23ab, and we have now designated the YDR198c gene product as Rkm2 ( ribosomal lysine methyltransferase 2). The effect of the loss of the enzyme on ribosomal complex stability was studied by polysomal fractionation. However, no difference was observed between the Delta rkm2 deletion strain and its parent wild type strain. With the identification of this enzyme, it appears that the 12 SET domain family members in yeast can now be divided into two subfamilies based on function and amino acid sequence identity. One branch includes enzymes that modify histones, including Set1 and Set2; the other branch includes Rkm1, Rkm2, and Ctm1, the cytochrome c methyltransferase. These studies suggest that the remaining seven SET domain proteins may also be lysine methyltransferases.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 611 Charles E Young Dr E,Paul Boyer Hall 639, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, F31GM075381, T32GM007185, R01GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07185, GM026020, GM075381] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachand F, 2006, MOL CELL BIOL, V26, P1731, DOI 10.1128/MCB.26.5.1731-1742.2006; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Boa S, 2003, YEAST, V20, P827, DOI 10.1002/yea.995; CHANG FN, 1978, BIOCHIM BIOPHYS ACTA, V518, P89, DOI 10.1016/0005-2787(78)90118-1; CHANG FN, 1976, ARCH BIOCHEM BIOPHYS, V172, P627, DOI 10.1016/0003-9861(76)90117-X; Chern MK, 2002, J BIOL CHEM, V277, P15345, DOI 10.1074/jbc.M111379200; Dirk LMA, 2006, ENZYMES, V24, P179, DOI 10.1016/S1874-6047(06)80009-0; HIRS CHW, 1970, CRC HDB BIOCHEMISTRY, pC125; Houtz RL, 2003, ARCH BIOCHEM BIOPHYS, V414, P150, DOI 10.1016/S0003-9861(03)00122-X; HOUTZ RL, 1989, P NATL ACAD SCI USA, V86, P1855, DOI 10.1073/pnas.86.6.1855; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; KRUISWIJK T, 1978, BIOCHEM J, V175, P221, DOI 10.1042/bj1750221; Lee SW, 2002, P NATL ACAD SCI USA, V99, P5942, DOI 10.1073/pnas.082119899; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; LOBET Y, 1989, BIOCHIM BIOPHYS ACTA, V997, P224, DOI 10.1016/0167-4838(89)90191-X; Louie DF, 1996, J BIOL CHEM, V271, P28189, DOI 10.1074/jbc.271.45.28189; Meng FY, 2004, ANAL CHEM, V76, P2852, DOI 10.1021/ac0354903; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Polevoda B, 2000, J BIOL CHEM, V275, P20508, DOI 10.1074/jbc.M001891200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Porras-Yakushi TR, 2005, J BIOL CHEM, V280, P34590, DOI 10.1074/jbc.M507672200; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; SCOLNIK P, 1979, EUR J BIOCHEM, V101, P93, DOI 10.1111/j.1432-1033.1979.tb04220.x; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Whitelegge Julian P, 2004, Methods Mol Biol, V251, P323; Williamson NA, 1997, EUR J BIOCHEM, V246, P786, DOI 10.1111/j.1432-1033.1997.00786.x; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3; Yu YH, 2005, PROTEIN SCI, V14, P1438, DOI 10.1110/ps.041293005; Zanchin NIT, 1997, MOL CELL BIOL, V17, P5001, DOI 10.1128/MCB.17.9.5001	38	44	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35835	35845		10.1074/jbc.M606578200	http://dx.doi.org/10.1074/jbc.M606578200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005568	hybrid			2022-12-25	WOS:000242100500030
J	Bird, JG; Sharma, S; Roshwalb, SC; Hoskins, JR; Wickner, S				Bird, Jeremy G.; Sharma, Suveena; Roshwalb, Sara C.; Hoskins, Joel R.; Wickner, Sue			Functional analysis of CbpA, a DnaJ homolog and nucleoid-associated DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; J-DOMAIN; THERMUS-THERMOPHILUS; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; HSP40; HSP70; REPLICATION; REPA	DnaK/Hsp70 proteins are universally conserved ATP-dependent molecular chaperones that help proteins adopt and maintain their native conformations. DnaJ/Hsp40 and GrpE are co-chaperones that assist DnaK. CbpA is an Escherichia coli DnaJ homolog. It acts as a multicopy suppressor for dnaJ mutations and functions in vitro in combination with DnaK and GrpE in protein remodeling reactions. CbpA binds nonspecifically to DNA with preference for curved DNA and is a nucleoid-associated protein. The DNA binding and co-chaperone activities of CbpA are modulated by CbpM, a small protein that binds specifically to CbpA. To identify the regions of CbpA involved in the interaction of CbpA with CbpM and those involved in DNA binding, we constructed and characterized deletion and substitution mutants of CbpA. We discovered that CbpA interacted with CbpM through its N-terminal J-domain. We found that the region C-terminal to the J-domain was required for DNA binding. Moreover, we found that the CbpM interaction, DNA binding, and co-chaperone activities were separable; some mutants were proficient in some functions and defective in others.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 5144,37 Convent Dr MSC37-4264, Bethesda, MD 20892 USA.	wickners@mail.nih.gov		Bird, Jeremy/0000-0003-2690-8474	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ali Azam T., 1999, J BACTERIOL, V181, P6361; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chae C, 2004, J BIOL CHEM, V279, P33147, DOI 10.1074/jbc.M404862200; Dumitru GL, 2004, J MOL BIOL, V339, P1179, DOI 10.1016/j.jmb.2004.04.052; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Huang K, 1999, PROTEIN SCI, V8, P203; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Shi YY, 2005, J BIOL CHEM, V280, P22761, DOI 10.1074/jbc.M503643200; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; Tucker DL, 2002, J BACTERIOL, V184, P6551, DOI 10.1128/JB.184.23.6551-6558.2002; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; UEGUCHI C, 1995, J BACTERIOL, V177, P3894, DOI 10.1128/jb.177.13.3894-3896.1995; WALL D, 1994, J BIOL CHEM, V269, P5446; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YAMASHINO T, 1994, MOL MICROBIOL, V13, P475, DOI 10.1111/j.1365-2958.1994.tb00442.x	32	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34349	34356		10.1074/jbc.M603365200	http://dx.doi.org/10.1074/jbc.M603365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973605	hybrid			2022-12-25	WOS:000241767600055
J	Angata, T; Hayakawa, T; Yamanaka, M; Varki, A; Nakamura, M				Angata, Takashi; Hayakawa, Toshiyuki; Yamanaka, Masahiro; Varki, Ajit; Nakamura, Mitsuru			Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates	FASEB JOURNAL			English	Article						innate immunity; paired receptors; gene conversion; DAP12; great apes	IMMUNOGLOBULIN-LIKE RECEPTORS; GENE; CELL; INNATE; RECOGNITION; EXPRESSION; CLONING; CD33; ENGAGEMENT; P75/AIRM1	Immune receptors that show high mutual sequence similarity and have antagonizing signaling properties are called paired receptors, and are believed to fine-tune immune responses. Siglecs are sialic acid-recognizing receptors of the immunoglobulin (Ig) superfamily expressed on immune cells. Human Siglec-5, encoded by SIGLEC5 gene, has four extracellular Ig-like domains and a cytosolic inhibitory motif. We discovered human Siglec-14 with three Ig-like domains, encoded by the SIGLEC14 gene, adjacent to SIGLEC5. Human Siglec-14 has almost complete sequence identity with human Siglec-5 at the first two Ig-like domains, shows a glycan binding preference similar to that of human Siglec-5, and associates with the activating adapter protein DAP12. Thus, Siglec-14 and Siglec-5 appear to be the first glycan binding paired receptors. Near-complete sequence identity of the amino-terminal part of human Siglec-14 and Siglec-5 indicates partial gene conversion between SIGLEC14 and SIGLEC5. Remarkably, SIGLEC14 and SIGLEC5 in other primates also show evidence of gene conversions within each lineage. Evidently, balancing the interactions between Siglec-14, Siglec-5 and their common ligand(s) had selective advantage during the course of evolution. The "essential arginine" critical for sialic acid recognition in both Siglec-14 and Siglec-5 is present in humans but mutated in almost all great ape alleles.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058568, Japan; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	National Institute of Advanced Industrial Science & Technology (AIST); University of California System; University of California San Diego; University of California System; University of California San Diego	Angata, T (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, 1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.	takashi-angata@aist.go.jp			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Angata T, 2001, J BIOL CHEM, V276, P45128, DOI 10.1074/jbc.M108573200; Angata T, 2004, P NATL ACAD SCI USA, V101, P13251, DOI 10.1073/pnas.0404833101; Arase H, 2002, MICROBES INFECT, V4, P1505, DOI 10.1016/S1286-4579(02)00033-3; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Avril T, 2005, J BIOL CHEM, V280, P19843, DOI 10.1074/jbc.M502041200; Blasius AL, 2006, BLOOD, V107, P2474, DOI 10.1182/blood-2005-09-3746; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8633, DOI 10.1074/jbc.275.12.8633; Brinkman-Vand der Linden ECM, 2003, MOL CELL BIOL, V23, P4199, DOI 10.1128/MCB.23.12.4199-4206.2003; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Connolly NP, 2002, BRIT J HAEMATOL, V119, P221, DOI 10.1046/j.1365-2141.2002.03808.x; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 2005, CURR OPIN PHARMACOL, V5, P431, DOI 10.1016/j.coph.2005.03.003; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Gunturi A, 2004, IMMUNOL RES, V30, P29, DOI 10.1385/IR:30:1:029; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; Hayakawa T, 2001, P NATL ACAD SCI USA, V98, P11399, DOI 10.1073/pnas.191268198; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Jukes T. H, 1969, MAMMALIAN PROTEIN ME, P21, DOI DOI 10.1093/BIOINFORMATICS/BTM404; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Lanier LL, 2001, CURR OPIN IMMUNOL, V13, P326, DOI 10.1016/S0952-7915(00)00222-3; Lock K, 2004, IMMUNOBIOLOGY, V209, P199, DOI 10.1016/j.imbio.2004.04.007; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; Muchmore EA, 1998, AM J PHYS ANTHROPOL, V107, P187, DOI 10.1002/(SICI)1096-8644(199810)107:2<187::AID-AJPA5>3.3.CO;2-M; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sonnenburg JL, 2004, GLYCOBIOLOGY, V14, P339, DOI 10.1093/glycob/cwh039; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; Yotsumoto K, 2003, J EXP MED, V198, P223, DOI 10.1084/jem.20021825; ZHANG J, 2006, IN PRESS BLOOD	45	116	125	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1964	1973		10.1096/fj.06-5800com	http://dx.doi.org/10.1096/fj.06-5800com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012248				2022-12-25	WOS:000241156900004
J	Nijenhuis, T; van der Eerden, BCJ; Zugel, U; Steinmeyer, A; Weinans, H; Hoenderop, JGJ; van Leeuwen, JPTM; Bindels, RJM				Nijenhuis, Tom; van der Eerden, Bram C. J.; Zuegel, Ulrich; Steinmeyer, Andreas; Weinans, Harrie; Hoenderop, Joost G. J.; van Leeuwen, Johannes P. T. M.; Bindels, Rene J. M.			The novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonist	FASEB JOURNAL			English	Article						TRPV5; TRPV6; Ca2+ homeostasis; 1,25(OH)(2)D-3	1-ALPHA,25-DIHYDROXYVITAMIN D-3 ANALOG; CA2+ TRANSPORT PROTEINS; CALCIUM-ABSORPTION; CHANNEL; TRPV5; DIFFERENTIATION; HYPERABSORPTION; TAMOXIFEN; BETA; MICE	Vitamin D [1,25(OH) D-2(3)] plays a crucial role in Ca2+ homeostasis by stimulating Ca2+ (re) absorption and bone turnover. The 1,25(OH)(2)D-3 analog ZK191784 was recently developed to dissociate the therapeutic immunomodulatory activity from the hypercalcemic side effects of 1,25(OH)(2)D-3 and contains a structurally modified side chain characterized by a 22,23-double bond, 24R-hydroxy group, 25-cyclopropyl ring, and 5-butyloxazole unit. We investigated the effect of ZK191784 on Ca2+ homeostasis and the regulation of Ca2+ transport proteins in wild-type (WT) mice and mice lacking the renal epithelial Ca2+ channel TRPV5 (TRPV5(-/-)). The latter display hypercalciuria, hypervitaminosis D, increased intestinal expression of the epithelial Ca2+ channel TRPV6, the Ca2+-binding protein calbindin-D-9K, and intestinal Ca2+ hyperabsorption. ZK191784 normalized the Ca2+ hyperabsorption and the expression of intestinal Ca2+ transport proteins in TRPV5(-/-) mice. Furthermore, the compound decreased intestinal Ca2+ absorption in WT mice and reduced 1,25(OH)(2)D-3-dependent Ca-45(2+) uptake by Caco-2 cells, substantiating a 1,25(OH)(2)D-3-antagonistic action of ZK191784 in the intestine. ZK191784 increased renal TRPV5 and calbindin-D-28K expression and decreased urine Ca2+ excretion in WT mice. Both 1,25(OH)(2)D-3 and ZK191784 enhanced transcellular Ca2+ transport in primary cultures of rabbit connecting tubules and cortical collecting ducts, indicating a 1,25(OH)(2)D-3-agonistic effect in kidney. ZK191784 enhanced bone TRPV6 mRNA levels and 1,25(OH)(2)D-3 as well as ZK191784 stimulated secretion of the bone formation marker osteocalcin in rat osteosarcoma cells, albeit to a different extent. In conclusion, ZK191784 is a synthetic 1,25(OH)(2)D-3 ligand displaying a unique tissue-specific profile when administered in vivo. Because ZK191784 acts as an intestine-specific 1,25(OH)(2)D-3 antagonist, this compound will be associated with less hypercalcemic side effects compared with the 1,25(OH)(2)D-3 analogs currently used in clinical practice.	Radboud Univ Nijmegen Med Ctr, Dept Physiol, Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Erasmus MC, Dept Internal Med & Orthoped, Rotterdam, Netherlands; Schering AG, Res Business Area Med Chem, Berlin, Germany	Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC; Schering AG	Bindels, RJM (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Physiol, Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.ru.nl	Nijenhuis, Tom/L-4547-2015; van Leeuwen, Johannes/D-5015-2014; Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013; Nijenhuis, Tom/ABE-5194-2021; van der Eerden, Bram CJ/I-7496-2012	Nijenhuis, Tom/0000-0002-4375-7236; van Leeuwen, Johannes/0000-0002-2282-4006; Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; Nijenhuis, Tom/0000-0002-4375-7236; van der Eerden, Bram CJ/0000-0003-4403-6497; Weinans, Harrie/0000-0002-2275-6170				BINDELS RJM, 1991, AM J PHYSIOL, V261, pF799, DOI 10.1152/ajprenal.1991.261.5.F799; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Fujishima T, 2003, BIOORGAN MED CHEM, V11, P3621, DOI 10.1016/S0968-0896(03)00371-7; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; HEWISON M, 1992, J ENDOCRINOL, V132, P173, DOI 10.1677/joe.0.1320173; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2004, KIDNEY INT, V66, P1082, DOI 10.1111/j.1523-1755.2004.00858.x; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2001, J AM SOC NEPHROL, V12, P1342, DOI 10.1681/ASN.V1271342; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Ji Y, 2004, CANCER RES, V64, P370, DOI 10.1158/0008-5472.CAN-03-3029; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471-4914(02)02294-3; McDowell N, 1999, SEMIN CELL DEV BIOL, V10, P311, DOI 10.1006/scdb.1999.0307; Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392; Nijenhuis T, 2005, J CLIN INVEST, V115, P1651, DOI 10.1172/JCI24134; Nijenhuis T, 2004, J AM SOC NEPHROL, V15, P549, DOI 10.1097/01.ASN.0000113318.56023.B6; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Norman AW, 2002, STEROIDS, V67, P457, DOI 10.1016/S0039-128X(01)00167-2; Ozono K, 1999, J BIOL CHEM, V274, P32376, DOI 10.1074/jbc.274.45.32376; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Renkema KY, 2005, J AM SOC NEPHROL, V16, P3188, DOI 10.1681/ASN.2005060632; Slatopolsky E, 2002, BLOOD PURIFICAT, V20, P109, DOI 10.1159/000046993; Smith EA, 2000, J ENDOCRINOL, V165, P163, DOI 10.1677/joe.0.1650163; Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331; van Abel M, 2005, KIDNEY INT, V68, P1708, DOI 10.1111/j.1523-1755.2005.00587.x; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102; van Leeuwen JPTM, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1571; WOOD CM, 2001, TARGET ORGAN TOXICIT, V1, P1; Zugel U, 2002, J INVEST DERMATOL, V119, P1434, DOI 10.1046/j.1523-1747.2002.19623.x	34	14	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					2171	+		10.1096/fj.06-5515fje	http://dx.doi.org/10.1096/fj.06-5515fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012263				2022-12-25	WOS:000241156900059
J	Hasegawa, M; Kawase, K; Inohara, N; Imamura, R; Yeh, WC; Kinoshita, T; Suda, T				Hasegawa, M.; Kawase, K.; Inohara, N.; Imamura, R.; Yeh, W. -C; Kinoshita, T.; Suda, T.			Mechanism of ASC-mediated apoptosis: Bid-dependent apoptosis in type II cells	ONCOGENE			English	Article						apoptosis; ASC; CARD12; caspase; Bid; Bax	NF-KAPPA-B; RECEPTOR-INDUCED APOPTOSIS; INTERLEUKIN-8 PRODUCTION; CONTAINING PROTEIN; FAMILY MEMBER; C-FLIP; ACTIVATION; DEATH; CASPASE-1; PATHWAY	Apoptosis-associated speck-like protein containing a CARD (ASC) is an adaptor molecule that mediates apoptotic and inflammatory signals, and implicated in tumor suppression. However, the mechanism of ASC-mediated apoptosis has not been well elucidated. Here, we investigated the molecular mechanisms of ASC-mediated apoptosis in several cell lines using a caspase recruitment domain 12-Nod2 chimeric protein that transduces the signal from muramyl dipeptide into ASC-mediated apoptosis. Experiments using dominant-negative mutants, small-interfering RNAs and peptide inhibitors for caspases indicated that caspase-8 was generally required for ASC-mediated apoptosis, whereas a requirement for caspase-9 depended on the cell type. In addition, caspase-like apoptosis-regulatory protein (CLARP)/Fas-like inhibitor protein, a natural caspase-8 inhibitor, suppressed ASC-mediated apoptosis, and Clarp-/- mouse embryonic fibroblasts were highly sensitive to ASC-mediated apoptosis. Bax-deficient HCT116 cells were resistant to ASC-mediated apoptosis as reported previously, although we failed to observe colocalization of ASC and Bax in cells. Like Fas-ligand-induced apoptosis, the ASC- mediated apoptosis was inhibited by Bcl-2 and/orBcl-XL in type-II but not type-I cell lines. Bid was cleaved upon ASC activation, and suppression of endogenous Bid expression using small-interfering RNAs in type-II cells reduced the ASC- mediated apoptosis. These results indicate that ASC, like death receptors, mediates two types of apoptosis depending on the cell type, in a manner involving caspase-8.	Kanazawa Univ, Inst Canc Res, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M4X 1K9, Canada	Kanazawa University; University of Michigan System; University of Michigan; University of Toronto	Suda, T (corresponding author), Kanazawa Univ, Inst Canc Res, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	IMAMURA, Ryu/D-8433-2015					Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Damiano JS, 2004, J IMMUNOL, V173, P6338, DOI 10.4049/jimmunol.173.10.6338; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elnemr A, 2001, INT J ONCOL, V18, P311; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gumucio DL, 2002, CLIN EXP RHEUMATOL, V20, pS45; Hasegawa M, 2005, J BIOL CHEM, V280, P15122, DOI 10.1074/jbc.M412284200; Imamura R, 2004, J BIOL CHEM, V279, P46415, DOI 10.1074/jbc.M403226200; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2005, J EXP MED, V202, P1043, DOI 10.1084/jem.20050977; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YT, 2004, INT IMMUNOL, V16, P777, DOI 10.1093/intimm/dxh081; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100	31	43	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1748	1756		10.1038/sj.onc.1209965	http://dx.doi.org/10.1038/sj.onc.1209965			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964285	Green Submitted			2022-12-25	WOS:000244955600009
J	Gerber, AN; Wilson, CW; Li, YJ; Chuang, PT				Gerber, A. N.; Wilson, C. W.; Li, Y-J; Chuang, P-T			The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation	ONCOGENE			English	Review						Gli; MyoD; hedgehog; cancer; rhabdomyosarcoma; development	LOOP-HELIX PROTEINS; SONIC HEDGEHOG; SKELETAL-MUSCLE; SIGNALING PATHWAY; TERMINAL DIFFERENTIATION; BRANCHING MORPHOGENESIS; REPRESSOR FUNCTIONS; FAMILY-MEMBERS; UP-REGULATION; DNA-BINDING	The mechanism by which activation of the Hedgehog (Hh) pathway modulates differentiation and promotes oncogenesis in specific tissues is poorly understood. We therefore, analysed rhabdomyosarcomas from mice that were haploinsufficient for the Hh-binding protein, Hip1, or for the Hh receptor, Patched 1 (Ptch1). Transfection of the Hh-regulated transcription factor Gli1, which is expressed in a subset of mouse and human rhabdomyosarcomas, suppressed differentiation of myogenic rhabdomyosarcoma lines generated from Hip1(+/+) and Ptch1(+/+) mice. The closely related factor, Gli2, had similar effects. Gli1 and Gli2 inhibited myogenesis by repressing the capacity of MyoD to activate transcription. Deletion analysis of Gli1 indicated that multiple domains of Gli1 are required for efficient inhibition of MyoD. Gli1 reduced the ability of MyoD to heterodimerize with E12 and bind DNA, providing one mechanism whereby the Gli proteins modulate the activity of MyoD. This novel activity of Gli proteins provides new insights into how Hh signaling modulates terminal differentiation through inhibition of tissue-specific factors such as MyoD. This mechanism may contribute to the broad role of Hh signaling and the Gli proteins in differentiation decisions and cancer formation.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chuang, PT (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.	pao-tien.chuang@ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL077159, R01HL067822, U01HL066600, T35HL007715] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL077159-01A1, HL067822, K08 HL077159, K08HL07715, U01 HL066600, R01 HL067822, HL66600, T35 HL007715] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Amthor H, 1999, DEVELOPMENT, V126, P1041; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Bai CYB, 2001, DEVELOPMENT, V128, P5161; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Bren-Mattison Y, 2002, DEV BIOL, V242, P130, DOI 10.1006/dbio.2001.0528; Briscoe J, 2005, DEV CELL, V8, P143, DOI 10.1016/j.devcel.2005.01.008; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; Chuang PT, 2003, TRENDS CELL BIOL, V13, P86, DOI 10.1016/S0962-8924(02)00031-4; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dai Z, 2004, CURR TOP MED CHEM, V4, P1347; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Duprez D, 1998, DEVELOPMENT, V125, P495; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jeong JH, 2005, DEVELOPMENT, V132, P143, DOI 10.1242/dev.01566; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Kappler R, 2003, J PATHOL, V200, P348, DOI 10.1002/path.1361; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Koleva M, 2005, CELL MOL LIFE SCI, V62, P1863, DOI 10.1007/s00018-005-5072-9; Kruger M, 2001, DEVELOPMENT, V128, P743; Kuang S, 2006, J CELL BIOL, V172, P103, DOI 10.1083/jcb.200508001; Li Xiaopeng, 2004, BMC Dev Biol, V4, P9, DOI 10.1186/1471-213X-4-9; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mal A, 2003, P NATL ACAD SCI USA, V100, P1735, DOI 10.1073/pnas.0437843100; Marigo V, 1996, DEVELOPMENT, V122, P1225; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Nagy A., 2003, MANIPULATING MOUSE E; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Olguin HC, 2004, DEV BIOL, V275, P375, DOI 10.1016/j.ydbio.2004.08.015; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sambrook J., 2001, MOL CLONING LAB MANU; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sirri V, 2003, ONCOGENE, V22, P5658, DOI 10.1038/sj.onc.1206690; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Teboul L, 2003, GENE DEV, V17, P2870, DOI 10.1101/gad.1117603; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Verzi MP, 2002, DEV BIOL, V249, P174, DOI 10.1006/dbio.2002.0753; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watson Joseph, 2004, Ear Nose Throat J, V83, P716; Weiner HL, 2002, CANCER RES, V62, P6385; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wolff C, 2003, CURR BIOL, V13, P1169, DOI 10.1016/S0960-9822(03)00461-5; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496	101	41	47	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1122	1136		10.1038/sj.onc.1209891	http://dx.doi.org/10.1038/sj.onc.1209891			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16964293	Green Accepted			2022-12-25	WOS:000244406400003
J	Lee, SA; Kovacs, J; Stahelin, RV; Cheever, ML; Overduin, M; Setty, TG; Burd, CG; Cho, W; Kutateladze, TG				Lee, Stephanie A.; Kovacs, James; Stahelin, Robert V.; Cheever, Matthew L.; Overduin, Michael; Setty, Thanuja Gangi; Burd, Christopher G.; Cho, Wonhwa; Kutateladze, Tatiana G.			Molecular mechanism of membrane docking by the Vam7p PX domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE RECOGNITION; PLECKSTRIN HOMOLOGY DOMAINS; FYVE DOMAIN; CRYSTAL-STRUCTURE; BINDING; P40(PHOX); MICELLES; PROTEIN; NMR	The Vam7p t-SNARE is an essential component of the vacuole fusion machinery that mediates membrane trafficking and protein sorting in yeast. Vam7p is recruited to vacuoles by its N-terminal PX domain that specifically recognizes PtdIns(3) P in the bilayers, however the precise mechanism of membrane anchoring remains unclear. Here we describe a molecular basis for membrane targeting and penetration by the Vam7p PX domain based on structural and quantitative analysis of its interactions with lipids and micelles. Our results derived from in vitro binding measurements using NMR, monolayer surface tension experiments and mutagenesis reveal a multivalent membrane docking mechanism involving specific PtdIns(3) P recognition that is facilitated by electrostatic interactions and accompanying hydrophobic insertion. Both the hydrophobic and electrostatic components enhance the Vam7p PX domain association with PtdIns(3) P-containing membranes. The inserting Val(70), Leu(71), and Trp(75) residues located next to the PtdIns(3) P binding pocket are surrounded by a basic patch, which is involved in nonspecific electrostatic contacts with acidic lipids, such as PtdSer. Substitution of the insertion residues significantly reduces the binding and penetrating power of the Vam7p PX domain and leads to cytoplasmic redistribution of the EGFP-tagged protein. The affinities of the PX domain for PtdIns(3) P and other lipids reveal a remarkable synergy within the multivalent complex that stably anchors Vam7p at the vacuolar membrane.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, South Bend, IN 46615 USA; Univ Notre Dame, Walther Ctr Canc Res, Dept Chem & Biochem, South Bend, IN 46617 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Birmingham, CR UK Inst Canc Studies, Birmingham B15 2T, W Midlands, England; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Indiana University System; Indiana University South Bend; University of Notre Dame; Walther Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Birmingham; University of Pennsylvania	Kutateladze, TG (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 12801 E 17th Ave, Aurora, CO 80045 USA.	Tatiana.Kutateladze@UCHSC.edu	Stahelin, Robert/L-3567-2019; Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Kutateladze, Tatiana/0000-0001-7375-6990; Stahelin, Robert/0000-0001-5443-7863; Burd, Christopher/0000-0003-1831-8706	Biotechnology and Biological Sciences Research Council [BBS/B/10714] Funding Source: Medline; NCI NIH HHS [CA95144, R01 CA095144] Funding Source: Medline; NIGMS NIH HHS [R01 GM071424, GM071424, R01 GM068849, GM68849] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068849, R01GM071424] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; DiNitto JP, 2006, BBA-MOL CELL BIOL L, V1761, P850, DOI 10.1016/j.bbalip.2006.04.008; Diraviyam K, 2003, J MOL BIOL, V328, P721, DOI 10.1016/S0022-2836(03)00325-5; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; GRZESIEK S, 1996, BIOCHEMISTRY; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hurley JH, 2006, BBA-MOL CELL BIOL L, V1761, P805, DOI 10.1016/j.bbalip.2006.02.020; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; Jarvet J, 1997, BIOCHEMISTRY-US, V36, P8153, DOI 10.1021/bi970193b; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 2006, BBA-MOL CELL BIOL L, V1761, P868, DOI 10.1016/j.bbalip.2006.03.011; Kutateladze TG, 2004, J BIOL CHEM, V279, P3050, DOI 10.1074/jbc.M309007200; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lee JS, 2005, J CELL SCI, V118, P4405, DOI 10.1242/jcs.02564; Lee SA, 2005, P NATL ACAD SCI USA, V102, P13052, DOI 10.1073/pnas.0503900102; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Lundmark R, 2003, J BIOL CHEM, V278, P46772, DOI 10.1074/jbc.M307334200; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; PAPAVOINE CHM, 1994, BIOCHEMISTRY-US, V33, P12990, DOI 10.1021/bi00248a007; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Seet LF, 2006, BBA-MOL CELL BIOL L, V1761, P878, DOI 10.1016/j.bbalip.2006.04.011; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2004, J BIOL CHEM, V279, P54918, DOI 10.1074/jbc.M407798200; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; vandenHooven HW, 1996, EUR J BIOCHEM, V235, P394, DOI 10.1111/j.1432-1033.1996.00394.x; Xing Y, 2004, J BIOL CHEM, V279, P30662, DOI 10.1074/jbc.M404107200; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699; Zhou CZ, 2003, J BIOL CHEM, V278, P50371, DOI 10.1074/jbc.M304392200	50	40	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37091	37101		10.1074/jbc.M608610200	http://dx.doi.org/10.1074/jbc.M608610200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16984909	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000242220800070
J	Canela, N; Orzaez, M; Fucho, R; Mateo, F; Gutierrez, R; Pineda-Lucena, A; Bachs, O; Perez-Paya, E				Canela, Nuria; Orzaez, Mar; Fucho, Raquel; Mateo, Francesca; Gutierrez, Ricardo; Pineda-Lucena, Antonio; Bachs, Oriol; Perez-Paya, Enrique			Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; PEPTIDE INHIBITORS; IN-VIVO; KINASE INHIBITORS; STRUCTURAL BASIS; DNA-REPLICATION; SMALL MOLECULES; CELL-CYCLE	The protein-protein complexes formed between different cyclins and cyclin-dependent kinases (CDKs) are central to cell cycle regulation. These complexes represent interesting points of chemical intervention for the development of antineoplastic molecules. Here we describe the identification of an all D-amino acid hexapeptide, termed NBI1, that inhibits the kinase activity of the cyclin-dependent kinase 2 (cdk2)-cyclin A complex through selective binding to cyclin A. The mechanism of inhibition is non-competitive for ATP and non-competitive for protein substrates. In contrast to the existing CDKs peptide inhibitors, the hexapeptide NBI1 interferes with the formation of the cdk2-cyclin A complex. Furthermore, a cell-permeable derivative of NBI1 induces apoptosis and inhibits proliferation of tumor cell lines. Thus, the NBI1-binding site on cyclin A may represent a new target site for the selective inhibition of activity cdk2-cyclin A complex.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Fac Med, Dept Biol Cellular & Anat Patol, E-08036 Barcelona, Spain; Ctr Invest Principe Felipe, Dept Quim Med, E-46013 Valencia, Spain; Univ Pompeu Fabra, Dept Ciencies Expt Salut, Unitat Recerca Farmacol, Inst Municipal Invest Med, E-08003 Barcelona, Spain; CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Prince Felipe Research Center; Pompeu Fabra University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Bachs, O (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Fac Med, Dept Biol Cellular & Anat Patol, C-Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu; eperez@cipf.es	Pineda-Lucena, Antonio/B-1320-2014; Fucho, Raquel/A-6684-2016; Mateo, Francesca/K-7746-2015; Orzaez, Mar/B-4992-2014; Canela, Núria/I-5401-2015	Pineda-Lucena, Antonio/0000-0002-3532-8781; Fucho, Raquel/0000-0002-1774-9099; Mateo, Francesca/0000-0002-2342-7010; Orzaez, Mar/0000-0003-3231-5835; Canela, Núria/0000-0003-0261-2396				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Andrews MJI, 2004, ORG BIOMOL CHEM, V2, P2735, DOI 10.1039/b409157d; Arkin M, 2005, CURR OPIN CHEM BIOL, V9, P317, DOI 10.1016/j.cbpa.2005.03.001; Berg T, 2003, ANGEW CHEM INT EDIT, V42, P2462, DOI 10.1002/anie.200200558; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cochran AG, 2001, CURR OPIN CHEM BIOL, V5, P654, DOI 10.1016/S1367-5931(01)00262-9; Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fischer P M, 2001, Curr Opin Drug Discov Devel, V4, P623; Fischer PM, 2004, CURR MED CHEM, V11, P1563, DOI 10.2174/0929867043365062; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Garcia-Martinez C, 2002, P NATL ACAD SCI USA, V99, P2374, DOI 10.1073/pnas.022285899; Gondeau C, 2005, J BIOL CHEM, V280, P13793, DOI 10.1074/jbc.M413690200; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Humet M, 2003, J COMB CHEM, V5, P597, DOI 10.1021/cc020075u; Huwe A, 2003, ANGEW CHEM INT EDIT, V42, P2122, DOI 10.1002/anie.200200540; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kontopidis G, 2003, STRUCTURE, V11, P1537, DOI 10.1016/j.str.2003.11.006; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; McInnes C, 2005, CURR PHARM DESIGN, V11, P1845, DOI 10.2174/1381612053764850; Mendoza N, 2003, CANCER RES, V63, P1020; Montoliu C, 2002, J PHARMACOL EXP THER, V301, P29, DOI 10.1124/jpet.301.1.29; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Planells-Cases R, 2002, J PHARMACOL EXP THER, V302, P163, DOI 10.1124/jpet.302.1.163; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Riera M, 1999, MOL CELL BIOCHEM, V191, P97, DOI 10.1023/A:1006810311743; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Winston N, 2000, DEV BIOL, V223, P139, DOI 10.1006/dbio.2000.9721; Wu SY, 2003, STRUCTURE, V11, P399, DOI 10.1016/S0969-2126(03)00060-1; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x	49	46	48	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35942	35953		10.1074/jbc.M603511200	http://dx.doi.org/10.1074/jbc.M603511200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17001081	hybrid			2022-12-25	WOS:000242100500041
J	Choi, Y; Rajkovic, A				Choi, Youngsok; Rajkovic, Aleksandar			Characterization of NOBOX DNA binding specificity and its regulation of Gdf9 and Pou5f1 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; TRANSCRIPTION FACTOR; EARLY FOLLICULOGENESIS; GENE-EXPRESSION; HOMEODOMAIN; PROTEIN; COMPLEX; CELLS; RECOGNITION; FERTILITY	Nobox ( newborn ovary homeobox gene) deficiency disrupts early folliculogenesis and the expression of oocyte-specific genes in mice. Here, we identified several cis-acting sites, TAATTG, TAGTTG, and TAATTA as NOBOX DNA binding elements (NBEs) using a library of randomly generated oligonucleotides by cyclic amplification of sequence target assay and mutation analyses. We show that NOBOX preferentially binds to the NOBOX binding elements with high affinity. In addition, we found that promoter regions of mouse Pou5f1 and Gdf9 contain one (-426) and three NOBOX binding elements (-786, -967, and -1259), respectively. NOBOX binds to these putative NOBOX binding elements with high affinity and augmented transcriptional activity of luciferase reporter driven by mouse Pou5f1 and Gdf9 promoters containing the NOBOX binding elements. In chromatin immunoprecipitation assays, DNA sequences from Pou5f1 and Gdf9 promoters co-precipitated with anti-NOBOX antibody. These results suggest that NOBOX directly regulates the transcription of Pou5f1 and Gdf9 in oocytes during early folliculogenesis.	Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA	Baylor College of Medicine	Rajkovic, A (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, 1709 Dryden St,Suite 1100, Houston, TX 77030 USA.	rajkovic@bcm.edu		Choi, Youngsok/0000-0002-3862-4105	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD044858] Funding Source: NIH RePORTER; NICHD NIH HHS [HD44858] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ba-Charvet KTN, 1998, DEVELOPMENT, V125, P4273; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOTFIELD MC, 1994, BIOCHEMISTRY-US, V33, P6177, DOI 10.1021/bi00186a017; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Dean J, 2002, J REPROD IMMUNOL, V53, P171, DOI 10.1016/S0165-0378(01)00100-0; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Elvin JA, 1998, REV REPROD, V3, P183, DOI 10.1530/ror.0.0030183; Epifano O, 2002, TRENDS ENDOCRIN MET, V13, P169, DOI 10.1016/S1043-2760(02)00576-3; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kehler J, 2004, EMBO REP, V5, P1078, DOI 10.1038/sj.embor.7400279; Kim DW, 2003, J BIOL CHEM, V278, P27532, DOI 10.1074/jbc.M301461200; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; Matzuk MM, 2000, MOL CELL ENDOCRINOL, V163, P61, DOI 10.1016/S0303-7207(99)00241-5; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; Rajkovic A, 2004, SCIENCE, V305, P1157, DOI 10.1126/science.1099755; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; Steadman DJ, 2000, NUCLEIC ACIDS RES, V28, P2389, DOI 10.1093/nar/28.12.2389; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; Suzumori N, 2002, MECH DEVELOP, V111, P137, DOI 10.1016/S0925-4773(01)00620-7; Vitt UA, 2000, BIOL REPROD, V62, P370, DOI 10.1095/biolreprod62.2.370; Vitt UA, 2001, MOL CELL ENDOCRINOL, V183, P171, DOI 10.1016/S0303-7207(01)00614-1; Yan YT, 2000, MOL CELL BIOL, V20, P661, DOI 10.1128/MCB.20.2.661-671.2000; Yeom YI, 1996, DEVELOPMENT, V122, P881	40	64	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35747	35756		10.1074/jbc.M604008200	http://dx.doi.org/10.1074/jbc.M604008200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16997917	hybrid			2022-12-25	WOS:000242100500020
J	Dempski, RE; Hartung, K; Friedrich, T; Bamberg, E				Dempski, Robert E.; Hartung, Klaus; Friedrich, Thomas; Bamberg, Ernst			Fluorometric measurements of intermolecular distances between the alpha- and beta-subunits of the Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-CLAMP FLUOROMETRY; SHAKER K+ CHANNEL; CALCIUM-PUMP; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; XENOPUS OOCYTES; NA/K PUMP; NA,K-ATPASE; FLUORESCENCE; MOVEMENT	The Na+/K+-ATPase maintains the physiological Na+ and K+ gradients across the plasma membrane in most animal cells. The functional unit of the ion pump is comprised of two mandatory subunits including the alpha-subunit, which mediates ATP hydrolysis and ion translocation, as well as the alpha-subunit, which acts as a chaperone to promote proper membrane insertion and trafficking in the plasma membrane. To examine the conformational dynamics between the alpha- and beta-subunits of the Na+/K+-ATPase during ion transport, we have used fluorescence resonance energy transfer, under voltage clamp conditions on Xenopus laevis oocytes, to differentiate between two models that have been proposed for the relative orientation of the alpha- and beta-subunits. These experiments were performed by measuring the time constant of irreversible donor fluorophore destruction with fluorescein-5-maleimide as the donor fluorophore and in the presence or absence of tetramethylrhodamine-6-maleimide as the acceptor fluorophore following labeling on the M3-M4 or M5-M6 loop of the alpha-subunit and the beta-subunit. We have also used fluorescence resonance energy transfer to investigate the relative movement between the two subunits as the ion pump shuttles between the two main conformational states (E-1 and E-2) as described by the Albers-Post scheme. The results from this study have identified a model for the orientation of the beta- subunit in relation to the alpha-subunit and suggest that the alpha- and beta-subunits move toward each other during the E-2 to E-1 conformational transition.	Max Planck Inst Biophys, Dept Biophys Chem, D-60438 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Biochem, D-60438 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Chem, D-60438 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Pharmaceut Sci, D-60438 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt	Bamberg, E (corresponding author), Max Planck Inst Biophys, Dept Biophys Chem, D-60438 Frankfurt, Germany.	ernst.bamberg@mpibp-frankfurt.mpg.de	Friedrich, Thomas/AAA-3418-2022					ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Cha A, 1998, J GEN PHYSIOL, V112, P391, DOI 10.1085/jgp.112.4.391; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; CHEN RF, 1965, SCIENCE, V147, P729, DOI 10.1126/science.147.3659.729; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Dempski RE, 2005, J GEN PHYSIOL, V125, P505, DOI 10.1085/jgp.200409186; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geibel S, 2003, P NATL ACAD SCI USA, V100, P964, DOI 10.1073/pnas.0337336100; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hasler U, 2001, J BIOL CHEM, V276, P16356, DOI 10.1074/jbc.M008778200; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Horisberger JD, 2002, J PHYSIOL-LONDON, V539, P669, DOI 10.1113/jphysiol.2001.013201; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Koch HP, 2005, J NEUROSCI, V25, P1730, DOI 10.1523/JNEUROSCI.4138-04.2005; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P395; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; POST RL, 1972, J BIOL CHEM, V247, P6530; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Zifarelli G, 2003, BIOPHYS J, V84, p268A	39	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36338	36346		10.1074/jbc.M604788200	http://dx.doi.org/10.1074/jbc.M604788200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16980302	hybrid			2022-12-25	WOS:000242100500085
J	Liu, AMF; Lo, RKH; Wong, CSS; Morris, C; Wise, H; Wong, YH				Liu, Andrew M. F.; Lo, Rico K. H.; Wong, Cecilia S. S.; Morris, Christina; Wise, Helen; Wong, Yung H.			Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MUTANT ALPHA-SUBUNIT; SERINE PHOSPHORYLATION; COUPLED RECEPTORS; TYROSINE PHOSPHORYLATION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; ADENYLATE-CYCLASE; NEOPLASTIC TRANSFORMATION; JAK/STAT PATHWAY	Signal transducer and activator of transcription 3 (STAT3) can be stimulated by several G(s)-coupled receptors, but the precise mechanism of action has not yet been elucidated. We therefore examined the ability of G alpha(s)Q226L (G alpha(s)QL), a constitutively active mutant of G alpha(s), to stimulate STAT3 Tyr(705) and Ser(727) phosphorylations in human embryonic kidney 293 cells. Apart from G alpha(s)QL, the stimulation of G alpha(s) by cholera toxin or beta(2)-adrenergic receptor and the activation of adenylyl cyclase by forskolin, (S-p)-cAMP, or dibutyryl-cAMP all promoted both STAT3 Tyr705 and Ser727 phosphorylations. Moreover, the removal of G alpha(s) by RNA interference significantly reduced the beta(2)-adrenergic receptor-mediated STAT3 phosphorylations, denoting its capacity to regulate STAT3 activation by a G protein-coupled receptor. The possible downstream signaling molecules involved were assessed by using specific inhibitors and dominant negative mutants. Induction of STAT3 Tyr705 and Ser727 phosphorylations by G alpha(s)QL was suppressed by inhibition of protein kinase A, Janus kinase 2/3, Rac1, c-Jun N-terminal kinase (JNK), or phosphatidylinositol 3-kinase, and a similar profile was observed in response to beta 2-adrenergic receptor stimulation. In contrast to the G alpha(16)-mediated regulation of STAT3 in HEK 293 cells (Lo, R. K., Cheung, H., and Wong, Y. H. ( 2003) J. Biol. Chem. 278, 52154 - 52165), the G alpha(s)-mediated responses, including STAT3-driven luciferase activation, were resistant to inhibition of phospholipase C beta. Surprisingly, G alpha(s)-mediated phosphorylation at Tyr705, but not at Ser727, was resistant to inhibition of c-Src, Raf-1, and MEK1/2 as well as to the expression of dominant negative Ras. Therefore, as with other G alpha-mediated activations of STAT3, the stimulatory signal arising from G alpha s is transduced via multiple signaling pathways. However, unlike the mechanisms employed by G alpha(i) and G alpha(14/16), G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase for STAT3 activation.	Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Kowloon, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Fac Med, Dept Pharmacol, Shatin, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	boyung@ust.hk	Wise, Helen/J-9650-2013	Wise, Helen/0000-0001-7027-6748; Wong, Yung Hou/0000-0002-0123-7697				ADARICHEV AA, 2003, AM J PHYSIOL, V285, pC922; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ASANO T, 1984, J BIOL CHEM, V259, P9351; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Buggy JJ, 1998, BIOCHEM J, V331, P211, DOI 10.1042/bj3310211; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chow KBS, 2004, PROSTAG LEUKOTR ESS, V70, P423, DOI 10.1016/j.plefa.2003.08.022; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Cole AL, 2003, ARTERIOSCL THROM VAS, V23, P1384, DOI 10.1161/01.ATV.0000081215.45714.71; Corner FI, 2005, CURR BIOL, V15, P134, DOI 10.1016/j.cub.2005.01.007; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; Crespo Piero, 2004, Methods Mol Biol, V250, P203; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; Han C, 2006, J BIOL CHEM, V281, P24831, DOI 10.1074/jbc.M602201200; Harayama H, 2005, J ANDROL, V26, P732, DOI 10.2164/jandrol.05053; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Holly SP, 2005, MOL BIOL CELL, V16, P2458, DOI 10.1091/mbc.E03-12-0917; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kam YW, 2001, CELL SIGNAL, V13, P841, DOI 10.1016/S0898-6568(01)00210-8; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Krumins AM, 2006, J BIOL CHEM, V281, P10250, DOI 10.1074/jbc.M511551200; Kumar RN, 2006, ONCOGENE, V25, P899, DOI 10.1038/sj.onc.1209132; LEGRAND AB, 1990, BIOCHEM PHARMACOL, V40, P1103, DOI 10.1016/0006-2952(90)90499-B; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Liu AMF, 2005, NEUROSIGNALS, V14, P136, DOI 10.1159/000086296; Liu XH, 2002, BIOCHEM BIOPH RES CO, V290, P249, DOI 10.1006/bbrc.2001.6188; Lo RKH, 2006, CELL SIGNAL, V18, P307, DOI 10.1016/j.cellsig.2005.05.001; Lo RKH, 2004, MOL PHARMACOL, V65, P1427, DOI 10.1124/mol.65.6.1427; Lo RKH, 2003, J BIOL CHEM, V278, P52154, DOI 10.1074/jbc.M307299200; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; McKillop IH, 1999, HEPATOLOGY, V29, P371, DOI 10.1002/hep.510290201; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Mellado M, 1998, J IMMUNOL, V161, P805; Norum JH, 2005, FEBS J, V272, P2304, DOI 10.1111/j.1742-4658.2005.04658.x; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; Park YJ, 2002, MOL CELL ENDOCRINOL, V194, P77, DOI 10.1016/S0303-7207(02)00185-5; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; QIAN NX, 1994, J BIOL CHEM, V269, P17417; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; Spiegel AM, 1997, HORM RES, V47, P89, DOI 10.1159/000185441; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vongs A, 2004, REGUL PEPTIDES, V120, P113, DOI 10.1016/j.regpep.2004.02.018; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WONG YH, 1995, ONCOGENE, V10, P1927; Woo CH, 2002, MOL CELLS, V13, P470; Wu EHT, 2003, BIOCHEM BIOPH RES CO, V303, P920, DOI 10.1016/S0006-291X(03)00451-0; Yang HB, 2006, MOL BIOL CELL, V17, P2177, DOI 10.1091/mbc.E05-10-0913; Yin F, 2003, J BIOL CHEM, V278, P21070, DOI 10.1074/jbc.M211028200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yuen JWF, 2004, NEUROREPORT, V15, P1431, DOI 10.1097/01.wnr.0000130433.90962.6e	72	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35812	35825		10.1074/jbc.M605288200	http://dx.doi.org/10.1074/jbc.M605288200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17008315	hybrid			2022-12-25	WOS:000242100500028
J	Nascimento, M; Zhang, WW; Ghosh, A; Houston, DR; Berghuis, AM; Olivier, M; Matlashewski, G				Nascimento, Mirna; Zhang, Wen-Wei; Ghosh, Anirban; Houston, Douglas R.; Berghuis, Albert M.; Olivier, Martin; Matlashewski, Greg			Identification and characterization of a protein-tyrosine phosphatase in Leishmania - Involvement in virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMASTIGOTE-SPECIFIC PROTEIN; DONOVANI; GENE; MODULATION; ACTIVATION; EXPRESSION; A2	Leishmania parasites are eukaryotic protozoans responsible for a variety of human diseases known as leishmaniasis, which ranges from skin lesions to fatal visceral infections. Leishmania is transmitted by the bite of an infected sandfly where it exists as promastigotes and, upon entry into a mammalian host, differentiates into amastigotes, which replicate exclusively in macrophages. The biochemical pathways enabling Leishmania to differentiate and survive in the mammalian host are poorly defined. We have therefore examined the role of protein-tyrosine phosphorylation, which is essential in regulating cell function in higher eukaryotes. Using the recently completed Leishmania genome, we have identified and cloned a Leishmania protein-tyrosine phosphatase (PTP) gene (LPTP1) by virtue of its homology with the human protein-tyrosine phosphatase 1B gene (hPTP1B). The enzyme activity of recombinant LPTP1 was confirmed using a combination of PTP-specific substrates and inhibitors. We further demonstrate, by creating LPTP1 null mutants through gene targeting, that LPTP1 is necessary for survival as amastigotes in mice, but it is dispensable for survival as promastigotes in culture. Human PTPs,including the PTP1B enzyme, are actively pursued drug targets for a variety of diseases. The observations with the LPTP1 mutants in mice suggest that it may also represent a drug target against the mammalian amastigote stage. However, in silico structure analysis of LPTP1 revealed a striking similarity with hPTP1B in the active site suggesting that, although this is an attractive drug target, it may be difficult to develop an inhibitor specific for the Leishmania LPTP1.	McGill Univ, Dept Microbiol & Immunol, McGill Univ Hlth Ctr, Dept Biochem, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol & Immunol, Ctr Hlth, Ctr Study Host Resistance,Res Inst, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Matlashewski, G (corresponding author), McGill Univ, Dept Microbiol & Immunol, McGill Univ Hlth Ctr, Dept Biochem, 3775 Univ St,Duff Med Bldg,Rm 511, Montreal, PQ H3A 2B4, Canada.	greg.matlashewski@mcgill.ca	Berghuis, Albert M/A-6495-2008	Houston, Douglas/0000-0002-3469-1546; Zhang, Wenwei/0000-0003-1996-876X; Berghuis, Albert/0000-0002-2663-025X				Aguirre-Garcia MM, 2006, PARASITOLOGY, V132, P641, DOI 10.1017/S0031182005009595; Bengs F, 2005, MOL MICROBIOL, V55, P1606, DOI 10.1111/j.1365-2958.2005.04498.x; CANSTANDET J, 2005, RES MICROBIOL, V156, P1005; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; Dadke S, 2002, BIOCHEM J, V364, P377, DOI 10.1042/BJ20011372; Desjeux P, 2004, NAT REV MICROBIOL, V2, P692, DOI 10.1038/nrmicro981; Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8; DeVinney R, 2000, TRENDS MICROBIOL, V8, P29, DOI 10.1016/S0966-842X(99)01657-1; Dube N, 2004, CELL CYCLE, V3, P550; Elchebly M, 2000, J MOL MED-JMM, V78, P473, DOI 10.1007/s001090000141; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5; Nascimento M, 2003, MOL MICROBIOL, V50, P1517, DOI 10.1046/j.1365-2958.2003.03811.x; Olivier M, 1998, J BIOL CHEM, V273, P13944, DOI 10.1074/jbc.273.22.13944; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Tsiani E, 1997, TRENDS ENDOCRIN MET, V8, P51, DOI 10.1016/S1043-2760(96)00262-7; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807; Zhang WW, 2001, MOL MICROBIOL, V39, P935, DOI 10.1046/j.1365-2958.2001.02286.x	25	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36257	36268		10.1074/jbc.M606256200	http://dx.doi.org/10.1074/jbc.M606256200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17005559	hybrid			2022-12-25	WOS:000242100500078
J	Okamura, SM; Oki-Idouchi, CE; Lorenzo, PS				Okamura, Sara M.; Oki-Idouchi, Carolyn E.; Lorenzo, Patricia S.			The exchange factor and diacylglycerol receptor RasGRP3 interacts with dynein light chain 1 through its C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL ESTER RECEPTORS; LIGHT-CHAIN BINDS; PKC-ALPHA; RAS; IDENTIFICATION; TRANSLOCATION; LOCALIZATION; SELECTIVITY; ACTIVATION	RasGRP3 is an exchange factor for Ras-like small GTPases that is activated in response to the second messenger diacylglycerol. As with other diacylglycerol receptors, RasGRP3 is redistributed upon diacylglycerol or phorbol ester binding. Several factors are important in determining the pattern of translocation, including the potency of the diacylglycerol analog, the affinity of the receptor for phospholipids, and in some cases, protein-protein interactions. However, little is known about the mechanisms that play a role in RasGRP3 redistribution aside from the nature of the ligand. To discover potential protein binding partners for RasGRP3, we screened a human brain cDNA library using a yeast two-hybrid approach. We identified dynein light chain 1 as a novel RasGRP3-interacting protein. The interaction was confirmed both in vitro and in vivo and required the C-terminal domain encompassing the last 127 amino acids of RasGRP3. A truncated mutant form of RasGRP3 that lacked this C-terminal domain was unable to interact with dynein light chain 1 and displayed a dramatically altered subcellular localization, with a strong reticular distribution and perinuclear and nuclear localization. These findings suggest that dynein light chain 1 represents a novel anchoring protein for RasGRP3 that may regulate subcellular localization of the exchange factor and, as such, may participate in the signaling mediated by diacylglycerol through RasGRP3.	Univ Hawaii, Canc Res Ctr Hawaii, Nat Prod & Canc Biol Program, Honolulu, HI 96813 USA	Cancer Research Center of Hawaii; University of Hawaii System	Lorenzo, PS (corresponding author), Univ Hawaii, Canc Res Ctr Hawaii, Nat Prod & Canc Biol Program, 651 Ilalo St,Suite 222-K, Honolulu, HI 96813 USA.	plorenzo@crch.hawaii.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003061] Funding Source: NIH RePORTER; NCRR NIH HHS [RCMI-G12RR003061] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Braun DC, 2005, MOL CANCER THER, V4, P141; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Conesa-Zamora P, 2001, BIOCHEMISTRY-US, V40, P13898, DOI 10.1021/bi011303o; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Li LX, 2002, MOL IMMUNOL, V38, P1283, DOI 10.1016/S0161-5890(02)00076-7; Lo KWH, 2005, J BIOL CHEM, V280, P8172, DOI 10.1074/jbc.M411408200; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Lorenzo PS, 2001, CANCER RES, V61, P943; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; Ninomiya K, 2005, CELL MOL NEUROBIOL, V25, P899, DOI 10.1007/s10571-005-4955-5; Pu YM, 2005, J BIOL CHEM, V280, P27329, DOI 10.1074/jbc.M414132200; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Shao L, 2001, J MED CHEM, V44, P3872, DOI 10.1021/jm010258f; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Wurzer G, 2001, J CELL BIOCHEM, P1; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200	24	18	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36132	36139		10.1074/jbc.M605093200	http://dx.doi.org/10.1074/jbc.M605093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17012239	hybrid			2022-12-25	WOS:000242100500063
J	De Seranno, S; Benaud, C; Assard, N; Khediri, S; Gerke, V; Baudier, J; Delphin, C				De Seranno, Sandrine; Benaud, Christelle; Assard, Nicole; Khediri, Sami; Gerke, Volker; Baudier, Jacques; Delphin, Christian			Identification of an AHNAK binding motif specific for the Annexin2/S100A10 tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-II; PHOSPHOLIPID-BINDING; ENDOTHELIAL-CELLS; TYROSINE KINASE; CALCIUM-BINDING; FUNCTIONAL EXPRESSION; MEMBRANE DYNAMICS; CHROMAFFIN CELLS; EARLY ENDOSOMES; PROTEIN-KINASE	The Annexin2 tetramer (A2t), which consists of two Annexin2 molecules bound to a S100A10 dimer, is implicated in membrane-trafficking events. Here, we showed using a yeast triple-hybrid experiment and in vitro binding assay that Annexin2 is required for strong binding of S100A10 to the C-terminal domain of the protein Ahnak. We also revealed that this effect involves only the Annexin2 N-terminal tail, which is implicated in S100A10/Annexin2 tetramerization. The minimal A2t binding motif (A2tBP1) in Ahnak was mapped to a 20-amino acid peptide, and this peptide is highly specific for A2t. We also identified a second A2t binding motif (A2tBP2) present in the N-terminal domain of Ahnak, which binds to A2t, albeit with less affinity. When overexpressed as an EGFP fusion protein in MDCK cells, A2tBPs cofractionate in a calcium-dependent manner and co-immunoprecipitate with S100A10 and Annexin2. In living cells, A2tBPs target EGFP to the cytoplasm as does Annexin2. In response to oxidative and mechanical stress, EGFP-A2tBPs relocalize within minutes to the plasma membrane; a behavior shared with Annexin2-GFP. These results suggest that the A2t complex exists within the cytoplasm of resting living cells and that its localization at the plasma membrane relies on cellular signaling. Together, our data demonstrate that A2tBP1 is a specific A2t complex binding domain and may be a powerful tool to help elucidate A2t structure and cellular functions.	CEA, INSERM EMI 0104, TS DRDC, F-38054 Grenoble 9, France; Univ Grenoble 1, F-38041 Grenoble, France; Univ Munster, Inst Med Biochem, Ctr Mol Biol Inflammat, D-48149 Munster, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Munster	Baudier, J (corresponding author), CEA, INSERM EMI 0104, TS DRDC, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jbaudier@cea.fr	Baudier, Jacques/O-2183-2016; jacques, baudier/T-3300-2019; Benaud, Christelle/M-1178-2018; Christian, Delphin/P-9284-2017	Christian, Delphin/0000-0003-3240-8695; jacques, baudier/0000-0001-8427-4444				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Burlando B, 2005, CELL CALCIUM, V38, P507, DOI 10.1016/j.ceca.2005.07.004; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; Deloulme JC, 2000, J BIOL CHEM, V275, P35302, DOI 10.1074/jbc.M003943200; Deora AB, 2004, J BIOL CHEM, V279, P43411, DOI 10.1074/jbc.M408078200; Diakonova M, 1997, J CELL SCI, V110, P1199; Donier E, 2005, J BIOL CHEM, V280, P38666, DOI 10.1074/jbc.M505981200; Eberhard DA, 2001, J CELL SCI, V114, P3155; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GERKE V, 1985, J BIOL CHEM, V260, P1688; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; Hinman LE, 1997, AM J PHYSIOL-LUNG C, V273, pL1242, DOI 10.1152/ajplung.1997.273.6.L1242; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; Jones AT, 1998, J BIOL CHEM, V273, P25301, DOI 10.1074/jbc.273.39.25301; JONES PG, 1992, J BIOL CHEM, V267, P13993; Jost M, 1997, J CELL SCI, V110, P221; Knop M, 2004, EMBO J, V23, P2982, DOI 10.1038/sj.emboj.7600319; Liu L, 1997, CELL SIGNAL, V9, P299, DOI 10.1016/S0898-6568(97)89891-9; Matsuda D, 2006, EXP CELL RES, V312, P1205, DOI 10.1016/j.yexcr.2006.02.003; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Poon WYL, 2004, FEBS LETT, V558, P114, DOI 10.1016/S0014-5793(03)01512-6; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Ryzhova EV, 2006, J VIROL, V80, P2694, DOI 10.1128/JVI.80.6.2694-2704.2006; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Smart EJ, 2004, P NATL ACAD SCI USA, V101, P3450, DOI 10.1073/pnas.0400441101; Spiteller G, 2006, FREE RADICAL BIO MED, V41, P362, DOI 10.1016/j.freeradbiomed.2006.03.013; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Zobiack N, 2001, FEBS LETT, V500, P137, DOI 10.1016/S0014-5793(01)02604-7	48	31	31	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35030	35038		10.1074/jbc.M606545200	http://dx.doi.org/10.1074/jbc.M606545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984913	hybrid			2022-12-25	WOS:000241933700036
J	Fikaris, AJ; Lewis, AE; Abulaiti, A; Tsygankova, OM; Meinkoth, JL				Fikaris, Aphrothiti J.; Lewis, Aurelia E.; Abulaiti, Adili; Tsygankova, Oxana M.; Meinkoth, Judy L.			Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; DNA-DAMAGE; ONCOGENIC RAS; THYROID-CELLS; MEDIATES APOPTOSIS; EPITHELIAL-CELLS; POINT MUTATIONS; PROTEIN-KINASES; CANCER CELLS	Genetic evidence indicates that Ras plays a critical role in the initiation and progression of human thyroid tumors. Paradoxically, acute expression of activated Ras in normal rat thyroid cells induced deregulated cell cycle progression and apoptosis. We investigated whether cell cycle progression was required for Ras-stimulated apoptosis. Ras increased CDK-2 activity following its introduction into quiescent cells. Apoptotic cells exhibited a sustained increase in CDK-2 activity, accompanied by the loss of CDK-2-associated p27. Blockade of Ras-induced CDK-2 activity and S phase entry via overexpression of p27 inhibited apoptosis. Inactivation of the retinoblastoma protein in quiescent cells through expression of HPV-E7 stimulated cell cycle progression and apoptosis, indicating that deregulated cell cycle progression is sufficient to induce apoptosis. Ras failed to induce G(1) phase growth arrest in normal rat thyroid cells. Rather, Ras-expressing thyroid cells progressed into S and G(2) phases and evoked a checkpoint response characterized by the activation of ATR. Ras-stimulated ATR activity, as evidenced by Chk1 and p53 phosphorylation, was blocked by p27, suggesting that cell cycle progression triggers checkpoint activation, likely as a consequence of replication stress. These data reveal that Ras is capable of inducing a DNA damage response with characteristics similar to those reported in precancerous lesions. Our findings also suggest that the frequent mutational activation of Ras in thyroid tumors reflects the ability of Ras-expressing cells to bypass checkpoints and evade apoptosis rather than to simply increase proliferative potential.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 421 Curie Blvd,1251 BRB 2-3, Philadelphia, PA 19104 USA.	meinkoth@pharm.med.upenn.edu	Meinkoth, Judy L/G-2900-2010; Lewis, Aurelia E./F-1589-2013	Lewis, Aurelia E./0000-0002-3613-5770	NIDDK NIH HHS [DK55757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055757] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BOND JA, 1994, ONCOGENE, V9, P281; Brown EJ, 2000, GENE DEV, V14, P397; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cheng GJ, 2003, MOL ENDOCRINOL, V17, P450, DOI 10.1210/me.2002-0344; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Chou CK, 2006, LIFE SCI, V78, P1823, DOI 10.1016/j.lfs.2005.08.039; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Finkielstein CV, 2002, J BIOL CHEM, V277, P38476, DOI 10.1074/jbc.M206184200; Garcia-Rostan G, 2003, J CLIN ONCOL, V21, P3226, DOI 10.1200/JCO.2003.10.130; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hahn WC, 2004, CANCER CELL, V6, P215, DOI 10.1016/j.ccr.2004.09.007; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Jackson JR, 2000, CANCER RES, V60, P566; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; Kohn EA, 2003, CANCER RES, V63, P31; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Lewis AE, 2004, MOL ENDOCRINOL, V18, P2321, DOI 10.1210/me.2004-0104; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Meinkoth JL, 2004, CANC TREAT, V122, P131; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shi LF, 1996, J IMMUNOL, V157, P2381; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Stack JH, 1997, DEVELOPMENT, V124, P3185; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tanaka Y, 2002, J BIOL CHEM, V277, P21446, DOI 10.1074/jbc.M202238200; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vasko V, 2003, J CLIN ENDOCR METAB, V88, P2745, DOI 10.1210/jc.2002-021186; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	74	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34759	34767		10.1074/jbc.M606737200	http://dx.doi.org/10.1074/jbc.M606737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16968694	hybrid			2022-12-25	WOS:000241933700007
J	Havemeyer, A; Bittner, F; Wollers, S; Mendel, R; Kunze, T; Clement, B				Havemeyer, Antje; Bittner, Florian; Wollers, Silke; Mendel, Ralf; Kunze, Thomas; Clement, Bernd			Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; RAT-LIVER; OUTER-MEMBRANE; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; ALDEHYDE OXIDASE; XANTHINE-OXIDASE; CYTOCHROME B(5); PIG-LIVER; COFACTOR	Amidoximes can be used as prodrugs for amidines and related functional groups to enhance their intestinal absorption. These prodrugs are reduced to their active amidines. Other N-hydroxylated structures are mutagenic or responsible for toxic effects of drugs and are detoxified by reduction. In this study, a N-reductive enzyme system of pig liver mitochondria using benzamidoxime as a model substrate was identified. A protein fraction free from cytochrome b(5) and cytochrome b(5) reductase was purified, enhancing 250-fold the minor benzamidoxime-reductase activity catalyzed by the membrane-bound cytochrome b(5)/NADH cytochrome b(5) reductase system. This fraction contained a 35-kDa protein with homologies to the C-terminal domain of the human molybdenum cofactor sulfurase. Here it was demonstrated that this 35-kDa protein contains molybdenum cofactor and forms the hitherto ill defined third component of the N-reductive complex in the outer mitochondrial membrane. Thus, the 35-kDa protein represents a novel group of molybdenum proteins in eukaryotes as it forms the catalytic part of a three-component enzyme complex consisting of separate proteins. Supporting these findings, recombinant C-terminal domain of the human molybdenum cofactor sulfurase exhibited N-reductive activity in vitro, which was strictly dependent on molybdenum cofactor.	Univ Kiel, Dept Pharmaceut & Med Chem, Inst Pharmaceut, D-24118 Kiel, Germany; Tech Univ Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany	University of Kiel; Braunschweig University of Technology	Clement, B (corresponding author), Univ Kiel, Dept Pharmaceut & Med Chem, Inst Pharmaceut, Gutenbergstr 76, D-24118 Kiel, Germany.	bclement@pharmazie.uni-kiel.de						Altuve A, 2001, BIOCHEMISTRY-US, V40, P9469, DOI 10.1021/bi010636i; Andersson S, 2005, DRUG METAB DISPOS, V33, P570, DOI 10.1124/dmd.104.002972; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; Clement B, 1997, J BIOL CHEM, V272, P19615, DOI 10.1074/jbc.272.31.19615; CLEMENT B, 1988, ARCH PHARM, V321, P955, DOI 10.1002/ardp.19883211228; Clement B, 2005, DRUG METAB DISPOS, V33, P1740, DOI 10.1124/dmd.105.005249; CLEMENT B, 1992, BIOCHEM PHARMACOL, V44, P1501, DOI 10.1016/0006-2952(92)90464-T; Clement B, 2005, LIFE SCI, V77, P205, DOI 10.1016/j.lfs.2004.12.028; Clement B, 2002, DRUG METAB REV, V34, P565, DOI 10.1081/DMR-120005643; Clement B, 2003, DRUG METAB DISPOS, V31, P645, DOI 10.1124/dmd.31.5.645; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Estabrook R W, 1978, Methods Enzymol, V52, P212; Ettmayer P, 2004, J MED CHEM, V47, P2393, DOI 10.1021/jm0303812; Frohlich AK, 2005, XENOBIOTICA, V35, P17, DOI 10.1080/00498250400021895; FUKUSHIMA H, 1981, J BIOL CHEM, V256, P4822; GONENNE A, 1978, ANAL BIOCHEM, V87, P28, DOI 10.1016/0003-2697(78)90565-1; HAUPTMANN J, 1988, PHARMAZIE, V43, P559; Heidenreich T, 2005, J BIOL CHEM, V280, P4213, DOI 10.1074/jbc.M411195200; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Ichida K, 2001, BIOCHEM BIOPH RES CO, V282, P1194, DOI 10.1006/bbrc.2001.4719; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1977, J BIOL CHEM, V252, P4994; KADLUBAR FF, 1974, ARCH BIOCHEM BIOPHYS, V162, P83, DOI 10.1016/0003-9861(74)90107-6; Kroneck PMH, 2002, MET IONS BIOL SYST, V39, P369; Kruger P., 1885, BER DTSCH CHEM GES, V18, P1055; Kurian JR, 2004, J PHARMACOL EXP THER, V311, P1171, DOI 10.1124/jpet.104.072389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mihara K, 1978, Methods Enzymol, V52, P102; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; RAMADOSS CS, 1980, Z NATURFORSCH C, V35, P702; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; TATSUMI K, 1987, ARCH BIOCHEM BIOPHYS, V253, P413, DOI 10.1016/0003-9861(87)90194-9; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	40	129	140	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34796	34802		10.1074/jbc.M607697200	http://dx.doi.org/10.1074/jbc.M607697200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973608	hybrid			2022-12-25	WOS:000241933700011
J	Lin, Q; Yang, WN; Baird, D; Feng, QY; Cerione, RA				Lin, Qiong; Yang, Wannian; Baird, Daniel; Feng, Qiyu; Cerione, Richard A.			Identification of a DOCK180-related guanine nucleotide exchange factor that is capable of mediating a positive feedback activation of Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SMALL GTPASE CDC42; TYROSINE KINASE; P21-ACTIVATED KINASES; ACTIN POLYMERIZATION; BINDING PROTEIN; CELL-MIGRATION; DBL FAMILY; RHO; RAC1	Cdc42, a member of the Rho subfamily of small GTPases, influences a wide range of activities including the establishment of cell polarity, migration, and the regulation of cell growth and differentiation. Here we describe the identification of an similar to 220kDa protein that formed a stable complex with activated forms of Cdc42 and thereby showed characteristics of a downstream target/effector for this GTPase. However, molecular cloning of the cDNA encoding this protein (p220) revealed that it was highly related to Zizimin-1 and identical in sequence to a gene product in the data base designated DOCK11, which are members of the DOCK180 family of guanine nucleotide exchange factors (GEFs) for Cdc42 and Rac. Biochemical characterization shows that p220 is a specific GEF for Cdc42, with the GEF activity originating from its DHR2 (for DOCK homology region 2) domain. Nucleotide-depleted Cdc42 forms a stable complex with the DHR2 domain, whereas the binding of activated Cdc42 requires both the DHR2 domain and residues 66-126 within the amino-terminal portion of p220. Moreover, the full-length protein shows markedly higher GEF activity than the isolated DHR2 domain, whereas removal of the amino-terminal 126 amino acids necessary for binding-activated Cdc42 dramatically diminishes the activity. These and other results point to activated Cdc42 providing a positive feedback regulation of the GEF activity of p220. Thus, we refer to p220/DOCK11 as activated Cdc42-associated GEF, befitting its functional activity.	Cornell Univ, Dept Mol Med, Coll Vet Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Coll Vet Med, Ithaca, NY 14853 USA.	rac1@cornell.edu	Yang, Wannian/K-4836-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Baird D, 2005, CURR BIOL, V15, P1, DOI 10.1016/j.cub.2004.12.040; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Driggers PH, 2001, J BIOL CHEM, V276, P46792, DOI 10.1074/jbc.M106927200; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; McGavin MKH, 2001, J EXP MED, V194, P1777, DOI 10.1084/jem.194.12.1777; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Namekata K, 2004, J BIOL CHEM, V279, P14331, DOI 10.1074/jbc.M311275200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Puls A, 1999, J CELL SCI, V112, P2983; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shekarabi M, 2002, MOL CELL NEUROSCI, V19, P1, DOI 10.1006/mcne.2001.1075; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819	43	42	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35253	35262		10.1074/jbc.M606248200	http://dx.doi.org/10.1074/jbc.M606248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16968698	hybrid			2022-12-25	WOS:000241933700059
J	McNeil, AK; Rescher, U; Gerke, V; McNeil, PL				McNeil, Anna K.; Rescher, Ursula; Gerke, Volker; McNeil, Paul L.			Requirement for annexin A1 in plasma membrane repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY; CUT END; FUSION; EXOCYTOSIS; DYSFERLIN; SITES; MACROMOLECULES; AGGREGATION; DISRUPTIONS; MECHANISM	Ca2+ entering a cell through a torn or disrupted plasma membrane rapidly triggers a combination of homotypic and exocytotic membrane fusion events. These events serve to erect a reparative membrane patch and then anneal it to the defect site. Annexin A1 is a cytosolic protein that, when activated by micromolar Ca2+, binds to membrane phospholipids, promoting membrane aggregation and fusion. We demonstrate here that an annexin A1 function-blocking antibody, a small peptide competitor, and a dominant-negative annexin A1 mutant protein incapable of Ca2+ binding all inhibit resealing. Moreover, we show that, coincident with a resealing event, annexin A1 becomes concentrated at disruption sites. We propose that Ca2+ entering through a disruption locally induces annexin A1 binding to membranes, initiating emergency fusion events whenever and wherever required.	Med Coll Georgia, Dept Cellular Biol & Anat, Inst Mol Med & Genet, Augusta, GA 30912 USA; Univ Munster, Inst Med Biochem, Ctr Mol Biol & Inflammat, D-48149 Munster, Germany	University System of Georgia; Augusta University; University of Munster	McNeil, PL (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, Inst Mol Med & Genet, 1120 15th St, Augusta, GA 30912 USA.	pmcneil@mail.mcg.edu						Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; CAGLIANI R, HUM MUTAT, V26, P283; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; McNeil PL, 2000, J CELL SCI, V113, P1891; McNeil PL, 2005, NAT REV MOL CELL BIO, V6, P499, DOI 10.1038/nrm1665; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MEERS P, 1992, BIOCHEMISTRY-US, V31, P6372, DOI 10.1021/bi00143a003; MEERS P, 1993, BIOCHIM BIOPHYS ACTA, V1147, P177, DOI 10.1016/0005-2736(93)90002-H; Miyake K, 2001, J CELL SCI, V114, P3487; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; OSHRY L, 1991, BIOCHIM BIOPHYS ACTA, V1066, P239, DOI 10.1016/0005-2736(91)90192-B; OSHRY L, 1991, T ASSOC AM PHYSICIAN, V104, P213; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Probst-Cousin S, 2004, MUSCLE NERVE, V30, P102, DOI 10.1002/mus.20077; Rescher U, 2000, J CELL SCI, V113, P3931; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; SWANSON JA, 1987, SCIENCE, V238, P548, DOI 10.1126/science.2443981; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; WANG W, 1994, BIOCHEMISTRY-US, V33, P275, DOI 10.1021/bi00167a036; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; YAWO H, 1985, J NEUROSCI, V5, P1626	33	174	181	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35202	35207		10.1074/jbc.M606406200	http://dx.doi.org/10.1074/jbc.M606406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984915	hybrid			2022-12-25	WOS:000241933700053
J	Motohashi, K; Hisabori, T				Motohashi, Ken; Hisabori, Toru			HCF164 receives reducing equivalents from stromal thioredoxin across the thylakoid membrane and mediates reduction of target proteins in the thylakoid lumen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-DISULFIDE OXIDOREDUCTASES; CYTOCHROME B(6)F COMPLEX; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; PHOTOSYSTEM-I; CHLOROPLAST THIOREDOXINS; PLASTIDIAL THIOREDOXINS; FUNDAMENTAL PROCESSES; ELECTRON-TRANSFER; REDOX REGULATION	HCF164 is a membrane-anchored thioredoxin-like protein known to be indispensable for assembly of cytochrome b(6)f in the thylakoid membranes. In this study, we report the finding that chloroplast stroma m-type thioredoxin is the source of reducing equivalents for reduction of HCF164 in the thylakoid lumen, providing strong evidence that higher plant chloroplasts possess a trans-membrane reducing equivalent transfer system similar to that found in bacteria. To probe the function of HCF164 in the lumen, a screen to identify the reducing equivalent acceptor proteins of HCF164 was carried out by using a resin-immobilized HCF164 single cysteine mutant, leading to the isolation of putative target thylakoid proteins. Among the newly identified target proteins, the reduction of the PSI-N subunit of photosystem I by HCF164 was confirmed both in vitro and in isolated thylakoids. Two components of the cytochrome b(6)f complex, the cytochrome f and Rieske FeS proteins, were also identified as novel potential target proteins. The data presented here suggest that HCF164 serves as an important transducer of reducing equivalents to proteins in the thylakoid lumen.	JST, ERATO, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Hisabori, T (corresponding author), JST, ERATO, ATP Syst Project, Midori Ku, Nagatsuta 5800-3, Yokohama, Kanagawa 2260026, Japan.	thisabor@res.titech.ac.jp	Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Balmer Y, 2006, P NATL ACAD SCI USA, V103, P2988, DOI 10.1073/pnas.0511040103; Balmer Y, 2004, P NATL ACAD SCI USA, V101, P2642, DOI 10.1073/pnas.0308583101; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Broin M, 2002, PLANT CELL, V14, P1417, DOI 10.1105/tpc.001644; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; Casazza AP, 2001, PHOTOSYNTH RES, V68, P175, DOI 10.1023/A:1011818021875; Collin V, 2004, PLANT PHYSIOL, V136, P4088, DOI 10.1104/pp.104.052233; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; Dai SD, 2000, SCIENCE, V287, P655, DOI 10.1126/science.287.5453.655; Dai SD, 2004, PHOTOSYNTH RES, V79, P233, DOI 10.1023/B:PRES.0000017194.34167.6d; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; Gelhaye E, 2005, CELL MOL LIFE SCI, V62, P24, DOI 10.1007/s00018-004-4296-4; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GOLBECK JH, 1979, BIOCHIM BIOPHYS ACTA, V547, P347, DOI 10.1016/0005-2728(79)90016-1; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; Hisabori T, 2005, J EXP BOT, V56, P1463, DOI 10.1093/jxb/eri170; HISABORI T, IN PRESS PHOTOCHEM P; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hosoya-Matsuda N, 2005, J BIOL CHEM, V280, P840, DOI 10.1074/jbc.M411493200; Hsu MF, 2005, BIOCHEM PHARMACOL, V70, P1320, DOI 10.1016/j.bcp.2005.07.029; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Inaba K, 2005, J BIOL CHEM, V280, P33035, DOI 10.1074/jbc.M506189200; Issakidis-Bourguet E, 2001, PLANT J, V25, P127, DOI 10.1046/j.0960-7412.2000.00943.x; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Katzen F, 2002, EMBO J, V21, P3960, DOI 10.1093/emboj/cdf405; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kieselbach T, 1998, J BIOL CHEM, V273, P6710, DOI 10.1074/jbc.273.12.6710; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Koriazova LK, 2003, NAT STRUCT BIOL, V10, P13, DOI 10.1038/nsb879; Krupp R, 2001, J BIOL CHEM, V276, P3696, DOI 10.1074/jbc.M009500200; Lemaire SD, 2004, P NATL ACAD SCI USA, V101, P7475, DOI 10.1073/pnas.0402221101; Lennartz K, 2001, PLANT CELL, V13, P2539, DOI 10.1105/tpc.13.11.2539; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Meyer Y, 2005, PHOTOSYNTH RES, V86, P419, DOI 10.1007/s11120-005-5220-y; Motohashi K, 2003, J BIOL CHEM, V278, P31848, DOI 10.1074/jbc.M304258200; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Mullineaux PM, 2005, PHOTOSYNTH RES, V86, P459, DOI 10.1007/s11120-005-8811-8; Nakamoto SS, 2000, BIOCHIMIE, V82, P603, DOI 10.1016/S0300-9084(00)00605-2; NIELSEN VS, 1994, J BIOL CHEM, V269, P3762; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; OKAYAMA S, 1976, BIOCHIM BIOPHYS ACTA, V440, P331, DOI 10.1016/0005-2728(76)90067-0; Onda Y, 2000, PLANT PHYSIOL, V123, P1037, DOI 10.1104/pp.123.3.1037; Ortenberg R, 2003, ANTIOXID REDOX SIGN, V5, P403, DOI 10.1089/152308603768295140; Page MLD, 2004, J BIOL CHEM, V279, P32474, DOI 10.1074/jbc.M404285200; Rey P, 2005, PLANT J, V41, P31, DOI 10.1111/j.1365-313X.2004.02271.x; ROST N, 1964, NATURE, V201, P185; Rouhier N, 2004, CELL MOL LIFE SCI, V61, P1266, DOI 10.1007/s00018-004-3410-y; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; SINGH R, 1995, METHOD ENZYMOL, V251, P167, DOI 10.1016/0076-6879(95)51119-9; Stumpp MT, 1999, BIOCHEM J, V341, P157, DOI 10.1042/0264-6021:3410157; Wong JH, 2004, PHYTOCHEMISTRY, V65, P1629, DOI 10.1016/j.phytochem.2004.05.010; Yamazaki D, 2004, PLANT CELL PHYSIOL, V45, P18, DOI 10.1093/pcp/pch019; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998	60	118	124	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35039	35047		10.1074/jbc.M605938200	http://dx.doi.org/10.1074/jbc.M605938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16997915	hybrid			2022-12-25	WOS:000241933700037
J	Saa, P; Castilla, J; Soto, C				Saa, Paula; Castilla, Joaquin; Soto, Claudio			Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRESYMPTOMATIC DETECTION; SCRAPIE; CONVERSION; VARIANT; MOLECULES; DIAGNOSIS; STRAINS	Prions are the unconventional infectious agents responsible for transmissible spongiform encephalopathies, which appear to be composed mainly or exclusively of the misfolded prion protein (PrPSc). Prion replication involves the conversion of the normal prion protein (PrPC) into the misfolded isoform, catalyzed by tiny quantities of PrPSc present in the infectious material. We have recently developed the protein misfolding cyclic amplification (PMCA) technology to sustain the autocatalytic replication of infectious prions in vitro. Here we show that PMCA enables the specific and reproducible amplification of exceptionally minute quantities of PrPSc. Indeed, after seven rounds of PMCA, we were able to generate large amounts of PrPSc starting from a 1 x 10(-12) dilution of scrapie hamster brain, which contains the equivalent of similar to 26 molecules of protein monomers. According to recent data, this quantity is similar to the minimum number of molecules present in a single particle of infectious PrPSc, indicating that PMCA may enable detection of as little as one oligomeric PrPSc infectious particle. Interestingly, the in vitro generated PrPSc was infectious when injected in wild-type hamsters, producing a disease identical to the one generated by inoculation of the brain infectious material. The unprecedented amplification efficiency of PMCA leads to a several billion-fold increase of sensitivity for PrPSc detection as compared with standard tests used to screen prion-infected cattle and at least 4000 times more sensitivity than the animal bioassay. Therefore, PMCA offers great promise for the development of highly sensitive, specific, and early diagnosis of transmissible spongiform encephalopathy and to further understand the molecular basis of prion propagation.	Univ Texas, Med Branch, Dept Neurol, George & Cynthia Mitchell Ctr Alzheimer Dis & Rel, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Autonomous University of Madrid	Soto, C (corresponding author), Univ Texas, Med Branch, Dept Neurol, George & Cynthia Mitchell Ctr Alzheimer Dis & Rel, 301 Univ Blvd, Galveston, TX 77555 USA.	clsoto@utmb.edu	Saa, Paula/AAB-6607-2019; Castilla, Joaquin/D-5261-2011; Castilla, Joaquín/J-8414-2019	Saa, Paula/0000-0001-6077-4532; Castilla, Joaquin/0000-0002-2216-1361; Castilla, Joaquín/0000-0002-2216-1361	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002246] Funding Source: NIH RePORTER; NIA NIH HHS [AG0224642] Funding Source: Medline; NINDS NIH HHS [NS049173] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN MA, 1995, J BIOL CHEM, V270, P19197, DOI 10.1074/jbc.270.33.19197; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Castilla J, 2005, NAT MED, V11, P982, DOI 10.1038/nm1286; CASTILLA J, 2004, METHODS TOOLS BIOSCI, P198; Castilla J, 2006, METHOD ENZYMOL, V412, P3, DOI 10.1016/s0076-6879(06)12001-7; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; FIELD EJ, 1972, NATURE, V240, P104, DOI 10.1038/240104a0; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; Grassi J, 2000, Arch Virol Suppl, P197; Ingrosso L, 2002, TRENDS MOL MED, V8, P273, DOI 10.1016/S1471-4914(02)02358-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Moynagh J, 1999, NATURE, V400, P105, DOI 10.1038/21981; Nishina K, 2004, J BIOL CHEM, V279, P40788, DOI 10.1074/jbc.M406548200; Oesch B, 2000, Arch Virol Suppl, P189; Orem NR, 2006, J NEUROCHEM, V96, P1409, DOI 10.1111/j.1471-4159.2006.03650.x; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; ROOS R, 1973, BRAIN, V96, P1; Saa P, 2006, SCIENCE, V313, P92, DOI 10.1126/science.1129051; Saa Paula, 2004, V299, P53; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Soto C, 2004, NAT REV MICROBIOL, V2, P809, DOI 10.1038/nrmicro1003; Soto C, 2005, FEBS LETT, V579, P638, DOI 10.1016/j.febslet.2004.12.035; Soto C, 2002, TRENDS NEUROSCI, V25, P390, DOI 10.1016/S0166-2236(02)02195-1; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	39	234	239	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35245	35252		10.1074/jbc.M603964200	http://dx.doi.org/10.1074/jbc.M603964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16982620	hybrid			2022-12-25	WOS:000241933700058
J	Yang, YZ; Liou, HC; Sun, XH				Yang, Yuanzheng; Liou, Hsiou-Chi; Sun, Xiao-Hong			Id1 potentiates NF-kappa B activation upon T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; LYMPHOCYTE DEVELOPMENT; PRE-TCR; INTERFERON-GAMMA; KINASE COMPLEX; C-REL; SELECTION; APOPTOSIS; SURVIVAL; CANCER	E2A and HEB are basic helix-loop-helix transcription factors that play important roles in T cell development. Expression of Id1, one of their inhibitors, severely impairs T cell development in transgenic mice. Aberrant activation of NF-kappa B transcription factors has been shown to contribute to the developmental defects, but it is not clear whether NF-kappa B activation is directly due to Id1 expression or is secondary to an abnormal thymic environment in Id1 transgenic mice. Here, by using a T cell line model, we demonstrate that Id1 expression stimulates basal levels of NF-kappa B activity and further enhances NF-kappa B activation upon T cell receptor (TCR) signaling achieved by anti-CD3 and anti-CD28 stimulation. Activation of NF-kappa B is partially mediated by the classical pathway involving the interaction between the regulatory subunit, NF-kappa B essential modulator (NEMO), and the catalytic subunit, I kappa B kinase beta. However, a NEMO-independent pathway also appears to be at play. Id1-potentiated activation of NF-kappa B leads to overproduction of cytokines such as tumor necrosis factor alpha and interferon-gamma in a T cell line as well as in thymocytes. Among members of the NF-kappa B family, c-Rel appears to be preferentially activated by Id1, especially during TCR stimulation. Consistently, c-rel deficiency diminishes tumor necrosis factor alpha and interferon-gamma expression induced by Id1 and TCR signaling.	Oklahoma Med Res Fdn, Immunobiol & Canc Program, Oklahoma City, OK 73104 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA	Oklahoma Medical Research Foundation; Cornell University	Sun, XH (corresponding author), Oklahoma Med Res Fdn, Immunobiol & Canc Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	sunx@omrf.ouhsc.edu			NATIONAL CANCER INSTITUTE [R01CA077553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033597, R21AI033597] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077553, CA77553] Funding Source: Medline; NIAID NIH HHS [R01 AI033597, AI33597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; GHOSH S, 2006, HDB TRANSCRIPTION FA, P107; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kisielow P, 1990, Semin Immunol, V2, P35; Kruisbeek AM, 2000, IMMUNOL TODAY, V21, P637, DOI 10.1016/S0167-5699(00)01744-8; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; Leon MLA, 2005, INFLAMM RES, V54, P395, DOI 10.1007/s00011-005-1377-2; Li QT, 2005, TRENDS IMMUNOL, V26, P318, DOI 10.1016/j.it.2005.04.003; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Liou HC, 2003, BIOESSAYS, V25, P767, DOI 10.1002/bies.10306; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Qi ZB, 2004, MOL CELL BIOL, V24, P7313, DOI 10.1128/MCB.24.17.7313-7323.2004; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Weil R, 2006, CELL DEATH DIFFER, V13, P826, DOI 10.1038/sj.cdd.4401856; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	34	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34989	34996		10.1074/jbc.M608078200	http://dx.doi.org/10.1074/jbc.M608078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	17012234	hybrid			2022-12-25	WOS:000241933700032
J	Pasquet, S; Naye, F; Faucheux, C; Bronchain, O; Chesneau, A; Thiebaud, P; Theze, N				Pasquet, Stephanie; Naye, Francois; Faucheux, Corinne; Bronchain, Odile; Chesneau, Albert; Thiebaud, Pierre; Theze, Nadine			Transcription enhancer factor-1-dependent expression of the alpha-tropomyosin gene in the three muscle cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; SERUM RESPONSE FACTOR; CAT BINDING-FACTOR; TROPONIN-T-GENE; IN-VIVO REGULATION; PROTEIN-KINASE-C; SMOOTH-MUSCLE; XENOPUS-LAEVIS; CARDIAC MYOCYTES; DNA-BINDING	In vertebrates, the actin-binding proteins tropomyosins are encoded by four distinct genes that are expressed in a complex pattern during development and muscle differentiation. In this study, we have characterized the transcriptional machinery of the alpha-tropomyosin (alpha-Tm) gene in muscle cells. Promoter analysis revealed that a 284-bp proximal promoter region of the Xenopus laevis alpha-Tm gene is sufficient for maximal activity in the three muscle cell types. The transcriptional activity of this promoter in the three muscle cell types depends on both distinct and common cis-regulatorysequences. We have identified a30-bp conserved sequence unique to all vertebrate alpha-Tm genes that contains anMCATsite that is critical for expression of the gene in all muscle cell types. This site can bind transcription enhancer factor-1 (TEF-1) present in muscle cells both in vitro and in vivo. In serum-deprived differentiated smooth muscle cells, TEF-1 was redistributed to the nucleus, and this correlated with increased activity of the alpha-Tm promoter. Overexpression of TEF-1 mRNA in Xenopus embryonic cells led to activation of both the endogenous alpha-Tm gene and the exogenous 284-bp promoter. Finally, we show that, in transgenic embryos and juveniles, an intact MCAT sequence is required for correct temporal and spatial expression of the 284-bp gene promoter. This study represents the first analysis of the transcriptional regulation of the alpha-Tm gene in vivo and highlights a common TEF-1-dependent regulatory mechanism necessary for expression of the gene in the three muscle lineages.	INSERM, Unite 441, F-33600 Pessac, France; Univ Bordeaux 2, Unite Mixte Rech 5164, CNRS, F-33076 Bordeaux, France; Univ Paris 11, CNRS, Unite Mixte Rech 8080, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Thiebaud, P (corresponding author), INSERM, Unite 441, Ave Haut Leveque, F-33600 Pessac, France.	nadine.theze@bordeaux.inserm.fr; nadine.theze@bordeaux.inserm.fr		Bronchain, Odile/0000-0001-8932-8907; THIEBAUD, Pierre/0000-0003-1174-1616				Anderson JP, 2004, MOL CELL BIOL, V24, P3757, DOI 10.1128/MCB.24.9.3757-3768.2004; Arnone MI, 1997, DEVELOPMENT, V124, P1851; Azakie A, 2005, AM J PHYSIOL-CELL PH, V289, pC1522, DOI 10.1152/ajpcell.00126.2005; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; Blanchard EM, 1997, CIRC RES, V81, P1005; Bronchain OJ, 1999, CURR BIOL, V9, P1195, DOI 10.1016/S0960-9822(00)80025-1; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chen HH, 2004, J BIOL CHEM, V279, P30800, DOI 10.1074/jbc.M400154200; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Gaillard C, 1999, INT J DEV BIOL, V43, P175; Gaillard C, 1998, DEV GENES EVOL, V207, P435, DOI 10.1007/s004270050134; Gaillard C, 1998, GENE, V207, P235, DOI 10.1016/S0378-1119(97)00634-3; Gunning PW, 2005, TRENDS CELL BIOL, V15, P333, DOI 10.1016/j.tcb.2005.04.007; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HARDY S, 1995, GENE, V156, P265, DOI 10.1016/0378-1119(94)00929-M; Hardy S, 1999, MECH DEVELOP, V87, P199, DOI 10.1016/S0925-4773(99)00148-3; HARDY S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P239, DOI 10.1016/0167-4781(92)90087-G; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; HERRERA VLM, 1990, J BIOL CHEM, V265, P9555; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; Hook J, 2004, MOL CELL BIOL, V24, P2318, DOI 10.1128/MCB.24.6.2318-2323.2004; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; Jiang SW, 2000, BIOCHEMISTRY-US, V39, P3505, DOI 10.1021/bi991048w; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; LARKIN SB, 1999, HEART DEV, P307; Larrieu D, 2005, EXP CELL RES, V310, P166, DOI 10.1016/j.yexcr.2005.07.021; Latinkic BV, 2004, DEVELOPMENT, V131, P669, DOI 10.1242/dev.00953; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Lin MH, 1996, P NATL ACAD SCI USA, V93, P4623, DOI 10.1073/pnas.93.10.4623; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; Nieuwkoop PD, 1967, NORMAL TABLES XENOPU; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pasquet S, 2004, IN VITRO CELL DEV-AN, V40, P133; Phiel CJ, 2001, J BIOL CHEM, V276, P34637, DOI 10.1074/jbc.M105826200; Rethinasamy P, 1998, CIRC RES, V82, P116; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN A, 1988, J BIOL CHEM, V263, P19132; Shie JL, 2004, J BIOL CHEM, V279, P25010, DOI 10.1074/jbc.M403103200; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; Small EA, 2003, DEV BIOL, V261, P116, DOI 10.1016/S0012-1606(03)00306-3; Sparrow D B, 2000, Nucleic Acids Res, V28, pE12, DOI 10.1093/nar/28.4.e12; Springer ML, 2002, CELL MOTIL CYTOSKEL, V51, P177, DOI 10.1002/cm.10022; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Swartz EA, 1998, AM J PHYSIOL-CELL PH, V275, pC608, DOI 10.1152/ajpcell.1998.275.2.C608; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; THEZE N, 1995, DEV BIOL, V171, P352, DOI 10.1006/dbio.1995.1287; Tidyman WE, 2003, DEV DYNAM, V227, P484, DOI 10.1002/dvdy.10328; TOUTANT M, 1994, NUCLEIC ACIDS RES, V22, P1838, DOI 10.1093/nar/22.10.1838; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaudin P, 1999, DEVELOPMENT, V126, P4807; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	76	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34406	34420		10.1074/jbc.M602282200	http://dx.doi.org/10.1074/jbc.M602282200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16959782	hybrid			2022-12-25	WOS:000241767600061
J	Yang, CY; Kuo, TH; Ting, LP				Yang, Chih-Yung; Kuo, Tzu-Hsing; Ting, Ling-Pai			Human hepatitis B viral e antigen interacts with cellular interleukin-1 receptor accessory protein and triggers interleukin-1 response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VACCINIA VIRUS; HEPATOCELLULAR-CARCINOMA; SOLUBLE FORM; CELLS; IL-1; INFECTION; APOPTOSIS; SEROCONVERSION; INFLAMMATION	Human hepatitis B virus (HBV) can cause acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HBV e antigen (HBeAg), a secreted protein and not required for viral replication, is thought to play an immunoregulatory role during viral infection. However, the functional involvement of HBeAg in host immune response has not been fully elucidated. We report in this study that HBeAg can bind to interleukin-1 receptor accessory protein (IL-1RAcP). Interleukin-1 (IL-1) plays an important role in inflammation and regulation of immune response, and membrane form of IL-1RAcP (mIL-1RAcP) is an essential component of trimeric IL-1/IL-1 receptor/mIL-1RAcP complex. We show that glutathione S-transferase- or polyhistidine-tagged recombinant HBeAg can interact with endogenous mIL-1RAcP in vitro. Purified (His)(6)-HBeAg added in the culture medium can interact with overexpressed FLAG-tagged mIL-1RAcP in vivo. Indirect immunofluorescence and confocal microscopy show that HBeAg colocalizes with mIL-1RAcP on the cell surface. Furthermore, HBeAg is able to induce the interaction of IL-1 receptor I (IL-1RI) with mIL-1RAcP and trigger the recruitment of adaptor protein myeloid differentiation factor 88 (MyD88) to the IL-1RI/ mIL-1RAcP complex. Assembly and activation of IL-1RI/mIL-1RAcP signaling complex by HBeAg can activate downstream NF-kappa B pathway through I kappa B degradation, induce NF-kappa B-dependent luciferase expression, and induce the expression of IL-1-responsive genes. Silencing of IL-1RAcP by small interfering RNA dramatically abolishes HBeAg-mediated NF-kappa B activation. These results demonstrate that HBeAg can trigger host IL-1 response by binding to mIL-1RAcP. The interaction of HBeAg with mIL-1RAcP may play an important role in modulating	Natl Yang Ming Univ, Sch Life Sci, Inst Microbiol & Immunol, Taipei 11221, Taiwan	National Yang Ming Chiao Tung University	Ting, LP (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Microbiol & Immunol, Taipei 11221, Taiwan.	lpting@ym.edu.tw						al-Ramadi BK, 2001, J IMMUNOL, V167, P6827, DOI 10.4049/jimmunol.167.12.6827; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; ALCAMI A, 1995, J VIROL, V69, P4633; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Baumert TF, 1996, HEPATOLOGY, V23, P184, DOI 10.1002/hep.510230125; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1981, LANCET, V2, P1129; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Bruix J, 2003, J HEPATOL, V39, pS59, DOI 10.1016/S0168-8278(03)00140-5; BRUNETTO MR, 1991, P NATL ACAD SCI USA, V88, P4186, DOI 10.1073/pnas.88.10.4186; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CHAK KF, 1991, J GEN MICROBIOL, V137, P91, DOI 10.1099/00221287-137-1-91; Chen HL, 2004, HEPATOLOGY, V39, P58, DOI 10.1002/hep.20006; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DiPerna G, 2004, J BIOL CHEM, V279, P36570, DOI 10.1074/jbc.M400567200; DUNNE A, 2003, SCI STKE; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Hultner L, 2000, J IMMUNOL, V164, P5556, DOI 10.4049/jimmunol.164.11.5556; Jensen LE, 2003, CELL SIGNAL, V15, P793, DOI 10.1016/S0898-6568(03)00039-1; Jensen LE, 2000, J IMMUNOL, V164, P5277, DOI 10.4049/jimmunol.164.10.5277; KATAYAMA K, 1994, SCAND J GASTROENTERO, V29, P849, DOI 10.3109/00365529409092522; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kuhn K, 2000, J IMMUNOL, V164, P2233, DOI 10.4049/jimmunol.164.4.2233; Lai CK, 1999, J VIROL, V73, P3197, DOI 10.1128/JVI.73.4.3197-3209.1999; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Milich D, 2003, HEPATOLOGY, V38, P1075, DOI 10.1053/jhep.2003.50453; Milich DR, 1998, J IMMUNOL, V160, P2013; Milich DR, 1997, J VIROL, V71, P2192, DOI 10.1128/JVI.71.3.2192-2201.1997; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Mphahlele MJ, 1997, HEPATOLOGY, V26, P743, DOI 10.1002/hep.510260329; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Ou JH, 1997, J GASTROEN HEPATOL, V12, pS178, DOI 10.1111/j.1440-1746.1997.tb00499.x; Petit F, 1996, J VIROL, V70, P5860, DOI 10.1128/JVI.70.9.5860-5866.1996; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; RAIMONDO G, 1993, J MED VIROL, V40, P87, DOI 10.1002/jmv.1890400202; REALDI G, 1980, GASTROENTEROLOGY, V79, P195; Reignat S, 2002, J EXP MED, V195, P1089, DOI 10.1084/jem.20011723; Ribeiro RM, 2002, MICROBES INFECT, V4, P829, DOI 10.1016/S1286-4579(02)01603-9; Schmidt M, 1999, J IMMUNOL, V163, P3484; Schoemaker MH, 2002, J HEPATOL, V36, P742, DOI 10.1016/S0168-8278(02)00063-6; Smith DE, 2003, IMMUNITY, V18, P87, DOI 10.1016/S1074-7613(02)00514-9; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; TERAZAWA S, 1991, PEDIATR RES, V29, P5, DOI 10.1203/00006450-199101000-00002; Webster GJM, 2004, J VIROL, V78, P5707, DOI 10.1128/JVI.78.11.5707-5719.2004; Wieland SF, 2005, J VIROL, V79, P9369, DOI 10.1128/JVI.79.15.9369-9380.2005; William R, 1998, J IMMUNOL, V161, P957; Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215	56	42	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34525	34536		10.1074/jbc.M510981200	http://dx.doi.org/10.1074/jbc.M510981200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16973626	hybrid			2022-12-25	WOS:000241767600073
J	Ban, T; Morigaki, K; Yagi, H; Kawasaki, T; Kobayashi, A; Yuba, S; Naiki, H; Goto, Y				Ban, Tadato; Morigaki, Kenichi; Yagi, Hisashi; Kawasaki, Takashi; Kobayashi, Atsuko; Yuba, Shunsuke; Naiki, Hironobu; Goto, Yuji			Real-time and single fibril observation of the formation of amyloid beta spherulitic structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; IN-VITRO; ALZHEIMERS-DISEASE; LIPID-BILAYERS; PEPTIDE; CONSEQUENCES; FLUORESCENCE; INSULIN; PLAQUES; PROTEIN	In Alzheimer disease, amyloid beta, a 39-43-residue peptide produced by cleavage from a large amyloid precursor protein, undergoes conformational change to form amyloid fibrils and deposits as senile amyloid plaques in the extracellular cerebral cortices of the brain. However, the mechanism of how the intrinsically linear amyloid fibrils form spherical senile plaques is unknown. With total internal reflection fluorescence microscopy combined with the use of thioflavin T, an amyloid-specific fluorescence dye, we succeeded in observing the formation of the senile plaque-like spherulitic structures with diameters of around 15 mu m on the chemically modified quartz surface. Real-time observation at a single fibrillar level revealed that, in the absence of tight contact with the surface, the cooperative and radial growth of amyloid fibrils from the core leads to a huge spherulitic structure. The results suggest the underlying physicochemical mechanism of senile plaque formation, essential for obtaining insight into prevention of Alzheimer disease.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Suita, Osaka 5650871, Japan; Natl Inst Adv Ind Sci & Technol, Res Inst Cell Engn, Osaka 5638577, Japan; Japan Sci & Technol Agcy, CREST, Fukui 9101193, Japan; Univ Fukui, Fac Med Sci, Dept Pathol Sci, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); University of Fukui	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014	Kobayashi, Atsuko/0000-0001-8743-9726				Anzai J, 1999, LANGMUIR, V15, P221, DOI 10.1021/la980743m; Ban T, 2004, J MOL BIOL, V344, P757, DOI 10.1016/j.jmb.2004.09.078; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; Gellermann GP, 2005, P NATL ACAD SCI USA, V102, P6297, DOI 10.1073/pnas.0407035102; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jin LW, 2003, P NATL ACAD SCI USA, V100, P15294, DOI 10.1073/pnas.2534647100; Jonas U, 2002, P NATL ACAD SCI USA, V99, P5034, DOI 10.1073/pnas.082634799; Kakio A, 2002, BIOCHEMISTRY-US, V41, P7385, DOI 10.1021/bi0255874; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Krebs MRH, 2004, P NATL ACAD SCI USA, V101, P14420, DOI 10.1073/pnas.0405933101; Manuelidis L, 1997, SCIENCE, V277, P94, DOI 10.1126/science.277.5322.94; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Morigaki K, 2002, LANGMUIR, V18, P10509, DOI 10.1021/la026579r; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Raffen R, 1999, PROTEIN SCI, V8, P509; Richter RP, 2005, BIOPHYS J, V88, P3422, DOI 10.1529/biophysj.104.053728; Rogers SS, 2006, BIOPHYS J, V90, P1043, DOI 10.1529/biophysj.105.072660; Sagis LMC, 2004, LANGMUIR, V20, P924, DOI 10.1021/la035390s; Wazawa T, 2005, ADV BIOCHEM ENG BIOT, V95, P77, DOI 10.1007/b102211; Westlind-Danielsson A, 2001, BIOCHEMISTRY-US, V40, P14736, DOI 10.1021/bi010375c; XIA YN, 1995, J AM CHEM SOC, V117, P9576, DOI 10.1021/ja00142a031; Yip CM, 2002, J MOL BIOL, V318, P97, DOI 10.1016/S0022-2836(02)00028-1; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	34	63	69	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33677	33683		10.1074/jbc.M606072200	http://dx.doi.org/10.1074/jbc.M606072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16959773	hybrid, Green Published			2022-12-25	WOS:000241621400075
J	Alvarez, A; Ibiza, S; Hernandez, C; Alvarez-Barrientos, A; Esplugues, JV; Calatayud, S				Alvarez, Angeles; Ibiza, Sales; Hernandez, Carlos; Alvarez-Barrientos, Alberto; Esplugues, Juan V.; Calatayud, Sara			Gastrin induces leukocyte-endothelial cell interactions in vivo and contributes to the inflammation caused by Helicobacter pylori	FASEB JOURNAL			English	Article						CCK-2 receptors; gastrin-releasing peptide	CHOLECYSTOKININ RECEPTORS; SOMATOSTATIN ANALOGS; CHEMOTACTIC ACTIVITY; B/GASTRIN RECEPTORS; SURFACE-PROTEINS; P-SELECTIN; CCK; ADHESION; RELEASE; MECHANISMS	Gastric mucosal inflammation causes hypergastrinemia, and gastrin receptors have been detected in several leukocyte types. We have analyzed whether gastrin affects the leukocyte-endothelial cell interactions in vivo by monitoring leukocyte rolling, adhesion, and emigration in rat mesenteric venules using intravital microscopy. Mesenteric superfusion with exogenous gastrin increased these processes in a concentration-and time-dependent manner, effects prevented by the cholecystokinin (CCK)-2 receptor antagonists (proglumide, L-365,260) but not by the CCK-1 receptor antagonist devazepide. A similar response was induced by exogenous CCK or endogenously released gastrin. CCK-2 receptors were localized in mesenteric macrophages and polymorphonuclear leukocytes. This effect of gastrin is not modulated by somatostatin and is independent of the endogenous release of histamine. To analyze whether hypergastrinemia elicited by Helicobacter pylori ( HP) modulates the inflammation induced by the germ, rats were chronically administered with an extract of a CagA+/VacA+ strain of HP. This protocol increased gastrinemia and induced an inflammatory response in the rat mesentery. Blockade of CCK-2 receptors attenuated this response and induced a qualitative change in the leukocyte infiltrate suggestive of a receding inflammatory process. Our results reveal a new proinflammatory role of gastrin that seems to contribute to the maintenance of the inflammation elicited by HP components.	Univ Valencia, Fac Med, Dept Farmacol, Valencia 46010, Spain; Univ Valencia, Fac Med, Unidad Mixta CNIC UVEG, Valencia 46010, Spain; Fdn Ctr Nacl Invest Cardiovasc, Cytometry Unit, Madrid, Spain	University of Valencia; University of Valencia; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Esplugues, JV (corresponding author), Univ Valencia, Fac Med, Dept Farmacol, Avd Blasco Ibanez 15, Valencia 46010, Spain.	juan.v.esplugues@uv.es	Calatayud, Sara/ABB-9665-2021; Esplugues, Juan/ABC-1488-2021; SAEZ, CARLOS HERNANDEZ/M-3029-2014; Alvarez-Barrientos, Alberto/L-9299-2014	Calatayud, Sara/0000-0001-9675-2423; SAEZ, CARLOS HERNANDEZ/0000-0001-8536-429X; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Esplugues Mota, Juan Vicente/0000-0001-8205-021X; Ibiza, Sales/0000-0002-0132-2971; Ibiza, Sales/0000-0002-5748-382X; Alvarez, Angeles/0000-0002-2301-9746				Alvarez A, 2004, BLOOD, V104, P402, DOI 10.1182/blood-2003-08-2974; Alvarez A, 2002, CIRC RES, V91, P1142, DOI 10.1161/01.RES.0000046018.23605.3E; ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; Beales I, 1997, GASTROENTEROLOGY, V113, P465, DOI 10.1053/gast.1997.v113.pm9247465; Blandizzi C, 1999, EUR J PHARMACOL, V373, P71, DOI 10.1016/S0014-2999(99)00212-5; Brzozowski T, 1999, DIGESTION, V60, P22, DOI 10.1159/000007585; Calatayud S, 1999, BRIT J PHARMACOL, V127, P1111, DOI 10.1038/sj.bjp.0702649; Carrasco M, 1997, REGUL PEPTIDES, V70, P135, DOI 10.1016/S0167-0115(97)00025-6; Cong B, 2003, WORLD J GASTROENTERO, V9, P1273, DOI 10.3748/wjg.v9.i6.1273; CRAIG PM, 1992, GUT, V33, P1020, DOI 10.1136/gut.33.8.1020; DECKTOR DL, 1989, J PHARMACOL EXP THER, V249, P1; DeLaFuente M, 1996, PEPTIDES, V17, P219, DOI 10.1016/0196-9781(95)02133-7; DelaFuente M, 1997, J ENDOCRINOL, V153, P475, DOI 10.1677/joe.0.1530475; Dial EJ, 1996, GASTROENTEROLOGY, V110, P801, DOI 10.1053/gast.1996.v110.pm8608890; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Dockray G, 2005, PFLUG ARCH EUR J PHY, V449, P344, DOI 10.1007/s00424-004-1347-5; Doong ML, 1998, BRIT J PHARMACOL, V124, P1123, DOI 10.1038/sj.bjp.0701937; Elizalde I, 1997, J CLIN INVEST, V100, P996, DOI 10.1172/JCI119650; ENGSTRAND L, 1995, FEMS IMMUNOL MED MIC, V10, P265; GABOURY JP, 1995, J IMMUNOL, V154, P804; Glatzle J, 2003, J PHYSIOL-LONDON, V550, P657, DOI 10.1113/jphysiol.2003.041673; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P690, DOI 10.3109/00365529309098274; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; Helyes Z, 2001, BRIT J PHARMACOL, V134, P1571, DOI 10.1038/sj.bjp.0704396; Iwata N, 1996, BLOOD, V88, P2683, DOI 10.1182/blood.V88.7.2683.bloodjournal8872683; Jones GE, 2000, J LEUKOCYTE BIOL, V68, P593; Juanola C, 1998, AM J PHYSIOL-GASTR L, V275, pG63, DOI 10.1152/ajpgi.1998.275.1.G63; KARALIS K, 1994, J CLIN INVEST, V93, P2000, DOI 10.1172/JCI117193; KARALIS K, 1995, ENDOCRINOLOGY, V136, P4133, DOI 10.1210/en.136.9.4133; KELLY SM, 1993, DIGEST DIS SCI, V38, P129, DOI 10.1007/BF01296784; KUROSE I, 1994, GASTROENTEROLOGY, V107, P70, DOI 10.1016/0016-5085(94)90062-0; Lehmann FS, 1996, AM J PHYSIOL-GASTR L, V270, pG783, DOI 10.1152/ajpgi.1996.270.5.G783; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; LICHTENBERGER LM, 1995, GASTROENTEROLOGY, V108, P320, DOI 10.1016/0016-5085(95)90056-X; Liu Y, 2005, J CLIN PATHOL, V58, P927, DOI 10.1136/jcp.2003.010710; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MATHISON R, 1995, J PHARMACOL EXP THER, V273, P337; MEZEY E, 1992, SCIENCE, V258, P1662, DOI 10.1126/science.1333642; Morisset J, 2000, AM J PHYSIOL-GASTR L, V279, pG148, DOI 10.1152/ajpgi.2000.279.1.G148; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; NIELSEN H, 1992, GUT, V33, P738, DOI 10.1136/gut.33.6.738; Niggli V, 2003, INT J BIOCHEM CELL B, V35, P1619, DOI 10.1016/S1357-2725(03)00144-4; ODUM L, 1994, GUT, V35, P615, DOI 10.1136/gut.35.5.615; Piqueras L, 2000, CIRCULATION, V102, P2118, DOI 10.1161/01.CIR.102.17.2118; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Sacerdote P, 1988, Peptides, V9 Suppl 1, P29, DOI 10.1016/0196-9781(88)90219-7; SACERDOTE P, 1991, PEPTIDES, V12, P167, DOI 10.1016/0196-9781(91)90184-Q; Scheiman JM, 1997, GUT, V40, P720, DOI 10.1136/gut.40.6.720; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Schmitz F, 2001, REGUL PEPTIDES, V101, P25, DOI 10.1016/S0167-0115(01)00281-6; WAGNER S, 1994, AM J GASTROENTEROL, V89, P1211; WALSH JH, 1994, GUT PEPTIDES BIOCH P, P75; Wang L, 1998, BRAIN RES, V791, P157, DOI 10.1016/S0006-8993(98)00091-2; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; Weigert N, 1996, GASTROENTEROLOGY, V110, P147, DOI 10.1053/gast.1996.v110.pm8536851; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P1431, DOI 10.1016/0016-5085(93)90148-6	57	16	16	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2396	+		10.1096/fj.05-5696fje	http://dx.doi.org/10.1096/fj.05-5696fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17015411				2022-12-25	WOS:000241702600032
J	Iwamaru, A; Kondo, Y; Iwado, E; Aoki, H; Fujiwara, K; Yokoyama, T; Mills, GB; Kondo, S				Iwamaru, A.; Kondo, Y.; Iwado, E.; Aoki, H.; Fujiwara, K.; Yokoyama, T.; Mills, G. B.; Kondo, S.			Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells	ONCOGENE			English	Article						rapamycin; autophagy; glioma; mTOR; siRNA	TUMOR-SUPPRESSOR; CANCER-THERAPY; GROWTH-CONTROL; MTOR; INHIBITION; PATHWAY; KINASE; AKT; TOR; BECLIN-1	The mammalian target of rapamycin ( mTOR) plays a central role in regulating the proliferation of malignant glioma cells, and mTOR-specific inhibitors such as rapamycin analogs are considered as promising therapy for malignant gliomas. However, the efficacy of mTOR inhibitors alone in the treatment of patients with malignant gliomas is only modest, potentially because these agents rather than acting as mTOR kinase inhibitors instead interfere with the function of only mTOR/raptor (regulatory-associated protein of mTOR) complex and thus do not perturb all mTOR functions. The purpose of this study was to determine whether global inhibition of the mTOR molecule enhances the antitumor effect of rapamycin on malignant glioma cells. We showed that rapamycin induced autophagy and that inhibition of autophagy by small interfering RNA ( siRNA) directed against autophagy-related gene Beclin 1 attenuated the cytotoxicity of rapamycin in rapamycin-sensitive tumor cells, indicating that the autophagy was a primary mediator of rapamycin's antitumor effect rather than a protective response. Exogenous expression of an mTOR mutant interfering with its kinase activity markedly enhanced the incidence of rapamycin-induced autophagy. Moreover, silencing of mTOR with siRNA augmented the inhibitory effect of rapamycin on tumor cell viability by stimulating autophagy. Importantly, not only rapamycin-sensitive malignant glioma cells with PTEN mutations but also rapamycin-resistant malignant glioma cells with wild-type PTEN were sensitized to rapamycin by mTOR siRNA. These results indicate that rapamycin-induced autophagy is one of the agent's antitumor effects and that silencing or inhibiting mTOR kinase activity could enhance the effectiveness of rapamycin.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Baylor College of Medicine	Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit BSRB 1004, Houston, TX 77030 USA.	seikondo@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA108558, R01CA088936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 088936, CA 108558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi J, 1999, J NEUROSURG, V91, P822, DOI 10.3171/jns.1999.91.5.0822; Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj/cdd/4400978; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; Edinger AL, 2003, CANCER RES, V63, P8451; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mitchell P, 2005, LANCET NEUROL, V4, P413, DOI 10.1016/S1474-4422(05)70118-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Nepomuceno RR, 2003, CANCER RES, V63, P4472; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Peralba JM, 2003, CLIN CANCER RES, V9, P2887; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Sekulic A, 2000, CANCER RES, V60, P3504; Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535-7163.MCT-05-0068; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	48	127	127	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1840	1851		10.1038/sj.onc.1209992	http://dx.doi.org/10.1038/sj.onc.1209992			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001313				2022-12-25	WOS:000245117700002
J	Lau, L; Hansford, LM; Cheng, LS; Hang, M; Baruchel, S; Kaplan, DR; Irwin, MS				Lau, L.; Hansford, L. M.; Cheng, L. S.; Hang, M.; Baruchel, S.; Kaplan, D. R.; Irwin, M. S.			Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; cyclooxygenase inhibitor; p53; HDM2; chemosensitivity	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE COX-2 INHIBITOR; P53 GENE-MUTATIONS; CANCER CELL-LINES; ANTICANCER AGENTS; NUCLEAR EXCLUSION; GROWTH-INHIBITION; NITRIC-OXIDE; MDM2; HDM2	Cyclooxygenase-2 (COX-2) is upregulated in many tumors including neuroblastoma, and its overexpression has been implicated in resistance to p53-dependent apoptosis. Although p53 is rarely mutated in neuroblastoma, the p53 protein is rendered inactive via several mechanisms including sequestration in the cytoplasm. Here, we show that COX inhibitors inhibit the growth of neuroblastoma and when combined with low doses of chemotherapy, exert synergistic effects on neuroblastoma cells. Following COX inhibitor treatment, HDM2, which targets p53 for ubiquitin-mediated degradation, is downregulated, resulting in an attenuation of p53 ubiquitination and an increase in p53 half-life. The level of HDM2 phosphorylation at ser166, which influences both HDM2 and p53 subcellular distribution, is markedly diminished in response to COX inhibitors and is associated with increased p53 nuclear localization. Combining COX inhibitors with low-dose chemotherapy potentiates apoptosis and p53 stability, nuclear localization, and activity. p53 knockdown by siRNA resulted in the rescue of COX-inhibitor-treated cells, indicating that COX inhibitor-induced apoptosis is, at least in part, p53-dependent. Taken together, these results provide the first evidence that COX inhibitors enhance chemosensitivity in neuroblastoma via downregulating HDM2 and augmenting p53 stability and nuclear accumulation.	Hosp Sick Children, Dept Pediat & Canc Res, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Irwin, MS (corresponding author), Hosp Sick Children, Dept Pediat & Canc Res, Div Haematol Oncol, Black Wing 9th Floor,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970				Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bianco R, 2005, CURR CANCER DRUG TAR, V5, P51, DOI 10.2174/1568009053332681; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks CL, 2004, CELL CYCLE, V3, P895; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Choi EM, 2005, BIOCHEM BIOPH RES CO, V328, P1107, DOI 10.1016/j.bbrc.2005.01.072; CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; CORVI R, 1995, ONCOGENE, V10, P1081; Cui HJ, 2002, MOL CANCER THER, V1, P679; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hida T, 2000, CLIN CANCER RES, V6, P2006; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; IMAMURA J, 1993, CANCER RES, V53, P4053; Inoue T, 2005, FEBS LETT, V579, P4978, DOI 10.1016/j.febslet.2005.08.006; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; KOMURO H, 1993, CANCER RES, V53, P5284; Liu XH, 2005, J BIOL CHEM, V280, P3817, DOI 10.1074/jbc.M406577200; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parashar B, 2005, J NEURO-ONCOL, V71, P141, DOI 10.1007/s11060-004-1721-3; Parashar B, 2006, J NEURO-ONCOL, V78, P129, DOI 10.1007/s11060-005-9079-8; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Swamy MV, 2003, CANCER RES, V63, P5239; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Trifan OC, 2002, CANCER RES, V62, P5778; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; VOGAN K, 1993, CANCER RES, V53, P5269; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Waskewich C, 2002, CANCER RES, V62, P2029; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Winters ME, 2005, CANCER RES, V65, P3853, DOI 10.1158/0008-5472.CAN-04-1989; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175	54	34	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1920	1931		10.1038/sj.onc.1209981	http://dx.doi.org/10.1038/sj.onc.1209981			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983334				2022-12-25	WOS:000245117700009
J	Thullberg, M; Gad, A; Beeser, A; Chernoff, J; Stromblad, S				Thullberg, M.; Gad, A.; Beeser, A.; Chernoff, J.; Stromblad, S.			The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity	ONCOGENE			English	Article						p21-activated kinase 1 (PAK1); cell cycle; cyclin D1; Rac; GTPase	BREAST-CANCER CELLS; ADAPTER PROTEIN; D1 EXPRESSION; BUDDING-YEAST; ALPHA-PAK; ACTIVATION; PHOSPHORYLATION; CDC42; REVEALS; FAMILY	p21-activated kinase 1 (PAK1) is a mediator of downstream signaling from the small GTPases Rac and Cdc42. In its inactive state, PAK1 forms a homodimer where two kinases inhibit each other in trans. The kinase inhibitory domain ( KID) of one molecule of PAK1 binds to the kinase domain of its counterpart and keeps it inactive. Therefore, the isolated KID of PAK1 has been widely used to specifically inhibit and study PAK function. Here, we show that the isolated KID induced a cell cycle arrest with accumulation of cells in the G1 phase of the cell cycle with an inhibition of cyclin D1 and D2 expression. This cell cycle arrest required the intact KID and was also induced by a mutated KID unable to block PAK1 kinase activity. Furthermore, the KID-induced cell cycle arrest could not be rescued by the expression of a constitutively active PAK1-T423E mutant, concluding that this arrest occurs independently of PAK1 kinase activity. Our results suggest that PAK1 through its KID inhibits cyclin D expression and thereby enforces a cell cycle arrest. Our results also call for serious precaution in the use of KID to study PAK function.	Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden	Karolinska Institutet; Fox Chase Cancer Center; Karolinska Institutet	Thullberg, M (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden.	minna.thullberg@ki.se	Gad, Annica/X-8294-2018; Chernoff, Jonathan/I-7631-2014; Gad, Annica/H-8758-2017	Gad, Annica/0000-0002-1098-9129; Chernoff, Jonathan/0000-0002-4803-7836; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chi S, 2004, BIOCHEM BIOPH RES CO, V319, P683, DOI 10.1016/j.bbrc.2004.05.042; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dadke D, 2003, CANCER RES, V63, P8837; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Nheu T, 2004, CELL CYCLE, V3, P71; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sundberg-Smith LJ, 2005, J BIOL CHEM, V280, P2055, DOI 10.1074/jbc.M406013200; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	41	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1820	1828		10.1038/sj.onc.1209983	http://dx.doi.org/10.1038/sj.onc.1209983			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001318				2022-12-25	WOS:000244955600016
J	Rasola, A; Fassetta, M; De Bacco, F; D'Alessandro, L; Gramaglia, D; Di Renzo, M; Comoglio, PM				Rasola, A.; Fassetta, M.; De Bacco, F.; D'Alessandro, L.; Gramaglia, D.; Di Renzo, M. F.; Comoglio, P. M.			A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth	ONCOGENE			English	Article						apoptosis; beta-catenin; colorectal carcinoma; hepatocyte growth factor; invasive growth	WNT SIGNALING PATHWAY; NF-KAPPA-B; C-MET; SCATTER-FACTOR; CARCINOMA-CELLS; COLON-CANCER; APOPTOSIS; EXPRESSION; GENE; OVEREXPRESSION	Overexpressed or activated hepatocyte growth factor receptor, encoded by the MET proto-oncogene, was found in the majority of colorectal carcinomas (CRCs), whose stepwise progression to malignancy requires transcriptional activation of beta-catenin. We here demonstrate that a functional crosstalk between Met and beta-catenin signaling sustains and increases CRC cell invasive properties. Hepatocyte growth factor (HGF) stimulation prompts beta-catenin tyrosine phosphorylation and dissociation from Met, and upregulates beta-catenin expression via the phosphatidylinositol 3- kinase pathway in conditions that mimic those found by the invading and metastasizing cells. Additionally, a transcriptionally active form of beta-catenin, known to be oncogenic, enhances Met expression. Furthermore, HGF treatment increases the activity of the beta-catenin-regulated T-cell factor transcription factor in cells expressing the wild-type or the oncogenic beta-catenin. In the mirror experiments, either Met or beta-catenin knocking down also reduces their protein level. In biological assays, beta-catenin knocking down abrogates the HGF-induced motile phenotype, whereas active beta-catenin fosters ligand-independent cell scattering. Met and beta-catenin also cooperate in promoting entry into the cell cycle and in protecting cells from apoptosis. In conclusion, Met and beta-catenin pathways are mutually activated in CRC cells. This might generate a self-amplifying positive feedback loop resulting in the upregulation of the invasive growth properties of CRC cells.	Univ Padua, Dept Biomed Sci, I-25121 Brescia, Italy; Univ Turin, Sch Med, Div Mol Oncol, I-10124 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Lab Canc Genet, Candiolo, Italy	University of Padua; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Rasola, A (corresponding author), Univ Padua, Dept Biomed Sci, Viale Giuseoppe Colombo 3, I-25121 Brescia, Italy.	rasola@bio.unipd.it	DI RENZO, Maria Flavia/B-6091-2012; GRAMAGLIA, DANIELA/A-6354-2012	DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328; Rasola, Andrea/0000-0003-4522-3008; Gramaglia, Daniela/0000-0001-6259-0059				Arakaki N, 1998, BIOCHEM BIOPH RES CO, V245, P211, DOI 10.1006/bbrc.1998.8397; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boon EMJ, 2005, BRIT J CANCER, V92, P1078, DOI 10.1038/sj.bjc.6602405; Boon EMJ, 2002, CANCER RES, V62, P5126; Bowers DC, 2000, CANCER RES, V60, P4277; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fazekas K, 2001, CLIN EXP METASTAS, V18, P639, DOI 10.1023/A:1013136303880; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gramaglia D, 2004, CELL DEATH DIFFER, V11, P342, DOI 10.1038/sj.cdd.4401326; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Herynk MH, 2003, CLIN EXP METASTAS, V20, P291, DOI 10.1023/A:1024024218529; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237; Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Monga SPS, 2002, CANCER RES, V62, P2064; Ougolkov A, 2004, JNCI-J NATL CANCER I, V96, P1161, DOI 10.1093/jnci/djh219; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rasola A, 2004, CANCER RES, V64, P1744, DOI 10.1158/0008-5472.CAN-03-2383; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Vigna E, 2000, J GENE MED, V2, P308; Wielenga VJM, 2000, AM J PATHOL, V157, P1563, DOI 10.1016/S0002-9440(10)64793-1; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	49	89	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1078	1087		10.1038/sj.onc.1209859	http://dx.doi.org/10.1038/sj.onc.1209859			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16953230				2022-12-25	WOS:000244245400014
J	Ficko-Blean, E; Boraston, AB				Ficko-Blean, Elizabeth; Boraston, Alisdair B.			The interaction of a carbohydrate-binding module from a Clostridium perfringens N-acetyl-beta-hexosaminidase with its carbohydrate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; X-RAY-DIFFRACTION; BACTERIAL SIALIDASE; LIGAND-BINDING; RECOGNITION; GALACTOSE; FAMILY; COEFFICIENTS; MECHANISM; REVEALS	Clostridium perfringens is a notable colonizer of the human gastrointestinal tract. This bacterium is quite remarkable for a human pathogen by the number of glycoside hydrolases found in its genome. The modularity of these enzymes is striking as is the frequent occurrence of modules having amino acid sequence identity with family 32 carbohydrate-binding modules (CBMs), often referred to as F5/8 domains. Here we report the properties of family 32 CBMs from a C. perfringens N-acetyl-beta-hexosaminidase. Macroarray, UV difference, and isothermal titration calorimetry binding studies indicate a preference for the disaccharide LacNAc (beta-D-galactosyl-1,4-beta-D-N-acetylglucosamine). The molecular details of the interaction of this CBM with galactose, LacNAc, and the type II blood group H-trisaccharide are revealed by x-ray crystallographic studies at resolutions of 1.49, 2.4, and 2.3 angstrom, respectively.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Boraston, AB (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055 STN CSC, Victoria, BC V8W 3P6, Canada.	boraston@uvic.ca	Ficko-Blean, Elizabeth/N-1746-2013	Ficko-Blean, Elizabeth/0000-0002-3915-4715; Boraston, Alisdair/0000-0001-6417-0592				Bachhawat-Sikder K, 2001, FEBS LETT, V500, P75, DOI 10.1016/S0014-5793(01)02586-8; Bianchet MA, 2002, NAT STRUCT BIOL, V9, P628, DOI 10.1038/nsb817; Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2001, BIOCHEMISTRY-US, V40, P14679, DOI 10.1021/bi015760g; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BORASTON AB, 2001, BIOCHEMISTRY-US, V40, P6204; Coutinho PM, 1999, ROY SOC CH, P3; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; Dennis RJ, 2006, NAT STRUCT MOL BIOL, V13, P365, DOI 10.1038/nsmb1079; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ficko-Blean E, 2005, ACTA CRYSTALLOGR F, V61, P834, DOI 10.1107/S1744309105024012; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; GERDING DN, 1997, CLOSTRIDIA MOL BIOL, P117; Gupta D, 1996, GLYCOBIOLOGY, V6, P843, DOI 10.1093/glycob/6.8.843; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; Jamal-Talabani S, 2004, STRUCTURE, V12, P1177, DOI 10.1016/j.str.2004.04.022; Johnson PE, 1998, BIOCHEMISTRY-US, V37, P12772, DOI 10.1021/bi980978x; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MCDONEL JL, 1980, PHARMACOL THERAPEUT, V10, P617, DOI 10.1016/0163-7258(80)90031-5; Morelle W, 2000, GLYCOBIOLOGY, V10, P295, DOI 10.1093/glycob/10.3.295; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Newstead SL, 2005, ACTA CRYSTALLOGR D, V61, P1483, DOI 10.1107/S0907444905026132; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rao FV, 2006, EMBO J, V25, P1569, DOI 10.1038/sj.emboj.7601026; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Robbe C, 2004, BIOCHEM J, V384, P307, DOI 10.1042/BJ20040605; ROOD JI, 1991, MICROBIOL REV, V55, P621, DOI 10.1128/MMBR.55.4.621-648.1991; Roske Y, 2004, J MOL BIOL, V340, P543, DOI 10.1016/j.jmb.2004.04.072; Shimizu T, 2001, MICROBIOL IMMUNOL, V45, P179, DOI 10.1111/j.1348-0421.2001.tb01278.x; Sultan NAM, 2005, ARCH BIOCHEM BIOPHYS, V437, P115, DOI 10.1016/j.abb.2005.03.005; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Bueren AL, 2005, J BIOL CHEM, V280, P530, DOI 10.1074/jbc.M410113200; van Bueren AL, 2004, J MOL BIOL, V340, P869, DOI 10.1016/j.jbm.2004.05.038; van Bueren AL, 2004, BIOCHEMISTRY-US, V43, P15633, DOI 10.1021/bi048215z; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	37	77	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37748	37757		10.1074/jbc.M606126200	http://dx.doi.org/10.1074/jbc.M606126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	16990278	hybrid			2022-12-25	WOS:000242477100052
J	Hamai, A; Richon, C; Meslin, F; Faure, F; Kauffmann, A; Lecluse, Y; Jalil, A; Larue, L; Avril, MF; Chouaib, S; Mehrpour, M				Hamai, A.; Richon, C.; Meslin, F.; Faure, F.; Kauffmann, A.; Lecluse, Y.; Jalil, A.; Larue, L.; Avril, M. F.; Chouaib, S.; Mehrpour, M.			Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation	ONCOGENE			English	Article						human melanoma; metastasis; apoptosis; gene expression profiling; TRAIL; tyrosine kinase	TYROSINE KINASE INHIBITOR; IN-VIVO EFFICACY; INDUCED APOPTOSIS; BCR-ABL; LUNG-CANCER; LIGAND; PROTEIN; BAX; SENSITIZES; RECEPTORS	In order to de. ne genetic determinants of primary and metastatic melanoma cell susceptibility to tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL), we have applied oligonucleotide microarrays to TRAIL-sensitive primary T1 cells and TRAIL-resistant metastatic G1 cells treated or not with TRAIL. T1 and G1 cells are isogenic melanoma cell subclones. We examined 22 000 spots, 4.2% of which displayed differential expression in G1 and T1 cells. Cell susceptibility to TRAIL-mediated apoptosis was found to be correlated with gene expression signatures in this model. Some of the differentially expressed genes were identified as involved in ATP-binding and signaling pathways, based on previously published data. Further analysis provided evidences that c-kit was overexpressed in G1 cells while it was absent in T1 cells. The c-kit inhibitor, imatinib, did not restore TRAIL sensitivity, excluding a role for c-kit in TRAIL resistance in G1 cells. Surprisingly, imatinib inhibited cell proliferation and TRAIL-mediated apoptosis in melanoma cells. We investigated the possible involvement of several molecules, including c-ABL, platelet-derived growth factor receptor (PDGFR), cellular FADD-like interleukin-1 alpha-converting enzyme-like inhibitory protein (c-FLIP)(L/S), Fas-associated DD kinase, p53, p21(WAF1), proteins of B-cell leukemia/lymphoma 2 (Bcl-2) family and cytochrome c. Imatinib did not modulate the expression or activation of its own targets, such as c-ABL, PDGFR alpha and PDGFR beta, but it did affect the expression of c-FLIPL, BCL2-associated X protein (Bax) and Bcl-2. Moreover, c-FLIPL knockdown sensitized T1 cells to TRAIL-mediated apoptosis, with a sensitivity similar to that of cells previously treated with imatinib. More notably, we found that the resistance to TRAIL in G1 cells was correlated with constitutive c-FLIPL recruitment to the DISC and the inhibition of caspase 8, 3 and 9 processing. Moreover, c-FLIPL knockdown partly restored TRAIL sensitivity in G1 cells, indicating that the expression level of c-FLIPL and its interaction with TRAIL receptor2 play a crucial role in determining TRAIL resistance in metastatic melanoma cells. Our results also show that imatinib enhances TRAIL-induced cell death independently of BH3-interacting domain death agonist translocation, in a process involving the Bax: Bcl-X-L ratio, Bax: Bcl-X-L/Bcl-2 translocation, cytochrome c release and caspase activation. Our data indicate that imatinib sensitizes T1 cells by directly downregulating c-FLIPL, with the use of an alternative pathway for antitumor activity, because PDGFRa is not activated in T1 cells and these cells do not express c-kit, c-ABL or PDGFR beta. Caspase cascade activation and mitochondria also play a key role in the imatinib-mediated sensitization of melanoma cells to the proapoptotic action of TRAIL.	Inst Gustave Roussy, INSERM, U753, Labs Immunol Tumeurs Humaines,PRI, F-94805 Villejuif, France; Inst Curie, INSERM, U520, Lab Biol Cellulaire Immun Antitumorale, Paris, France; Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol,PRI, F-94805 Villejuif, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; Chinese Acad Sci, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing, Peoples R China	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Chinese Academy of Sciences; Institute of Zoology, CAS	Mehrpour, M (corresponding author), Inst Gustave Roussy, INSERM, U753, Labs Immunol Tumeurs Humaines,PRI, Rue Camille Desmoulins, F-94805 Villejuif, France.	mehrpour@igr.fr	Larue, Lionel/F-7355-2013; Mehrpour, Maryam/D-8640-2017; Larue, Lionel/I-6532-2016; Chouaib, Salem/F-7939-2016; faure, florence/P-9064-2016	faure, florence/0000-0002-8359-4283; RICHON, Catherine/0000-0002-3556-3941; JALIL, Abdelali/0000-0003-2710-8735				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; All-Ericsson C, 2004, INVEST OPHTH VIS SCI, V45, P2075, DOI 10.1167/iovs.03-1196; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Carcelain G, 1997, INT J CANCER, V72, P241, DOI 10.1002/(SICI)1097-0215(19970717)72:2<241::AID-IJC7>3.0.CO;2-R; Carr KM, 2003, ONCOGENE, V22, P3076, DOI 10.1038/sj.onc.1206448; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cory GOC, 2002, NATURE, V418, P732, DOI 10.1038/418732a; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Decaudin D, 2005, INT J CANCER, V113, P849, DOI 10.1002/ijc.20652; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Dufour E, 1997, J IMMUNOL, V158, P3787; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Hasegawa J, 1996, CANCER RES, V56, P1713; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Ivanov VN, 2005, ONCOGENE, V24, P616, DOI 10.1038/sj.onc.1208125; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jin TG, 2004, J BIOL CHEM, V279, P55594, DOI 10.1074/jbc.M401056200; Johnston JB, 2003, ONCOGENE, V22, P8356, DOI 10.1038/sj.onc.1207004; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kim KM, 2005, ONCOGENE, V24, P355, DOI 10.1038/sj.onc.1208213; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leverkus M, 2000, CANCER RES, V60, P553; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Muhlethaler-Mottet A, 2004, ONCOGENE, V23, P5415, DOI 10.1038/sj.onc.1207704; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Nimmanapalli R, 2002, ONCOGENE, V21, P8584, DOI 10.1038/sj.onc.1206086; Pandiella A, 2003, BRIT J HAEMATOL, V123, P858, DOI 10.1046/j.1365-2141.2003.04706.x; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Taylor JR, 2006, ONCOGENE, V25, P147, DOI 10.1038/sj.onc.1209007; Thomas WD, 1998, J IMMUNOL, V161, P2195; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Uziel O, 2005, BRIT J CANCER, V92, P1881, DOI 10.1038/sj.bjc.6602592; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Wei MC, 2000, GENE DEV, V14, P2060; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Wittnebel S, 2005, EUR CYTOKINE NETW, V16, P123; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamaguchi K, 2005, ONCOGENE, V24, P5868, DOI 10.1038/sj.onc.1208742	59	34	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7618	7634		10.1038/sj.onc.1209738	http://dx.doi.org/10.1038/sj.onc.1209738			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16983347				2022-12-25	WOS:000242655500007
J	Soboh, B; Igarashi, RY; Hernandez, JA; Rubio, LM				Soboh, Basem; Igarashi, Robert Y.; Hernandez, Jose A.; Rubio, Luis M.			Purification of a NifEN protein complex that contains bound molybdenum and a FeMo-Co precursor from an Azotobacter vinelandii Delta nifHDK strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SYNTHESIS; IRON-MOLYBDENUM; CRYSTALLOGRAPHIC STRUCTURE; FERRICYANIDE OXIDATION; COFACTOR PRECURSOR; FERREDOXIN-I; MOFE-PROTEIN; NITROGENASE; DINITROGENASE; GENE	The NifEN protein complex serves as a molecular scaffold where some of the steps for the assembly of the iron-molybdenum cofactor (FeMo-co) of nitrogenase take place. A His-tagged version of the NifEN complex has been previously purified and shown to carry two identical [4Fe-4S] clusters of unknown function and a [Fe-S]-containing FeMo-co precursor. We have improved the purification of the his-NifEN protein from a Delta nifHDK strain of Azotobacter vinelandii and have found that the amounts of iron and molybdenum within NifEN were significantly higher than those reported previously. In an in vitro FeMo-co synthesis system with purified components, the NifEN protein served as a source of both molybdenum and a [Fe-S]-containing FeMo-co precursor, showing significant FeMo-co synthesis activity in the absence of externally added molybdate. Thus, the NifEN scaffold protein, purified from Delta nifHDK background, contained the Nif-Bco-derived Fe-S cluster and molybdenum, although these FeMo-co constituents were present at different levels within the protein complex.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rubio, LM (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 111 Koshland Hall, Berkeley, CA 94720 USA.	lrubio@nature.berkeley.edu	Rubio, Luis M./B-5827-2009	Rubio, Luis M./0000-0003-1596-2475	NIGMS NIH HHS [GM 35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RM, 1999, J BIOL CHEM, V274, P15869, DOI 10.1074/jbc.274.22.15869; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; Corbett MC, 2006, P NATL ACAD SCI USA, V103, P1238, DOI 10.1073/pnas.0507853103; Curatti L, 2006, P NATL ACAD SCI USA, V103, P5297, DOI 10.1073/pnas.0601115103; Dos Santos PC, 2004, CHEM REV, V104, P1159, DOI 10.1021/cr020608l; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; GOODWIN PJ, 1999, THESIS DEP BIOCH, P197; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; Hu YL, 2005, P NATL ACAD SCI USA, V102, P3236, DOI 10.1073/pnas.0409201102; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOHNSON MK, 1987, BIOCHIM BIOPHYS ACTA, V911, P81, DOI 10.1016/0167-4838(87)90273-1; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MORGAN TV, 1985, FEBS LETT, V183, P206, DOI 10.1016/0014-5793(85)80777-8; MORGAN TV, 1984, P NATL ACAD SCI-BIOL, V81, P1931, DOI 10.1073/pnas.81.7.1931; Muchmore SW, 1996, ADV INORG BIOCHEM, P111; NAGATANI HH, 1974, J BACTERIOL, V120, P697, DOI 10.1128/JB.120.2.697-701.1974; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; Rangaraj P, 2002, J BIOL CHEM, V277, P40106, DOI 10.1074/jbc.M204581200; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Rubio L. M., 2002, Nitrogen fixation at the millennium, P101, DOI 10.1016/B978-044450965-9/50004-5; Rubio LM, 2004, J BIOL CHEM, V279, P19739, DOI 10.1074/jbc.M400965200; Rubio LM, 2002, J BIOL CHEM, V277, P14299, DOI 10.1074/jbc.M107289200; Rubio LM, 2005, J BACTERIOL, V187, P405, DOI 10.1128/JB.187.2.405-414.2005; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Yang TC, 2005, J AM CHEM SOC, V127, P12804, DOI 10.1021/ja0552489	42	21	20	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36701	36709		10.1074/jbc.M606820200	http://dx.doi.org/10.1074/jbc.M606820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17012743	hybrid			2022-12-25	WOS:000242220800027
J	Jin, NL; Kolliputi, N; Gou, DM; Weng, TT; Liu, L				Jin, Nili; Kolliputi, Narasiah; Gou, Deming; Weng, Tingting; Liu, Lin			A novel function of ionotropic gamma-aminobutyric acid receptors involving alveolar fluid homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL-CHANNEL ACTIVATION; EPITHELIAL-CELLS; II CELLS; ION-TRANSPORT; PULMONARY-EDEMA; PI-SUBUNIT; RAT LUNGS; IN-VITRO; GABA; SECRETION	Polarized distribution of chloride channels on the plasma membrane of epithelial cells is required for fluid transport across the epithelium of fluid-transporting organs. Ionotropic gamma-aminobutyric acid receptors are primary ligand-gated chloride channels that mediate inhibitory neurotransmission. Traditionally, these receptors are not considered to be contributors to fluid transport. Here, we report a novel function of gamma-aminobutyric acid receptors involving alveolar fluid homeostasis in adult lungs. We demonstrated the expression of functional ionotropic gamma-aminobutyric acid receptors on the apical plasma membrane of alveolar epithelial type II cells. gamma-Aminobutyric acid significantly increased chloride efflux in the isolated type II cells and inhibited apical to basolateral chloride transport on type II cell monolayers. Reduction of the gamma-aminobutyric acid receptor pi subunit using RNA interference abolished the gamma-aminobutyric acid-mediated chloride transport. In intact rat lungs, gamma-aminobutyric acid inhibited both basal and beta agonist-stimulated alveolar fluid clearance. Thus, we provide molecular and pharmacological evidence that ionotropic gamma-aminobutyric acid receptors contribute to fluid transport in the lung via luminal secretion of chloride. This finding may have the potential to develop clinical approaches for pulmonary diseases involving abnormal fluid dynamics.	Oklahoma State Univ, Dept Physiol Sci, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Liu, L (corresponding author), 264 McElroy Hall, Stillwater, OK 74078 USA.	lin.liu@okstate.edu	Kolliputi, Narasaiah/I-6050-2012	Kolliputi, Narasaiah/0000-0002-2654-1900	NHLBI NIH HHS [R01 HL-083188, R01 HL-071628, R01 HL-052146] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052146, R01HL071628, R01HL083188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTINIC MK, 1999, NEUROSCI RES, V35, P145; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Braun M, 2004, J GEN PHYSIOL, V123, P191, DOI 10.1085/jgp.200308966; Brochiero E, 2004, AM J PHYSIOL-LUNG C, V287, pL382, DOI 10.1152/ajplung.00320.2002; Chen JW, 2004, LAB INVEST, V84, P727, DOI 10.1038/labinvest.3700095; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Fang X, 2002, J GEN PHYSIOL, V119, P199, DOI 10.1085/jgp.119.2.199; Fang XH, 2006, AM J PHYSIOL-LUNG C, V290, pL242, DOI 10.1152/ajplung.00178.2005; Franklin IK, 2004, J GEN PHYSIOL, V123, P185, DOI 10.1085/jgp.200409016; Gamel-Didelon K, 2003, J BIOL CHEM, V278, P20192, DOI 10.1074/jbc.M301729200; Gou D, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh129; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jiang X, 2001, J MEMBRANE BIOL, V181, P195, DOI 10.1007/s00232-001-0022-4; Jiang XP, 1998, AM J PHYSIOL-CELL PH, V275, pC1610, DOI 10.1152/ajpcell.1998.275.6.C1610; Jin N, 2005, CELL TISSUE RES, V321, P173, DOI 10.1007/s00441-005-1130-8; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KEMP PJ, 1994, J PHYSIOL-LONDON, V476, P79; KIM KJ, 1991, RESP PHYSIOL, V85, P245, DOI 10.1016/0034-5687(91)90065-Q; Lazrak A, 2002, AM J PHYSIOL-LUNG C, V282, pL650, DOI 10.1152/ajplung.00370.2001; Lee SY, 2003, J MEMBRANE BIOL, V191, P133, DOI 10.1007/s00232-002-1049-x; Liedtke CM, 2002, AM J PHYSIOL-LUNG C, V282, pL1151, DOI 10.1152/ajplung.00143.2001; Liu L, 1996, AM J PHYSIOL-LUNG C, V270, pL668, DOI 10.1152/ajplung.1996.270.4.L668; Mason RJ, 2002, AM J PHYSIOL-LUNG C, V282, pL249, DOI 10.1152/ajplung.00027.2001; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; Mayerhofer Artur, 2001, FASEB Journal, V15, P1089; MEYER KH, 1991, J HISTOCHEM CYTOCHEM, V39, P749, DOI 10.1177/39.6.1674516; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Mutlu GM, 2005, AM J PHYSIOL-LUNG C, V289, pL685, DOI 10.1152/ajplung.00247.2005; Narasaraju TA, 2003, AM J PHYSIOL-LUNG C, V285, pL1037, DOI 10.1152/ajplung.00008.2003; Neelands TR, 1999, MOL PHARMACOL, V56, P598, DOI 10.1124/mol.56.3.598; Nielsen VG, 1998, AM J PHYSIOL-LUNG C, V275, pL1127, DOI 10.1152/ajplung.1998.275.6.L1127; Norlin A, 2001, J APPL PHYSIOL, V90, P1489, DOI 10.1152/jappl.2001.90.4.1489; O'Grady SM, 2003, AM J PHYSIOL-LUNG C, V284, pL689, DOI 10.1152/ajplung.00256.2002; O'Grady SM, 2000, AM J PHYSIOL-LUNG C, V278, pL239, DOI 10.1152/ajplung.2000.278.2.L239; Owens DF, 1996, J NEUROSCI, V16, P6414; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Park HS, 2000, AM J PHYSIOL-GASTR L, V279, pG677, DOI 10.1152/ajpgi.2000.279.4.G677; Park MK, 2001, P NATL ACAD SCI USA, V98, P10948, DOI 10.1073/pnas.181353798; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200; Scarpelli EM, 2003, COMP BIOCHEM PHYS A, V135, P39, DOI 10.1016/S1095-6433(02)00352-5; TIZZANO EF, 1994, AM J RESP CELL MOL, V10, P355, DOI 10.1165/ajrcmb.10.4.7510983; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; Xu E, 2006, CELL METAB, V3, P47, DOI 10.1016/j.cmet.2005.11.015	46	33	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36012	36020		10.1074/jbc.M606895200	http://dx.doi.org/10.1074/jbc.M606895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003036	hybrid			2022-12-25	WOS:000242100500049
J	Luu, T; Gage, PW; Tierney, ML				Luu, Tien; Gage, Peter W.; Tierney, M. Louise			GABA increases both the conductance and mean open time of recombinant GABA(A) channels co-expressed with GABARAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; RECEPTOR-ASSOCIATED PROTEIN; CHLORIDE CHANNELS; RAT; DIAZEPAM; CELLS; ACTIVATION; RESPONSES; KINETICS; SUBUNIT	The single channel properties of recombinant gamma-aminobutyric acid type A(GABA(A)) alpha beta gamma receptors co-expressed with the trafficking protein GABARAP were investigated using membrane patches in the outside-out patch clamp configuration from transiently transfected L929 cells. In control cells expressing alpha beta gamma receptors alone, GABA activated single channels whose main conductance was 30 picosiemens (pS) with a subconductance state of 20 pS, and increasing the GABA concentration did not alter their conductance. In contrast, when GABAA receptors were co-expressed with GABARAP, the GABA-activated single channels displayed multiple, high conductances (>= 40 pS), and GABA (>= 10 mu M) was able to increase their conductance, up to a maximum of 60 pS. The mean open time of GABA-activated channels in control cells expressing alpha beta gamma receptors alone was 2.3 +/- 0.1 ms for the main 30-pS channel and shorter for the subconductance state ( 20 pS, 0.8 +/- 0.1 ms). Similar values were measured for the 30- and 20-pS channels active in patches from cells co-expressing GABARAP. However higher conductance channels (>= 40 pS) remained open longer, irrespective of whether GABA or GABA plus diazepam activated them. Plotting mean open times against mean conductances revealed a linear relationship between these two parameters. Since high GABA concentrations increase both the maximum single channel conductance and mean open time of GABA(A) channels co-expressed with GABARAP, trafficking processes must influence ion channel properties. This suggests that the organization of extra-synaptic GABA(A) receptors may provide a range of distinct inhibitory currents in the brain and, further, provide differential drug responses.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research	Tierney, ML (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia.	Louise.Tierney@anu.edu.au	Luu, Tien/C-8303-2009					Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; Birnir B, 2001, J MEMBRANE BIOL, V181, P171, DOI 10.1007/s00232-001-0021-5; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Christie SB, 2006, MOL CELL NEUROSCI, V31, P1, DOI 10.1016/j.mcn.2005.08.014; CURMI JP, 1993, J MEMBRANE BIOL, V136, P273; Eghbali M, 2000, MOL PHARMACOL, V58, P463, DOI 10.1124/mol.58.3.463; Eghbali M, 2003, J PHYSIOL-LONDON, V552, P13, DOI 10.1113/jphysiol.2003.047415; Eghbali M, 2003, EUR J PHARMACOL, V468, P75, DOI 10.1016/S0014-2999(03)01641-8; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; Everitt AB, 2004, J BIOL CHEM, V279, P21701, DOI 10.1074/jbc.M312806200; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; Guyon A, 1999, J PHYSIOL-LONDON, V516, P719, DOI 10.1111/j.1469-7793.1999.0719u.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1987, BIOPHYS J, V51, P255, DOI 10.1016/S0006-3495(87)83331-3; HORNE AL, 1993, BRIT J PHARMACOL, V108, P711; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; KROUSE ME, 1986, NATURE, V319, P58, DOI 10.1038/319058a0; Lindquist CEL, 2006, J NEUROCHEM, V97, P1349, DOI 10.1111/j.1471-4159.2006.03811.x; Luu T, 2005, J MEMBRANE BIOL, V205, P17, DOI 10.1007/s00232-005-0759-2; Nusser Z, 1998, J NEUROSCI, V18, P1693; OLIVERAS JL, 1994, NEUROSCI LETT, V179, P21, DOI 10.1016/0304-3940(94)90925-3; SAKMANN B, 1983, SINGLE CHANNEL RECOR, P163; SMITH SM, 1989, J MEMBRANE BIOL, V108, P45, DOI 10.1007/BF01870424; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; Tomita S, 2005, NATURE, V435, P1052, DOI 10.1038/nature03624; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129	28	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35699	35708		10.1074/jbc.M605590200	http://dx.doi.org/10.1074/jbc.M605590200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	16954214	hybrid			2022-12-25	WOS:000242100500014
J	Wang, YP; Su, B; Xia, ZG				Wang, Yupeng; Su, Bing; Xia, Zhengui			Brain-derived neurotrophic factor activates ERK5 in cortical neurons via a Rap1-MEKK2 signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; N-TERMINAL KINASE; C-JUN PROMOTER; PROTEIN-KINASE; GENE-EXPRESSION; NH2-TERMINAL KINASE; CELL-PROLIFERATION; REGULATED KINASE-5; INDUCED APOPTOSIS; TRK RECEPTORS	The extracellular signal-regulated kinase 5 (ERK5)is activated in neurons of the central nervous system by neurotrophins including brain-derived neurotrophic factor ( BDNF). Although MEK5 is known to mediate BDNF stimulation of ERK5 in central nervous system neurons, other upstream signaling components have not been identified. Here, we report that BDNF induces a sustained activation of ERK5 in rat cortical neurons and activates Rap1, a small GTPase, as well as MEKK2,a MEK5 kinase. Our data indicate that activation of Rap1 or MEKK2 is sufficient to stimulate ERK5, whereas inhibition of either Rap1 or MEKK2 attenuates BDNF activation of ERK5. Furthermore, BDNF stimulation of MEKK2 is regulated by Rap1. Our evidence also indicates that Ras and MEKK3, a MEK5 kinase in non- neuronal cells, do not play a significant role in BDNF activation of ERK5. This study identifies Rap1 and MEKK2 as critical upstream signaling molecules mediating BDNF stimulation of ERK5 in central nervous system neurons.	Univ Washington, Dept Environm & Occupat Hlth Sci, Toxicol Program, Seattle, WA 98195 USA; Univ Washington, Grad Program Neurobiol & Behav, Seattle, WA 98195 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center	Xia, ZG (corresponding author), Univ Washington, Dept Environm & Occupat Hlth Sci, Toxicol Program, Box 357234,HSB,Rm F561C, Seattle, WA 98195 USA.	zxia@u.washington.edu			NIA NIH HHS [AG19193] Funding Source: Medline; NICHD NIH HHS [P30 HD02274] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019193] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Boudin H, 2000, J NEUROSCI, V20, P5932, DOI 10.1523/JNEUROSCI.20-16-05932.2000; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Devon RS, 2006, P NATL ACAD SCI USA, V103, P9595, DOI 10.1073/pnas.0510197103; Du J, 2003, J CELL BIOL, V163, P385, DOI 10.1083/jcb.200305134; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; GIBSON AE, 1989, AM J PHYSIOL, V257, pC182, DOI 10.1152/ajpcell.1989.257.2.C182; Grimes ML, 1996, J NEUROSCI, V16, P7950; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761-5768.2002; Hayashi T, 2000, NEUROSCI LETT, V284, P195, DOI 10.1016/S0304-3940(00)01024-7; Hayashi Y, 2001, BIOCHEM BIOPH RES CO, V281, P682, DOI 10.1006/bbrc.2001.4338; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Piper M, 2005, NAT NEUROSCI, V8, P179, DOI 10.1038/nn1380; Poser S, 2003, J NEUROSCI, V23, P4420; Prieto-Sanchez RM, 2006, ONCOGENE, V25, P2961, DOI 10.1038/sj.onc.1209333; Shalizi A, 2003, J NEUROSCI, V23, P7326; Shao YF, 2002, J CELL BIOL, V157, P679, DOI 10.1083/jcb.200201063; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; XIA Z, 1996, MAMMALIAN ADENYLYL C; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Yano H, 2004, J NEUROBIOL, V58, P244, DOI 10.1002/neu.10321; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	62	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35965	35974		10.1074/jbc.M605503200	http://dx.doi.org/10.1074/jbc.M605503200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17003042	hybrid			2022-12-25	WOS:000242100500043
J	Ballar, P; Shen, YX; Yang, H; Fang, SY				Ballar, Petek; Shen, Yuxian; Yang, Hui; Fang, Shengyun			The role of a novel p97/valosin-containing protein-interacting motif of gp78 in endoplasmic reticulum-associated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; MOTILITY FACTOR-RECEPTOR; PEPTIDE-N-GLYCANASE; UBIQUITIN LIGASE; QUALITY-CONTROL; AAA-ATPASE; P97-UFD1-NPL4 COMPLEX; RETRO-TRANSLOCATION; P97; RETROTRANSLOCATION	Improperly folded proteins in the endoplasmic reticulum (ER) are eliminated via ER-associated degradation, a process that dislocates misfolded proteins from the ER membrane into the cytosol, where they undergo proteasomal degradation. Dislocation requires a subclass of ubiquitin ligases that includes gp78 in addition to the AAA ATPase p97/VCP and its cofactor, the Ufd1-Np14 dimer. We have previously reported that gp78 interacts directly with p97/VCP. Here, we identify a novel p97/VCP-interacting motif (VIM) within gp78 that mediates this interaction. We demonstrate that the VIM of gp78 recruits p97/VCP to the ER, but has no effect on Ufd1 localization. We also show that gp78 VIM interacts with the ND1 domain of p97/VCP that was shown previously to be the binding site for Ufd1. To evaluate the role of Ufd1 in gp78-p97/VCP-mediated degradation of CD3 delta, a known substrate of gp78, RNA interference was used to silence the expression of Ufd1 and p97/VCP. Inhibition of p97/VCP, but not Ufd1, stabilized CD3 delta in cells that overexpress gp78. However, both p97/VCP and Ufd1 appear to be required for CD3 delta degradation in cells expressing physiological levels of gp78. These results raise the possibility that Ufd1 and gp78 may bind p97/VCP in a mutually exclusive manner and suggest that gp78 might act in a Ufd1-independent degradation pathway for misfolded ER proteins, which operates in parallel with the previously established p97/VCP-Ufd1-Npl4-mediated mechanism.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Anhui Med Univ, Inst Clin Pharmacol, Hefei, Peoples R China; Univ Maryland, Sch Med, Program Mol Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Anhui Medical University; University System of Maryland; University of Maryland Baltimore	Fang, SY (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, UMBI Bldg,N359,725 W Lombard St, Baltimore, MD 21201 USA.	fangs@umbi.umd.edu	Kirmizibayrak, Petek Ballar/Y-6869-2018; Fang, Shengyun/H-3802-2011	Kirmizibayrak, Petek Ballar/0000-0002-6189-1818; Shen, Yuxian/0000-0002-0916-0743; Fang, Shengyun/0000-0001-7280-5463	NIGMS NIH HHS [R01 GM69967, R01 GM069967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Alzayady KJ, 2005, J BIOL CHEM, V280, P34530, DOI 10.1074/jbc.M508890200; Ando H, 2004, J BIOL CHEM, V279, P15427, DOI 10.1074/jbc.M313701200; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Chavan M, 2006, P NATL ACAD SCI USA, V103, P8947, DOI 10.1073/pnas.0603262103; Chen B, 2006, P NATL ACAD SCI USA, V103, P341, DOI 10.1073/pnas.0506618103; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dreveny I, 2004, BIOCHEM SOC T, V32, P715, DOI 10.1042/BST0320715; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Federovitch CM, 2005, CURR OPIN CELL BIOL, V17, P409, DOI 10.1016/j.ceb.2005.06.010; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Katiyar S, 2005, MOL BIOL CELL, V16, P4584, DOI 10.1091/mbc.E05-04-0345; Lee JH, 2005, P NATL ACAD SCI USA, V102, P9144, DOI 10.1073/pnas.0502082102; Levine T, 2005, CURR OPIN CELL BIOL, V17, P362, DOI 10.1016/j.ceb.2005.06.005; Li GT, 2005, P NATL ACAD SCI USA, V102, P15809, DOI 10.1073/pnas.0507155102; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Medicherla B, 2004, EMBO REP, V5, P692, DOI 10.1038/sj.embor.7400164; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MULLALLYJE, 2006, MOL CELL BIOL, V26, P822; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Neuber O, 2005, NAT CELL BIOL, V7, P993, DOI 10.1038/ncb1298; Oda Y, 2006, J CELL BIOL, V172, P383, DOI 10.1083/jcb.200507057; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Schuberth C, 2005, NAT CELL BIOL, V7, P999, DOI 10.1038/ncb1299; Schulze A, 2005, J MOL BIOL, V354, P1021, DOI 10.1016/j.jmb.2005.10.020; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Zhong XY, 2004, J BIOL CHEM, V279, P45676, DOI 10.1074/jbc.M409034200	43	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35359	35368		10.1074/jbc.M603355200	http://dx.doi.org/10.1074/jbc.M603355200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987818	hybrid			2022-12-25	WOS:000241933700070
J	Jenei, V; Deevi, RK; Adams, CA; Axelsson, L; Hirst, DG; Andersson, T; Dib, K				Jenei, Veronika; Deevi, Ravi Kiran; Adams, Catherine Anne; Axelsson, Lena; Hirst, David Graham; Andersson, Tommy; Dib, Karim			Nitric oxide produced in response to engagement of beta 2 integrins on human neutrophils activates the monomeric GTPases Rap1 and Rap2 and promotes adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; ADHERENT HUMAN NEUTROPHILS; DEPENDENT PROTEIN-KINASE; BETA(2) INTEGRIN; TYROSINE KINASE; SELECTIVE-INHIBITION; ACTIN POLYMERIZATION; CHEMOTACTIC PEPTIDE; RESPIRATORY BURST; MEDIATED ADHESION	We found that engagement of beta 2 integrins on human neutrophils increased the levels of GTP-bound Rap1 and Rap2. Also, the activation of Rap1 was blocked by PP1, SU6656, LY294002, GF109203X, or BAPTA-AM, which indicates that the downstream signaling events in Rap1 activation involve Src tyrosine kinases, phosphoinositide 3-kinase, protein kinase C, and release of calcium. Surprisingly, the beta 2 integrin-induced activation of Rap2 was not regulated by any of the signaling pathways mentioned above. However, we identified nitric oxide as the signaling molecule involved in beta 2 integrin-induced activation of Rap1 and Rap2. This was illustrated by the fact that engagement of beta 2 integrins increased the production of nitrite, a stable end-product of nitric oxide. Furthermore, pretreatment of neutrophils with N-omega-mono-methy1-L-arginine, or 1400W, which are inhibitors of inducible nitric- oxide synthase, blocked beta 2 integrin-induced activation of Rap1 and Rap2. Similarly, R-P-8pCPT-cGMPS, an inhibitor of cGMP-dependent serine/threonine kinases, also blunted the beta 2 integrin-induced activation of Rap GTPases. Also nitric oxide production and its downstream activation of cGMP-dependent serine/threonine kinases were essential for proper neutrophil adhesion by beta 2 integrins. Thus, we made the novel findings that beta 2 integrin engagement on human neutrophils triggers production of nitric oxide and its downstream signaling is essential for activation of Rap GTPases and neutrophil adhesion.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, SE-20502 Malmo, Sweden; Queens Univ Belfast, Ctr Canc Res & Cell Biol, Div Infect & Immun, Immunol Sect, Belfast BT9 7BL, Antrim, North Ireland; Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland	Lund University; Skane University Hospital; Queens University Belfast; Queens University Belfast	Dib, K (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, SE-20502 Malmo, Sweden.	k.dib@qub.ac.uk						Axelsson L, 2000, EXP CELL RES, V256, P257, DOI 10.1006/excr.2000.4816; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; Cabanis A, 1996, GEN PHARMACOL, V27, P1409, DOI 10.1016/S0306-3623(96)00053-5; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Cedergren J, 2003, APMIS, V111, P963, DOI 10.1034/j.1600-0463.2003.1111008.x; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; Dib K, 2001, J IMMUNOL, V166, P6311, DOI 10.4049/jimmunol.166.10.6311; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hellberg C, 1996, BIOCHEM J, V317, P403, DOI 10.1042/bj3170403; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; KIKKAWA U, 1984, ADV CYCLIC NUCL PROT, V17, P437; Kinashi T, 2004, BLOOD, V103, P1033, DOI 10.1182/blood-2003-07-2499; KLEBANOFF SJ, 1993, BIOCHEM BIOPH RES CO, V197, P192, DOI 10.1006/bbrc.1993.2459; Korhonen Riku, 2005, Current Drug Targets - Inflammation and Allergy, V4, P471, DOI 10.2174/1568010054526359; Kosonen O, 1999, EUR J PHARMACOL, V382, P111, DOI 10.1016/S0014-2999(99)00581-6; Larfars G, 1999, BLOOD, V93, P1399, DOI 10.1182/blood.V93.4.1399.404k07_1399_1405; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; Lowell CA, 1998, P NATL ACAD SCI USA, V95, P7580, DOI 10.1073/pnas.95.13.7580; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Mittar D, 2004, BIOCHEM BIOPH RES CO, V322, P203, DOI 10.1016/j.bbrc.2004.07.107; Mocsai A, 1999, J IMMUNOL, V162, P1120; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; MOLLINEDO F, 1993, FEBS LETT, V326, P209, DOI 10.1016/0014-5793(93)81792-X; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; OKADA T, 1994, J BIOL CHEM, V269, P3563; PRYZWANSKY KB, 1990, BLOOD, V76, P612; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; Saini R, 2006, J LEUKOCYTE BIOL, V79, P519, DOI 10.1189/jlb.0605320; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wallerath T, 1997, THROMB HAEMOSTASIS, V77, P163; Wanikiat P, 1997, BRIT J PHARMACOL, V122, P1135, DOI 10.1038/sj.bjp.0701477; Webb JL, 2001, CLIN EXP IMMUNOL, V123, P42, DOI 10.1046/j.1365-2249.2001.01402.x; Wheeler MA, 1997, J CLIN INVEST, V99, P110, DOI 10.1172/JCI119121; WINEGAR DA, 1991, J BIOL CHEM, V266, P4381; Worthington J, 2005, GENE THER, V12, P1417, DOI 10.1038/sj.gt.3302552; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Yan SR, 1997, J IMMUNOL, V158, P1902; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	68	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35008	35020		10.1074/jbc.M601335200	http://dx.doi.org/10.1074/jbc.M601335200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16963453	hybrid			2022-12-25	WOS:000241933700034
J	Johnson, A; Yao, NY; Bowman, GD; Kuriyan, J; O'Donnell, M				Johnson, Aaron; Yao, Nina Y.; Bowman, Gregory D.; Kuriyan, John; O'Donnell, Mike			The replication factor C clamp loader requires arginine finger sensors to drive DNA binding and proliferating cell nuclear antigen loading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; ESCHERICHIA-COLI; POLYMERASE-DELTA; SLIDING CLAMP; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; GAMMA-COMPLEX; STRUCTURAL-ANALYSIS; ACCESSORY PROTEINS	Replication factor C (RFC) is an AAA+ heteropentamer that couples the energy of ATP binding and hydrolysis to the loading of the DNA polymerase processivity clamp, proliferating cell nuclear antigen (PCNA), onto DNA. RFC consists of five subunits in a spiral arrangement (RFC-A, -B, -C, -D, and -E, corresponding to subunits RFC1, RFC4, RFC3, RFC2, and RFC5, respectively). The RFC subunits are AAA+ family proteins and the complex contains four ATP sites (sites A, B, C, and D) located at subunit interfaces. In each ATP site, an arginine residue from one subunit is located near the gamma-phosphate of ATP bound in the adjacent subunit. These arginines act as "arginine fingers" that can potentially perform two functions: sensing that ATP is bound and catalyzing ATP hydrolysis. In this study, the arginine fingers in RFC were mutated to examine the steps in the PCNA loading mechanism that occur after RFC binds ATP. This report finds that the ATP sites of RFC function in distinct steps during loading of PCNA onto DNA. ATP binding to RFC powers recruitment and opening of PCNA and activates a gamma-phosphate sensor in ATP site C that promotes DNA association. ATP hydrolysis in site D is uniquely stimulated by PCNA, and we propose that this event is coupled to PCNA closure around DNA, which starts an ordered hydrolysis around the ring. PCNA closure severs contact to RFC subunits D and E (RFC2 and RFC5), and the gamma-phosphate sensor of ATP site C is switched off, resulting in low affinity of RFC for DNA and ejection of RFC from the site of PCNA loading.	Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Johns Hopkins University	O'Donnell, M (corresponding author), 1230 York Ave,Box 228, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839, GM45547, F32 GM066586-02, F32 GM066586, F32 GM066586-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, F32GM066586, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Ason B, 2003, J BIOL CHEM, V278, P10033, DOI 10.1074/jbc.M211741200; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P10237, DOI 10.1073/pnas.1434308100; Bowman GD, 2005, FEBS LETT, V579, P863, DOI 10.1016/j.febslet.2004.11.038; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Bylund GO, 2005, MOL CELL BIOL, V25, P5445, DOI 10.1128/MCB.25.13.5445-5455.2005; Cai JS, 1998, P NATL ACAD SCI USA, V95, P11607, DOI 10.1073/pnas.95.20.11607; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Finkelstein J, 2003, ANAL BIOCHEM, V319, P78, DOI 10.1016/S0003-2697(03)00273-2; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Goedken ER, 2005, NAT STRUCT MOL BIOL, V12, P183, DOI 10.1038/nsmb889; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Hingorani MM, 2002, J BIOL CHEM, V277, P47213, DOI 10.1074/jbc.M206764200; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; Kazmirski SL, 2005, P NATL ACAD SCI USA, V102, P13801, DOI 10.1073/pnas.0506430102; Kazmirski SL, 2004, P NATL ACAD SCI USA, V101, P16750, DOI 10.1073/pnas.0407904101; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; Kornberg A., 1992, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Miyata T, 2005, P NATL ACAD SCI USA, V102, P13795, DOI 10.1073/pnas.0506447102; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; Seybert A, 2004, EMBO J, V23, P1360, DOI 10.1038/sj.emboj.7600130; Seybert A, 2006, EMBO J, V25, P2209, DOI 10.1038/sj.emboj.7601093; Snyder AK, 2004, J BIOL CHEM, V279, P4386, DOI 10.1074/jbc.M310430200; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Yao N, 2003, J BIOL CHEM, V278, P50744, DOI 10.1074/jbc.M309206200; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421; Yao NY, 2006, J BIOL CHEM, V281, P17528, DOI 10.1074/jbc.M601273200; ZHUANG Z, 2006, P NATL ACAD SCI US	71	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35531	35543		10.1074/jbc.M606090200	http://dx.doi.org/10.1074/jbc.M606090200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16980295	hybrid			2022-12-25	WOS:000241933700086
J	Lindvall, C; Evans, NC; Zylstra, CR; Li, Y; Alexander, CM; Williams, BO				Lindvall, Charlotta; Evans, Nicole C.; Zylstra, Cassandra R.; Li, Yi; Alexander, Caroline M.; Williams, Bart O.			The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIR FOLLICLE MORPHOGENESIS; BETA-CATENIN; PROGENITOR CELLS; BREAST-CANCER; TRANSGENIC MICE; SELF-RENEWAL; GLAND; MOUSE; EXPRESSION; TUMORS	Canonical Wnt signaling has emerged as a critical regulatory pathway for stem cells. The association between ectopic activation of Wnt signaling and many different types of human cancer suggests that Wnt ligands can initiate tumor formation through altered regulation of stem cell populations. Here we have shown that mice deficient for the Wnt co-receptor Lrp5 are resistant to Wnt1-induced mammary tumors, which have been shown to be derived from the mammary stem/progenitor cell population. These mice exhibit a profound delay in tumorigenesis that is associated with reduced Wnt1-induced accumulation of mammary progenitor cells. In addition to the tumor resistance phenotype, loss of Lrp5 delays normal mammary development. The ductal trees of 5-week-old Lrp5(-/-) females have fewer terminal end buds, which are structures critical for juvenile ductal extension presumed to be rich in stem/progenitor cells. Consequently, the mature ductal tree is hypomorphic and does not completely fill the fat pad. Furthermore, Lrp5(-/-) ductal cells from mature females exhibit little to no stem cell activity in limiting dilution transplants. Finally, we have shown that Lrp5(-/-) embryos exhibit substantially impaired canonical Wnt signaling in the primitive stem cell compartment of the mammary placodes. These findings suggest that Lrp5-mediated canonical signaling is required for mammary ductal stem cell activity and for tumor development in response to oncogenic Wnt effectors.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI 49503 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	University of Wisconsin System; University of Wisconsin Madison; Van Andel Institute; Baylor College of Medicine	Williams, BO (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	Bart.Williams@vai.org	Williams, Bart/A-3539-2013; Li, Yi/A-7635-2009	Williams, Bart/0000-0002-5261-5301; Li, Yi/0000-0002-9976-518X; Diegel, Cassandra/0000-0002-6526-9372	NATIONAL CANCER INSTITUTE [R01CA113869] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA113869-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Boras-Granic K, 2006, DEV BIOL, V295, P219, DOI 10.1016/j.ydbio.2006.03.030; Brisken C, 2000, GENE DEV, V14, P650; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Klopocki E, 2004, INT J ONCOL, V25, P641; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu GZ, 2005, MOL CELL BIOL, V25, P3475, DOI 10.1128/MCB.25.9.3475-3482.2005; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Paguirigan A, 2006, EUR J CANCER, V42, P1225, DOI 10.1016/j.ejca.2006.01.048; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Veltmaat JM, 2003, DIFFERENTIATION, V71, P1, DOI 10.1046/j.1432-0436.2003.700601.x; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6	43	125	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					35081	35087		10.1074/jbc.M607571200	http://dx.doi.org/10.1074/jbc.M607571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973609	hybrid			2022-12-25	WOS:000241933700041
J	Park, SS; Kim, JM; Kim, DS; Kim, IH; Kim, SY				Park, Sung-Soo; Kim, Jung-Mo; Kim, Dae-Seok; Kim, In-Hoo; Kim, Soo-Youl			Transglutaminase 2 mediates polymer formation of I-kappa B alpha through C-terminal glutamine cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-THERAPY; ACTIVATION; KINASE; PHOSPHORYLATION; INFLAMMATION; INHIBITION; PEPTIDE; DEGRADATION; PROTEOLYSIS; PROTEASOME	Recently we reported that transglutaminase 2 (TGase 2) activates nuclear factor-kappa B (NF-kappa B) independently of I-kappa B kinase (IKK) activation, by inducing cross-linking and protein polymer formation of inhibitor of nuclear factor-kappa B alpha (I-kappa B alpha). TGase 2 catalyzes covalent isopeptide bond formation between the peptide bound-glutamine and the lysine residues. Using matrix-assisted laser desorption ionization time-of-flight mass spectra analysis of I-kappa B alpha polymers cross-linked by TGase 2, as well as synthetic peptides in an in vitro competition assay, we identified a glutamine cluster at the C terminus of I-kappa B alpha (amino acids 266-268) that appeared to play a key role in the formation of I-kappa B alpha polymers. Although there appeared to be no requirement for specific lysine residues, we found a considerably higher preference for the use of lysine residues at positions 21, 22, and 177 in TGase 2-mediated cross-linking of I-kappa B alpha. We demonstrated that synthetic peptides encompassing the glutamine cluster at amino acid positions 266-268 reversed I-kappa B alpha polymerization in vitro. Furthermore, the depletion of free I-kappa B alpha in EcR/TG cells was completely rescued in vivo by transfection of mutant I-kappa B alpha s in glutamine sites (Q266G, Q267G, and Q313G) as well as in a lysine site (K177G). These findings provide additional clues into the mechanism by which TGase 2 contributes to the inflammatory process via activation of NF-kappa B.	Natl Canc Ctr, Inst Res, Mol Oncol Branch, Div Basic Sci, Goyang 411769, Gyeonggi, South Korea	National Cancer Center - Korea (NCC)	Kim, SY (corresponding author), Natl Canc Ctr, Inst Res, Mol Oncol Branch, Div Basic Sci, 809 Madu 1 Dong, Goyang 411769, Gyeonggi, South Korea.	kimsooyoul@gmail.com						Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim SY, 2006, FRONT BIOSCI-LANDMRK, V11, P3026, DOI 10.2741/2030; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Matsumoto N, 2000, BIOORG MED CHEM LETT, V10, P865, DOI 10.1016/S0960-894X(00)00114-1; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281, DOI 10.1152/ajpgi.1997.272.2.G281; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Suh GY, 2006, EXP LUNG RES, V32, P43, DOI 10.1080/01902140600691514; SUN S, 1996, MOL CELL BIOL, V6, P1058; Swaroop N, 2001, PHARMACEUT RES, V18, P1631, DOI 10.1023/A:1013051019098; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Umezawa K, 2002, MOL CELLS, V14, P163; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zavrski I, 2005, ANTI-CANCER DRUG, V16, P475, DOI 10.1097/00001813-200506000-00002	30	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34965	34972		10.1074/jbc.M604150200	http://dx.doi.org/10.1074/jbc.M604150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16987813	hybrid			2022-12-25	WOS:000241933700029
J	Wang, SY; Iordanov, M; Zhang, QH				Wang, Su-Yan; Iordanov, Mihail; Zhang, Qinghong			C-Jun NH2-terminal kinase promotes apoptosis by down-regulating the transcriptional co-repressor CtBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN KINASE-2; METASTASIS SUPPRESSOR GENE; SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; OVARIAN-CARCINOMA; CELL-DEATH; CANCER METASTASIS; TUMOR-SUPPRESSOR; BINDING PROTEIN; E1A PROTEIN	Genetic knock out of the transcriptional co-repressor carboxyl-terminal- binding protein (CtBP) in mouse embryonic fibroblasts results in up-regulation of several genes involved in apoptosis. We predicted, therefore, that a propensity toward apoptosis might be regulated through changes in cellular CtBP levels. Previously, we have identified the homeodomain-interacting protein kinase 2 as such a regulator and demonstrated that HIPK2 activation causes Ser-422 phosphorylation and degradation of CtBP. In this study, we found that c-Jun NH2-terminal kinase 1 activation triggered CtBP phosphorylation on Ser-422 and subsequent degradation, inducing p53-independent apoptosis in human lung cancer cells. JNK1 has previously been linked to UV-directed apoptosis. Expression of MKK7-JNK1 or exposure to UV irradiation reduced cellular levels of CtBP via a proteasome-mediated pathway. This effect was prevented by JNK1 deficiency. In addition, sustained activation of the JNK1 pathway by cisplatin similarly triggered CtBP degradation. These findings provide a novel target for chemotherapy in cancers lacking p53.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Zhang, QH (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhangq@ohsu.edu			NCI NIH HHS [R01 CA115468, R01 CA115468-05, 5K01CA096561, K01 CA096561] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115468, K01CA096561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; CHINNADURAI G, 2005, CTBP FAMILY PROTEINS; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Debies MT, 2001, J MAMMARY GLAND BIOL, V6, P441, DOI 10.1023/A:1014739131690; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Iordanov Mihail S., 2000, Molecular Cell Biology Research Communications, V4, P122, DOI 10.1006/mcbr.2000.0266; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim HL, 2001, CANCER RES, V61, P2833; La Rosee-Borggreve A, 1999, MECH DEVELOP, V89, P133, DOI 10.1016/S0925-4773(99)00219-1; Lai ZC, 1999, GENETICS, V152, P299; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Levresse V, 2002, MOL PHARMACOL, V62, P689, DOI 10.1124/mol.62.3.689; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Mansouri A, 2003, ONCOL RES, V13, P399; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Teng DHF, 1997, CANCER RES, V57, P4177; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wu CW, 2000, AM J PATHOL, V156, P2007, DOI 10.1016/S0002-9440(10)65073-0; Yamada SD, 2002, CANCER RES, V62, P6717; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yoshida BA, 1999, CANCER RES, V59, P5483; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102	42	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34810	34815		10.1074/jbc.M607484200	http://dx.doi.org/10.1074/jbc.M607484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16984892	hybrid			2022-12-25	WOS:000241933700013
J	Gaigg, B; Toulmay, A; Schneiter, R				Gaigg, Barbara; Toulmay, Alexandre; Schneiter, Roger			Very long-chain fatty acid-containing lipids rather than sphingolipids per se are required for raft association and stable surface transport of newly synthesized plasma membrane ATPase in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; SPHINGOID BASE SYNTHESIS; GPI-ANCHORED PROTEINS; SACCHAROMYCES-CEREVISIAE; CELL-SURFACE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; SUBCELLULAR MEMBRANES; SECRETORY VESICLES; EXOCYTIC PATHWAY	The proton-pumping H+-ATPase, Pma1p, is an abundant and very long lived polytopic protein of the yeast plasma membrane. Pma1p constitutes a major cargo of the secretory pathway and thus serves as a model to study plasma membrane biogenesis. Pma1p associates with detergent-resistant membrane domains (lipid "rafts") already in the ER, and a lack of raft association correlates with mistargeting of the protein to the vacuole, where it is degraded. We are analyzing the role of specific lipids in membrane domain formation and have previously shown that surface transport of Pma1p is independent of newly synthesized sterols but that sphingolipids with C26 very long chain fatty acid are crucial for raft association and surface transport of Pma1p (Gaigg, B., Timischl, B., Corbino, L., and Schneiter, R. (2005) J. Biol. Chem. 280, 22515 - 22522). We now describe a more detailed analysis of the function that sphingolipids play in this process. Using a yeast strain in which the essential function of sphingolipids is substituted by glycerophospholipids containing C26 very long chain fatty acids, we find that sphingolipids per se are dispensable for raft association and surface delivery of Pma1p but that the C26 fatty acid is crucial. We thus conclude that the essential function of sphingolipids for membrane domain formation and stable surface delivery of Pma1p is provided by the C26 fatty acid that forms part of the yeast ceramide.	Univ Fribourg, Div Biochem, Dept Med, CH-1700 Fribourg, Switzerland	University of Fribourg	Schneiter, R (corresponding author), Univ Fribourg, Div Biochem, Dept Med, Chem Musee 5, CH-1700 Fribourg, Switzerland.	roger.schneiter@unifr.ch		Schneiter, Roger/0000-0002-9102-8396				Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Balguerie A, 2002, EUKARYOT CELL, V1, P1021, DOI 10.1128/EC.1.6.1021-1031.2002; Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; Behnia R, 2005, NATURE, V438, P597, DOI 10.1038/nature04397; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Eisenkolb M, 2002, MOL BIOL CELL, V13, P4414, DOI 10.1091/mbc.E02-02-0116; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Gaigg B, 2005, J BIOL CHEM, V280, P22515, DOI 10.1074/jbc.M413472200; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; GROVE SN, 1968, SCIENCE, V161, P171, DOI 10.1126/science.161.3837.171; Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; HUI SW, 1984, BIOCHEMISTRY-US, V23, P5570, DOI 10.1021/bi00318a029; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; Lee MCS, 2002, J BIOL CHEM, V277, P22395, DOI 10.1074/jbc.M200450200; LESTER RL, 1993, J BIOL CHEM, V268, P845; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Malinska K, 2003, MOL BIOL CELL, V14, P4427, DOI 10.1091/mbc.E03-04-0221; MATTAI J, 1987, BIOCHEMISTRY-US, V26, P3287, DOI 10.1021/bi00386a007; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Mitra K, 2004, P NATL ACAD SCI USA, V101, P4083, DOI 10.1073/pnas.0307332101; MOURITSEN OG, 1993, ANNU REV BIOPH BIOM, V22, P145, DOI 10.1146/annurev.bb.22.060193.001045; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Proszynski TJ, 2005, P NATL ACAD SCI USA, V102, P17981, DOI 10.1073/pnas.0509107102; Ramstedt B, 2002, FEBS LETT, V531, P33, DOI 10.1016/S0014-5793(02)03406-3; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Schneiter R, 2004, BIOCHEM J, V381, P941, DOI 10.1042/BJ20040320; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; Sutterlin C, 1997, J CELL SCI, V110, P2703; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824	49	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34135	34145		10.1074/jbc.M603791200	http://dx.doi.org/10.1074/jbc.M603791200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16980694	Green Submitted, hybrid			2022-12-25	WOS:000241767600034
J	Kar, K; Amin, P; Bryan, MA; Persikov, AV; Mohs, A; Wang, YH; Brodsky, B				Kar, Karunakar; Amin, Priyal; Bryan, Michael A.; Persikov, Anton V.; Mohs, Angela; Wang, Yuh-Hwa; Brodsky, Barbara			Self-association of collagen triple helix peptides into higher order structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; I COLLAGEN; FIBRIL FORMATION; MODEL PEPTIDES; SALT CONCENTRATION; CRYSTAL-STRUCTURE; STABILITY; SEQUENCE; INVITRO; HYDROXYPROLINE	Interest in self-association of peptides and proteins is motivated by an interest in the mechanism of physiologically higher order assembly of proteins such as collagen as well as the mechanism of pathological aggregation such as beta-amyloid formation. The triple helical form of (Pro-Hyp-Gly)(10), a peptide that has proved a useful model for molecular features of collagen, was found to self-associate, and its association properties are reported here. Turbidity experiments indicate that the triple helical peptide self-assembles at neutral pH via a nucleation-growth mechanism, with a critical concentration near 1 mM. The associated form is more stable than individual molecules by about 25 degrees C, and the association is reversible. The rate of self-association increases with temperature, supporting an entropically favored process. After self-association, (Pro-Hyp-Gly)(10) forms branched filamentous structures, in contrast with the highly ordered axially periodic structure of collagen fibrils. Yet a number of characteristics of triple helix assembly for the peptide resemble those of collagen fibril formation. These include promotion of fibril formation by neutral pH and increasing temperature; inhibition by sugars; and a requirement for hydroxyproline. It is suggested that these similar features for peptide and collagen self-association are based on common lateral underlying interactions between triple helical molecules mediated by hydrogen-bonded hydration networks involving hydroxyproline.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Brodsky, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brodsky@umdnj.edu		/0000-0001-7047-6539	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM072149, R01GM060048] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60048, GM072149] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2001, BIOPOLYMERS, V56, P8, DOI 10.1002/1097-0282(2000)56:1<8::AID-BIP1037>3.0.CO;2-W; BIANCHI E, 1967, J BIOL CHEM, V242, P1361; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Brittingham R, 2005, J BIOL CHEM, V280, P191, DOI 10.1074/jbc.M406210200; Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065-3233(05)70009-7; Chen M, 2001, J BIOL CHEM, V276, P21649, DOI 10.1074/jbc.M100180200; COMPER WD, 1977, BIOPOLYMERS, V16, P2113, DOI 10.1002/bip.1977.360161004; COOPER A, 1970, BIOCHEM J, V118, P355, DOI 10.1042/bj1180355; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FRASER RDB, 1973, CONFORMATION FIBROUS, P385; GELMAN RA, 1980, J BIOL CHEM, V255, P8098; Goodman M, 1998, BIOPOLYMERS, V47, P127, DOI 10.1002/(SICI)1097-0282(1998)47:2<127::AID-BIP2>3.0.CO;2-W; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; GUSTAVSON KH, 1955, NATURE, V175, P70, DOI 10.1038/175070a0; HAYASHI T, 1978, J BIOCHEM-TOKYO, V84, P245, DOI 10.1093/oxfordjournals.jbchem.a132124; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KADLER KE, 1987, J BIOL CHEM, V262, P15696; Kishimoto T, 2005, BIOPOLYMERS, V79, P163, DOI 10.1002/bip.20348; Kotch FW, 2006, P NATL ACAD SCI USA, V103, P3028, DOI 10.1073/pnas.0508783103; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; Kuznetsova N, 1998, BIOCHEMISTRY-US, V37, P11888, DOI 10.1021/bi980089+; LEIKIN S, 1995, NAT STRUCT BIOL, V2, P205, DOI 10.1038/nsb0395-205; Martin R, 2003, BIOPOLYMERS, V70, P435, DOI 10.1002/bip.10464; MILES CA, 1995, J MOL BIOL, V245, P437, DOI 10.1006/jmbi.1994.0035; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; NA GC, 1986, J BIOL CHEM, V261, P2290; NA GC, 1989, BIOCHEMISTRY-US, V28, P7153, DOI 10.1021/bi00444a004; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Oosawa F., 1975, THERMODYNAMICS POLYM; Perret S, 2001, J BIOL CHEM, V276, P43693, DOI 10.1074/jbc.M105507200; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Rousseau F, 2006, CURR OPIN STRUC BIOL, V16, P118, DOI 10.1016/j.sbi.2006.01.011; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; Thirumalai D, 2003, CURR OPIN STRUC BIOL, V13, P146, DOI 10.1016/S0959-440X(03)00032-0; Tiktopulo EI, 1998, BIOCHEMISTRY-US, V37, P8147, DOI 10.1021/bi980360n; Valluzzi R, 2000, BIOPOLYMERS, V53, P350, DOI 10.1002/(SICI)1097-0282(20000405)53:4<350::AID-BIP7>3.0.CO;2-O; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; WALLACE DG, 1983, BIOPOLYMERS, V22, P1793, DOI 10.1002/bip.360220713; Wilson DL, 2001, P NATL ACAD SCI USA, V98, P13660, DOI 10.1073/pnas.241323198; YURCHENCO PD, 1988, AM J PATHOL, V132, P278	52	110	114	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33283	33290		10.1074/jbc.M605747200	http://dx.doi.org/10.1074/jbc.M605747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963782	hybrid			2022-12-25	WOS:000241621400038
J	Luke, MPS; Sui, GC; Liu, HF; Shi, Y				Luke, Margaret Po-Shan; Sui, Guangchao; Liu, Huifei; Shi, Yang			Yin Yang 1 physically interacts with Hoxa11 and represses Hoxa11-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; GENE-EXPRESSION; DNA-BINDING; FACTOR YY1; HOMEOTIC TRANSFORMATIONS; HISTONE DEACETYLASES; HOMEODOMAIN PROTEINS; TUMOR-SUPPRESSOR; MUTANT MICE; POLYCOMB	Yin Yang 1 (YY1) plays an indispensable role in embryonic development. YY1 contains an evolutionarily conserved, 22-amino acid segment, the PHO homology region (PHR), which is located within its central domain (spacer) and has been shown previously to participate in the recruitment of Polycomb group of proteins and in YY1-mediated transcription. In this report, we show that the PHR physically interacts with several Abd-B-type Hox proteins. Although ectopic expression of Hoxa11 enhanced target promoter activity, overexpression of YY1 repressed this effect, which was abrogated by YY1 siRNA and the histone deacetylase inhibitor trichostatin A. We have further demonstrated that this suppression effect was the result of YY1-dependent recruitment of HDAC2 to the Hoxa11 target promoter. Taken together, our findings show that YY1 represses Hoxa11-dependent transcription via interactions with the Hox proteins and HDAC recruitment, providing a link between an Abd-type Hox protein and a Polycomb group protein at the level of direct protein-protein interactions. These findings not only provide a novel insight into YY1 function but also identify a new regulation of homeotic protein-mediated transcriptional regulation in general.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Shi, Y (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	yang_shi@hms.harvard.edu		Sui, Guangchao/0000-0002-8164-5585	NIGMS NIH HHS [GM53874] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Beuchle D, 2001, DEVELOPMENT, V128, P993; Bomgardner D, 2003, BIOL REPROD, V68, P644, DOI 10.1095/biolreprod.102.009324; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; Huang H, 2005, J BIOL CHEM, V280, P10119, DOI 10.1074/jbc.M413963200; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; Lorente M, 2006, MECH DEVELOP, V123, P312, DOI 10.1016/j.mod.2006.02.003; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Miguel-Aliaga I, 2004, DEVELOPMENT, V131, P6093, DOI 10.1242/dev.01521; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0; Zhao YX, 2002, DEV BIOL, V244, P21, DOI 10.1006/dbio.2002.0595	43	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2006	281	44					33226	33232		10.1074/jbc.M606584200	http://dx.doi.org/10.1074/jbc.M606584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	099UJ	16963455	hybrid			2022-12-25	WOS:000241621400031
